TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
standardised	O
coefficient	O
beta	O
=	O
0	O
.	O
410	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
(	O
standardised	O
coefficient	O
beta	O
=	O
0	O
.	O
311	O
,	O
p	O
=	O
0	O
.	O
006	O
)	O
were	O
most	O
strongly	O
associated	O
with	O
the	O
degree	O
of	O
lung	O
injury	O
,	O
even	O
when	O
the	O
diagnostic	O
group	O
was	O
included	O
in	O
the	O
statistical	O
model	O
.	O

Using	O
targeted	O
RNA	O
recombination	O
,	O
we	O
constructed	O
a	O
mutant	O
of	O
the	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
in	O
which	O
the	O
ectodomain	O
of	O
the	O
spike	O
glycoprotein	O
(	O
S	O
)	O
was	O
replaced	O
with	O
the	O
highly	O
divergent	O
ectodomain	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
of	O
feline	O
infectious	O
peritonitis	O
virus	O
.	O

The	O
contributions	O
of	O
CD4	B-PRGE
(+)	O
and	O
CD8	B-PRGE
(+)	O
T	O
cells	O
in	O
the	O
pathogenesis	O
of	O
the	O
disease	O
were	O
investigated	O
.	O

These	O
processes	O
all	O
involve	O
RNA	O
-	O
protein	O
interactions	O
between	O
the	O
N	B-PRGE
protein	I-PRGE
and	O
viral	O
RNAs	O
.	O

Together	O
these	O
data	O
demonstrate	O
a	O
high	O
-	O
affinity	O
,	O
specific	O
interaction	O
between	O
the	O
N	B-PRGE
protein	I-PRGE
and	O
a	O
conserved	O
RNA	O
sequence	O
present	O
at	O
the	O
5	O
'-	O
ends	O
of	O
MHV	B-PRGE
mRNA	I-PRGE
.	O

Site	O
-	O
directed	O
mutagenesis	O
and	O
expression	O
studies	O
showed	O
that	O
a	O
previously	O
predicted	O
cleavage	O
site	O
(	O
Q	O
(	O
2583	O
)-	O
G	O
(	O
2584	O
))	O
located	O
within	O
the	O
41	B-PRGE
-	I-PRGE
kDa	I-PRGE
protein	I-PRGE
-	I-PRGE
encoding	I-PRGE
region	I-PRGE
was	O
not	O
utilized	O
by	O
3CLP	O
,	O
supporting	O
the	O
conclusion	O
that	O
the	O
41	B-PRGE
-	I-PRGE
kDa	I-PRGE
protein	I-PRGE
is	O
a	O
mature	O
viral	O
product	O
.	O

In	O
contrast	O
to	O
the	O
parental	O
virus	O
,	O
the	O
mutants	O
were	O
unable	O
to	O
bind	O
to	O
porcine	B-PRGE
submandibulary	I-PRGE
mucin	I-PRGE
,	O
a	O
substrate	O
rich	O
in	O
sialic	O
acid	O
.	O

These	O
findings	O
indicated	O
that	O
the	O
FIPV	O
replication	O
mechanism	O
differs	O
between	O
feline	O
macrophages	O
and	O
CrFK	O
/	O
fcwf	O
-	O
4	O
cells	O
and	O
that	O
a	O
neutralizing	O
epitope	O
that	O
can	O
prevent	O
FIPV	O
infection	O
of	O
feline	O
macrophages	O
after	O
viral	O
absorption	O
is	O
present	O
on	O
M	B-PRGE
protein	I-PRGE
.	O

Expression	O
studies	O
revealed	O
that	O
for	O
formation	O
of	O
the	O
viral	O
envelope	O
,	O
actually	O
only	O
the	O
E	B-PRGE
protein	I-PRGE
and	O
the	O
membrane	O
(	O
M	O
)	O
protein	O
are	O
required	O
.	O

TITLE	O
:	O
Contributions	O
of	O
Fas	B-PRGE
-	O
Fas	B-PRGE
ligand	O
interactions	O
to	O
the	O
pathogenesis	O
of	O
mouse	O
hepatitis	O
virus	O
in	O
the	O
central	O
nervous	O
system	O
.	O

The	O
correlation	O
between	O
oxidative	O
measures	O
and	O
myeloperoxidase	B-PRGE
concentrations	O
in	O
the	O
lung	O
indicates	O
that	O
neutrophil	O
oxidants	O
could	O
be	O
responsible	O
for	O
the	O
injury	O
.	O

From	O
October	O
1985	O
to	O
September	O
1998	O
the	O
authors	O
supported	O
128	O
children	O
with	O
severe	O
acute	O
hypoxemic	O
respiratory	O
failure	O
(	O
n	O
=	O
121	O
,	O
Pao2	B-PRGE
/	O
FIo2	O
ratio	O
=	O
58	O
+/-	O
29	O
)	O
or	O
acute	O
hypercarbic	O
respiratory	O
failure	O
(	O
n	O
=	O
7	O
,	O
Paco2	O
=	O
128	O
+/-	O
37	O
),	O
despite	O
maximal	O
conventional	O
ventilation	O
.	O

TITLE	O
:	O
Cocaine	O
causes	O
increased	O
type	B-PRGE
I	I-PRGE
interferon	I-PRGE
secretion	O
by	O
both	O
L929	O
cells	O
and	O
murine	O
macrophages	O
.	O

The	O
increase	O
in	O
IFN	B-PRGE
secretion	O
was	O
most	O
pronounced	O
when	O
cells	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
the	O
IFN	O
inducer	O
poly	O
(	O
I	O
.	O
C	O
).	O

At	O
baseline	O
,	O
before	O
the	O
initiation	O
of	O
inhaled	O
NO	O
,	O
the	O
Pao2	B-PRGE
/	O
Fio2	O
ratio	O
was	O
97	O
+/-	O
46	O
torr	O
and	O
before	O
prone	O
positioning	O
,	O
92	O
+/-	O
26	O
torr	O
.	O

TITLE	O
:	O
Lidocaine	O
attenuates	O
acute	O
lung	O
injury	O
induced	O
by	O
a	O
combination	O
of	O
phospholipase	B-PRGE
A2	I-PRGE
and	O
trypsin	B-PRGE
.	O

Monospecific	O
antibodies	O
directed	O
against	O
the	O
four	O
distinct	O
domains	O
detected	O
proteins	O
of	O
10	O
,	O
12	O
,	O
and	O
15	O
kDa	O
(	O
p1a	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
p1a	B-PRGE
-	I-PRGE
12	I-PRGE
,	O
and	O
p1a	B-PRGE
-	I-PRGE
15	I-PRGE
)	O
in	O
MHV	O
-	O
A59	O
-	O
infected	O
DBT	O
cells	O
,	O
in	O
addition	O
to	O
a	O
previously	O
identified	O
22	B-PRGE
-	I-PRGE
kDa	I-PRGE
protein	I-PRGE
(	O
p1a	B-PRGE
-	I-PRGE
22	I-PRGE
).	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
inhibition	O
of	O
the	O
adhesion	O
molecule	O
CD11	O
-	O
CD18	B-PRGE
on	O
polymorphonuclear	O
leukocytes	O
(	O
PMNs	O
)	O
would	O
have	O
any	O
beneficial	O
effects	O
on	O
pulmonary	O
function	O
and	O
mortality	O
in	O
an	O
animal	O
model	O
reproducing	O
these	O
clinical	O
conditions	O
.	O

It	O
was	O
shown	O
that	O
major	B-PRGE
histocompatibility	I-PRGE
complex	I-PRGE
restricted	O
CTL	O
are	O
responsible	O
for	O
early	O
control	O
of	O
IBV	O
infection	O
.	O

Adoptive	O
transfer	O
of	O
immune	O
T	O
cells	O
to	O
chicks	O
prior	O
to	O
infection	O
demonstrated	O
that	O
IBV	O
primed	O
CD8	B-PRGE
(+),	O
alphabeta	O
T	O
lymphocytes	O
could	O
protect	O
chicks	O
from	O
acute	O
infection	O
.	O

For	O
three	O
other	O
strains	O
of	O
TGEV	O
,	O
the	O
virulent	O
British	O
FS772	O
/	O
70	O
and	O
Taiwanese	O
TFI	B-PRGE
and	O
avirulent	O
Purdue	O
-	O
116	O
,	O
mRNA	O
species	O
3	B-PRGE
-	I-PRGE
1	I-PRGE
is	O
not	O
made	O
and	O
ORF	O
3b	O
is	O
present	O
as	O
a	O
non	O
-	O
overlapping	O
second	O
ORF	O
on	O
mRNA	O
3	O
.	O

These	O
results	O
indicated	O
that	O
alphabeta	O
T	O
lymphocytes	O
bearing	O
CD8	B-PRGE
(+)	O
antigens	O
are	O
critical	O
in	O
protecting	O
chicks	O
from	O
IBV	O
infection	O
.	O

The	O
virus	O
neutralization	O
assay	O
was	O
performed	O
by	O
inoculating	O
24	O
-	O
to	O
-	O
25	O
-	O
day	O
-	O
old	O
turkey	O
embryos	O
via	O
the	O
amniotic	O
route	O
and	O
by	O
assessing	O
the	O
embryo	O
infectivity	O
on	O
the	O
basis	O
of	O
gross	O
intestinal	O
lesions	O
and	O
intestinal	B-PRGE
maltase	I-PRGE
activity	O
at	O
72	O
hr	O
postinoculation	O
.	O

ABSTRACT	O
:	O
A	O
582	O
-	O
base	O
pair	O
segment	O
located	O
in	O
the	O
nucleocapsid	O
protein	O
terminal	O
part	O
of	O
the	O
S1	B-PRGE
gene	I-PRGE
of	O
26	O
Arkansas	O
(	O
Ark	O
)-	O
type	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
isolates	O
from	O
Mississippi	O
broilers	O
was	O
amplified	O
and	O
sequenced	O
.	O

So	O
the	O
grouping	O
method	O
based	O
on	O
HVR	O
1	O
could	O
represent	O
the	O
grouping	O
method	O
based	O
on	O
the	O
whole	O
S1	B-PRGE
gene	I-PRGE
.	O

However	O
,	O
after	O
infectious	O
virus	O
was	O
cleared	O
,	O
twice	O
as	O
many	O
virus	O
-	O
specific	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	I-PRGE
secreting	I-PRGE
CD8	I-PRGE
+	I-PRGE
T	O
cells	O
were	O
recovered	O
from	O
the	O
brains	O
of	O
asymptomatic	O
mice	O
compared	O
with	O
mice	O
undergoing	O
demyelination	O
,	O
suggesting	O
that	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
ameliorates	O
rather	O
than	O
perpetuates	O
JHM	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
-	O
induced	O
demyelination	O
.	O

We	O
generated	O
a	O
cDNA	O
clone	O
of	O
IBV	O
E	O
and	O
antibodies	O
to	O
the	O
E	B-PRGE
protein	I-PRGE
to	O
study	O
its	O
cell	O
biological	O
properties	O
in	O
the	O
absence	O
of	O
virus	O
infection	O
.	O

The	O
IBV	B-PRGE
M	I-PRGE
protein	I-PRGE
is	O
incorporated	O
into	O
these	O
particles	O
when	O
present	O
.	O

TITLE	O
:	O
The	O
amino	O
and	O
carboxyl	O
domains	O
of	O
the	O
infectious	O
bronchitis	B-PRGE
virus	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
interact	O
with	O
3	O
'	O
genomic	O
RNA	O
.	O

Comparison	O
with	O
a	O
first	O
-	O
generation	O
adenovirus	O
carrying	O
the	O
same	O
mIFN	B-PRGE
-	I-PRGE
alpha2	I-PRGE
expression	I-PRGE
cassette	I-PRGE
indicates	O
that	O
at	O
certain	O
HD	B-PRGE
-	I-PRGE
IFN	I-PRGE
doses	O
,	O
induction	O
of	O
antiviral	O
genes	O
can	O
be	O
achieved	O
in	O
the	O
absence	O
of	O
detectable	O
circulating	O
mIFN	B-PRGE
-	I-PRGE
alpha2	I-PRGE
.	O

ABSTRACT	O
:	O
Our	O
prior	O
studies	O
showed	O
that	O
polyhydroxylated	O
styrylquinolines	O
are	O
potent	O
HIV	O
-	O
1	O
integrase	B-PRGE
(	O
IN	O
)	O
inhibitors	O
that	O
block	O
the	O
replication	O
of	O
HIV	O
-	O
1	O
in	O
cell	O
culture	O
at	O
nontoxic	O
concentrations	O
.	O

Activation	O
of	O
nuclear	B-PRGE
factor	I-PRGE
kappa	I-PRGE
B	I-PRGE
occurred	O
30	O
min	O
after	O
elastase	O
administration	O
.	O

Subgroup	O
analyses	O
shows	O
a	O
significant	O
increase	O
in	O
risk	O
of	O
PVL	O
in	O
the	O
trial	O
by	O
Wiswell	O
1996	O
[	O
RR	O
5	O
.	O
0	O
(	O
1	O
.	O
19	O
,	O
21	O
.	O
04	O
),	O
RD	O
0	O
.	O
250	O
(	O
0	O
.	O
069	O
,	O
0	O
.	O
431	O
),	O
NNH	B-PRGE
4	I-PRGE
.	O
0	O
(	O
2	O
.	O
3	O
,	O
14	O
.	O
5	O
)]	O
where	O
a	O
'	O
low	O
volume	O
strategy	O
'	O
was	O
the	O
standard	O
protocol	O
for	O
HFJV	O
.	O

The	O
RT	O
-	O
PCR	O
used	O
for	O
detecting	O
the	O
hemagglutinin	B-PRGE
gene	I-PRGE
demonstrated	O
positive	O
bands	O
in	O
all	O
frozen	O
tissues	O
and	O
cerebrospinal	O
fluid	O
taken	O
at	O
autopsy	O
and	O
not	O
in	O
samples	O
obtained	O
on	O
admission	O
.	O

These	O
results	O
indicate	O
that	O
CL	B-PRGE
antigen	I-PRGE
with	O
high	O
HA	O
titer	O
induces	O
antibody	O
production	O
in	O
cattle	O
that	O
provides	O
effective	O
protection	O
against	O
winter	O
dysentery	O
.	O

A	O
total	O
of	O
1295	O
adults	O
who	O
died	O
during	O
hospitalization	O
for	O
ARF	B-PRGE
or	O
MOSF	O
.	O

Accordingly	O
,	O
the	O
immune	O
response	O
of	O
mice	O
immunized	O
with	O
a	O
Salmonella	O
enterica	O
serovar	O
Typhimurium	O
vaccine	O
strain	O
expressing	O
the	O
Escherichia	O
coli	O
987P	O
fimbrial	O
antigen	O
on	O
its	O
surface	O
(	O
Fas	B-PRGE
(+))	O
was	O
compared	O
with	O
the	O
expression	O
in	O
the	O
periplasmic	O
compartment	O
(	O
Fas	B-PRGE
(-)).	O

Orally	O
immunized	O
BALB	O
/	O
c	O
mice	O
showed	O
that	O
987P	O
fimbriated	O
Salmonella	O
serovar	O
Typhimurium	O
CS3263	O
(	O
aroA	B-PRGE
asd	I-PRGE
)	O
with	O
pCS151	O
(	O
fas	O
(+)	O
asd	O
(+))	O
elicited	O
a	O
significantly	O
higher	O
level	O
of	O
987P	O
-	O
specific	O
systemic	O
immunoglobulin	B-PRGE
G	I-PRGE
(	O
IgG	B-PRGE
)	O
and	O
mucosal	O
IgA	B-PRGE
than	O
serovar	O
Typhimurium	O
CS3263	O
with	O
pCS152	O
(	O
fasD	B-PRGE
mutant	I-PRGE
,	O
asd	B-PRGE
(+))	O
expressing	O
987P	O
periplasmic	O
antigen	O
.	O

For	O
this	O
,	O
the	O
vaccine	O
strain	O
was	O
genetically	O
engineered	O
to	O
express	O
chimeric	O
fimbriae	O
carrying	O
the	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
C	O
(	O
379	O
-	O
388	O
)	O
and	O
A	O
(	O
521	O
-	O
531	O
)	O
epitopes	O
of	O
the	O
spike	O
protein	O
inserted	O
into	O
the	O
987P	O
major	O
fimbrial	O
subunit	O
FasA	O
.	O
BALB	O
/	O
c	O
mice	O
administered	O
orally	O
serovar	O
Typhimurium	O
chi4550	O
expressing	O
the	O
chimeric	O
fimbriae	O
from	O
the	O
tet	B-PRGE
promoter	I-PRGE
in	O
pCS154	O
(	O
fas	O
(+)	O
asd	O
(+))	O
produced	O
systemic	O
antibodies	O
against	O
both	O
fimbria	O
and	O
the	O
TGEV	O
C	O
epitope	O
but	O
not	O
against	O
the	O
TGEV	O
A	O
epitope	O
.	O

To	O
improve	O
the	O
immunogenicity	O
of	O
the	O
chimeric	O
fimbriae	O
,	O
the	O
in	O
vivo	O
inducible	O
nirB	O
promoter	O
was	O
inserted	O
into	O
pCS154	O
,	O
upstream	O
of	O
the	O
fas	B-PRGE
genes	I-PRGE
,	O
to	O
create	O
pCS155	O
.	O

Moreover	O
,	O
mucosal	O
IgA	B-PRGE
against	O
the	O
TGEV	O
C	O
epitope	O
was	O
only	O
detected	O
with	O
serovar	O
Typhimurium	O
chi4550	O
/	O
pCS155	O
.	O

CD3	B-PRGE
+,	I-PRGE
CD4	B-PRGE
+	I-PRGE
and	O
CD8	B-PRGE
+	I-PRGE
cells	O
tend	O
to	O
distribute	O
diffusely	O
,	O
perivascular	O
area	O
,	O
and	O
surrounding	O
area	O
of	O
CD4	B-PRGE
+	I-PRGE
cells	O
,	O
respectively	O
.	O

Following	O
differential	O
centrifugation	O
of	O
lysates	O
of	O
MHV	O
-	O
infected	O
DBT	O
cells	O
,	O
gene	B-PRGE
1	I-PRGE
proteins	I-PRGE
as	O
well	O
as	O
the	O
structural	O
N	O
and	O
M	O
proteins	O
were	O
detected	O
almost	O
exclusively	O
in	O
a	O
high	O
-	O
speed	O
small	O
membrane	O
pellet	O
.	O

These	O
results	O
demonstrate	O
that	O
multiple	O
gene	B-PRGE
1	I-PRGE
proteins	I-PRGE
segregate	O
into	O
two	O
biochemically	O
distinct	O
but	O
tightly	O
associated	O
membrane	O
populations	O
and	O
that	O
only	O
one	O
of	O
these	O
populations	O
appears	O
to	O
be	O
a	O
site	O
for	O
viral	O
RNA	O
synthesis	O
.	O

The	O
results	O
further	O
suggest	O
that	O
p28	B-PRGE
is	O
a	O
component	O
of	O
the	O
viral	O
replication	O
complex	O
whereas	O
the	O
gene	B-PRGE
1	I-PRGE
proteins	O
p1a	B-PRGE
-	I-PRGE
22	I-PRGE
and	O
p65	B-PRGE
may	O
serve	O
roles	O
during	O
infection	O
that	O
are	O
distinct	O
from	O
viral	O
RNA	O
transcription	O
or	O
replication	O
.	O

The	O
arousal	O
index	O
was	O
also	O
increased	O
(	O
32	O
/	O
h	O
;	O
normal	O
0	O
-	O
25	O
/	O
h	O
),	O
as	O
were	O
arousals	O
due	O
to	O
PLM	B-PRGE
.	O

TITLE	O
:	O
Localization	O
of	O
linear	O
B	O
-	O
cell	O
epitopes	O
on	O
infectious	O
bronchitis	B-PRGE
virus	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
.	O

The	O
responsiveness	O
of	O
PBLs	O
to	O
Con	B-PRGE
A	I-PRGE
at	O
2	O
DPI	O
was	O
significantly	O
reduced	O
in	O
all	O
virus	O
challenge	O
groups	O
(	O
e	O
.	O
g	O
.,	O
28	O
%	O
and	O
22	O
%	O
in	O
the	O
SRV	O
-	O
alone	O
group	O
in	O
studies	O
1	O
and	O
2	O
,	O
respectively	O
)	O
below	O
the	O
uninfected	O
group	O
.	O

TITLE	O
:	O
Role	O
of	O
gelatinases	O
MMP	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
MMP	B-PRGE
-	I-PRGE
9	I-PRGE
in	O
tissue	O
remodeling	O
following	O
acute	O
lung	O
injury	O
.	O

These	O
data	O
show	O
that	O
exposure	O
to	O
high	O
endotoxin	O
concentrations	O
in	O
swine	O
buildings	O
can	O
precipitate	O
respiratory	O
disease	O
in	O
PRCV	O
-	O
infected	O
pigs	O
,	O
and	O
that	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
is	O
probably	O
an	O
important	O
mediator	O
of	O
these	O
effects	O
.	O

Large	O
insertions	O
of	O
172	O
,	O
127	O
,	O
and	O
44	O
aa	O
were	O
detected	O
in	O
the	O
N	O
-	O
terminal	O
half	O
of	O
the	O
predicted	O
S	B-PRGE
protein	I-PRGE
of	O
SDAV	O
when	O
its	O
sequence	O
was	O
compared	O
to	O
the	O
sequences	O
of	O
MHV	O
2	O
,	O
MHV	O
JHM	O
,	O
and	O
MHV	O
A59	O
,	O
respectively	O
.	O

Infections	O
by	O
these	O
srr	B-PRGE
mutants	I-PRGE
in	O
BHK	O
-	O
R2	O
cells	O
were	O
0	O
.	O
7	O
to	O
1	O
.	O
5	O
log10	O
less	O
efficient	O
than	O
those	O
of	O
wt	O
virus	O
.	O

Previous	O
results	O
suggest	O
that	O
inducible	O
nitric	B-PRGE
oxide	I-PRGE
synthase	I-PRGE
(	O
NOS2	B-PRGE
)	O
contributes	O
transiently	O
to	O
MHV	O
-	O
induced	O
demyelination	O
.	O

Herein	O
,	O
we	O
show	O
that	O
equivalent	O
amounts	O
of	O
demyelination	O
were	O
evident	O
at	O
day	O
12	O
after	O
MHV	O
infection	O
in	O
mice	O
genetically	O
deficient	O
in	O
NOS2	B-PRGE
(	O
NOS2	B-PRGE
(-/-))	O
and	O
in	O
C57BL	O
/	O
6	O
mice	O
.	O

Furthermore	O
,	O
using	O
an	O
established	O
adoptive	O
transfer	O
model	O
and	O
pharmacological	O
inhibitors	O
of	O
NOS2	B-PRGE
function	O
,	O
we	O
could	O
demonstrate	O
no	O
effect	O
on	O
MHV	O
-	O
induced	O
demyelination	O
.	O

These	O
results	O
indicate	O
that	O
NOS2	B-PRGE
function	O
is	O
not	O
required	O
for	O
demyelination	O
in	O
mice	O
infected	O
with	O
MHV	O
.	O

A	O
reverse	O
transcription	O
(	O
RT	O
)-	O
nested	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
with	O
primers	O
targeted	O
to	O
the	O
S	B-PRGE
gene	I-PRGE
deletion	O
region	O
to	O
differentiate	O
TGEV	O
/	O
PRCV	O
was	O
developed	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
inhibition	O
of	O
TNFalpha	B-PRGE
and	I-PRGE
NO	I-PRGE
(	O
via	O
iNOS	O
)	O
production	O
as	O
well	O
as	O
the	O
increment	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
production	O
contribute	O
to	O
the	O
beneficial	O
effect	O
of	O
terbutaline	O
in	O
animals	O
with	O
endotoxic	O
shock	O
.	O

Inhibition	O
of	O
p38	B-PRGE
mitogen	O
activated	O
kinase	O
decreases	O
the	O
pulmonary	O
injury	O
through	O
attenuated	O
production	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
NO	O
suggesting	O
a	O
primary	O
role	O
for	O
these	O
mediators	O
in	O
pancreatitis	O
-	O
induced	O
ARDS	O
.	O

This	O
study	O
explores	O
the	O
effect	O
of	O
systemic	O
pancreatic	O
enzymes	O
on	O
pulmonary	B-PRGE
NF	I-PRGE
-	I-PRGE
kappaB	I-PRGE
and	O
inhibitory	B-PRGE
kappa	I-PRGE
B	I-PRGE
(	O
IkappaB	O
)	O
proteins	O
and	O
their	O
role	O
in	O
enzyme	O
-	O
induced	O
pulmonary	O
injury	O
.	O

Indicators	O
of	O
a	O
poor	O
prognosis	O
include	O
the	O
presence	O
of	O
frank	O
pus	O
,	O
a	O
positive	O
Gram	O
-	O
stain	O
,	O
a	O
pleural	O
glucose	O
concentration	O
of	O
less	O
than	O
2	O
.	O
2	O
mmol	O
/	O
L	O
,	O
a	O
pH	O
less	O
than	O
7	O
.	O
00	O
,	O
the	O
presence	O
of	O
pleural	O
loculations	O
,	O
and	O
an	O
LDH	B-PRGE
concentration	O
greater	O
than	O
three	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
in	O
serum	O
.	O

By	O
contrast	O
,	O
a	O
significant	O
number	O
of	O
CD8	B-PRGE
(+)	O
T	O
cells	O
which	O
contained	O
detectable	O
viral	O
RNA	O
were	O
recovered	O
from	O
spinal	O
cords	O
of	O
V	O
-	O
1	O
-	O
infected	O
mice	O
.	O

Pulse	O
-	O
chase	O
experiments	O
showed	O
that	O
p150	B-PRGE
is	O
rapidly	O
generated	O
in	O
MHV	O
-	O
infected	O
cells	O
and	O
that	O
p44	B-PRGE
is	O
processed	O
from	O
the	O
p150	B-PRGE
precursor	I-PRGE
.	O

The	O
viraemic	O
period	O
in	O
vaccinated	O
slaughter	O
ostriches	O
is	O
between	O
nine	O
and	O
eleven	O
days	O
and	O
there	O
are	O
no	O
indications	O
of	O
a	O
carrier	O
state	O
or	O
presence	O
of	O
the	O
virus	O
in	O
the	O
meat	O
or	O
any	O
other	O
tissues	O
after	O
this	O
period	O
,	O
with	O
peak	O
immunoglobulin	B-PRGE
G	I-PRGE
response	O
reached	O
on	O
day	O
fourteen	O
post	O
infection	O
.	O

ABSTRACT	O
:	O
The	O
contribution	O
of	O
the	O
T	B-PRGE
cell	I-PRGE
chemoattractant	I-PRGE
chemokine	I-PRGE
IFN	B-PRGE
-	O
inducible	O
protein	O
10	O
(	O
IP	O
-	O
10	O
)	O
in	O
host	O
defense	O
following	O
viral	O
infection	O
of	O
the	O
CNS	O
was	O
examined	O
.	O

Further	O
,	O
administration	O
of	O
anti	O
-	O
IP	O
-	O
10	O
led	O
to	O
a	O
>	O
70	O
%	O
reduction	O
(	O
p	O
</=	O
0	O
.	O
001	O
)	O
in	O
CD4	B-PRGE
+	I-PRGE
and	O
CD8	B-PRGE
+	I-PRGE
T	O
lymphocyte	O
infiltration	O
into	O
the	O
CNS	O
,	O
which	O
correlated	O
with	O
decreased	O
(	O
p	O
</=	O
0	O
.	O
01	O
)	O
levels	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
.	O

Sequence	O
analysis	O
of	O
the	O
S	B-PRGE
gene	I-PRGE
deletion	O
region	O
of	O
the	O
three	O
PRCV	O
isolates	O
revealed	O
identical	O
deletions	O
between	O
nt	O
105	O
-	O
752	O
,	O
which	O
differ	O
from	O
deletions	O
previously	O
reported	O
among	O
PRCV	O
strains	O
.	O

ABSTRACT	O
:	O
Together	O
with	O
the	O
evidence	O
that	O
the	O
reduced	O
virus	O
growth	O
and	O
the	O
antiviral	O
state	O
induced	O
by	O
interferon	B-PRGE
(	O
IFN	O
)-	O
gamma	O
,	O
occurring	O
only	O
in	O
macrophages	O
from	O
resistant	O
animals	O
,	O
correlated	O
with	O
the	O
decrease	O
of	O
MHV3	O
binding	O
to	O
macrophage	O
membrane	O
proteins	O
,	O
we	O
show	O
here	O
the	O
expression	O
of	O
cellular	O
and	O
viral	O
genes	O
in	O
resistant	O
(	O
A	O
/	O
J	O
)	O
and	O
susceptible	O
(	O
BALB	O
/	O
c	O
)	O
mouse	O
macrophages	O
after	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
activation	O
/	O
infection	O
.	O

APL	B-PRGE
was	O
diagnosed	O
and	O
he	O
underwent	O
treatment	O
with	O
idarubicin	O
and	O
ATRA	O
(	O
GIMEMA	O
protocol	O
);	O
24	O
hrs	O
after	O
ATRA	O
treatment	O
he	O
developed	O
retinoic	O
acid	O
syndrome	O
and	O
was	O
admitted	O
to	O
the	O
Intensive	O
Care	O
Unit	O
because	O
of	O
severe	O
respiratory	O
insufficiency	O
(	O
dyspnoea	O
,	O
tachypnea	O
and	O
severe	O
hypoxemia	O
(	O
SpO2	O
75	O
%).	O

ABSTRACT	O
:	O
Respiratory	O
tract	O
infections	O
with	O
viruses	O
and	O
Pasteurella	B-PRGE
spp	I-PRGE
.	O
were	O
determined	O
sequentially	O
among	O
26	O
cattle	O
that	O
died	O
during	O
two	O
severe	O
epizootics	O
of	O
shipping	O
fever	O
pneumonia	O
.	O

However	O
,	O
in	O
contrast	O
to	O
the	O
wild	B-PRGE
-	I-PRGE
type	I-PRGE
hnRNP	I-PRGE
A1	I-PRGE
,	O
the	O
mutant	O
protein	O
failed	O
to	O
bind	O
a	O
250	O
kDa	O
cellular	O
protein	O
,	O
suggesting	O
that	O
the	O
recruitment	O
of	O
cellular	O
proteins	O
by	O
hnRNP	O
A1	O
is	O
important	O
for	O
MHV	O
RNA	O
synthesis	O
.	O

The	O
28S	B-PRGE
rRNA	I-PRGE
cleavage	O
occurred	O
as	O
early	O
as	O
4	O
h	O
postinfection	O
(	O
p	O
.	O
i	O
.)	O
in	O
MHV	O
-	O
infected	O
DBT	O
cells	O
,	O
with	O
the	O
appearance	O
of	O
subsequent	O
cleavage	O
products	O
and	O
a	O
decrease	O
in	O
the	O
amount	O
of	O
intact	O
28S	B-PRGE
rRNA	I-PRGE
with	O
increasing	O
times	O
of	O
infection	O
;	O
almost	O
all	O
of	O
the	O
intact	O
28S	B-PRGE
rRNA	I-PRGE
disappeared	O
by	O
24	O
h	O
p	O
.	O
i	O
.	O

Thus	O
,	O
MHV	O
-	O
induced	O
28S	B-PRGE
rRNA	I-PRGE
cleavage	O
was	O
independent	O
of	O
the	O
activation	O
of	O
RNase	B-PRGE
L	I-PRGE
.	O
MHV	O
-	O
induced	O
28S	B-PRGE
rRNA	I-PRGE
cleavage	O
was	O
also	O
different	O
from	O
apoptosis	O
-	O
related	O
rRNA	O
degradation	O
,	O
which	O
usually	O
occurs	O
concomitantly	O
with	O
DNA	O
fragmentation	O
.	O

Instead	O
,	O
at	O
high	O
levels	O
of	O
expression	O
,	O
a	O
helicase	B-PRGE
mutant	I-PRGE
dominantly	O
interfered	O
with	O
the	O
function	O
of	O
the	O
wild	O
-	O
type	O
protein	O
.	O

EDI	O
RNA	O
consists	O
of	O
three	O
noncontiguous	O
parts	O
of	O
the	O
EAV	O
genome	O
fused	O
in	O
frame	O
with	O
respect	O
to	O
the	O
replicase	B-PRGE
gene	I-PRGE
.	O

TITLE	O
:	O
The	O
arterivirus	O
replicase	B-PRGE
is	O
the	O
only	O
viral	O
protein	O
required	O
for	O
genome	O
replication	O
and	O
subgenomic	O
mRNA	O
transcription	O
.	O

A	O
recombinant	O
form	O
of	O
nsp10	O
,	O
MBP	B-PRGE
-	I-PRGE
nsp10	I-PRGE
,	O
was	O
produced	O
in	O
Escherichia	O
coli	O
as	O
a	O
fusion	O
protein	O
with	O
the	O
maltose	B-PRGE
-	I-PRGE
binding	I-PRGE
protein	I-PRGE
.	O

Furthermore	O
,	O
when	O
potato	O
tubers	O
expressing	O
N	O
-	O
gS	O
were	O
fed	O
directly	O
to	O
mice	O
,	O
they	O
developed	O
serum	O
antibodies	O
specific	O
for	O
gS	B-PRGE
protein	I-PRGE
,	O
demonstrating	O
the	O
oral	O
immunogenicity	O
of	O
the	O
plant	O
derived	O
spike	O
protein	O
from	O
TGEV	O
.	O

Goat	O
anti	O
-	O
turkey	O
immunoglobulin	O
G	O
(	O
light	O
plus	O
heavy	O
chains	O
)	O
conjugated	O
with	O
horseradish	B-PRGE
peroxidase	I-PRGE
was	O
used	O
as	O
detector	O
antibody	O
.	O

ABSTRACT	O
:	O
Diagnosis	O
of	O
the	O
DE072	O
strain	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
by	O
the	O
reverse	B-PRGE
transcriptase	I-PRGE
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
serotype	O
identification	O
test	O
was	O
not	O
possible	O
because	O
the	O
primer	O
used	O
in	O
the	O
RT	O
-	O
PCR	O
did	O
not	O
amplify	O
the	O
S1	B-PRGE
gene	I-PRGE
of	O
the	O
DE072	O
strain	O
.	O

Although	O
there	O
are	O
significant	O
differences	O
among	O
species	O
in	O
the	O
basal	O
rates	O
of	O
sodium	O
and	O
fluid	O
transport	O
,	O
the	O
basic	O
mechanism	O
seems	O
to	O
depend	O
on	O
sodium	O
uptake	O
by	O
channels	O
on	O
the	O
apical	O
membrane	O
of	O
alveolar	O
type	O
II	O
cells	O
,	O
followed	O
by	O
extrusion	O
of	O
sodium	O
on	O
the	O
basolateral	O
surface	O
by	O
Na	B-PRGE
,	I-PRGE
K	I-PRGE
-	I-PRGE
ATPase	I-PRGE
.	O

The	O
expression	O
of	O
corresponding	O
FGF	B-PRGE
receptors	I-PRGE
was	O
significantly	O
increased	O
in	O
lesion	O
areas	O
during	O
the	O
initial	O
stage	O
of	O
remyelination	O
.	O

In	O
addition	O
,	O
in	O
lesion	O
areas	O
,	O
astrocytes	O
expressed	O
FGFR1	B-PRGE
,	O
FGFR2	B-PRGE
,	O
and	O
FGFR3	B-PRGE
.	O

These	O
findings	O
indicate	O
that	O
,	O
during	O
remyelination	O
,	O
FGF2	B-PRGE
may	O
play	O
a	O
role	O
in	O
directly	O
regulating	O
oligodendrocyte	O
lineage	O
cell	O
responses	O
and	O
may	O
also	O
act	O
through	O
paracrine	O
or	O
autocrine	O
effects	O
on	O
astrocytes	O
,	O
which	O
are	O
known	O
to	O
synthesize	O
other	O
growth	O
factors	O
and	O
immunoregulatory	O
molecules	O
that	O
influence	O
oligodendrocyte	O
lineage	O
cells	O
.	O

ABSTRACT	O
:	O
Pulmonary	O
capillary	O
endothelium	O
-	O
bound	O
(	O
PCEB	O
)	O
angiotensin	O
-	O
converting	O
ectoenzyme	O
(	O
ACE	B-PRGE
)	O
activity	O
alteration	O
is	O
an	O
early	O
,	O
sensitive	O
,	O
and	O
quantifiable	O
lung	O
injury	O
index	O
in	O
animal	O
models	O
.	O

However	O
,	O
the	O
recombinant	B-PRGE
BAV	I-PRGE
-	I-PRGE
3	I-PRGE
containing	I-PRGE
HE	I-PRGE
under	O
the	O
HCMV	O
IE	O
promoter	O
replicated	O
less	O
efficiently	O
than	O
the	O
wild	O
-	O
type	O
BAV	O
-	O
3	O
.	O

Cells	O
were	O
co	O
-	O
infected	O
simultaneously	O
with	O
IBV	O
,	O
the	O
recombinant	O
FPV	O
(	O
rFPV	O
)	O
containing	O
the	O
D	B-PRGE
-	I-PRGE
RNA	I-PRGE
sequence	I-PRGE
and	O
a	O
second	O
rFPV	O
expressing	O
T7	B-PRGE
RNA	I-PRGE
polymerase	I-PRGE
for	O
the	O
initial	O
expression	O
of	O
the	O
D	B-PRGE
-	I-PRGE
RNA	I-PRGE
transcript	I-PRGE
,	O
subsequently	O
rescued	O
by	O
helper	O
IBV	O
.	O

These	O
results	O
suggest	O
that	O
S2A	O
may	O
mediate	O
the	O
fusion	O
activity	O
of	O
the	O
MHV	B-PRGE
S	I-PRGE
protein	I-PRGE
during	O
virus	O
entry	O
into	O
cells	O
.	O

Using	O
previously	O
described	O
BCV	O
primers	O
,	O
the	O
N	B-PRGE
protein	I-PRGE
gene	I-PRGE
of	O
isolate	O
NC99	O
was	O
amplified	O
by	O
a	O
reverse	B-PRGE
transcriptase	I-PRGE
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
procedure	O
.	O

The	O
RT	O
-	O
PCR	O
product	O
was	O
cloned	O
into	O
pUC19	O
and	O
sequenced	O
;	O
the	O
complete	O
N	B-PRGE
protein	I-PRGE
of	O
NC99	O
(	O
446	O
amino	O
acids	O
)	O
was	O
then	O
compared	O
with	O
published	O
N	B-PRGE
protein	I-PRGE
sequences	O
of	O
other	O
avian	O
and	O
mammalian	O
coronaviruses	O
.	O

We	O
examined	O
by	O
confocal	O
microscopy	O
the	O
subcellular	O
localization	O
of	O
the	O
avian	O
infectious	O
bronchitis	O
virus	O
N	O
protein	O
both	O
in	O
the	O
absence	O
and	O
in	O
the	O
context	O
of	O
an	O
infected	O
cell	O
and	O
found	O
that	O
N	B-PRGE
protein	I-PRGE
localizes	O
both	O
to	O
the	O
cytoplasmic	O
and	O
nucleolar	O
compartments	O
.	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
shown	O
that	O
hepatic	O
cryoablation	O
(	O
cryo	O
),	O
but	O
not	O
partial	O
hepatectomy	O
,	O
induces	O
a	O
systemic	O
inflammatory	O
response	O
,	O
with	O
distant	O
organ	O
injury	O
and	O
overproduction	O
of	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
-	O
dependent	O
cytokines	O
.	O

NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
activation	O
(	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
)	O
is	O
strikingly	O
increased	O
in	O
the	O
noncryo	O
liver	O
(	O
but	O
not	O
in	O
the	O
lung	O
)	O
at	O
30	O
min	O
and	O
in	O
both	O
the	O
liver	O
and	O
lung	O
tissue	O
1	O
h	O
after	O
cryo	O
,	O
returning	O
to	O
the	O
baseline	O
by	O
2	O
h	O
and	O
beyond	O
.	O

Animals	O
underwent	O
35	O
%	O
hepatic	O
resection	O
or	O
a	O
similar	O
volume	O
hepatic	O
cryo	O
and	O
were	O
sacrificed	O
at	O
1	O
,	O
2	O
,	O
6	O
,	O
and	O
24	O
h	O
.	O
Pulmonary	O
histologic	O
features	O
were	O
assessed	O
using	O
hematoxylin	B-PRGE
and	I-PRGE
eosin	I-PRGE
and	O
immunoperoxidase	O
staining	O
with	O
a	O
macrophage	B-PRGE
-	I-PRGE
specific	I-PRGE
antibody	I-PRGE
(	O
anti	B-PRGE
-	I-PRGE
lysozyme	I-PRGE
,	O
1	O
:	O
200	O
dilution	O
,	O
Dako	O
,	O
Carpinteria	O
,	O
CA	O
).	O

Only	O
those	O
viruses	O
that	O
carried	O
the	O
S	B-PRGE
gene	I-PRGE
in	O
the	O
left	O
to	O
right	O
orientation	O
expressed	O
the	O
S	B-PRGE
gene	I-PRGE
.	O

TITLE	O
:	O
Temperature	O
-	O
sensitive	O
acetylesterase	O
activity	O
of	O
haemagglutinin	B-PRGE
-	I-PRGE
esterase	I-PRGE
specified	O
by	O
respiratory	O
bovine	O
coronaviruses	O
.	O

One	O
assay	O
used	O
p	O
-	O
nitrophenyl	O
acetate	O
(	O
PNPA	O
)	O
as	O
substrate	O
and	O
detected	O
serine	B-PRGE
-	I-PRGE
esterase	I-PRGE
activity	O
;	O
the	O
second	O
assay	O
monitored	O
AE	O
function	O
with	O
bovine	B-PRGE
submaxillary	I-PRGE
mucin	I-PRGE
(	O
BSM	B-PRGE
)	O
as	O
substrate	O
.	O

Neuraminidase	B-PRGE
treatment	O
of	O
purified	O
virions	O
resulted	O
in	O
a	O
shift	O
of	O
the	O
sedimentation	O
value	O
from	O
the	O
higher	O
to	O
the	O
lower	O
density	O
.	O

At	O
high	O
salt	O
concentrations	O
(	O
200	O
to	O
300	O
mM	O
),	O
the	O
M	B-PRGE
protein	I-PRGE
was	O
no	O
longer	O
associated	O
with	O
the	O
nucleocapsid	O
,	O
which	O
resulted	O
in	O
destruction	O
of	O
the	O
core	O
structure	O
.	O

TITLE	O
:	O
von	B-PRGE
Willebrand	I-PRGE
factor	I-PRGE
antigen	I-PRGE
as	O
a	O
prognostic	O
marker	O
in	O
posttraumatic	O
acute	O
lung	O
injury	O
.	O

To	O
determine	O
functional	O
significance	O
,	O
mouse	O
hepatitis	O
virus	O
-	O
infected	O
mice	O
were	O
treated	O
with	O
anti	B-PRGE
-	I-PRGE
Mig	I-PRGE
antisera	I-PRGE
,	O
and	O
the	O
severity	O
of	O
disease	O
was	O
evaluated	O
.	O

Viral	O
RI	B-PRGE
/	I-PRGE
TIs	I-PRGE
and	O
native	O
RF	O
/	O
TFs	O
bound	O
to	O
magnetic	O
beads	O
containing	O
oligo	O
(	O
dT	O
)(	O
25	O
),	O
suggesting	O
that	O
the	O
poly	O
(	O
A	O
)	O
sequence	O
on	O
the	O
3	O
'	O
end	O
of	O
the	O
positive	O
strands	O
was	O
longer	O
than	O
any	O
poly	O
(	O
U	O
)	O
on	O
the	O
negative	O
strands	O
.	O

Furthermore	O
,	O
no	O
possible	O
recombination	O
site	O
on	O
S1	B-PRGE
gene	I-PRGE
among	O
Massachusetts	O
41	O
,	O
Arkansas	O
99	O
,	O
and	O
JMK	O
was	O
detected	O
in	O
the	O
isolate	O
.	O

Immunohistochemistry	O
was	O
negative	O
for	O
FIP	B-PRGE
antigen	I-PRGE
.	O

ABSTRACT	O
:	O
Increased	O
levels	O
of	O
the	O
neutrophil	O
chemokine	O
interleukin	B-PRGE
(	O
IL	O
)-	O
8	O
in	O
the	O
lungs	O
of	O
severe	O
trauma	O
patients	O
can	O
predict	O
subsequent	O
development	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

TITLE	O
:	O
High	O
-	O
magnitude	O
,	O
virus	O
-	O
specific	O
CD4	B-PRGE
T	O
-	O
cell	O
response	O
in	O
the	O
central	O
nervous	O
system	O
of	O
coronavirus	O
-	O
infected	O
mice	O
.	O

Hepatitis	O
serology	O
:	O
anti	B-PRGE
-	I-PRGE
HBc	I-PRGE
,	I-PRGE
HBs	I-PRGE
-	I-PRGE
Ag	I-PRGE
and	I-PRGE
HBe	I-PRGE
-	I-PRGE
Ag	I-PRGE
positive	O
,	O
anti	B-PRGE
-	I-PRGE
HBs	I-PRGE
and	O
anti	B-PRGE
-	I-PRGE
HBe	I-PRGE
negative	O
,	O
hepatitis	O
A	O
-	O
Ab	O
(	O
IgG	B-PRGE
)	O
positive	O
,	O
hepatitis	O
A	O
-	O
Ab	O
(	O
IgM	B-PRGE
)	O
negative	O
,	O
hepatitis	O
C	O
-	O
Ab	O
negative	O
.	O

Sequence	O
analysis	O
of	O
a	O
637	O
-	O
bp	O
fragment	O
of	O
the	O
spike	O
gene	O
containing	O
most	O
of	O
the	O
aminopeptidase	B-PRGE
receptor	I-PRGE
and	O
the	O
4	O
major	O
antigenic	O
sites	O
from	O
the	O
original	O
and	O
the	O
serially	O
passed	O
viruses	O
were	O
nearly	O
identical	O
.	O

Sequence	O
analysis	O
of	O
the	O
fragment	O
from	O
the	O
passed	O
virus	O
revealed	O
that	O
the	O
sequence	O
between	O
nt	O
5310	O
and	O
nt	O
5434	O
was	O
replaced	O
by	O
a	O
636	O
-	O
bp	O
fragment	O
from	O
the	O
polymerase	B-PRGE
1A	I-PRGE
gene	I-PRGE
.	O

A	O
substantial	O
rise	O
in	O
the	O
serum	O
HAI	B-PRGE
antibody	I-PRGE
was	O
observed	O
during	O
the	O
initial	O
phase	O
among	O
the	O
sick	O
but	O
not	O
the	O
clinically	O
normal	O
cattle	O
which	O
were	O
infected	O
with	O
RBCV	O
.	O

The	O
RBCV	O
-	O
neutralizing	O
activity	O
is	O
associated	O
with	O
serum	O
immunoglobulin	B-PRGE
G	I-PRGE
(	O
IgG	B-PRGE
),	O
particularly	O
the	O
IgG2	B-PRGE
subclass	O
,	O
while	O
RBCV	B-PRGE
-	I-PRGE
specific	I-PRGE
HAI	I-PRGE
antibody	I-PRGE
is	O
related	O
to	O
both	O
serum	B-PRGE
IgG	I-PRGE
and	O
IgM	B-PRGE
fractions	O
.	O

The	O
complex	O
observed	O
in	O
gel	O
shift	O
assays	O
has	O
been	O
resolved	O
by	O
second	O
-	O
dimension	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
into	O
four	O
proteins	O
of	O
approximately	O
90	O
,	O
70	O
,	O
58	O
,	O
and	O
40	O
kDa	O
after	O
RNase	B-PRGE
treatment	O
.	O

Caesarean	O
-	O
derived	O
colostrum	O
-	O
deprived	O
piglets	O
were	O
infected	O
orally	O
with	O
the	O
TGEV	O
virulent	O
Miller	O
strain	O
and	O
IPC	O
were	O
characterized	O
in	O
situ	O
by	O
immunohistochemistry	O
,	O
using	O
a	O
rabbit	O
anti	O
-	O
pig	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
antiserum	O
.	O

Double	O
immunohistochemical	O
staining	O
for	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
leukocyte	O
markers	O
on	O
MLN	O
cryosections	O
showed	O
that	O
IPC	O
were	O
mainly	O
Swine	O
Leukocyte	O
Antigen	O
(	O
SLA	O
)	O
class	O
II	O
positive	O
,	O
and	O
were	O
not	O
stained	O
by	O
an	O
anti	B-PRGE
-	I-PRGE
macrophage	I-PRGE
(	I-PRGE
SWC3a	I-PRGE
)	I-PRGE
MAb	I-PRGE
.	O

TITLE	O
:	O
Albumin	B-PRGE
and	O
artificial	O
colloids	O
in	O
fluid	O
management	O
:	O
where	O
does	O
the	O
clinical	O
evidence	O
of	O
their	O
utility	O
stand	O
?	O

Recent	O
randomized	O
controlled	O
trial	O
results	O
indicate	O
that	O
,	O
at	O
least	O
in	O
certain	O
forms	O
of	O
fluid	O
imbalance	O
,	O
albumin	B-PRGE
is	O
effective	O
in	O
significantly	O
reducing	O
morbidity	O
and	O
mortality	O
.	O

ABSTRACT	O
:	O
Numerous	O
studies	O
have	O
shown	O
that	O
viral	O
epitopes	O
and	O
subunits	O
of	O
bacterial	B-PRGE
toxins	I-PRGE
can	O
be	O
expressed	O
and	O
correctly	O
processed	O
in	O
transgenic	O
plants	O
.	O

The	O
E	B-PRGE
protein	I-PRGE
is	O
an	O
integral	O
membrane	O
protein	O
.	O

Moreover	O
L	O
-	O
Arginine	O
,	O
the	O
precursor	O
for	O
the	O
formation	O
of	O
endogenous	O
NO	O
,	O
has	O
been	O
found	O
to	O
be	O
deficient	O
in	O
neonates	O
with	O
PPHN	B-PRGE
,	O
so	O
we	O
speculated	O
that	O
by	O
inhibiting	O
phosphodiesterase	O
and	O
administrating	O
L	O
-	O
Arginine	O
smooth	O
muscle	O
relaxation	O
occurred	O
,	O
and	O
consequent	O
weaning	O
from	O
iNO	O
was	O
achieved	O
.	O

Further	O
,	O
the	O
mechanism	O
of	O
their	O
involvement	O
in	O
the	O
lung	O
injury	O
appears	O
to	O
be	O
different	O
,	O
with	O
the	O
stromelysin	B-PRGE
1	I-PRGE
-	O
deficient	O
mice	O
having	O
a	O
reduction	O
in	O
the	O
numbers	O
of	O
neutrophils	O
recruited	O
into	O
the	O
lung	O
whereas	O
the	O
gelatinase	B-PRGE
B	I-PRGE
-	O
deficient	O
mice	O
had	O
the	O
same	O
numbers	O
of	O
lung	O
neutrophils	O
as	O
did	O
the	O
injured	O
WT	O
controls	O
.	O

Four	O
factors	O
independently	O
predicted	O
mortality	O
:	O
a	O
time	O
from	O
symptom	O
onset	O
to	O
treatment	O
of	O
more	O
than	O
1	O
month	O
(	O
OR	O
,	O
3	O
.	O
49	O
;	O
CI	O
,	O
1	O
.	O
20	O
-	O
10	O
.	O
20	O
),	O
the	O
number	O
of	O
organ	O
failures	O
(	O
OR	O
,	O
3	O
.	O
15	O
;	O
CI	O
,	O
1	O
.	O
76	O
-	O
5	O
.	O
76	O
),	O
a	O
serum	O
albumin	B-PRGE
level	O
above	O
20	O
g	O
/	O
l	O
(	O
OR	O
,	O
3	O
.	O
96	O
;	O
CI	O
,	O
1	O
.	O
04	O
-	O
15	O
.	O
10	O
),	O
and	O
a	O
larger	O
number	O
of	O
lobes	O
involved	O
on	O
chest	O
radiograph	O
(	O
OR	O
,	O
1	O
.	O
83	O
;	O
CI	O
,	O
1	O
.	O
12	O
-	O
2	O
.	O
98	O
).	O

A	O
monoclonal	O
antibody	O
-	O
based	O
blocking	O
ELISA	O
that	O
measured	O
antibody	O
levels	O
specific	O
to	O
S1	B-PRGE
glycoprotein	I-PRGE
of	O
IBV	O
correlated	O
well	O
with	O
virus	O
-	O
neutralizing	O
antibody	O
titers	O
.	O

Serologically	O
,	O
three	O
MAbs	O
directed	O
to	O
the	O
HE	B-PRGE
glycoprotein	I-PRGE
of	O
the	O
WDBCoV	O
strain	O
BCQ	O
.	O
2590	O
recognized	O
two	O
serogroups	O
amongst	O
NCDBCoV	O
strains	O
by	O
hemagglutination	O
inhibition	O
,	O
whereas	O
only	O
one	O
of	O
the	O
MAbs	O
failed	O
to	O
react	O
toward	O
three	O
of	O
the	O
four	O
RBCoV	O
isolates	O
tested	O
.	O

Analysis	O
of	O
viral	O
7a	O
/	O
7b	O
open	O
reading	O
frame	O
(	O
ORFs	O
)	O
were	O
analyzed	O
and	O
revealed	O
two	O
distinct	O
virus	O
variants	O
circulating	O
in	O
the	O
population	O
,	O
one	O
with	O
an	O
intact	B-PRGE
7a	I-PRGE
ORF	I-PRGE
and	O
one	O
with	O
two	O
major	O
deletions	O
in	O
the	O
7a	O
ORF	O
.	O

It	O
was	O
also	O
observed	O
that	O
the	O
N	B-PRGE
gene	I-PRGE
of	O
eight	O
TCV	O
isolates	O
originating	O
from	O
various	O
regions	O
of	O
the	O
USA	O
could	O
not	O
be	O
amplified	O
by	O
the	O
primers	O
designed	O
from	O
the	O
N	B-PRGE
gene	I-PRGE
of	O
bovine	O
coronavirus	O
(	O
BCV	O
).	O

Specifically	O
,	O
one	O
membrane	O
population	O
contains	O
the	O
gene	B-PRGE
1	I-PRGE
proteins	O
p65	B-PRGE
and	O
p1a	B-PRGE
-	I-PRGE
22	I-PRGE
,	O
while	O
the	O
other	O
contains	O
the	O
gene	B-PRGE
1	I-PRGE
proteins	O
p28	B-PRGE
and	O
helicase	B-PRGE
,	O
as	O
well	O
as	O
the	O
structural	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
and	O
newly	O
synthesized	O
viral	O
RNA	O
.	O

At	O
5	O
.	O
5	O
h	O
postinfection	O
(	O
p	O
.	O
i	O
.)	O
the	O
membranes	O
containing	O
N	O
and	O
helicase	O
colocalized	O
with	O
the	O
membranes	O
containing	O
p1a	B-PRGE
-	I-PRGE
22	I-PRGE
/	O
p65	B-PRGE
at	O
foci	O
distinct	O
from	O
sites	O
of	O
M	O
accumulation	O
.	O

By	O
8	O
to	O
12	O
h	O
p	O
.	O
i	O
.,	O
however	O
,	O
the	O
membranes	O
containing	O
helicase	O
and	O
N	O
had	O
a	O
predominantly	O
perinuclear	O
distribution	O
and	O
colocalized	O
with	O
M	O
.	O
In	O
contrast	O
,	O
the	O
p1a	B-PRGE
-	I-PRGE
22	I-PRGE
/	O
p65	B-PRGE
-	O
containing	O
membranes	O
retained	O
a	O
peripheral	O
,	O
punctate	O
distribution	O
at	O
all	O
times	O
of	O
infection	O
and	O
did	O
not	O
colocalize	O
with	O
M	O
.	O
By	O
late	O
times	O
of	O
infection	O
,	O
helicase	B-PRGE
,	O
N	O
,	O
and	O
M	O
each	O
also	O
colocalized	O
with	O
ERGIC	B-PRGE
p53	I-PRGE
,	O
a	O
specific	O
marker	O
for	O
the	O
endoplasmic	O
reticulum	O
-	O
Golgi	O
-	O
intermediate	O
compartment	O
.	O

These	O
results	O
suggest	O
that	O
the	O
membrane	O
populations	O
within	O
the	O
MHV	B-PRGE
replication	I-PRGE
complex	I-PRGE
serve	O
distinct	O
functions	O
both	O
in	O
RNA	O
synthesis	O
and	O
in	O
delivery	O
of	O
replication	O
products	O
to	O
sites	O
of	O
virus	O
assembly	O
.	O

Early	O
dialytic	O
treatment	O
of	O
RML	O
allows	O
not	O
only	O
to	O
avoid	O
life	O
-	O
threatening	O
complications	O
(	O
first	O
of	O
all	O
the	O
acute	O
renal	O
failure	O
)	O
but	O
moreover	O
it	O
'	O
s	O
a	O
pathogenetic	O
treatment	O
because	O
it	O
removes	O
great	O
amount	O
of	O
myoglobin	B-PRGE
from	O
the	O
plasma	O
.	O

TITLE	O
:	O
The	O
autocatalytic	O
release	O
of	O
a	O
putative	O
RNA	O
virus	O
transcription	O
factor	O
from	O
its	O
polyprotein	O
precursor	O
involves	O
two	O
paralogous	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
proteases	I-PRGE
that	O
cleave	O
the	O
same	O
peptide	O
bond	O
.	O

Based	O
upon	O
these	O
predictions	O
,	O
the	O
processing	O
of	O
the	O
human	O
coronavirus	O
229E	O
p195	B-PRGE
/	O
p210	B-PRGE
N	O
terminus	O
was	O
studied	O
in	O
detail	O
.	O

Striking	O
results	O
were	O
seen	O
with	O
a	O
mAb	O
(	O
1F8	O
)	O
reactive	O
with	O
the	O
positively	O
signaling	O
molecule	O
Ly49H	B-PRGE
,	O
present	O
in	O
MCMV	O
-	O
resistant	O
C57BL	O
/	O
6	O
mice	O
.	O

The	O
large	O
spike	B-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
glycoprotein	I-PRGE
is	O
an	O
important	O
determinant	O
of	O
species	O
specificity	O
,	O
tissue	O
tropism	O
and	O
virulence	O
of	O
coronavirus	O
infection	O
.	O

ABSTRACT	O
:	O
Cells	O
expressing	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	O
of	O
the	O
neurotropic	O
JHM	O
strain	O
(	O
JHMV	O
)	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
are	O
susceptible	O
to	O
lysis	O
by	O
B	O
cells	O
derived	O
from	O
naïve	O
mice	O
,	O
including	O
B	O
cells	O
from	O
perforin	B-PRGE
-	O
deficient	O
mice	O
.	O

ABSTRACT	O
:	O
CD8	B-PRGE
(+)	O
T	O
cells	O
are	O
required	O
to	O
control	O
acute	O
viral	O
replication	O
in	O
the	O
CNS	O
following	O
infection	O
with	O
neurotropic	O
coronavirus	O
.	O

Thus	O
,	O
in	O
addition	O
to	O
the	O
lack	O
of	O
Ab	O
,	O
limited	O
CD8	B-PRGE
(+)	I-PRGE
and	O
CD4	B-PRGE
(+)	O
T	O
cell	O
responses	O
in	O
muMT	O
mice	O
contribute	O
to	O
the	O
ultimate	O
loss	O
of	O
control	O
of	O
CNS	O
infection	O
.	O

Type	O
-	O
specific	O
primers	O
designed	O
to	O
the	O
hypervariable	O
regions	O
correctly	O
identified	O
Ad3	B-PRGE
,	O
Ad7	O
,	O
and	O
Ad21	O
prototype	O
strains	O
and	O
53	O
previously	O
typed	O
Ad	O
field	O
isolates	O
.	O

Angioedema	O
is	O
well	O
documented	O
in	O
patients	O
taking	O
ACE	B-PRGE
inhibitors	O
.	O

To	O
elucidate	O
the	O
mechanisms	O
responsible	O
for	O
the	O
many	O
biological	O
activities	O
of	O
CEACAM1	O
,	O
we	O
modified	O
the	O
expression	O
of	O
the	O
mouse	B-PRGE
Ceacam1	I-PRGE
gene	I-PRGE
in	O
vivo	O
.	O

Manipulation	O
of	O
the	O
Ceacam1	B-PRGE
gene	I-PRGE
in	O
mouse	O
embryonic	O
stem	O
cells	O
that	O
contained	O
the	O
Ceacam1a	O
allele	O
yielded	O
a	O
partial	O
knockout	O
.	O

We	O
obtained	O
one	O
line	O
of	O
mice	O
in	O
which	O
the	O
insert	O
in	O
the	O
Ceacam1a	B-PRGE
gene	I-PRGE
had	O
sustained	O
a	O
recombination	O
event	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
we	O
attempted	O
to	O
define	O
differences	O
in	O
the	O
hemagglutinin	B-PRGE
-	I-PRGE
esterase	I-PRGE
(	O
HE	O
)	O
glycoprotein	O
between	O
11	O
bovine	O
coronaviruses	O
(	O
BCV	O
)	O
recent	O
(	O
post	O
-	O
1991	O
)	O
and	O
past	O
(	O
pre	O
-	O
1991	O
)	O
isolates	O
from	O
neonatal	O
calf	O
diarrhoea	O
(	O
NCD	O
)	O
and	O
winter	O
dysentery	O
(	O
WD	O
)	O
syndromes	O
as	O
a	O
basis	O
for	O
strain	O
differentiation	O
related	O
to	O
the	O
clinical	O
source	O
of	O
the	O
isolates	O
.	O

The	O
five	O
WD	O
-	O
associated	O
BCV	O
isolates	O
studied	O
could	O
be	O
distinguished	O
from	O
past	O
NCD	O
-	O
isolates	O
by	O
their	O
hemagglutinating	O
(	O
HA	O
)	O
properties	O
at	O
4	O
degrees	O
and	O
37	O
degrees	O
C	O
,	O
their	O
receptor	O
-	O
destroying	O
enzyme	O
(	O
RDE	O
)	O
activities	O
with	O
rat	O
erythrocytes	O
and	O
lack	O
of	O
reactivity	O
of	O
these	O
NCD	O
isolates	O
to	O
four	O
HA	O
inhibiting	O
(	O
HAI	B-PRGE
)	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
directed	O
against	O
the	O
HE	B-PRGE
glycoprotein	I-PRGE
of	O
the	O
reference	O
WD	O
-	O
associated	O
BCQ	O
.	O
2590	O
Quebec	O
strain	O
.	O

The	O
present	O
study	O
demonstrated	O
that	O
DI	B-PRGE
RNA	I-PRGE
accumulation	O
from	O
the	O
expressed	O
negative	O
-	O
strand	O
DI	O
RNA	O
transcripts	O
in	O
MHV	O
-	O
infected	O
cells	O
was	O
enhanced	O
by	O
the	O
coexpression	O
of	O
complementary	O
RNA	O
transcripts	O
that	O
correspond	O
to	O
the	O
5	O
'	O
region	O
of	O
positive	O
-	O
strand	O
DI	O
RNA	O
.	O

Sequence	O
analyses	O
unexpectedly	O
demonstrated	O
that	O
the	O
leader	O
sequence	O
of	O
the	O
majority	O
of	O
accumulated	O
DI	O
RNAs	O
switched	O
to	O
helper	O
virus	O
derived	O
leader	O
sequence	O
,	O
suggesting	O
that	O
enhancement	O
of	O
DI	B-PRGE
RNA	I-PRGE
accumulation	O
was	O
mediated	O
by	O
the	O
efficient	O
utilization	O
of	O
helper	O
virus	O
derived	O
leader	O
sequence	O
for	O
DI	B-PRGE
RNA	I-PRGE
synthesis	O
.	O

This	O
feature	O
was	O
confirmed	O
to	O
be	O
the	O
nucleolus	O
by	O
using	O
specific	O
antibodies	O
to	O
nucleolin	B-PRGE
,	O
a	O
major	O
component	O
of	O
the	O
nucleolus	O
,	O
and	O
by	O
confocal	O
microscopy	O
to	O
image	O
sections	O
through	O
a	O
cell	O
expressing	O
N	B-PRGE
protein	I-PRGE
.	O

In	O
addition	O
,	O
our	O
results	O
suggest	O
that	O
the	O
N	B-PRGE
protein	I-PRGE
might	O
function	O
to	O
disrupt	O
cell	O
division	O
.	O

TITLE	O
:	O
Procalcitonin	O
versus	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
levels	O
in	O
bronchoalveolar	O
lavage	O
fluids	O
of	O
trauma	O
victims	O
with	O
severe	O
lung	O
contusion	O
.	O

TITLE	O
:	O
Complete	O
genome	O
sequence	O
of	O
transmissible	O
gastroenteritis	O
coronavirus	O
PUR46	O
-	O
MAD	B-PRGE
clone	O
and	O
evolution	O
of	O
the	O
purdue	O
virus	O
cluster	O
.	O

Nasal	O
brush	O
cells	O
were	O
stained	O
immunohistochemically	O
for	O
Langerhans	O
cells	O
,	O
T	O
cells	O
,	O
monocytes	O
,	O
neutrophils	O
,	O
B	O
cells	O
,	O
macrophages	O
,	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
,	O
mast	O
cells	O
,	O
eosinophils	O
,	O
eotaxin	O
,	O
and	O
RANTES	B-PRGE
.	O

Collectively	O
,	O
these	O
results	O
indicate	O
an	O
important	O
role	O
for	O
CCR2	B-PRGE
in	O
host	O
defense	O
and	O
disease	O
by	O
regulating	O
leukocyte	O
activation	O
and	O
trafficking	O
.	O

These	O
results	O
suggest	O
that	O
the	O
construct	O
can	O
elicit	O
both	O
humoral	O
and	O
cell	O
-	O
mediated	O
immune	O
(	O
CMI	O
)	O
responses	O
against	O
TGEV	B-PRGE
N	I-PRGE
protein	I-PRGE
in	O
mice	O
.	O

In	O
Experiment	O
3	O
,	O
the	O
IgG	B-PRGE
isotype	I-PRGE
antibody	I-PRGE
response	O
to	O
TCV	O
was	O
markedly	O
increased	O
after	O
21	O
d	O
PI	O
and	O
remained	O
high	O
until	O
63	O
d	O
PI	O
.	O

In	O
cells	O
infected	O
with	O
avian	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
three	O
proteins	O
of	O
100	O
,	O
39	O
,	O
and	O
35	O
kDa	O
,	O
respectively	O
,	O
were	O
previously	O
identified	O
as	O
mature	O
cleavage	O
products	O
released	O
from	O
the	O
1b	O
region	O
of	O
the	O
1a	O
/	O
1b	O
polyprotein	O
by	O
the	O
3C	B-PRGE
-	I-PRGE
like	I-PRGE
proteinase	I-PRGE
.	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
reported	O
the	O
cloning	O
and	O
characterisation	O
of	O
the	O
heavy	B-PRGE
and	I-PRGE
light	I-PRGE
chain	I-PRGE
variable	I-PRGE
domain	I-PRGE
genes	I-PRGE
encoding	O
three	O
monoclonal	O
antibodies	O
(	O
Mabs	O
)	O
that	O
bind	O
viral	O
haemorrhagic	O
septicaemia	O
virus	O
(	O
VHSV	O
).	O

These	O
investigations	O
,	O
together	O
with	O
computer	O
assisted	O
molecular	O
analysis	O
of	O
the	O
theoretical	O
influence	O
of	O
each	O
mutation	O
on	O
antigen	O
binding	O
,	O
led	O
to	O
the	O
identification	O
of	O
a	O
single	O
mutation	O
at	O
position	O
35a	O
in	O
the	O
VH	B-PRGE
domain	I-PRGE
as	O
having	O
the	O
most	O
marked	O
impact	O
on	O
viral	O
neutralisation	O
.	O

Virus	O
lacking	O
gene	B-PRGE
4	I-PRGE
expression	O
replicated	O
in	O
tissue	O
culture	O
cells	O
with	O
similar	O
kinetics	O
to	O
recombinant	O
virus	O
in	O
which	O
gene	B-PRGE
4	I-PRGE
expression	O
was	O
not	O
disrupted	O
.	O

The	O
introduction	O
of	O
second	O
complementary	O
mutations	O
which	O
restored	O
the	O
predicted	O
base	O
pairing	O
of	O
positions	O
142	O
to	O
136	O
with	O
68	O
to	O
74	O
and	O
nucleotides	O
96	O
to	O
99	O
with	O
116	O
to	O
113	O
largely	O
ameliorated	O
defects	O
in	O
replication	O
ability	O
,	O
restoring	O
DI	O
RNA	O
replication	O
to	O
levels	O
comparable	O
to	O
that	O
of	O
wild	B-PRGE
-	I-PRGE
type	I-PRGE
DIssE	I-PRGE
RNA	I-PRGE
,	O
suggesting	O
that	O
these	O
secondary	O
structures	O
are	O
important	O
for	O
efficient	O
MHV	O
replication	O
.	O

Two	O
-	O
thirds	O
of	O
the	O
total	O
number	O
of	O
M	B-PRGE
protein	I-PRGE
molecules	I-PRGE
found	O
in	O
the	O
virion	O
were	O
associated	O
with	O
the	O
cores	O
,	O
and	O
one	O
-	O
third	O
was	O
lost	O
during	O
core	O
purification	O
.	O

According	O
to	O
this	O
working	O
model	O
,	O
the	O
TGEV	O
virion	O
consists	O
of	O
an	O
internal	O
core	O
,	O
made	O
of	O
the	O
nucleocapsid	O
and	O
the	O
carboxy	O
terminus	O
of	O
the	O
M	B-PRGE
protein	I-PRGE
,	O
and	O
the	O
envelope	B-PRGE
,	O
containing	O
the	O
spike	O
(	O
S	O
)	O
protein	O
,	O
the	O
envelope	B-PRGE
(	I-PRGE
E	I-PRGE
)	I-PRGE
protein	I-PRGE
,	O
and	O
the	O
M	B-PRGE
protein	I-PRGE
in	O
two	O
conformations	O
.	O

We	O
have	O
previously	O
demonstrated	O
significantly	O
raised	O
interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
(	O
IL	O
-	O
8	O
)	O
levels	O
in	O
the	O
lungs	O
of	O
at	O
-	O
risk	O
patients	O
that	O
progress	O
to	O
ARDS	O
,	O
and	O
identified	O
the	O
alveolar	O
macrophage	O
as	O
an	O
important	O
source	O
of	O
this	O
chemokine	O
.	O

Hypoxia	O
increased	O
DNA	O
binding	O
activity	O
of	O
AP	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
C	B-PRGE
/	I-PRGE
EBP	I-PRGE
but	O
not	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
.	O
Hypoxia	O
induced	O
HIF	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
,	O
but	O
cobaltous	O
ions	O
and	O
desferrioxamine	O
did	O
not	O
mimic	O
hypoxic	O
IL	O
-	O
8	O
induction	O
.	O

ORF1a	O
and	O
ORF1b	O
encode	O
replicative	O
polyproteins	O
pp1a	B-PRGE
and	O
pp1ab	O
,	O
respectively	O
,	O
that	O
contain	O
all	O
of	O
the	O
putative	O
functional	O
domains	O
documented	O
previously	O
for	O
the	O
closest	O
relative	O
,	O
mouse	O
hepatitis	O
virus	O
.	O

RESULTS	O
:	O
Endotoxin	O
induced	O
a	O
severe	O
lung	O
injury	O
characterised	O
by	O
a	O
decrease	O
in	O
mean	O
systemic	O
blood	O
pressure	O
and	O
an	O
increase	O
in	O
pulmonary	O
artery	O
pressure	O
,	O
hypoxia	O
,	O
and	O
an	O
increase	O
in	O
pulmonary	O
myeloperoxidase	B-PRGE
activity	O
.	O

Ex	O
vivo	O
studies	O
showed	O
that	O
only	O
the	O
intrahepatic	O
CD8	B-PRGE
(+)	O
cells	O
that	O
were	O
increased	O
in	O
YAC	O
-	O
MHV3	O
-	O
infected	O
mice	O
could	O
be	O
stimulated	O
by	O
lectins	O
.	O

The	O
lower	O
pulmonary	O
VEGF	B-PRGE
in	O
preterm	O
infants	O
with	O
more	O
severe	O
RDS	O
may	O
contribute	O
to	O
the	O
pathophysiology	O
of	O
the	O
acute	O
lung	O
injury	O
.	O

In	O
BPD	O
,	O
the	O
expression	O
of	O
VEGF	B-PRGE
in	O
alveolar	O
epithelium	O
may	O
represent	O
a	O
compensatory	O
increase	O
after	O
the	O
acute	O
phase	O
of	O
the	O
lung	O
disease	O
.	O

We	O
investigated	O
whether	O
methylprednisolone	O
,	O
a	O
synthetic	O
glucocorticoid	O
,	O
could	O
inhibit	O
increase	O
of	O
phospholipase	B-PRGE
A	I-PRGE
(	I-PRGE
2	I-PRGE
)	I-PRGE
activity	O
in	O
the	O
lung	O
and	O
lead	O
to	O
protection	O
against	O
a	O
model	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
rabbits	O
.	O

for	O
6	O
h	O
)	O
did	O
not	O
improve	O
the	O
above	O
described	O
lung	O
injury	O
induced	O
by	O
oleic	O
acid	O
,	O
nor	O
did	O
it	O
suppress	O
phospholipase	B-PRGE
A	I-PRGE
(	O
2	O
)	O
activity	O
and	O
degradation	O
of	O
surfactant	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
,	O
while	O
it	O
strongly	O
reduced	O
interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
levels	O
in	O
both	O
plasma	O
and	O
bronchoalveolar	O
lavage	O
fluid	O
.	O

We	O
determined	O
the	O
influence	O
of	O
trauma	O
severity	O
for	O
endothelium	O
activation	O
/	O
injury	O
by	O
measurement	O
of	O
specific	O
endothelial	O
cell	O
markers	O
--	O
soluble	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
(	O
sES	B-PRGE
)	O
and	O
von	B-PRGE
Willebrand	I-PRGE
factor	I-PRGE
antigen	I-PRGE
(	O
vWF	B-PRGE
:	O
Ag	O
).	O

Significant	O
correlation	O
between	O
plasma	O
vWF	B-PRGE
:	O
Ag	O
and	O
serum	O
sES	B-PRGE
concentration	O
was	O
also	O
observed	O
(	O
Rs	O
=	O
0	O
.	O
501	O
,	O
p	O
<	O
0	O
.	O
001	O
).	O

soMHVR	O
also	O
enhanced	O
wt	O
virus	O
MHVR	B-PRGE
-	O
independent	O
fusion	O
.	O

Furthermore	O
,	O
fusion	O
of	O
BHK	O
cells	O
expressing	O
the	O
JHMV	B-PRGE
srr7	I-PRGE
S	I-PRGE
protein	I-PRGE
was	O
also	O
induced	O
by	O
soMHVR	O
.	O

Upon	O
treatment	O
with	O
brefeldin	O
A	O
,	O
both	O
the	O
E	O
and	O
CTE	O
proteins	O
redistributed	O
to	O
punctate	O
structures	O
that	O
colocalized	O
with	O
the	O
Golgi	O
matrix	O
proteins	O
GM130	B-PRGE
and	O
p115	B-PRGE
instead	O
of	O
being	O
localized	O
to	O
the	O
endoplasmic	O
reticulum	O
like	O
Golgi	O
glycosylation	O
enzymes	O
.	O

The	O
expression	O
of	O
a	O
reporter	O
gene	O
(	O
beta	B-PRGE
-	I-PRGE
glucuronidase	I-PRGE
)	O
by	O
using	O
the	O
selected	O
TRS	O
led	O
to	O
the	O
production	O
of	O
2	O
to	O
8	O
microg	O
of	O
protein	O
per	O
10	O
(	O
6	O
)	O
cells	O
.	O

Sequence	O
analysis	O
of	O
the	O
S1	B-PRGE
gene	I-PRGE
identified	O
two	O
unique	O
genotypes	O
that	O
have	O
been	O
described	O
,	O
as	O
of	O
this	O
time	O
,	O
only	O
in	O
Mexico	O
and	O
thus	O
appear	O
to	O
represent	O
strains	O
indigenous	O
to	O
the	O
country	O
.	O

These	O
primers	O
amplified	O
a	O
1082	O
-	O
base	O
pair	O
region	O
spanning	O
portions	O
of	O
the	O
membrane	O
glycoprotein	O
(	O
M	O
)	O
and	O
N	B-PRGE
protein	I-PRGE
genes	O
of	O
IBV	O
and	O
TCV	O
.	O

This	O
study	O
describes	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
anti	O
-	O
IBV	O
activity	O
of	O
natural	O
spleen	O
cell	O
-	O
derived	O
and	O
recombinant	B-PRGE
chicken	I-PRGE
interferon	I-PRGE
type	I-PRGE
I	I-PRGE
(	O
rChIFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
).	O

Both	O
natural	O
and	O
rChIFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
inhibited	O
replication	O
of	O
the	O
Beaudette	O
strain	O
of	O
IBV	O
in	O
chicken	B-PRGE
kidney	I-PRGE
cells	I-PRGE
(	O
CKC	B-PRGE
)	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
with	O
the	O
antiviral	O
activity	O
of	O
the	O
former	O
accounted	O
for	O
entirely	O
by	O
its	O
content	O
of	O
type	B-PRGE
I	I-PRGE
IFN	I-PRGE
.	O

IFN	B-PRGE
at	O
100	O
U	O
/	O
ml	O
reduced	O
viral	O
replication	O
by	O
50	O
%	O
as	O
measured	O
by	O
syncytia	O
formation	O
.	O

Altered	O
tropism	O
coincided	O
with	O
distinct	O
regulation	O
of	O
CNS	O
virus	O
-	O
specific	O
CD4	B-PRGE
+	I-PRGE
T	O
cells	O
.	O

ABSTRACT	O
:	O
A	O
1	O
-	O
step	O
RT	O
-	O
PCR	O
assay	O
,	O
targeting	O
a	O
730	O
bp	O
fragment	O
of	O
the	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
of	O
bovine	O
coronavirus	O
(	O
BCV	O
),	O
and	O
a	O
nested	O
PCR	O
assay	O
,	O
targeting	O
a	O
407	O
bp	O
fragment	O
of	O
the	O
N	B-PRGE
gene	I-PRGE
,	O
were	O
developed	O
to	O
detect	O
BCV	O
in	O
nasal	O
swab	O
and	O
fecal	O
samples	O
of	O
calves	O
experimentally	O
exposed	O
to	O
BCV	O
.	O

All	O
calves	O
developed	O
diarrhea	O
after	O
inoculation	O
and	O
BCV	B-PRGE
antigen	I-PRGE
(	O
ELISA	O
)	O
or	O
RNA	O
(	O
RT	O
-	O
PCR	O
)	O
was	O
detected	O
in	O
the	O
diarrheic	O
fecal	O
samples	O
or	O
the	O
corresponding	O
nasal	O
swab	O
samples	O
.	O

Herein	O
we	O
show	O
that	O
transfer	O
of	O
CD8	B-PRGE
T	I-PRGE
cell	O
-	O
enriched	O
splenocytes	O
from	O
MHV	B-PRGE
-	I-PRGE
immune	I-PRGE
IFN	I-PRGE
-	I-PRGE
gamma	I-PRGE
(-/-)	O
donors	O
resulted	O
in	O
a	O
substantial	O
decrease	O
in	O
demyelination	O
(	O
4	O
.	O
8	O
%	O
of	O
the	O
white	O
matter	O
of	O
the	O
spinal	O
cord	O
compared	O
with	O
26	O
.	O
3	O
%	O
in	O
those	O
receiving	O
cells	O
from	O
C57BL	O
/	O
6	O
donors	O
).	O

IgA	B-PRGE
and	O
IgG	B-PRGE
ASC	I-PRGE
responses	O
were	O
evident	O
in	O
the	O
intestinal	O
lymphoid	O
tissues	O
from	O
PID	O
21	O
,	O
the	O
highest	O
number	O
of	O
specific	O
ASC	O
corresponded	O
to	O
the	O
duodenum	O
lamina	O
propria	O
.	O

ABSTRACT	O
:	O
Formation	O
of	O
the	O
coronavirus	O
replication	O
-	O
transcription	O
complex	O
involves	O
the	O
synthesis	O
of	O
large	O
polyprotein	O
precursors	O
that	O
are	O
extensively	O
processed	O
by	O
virus	O
-	O
encoded	O
cysteine	B-PRGE
proteases	I-PRGE
.	O

These	O
data	O
lead	O
us	O
to	O
conclude	O
that	O
both	O
the	O
catalytic	O
systems	O
and	O
substrate	O
-	O
binding	O
pockets	O
of	O
coronavirus	O
main	O
proteases	O
differ	O
from	O
those	O
of	O
other	O
RNA	B-PRGE
virus	I-PRGE
3C	I-PRGE
and	I-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
proteases	I-PRGE
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
mechanisms	O
of	O
CYP1A1	B-PRGE
regulation	O
by	O
hyperoxia	O
and	O
tested	O
the	O
hypothesis	O
that	O
aryl	B-PRGE
hydrocarbon	I-PRGE
receptor	I-PRGE
(	O
AHR	B-PRGE
)-	O
dependent	O
mechanisms	O
contribute	O
to	O
induction	O
of	O
CYP1A1	B-PRGE
and	O
that	O
modulation	O
of	O
CYP1A	O
by	O
hyperoxia	O
may	O
have	O
implications	O
for	O
lung	O
injury	O
.	O

Similarly	O
,	O
hepatic	O
CYP1A1	B-PRGE
/	I-PRGE
1A2	I-PRGE
mRNAs	I-PRGE
were	O
markedly	O
induced	O
between	O
24	O
and	O
48	O
h	O
of	O
hyperoxia	O
,	O
with	O
induction	O
declining	O
by	O
60	O
h	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
and	O
experiments	O
with	O
AHR	O
(-/-)	O
mice	O
indicated	O
that	O
AHR	B-PRGE
-	O
dependent	O
mechanisms	O
contributed	O
to	O
CYP1A	O
induction	O
.	O

Thus	O
,	O
to	O
develop	O
and	O
express	O
protein	O
fragment	O
from	O
S	B-PRGE
gene	I-PRGE
and	O
to	O
use	O
the	O
protein	O
as	O
a	O
coating	O
antigen	O
for	O
antibody	O
detection	O
against	O
IBV	O
are	O
the	O
purposes	O
of	O
this	O
experiment	O
.	O

The	O
envelop	O
contains	O
2	O
or	O
3	O
glycoproteins	O
:	O
spike	O
protein	O
(	O
or	O
protein	B-PRGE
S	I-PRGE
),	I-PRGE
matrix	I-PRGE
protein	I-PRGE
(	I-PRGE
or	I-PRGE
protein	I-PRGE
M	I-PRGE
)	O
and	O
a	O
hemagglutinin	O
(	O
or	O
protein	O
HE	O
).	O

In	O
addition	O
,	O
the	O
IgA	B-PRGE
and	O
IgG	B-PRGE
ASC	I-PRGE
responses	O
detected	O
in	O
the	O
blood	O
on	O
PID	O
21	O
also	O
correlated	O
with	O
the	O
responses	O
found	O
in	O
the	O
gut	O
associated	O
lymphoid	O
tissues	O
.	O

In	O
contrast	O
,	O
chimeric	O
viruses	O
that	O
contain	O
biologically	O
active	O
and	O
functional	O
BCV	B-PRGE
HE	I-PRGE
protein	I-PRGE
on	O
the	O
surface	O
failed	O
to	O
enter	O
HRT	O
-	O
18	O
cells	O
,	O
indicating	O
that	O
the	O
BCV	B-PRGE
HE	I-PRGE
protein	I-PRGE
alone	O
is	O
not	O
sufficient	O
for	O
BCV	O
infection	O
.	O

TITLE	O
:	O
Vascular	O
immunotargeting	O
of	O
glucose	O
oxidase	B-PRGE
to	O
the	O
endothelial	O
antigens	O
induces	O
distinct	O
forms	O
of	O
oxidant	O
acute	O
lung	O
injury	O
:	O
targeting	O
to	O
thrombomodulin	B-PRGE
,	O
but	O
not	O
to	O
PECAM	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
causes	O
pulmonary	O
thrombosis	O
and	O
neutrophil	O
transmigration	O
.	O

T	O
cell	O
proliferation	O
to	O
allogeneic	O
and	O
antigenic	O
stimulation	O
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
secretion	O
in	O
response	O
to	O
antigenic	O
challenge	O
were	O
impaired	O
in	O
IP	O
-	O
10	O
(-/-)	O
mice	O
.	O

iNO	B-PRGE
at	O
0	O
.	O
8	O
,	O
1	O
.	O
6	O
,	O
and	O
3	O
.	O
2	O
micromol	O
/	O
L	O
(	O
20	O
,	O
40	O
,	O
and	O
80	O
ppm	O
)	O
resulted	O
in	O
>	O
40	O
%	O
increase	O
of	O
paO2	B-PRGE
/	O
FiO2	O
and	O
Cdyn	O
,	O
a	O
reduction	O
of	O
VD	O
/	O
VT	O
to	O
0	O
.	O
32	O
,	O
Qs	O
/	O
Qt	O
to	O
<	O
25	O
%,	O
and	O
PVRI	O
by	O
>	O
50	O
%	O
(	O
30	O
.	O
8	O
kPa	O
.	O

Optimal	O
iNO	B-PRGE
dose	O
was	O
around	O
0	O
.	O
8	O
micromol	O
/	O
L	O
as	O
higher	O
methemoglobin	B-PRGE
(	O
MetHb	O
,	O
>	O
3	O
%)	O
was	O
found	O
at	O
higher	O
NO	O
.	O

Phylogenetic	O
analysis	O
of	O
these	O
MHV	O
strains	O
along	O
with	O
those	O
reported	O
previously	O
indicated	O
that	O
sequence	O
analysis	O
of	O
the	O
N	B-PRGE
gene	I-PRGE
was	O
a	O
useful	O
tool	O
for	O
differentiation	O
of	O
MHV	O
strains	O
,	O
although	O
most	O
MHV	O
strains	O
in	O
Japanese	O
facilities	O
were	O
phylogenetically	O
close	O
.	O

The	O
molecular	O
adsorbent	O
regenerating	O
system	O
(	O
MARS	O
)	O
device	O
employs	O
a	O
polysulfone	O
high	O
-	O
permeability	O
dialyzer	O
with	O
albumin	B-PRGE
on	O
the	O
dialysate	O
side	O
to	O
aid	O
transfer	O
of	O
protein	O
-	O
bound	O
toxins	O
such	O
as	O
bilirubin	O
and	O
bile	O
acids	O
across	O
the	O
membranes	O
.	O

In	O
particular	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
sPLA	B-PRGE
(	I-PRGE
2	I-PRGE
)	I-PRGE
inhibitors	O
,	O
specifically	O
,	O
the	O
extracellular	O
PLA	O
(	O
2	O
)	O
inhibitors	O
(	O
ExPLIs	O
),	O
composed	O
of	O
N	O
-	O
derivatized	O
phosphatidyl	O
-	O
ethanolamine	O
linked	O
to	O
polymeric	O
carriers	O
,	O
and	O
LY311727	O
,	O
a	O
specific	O
inhibitor	O
of	O
non	O
-	O
pancreatic	O
sPLA	O
(	O
2	O
).	O

Mutagenesis	O
was	O
also	O
used	O
to	O
investigate	O
cleavage	O
between	O
Gly	O
-	O
904	O
and	O
Val	O
-	O
905	O
,	O
a	O
cleavage	O
site	O
predicted	O
to	O
produce	O
a	O
precursor	O
of	O
p65	B-PRGE
,	O
p72	B-PRGE
,	O
that	O
was	O
detected	O
in	O
cells	O
infected	O
with	O
MHV	O
strain	O
JHM	O
,	O
but	O
not	O
with	O
MHV	O
-	O
A59	O
.	O

As	O
his	O
clinical	O
situation	O
deteriorated	O
rapidly	O
,	O
BMT	O
was	O
performed	O
with	O
unmanipulated	O
marrow	O
stem	O
cells	O
from	O
his	O
EBV	O
-	O
positive	O
HLA	B-PRGE
-	O
identical	O
sister	O
after	O
conditioning	O
with	O
dexamethasone	O
(	O
1	O
.	O
75	O
mg	O
/	O
kg	O
/	O
day	O
),	O
cyclophosphamide	O
(	O
114	O
mg	O
/	O
kg	O
)	O
and	O
etoposide	O
(	O
10	O
mg	O
/	O
kg	O
),	O
with	O
no	O
immunosuppression	O
given	O
post	O
transplant	O
.	O

We	O
have	O
constructed	O
a	O
mutant	O
,	O
M	O
(	O
Delta	O
)	O
2	O
,	O
containing	O
a	O
two	O
-	O
amino	O
-	O
acid	O
truncation	O
of	O
the	O
M	B-PRGE
protein	I-PRGE
that	O
was	O
previously	O
thought	O
to	O
be	O
lethal	O
.	O

Pull	O
-	O
down	O
assays	O
demonstrated	O
that	O
IBV	B-PRGE
N	I-PRGE
protein	I-PRGE
interacted	O
with	O
nucleolin	B-PRGE
and	O
therefore	O
provided	O
a	O
possible	O
explanation	O
as	O
to	O
how	O
coronavirus	O
N	O
proteins	O
localize	O
to	O
the	O
nucleolus	O
.	O

Isoforms	O
of	O
murine	B-PRGE
CEACAM1	I-PRGE
serve	I-PRGE
as	O
receptors	O
for	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
a	O
murine	O
coronavirus	O
.	O

Nasopharyngeal	O
secretion	O
obtained	O
at	O
onset	O
of	O
illness	O
was	O
cultured	O
for	O
bacterial	O
pathogens	O
of	O
otitis	O
media	O
using	O
selective	O
agars	O
and	O
tested	O
for	O
rhinovirus	O
,	O
coronavirus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
influenza	O
A	O
and	O
B	O
,	O
and	O
parainfluenza	O
1	O
-	O
3	O
by	O
reverse	B-PRGE
transcriptase	I-PRGE
polymerase	I-PRGE
chain	O
reaction	O
technology	O
.	O

In	O
this	O
study	O
,	O
the	O
molecular	O
basis	O
of	O
fgl2	B-PRGE
prothrombinase	I-PRGE
activity	O
was	O
examined	O
in	O
detail	O
.	O

In	O
this	O
work	O
we	O
provide	O
direct	O
evidence	O
that	O
fgl2	B-PRGE
cleaves	O
prothrombin	B-PRGE
to	O
thrombin	B-PRGE
consistent	O
with	O
serine	B-PRGE
protease	I-PRGE
activity	O
and	O
requires	O
calcium	O
,	O
phospholipids	O
,	O
and	O
factor	O
Va	O
for	O
its	O
full	O
activity	O
.	O

TITLE	O
:	O
Congenital	O
Guillain	O
-	O
Barré	O
syndrome	O
associated	O
with	O
maternal	O
inflammatory	O
bowel	O
disease	O
is	O
responsive	O
to	O
intravenous	O
immunoglobulin	B-PRGE
.	O

The	O
upstream	O
kinase	O
responsible	O
for	O
activating	O
MHV	O
-	O
induced	O
p38	B-PRGE
MAPK	O
was	B-PRGE
the	O
MAPK	B-PRGE
kinase	I-PRGE
3	I-PRGE
.	O

(	O
ii	O
)	O
Binding	O
to	O
sialic	B-PRGE
acid	I-PRGE
residues	I-PRGE
on	I-PRGE
glycoproteins	I-PRGE
is	O
dispensable	O
for	O
the	O
infection	O
of	O
cultured	O
cells	O
but	O
is	O
required	O
for	O
enteropathogenicity	O
.	O

The	O
attachment	O
of	O
parental	O
virus	O
was	O
reduced	O
to	O
levels	O
observed	O
with	O
the	O
mutants	O
when	O
sialic	O
acid	O
containing	O
inhibitors	O
was	O
present	O
or	O
when	O
the	O
cells	O
were	O
pretreated	O
with	O
neuraminidase	B-PRGE
.	O

TITLE	O
:	O
Membrane	O
association	O
and	O
dimerization	O
of	O
a	O
cysteine	O
-	O
rich	O
,	O
16	B-PRGE
-	I-PRGE
kilodalton	I-PRGE
polypeptide	I-PRGE
released	O
from	O
the	O
C	O
-	O
terminal	O
region	O
of	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
1a	O
polyprotein	O
.	O

TITLE	O
:	O
Detection	O
of	O
rodent	O
coronaviruses	O
by	O
use	O
of	O
fluorogenic	O
reverse	B-PRGE
transcriptase	I-PRGE
-	O
polymerase	O
chain	O
reaction	O
analysis	O
.	O

These	O
included	O
a	O
massive	O
alveolar	O
protein	O
load	O
,	O
a	O
reduced	O
percentage	O
of	O
large	O
surfactant	O
aggregates	O
(	O
LA	O
),	O
a	O
loss	O
of	O
palmitoylated	O
phosphatidylcholine	O
species	O
and	O
a	O
significant	O
reduction	O
of	O
surfactant	O
apoprotein	O
(	O
SP	O
)-	O
A	O
,	O
SP	B-PRGE
-	I-PRGE
B	I-PRGE
and	O
SP	B-PRGE
-	I-PRGE
C	I-PRGE
in	O
the	O
LA	O
fraction	O
.	O

Far	O
-	O
reaching	O
or	O
even	O
complete	O
normalization	O
of	O
the	O
PL	O
profile	O
,	O
the	O
LA	O
fraction	O
and	O
its	O
SP	B-PRGE
-	I-PRGE
B	I-PRGE
and	O
SP	B-PRGE
-	I-PRGE
C	I-PRGE
(	O
but	O
not	O
SP	B-PRGE
-	I-PRGE
A	I-PRGE
)	O
content	O
as	O
well	O
as	O
the	O
fatty	O
acid	O
composition	O
of	O
the	O
phosphatidylcholine	O
class	O
was	O
noted	O
.	O

First	O
,	O
we	O
compared	O
intra	O
-	O
and	O
intermolecular	O
integrative	O
as	O
well	O
as	O
excisive	O
recombination	O
pathways	O
on	O
episomal	O
substrates	O
after	O
co	O
-	O
transfection	O
with	O
recombinase	B-PRGE
expression	O
vectors	O
.	O

Therefore	O
,	O
one	O
recombination	O
pathway	O
in	O
human	O
cells	O
involves	O
mutant	O
integrases	O
bound	O
solely	O
at	O
core	O
sites	O
,	O
which	O
is	O
reminiscent	O
of	O
the	O
Flp	B-PRGE
/	O
FRT	B-PRGE
and	O
Cre	O
/	O
loxP	O
pathways	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
low	O
level	O
integrative	O
recombination	O
by	O
wild	B-PRGE
-	I-PRGE
type	I-PRGE
integrase	I-PRGE
is	O
stimulated	O
when	O
purified	O
integration	O
host	O
factor	O
is	O
co	O
-	O
transfected	O
.	O

Escherichia	O
coli	O
isolates	O
were	O
characterized	O
on	O
the	O
basis	O
of	O
epithelial	O
cell	O
attachment	O
,	O
fluorescent	B-PRGE
actin	I-PRGE
staining	I-PRGE
(	O
FAS	B-PRGE
)	O
test	O
,	O
and	O
presence	O
of	O
E	O
.	O
coli	O
attaching	O
/	O
effacing	O
(	O
EAE	O
),	O
shigalike	O
toxin	O
(	O
SLT	O
)	O
type	O
I	O
,	O
SLT	O
II	O
,	O
and	O
bundle	O
-	O
forming	O
pilus	O
(	O
BFP	O
)	O
genes	O
by	O
polymerase	O
chain	O
reaction	O
procedures	O
.	O

The	O
remaining	O
two	O
isolates	O
,	O
N	O
-	O
M24	O
and	O
N	O
-	O
M39	O
,	O
that	O
did	O
not	O
react	O
with	O
Mass	O
-	O
specific	O
Mab	O
,	O
resisted	O
neutralization	O
by	O
Mass	O
-	O
specific	O
chicken	O
serum	O
,	O
and	O
were	O
neutralized	O
only	O
by	O
homologous	B-PRGE
chicken	I-PRGE
antibody	I-PRGE
were	O
identified	O
as	O
non	O
-	O
Mass	O
IBV	O
.	O

When	O
the	O
first	O
900	O
nucleotides	O
(	O
nt	O
)	O
from	O
the	O
5	O
'-	O
end	O
of	O
the	O
spike	B-PRGE
(	I-PRGE
S1	I-PRGE
)	I-PRGE
glycoprotein	I-PRGE
gene	I-PRGE
and	O
their	O
deduced	O
amino	O
acid	O
(	O
aa	O
)	O
sequences	O
were	O
compared	O
,	O
the	O
two	O
non	O
-	O
Mass	O
isolates	O
differed	O
from	O
each	O
other	O
by	O
24	O
%	O
and	O
28	O
%,	O
respectively	O
.	O

TITLE	O
:	O
CD4	B-PRGE
T	O
-	O
cell	O
-	O
mediated	O
demyelination	O
is	O
increased	O
in	O
the	O
absence	O
of	O
gamma	B-PRGE
interferon	I-PRGE
in	O
mice	O
infected	O
with	O
mouse	O
hepatitis	O
virus	O
.	O

TITLE	O
:	O
The	O
use	O
of	O
bovine	B-PRGE
serum	I-PRGE
protein	I-PRGE
as	O
an	O
oral	O
support	O
therapy	O
following	O
coronavirus	O
challenge	O
in	O
calves	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
elucidate	O
the	O
kinetics	O
and	O
magnitudes	O
of	O
specific	O
IgA	B-PRGE
antibody	I-PRGE
responses	O
in	O
intestines	O
of	O
turkey	O
poults	O
infected	O
with	O
turkey	O
coronavirus	O
(	O
TCV	O
).	O

The	O
results	O
indicate	O
that	O
intestinal	O
mucosal	O
IgA	B-PRGE
antibodies	I-PRGE
to	O
TCV	O
are	O
elicited	O
in	O
turkeys	O
following	O
infection	O
with	O
TCV	O
.	O

TITLE	O
:	O
Matrix	B-PRGE
metalloproteinase	I-PRGE
expression	O
correlates	O
with	O
virulence	O
following	O
neurotropic	O
mouse	O
hepatitis	O
virus	O
infection	O
.	O

Lethal	O
infection	O
induced	O
increased	O
levels	O
of	O
MMP	B-PRGE
-	I-PRGE
3	I-PRGE
and	O
MMP	B-PRGE
-	I-PRGE
12	I-PRGE
mRNAs	I-PRGE
as	O
well	O
as	O
that	O
of	O
tissue	O
inhibitor	O
of	O
matrix	O
metalloproteinases	O
1	O
(	O
TIMP	O
-	O
1	O
)	O
compared	O
to	O
sublethal	O
infection	O
.	O

Increased	O
induction	O
of	O
MMP	B-PRGE
,	O
TIMP	B-PRGE
,	O
and	O
chemokine	O
expression	O
correlated	O
with	O
increased	O
virus	O
replication	O
but	O
not	O
with	O
inflammatory	O
cell	O
infiltration	O
.	O

By	O
contrast	O
,	O
MMP	B-PRGE
-	I-PRGE
9	I-PRGE
protein	I-PRGE
activity	O
was	O
associated	O
with	O
the	O
infiltration	O
of	O
neutrophils	O
into	O
the	O
CNS	O
.	O

A	O
repeat	O
screening	O
test	O
for	O
urine	O
porphyrins	O
was	O
positive	O
,	O
and	O
AIP	O
was	O
confirmed	O
by	O
specific	O
porphobilinogen	B-PRGE
deaminase	I-PRGE
in	O
the	O
blood	O
.	O

In	O
this	O
series	O
of	O
3	O
patients	O
,	O
etanercept	O
(	O
Enbrel	O
;	O
Immunex	O
,	O
Seattle	O
,	O
WA	O
),	O
a	O
soluble	O
,	O
dimeric	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
-	I-PRGE
binding	I-PRGE
protein	I-PRGE
,	O
was	O
administered	O
to	O
3	O
consecutive	O
pediatric	O
allogeneic	O
BMT	O
recipients	O
with	O
IPS	O
.	O

We	O
hypothesized	O
that	O
alveolar	O
macrophage	O
(	O
AMPhi	O
)	O
chemokine	O
and	O
cytokine	O
release	O
after	O
hemorrhage	O
and	O
sepsis	O
is	O
regulated	O
by	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
and	O
MAPK	B-PRGE
.	O

Serum	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
levels	O
and	O
spontaneous	O
AMPhi	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
MIP	B-PRGE
-	I-PRGE
2	I-PRGE
release	O
were	O
elevated	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
after	O
HCLP	O
,	O
concomitantly	O
with	O
the	O
development	O
of	O
lung	O
edema	O
and	O
leukocyte	O
activation	O
.	O

The	O
underlying	O
pathological	O
events	O
were	O
respectively	O
pulmonary	O
tuberculosis	O
and	O
upper	O
respiratory	O
infection	O
in	O
the	O
two	O
monophasic	O
cases	O
;	O
in	O
the	O
22	O
recurrent	O
ONM	O
patients	O
:	O
pulmonary	O
tuberculosis	O
(	O
3	O
),	O
neurocysticercosis	O
(	O
1	O
),	O
polyarteritis	O
nodosa	O
(	O
1	O
),	O
antinuclear	O
antibody	O
and	O
rheumatoid	B-PRGE
factor	I-PRGE
(	I-PRGE
1	I-PRGE
),	I-PRGE
antiphospholipid	O
antibody	O
primary	O
syndrome	O
(	O
1	O
),	O
diabetes	O
mellitus	O
(	O
1	O
),	O
hypothyroidism	O
(	O
1	O
),	O
and	O
amenorrhea	O
-	O
galactorrhea	O
(	O
4	O
).	O

Major	O
variations	O
were	O
observed	O
in	O
the	O
S1	O
portion	O
of	O
the	O
S	B-PRGE
gene	I-PRGE
of	O
both	O
HEV	O
strains	O
,	O
with	O
only	O
73	O
/	O
71	O
%	O
amino	O
acid	O
identities	O
compared	O
with	O
those	O
of	O
the	O
two	O
other	O
haemagglutinating	O
coronaviruses	O
.	O

TITLE	O
:	O
Absence	O
of	O
fibroblast	B-PRGE
growth	I-PRGE
factor	I-PRGE
2	I-PRGE
promotes	O
oligodendroglial	O
repopulation	O
of	O
demyelinated	O
white	O
matter	O
.	O

To	O
directly	O
analyze	O
progenitor	O
differentiation	O
,	O
glial	O
cultures	O
from	O
spinal	O
cords	O
of	O
wild	O
-	O
type	O
mice	O
undergoing	O
remyelination	O
after	O
MHV	O
-	O
A59	O
demyelination	O
were	O
treated	O
for	O
3	O
d	O
with	O
either	O
exogenous	O
FGF2	B-PRGE
or	O
an	O
FGF2	B-PRGE
neutralizing	I-PRGE
antibody	I-PRGE
.	O

ABSTRACT	O
:	O
Ischemic	O
optic	O
neuropathy	O
is	O
a	O
rare	O
cause	O
of	O
blindness	O
reported	O
most	O
commonly	O
in	O
association	O
with	O
collagen	B-PRGE
-	O
vascular	O
diseases	O
,	O
infectious	O
processes	O
,	O
and	O
systemic	O
hypotension	O
related	O
to	O
massive	O
exsanguinating	O
hemorrhage	O
.	O

These	O
cells	O
,	O
but	O
not	O
conventional	O
CD4	B-PRGE
or	O
CD8	B-PRGE
alpha	I-PRGE
beta	I-PRGE
T	I-PRGE
cells	O
,	O
were	O
detected	O
in	O
the	O
central	O
nervous	O
system	O
of	O
MHV	O
-	O
infected	O
nude	O
mice	O
and	O
their	O
depletion	O
with	O
neutralizing	O
antibody	O
resulted	O
in	O
an	O
80	O
%	O
reduction	O
in	O
demyelination	O
.	O

Full	O
-	O
length	O
infectious	O
constructs	O
of	O
MHV	O
-	O
A59	O
will	O
permit	O
genetic	O
modifications	O
of	O
the	O
entire	O
coronavirus	O
genome	O
,	O
particularly	O
in	O
the	O
replicase	B-PRGE
gene	I-PRGE
.	O

TITLE	O
:	O
Amyloid	O
associated	O
with	O
elastin	B-PRGE
-	O
staining	O
laminar	O
aggregates	O
in	O
the	O
lungs	O
of	O
patients	O
diagnosed	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

The	O
ordered	O
nature	O
of	O
the	O
ELS	O
,	O
as	O
indicated	O
by	O
both	O
elastin	B-PRGE
and	O
amyloid	O
stains	O
,	O
together	O
with	O
little	O
morphological	O
evidence	O
of	O
inflammation	O
or	O
edema	O
,	O
suggests	O
that	O
this	O
cohort	O
of	O
ARDS	O
may	O
represent	O
another	O
form	O
of	O
conformational	O
disease	O
.	O

rTGEV	O
-	O
Delta3abDeltaE	O
reached	O
high	O
titers	O
(	O
10	O
(	O
7	O
)	O
PFU	O
/	O
ml	O
)	O
in	O
baby	O
hamster	O
kidney	O
cells	O
expressing	O
porcine	B-PRGE
aminopeptidase	I-PRGE
N	I-PRGE
(	O
BHK	O
-	O
pAPN	O
),	O
the	O
cellular	O
receptor	O
for	O
TGEV	O
,	O
using	O
Sindbis	O
replicon	O
and	O
reached	O
titers	O
up	O
to	O
5	O
x	O
10	O
(	O
5	O
)	O
PFU	O
/	O
ml	O
in	O
cells	O
stably	O
expressing	O
E	B-PRGE
protein	I-PRGE
under	O
the	O
control	O
of	O
the	O
CMV	O
promoter	O
.	O

However	O
,	O
comparative	O
sequence	O
analysis	O
of	O
the	O
S1	B-PRGE
gene	I-PRGE
revealed	O
that	O
the	O
identity	O
was	O
not	O
100	O
%	O
to	O
any	O
of	O
the	O
strains	O
of	O
this	O
serotype	O
that	O
we	O
analysed	O
.	O

Administration	O
of	O
iNO	B-PRGE
to	O
the	O
premature	O
infants	O
with	O
less	O
severe	O
pulmonary	O
illness	O
has	O
not	O
yet	O
been	O
studied	O
extensively	O
.	O

Coimmunoprecipitation	O
indicated	O
that	O
the	O
direct	O
binding	O
of	O
soMHVR	O
to	O
srr7	B-PRGE
S	I-PRGE
protein	I-PRGE
induced	O
these	O
conformational	O
changes	O
;	O
this	O
was	O
also	O
suggested	O
by	O
the	O
inhibition	O
of	O
the	O
changes	O
following	O
pretreatment	O
of	O
soMHVR	O
with	O
anti	B-PRGE
-	I-PRGE
MHVR	I-PRGE
MAb	I-PRGE
CC1	I-PRGE
.	O

ABSTRACT	O
:	O
Feline	B-PRGE
aminopeptidase	I-PRGE
N	I-PRGE
(	O
fAPN	O
)	O
has	O
been	O
shown	O
to	O
serve	O
as	O
a	O
receptor	O
for	O
feline	O
,	O
canine	O
,	O
porcine	O
and	O
human	O
coronaviruses	O
.	O

The	O
usefulness	O
of	O
genetic	O
detection	O
of	O
FCoV	O
using	O
reverse	O
transcription	O
and	O
nested	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
/	O
nPCR	B-PRGE
)	O
for	O
viral	O
screening	O
was	O
investigated	O
.	O

Caspase	B-PRGE
-	I-PRGE
8	I-PRGE
and	O
Bid	B-PRGE
activation	O
appeared	O
to	O
be	O
downstream	O
of	O
mitochondria	O
,	O
because	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
overexpression	O
suppressed	O
both	O
events	O
,	O
suggesting	O
that	O
infected	O
17Cl	O
-	O
1	O
cells	O
might	O
have	O
activated	O
a	O
receptor	O
-	O
mediated	O
""""	O
type	O
II	O
""""	O
signaling	O
pathway	O
,	O
in	O
which	O
primary	O
and	O
low	O
levels	O
of	O
receptor	O
-	O
mediated	O
pathway	O
activation	O
lead	O
to	O
the	O
activation	O
of	O
the	O
mitochondria	O
-	O
mediated	O
pathway	O
.	O

Using	O
a	O
defective	O
interfering	O
(	O
DI	O
)	O
RNA	O
-	O
like	O
cDNA	O
construct	O
derived	O
from	O
pMH54	O
,	O
690	O
nucleotides	O
representing	O
the	O
entire	O
M	B-PRGE
gene	I-PRGE
and	O
the	O
5	O
'	O
most	O
915	O
nucleotides	O
of	O
the	O
N	B-PRGE
gene	I-PRGE
of	O
the	O
mouse	O
hepatitis	O
virus	O
Albany	O
4	O
mutant	O
were	O
attempted	O
to	O
be	O
replaced	O
.	O

Further	O
analysis	O
of	O
the	O
recombinant	O
viruses	O
indicated	O
that	O
there	O
combination	O
had	O
taken	O
place	O
within	O
the	O
region	O
of	O
222	O
nucleotides	O
between	O
positions	O
916	O
and	O
1	O
,	O
137	O
of	O
the	O
N	B-PRGE
gene	I-PRGE
.	O

Post	O
hoc	O
analysis	O
of	O
data	O
from	O
children	O
enrolled	O
in	O
a	O
multicenter	O
,	O
randomized	O
,	O
masked	O
study	O
of	O
the	O
use	O
of	O
iNO	B-PRGE
in	O
the	O
treatment	O
of	O
AHRF	O
.	O

Perforin	B-PRGE
-	O
mediated	O
cytolysis	O
controls	O
virus	O
in	O
microglia	O
/	O
macrophages	O
and	O
astrocytes	O
,	O
whereas	O
interferon	B-PRGE
(	O
IFN	O
)-	O
gamma	O
regulates	O
viral	O
replication	O
in	O
oligodendroglia	O
.	O

We	O
have	O
previously	O
characterized	O
a	O
novel	O
transgenic	O
(	O
Tg	O
)	O
mouse	O
on	O
the	O
IL	B-PRGE
-	I-PRGE
2Rbeta	I-PRGE
-/-	O
genetic	O
background	O
(	O
Tg	O
-/-	O
mice	O
)	O
that	O
lacks	O
autoimmune	O
disease	O
but	O
still	O
contains	O
peripheral	O
T	O
cells	O
that	O
are	O
nonresponsive	O
to	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
15	I-PRGE
.	O

TITLE	O
:	O
Conformational	O
changes	O
in	O
the	O
spike	O
glycoprotein	O
of	O
murine	O
coronavirus	O
are	O
induced	O
at	O
37	O
degrees	O
C	O
either	O
by	O
soluble	O
murine	B-PRGE
CEACAM1	I-PRGE
receptors	I-PRGE
or	O
by	O
pH	O
8	O
.	O

ABSTRACT	O
:	O
Gill	O
-	O
associated	O
virus	O
(	O
GAV	O
),	O
a	O
positive	O
-	O
stranded	O
RNA	O
virus	O
of	O
prawns	O
,	O
is	O
the	O
prototype	O
of	O
newly	O
recognized	O
taxa	O
(	O
genus	O
Okavirus	O
,	O
family	O
Roniviridae	O
)	O
within	O
the	O
order	O
NIDOVIRALES	O
:	O
In	O
this	O
study	O
,	O
a	O
putative	O
GAV	O
cysteine	O
proteinase	O
(	O
3C	O
-	O
like	O
proteinase	O
[	O
3CL	O
(	O
pro	O
)]),	O
which	O
is	O
predicted	O
to	O
be	O
the	O
key	O
enzyme	O
involved	O
in	O
processing	O
of	O
the	O
GAV	B-PRGE
replicase	I-PRGE
polyprotein	I-PRGE
precursors	I-PRGE
,	O
pp1a	B-PRGE
and	O
pp1ab	O
,	O
was	O
characterized	O
.	O

The	O
putative	O
3CL	O
(	O
pro	O
)	O
domain	O
including	O
flanking	O
regions	O
(	O
pp1a	O
residues	O
2793	O
to	O
3143	O
)	O
was	O
fused	O
to	O
the	O
Escherichia	B-PRGE
coli	I-PRGE
maltose	I-PRGE
-	I-PRGE
binding	I-PRGE
protein	I-PRGE
(	O
MBP	B-PRGE
)	O
and	O
,	O
when	O
expressed	O
in	O
E	O
.	O
coli	O
,	O
was	O
found	O
to	O
possess	O
N	O
-	O
terminal	O
autoprocessing	O
activity	O
that	O
was	O
not	O
dependent	O
on	O
the	O
presence	O
of	O
the	O
3CL	B-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
C	I-PRGE
-	I-PRGE
terminal	I-PRGE
domain	I-PRGE
.	O

Taken	O
together	O
,	O
the	O
data	O
tentatively	O
identify	O
VxHE	O
downward	O
arrow	O
(	O
L	O
,	O
V	O
)	O
as	O
the	O
substrate	O
consensus	O
sequence	O
for	O
the	O
GAV	B-PRGE
3CL	I-PRGE
(	I-PRGE
pro	I-PRGE
).	I-PRGE

Analysis	O
of	O
the	O
proteolytic	O
activities	O
of	O
MBP	B-PRGE
-	I-PRGE
3CL	I-PRGE
(	O
pro	B-PRGE
)	O
fusion	O
proteins	O
carrying	O
replacements	O
of	O
putative	O
active	O
-	O
site	O
residues	O
provided	O
evidence	O
that	O
,	O
in	O
contrast	O
to	O
most	O
other	O
3C	B-PRGE
/	I-PRGE
3CL	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
s	I-PRGE
but	O
in	O
common	O
with	O
coronavirus	B-PRGE
3CL	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
s	I-PRGE
,	O
the	O
GAV	O
3CL	O
(	O
pro	B-PRGE
)	O
employs	O
a	O
Cys	O
(	O
2968	O
)-	O
His	O
(	O
2879	O
)	O
catalytic	O
dyad	O
.	O

TITLE	O
:	O
STAT1	B-PRGE
and	O
STAT3	B-PRGE
alpha	I-PRGE
/	I-PRGE
beta	I-PRGE
splice	O
form	O
activation	O
predicts	O
host	O
responses	O
in	O
mouse	O
hepatitis	O
virus	O
type	O
3	O
infection	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
the	O
STAT	B-PRGE
activation	O
will	O
predict	O
the	O
host	O
immune	O
response	O
to	O
viral	O
infection	O
and	O
possibly	O
a	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
viral	O
infection	O
.	O

Treatment	O
of	O
sensitive	O
Balb	O
/	O
cJ	O
mice	O
with	O
neutralizing	O
anti	B-PRGE
-	I-PRGE
TGF	I-PRGE
-	I-PRGE
beta	I-PRGE
antibody	I-PRGE
could	O
increase	O
the	O
STAT1	B-PRGE
alpha	I-PRGE
/	O
beta	O
ratio	O
to	O
<	O
1	O
.	O
0	O
in	O
spleens	O
,	O
predicting	O
enhanced	O
rates	O
of	O
survival	O
.	O

Furthermore	O
,	O
this	O
M	O
protein	O
-	O
packaging	O
signal	O
interaction	O
led	O
to	O
specific	O
packaging	O
of	O
the	O
packaging	O
signal	O
-	O
containing	O
RNA	O
transcripts	O
into	O
coronavirus	O
-	O
like	O
particles	O
in	O
the	O
absence	O
of	O
N	B-PRGE
protein	I-PRGE
.	O

ABSTRACT	O
:	O
An	O
indirect	O
liquid	O
-	O
phase	O
blocking	O
(	O
LPB	O
)	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
using	O
chicken	O
and	O
rabbit	O
affinity	O
purified	O
immunoglobulin	B-PRGE
G	I-PRGE
(	O
IgG	B-PRGE
)	O
has	O
been	O
developed	O
to	O
detect	O
and	O
estimate	O
avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
antigen	O
concentration	O
directly	O
in	O
infected	O
allantoic	O
fluid	O
.	O

The	O
immunoglobulins	O
are	O
chicken	B-PRGE
N	I-PRGE
-	I-PRGE
terminal	I-PRGE
S2	I-PRGE
peplomeric	I-PRGE
protein	I-PRGE
-	I-PRGE
specific	I-PRGE
IgG	I-PRGE
isolated	O
by	O
immunoaffinity	O
chromatography	O
on	O
synthetic	O
peptide	O
coupled	O
to	O
CNBr	O
-	O
activated	O
Sepharose	O
4B	O
or	O
rabbit	B-PRGE
polyclonal	I-PRGE
IgG	I-PRGE
purified	O
from	O
the	O
serum	O
using	O
Protein	B-PRGE
A	I-PRGE
Sepharose	I-PRGE
4B	I-PRGE
.	O

The	O
relative	O
sensitivity	O
of	O
the	O
test	O
ranged	O
between	O
10	O
(	O
5	O
)	O
and	O
10	O
(	O
6	O
)	O
median	O
egg	O
infectious	O
doses	O
(	O
EID	O
(	O
50	O
))	O
for	O
chicken	O
IgG	B-PRGE
and	O
between	O
10	O
(	O
3	O
)	O
and	O
10	O
(	O
4	O
)	O
EID	O
(	O
50	O
)	O
for	O
rabbit	B-PRGE
IgG	I-PRGE
,	O
depending	O
on	O
the	O
test	O
strain	O
.	O

It	O
does	O
not	O
require	O
expensive	O
reagents	O
and	O
can	O
be	O
readily	O
adapted	O
to	O
monitor	O
the	O
IBV	B-PRGE
antigen	I-PRGE
concentration	O
in	O
allantoic	O
fluids	O
during	O
propagation	O
of	O
vaccine	O
strains	O
or	O
in	O
samples	O
of	O
freeze	O
-	O
dried	O
,	O
live	O
-	O
attenuated	O
IBV	O
vaccines	O
.	O

ABSTRACT	O
:	O
Fibrinogen	B-PRGE
-	I-PRGE
like	I-PRGE
protein	I-PRGE
2	I-PRGE
/	O
fibroleukin	B-PRGE
(	O
Fgl2	B-PRGE
)	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
pathogenesis	O
of	O
both	O
experimental	O
and	O
human	O
fulminant	O
hepatic	O
failure	O
.	O

We	O
further	O
report	O
the	O
unprecedented	O
presence	O
of	O
HNF4alpha	B-PRGE
in	O
peritoneal	O
macrophages	O
.	O

We	O
suggest	O
that	O
PEP	B-PRGE
is	O
a	O
promising	O
candidate	O
to	O
prevent	O
hypoxemia	O
in	O
acute	O
lung	O
injuries	O
associated	O
with	O
increased	O
vascular	O
permeability	O
,	O
such	O
as	O
ARDS	O
.	O

Of	O
the	O
proinflammatory	O
cytokines	O
,	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
was	O
present	O
in	O
PF	O
but	O
not	O
in	O
plasma	O
,	O
interleukin	B-PRGE
(	O
IL	O
)-	O
1beta	O
and	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
were	O
found	O
in	O
low	O
concentrations	O
in	O
both	O
PF	O
and	O
plasma	O
,	O
and	O
IL	O
-	O
12	O
(	O
p70	B-PRGE
)	O
was	O
detectable	O
in	O
plasma	O
but	O
not	O
PF	O
.	O

The	O
ability	O
of	O
MBL	B-PRGE
to	O
activate	O
the	O
complement	O
cascade	O
was	O
tested	O
in	O
a	O
heterologous	O
system	O
by	O
deposition	O
of	O
human	O
C4	O
on	O
the	O
chicken	O
MBL	B-PRGE
/	O
MASP	B-PRGE
complex	O
.	O

We	O
found	O
that	O
nuclear	O
translocation	O
of	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
in	O
this	O
setting	O
was	O
dependent	O
on	O
the	O
activation	O
of	O
p38	B-PRGE
and	O
Akt	B-PRGE
kinases	I-PRGE
.	O

ABSTRACT	O
:	O
CD8	B-PRGE
(+)	O
T	O
cells	O
infiltrating	O
the	O
CNS	O
control	O
infection	O
by	O
the	O
neurotropic	O
JHM	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
.	O

Uncontrolled	O
infection	O
was	O
associated	O
with	O
limited	O
MHC	O
class	O
I	O
up	O
-	O
regulation	O
and	O
an	O
absence	O
of	O
class	O
II	O
expression	O
on	O
microglia	O
,	O
coinciding	O
with	O
decreased	O
CD4	B-PRGE
(+)	O
T	O
cells	O
in	O
CNS	O
infiltrates	O
.	O

TITLE	O
:	O
CC	B-PRGE
chemokine	I-PRGE
ligand	I-PRGE
3	I-PRGE
(	O
CCL3	B-PRGE
)	O
regulates	O
CD8	B-PRGE
(+)-	O
T	O
-	O
cell	O
effector	O
function	O
and	O
migration	O
following	O
viral	O
infection	O
.	O

The	O
MHV	O
replication	O
in	O
BALB	O
/	O
c	O
hepatocytes	O
with	O
or	O
without	O
the	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
gene	I-PRGE
was	O
significantly	O
higher	O
than	O
that	O
in	O
B6	O
hepatocytes	O
with	O
or	O
without	O
the	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
gene	I-PRGE
,	O
suggesting	O
that	O
there	O
is	O
a	O
strain	O
difference	O
in	O
MHV	O
replication	O
in	O
hepatocytes	O
.	O

Annexin	B-PRGE
-	I-PRGE
V	I-PRGE
staining	O
of	O
the	O
spleen	O
cells	O
demonstrated	O
that	O
the	O
cells	O
collected	O
at	O
2	O
weeks	O
p	O
.	O
i	O
.	O
were	O
undergoing	O
significantly	O
more	O
apoptosis	O
than	O
cells	O
collected	O
at	O
10	O
days	O
p	O
.	O
i	O
.	O

T	O
cell	O
subtype	O
depletion	O
demonstrated	O
that	O
CD8	B-PRGE
(+),	O
not	O
CD4	B-PRGE
(+),	O
T	O
cells	O
were	O
critical	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
we	O
examined	O
the	O
role	O
of	O
inducible	B-PRGE
nitric	I-PRGE
oxide	I-PRGE
synthase	I-PRGE
(	O
iNOS	B-PRGE
)	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
sheep	O
with	O
severe	O
combined	O
burn	O
and	O
smoke	O
inhalation	O
injury	O
.	O

ABSTRACT	O
:	O
The	O
importance	O
of	O
the	O
small	B-PRGE
envelope	I-PRGE
(	I-PRGE
E	I-PRGE
)	I-PRGE
protein	I-PRGE
in	O
the	O
assembly	O
of	O
coronaviruses	O
has	O
been	O
demonstrated	O
in	O
several	O
studies	O
.	O

We	O
have	O
now	O
been	O
able	O
to	O
obtain	O
a	O
viable	O
MHV	O
mutant	O
in	O
which	O
the	O
entire	O
E	B-PRGE
gene	I-PRGE
,	O
as	O
well	O
as	O
the	O
nonessential	O
upstream	O
genes	O
4	O
and	O
5a	O
,	O
has	O
been	O
deleted	O
.	O

Cortisol	O
supports	O
vascular	O
tone	O
and	O
endothelial	O
integrity	O
,	O
modulates	O
a	O
large	O
number	O
of	O
proinflammatory	O
cytokines	O
,	O
and	O
suppresses	O
phospholipase	B-PRGE
A	I-PRGE
(	I-PRGE
2	I-PRGE
),	I-PRGE
cyclo	O
-	O
oxygenase	O
,	O
and	O
nitric	B-PRGE
oxide	I-PRGE
synthase	I-PRGE
.	O

Establishment	O
of	O
coronavirus	O
NS2	O
-	O
specific	O
,	O
HLA	B-PRGE
-	I-PRGE
A2	I-PRGE
-	O
restricted	O
CD8	B-PRGE
(+)-	O
T	O
-	O
cell	O
clones	O
and	O
ex	O
vivo	O
analysis	O
of	O
HPV16	O
E7	O
specific	O
T	O
cells	O
obtained	O
by	O
HLA	B-PRGE
-	I-PRGE
A2	I-PRGE
tetramer	I-PRGE
-	O
guided	O
sorting	O
from	O
PBL	O
or	O
tumor	O
-	O
infiltrating	O
lymphocytes	O
obtained	O
from	O
patients	O
with	O
cervical	O
cancer	O
showed	O
that	O
cross	O
-	O
reactivity	O
with	O
HPV16	O
E7	O
(	O
11	O
-	O
19	O
(	O
20	O
))	O
and	O
coronavirus	O
NS2	O
(	O
52	O
-	O
60	O
)	O
represents	O
a	O
common	O
feature	O
of	O
this	O
antiviral	O
immune	O
response	O
defined	O
by	O
cytokine	O
production	O
.	O

Fecal	O
samples	O
collected	O
on	O
days	O
0	O
,	O
4	O
,	O
14	O
,	O
and	O
35	O
after	O
arrival	O
were	O
tested	O
for	O
BoTV	O
by	O
use	O
of	O
ELISA	O
and	O
reverse	B-PRGE
transcriptase	I-PRGE
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
.	O

TITLE	O
:	O
Recombinant	B-PRGE
M	I-PRGE
protein	I-PRGE
-	O
based	O
ELISA	O
test	O
for	O
detection	O
of	O
antibodies	O
to	O
canine	O
coronavirus	O
.	O

The	O
ELISA	O
based	O
on	O
recombinant	B-PRGE
M	I-PRGE
protein	I-PRGE
represents	O
an	O
alternative	O
and	O
valid	O
test	O
for	O
detection	O
of	O
antibodies	O
to	O
CCoV	O
in	O
dog	O
sera	O
.	O

Six	O
animals	O
were	O
treated	O
2	O
hours	O
after	O
the	O
live	O
bacteria	O
with	O
site	O
-	O
inactivated	O
Factor	B-PRGE
VIIa	I-PRGE
,	O
a	O
competitive	O
tissue	O
factor	O
inhibitor	O
,	O
and	O
six	O
animals	O
were	O
vehicle	O
-	O
treated	O
sepsis	O
control	O
subjects	O
.	O

D	O
-	O
RNAs	O
expressing	O
chIFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
were	O
shown	O
to	O
be	O
capable	O
of	O
rescue	O
,	O
replication	O
,	O
and	O
packaging	O
into	O
virions	O
in	O
a	O
helper	O
virus	O
-	O
dependent	O
system	O
following	O
electroporation	O
of	O
in	O
vitro	O
-	O
derived	O
T7	O
RNA	O
transcripts	O
into	O
IBV	O
-	O
infected	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
sequence	O
of	O
the	O
S	B-PRGE
gene	I-PRGE
of	O
a	O
field	O
canine	O
coronavirus	O
(	O
CCoV	O
),	O
strain	O
Elmo	O
/	O
02	O
,	O
revealed	O
low	O
nucleotide	O
(	O
61	O
%)	O
and	O
amino	O
acid	O
(	O
54	O
%)	O
identity	O
to	O
reference	O
CCoV	O
strains	O
.	O

0	O
.	O
06	O
mL	O
/	O
kPa	O
;	O
and	O
bleomycin	O
+	O
granulocyte	B-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
,	O
0	O
.	O
65	O
+/-	O

The	O
decreased	O
cytokine	O
production	O
was	O
associated	O
with	O
a	O
reduction	O
of	O
hydrogen	O
peroxide	O
formation	O
with	O
albumin	B-PRGE
resuscitation	O
.	O

These	O
effects	O
of	O
albumin	B-PRGE
seen	O
in	O
the	O
hemorrhagic	O
shock	O
model	O
were	O
not	O
observed	O
in	O
the	O
endotoxic	O
shock	O
model	O
.	O

Blood	O
tests	O
showed	O
lymphopenia	O
,	O
mild	O
thrombocytopenia	O
,	O
and	O
prolonged	O
activated	O
partial	O
thromboplastin	B-PRGE
time	O
with	O
normal	O
d	O
-	O
dimer	O
level	O
.	O

ABSTRACT	O
:	O
Gamma	B-PRGE
interferon	B-PRGE
-	O
deficient	O
(	O
IFN	O
-	O
gamma	O
KO	O
)	O
mice	O
developed	O
a	O
wasting	O
syndrome	O
and	O
were	O
found	O
to	O
be	O
co	O
-	O
infected	O
with	O
Helicobacter	O
sp	O
.,	O
and	O
a	O
new	O
isolate	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
designated	O
MHV	O
-	O
G	O
.	O
The	O
disease	O
was	O
characterized	O
by	O
pleuritis	O
,	O
peritonitis	O
,	O
hepatitis	O
,	O
pneumonia	O
,	O
and	O
meningitis	O
.	O

Initial	O
experiments	O
used	O
a	O
cecal	O
homogenate	O
inoculum	O
from	O
the	O
clinical	O
cases	O
that	O
contained	O
H	O
.	O
hepaticus	O
and	O
MHV	O
-	O
G	O
to	O
reproduce	O
the	O
development	O
of	O
peritonitis	O
and	O
pleuritis	O
in	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
KO	O
mice	O
.	O

The	O
binding	O
for	O
one	O
protein	O
-	O
protein	O
interaction	O
pair	O
(	O
D757	O
-	O
R761	O
motif	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
to	O
P585	O
-	O
A653	O
domain	O
of	O
CD13	O
)	O
has	O
been	O
simulated	O
by	O
molecular	O
modeling	O
and	O
docking	O
simulation	O
methods	O
.	O

CD13	B-PRGE
may	O
be	O
a	O
possible	O
receptor	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
,	O
which	O
may	O
be	O
associated	O
with	O
the	O
SARS	O
infection	O
.	O

RESULTS	O
:	O
Possible	O
binding	O
sites	O
in	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
to	O
CD13	B-PRGE
have	O
been	O
mapped	O
out	O
by	O
using	O
bioinformatics	O
analysis	O
tools	O
.	O

CONCLUSIONS	O
:	O
CD13	B-PRGE
may	O
be	O
a	O
possible	O
receptor	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
,	O
which	O
may	O
be	O
associated	O
with	O
the	O
SARS	O
infection	O
.	O

Multi	O
-	O
alignment	O
for	O
the	O
genomic	O
sequences	O
was	O
performed	O
among	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
MHV	O
,	O
BCoV	O
,	O
PEDV	O
and	O
HCoV	O
229E	O
.	O

It	O
seems	O
that	O
the	O
mutation	O
rate	O
of	O
packaging	O
signal	O
sequences	O
is	O
much	O
higher	O
than	O
the	O
N	B-PRGE
protein	I-PRGE
,	O
while	O
only	O
subtle	O
variations	O
for	O
the	O
M	B-PRGE
protein	I-PRGE
.	O

Bioinformatics	O
analyses	O
were	O
performed	O
to	O
search	O
the	O
homologous	O
proteins	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
proteinase	I-PRGE
from	O
the	O
GenBank	O
and	O
PDB	O
database	O
.	O

Targeting	O
to	O
the	O
3D	O
model	O
and	O
its	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
the	O
main	O
proteinase	O
(	O
Mpro	O
)	O
of	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
),	O
virtual	O
screening	O
was	O
performed	O
employing	O
molecular	O
docking	O
method	O
to	O
identify	O
possible	O
3CL	B-PRGE
proteinase	I-PRGE
inhibitors	O
from	O
small	O
molecular	O
databases	O
.	O

ABSTRACT	O
:	O
The	O
spike	B-PRGE
peplomer	I-PRGE
S1	I-PRGE
subunit	I-PRGE
sequence	I-PRGE
from	O
avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
Vic	O
S	O
strain	O
was	O
expressed	O
in	O
a	O
plasmid	O
under	O
the	O
control	O
of	O
the	O
fowl	O
adenovirus	O
(	O
FAV	O
)	O
major	B-PRGE
late	I-PRGE
promoter	I-PRGE
(	O
MLP	B-PRGE
).	O

Previously	O
,	O
we	O
established	O
a	O
trans	O
-	O
cleavage	O
assay	O
and	O
showed	O
that	O
PLP2	B-PRGE
cleaves	O
the	O
replicase	B-PRGE
polyprotein	I-PRGE
between	O
p210	B-PRGE
and	O
membrane	B-PRGE
protein	I-PRGE
1	I-PRGE
(	O
MP1	B-PRGE
)	O
(	O
A	O
.	O
Kanjanahaluethai	O
and	O
S	O
.	O
C	O
.	O
Baker	O
,	O
J	O
.	O
Virol	O
.	O

We	O
found	O
that	O
substitutions	O
at	O
phenylalanine	O
2835	O
,	O
glycine	O
2839	O
,	O
or	O
glycine	O
2840	O
resulted	O
in	O
a	O
reduction	O
in	O
cleavage	O
of	O
MP1	B-PRGE
.	O

No	O
adverse	O
interactions	O
were	O
observed	O
related	O
to	O
INO	B-PRGE
plus	O
surfactant	O
therapy	O
.	O

Low	O
counts	O
of	O
CD4	B-PRGE
and	O
CD8	B-PRGE
cells	O
at	O
presentation	O
were	O
associated	O
with	O
adverse	O
outcomes	O
.	O

TGEV	O
virions	O
were	O
purified	O
by	O
three	O
different	O
techniques	O
,	O
including	O
an	O
immunopurification	O
using	O
an	O
M	B-PRGE
protein	I-PRGE
-	I-PRGE
specific	I-PRGE
monoclonal	I-PRGE
antibody	I-PRGE
.	O

Corticosteroid	O
prevented	O
collagen	B-PRGE
increment	O
and	O
avoided	O
elastogenesis	O
.	O

We	O
postulate	O
that	O
hematopoietic	B-PRGE
growth	I-PRGE
factors	I-PRGE
such	O
as	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
,	O
by	O
mobilizing	O
endogenous	O
blood	O
stem	O
cells	O
and	O
endogenous	O
cytokines	O
,	O
could	O
become	O
a	O
hematological	O
treatment	O
for	O
SARS	O
patients	O
,	O
which	O
may	O
enhance	O
the	O
immune	O
system	O
against	O
these	O
virus	O
.	O

TITLE	O
:	O
[	O
Antibody	O
response	O
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
to	O
nucleocapsid	B-PRGE
antigen	I-PRGE
of	O
SARS	B-PRGE
-	O
associated	O
coronavirus	O
].	O

The	O
antibody	O
responses	O
suggest	O
that	O
N	B-PRGE
protein	I-PRGE
of	O
SARS	O
is	O
immunodominant	O
and	O
plays	O
an	O
important	O
role	O
in	O
viral	O
pathogenesis	O
.	O

The	O
IgG	B-PRGE
peaked	O
one	O
month	O
after	O
the	O
onset	O
and	O
remained	O
at	O
high	O
levels	O
in	O
the	O
following	O
2	O
months	O
.	O

Four	O
strains	O
of	O
hybridomas	O
were	O
obtained	O
that	O
produced	O
the	O
mAb	O
specific	O
to	O
the	O
N	B-PRGE
protein	I-PRGE
without	O
detectable	O
cross	O
-	O
reactivity	O
with	O
other	O
pathogens	O
.	O

RESULTS	O
:	O
Four	O
strains	O
of	O
hybridomas	O
were	O
obtained	O
that	O
produced	O
the	O
mAb	O
specific	O
to	O
the	O
N	B-PRGE
protein	I-PRGE
without	O
detectable	O
cross	O
-	O
reactivity	O
with	O
other	O
pathogens	O
.	O

The	O
laboratory	O
findings	O
in	O
SARS	O
cases	O
include	O
leukopenia	O
,	O
thrombocytopenia	O
,	O
and	O
a	O
rise	O
in	O
transaminases	O
and	O
lactic	B-PRGE
dehydrogenase	I-PRGE
levels	O
.	O

Compared	O
to	O
the	O
ssaH	O
promoter	O
,	O
the	O
Salmonella	O
cya	O
crp	O
vector	O
elicited	O
significantly	O
higher	O
levels	O
of	O
mucosal	O
and	O
systemic	O
antibodies	O
in	O
orally	O
immunized	O
mice	O
when	O
the	O
chimeric	O
fimbriae	O
were	O
expressed	O
from	O
the	O
spiC	B-PRGE
promoter	I-PRGE
.	O

Mice	O
immunized	O
orally	O
with	O
the	O
Salmonella	O
pgtE	O
vaccine	O
expressing	O
chimeric	O
fimbriae	O
from	O
the	O
spiC	B-PRGE
promoter	I-PRGE
elicited	O
significantly	O
higher	O
systemic	O
and	O
mucosal	O
antibody	O
titers	O
against	O
the	O
TGEV	O
epitopes	O
compared	O
to	O
the	O
parental	O
vaccine	O
.	O

This	O
study	O
indicates	O
that	O
the	O
Salmonella	B-PRGE
cya	I-PRGE
crp	I-PRGE
pgtE	I-PRGE
vector	O
and	O
the	O
spiC	B-PRGE
promoter	I-PRGE
can	O
be	O
used	O
successfully	O
to	O
improve	O
immune	O
responses	O
toward	O
heterologous	O
antigens	O
.	O

The	O
Chinju99	B-PRGE
S	I-PRGE
protein	I-PRGE
had	O
92	O
.	O
8	O
%	O
amino	O
acid	O
identity	O
with	O
that	O
of	O
Br1	O
/	O
87	O
and	O
CV777	O
,	O
respectively	O
.	O

Part	O
of	O
the	O
lung	O
tissue	O
specimens	O
were	O
studied	O
further	O
with	O
Macchiavello	O
'	O
s	O
stain	O
,	O
viral	O
inclusion	O
body	O
stain	O
,	O
reticulin	O
and	O
PAS	B-PRGE
stains	O
,	O
immunohistochemistry	O
,	O
thin	O
sections	O
with	O
staining	O
,	O
light	O
microscopy	O
and	O
transmission	O
electronic	O
microscope	O
investigation	O
.	O

A	O
pair	O
of	O
primers	O
and	O
a	O
probe	O
(	O
molecular	O
beacon	O
)	O
had	O
been	O
designed	O
that	O
were	O
specific	O
for	O
the	O
recognition	O
of	O
a	O
highly	O
conservative	O
region	O
between	O
15	O
301	O
and	O
15	O
480	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
related	I-PRGE
coronavirus	I-PRGE
polymerase	I-PRGE
gene	I-PRGE
sequences	O
obtained	O
from	O
GenBank	O
(	O
G130027616	O
).	O

Moreover	O
,	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
mRNA	I-PRGE
was	O
detected	O
within	O
the	O
retinas	O
of	O
infected	O
animals	O
during	O
the	O
acute	O
phase	O
of	O
the	O
disease	O
but	O
was	O
not	O
detected	O
in	O
normal	O
or	O
mock	O
-	O
injected	O
animals	O
.	O

IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
mRNA	I-PRGE
was	O
detected	O
at	O
the	O
time	O
of	O
T	O
-	O
cell	O
infiltration	O
,	O
and	O
earlier	O
studies	O
have	O
shown	O
that	O
this	O
is	O
temporally	O
related	O
to	O
granzyme	B-PRGE
B	I-PRGE
gene	I-PRGE
expression	O
and	O
the	O
clearance	O
of	O
infectious	O
virus	O
from	O
the	O
retina	O
.	O

Mice	O
and	O
chickens	O
vaccinated	O
with	O
the	O
expressed	O
IBV	B-PRGE
S1	I-PRGE
glycoprotein	I-PRGE
produced	O
antibodies	O
that	O
neutralized	O
IBV	O
infectivity	O
.	O

TITLE	O
:	O
[	O
The	O
study	O
of	O
cis	O
-	O
element	O
HNF4	B-PRGE
in	O
the	O
regulation	O
of	O
mfg12	O
prothrombinase	B-PRGE
/	O
fibroleukin	B-PRGE
gene	O
expression	O
in	O
response	O
to	O
nucleocapsid	O
protein	O
of	O
MHV	O
-	O
3	O
].	O

To	O
facilitate	O
the	O
identification	O
of	O
three	O
candidate	O
factor	O
(	O
s	O
)	O
including	O
hepatocyte	B-PRGE
nuclear	I-PRGE
factor	I-PRGE
4	I-PRGE
(	O
HNF4	B-PRGE
)/	O
liver	B-PRGE
factor	I-PRGE
A1	I-PRGE
(	O
LF	O
-	O
A1	O
),	O
cytomegalovirus	B-PRGE
immediate	I-PRGE
early	I-PRGE
gene	I-PRGE
1	I-PRGE
.	I-PRGE
2	I-PRGE
(	O
IE1	O
.	O
2	O
)	O
regulatory	O
element	O
and	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
in	O
response	O
to	O
mfgl2	O
activation	O
upon	O
the	O
stimulation	O
of	O
MHV	B-PRGE
-	I-PRGE
A59	I-PRGE
N	I-PRGE
protein	I-PRGE
,	O
gel	O
mobility	O
shift	O
assay	O
(	O
GMSA	O
),	O
competition	O
experiments	O
and	O
site	O
directed	O
mutagenesis	O
were	O
performed	O
.	O

A	O
super	O
shift	O
band	O
was	O
observed	O
when	O
HNF4	B-PRGE
antibody	I-PRGE
was	O
pre	O
-	O
incubated	O
with	O
the	O
nuclear	O
extracts	O
indicating	O
the	O
interaction	O
between	O
the	O
HNF4	B-PRGE
element	I-PRGE
and	O
mfgl2	O
promoter	O
.	O

RESULTS	O
:	O
Western	O
blotting	O
displayed	O
that	O
HNF4	B-PRGE
was	O
constitutively	O
expressed	O
in	O
macrophages	O
and	O
did	O
not	O
show	O
significant	O
change	O
under	O
the	O
stimulation	O
of	O
different	O
MHV	O
.	O

Interferon	B-PRGE
beta	I-PRGE
could	O
be	O
useful	O
alone	O
or	O
in	O
combination	O
with	O
other	O
antiviral	O
drugs	O
for	O
the	O
treatment	O
of	O
SARS	O
.	O

The	O
Kappa	O
of	O
IFA	O
and	O
ELISA	O
for	O
IgM	B-PRGE
and	O
IgG	B-PRGE
were	O
0	O
.	O
640	O
and	O
0	O
.	O
779	O
respectively	O
.	O

There	O
were	O
54	O
(	O
44	O
%)	O
patients	O
in	O
SARS	O
group	O
and	O
39	O
(	O
76	O
%)	O
patients	O
in	O
AIDS	O
group	O
showed	O
low	O
levels	O
of	O
CD4	B-PRGE
(+)	O
T	O
-	O
lymphocyte	O
(<	O
200	O
x	O
10	O
(	O
6	O
)/	O
L	O
).	O

Although	O
CTL	O
escape	O
at	O
multiple	O
epitopes	O
seems	O
intuitively	O
unlikely	O
,	O
CTL	O
escape	O
at	O
multiple	O
CD8	B-PRGE
T	I-PRGE
cell	I-PRGE
epitopes	I-PRGE
has	O
been	O
documented	O
in	O
some	O
chronically	O
infected	O
individual	O
animals	O
.	O

The	O
results	O
show	O
that	O
the	O
presence	O
of	O
a	O
host	O
response	O
to	O
this	O
second	O
epitope	O
protected	O
mice	O
against	O
CTL	O
escape	O
at	O
the	O
immunodominant	B-PRGE
JHM	I-PRGE
-	I-PRGE
specific	I-PRGE
CD8	I-PRGE
T	I-PRGE
cell	I-PRGE
epitope	I-PRGE
,	O
the	O
persistence	O
of	O
infectious	O
virus	O
,	O
and	O
the	O
development	O
of	O
clinical	O
disease	O
.	O

1	O
.	O
8	O
)	O
mmol	O
/	O
L	O
]	O
[(	O
196	O
+/-	O
70	O
)	O
mg	O
/	O
dl	O
vs	O
(	O
110	O
+/-	O
21	O
)	O
mg	O
/	O
dl	O
]	O
(	O
P	O
=	O
0	O
.	O
0002	O
),	O
and	O
the	O
abnormally	O
high	O
ALT	B-PRGE
levels	O
presented	O
in	O
some	O
of	O
the	O
patients	O
decreased	O
but	O
not	O
significantly	O
(	O
81	O
.	O
0	O
%	O
vs	O
57	O
.	O
1	O
%)	O
(	O
P	O
=	O
0	O
.	O
18	O
).	O

TITLE	O
:	O
[	O
Primary	O
investigation	O
on	O
the	O
changing	O
mode	O
of	O
plasma	O
specific	O
IgG	B-PRGE
antibody	I-PRGE
in	O
SARS	O
patients	O
and	O
their	O
physicians	O
and	O
nurses	O
].	O

The	O
specificity	O
and	O
sensitivity	O
of	O
ELISA	O
to	O
detect	O
plasma	B-PRGE
anti	I-PRGE
-	I-PRGE
SARS	I-PRGE
IgG	I-PRGE
antibody	I-PRGE
were	O
satisfactory	O
.	O

CONCLUSIONS	O
:	O
The	O
specificity	O
and	O
sensitivity	O
of	O
ELISA	O
to	O
detect	O
plasma	B-PRGE
anti	I-PRGE
-	I-PRGE
SARS	I-PRGE
IgG	I-PRGE
antibody	I-PRGE
were	O
satisfactory	O
.	O

We	O
have	O
cloned	O
,	O
expressed	O
,	O
and	O
purified	O
this	O
protein	O
as	O
an	O
N	O
-	O
terminal	O
hexahistidine	O
fusion	O
in	O
Escherichia	O
coli	O
and	O
have	O
characterized	O
its	O
helicase	B-PRGE
and	O
NTPase	B-PRGE
activities	O
.	O

All	O
eight	O
common	O
NTPs	O
and	O
dNTPs	O
were	O
hydrolyzed	O
by	O
the	O
SARS	B-PRGE
helicase	I-PRGE
in	O
a	O
magnesium	O
-	O
dependent	O
reaction	O
,	O
stimulated	O
by	O
the	O
presence	O
of	O
either	O
single	O
-	O
stranded	O
DNA	O
or	O
RNA	O
.	O

Homopolynucleotides	O
significantly	O
stimulated	O
the	O
ATPase	B-PRGE
activity	O
(	O
15	O
-	O
25	O
-	O
fold	O
)	O
with	O
the	O
notable	O
exception	O
of	O
poly	O
(	O
G	O
)	O
and	O
poly	O
(	O
dG	O
),	O
which	O
were	O
non	O
-	O
stimulatory	O
.	O

TITLE	O
:	O
Amino	O
acid	O
substitutions	O
within	O
the	O
heptad	O
repeat	O
domain	O
1	O
of	O
murine	B-PRGE
coronavirus	I-PRGE
spike	I-PRGE
protein	I-PRGE
restrict	O
viral	B-PRGE
antigen	I-PRGE
spread	O
in	O
the	O
central	O
nervous	O
system	O
.	O

RAG1	B-PRGE
(-/-)	O
recipients	O
of	O
CCR5	B-PRGE
(-/-)-	O
derived	O
CD8	B-PRGE
(+)	O
T	O
cells	O
exhibited	O
a	O
modest	O
,	O
yet	O
significant	O
(	O
P	O
</=	O
0	O
.	O
05	O
),	O
reduction	O
in	O
viral	O
burden	O
within	O
the	O
brain	O
which	O
correlated	O
with	O
increased	O
CTL	O
activity	O
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
expression	O
.	O

The	O
positive	O
rates	O
of	O
TnI	B-PRGE
,	O
CK	O
-	O
MB	O
and	O
MYO	O
in	O
patients	O
were	O
higher	O
than	O
those	O
in	O
controls	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

CONCLUSIONS	O
:	O
CVVH	O
could	O
decrease	O
the	O
mortality	O
rate	O
of	O
SAP	B-PRGE
with	O
multiple	O
organ	O
dysfunction	O
syndrome	O
.	O

Further	O
,	O
scIHF2	O
is	O
required	O
for	O
site	O
-	O
specific	O
integrative	O
recombination	O
by	O
phage	B-PRGE
lambda	I-PRGE
integrase	I-PRGE
and	O
for	O
pSC101	O
replication	O
in	O
a	O
DeltaIHF	O
E	O
.	O
coli	O
host	O
.	O

RESULTS	O
:	O
Among	O
the	O
96	O
cases	O
,	O
26	O
cases	O
(	O
27	O
%)	O
had	O
diarrhea	O
,	O
17	O
(	O
18	O
%)	O
had	O
nausea	O
,	O
6	O
(	O
6	O
%)	O
had	O
vomiting	O
,	O
16	O
(	O
17	O
%)	O
had	O
bellyache	O
,	O
and	O
8	O
(	O
8	O
%)	O
had	O
ALT	B-PRGE
elevation	O
.	O

RESULTS	O
:	O
MARS	O
therapy	O
was	O
associated	O
with	O
marked	O
reduction	O
of	O
albumin	B-PRGE
bound	O
toxins	O
and	O
water	O
soluble	O
toxins	O
,	O
together	O
with	O
a	O
significant	O
removal	O
of	O
NO	O
and	O
certain	O
cytokines	O
,	O
such	O
as	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	O
-	O
8	O
,	O
and	O
INF	B-PRGE
-	I-PRGE
gamma	I-PRGE
.	O

The	O
six	O
kinds	O
of	O
interleukins	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
levels	O
during	O
the	O
first	O
week	O
of	O
hospitalization	O
were	O
higher	O
than	O
those	O
in	O
the	O
fourth	O
week	O
and	O
in	O
control	O
groups	O
(	O
t	O
>	O
or	O
=	O
1	O
.	O
67	O
,	O
P	O
<	O
0	O
.	O
05	O
).	O

In	O
the	O
first	O
week	O
,	O
only	O
15	O
.	O
2	O
%	O
patients	O
had	O
elevated	O
serum	B-PRGE
endotoxin	I-PRGE
level	O
.	O

TITLE	O
:	O
5	B-PRGE
-	I-PRGE
lipoxygenase	I-PRGE
knockout	O
mice	O
exhibit	O
a	O
resistance	O
to	O
acute	O
pancreatitis	O
induced	O
by	O
cerulein	O
.	O

Immunohistochemical	O
examination	O
demonstrated	O
a	O
marked	O
increase	O
in	O
immunoreactivity	O
for	O
intracellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
),	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
and	O
E	B-PRGE
-	I-PRGE
selectin	I-PRGE
in	O
the	O
pancreas	O
and	O
lung	O
of	O
cerulein	O
-	O
treated	O
mice	O
.	O

The	O
transfection	O
of	O
vector	O
RNA	O
and	O
human	B-PRGE
coronavirus	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
mRNA	I-PRGE
into	O
BHK	O
-	O
21	O
cells	O
resulted	O
in	O
the	O
expression	O
of	O
the	O
CAT	B-PRGE
,	O
LUC	O
,	O
and	O
GFP	O
reporter	O
proteins	O
.	O

Aerosolisation	O
of	O
iloprost	O
(	O
in	O
total	O
0	O
.	O
7	O
microg	O
x	O
kg	O
(-	O
1	O
))	O
for	O
15	O
min	O
caused	O
a	O
more	O
sustained	O
decrease	O
in	O
Ppa	B-PRGE
,	O
some	O
enhanced	O
reduction	O
of	O
oedema	O
formation	O
as	O
compared	O
with	O
PGI2	O
and	O
a	O
decrease	O
in	O
shunt	O
flow	O
to	O
approximately	O
32	O
%.	O

Inhibition	O
of	O
HO	O
activity	O
by	O
tin	B-PRGE
-	O
mesoporphyrin	O
(	O
Sn	O
-	O
MP	O
),	O
which	O
resulted	O
in	O
a	O
sustained	O
increase	O
in	O
microsomal	O
free	O
heme	O
concentration	O
,	O
exacerbated	O
liver	O
injury	O
,	O
as	O
judged	O
by	O
the	O
sustained	O
increase	O
in	O
serum	O
ALT	B-PRGE
activity	O
,	O
extensive	O
hepatocytes	O
injuries	O
,	O
a	O
more	O
pronounced	O
expression	O
of	O
hepatic	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
mRNA	I-PRGE
and	O
an	O
enhanced	O
NF	B-PRGE
-	I-PRGE
kappa	I-PRGE
B	I-PRGE
activation	O
.	O

More	O
use	O
of	O
rapid	O
diagnostic	O
tests	O
for	O
flu	B-PRGE
may	O
help	O
,	O
but	O
don	O
'	O
t	O
depend	O
too	O
much	O
on	O
them	O
.	O

HLA	B-PRGE
-	O
class	O
I	O
and	O
II	O
allele	O
typing	O
by	O
PCR	O
-	O
SSOP	O
was	O
performed	O
on	O
37	O
cases	O
of	O
probable	O
SARS	O
,	O
28	O
fever	O
patients	O
excluded	O
later	O
as	O
probable	O
SARS	O
,	O
and	O
101	O
non	O
-	O
infected	O
health	O
care	O
workers	O
who	O
were	O
exposed	O
or	O
possibly	O
exposed	O
to	O
SARS	O
coronavirus	O
.	O

After	O
selecting	O
only	O
a	O
""""	O
severe	O
cases	O
""""	O
patient	O
group	O
from	O
the	O
infected	O
""""	O
probable	O
SARS	O
""""	O
patient	O
group	O
and	O
comparing	O
them	O
with	O
the	O
high	O
risk	O
health	O
care	O
workers	O
group	O
,	O
the	O
severity	O
of	O
SARS	B-PRGE
was	O
shown	O
to	O
be	O
significantly	O
associated	O
with	O
HLA	B-PRGE
-	O
B	O
*	O
4601	O
(	O
P	O
=	O
0	O
.	O
0008	O
or	O
Pc	O
=	O
0	O
.	O
0279	O
).	O

EBC	O
was	O
collected	O
and	O
analyzed	O
for	O
NO	O
(	O
2	O
)(-),	O
interleukin	B-PRGE
(	O
IL	O
)-	O
6	O
,	O
and	O
IL	O
-	O
8	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
a	O
100	O
-	O
kDa	O
protein	O
was	O
stably	O
detected	O
by	O
an	O
anti	B-PRGE
-	I-PRGE
Pol	I-PRGE
antiserum	I-PRGE
as	O
a	O
mature	O
product	O
throughout	O
the	O
virus	O
life	O
cycle	O
.	O

By	O
immunofluorescence	O
confocal	O
microscopy	O
,	O
Pol	B-PRGE
colocalized	O
with	O
viral	O
proteins	O
at	O
replication	O
complexes	O
,	O
distinct	O
from	O
sites	O
of	O
virion	O
assembly	O
,	O
over	O
the	O
entire	O
course	O
of	O
infection	O
.	O

These	O
proteins	O
were	O
purified	O
by	O
RNA	O
affinity	O
column	O
with	O
biotinylated	O
negative	O
-	O
strand	O
MHV	O
leader	O
RNA	O
and	O
identified	O
by	O
mass	O
spectrometry	O
to	O
be	O
hnRNP	O
A2	O
/	O
B1	O
,	O
hnRNP	B-PRGE
A	I-PRGE
/	I-PRGE
B	I-PRGE
,	O
and	O
hnRNP	B-PRGE
A3	I-PRGE
,	O
all	O
of	O
which	O
belong	O
to	O
the	O
type	B-PRGE
A	I-PRGE
/	I-PRGE
B	I-PRGE
hnRNPs	I-PRGE
.	O

Bad	B-PRGE
prognosis	I-PRGE
factors	I-PRGE
were	O
identified	O
:	O
severe	O
state	O
on	O
admission	O
,	O
shock	O
on	O
admission	O
or	O
subsequently	O
,	O
non	O
adapted	O
initial	O
antibiotherapy	O
,	O
Child	O
'	O
s	O
score	O
B	O
and	O
C	O
,	O
Streptococus	O
pneumoniae	O
,	O
complications	O
:	O
ARDS	O
,	O
superinfections	O
,	O
coagulopathy	O
,	O
multi	O
organ	O
failure	O
.	O

CD3	B-PRGE
,	O
CD4	B-PRGE
and	O
CD8	B-PRGE
in	O
20	O
patients	O
,	O
which	O
were	O
lower	O
than	O
the	O
normal	O
range	O
when	O
hospitalization	O
,	O
began	O
to	O
increase	O
3	O
days	O
later	O
and	O
gradually	O
recovered	O
to	O
the	O
normal	O
in	O
6	O
-	O
10	O
days	O
.	O

SARS	O
-	O
CoV	O
RNA	O
was	O
identified	O
by	O
reverse	B-PRGE
transcriptase	I-PRGE
-	O
polymerase	O
chain	O
reaction	O
in	O
7	O
of	O
8	O
cases	O
in	O
fresh	O
autopsy	O
tissue	O
and	O
in	O
8	O
of	O
8	O
cases	O
in	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
lung	O
tissue	O
,	O
including	O
the	O
1	O
negative	O
case	O
in	O
fresh	O
tissue	O
.	O

TITLE	O
:	O
Fas	B-PRGE
ligand	O
-	O
induced	O
murine	O
pulmonary	O
inflammation	O
is	O
reduced	O
by	O
a	O
stable	O
decoy	O
receptor	O
3	O
analogue	O
.	O

TITLE	O
:	O
Molecular	O
modelling	O
of	O
S1	O
and	O
S2	O
subunits	O
of	O
SARS	B-PRGE
coronavirus	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
.	O

The	O
crystal	O
structure	O
of	O
Clostridium	O
botulinum	O
neurotoxin	O
B	O
appeared	O
to	O
be	O
structurally	O
adaptable	O
to	O
human	O
and	O
canine	O
coronavirus	O
spike	O
protein	O
sequences	O
and	O
it	O
was	O
successfully	O
used	O
to	O
model	O
the	O
two	O
subunits	O
of	O
SARS	B-PRGE
coronavirus	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
.	O

RESULTS	O
:	O
All	O
SARS	O
patients	O
had	O
remarkably	O
increased	O
plasma	B-PRGE
IL	I-PRGE
-	I-PRGE
8	I-PRGE
concentrations	O
(	O
median	O
31	O
.	O
23	O
ng	O
/	O
L	O
)	O
at	O
the	O
onset	O
of	O
disease	O
compared	O
with	O
those	O
of	O
normal	O
controls	O
(	O
6	O
.	O
28	O
ng	O
/	O
L	O
,	O
P	O
<	O
0	O
.	O
01	O
).	O

In	O
this	O
report	O
,	O
recombinant	B-PRGE
N	I-PRGE
protein	I-PRGE
from	O
the	O
Beaudette	O
strain	O
of	O
IBV	O
was	O
produced	O
and	O
purified	O
from	O
Escherichia	O
coli	O
as	O
well	O
as	O
Sf9	O
(	O
insect	O
)	O
cells	O
,	O
and	O
used	O
for	O
the	O
coating	O
of	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
plates	O
.	O

Treatment	O
delay	O
was	O
associated	O
with	O
AST	B-PRGE
level	O
at	O
maximal	O
radiographic	O
score	O
(	O
r	O
=	O
0	O
.	O
53	O
,	O
P	O
=.	O
001	O
),	O
treatment	O
radiographic	O
score	O
(	O
r	O
=	O
0	O
.	O
60	O
,	O
P	O
<.	O
001	O
),	O
and	O
time	O
to	O
maximal	O
radiographic	O
score	O
(	O
r	O
=	O
-	O
0	O
.	O
36	O
,	O
P	O
=.	O
02	O
).	O

Therefore	O
,	O
a	O
target	O
of	O
interest	O
could	O
be	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
zinc	O
finger	O
HIV	O
-	O
1	O
RNA	O
-	O
binding	O
nucleocapsid	B-PRGE
protein	I-PRGE
p7	I-PRGE
(	O
NCp7	O
).	O

The	O
expression	O
of	O
rat	B-PRGE
NIP3L	I-PRGE
identified	O
in	O
this	O
study	O
increased	O
slightly	O
in	O
the	O
pancreas	O
after	O
induction	O
of	O
acute	O
pancreatitis	O
but	O
showed	O
a	O
marked	O
increase	O
in	O
the	O
lung	O
by	O
both	O
Northern	O
and	O
Western	O
blot	O
analysis	O
.	O

CONCLUSIONS	O
:	O
NIP3L	B-PRGE
may	O
be	O
involved	O
in	O
lung	O
injury	O
,	O
which	O
is	O
one	O
of	O
the	O
major	O
causes	O
of	O
death	O
in	O
cases	O
of	O
severe	O
acute	O
pancreatitis	O
.	O

ABSTRACT	O
:	O
To	O
obtain	O
the	O
information	O
of	O
protein	O
-	O
protein	O
interaction	O
between	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
proteins	I-PRGE
and	O
caveolin	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
identify	O
the	O
possible	O
caveolin	B-PRGE
-	I-PRGE
binding	I-PRGE
sites	I-PRGE
in	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
proteins	I-PRGE
.	O

The	O
enterotropism	O
of	O
TGEV	O
is	O
connected	O
with	O
the	O
sialic	O
acid	O
binding	O
activity	O
of	O
the	O
viral	O
surface	O
protein	O
S	O
.	O
Here	O
we	O
show	O
that	O
,	O
among	O
porcine	O
intestinal	O
brush	O
border	O
membrane	O
proteins	O
,	O
TGEV	O
recognizes	O
a	O
mucin	B-PRGE
-	I-PRGE
type	I-PRGE
glycoprotein	I-PRGE
designated	O
MGP	B-PRGE
in	O
a	O
sialic	O
acid	O
-	O
dependent	O
fashion	O
.	O

A	O
nonenteropathogenic	O
mutant	O
virus	O
that	O
lacked	O
a	O
sialic	O
acid	O
binding	O
activity	O
was	O
unable	O
to	O
bind	O
to	O
MGP	B-PRGE
and	O
to	O
attach	O
to	O
goblet	O
cells	O
.	O

In	O
order	O
to	O
understand	O
the	O
active	O
form	O
and	O
the	O
substrate	O
specificity	O
of	O
the	O
enzyme	O
,	O
we	O
have	O
cloned	O
,	O
expressed	O
,	O
and	O
purified	O
SARS	B-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
proteinase	I-PRGE
.	O

ABSTRACT	O
:	O
In	O
this	O
report	O
,	O
we	O
describe	O
a	O
real	O
-	O
time	O
reverse	B-PRGE
transcriptase	I-PRGE
-	O
polymerase	O
chain	O
reaction	O
(	O
RRT	O
-	O
PCR	O
)	O
diagnostic	O
test	O
for	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
with	O
the	O
use	O
of	O
fluorescence	O
resonance	O
energy	O
transfer	O
(	O
FRET	O
)	O
technology	O
.	O

Within	O
a	O
few	O
weeks	O
,	O
the	O
coronavirus	O
associated	O
with	O
SARS	B-PRGE
(	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
)	O
was	O
identified	O
and	O
sequenced	O
.	O

There	O
was	O
no	O
significant	O
correlation	O
between	O
the	O
titers	O
of	O
IgG	B-PRGE
/	O
IgM	B-PRGE
and	O
sex	O
,	O
age	O
,	O
course	O
of	O
diseases	O
and	O
duration	O
of	O
body	O
temperature	O
recovery	O
.	O

It	O
was	O
concluded	O
that	O
not	O
all	O
SARS	O
patients	O
could	O
produce	O
the	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
coronavirus	I-PRGE
specific	I-PRGE
antibody	I-PRGE
.	O

In	O
this	O
report	O
we	O
present	O
results	O
of	O
comparative	O
sequence	O
analysis	O
of	O
the	O
spike	O
(	O
S	O
),	O
envelope	B-PRGE
(	O
E	O
),	O
membrane	O
(	O
M	O
),	O
and	O
nucleoprotein	O
(	O
N	O
)	O
structural	O
proteins	O
,	O
and	O
the	O
two	O
most	O
conserved	O
replicase	B-PRGE
domains	O
,	O
putative	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
(	O
RdRp	O
)	O
and	O
RNA	O
helicase	B-PRGE
(	O
HEL	B-PRGE
),	O
aimed	O
at	O
a	O
revision	O
of	O
the	O
Coronaviridae	O
taxonomy	O
.	O

Infectious	O
virus	O
can	O
be	O
isolated	O
from	O
the	O
spinal	O
cords	O
of	O
these	O
mice	O
and	O
is	O
invariably	O
mutated	O
in	O
the	O
immunodominant	O
CD8	B-PRGE
T	I-PRGE
-	I-PRGE
cell	I-PRGE
epitope	I-PRGE
recognized	O
in	O
this	O
strain	O
.	O

Advanced	O
age	O
and	O
high	O
lactate	B-PRGE
dehydrogenase	I-PRGE
level	O
at	O
presentation	O
predict	O
mortality	O
.	O

Here	O
we	O
performed	O
DNA	O
microarray	O
analysis	O
on	O
differential	O
gene	O
expression	O
in	O
astrocyte	O
DBT	O
cells	O
by	O
MHV	O
infection	O
and	O
found	O
that	O
the	O
mRNA	O
of	O
the	O
proapoptotic	B-PRGE
gene	I-PRGE
BNip3	I-PRGE
was	O
significantly	O
decreased	O
following	O
MHV	O
infection	O
.	O

TITLE	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
in	O
long	O
-	O
chain	B-PRGE
3	I-PRGE
-	I-PRGE
hydroxyacyl	I-PRGE
-	I-PRGE
CoA	I-PRGE
dehydrogenase	I-PRGE
and	O
mitochondrial	B-PRGE
trifunctional	I-PRGE
protein	I-PRGE
deficiencies	O
.	O

Predictors	O
of	O
mortality	O
included	O
advanced	O
age	O
,	O
the	O
presence	O
of	O
comorbidities	O
,	O
and	O
a	O
high	B-PRGE
lactic	I-PRGE
dehydrogenase	I-PRGE
or	O
high	O
neutrophil	O
count	O
at	O
admission	O
.	O

Where	O
single	O
agent	O
therapy	O
fails	O
,	O
combination	O
antiviral	O
and	O
anti	B-PRGE
-	I-PRGE
CCL3	I-PRGE
treatment	O
is	O
synergistic	O
and	O
able	O
to	O
prevent	O
mortality	O
in	O
mice	O
infected	O
with	O
the	O
highly	O
lethal	O
pneumonia	O
virus	O
of	O
mice	O
.	O

Transcription	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
appeared	O
upregulated	O
in	O
cats	O
with	O
systemic	O
FIP	O
and	O
slightly	O
downregulated	O
in	O
neurological	O
FIP	O
.	O

We	O
also	O
found	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
protein	I-PRGE
does	O
not	O
activate	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
pathway	O
,	O
demonstrating	O
that	O
activation	O
of	O
important	O
cellular	O
pathways	O
by	O
SAS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
protein	I-PRGE
is	O
selective	O
.	O

The	O
detection	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
in	O
the	O
sweat	O
glands	O
,	O
alimentary	O
tracts	O
and	O
epithelia	O
of	O
the	O
distal	O
convoluted	O
tubules	O
of	O
the	O
kidney	O
may	O
help	O
identify	O
the	O
transmission	O
routes	O
of	O
SARS	O
-	O
CoV	O
.	O

RESULTS	O
:	O
Immunohistochemistry	O
identified	O
positive	O
monoclonal	O
antibody	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
nuceeocapsid	I-PRGE
(	I-PRGE
N	I-PRGE
)	I-PRGE
protein	I-PRGE
in	O
the	O
alveolar	O
epithelium	O
and	O
the	O
infiltrating	O
monocytes	O
or	O
macrophages	O
in	O
the	O
lung	O
,	O
spleen	O
and	O
lymph	O
nodes	O
;	O
the	O
presence	O
of	O
the	O
antibody	O
was	O
also	O
detected	O
in	O
the	O
serous	O
gland	O
epithelium	O
of	O
the	O
trachea	O
/	O
bronchus	O
,	O
squamous	O
epithelium	O
of	O
the	O
esophagus	O
,	O
the	O
gastric	O
parietal	O
cells	O
,	O
the	O
epithelium	O
of	O
the	O
intestinal	O
tract	O
,	O
acidophilic	O
cells	O
in	O
the	O
parathyroids	O
and	O
pituitary	O
,	O
acinus	O
cells	O
in	O
the	O
pancreas	O
,	O
adrenal	O
cortical	O
cells	O
,	O
sweat	O
gland	O
cells	O
,	O
small	O
vessel	O
endothelium	O
,	O
bone	O
marrow	O
promyelocytes	O
,	O
epithelial	O
cells	O
of	O
the	O
distal	O
convoluted	O
tubule	O
of	O
the	O
kidney	O
,	O
brain	O
neurons	O
,	O
and	O
the	O
hepatocytes	O
near	O
the	O
central	O
vein	O
.	O

The	O
serum	B-PRGE
anti	I-PRGE
-	I-PRGE
coronavirus	I-PRGE
IgG	I-PRGE
antibody	I-PRGE
titer	O
in	O
patients	O
recovered	O
from	O
SARS	O
was	O
0	O
.	O
07	O
+/-	O

SARS	O
patients	O
experienced	O
higher	O
concentration	O
of	O
serum	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
as	O
compared	O
to	O
controls	O
in	O
3	O
-	O
7	O
day	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
but	O
it	O
returned	O
to	O
normal	O
levels	O
in	O
8	O
-	O
14	O
day	O
group	O
and	O
the	O
over	O
14	O
day	O
group	O
.	O

The	O
mean	O
concentration	O
of	O
serum	B-PRGE
IL	I-PRGE
-	I-PRGE
18	I-PRGE
in	O
SARS	O
patients	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
the	O
control	O
group	O
during	O
all	O
groups	O
of	O
SARS	O
patients	O
(	O
P	O
<	O
0	O
.	O
05	O
);	O
The	O
mean	O
concentration	O
of	O
TGF	B-PRGE
-	I-PRGE
beta1	I-PRGE
in	O
all	O
groups	O
of	O
SARS	O
patients	O
was	O
higher	O
than	O
that	O
of	O
the	O
control	O
group	O
.	O

Proinflammatory	O
cytokines	O
and	O
TGF	B-PRGE
-	I-PRGE
beta1	I-PRGE
were	O
elevated	O
during	O
the	O
early	O
phase	O
of	O
SARS	O
,	O
a	O
phenomenon	O
which	O
may	O
be	O
associated	O
with	O
lung	O
infiltration	O
and	O
proliferation	O
.	O

TITLE	O
:	O
[	O
B	O
cell	O
subsets	O
and	O
the	O
expression	O
of	O
CD40	B-PRGE
in	O
peripheral	O
blood	O
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
].	O

The	O
monitoring	O
of	O
B	O
cells	O
,	O
B1	O
cells	O
and	O
the	O
expression	O
of	O
CD40	B-PRGE
on	O
B	O
cells	O
is	O
useful	O
in	O
the	O
differential	O
diagnosis	O
of	O
SARS	O
.	O

A	O
possible	O
role	O
for	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
in	O
the	O
previously	O
described	O
FIPV	O
-	O
induced	O
lymphocyte	O
apoptosis	O
is	O
also	O
suggested	O
.	O

Cats	O
immunized	O
with	O
this	O
vaccine	O
produced	O
antibodies	O
against	O
FIPV	O
virion	O
-	O
derived	O
N	B-PRGE
protein	I-PRGE
but	O
did	O
not	O
produce	O
virus	O
-	O
neutralizing	O
antibodies	O
.	O

A	O
delayed	O
type	O
hypersensitivity	O
skin	O
response	O
to	O
N	B-PRGE
protein	I-PRGE
was	O
observed	O
in	O
these	O
vaccinated	O
cats	O
,	O
showing	O
that	O
cell	O
mediated	O
immunity	O
against	O
the	O
FIPV	B-PRGE
antigen	I-PRGE
was	O
induced	O
.	O

This	O
study	O
showed	O
that	O
immunization	O
with	O
the	O
cell	O
lysate	O
with	O
baculovirus	O
-	O
expressed	O
N	B-PRGE
protein	I-PRGE
was	O
effective	O
in	O
preventing	O
the	O
progression	O
of	O
FIP	O
without	O
inducing	O
ADE	O
of	O
FIPV	O
infection	O
in	O
cats	O
.	O

293T	O
cells	O
transfected	O
with	O
ACE2	B-PRGE
,	O
but	O
not	O
those	O
transfected	O
with	O
human	B-PRGE
immunodeficiency	I-PRGE
virus	I-PRGE
-	I-PRGE
1	I-PRGE
receptors	I-PRGE
,	O
formed	O
multinucleated	O
syncytia	O
with	O
cells	O
expressing	O
S	B-PRGE
protein	I-PRGE
.	O

RESULTS	O
:	O
Eighteen	O
children	O
(	O
10	O
males	O
),	O
whose	O
mean	O
age	O
was	O
11	O
.	O
5	O
-/+	O
11	O
.	O
5	O
months	O
,	O
with	O
initial	O
PaO	B-PRGE
(	I-PRGE
2	I-PRGE
)/	I-PRGE
FiO	I-PRGE
(	I-PRGE
2	I-PRGE
)	I-PRGE
of	O
96	O
.	O
06	O
-/+	O
41	O
.	O
78	O
,	O
participated	O
in	O
the	O
study	O
.	O

ABSTRACT	O
:	O
To	O
clone	O
,	O
express	O
and	O
purify	O
nucleocapsid	O
protein	O
from	O
SARS	B-PRGE
coronavirus	I-PRGE
PUMC2	I-PRGE
strain	O
.	O

T	O
lymphocyte	O
subsets	O
including	O
CD3	B-PRGE
+	I-PRGE
CD4	I-PRGE
+	I-PRGE
cells	O
,	O
CD3	B-PRGE
+	I-PRGE
CD8	I-PRGE
+	I-PRGE
cells	O
,	O
naive	O
CD4	B-PRGE
+	I-PRGE
cells	O
(	O
CD4	B-PRGE
+	I-PRGE
CD45RA	I-PRGE
+	I-PRGE
CD62L	I-PRGE
+)	I-PRGE
and	O
activated	O
CD8	B-PRGE
+	I-PRGE
cells	O
(	O
CD8	B-PRGE
+	I-PRGE
CD38	I-PRGE
+)	I-PRGE
were	O
detected	O
by	O
3	O
-	O
color	O
flow	O
cytometry	O
.	O

RESULTS	O
:	O
Compared	O
with	O
the	O
results	O
of	O
normal	O
controls	O
,	O
both	O
of	O
the	O
percentages	O
of	O
CD4	B-PRGE
+	I-PRGE
cells	O
and	O
CD8	B-PRGE
+	I-PRGE
cells	O
of	O
SARS	O
patients	O
were	O
in	O
normal	O
levels	O
during	O
the	O
1st	O
week	O
,	O
but	O
the	O
cell	O
counts	O
decreased	O
significantly	O
to	O
(	O
306	O
+/-	O

TITLE	O
:	O
[	O
Reliability	O
of	O
detecting	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
antibody	I-PRGE
for	O
diagnosis	O
of	O
SARS	O
].	O

In	O
addition	O
,	O
the	O
AC	O
and	O
PC	O
of	O
CD95	B-PRGE
+	I-PRGE
CD4	I-PRGE
+/	I-PRGE
CD4	B-PRGE
and	O
CD95	B-PRGE
+	I-PRGE
CD8	I-PRGE
/	O
CD8	B-PRGE
subset	O
in	O
group	O
III	O
were	O
highest	O
while	O
group	O
I	O
was	O
lowest	O
.	O

Diagnostic	O
utility	O
of	O
serum	O
albumin	B-PRGE
to	O
globulin	O
ratio	O
for	O
the	O
diagnosis	O
of	O
FIP	O
was	O
greater	O
than	O
of	O
the	O
utility	O
of	O
serum	O
total	O
protein	O
and	O
gamma	B-PRGE
-	I-PRGE
globulin	I-PRGE
concentrations	O
.	O

TITLE	O
:	O
Characterization	O
of	O
N	B-PRGE
protein	I-PRGE
self	O
-	O
association	O
in	O
coronavirus	O
ribonucleoprotein	O
complexes	O
.	O

In	O
contrast	O
,	O
N	B-PRGE
protein	I-PRGE
association	O
in	O
the	O
majority	O
of	O
the	O
intracellular	O
RNP	O
complexes	O
was	O
susceptible	O
to	O
RNase	B-PRGE
A	I-PRGE
-	O
treatment	O
.	O

Angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
)	O
is	O
a	O
functional	O
receptor	O
for	O
the	O
coronavirus	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	O
)	O
that	O
causes	O
SARS	O
.	O

ABSTRACT	O
:	O
The	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
receptor	O
(	O
MHVR	O
),	O
CEACAM1	O
,	O
has	O
two	O
different	O
functions	O
for	O
MHV	O
entry	O
into	O
cells	O
:	O
binding	O
to	O
MHV	O
spike	B-PRGE
protein	I-PRGE
(	O
S	B-PRGE
protein	I-PRGE
)	O
and	O
activation	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
to	O
execute	O
virus	O
-	O
cell	O
membrane	O
fusion	O
,	O
the	O
latter	O
of	O
which	O
is	O
accompanied	O
by	O
conformational	O
changes	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
.	O

Postoperative	O
complications	O
,	O
metabolic	O
studies	O
,	O
insulin	B-PRGE
usage	O
,	O
pain	O
scores	O
,	O
and	O
quality	O
of	O
life	O
were	O
recorded	O
for	O
all	O
of	O
these	O
patients	O
.	O

Forty	O
-	O
one	O
percent	O
are	O
insulin	B-PRGE
independent	O
,	O
and	O
27	O
%	O
required	O
minimal	O
amount	O
of	O
insulin	B-PRGE
or	O
a	O
sliding	O
scale	O
.	O

Diagnostic	O
tests	O
based	O
on	O
the	O
detection	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
were	O
developed	O
and	O
made	O
available	O
freely	O
and	O
widely	O
;	O
nevertheless	O
the	O
SARS	O
case	O
definition	O
still	O
remains	O
based	O
on	O
clinical	O
and	O
epidemiological	O
criteria	O
.	O

Looking	O
further	O
into	O
the	O
future	O
,	O
the	O
high	O
efficacy	O
of	O
the	O
fowl	O
adenovirus	O
vector	O
expressing	O
the	O
IBV	O
S1	O
subunit	O
provides	O
optimism	O
for	O
a	O
live	O
SARS	O
vaccine	O
,	O
if	O
that	O
were	O
deemed	O
to	O
be	O
necessary	O
,	O
with	O
the	O
possibility	O
of	O
including	O
the	O
N	B-PRGE
protein	I-PRGE
gene	I-PRGE
.	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
shown	O
that	O
mitochondrial	B-PRGE
-	I-PRGE
aconitase	I-PRGE
binds	O
specifically	O
to	O
the	O
3	O
'	O
terminal	O
42	O
nucleotides	O
of	O
the	O
Murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
RNA	O
along	O
with	O
three	O
additional	O
proteins	O
of	O
70	O
,	O
58	O
and	O
40	O
kDa	O
to	O
form	O
a	O
stable	O
RNA	O
-	O
protein	O
complex	O
.	O

However	O
,	O
the	O
presence	O
of	O
a	O
synthetic	O
RNA	O
containing	O
the	O
sequence	O
bound	O
by	O
these	O
four	O
proteins	O
does	O
increase	O
the	O
amount	O
of	O
co	O
-	O
precipitated	O
protein	O
,	O
in	O
particular	O
the	O
amount	O
of	O
HSP60	B-PRGE
which	O
is	O
brought	O
down	O
with	O
antibodies	O
directed	O
against	O
HSP40	B-PRGE
and	O
mtHSP70	B-PRGE
.	O

Intracerebral	O
infection	O
of	O
RAG1	O
(-/-)	O
mice	O
with	O
a	O
recombinant	O
CXCL10	B-PRGE
-	O
expressing	O
murine	O
coronavirus	O
(	O
mouse	O
hepatitis	O
virus	O
)	O
resulted	O
in	O
protection	O
from	O
disease	O
and	O
increased	O
survival	O
that	O
correlated	O
with	O
a	O
significant	O
increase	O
in	O
recruitment	O
and	O
activation	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
within	O
the	O
CNS	O
.	O

Thus	O
,	O
CD28	B-PRGE
,	O
the	O
costimulatory	O
T	O
cell	O
molecule	O
,	O
is	O
not	O
required	O
for	O
MHV	O
infection	O
and	O
MHV	O
-	O
induced	O
demyelination	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
inflammatory	O
cytokine	O
profile	O
in	O
children	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
to	O
investigate	O
whether	O
monoclonal	O
antibody	O
to	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
could	O
be	O
considered	O
for	O
treatment	O
of	O
these	O
patients	O
.	O

In	O
contrast	O
,	O
the	O
plasma	O
concentrations	O
of	O
other	O
key	O
proinflammatory	O
cytokines	O
,	O
including	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
were	O
not	O
overtly	O
increased	O
in	O
any	O
of	O
the	O
patients	O
throughout	O
the	O
course	O
of	O
illness	O
.	O

After	O
the	O
isopropyl	O
-	O
beta	O
-	O
D	O
-	O
thiogalactoside	O
induction	O
,	O
S	B-PRGE
protein	I-PRGE
was	O
expressed	O
in	O
the	O
soluble	O
form	O
and	O
purified	O
by	O
nickel	O
-	O
affinity	O
chromatography	O
to	O
homogeneity	O
.	O

ABSTRACT	O
:	O
Tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
has	O
a	O
central	O
role	O
in	O
the	O
pathogenesis	O
of	O
acute	O
pancreatitis	O
and	O
related	O
systemic	O
complications	O
.	O

Serum	O
amylase	B-PRGE
activity	O
,	O
pancreatic	O
histopathology	O
,	O
myeloperoxidase	B-PRGE
enzyme	I-PRGE
activity	I-PRGE
(	O
MPO	B-PRGE
),	O
and	O
pulmonary	O
changes	O
were	O
assessed	O
.	O

The	O
recombination	O
event	O
was	O
assessed	O
by	O
reverse	B-PRGE
transcriptase	I-PRGE
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
using	O
a	O
combination	O
of	O
specific	O
primers	O
designed	O
to	O
flank	O
a	O
known	O
recombination	O
hot	O
spot	O
of	O
the	O
viral	O
genomic	O
sequence	O
that	O
codes	O
for	O
the	O
S1	O
subunit	O
of	O
the	O
spike	B-PRGE
envelope	I-PRGE
protein	I-PRGE
.	O

Real	O
-	O
time	O
assays	O
targeted	O
at	O
the	O
ORF	O
1b	O
region	O
and	O
the	O
N	B-PRGE
gene	I-PRGE
revealed	O
that	O
copy	O
numbers	O
of	O
ORF	O
1b	O
and	O
N	O
gene	O
sequences	O
in	O
clinical	O
samples	O
were	O
similar	O
.	O

TITLE	O
:	O
A	O
model	O
of	O
the	O
ACE2	B-PRGE
structure	O
and	O
function	O
as	O
a	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
.	O

Interestingly	O
,	O
dogs	O
inoculated	O
with	O
the	O
ML	O
CCV	O
vaccine	O
by	O
the	O
oronasal	O
route	O
developed	O
levels	O
of	O
fecal	O
IgA	B-PRGE
that	O
were	O
higher	O
than	O
those	O
observed	O
in	O
the	O
dogs	O
inoculated	O
with	O
the	O
same	O
CCV	O
vaccine	O
by	O
the	O
intramuscular	O
route	O
or	O
those	O
observed	O
in	O
dogs	O
inoculated	O
with	O
the	O
inactivated	O
vaccine	O
.	O

The	O
RT	O
-	O
PCR	O
-	O
positive	O
patients	O
had	O
significantly	O
more	O
shortness	O
of	O
breath	O
,	O
a	O
lower	O
lymphocyte	O
count	O
,	O
and	O
a	O
lower	O
lactate	B-PRGE
dehydrogenase	I-PRGE
level	O
;	O
they	O
were	O
also	O
more	O
likely	O
to	O
have	O
bilateral	O
and	O
multifocal	O
chest	O
radiograph	O
involvement	O
,	O
to	O
be	O
admitted	O
to	O
intensive	O
care	O
,	O
to	O
need	O
mechanical	O
ventilation	O
,	O
and	O
to	O
have	O
higher	O
mortality	O
rates	O
.	O

TITLE	O
:	O
The	O
role	O
of	O
nuclear	B-PRGE
factor	I-PRGE
kappa	I-PRGE
B	I-PRGE
in	O
the	O
pathogenesis	O
of	O
pulmonary	O
diseases	O
:	O
implications	O
for	O
therapy	O
.	O

NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
plays	O
a	O
central	O
role	O
in	O
a	O
variety	O
of	O
acute	O
and	O
chronic	O
inflammatory	O
diseases	O
.	O

In	O
the	O
common	O
lung	O
diseases	O
associated	O
with	O
a	O
significant	O
inflammatory	O
component	O
such	O
as	O
severe	O
sepsis	O
,	O
acute	O
lung	O
injury	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
cystic	O
fibrosis	O
and	O
asthma	O
,	O
the	O
pathogenic	O
roles	O
of	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
have	O
been	O
extensively	O
investigated	O
.	O

In	O
addition	O
,	O
genomes	O
of	O
viruses	O
from	O
about	O
half	O
the	O
plaques	O
that	O
retained	O
the	O
EGFP	B-PRGE
gene	I-PRGE
had	O
mutations	O
within	O
the	O
gp33	B-PRGE
-	I-PRGE
41	I-PRGE
epitope	I-PRGE
.	O

These	O
observations	O
suggest	O
that	O
the	O
cytotoxic	O
T	O
-	O
cell	O
response	O
to	O
gp33	B-PRGE
-	I-PRGE
41	I-PRGE
exerts	O
a	O
strong	O
immune	O
pressure	O
that	O
quickly	O
selects	O
epitope	O
escape	O
mutants	O
to	O
gp33	O
-	O
41	O
.	O

CONCLUSIONS	O
:	O
The	O
successful	O
amplification	O
and	O
cloning	O
of	O
N	B-PRGE
gene	I-PRGE
facilitates	O
further	O
investigation	O
of	O
the	O
expression	O
of	O
the	O
N	B-PRGE
protein	I-PRGE
and	O
study	O
of	O
its	O
structure	O
and	O
functions	O
.	O

Based	O
on	O
seroconversion	O
to	O
BRSV	O
and	O
clinical	O
picture	O
,	O
67	O
pairs	O
of	O
sera	O
were	O
selected	O
from	O
calves	O
with	O
a	O
BRSV	O
-	O
associated	O
PRDS	O
for	O
circulating	O
MC	B-PRGE
tryptase	I-PRGE
determination	O
.	O

These	O
results	O
provide	O
important	O
information	O
concerning	O
the	O
tissue	O
tropism	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
which	O
is	O
distinct	O
from	O
previously	O
identified	O
human	O
coronaviruses	O
,	O
and	O
suggest	O
the	O
possible	O
involvement	O
of	O
novel	O
receptors	O
in	O
this	O
infection	O
.	O

Although	O
the	O
amendments	O
to	O
the	O
Health	O
Protection	O
and	O
Promotion	O
Act	O
(	O
HPPA	O
)	O
were	O
clearly	O
designed	O
to	O
address	O
emergency	O
situations	O
like	O
SARS	B-PRGE
,	O
they	O
may	O
have	O
unintended	O
and	O
negative	O
consequences	O
for	O
people	O
living	O
with	O
HIV	O
/	O
AIDS	O
.	O

While	O
wt	O
CD8	B-PRGE
(+)	O
T	O
cells	O
inhibited	O
virus	O
replication	O
in	O
all	O
CNS	O
cell	O
types	O
,	O
cytolytic	O
activity	O
in	O
the	O
absence	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
suppressed	O
the	O
infection	O
of	O
astrocytes	O
,	O
but	O
not	O
oligodendroglia	O
.	O

To	O
gain	O
further	O
insights	O
into	O
this	O
enzyme	O
,	O
the	O
first	O
crystal	O
structures	O
of	O
the	O
native	O
and	O
inhibitor	O
-	O
bound	O
forms	O
of	O
the	O
ACE2	B-PRGE
extracellular	O
domains	O
were	O
solved	O
to	O
2	O
.	O
2	O
-	O
and	O
3	O
.	O
0	O
-	O
A	O
resolution	O
,	O
respectively	O
.	O

Intriguingly	O
,	O
a	O
series	O
of	O
shorter	O
isoforms	O
of	O
N	B-PRGE
protein	I-PRGE
was	O
observed	O
by	O
SDS	O
-	O
PAGE	O
and	O
identified	O
by	O
mass	O
spectrometry	O
characterization	O
.	O

For	O
further	O
confirmation	O
of	O
this	O
phenomenon	O
and	O
its	O
related	O
mechanism	O
,	O
recombinant	B-PRGE
N	I-PRGE
protein	I-PRGE
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
was	O
cleaved	O
in	O
vitro	O
by	O
caspase	B-PRGE
-	I-PRGE
3	I-PRGE
and	I-PRGE
-	I-PRGE
6	I-PRGE
respectively	O
.	O

These	O
data	O
clearly	O
demonstrated	O
that	O
ACE2	B-PRGE
was	O
the	O
functional	O
receptor	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O

ABSTRACT	O
:	O
As	O
part	O
of	O
a	O
high	O
-	O
throughput	O
structural	O
analysis	O
of	O
SARS	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
proteins	O
,	O
we	O
have	O
solved	O
the	O
structure	O
of	O
the	O
non	O
-	O
structural	O
protein	B-PRGE
9	I-PRGE
(	O
nsp9	O
).	O

TITLE	O
:	O
[	O
Expression	O
and	O
purification	O
of	O
recombinant	B-PRGE
N	I-PRGE
-	I-PRGE
terminal	I-PRGE
protein	I-PRGE
of	O
SARS	B-PRGE
S1	I-PRGE
subunit	I-PRGE
expressed	O
in	O
E	O
.	O
Coli	O
].	O

Sequencing	O
analysis	O
confirmed	O
that	O
the	O
desired	O
DNA	O
sequence	O
in	O
recombinant	O
plasmid	O
was	O
correct	O
and	O
had	O
the	O
same	O
sequence	O
of	O
natural	O
N	O
-	O
terminal	O
of	O
SARS	B-PRGE
virus	I-PRGE
S1	I-PRGE
subunit	I-PRGE
.	O

The	O
recombinant	B-PRGE
N	I-PRGE
-	I-PRGE
terminal	I-PRGE
protein	I-PRGE
of	O
SARS	B-PRGE
virus	O
S1	O
subunit	O
displays	O
specific	O
reaction	O
with	O
SARS	B-PRGE
antibody	I-PRGE
and	O
may	O
provide	O
a	O
good	O
tool	O
for	O
further	O
research	O
of	O
immune	O
response	O
to	O
SARS	O
virus	O
.	O

RESULTS	O
:	O
Sequencing	O
analysis	O
confirmed	O
that	O
the	O
desired	O
DNA	O
sequence	O
in	O
recombinant	O
plasmid	O
was	O
correct	O
and	O
had	O
the	O
same	O
sequence	O
of	O
natural	O
N	O
-	O
terminal	O
of	O
SARS	B-PRGE
virus	I-PRGE
S1	I-PRGE
subunit	I-PRGE
.	O

Hence	O
,	O
drugs	O
that	O
suppresses	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
or	O
restore	O
p53	B-PRGE
function	O
might	O
be	O
effective	O
in	O
restoring	O
the	O
parity	O
of	O
resistance	O
to	O
apoptosis	O
between	O
infected	O
and	O
uninfected	O
cells	O
.	O

We	O
therefore	O
suggest	O
that	O
pegylated	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
protects	O
type	O
1	O
pneumocytes	O
from	O
SCV	O
infection	O
,	O
and	O
should	O
be	O
considered	O
a	O
candidate	O
drug	O
for	O
SARS	O
therapy	O
.	O

In	O
addition	O
,	O
mice	O
immunized	O
with	O
plasmids	O
encoding	O
S1	O
fragment	O
developed	O
a	O
Th1	B-PRGE
-	O
mediated	O
antibody	O
isotype	O
switching	O
.	O

Another	O
interesting	O
finding	O
was	O
that	O
mouse	O
antibodies	O
elicited	O
separately	O
by	O
plasmids	O
encoding	O
S1	O
and	O
S2	O
subunits	O
cooperatively	O
neutralized	O
SARS	B-PRGE
-	O
CoV	O
but	O
neither	O
the	O
S1	O
nor	O
S2	O
specific	O
antibodies	O
did	O
,	O
suggesting	O
the	O
possible	O
role	O
of	O
both	O
S1	O
and	O
S2	O
subunits	O
in	O
host	O
cell	O
docking	O
and	O
entry	O
.	O

Lopinavir	O
/	O
ritonavir	O
treatment	O
was	O
associated	O
with	O
a	O
better	O
outcome	O
even	O
when	O
adjusted	O
for	O
baseline	O
lactate	B-PRGE
dehydrogenase	I-PRGE
level	O
.	O

Viable	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
could	O
be	O
isolated	O
from	O
postmortem	O
tissues	O
.	O

TITLE	O
:	O
S1	B-PRGE
glycoprotein	I-PRGE
gene	O
analysis	O
of	O
infectious	O
bronchitis	O
viruses	O
isolated	O
in	O
Korea	O
.	O

The	O
S1	B-PRGE
glycoprotein	I-PRGE
gene	O
of	O
IBV	O
isolates	O
were	O
amplified	O
by	O
reverse	B-PRGE
transcriptase	I-PRGE
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
analyzed	O
by	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
analysis	O
.	O

Detailed	O
comparisons	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
genomic	I-PRGE
sequence	I-PRGE
with	O
those	O
of	O
six	O
other	O
coronaviruses	O
failed	O
to	O
find	O
evidence	O
of	O
recombination	O
or	O
genomic	O
rearrangement	O
using	O
computational	O
methods	O
designed	O
for	O
that	O
purpose	O
.	O

Overall	O
,	O
the	O
structure	O
of	O
the	O
hetero	O
-	O
stranded	O
complex	O
is	O
consistent	O
with	O
the	O
structures	O
observed	O
for	O
other	O
type	B-PRGE
1	I-PRGE
viral	I-PRGE
fusion	I-PRGE
proteins	I-PRGE
in	O
their	O
fusion	O
-	O
competent	O
state	O
.	O

We	O
show	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
nsp9	I-PRGE
is	O
a	O
single	O
-	O
stranded	O
RNA	O
-	O
binding	O
protein	O
displaying	O
a	O
previously	O
unreported	O
,	O
oligosaccharide	O
/	O
oligonucleotide	O
fold	O
-	O
like	O
fold	O
.	O

Numbers	O
of	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
interleukin	B-PRGE
(	O
IL	O
)-	O
2	O
,	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
IL	O
-	O
12	O
secreting	O
cells	O
induced	O
by	O
T	O
cell	O
activators	O
were	O
below	O
normal	O
in	O
many	O
or	O
most	O
patients	O
before	O
and	O
during	O
treatment	O
with	O
corticosteroids	O
and	O
ribavirin	O
but	O
returned	O
essentially	O
to	O
normal	O
after	O
completion	O
of	O
treatment	O
.	O

We	O
found	O
that	O
although	O
some	O
primate	O
cell	O
lines	O
,	O
including	O
Vero	O
E6	O
,	O
293T	O
and	O
Huh	O
-	O
7	O
cells	O
,	O
could	O
be	O
efficiently	O
transduced	O
by	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
glycoprotein	I-PRGE
pseudoviruses	O
,	O
other	O
cells	O
lines	O
were	O
either	O
resistant	O
or	O
very	O
poorly	O
permissive	O
to	O
virus	O
entry	O
.	O

However	O
,	O
TGEV	O
infection	O
did	O
enhance	O
the	O
primary	O
immunoglobulin	B-PRGE
M	I-PRGE
(	O
IgM	B-PRGE
)	O
and	O
IgG1	B-PRGE
,	O
but	O
not	O
IgG2	B-PRGE
,	O
antibody	O
responses	O
to	O
injected	O
soy	O
in	O
comparison	O
to	O
those	O
of	O
uninfected	O
animals	O
.	O

SSp	O
-	O
1	O
-	O
specific	O
CTLs	O
also	O
lysed	O
major	B-PRGE
histocompatibility	I-PRGE
complex	I-PRGE
(	O
MHC	B-PRGE
)-	O
matched	O
tumor	O
cell	O
lines	O
engineered	O
to	O
express	O
S	O
proteins	O
.	O

We	O
found	O
that	O
the	O
level	O
of	O
neurovirulence	O
of	O
the	O
virus	O
correlates	O
with	O
its	O
differential	O
ability	O
to	O
induce	O
proinflammatory	O
cytokines	O
(	O
interleukin	B-PRGE
12	I-PRGE
[	O
IL	O
-	O
12	O
]	O
p40	B-PRGE
,	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
15	I-PRGE
,	O
and	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
)	O
in	O
astrocytes	O
and	O
microglia	O
and	O
in	O
mouse	O
brains	O
and	O
spinal	O
cords	O
.	O

These	O
findings	O
demonstrate	O
that	O
in	O
FIP	B-PRGE
cases	I-PRGE
FCoV	I-PRGE
type	I-PRGE
I	I-PRGE
predominates	O
,	O
too	O
,	O
nonetheless	O
,	O
in	O
14	O
%	O
of	O
the	O
cases	O
FCoV	O
type	O
II	O
was	O
detected	O
,	O
suggesting	O
its	O
causative	O
involvement	O
in	O
cases	O
of	O
FIP	O
.	O

The	O
ability	O
to	O
detect	O
MHV	O
-	O
Y	O
transmission	O
to	O
sentinel	O
mice	O
exposed	O
directly	O
to	O
infected	O
mice	O
or	O
to	O
soil	O
bedding	O
from	O
infected	O
mice	O
was	O
compared	O
with	O
reverse	B-PRGE
transcriptase	I-PRGE
-	O
polymerase	O
chain	O
reaction	O
-	O
based	O
detection	O
of	O
viral	O
RNA	O
in	O
the	O
feces	O
.	O

The	O
chemokine	O
profile	O
demonstrated	O
significant	O
elevation	O
of	O
neutrophil	B-PRGE
chemokine	I-PRGE
IL	I-PRGE
-	I-PRGE
8	I-PRGE
,	I-PRGE
monocyte	I-PRGE
chemoattractant	I-PRGE
protein	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
),	O
and	O
Th1	B-PRGE
chemokine	I-PRGE
IFN	I-PRGE
-	I-PRGE
gamma	I-PRGE
-	O
inducible	O
protein	O
-	O
10	O
(	O
IP	O
-	O
10	O
).	O

Among	O
31	O
case	O
-	O
patients	O
for	O
whom	O
convalescent	O
-	O
phase	O
(>	O
21	O
days	O
)	O
sera	O
were	O
available	O
,	O
26	O
%	O
had	O
immunoglobulin	B-PRGE
G	I-PRGE
to	O
SARS	O
-	O
associated	O
coronavirus	O
.	O

We	O
cloned	O
and	O
purified	O
the	O
nucleocapsid	B-PRGE
protein	I-PRGE
and	O
spike	O
polypeptide	O
of	O
SARS	O
-	O
CoV	O
and	O
examined	O
their	O
immunogenicity	O
with	O
serum	O
from	O
patients	O
with	O
SARS	O
-	O
CoV	O
pneumonia	O
.	O

All	O
positive	O
samples	O
were	O
confirmed	O
by	O
two	O
separate	O
western	O
-	O
blot	O
assays	O
(	O
with	O
recombinant	B-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
and	O
recombinant	B-PRGE
spike	I-PRGE
polypeptide	I-PRGE
).	O

Clinical	O
trials	O
with	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
might	O
be	O
justified	O
to	O
determine	O
a	O
beneficial	O
effect	O
on	O
the	O
outcome	O
of	O
SARS	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
severity	O
of	O
CNS	O
disease	O
can	O
be	O
reduced	O
through	O
the	O
use	O
of	O
a	O
neutralizing	O
mAb	O
directed	O
against	O
CCL5	B-PRGE
in	O
a	O
viral	O
model	O
of	O
demyelination	O
.	O

CP	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
NP	B-PRGE
-	I-PRGE
1	I-PRGE
mixed	O
in	O
equimolar	O
concentrations	O
formed	O
a	O
six	O
-	O
helix	O
bundle	O
,	O
similar	O
to	O
the	O
fusogenic	O
core	O
structure	O
of	O
HIV	O
-	O
1	O
gp41	O
.	O

We	O
focused	O
on	O
using	O
synthetic	O
peptides	O
for	O
developing	O
antibodies	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
which	O
aimed	O
to	O
block	O
viral	O
invasion	O
by	O
eliciting	O
an	O
immune	O
response	O
specific	O
to	O
the	O
native	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
.	O

RESULTS	O
:	O
Four	O
of	O
our	O
six	O
synthetic	O
peptides	O
(	O
S2	O
,	O
S3	O
,	O
S5	O
,	O
and	O
S6	O
)	O
elicited	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
specific	I-PRGE
antibodies	I-PRGE
,	O
of	O
which	O
S5	O
(	O
residues	O
788	O
-	O
820	O
)	O
and	O
S6	O
(	O
residues	O
1002	O
-	O
1030	O
)	O
exhibited	O
immunogenic	O
responses	O
similar	O
to	O
those	O
found	O
in	O
a	O
parallel	O
investigation	O
using	O
truncated	O
recombinant	O
protein	O
analogs	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
.	O

Among	O
the	O
changes	O
in	O
the	O
recommendations	O
to	O
prevent	O
bacterial	O
pneumonia	O
,	O
especially	O
ventilator	O
-	O
associated	O
pneumonia	O
,	O
are	O
the	O
preferential	O
use	O
of	O
oro	O
-	O
tracheal	O
rather	O
than	O
naso	O
-	O
tracheal	O
tubes	O
in	O
patients	O
who	O
receive	O
mechanically	O
assisted	O
ventilation	O
,	O
the	O
use	O
of	O
noninvasive	O
ventilation	O
to	O
reduce	O
the	O
need	O
for	O
and	O
duration	O
of	O
endotracheal	O
intubation	O
,	O
changing	O
the	O
breathing	O
circuits	O
of	O
ventilators	O
when	O
they	O
malfunction	O
or	O
are	O
visibly	O
contaminated	O
,	O
and	O
(	O
when	O
feasible	O
)	O
the	O
use	O
of	O
an	O
endotracheal	O
tube	O
with	O
a	O
dorsal	O
lumen	O
to	O
allow	O
drainage	O
of	O
respiratory	O
secretions	O
;	O
no	O
recommendations	O
were	O
made	O
about	O
the	O
use	O
of	O
sucralfate	O
,	O
histamine	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	I-PRGE
antagonists	O
,	O
or	O
antacids	O
for	O
stress	O
-	O
bleeding	O
prophylaxis	O
.	O

The	O
passive	O
transfer	O
of	O
anti	B-PRGE
-	I-PRGE
human	I-PRGE
leukocyte	I-PRGE
antigen	I-PRGE
(	O
HLA	B-PRGE
)	O
or	O
antineutrophil	O
antibodies	O
in	O
the	O
donated	O
blood	O
products	O
are	O
responsible	O
for	O
the	O
pathophysiological	O
process	O
in	O
TRALI	O
.	O

The	O
cDNA	O
for	O
full	B-PRGE
-	I-PRGE
length	I-PRGE
N	I-PRGE
protein	I-PRGE
and	O
its	O
various	O
regions	O
from	O
the	O
SARS	O
-	O
CoV	O
was	O
cloned	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

EP2	B-PRGE
and	O
EP4	B-PRGE
possessed	O
linear	O
epitopes	O
,	O
whereas	O
EP1	B-PRGE
and	O
EP2	B-PRGE
were	O
able	O
to	O
form	O
conformational	O
epitopes	O
that	O
could	O
react	O
with	O
most	O
(>	O
80	O
%)	O
of	O
the	O
tested	O
sera	O
.	O

EP3	B-PRGE
and	O
EP4	B-PRGE
also	O
formed	O
conformational	O
epitopes	O
,	O
and	O
antibodies	O
against	O
these	O
epitopes	O
existed	O
in	O
all	O
52	O
of	O
the	O
sera	O
tested	O
.	O

EP3	B-PRGE
and	O
EP4	B-PRGE
also	O
formed	O
conformational	O
epitopes	O
,	O
and	O
antibodies	O
against	O
these	O
epitopes	O
existed	O
in	O
all	O
52	O
of	O
the	O
sera	O
tested	O
.	O

CONCLUSIONS	O
:	O
Positive	O
rate	O
and	O
load	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
in	O
stool	O
of	O
SARS	O
patients	O
was	O
the	O
highest	O
at	O
their	O
acute	O
phase	O
,	O
and	O
decreased	O
with	O
the	O
extension	O
of	O
its	O
course	O
.	O

Serum	O
levels	O
of	O
C3	O
,	O
C4	O
,	O
PA	O
and	O
CRP	B-PRGE
were	O
determined	O
by	O
turbidimetry	O
in	O
54	O
cases	O
of	O
SARS	O
,	O
20	O
of	O
other	O
pneumonia	O
and	O
30	O
normal	O
persons	O
.	O

RESULTS	O
:	O
Serum	O
concentrations	O
of	O
C3	O
,	O
C4	O
,	O
CRP	B-PRGE
and	O
PA	O
were	O
(	O
1	O
.	O
18	O
+/-	O

Then	O
,	O
after	O
reducing	O
total	O
PEEP	O
by	O
decreasing	O
respiratory	O
rate	O
,	O
Pao2	B-PRGE
/	O
Fio2	O
ratio	O
was	O
reevaluated	O
.	O

After	O
recruitment	O
,	O
Pao2	B-PRGE
/	O
Fio2	O
ratio	O
was	O
higher	O
in	O
all	O
patients	O
.	O

S	O
(	O
1190	O
)	O
binds	O
to	O
the	O
surface	O
of	O
Vero	O
E6	O
cells	O
,	O
a	O
cell	O
permissive	O
to	O
infection	O
,	O
as	O
demonstrated	O
by	O
fluorescence	O
-	O
activated	O
cell	O
sorter	O
analysis	O
,	O
suggesting	O
that	O
S	O
(	O
1190	O
)	O
maintains	O
the	O
biologic	O
activity	O
present	O
in	O
native	B-PRGE
S	I-PRGE
glycoprotein	I-PRGE
.	O

Amino	O
acids	O
270	O
to	O
510	O
were	O
the	O
minimal	O
receptor	O
-	O
binding	O
region	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
glycoprotein	I-PRGE
as	O
determined	O
by	O
flow	O
cytometry	O
.	O

Our	O
investigators	O
have	O
previously	O
shown	O
that	O
DNA	O
vaccination	O
with	O
antigen	O
linked	O
to	O
calreticulin	B-PRGE
(	O
CRT	B-PRGE
)	O
dramatically	O
enhances	O
major	B-PRGE
histocompatibility	I-PRGE
complex	I-PRGE
class	I-PRGE
I	I-PRGE
presentation	I-PRGE
of	I-PRGE
linked	I-PRGE
antigen	I-PRGE
to	O
CD8	B-PRGE
(+)	O
T	O
cells	O
.	O

Interestingly	O
,	O
we	O
found	O
that	O
similar	O
structure	O
patterns	O
exist	O
in	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
main	I-PRGE
proteinase	I-PRGE
with	O
Poliovirus	B-PRGE
3c	I-PRGE
Proteinase	I-PRGE
,	O
Rhinovirus	B-PRGE
3c	I-PRGE
Protease	I-PRGE
,	O
Nsp4	B-PRGE
Proteinase	I-PRGE
From	O
Equine	O
Arteritis	O
Virus	O
,	O
Hepatitis	B-PRGE
C	I-PRGE
Virus	I-PRGE
Ns3	I-PRGE
Protease	I-PRGE
,	O
Hepatitis	B-PRGE
A	I-PRGE
Virus	I-PRGE
3c	I-PRGE
Protease	I-PRGE
,	O
and	O
Dengue	B-PRGE
Virus	I-PRGE
Ns3	I-PRGE
Protease	I-PRGE
.	O

However	O
,	O
81	O
%	O
of	O
my	O
48	O
recently	O
-	O
summarized	O
type	O
-	O
2	O
diabetes	O
patients	O
with	O
polyneuropathy	O
,	O
adequately	O
-	O
treated	O
with	O
intravenous	O
immunoglobulin	B-PRGE
-	I-PRGE
G	I-PRGE
,	O
off	O
-	O
label	O
,	O
were	O
relieved	O
,	O
sometimes	O
completely	O
,	O
of	O
various	O
motor	O
and	O
sensory	O
symptoms	O
,	O
including	O
pain	O
,	O
thereby	O
resembling	O
Chronic	O
Immune	O
Dysschwannian	O
/	O
Dysneuronal	O
Polyneuropathy	O
.	O

The	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
nucleocapsid	I-PRGE
(	I-PRGE
N	I-PRGE
)	I-PRGE
protein	I-PRGE
is	O
a	O
423	O
amino	O
-	O
acid	O
,	O
predicted	O
phospho	O
-	O
protein	O
of	O
46	O
kDa	O
that	O
shares	O
little	O
homology	O
with	O
other	O
members	O
of	O
the	O
coronavirus	O
family	O
.	O

IgG	B-PRGE
antibodies	I-PRGE
,	O
however	O
,	O
remained	O
detectable	O
for	O
a	O
period	O
beyond	O
11	O
weeks	O
and	O
were	O
found	O
in	O
100	O
%	O
of	O
patients	O
in	O
the	O
early	O
convalescent	O
phase	O
.	O

Intranasal	O
or	O
intramuscular	O
inoculations	O
of	O
BALB	O
/	O
c	O
mice	O
with	O
MVA	O
/	O
S	O
produced	O
serum	O
antibodies	O
that	O
recognized	O
the	O
SARS	B-PRGE
S	I-PRGE
in	O
ELISA	O
and	O
neutralized	O
SARS	B-PRGE
-	O
CoV	O
in	O
vitro	O
.	O

IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	O
-	O
8	O
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
and	O
TNFalpha	B-PRGE
production	O
were	O
determined	O
by	O
ELISA	O
.	O

All	O
confirmed	O
SARS	O
cases	O
demonstrated	O
seroconversion	O
or	O
fourfold	O
rise	O
in	O
IgG	B-PRGE
antibody	I-PRGE
titer	O
;	O
no	O
control	O
was	O
positive	O
.	O

There	O
were	O
significant	O
differences	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
for	O
CD45	B-PRGE
,	O
CD3	B-PRGE
,	O
CD4	B-PRGE
,	O
CD8	B-PRGE
,	O
but	O
with	O
no	O
significant	O
difference	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
for	O
CD4	B-PRGE
/	O
CD8	B-PRGE
ratio	O
between	O
severe	O
and	O
mild	O
,	O
recovery	O
and	O
death	O
groups	O
.	O

TITLE	O
:	O
Development	O
of	O
reverse	B-PRGE
transcriptase	I-PRGE
PCR	O
and	O
nested	O
PCR	O
to	O
detect	O
porcine	O
hemagglutinating	O
encephalomyelitis	O
virus	O
.	O

Expression	O
of	O
SARS	B-PRGE
protein	I-PRGE
3a	I-PRGE
was	O
detected	O
at	O
8	O
-	O
12	O
h	O
after	O
infection	O
and	O
reached	O
a	O
higher	O
level	O
after	O
approximately	O
24	O
h	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	O
.	O

The	O
human	B-PRGE
MxA	I-PRGE
protein	I-PRGE
is	O
one	O
of	O
the	O
most	O
prominent	O
proteins	O
induced	O
by	O
interferon	B-PRGE
-	I-PRGE
beta	I-PRGE
.	O

In	O
particular	O
,	O
Sambucus	O
nigra	O
agglutinin	O
I	O
and	O
Maackia	O
amurensis	O
agglutinin	O
lectins	O
were	O
used	O
to	O
detect	O
sialic	B-PRGE
acid	I-PRGE
residues	I-PRGE
,	I-PRGE
Aleuria	I-PRGE
aurantia	I-PRGE
lectin	I-PRGE
was	O
used	O
to	O
detect	O
L	O
-	O
fucose	O
residues	O
and	O
Concanavalin	O
A	O
was	O
used	O
to	O
evaluate	O
the	O
branching	O
degree	O
.	O

Online	O
database	O
analysis	O
and	O
the	O
T2	O
cell	O
binding	O
test	O
disclosed	O
that	O
the	O
number	O
of	O
HLA	B-PRGE
-	I-PRGE
A2	I-PRGE
-	O
restricted	O
immunogenic	O
epitopes	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
was	O
decreased	O
or	O
even	O
lost	O
in	O
comparison	O
with	O
the	O
homologous	O
sequences	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
of	O
HCoV	O
-	O
229e	O
.	O

Among	O
the	O
peptides	O
used	O
in	O
the	O
study	O
,	O
the	O
affinity	O
of	O
peptides	O
from	O
HCoV	O
-	O
229e	O
(	O
H77	O
and	O
H881	O
)	O
and	O
peptides	O
from	O
SARS	O
-	O
CoV	O
(	O
S978	O
and	O
S1203	O
)	O
for	O
binding	O
to	O
HLA	B-PRGE
-	I-PRGE
A2	I-PRGE
was	O
higher	O
than	O
that	O
of	O
other	O
sequences	O
.	O

Finally	O
,	O
we	O
established	O
that	O
,	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	O
,	O
nsp13	O
localizes	O
to	O
membranes	O
that	O
appear	O
to	O
be	O
derived	O
from	O
the	O
endoplasmic	O
reticulum	O
and	O
are	O
the	O
likely	O
site	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
synthesis	O
.	O

While	O
the	O
amounts	O
of	O
the	O
cellular	O
cyclin	B-PRGE
-	I-PRGE
dependent	I-PRGE
kinase	I-PRGE
(	O
Cdk	B-PRGE
)	O
inhibitors	O
p21	B-PRGE
(	O
Cip1	B-PRGE
),	O
p27	B-PRGE
(	O
Kip1	B-PRGE
),	O
and	O
p16	B-PRGE
(	O
INK4a	B-PRGE
)	O
did	O
not	O
change	O
in	O
infected	O
cells	O
,	O
MHV	O
infection	O
in	O
asynchronous	O
cultures	O
induced	O
a	O
clear	O
reduction	O
in	O
the	O
amounts	O
of	O
Cdk4	B-PRGE
and	O
G	O
(	O
1	O
)	O
cyclins	O
(	O
cyclins	O
D1	O
,	O
D2	O
,	O
D3	O
,	O
and	O
E	O
)	O
in	O
both	O
DBT	O
and	O
17Cl	O
-	O
1	O
cells	O
and	O
a	O
reduction	O
in	O
Cdk6	B-PRGE
levels	O
in	O
17Cl	O
-	O
1	O
cells	O
.	O

ABSTRACT	O
:	O
Conjugation	O
of	O
a	O
peptide	O
related	O
to	O
the	O
human	B-PRGE
immunodeficiency	I-PRGE
virus	I-PRGE
type	I-PRGE
1	I-PRGE
Tat	I-PRGE
represents	O
a	O
novel	O
method	O
for	O
delivery	O
of	O
antisense	O
morpholino	O
-	O
oligomers	O
.	O

This	O
signal	O
can	O
retain	O
a	O
chimeric	O
reporter	O
protein	O
in	O
the	O
ERGIC	O
and	O
when	O
mutated	O
allows	O
transport	O
of	O
the	O
full	O
-	O
length	O
S	B-PRGE
protein	I-PRGE
as	O
well	O
as	O
the	O
chimera	O
to	O
the	O
plasma	O
membrane	O
.	O

The	O
most	O
remarkable	O
finding	O
was	O
the	O
surface	O
expression	O
of	O
ACE2	B-PRGE
protein	I-PRGE
on	O
lung	O
alveolar	O
epithelial	O
cells	O
and	O
enterocytes	O
of	O
the	O
small	O
intestine	O
.	O

Furthermore	O
,	O
ACE2	B-PRGE
was	O
present	O
in	O
arterial	O
and	O
venous	O
endothelial	O
cells	O
and	O
arterial	O
smooth	O
muscle	O
cells	O
in	O
all	O
organs	O
studied	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
a	O
highly	O
contagious	O
and	O
predominantly	O
pneumonic	O
illness	O
caused	O
by	O
a	O
novel	O
coronavirus	O
now	O
commonly	O
known	O
as	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
This	O
article	O
describes	O
the	O
key	O
diagnostic	O
clinical	O
features	O
,	O
radiologic	O
features	O
,	O
and	O
investigation	O
profiles	O
of	O
affected	O
patients	O
.	O

Analogous	O
to	O
other	O
class	B-PRGE
I	I-PRGE
viral	I-PRGE
fusion	I-PRGE
proteins	I-PRGE
,	O
the	O
six	O
-	O
helix	O
complex	O
supposedly	O
represents	O
a	O
postfusion	O
conformation	O
that	O
is	O
formed	O
after	O
insertion	O
of	O
the	O
fusion	O
peptide	O
,	O
proposed	O
here	O
for	O
coronaviruses	O
to	O
be	O
located	O
immediately	O
upstream	O
of	O
HR1	O
,	O
into	O
the	O
target	O
membrane	O
.	O

From	O
this	O
perspective	O
,	O
we	O
analyzed	O
eGFP	B-PRGE
mRNA	I-PRGE
expression	O
and	O
eGFP	O
fluorescence	O
in	O
experimental	O
models	O
of	O
nervous	O
system	O
lesions	O
,	O
such	O
as	O
motoneuron	O
axotomy	O
and	O
cerebral	O
stroke	O
induced	O
by	O
middle	O
cerebral	O
artery	O
occlusion	O
.	O

This	O
increased	O
fluorescence	O
is	O
correlated	O
with	O
an	O
increased	O
transcription	O
of	O
eGFP	O
in	O
lesioned	O
cells	O
,	O
presumably	O
enhanced	O
by	O
a	O
release	O
of	O
the	O
translational	O
silencing	O
mediated	O
by	O
the	O
3	O
'	O
UTR	O
region	O
of	O
the	O
t	B-PRGE
-	I-PRGE
PA	I-PRGE
mRNA	I-PRGE
.	O

TITLE	O
:	O
[	O
Determination	O
and	O
comparison	O
of	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
antibody	I-PRGE
in	O
children	O
and	O
adults	O
].	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
positive	O
rate	O
of	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
antibody	I-PRGE
in	O
children	O
and	O
adults	O
without	O
SARS	O
,	O
197	O
paediatric	O
patients	O
under	O
14	O
years	O
old	O
from	O
inpatient	O
and	O
outpatient	O
department	O
of	O
our	O
hospital	O
,	O
156	O
healthy	O
children	O
pupils	O
from	O
primary	O
school	O
,	O
453	O
adult	O
patients	O
over	O
18	O
years	O
old	O
from	O
inpatient	O
and	O
outpatient	O
department	O
of	O
our	O
hospital	O
and	O
other	O
502	O
healthy	O
adult	O
blood	O
donors	O
were	O
selected	O
.	O

IgM	B-PRGE
antibody	O
was	O
negative	O
in	O
all	O
the	O
samples	O
.	O

The	O
results	O
do	O
show	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
follows	O
the	O
general	O
fusion	O
mechanism	O
of	O
class	O
I	O
viruses	O
and	O
this	O
lays	O
the	O
ground	O
for	O
identification	O
of	O
virus	O
fusion	O
/	O
entry	O
inhibitors	O
for	O
this	O
devastating	O
emerging	O
virus	O
.	O

These	O
antibodies	O
were	O
bound	O
to	O
protein	O
A	O
-	O
coated	O
ELISA	O
wells	O
armed	O
with	O
rabbit	B-PRGE
anti	I-PRGE
-	I-PRGE
mouse	I-PRGE
IgG	I-PRGE
antibodies	I-PRGE
.	O

The	O
CCoV	O
fluorogenic	O
RT	O
-	O
PCR	O
assay	O
,	O
which	O
targeted	O
the	O
ORF5	B-PRGE
(	O
M	B-PRGE
gene	I-PRGE
),	O
was	O
more	O
sensitive	O
than	O
a	O
conventional	O
RT	O
-	O
PCR	O
assay	O
targeting	O
the	O
same	O
gene	O
,	O
showing	O
a	O
detection	O
limit	O
of	O
10	O
copies	O
of	O
CCoV	O
standard	O
RNA	O
,	O
and	O
was	O
linear	O
from	O
10	O
to	O
10	O
(	O
8	O
)	O
copies	O
,	O
allowing	O
quantitation	O
of	O
samples	O
with	O
a	O
wide	O
range	O
of	O
CCoV	O
RNA	O
loads	O
.	O

We	O
found	O
that	O
lectin	B-PRGE
PHA	I-PRGE
-	I-PRGE
L	I-PRGE
(	I-PRGE
Phaseolus	I-PRGE
vulgaris	I-PRGE
L	I-PRGE
.),	I-PRGE
which	O
is	O
specific	O
for	O
a	O
defined	O
complex	O
carbohydrate	O
of	O
ASOR	O
,	O
stained	O
the	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	O
specifically	O
and	O
intensively	O
.	O

Fusion	O
of	O
coronaviruses	O
with	O
the	O
host	O
cell	O
is	O
mediated	O
by	O
the	O
envelope	B-PRGE
spike	I-PRGE
protein	I-PRGE
.	O

Entry	O
of	O
coronaviruses	O
into	O
target	O
cells	O
is	O
mediated	O
by	O
the	O
viral	B-PRGE
S	I-PRGE
protein	I-PRGE
.	O

The	O
soluble	O
fibrin	B-PRGE
monomer	I-PRGE
-	I-PRGE
fibrinogen	I-PRGE
complex	I-PRGE
(	O
SF	O
)	O
is	O
a	O
complex	O
coupling	O
fibrin	O
monomer	O
and	O
fibrinogen	B-PRGE
molecules	O
to	O
be	O
formed	O
in	O
the	O
early	O
-	O
activated	O
state	O
of	O
blood	O
coagulation	O
.	O

TITLE	O
:	O
Rapid	O
identification	O
of	O
coronavirus	O
replicase	B-PRGE
inhibitors	O
using	O
a	O
selectable	O
replicon	O
RNA	O
.	O

Amongst	O
those	O
,	O
interferon	B-PRGE
-	I-PRGE
alpha	I-PRGE
displayed	O
the	O
strongest	O
inhibitory	O
activity	O
.	O

Once	O
this	O
technology	O
is	O
adapted	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
replicon	I-PRGE
RNAs	I-PRGE
,	O
it	O
will	O
allow	O
high	O
throughput	O
screening	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
replicase	I-PRGE
inhibitors	O
without	O
the	O
need	O
to	O
grow	O
infectious	O
SARS	O
-	O
CoV	O
.	O

Intraperitoneal	O
injection	O
of	O
cerulein	O
in	O
mice	O
resulted	O
in	O
severe	O
,	O
acute	O
pancreatitis	O
characterised	O
by	O
oedema	O
,	O
neutrophil	O
infiltration	O
,	O
tissue	O
haemorrhage	O
and	O
necrosis	O
and	O
elevated	O
serum	O
levels	O
of	O
amylase	B-PRGE
and	O
lipase	B-PRGE
.	O

Taken	O
together	O
,	O
our	O
results	O
clearly	O
demonstrate	O
that	O
prevention	O
of	O
the	O
activation	O
of	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
by	O
calpain	B-PRGE
I	I-PRGE
inhibitor	O
ameliorates	O
experimental	O
murine	O
acute	O
pancreatitis	O
.	O

Recombinant	O
N	O
and	O
S	O
proteins	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
were	O
purified	O
from	O
transformed	O
E	O
.	O
coli	O
.	O

Canine	O
coronavirus	O
BGF	O
revealed	O
a	O
full	O
length	O
non	O
-	O
structural	O
protein	O
3b	O
(	O
nsp	B-PRGE
3b	I-PRGE
),	O
associated	O
with	O
virulence	O
in	O
other	O
coronaviruses	O
,	O
and	O
a	O
highly	O
divergent	O
region	O
at	O
the	O
amino	O
terminal	O
domain	O
of	O
the	O
membrane	O
protein	O
that	O
may	O
be	O
implicated	O
in	O
avoiding	O
the	O
host	O
immune	O
reaction	O
.	O

The	O
remaining	O
68	O
received	O
combination	O
treatment	O
at	O
a	O
mean	O
of	O
5	O
.	O
8	O
days	O
after	O
symptom	O
onset	O
,	O
of	O
whom	O
30	O
subsequently	O
required	O
pulsed	O
methylprednisolone	O
rescue	O
(	O
independent	O
predictors	O
:	O
older	O
age	O
and	O
higher	O
LDH	B-PRGE
)	O
and	O
18	O
required	O
assisted	O
ventilation	O
(	O
independent	O
predictors	O
:	O
older	O
age	O
,	O
higher	O
oxygen	O
requirement	O
and	O
creatinine	O
level	O
).	O

TITLE	O
:	O
Attenuation	O
of	O
SARS	O
coronavirus	O
by	O
a	O
short	O
hairpin	O
RNA	O
expression	O
plasmid	O
targeting	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
.	O

Here	O
,	O
we	O
provide	O
evidences	O
that	O
RNAi	O
targeting	O
at	O
coronavirus	O
RNA	O
-	O
dependent	O
RNA	B-PRGE
polymerase	I-PRGE
(	O
RDRP	O
)	O
using	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
expression	O
plasmids	O
can	O
specifically	O
inhibit	O
expression	O
of	O
extraneous	O
coronavirus	O
RDRP	O
in	O
293	O
and	O
HeLa	O
cells	O
.	O

TITLE	O
:	O
Comparison	O
of	O
four	O
regions	O
in	O
the	O
replicase	B-PRGE
gene	I-PRGE
of	O
heterologous	O
infectious	O
bronchitis	O
virus	O
strains	O
.	O

However	O
,	O
the	O
IBV	O
strain	O
classification	O
based	O
on	O
replicase	B-PRGE
gene	O
domains	O
did	O
not	O
correlate	O
with	O
that	O
of	O
the	O
type	O
-	O
specific	O
antigenic	O
groups	O
.	O

HR1	O
-	O
1	O
and	O
HR2	B-PRGE
-	I-PRGE
18	I-PRGE
can	O
serve	O
as	O
functional	O
probes	O
for	O
dissecting	O
the	O
fusion	O
mechanism	O
of	O
SARS	O
-	O
CoV	O
and	O
also	O
provide	O
the	O
potential	O
of	O
further	O
identifying	O
potent	O
inhibitors	O
for	O
SARS	O
-	O
CoV	O
entry	O
.	O

TITLE	O
:	O
Identification	O
of	O
two	O
antigenic	O
epitopes	O
on	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
.	O

TITLE	O
:	O
[	O
The	O
cloning	O
,	O
expression	O
,	O
purification	O
and	O
identification	O
of	O
SARS	B-PRGE
virus	I-PRGE
S2	I-PRGE
gene	I-PRGE
and	O
study	O
on	O
its	O
immunological	O
characteristics	O
].	O

In	O
two	O
follow	O
-	O
up	O
surveys	O
,	O
the	O
percentages	O
of	O
CD3	B-PRGE
(+),	I-PRGE
CD4	B-PRGE
(+),	O
CD8	B-PRGE
(+)	O
CD28	O
(+)	O
T	O
cells	O
and	O
the	O
ratio	O
of	O
CD4	B-PRGE
(+)/	O
CD8	B-PRGE
(+)	O
T	O
cells	O
were	O
remarkably	O
lower	O
than	O
those	O
of	O
normal	O
values	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
while	O
the	O
percentage	O
of	O
CD8	B-PRGE
(+)	O
CD28	O
(-)	O
T	O
cells	O
was	O
higher	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

Phosphorylation	O
of	O
p38	B-PRGE
MAPK	I-PRGE
was	O
significantly	O
up	O
-	O
regulated	O
at	O
18	O
h	O
.	O
p	O
.	O
i	O
.	O

The	O
p38	B-PRGE
MAPK	I-PRGE
inhibitor	O
,	O
SB203580	O
,	O
inhibited	O
effectively	O
phosphorylation	O
of	O
HSP	B-PRGE
-	I-PRGE
27	I-PRGE
,	O
CREB	B-PRGE
,	O
and	O
eIF4E	B-PRGE
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	O
.	O

Recombinant	B-PRGE
SCoV	I-PRGE
S	I-PRGE
protein	I-PRGE
appears	O
to	O
be	O
a	O
suitable	O
antigen	O
for	O
the	O
development	O
of	O
an	O
efficient	O
and	O
sensitive	O
diagnostic	O
test	O
for	O
SARS	O
,	O
but	O
our	O
data	O
suggest	O
that	O
assay	O
format	O
and	O
choice	O
of	O
S	B-PRGE
antigen	I-PRGE
are	O
important	O
considerations	O
.	O

Furthermore	O
,	O
administration	O
of	O
NO	O
donors	O
,	O
independent	O
of	O
cytokine	O
stimulation	O
,	O
decreased	O
SP	B-PRGE
-	I-PRGE
B	I-PRGE
promoter	I-PRGE
activity	O
and	O
mRNA	O
expression	O
in	O
mouse	O
lung	O
epithelial	O
cells	O
.	O

We	O
conclude	O
that	O
NPPV	O
is	O
a	O
feasible	O
and	O
appropriate	O
treatment	O
for	O
ARF	B-PRGE
occurring	O
as	O
a	O
result	O
of	O
a	O
SARS	O
infection	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
two	O
homology	O
models	O
(	O
denoted	O
as	O
MproST	O
and	O
MproSH	O
)	O
of	O
main	B-PRGE
proteinase	I-PRGE
(	O
Mpro	O
)	O
from	O
the	O
novel	O
coronavirus	O
associated	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
-	O
CoV	O
)	O
were	O
constructed	O
based	O
on	O
the	O
crystal	O
structures	O
of	O
Mpro	O
from	O
transmissible	O
gastroenteritis	O
coronavirus	O
(	O
TGEV	O
)	O
(	O
MproT	O
)	O
and	O
human	B-PRGE
coronavirus	I-PRGE
HcoV	I-PRGE
-	I-PRGE
229E	I-PRGE
(	O
MproH	O
),	O
respectively	O
.	O

The	O
results	O
indicated	O
that	O
S	B-PRGE
protein	I-PRGE
expressed	O
in	O
transgenic	O
plants	O
might	O
be	O
a	O
new	O
source	O
for	O
the	O
production	O
of	O
Coronaviridae	O
IBV	O
vaccine	O
.	O

TITLE	O
:	O
Coronavirus	O
spike	O
glycoprotein	O
,	O
extended	O
at	O
the	O
carboxy	O
terminus	O
with	O
green	B-PRGE
fluorescent	I-PRGE
protein	I-PRGE
,	O
is	O
assembly	O
competent	O
.	O

Knowing	O
that	O
subtle	O
mutations	O
in	O
the	O
carboxy	O
-	O
terminal	O
endodomain	O
of	O
the	O
M	B-PRGE
protein	I-PRGE
are	O
already	O
lethal	O
,	O
we	O
have	O
now	O
probed	O
the	O
equivalent	O
domain	O
of	O
the	O
spike	O
(	O
S	O
)	O
protein	O
by	O
extending	O
it	O
terminally	O
with	O
a	O
foreign	O
sequence	O
of	O
27	O
kDa	O
:	O
the	O
green	B-PRGE
fluorescent	I-PRGE
protein	I-PRGE
(	O
GFP	O
).	O

Characterization	O
of	O
the	O
nsp13	O
-	O
associated	O
nucleoside	B-PRGE
triphosphatase	I-PRGE
(	O
NTPase	B-PRGE
)	O
activities	O
revealed	O
that	O
all	O
natural	O
ribonucleotides	O
and	O
nucleotides	O
are	O
substrates	O
of	O
nsp13	O
,	O
with	O
ATP	O
,	O
dATP	O
,	O
and	O
GTP	O
being	O
hydrolyzed	O
most	O
efficiently	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
an	O
emerging	O
infectious	O
disease	O
associated	O
with	O
a	O
new	O
coronavirus	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
Pulmonary	O
involvement	O
is	O
the	O
dominant	O
clinical	O
feature	O
but	O
extra	O
-	O
pulmonary	O
manifestations	O
are	O
also	O
common	O
.	O

ACE2	B-PRGE
is	O
expressed	O
at	O
high	O
level	O
in	O
the	O
primary	O
target	O
cells	O
of	O
SARS	O
-	O
CoV	O
,	O
namely	O
pneumocytes	O
and	O
surface	O
enterocytes	O
of	O
the	O
small	O
intestine	O
.	O

Horse	O
polyclonal	O
antibody	O
against	O
SARS	O
-	O
CoV	O
was	O
bound	O
onto	O
the	O
PZ	O
crystal	O
surface	O
in	O
an	O
ordered	O
orientation	O
through	O
protein	O
A	O
.	O
The	O
antigen	O
sample	O
was	O
atomized	O
into	O
aerosol	O
by	O
an	O
ultrasonator	O
,	O
by	O
which	O
the	O
antibody	O
on	O
the	O
crystal	O
could	O
specifically	O
adsorb	O
SARS	B-PRGE
antigen	I-PRGE
and	O
the	O
changed	O
mass	O
of	O
crystal	O
would	O
lead	O
a	O
frequency	O
shift	O
.	O

Nucleotide	O
acid	O
sequence	O
of	O
S1	B-PRGE
gene	I-PRGE
of	O
the	O
isolate	O
SC021202	O
was	O
further	O
sequenced	O
and	O
analysed	O
.	O

It	O
was	O
preliminarily	O
demonstrated	O
that	O
the	O
assay	O
could	O
efficiently	O
detect	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
from	O
clinical	O
specimens	O
of	O
SARS	O
probable	O
and	O
suspected	O
patients	O
identified	O
in	O
Taiwan	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
inhibitory	O
effect	O
of	O
serum	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
-	O
specific	O
antibodies	O
from	O
convalescent	O
patients	O
after	O
half	O
an	O
year	O
of	O
onset	O
on	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	O
mediated	O
cytopathic	O
response	O
.	O

Further	O
studies	O
should	O
be	O
performed	O
to	O
see	O
whether	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
antibody	I-PRGE
positivity	O
has	O
any	O
prognostic	O
significance	O
.	O

The	O
appearance	O
and	O
persistence	O
of	O
SARS	O
-	O
CoV	O
-	O
specific	O
antibodies	O
were	O
assessed	O
,	O
with	O
immunoglobulin	B-PRGE
G	I-PRGE
detected	O
in	O
59	O
%	O
of	O
samples	O
collected	O
within	O
14	O
days	O
and	O
persisting	O
for	O
60	O
to	O
95	O
days	O
after	O
the	O
onset	O
of	O
illness	O
.	O

We	O
report	O
here	O
a	O
modification	O
of	O
standard	O
DNA	O
sequencing	O
technology	O
for	O
accurate	O
identification	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
in	O
routine	O
testing	O
.	O

TITLE	O
:	O
Association	O
of	O
human	B-PRGE
-	I-PRGE
leukocyte	I-PRGE
-	I-PRGE
antigen	I-PRGE
class	O
I	O
(	O
B	O
*	O
0703	O
)	O
and	O
class	O
II	O
(	O
DRB1	O
*	O
0301	O
)	O
genotypes	O
with	O
susceptibility	O
and	O
resistance	O
to	O
the	O
development	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

For	O
the	O
first	O
time	O
,	O
all	O
of	O
the	O
four	O
predicted	O
structural	O
proteins	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
were	O
identified	O
,	O
including	O
S	O
(	O
Spike	O
),	O
M	O
(	O
Membrane	O
),	O
N	O
(	O
Nucleocapsid	O
),	O
and	O
E	O
(	O
Envolope	O
)	O
proteins	O
.	O

CD66a	B-PRGE
is	O
an	O
adhesion	O
molecule	O
expressed	O
on	O
bone	O
marrow	O
CD34	O
+	O
cells	O
,	O
platelets	O
,	O
granulocytes	O
and	O
activated	O
lymphocytes	O
.	O

We	O
were	O
able	O
to	O
pseudotype	O
murine	O
leukemia	O
virus	O
particles	O
with	O
S	B-PRGE
-	I-PRGE
protein	I-PRGE
and	O
produce	O
SARS	O
pseudoviruses	O
.	O

ABSTRACT	O
:	O
Processing	O
and	O
presentation	O
of	O
major	B-PRGE
histocompatibility	I-PRGE
complex	I-PRGE
class	I-PRGE
I	I-PRGE
antigens	I-PRGE
to	O
cytotoxic	O
T	O
-	O
lymphocytes	O
is	O
crucial	O
for	O
immune	O
surveillance	O
against	O
intracellular	O
bacteria	O
,	O
parasites	O
,	O
viruses	O
and	O
tumors	O
.	O

The	O
models	O
were	O
rigorously	O
trained	O
,	O
tested	O
and	O
validated	O
using	O
experimentally	O
identified	O
HLA	B-PRGE
class	I-PRGE
I	I-PRGE
T	I-PRGE
-	I-PRGE
cell	I-PRGE
epitopes	I-PRGE
from	O
human	B-PRGE
melanoma	I-PRGE
related	I-PRGE
proteins	I-PRGE
and	O
human	B-PRGE
papillomavirus	I-PRGE
proteins	I-PRGE
E6	I-PRGE
and	O
E7	O
.	O

Our	O
predictions	O
against	O
experimental	O
data	O
from	O
four	O
melanoma	O
-	O
related	O
proteins	O
showed	O
that	O
MULTIPRED	O
ANN	O
and	O
HMM	O
models	O
could	O
predict	O
T	B-PRGE
-	I-PRGE
cell	I-PRGE
epitopes	I-PRGE
with	O
high	O
accuracy	O
.	O

Protease	O
inhibitors	O
(	O
lopinavir	O
/	O
ritonavir	O
)	O
in	O
combination	O
with	O
ribavirin	O
may	O
play	O
a	O
role	O
as	O
antiviral	O
therapy	O
in	O
the	O
early	O
phase	O
,	O
whereas	O
the	O
role	O
of	O
IFN	B-PRGE
and	O
systemic	O
steroid	O
in	O
preventing	O
immune	O
-	O
mediated	O
lung	O
injury	O
deserves	O
further	O
investigation	O
.	O

About	O
10	O
%	O
convalescence	O
SARS	O
patients	O
might	O
still	O
carry	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
in	O
hospitalization	O
.	O

To	O
find	O
disease	O
-	O
specific	O
B	O
cell	O
epitopes	O
,	O
phage	O
-	O
displayed	O
random	O
peptide	O
libraries	O
were	O
panned	O
on	O
serum	O
immunoglobulin	B-PRGE
(	O
Ig	O
)	O
G	O
antibodies	O
from	O
patients	O
with	O
SARS	O
.	O

SARS	B-PRGE
is	O
a	O
novel	O
,	O
highly	O
infectious	O
pneumonia	O
,	O
and	O
its	O
psychological	O
impact	O
is	O
still	O
unclear	O
.	O

The	O
complete	O
genome	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
(	O
SARS	B-PRGE
coronavirus	O
)	O
has	O
since	O
been	O
sequenced	O
.	O

Two	O
of	O
them	O
,	O
B10	O
and	O
C20	O
,	O
could	O
recognize	O
non	O
-	O
overlapping	O
epitopes	O
of	O
the	O
E	B-PRGE
protein	I-PRGE
according	O
to	O
the	O
two	O
-	O
site	O
binding	O
test	O
result	O
.	O

A	O
number	O
of	O
variants	O
with	O
deletions	O
and	O
mutations	O
in	O
the	O
S	B-PRGE
protein	I-PRGE
have	O
been	O
isolated	O
from	O
naturally	O
and	O
persistently	O
infected	O
animals	O
and	O
tissue	O
cultures	O
.	O

Throat	O
or	O
nasopharyngeal	O
swab	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
by	O
reverse	B-PRGE
transcriptase	I-PRGE
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
real	O
-	O
time	O
PCR	O
was	O
positive	O
in	O
40	O
of	O
the	O
47	O
patients	O
(	O
85	O
%)	O
in	O
whom	O
the	O
test	O
was	O
performed	O
.	O

TITLE	O
:	O
A	O
novel	O
sorting	O
signal	O
for	O
intracellular	O
localization	O
is	O
present	O
in	O
the	O
S	B-PRGE
protein	I-PRGE
of	O
a	O
porcine	O
coronavirus	O
but	O
absent	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
.	O

Replication	O
of	O
the	O
approximately	O
30	O
-	O
kb	O
positive	O
-	O
strand	O
RNA	O
genome	O
of	O
coronaviruses	O
and	O
discontinuous	O
synthesis	O
of	O
an	O
extensive	O
set	O
of	O
subgenome	O
-	O
length	O
RNAs	O
(	O
transcription	O
)	O
are	O
mediated	O
by	O
the	O
replicase	B-PRGE
-	I-PRGE
transcriptase	I-PRGE
,	O
a	O
barely	O
characterized	O
protein	O
complex	O
that	O
comprises	O
several	O
cellular	O
proteins	O
and	O
up	O
to	O
16	O
viral	O
subunits	O
.	O

This	O
completed	O
the	O
fulfilment	O
of	O
Koch	O
'	O
s	O
postulates	O
,	O
as	O
modified	O
by	O
Rivers	O
for	O
viral	O
diseases	O
,	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
as	O
the	O
aetiological	O
agent	O
of	O
SARS	O
.	O

TITLE	O
:	O
Sequential	O
changes	O
of	O
serum	B-PRGE
aminotransferase	I-PRGE
levels	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

Flow	O
cytometry	O
showed	O
that	O
MHV	O
-	O
A59	O
bound	O
only	O
to	O
cells	O
that	O
expressed	O
the	O
murine	B-PRGE
glycoprotein	I-PRGE
receptor	I-PRGE
CEACAM1a	I-PRGE
.	O

Thus	O
,	O
21	O
amino	O
acid	O
substitutions	O
and	O
a	O
7	O
-	O
amino	O
-	O
acid	O
insert	O
in	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
S	B-PRGE
glycoprotein	I-PRGE
of	O
MHV	O
/	O
BHK	O
confer	O
the	O
ability	O
to	O
bind	O
and	O
in	O
some	O
cases	O
infect	O
cells	O
of	O
nonmurine	O
species	O
.	O

We	O
have	O
previously	O
expressed	O
various	O
soluble	O
fragments	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
SU	I-PRGE
and	O
identified	O
stably	O
folded	O
fragments	O
(	O
residues	O
272	O
-	O
537	O
)	O
that	O
contain	O
the	O
RBD	O
[	O
Biochem	O
.	O

NAbs	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
are	O
broadly	O
elicited	O
in	O
patients	O
with	O
SARS	O
and	O
,	O
according	O
to	O
their	O
kinetics	O
,	O
may	O
correlate	O
with	O
viral	O
load	O
during	O
the	O
early	O
stages	O
of	O
the	O
disease	O
.	O

APC	B-PRGE
reduces	O
the	O
pulmonary	O
endothelial	O
cell	O
injury	O
and	O
hypotension	O
in	O
rats	O
administered	O
endotoxin	O
(	O
ET	O
)	O
by	O
inhibiting	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
production	O
through	O
inhibition	O
of	O
its	O
transcription	O
.	O

Inhibition	O
by	O
APC	B-PRGE
of	O
the	O
endothelial	O
cell	O
damage	O
inhibited	O
the	O
decrease	O
in	O
the	O
endothelial	O
production	O
of	O
prostacyclin	O
in	O
vivo	O
.	O

APC	B-PRGE
inhibits	O
ET	O
-	O
induced	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
production	O
in	O
vitro	O
in	O
human	O
monocytes	O
by	O
inhibiting	O
activation	O
of	O
NFkappaB	O
and	O
AP	B-PRGE
-	I-PRGE
1	I-PRGE
by	O
inhibiting	O
degradation	O
of	O
IkappaB	O
and	O
mitogen	B-PRGE
-	I-PRGE
activated	I-PRGE
protein	I-PRGE
kinase	I-PRGE
pathways	O
,	O
respectively	O
.	O

Recombinant	B-PRGE
APC	I-PRGE
was	O
reported	O
to	O
reduce	O
the	O
mortality	O
of	O
patients	O
with	O
severe	O
sepsis	O
.	O

N	B-PRGE
protein	I-PRGE
is	O
denatured	O
reversibly	O
at	O
pH	O
7	O
.	O
4	O
either	O
by	O
urea	O
(	O
with	O
C	O
(	O
m	O
)	O
of	O
2	O
.	O
77	O
M	O
and	O
m	O
value	O
of	O
2	O
.	O
74	O
kcal	O
mol	O
(-	O
1	O
)	O
M	O
(-	O
1	O
))	O
or	O
GdmCl	O
(	O
with	O
C	O
(	O
m	O
)	O
of	O
1	O
.	O
46	O
M	O
and	O
m	O
value	O
of	O
4	O
.	O
50	O
kcal	O
mol	O
(-	O
1	O
)	O
M	O
(-	O
1	O
)).	O

Thus	O
,	O
binding	O
of	O
autoAb	O
to	O
insolubilized	O
FAH	B-PRGE
could	O
be	O
inhibited	O
by	O
MHV	O
depending	O
on	O
the	O
mouse	O
serum	O
or	O
the	O
experimental	O
protocol	O
used	O
.	O

We	O
have	O
genetically	O
dissected	O
these	O
domains	O
in	O
the	O
MHV	B-PRGE
S	I-PRGE
protein	I-PRGE
to	O
localize	O
the	O
determinants	O
of	O
S	O
incorporation	O
into	O
virions	O
.	O

Immunofluorescence	O
microscopy	O
detected	O
similar	O
patterns	O
of	O
punctate	O
perinuclear	O
and	O
distributed	O
cytoplasmic	O
foci	O
with	O
all	O
replicase	B-PRGE
antibodies	I-PRGE
and	O
as	O
early	O
as	O
6	O
h	O
postinfection	O
.	O

These	O
results	O
confirm	O
the	O
predicted	O
protein	O
processing	O
pattern	O
for	O
mature	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
replicase	I-PRGE
proteins	I-PRGE
,	O
demonstrate	O
localization	O
of	O
replicase	B-PRGE
proteins	I-PRGE
to	O
cytoplasmic	O
complexes	O
containing	O
markers	O
for	O
autophagosome	O
membranes	O
,	O
and	O
suggest	O
conservation	O
of	O
protein	O
epitopes	O
in	O
the	O
replicase	B-PRGE
and	O
nucleocapsid	O
of	O
SARS	O
-	O
CoV	O
and	O
the	O
group	O
II	O
coronavirus	O
,	O
MHV	O
.	O

We	O
have	O
now	O
engineered	O
and	O
produced	O
a	O
Ceacam1a	O
-/-	O
mouse	O
that	O
exhibits	O
complete	O
ablation	O
of	O
the	O
CEACAM1a	B-PRGE
protein	I-PRGE
in	O
every	O
tissue	O
where	O
it	O
is	O
normally	O
expressed	O
.	O

The	O
positive	O
rates	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
IgG	I-PRGE
in	O
those	O
chains	O
were	O
85	O
.	O
70	O
%-	O
100	O
.	O
00	O
%	O
and	O
the	O
overall	O
rate	O
was	O
94	O
.	O
30	O
%	O
(	O
149	O
/	O
158	O
).	O

CONCLUSIONS	O
:	O
More	O
than	O
94	O
%	O
of	O
cases	O
with	O
SARS	O
could	O
produce	O
IgG	B-PRGE
antibody	I-PRGE
when	O
they	O
were	O
infected	O
by	O
SARS	O
-	O
CoV	O
.	O
Detecting	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
IgG	I-PRGE
could	O
provide	O
a	O
diagnostic	O
evidence	O
for	O
case	O
confirmation	O
.	O

CONCLUSIONS	O
:	O
With	O
or	O
without	O
treatment	O
with	O
glucocorticoids	O
,	O
the	O
lowered	O
CD3	B-PRGE
+,	I-PRGE
CD4	B-PRGE
+,	I-PRGE
CD8	B-PRGE
+	I-PRGE
T	O
-	O
lymphocyte	O
counts	O
in	O
the	O
early	O
stage	O
are	O
of	O
very	O
important	O
significance	O
in	O
differential	O
diagnosis	O
between	O
severe	O
acute	O
respiratory	O
syndrome	O
and	O
common	O
atypical	O
pneumonia	O
.	O

The	O
average	O
minimum	O
amount	O
of	O
interferon	B-PRGE
alpha	I-PRGE
2b	I-PRGE
,	I-PRGE
alpha	I-PRGE
1b	I-PRGE
,	I-PRGE
beta	I-PRGE
1b	I-PRGE
or	O
omega	B-PRGE
1b	I-PRGE
to	O
inhibit	O
50	O
%	O
CPE	O
in	O
Rda	O
cell	O
culture	O
was	O
(	O
160	O
.	O
5	O
+/-	O
129	O
.	O
5	O
)	O
IU	O
/	O
ml	O
,	O
(	O
149	O
.	O
0	O
+/-	O
71	O
.	O
7	O
)	O
IU	O
/	O
ml	O
,	O
(	O
69	O
.	O
5	O
+/-	O
61	O
.	O
5	O
)	O
IU	O
/	O
ml	O
,	O
(	O
87	O
.	O
3	O
+/-	O
47	O
.	O
1	O
)	O
IU	O
/	O
ml	O
,	O
respectively	O
or	O
(	O
0	O
.	O
6	O
+/-	O
0	O
.	O
5	O
)	O
ng	O
/	O
ml	O
,	O
(	O
10	O
.	O
6	O
+/-	O
5	O
.	O
1	O
)	O
ng	O
/	O
ml	O
,	O
(	O
3	O
.	O
5	O
+/-	O
3	O
.	O
1	O
)	O
ng	O
/	O
ml	O
,	O
(	O
0	O
.	O
9	O
+/-	O
0	O
.	O
5	O
)	O
ng	O
/	O
ml	O
,	O
respectively	O
.	O

RESULTS	O
:	O
The	O
average	O
minimum	O
amount	O
of	O
interferon	B-PRGE
alpha	I-PRGE
2b	I-PRGE
,	I-PRGE
alpha	I-PRGE
1b	I-PRGE
,	I-PRGE
beta	I-PRGE
1b	I-PRGE
or	O
omega	B-PRGE
1b	I-PRGE
to	O
inhibit	O
50	O
%	O
CPE	O
in	O
Rda	O
cell	O
culture	O
was	O
(	O
160	O
.	O
5	O
+/-	O
129	O
.	O
5	O
)	O
IU	O
/	O
ml	O
,	O
(	O
149	O
.	O
0	O
+/-	O
71	O
.	O
7	O
)	O
IU	O
/	O
ml	O
,	O
(	O
69	O
.	O
5	O
+/-	O
61	O
.	O
5	O
)	O
IU	O
/	O
ml	O
,	O
(	O
87	O
.	O
3	O
+/-	O
47	O
.	O
1	O
)	O
IU	O
/	O
ml	O
,	O
respectively	O
or	O
(	O
0	O
.	O
6	O
+/-	O
0	O
.	O
5	O
)	O
ng	O
/	O
ml	O
,	O
(	O
10	O
.	O
6	O
+/-	O
5	O
.	O
1	O
)	O
ng	O
/	O
ml	O
,	O
(	O
3	O
.	O
5	O
+/-	O
3	O
.	O
1	O
)	O
ng	O
/	O
ml	O
,	O
(	O
0	O
.	O
9	O
+/-	O
0	O
.	O
5	O
)	O
ng	O
/	O
ml	O
,	O
respectively	O
.	O

The	O
semi	O
-	O
quantitative	O
analysis	O
of	O
lymphocyte	O
subpopulations	O
revealed	O
that	O
the	O
proportion	O
of	O
CD8	B-PRGE
+	I-PRGE
T	O
lymphocytes	O
were	O
about	O
80	O
%	O
of	O
the	O
total	O
infiltrative	O
inflammatory	O
cells	O
in	O
the	O
pulmonary	O
interstitium	O
,	O
with	O
a	O
few	O
CD4	B-PRGE
+	I-PRGE
lymphocytes	O
CD3	B-PRGE
+,	I-PRGE
CD4	B-PRGE
+,	I-PRGE
CD8	B-PRGE
+	I-PRGE
or	O
CD20	O
+	O
lymphocyte	O
subpopulations	O
were	O
obviously	O
decreased	O
and	O
there	O
was	O
imbalance	O
in	O
number	O
and	O
proportion	O
,	O
while	O
CD57	B-PRGE
+,	I-PRGE
CD68	B-PRGE
+,	I-PRGE
S	O
-	O
100	O
+	O
and	O
HLA	B-PRGE
-	I-PRGE
DR	I-PRGE
+	I-PRGE
cells	O
were	O
relatively	O
increased	O
in	O
lymph	O
nodes	O
and	O
spleens	O
.	O

Phosphorylation	O
of	O
a	O
serine	O
residue	O
on	O
Akt	B-PRGE
was	O
detected	O
at	O
least	O
8	O
h	O
postinfection	O
(	O
hpi	O
),	O
which	O
declined	O
after	O
18	O
hpi	O
.	O

Thus	O
,	O
the	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI3K	B-PRGE
)/	O
Akt	B-PRGE
pathway	O
is	O
activated	O
in	O
virus	O
-	O
infected	O
Vero	O
E6	O
cells	O
.	O

Inflammatory	O
cytokines	O
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
),	O
protein	O
concentration	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluid	O
,	O
lung	O
wet	O
-	O
to	O
-	O
dry	O
weight	O
ratio	O
,	O
histology	O
,	O
immunohistochemistry	O
,	O
and	O
AQP1	B-PRGE
Western	O
blot	O
were	O
performed	O
.	O

AQP1	B-PRGE
-	O
immunoreactivity	O
in	O
the	O
pulmonary	O
capillary	O
endothelium	O
was	O
reduced	O
at	O
2	O
days	O
and	O
7	O
days	O
.	O

Administration	O
of	O
dexamethasone	O
improved	O
LPS	O
-	O
induced	O
ALI	O
and	O
retained	O
expression	O
of	O
AQP1	B-PRGE
.	O

Researchers	O
at	O
the	O
Rega	O
Institute	O
in	O
Belgium	O
have	O
published	O
results	O
from	O
an	O
animal	O
study	O
demonstrating	O
that	O
Ampligen	O
was	O
superior	O
at	O
protecting	O
mice	O
against	O
coxsackie	O
B3	O
virus	O
-	O
induced	O
myocarditis	O
compared	O
with	O
pegylated	O
interferon	B-PRGE
.	O

Array	O
data	O
showed	O
monocyte	O
-	O
macrophage	O
cell	O
activation	O
,	O
coagulation	O
pathway	O
upregulation	O
and	O
cytokine	O
production	O
together	O
with	O
lung	O
trafficking	O
chemokines	O
such	O
as	O
IL8	B-PRGE
and	O
IL17	B-PRGE
,	O
possibly	O
activated	O
through	O
the	O
TLR9	B-PRGE
signaling	O
pathway	O
;	O
that	O
mimicked	O
clinical	O
features	O
of	O
the	O
disease	O
.	O

Protein	B-PRGE
-	I-PRGE
protein	I-PRGE
interaction	O
analysis	O
using	O
bioinformatics	O
tools	O
indicated	O
that	O
SARS_NP	O
may	O
bind	O
to	O
human	B-PRGE
cyclophilin	I-PRGE
A	I-PRGE
(	O
hCypA	O
),	O
and	O
surface	O
plasmon	O
resonance	O
(	O
SPR	O
)	O
technology	O
revealed	O
this	O
binding	O
with	O
the	O
equilibrium	O
dissociation	O
constant	O
ranging	O
from	O
6	O
to	O
160nM	O
.	O
The	O
probable	O
binding	O
sites	O
of	O
these	O
two	O
proteins	O
were	O
detected	O
by	O
modeling	O
the	O
three	O
-	O
dimensional	O
structure	O
of	O
the	O
SARS_NP	O
-	O
hCypA	O
complex	O
,	O
from	O
which	O
the	O
important	O
interaction	O
residue	O
pairs	O
between	O
the	O
proteins	O
were	O
deduced	O
.	O

These	O
data	O
suggest	O
that	O
CKLF1	B-PRGE
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
these	O
important	O
diseases	O
and	O
the	O
study	O
also	O
implies	O
that	O
gene	O
electro	O
-	O
transfer	O
in	O
vivo	O
could	O
serve	O
as	O
a	O
valuable	O
approach	O
for	O
evaluating	O
the	O
function	O
of	O
a	O
novel	O
gene	O
in	O
animals	O
.	O

These	O
changes	O
included	O
peribronchial	O
leukocyte	O
infiltration	O
,	O
epithelial	O
shedding	O
,	O
collagen	B-PRGE
deposition	O
,	O
proliferation	O
of	O
bronchial	O
smooth	O
muscle	O
cells	O
and	O
fibrosis	O
of	O
the	O
lung	O
.	O

CONCLUSIONS	O
:	O
Phage	O
antibody	O
library	O
for	O
human	O
Fab	B-PRGE
fragment	I-PRGE
has	O
been	O
constructed	O
successfully	O
,	O
which	O
lays	O
the	O
foundation	O
for	O
further	O
study	O
.	O

The	O
functions	O
are	O
unknown	O
for	O
most	O
of	O
these	O
nonstructural	O
proteins	O
,	O
including	O
p28	B-PRGE
,	O
which	O
is	O
encoded	O
at	O
the	O
5	O
'	O
end	O
of	O
the	O
MHV	O
genome	O
.	O

Expression	O
of	O
p28	B-PRGE
did	O
not	O
alter	O
the	O
amount	O
of	O
p53	B-PRGE
transcripts	I-PRGE
yet	O
increased	O
the	O
amount	O
of	O
p21	B-PRGE
(	O
Cip1	B-PRGE
)	O
transcripts	O
,	O
suggesting	O
that	O
p28	B-PRGE
expression	O
increased	O
p53	B-PRGE
stability	O
and	O
that	O
p21	B-PRGE
(	O
Cip1	B-PRGE
)	O
was	O
transcriptionally	O
activated	O
in	O
a	O
p53	B-PRGE
-	O
dependent	O
manner	O
.	O

Finally	O
,	O
we	O
show	O
that	O
a	O
soluble	O
and	O
catalytically	O
inactive	O
form	O
of	O
ACE2	O
potently	O
blocked	O
infection	O
by	O
S	O
-	O
protein	O
-	O
pseudotyped	O
retrovirus	O
and	O
by	O
SARS	O
-	O
CoV	O
.	O
These	O
results	O
permit	O
studies	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
entry	O
inhibitors	O
without	O
the	O
use	O
of	O
live	O
virus	O
and	O
suggest	O
a	O
candidate	O
therapy	O
for	O
SARS	O
.	O

Mid	B-PRGE
to	O
end	O
expiratory	O
tracheal	O
gas	O
insufflation	O
at	O
8	O
l	O
/	O
min	O
flow	O
rate	O
was	O
delivered	O
for	O
90	O
min	O
while	O
normocapnia	O
was	O
maintained	O
by	O
simultaneous	O
reductions	O
in	O
tidal	O
volume	O
.	O

These	O
findings	O
indicate	O
that	O
increased	O
TF	B-PRGE
-	I-PRGE
alpha	I-PRGE
(	I-PRGE
1	I-PRGE
)-	I-PRGE
AT	I-PRGE
may	O
be	O
therapeutically	O
relevant	O
,	O
and	O
may	O
also	O
be	O
a	O
useful	O
biological	O
marker	O
for	O
the	O
diagnosis	O
of	O
SARS	O
.	O

ABSTRACT	O
:	O
Genomic	O
epidemiologic	O
data	O
,	O
increasingly	O
supported	O
by	O
clinical	O
outcomes	O
results	O
,	O
strongly	O
suggest	O
that	O
overactivity	O
of	O
angiotensin	O
I	O
-	O
converting	O
enzyme	O
(	O
ACE	B-PRGE
)	O
may	O
underlie	O
most	O
age	O
-	O
related	O
diseases	O
.	O

Three	O
selected	O
compounds	O
,	O
MP576	B-PRGE
,	O
HE602	O
,	O
and	O
VE607	O
,	O
validated	O
to	O
be	O
inhibitors	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
(	I-PRGE
pro	I-PRGE
),	I-PRGE
Hel	B-PRGE
,	O
and	O
viral	O
entry	O
,	O
respectively	O
,	O
exhibited	O
potent	O
antiviral	O
activity	O
(	O
EC	O
(	O
50	O
)	O
<	O
10	O
microM	O
)	O
and	O
comparable	O
inhibitory	O
activities	O
in	O
target	O
-	O
specific	O
in	O
vitro	O
assays	O
.	O

Of	O
the	O
40	O
patients	O
,	O
36	O
were	O
IgG	B-PRGE
positive	O
with	O
an	O
average	O
A	O
value	O
of	O
(	O
0	O
.	O
91	O
+/-	O

Statistics	O
showed	O
that	O
serum	O
IgG	B-PRGE
was	O
not	O
related	O
with	O
avascular	O
necrosis	O
of	O
femoral	O
head	O
and	O
osteoporosis	O
.	O

Analysis	O
of	O
the	O
antibody	O
specificity	O
revealed	O
that	O
the	O
mouse	O
antisera	O
contained	O
a	O
mixture	O
of	O
antibodies	O
specifically	O
against	O
the	O
structure	O
proteins	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
Furthermore	O
,	O
the	O
mouse	O
antisera	O
conferred	O
higher	O
amount	O
of	O
antibodies	O
against	O
protein	B-PRGE
N	I-PRGE
,	I-PRGE
polypeptide	I-PRGE
S4	I-PRGE
and	O
S2	O
than	O
those	O
of	O
proteins	O
M	O
and	O
3CL	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
inactivated	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
could	O
preserve	O
its	O
antigenicity	O
and	O
the	O
inactivated	O
vaccine	O
can	O
stimulate	O
mice	O
to	O
produce	O
high	O
levels	O
of	O
antibodies	O
with	O
neutralization	O
activity	O
.	O

ABSTRACT	O
:	O
Spike	B-PRGE
protein	I-PRGE
is	O
one	O
of	O
the	O
major	O
structural	O
proteins	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
.	O

Intranasal	O
BCV	O
(	O
125	O
/	O
407	O
[	O
31	O
%])	O
and	O
serum	B-PRGE
antibody	I-PRGE
titers	O
>	O
or	O
=	O
20	O
against	O
BCV	O
(	O
246	O
/	O
396	O
[	O
62	O
%])	O
were	O
identified	O
in	O
calves	O
entering	O
the	O
feedlot	O
.	O

ABSTRACT	O
:	O
Reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
with	O
specific	O
primers	O
for	O
the	O
S1	B-PRGE
gene	I-PRGE
of	O
IBV	O
and	O
for	O
the	O
fusion	O
protein	O
cleavage	O
site	O
of	O
NDV	O
was	O
used	O
for	O
detection	O
of	O
Infectious	O
bronchitis	O
virus	O
(	O
IBV	O
,	O
the	O
family	O
Coronaviridae	O
)	O
and	O
Newcastle	O
disease	O
virus	O
(	O
NDV	O
)	O
genomes	O
.	O

TITLE	O
:	O
Temporal	O
relationship	O
of	O
viral	O
load	O
,	O
ribavirin	O
,	O
interleukin	B-PRGE
(	O
IL	O
)-	O
6	O
,	O
IL	O
-	O
8	O
,	O
and	O
clinical	O
progression	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

The	O
high	O
level	O
expression	O
of	O
VLPs	O
with	O
correct	O
S	B-PRGE
protein	I-PRGE
conformation	O
by	O
a	O
single	O
recombinant	O
baculovirus	O
offers	O
a	O
potential	O
candidate	O
vaccine	O
for	O
SARS	O
.	O

Based	O
on	O
these	O
data	O
,	O
comparative	O
modeling	O
of	O
the	O
SARS	B-PRGE
-	O
CoV	O
fusion	O
core	O
was	O
performed	O
.	O

These	O
studies	O
suggest	O
that	O
combination	B-PRGE
IFN	I-PRGE
treatment	O
warrants	O
further	O
investigation	O
as	O
a	O
treatment	O
for	O
SARS	O
.	O

Recently	O
,	O
the	O
formation	O
of	O
anti	O
-	O
parallel	O
6	O
-	O
helix	O
bundle	O
of	O
the	O
MHV	B-PRGE
S	I-PRGE
protein	I-PRGE
heptad	O
repeat	O
(	O
HR	O
)	O
regions	O
(	O
HR1	O
and	O
HR2	O
)	O
has	O
been	O
confirmed	O
,	O
implying	O
coronavirus	O
has	O
a	O
class	O
I	O
fusion	O
protein	O
.	O

Deletion	O
mutagenesis	O
experiments	O
determined	O
that	O
the	O
carboxy	O
terminus	O
of	O
p28	B-PRGE
is	O
not	O
required	O
for	O
its	O
interactions	O
with	O
p10	B-PRGE
and	O
p15	B-PRGE
.	O

To	O
express	O
the	O
membrane	O
(	O
M	O
)	O
protein	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
at	O
high	O
-	O
level	O
in	O
vitro	O
,	O
the	O
M	O
gene	O
fragment	O
was	O
amplified	O
and	O
cloned	O
it	O
into	O
the	O
Pichia	O
Pastoris	O
expression	O
vector	O
pPICZalphaA	O
.	O
SDS	O
-	O
PAGE	O
and	O
Western	O
blotting	O
analysis	O
of	O
the	O
induced	O
products	O
of	O
recombinant	O
yeast	O
transformant	O
indicated	O
that	O
successful	O
high	O
-	O
level	O
expression	O
of	O
M	B-PRGE
protein	I-PRGE
was	O
achieved	O
,	O
and	O
that	O
the	O
expression	O
product	O
was	O
similar	O
antigenically	O
to	O
the	O
natural	O
protein	O
.	O

TITLE	O
:	O
Molecular	O
mimicry	O
of	O
ACTH	B-PRGE
in	O
SARS	O
-	O
implications	O
for	O
corticosteroid	O
treatment	O
and	O
prophylaxis	O
.	O

In	O
this	O
article	O
,	O
amino	O
acid	O
sequences	O
from	O
the	O
SARS	O
and	O
influenza	O
viruses	O
representing	O
likely	O
homology	O
to	O
human	B-PRGE
ACTH	I-PRGE
are	O
identified	O
.	O

A	O
molecular	O
characterization	O
of	O
nine	O
monoclonal	O
antibodies	O
raised	O
in	O
immune	O
mice	O
,	O
using	O
highly	O
purified	O
,	O
inactivated	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
as	O
the	O
inoculating	O
antigen	O
,	O
is	O
presented	O
in	O
this	O
report	O
.	O

In	O
this	O
study	O
,	O
genetic	O
variation	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
is	O
analyzed	O
based	O
on	O
available	O
documented	O
data	O
and	O
our	O
study	O
.	O

TITLE	O
:	O
Structure	O
-	O
based	O
discovery	O
of	O
a	O
novel	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
inhibitor	O
.	O

Recently	O
solved	O
high	O
-	O
resolution	O
crystal	O
structures	O
of	O
the	O
apo	O
-	O
bound	O
and	O
inhibitor	O
-	O
bound	O
forms	O
of	O
ACE2	B-PRGE
have	O
provided	O
the	O
basis	O
for	O
a	O
novel	O
molecular	O
docking	O
approach	O
in	O
an	O
attempt	O
to	O
identify	O
ACE2	B-PRGE
inhibitors	O
and	O
compounds	O
that	O
block	O
SARS	O
coronavirus	O
spike	O
protein	O
-	O
mediated	O
cell	O
fusion	O
.	O

In	O
this	O
structure	O
-	O
activity	O
relation	O
study	O
,	O
the	O
molecules	O
with	O
the	O
highest	O
predicted	O
binding	O
scores	O
were	O
identified	O
and	O
assayed	O
for	O
ACE2	B-PRGE
enzymatic	O
inhibitory	O
activity	O
and	O
for	O
their	O
ability	O
to	O
inhibit	O
SARS	O
coronavirus	O
spike	O
protein	O
-	O
mediated	O
cell	O
fusion	O
.	O

SARS	O
-	O
CoV	O
RNA	O
was	O
quantified	O
using	O
a	O
one	O
-	O
step	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assay	O
targeting	O
the	O
nucleocapsid	B-PRGE
gene	I-PRGE
.	O

ABSTRACT	O
:	O
A	O
total	O
of	O
1	O
,	O
068	O
asymptomatic	O
close	O
contacts	O
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
(	O
SARS	O
)	O
from	O
the	O
2003	O
epidemic	O
in	O
Hong	O
Kong	O
were	O
serologically	O
tested	O
,	O
and	O
2	O
(	O
0	O
.	O
19	O
%)	O
were	O
positive	O
for	O
SARS	B-PRGE
coronavirus	I-PRGE
immunoglobulin	I-PRGE
G	I-PRGE
antibody	I-PRGE
.	O

The	O
identified	O
inhibitors	O
have	O
Ki	O
values	O
at	O
low	O
microM	O
range	O
with	O
comparable	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
activity	O
in	O
cell	O
-	O
based	O
assays	O
.	O

Conjunctival	O
,	O
throat	O
,	O
stool	O
,	O
and	O
urine	O
specimens	O
were	O
collected	O
weekly	O
from	O
64	O
patients	O
and	O
tested	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
by	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
;	O
serum	O
samples	O
were	O
collected	O
weekly	O
and	O
tested	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
antibody	I-PRGE
with	O
indirect	O
enzyme	O
immunoassay	O
and	O
immunofluorescence	O
assay	O
.	O

The	O
plasmid	O
pEGFP	O
-	O
optS	O
,	O
which	O
contains	O
the	O
codon	O
-	O
optimized	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
gene	I-PRGE
and	O
expresses	O
spike	O
-	O
EGFP	O
fusion	O
protein	O
(	O
S	O
-	O
EGFP	O
)	O
as	O
silencing	O
target	O
and	O
expressing	O
reporter	O
,	O
was	O
transfected	O
with	O
siRNAs	O
into	O
HEK	O
293T	O
cells	O
.	O

Toroviruses	O
and	O
group	O
2	O
coronaviruses	O
bind	O
to	O
O	O
-	O
acetylated	O
Sias	O
,	O
presumably	O
via	O
their	O
spike	O
proteins	O
(	O
S	O
),	O
whereas	O
other	O
glycoproteins	O
,	O
the	O
hemagglutinin	O
-	O
esterases	O
(	O
HE	O
),	O
destroy	O
Sia	B-PRGE
receptors	I-PRGE
by	O
de	O
-	O
O	O
-	O
acetylation	O
.	O

Glutaraldehyde	O
cross	O
-	O
linking	O
SDS	O
-	O
PAGE	O
and	O
size	O
-	O
exclusion	O
chromatography	O
results	O
show	O
that	O
,	O
similar	O
to	O
the	O
full	B-PRGE
-	I-PRGE
length	I-PRGE
SARS	I-PRGE
3CL	I-PRGE
(	O
pro	B-PRGE
),	O
the	O
N	O
-	O
terminal	O
deleted	O
SARS	B-PRGE
3CL	I-PRGE
(	O
pro	O
)	O
still	O
remains	O
a	O
dimer	O
/	O
monomer	O
mixture	O
within	O
a	O
wide	O
range	O
of	O
protein	O
concentrations	O
.	O

These	O
findings	O
advance	O
the	O
understanding	O
of	O
the	O
morphogenesis	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
enable	O
the	O
generation	O
of	O
safe	O
,	O
conformational	O
mimetics	O
of	O
the	O
SARS	O
virus	O
that	O
may	O
facilitate	O
the	O
development	O
of	O
vaccines	O
and	O
antiviral	O
drugs	O
.	O

The	O
coronavirus	O
spike	O
proteins	O
belong	O
to	O
class	B-PRGE
I	I-PRGE
fusion	I-PRGE
proteins	I-PRGE
,	O
and	O
are	O
characterized	O
by	O
the	O
existence	O
of	O
two	O
heptad	O
repeat	O
(	O
HR	O
)	O
regions	O
,	O
HR1	O
and	O
HR2	O
.	O

A	O
similar	O
reduction	O
in	O
macrophage	O
infiltration	O
into	O
the	O
CNS	O
was	O
observed	O
in	O
both	O
CCL2	B-PRGE
(-/-)	O
and	O
CCR2	B-PRGE
(-/-)	O
mice	O
when	O
compared	O
to	O
wild	O
-	O
type	O
mice	O
,	O
indicating	O
that	O
both	O
CCL2	B-PRGE
and	O
CC	O
chemokine	B-PRGE
receptor	I-PRGE
2	I-PRGE
(	O
CCR2	B-PRGE
)	O
contribute	O
to	O
macrophage	O
migration	O
and	O
accumulation	O
within	O
the	O
CNS	O
following	O
MHV	O
infection	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
studies	O
revealed	O
that	O
two	O
cysteine	O
residues	O
of	O
the	O
E	B-PRGE
protein	I-PRGE
were	O
essential	O
for	O
oligomerization	O
,	O
leading	O
to	O
induction	O
of	O
membrane	O
permeability	O
.	O

Pair	O
-	O
wise	O
comparison	O
of	O
gene	B-PRGE
3	I-PRGE
,	O
M	B-PRGE
gene	I-PRGE
,	O
gene	O
5	O
,	O
or	O
N	B-PRGE
gene	I-PRGE
sequences	O
with	O
their	O
counterparts	O
of	O
IBV	O
revealed	O
high	O
levels	O
(	O
82	O
.	O
1	O
-	O
92	O
.	O
0	O
%)	O
of	O
similarity	O
.	O

Fourteen	O
(	O
15	O
.	O
5	O
%)	O
faeces	O
were	O
positive	O
for	O
CCoV	B-PRGE
RNA	I-PRGE
,	O
five	O
of	O
which	O
were	O
characterized	O
as	O
CCoV	O
type	O
I	O
.	O
The	O
widespread	O
CCoV	O
infection	O
in	O
the	O
Turkish	O
dog	O
population	O
may	O
be	O
attributed	O
as	O
an	O
important	O
cause	O
of	O
viral	O
diarrhoea	O
in	O
dogs	O
.	O

To	O
attempt	O
to	O
determine	O
the	O
clinical	O
efficacy	O
of	O
pentaglobin	O
,	O
an	O
IgM	B-PRGE
-	O
enriched	O
immunoglobulin	B-PRGE
preparation	O
,	O
on	O
12	O
severe	O
SARS	O
patients	O
who	O
continued	O
to	O
deteriorate	O
despite	O
corticosteroid	O
and	O
ribavirin	O
therapy	O
.	O

In	O
addition	O
,	O
weak	O
activation	O
of	O
Akt	B-PRGE
cannot	O
prevent	O
SARS	O
-	O
CoV	O
infection	O
-	O
induced	O
apoptosis	O
in	O
Vero	O
E6	O
cells	O
.	O

We	O
report	O
that	O
,	O
in	O
planar	O
lipid	O
bilayers	O
,	O
synthetic	O
peptides	O
corresponding	O
to	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
E	I-PRGE
protein	I-PRGE
forms	O
ion	O
channels	O
that	O
are	O
more	O
permeable	O
to	O
monovalent	O
cations	O
than	O
to	O
monovalent	O
anions	O
.	O

Unlike	O
primary	O
CD8	B-PRGE
+	I-PRGE
T	O
cells	O
,	O
persisting	O
secondary	O
CD8	O
+	O
T	O
cells	O
retained	O
ex	O
vivo	O
cytolytic	O
activity	O
and	O
expressed	O
high	O
levels	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
following	I-PRGE
Ag	I-PRGE
stimulation	O
.	O

Several	O
monoclonal	O
antibodies	O
against	O
SARS	B-PRGE
-	O
CoV	O
bound	O
to	O
the	O
N	O
-	O
or	O
C	O
-	O
terminal	O
antigenic	O
sites	O
.	O

This	O
will	O
depend	O
on	O
understanding	O
the	O
pathogenesis	O
and	O
immune	O
response	O
to	O
SARS	B-PRGE
CoV	I-PRGE
.	O
Further	O
understanding	O
of	O
the	O
ecology	O
of	O
SARS	B-PRGE
CoV	I-PRGE
in	O
human	O
and	O
animals	O
will	O
help	O
prevent	O
future	O
cross	O
species	O
transmission	O
.	O

Normalization	O
of	O
thyroid	O
function	O
was	O
observed	O
at	O
discharge	O
with	O
a	O
significant	O
correlation	O
between	O
the	O
percent	O
increase	O
in	O
both	O
fT3	O
and	O
PaO	B-PRGE
(	I-PRGE
2	I-PRGE
)/	I-PRGE
FiO	I-PRGE
(	I-PRGE
2	I-PRGE
)	I-PRGE
(	O
P	O
=	O
0	O
.	O
015	O
).	O

ABSTRACT	O
:	O
A	O
Western	O
immunoblot	O
assay	O
for	O
confirmatory	O
serodiagnosis	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
was	O
developed	O
utilizing	O
viral	O
lysate	O
antigens	O
combined	O
with	O
a	O
recombinant	B-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
,	O
GST	B-PRGE
-	I-PRGE
N	I-PRGE
(	O
glutathione	O
S	O
-	O
transferase	O
-	O
nucleocapsid	O
)	O
of	O
the	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

TITLE	O
:	O
SYNCRIP	B-PRGE
,	O
a	O
member	O
of	O
the	O
heterogeneous	B-PRGE
nuclear	I-PRGE
ribonucleoprotein	I-PRGE
family	I-PRGE
,	O
is	O
involved	O
in	O
mouse	O
hepatitis	O
virus	O
RNA	O
synthesis	O
.	O

Here	O
,	O
we	O
identified	O
another	O
cellular	O
protein	O
,	O
p70	B-PRGE
,	O
which	O
has	O
been	O
shown	O
by	O
UV	O
cross	O
-	O
linking	O
to	O
bind	O
both	O
the	O
positive	O
-	O
and	O
negative	O
-	O
strand	O
UTRs	O
of	O
MHV	O
RNA	O
specifically	O
.	O

The	O
SYNCRIP	B-PRGE
-	I-PRGE
binding	I-PRGE
site	I-PRGE
was	O
mapped	O
to	O
the	O
leader	O
sequence	O
of	O
the	O
5	O
'-	O
UTR	O
,	O
requiring	O
the	O
UCUAA	O
repeat	O
sequence	O
.	O

Furthermore	O
,	O
downregulation	O
of	O
the	O
endogenous	O
SYNCRIP	O
with	O
a	O
specific	O
short	O
interfering	O
RNA	O
delayed	O
MHV	B-PRGE
RNA	I-PRGE
synthesis	O
;	O
in	O
contrast	O
,	O
overexpression	O
or	O
downregulation	O
of	O
SYNCRIP	O
did	O
not	O
affect	O
MHV	O
translation	O
.	O

TITLE	O
:	O
Recombinant	B-PRGE
human	I-PRGE
activated	I-PRGE
protein	I-PRGE
C	I-PRGE
in	O
the	O
treatment	O
of	O
severe	O
sepsis	O
:	O
an	O
evidence	O
-	O
based	O
review	O
.	O

ABSTRACT	O
:	O
In	O
2003	O
,	O
critical	O
care	O
and	O
infectious	O
disease	O
experts	O
representing	O
11	O
international	O
organizations	O
developed	O
management	O
guidelines	O
for	O
recombinant	B-PRGE
human	I-PRGE
activated	I-PRGE
protein	I-PRGE
C	I-PRGE
that	O
would	O
be	O
of	O
practical	O
use	O
for	O
the	O
bedside	O
clinician	O
,	O
under	O
the	O
auspices	O
of	O
the	O
Surviving	O
Sepsis	O
Campaign	O
,	O
an	O
international	O
effort	O
to	O
increase	O
awareness	O
and	O
improve	O
outcome	O
in	O
severe	O
sepsis	O
.	O

Recombinant	B-PRGE
human	I-PRGE
activated	I-PRGE
protein	I-PRGE
C	I-PRGE
is	O
recommended	O
in	O
patients	O
at	O
high	O
risk	O
of	O
death	O
(	O
septic	O
shock	O
,	O
sepsis	O
-	O
induced	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
score	O
of	O
>/=	O
25	O
,	O
and	O
sepsis	O
-	O
induced	O
multiorgan	O
failure	O
)	O
and	O
no	O
absolute	O
contraindication	O
related	O
to	O
bleeding	O
risk	O
or	O
relative	O
contraindication	O
that	O
outweighs	O
the	O
potential	O
benefit	O
.	O

The	O
presence	O
or	O
absence	O
of	O
disseminated	O
intravascular	O
coagulation	O
should	O
not	O
influence	O
the	O
decision	O
to	O
administer	O
recombinant	O
human	O
activated	O
protein	O
C	O
.	O
Heparin	O
should	O
be	O
withheld	O
during	O
administration	O
of	O
recombinant	B-PRGE
human	I-PRGE
activated	I-PRGE
protein	I-PRGE
C	I-PRGE
.	O

A	O
physiological	O
role	O
for	O
ACE2	B-PRGE
has	O
been	O
implicated	O
in	O
hypertension	O
,	O
cardiac	O
function	O
,	O
heart	O
function	O
and	O
diabetes	O
,	O
and	O
as	O
a	O
receptor	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Viral	B-PRGE
envelope	I-PRGE
proteins	I-PRGE
bind	O
these	O
receptors	O
,	O
and	O
,	O
in	O
an	O
incompletely	O
understood	O
process	O
,	O
facilitate	O
fusion	O
of	O
the	O
cellular	O
and	O
viral	O
membranes	O
so	O
as	O
to	O
introduce	O
the	O
viral	O
core	O
into	O
the	O
cytoplasm	O
.	O

Thickening	O
of	O
the	O
actin	B-PRGE
filaments	I-PRGE
at	O
the	O
cell	O
edge	O
provided	O
the	O
bending	O
force	O
to	O
extrude	O
the	O
virus	O
particles	O
.	O

CVI	B-PRGE
was	O
shown	O
to	O
be	O
activated	O
in	O
three	O
year	O
cycles	O
in	O
immunodeficient	O
patients	O
,	O
which	O
occurred	O
,	O
respectively	O
,	O
in	O
66	O
.	O
1	O
,	O
56	O
.	O
9	O
,	O
47	O
.	O
8	O
and	O
51	O
.	O
6	O
%	O
of	O
cases	O
in	O
the	O
above	O
mentioned	O
groups	O
of	O
patients	O
.	O

Promising	O
results	O
were	O
also	O
obtained	O
in	O
the	O
delivery	O
of	O
Epstein	B-PRGE
-	I-PRGE
Barr	I-PRGE
virus	I-PRGE
or	I-PRGE
human	I-PRGE
cytomegalovirus	I-PRGE
antigens	I-PRGE
and	O
from	O
the	O
clinical	O
testing	O
of	O
MVA	O
vectors	O
for	O
vaccination	O
against	O
immunodeficiency	O
virus	O
,	O
papilloma	O
virus	O
,	O
Plasmodium	O
falciparum	O
or	O
melanoma	O
.	O

Here	O
,	O
we	O
identify	O
SARS	B-PRGE
coronavirus	I-PRGE
amino	I-PRGE
-	I-PRGE
terminal	I-PRGE
replicase	I-PRGE
products	I-PRGE
nsp1	I-PRGE
,	O
nsp2	B-PRGE
,	O
and	O
nsp3	B-PRGE
and	O
describe	O
trans	O
-	O
cleavage	O
assays	O
that	O
characterize	O
the	O
protease	O
activity	O
required	O
to	O
generate	O
these	O
products	O
.	O

We	O
generated	O
polyclonal	O
antisera	O
to	O
glutathione	B-PRGE
S	I-PRGE
-	I-PRGE
transferase	I-PRGE
-	O
replicase	B-PRGE
fusion	O
proteins	O
and	O
used	O
the	O
antisera	O
to	O
detect	O
replicase	B-PRGE
intermediates	O
and	O
products	O
in	O
pulse	O
-	O
chase	O
experiments	O
.	O

In	O
contrast	O
,	O
processing	O
at	O
the	O
nsp2	B-PRGE
/	I-PRGE
3	I-PRGE
site	I-PRGE
is	O
less	O
efficient	O
,	O
since	O
a	O
approximately	O
300	O
-	O
kDa	O
intermediate	O
(	O
NSP2	B-PRGE
-	I-PRGE
3	I-PRGE
)	O
is	O
detected	O
,	O
but	O
ultimately	O
nsp2	B-PRGE
(	O
p71	B-PRGE
)	O
and	O
nsp3	B-PRGE
(	O
p213	O
)	O
are	O
generated	O
.	O

Bronchoalveolar	O
lavage	O
fluid	O
from	O
ALI	O
/	O
ARDS	O
patients	O
activates	O
procollagen	B-PRGE
I	I-PRGE
promoter	I-PRGE
,	O
which	O
is	O
due	O
partly	O
to	O
TGF	B-PRGE
-	I-PRGE
beta1	I-PRGE
.	O

The	O
mean	O
IgG	B-PRGE
level	O
peaked	O
in	O
July	O
(	O
1	O
.	O
203	O
),	O
about	O
35	O
days	O
after	O
discharge	O
,	O
and	O
then	O
gradually	O
declined	O
to	O
0	O
.	O
857	O
in	O
December	O
,	O
a	O
decline	O
by	O
27	O
.	O
3	O
%.	O

Cross	O
neutralization	O
response	O
existed	O
between	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
F69	I-PRGE
strain	O
and	O
Z2	O
-	O
Y3	O
strain	O
.	O

Although	O
a	O
specific	O
antiviral	O
agent	O
and	O
vaccines	O
for	O
SARS	O
are	O
not	O
available	O
at	O
the	O
time	O
of	O
writing	O
,	O
a	O
standard	O
treatment	O
protocol	O
for	O
SARS	B-PRGE
has	O
been	O
developed	O
.	O

TITLE	O
:	O
Pre	B-PRGE
-	I-PRGE
B	I-PRGE
-	I-PRGE
cell	I-PRGE
colony	I-PRGE
-	I-PRGE
enhancing	I-PRGE
factor	I-PRGE
as	O
a	O
potential	O
novel	O
biomarker	O
in	O
acute	O
lung	O
injury	O
.	O

The	O
major	O
immunoglobulin	B-PRGE
G	I-PRGE
subclass	O
recognizing	O
N	O
protein	O
was	O
immunoglobulin	B-PRGE
G2a	I-PRGE
,	O
and	O
stimulated	O
splenocytes	O
secreted	O
high	O
levels	O
of	O
gamma	B-PRGE
interferon	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
response	O
to	O
N	B-PRGE
protein	I-PRGE
.	O

More	O
importantly	O
,	O
the	O
immunized	O
mice	O
produced	O
strong	O
delayed	O
-	O
type	O
hypersensitivity	O
(	O
DTH	O
)	O
and	O
CD8	B-PRGE
(+)	O
CTL	O
responses	O
to	O
N	B-PRGE
protein	I-PRGE
.	O

TITLE	O
:	O
A	O
novel	O
cell	O
-	O
based	O
binding	O
assay	O
system	O
reconstituting	O
interaction	O
between	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
and	O
its	O
cellular	O
receptor	O
.	O

In	O
order	O
to	O
study	O
the	O
spike	O
(	O
S	O
)	O
protein	O
of	O
this	O
highly	O
contagious	O
virus	O
,	O
we	O
established	O
a	O
clonal	O
cell	O
-	O
line	O
,	O
CHO	O
-	O
SG	O
,	O
from	O
the	O
Chinese	O
hamster	O
ovary	O
cells	O
that	O
stably	O
expresses	O
C	O
-	O
terminally	O
EGFP	O
-	O
tagged	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
(	O
S	O
-	O
EGFP	O
).	O

CHO	O
-	O
SG	O
cells	O
associated	O
tightly	O
with	O
Vero	O
E6	O
cells	O
,	O
a	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
(	O
ACE2	B-PRGE
)	O
expressing	O
cell	O
-	O
line	O
,	O
and	O
the	O
interaction	O
remained	O
stable	O
under	O
highly	O
stringent	O
condition	O
(	O
1M	O
NaCl	O
).	O

However	O
,	O
the	O
different	O
composition	O
of	O
the	O
tested	O
samples	O
affected	O
the	O
heat	O
sensitivity	O
of	O
the	O
virus	O
strain	O
:	O
the	O
infectivity	O
of	O
the	O
virus	O
in	O
Antithrombin	B-PRGE
III	I-PRGE
preparation	O
still	O
remained	O
after	O
heating	O
for	O
30	O
min	O
at	O
60	O
degrees	O
C	O
.	O
If	O
by	O
rare	O
chance	O
SARS	O
-	O
CoV	O
contaminates	O
source	O
plasma	O
,	O
there	O
should	O
be	O
no	O
or	O
only	O
minor	O
risk	O
of	O
this	O
virus	O
infection	O
,	O
due	O
to	O
sufficient	O
inactivation	O
by	O
the	O
60	O
degrees	O
C	O
10	O
h	O
liquid	O
heating	O
step	O
,	O
although	O
we	O
must	O
pay	O
attention	O
to	O
the	O
composition	O
used	O
for	O
blood	O
product	O
preparation	O
.	O

SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
-	O
encoding	O
plasmid	O
induced	O
activations	O
of	O
IL	O
-	O
8	O
promoter	O
and	O
AP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
but	O
not	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
in	O
these	O
cells	O
.	O

The	O
convertase	O
inhibitor	O
dec	O
-	O
RVKR	O
-	O
cmk	O
significantly	O
reduced	O
proS	B-PRGE
cleavage	O
and	O
viral	O
titers	O
of	O
SARS	O
-	O
CoV	O
infected	O
cells	O
.	O

TITLE	O
:	O
Expression	O
of	O
cellular	O
oncogene	O
Bcl	B-PRGE
-	I-PRGE
xL	I-PRGE
prevents	O
coronavirus	O
-	O
induced	O
cell	O
death	O
and	O
converts	O
acute	O
infection	O
to	O
persistent	O
infection	O
in	O
progenitor	O
rat	O
oligodendrocytes	O
.	O

Although	O
viral	O
genomic	O
RNAs	O
continuously	O
persisted	O
in	O
Bcl	B-PRGE
-	I-PRGE
xL	I-PRGE
-	O
expressing	O
CG	O
-	O
4	O
cells	O
over	O
10	O
passages	O
,	O
infectious	O
virus	O
could	O
no	O
longer	O
be	O
isolated	O
beyond	O
2	O
passages	O
of	O
the	O
cell	O
.	O

Potential	O
pathophysiologic	O
mechanisms	O
linking	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
inhaled	O
nitric	O
oxide	O
,	O
methemoglobin	B-PRGE
,	O
and	O
carboxyhemoglobin	O
are	O
discussed	O
.	O

Peptides	O
from	O
the	O
HR2	O
region	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
have	O
been	O
shown	O
to	O
inhibit	O
viral	O
entry	O
and	O
infection	O
in	O
vitro	O
.	O

The	O
N	B-PRGE
protein	I-PRGE
,	O
expressed	O
in	O
vitro	O
by	O
Ad5	O
-	O
N	O
-	O
V	O
,	O
was	O
of	O
the	O
expected	O
molecular	O
mass	O
of	O
50	O
kDa	O
and	O
was	O
phosphorylated	O
.	O

MHV	O
molecular	O
viruses	O
were	O
engineered	O
to	O
express	O
green	B-PRGE
fluorescent	I-PRGE
protein	I-PRGE
(	O
GFP	O
),	O
demonstrating	O
the	O
feasibility	O
of	O
the	O
systematic	O
assembly	O
approach	O
to	O
create	O
recombinant	O
viruses	O
expressing	O
foreign	O
genes	O
.	O

Prevention	O
of	O
oxidative	O
stress	O
has	O
been	O
achieved	O
by	O
application	O
of	O
antioxidant	O
redox	O
metalloenzymes	O
such	O
as	O
superoxide	O
dismutases	O
(	O
containing	O
Cu	O
/	O
Zn	O
cytosolic	O
,	O
Mn	O
mitochondrial	O
and	O
Fe	O
bacterial	O
)	O
glutathione	O
peroxidases	O
(	O
and	O
other	O
Se	O
-	O
containing	O
proteins	O
and	O
enzymes	O
such	O
as	O
the	O
thioredoxins	O
),	O
catalases	O
(	O
Fe	O
-	O
containing	O
),	O
cytochrome	B-PRGE
c	I-PRGE
peroxidases	I-PRGE
(	O
Fe	O
-	O
containing	O
),	O
ceruloplasmins	O
(	O
Cu	O
-	O
containing	O
),	O
metallothionines	O
(	O
these	O
cysteine	O
thiol	O
-	O
rich	O
proteins	O
bind	O
ions	O
of	O
cadmium	O
and	O
mercury	O
)	O
and	O
tyrosinases	O
(	O
Cu	O
-	O
containing	O
).	O

ABSTRACT	O
:	O
Nidoviruses	O
(	O
Coronaviridae	O
,	O
Arteriviridae	O
,	O
and	O
Roniviridae	O
)	O
encode	O
a	O
nonstructural	O
protein	O
,	O
called	O
nsp10	O
in	O
arteriviruses	O
and	O
nsp13	O
in	O
coronaviruses	O
,	O
that	O
is	O
comprised	O
of	O
a	O
C	B-PRGE
-	I-PRGE
terminal	I-PRGE
superfamily	I-PRGE
1	I-PRGE
helicase	I-PRGE
domain	I-PRGE
and	O
an	O
N	O
-	O
terminal	O
,	O
putative	O
zinc	O
-	O
binding	O
domain	O
(	O
ZBD	O
).	O

Collectively	O
,	O
our	O
data	O
suggest	O
that	O
the	O
ZBD	O
is	O
critically	O
involved	O
in	O
nidovirus	O
replication	O
and	O
transcription	O
by	O
modulating	O
the	O
enzymatic	O
activities	O
of	O
the	O
helicase	B-PRGE
domain	I-PRGE
and	O
other	O
,	O
yet	O
unknown	O
,	O
mechanisms	O
.	O

Screening	O
of	O
400	O
NPAs	O
,	O
negative	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
from	O
patients	O
with	O
respiratory	O
illness	O
during	O
the	O
SARS	O
period	O
identified	O
the	O
presence	O
of	O
CoV	B-PRGE
-	I-PRGE
HKU1	I-PRGE
RNA	I-PRGE
in	O
an	O
additional	O
specimen	O
,	O
with	O
a	O
viral	O
load	O
of	O
1	O
.	O
13	O
x	O
10	O
(	O
6	O
)	O
copies	O
per	O
ml	O
,	O
from	O
a	O
35	O
-	O
year	O
-	O
old	O
woman	O
with	O
pneumonia	O
.	O

Cellular	B-PRGE
receptors	I-PRGE
play	O
an	O
important	O
role	O
in	O
virus	O
attachment	O
and	O
entry	O
.	O

However	O
,	O
the	O
low	O
permissiveness	O
of	O
PEDV	O
to	O
APN	B-PRGE
-	O
expressing	O
porcine	O
cell	O
lines	O
has	O
made	O
it	O
difficult	O
to	O
elucidate	O
the	O
role	O
of	O
pAPN	O
in	O
vitro	O
.	O

The	O
method	O
was	O
tested	O
on	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
the	O
results	O
were	O
compared	O
to	O
the	O
outcome	O
of	O
other	O
widely	O
known	O
methods	O
.	O

We	O
identified	O
a	O
segment	O
(	O
NH2	B-PRGE
-	I-PRGE
_L	I-PRGE
-	I-PRGE
Cys	I-PRGE
-	I-PRGE
A	I-PRGE
-	I-PRGE
Y	I-PRGE
-	I-PRGE
Cys	I-PRGE
-	I-PRGE
Cys	I-PRGE
-	I-PRGE
N_	I-PRGE
-	I-PRGE
COOH	I-PRGE
)	O
in	O
the	O
carboxyl	O
-	O
terminal	O
region	O
of	O
the	O
E	O
protein	O
that	O
appears	O
to	O
form	O
three	O
disulfide	O
bonds	O
with	O
another	O
segment	O
of	O
corresponding	O
cysteines	O
in	O
the	O
carboxyl	O
-	O
terminus	O
of	O
the	O
S	O
(	O
spike	O
)	O
protein	O
.	O

TITLE	O
:	O
The	O
R	B-PRGE
protein	I-PRGE
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
:	O
analyses	O
of	O
structure	O
and	O
function	O
based	O
on	O
four	O
complete	O
genome	O
sequences	O
of	O
isolates	O
BJ01	O
-	O
BJ04	O
.	O

A	O
hydrophobic	O
domain	O
(	O
HOD	O
)	O
and	O
a	O
hydrophilic	O
domain	O
(	O
HID	O
)	O
are	O
newly	O
identified	O
within	O
NSP1	B-PRGE
.	O

Western	O
analysis	O
on	O
the	O
purified	O
protein	O
confirmed	O
the	O
expression	O
and	O
purification	O
of	O
the	O
NC	B-PRGE
fusion	I-PRGE
proteins	I-PRGE
from	O
yeast	O
.	O

Using	O
Western	O
blot	O
and	O
Enzyme	O
-	O
linked	O
Immunosorbent	O
Assay	O
(	O
ELISA	O
),	O
the	O
recombinant	O
N	O
proteins	O
and	O
the	O
synthesized	O
peptides	O
derived	O
from	O
the	O
N	B-PRGE
protein	I-PRGE
were	O
screened	O
in	O
sera	O
from	O
SARS	O
patients	O
.	O

To	O
these	O
ends	O
,	O
we	O
investigated	O
the	O
antigenicity	O
of	O
the	O
spike	B-PRGE
protein	I-PRGE
(	O
S	B-PRGE
protein	I-PRGE
),	O
a	O
major	O
structural	O
protein	O
in	O
the	O
SARS	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

According	O
to	O
these	O
results	O
,	O
two	O
fragments	O
of	O
the	O
S	B-PRGE
gene	I-PRGE
were	O
amplified	O
by	O
PCR	O
and	O
cloned	O
into	O
pET	B-PRGE
-	I-PRGE
32a	I-PRGE
.	O

The	O
percentage	O
of	O
CD8	B-PRGE
(+)	O
T	O
lymphocytes	O
was	O
higher	O
than	O
normal	O
reference	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
while	O
the	O
percentage	O
of	O
CD8	B-PRGE
(+)/	O
CD28	B-PRGE
(-)	O
T	O
cells	O
(	O
Ts	O
)	O
in	O
49	O
convalescent	O
SARS	O
patients	O
increased	O
,	O
and	O
that	O
of	O
CD8	B-PRGE
(+)/	O
CD28	B-PRGE
(+)	O
T	O
cells	O
(	O
Tc	O
)	O
in	O
39	O
patients	O
decreased	O
.	O

Increased	O
Ts	O
cell	O
may	O
lead	O
to	O
increased	O
CD8	B-PRGE
(+)	O
T	O
cells	O
in	O
convalescent	O
SARS	O
patients	O
.	O

Based	O
on	O
its	O
conservation	O
in	O
viral	O
pathogen	O
genomes	O
and	O
its	O
absence	O
in	O
the	O
human	O
genome	O
,	O
we	O
suggest	O
that	O
these	O
unusual	O
structural	O
features	O
in	O
the	O
s2m	B-PRGE
RNA	I-PRGE
element	I-PRGE
are	O
attractive	O
targets	O
for	O
the	O
design	O
of	O
anti	O
-	O
viral	O
therapeutic	O
agents	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
evidence	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
infection	O
among	O
close	O
contacts	O
to	O
SARS	O
patients	O
and	O
the	O
level	O
of	O
sera	B-PRGE
IgG	I-PRGE
antibody	I-PRGE
in	O
SARS	O
cases	O
.	O

The	O
hybridomas	O
were	O
tested	O
to	O
have	O
specific	O
reactions	O
with	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
no	O
cross	O
-	O
reactivates	O
with	O
other	O
common	O
respiratory	O
disease	O
causing	O
pathogens	O
.	O

An	O
anti	O
-	O
MHV3	O
state	O
was	O
observed	O
only	O
in	O
A	O
/	O
J	O
Mphi	O
upon	O
activation	O
with	O
IL	B-PRGE
-	I-PRGE
12	I-PRGE
/	I-PRGE
IL	I-PRGE
-	I-PRGE
18	I-PRGE
or	O
IFNgamma	O
regardless	O
of	O
their	O
origin	O
from	O
the	O
peritoneum	O
or	O
bone	O
marrow	O
.	O

As	O
a	O
consequence	O
of	O
nitric	B-PRGE
oxide	I-PRGE
synthase	I-PRGE
synthesis	O
and	O
arginine	O
consumption	O
in	O
IFNgamma	O
activated	O
BMMphi	O
,	O
we	O
observed	O
a	O
higher	O
synthesis	O
of	O
citrulline	O
.	O

The	O
comparison	O
of	O
genome	O
structures	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
other	O
coronaviruses	O
shows	O
that	O
SARS	O
-	O
CoV	O
and	O
IBV	O
share	O
the	O
same	O
genome	O
structure	O
.	O

Blockade	O
of	O
HMGB1	B-PRGE
by	O
administration	O
of	O
anti	B-PRGE
-	I-PRGE
HMGB1	I-PRGE
antibodies	I-PRGE
prevented	O
hemorrhage	O
-	O
induced	O
increases	O
in	O
nuclear	O
translocation	O
of	O
NF	B-PRGE
-	I-PRGE
kappa	I-PRGE
B	I-PRGE
in	O
the	O
lungs	O
and	O
pulmonary	O
levels	O
of	O
proinflammatory	O
cytokines	O
,	O
including	O
keratinocyte	B-PRGE
-	I-PRGE
derived	I-PRGE
chemokine	I-PRGE
,	I-PRGE
IL	I-PRGE
-	I-PRGE
6	I-PRGE
,	O
and	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
.	O

As	O
compared	O
with	O
controls	O
,	O
homogenates	O
of	O
lung	O
tissue	O
from	O
ARDS	O
patients	O
contained	O
less	O
VEGF	B-PRGE
(	O
median	O
(	O
interquartile	O
range	O
)	O
ARDS	O
8	O
.	O
2	O
(	O
4	O
.	O
7	O
-	O
12	O
.	O
2	O
)	O
versus	O
controls	O
28	O
.	O
4	O
(	O
9	O
.	O
9	O
-	O
47	O
.	O
1	O
)	O
ng	O
x	O
g	O
(-	O
1	O
)	O
protein	O
).	O

This	O
result	O
suggested	O
that	O
S1	B-PRGE
domain	I-PRGE
could	O
be	O
an	O
effective	O
subunit	O
vaccines	O
against	O
SARS	O
-	O
CoV	O
.	O
RESULTS	O
:	O
S1	O
domain	O
of	O
SARS	O
-	O
CoV	O
spike	O
,	O
which	O
has	O
been	O
demonstrated	O
harboring	O
the	O
receptor	O
binding	O
domain	O
,	O
successfully	O
elicited	O
SARS	B-PRGE
-	O
CoV	O
specific	O
IgG	B-PRGE
antibody	I-PRGE
in	O
mouse	O
after	O
combined	O
immunization	O
with	O
DNA	O
and	O
purified	O
S1	B-PRGE
protein	I-PRGE
;	O
the	O
antibody	O
elicited	O
solely	O
by	O
S1	O
could	O
potently	O
neutralize	O
SARS	B-PRGE
-	O
CoV	O
(	O
HKU	O
-	O
39849	O
)	O
in	O
vitro	O
,	O
50	O
%	O
of	O
1	O
000	O
TCID50	O
SARS	O
-	O
CoV	O
challenged	O
cells	O
were	O
protected	O
from	O
viral	O
infection	O
by	O
a	O
1	O
:	O
1499	O
.	O
68	O
dilution	O
of	O
mice	O
sera	O
immunized	O
with	O
S1	B-PRGE
protein	I-PRGE
,	O
but	O
negative	O
control	O
sera	O
showed	O
no	O
protection	O
.	O

ABSTRACT	O
:	O
The	O
spike	B-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
glycoprotein	I-PRGE
is	O
one	O
of	O
the	O
major	O
structure	O
proteins	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
CoV	O
).	O

Here	O
,	O
we	O
investigated	O
the	O
influence	O
of	O
SARS	O
-	O
CoV	O
infection	O
on	O
CXCL8	B-PRGE
(	O
interleukin	B-PRGE
8	I-PRGE
)	O
and	O
CXCL10	B-PRGE
(	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	I-PRGE
inducible	I-PRGE
protein	I-PRGE
10	I-PRGE
)	O
in	O
human	O
intestinal	O
epithelial	O
(	O
Caco2	O
)	O
cells	O
.	O

In	O
the	O
region	O
between	O
the	O
spike	O
and	O
membrane	O
protein	O
genes	O
,	O
a	O
290	O
-	O
nucleotide	O
deletion	O
is	O
present	O
,	O
corresponding	O
to	O
the	O
absence	O
of	O
BCoV	B-PRGE
ORFs	I-PRGE
ns4	I-PRGE
.	O
9	O
and	O
ns4	O
.	O
8	O
.	O

We	O
identified	O
eight	O
human	O
MAbs	O
binding	O
to	O
virus	O
and	O
infected	O
cells	O
,	O
six	O
of	O
which	O
could	O
be	O
mapped	O
to	O
two	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
structural	I-PRGE
proteins	I-PRGE
:	O
the	O
nucleocapsid	O
(	O
N	O
)	O
and	O
spike	O
(	O
S	O
)	O
proteins	O
.	O

The	O
MAb	O
ability	O
to	O
block	O
S1	B-PRGE
-	I-PRGE
receptor	I-PRGE
binding	O
and	O
the	O
level	O
of	O
neutralization	O
of	O
the	O
two	O
strongly	O
neutralizing	O
S1	O
MAbs	O
correlated	O
with	O
the	O
binding	O
affinity	O
to	O
the	O
S1	B-PRGE
domain	I-PRGE
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
levels	O
of	O
SARS	B-PRGE
-	I-PRGE
associated	I-PRGE
coronavirus	I-PRGE
IgG	I-PRGE
antibody	I-PRGE
of	O
SARS	O
patients	O
,	O
people	O
who	O
closely	O
contacted	O
SARS	O
patients	O
and	O
normal	O
subjects	O
in	O
Gansu	O
province	O
.	O

The	O
data	O
,	O
however	O
,	O
suggest	O
that	O
the	O
antiviral	O
activity	O
of	O
IFN	B-PRGE
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
virus	O
is	O
independent	O
of	O
MxA	B-PRGE
expression	O
.	O

We	O
propose	O
that	O
,	O
when	O
aligned	O
with	O
the	O
fusion	O
peptide	O
and	O
transmembrane	O
domains	O
during	O
membrane	O
apposition	O
,	O
the	O
aromatic	O
domain	O
of	O
the	O
CoV	B-PRGE
S	I-PRGE
protein	I-PRGE
functions	O
to	O
perturb	O
the	O
target	O
cell	O
membrane	O
and	O
provides	O
a	O
continuous	O
track	O
of	O
hydrophobic	O
surface	O
,	O
resulting	O
in	O
lipid	O
-	O
membrane	O
fusion	O
and	O
subsequent	O
viral	O
nucleocapsid	O
entry	O
.	O

Several	O
genes	O
were	O
highly	O
up	O
-	O
regulated	O
in	O
patients	O
with	O
SARS	O
,	O
such	O
as	O
,	O
the	O
genes	O
coding	O
for	O
Lactoferrin	B-PRGE
,	O
S100A9	B-PRGE
and	O
Lipocalin	B-PRGE
2	I-PRGE
.	O

PCR	O
probes	O
that	O
target	O
regions	O
of	O
the	O
replicase	B-PRGE
1a	I-PRGE
gene	I-PRGE
that	O
are	O
conserved	O
among	O
genetically	O
diverse	O
animal	O
CoVs	O
and	O
HCoVs	O
were	O
designed	O
.	O

The	O
levels	O
of	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
,	I-PRGE
and	I-PRGE
monocyte	I-PRGE
chemoattractant	I-PRGE
protein	I-PRGE
-	I-PRGE
1	I-PRGE
were	O
concomitantly	O
increased	O
in	O
the	O
blood	O
of	O
the	O
patients	O
with	O
superinfection	O
,	O
and	O
the	O
mRNAs	O
for	O
these	O
cytokines	O
were	O
also	O
increased	O
in	O
lung	O
tissues	O
.	O

The	O
prompt	O
elevation	O
of	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
,	I-PRGE
and	I-PRGE
monocyte	I-PRGE
chemoattractant	I-PRGE
protein	I-PRGE
-	I-PRGE
1	I-PRGE
is	O
a	O
sign	O
of	O
superinfection	O
,	O
indicating	O
a	O
high	O
risk	O
of	O
death	O
.	O

Based	O
on	O
the	O
fluorescence	O
resonance	O
energy	O
transfer	O
(	O
FRET	O
)	O
principle	O
using	O
5	O
-[(	O
2	O
'-	O
aminoethyl	O
)-	O
amino	O
]	O
naphthelenesulfonic	O
acid	O
(	O
EDANS	O
)	O
and	O
4	O
-[[	O
4	O
-(	O
dimethylamino	O
)	O
phenyl	O
]	O
azo	O
]	O
benzoic	O
acid	O
(	O
Dabcyl	O
)	O
as	O
the	O
energy	O
transfer	O
pair	O
,	O
one	O
fluorogenic	O
substrate	O
was	O
designed	O
for	O
the	O
evaluation	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
(	O
pro	B-PRGE
)	O
proteolytic	O
activity	O
.	O

This	O
recombinant	B-PRGE
N	I-PRGE
protein	I-PRGE
(	O
hGST	O
-	O
N	O
)	O
was	O
purified	O
and	O
used	O
to	O
measure	O
the	O
SARS	O
-	O
CoV	O
N	O
-	O
specific	O
antibody	O
in	O
the	O
sera	O
of	O
eight	O
SARS	O
patients	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

The	O
recombinant	O
virus	O
was	O
further	O
manipulated	O
to	O
express	O
enhanced	B-PRGE
green	I-PRGE
fluorescent	I-PRGE
protein	I-PRGE
(	O
EGFP	O
)	O
by	O
replacing	O
an	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
of	O
the	O
group	O
-	O
specific	O
gene	O
,	O
ORF	B-PRGE
5a	I-PRGE
,	O
with	O
the	O
EGFP	B-PRGE
ORF	I-PRGE
.	O

The	O
S	B-PRGE
glycoprotein	I-PRGE
was	O
cloned	O
into	O
a	O
Lactobacillus	O
/	O
E	O
.	O
coli	O
shuttle	O
vector	O
(	O
pLP500	O
)	O
where	O
expression	O
and	O
secretion	O
of	O
the	O
glycoprotein	B-PRGE
S	I-PRGE
from	O
the	O
recombinant	O
lactobacilli	O
was	O
detected	O
via	O
immunoblotting	O
.	O

The	O
basis	O
of	O
the	O
assay	O
is	O
the	O
cleavage	O
of	O
target	O
RNA	O
by	O
RNase	B-PRGE
H	I-PRGE
mediated	O
by	O
sequence	O
-	O
specific	O
chimeric	O
oligonucleotides	O
followed	O
by	O
sample	O
to	O
residual	O
ratio	O
quantitation	O
(	O
SRRQ	O
)	O
using	O
RRT	O
-	O
PCR	O
.	O

ABSTRACT	O
:	O
The	O
SARS	B-PRGE
coronavirus	I-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
proteinase	I-PRGE
is	O
considered	O
as	O
a	O
potential	O
drug	O
design	O
target	O
for	O
the	O
treatment	O
of	O
severe	B-PRGE
acute	I-PRGE
respiratory	I-PRGE
syndrome	I-PRGE
(	O
SARS	O
).	O

Of	O
633	O
consecutively	O
enrolled	O
febrile	O
patients	O
,	O
321	O
(	O
50	O
.	O
7	O
%)	O
had	O
antileptospiral	B-PRGE
IgM	I-PRGE
antibodies	I-PRGE
or	O
high	O
titers	O
of	O
antileptospiral	O
antibodies	O
.	O

RESULTS	O
:	O
Of	O
633	O
consecutively	O
enrolled	O
febrile	O
patients	O
,	O
321	O
(	O
50	O
.	O
7	O
%)	O
had	O
antileptospiral	B-PRGE
IgM	I-PRGE
antibodies	I-PRGE
or	O
high	O
titers	O
of	O
antileptospiral	O
antibodies	O
.	O

Analysis	O
of	O
the	O
downstream	O
pseudoknot	O
stimulator	O
of	O
frameshifting	O
in	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
shows	O
that	O
a	O
proposed	O
RNA	O
secondary	O
structure	O
in	O
loop	O
II	O
and	O
two	O
unpaired	O
nucleotides	O
at	O
the	O
stem	O
I	O
-	O
stem	O
II	O
junction	O
in	O
SARS	B-PRGE
-	O
CoV	O
are	O
important	O
for	O
frameshift	O
stimulation	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
caused	O
by	O
a	O
novel	O
coronavirus	O
termed	O
SARS	O
-	O
CoV	O
.	O
We	O
and	O
others	O
have	O
previously	O
shown	O
that	O
the	O
replication	O
of	O
SARS	O
-	O
CoV	O
can	O
be	O
suppressed	O
by	O
exogenously	O
added	O
interferon	B-PRGE
(	O
IFN	B-PRGE
),	O
a	O
cytokine	O
which	O
is	O
normally	O
synthesized	O
by	O
cells	O
as	O
a	O
reaction	O
to	O
virus	O
infection	O
.	O

By	O
contrast	O
,	O
IRF	B-PRGE
-	I-PRGE
3	I-PRGE
remained	O
in	O
the	O
nucleus	O
of	O
cells	O
infected	O
with	O
the	O
IFN	B-PRGE
-	I-PRGE
inducing	I-PRGE
control	I-PRGE
virus	I-PRGE
Bunyamwera	I-PRGE
delNSs	I-PRGE
.	O

These	O
investigations	O
can	O
be	O
broadly	O
classified	O
into	O
three	O
groups	O
:	O
(	O
a	O
)	O
studies	O
on	O
the	O
replicase	B-PRGE
1a	I-PRGE
/	I-PRGE
1b	I-PRGE
gene	I-PRGE
products	I-PRGE
which	O
are	O
important	O
for	O
viral	O
replication	O
,	O
(	O
b	O
)	O
studies	O
on	O
the	O
structural	O
proteins	O
,	O
spike	O
,	O
nucleocapsid	O
,	O
membrane	O
and	O
envelope	B-PRGE
,	O
which	O
have	O
homologues	O
in	O
all	O
coronaviruses	O
,	O
and	O
are	O
important	O
for	O
viral	O
assembly	O
and	O
(	O
c	O
)	O
expression	O
and	O
functional	O
studies	O
of	O
the	O
""""	O
accessory	O
""""	O
proteins	O
that	O
are	O
specifically	O
encoded	O
by	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
A	O
comparison	O
of	O
the	O
properties	O
of	O
these	O
three	O
groups	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
proteins	I-PRGE
with	O
the	O
knowledge	O
that	O
coronavirologists	O
have	O
generated	O
over	O
more	O
than	O
30	O
years	O
of	O
research	O
can	O
help	O
us	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
SARS	O
in	O
the	O
event	O
of	O
the	O
re	O
-	O
emergence	O
of	O
this	O
new	O
infectious	O
disease	O
.	O

The	O
full	O
-	O
length	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
envelope	I-PRGE
Spike	I-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
glycoprotein	I-PRGE
gene	I-PRGE
was	O
introduced	O
into	O
the	O
deletion	O
III	O
region	O
of	O
the	O
MVA	O
genome	O
.	O

TITLE	O
:	O
Recombinant	O
mouse	O
hepatitis	O
virus	O
strain	O
A59	O
from	O
cloned	O
,	O
full	B-PRGE
-	I-PRGE
length	I-PRGE
cDNA	I-PRGE
replicates	O
to	O
high	O
titers	O
in	O
vitro	O
and	O
is	O
fully	O
pathogenic	O
in	O
vivo	O
.	O

Thus	O
,	O
this	O
protein	O
microarray	O
can	O
be	O
alternatively	O
used	O
as	O
a	O
high	O
throughput	O
screening	O
method	O
for	O
rapid	O
detection	O
against	O
SARS	B-PRGE
CoV	I-PRGE
3CLpro	I-PRGE
and	O
/	O
or	O
efficient	O
purification	O
of	O
other	O
Tagged	O
proteins	O
.	O

TITLE	O
:	O
Fatal	B-PRGE
avian	I-PRGE
influenza	I-PRGE
A	I-PRGE
(	O
H5N1	O
)	O
in	O
a	O
child	O
presenting	O
with	O
diarrhea	O
followed	O
by	O
coma	O
.	O

ABSTRACT	O
:	O
CD8	B-PRGE
+	I-PRGE
T	O
cells	O
are	O
important	O
for	O
clearance	O
of	O
neurotropic	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
strain	O
A59	O
,	O
although	O
their	O
possible	O
role	O
in	O
A59	O
-	O
induced	O
demyelination	O
is	O
not	O
well	O
understood	O
.	O

This	O
Q	O
-	O
RT	O
-	O
PCR	O
assay	O
can	O
be	O
used	O
to	O
detect	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
Moreover	O
,	O
GAPDH	B-PRGE
mRNA	I-PRGE
may	O
be	O
useful	O
to	O
rule	O
out	O
false	O
negative	O
results	O
in	O
SARS	O
-	O
CoV	O
detection	O
,	O
and	O
the	O
current	O
extraction	O
method	O
for	O
urine	O
may	O
not	O
be	O
sensitive	O
enough	O
to	O
detect	O
low	O
titres	O
of	O
SARS	O
-	O
CoV	O
.	O
RESULTS	O
:	O
Varying	O
amounts	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
were	O
found	O
in	O
the	O
26	O
SARS	O
-	O
CoV	O
positive	O
specimens	O
and	O
SARS	O
-	O
CoV	O
was	O
not	O
detected	O
in	O
the	O
40	O
follow	O
up	O
specimens	O
and	O
controls	O
.	O

Then	O
,	O
the	O
binding	O
ability	O
of	O
SA59B	B-PRGE
-	I-PRGE
HRP	I-PRGE
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
was	O
evaluated	O
by	O
ELISA	O
with	O
S	O
/	O
N	O
of	O
11	O
.	O
6	O
,	O
indicating	O
higher	O
binding	O
specificity	O
between	O
them	O
.	O

We	O
expressed	O
and	O
purified	O
soluble	O
recombinant	B-PRGE
protein	I-PRGE
X4	I-PRGE
from	O
E	O
.	O
coli	O
,	O
and	O
generated	O
specific	O
antibodies	O
against	O
protein	O
X4	O
.	O

Multivariate	O
analyses	O
showed	O
that	O
age	O
greater	O
than	O
65	O
years	O
(	O
odds	O
ratio	O
,	O
OR	O
,	O
10	O
.	O
6	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
CI	O
,	O
2	O
.	O
1	O
-	O
54	O
.	O
1	O
),	O
pre	O
-	O
existing	O
diabetes	O
mellitus	O
(	O
OR	O
,	O
13	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
3	O
-	O
146	O
.	O
9	O
),	O
and	O
elevated	O
levels	O
of	O
LDH	B-PRGE
(	O
OR	O
,	O
8	O
.	O
4	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
9	O
-	O
36	O
.	O
9	O
)	O
at	O
admission	O
,	O
were	O
independent	O
predictors	O
of	O
ARDS	O
.	O

The	O
patient	O
had	O
normal	O
levels	O
of	O
functional	B-PRGE
protein	I-PRGE
C	I-PRGE
and	O
protein	B-PRGE
S	I-PRGE
and	O
a	O
normal	O
level	O
of	O
plasma	O
homocysteine	O
.	O

Tests	O
for	O
common	O
thromophilic	O
gene	O
mutations	O
including	O
prothrombin	B-PRGE
20210	I-PRGE
,	I-PRGE
factor	I-PRGE
V	I-PRGE
Leiden	I-PRGE
1691	I-PRGE
,	O
and	O
methylene	B-PRGE
tetrahydrofolate	I-PRGE
reductase	I-PRGE
677	I-PRGE
were	O
negative	O
.	O

However	O
,	O
viruses	O
with	O
Y162F	O
substitutions	O
had	O
wild	O
type	O
growth	O
,	O
suggesting	O
that	O
Y162	O
may	O
comprise	O
part	O
of	O
a	O
hydrophobic	O
domain	O
that	O
contacts	O
the	O
MHV	B-PRGE
-	I-PRGE
binding	I-PRGE
site	I-PRGE
of	O
mCEACAM1a	O
.	O

Here	O
,	O
we	O
describe	O
a	O
healthy	O
donor	O
for	O
allogeneic	O
hematopoietic	O
stem	O
cell	O
transplantation	O
who	O
developed	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
after	O
4	O
days	O
of	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
administration	O
.	O

The	O
present	O
report	O
describes	O
a	O
healthy	O
donor	O
for	O
allo	O
-	O
HSCT	O
with	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
after	O
4	O
days	O
of	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
administration	O
.	O

Published	O
studies	O
evaluating	O
the	O
use	O
of	O
iNO	B-PRGE
,	O
PP	O
,	O
and	O
HFOV	O
in	O
adult	O
patients	O
with	O
ARDS	O
.	O

Following	O
the	O
initial	O
cycle	O
of	O
recruitment	O
,	O
the	O
mean	O
(+/-	O
sd	O
)	O
Pao2	B-PRGE
/	O
Fio2	O
increased	O
significantly	O
compared	O
with	O
standardized	O
conventional	O
ventilation	O
(	O
200	O
+/-	O
117	O
vs	O
.	O
92	O
+/-	O

In	O
this	O
communication	O
,	O
we	O
evaluated	O
the	O
efficacy	O
and	O
safety	O
of	O
two	O
SARS	O
vaccine	O
candidates	O
based	O
on	O
the	O
recombinant	O
modified	O
vaccinia	O
Ankara	O
(	O
MVA	O
)	O
expressing	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
or	I-PRGE
nucleocapsid	I-PRGE
proteins	I-PRGE
in	O
ferrets	O
.	O

Thus	O
,	O
our	O
data	O
suggest	O
that	O
enhanced	O
hepatitis	O
is	O
linked	O
to	O
vaccination	O
with	O
rMVA	O
expressing	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
antigens	I-PRGE
.	O

The	O
high	O
cost	O
of	O
rabies	B-PRGE
immunoglobulin	I-PRGE
and	O
tissue	O
culture	O
vaccines	O
are	O
remaining	O
barriers	O
,	O
but	O
new	O
manufacturers	O
and	O
the	O
use	O
of	O
intradermal	O
vaccination	O
schedules	O
can	O
reduce	O
costs	O
.	O

The	O
pseudotype	O
assay	O
was	O
used	O
to	O
profile	O
neutralizing	O
antibody	O
responses	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
in	O
sequential	O
serum	O
samples	O
taken	O
from	O
41	O
confirmed	O
SARS	O
patients	O
during	O
the	O
2003	O
outbreak	O
in	O
Hong	O
Kong	O
and	O
shows	O
long	O
-	O
lasting	O
immunity	O
in	O
most	O
recovered	O
patients	O
.	O

TITLE	O
:	O
Subcellular	O
localization	O
and	O
membrane	O
association	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3a	I-PRGE
protein	I-PRGE
.	O

These	O
findings	O
suggest	O
that	O
oxymatrine	O
has	O
a	O
beneficial	O
effect	O
on	O
acute	O
lung	O
injury	O
induced	O
by	O
oleic	O
acid	O
in	O
mice	O
and	O
may	O
inhibit	O
the	O
production	O
of	O
proinflammatory	O
cytokine	O
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
by	O
means	O
of	O
the	O
inhibition	O
of	O
p38	B-PRGE
MAPK	I-PRGE
.	O

The	O
number	O
of	O
CD3	B-PRGE
-	O
positive	O
lymphocytes	O
and	O
of	O
CD68	B-PRGE
-	O
positive	O
macrophages	O
in	O
this	O
specimen	O
from	O
a	O
patient	O
in	O
the	O
fibrotic	O
phase	O
of	O
diffuse	O
alveolar	O
damage	O
(	O
DAD	O
)	O
whose	O
condition	O
deteriorated	O
was	O
less	O
than	O
in	O
the	O
specimen	O
from	O
case	O
3	O
who	O
was	O
in	O
the	O
early	O
proliferative	O
phase	O
of	O
DAD	O
and	O
eventually	O
recovered	O
.	O

We	O
further	O
demonstrated	O
,	O
via	O
transient	O
transfection	O
experiments	O
,	O
that	O
the	O
siRNA	O
targeting	O
the	O
Leader	O
sequence	O
had	O
a	O
much	O
stronger	O
inhibitory	O
effect	O
on	O
SARS	O
-	O
CoV	O
replication	O
than	O
the	O
siRNAs	O
targeting	O
the	O
Spike	B-PRGE
gene	I-PRGE
or	O
the	O
antisense	O
oligodeoxynucleotides	O
did	O
.	O

The	O
data	O
indicate	O
that	O
GST	B-PRGE
-	O
N2	O
fusion	O
protein	O
,	O
which	O
was	O
screened	O
by	O
protein	O
microarray	O
,	O
may	O
be	O
a	O
valuable	O
diagnostic	O
antigen	O
for	O
the	O
development	O
of	O
serological	O
assays	O
for	O
SARS	O
.	O

The	O
MPO	B-PRGE
activities	O
in	O
serum	O
and	O
lung	O
homogenates	O
were	O
found	O
to	O
be	O
significantly	O
decreased	O
in	O
ILO	O
group	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
01	O
).	O

Earlier	O
we	O
showed	O
that	O
the	O
ectodomain	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
is	O
not	O
involved	O
in	O
this	O
process	O
.	O

ABSTRACT	O
:	O
Entry	O
of	O
SARS	O
-	O
CoV	O
into	O
a	O
target	O
cell	O
is	O
initiated	O
by	O
binding	O
of	O
the	O
S1	B-PRGE
domain	I-PRGE
of	O
spike	O
protein	O
to	O
a	O
receptor	O
,	O
followed	O
by	O
conformational	O
changes	O
of	O
the	O
spike	O
protein	O
S2	O
domain	O
,	O
resulting	O
in	O
the	O
formation	O
of	O
a	O
six	O
-	O
helix	O
bundle	O
by	O
the	O
heptad	O
-	O
repeat	O
(	O
HR1	O
and	O
HR2	O
)	O
regions	O
.	O

Both	O
serum	O
-	O
positive	O
rates	O
and	O
titers	O
of	O
specific	O
IgM	B-PRGE
and	O
IgG	B-PRGE
antibodies	I-PRGE
responding	O
to	O
SARS	O
-	O
CoV	O
peaked	O
at	O
days	O
41	O
-	O
60	O
from	O
the	O
onset	O
of	O
SARS	O
.	O

RESULTS	O
:	O
The	O
sensitivity	O
and	O
specificity	O
of	O
ELISA	O
for	O
detecting	O
IgG	B-PRGE
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
were	O
100	O
.	O
0	O
%	O
and	O
97	O
.	O
2	O
%	O
and	O
for	O
IgM	B-PRGE
89	O
.	O
8	O
%	O
and	O
97	O
.	O
6	O
%	O
respectively	O
;	O
the	O
figures	O
using	O
IFA	O
for	O
IgG	B-PRGE
were	O
100	O
.	O
0	O
%	O
and	O
100	O
.	O
0	O
%	O
and	O
for	O
IgM	B-PRGE
81	O
.	O
8	O
%	O
and	O
100	O
.	O
0	O
%	O
respectively	O
.	O

TITLE	O
:	O
Receptor	O
and	O
viral	O
determinants	O
of	O
SARS	O
-	O
coronavirus	O
adaptation	O
to	O
human	B-PRGE
ACE2	I-PRGE
.	O

All	O
three	O
S	O
proteins	O
bound	O
to	O
and	O
utilized	O
palm	O
-	O
civet	O
ACE2	O
efficiently	O
,	O
but	O
the	O
latter	O
two	O
S	O
proteins	O
utilized	O
human	B-PRGE
ACE2	I-PRGE
markedly	O
less	O
efficiently	O
than	O
did	O
the	O
S	B-PRGE
protein	I-PRGE
obtained	O
during	O
the	O
earlier	O
human	O
outbreak	O
.	O

The	O
lower	O
affinity	O
of	O
these	O
S	O
proteins	O
could	O
be	O
complemented	O
by	O
altering	O
specific	O
residues	O
within	O
the	O
S	B-PRGE
-	I-PRGE
protein	I-PRGE
-	I-PRGE
binding	I-PRGE
site	I-PRGE
of	O
human	B-PRGE
ACE2	I-PRGE
to	O
those	O
of	O
civet	O
ACE2	O
,	O
or	O
by	O
altering	O
S	O
-	O
protein	O
residues	O
479	O
and	O
487	O
to	O
residues	O
conserved	O
during	O
the	O
2002	O
-	O
2003	O
outbreak	O
.	O

The	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
rNP	I-PRGE
-	I-PRGE
based	I-PRGE
IgG	I-PRGE
ELISA	I-PRGE
has	O
92	O
%	O
of	O
sensitivity	O
and	O
specificity	O
compared	O
with	O
the	O
neutralizing	O
antibody	O
assay	O
and	O
94	O
%	O
sensitivity	O
and	O
specificity	O
compared	O
with	O
the	O
authentic	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
antigen	I-PRGE
-	I-PRGE
based	I-PRGE
IgG	I-PRGE
ELISA	I-PRGE
.	O

The	O
results	O
suggest	O
that	O
the	O
newly	O
developed	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
rNP	I-PRGE
-	I-PRGE
based	I-PRGE
IgG	I-PRGE
ELISA	I-PRGE
is	O
a	O
valuable	O
tool	O
for	O
the	O
diagnosis	O
and	O
seroepidemiological	O
study	O
of	O
SARS	O
.	O

CD4	B-PRGE
+	I-PRGE
T	O
cells	O
which	O
localize	O
to	O
the	O
perivascular	O
and	O
subarachnoid	O
spaces	O
were	O
identified	O
as	O
the	O
primary	O
source	O
of	O
TIMP	B-PRGE
-	I-PRGE
1	I-PRGE
protein	I-PRGE
.	O

Amino	O
acid	O
residues	O
450	O
-	O
650	O
of	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
(	O
S450	O
-	O
650	O
)	O
contains	O
dominant	O
epitopes	O
for	O
anti	O
-	O
viral	O
antibodies	O
(	O
Abs	O
)	O
in	O
patient	O
sera	O
.	O

The	O
S450	O
-	O
650	O
-	O
based	O
ELISA	O
detected	O
IgG	B-PRGE
Abs	I-PRGE
in	O
41	O
out	O
of	O
51	O
serum	O
samples	O
from	O
22	O
hospitalized	O
patients	O
with	O
probable	O
SARS	O
,	O
a	O
result	O
closely	O
correlated	O
with	O
that	O
obtained	O
with	O
a	O
virus	O
-	O
based	O
ELISA	O
(	O
r	O
=	O
0	O
.	O
75	O
,	O
k	O
=	O
0	O
.	O
8	O
).	O

Some	O
of	O
them	O
produced	O
anti	B-PRGE
-	I-PRGE
S	I-PRGE
Abs	I-PRGE
early	O
during	O
their	O
infection	O
,	O
while	O
others	O
failed	O
to	O
make	O
IgG	B-PRGE
Abs	I-PRGE
against	O
the	O
S450	O
-	O
650	O
polypeptide	O
.	O

The	O
S450	O
-	O
650	O
-	O
based	O
ELISA	O
can	O
detect	O
anti	B-PRGE
-	I-PRGE
S	I-PRGE
IgG	I-PRGE
Abs	I-PRGE
with	O
high	O
sensitivity	O
and	O
specificity	O
.	O

However	O
,	O
several	O
reports	O
have	O
shown	O
that	O
conventional	O
and	O
real	O
-	O
time	O
PCR	O
assays	O
were	O
very	O
specific	O
for	O
SARS	B-PRGE
CoV	I-PRGE
but	O
lack	O
sensitivity	O
depending	O
on	O
the	O
assay	O
,	O
specimen	O
,	O
and	O
time	O
course	O
of	O
disease	O
.	O

As	O
no	O
SARS	B-PRGE
CoV	I-PRGE
was	O
detected	O
among	O
specimens	O
collected	O
during	O
post	O
-	O
epidemic	O
period	O
,	O
the	O
positive	O
predictive	O
value	O
of	O
real	O
-	O
time	O
PCR	O
assays	O
for	O
detection	O
of	O
SARS	B-PRGE
CoV	I-PRGE
during	O
low	O
epidemic	O
requires	O
further	O
evaluation	O
.	O

In	O
contrast	O
to	O
depletion	O
of	O
CD4	B-PRGE
(+)	O
T	O
cells	O
,	O
inhibition	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
signaling	O
did	O
not	O
influence	O
CD8	B-PRGE
(+)	O
T	O
cell	O
infiltration	O
,	O
effector	O
cell	O
function	O
or	O
survival	O
within	O
the	O
CNS	O
.	O

Multivariate	O
analysis	O
showed	O
that	O
peak	O
level	O
of	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
was	O
the	O
only	O
independent	O
predictor	O
of	O
respiratory	O
failure	O
and	O
intubation	O
(	O
odds	O
ratio	O
for	O
every	O
increment	O
of	O
1	O
mg	O
/	O
dL	O
=	O
1	O
.	O
45	O
;	O
95	O
%	O
confidence	O
interval	O
=	O
1	O
.	O
003	O
,	O
2	O
.	O
097	O
;	O
p	O
=	O
0	O
.	O
048	O
).	O

Synthetic	O
ACTH	B-PRGE
was	O
added	O
in	O
3	O
children	O
with	O
spasms	O
and	O
hypsarrhythmia	O
disappeared	O
in	O
1	O
child	O
.	O

Lennox	O
-	O
Gastaut	O
syndrome	O
developed	O
in	O
14	O
.	O
2	O
%	O
(	O
3	O
/	O
21	O
children	O
);	O
1	O
of	O
them	O
died	O
at	O
the	O
age	O
of	O
3	O
.	O
5	O
years	O
from	O
acute	O
gastric	O
bleeding	O
during	O
the	O
administration	O
of	O
synthetic	O
ACTH	B-PRGE
,	O
and	O
an	O
other	O
child	O
died	O
at	O
the	O
age	O
of	O
5	O
.	O
5	O
years	O
from	O
infection	O
and	O
respiratory	O
insufficiency	O
.	O

TITLE	O
:	O
Human	B-PRGE
coronavirus	I-PRGE
OC43	I-PRGE
causes	O
influenza	O
-	O
like	O
illness	O
in	O
residents	O
and	O
staff	O
of	O
aged	O
-	O
care	O
facilities	O
in	O
Melbourne	O
,	O
Australia	O
.	O

An	O
association	O
between	O
hyperglycemia	O
and	O
CIP	B-PRGE
/	O
CIM	B-PRGE
has	O
been	O
found	O
.	O

In	O
the	O
patient	O
who	O
had	O
symptoms	O
of	O
diarrhea	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
staining	O
was	O
also	O
identified	O
in	O
the	O
mucosal	O
epithelium	O
of	O
the	O
colon	O
.	O

CD8	B-PRGE
T	O
cells	O
play	O
an	O
important	O
role	O
in	O
controlling	O
diseases	O
caused	O
by	O
other	O
coronaviruses	O
and	O
in	O
mediating	O
vaccine	O
-	O
induced	O
protective	O
immunity	O
in	O
corresponding	O
animal	O
models	O
.	O

Overlapping	O
peptides	O
were	O
used	O
to	O
identify	O
major	B-PRGE
histocompatibility	I-PRGE
complex	I-PRGE
class	O
I	O
-	O
restricted	O
epitopes	O
in	O
mice	O
immunized	O
with	O
vectors	O
encoding	O
codon	O
-	O
optimized	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
.	O

CD8	B-PRGE
T	O
-	O
cell	O
responses	O
were	O
mapped	O
to	O
two	O
H	O
-	O
2	O
(	O
b	O
)-	O
restricted	O
epitopes	O
(	O
S436	O
-	O
443	O
and	O
S525	O
-	O
532	O
)	O
and	O
one	O
H	O
-	O
2	O
(	O
d	O
)-	O
restricted	O
epitope	O
(	O
S366	O
-	O
374	O
).	O

However	O
,	O
the	O
amino	B-PRGE
acids	I-PRGE
1	I-PRGE
-	I-PRGE
4	I-PRGE
-	I-PRGE
truncated	I-PRGE
protease	I-PRGE
showed	O
the	O
major	O
form	O
to	O
be	O
a	O
monomer	O
and	O
had	O
little	O
enzyme	O
activity	O
.	O

E	B-PRGE
protein	I-PRGE
is	O
found	O
in	O
bright	O
perinuclear	O
patches	O
colocalizing	O
with	O
endoplasmic	O
reticulum	O
markers	O
.	O

Recombinant	O
vectors	O
expressing	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
or	O
S	B-PRGE
protein	I-PRGE
were	O
recovered	O
and	O
their	O
immunogenicity	O
was	O
studied	O
in	O
mice	O
.	O

TITLE	O
:	O
Mutations	O
in	O
Sendai	O
virus	O
variant	O
F1	O
-	O
R	O
that	O
correlate	O
with	O
plaque	O
formation	O
in	O
the	O
absence	O
of	O
trypsin	B-PRGE
.	O

To	O
confirm	O
that	O
the	O
F	B-PRGE
and	I-PRGE
M	I-PRGE
gene	I-PRGE
mutations	O
described	O
above	O
are	O
solely	O
responsible	O
for	O
the	O
phenotypic	O
differences	O
seen	O
in	O
wild	O
-	O
type	O
versus	O
F1	O
-	O
R	O
infections	O
,	O
reverse	O
genetics	O
was	O
used	O
to	O
construct	O
recombinant	O
Sendai	O
viruses	O
with	O
various	O
combinations	O
of	O
the	O
mutations	O
found	O
in	O
the	O
M	O
and	O
F	O
genes	O
of	O
F1	O
-	O
R	O
.	O
Plaque	O
assays	O
were	O
performed	O
with	O
or	O
without	O
trypsin	B-PRGE
addition	O
.	O

The	O
distribution	O
of	O
MBL	B-PRGE
gene	I-PRGE
polymorphisms	O
was	O
significantly	O
different	O
between	O
patients	O
with	O
SARS	O
and	O
control	O
subjects	O
,	O
with	O
a	O
higher	O
frequency	O
of	O
haplotypes	O
associated	O
with	O
low	O
or	O
deficient	O
serum	O
levels	O
of	O
MBL	O
in	O
patients	O
with	O
SARS	O
than	O
in	O
control	O
subjects	O
.	O

Serum	O
levels	O
of	O
MBL	B-PRGE
were	O
also	O
significantly	O
lower	O
in	O
patients	O
with	O
SARS	O
than	O
in	O
control	O
subjects	O
.	O

These	O
results	O
suggest	O
that	O
MBL	B-PRGE
contributes	O
to	O
the	O
first	O
-	O
line	O
host	O
defense	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
that	O
MBL	B-PRGE
deficiency	O
is	O
a	O
susceptibility	O
factor	O
for	O
acquisition	O
of	O
SARS	O
.	O

We	O
report	O
here	O
the	O
cloning	O
,	O
expression	O
,	O
and	O
purification	O
of	O
the	O
N	O
-	O
terminal	O
GST	B-PRGE
-	O
fused	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RdRp	I-PRGE
and	O
its	O
polymerase	O
catalytic	O
domain	O
in	O
Escherichia	O
coli	O
.	O

Nonnucleoside	O
HIV	O
-	O
1	O
RT	O
inhibitors	O
are	O
shown	O
to	O
have	O
no	O
evident	O
inhibitory	O
effect	O
on	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RdRp	I-PRGE
activity	O
.	O

ABSTRACT	O
:	O
Aminopeptidase	B-PRGE
N	O
,	O
or	O
CD13	B-PRGE
,	O
is	O
a	O
receptor	O
for	O
serologically	O
related	O
coronaviruses	O
of	O
humans	O
,	O
pigs	O
,	O
and	O
cats	O
.	O

Primary	O
embryonic	O
cells	O
and	O
bone	O
marrow	O
dendritic	O
cells	O
derived	O
from	O
hAPN	O
-	O
transgenic	O
mice	O
also	O
expressed	O
hAPN	B-PRGE
protein	I-PRGE
.	O

In	O
addition	O
,	O
the	O
inactivation	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
in	O
wastewater	O
with	O
sodium	O
hypochlorite	O
and	O
chlorine	O
dioxide	O
was	O
also	O
studied	O
.	O

Free	O
residue	O
chlorine	O
over	O
0	O
.	O
5	O
mg	O
/	O
L	O
for	O
chlorine	O
or	O
2	O
.	O
19	O
mg	O
/	O
L	O
for	O
chlorine	O
dioxide	O
in	O
wastewater	O
ensures	O
complete	O
inactivation	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
while	O
it	O
does	O
not	O
inactivate	O
completely	O
E	O
.	O
coli	O
and	O
f2	O
phage	O
.	O

TITLE	O
:	O
Small	O
interfering	O
RNA	O
inhibits	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
nucleocapsid	I-PRGE
gene	I-PRGE
expression	O
in	O
cultured	O
cells	O
and	O
mouse	O
muscles	O
.	O

Four	O
siRNA	O
expression	O
cassettes	O
driven	O
by	O
mouse	O
U6	O
promoter	O
targeting	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
gene	I-PRGE
were	O
prepared	O
,	O
and	O
their	O
inhibitory	O
effects	O
on	O
expression	O
of	O
N	O
and	O
enhanced	B-PRGE
green	I-PRGE
fluorescence	I-PRGE
protein	I-PRGE
(	O
EGFP	O
)	O
fusion	O
protein	O
were	O
observed	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
human	B-PRGE
monoclonal	I-PRGE
antibody	I-PRGE
80R	I-PRGE
for	O
immunoprophylaxis	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
by	O
an	O
animal	O
study	O
,	O
epitope	O
mapping	O
,	O
and	O
analysis	O
of	O
spike	O
variants	O
.	O

ABSTRACT	O
:	O
In	O
this	O
report	O
,	O
the	O
antiviral	O
activity	O
of	O
80R	O
immunoglobulin	B-PRGE
G1	I-PRGE
(	O
IgG1	B-PRGE
),	O
a	O
human	O
monoclonal	O
antibody	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
protein	O
that	O
acts	O
as	O
a	O
viral	O
entry	O
inhibitor	O
in	O
vitro	O
,	O
was	O
investigated	O
in	O
vivo	O
in	O
a	O
mouse	O
model	O
.	O

These	O
monoclonal	O
antibodies	O
enabled	O
the	O
immunological	O
detection	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
by	O
immunofluorescence	O
staining	O
,	O
Western	O
blot	O
or	O
immunohistology	O
.	O

The	O
detection	O
of	O
negative	O
strands	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
in	O
DCs	O
suggested	O
viral	O
replication	O
.	O

GST	B-PRGE
pull	O
-	O
down	O
results	O
clearly	O
demonstrated	O
that	O
SARS_N	O
protein	O
could	O
directly	O
and	O
specifically	O
bind	O
to	O
human	B-PRGE
hnRNP	I-PRGE
A1	I-PRGE
in	O
vitro	O
.	O

Expression	O
levels	O
for	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
and	O
CXCL10	B-PRGE
consistently	O
peaked	O
within	O
4	O
days	O
of	O
peak	O
viral	O
load	O
.	O

Two	O
S1	O
(	O
Sp4	B-PRGE
and	O
Sp6	B-PRGE
)	O
and	O
one	O
S2	O
peptide	O
(	O
Sp7	B-PRGE
),	O
protected	O
kidney	O
tissue	O
against	O
virulent	O
challenge	O
.	O

We	O
have	O
developed	O
a	O
multitarget	O
real	O
-	O
time	O
Taqman	O
reverse	O
transcription	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
for	O
the	O
quantitative	O
detection	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
The	O
sequences	O
of	O
the	O
Taqman	O
probes	O
with	O
a	O
minor	O
groove	O
binder	O
and	O
the	O
corresponding	O
primers	O
were	O
based	O
on	O
the	O
sequences	O
of	O
the	O
N	B-PRGE
gene	I-PRGE
,	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
3	O
,	O
and	O
ORF	O
8	O
.	O

Two	O
of	O
five	O
S	O
protein	O
mAbs	O
neutralized	O
SARS	O
-	O
CoV	O
infection	O
of	O
Vero	O
E6	O
cells	O
and	O
reacted	O
to	O
an	O
epitope	O
within	O
amino	O
acids	O
490	O
-	O
510	O
in	O
the	O
S	B-PRGE
protein	I-PRGE
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
construct	O
a	O
sensitive	O
and	O
specific	O
real	O
-	O
time	O
quantitative	O
fluorescent	O
(	O
QF	O
)	O
reverse	B-PRGE
transcriptase	I-PRGE
(	O
RT	O
)-	O
PCR	O
method	O
for	O
the	O
detection	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
.	O

Two	O
pairs	O
of	O
primers	O
were	O
synthesized	O
by	O
the	O
Shanghai	O
Sangon	O
Company	O
according	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
BJ01	I-PRGE
strain	I-PRGE
sequence	I-PRGE
(	O
AY278488	O
),	O
and	O
then	O
a	O
pair	O
of	O
primers	O
were	O
designed	O
and	O
compared	O
with	O
a	O
pair	O
of	O
primers	O
published	O
by	O
WHO	O
.	O

We	O
found	O
that	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
vector	O
RNAs	O
that	O
lack	O
the	O
N	B-PRGE
gene	I-PRGE
were	O
greatly	O
impaired	O
in	O
their	O
ability	O
to	O
replicate	O
,	O
whereas	O
the	O
transcription	O
of	O
subgenomic	O
mRNA	O
from	O
these	O
vectors	O
was	O
easily	O
detectable	O
.	O

A	O
fusion	O
peptide	O
present	O
at	O
the	O
N	O
-	O
terminal	O
region	O
of	O
class	B-PRGE
I	I-PRGE
viral	I-PRGE
fusion	I-PRGE
proteins	I-PRGE
is	O
believed	O
to	O
initiate	O
viral	O
and	O
cell	O
membrane	O
interactions	O
and	O
subsequent	O
fusion	O
.	O

Based	O
on	O
the	O
conserved	O
features	O
of	O
known	O
viral	O
fusion	O
peptides	O
and	O
using	O
Wimley	O
and	O
White	O
interfacial	O
hydrophobicity	O
plots	O
,	O
we	O
have	O
identified	O
two	O
putative	O
fusion	O
peptides	O
(	O
SARS	O
(	O
WW	O
-	O
I	O
)	O
and	O
SARS	O
(	O
WW	O
-	O
II	O
))	O
at	O
the	O
N	O
terminus	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S2	I-PRGE
subunit	I-PRGE
.	O

Secondly	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
could	O
be	O
detected	O
in	O
pharyngeal	O
swab	O
samples	O
using	O
nested	O
RT	O
-	O
PCR	O
in	O
all	O
infected	O
animals	O
from	O
5	O
days	O
after	O
virus	O
inoculation	O
.	O

ABSTRACT	O
:	O
This	O
report	O
describes	O
the	O
production	O
of	O
several	O
MAbs	O
against	O
N195	B-PRGE
protein	I-PRGE
,	O
a	O
major	O
immunodomain	O
of	O
SARS	B-PRGE
CoV	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
[	O
He	O
,	O
Q	O
.,	O
Chong	O
,	O
K	O
.	O
H	O
.,	O
Chang	O
,	O
H	O
.	O
H	O
.,	O
Leung	O
,	O
B	O
.,	O
Ling	O
,	O
A	O
.	O
E	O
.,	O
Wei	O
,	O
T	O
.,	O
Chan	O
,	O
S	O
.	O
W	O
.,	O
Ooi	O
,	O
E	O
.	O
E	O
.,	O
Kwang	O
,	O
J	O
.,	O
2004	O
.	O

One	O
representative	O
IgG1	B-PRGE
monoclonal	O
antibody	O
(	O
MAb	O
),	O
S	O
-	O
A5D5	O
,	O
was	O
selected	O
and	O
characterized	O
.	O

N	B-PRGE
protein	I-PRGE
was	O
detected	O
in	O
18	B-PRGE
IFA	I-PRGE
IgM	I-PRGE
-	O
positive	O
serum	O
samples	O
collected	O
from	O
SARS	O
confirmed	O
patients	O
,	O
but	O
not	O
in	O
nine	O
samples	O
collected	O
from	O
SARS	O
recovery	O
patient	O
.	O

The	O
NL63	O
spike	O
(	O
S	O
)	O
protein	O
mediated	O
infection	O
of	O
different	O
target	O
cells	O
compared	O
with	O
the	O
closely	O
related	O
229E	B-PRGE
-	I-PRGE
S	I-PRGE
protein	I-PRGE
but	O
facilitated	O
entry	O
into	O
cells	O
known	O
to	O
be	O
permissive	O
to	O
SARS	O
-	O
CoV	O
-	O
S	O
-	O
driven	O
infection	O
.	O

Here	O
,	O
we	O
show	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
shares	O
its	O
receptor	O
ACE2	B-PRGE
with	O
HCoV	O
-	O
NL63	O
.	O

The	O
nsp2	B-PRGE
gene	I-PRGE
was	O
amplified	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
cloned	O
into	O
eukaryotic	O
expression	O
vector	O
pCI	B-PRGE
-	I-PRGE
neo	I-PRGE
(	O
pCI	B-PRGE
-	I-PRGE
neo	I-PRGE
/	O
nsp2	B-PRGE
).	O

Three	O
-	O
dimensional	O
-	O
PSSM	O
Protein	O
Fold	O
Recognition	O
(	O
Threading	O
)	O
Server	O
was	O
employed	O
to	O
construct	O
the	O
three	O
-	O
dimensional	O
model	O
of	O
the	O
nsp2	B-PRGE
protein	I-PRGE
.	O

The	O
three	O
-	O
dimensional	O
structure	O
result	O
indicates	O
that	O
the	O
nsp2	B-PRGE
protein	I-PRGE
of	O
GD	O
strain	O
is	O
high	O
homologous	O
with	O
3CL	O
(	O
pro	O
)	O
of	O
SARS	O
-	O
CoV	O
urbani	O
strain	O
,	O
3CL	O
(	O
pro	O
)	O
of	O
transmissible	O
gastroenteritis	O
virus	O
and	O
3CL	O
(	O
pro	O
)	O
of	O
human	O
coronavirus	O
229E	O
strain	O
,	O
which	O
further	O
suggests	O
that	O
nsp2	B-PRGE
protein	I-PRGE
of	O
GD	O
strain	O
possesses	O
the	O
activity	O
of	O
3CL	O
(	O
pro	O
).	O

The	O
three	O
-	O
dimensional	O
structure	O
of	O
the	O
nsp2	B-PRGE
protein	I-PRGE
was	O
successfully	O
constructed	O
.	O

In	O
n	O
=	O
6	O
non	O
-	O
responders	O
to	O
iNO	B-PRGE
(	O
DeltaPaO2	O
<	O
10	O
%),	O
we	O
determined	O
a	O
short	O
relative	O
borderline	O
between	O
normal	O
and	O
consolidated	O
lung	O
tissue	O
due	O
to	O
the	O
presence	O
of	O
large	O
and	O
coherently	O
consolidated	O
lung	O
regions	O
.	O

Two	O
weeks	O
later	O
,	O
patients	O
'	O
respiratory	O
symptoms	O
started	O
to	O
alleviate	O
,	O
the	O
infiltrates	O
on	O
the	O
lung	O
began	O
to	O
absorb	O
gradually	O
,	O
the	O
counts	O
of	O
WBC	O
,	O
lymphocyte	O
and	O
CD3	B-PRGE
,	O
CD4	B-PRGE
,	O
CD8	B-PRGE
positive	O
T	O
cells	O
were	O
restored	O
to	O
normality	O
.	O

SPR	B-PRGE
Opt	I-PRGE
calculates	O
all	O
SNP	O
or	O
PCR	O
-	O
RFLP	O
variations	O
present	O
in	O
the	O
sequences	O
,	O
groups	O
them	O
into	O
haplotypes	O
according	O
to	O
their	O
co	O
-	O
segregation	O
across	O
those	O
sequences	O
,	O
and	O
performs	O
combinatoric	O
analyses	O
to	O
determine	O
which	O
sets	O
of	O
haplotypes	O
provide	O
maximal	O
discrimination	O
among	O
all	O
the	O
input	O
sequences	O
.	O

TITLE	O
:	O
Interferon	B-PRGE
alfacon1	I-PRGE
is	O
an	O
inhibitor	O
of	O
SARS	O
-	O
corona	O
virus	O
in	O
cell	O
-	O
based	O
models	O
.	O

Sukumo	O
extract	O
was	O
found	O
to	O
interact	O
with	O
both	O
the	O
viral	B-PRGE
envelope	I-PRGE
glycoprotein	I-PRGE
and	I-PRGE
cellular	I-PRGE
receptors	I-PRGE
,	O
thus	O
blocking	O
virus	O
-	O
cell	O
binding	O
and	O
virus	O
-	O
induced	O
syncytium	O
formation	O
.	O

Serum	B-PRGE
epidermal	I-PRGE
growth	I-PRGE
factor	I-PRGE
levels	O
also	O
were	O
not	O
significantly	O
different	O
between	O
the	O
furosemide	O
treatment	O
group	O
and	O
the	O
control	O
group	O
(	O
P	O
>	O
.	O
05	O
).	O

Interestingly	O
,	O
a	O
viral	O
receptor	O
,	O
angiotensin	B-PRGE
converting	I-PRGE
enzyme	I-PRGE
(	O
ACE	B-PRGE
)-	O
2	O
,	O
was	O
down	O
-	O
regulated	O
in	O
persistently	O
infected	O
cells	O
.	O

These	O
results	O
indicated	O
that	O
two	O
signaling	O
pathways	O
of	O
JNK	B-PRGE
and	O
PI3K	B-PRGE
/	O
Akt	B-PRGE
were	O
important	O
for	O
the	O
establishment	O
of	O
persistence	O
in	O
Vero	O
E6	O
cells	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
Hsp60	B-PRGE
could	O
be	O
detected	O
in	O
the	O
serum	O
of	O
patients	O
early	O
after	O
severe	O
trauma	O
and	O
whether	O
its	O
serum	O
level	O
might	O
correlate	O
with	O
the	O
development	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
in	O
trauma	O
patients	O
.	O

Immature	O
but	O
mature	O
Hsp60	B-PRGE
causes	O
in	O
vitro	O
the	O
release	O
of	O
NO	O
by	O
macrophages	O
,	O
suggesting	O
that	O
the	O
extracellular	O
release	O
of	O
the	O
immature	O
Hsp60	B-PRGE
associated	O
with	O
traumatic	O
cell	O
necrosis	O
could	O
be	O
involved	O
in	O
the	O
release	O
of	O
NO	O
by	O
immune	O
competent	O
cells	O
,	O
leading	O
to	O
an	O
activation	O
of	O
the	O
inflammatory	O
response	O
within	O
the	O
lung	O
or	O
other	O
organs	O
.	O

The	O
gene	O
expression	O
profiles	O
of	O
macrophages	O
infected	O
with	O
SARS	O
-	O
CoV	O
,	O
human	O
coronavirus	O
229E	O
,	O
and	O
influenza	O
A	O
(	O
H1N1	O
)	O
virus	O
were	O
compared	O
by	O
using	O
microarrays	O
and	O
real	O
-	O
time	O
quantitative	O
reverse	B-PRGE
transcriptase	I-PRGE
PCR	O
.	O

In	O
31	O
animals	O
sampled	O
in	O
January	O
5	O
2004	O
before	O
culling	O
of	O
wild	O
animals	O
at	O
Guangdong	O
Province	O
,	O
including	O
20	O
cats	O
(	O
Felis	O
catus	O
),	O
5	O
red	O
fox	O
(	O
Vulpes	O
vulpes	O
)	O
and	O
6	O
Lesser	O
rice	O
field	O
rats	O
(	O
Rattus	O
losea	O
),	O
8	O
(	O
25	O
.	O
8	O
%)	O
animals	O
were	O
tested	O
positive	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
like	I-PRGE
virus	O
by	O
RT	O
-	O
PCR	O
methods	O
,	O
of	O
which	O
4	O
cats	O
,	O
3	O
red	O
fox	O
and	O
one	O
Lesser	O
rice	O
field	O
rats	O
were	O
included	O
.	O

In	O
them	O
,	O
ARF	B-PRGE
was	O
caused	O
by	O
acute	O
interstitial	O
nephritis	O
in	O
18	O
.	O
8	O
%,	O
by	O
urosepsis	O
in	O
18	O
.	O
8	O
%,	O
by	O
non	O
-	O
urological	O
sepsis	O
in	O
19	O
%,	O
by	O
destructive	O
pancreatitis	O
in	O
18	O
%,	O
in	O
13	O
%	O
rapidly	O
progressive	O
glomerulonephritis	O
was	O
present	O
in	O
systemic	O
vasculitis	O
.	O

Serum	O
CRP	B-PRGE
levels	O
,	O
white	O
blood	O
cell	O
(	O
WBC	O
)	O
counts	O
and	O
body	O
temperature	O
were	O
measured	O
serially	O
for	O
at	O
least	O
4	O
days	O
.	O

A	O
unique	O
feature	O
of	O
the	O
system	O
is	O
the	O
SUMO	B-PRGE
tag	I-PRGE
,	O
which	O
enhances	O
expression	O
,	O
facilitates	O
purification	O
,	O
and	O
can	O
be	O
efficiently	O
cleaved	O
by	O
a	O
SUMO	B-PRGE
-	I-PRGE
specific	I-PRGE
protease	I-PRGE
to	O
generate	O
native	O
protein	O
with	O
a	O
desired	O
N	O
-	O
terminus	O
.	O

ABSTRACT	O
:	O
To	O
detect	O
the	O
level	O
and	O
dynamic	O
change	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
coronavirus	O
-	O
specific	O
IgG	B-PRGE
antibody	I-PRGE
in	O
conavalescent	O
SARS	O
patients	O
,	O
and	O
to	O
provide	O
information	O
for	O
prevention	O
and	O
vaccine	O
development	O
.	O

IgG	B-PRGE
antibody	O
level	O
showed	O
a	O
35	O
.	O
8	O
%	O
decrease	O
within	O
one	O
year	O
.	O

Using	O
paired	O
ELISA	O
assay	O
,	O
three	O
mAbs	O
N1E8	O
,	O
N8E1	O
and	O
N10E4	O
were	O
selected	O
as	O
capturing	O
antibody	O
and	O
rabbit	O
polyclonal	O
antibodies	O
as	O
detecting	O
antibody	O
then	O
triple	O
antibodies	O
-	O
based	O
sandwich	O
ELISA	O
was	O
established	O
following	O
horseradish	B-PRGE
peroxidase	I-PRGE
(	O
HRP	B-PRGE
)-	O
conjugated	O
goat	O
anti	B-PRGE
-	I-PRGE
rabbit	I-PRGE
immunoglobulin	I-PRGE
G	O
.	O
The	O
recombinant	B-PRGE
N	I-PRGE
protein	I-PRGE
was	O
used	O
as	O
a	O
standard	O
to	O
establish	O
a	O
detection	O
sensitivity	O
of	O
approximated	O
50	O
pg	O
/	O
ml	O
with	O
this	O
assay	O
.	O

One	O
group	O
of	O
piglets	O
served	O
as	O
a	O
control	O
(	O
n	O
=	O
8	O
),	O
a	O
second	O
group	O
(	O
S	O
,	O
n	O
=	O
8	O
)	O
received	O
a	O
porcine	O
surfactant	O
preparation	O
(	O
Curosurf	O
),	O
and	O
a	O
third	O
group	O
received	O
IKK	B-PRGE
-	I-PRGE
NBD	I-PRGE
peptide	I-PRGE
admixed	O
to	O
surfactant	O
(	O
S	O
+	O
IN	O
,	O
n	O
=	O
8	O
).	O

A	O
topically	O
applied	O
nuclear	B-PRGE
factor	I-PRGE
-	I-PRGE
kappaB	I-PRGE
inhibitor	O
improves	O
lung	O
edema	O
and	O
lung	O
volumes	O
and	O
reduces	O
inflammation	O
in	O
this	O
newborn	O
piglet	O
model	O
of	O
airway	O
lavage	O
.	O

Positive	O
SARS	B-PRGE
-	I-PRGE
Co	I-PRGE
virus	I-PRGE
IgG	I-PRGE
antibody	I-PRGE
results	O
were	O
seen	O
in	O
208	O
of	O
258	O
patients	O
,	O
with	O
21	O
.	O
3	O
%	O
(	O
55	O
of	O
258	O
patients	O
)	O
still	O
having	O
a	O
pulmonary	O
diffusion	O
abnormality	O
(	O
D	O
(	O
LCO	O
)	O
<	O
80	O
%	O
of	O
predicted	O
).	O

By	O
comparing	O
the	O
155	O
survivors	O
with	O
positive	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
IgG	I-PRGE
antibody	I-PRGE
results	O
and	O
D	O
(	O
LCO	O
)	O
>	O
or	O
=	O
80	O
%	O
predicted	O
with	O
the	O
50	O
patients	O
with	O
negative	O
SARS	O
-	O
CoV	O
IgG	B-PRGE
results	O
,	O
we	O
found	O
that	O
53	O
patients	O
with	O
positive	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
IgG	I-PRGE
results	O
and	O
a	O
lung	O
diffusion	O
abnormality	O
had	O
endured	O
a	O
much	O
longer	O
course	O
of	O
fever	O
and	O
received	O
larger	O
doses	O
of	O
glucocorticoid	O
,	O
as	O
well	O
as	O
higher	O
ratios	O
of	O
oxygen	O
inhalation	O
and	O
noninvasive	O
ventilation	O
treatment	O
.	O

For	O
these	O
patients	O
,	O
51	O
of	O
53	O
patients	O
with	O
positive	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
IgG	I-PRGE
results	O
and	O
a	O
lung	O
diffusion	O
abnormality	O
underwent	O
pulmonary	O
function	O
testing	O
after	O
approximately	O
1	O
month	O
.	O

RESULTS	O
:	O
Positive	O
SARS	B-PRGE
-	I-PRGE
Co	I-PRGE
virus	I-PRGE
IgG	I-PRGE
antibody	I-PRGE
results	O
were	O
seen	O
in	O
208	O
of	O
258	O
patients	O
,	O
with	O
21	O
.	O
3	O
%	O
(	O
55	O
of	O
258	O
patients	O
)	O
still	O
having	O
a	O
pulmonary	O
diffusion	O
abnormality	O
(	O
D	O
(	O
LCO	O
)	O
<	O
80	O
%	O
of	O
predicted	O
).	O

TITLE	O
:	O
[	O
Specific	O
antibodies	O
against	O
the	O
nucleocapsid	B-PRGE
protein	I-PRGE
and	I-PRGE
S1	I-PRGE
domain	I-PRGE
of	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
].	O

The	O
agreement	O
rates	O
of	O
the	O
results	O
of	O
anti	B-PRGE
-	I-PRGE
N	I-PRGE
-	I-PRGE
IgG	I-PRGE
and	O
anti	B-PRGE
-	I-PRGE
s1	I-PRGE
-	I-PRGE
IgG	I-PRGE
with	O
that	O
of	O
the	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
IgG	I-PRGE
were	O
88	O
%	O
(	O
76	O
/	O
86	O
)	O
and	O
83	O
%	O
(	O
71	O
/	O
86	O
)	O
respectively	O
.	O

The	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
IgG	I-PRGE
positive	O
rate	O
in	O
the	O
healthy	O
persons	O
was	O
1	O
.	O
88	O
%	O
(	O
14	O
.	O
745	O
).	O

TITLE	O
:	O
[	O
An	O
immunofluorescence	O
assay	O
for	O
the	O
detection	O
of	O
SARS	B-PRGE
associated	O
coronavirus	O
antibody	O
based	O
on	O
recombinant	B-PRGE
nucleocapsid	I-PRGE
antigen	I-PRGE
and	O
its	O
application	O
].	O

Of	O
a	O
thousand	O
existing	O
drugs	O
examined	O
,	O
hexachlorophene	O
was	O
identified	O
as	O
the	O
most	O
potent	O
in	O
inhibiting	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
protease	I-PRGE
.	O

These	O
analogues	O
gave	O
optimal	O
inhibitory	O
activity	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
protease	O
with	O
IC	O
(	O
50	O
)	O
values	O
ranging	O
from	O
7	O
.	O
6	O
to	O
84	O
.	O
5	O
microM	O
.	O
Optimization	O
of	O
hexachlorophene	O
analogues	O
was	O
shown	O
to	O
provide	O
several	O
active	B-PRGE
3CL	I-PRGE
protease	I-PRGE
inhibitors	I-PRGE
that	O
function	O
as	O
potential	O
anti	O
-	O
SARS	O
agents	O
.	O

Our	O
experiments	O
contribute	O
to	O
the	O
hypothesis	O
that	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
activation	O
of	O
macrophages	O
plays	O
an	O
important	O
role	O
against	O
MHV3	O
infection	O
by	O
downregulating	O
the	O
expression	O
of	O
viral	O
receptors	O
.	O

The	O
3a	B-PRGE
gene	I-PRGE
encodes	O
a	O
non	O
-	O
structural	O
viral	O
protein	O
,	O
which	O
is	O
predicted	O
to	O
be	O
a	O
transmembrane	O
protein	O
.	O

The	O
results	O
show	O
that	O
these	O
assays	O
can	O
be	O
applied	O
to	O
high	O
-	O
throughput	O
screening	O
for	O
identification	O
of	O
inhibitors	O
selectively	O
active	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O

In	O
addition	O
,	O
numbers	O
of	O
circulating	O
CD4	B-PRGE
and	O
CD8	B-PRGE
T	I-PRGE
cells	O
exhibited	O
milder	O
reductions	O
(	O
2	O
.	O
1	O
-	O
and	O
1	O
.	O
8	O
-	O
fold	O
at	O
week	O
1	O
)	O
and	O
earlier	O
return	O
to	O
normal	O
at	O
a	O
mean	O
of	O
weeks	O
3	O
and	O
4	O
,	O
respectively	O
.	O

Three	O
of	O
SARS	O
genes	O
,	O
RNA	B-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
(	O
RdRp	O
),	O
spike	O
and	O
nucleocapsid	O
,	O
were	O
amplified	O
with	O
T7	O
promoter	O
-	O
flanked	O
primers	O
.	O

Above	O
plasmids	O
and	O
esiRNAs	O
were	O
co	O
-	O
transfected	O
to	O
HEK293F	O
cells	O
with	O
reference	O
plasmid	B-PRGE
pRL	I-PRGE
-	I-PRGE
TK	I-PRGE
.	O

Both	O
SARS	B-PRGE
-	I-PRGE
IgM	I-PRGE
and	O
IgG	B-PRGE
sero	O
-	O
conversion	O
occurred	O
earlier	O
in	O
all	O
the	O
patients	O
with	O
the	O
titer	O
increased	O
more	O
than	O
4	O
-	O
fold	O
shortly	O
.	O

This	O
anilide	O
is	O
a	O
competitive	O
inhibitor	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
protease	O
with	O
K	O
(	O
i	O
)	O
=	O
0	O
.	O
03	O
muM	O
.	O
The	O
molecular	O
docking	O
experiment	O
indicates	O
that	O
the	O
P1	O
residue	O
of	O
this	O
anilide	O
inhibitor	O
is	O
distant	O
from	O
the	O
nucleophilic	O
SH	O
of	O
Cys145	O
in	O
the	O
active	O
site	O
.	O

We	O
expanded	O
the	O
specificity	O
of	O
the	O
N	B-PRGE
protein	I-PRGE
epitope	O
and	O
identified	O
4	O
novel	O
conformational	O
epitopes	O
(	O
amino	O
acids	O
1	O
-	O
69	O
,	O
68	O
-	O
213	O
,	O
212	O
-	O
341	O
,	O
and	O
337	O
-	O
422	O
).	O

Mutations	O
in	O
the	O
membrane	O
protein	O
and	O
a	O
deletion	O
in	O
ORF	B-PRGE
6	I-PRGE
--	I-PRGE
8	I-PRGE
were	O
already	O
observed	O
in	O
passage	O
0	O
,	O
suggesting	O
these	O
amino	O
acid	O
substitutions	O
are	O
important	O
in	O
the	O
adaptation	O
of	O
the	O
virus	O
isolate	O
in	O
primate	O
cell	O
culture	O
.	O

TITLE	O
:	O
A	O
molecular	O
docking	O
model	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S1	I-PRGE
protein	I-PRGE
in	O
complex	O
with	O
its	O
receptor	O
,	O
human	B-PRGE
ACE2	I-PRGE
.	O

These	O
results	O
suggest	O
that	O
amino	O
acid	O
residues	O
at	O
position	O
479	O
and	O
487	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
are	O
important	O
determinants	O
for	O
SARS	O
-	O
CoV	O
tropism	O
and	O
animal	O
-	O
to	O
-	O
human	O
transmission	O
.	O

We	O
observed	O
a	O
six	O
-	O
fold	O
increase	O
in	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
concentration	O
across	O
the	O
liver	O
during	O
AP	O
.	O

All	O
livers	O
produced	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
after	O
the	O
portal	O
LPS	O
challenge	O
,	O
but	O
this	O
was	O
not	O
exaggerated	O
by	O
AP	O
.	O

PaO2	O
/	O
FIO2	O
was	O
significantly	O
better	O
in	O
PP	O
:	O
190	O
+/-	O
26	O
vs	O
.	O
113	O
+/-	O
9	O
mmHg	O
for	O
PP1	B-PRGE
/	O
SP1	B-PRGE
,	O
175	O
+/-	O
22	O
vs	O
.	O
135	O
+/-	O
16	O
mmHg	O
for	O
PP2	B-PRGE
/	O
SP2	B-PRGE
,	O
and	O
199	O
+/-	O
24	O
vs	O
.	O
151	O
+/-	O
13	O
mmHg	O
for	O
PP3	B-PRGE
/	O
SP3	B-PRGE
.	O

The	O
SARS	O
-	O
CoV	O
S	O
-	O
based	O
immunoglobulin	B-PRGE
M	I-PRGE
(	O
IgM	B-PRGE
)	O
and	O
IgG	B-PRGE
ELISAs	I-PRGE
were	O
evaluated	O
and	O
compared	O
with	O
the	O
corresponding	O
N	O
-	O
based	O
ELISA	O
for	O
serodiagnosis	O
of	O
SARS	O
-	O
CoV	O
pneumonia	O
,	O
using	O
sera	O
from	O
148	O
healthy	O
blood	O
donors	O
who	O
donated	O
blood	O
3	O
years	O
ago	O
as	O
controls	O
and	O
95	O
SARS	O
-	O
CoV	O
pneumonia	O
patients	O
in	O
Hong	O
Kong	O
.	O

The	O
sensitivity	O
of	O
the	O
rN	O
IgG	B-PRGE
ELISA	O
(	O
94	O
.	O
7	O
%)	O
is	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
rS	O
IgG	B-PRGE
ELISA	O
(	O
P	O
<	O
0	O
.	O
001	O
),	O
whereas	O
the	O
sensitivity	O
of	O
the	O
rS	B-PRGE
IgM	I-PRGE
ELISA	O
is	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
rN	B-PRGE
IgM	I-PRGE
ELISA	O
(	O
55	O
.	O
2	O
%)	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

Our	O
data	O
identify	O
a	O
critical	O
function	O
for	O
ACE2	B-PRGE
in	O
acute	O
lung	O
injury	O
,	O
pointing	O
to	O
a	O
possible	O
therapy	O
for	O
a	O
syndrome	O
affecting	O
millions	O
of	O
people	O
worldwide	O
every	O
year	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
inapparent	O
nosocomial	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
in	O
Vietnam	O
by	O
use	O
of	O
highly	O
specific	O
recombinant	B-PRGE
truncated	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
-	O
based	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

On	O
multivariate	O
analysis	O
,	O
hemoglobin	B-PRGE
level	O
was	O
an	O
independent	O
prognostic	O
correlate	O
of	O
hypoxemia	O
or	O
mortality	O
(	O
odds	O
ratio	O
,	O
2	O
.	O
0	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
1	O
to	O
3	O
.	O
8	O
;	O
p	O
=	O
0	O
.	O
03	O
).	O

Of	O
the	O
17	O
hypoxemic	O
patients	O
,	O
11	O
(	O
65	O
%)	O
had	O
a	O
drop	O
in	O
hemoglobin	B-PRGE
of	O
>	O
2	O
g	O
/	O
dL	O
,	O
and	O
4	O
patients	O
(	O
24	O
%)	O
required	O
a	O
blood	O
transfusion	O
.	O

Thus	O
ACE2	O
has	O
only	O
one	O
chloride	B-PRGE
-	I-PRGE
binding	I-PRGE
site	I-PRGE
(	O
CL1	B-PRGE
)	O
whereas	O
ACE	B-PRGE
has	O
two	O
sites	O
.	O

ABSTRACT	O
:	O
Based	O
on	O
the	O
genomic	O
sequence	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
strain	O
BJ101	O
,	O
antigenic	O
immunodominant	O
genes	O
coding	O
for	O
the	O
structure	O
proteins	O
of	O
SARS	O
-	O
CoV	O
were	O
predicted	O
by	O
bio	O
-	O
informatics	O
methods	O
,	O
and	O
two	O
chimeric	O
genes	O
A	O
and	O
B	O
with	O
multi	O
-	O
immunodominants	O
lined	O
up	O
by	O
Gly	O
-	O
Pro	O
-	O
Gly	O
linker	O
were	O
synthesized	O
.	O

Most	O
strikingly	O
,	O
our	O
results	O
also	O
show	O
a	O
major	O
role	O
for	O
NKG2D	B-PRGE
,	O
expressed	O
on	O
gammadelta	O
T	O
cells	O
,	O
in	O
the	O
demyelinating	O
process	O
with	O
in	O
vivo	O
blockade	O
of	O
NKG2D	B-PRGE
interactions	O
resulting	O
in	O
a	O
60	O
%	O
reduction	O
in	O
demyelination	O
.	O

Indirect	O
immunofluorescence	O
studies	O
revealed	O
a	O
preferential	O
expression	O
of	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE	B-PRGE
-	I-PRGE
2	I-PRGE
),	O
the	O
functional	O
receptor	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
on	O
the	O
apical	O
surface	O
.	O

However	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
membrane	I-PRGE
protein	I-PRGE
seems	O
to	O
be	O
more	O
sensitive	O
to	O
heat	O
treatment	O
,	O
since	O
the	O
membrane	O
protein	O
of	O
MHV	O
-	O
JHM	O
,	O
another	O
member	O
of	O
the	O
Coronaviridae	O
,	O
would	O
not	O
aggregate	O
after	O
the	O
same	O
treatment	O
.	O

The	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
IgG	I-PRGE
and	O
the	O
viral	O
RNA	O
were	O
also	O
detected	O
in	O
the	O
sera	O
by	O
ELISA	O
and	O
RT	O
-	O
PCR	O
,	O
respectively	O
.	O

The	O
toxicity	O
of	O
beta	B-PRGE
-	I-PRGE
propiolactone	I-PRGE
was	O
hydrolyzed	O
completely	O
when	O
the	O
inactivated	O
virus	O
was	O
cultured	O
for	O
16	O
hours	O
at	O
2	O
degrees	O
C	O
,	O
8	O
degrees	O
C	O
and	O
in	O
water	O
bath	O
for	O
2	O
hours	O
at	O
37	O
degrees	O
C	O
.	O
The	O
titer	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
was	O
the	O
highest	O
when	O
it	O
was	O
cultured	O
in	O
Vero	O
or	O
Vero	O
-	O
E6	O
cells	O
for	O
72	O
hours	O
at	O
37	O
degrees	O
C	O
in	O
5	O
percent	O
CO2	O
incubator	O
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	B-PRGE
(	I-PRGE
N	I-PRGE
)	I-PRGE
protein	I-PRGE
is	O
the	O
only	O
phosphorylated	O
structural	O
protein	O
of	O
the	O
coronavirus	O
Transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
).	O

Cell	O
culture	O
and	O
semi	O
-	O
nested	O
RT	O
-	O
PCR	O
were	O
used	O
to	O
detect	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
its	O
RNA	O
from	O
21	O
stool	O
and	O
urine	O
samples	O
,	O
and	O
a	O
kind	O
of	O
electropositive	O
filter	O
media	O
particles	O
was	O
used	O
to	O
concentrate	O
the	O
virus	O
in	O
10	O
sewage	O
samples	O
from	O
two	O
hospitals	O
receiving	O
SARS	O
patients	O
in	O
Beijing	O
in	O
China	O
.	O

Results	O
showed	O
that	O
the	O
plasmid	O
-	O
derived	O
siRNAs	O
targeting	O
the	O
non	B-PRGE
-	I-PRGE
structural	I-PRGE
protein	I-PRGE
1	I-PRGE
(	O
NSP1	B-PRGE
)	O
sequence	O
of	O
the	O
SARS	O
-	O
CoV	O
genome	O
could	O
specifically	O
inhibit	O
the	O
expression	O
of	O
the	O
NSP1	B-PRGE
sequence	I-PRGE
and	O
effectively	O
suppress	O
the	O
replication	O
and	O
propagation	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
in	O
cultured	O
Vero	O
E6	O
cell	O
lines	O
.	O

The	O
LDH	B-PRGE
level	O
was	O
similar	O
in	O
both	O
groups	O
.	O

Following	O
coronavirus	O
injection	O
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
mRNA	I-PRGE
was	O
detected	O
at	O
higher	O
levels	O
within	O
the	O
retinas	O
,	O
and	O
concentrations	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
p	O
<	O
0	O
.	O
005	O
)	O
and	O
sTNFR1	O
(	O
p	O
<	O
0	O
.	O
0005	O
)	O
proteins	O
were	O
increased	O
within	O
the	O
sera	O
of	O
BALB	O
/	O
c	O
but	O
not	O
CD	O
-	O
1	O
mice	O
.	O

Little	O
information	O
is	O
available	O
on	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
papain	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
2	I-PRGE
(	O
PLP2	B-PRGE
),	O
and	O
development	O
of	O
inhibitors	O
against	O
PLP2	B-PRGE
is	O
attractive	O
for	O
antiviral	O
therapy	O
.	O

We	O
demonstrate	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
PLP2	I-PRGE
by	O
itself	O
differentially	O
cleaves	O
between	O
the	O
amino	O
acids	O
Gly180	O
and	O
Ala181	O
,	O
Gly818	O
and	O
Ala819	O
,	O
and	O
Gly2740	O
and	O
Lys2741	O
of	O
the	O
viral	B-PRGE
polypeptide	I-PRGE
pp1a	I-PRGE
,	O
as	O
determined	O
by	O
reversed	O
-	O
phase	O
high	O
-	O
performance	O
liquid	O
chromatography	O
analysis	O
coupled	O
with	O
mass	O
spectrometry	O
.	O

C23	B-PRGE
,	O
B23	B-PRGE
and	O
fibrillarin	B-PRGE
all	O
are	O
important	O
nucleolar	O
proteins	O
,	O
which	O
localize	O
in	O
the	O
region	O
of	O
the	O
nucleolus	O
.	O

These	O
results	O
provide	O
a	O
new	O
insight	O
for	O
further	O
functional	O
studies	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3b	I-PRGE
protein	I-PRGE
.	O

However	O
,	O
apoptosis	O
was	O
inhibited	O
by	O
overexpressed	O
antiapoptotic	B-PRGE
protein	I-PRGE
Bcl	I-PRGE
-	I-PRGE
xL	I-PRGE
.	O
Moreover	O
,	O
we	O
found	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
E	I-PRGE
protein	I-PRGE
interacted	O
with	O
Bcl	B-PRGE
-	I-PRGE
xL	I-PRGE
in	O
vitro	O
and	O
endogenous	O
Bcl	B-PRGE
-	I-PRGE
xL	I-PRGE
in	O
vivo	O
and	O
that	O
Bcl	B-PRGE
-	I-PRGE
xL	I-PRGE
interaction	O
with	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
E	I-PRGE
protein	I-PRGE
was	O
mediated	O
by	O
BH3	O
(	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
homology	I-PRGE
domain	I-PRGE
3	I-PRGE
)	O
of	O
Bcl	B-PRGE
-	I-PRGE
xL	I-PRGE
.	O
Finally	O
,	O
we	O
identified	O
a	O
novel	O
BH3	B-PRGE
-	I-PRGE
like	I-PRGE
region	I-PRGE
located	O
in	O
the	O
C	O
-	O
terminal	O
cytosolic	O
domain	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
E	I-PRGE
protein	I-PRGE
,	O
which	O
mediates	O
its	O
binding	O
to	O
Bcl	B-PRGE
-	I-PRGE
xL	I-PRGE
.	O
These	O
results	O
demonstrate	O
,	O
for	O
the	O
first	O
time	O
,	O
a	O
novel	O
molecular	O
mechanism	O
of	O
T	O
-	O
cell	O
apoptosis	O
that	O
contributes	O
to	O
the	O
SARS	O
-	O
CoV	O
-	O
induced	O
lymphopenia	O
observed	O
in	O
most	O
SARS	O
patients	O
.	O

In	O
the	O
current	O
study	O
,	O
a	O
reverse	O
genetic	O
approach	O
was	O
used	O
to	O
define	O
the	O
role	O
of	O
the	O
28	B-PRGE
-	I-PRGE
kDa	I-PRGE
amino	I-PRGE
-	I-PRGE
terminal	I-PRGE
product	I-PRGE
(	O
nsp1	B-PRGE
)	O
of	O
the	O
gene	B-PRGE
1	I-PRGE
polyprotein	O
during	O
replication	O
of	O
the	O
coronavirus	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
in	O
cell	O
culture	O
.	O

The	O
results	O
demonstrated	O
that	O
the	O
carboxy	O
-	O
terminal	O
half	O
of	O
nsp1	B-PRGE
(	O
residues	O
K	O
(	O
124	O
)	O
through	O
L	O
(	O
241	O
))	O
was	O
dispensable	O
for	O
virus	O
replication	O
in	O
culture	O
but	O
was	O
required	O
for	O
efficient	O
proteolytic	O
cleavage	O
of	O
nsp1	B-PRGE
from	O
the	O
gene	O
1	O
polyprotein	O
and	O
for	O
optimal	O
viral	O
replication	O
.	O

Here	O
,	O
we	O
show	O
that	O
LSECtin	B-PRGE
enhances	O
infection	O
driven	O
by	O
filovirus	O
glycoproteins	O
(	O
GP	O
)	O
and	O
the	O
S	B-PRGE
protein	I-PRGE
of	O
SARS	O
coronavirus	O
,	O
but	O
does	O
not	O
interact	O
with	O
human	B-PRGE
immunodeficiency	I-PRGE
virus	I-PRGE
type	I-PRGE
-	I-PRGE
1	I-PRGE
and	O
hepatitis	B-PRGE
C	I-PRGE
virus	I-PRGE
envelope	I-PRGE
proteins	I-PRGE
.	O

In	O
summary	O
,	O
we	O
identified	O
LSECtin	B-PRGE
as	O
an	O
attachment	O
factor	O
that	O
in	O
conjunction	O
with	O
DC	O
-	O
SIGNR	O
might	O
concentrate	O
viral	O
pathogens	O
in	O
liver	O
and	O
lymph	O
nodes	O
.	O

Volume	O
resuscitation	O
,	O
vasopressors	O
,	O
high	O
PEEP	O
mechanical	O
ventilation	O
,	O
paralysis	O
,	O
nitric	O
oxide	O
,	O
steroids	O
,	O
rapid	O
albumin	B-PRGE
infusion	O
.	O

Our	O
study	O
provides	O
genetic	O
evidence	O
for	O
the	O
important	O
role	O
of	O
alpha	O
-	O
helical	O
packing	O
in	O
promoting	O
S	B-PRGE
glycoprotein	I-PRGE
-	O
mediated	O
membrane	O
fusion	O
.	O

SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
mediates	O
receptor	O
binding	O
and	O
entry	O
by	O
its	O
spike	O
(	O
S	O
)	O
glycoprotein	O
,	O
and	O
infection	O
is	O
sensitive	O
to	O
lysosomotropic	O
agents	O
that	O
perturb	O
endosomal	O
pH	O
.	O
We	O
demonstrate	O
here	O
that	O
the	O
lysosomotropic	O
-	O
agent	O
-	O
mediated	O
block	O
to	O
SARS	O
-	O
CoV	O
infection	O
is	O
overcome	O
by	O
protease	O
treatment	O
of	O
target	O
-	O
cell	O
-	O
associated	O
virus	O
.	O

Participating	O
laboratories	O
(	O
9	O
/	O
20	O
)	O
correctly	O
detected	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
antibodies	I-PRGE
in	O
serum	O
samples	O
without	O
false	O
positive	O
results	O
in	O
an	O
immunofluorescence	O
assay	O
.	O

ABSTRACT	O
:	O
Histidine	O
-	O
tagged	O
N	B-PRGE
(	I-PRGE
rNH	I-PRGE
)	I-PRGE
and	I-PRGE
E	I-PRGE
(	O
rEH	B-PRGE
)	O
proteins	O
of	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)-	O
coronovirus	O
were	O
expressed	O
in	O
the	O
baculovirus	O
/	O
insect	O
cell	O
system	O
and	O
purified	O
by	O
immobilized	O
metal	O
affinity	O
chromatography	O
.	O

rNH	B-PRGE
and	O
rEH	B-PRGE
proteins	I-PRGE
differed	O
markedly	O
with	O
respect	O
to	O
expression	O
levels	O
,	O
cell	O
death	O
kinetics	O
and	O
subcellular	O
localizations	O
that	O
led	O
to	O
different	O
extraction	O
and	O
purification	O
schemes	O
.	O

Released	O
IFN	B-PRGE
(	O
both	O
types	O
)	O
reached	O
a	O
plateau	O
after	O
24	O
-	O
48	O
h	O
.	O
p	O
.	O
i	O
.	O
and	O
remained	O
rather	O
stable	O
over	O
a	O
5	O
-	O
day	O
period	O
.	O

A	O
combination	O
of	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	I-PRGE
-	I-PRGE
gamma	I-PRGE
strongly	O
inhibited	O
SARS	B-PRGE
-	O
CoV	O
replication	O
in	O
Vero	O
cells	O
,	O
while	O
the	O
single	O
cytokines	O
were	O
much	O
less	O
effective	O
.	O

The	O
lymphopenia	O
was	O
prolonged	O
,	O
reaching	O
a	O
nadir	O
during	O
days	O
7	O
-	O
9	O
in	O
the	O
second	O
week	O
of	O
illness	O
before	O
returning	O
towards	O
normal	O
after	O
five	O
weeks	O
,	O
with	O
the	O
lowest	O
mean	O
CD4	B-PRGE
+	I-PRGE
cell	O
count	O
of	O
317	O
cellsx10	O
(	O
6	O
)/	O
L	O
at	O
day	O
7	O
,	O
and	O
CD8	B-PRGE
+	I-PRGE
cell	O
count	O
of	O
239	O
cellsx10	O
(	O
6	O
)/	O
L	O
at	O
day	O
8	O
.	O

Patients	O
with	O
more	O
severe	O
clinical	O
illness	O
,	O
or	O
patients	O
who	O
died	O
,	O
had	O
significantly	O
more	O
profound	O
CD4	B-PRGE
+	I-PRGE
and	O
CD8	B-PRGE
+	I-PRGE
lymphopenia	O
.	O

This	O
nucleic	O
acid	O
capture	O
system	O
was	O
effective	O
in	O
improving	O
the	O
sensitivity	O
of	O
the	O
RT	O
-	O
PCR	O
,	O
due	O
to	O
enriching	O
and	O
purifying	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
.	O

Animals	O
infected	O
with	O
ReoV	O
died	O
between	O
day	O
22	O
and	O
day	O
30	O
postinoculation	O
(	O
PI	O
)	O
while	O
70	O
%	O
of	O
the	O
animals	O
inoculated	O
with	O
ReoV	O
and	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
died	O
between	O
day	O
4	O
to	O
day	O
7	O
PI	O
.	O

The	O
ELISA	O
results	O
,	O
which	O
showed	O
positive	O
rates	O
of	O
IgG	B-PRGE
reactivity	O
against	O
recombinant	O
proteins	O
N	O
,	O
S1	O
,	O
S2	O
,	O
and	O
S3	O
,	O
were	O
,	O
respectively	O
,	O
28	O
.	O
57	O
,	O
14	O
.	O
29	O
,	O
14	O
.	O
29	O
,	O
and	O
14	O
.	O
29	O
%	O
at	O
week	O
1	O
,	O
77	O
.	O
78	O
,	O
55	O
.	O
56	O
,	O
44	O
.	O
44	O
,	O
and	O
66	O
.	O
67	O
%	O
at	O
week	O
2	O
,	O
100	O
,	O
75	O
,	O
75	O
,	O
and	O
87	O
.	O
5	O
%	O
at	O
week	O
3	O
,	O
and	O
100	O
,	O
77	O
.	O
78	O
,	O
77	O
.	O
78	O
,	O
and	O
88	O
.	O
89	O
%	O
after	O
3	O
weeks	O
.	O

Potent	O
inactivation	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
therefore	O
extends	O
the	O
capability	O
of	O
the	O
INTERCEPT	O
Blood	O
System	O
in	O
inactivating	O
a	O
broad	O
spectrum	O
of	O
human	O
pathogens	O
including	O
recently	O
emerging	O
respiratory	O
viruses	O
.	O

One	O
protein	O
,	O
the	O
product	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
ORF6	I-PRGE
,	O
converted	O
a	O
sublethal	O
infection	O
to	O
a	O
uniformly	O
lethal	O
encephalitis	O
and	O
enhanced	O
virus	O
growth	O
in	O
tissue	O
culture	O
cells	O
,	O
indicating	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
proteins	I-PRGE
function	O
in	O
the	O
context	O
of	O
a	O
heterologous	O
coronavirus	O
infection	O
.	O

Coincidentally	O
,	O
the	O
N	B-PRGE
protein	I-PRGE
was	O
also	O
found	O
to	O
downregulate	O
the	O
expression	O
of	O
the	O
theta	O
isoform	O
of	O
14	O
-	O
3	O
-	O
3	O
(	O
14	O
-	O
3	O
-	O
3theta	O
),	O
leading	O
to	O
the	O
accumulation	O
of	O
phosphorylated	O
N	B-PRGE
protein	I-PRGE
in	O
the	O
nucleus	O
,	O
in	O
the	O
absence	O
of	O
growth	O
factors	O
.	O

However	O
,	O
confocal	O
microscopy	O
of	O
N	O
protein	O
localization	O
in	O
Vero	O
cells	O
infected	O
with	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
or	O
transfected	O
with	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
gene	I-PRGE
failed	O
to	O
show	O
the	O
presence	O
of	O
N	O
in	O
the	O
nucleoplasm	O
or	O
nucleolus	O
.	O

TITLE	O
:	O
Anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
IgG	I-PRGE
response	O
in	O
relation	O
to	O
disease	O
severity	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

Correlations	O
between	O
IgG	B-PRGE
levels	O
and	O
important	O
laboratory	O
parameters	O
were	O
assessed	O
.	O

According	O
to	O
the	O
sequence	O
polymorphism	O
,	O
all	O
SARS	O
-	O
CoVs	O
can	O
be	O
divided	O
into	O
three	O
groups	O
:	O
(	O
I	O
)	O
group	O
1	O
,	O
animal	O
-	O
origin	O
viruses	O
(	O
such	O
as	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
SZ1	I-PRGE
,	O
SZ3	O
,	O
SZ13	O
and	O
SZ16	O
);	O
(	O
II	O
)	O
group	O
2	O
,	O
all	O
viruses	O
with	O
clinical	O
origin	O
during	O
first	O
epidemic	O
;	O
and	O
(	O
III	O
)	O
group	O
3	O
,	O
SARS	O
-	O
CoV	O
GD03T0013	O
.	O

This	O
may	O
negatively	O
influence	O
the	O
virus	B-PRGE
-	I-PRGE
receptor	I-PRGE
binding	O
and	O
abrogate	O
the	O
infection	O
,	O
with	O
further	O
ramifications	O
by	O
the	O
elevation	O
of	O
vesicular	O
pH	O
,	O
resulting	O
in	O
the	O
inhibition	O
of	O
infection	O
and	O
spread	O
of	O
SARS	O
CoV	O
at	O
clinically	O
admissible	O
concentrations	O
.	O

TITLE	O
:	O
Anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
coronavirus	I-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
effects	O
of	O
Isatis	O
indigotica	O
root	O
and	O
plant	O
-	O
derived	O
phenolic	O
compounds	O
.	O

This	O
finding	O
shows	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
has	O
the	O
potential	O
to	O
take	O
two	O
distinct	O
pathways	O
for	O
cell	O
entry	O
,	O
depending	O
on	O
the	O
presence	O
of	O
proteases	O
in	O
the	O
environment	O
.	O

The	O
Kolmogorov	O
-	O
Smirnov	O
test	O
showed	O
that	O
the	O
neutralizing	O
antibody	O
titers	O
conform	O
to	O
normal	O
distribution	O
,	O
which	O
suggests	O
that	O
the	O
average	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
antibody	I-PRGE
level	O
in	O
this	O
study	O
was	O
representative	O
of	O
the	O
convalescent	O
antibody	O
level	O
of	O
the	O
SARS	O
population	O
.	O

ABSTRACT	O
:	O
The	O
entry	O
of	O
the	O
SARS	O
coronavirus	O
(	O
SCV	O
)	O
into	O
cells	O
is	O
initiated	O
by	O
binding	O
of	O
its	O
spike	B-PRGE
envelope	I-PRGE
glycoprotein	I-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
to	O
a	O
receptor	O
,	O
ACE2	B-PRGE
.	O

Compared	O
to	O
the	O
healthy	O
control	O
or	O
the	O
convalescent	O
case	O
,	O
plenty	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
such	O
as	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
IL	O
-	O
8	O
,	O
and	O
MAPK	B-PRGE
signaling	O
pathway	O
were	O
significantly	O
upregulated	O
in	O
the	O
acute	O
severe	O
case	O
.	O

The	O
enhanced	O
green	B-PRGE
fluorescent	I-PRGE
protein	I-PRGE
,	O
red	B-PRGE
fluorescent	I-PRGE
protein	I-PRGE
,	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
envelope	O
protein	O
were	O
used	O
as	O
model	O
proteins	O
,	O
and	O
were	O
selectively	O
and	O
functionally	O
immobilized	O
to	O
the	O
PHA	B-PRGE
microbeads	O
by	O
fusing	O
them	O
to	O
the	O
SBD	O
.	O

In	O
this	O
study	O
,	O
a	O
recombinant	O
protein	O
(	O
rS268	O
,	O
corresponding	O
to	O
residues	O
268	O
-	O
1255	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
)	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
and	O
was	O
purified	O
to	O
near	O
homogeneity	O
.	O

CONCLUSIONS	O
:	O
IAH	O
is	O
a	O
frequent	O
finding	O
in	O
patients	O
admitted	O
to	O
the	O
ICU	O
because	O
of	O
SAP	B-PRGE
,	O
and	O
is	O
associated	O
with	O
a	O
high	O
occurrence	O
rate	O
of	O
organ	O
dysfunction	O
.	O

The	O
nuclear	B-PRGE
factor	I-PRGE
kappa	I-PRGE
B	I-PRGE
(	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
)	O
is	O
a	O
key	O
transcription	O
factor	O
that	O
activates	O
numerous	O
genes	O
involved	O
in	O
cellular	O
immune	O
response	O
and	O
inflammation	O
.	O

Important	O
questions	O
pertaining	O
to	O
the	O
contribution	O
of	O
HCoV	O
-	O
NL63	O
to	O
ARI	B-PRGE
and	O
its	O
impact	O
on	O
public	O
health	O
remain	O
.	O

Obstructive	O
apnea	O
is	O
associated	O
with	O
endothelial	O
dysfunction	O
,	O
increased	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
and	O
cytokine	O
expression	O
,	O
elevated	O
fibrinogen	B-PRGE
levels	O
and	O
decreased	O
fibrinolytic	O
activity	O
.	O

Apoptosis	O
is	O
likely	O
mediated	O
by	O
the	O
mitochondrial	O
pathway	O
,	O
as	O
demonstrated	O
by	O
its	O
inhibition	O
using	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
and	O
by	O
the	O
activation	O
of	O
the	O
caspase	B-PRGE
cascade	O
,	O
resulting	O
in	O
PARP	B-PRGE
cleavage	O
.	O

Immunostaining	O
demonstrated	O
that	O
monokine	B-PRGE
induced	I-PRGE
by	I-PRGE
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
(	O
Mig	B-PRGE
)	O
was	O
expressed	O
in	O
gliocytes	O
with	O
the	O
infiltration	O
of	O
CD68	B-PRGE
+	I-PRGE
monocytes	O
/	O
macrophages	O
and	O
CD3	B-PRGE
+	I-PRGE
T	O
lymphocytes	O
in	O
the	O
brain	O
mesenchyme	O
.	O

This	O
study	O
provides	O
direct	O
evidence	O
that	O
SARS	O
human	O
coronavirus	O
is	O
capable	O
of	O
infecting	O
the	O
central	O
nervous	O
system	O
,	O
and	O
that	O
Mig	B-PRGE
might	O
be	O
involved	O
in	O
the	O
brain	O
immunopathology	O
of	O
SARS	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
protein	O
(	O
S	O
)	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
attaches	O
the	O
virus	O
to	O
its	O
cellular	O
receptor	O
,	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
).	O

Phylogenetic	O
analysis	O
showed	O
that	O
bat	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
formed	O
a	O
distinct	O
cluster	O
with	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
as	I-PRGE
group	I-PRGE
2b	I-PRGE
CoV	I-PRGE
,	O
distantly	O
related	O
to	O
known	O
group	O
2	O
CoV	O
.	O
Most	O
differences	O
between	O
the	O
bat	O
-	O
SARS	O
-	O
CoV	O
and	O
SARS	O
-	O
CoV	O
genomes	O
were	O
observed	O
in	O
the	O
spike	O
genes	O
,	O
ORF	B-PRGE
3	I-PRGE
and	O
ORF	B-PRGE
8	I-PRGE
,	O
which	O
are	O
the	O
regions	O
where	O
most	O
variations	O
also	O
were	O
observed	O
between	O
human	O
and	O
civet	O
SARS	O
-	O
CoV	O
genomes	O
.	O

Without	O
such	O
knowledge	O
,	O
blood	O
products	O
can	O
be	O
discarded	O
mistakenly	O
even	O
though	O
they	O
contain	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
antibodies	I-PRGE
that	O
may	O
be	O
potentially	O
valuable	O
for	O
SARS	O
therapy	O
.	O

Western	O
-	O
blot	O
showed	O
that	O
the	O
recombinant	B-PRGE
N	I-PRGE
protein	I-PRGE
had	O
high	O
specificity	O
against	O
mouse	B-PRGE
-	I-PRGE
anti	I-PRGE
-	I-PRGE
N	I-PRGE
protein	I-PRGE
-	I-PRGE
mAb	I-PRGE
and	O
SARS	O
positive	O
sera	O
,	O
but	O
had	O
no	O
cross	O
-	O
reaction	O
with	O
normal	O
human	O
sera	O
.	O

Low	O
sirolimus	O
blood	O
levels	O
and	O
acute	O
CD4	B-PRGE
lymphocytic	O
alveolitis	O
suggested	O
an	O
immune	O
-	O
related	O
mechanism	O
rather	O
than	O
a	O
direct	O
toxic	O
effect	O
of	O
the	O
drug	O
.	O

TITLE	O
:	O
ADP	B-PRGE
-	I-PRGE
ribose	I-PRGE
-	I-PRGE
1	I-PRGE
"""-"	I-PRGE
monophosphatase	I-PRGE
:	O
a	O
conserved	O
coronavirus	O
enzyme	O
that	O
is	O
dispensable	O
for	O
viral	O
replication	O
in	O
tissue	O
culture	O
.	O

Guided	O
by	O
the	O
crystal	O
structure	O
of	O
AF1521	O
,	O
an	O
X	B-PRGE
domain	I-PRGE
homolog	I-PRGE
from	I-PRGE
Archaeoglobus	I-PRGE
fulgidus	O
,	O
potential	O
active	O
-	O
site	O
residues	O
of	O
the	O
HCoV	B-PRGE
-	I-PRGE
229E	I-PRGE
X	I-PRGE
domain	I-PRGE
were	O
targeted	O
by	O
site	O
-	O
directed	O
mutagenesis	O
.	O

ABSTRACT	O
:	O
Here	O
,	O
we	O
report	O
the	O
three	O
-	O
dimensional	O
structure	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
)	O
nsP7	O
,	O
a	O
component	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
replicase	I-PRGE
polyprotein	I-PRGE
.	O

Taken	O
together	O
,	O
our	O
results	O
indicated	O
that	O
intron	O
had	O
a	O
better	O
enhancing	O
effect	O
on	O
STR2	B-PRGE
protein	I-PRGE
expression	O
than	O
exon	O
splicing	O
enhancers	O
,	O
and	O
the	O
expression	O
of	O
approximately	O
130	B-PRGE
kDa	I-PRGE
STR2	I-PRGE
glycoprotein	I-PRGE
was	O
enhanced	O
by	O
the	O
intron	O
addition	O
into	O
the	O
expression	O
vector	O
construct	O
.	O

The	O
recombinant	O
expression	O
vector	O
produced	O
high	O
level	O
of	O
the	O
N	B-PRGE
fusion	I-PRGE
protein	I-PRGE
after	O
induction	O
,	O
and	O
that	O
protein	O
was	O
purified	O
successfully	O
by	O
affinity	O
chromatography	O
and	O
displayed	O
higher	O
antigenicity	O
and	O
specificity	O
as	O
compared	O
with	O
whole	O
virus	O
lysates	O
.	O

We	O
conclude	O
that	O
a	O
vaccine	O
against	O
FCoV	O
should	O
be	O
based	O
on	O
FCoV	B-PRGE
type	I-PRGE
1	I-PRGE
-	I-PRGE
related	I-PRGE
antigens	I-PRGE
and	O
that	O
for	O
serodiagnosis	O
of	O
FCoV	O
infection	O
TGEV	O
should	O
be	O
used	O
to	O
attain	O
the	O
highest	O
diagnostic	O
efficiency	O
.	O

When	O
serology	O
is	O
used	O
in	O
addition	O
to	O
clinical	O
signs	O
,	O
hematology	O
,	O
and	O
clinical	O
chemistry	O
results	O
as	O
an	O
aid	O
to	O
diagnose	O
clinical	O
FIP	O
,	O
TGEV	O
shows	O
a	O
diagnostic	O
efficiency	O
equal	O
to	O
that	O
of	O
a	O
FCoV	B-PRGE
antigen	I-PRGE
.	O

A	O
web	O
version	O
of	O
our	O
software	O
,	O
SVMProt	O
,	O
is	O
accessible	O
at	O
http	O
://	O
jing	O
.	O
cz3	O
.	O
nus	O
.	O
edu	O
.	O
sg	O
/	O
cgi	B-PRGE
-	O
bin	O
/	O
svmprot	O
.	O
cgi	B-PRGE
.	O

Our	O
understanding	O
on	O
the	O
interaction	O
between	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
the	O
immune	O
system	O
and	O
local	O
tissues	O
is	O
essential	O
to	O
future	O
diagnosis	O
,	O
control	O
and	O
treatment	O
of	O
this	O
very	O
contagious	O
disease	O
.	O

The	O
peak	O
inflammatory	O
response	O
was	O
obtained	O
at	O
24	O
h	O
when	O
the	O
fluid	O
volume	O
,	O
protein	O
concentration	O
,	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
and	O
cell	O
infiltration	O
were	O
maximums	O
.	O

TITLE	O
:	O
The	O
dimer	O
interface	O
of	O
the	O
SARS	B-PRGE
coronavirus	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
adapts	O
a	O
porcine	O
respiratory	O
and	O
reproductive	O
syndrome	O
virus	O
-	O
like	O
structure	O
.	O

Moreover	O
,	O
the	O
vaccine	O
confers	O
protective	O
immunity	O
as	O
demonstrated	O
by	O
prevention	O
of	O
SARS	O
-	O
CoV	O
replication	O
in	O
the	O
respiratory	O
tract	O
of	O
mice	O
after	O
intranasal	O
challenge	O
with	O
SARS	O
-	O
CoV	O
.	O
Protection	O
of	O
mice	O
was	O
correlated	O
to	O
antibody	O
titre	O
against	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
and	O
neutralising	O
antibody	O
titre	O
.	O

Following	O
induction	O
of	O
acute	O
lung	O
injury	O
,	O
gut	O
epithelial	O
proliferation	O
and	O
apoptosis	O
were	O
assessed	O
in	O
a	O
)	O
C3H	O
/	O
HeN	B-PRGE
wild	O
-	O
type	O
and	O
C3H	O
/	O
HeJ	O
mice	O
,	O
which	O
lack	O
functional	O
Toll	B-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
4	O
(	O
n	O
=	O
17	O
);	O
b	O
)	O
C57Bl	O
/	O
6	O
mice	O
that	O
received	O
monoclonal	O
anti	B-PRGE
-	I-PRGE
tumor	I-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
or	O
control	O
antibody	O
(	O
n	O
=	O
22	O
);	O
and	O
c	O
)	O
C57Bl	O
/	O
6	O
wild	O
-	O
type	O
and	O
transgenic	O
mice	O
that	O
overexpress	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
their	O
gut	O
epithelium	O
(	O
n	O
=	O
21	O
).	O

SARS	O
-	O
Cov	O
infection	O
stimulates	O
cytokines	O
(	O
e	O
.	O
g	O
.,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
etc	O
.	O

SARS	B-PRGE
-	I-PRGE
specific	I-PRGE
IgG	I-PRGE
antibody	I-PRGE
is	O
generated	O
in	O
the	O
second	O
week	O
and	O
persists	O
for	O
a	O
long	O
time	O
,	O
whereas	O
IgM	B-PRGE
is	O
expressed	O
transiently	O
.	O

The	O
spike	O
protein	O
and	O
neucleocapsid	B-PRGE
protein	I-PRGE
are	O
most	O
abundant	O
in	O
SARS	B-PRGE
-	I-PRGE
Cov	I-PRGE
and	O
contribute	O
dominantly	O
to	O
the	O
antibody	O
production	O
during	O
the	O
course	O
of	O
disease	O
.	O

Spike	B-PRGE
protein	I-PRGE
,	O
especially	O
the	O
ACE	B-PRGE
-	I-PRGE
2	I-PRGE
binding	I-PRGE
region	I-PRGE
(	O
318	O
-	O
510aa	O
)	O
is	O
capable	O
of	O
producing	O
neutralizing	O
antibody	O
to	O
SARS	O
-	O
Cov	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
significance	O
of	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
antibody	O
,	O
detected	O
by	O
ELISA	O
and	O
indirect	O
immunofluorescence	O
assays	O
(	O
IFA	O
)	O
for	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
Vero	I-PRGE
E6	I-PRGE
cell	O
lysates	O
,	O
in	O
non	O
-	O
SARS	O
subjects	O
,	O
114	O
serum	O
samples	O
from	O
healthy	O
controls	O
and	O
104	O
serum	O
specimens	O
from	O
autoimmune	O
disease	O
patients	O
were	O
collected	O
.	O

The	O
vacuolar	O
-	O
H	O
+	O
ATPase	O
(	O
V	O
-	O
ATPase	O
)	O
G1	O
subunit	O
that	O
contained	O
a	O
3CL	O
(	O
pro	O
)	O
cleavage	O
site	O
-	O
like	O
motif	O
was	O
identified	O
as	O
a	O
3CL	B-PRGE
(	I-PRGE
pro	I-PRGE
)-	I-PRGE
interacting	I-PRGE
protein	I-PRGE
,	O
as	O
confirmed	O
using	O
the	O
co	O
-	O
immunoprecipitation	O
assay	O
and	O
the	O
relative	O
affinity	O
assay	O
.	O

In	O
addition	O
,	O
our	O
result	O
also	O
demonstrated	O
the	O
cleavage	O
of	O
the	O
V	B-PRGE
-	I-PRGE
ATPase	I-PRGE
G1	O
fusion	O
protein	O
and	O
the	O
immunoprecipitation	O
of	O
cellular	B-PRGE
V	I-PRGE
-	I-PRGE
ATPase	I-PRGE
G1	O
by	O
the	O
3CL	O
(	O
pro	O
).	O

Further	O
,	O
we	O
found	O
that	O
fusion	O
of	O
domain	O
3	O
of	O
the	O
N	B-PRGE
protein	I-PRGE
to	O
the	O
carboxy	O
terminus	O
of	O
a	O
heterologous	O
protein	O
caused	O
it	O
to	O
be	O
incorporated	O
into	O
MHV	O
virions	O
.	O

Replication	O
complexes	O
in	O
MHVDeltansp2	O
-	O
infected	O
cells	O
lacked	O
nsp2	B-PRGE
but	O
were	O
morphologically	O
indistinguishable	O
from	O
those	O
of	O
wild	O
-	O
type	O
MHV	O
by	O
immunofluorescence	O
.	O

nsp2	B-PRGE
expressed	O
in	O
cells	O
by	O
stable	O
retroviral	O
transduction	O
was	O
specifically	O
recruited	O
to	O
viral	O
replication	O
complexes	O
upon	O
infection	O
with	O
MHVDeltansp2	O
.	O

With	O
an	O
internal	O
diameter	O
of	O
approximately	O
30	O
angstroms	O
,	O
the	O
central	O
channel	O
has	O
dimensions	O
and	O
positive	O
electrostatic	O
properties	O
favorable	O
for	O
nucleic	O
acid	O
binding	O
,	O
implying	O
that	O
its	O
role	O
is	O
to	O
confer	O
processivity	O
on	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
.	O

Here	O
,	O
we	O
report	O
that	O
TGEV	O
fusion	O
core	O
(	O
HR1	O
-	O
SGGRGG	O
-	O
HR2	O
),	O
in	O
vitro	O
expressed	O
in	O
GST	B-PRGE
prokaryotic	O
expression	O
system	O
,	O
shares	O
the	O
typical	O
properties	O
of	O
the	O
trimer	O
of	O
coiled	O
-	O
coil	O
heterodimer	O
(	O
six	O
alpha	O
-	O
helix	O
bundle	O
),	O
which	O
has	O
been	O
confirmed	O
by	O
a	O
combined	O
series	O
of	O
biochemical	O
and	O
biophysical	O
evidences	O
including	O
size	O
exclusion	O
chromatography	O
(	O
gel	O
-	O
filtration	O
),	O
chemical	O
crossing	O
,	O
and	O
circular	O
diagram	O
.	O

Blinded	O
studies	O
using	O
RNA	O
extracted	O
from	O
various	O
tissues	O
of	O
a	O
SARS	O
-	O
infected	O
individual	O
showed	O
that	O
STAR	B-PRGE
correctly	O
identified	O
all	O
samples	O
containing	O
SARS	O
virus	O
and	O
yielded	O
negative	O
results	O
for	O
non	O
-	O
SARS	O
control	O
samples	O
.	O

Although	O
polymorphisms	O
in	O
Toll	B-PRGE
-	I-PRGE
like	I-PRGE
receptors	I-PRGE
play	O
a	O
contributory	O
role	O
in	O
determining	O
cellular	O
activation	O
,	O
other	O
factors	O
are	O
involved	O
as	O
well	O
.	O

Identification	O
of	O
patients	O
with	O
cellular	O
phenotypes	O
characterized	O
by	O
increased	O
activation	O
of	O
NF	B-PRGE
-	I-PRGE
kappa	I-PRGE
B	I-PRGE
,	O
Akt	B-PRGE
,	O
and	O
protein	O
38	O
,	O
as	O
well	O
as	O
discrete	O
patterns	O
of	O
gene	O
activation	O
,	O
may	O
permit	O
identification	O
of	O
patients	O
with	O
sepsis	O
who	O
are	O
likely	O
to	O
have	O
a	O
worse	O
clinical	O
outcome	O
,	O
thereby	O
permitting	O
early	O
institution	O
of	O
therapies	O
that	O
modulate	O
deleterious	O
signaling	O
pathways	O
before	O
organ	O
system	O
dysfunction	O
develops	O
,	O
reducing	O
morbidity	O
and	O
improving	O
survival	O
.	O

Nine	O
sequences	O
,	O
encoding	O
for	O
the	O
predicted	O
epitopes	O
in	O
spike	O
,	O
nucleocapside	O
,	O
and	O
membranous	O
SARS	B-PRGE
CoV	I-PRGE
proteins	I-PRGE
,	O
were	O
synthesized	O
by	O
polymyrase	O
chain	O
reaction	O
and	O
cloned	O
into	O
the	O
pGEX	O
4	O
-	O
T2	O
vector	O
.	O

ABSTRACT	O
:	O
Design	O
,	O
synthesis	O
,	O
and	O
biological	O
evaluation	O
of	O
peptidomimetic	O
severe	O
acute	O
respiratory	O
syndrome	B-PRGE
chymotrypsin	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
SARS	B-PRGE
-	I-PRGE
3CLpro	I-PRGE
)	O
inhibitors	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
are	O
described	O
.	O

These	O
inhibitors	O
exhibited	O
antiviral	O
activity	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
in	O
infected	O
cells	O
in	O
the	O
micromolar	O
range	O
.	O

An	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
our	O
lead	O
inhibitor	O
(	O
4	O
)	O
bound	O
to	O
SARS	B-PRGE
-	I-PRGE
3CLpro	I-PRGE
provided	O
important	O
drug	O
-	O
design	O
templates	O
for	O
the	O
design	O
of	O
small	O
-	O
molecule	O
inhibitors	O
.	O

Interestingly	O
,	O
this	O
property	O
mapped	O
to	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
the	O
protein	O
,	O
implying	O
that	O
the	O
difference	O
in	O
infection	O
efficiency	O
between	O
the	O
two	O
viruses	O
is	O
not	O
determined	O
at	O
the	O
level	O
of	O
receptor	O
usage	O
,	O
which	O
we	O
confirmed	O
by	O
showing	O
that	O
infection	O
by	O
both	O
viruses	O
was	O
equally	O
blocked	O
by	O
antibodies	O
directed	O
against	O
the	O
feline	B-PRGE
aminopeptidase	I-PRGE
N	I-PRGE
receptor	I-PRGE
.	O

Recombinant	B-PRGE
N	I-PRGE
protein	I-PRGE
reacted	O
strongly	O
and	O
specifically	O
with	O
the	O
sera	O
from	O
immunized	O
mice	O
and	O
SARS	O
patients	O
.	O

The	O
DNA	O
vaccine	O
pSecN	O
could	O
also	O
efficiently	O
induce	O
the	O
production	O
of	O
IgG	B-PRGE
against	O
N	B-PRGE
protein	I-PRGE
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
which	O
offered	O
clues	O
to	O
the	O
development	O
of	O
a	O
potential	O
DNA	O
vaccine	O
.	O

The	O
first	O
qualitative	O
reverse	B-PRGE
transcriptase	I-PRGE
-	O
polymerase	O
chain	O
reaction	O
tests	O
for	O
SARS	O
-	O
coronavirus	O
(	O
CoV	O
)	O
were	O
sensitive	O
and	O
capable	O
of	O
detecting	O
1	O
to	O
10	O
genome	O
equivalents	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
preventive	O
and	O
therapeutic	O
effects	O
of	O
recombinant	B-PRGE
IFN	I-PRGE
-	I-PRGE
alpha2b	I-PRGE
for	O
nasal	O
spray	O
on	O
SARS	O
-	O
CoV	O
infection	O
in	O
Macaca	O
mulata	O
(	O
rhesus	O
monkey	O
).	O

CONCLUSIONS	O
:	O
Using	O
recombinant	B-PRGE
human	I-PRGE
interferon	I-PRGE
alpha	I-PRGE
-	I-PRGE
2b	I-PRGE
for	O
nasal	O
spray	O
could	O
lead	O
to	O
some	O
influenza	O
-	O
like	O
symptoms	O
,	O
however	O
,	O
all	O
those	O
symptoms	O
were	O
mild	O
,	O
reversible	O
,	O
and	O
relieved	O
after	O
completion	O
of	O
the	O
use	O
of	O
the	O
trial	O
drug	O
.	O

ABSTRACT	O
:	O
Angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
has	O
been	O
identified	O
as	O
a	O
functional	O
receptor	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
so	O
its	O
gene	O
was	O
cloned	O
and	O
eukaryotic	O
expressed	O
for	O
further	O
insight	O
into	O
mechanisms	O
in	O
SARS	O
-	O
CoV	O
entry	O
and	O
pathogenesis	O
,	O
as	O
well	O
as	O
development	O
of	O
a	O
safe	O
and	O
reliable	O
neutralization	O
assay	O
for	O
SARS	O
-	O
CoV	O
.	O
Total	O
RNA	O
was	O
extracted	O
from	O
right	O
atrial	O
tissue	O
of	O
a	O
patient	O
with	O
right	O
heart	O
failure	O
resected	O
during	O
a	O
valvular	O
replacement	O
surgery	O
by	O
Trizol	O
one	O
-	O
step	O
method	O
,	O
and	O
the	O
full	B-PRGE
-	I-PRGE
length	I-PRGE
ACE	I-PRGE
-	I-PRGE
2	I-PRGE
encoding	I-PRGE
gene	I-PRGE
was	O
acquired	O
by	O
RT	O
-	O
nested	O
-	O
PCR	O
.	O

RESULTS	O
:	O
The	O
recombinant	B-PRGE
plasmid	I-PRGE
pcDNA4	I-PRGE
/	I-PRGE
ACE	I-PRGE
-	I-PRGE
2	I-PRGE
could	O
express	O
ACE	B-PRGE
-	I-PRGE
2	I-PRGE
protein	I-PRGE
in	O
eukaryotic	O
cells	O
and	O
induce	O
cell	O
-	O
cell	O
fusion	O
between	O
S	B-PRGE
protein	I-PRGE
-	O
and	O
ACE2	B-PRGE
-	O
expressing	O
cells	O
.	O

In	O
a	O
neutralization	O
assay	O
,	O
IL	B-PRGE
-	I-PRGE
11	I-PRGE
-	O
induced	O
STAT	B-PRGE
3	I-PRGE
phosphorylation	O
in	O
rat	O
intestinal	O
epithelial	O
IEC	O
-	O
18	O
cells	O
was	O
completely	O
suppressed	O
by	O
the	O
anti	O
-	O
N	O
scFv	O
clone	O
L9N01	O
.	O

In	O
particular	O
,	O
the	O
spike	O
protein	O
fusion	O
core	O
and	O
the	O
main	O
protease	O
have	O
been	O
the	O
most	O
extensively	O
studied	O
,	O
with	O
the	O
aim	O
of	O
designing	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
therapeutics	O
.	O

The	O
combination	O
of	O
pulse	O
corticosteroids	O
,	O
pulse	O
cyclophosphamide	O
,	O
and	O
high	O
-	O
dose	O
intravenous	O
immunoglobulin	B-PRGE
seemed	O
effective	O
for	O
the	O
acute	O
phase	O
of	O
severe	O
Churg	O
-	O
Strauss	O
syndrome	O
.	O

In	O
the	O
6	O
patients	O
from	O
whom	O
serum	O
samples	O
were	O
available	O
,	O
all	O
had	O
a	O
4	O
-	O
fold	O
change	O
in	O
immunoglobulin	B-PRGE
(	O
Ig	O
)	O
G	O
titer	O
and	O
/	O
or	O
presence	O
of	O
IgM	B-PRGE
against	O
CoV	O
-	O
HKU1	O
.	O

The	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
,	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
,	O
was	O
almost	O
completely	O
down	O
regulated	O
from	O
the	O
cell	O
surface	O
of	O
persistently	O
infected	O
cells	O
.	O

TITLE	O
:	O
An	O
immunoturbidimetric	O
assay	O
for	O
rapid	O
quantitative	O
measurement	O
of	O
feline	O
alpha	B-PRGE
-	I-PRGE
1	I-PRGE
-	I-PRGE
acid	I-PRGE
glycoprotein	I-PRGE
in	O
serum	O
and	O
peritoneal	O
fluid	O
.	O

Its	O
sequence	O
is	O
similar	O
to	O
yeast	O
YBR022W	O
(	O
also	O
known	O
as	O
Poa1P	B-PRGE
),	O
a	O
known	O
phosphatase	O
that	O
acts	O
on	O
ADP	O
-	O
ribose	O
-	O
1	O
''-	O
phosphate	O
(	O
Appr	O
-	O
1	O
''-	O
p	O
).	O

And	O
the	O
recombinant	O
RBD	O
derived	O
from	O
E	O
.	O
coli	O
can	O
be	O
used	O
to	O
developing	O
subunit	O
vaccine	O
to	O
block	O
S	B-PRGE
protein	I-PRGE
binding	O
with	O
receptor	O
and	O
to	O
neutralizing	O
SARS	O
-	O
Cov	O
infection	O
.	O

CONCLUSIONS	O
:	O
In	O
this	O
paper	O
,	O
we	O
get	O
sufficient	O
soluble	O
N	O
terminal	O
GST	B-PRGE
tagged	O
RBD	B-PRGE
protein	I-PRGE
expressed	O
in	O
E	O
.	O
coli	O
BL21	O
(	O
DE3	O
);	O
data	O
from	O
ELISA	O
and	O
flow	O
cytometry	O
assay	O
demonstrate	O
that	O
the	O
recombinant	O
protein	O
is	O
functional	O
and	O
binding	O
to	O
ACE2	B-PRGE
positive	O
Vero	O
E6	O
cell	O
efficiently	O
.	O

Increased	O
plasma	O
concentrations	O
of	O
tPA	B-PRGE
and	O
sTM	B-PRGE
in	O
patients	O
with	O
SARS	O
suggest	O
the	O
possibility	O
of	O
endothelial	O
injury	O
.	O

Using	O
a	O
novel	O
data	O
representation	O
,	O
we	O
developed	O
a	O
system	O
termed	O
MULTIPRED	O
that	O
can	O
predict	O
peptide	O
binding	O
to	O
multiple	O
related	O
human	B-PRGE
leukocyte	I-PRGE
antigens	I-PRGE
(	O
HLA	B-PRGE
).	O

This	O
implementation	O
showed	O
high	O
accuracy	O
in	O
the	O
prediction	O
of	O
the	O
promiscuous	O
peptides	O
that	O
bind	O
to	O
five	O
HLA	B-PRGE
-	I-PRGE
A2	I-PRGE
allelic	O
variants	O
.	O

Data	O
on	O
annual	O
patient	O
-	O
days	O
and	O
annual	O
consumption	O
(	O
defined	O
daily	O
dose	O
(	O
DDD	O
)	O
per	O
1000	O
patient	O
-	O
days	O
)	O
of	O
extended	O
-	O
spectrum	O
cephalosporins	O
(	O
cefotaxime	O
,	O
ceftriaxone	O
,	O
ceftazidime	O
,	O
flumoxef	O
,	O
cefepime	O
and	O
cefpirome	O
),	O
beta	B-PRGE
-	I-PRGE
lactam	I-PRGE
-	I-PRGE
beta	I-PRGE
-	I-PRGE
lactamase	I-PRGE
inhibitor	O
combinations	O
(	O
ticarcillin	O
/	O
clavulanic	O
acid	O
and	O
piperacillin	O
/	O
tazobactam	O
),	O
carbapenems	O
(	O
imipenem	O
and	O
meropenem	O
),	O
aminoglycosides	O
(	O
amikacin	O
,	O
gentamicin	O
and	O
tobramycin	O
),	O
fluoroquinolones	O
(	O
ciprofloxacin	O
(	O
oral	O
and	O
injectable	O
)	O
and	O
oral	O
levofloxacin	O
and	O
moxifloxacin	O
)	O
from	O
1991	O
to	O
2003	O
were	O
analysed	O
.	O

Using	O
gel	B-PRGE
mobility	I-PRGE
shift	I-PRGE
RNase	I-PRGE
T1	I-PRGE
protection	O
assays	O
and	O
secondary	O
structure	O
modeling	O
,	O
we	O
have	O
characterized	O
a	O
possible	O
role	O
for	O
RNA	O
secondary	O
structure	O
in	O
host	O
protein	O
binding	O
to	O
the	O
3	O
'-	O
terminal	O
42	O
-	O
nucleotide	O
element	O
.	O

The	O
results	O
indicate	O
that	O
infection	O
of	O
human	O
airway	O
epithelia	O
by	O
SARS	O
coronavirus	O
correlates	O
with	O
the	O
state	O
of	O
cell	O
differentiation	O
and	O
ACE2	B-PRGE
expression	O
and	O
localization	O
.	O

TITLE	O
:	O
SR	O
-	O
rich	O
motif	O
plays	O
a	O
pivotal	O
role	O
in	O
recombinant	B-PRGE
SARS	I-PRGE
coronavirus	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
multimerization	O
.	O

All	O
of	O
these	O
data	O
suggested	O
that	O
the	O
SR	O
-	O
rich	O
motif	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
protein	I-PRGE
might	O
play	O
an	O
import	O
role	O
in	O
the	O
transformation	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
protein	I-PRGE
between	O
the	O
dimer	O
and	O
multimer	O
during	O
its	O
binding	O
to	O
its	O
central	O
region	O
for	O
self	O
-	O
association	O
or	O
dissociation	O
.	O

We	O
tested	O
the	O
possibility	O
of	O
interaction	O
between	O
both	O
T20	O
(	O
HIV	O
-	O
1	O
gp41	B-PRGE
HR2	I-PRGE
-	I-PRGE
derived	I-PRGE
peptide	I-PRGE
)	O
and	O
T	O
-	O
1249	O
with	O
S	O
protein	O
HR1	O
-	O
and	O
HR2	O
-	O
derived	O
peptides	O
.	O

Sera	O
were	O
collected	O
in	O
large	O
amounts	O
at	O
the	O
peak	O
,	O
where	O
IgG	B-PRGE
was	O
precipitated	O
using	O
ammonium	O
sulphate	O
and	O
subsequently	O
digested	O
with	O
pepsin	B-PRGE
.	O

N	B-PRGE
protein	I-PRGE
is	O
composed	O
of	O
three	O
distinct	O
regions	O
containing	O
RNA	O
-	O
binding	O
motif	O
(	O
s	O
),	O
and	O
appropriate	O
signals	O
for	O
modulating	O
cell	O
signalling	O
.	O

RESULTS	O
:	O
After	O
implementation	O
of	O
iLA	B-PRGE
,	O
a	O
rapid	O
increase	O
in	O
CO2	O
-	O
elimination	O
(	O
Pa	O
(	O
CO2	O
)	O
before	O
iLA	O
:	O
8	O
.	O
92	O
+/-	O
2	O
.	O
9	O
kPa	O
,	O
immediately	O
after	O
implementation	O
:	O
5	O
.	O
06	O
+/-	O
0	O
.	O
93	O
kPa	O
,	O
24	O
h	O
after	O
implementation	O
:	O
4	O
.	O
53	O
+/-	O
1	O
.	O
20	O
kPa	O
[	O
mean	O
+/-	O
SD	O
],	O
P	O
<	O
0	O
.	O
05	O
)	O
was	O
observed	O
and	O
a	O
significant	O
improvement	O
in	O
oxygenation	O
(	O
Pa	O
(	O
O2	O
)	O
before	O
iLA	O
:	O
6	O
.	O
66	O
+/-	O
2	O
.	O
26	O
kPa	O
,	O
immediately	O
after	O
implementation	O
:	O
10	O
.	O
39	O
+/-	O
3	O
.	O
33	O
kPa	O
,	O
24	O
h	O
after	O
implementation	O
:	O
10	O
.	O
25	O
+/-	O
5	O
.	O
46	O
kPa	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
was	O
noted	O
.	O

Expression	O
of	O
one	O
of	O
these	O
subgroup	O
-	O
specific	O
genes	O
,	O
ORF7a	O
,	O
resulted	O
in	O
apoptosis	O
via	O
a	O
caspase	B-PRGE
-	O
dependent	O
pathway	O
.	O

We	O
performed	O
bioinformatics	O
analysis	O
on	O
16	B-PRGE
papain	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
domains	I-PRGE
from	O
nine	O
different	O
coronaviruses	O
and	O
identified	O
a	O
putative	O
catalytic	O
triad	O
(	O
Cys1651	O
-	O
His1812	O
-	O
Asp1826	O
)	O
and	O
zinc	O
-	O
binding	O
site	O
.	O

Furthermore	O
,	O
the	O
soR	B-PRGE
-	I-PRGE
425	I-PRGE
-	O
mediated	O
infections	O
were	O
blocked	O
by	O
heptad	O
repeat	O
-	O
mimicking	O
peptides	O
,	O
indicating	O
that	O
virus	O
entry	O
requires	O
the	O
regular	B-PRGE
S	I-PRGE
protein	I-PRGE
fusion	O
process	O
.	O

The	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
,	O
human	B-PRGE
angiotensin	I-PRGE
1	O
-	O
converting	O
enzyme	O
2	O
(	O
hACE2	O
),	O
was	O
detected	O
in	O
ciliated	O
airway	O
epithelial	O
cells	O
of	O
human	O
airway	O
tissues	O
derived	O
from	O
nasal	O
or	O
tracheobronchial	O
regions	O
,	O
suggesting	O
that	O
SARS	B-PRGE
-	O
CoV	O
may	O
infect	O
the	O
proximal	O
airways	O
.	O

To	O
assess	O
infectivity	O
in	O
an	O
in	O
vitro	O
model	O
of	O
human	O
ciliated	O
airway	O
epithelia	O
(	O
HAE	O
)	O
derived	O
from	O
nasal	O
and	O
tracheobronchial	O
airway	O
regions	O
,	O
we	O
generated	O
recombinant	O
SARS	O
-	O
CoV	O
by	O
deletion	O
of	O
open	O
reading	O
frame	O
7a	O
/	O
7b	O
(	O
ORF7a	O
/	O
7b	O
)	O
and	O
insertion	O
of	O
the	O
green	B-PRGE
fluorescent	I-PRGE
protein	I-PRGE
(	O
GFP	O
),	O
resulting	O
in	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
GFP	I-PRGE
.	O

In	O
this	O
study	O
,	O
we	O
have	O
confirmed	O
the	O
SARS	B-PRGE
6	I-PRGE
protein	I-PRGE
expression	O
in	O
lung	O
and	O
intestine	O
tissues	O
of	O
the	O
SARS	O
patients	O
and	O
in	O
SARS	O
-	O
CoV	O
infected	O
Vero	O
E6	O
cells	O
by	O
immunohistochemistry	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
demonstrates	O
that	O
the	O
RNA	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
could	O
be	O
detected	O
from	O
the	O
concentrates	O
of	O
sewage	O
of	O
both	O
hospitals	O
receiving	O
SARS	O
patients	O
before	O
disinfection	O
and	O
occasionally	O
after	O
disinfection	O
though	O
there	O
was	O
no	O
live	O
SARS	O
-	O
CoV	O
;	O
thus	O
much	O
attention	O
should	O
be	O
paid	O
to	O
the	O
treatment	O
of	O
stools	O
of	O
patients	O
and	O
the	O
sewage	O
of	O
hospitals	O
receiving	O
SARS	O
patients	O
.	O

Sequence	O
analysis	O
of	O
a	O
hypervariable	O
region	O
from	O
the	O
S1	B-PRGE
gene	I-PRGE
was	O
informative	O
for	O
the	O
differentiation	O
of	O
closely	O
-	O
related	O
strains	O
.	O

Lyophilization	O
and	O
stability	O
tests	O
showed	O
that	O
lyophilized	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
coronavirus	I-PRGE
IgY	I-PRGE
had	O
promising	O
physical	O
properties	O
,	O
with	O
no	O
significant	O
reduction	O
in	O
reactive	O
activity	O
and	O
good	O
thermal	O
stability	O
.	O

TITLE	O
:	O
The	O
N	O
-	O
terminal	O
octapeptide	O
acts	O
as	O
a	O
dimerization	O
inhibitor	O
of	O
SARS	B-PRGE
coronavirus	I-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
proteinase	I-PRGE
.	O

The	O
use	O
of	O
commercially	O
available	O
rapid	O
diagnostic	O
tests	O
for	O
influenza	O
associated	O
pneumonia	O
,	O
allows	O
the	O
potential	O
use	O
of	O
new	O
specific	O
anti	B-PRGE
-	I-PRGE
neuraminidase	I-PRGE
drugs	O
,	O
which	O
can	O
be	O
efficient	O
during	O
the	O
30	O
hours	O
after	O
the	O
beginning	O
of	O
the	O
clinical	O
influenza	O
syndrome	O
.	O

The	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
part	O
covers	O
the	O
pathogenesis	O
of	O
SARS	O
,	O
the	O
developing	O
animal	O
models	O
for	O
infection	O
,	O
and	O
the	O
progress	O
in	O
vaccine	O
development	O
and	O
antiviral	O
therapies	O
.	O

Further	O
biochemical	O
analysis	O
of	O
these	O
mutants	O
should	O
allow	O
us	O
to	O
identify	O
intermediates	O
in	O
this	O
pathway	O
and	O
elucidate	O
the	O
precise	O
function	O
(	O
s	O
)	O
of	O
the	O
viral	B-PRGE
replicase	I-PRGE
proteins	I-PRGE
involved	O
.	O

In	O
the	O
application	O
phase	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
diagnosis	O
based	O
on	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
microfluidic	O
chip	O
electrophoresis	O
(	O
MCE	O
)	O
with	O
18	O
cases	O
,	O
methylation	O
analysis	O
of	O
the	O
P16	B-PRGE
gene	I-PRGE
in	O
159	O
samples	O
of	O
patients	O
and	O
references	O
for	O
cancer	O
diagnosis	O
and	O
polymorphism	O
analysis	O
of	O
angiotenigen	B-PRGE
gene	I-PRGE
in	O
226	O
patients	O
and	O
references	O
with	O
essential	O
hypertension	O
are	O
described	O
.	O

ABSTRACT	O
:	O
Gene	O
3	O
of	O
infectious	O
bronchitis	O
virus	O
is	O
tricistronic	O
;	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
3a	O
and	O
3b	O
encode	O
two	O
small	O
nonstructural	O
(	O
ns	O
)	O
proteins	O
,	O
3a	O
and	O
3b	O
,	O
of	O
unknown	O
function	O
,	O
and	O
a	O
third	O
,	O
structural	O
protein	O
E	O
,	O
is	O
encoded	O
by	O
ORF	B-PRGE
3c	I-PRGE
.	O

Translation	O
of	O
the	O
IBV	B-PRGE
E	I-PRGE
protein	I-PRGE
is	O
believed	O
to	O
be	O
initiated	O
by	O
internal	O
entry	O
of	O
ribosomes	O
at	O
a	O
structure	O
formed	O
by	O
the	O
sequences	O
corresponding	O
to	O
ORFs	O
3a	O
and	O
3b	O
.	O

Analyses	O
of	O
cytochrome	B-PRGE
c	I-PRGE
release	O
further	O
revealed	O
an	O
activation	O
of	O
the	O
mitochondrial	O
apoptotic	O
pathway	O
.	O

The	O
control	O
and	O
simvastatin	O
groups	O
had	O
similar	O
serum	O
levels	O
and	O
similar	O
bronchoalveolar	O
lavage	O
fluid	O
levels	O
of	O
cytokines	O
(	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
and	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
at	O
all	O
measurements	O
,	O
except	O
for	O
a	O
significantly	O
higher	O
level	O
of	O
bronchoalveolar	O
lavage	O
fluid	O
P	B-PRGE
-	I-PRGE
selectin	I-PRGE
in	O
the	O
control	O
group	O
(	O
P	O
=	O
0	O
.	O
006	O
).	O

Compared	O
with	O
cells	O
heterozygous	O
for	B-PRGE
L	I-PRGE
-	I-PRGE
SIGN	I-PRGE
,	O
cells	O
homozygous	O
for	O
L	O
-	O
SIGN	O
show	O
higher	O
binding	O
capacity	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
higher	O
proteasome	O
-	O
dependent	O
viral	O
degradation	O
and	O
a	O
lower	O
capacity	O
for	O
trans	O
infection	O
.	O

SARS	B-PRGE
is	O
a	O
highly	O
contagious	O
condition	O
associated	O
with	O
substantial	O
case	O
fatality	O
;	O
an	O
outbreak	O
can	O
result	O
from	O
one	O
patient	O
in	O
a	O
relatively	O
short	O
period	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
the	O
induction	O
of	O
apoptosis	O
by	O
the	O
7a	B-PRGE
protein	I-PRGE
may	O
be	O
related	O
to	O
its	O
ability	O
to	O
inhibit	O
cellular	O
translation	O
and	O
activate	O
p38	B-PRGE
MAPK	O
.	O

Rapid	O
elevation	O
of	O
inflammatory	O
cytokines	B-PRGE
-	I-PRGE
IL	I-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	O
-	O
8	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
might	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
SARS	O
-	O
related	O
ARDS	O
.	O

Our	O
results	O
indicate	O
that	O
CRP	B-PRGE
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
might	O
be	O
used	O
as	O
prognostic	O
markers	O
of	O
SARS	O
.	O

These	O
results	O
demonstrate	O
that	O
processing	O
and	O
presentation	O
of	O
N	O
,	O
whether	O
exogenously	O
or	O
endogenously	O
derived	O
,	O
resulted	O
in	O
common	O
immunodominant	O
epitopes	O
,	O
supporting	O
the	O
usefulness	O
of	O
modified	O
antigen	O
delivery	O
and	O
trafficking	O
forms	O
and	O
,	O
in	O
particular	O
,	O
LAMP	B-PRGE
chimeras	O
as	O
vaccine	O
candidates	O
.	O

The	O
cultures	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
BJ	O
-	O
01	O
strain	O
infected	O
Vero	O
cells	O
were	O
inactivated	O
with	O
beta	B-PRGE
-	I-PRGE
propiolactone	I-PRGE
.	O

It	O
just	O
highlights	O
some	O
of	O
the	O
more	O
striking	O
findings	O
made	O
with	O
interferon	B-PRGE
(	O
or	O
its	O
inducers	O
)	O
over	O
a	O
time	O
span	O
of	O
almost	O
50	O
years	O
since	O
its	O
original	O
discovery	O
(	O
in	O
1957	O
)	O
by	O
Isaacs	O
and	O
Lindenmann	O
.	O

VEGF	B-PRGE
is	O
critical	O
for	O
the	O
development	O
of	O
the	O
lung	O
and	O
serves	O
as	O
a	O
maintenance	O
factor	O
during	O
adult	O
life	O
.	O

This	O
method	O
uses	O
reverse	O
transcriptase	B-PRGE
-	I-PRGE
polymerase	I-PRGE
chain	I-PRGE
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
analysis	O
of	O
the	O
spike	O
gene	O
to	O
obtain	O
RFLP	O
patterns	O
that	O
correlate	O
with	O
serotype	O
.	O

For	O
example	O
,	O
infliximab	O
,	O
a	O
monoclonal	O
TNF	B-PRGE
antibody	I-PRGE
,	O
was	O
experimentally	O
tested	O
in	O
rats	O
and	O
it	O
was	O
able	O
to	O
significantly	O
reduce	O
the	O
pathologic	O
score	O
and	O
serum	O
amylase	B-PRGE
activity	O
,	O
and	O
also	O
alleviate	O
alveolar	O
edema	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
;	O
no	O
studies	O
are	O
available	O
in	O
clinical	O
human	O
acute	O
pancreatitis	O
.	O

(	O
4	O
)	O
Compared	O
with	O
Nc	O
group	O
,	O
the	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
TGF	B-PRGE
-	I-PRGE
beta1	I-PRGE
in	O
both	O
serum	O
and	O
BALF	O
of	O
P1	O
group	O
were	O
significantly	O
increased	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
and	O
the	O
levels	O
of	O
these	O
cytokines	O
in	O
P2	O
group	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
P1	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
but	O
significantly	O
lower	O
in	O
P	O
+	O
D	O
group	O
compared	O
with	O
P2	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

Postmortem	O
tissue	O
samples	O
show	O
high	O
levels	O
of	O
viral	B-PRGE
antigen	I-PRGE
within	O
the	O
respiratory	O
endothelium	O
,	O
but	O
it	O
is	O
not	O
clear	O
how	O
the	O
virus	O
can	O
traverse	O
the	O
respiratory	O
epithelium	O
in	O
order	O
to	O
initiate	O
infection	O
in	O
the	O
microvasculature	O
.	O

To	O
address	O
the	O
importance	O
of	O
these	O
fatty	O
acylations	O
to	O
coronavirus	O
infection	O
,	O
we	O
exposed	O
infected	O
cells	O
to	O
2	O
-	O
bromopalmitate	O
(	O
2	O
-	O
BP	O
),	O
a	O
specific	O
PAT	B-PRGE
inhibitor	O
.	O

These	O
studies	O
involving	O
pharmacologic	O
inhibition	O
of	O
S	B-PRGE
protein	I-PRGE
palmitoylation	O
were	O
complemented	O
with	O
molecular	O
genetic	O
analyses	O
in	O
which	O
cysteine	O
acylation	O
substrates	O
were	O
mutated	O
.	O

Thus	O
,	O
in	O
contrast	O
to	O
various	O
viruses	O
including	O
HIV	O
(	O
human	O
immunodeficiency	O
virus	O
)	O
examined	O
in	O
parallel	O
,	O
the	O
functions	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
Spike	I-PRGE
glycoprotein	I-PRGE
exhibit	O
a	O
significant	O
and	O
surprising	O
independence	O
of	O
redox	O
state	O
,	O
which	O
may	O
contribute	O
to	O
the	O
wide	O
host	O
range	O
of	O
the	O
virus	O
.	O

CONCLUSIONS	O
:	O
The	O
persistence	O
of	O
detectable	O
IgG	B-PRGE
antibodies	I-PRGE
and	O
neutralizing	O
viral	O
antibodies	O
for	O
up	O
to	O
720	O
days	O
suggest	O
that	O
SARS	O
patients	O
may	O
be	O
protected	O
from	O
recurrent	O
SARS	O
-	O
CoV	O
infection	O
for	O
up	O
to	O
2	O
years	O
.	O

Cytokine	O
ELISA	O
analysis	O
revealed	O
that	O
co	O
-	O
injection	O
of	O
M	O
could	O
enhance	O
the	O
levels	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
release	O
induced	O
by	O
N	B-PRGE
antigen	I-PRGE
.	O

Virus	O
challenge	O
test	O
was	O
conducted	O
in	O
BSL3	B-PRGE
bio	O
safety	O
laboratory	O
with	O
Brandt	O
'	O
s	O
vole	O
SARS	O
-	O
CoV	O
model	O
,	O
and	O
the	O
results	O
indicated	O
that	O
co	O
-	O
immunization	O
of	O
M	O
and	O
N	O
antigens	O
could	O
reduce	O
the	O
mortality	O
and	O
pathological	O
changes	O
in	O
lung	O
from	O
the	O
virus	O
infection	O
.	O

ROC	O
curve	O
areas	O
were	O
largest	O
for	O
an	O
N	O
-	O
terminal	O
fragment	O
of	O
complement	O
C3c	O
alpha	O
chain	O
(	O
m	O
/	O
z	O
28	O
119	O
)	O
and	O
an	O
internal	O
fragment	O
of	O
fibrinogen	B-PRGE
alpha	I-PRGE
-	O
E	O
chain	O
(	O
m	O
/	O
z	O
5908	O
).	O

The	O
expression	O
and	O
function	O
of	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
-	I-PRGE
2	I-PRGE
were	O
not	O
different	O
among	O
these	O
HCWs	O
.	O

In	O
many	O
coronaviruses	O
,	O
the	O
nucleocapsid	B-PRGE
protein	I-PRGE
(	O
N	B-PRGE
protein	I-PRGE
)	O
has	O
been	O
shown	O
to	O
inhibit	O
cell	O
cycle	O
progression	O
although	O
the	O
mechanism	O
behind	O
this	O
is	O
poorly	O
understood	O
.	O

TITLE	O
:	O
Fibrinogen	B-PRGE
-	I-PRGE
like	I-PRGE
protein	I-PRGE
2	I-PRGE
fibroleukin	I-PRGE
expression	O
and	O
its	O
correlation	O
with	O
disease	O
progression	O
in	O
murine	O
hepatitis	O
virus	O
type	O
3	O
-	O
induced	O
fulminant	O
hepatitis	O
and	O
in	O
patients	O
with	O
severe	O
viral	O
hepatitis	O
B	O
.	O
ABSTRACT	O
:	O
To	O
evaluate	O
the	O
expression	O
of	O
fibrinogen	B-PRGE
-	I-PRGE
like	I-PRGE
protein	I-PRGE
2	I-PRGE
(	O
fgl2	B-PRGE
)	O
and	O
its	O
correlation	O
with	O
disease	O
progression	O
in	O
both	O
mice	O
and	O
patients	O
with	O
severe	O
viral	O
hepatitis	O
.	O

We	O
investigated	O
the	O
immunomodulating	O
effects	O
of	O
an	O
innovative	O
TCM	O
regimen	O
derived	O
from	O
two	O
herbal	O
formulas	O
(	O
Sang	O
Ju	O
Yin	O
and	O
Yu	B-PRGE
Ping	I-PRGE
Feng	I-PRGE
San	I-PRGE
)	O
for	O
treating	O
febrile	O
diseases	O
.	O

No	O
participants	O
showed	O
significant	O
changes	O
in	O
their	O
blood	O
test	O
results	O
,	O
except	O
that	O
the	O
T	O
-	O
lymphocyte	O
CD4	B-PRGE
/	O
CD8	B-PRGE
ratio	O
increased	O
significantly	O
from	O
1	O
.	O
31	O
+/-	O

Seventy	O
out	O
of	O
81	O
healthy	O
dog	O
feces	O
from	O
three	O
cities	O
and	O
21	O
out	O
of	O
48	O
diarrhea	O
feces	O
from	O
pet	O
dogs	O
were	O
positive	O
for	O
type	B-PRGE
II	I-PRGE
CCV	I-PRGE
.	O

Sequence	O
analysis	O
found	O
that	O
ten	O
type	O
II	O
CCVs	O
fragments	O
of	O
M	B-PRGE
gene	I-PRGE
shared	O
a	O
high	O
similarity	O
with	O
reference	O
strain	O
CCV	O
1	O
-	O
71	O
(	O
96	O
.	O
5	O
-	O
99	O
.	O
5	O
%),	O
and	O
four	O
type	O
I	O
CCVs	O
shared	O
a	O
high	O
similarity	O
(	O
96	O
.	O
7	O
%-	O
98	O
.	O
1	O
%)	O
with	O
a	O
reported	O
FCV	O
-	O
like	O
CCV	O
strain	O
.	O

Aniline	O
blue	O
-	O
stained	O
collagen	B-PRGE
fibers	O
with	O
an	O
infiltration	O
of	O
inflammatory	O
cells	O
were	O
present	O
7	O
days	O
after	O
exposure	O
.	O

Identified	O
SARS	O
-	O
CoV	O
infection	O
risk	O
factors	O
include	O
working	O
in	O
the	O
same	O
building	O
as	O
the	O
hospital	O
'	O
s	O
emergency	O
room	O
and	O
infection	O
ward	O
,	O
providing	O
direct	O
care	O
to	O
SARS	O
patients	O
,	O
and	O
carrying	O
a	O
Cw	B-PRGE
*	I-PRGE
0801	I-PRGE
HLA	I-PRGE
allele	I-PRGE
.	O

We	O
amplified	O
,	O
by	O
RT	O
-	O
PCR	O
,	O
group	O
2	O
coronavirus	O
-	O
specific	O
hemagglutination	O
/	O
esterase	B-PRGE
genes	O
in	O
the	O
oral	O
swabs	O
of	O
a	O
total	O
of	O
10	O
young	O
pups	O
presenting	O
with	O
or	O
having	O
recovered	O
from	O
respiratory	O
signs	O
,	O
or	O
having	O
anti	O
-	O
BCoV	O
antibodies	O
,	O
with	O
the	O
result	O
that	O
2	O
pups	O
were	O
positive	O
for	O
the	O
hemagglutination	B-PRGE
/	I-PRGE
esterase	I-PRGE
genes	I-PRGE
.	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
developed	O
a	O
test	O
for	O
the	O
diagnosis	O
and	O
prognostic	O
assessment	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
based	O
on	O
the	O
detection	O
of	O
the	O
SARS	O
-	O
coronavirus	O
RNA	O
in	O
serum	O
by	O
real	O
-	O
time	O
quantitative	O
reverse	B-PRGE
transcriptase	I-PRGE
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

Transfected	O
with	O
expression	O
luciferase	B-PRGE
plasmid	I-PRGE
pGL3	I-PRGE
-	I-PRGE
5	I-PRGE
'	I-PRGE
UTR	I-PRGE
in	O
which	O
SARS	O
-	O
CoV	O
5	O
'	O
UTR	O
acts	O
as	O
the	O
promoter	O
,	O
the	O
luciferase	O
could	O
express	O
in	O
five	O
cell	O
lines	O
in	O
different	O
degrees	O
.	O

The	O
present	O
report	O
is	O
a	O
retrospective	O
study	O
evaluating	O
the	O
incidence	O
and	O
impact	O
of	O
laboratory	O
-	O
confirmed	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
other	O
pulmonary	O
pathogens	O
in	O
117	O
patients	O
.	O

Additionally	O
,	O
we	O
provide	O
evidence	O
for	O
the	O
contribution	O
of	O
two	O
kinases	O
,	O
the	O
MAP	B-PRGE
kinase	I-PRGE
p38MAPK	B-PRGE
,	O
and	O
protein	B-PRGE
kinase	I-PRGE
C	I-PRGE
(	O
PKC	B-PRGE
)	O
delta	O
to	O
antiviral	O
protection	O
from	O
MHV	O
-	O
1	O
infection	O
.	O

TITLE	O
:	O
Identification	O
of	O
protease	O
and	O
ADP	B-PRGE
-	I-PRGE
ribose	I-PRGE
1	I-PRGE
''-	I-PRGE
monophosphatase	I-PRGE
activities	O
associated	O
with	O
transmissible	O
gastroenteritis	O
virus	O
non	O
-	O
structural	O
protein	O
3	O
.	O

These	O
preliminary	O
data	O
suggest	O
that	O
a	O
severe	O
reduction	O
in	O
compliance	O
in	O
the	O
early	O
phase	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
is	O
associated	O
with	O
both	O
collagen	B-PRGE
deposition	O
and	O
surfactant	O
degradation	O
.	O

Toll	B-PRGE
-	I-PRGE
like	I-PRGE
receptors	I-PRGE
4	O
and	O
9	O
,	O
which	O
correlate	O
with	O
the	O
induction	O
of	O
inflammatory	O
response	O
,	O
were	O
upregulated	O
by	O
SARS	O
-	O
CoV	O
infection	O
.	O

These	O
results	O
suggested	O
that	O
inhibition	O
of	O
cell	O
proliferation	O
is	O
regulated	O
by	O
both	O
the	O
phosphatidylinositol	B-PRGE
3	I-PRGE
'-	I-PRGE
kinase	I-PRGE
/	O
Akt	B-PRGE
signaling	O
pathway	O
and	O
by	O
apoptosis	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
E6	O
cells	O
.	O

TITLE	O
:	O
Seroprevalence	O
of	O
IgG	B-PRGE
antibodies	I-PRGE
to	O
SARS	O
-	O
coronavirus	O
in	O
asymptomatic	O
or	O
subclinical	O
population	O
groups	O
.	O

The	O
sequence	O
similarity	O
of	O
S	B-PRGE
gene	I-PRGE
between	O
TCoV	O
and	O
IBV	O
was	O
lower	O
than	O
that	O
among	O
TCoV	O
isolates	O
or	O
that	O
among	O
IBV	O
strains	O
.	O

These	O
studies	O
demonstrate	O
that	O
vaccine	O
-	O
induced	O
T	O
cell	O
memory	O
alone	O
is	O
unable	O
to	O
control	O
persisting	O
virus	O
in	O
a	O
tissue	O
with	O
strict	O
IFN	B-PRGE
-	I-PRGE
dependent	I-PRGE
MHC	I-PRGE
regulation	O
,	O
as	O
evident	O
in	O
immune	O
privileged	O
sites	O
.	O

We	O
also	O
only	O
observed	O
that	O
peptides	O
corresponding	O
to	O
residues	O
336	O
-	O
350	O
were	O
capable	O
of	O
stimulating	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
production	O
in	O
T	O
-	O
cell	O
cultures	O
derived	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
of	O
macaques	O
immunized	O
with	O
the	O
rN	B-PRGE
protein	I-PRGE
emulsified	O
in	O
ISA	O
/	O
CpG	O
adjuvant	O
.	O

Insulin	B-PRGE
is	O
effective	O
in	O
reducing	O
or	O
preventing	O
the	O
lipopolysaccharide	O
-	O
induced	O
increases	O
in	O
plasma	O
nitrate	O
/	O
nitrite	O
and	O
methyl	O
guanidine	O
and	O
the	O
occurrence	O
of	O
acute	O
lung	O
injury	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
expression	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
E	I-PRGE
protein	I-PRGE
in	O
mammalian	O
cells	O
alters	O
the	O
membrane	O
permeability	O
of	O
these	O
cells	O
.	O

Alanine	O
scanning	O
mutagenesis	O
analysis	O
was	O
performed	O
to	O
identify	O
determinants	O
on	O
ACE2	B-PRGE
critical	O
for	O
SARS	O
-	O
CoV	O
infection	O
.	O

Similar	O
kinetics	O
of	O
class	O
I	O
and	O
class	O
II	O
upregulation	O
on	O
microglia	O
further	O
suggested	O
no	O
role	O
of	O
NK	O
cells	O
in	O
regulating	O
major	B-PRGE
histocompatibility	I-PRGE
complex	I-PRGE
(	O
MHC	B-PRGE
)	O
molecule	O
expression	O
on	O
resident	O
CNS	O
cells	O
.	O

scFv	B-PRGE
H12	I-PRGE
bound	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
with	O
high	O
affinity	O
(	O
equilibrium	O
dissociation	O
constant	O
,	O
Kd	O
=	O
73	O
.	O
5	O
nM	O
),	O
and	O
neutralized	O
SARS	B-PRGE
virions	O
in	O
vitro	O
.	O

The	O
lack	O
of	O
effect	O
of	O
furin	B-PRGE
cleavage	O
on	O
virion	O
infectivity	O
mirrors	O
that	O
observed	O
in	O
the	O
normally	O
cleaved	O
S	O
glycoprotein	O
of	O
the	O
murine	O
coronavirus	O
and	O
highlights	O
an	O
additional	O
level	O
of	O
complexity	O
in	O
coronavirus	O
entry	O
.	O

Because	O
of	O
its	O
critical	O
role	O
in	O
viral	O
entry	O
,	O
the	O
S	B-PRGE
protein	I-PRGE
is	O
an	O
important	O
target	O
for	O
the	O
development	O
of	O
anti	O
-	O
SARS	O
CoV	O
therapeutics	O
and	O
prophylactics	O
.	O

As	O
antigen	O
for	O
detection	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
the	O
nucleocapsid	O
protein	O
(	O
N	O
)	O
showed	O
high	O
sensitivity	O
and	O
strong	O
reactivity	O
with	O
all	O
samples	O
from	O
SARS	O
-	O
CoV	O
patients	O
and	O
cross	O
-	O
reacted	O
with	O
all	O
serum	O
samples	O
from	O
healthy	O
subjects	O
,	O
with	O
either	O
those	O
obtained	O
from	O
China	O
(	O
10	O
samples	O
)	O
or	O
those	O
obtained	O
from	O
France	O
(	O
38	O
serum	O
samples	O
),	O
giving	O
then	O
a	O
significant	O
rate	O
of	O
false	O
positives	O
.	O

The	O
test	O
assigned	O
patients	O
into	O
two	O
distinct	O
groups	O
:	O
those	O
with	O
antibodies	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
those	O
without	O
.	O

Drugs	O
that	O
selectively	O
inhibit	O
this	O
enzyme	O
,	O
when	O
used	O
in	O
combination	O
with	O
inhibitors	O
of	O
reverse	B-PRGE
transcriptase	I-PRGE
and	O
protease	O
,	O
are	O
believed	O
to	O
be	O
highly	O
effective	O
in	O
suppressing	O
the	O
viral	O
replication	O
.	O

To	O
obtain	O
the	O
neutralizing	O
antibody	O
to	O
SARS	O
virus	O
surface	O
proteins	O
,	O
the	O
library	O
panning	O
procedure	O
was	O
performed	O
on	O
purified	O
SARS	O
virions	O
and	O
the	O
specific	O
Fab	B-PRGE
antibody	I-PRGE
clones	O
were	O
enriched	O
by	O
four	O
rounds	O
of	O
repeated	O
panning	O
procedure	O
and	O
screened	O
by	O
highthroughput	O
selection	O
.	O

However	O
,	O
the	O
N	B-PRGE
protein	I-PRGE
-	O
targeted	O
Fab	B-PRGE
or	O
IgG	B-PRGE
antibodies	I-PRGE
failed	O
to	O
neutralize	O
the	O
virus	O
.	O

TITLE	O
:	O
Nucleocapsid	B-PRGE
protein	I-PRGE
of	O
SARS	B-PRGE
-	O
CoV	O
activates	O
the	O
expression	O
of	O
cyclooxygenase	B-PRGE
-	I-PRGE
2	I-PRGE
by	O
binding	O
directly	O
to	O
regulatory	O
elements	O
for	O
nuclear	B-PRGE
factor	I-PRGE
-	I-PRGE
kappa	I-PRGE
B	I-PRGE
and	O
CCAAT	B-PRGE
/	I-PRGE
enhancer	I-PRGE
binding	I-PRGE
protein	I-PRGE
.	O

ABSTRACT	O
:	O
To	O
develop	O
a	O
highly	O
efficacious	O
method	O
for	O
preparation	O
of	O
soluble	O
SARS	B-PRGE
S	I-PRGE
-	I-PRGE
protein	I-PRGE
using	O
adenovirus	O
vector	O
to	O
meet	O
the	O
requirement	O
for	O
S	O
-	O
protein	O
investigation	O
.	O

The	O
S	B-PRGE
-	I-PRGE
protein	I-PRGE
was	O
detected	O
by	O
Western	O
blot	O
and	O
its	O
biologic	O
activity	O
was	O
analyzed	O
by	O
binding	O
to	O
Vero	O
cells	O
.	O

The	O
proteins	O
possess	O
the	O
biologic	O
activity	O
,	O
which	O
lays	O
a	O
foundation	O
for	O
further	O
investigation	O
of	O
S	B-PRGE
-	I-PRGE
protein	I-PRGE
biological	O
function	O
.	O

2	O
.	O
9	O
;	O
p	O
=	O
0	O
.	O
01	O
)	O
and	O
a	O
lower	O
ratio	O
of	O
GRalpha	O
:	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
in	O
nuclear	O
staining	O
(	O
0	O
.	O
5	O
+/-	O
0	O
.	O
2	O
vs	O
.	O
1	O
.	O
5	O
+/-	O

Strong	O
expression	O
of	O
inducible	B-PRGE
nitric	I-PRGE
oxide	I-PRGE
synthase	I-PRGE
(	O
iNOS	B-PRGE
)	O
was	O
detected	O
in	O
the	O
alveolar	O
macrophages	O
.	O

Interestingly	O
,	O
however	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
strongly	O
induced	O
the	O
chemokines	O
IP	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
IL	O
-	O
8	O
in	O
the	O
colon	O
carcinoma	O
cell	O
line	O
Caco	O
-	O
2	O
,	O
but	O
not	O
in	O
the	O
embryonic	O
kidney	O
cell	O
line	O
293	O
.	O

Our	O
data	O
indicate	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
suppresses	O
the	O
antiviral	O
cytokine	O
system	O
of	O
non	O
-	O
immune	O
cells	O
to	O
a	O
large	O
extent	O
,	O
thus	O
buying	O
time	O
for	O
dissemination	O
in	O
the	O
host	O
.	O

Recombinant	B-PRGE
fusion	I-PRGE
proteins	I-PRGE
comprised	O
of	O
PgsA	B-PRGE
and	O
the	O
Spike	O
(	O
S	O
)	O
protein	O
segments	O
SA	O
(	O
residues	O
2	O
to	O
114	O
)	O
and	O
SB	O
(	O
residues	O
264	O
to	O
596	O
)	O
were	O
stably	O
expressed	O
in	O
Lactobacillus	O
casei	O
.	O

Three	O
new	O
neutralizing	O
epitopes	O
were	O
identified	O
on	O
the	O
S	B-PRGE
protein	I-PRGE
using	O
a	O
peptide	O
neutralization	O
interference	O
assay	O
(	O
residues	O
291	O
to	O
308	O
,	O
520	O
to	O
529	O
,	O
and	O
564	O
to	O
581	O
).	O

These	O
results	O
indicate	O
that	O
mucosal	O
immunization	O
with	O
recombinant	O
L	O
.	O
casei	O
expressing	O
SARS	B-PRGE
-	I-PRGE
associated	I-PRGE
coronavirus	I-PRGE
S	I-PRGE
protein	I-PRGE
on	O
its	O
surface	O
provides	O
an	O
effective	O
means	O
for	O
eliciting	O
protective	O
immune	O
response	O
against	O
the	O
virus	O
.	O

TITLE	O
:	O
Structure	O
,	O
function	O
and	O
evolution	O
of	O
the	O
hemagglutinin	B-PRGE
-	I-PRGE
esterase	I-PRGE
proteins	I-PRGE
of	O
corona	O
-	O
and	O
toroviruses	O
.	O

The	O
major	O
human	O
pathogen	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
encodes	O
16	O
non	O
-	O
structural	O
proteins	O
(	O
nsps	O
),	O
one	O
of	O
which	O
(	O
nsp3	B-PRGE
)	O
encompasses	O
a	O
macro	O
domain	O
.	O

In	O
addition	O
,	O
in	O
vitro	O
experiments	O
demonstrated	O
that	O
stimulated	O
V	B-PRGE
gamma	I-PRGE
9V	I-PRGE
delta	I-PRGE
2	I-PRGE
T	O
cells	O
display	O
an	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	I-PRGE
dependent	I-PRGE
anti	I-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
activity	O
and	O
are	O
able	O
to	O
directly	O
kill	O
SARS	O
-	O
CoV	O
-	O
infected	O
target	O
cells	O
.	O

Human	B-PRGE
monoclonal	I-PRGE
antibody	I-PRGE
blocking	O
S1	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
immunoprophylaxis	O
of	O
SARS	O
.	O

Interestingly	O
,	O
the	O
overall	O
structure	O
of	O
the	O
m396	O
-	O
bound	O
RBD	O
is	O
not	O
significantly	O
different	O
from	O
that	O
of	O
the	O
ACE2	B-PRGE
-	O
bound	O
RBD	O
.	O

Here	O
we	O
present	O
a	O
rapid	O
and	O
high	O
-	O
throughput	O
screening	O
method	O
to	O
study	O
the	O
substrate	O
specificity	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
(	O
pro	B-PRGE
).	O

Each	O
batch	O
of	O
mixed	O
peptide	O
substrates	O
with	O
defined	O
amino	O
acid	O
substitutions	O
at	O
the	O
target	O
amino	O
acid	O
position	O
was	O
synthesized	O
via	O
the	O
""""	O
cartridge	O
replacement	O
""""	O
approach	O
and	O
was	O
subjected	O
to	O
enzymatic	O
cleavage	O
by	O
recombinant	B-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
(	O
pro	B-PRGE
).	O

In	O
comparison	O
with	O
Influenza	O
A	O
virus	O
and	O
Sendai	O
virus	O
,	O
IBV	O
was	O
most	O
sensitive	O
to	O
pre	O
-	O
treatment	O
of	O
cells	O
with	O
neuraminidase	B-PRGE
.	O

Oxygenation	O
is	O
increased	O
by	O
ILA	B-PRGE
in	O
severe	O
lung	O
injury	O
.	O

Comorbidities	O
of	O
diabetes	O
and	O
heart	O
failure	O
were	O
more	O
common	O
in	O
patients	O
who	O
developed	O
ARF	B-PRGE
(	O
38	O
%	O
vs	O
6	O
%,	O
p	O
<	O
0	O
.	O
01	O
and	O
38	O
%	O
vs	O
2	O
%,	O
p	O
<	O
0	O
.	O
001	O
,	O
respectively	O
)	O
and	O
the	O
incidence	O
of	O
respiratory	O
failure	O
(	O
85	O
%	O
vs	O
26	O
%,	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
mortality	O
(	O
77	O
%	O
vs	O
8	O
%,	O
p	O
<	O
0	O
.	O
001	O
)	O
were	O
also	O
higher	O
.	O

RESULTS	O
:	O
Patients	O
were	O
assigned	O
to	O
ARF	O
(	O
n	O
=	O
13	O
;	O
17	O
%)	O
and	O
non	O
-	O
ARF	B-PRGE
groups	O
(	O
n	O
=	O
65	O
).	O

The	O
paired	B-PRGE
-	I-PRGE
t	I-PRGE
and	O
Dunnett	O
tests	O
were	O
used	O
.	O

TITLE	O
:	O
A	O
single	O
amino	O
acid	O
substitution	O
(	O
R441A	O
)	O
in	O
the	O
receptor	O
-	O
binding	O
domain	O
of	O
SARS	B-PRGE
coronavirus	I-PRGE
spike	I-PRGE
protein	I-PRGE
disrupts	O
the	O
antigenic	O
structure	O
and	O
binding	O
activity	O
.	O

In	O
addition	O
,	O
ribavirin	O
treatment	O
seemed	O
also	O
to	O
promote	O
the	O
production	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
4	O
days	O
after	O
cessation	O
of	O
treatment	O
,	O
although	O
after	O
3	O
days	O
of	O
treatment	O
ribavirin	O
inhibited	O
pro	O
-	O
inflammatory	O
cytokine	O
production	O
in	O
infected	O
mice	O
,	O
significantly	O
reducing	O
the	O
levels	O
of	O
the	O
cytokines	O
IL	O
-	O
1alpha	O
,	O
interleukin	B-PRGE
-	I-PRGE
5	I-PRGE
(	O
IL	O
-	O
5	O
),	O
monocyte	O
chemotactic	O
protein	O
-	O
1	O
(	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
),	O
and	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
).	O

Expression	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
X4	I-PRGE
protein	I-PRGE
in	O
the	O
lungs	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
and	O
progression	O
of	O
SARS	O
.	O

ABSTRACT	O
:	O
The	O
causative	O
agent	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
plays	O
an	O
essential	O
role	O
in	O
SARS	O
-	O
CoV	O
genome	O
packaging	O
and	O
virion	O
assembly	O
.	O

Although	O
lacking	O
significant	O
sequence	O
similarity	O
,	O
the	O
dimerization	O
domain	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
protein	I-PRGE
has	O
a	O
fold	O
similar	O
to	O
that	O
of	O
the	O
nucleocapsid	O
protein	O
of	O
the	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
.	O

Salmonella	B-PRGE
spp	I-PRGE
.	O

TITLE	O
:	O
Mapping	O
a	O
neutralizing	O
epitope	O
on	O
the	O
SARS	B-PRGE
coronavirus	I-PRGE
spike	I-PRGE
protein	I-PRGE
:	O
computational	O
prediction	O
based	O
on	O
affinity	O
-	O
selected	O
peptides	O
.	O

SARS	B-PRGE
-	I-PRGE
3CL	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
has	O
been	O
shown	O
to	O
be	O
essential	O
for	O
replication	O
and	O
is	O
thus	O
a	O
target	O
for	O
drug	O
discovery	O
.	O

Here	O
,	O
we	O
report	O
effective	O
siRNAs	O
targeting	O
structural	O
genes	O
(	O
i	O
.	O
e	O
.,	O
spike	O
,	O
envelope	B-PRGE
,	O
membrane	O
,	O
and	O
nucleocapsid	O
)	O
and	O
their	O
antiviral	O
kinetics	O
.	O

ABSTRACT	O
:	O
A	O
highly	O
neurovirulent	O
murine	O
coronavirus	O
JHMV	O
(	O
wild	O
-	O
type	O
[	O
wt	O
]	O
JHMV	O
)	O
is	O
known	O
to	O
spread	O
from	O
cells	O
infected	O
via	O
the	O
murine	B-PRGE
coronavirus	I-PRGE
mouse	I-PRGE
hepatitis	I-PRGE
virus	I-PRGE
receptor	I-PRGE
(	O
MHVR	B-PRGE
)	O
to	O
cells	O
without	O
MHVR	B-PRGE
(	O
MHVR	B-PRGE
-	O
independent	O
infection	O
),	O
whereas	O
a	O
mutant	O
virus	O
isolated	O
from	O
wt	O
JHMV	O
,	O
srr7	O
,	O
spread	O
only	O
in	O
an	O
MHVR	O
-	O
dependent	O
fashion	O
.	O

MHVR	O
-	O
independent	O
infection	O
is	O
hypothetically	O
thought	O
to	O
be	O
attributed	O
to	O
a	O
naturally	O
occurring	O
fusion	O
activation	O
of	O
the	O
wt	B-PRGE
JHMV	I-PRGE
S	I-PRGE
protein	I-PRGE
,	O
which	O
did	O
not	O
occur	O
in	O
the	O
case	O
of	O
srr7	O
.	O

Enzyme	O
activity	O
from	O
the	O
SARS	B-PRGE
CoV	I-PRGE
main	I-PRGE
proteinase	I-PRGE
dimer	I-PRGE
could	O
readily	O
be	O
detected	O
at	O
low	O
pM	O
concentrations	O
.	O

Here	O
,	O
we	O
generated	O
coronavirus	O
-	O
like	O
particles	O
carrying	O
in	O
their	O
envelope	B-PRGE
chimeric	I-PRGE
HCV	I-PRGE
glycoproteins	I-PRGE
composed	O
of	O
the	O
ectodomains	O
of	O
E1	O
and	O
E2	O
,	O
each	O
fused	O
to	O
the	O
transmembrane	O
plus	O
endodomain	O
of	O
the	O
mouse	O
hepatitis	B-PRGE
coronavirus	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
.	O

The	O
up	O
-	O
regulated	O
proteins	O
were	O
identified	O
as	O
alpha	B-PRGE
-	I-PRGE
1	I-PRGE
acid	I-PRGE
glycoprotein	I-PRGE
,	O
haptoglobin	B-PRGE
,	O
alpha	B-PRGE
-	I-PRGE
1	I-PRGE
anti	I-PRGE
-	I-PRGE
chymotrypsin	I-PRGE
and	O
fetuin	B-PRGE
.	O

Detectable	O
nasopharyngeal	O
shedding	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
was	O
associated	O
with	O
polymorphic	O
alleles	O
of	O
interleukins	O
18	O
(	O
P	O
=.	O
014	O
)	O
and	O
1A	O
(	O
P	O
=.	O
031	O
)	O
and	O
a	O
member	O
of	O
NF	B-PRGE
kappa	I-PRGE
B	I-PRGE
complex	I-PRGE
(	O
reticuloendotheliosis	B-PRGE
viral	I-PRGE
oncogene	I-PRGE
homolog	I-PRGE
B	I-PRGE
[	I-PRGE
RelB	I-PRGE
])	I-PRGE
(	O
P	O
=.	O
034	O
),	O
all	O
of	O
which	O
are	O
proinflammatory	O
in	O
nature	O
,	O
as	O
well	O
as	O
the	O
procoagulation	B-PRGE
molecule	I-PRGE
fibrinogen	I-PRGE
-	I-PRGE
like	I-PRGE
protein	I-PRGE
2	I-PRGE
(	O
P	O
=.	O
008	O
).	O

Here	O
we	O
show	O
that	O
the	O
recombinant	O
RBDs	O
derived	O
from	O
the	O
S	O
protein	O
sequences	O
of	O
Tor2	B-PRGE
,	O
GD03	O
,	O
and	O
SZ3	O
,	O
the	O
representative	O
strains	O
of	O
human	O
2002	O
-	O
2003	O
and	O
2003	O
-	O
2004	O
SARS	O
-	O
CoV	O
and	O
palm	O
civet	O
SARS	O
-	O
CoV	O
,	O
respectively	O
,	O
induce	O
in	O
the	O
immunized	O
mice	O
and	O
rabbits	O
high	O
titers	O
of	O
cross	O
-	O
neutralizing	O
Abs	O
against	O
pseudoviruses	O
expressing	O
S	O
proteins	O
of	O
Tor2	B-PRGE
,	O
GD03	O
,	O
and	O
SZ3	O
.	O

We	O
examined	O
whether	O
polymorphisms	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
affect	O
the	O
susceptibility	O
to	O
and	O
outcome	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
+	I-PRGE
874A	I-PRGE
allele	I-PRGE
was	O
associated	O
with	O
susceptibility	O
to	O
SARS	B-PRGE
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

The	O
polymorphisms	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
were	O
not	O
associated	O
with	O
SARS	B-PRGE
susceptibility	I-PRGE
.	O

No	O
mutations	O
of	O
F	O
V	O
Leiden	O
and	O
prothrombin	B-PRGE
G20210A	O
was	O
found	O
in	O
both	O
groups	O
.	O

Mice	O
that	O
were	O
subcutaneously	O
vaccinated	O
with	O
rDIs	O
expressing	O
S	B-PRGE
protein	I-PRGE
with	O
or	O
without	O
other	O
structural	O
proteins	O
induced	O
a	O
high	O
level	O
of	O
serum	O
neutralizing	O
IgG	B-PRGE
antibodies	I-PRGE
and	O
demonstrated	O
marked	O
protective	O
immunity	O
against	O
SARS	O
-	O
CoV	O
challenge	O
in	O
the	O
absence	O
of	O
a	O
mucosal	O
IgA	B-PRGE
response	O
.	O

The	O
library	O
was	O
screened	O
for	O
the	O
production	O
of	O
Fab	B-PRGE
antibody	I-PRGE
fragments	O
to	O
a	O
recombinant	O
spike	O
protein	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

Mutation	O
analysis	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3b	I-PRGE
revealed	O
that	O
the	O
domain	O
spanning	O
amino	O
acids	O
80	O
to	O
138	O
was	O
essential	O
for	O
its	O
mitochondria	O
localization	O
.	O

ABSTRACT	O
:	O
Coronavirus	B-PRGE
envelope	I-PRGE
(	I-PRGE
E	I-PRGE
)	I-PRGE
protein	I-PRGE
is	O
a	O
small	O
integral	O
membrane	O
protein	O
with	O
multi	O
-	O
functions	O
in	O
virion	O
assembly	O
,	O
morphogenesis	O
and	O
virus	O
-	O
host	O
interaction	O
.	O

Two	O
relevant	O
protein	O
families	O
,	O
the	O
alpha	B-PRGE
-	I-PRGE
carbonic	I-PRGE
anhydrases	I-PRGE
and	O
the	O
protein	O
kinases	O
,	O
are	O
used	O
to	O
demonstrate	O
the	O
scope	O
of	O
our	O
cluster	O
approach	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
investigated	O
an	O
approach	O
to	O
generate	O
antibodies	O
that	O
specifically	O
recognize	O
the	O
HRN	O
and	O
HRC	O
regions	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
glycoprotein	I-PRGE
in	O
order	O
to	O
evaluate	O
whether	O
these	O
antibodies	O
can	O
inhibit	O
viral	O
infectivity	O
and	O
thus	O
neutralize	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
In	O
this	O
regard	O
,	O
we	O
incorporated	O
HRN	O
and	O
HRC	O
coiled	O
-	O
coil	O
surface	O
residues	O
into	O
a	O
de	O
novo	O
designed	O
two	O
-	O
stranded	O
alpha	O
-	O
helical	O
coiled	O
-	O
coil	O
template	O
for	O
generating	O
conformation	O
-	O
specific	O
antibodies	O
that	O
recognize	O
alpha	O
-	O
helices	O
in	O
proteins	O
(	O
Lu	O
,	O
S	O
.	O
M	O
.,	O
Hodges	O
,	O
R	O
.	O
S	O
.,	O
2002	O
.	O

Overall	O
,	O
these	O
results	O
clearly	O
demonstrate	O
that	O
the	O
two	O
-	O
stranded	O
coiled	O
-	O
coil	O
template	O
acts	O
as	O
an	O
excellent	O
presentation	O
system	O
for	O
eliciting	O
helix	O
-	O
specific	O
antibodies	O
against	O
highly	O
conserved	O
viral	O
antigens	O
and	O
HRC1	B-PRGE
and	O
HRC2	O
peptides	O
may	O
represent	O
potential	O
candidates	O
for	O
use	O
in	O
a	O
peptide	O
vaccine	O
against	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O

The	O
induction	O
of	O
human	B-PRGE
anti	I-PRGE
-	I-PRGE
mouse	I-PRGE
/	I-PRGE
anti	I-PRGE
-	I-PRGE
rat	I-PRGE
antibodies	I-PRGE
was	O
detected	O
in	O
5	O
out	O
of	O
16	O
(	O
31	O
%)	O
patients	O
.	O

Furthermore	O
,	O
it	O
has	O
been	O
shown	O
that	O
a	O
bradykinin	B-PRGE
2	I-PRGE
receptor	I-PRGE
(	O
B2R	B-PRGE
)	O
antagonist	O
attenuates	O
the	O
inflammatory	O
changes	O
in	O
the	O
same	O
animal	O
model	O
.	O

Collectively	O
,	O
HCoV	B-PRGE
-	I-PRGE
229E	I-PRGE
S	I-PRGE
protein	I-PRGE
belongs	O
to	O
the	O
type	B-PRGE
I	I-PRGE
fusion	I-PRGE
protein	I-PRGE
,	O
which	O
is	O
characterized	O
by	O
the	O
existence	O
of	O
two	O
heptad	O
-	O
repeat	O
regions	O
(	O
HR1	O
and	O
HR2	O
),	O
furthermore	O
,	O
the	O
available	O
knowledge	O
concerning	O
HCoV	O
-	O
229E	O
fusion	O
core	O
may	O
make	O
it	O
possible	O
to	O
design	O
small	O
molecule	O
or	O
polypeptide	O
drugs	O
targeting	O
the	O
membrane	O
fusion	O
,	O
a	O
crucial	O
step	O
of	O
HCoV	O
-	O
229E	O
infection	O
.	O

Efficacy	O
was	O
assessed	O
after	O
intramuscular	O
injection	O
of	O
the	O
vector	O
into	O
mice	O
and	O
was	O
measured	O
as	O
the	O
frequency	O
of	O
SARS	O
-	O
CoV	O
-	O
specific	O
T	O
cells	O
and	O
NAbs	O
against	O
SARS	O
-	O
CoV	O
.	O
Immunogenicity	O
of	O
the	O
AdH5	O
-	O
based	O
vaccine	O
was	O
significantly	O
attenuated	O
or	O
completely	O
abolished	O
when	O
the	O
preexisting	O
anti	B-PRGE
-	I-PRGE
AdH5	I-PRGE
NAb	I-PRGE
titer	O
was	O
higher	O
than	O
40	O
.	O

ABSTRACT	O
:	O
Two	O
neutralizing	O
human	O
scFv	O
,	O
b1	O
and	O
h12	O
were	O
identified	O
initially	O
using	O
ELISA	O
,	O
employing	O
highly	O
purified	O
virus	O
as	O
the	O
coating	B-PRGE
antigen	I-PRGE
.	O

Ten	O
of	O
the	O
RBD	O
-	O
specific	O
mAbs	O
were	O
mapped	O
to	O
four	O
distinct	O
groups	O
of	O
conformational	O
epitopes	O
(	O
designated	O
Group	O
A	O
to	O
D	O
),	O
and	O
all	O
of	O
which	O
had	O
potent	O
neutralizing	O
activity	O
against	O
S	B-PRGE
protein	I-PRGE
-	O
pseudotyped	O
SARS	O
viruses	O
.	O

Surprisingly	O
,	O
most	O
neutralizing	O
epitopes	O
(	O
Groups	O
A	O
to	O
C	O
)	O
could	O
be	O
completely	O
disrupted	O
by	O
single	O
amino	O
acid	O
substitutions	O
(	O
e	O
.	O
g	O
.,	O
D429A	O
,	O
R441A	O
or	O
D454A	O
)	O
or	O
by	O
deletions	O
of	O
several	O
amino	O
acids	O
at	O
the	O
N	O
-	O
terminal	O
or	O
C	O
-	O
terminal	O
region	O
of	O
the	O
RBD	O
;	O
however	O
,	O
the	O
Group	B-PRGE
D	I-PRGE
epitope	I-PRGE
was	O
not	O
sensitive	O
to	O
the	O
mutations	O
,	O
highlighting	O
its	O
importance	O
for	O
vaccine	O
development	O
.	O

In	O
particular	O
,	O
the	O
concentration	O
of	O
IgA	B-PRGE
against	O
PEDV	O
was	O
higher	O
in	O
piglets	O
of	O
sows	O
in	O
the	O
oral	O
group	O
,	O
compared	O
to	O
the	O
IM	O
group	O
.	O

In	O
contrast	O
,	O
trypsin	B-PRGE
treatment	O
can	O
both	O
overcome	O
ammonium	O
chloride	O
inhibition	O
and	O
promote	O
cell	O
-	O
cell	O
fusion	O
.	O

Here	O
,	O
using	O
a	O
panel	O
of	O
replicase	B-PRGE
-	O
specific	O
antisera	O
,	O
we	O
have	O
analyzed	O
the	O
earlier	O
stages	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
infection	O
in	O
Vero	O
E6	O
cells	O
,	O
in	O
particular	O
focusing	O
on	O
the	O
subcellular	O
localization	O
of	O
the	O
replicase	B-PRGE
and	O
the	O
ultrastructure	O
of	O
the	O
associated	O
membranes	O
.	O

Additionally	O
,	O
a	O
classical	O
nuclear	O
export	O
signal	O
(	O
NES	O
)	O
functioned	O
to	O
direct	O
N	B-PRGE
protein	I-PRGE
to	O
the	O
cytoplasm	O
.	O

We	O
hypothesise	O
that	O
the	O
N	B-PRGE
-	I-PRGE
protein	I-PRGE
uses	O
these	O
signals	O
to	O
traffic	O
to	O
and	O
from	O
the	O
nucleolus	O
and	O
the	O
cytoplasm	O
.	O

We	O
report	O
a	O
patient	O
with	O
UC	O
and	O
alpha1	B-PRGE
-	I-PRGE
antitrypsin	I-PRGE
deficiency	O
who	O
presented	O
with	O
disseminated	O
cutaneous	O
leucocytoclastic	O
vasculitis	O
clinically	O
appearing	O
with	O
target	O
-	O
like	O
purpuric	O
patches	O
and	O
haemorrhagic	O
oedemas	O
.	O

Two	O
of	O
the	O
siRNA	O
expression	O
cassettes	O
for	O
RDRP	O
successfully	O
inhibited	O
the	O
expression	O
of	O
the	O
gene	O
,	O
whereas	O
both	O
of	O
the	O
siRNA	O
expression	O
cassettes	O
for	O
envelope	O
E	O
decreased	O
approx	O
90	O
%	O
of	O
the	O
envelope	B-PRGE
E	I-PRGE
gene	I-PRGE
expression	O
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
isatin	O
derivatives	O
were	O
synthesized	O
and	O
tested	O
against	O
SARS	B-PRGE
CoV	I-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
.	O

Compound	O
5f	O
shows	O
significant	O
inhibition	O
with	O
an	O
IC	O
(	O
50	O
)	O
of	O
0	O
.	O
37	O
microM	O
.	O
Further	O
study	O
showed	O
that	O
,	O
unlike	O
the	O
irreversible	O
covalent	O
binding	O
of	O
isatin	O
derivatives	O
to	O
human	B-PRGE
rhinovirus	I-PRGE
3C	I-PRGE
protease	I-PRGE
,	O
the	O
compounds	O
tested	O
in	O
this	O
study	O
are	O
all	O
noncovalent	O
reversible	O
inhibitors	O
.	O

Out	O
of	O
the	O
59	O
,	O
363	O
compounds	O
docked	O
,	O
93	O
were	O
selected	O
for	O
the	O
inhibition	O
assay	O
,	O
and	O
21	O
showed	O
inhibition	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
(	O
pro	B-PRGE
)	O
(	O
IC	O
(	O
50	O
)	O
<	O
or	O
=	O
30	O
microM	O
),	O
with	O
three	O
of	O
them	O
having	O
common	O
substructures	O
.	O

Furthermore	O
,	O
a	O
search	O
for	O
analogues	O
with	O
common	O
substructure	O
in	O
the	O
Maybridge	O
,	O
ChemBridge	O
,	O
and	O
SPECS_SC	O
databases	O
led	O
to	O
the	O
identification	O
of	O
another	O
25	O
compounds	O
that	O
exhibited	O
inhibition	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
(	O
pro	B-PRGE
)	O
(	O
IC	O
(	O
50	O
)	O
=	O
3	O
-	O
1	O
,	O
000	O
microM	O
).	O

These	O
compounds	O
,	O
28	O
in	O
total	O
,	O
were	O
subjected	O
to	O
3D	O
-	O
QSAR	O
studies	O
to	O
elucidate	O
the	O
pharmacophore	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
(	O
pro	B-PRGE
).	O

Survival	O
analysis	O
showed	O
that	O
FPG	B-PRGE
was	O
independently	O
associated	O
with	O
an	O
increased	O
hazard	O
ratio	O
(	O
HR	O
)	O
of	O
mortality	O
(	O
HR	O
=	O
1	O
.	O
1	O
,	O
95	O
%	O
CI	O
1	O
.	O
0	O
,	O
1	O
.	O
1	O
,	O
P	O
=	O
0	O
.	O
001	O
)	O
and	O
hypoxia	O
(	O
HR	O
=	O
1	O
.	O
1	O
,	O
95	O
%	O
CI	O
1	O
.	O
0	O
,	O
1	O
.	O
1	O
,	O
P	O
=	O
0	O
.	O
002	O
)	O
after	O
controlling	O
for	O
age	O
and	O
gender	O
.	O

According	O
to	O
the	O
pathophysiology	O
of	O
acute	O
pancreatitis	O
,	O
the	O
efficacy	O
of	O
the	O
drugs	O
already	O
available	O
,	O
such	O
as	O
gabexate	O
mesilate	O
,	O
lexipafant	O
and	O
somatostatin	B-PRGE
should	O
be	O
re	O
-	O
evaluated	O
and	O
should	O
be	O
probably	O
administered	O
in	O
a	O
different	O
manner	O
.	O

In	O
this	O
study	O
,	O
the	O
interaction	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
with	O
dendritic	O
cells	O
(	O
DCs	O
),	O
the	O
key	O
regulators	O
of	O
immune	O
responses	O
,	O
was	O
analysed	O
.	O

Interferon	O
responses	O
are	O
not	O
triggered	O
during	O
infection	O
,	O
although	O
the	O
L	O
cells	O
can	O
be	O
readily	O
stimulated	O
to	O
produce	O
interferon	B-PRGE
by	O
dsRNA	O
,	O
a	O
known	O
potent	O
inducer	O
of	O
interferon	B-PRGE
.	O

TITLE	O
:	O
Biophysical	O
characterization	O
of	O
HRC	B-PRGE
peptide	I-PRGE
analogs	O
interaction	O
with	O
heptad	O
repeat	O
regions	O
of	O
the	O
SARS	O
-	O
coronavirus	O
Spike	O
fusion	O
protein	O
core	O
.	O

In	O
addition	O
,	O
we	O
have	O
demonstrated	O
the	O
presence	O
of	O
Oct	B-PRGE
-	I-PRGE
4	I-PRGE
+	I-PRGE
long	O
-	O
term	O
BrdU	O
label	O
-	O
retaining	O
cells	O
at	O
the	O
bronchoalveolar	O
junction	O
of	O
neonatal	O
lung	O
,	O
providing	O
a	O
link	O
between	O
the	O
Oct	B-PRGE
-	I-PRGE
4	I-PRGE
+	I-PRGE
cells	O
in	O
vivo	O
and	O
in	O
vitro	O
and	O
strengthening	O
their	O
identity	O
as	O
putative	O
neonatal	O
lung	O
stem	O
/	O
progenitor	O
cells	O
.	O

The	O
N	B-PRGE
protein	I-PRGE
is	O
a	O
highly	O
immunogenic	O
phosphoprotein	O
also	O
implicated	O
in	O
viral	O
genome	O
replication	O
and	O
in	O
modulating	O
cell	O
signaling	O
pathways	O
.	O

We	O
describe	O
the	O
structure	O
of	O
the	O
two	O
proteolytically	O
resistant	O
domains	O
of	O
the	O
N	B-PRGE
protein	I-PRGE
from	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
a	O
prototype	O
coronavirus	O
.	O

TITLE	O
:	O
Novel	O
mfgl2	O
antisense	O
plasmid	O
inhibits	O
murine	O
fgl2	B-PRGE
expression	O
and	O
ameliorates	O
murine	O
hepatitis	O
virus	O
type	O
3	O
-	O
induced	O
fulminant	O
hepatitis	O
in	O
BALB	O
/	O
cJ	O
mice	O
.	O

To	O
interfere	O
with	O
this	O
potentially	O
effective	O
target	O
,	O
a	O
322	O
-	O
bp	O
mouse	B-PRGE
fgl2	I-PRGE
(	O
mfgl2	O
)	O
antisense	O
plasmid	O
complementary	O
to	O
the	O
exon	O
1	O
sequence	O
of	O
the	O
gene	O
,	O
including	O
the	O
translation	O
initiation	O
site	O
AUG	O
,	O
was	O
successfully	O
constructed	O
.	O

The	O
anti	B-PRGE
-	I-PRGE
3a	I-PRGE
N	I-PRGE
-	I-PRGE
terminal	I-PRGE
antibody	I-PRGE
could	O
detect	O
intracellular	O
3a	O
as	O
well	O
as	O
3a	O
expressed	O
on	O
the	O
cell	O
surface	O
.	O

These	O
hemodynamic	O
changes	O
were	O
differentially	O
inhibited	O
by	O
antagonism	O
of	O
C5a	B-PRGE
receptors	I-PRGE
,	O
C3a	B-PRGE
receptors	I-PRGE
or	O
by	O
inhibition	O
of	O
the	O
entire	O
complement	O
cascade	O
using	O
RMA	O
.	O

NF	B-PRGE
-	I-PRGE
KappaB	I-PRGE
p65	B-PRGE
activity	O
in	O
B	O
group	O
[(	O
33	O
.	O
56	O
+/-	O
2	O
.	O
85	O
)%]	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
A	O
[(	O
10	O
.	O
35	O
+/-	O
0	O
.	O
60	O
)%]	O
and	O
D	O
[(	O
10	O
.	O
79	O
+/-	O
1	O
.	O
02	O
)%]	O
groups	O
,	O
but	O
there	O
was	O
no	O
difference	O
between	O
B	O
and	O
C	O
[(	O
30	O
.	O
87	O
+/-	O
1	O
.	O
16	O
)%]	O
groups	O
.	O

Because	O
enhancement	O
of	O
SARS	O
-	O
CoV	O
infection	O
by	O
subneutralizing	O
antibody	O
concentrations	O
is	O
of	O
concern	O
,	O
we	O
show	O
here	O
that	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
antibodies	I-PRGE
do	O
not	O
convert	O
the	O
abortive	O
infection	O
of	O
primary	O
human	O
macrophages	O
by	O
SARS	O
-	O
CoV	O
into	O
a	O
productive	O
one	O
.	O

After	O
controlling	O
for	O
age	O
and	O
sex	O
,	O
multiple	O
logistic	O
regression	O
analysis	O
showed	O
that	O
hematological	O
factors	O
significantly	O
associated	O
with	O
fatality	O
included	O
initial	O
neutrophil	O
count	O
>	O
7000	O
/	O
microL	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
=	O
6	O
.	O
4	O
),	O
initial	O
CRP	B-PRGE
concentration	O
>	O
47	O
.	O
5	O
mg	O
/	O
L	O
(	O
OR	O
=	O
5	O
.	O
8	O
)	O
and	O
lactic	B-PRGE
acid	I-PRGE
dehydrogenase	I-PRGE
(	O
LDH	B-PRGE
)	O
>	O
593	O
.	O
5	O
IU	O
/	O
L	O
(	O
OR	O
=	O
4	O
.	O
2	O
).	O

In	O
this	O
study	O
,	O
we	O
investigated	O
which	O
signaling	O
pathways	O
play	O
important	O
roles	O
in	O
escape	O
from	O
apoptosis	O
in	O
cells	O
infected	O
with	O
SARS	O
-	O
CoV	O
.	O
In	O
persistently	O
infected	O
cells	O
at	O
50h	O
.	O
p	O
.	O
i	O
.,	O
PI3K	B-PRGE
/	O
Akt	B-PRGE
,	O
JNK	B-PRGE
,	O
p38	B-PRGE
MAPK	I-PRGE
and	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
were	O
phosphorylated	O
and	O
the	O
protein	O
levels	O
of	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
Bcl	B-PRGE
-	I-PRGE
xL	I-PRGE
were	O
increased	O
.	O

From	O
hemagglutinin	B-PRGE
esterase	I-PRGE
(	O
HE	O
)	O
to	O
nucleocapsid	O
(	O
N	O
),	O
the	O
genotype	O
B	O
strains	O
were	O
clustered	O
closely	O
with	O
the	O
genotype	O
C	O
strains	O
.	O

Genome	O
analysis	O
also	O
revealed	O
various	O
numbers	O
of	O
tandem	O
copies	O
of	O
a	O
perfect	O
30	O
-	O
base	O
acidic	O
tandem	O
repeat	O
(	O
ATR	O
)	O
which	O
encodes	O
NDDEDVVTGD	O
and	O
various	O
numbers	O
and	O
sequences	O
of	O
imperfect	O
repeats	O
in	O
the	O
N	O
terminus	O
of	O
nsp3	B-PRGE
inside	O
the	O
acidic	O
domain	O
upstream	O
of	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
1	I-PRGE
among	O
the	O
22	O
genomes	O
.	O

However	O
,	O
introduction	O
of	O
a	O
CD4	B-PRGE
T	O
-	O
cell	O
epitope	O
from	O
Listeria	O
monocytogenes	O
into	O
rJ	O
.	O
M	O
(	O
Y135Q	O
)	O
generated	O
a	O
highly	O
virulent	O
virus	O
.	O

Also	O
,	O
a	O
GT	O
genotype	O
at	O
position	O
88	O
in	O
the	O
MxA	B-PRGE
gene	I-PRGE
promoter	I-PRGE
was	O
associated	O
with	O
increased	O
susceptibility	O
to	O
SARS	O
infection	O
compared	O
to	O
a	O
GG	O
genotype	O
(	O
OR	O
=	O
3	O
.	O
06	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
25	O
-	O
7	O
.	O
50	O
).	O

RESULTS	O
:	O
Clinical	O
(	O
temperature	O
,	O
FiO2	O
)	O
and	O
laboratory	O
[	O
leukocyte	O
,	O
lymphocyte	O
,	O
neutrophil	O
,	O
platelet	O
,	O
lactate	B-PRGE
dehydrogenase	I-PRGE
(	O
LDH	B-PRGE
),	O
albumin	B-PRGE
]	O
trends	O
in	O
groups	O
with	O
and	O
without	O
an	O
adversarial	O
event	O
were	O
presented	O
.	O

CONCLUSIONS	O
:	O
Advanced	O
age	O
,	O
neutrophilia	O
and	O
high	O
LDH	B-PRGE
predict	O
poor	O
outcomes	O
in	O
patients	O
with	O
SARS	O
.	O

In	O
expressing	O
cells	O
,	O
7a	O
protein	O
exhibits	O
a	O
variety	O
of	O
biological	O
activities	O
,	O
including	O
induction	O
of	O
apoptosis	O
,	O
activation	O
of	O
the	O
mitogen	B-PRGE
-	I-PRGE
activated	I-PRGE
protein	I-PRGE
kinase	I-PRGE
signaling	O
pathway	O
,	O
inhibition	O
of	O
host	O
protein	O
translation	O
,	O
and	O
suppression	O
of	O
cell	O
growth	O
progression	O
.	O

Moreover	O
,	O
progress	O
in	O
the	O
drug	O
development	O
based	O
on	O
different	O
molecular	O
targets	O
is	O
also	O
summarized	O
,	O
including	O
1	O
)	O
Compounds	O
that	O
block	O
the	O
S	B-PRGE
protein	I-PRGE
-	O
ACE2	B-PRGE
-	O
mediated	O
viral	O
entry	O
;	O
2	O
)	O
Compounds	O
targeting	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	O
);	O
3	O
)	O
Compounds	O
targeting	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
2	I-PRGE
(	O
PLP2	B-PRGE
);	O
4	O
)	O
Compounds	O
targeting	O
SARS	O
-	O
CoV	O
RdRp	O
;	O
5	O
)	O
Compounds	O
targeting	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
helicase	I-PRGE
;	O
6	O
)	O
Active	O
compounds	O
with	O
unspecified	O
targets	O
;	O
and	O
7	O
)	O
Research	O
on	O
siRNA	O
.	O

This	O
indicates	O
that	O
formyl	B-PRGE
peptide	I-PRGE
receptor	I-PRGE
may	O
be	O
important	O
in	O
viral	O
infections	O
and	O
that	O
variations	O
in	O
its	O
sequence	O
among	O
individuals	O
may	O
affect	O
their	O
likelihood	O
of	O
viral	O
and	O
bacterial	O
infections	O
.	O

Genotyping	O
of	O
the	O
HRV	B-PRGE
VP4	I-PRGE
/	O
VP2	B-PRGE
region	O
resulted	O
in	O
a	O
proposed	O
subdivision	O
of	O
HRV	O
type	O
A	O
into	O
sublineages	O
A1	O
and	O
A2	O
.	O

To	O
better	O
understand	O
innate	O
and	O
adaptive	O
immune	O
responses	O
after	O
infection	O
with	O
Porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
),	O
we	O
investigated	O
serum	B-PRGE
IFN	I-PRGE
-	I-PRGE
gamma	I-PRGE
concentrations	O
and	O
the	O
duration	O
of	O
viremia	O
.	O

Recombinant	O
IBVs	O
based	O
on	O
the	O
Beaudette	O
strain	O
expressing	O
the	O
Beaudette	B-PRGE
spike	I-PRGE
protein	I-PRGE
(	O
Beau	O
-	O
R	O
)	O
or	O
that	O
from	O
the	O
virulent	O
M41	O
strain	O
(	O
BeauR	O
-	O
M41	O
(	O
S	O
))	O
were	O
assessed	O
for	O
their	O
potential	O
as	O
prototype	O
vaccines	O
for	O
application	O
to	O
18	O
-	O
day	O
-	O
old	O
embryos	O
.	O

Consistent	O
with	O
these	O
observations	O
,	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
downregulated	O
cell	O
surface	O
expression	O
of	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
),	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
.	O

In	O
general	O
,	O
the	O
Mass	O
strain	O
was	O
more	O
frequently	O
recovered	O
from	O
the	O
tracheal	O
and	O
cecal	O
tonsil	O
tissues	O
at	O
earlier	O
stages	O
of	O
infection	O
and	O
the	O
Ark	B-PRGE
strain	O
was	O
recovered	O
at	O
later	O
stages	O
of	O
infection	O
.	O

Here	O
,	O
we	O
report	O
the	O
crystal	O
structure	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
nsp10	I-PRGE
at	O
a	O
resolution	O
of	O
1	O
.	O
8	O
A	O
as	O
determined	O
by	O
single	O
-	O
wavelength	O
anomalous	O
dispersion	O
using	O
phases	O
derived	O
from	O
hexatantalum	O
dodecabromide	O
.	O

Two	O
zinc	O
fingers	O
have	O
been	O
identified	O
from	O
the	O
nsp10	O
monomer	O
structure	O
with	O
the	O
sequence	O
motifs	O
C	O
-(	O
X	O
)	O
2	O
-	O
C	O
-(	O
X	O
)	O
5	O
-	O
H	O
-(	O
X	O
)	O
6	O
-	O
C	O
and	O
C	O
-(	O
X	O
)	O
2	O
-	O
C	O
-(	O
X	O
)	O
7	O
-	O
C	O
-(	O
X	O
)-	O
C	O
.	O
The	O
nsp10	O
crystal	O
structure	O
is	O
the	O
first	O
of	O
a	O
new	O
class	O
of	O
zinc	B-PRGE
finger	I-PRGE
protein	I-PRGE
three	O
-	O
dimensional	O
structures	O
to	O
be	O
revealed	O
experimentally	O
.	O

Here	O
,	O
we	O
compared	O
the	O
cellular	O
properties	O
of	O
the	O
8a	O
,	O
8b	O
and	O
8ab	O
proteins	O
by	O
examining	O
their	O
cellular	O
localizations	O
and	O
their	O
abilities	O
to	O
interact	O
with	O
other	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
proteins	I-PRGE
.	O

TG	O
-	O
0205221	O
showed	O
remarkable	O
activity	O
against	O
SARS	B-PRGE
CoV	I-PRGE
and	O
human	O
coronavirus	O
(	O
HCoV	O
)	O
229E	O
replications	O
by	O
reducing	O
the	O
viral	O
titer	O
by	O
4	O
.	O
7	O
log	O
(	O
at	O
5	O
microM	O
)	O
for	O
SARS	B-PRGE
CoV	I-PRGE
and	O
5	O
.	O
2	O
log	O
(	O
at	O
1	O
.	O
25	O
microM	O
)	O
for	O
HCoV	O
229E	O
.	O

In	O
this	O
study	O
,	O
potential	O
HLA	B-PRGE
-	I-PRGE
A	I-PRGE
*	I-PRGE
0201	I-PRGE
-	O
restricted	O
spike	O
(	O
S	O
)	O
and	O
nucleocapsid	B-PRGE
protein	I-PRGE
-	I-PRGE
derived	I-PRGE
peptides	I-PRGE
were	O
selected	O
from	O
an	O
online	O
database	O
and	O
screened	O
for	O
potential	O
CTL	O
epitopes	O
by	O
in	O
vitro	O
refolding	O
and	O
T2	O
cell	O
-	O
stabilization	O
assays	O
.	O

Furthermore	O
,	O
significant	O
P15	O
-	O
specific	O
CTLs	O
were	O
induced	O
from	O
HLA	B-PRGE
-	O
A2	O
.	O
1	O
-	O
transgenic	O
mice	O
immunized	O
by	O
a	O
DNA	O
vaccine	O
encoding	O
the	O
S	B-PRGE
protein	I-PRGE
;	O
suggesting	O
that	O
P15	B-PRGE
was	O
a	O
naturally	O
processed	O
epitope	O
.	O

Our	O
study	O
objectives	O
were	O
to	O
determine	O
the	O
optimal	O
extraction	O
method	O
for	O
SARS	O
CoV	O
RNA	O
detection	O
and	O
to	O
examine	O
the	O
effect	O
of	O
increased	O
specimen	O
volume	O
for	O
the	O
detection	O
of	O
SARS	B-PRGE
CoV	I-PRGE
RNA	I-PRGE
in	O
stool	O
specimens	O
.	O

Among	O
50	O
randomly	O
picked	O
clones	O
,	O
12	O
Fabs	O
specially	O
reacted	O
with	O
S	B-PRGE
protein	I-PRGE
by	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

The	O
microneutralizing	O
test	O
showed	O
that	O
one	O
clone	O
,	O
designated	O
M1A	O
,	O
had	O
neutralizing	O
activity	O
on	O
Vero	O
E6	O
cells	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
DNA	O
sequence	O
analysis	O
indicated	O
that	O
the	O
light	O
-	O
and	O
heavy	O
-	O
chain	O
genes	O
of	O
M1A	B-PRGE
Fab	I-PRGE
belong	O
to	O
the	O
kappa2a	B-PRGE
and	I-PRGE
4f	I-PRGE
families	I-PRGE
,	O
respectively	O
.	O

Our	O
experiments	O
showed	O
that	O
recombinant	B-PRGE
3a	I-PRGE
protein	I-PRGE
can	O
form	O
a	O
homotetramer	O
complex	O
through	O
interprotein	O
disulfide	O
bridges	O
in	O
3a	O
-	O
cDNA	O
-	O
transfected	O
cells	O
,	O
providing	O
a	O
clue	O
to	O
ion	O
channel	O
function	O
.	O

Ten	O
consecutive	O
patients	O
(	O
seven	O
men	O
,	O
mean	O
age	O
64	O
+/-	O
12years	O
,	O
mean	O
SAPS	B-PRGE
II	I-PRGE
26	I-PRGE
+/-	I-PRGE
6	I-PRGE
)	O
with	O
definite	O
diagnosis	O
of	O
WNV	O
related	O
meningoencephalitis	O
and	O
variable	O
proportion	O
of	O
organ	O
/	O
system	O
failure	O
.	O

In	O
this	O
study	O
the	O
full	O
length	O
codon	O
optimized	O
NP	B-PRGE
gene	I-PRGE
and	O
its	O
subfragment	O
gene	O
segment	O
was	O
cloned	O
in	O
a	O
bacterial	O
expression	O
vector	O
.	O

TITLE	O
:	O
Induction	O
of	O
transcription	O
factor	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
gene	I-PRGE
expression	O
in	O
astrocytoma	O
cells	O
by	O
Murine	O
coronavirus	O
infection	O
.	O

Furthermore	O
,	O
knockdown	O
of	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
by	O
an	O
siRNA	O
inhibited	O
MHV	O
propagation	O
,	O
suggesting	O
the	O
biological	O
relevance	O
of	O
Egr	B-PRGE
-	I-PRGE
1	I-PRGE
induction	O
to	O
virus	O
replication	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
nsp1	B-PRGE
protein	I-PRGE
suppresses	O
host	O
gene	O
expression	O
by	O
promoting	O
host	O
mRNA	O
degradation	O
.	O

As	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
murine	B-PRGE
ACE2	I-PRGE
is	O
used	O
less	O
efficiently	O
by	O
NL63	O
-	O
S	O
for	O
entry	O
than	O
human	O
ACE2	O
.	O

In	O
this	O
study	O
,	O
several	O
monoclonal	O
antibodies	O
against	O
the	O
nucleocapsid	B-PRGE
protein	I-PRGE
have	O
been	O
generated	O
to	O
examine	O
distribution	O
of	O
the	O
nucleocapsid	O
in	O
virus	O
-	O
infected	O
cells	O
and	O
to	O
study	O
antigenic	O
regions	O
of	O
the	O
protein	O
.	O

Genomes	O
in	O
which	O
the	O
MHV	B-PRGE
5	I-PRGE
'	I-PRGE
UTR	I-PRGE
SL1	I-PRGE
,	O
SL2	B-PRGE
,	O
and	O
SL4	O
were	O
individually	O
replaced	O
by	O
their	O
SCoV	O
counterparts	O
were	O
viable	O
.	O

A	O
chimera	O
containing	O
the	O
SCoV	B-PRGE
5	I-PRGE
'	I-PRGE
UTR	I-PRGE
in	O
which	O
the	O
SCoV	O
TRS	O
was	O
replaced	O
with	O
the	O
MHV	O
TRS	O
was	O
also	O
not	O
viable	O
.	O

Finally	O
,	O
we	O
performed	O
a	O
challenge	O
study	O
with	O
Cal99	O
and	O
demonstrated	O
that	O
the	O
virus	O
causes	O
late	O
-	O
onset	O
respiratory	O
disease	O
,	O
with	O
a	O
severity	O
comparable	O
to	O
that	O
of	O
the	O
M41	B-PRGE
IBV	I-PRGE
challenge	O
strain	O
.	O

However	O
,	O
only	O
seven	O
of	O
these	O
(	O
group	O
1	O
)	O
had	O
sera	O
which	O
also	O
reacted	O
with	O
the	O
native	O
N	B-PRGE
antigen	I-PRGE
expressed	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
Vero	O
cells	O
,	O
N	O
-	O
transfected	O
293T	O
cells	O
,	O
and	O
tissues	O
of	O
infected	O
SARS	O
patients	O
.	O

The	O
N	B-PRGE
antigen	I-PRGE
is	O
thus	O
highly	O
unique	O
.	O

Particularly	O
,	O
it	O
induces	O
GRP78	B-PRGE
/	I-PRGE
94	I-PRGE
through	O
PKR	B-PRGE
-	I-PRGE
like	I-PRGE
ER	I-PRGE
kinase	I-PRGE
but	O
has	O
no	O
influence	O
on	O
activating	B-PRGE
transcription	I-PRGE
factor	I-PRGE
6	I-PRGE
or	I-PRGE
X	I-PRGE
box	I-PRGE
-	I-PRGE
binding	I-PRGE
protein	I-PRGE
1	I-PRGE
.	O

In	O
the	O
lungs	O
,	O
expression	O
of	O
the	O
epithelial	O
sodium	O
channel	O
was	O
lower	O
,	O
and	O
NKCC1	B-PRGE
expression	O
was	O
upregulated	O
.	O

A	O
specific	O
amplification	O
was	O
also	O
observed	O
with	O
the	O
human	B-PRGE
coronaviruses	I-PRGE
(	O
HCoV	O
)	O
HCoV	O
-	O
NL63	O
,	O
HCoV	O
-	O
OC43	O
,	O
HCoV	O
-	O
229E	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

In	O
the	O
construction	O
of	O
both	O
nuclear	O
and	O
plastid	O
transformation	O
vectors	O
,	O
a	O
2	O
-	O
kilobase	O
nucleotide	O
sequence	O
encoding	O
amino	O
acids	O
1	O
-	O
658	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
(	O
S1	O
)	O
was	O
modified	O
with	O
nucleotide	O
changes	O
,	O
but	O
not	O
amino	O
acid	O
changes	O
,	O
to	O
optimize	O
codon	O
usage	O
for	O
expression	O
in	O
plants	O
.	O

Furthermore	O
,	O
when	O
the	O
virus	O
was	O
inoculated	O
into	O
SPF	B-PRGE
chickens	I-PRGE
,	O
pancreatitis	O
developed	O
.	O

We	O
show	O
that	O
the	O
80R	B-PRGE
-	I-PRGE
binding	I-PRGE
epitope	I-PRGE
on	O
the	O
S1	O
RBD	O
overlaps	O
very	O
closely	O
with	O
the	O
ACE2	B-PRGE
-	I-PRGE
binding	I-PRGE
site	I-PRGE
,	O
providing	O
a	O
rationale	O
for	O
the	O
strong	O
binding	O
and	O
broad	O
neutralizing	O
ability	O
of	O
the	O
antibody	O
.	O

TITLE	O
:	O
Cooperative	O
involvement	O
of	O
the	O
S1	O
and	O
S2	O
subunits	O
of	O
the	O
murine	B-PRGE
coronavirus	I-PRGE
spike	I-PRGE
protein	I-PRGE
in	O
receptor	O
binding	O
and	O
extended	O
host	O
range	O
.	O

However	O
,	O
when	O
the	O
mutations	O
in	O
both	O
parts	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
were	O
combined	O
,	O
the	O
resulting	O
viruses	O
became	O
independent	O
of	O
CEACAM1a	O
and	O
acquired	O
the	O
extended	O
host	O
range	O
.	O

These	O
microclots	O
can	O
be	O
safely	O
lysed	O
by	O
a	O
plasminogen	B-PRGE
activator	I-PRGE
,	O
thus	O
treating	O
ARDS	O
and	O
saving	O
lives	O
.	O

Interestingly	O
,	O
our	O
patient	O
was	O
asymptomatically	O
anti	O
-	O
Ro	O
/	O
SS	O
-	O
A	O
positive	O
at	O
the	O
onset	O
of	O
TEN	B-PRGE
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
the	O
induction	O
of	O
necrosis	O
by	O
a	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
protein	I-PRGE
.	O

The	O
nucleotide	O
sequence	O
encoding	O
the	O
entire	O
N	B-PRGE
gene	I-PRGE
open	O
reading	O
frame	O
(	O
ORF	O
)	O
of	O
LJB	O
/	O
03	O
was	O
1326	O
bases	O
long	O
and	O
encoded	O
a	O
protein	O
of	O
441	O
amino	O
acids	O
with	O
predicted	O
Mr	O
of	O
49	O
kDa	O
.	O

Purified	O
N	B-PRGE
protein	I-PRGE
enhanced	O
hammerhead	O
ribozyme	O
self	O
-	O
cleavage	O
and	O
nucleic	O
acids	O
annealing	O
,	O
which	O
are	O
properties	O
that	O
define	O
RNA	O
chaperones	O
.	O

In	O
contrast	O
,	O
another	O
RNA	B-PRGE
-	I-PRGE
binding	I-PRGE
protein	I-PRGE
,	O
PTB	B-PRGE
,	O
did	O
not	O
show	O
these	O
activities	O
.	O

Using	O
molecular	O
modeling	O
,	O
we	O
show	O
that	O
the	O
SCoV	B-PRGE
spike	I-PRGE
protein	I-PRGE
TMD	I-PRGE
adopts	O
a	O
distinct	O
and	O
unique	O
structure	O
as	O
opposed	O
to	O
all	O
other	O
coronaviruses	O
.	O

We	O
investigated	O
whether	O
genetically	O
determined	O
differences	O
in	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
(	O
TNF	B-PRGE
)-	O
alpha	O
production	O
can	O
influence	O
the	O
severity	O
of	O
Hantavirus	O
disease	O
.	O

We	O
studied	O
a	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
single	I-PRGE
-	I-PRGE
nucleotide	I-PRGE
promoter	I-PRGE
polymorphism	I-PRGE
(	I-PRGE
SNP	I-PRGE
)	I-PRGE
at	O
position	O
-	O
238	O
(	O
a	O
guanine	O
[	O
G	O
]-	O
to	O
-	O
adenine	O
[	O
A	O
]	O
transition	O
)	O
and	O
ex	O
vivo	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
production	O
in	O
a	O
recall	O
study	O
of	O
36	O
Belgian	O
patients	O
who	O
had	O
a	O
serologically	O
proven	O
form	O
of	O
Puumala	O
virus	O
-	O
induced	O
Hantavirus	O
infection	O
with	O
the	O
kidney	O
as	O
main	O
target	O
organ	O
.	O

Like	O
other	O
nidoviruses	O
with	O
large	O
genomes	O
(>	O
26	O
kb	O
),	O
WBV	O
encodes	O
in	O
its	O
ORF1b	O
an	O
extensive	O
set	O
of	O
enzymes	O
,	O
including	O
putative	O
polymerase	B-PRGE
,	I-PRGE
helicase	I-PRGE
,	I-PRGE
ribose	I-PRGE
methyltransferase	I-PRGE
,	O
exoribonuclease	O
,	O
and	O
endoribonuclease	O
activities	O
.	O

Ninety	O
-	O
one	O
IBV	O
isolates	O
were	O
characterized	O
by	O
phylogenetic	O
analysis	O
of	O
the	O
S1	B-PRGE
gene	I-PRGE
hypervariable	O
region	O
comprising	O
136	O
to	O
558	O
nucleotides	O
.	O

TITLE	O
:	O
Infectious	O
bronchitis	O
virus	O
:	O
S1	B-PRGE
gene	I-PRGE
characteristics	O
of	O
vaccines	O
used	O
in	O
China	O
and	O
efficacy	O
of	O
vaccination	O
against	O
heterologous	O
strains	O
from	O
China	O
.	O

hUbc9	B-PRGE
,	O
a	O
ubiquitin	B-PRGE
conjugating	O
enzyme	O
of	O
sumoylation	O
system	O
,	O
was	O
found	O
to	O
interact	O
specifically	O
with	O
the	O
N	B-PRGE
protein	I-PRGE
,	O
implying	O
the	O
post	O
-	O
translational	O
sumoylation	O
of	O
the	O
N	B-PRGE
protein	I-PRGE
.	O

Mutations	O
of	O
hUbc9	B-PRGE
at	O
the	O
enzyme	O
active	O
site	O
C93A	O
or	O
C93S	O
severely	O
impair	O
the	O
interaction	O
with	O
the	O
N	B-PRGE
protein	I-PRGE
.	O

Since	O
N	B-PRGE
protein	I-PRGE
oligomerization	O
is	O
usually	O
a	O
crucial	O
step	O
in	O
this	O
process	O
,	O
characterization	O
of	O
such	O
an	O
oligomerization	O
will	O
help	O
in	O
the	O
understanding	O
of	O
the	O
possible	O
mechanisms	O
for	O
nucleocapsid	O
formation	O
.	O

The	O
fact	O
that	O
nucleic	O
acid	O
binding	O
could	O
promote	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
protein	I-PRGE
C	I-PRGE
-	I-PRGE
terminus	I-PRGE
to	O
form	O
high	O
-	O
order	O
oligomers	O
implies	O
that	O
the	O
oligomeric	O
SARS	O
-	O
CoV	O
N	O
protein	O
probably	O
combines	O
with	O
the	O
viral	O
genomic	O
RNA	O
in	O
triggering	O
long	O
nucleocapsid	O
formation	O
.	O

CONCLUSIONS	O
:	O
Heat	O
,	O
UVC	O
irradiation	O
,	O
and	O
S	O
/	O
D	O
treatments	O
effectively	O
inactivate	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
whereas	O
octanoic	O
acid	O
treatment	O
is	O
insufficient	O
for	O
inactivation	O
of	O
the	O
virus	O
.	O

The	O
alphaSIP	O
molecule	O
consisted	O
of	O
a	O
single	O
chain	O
antibody	O
(	O
scFv	O
)	O
specific	O
for	O
the	O
porcine	O
coronavirus	O
,	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
linked	O
to	O
the	O
alpha	B-PRGE
-	I-PRGE
CH3	I-PRGE
domain	I-PRGE
from	O
human	B-PRGE
IgA	I-PRGE
.	O
To	O
express	O
the	O
full	O
-	O
length	O
IgA	B-PRGE
,	O
the	O
individual	O
light	O
and	O
heavy	O
chains	O
from	O
the	O
TGEV	O
-	O
specific	O
mAb	O
6A	O
.	O
C3	O
were	O
inserted	O
into	O
separate	O
PVX	O
constructs	O
and	O
plants	O
were	O
co	O
-	O
infected	O
with	O
both	O
constructs	O
.	O

Western	O
blot	O
analysis	O
revealed	O
the	O
efficient	O
expression	O
of	O
both	O
the	O
SIP	B-PRGE
and	O
IgA	B-PRGE
molecules	O
.	O

Intradermal	O
administration	O
of	O
RVV	O
-	O
S	O
into	O
rabbits	O
induced	O
neutralizing	O
(	O
NT	O
)	O
antibodies	O
against	O
SARS	O
-	O
CoV	O
1	O
week	O
after	O
administration	O
and	O
the	O
NT	O
titer	O
reached	O
1	O
:	O
1000	O
after	O
boost	O
immunization	O
with	O
RVV	O
-	O
S	O
.	O
Significantly	O
,	O
NT	O
antibodies	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
were	O
induced	O
by	O
administration	O
of	O
RVV	O
-	O
S	O
to	O
rabbits	O
that	O
had	O
been	O
pre	O
-	O
immunized	O
with	O
LC16m8	O
.	O

However	O
,	O
the	O
process	O
of	O
adaptive	O
evolution	O
of	O
S	B-PRGE
protein	I-PRGE
and	O
the	O
exact	O
positively	O
selected	O
sites	O
associated	O
with	O
this	O
process	O
remain	O
unknown	O
.	O

Particularly	O
noteworthy	O
,	O
the	O
serine	O
to	O
alanine	O
mutation	O
resides	O
in	O
the	O
region	O
of	O
the	O
major	O
antigenic	O
site	O
A	O
/	O
B	O
(	O
aa	O
506	O
-	O
706	O
)	O
that	O
elicits	O
neutralizing	O
antibodies	O
and	O
within	O
the	O
domain	O
mediating	O
the	O
cell	O
surface	B-PRGE
receptor	I-PRGE
aminopeptidase	I-PRGE
N	I-PRGE
binding	O
(	O
aa	O
522	O
-	O
744	O
).	O

Recent	O
studies	O
have	O
suggested	O
a	O
remote	O
effect	O
of	O
ARF	B-PRGE
on	O
pulmonary	O
homeostasis	O
.	O

Using	O
the	O
enhanced	B-PRGE
green	I-PRGE
fluorescent	I-PRGE
protein	I-PRGE
(	O
EGFP	O
),	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
envelope	O
protein	O
(	O
SCVme	O
),	O
and	O
core	O
streptavidin	O
(	O
cSA	B-PRGE
)	O
of	O
Streptomyces	O
avidinii	O
as	O
model	O
proteins	O
,	O
specific	O
immobilization	O
of	O
the	O
GBP	B-PRGE
-	I-PRGE
fusion	I-PRGE
proteins	I-PRGE
onto	O
the	O
gold	O
nanoparticles	O
and	O
generation	O
of	O
protein	O
nanopatterns	O
on	O
the	O
bare	O
gold	O
surface	O
were	O
demonstrated	O
.	O

Currently	O
,	O
concern	O
of	O
H5N1	B-PRGE
flu	I-PRGE
transmission	O
from	O
migratory	O
bird	O
populations	O
has	O
increased	O
with	O
foci	O
of	O
fatal	O
human	O
cases	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
uses	O
dendritic	O
cell	O
-	O
specific	O
ICAM	B-PRGE
-	I-PRGE
3	I-PRGE
grabbing	I-PRGE
nonintegrin	I-PRGE
(	O
DC	B-PRGE
-	I-PRGE
SIGN	I-PRGE
)	O
to	O
facilitate	O
cell	O
entry	O
via	O
cellular	O
receptor	O
-	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
.	O

Our	O
results	O
identified	O
the	O
region	O
location	O
between	O
amino	O
acid	O
(	O
aa	O
)	O
residues	O
324	O
to	O
386	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
.	O

These	O
animals	O
developed	O
a	O
less	O
robust	O
type	B-PRGE
I	I-PRGE
interferon	I-PRGE
response	O
to	O
MHV	O
-	O
1	O
infection	O
than	O
resistant	O
C57BL	O
/	O
6J	O
mice	O
,	O
and	O
treatment	O
with	O
recombinant	B-PRGE
beta	I-PRGE
interferon	I-PRGE
improved	O
survival	O
.	O

In	O
parallel	O
,	O
liver	O
histology	O
,	O
virus	O
titers	O
,	O
and	O
plasma	O
alanine	B-PRGE
aminotransferase	I-PRGE
(	O
ALT	B-PRGE
)	O
activity	O
were	O
monitored	O
.	O

Serum	O
IgG	B-PRGE
blocked	O
binding	O
of	O
the	O
S	B-PRGE
-	I-PRGE
protein	I-PRGE
to	O
the	O
ACE2	B-PRGE
receptor	I-PRGE
and	O
neutralized	O
SARS	B-PRGE
-	O
CoV	O
infection	O
in	O
vitro	O
.	O

Entry	O
into	O
human	O
B	O
cell	O
lines	O
occurred	O
in	O
a	O
FcgammaRII	O
-	O
dependent	O
and	O
ACE2	B-PRGE
-	O
independent	O
fashion	O
indicating	O
that	O
ADE	O
of	O
virus	O
entry	O
is	O
a	O
novel	O
cell	O
entry	O
mechanism	O
of	O
SARS	O
-	O
CoV	O
.	O
Vaccinated	O
animals	O
showed	O
no	O
signs	O
of	O
enhanced	O
lung	O
pathology	O
or	O
hepatitis	O
and	O
viral	O
load	O
was	O
undetectable	O
or	O
greatly	O
reduced	O
in	O
lungs	O
following	O
challenge	O
with	O
SARS	O
-	O
CoV	O
.	O
Altogether	O
our	O
results	O
indicate	O
that	O
a	O
recombinant	B-PRGE
trimeric	I-PRGE
S	I-PRGE
protein	I-PRGE
was	O
able	O
to	O
elicit	O
an	O
efficacious	O
protective	O
immune	O
response	O
in	O
vivo	O
and	O
warrant	O
concern	O
in	O
the	O
safety	O
evaluation	O
of	O
a	O
human	O
vaccine	O
against	O
SARS	O
-	O
CoV	O
.	O

The	O
serum	O
levels	O
of	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	O
inducible	O
protein	O
-	O
10	O
(	O
IP	O
-	O
10	O
),	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
were	O
significantly	O
elevated	O
during	O
SARS	O
infection	O
.	O

In	O
patients	O
with	O
CAP	O
,	O
but	O
not	O
in	O
those	O
with	O
SARS	O
,	O
the	O
levels	O
of	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
IL	O
-	O
8	O
and	O
monokine	B-PRGE
induced	I-PRGE
by	I-PRGE
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
(	O
MIG	B-PRGE
)	O
were	O
significantly	O
elevated	O
compared	O
with	O
the	O
levels	O
in	O
healthy	O
controls	O
.	O

RESULTS	O
:	O
The	O
serum	O
levels	O
of	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	O
inducible	O
protein	O
-	O
10	O
(	O
IP	O
-	O
10	O
),	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
were	O
significantly	O
elevated	O
during	O
SARS	O
infection	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
responsible	O
for	O
viral	O
binding	O
with	O
ACE2	B-PRGE
molecules	I-PRGE
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
fragment	O
450	O
-	O
650	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
(	O
S450	O
-	O
650	O
)	O
is	O
predominantly	O
recognized	O
by	O
convalescent	O
sera	O
of	O
SARS	O
patients	O
.	O

Unlike	O
patient	O
sera	O
,	O
however	O
,	O
the	O
mouse	O
antisera	O
were	O
unable	O
to	O
inhibit	O
the	O
infectivity	O
of	O
S	B-PRGE
protein	I-PRGE
-	O
expressing	O
(	O
SARS	O
-	O
CoV	O
-	O
S	O
)	O
pseudovirus	O
.	O

Phylogenetic	O
analyses	O
performed	O
on	O
both	O
replicase	B-PRGE
gene	I-PRGE
and	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
could	O
not	O
add	O
support	O
to	O
a	O
close	O
relationship	O
between	O
avian	O
and	O
SARS	O
coronaviruses	O
,	O
but	O
all	O
the	O
novel	O
avian	O
coronaviruses	O
were	O
found	O
to	O
harbour	O
s2m	O
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
of	O
human	B-PRGE
coronavirus	I-PRGE
strain	I-PRGE
OC43	I-PRGE
(	O
HCoV	O
-	O
OC43	O
)	O
was	O
amplified	O
by	O
reverse	B-PRGE
transcriptase	I-PRGE
-	O
polymerase	O
chain	O
reaction	O
,	O
and	O
cloned	O
in	O
pENTR	O
/	O
D	O
-	O
TOPO	O
plasmid	O
.	O

Thus	O
,	O
although	O
the	O
character	O
of	O
the	O
response	O
to	O
the	O
two	O
epitopes	O
appeared	O
to	O
be	O
different	O
(	O
private	O
and	O
diverse	O
vs	O
public	O
and	O
dominated	O
by	O
a	O
few	O
clonotypes	O
),	O
similar	O
numbers	O
of	O
precursor	O
cells	O
responded	O
to	O
both	O
epitopes	O
and	O
this	O
number	O
was	O
of	O
similar	O
magnitude	O
to	O
that	O
previously	O
reported	O
for	O
other	O
viral	B-PRGE
CD8	I-PRGE
T	I-PRGE
cell	I-PRGE
epitopes	I-PRGE
.	O

CBP	B-PRGE
was	O
effective	O
in	O
treatment	O
of	O
pediatric	O
septic	O
shock	O
by	O
improving	O
the	O
oxygenation	O
,	O
correcting	O
metabolic	O
acidosis	O
,	O
stabilizing	O
BP	O
,	O
increasing	O
the	O
tissue	O
perfusion	O
and	O
eliminating	O
the	O
medium	O
molecule	O
substances	O
.	O

CONCLUSIONS	O
:	O
CBP	B-PRGE
was	O
effective	O
in	O
treatment	O
of	O
pediatric	O
septic	O
shock	O
by	O
improving	O
the	O
oxygenation	O
,	O
correcting	O
metabolic	O
acidosis	O
,	O
stabilizing	O
BP	O
,	O
increasing	O
the	O
tissue	O
perfusion	O
and	O
eliminating	O
the	O
medium	O
molecule	O
substances	O
.	O

The	O
MPO	B-PRGE
activity	O
in	O
the	O
P	O
group	O
was	O
greatly	O
increased	O
over	O
that	O
of	O
the	O
C	O
group	O
.	O

TITLE	O
:	O
Receptor	O
-	O
binding	O
domain	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
induces	O
long	O
-	O
term	O
protective	O
immunity	O
in	O
an	O
animal	O
model	O
.	O

In	O
contrast	O
,	O
high	O
copies	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
and	O
virus	O
replication	O
were	O
detected	O
,	O
and	O
pathological	O
changes	O
were	O
observed	O
in	O
the	O
lung	O
tissues	O
of	O
the	O
control	O
mice	O
.	O

Based	O
on	O
this	O
integrated	O
assay	O
platform	O
,	O
8	O
new	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
inhibitors	O
were	O
discovered	O
.	O

We	O
developed	O
transgenic	O
mice	O
expressing	O
human	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
,	O
a	O
functional	O
receptor	O
for	O
the	O
virus	O
,	O
under	O
the	O
regulation	O
of	O
a	O
global	O
promoter	O
.	O

All	O
three	O
proteins	O
inhibit	O
the	O
expression	O
of	O
beta	B-PRGE
interferon	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
beta	I-PRGE
),	O
and	O
further	O
examination	O
revealed	O
that	O
these	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
proteins	I-PRGE
inhibit	O
a	O
key	O
protein	O
necessary	O
for	O
the	O
expression	O
of	O
IFN	B-PRGE
-	I-PRGE
beta	I-PRGE
,	O
IRF	B-PRGE
-	I-PRGE
3	I-PRGE
.	O

N	B-PRGE
protein	I-PRGE
dramatically	O
inhibited	O
expression	O
from	O
an	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
-	I-PRGE
responsive	I-PRGE
promoter	I-PRGE
.	O

ORF	O
6	O
protein	O
,	O
but	O
not	O
ORF	O
3b	O
or	O
N	O
protein	O
,	O
inhibited	O
nuclear	O
translocation	O
but	O
not	O
phosphorylation	O
of	O
STAT1	B-PRGE
.	O

Therefore	O
,	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
that	O
lacks	O
the	O
E	B-PRGE
gene	I-PRGE
is	O
attenuated	O
in	O
hamsters	O
,	O
might	O
be	O
a	O
safer	O
research	O
tool	O
,	O
and	O
may	O
be	O
a	O
good	O
candidate	O
for	O
the	O
development	O
of	O
a	O
live	O
attenuated	O
SARS	O
-	O
CoV	O
vaccine	O
.	O

Fifty	O
-	O
six	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
-	I-PRGE
gene	I-PRGE
sequences	I-PRGE
,	O
obtained	O
from	O
patients	O
who	O
presented	O
with	O
SARS	O
to	O
the	O
Prince	O
of	O
Wales	O
Hospital	O
during	O
March	O
-	O
May	O
2003	O
,	O
were	O
analysed	O
using	O
a	O
maximum	O
likelihood	O
(	O
ML	O
)	O
approach	O
,	O
together	O
with	O
138	O
other	O
(	O
both	O
human	O
and	O
animal	O
)	O
S	O
-	O
gene	O
sequences	O
downloaded	O
from	O
GenBank	O
.	O

100	O
,	O
000	O
SQ	O
-	O
U	O
/	O
ml	O
of	O
Der	O
p	O
extract	O
contains	O
9	O
.	O
8	O
microg	O
/	O
ml	O
of	O
the	O
majoy	B-PRGE
allergen	I-PRGE
Der	I-PRGE
p1	I-PRGE
).	O

TITLE	O
:	O
Palmitoylation	O
of	O
the	O
cysteine	O
-	O
rich	O
endodomain	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
coronavirus	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
is	O
important	O
for	O
spike	O
-	O
mediated	O
cell	O
fusion	O
.	O

hMPV	O
infection	O
was	O
excluded	O
by	O
nested	O
RT	O
-	O
PCR	O
using	O
primers	O
for	O
F	B-PRGE
-	I-PRGE
gene	I-PRGE
.	O

TITLE	O
:	O
Inhibition	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
gene	I-PRGE
expression	O
by	O
adenovirus	O
-	O
delivered	O
small	O
hairpin	O
RNA	O
.	O

Here	O
,	O
we	O
demonstrated	O
that	O
,	O
among	O
five	O
accessory	O
proteins	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
tested	O
,	O
3a	O
/	O
X1	O
and	O
7a	O
/	O
X4	O
were	O
capable	O
of	O
activating	B-PRGE
nuclear	I-PRGE
factor	I-PRGE
kappa	I-PRGE
B	I-PRGE
(	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
)	O
and	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
N	I-PRGE
-	I-PRGE
terminal	I-PRGE
kinase	I-PRGE
(	O
JNK	B-PRGE
),	O
and	O
significantly	O
enhanced	O
interleukin	B-PRGE
8	I-PRGE
(	O
IL	O
-	O
8	O
)	O
promoter	O
activity	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
extend	O
our	O
understanding	O
of	O
the	O
functional	O
role	O
of	O
CXCL10	B-PRGE
in	O
response	O
to	O
MHV	O
infection	O
given	O
that	O
CXCL10	B-PRGE
signaling	O
has	O
been	O
implicated	O
in	O
coordinating	O
both	O
effector	O
T	O
cell	O
generation	O
and	O
trafficking	O
.	O

We	O
show	O
that	O
MHV	O
infection	O
of	O
CXCL10	O
(+/+)	O
or	O
CXCL10	O
(-/-)	O
mice	O
results	O
in	O
comparable	O
levels	O
of	O
T	O
cell	O
activation	O
and	O
similar	O
numbers	O
of	O
virus	O
-	O
specific	O
CD4	B-PRGE
+	I-PRGE
and	O
CD8	B-PRGE
+	I-PRGE
T	O
cells	O
.	O

TITLE	O
:	O
SARS	B-PRGE
CoV	I-PRGE
main	I-PRGE
proteinase	I-PRGE
:	O
The	O
monomer	O
-	O
dimer	O
equilibrium	O
dissociation	O
constant	O
.	O

ABSTRACT	O
:	O
The	O
SARS	B-PRGE
coronavirus	I-PRGE
main	I-PRGE
proteinase	I-PRGE
(	O
SARS	B-PRGE
CoV	I-PRGE
main	I-PRGE
proteinase	I-PRGE
)	O
is	O
required	O
for	O
the	O
replication	O
of	O
the	O
severe	B-PRGE
acute	I-PRGE
respiratory	I-PRGE
syndrome	I-PRGE
coronavirus	I-PRGE
(	O
SARS	O
CoV	O
),	O
the	O
virus	O
that	O
causes	O
SARS	O
.	O

TITLE	O
:	O
Anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
activity	O
of	O
nucleoside	O
analogs	O
having	O
6	O
-	O
chloropurine	O
as	O
a	O
nucleobase	O
.	O

The	O
HI	O
test	O
results	O
indicated	O
that	O
the	O
exposure	O
of	O
some	O
of	O
these	O
flocks	O
were	O
to	O
Ark	B-PRGE
,	O
DE	O
-	O
072	O
,	O
and	O
Mass	O
like	O
serotypes	O
.	O

First	O
,	O
the	O
receptor	O
of	O
HCoV	O
229E	O
,	O
human	B-PRGE
aminopeptidase	I-PRGE
N	I-PRGE
(	O
hAPN	O
or	O
CD13	B-PRGE
)	O
is	O
expressed	O
mainly	O
on	O
human	O
dendritic	O
cells	O
(	O
DCs	O
)	O
and	O
macrophages	O
indicating	O
that	O
targeting	O
of	O
HCoV	O
229E	O
-	O
based	O
vectors	O
to	O
professional	O
antigen	O
presenting	O
cells	O
can	O
be	O
achieved	O
by	O
receptor	O
-	O
mediated	O
transduction	O
.	O

All	O
of	O
the	O
results	O
suggested	O
that	O
DIP	B-PRGE
liposomes	I-PRGE
have	O
the	O
potential	O
efficacy	O
in	O
treating	O
ALI	O
/	O
ARDS	O
due	O
to	O
their	O
obvious	O
lung	O
targeting	O
.	O

Due	O
to	O
the	O
lack	O
of	O
potential	O
drugs	O
for	O
the	O
treatment	O
of	O
SARS	O
,	O
the	O
discovery	O
of	O
inhibitors	O
against	O
SARS	B-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
proteinase	I-PRGE
,	O
which	O
can	O
potentially	O
be	O
optimized	O
as	O
drugs	O
appears	O
to	O
be	O
highly	O
desirable	O
.	O

Molecular	O
evolution	O
studies	O
have	O
revealed	O
that	O
SARS	O
must	O
be	O
originated	O
from	O
wild	O
animals	O
,	O
and	O
it	O
was	O
demonstrated	O
that	O
the	O
major	O
genetic	O
variations	O
in	O
some	O
critical	O
genes	O
,	O
particularly	O
the	O
Spike	B-PRGE
gene	I-PRGE
,	O
was	O
essential	O
for	O
the	O
transition	O
from	O
animal	O
-	O
to	O
-	O
human	O
transmission	O
to	O
human	O
-	O
to	O
-	O
human	O
transmission	O
.	O

The	O
CoV	O
main	O
protease	O
(	O
M	O
(	O
pro	O
)),	O
which	O
plays	O
a	O
pivotal	O
role	O
in	O
viral	O
gene	O
expression	O
and	O
replication	O
through	O
a	O
highly	O
complex	O
cascade	O
involving	O
the	O
proteolytic	O
processing	O
of	O
replicase	B-PRGE
polyproteins	I-PRGE
,	O
is	O
an	O
attractive	O
target	O
for	O
drug	O
design	O
.	O

ABSTRACT	O
:	O
Small	B-PRGE
immunoproteins	I-PRGE
(	O
SIPs	O
)	O
are	O
single	O
-	O
chain	O
molecules	O
comprising	O
the	O
variable	O
regions	O
of	O
an	O
antibody	O
assembled	O
in	O
a	O
single	O
polypeptide	O
(	O
scFv	O
)	O
and	O
joined	O
to	O
the	O
immunoglobulin	B-PRGE
heavy	I-PRGE
-	I-PRGE
chain	I-PRGE
dimerizing	I-PRGE
domain	I-PRGE
.	O

We	O
have	O
now	O
constructed	O
an	O
E	O
knockout	O
mutant	O
that	O
confirms	O
that	O
the	O
highly	O
defective	O
phenotype	O
of	O
the	O
DeltaE	O
mutant	O
is	O
due	O
to	O
loss	O
of	O
the	O
E	B-PRGE
gene	I-PRGE
.	O

Additionally	O
,	O
we	O
have	O
created	O
substitution	O
mutants	O
in	O
which	O
the	O
MHV	B-PRGE
E	I-PRGE
gene	I-PRGE
was	O
replaced	O
by	O
heterologous	O
E	O
genes	O
from	O
viruses	O
spanning	O
all	O
three	O
groups	O
of	O
the	O
coronavirus	O
family	O
.	O

Using	O
Venezuelan	O
equine	O
encephalitis	O
virus	O
replicon	O
particles	O
(	O
VRP	B-PRGE
)	O
expressing	O
the	O
2003	O
epidemic	O
Urbani	O
SARS	O
-	O
CoV	O
strain	O
spike	O
(	O
S	O
)	O
glycoprotein	O
(	O
VRP	B-PRGE
-	I-PRGE
S	I-PRGE
)	O
or	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
from	O
the	O
same	O
strain	O
(	O
VRP	O
-	O
N	O
),	O
we	O
demonstrate	O
that	O
VRP	B-PRGE
-	I-PRGE
S	I-PRGE
,	O
but	O
not	O
VRP	O
-	O
N	O
vaccines	O
provide	O
complete	O
short	O
-	O
and	O
long	O
-	O
term	O
protection	O
against	O
homologous	O
strain	O
challenge	O
in	O
young	O
and	O
senescent	O
mice	O
.	O

TITLE	O
:	O
Development	O
and	O
validation	O
of	O
a	O
high	O
-	O
throughput	O
screen	O
for	O
inhibitors	O
of	O
SARS	B-PRGE
CoV	I-PRGE
and	O
its	O
application	O
in	O
screening	O
of	O
a	O
100	O
,	O
000	O
-	O
compound	O
library	O
.	O

TITLE	O
:	O
Characterization	O
of	O
the	O
nuclear	O
export	O
signal	O
in	O
the	O
coronavirus	O
infectious	O
bronchitis	B-PRGE
virus	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
.	O

These	O
positive	O
strand	O
RNA	O
viruses	O
encode	O
a	O
replicase	B-PRGE
polyprotein	O
that	O
is	O
processed	O
into	O
16	O
nonstructural	O
proteins	O
(	O
nsps	O
).	O

Surprisingly	O
,	O
IgA	B-PRGE
plasma	O
cells	O
infiltrate	O
inflamed	O
tissues	O
in	O
acute	O
Kawasaki	O
disease	O
,	O
including	O
the	O
coronary	O
artery	O
,	O
and	O
are	O
oligoclonal	O
,	O
or	O
antigen	O
-	O
driven	O
.	O

Synthetic	O
versions	O
of	O
predominant	O
IgA	B-PRGE
antibodies	I-PRGE
in	O
acute	O
Kawasaki	O
disease	O
arterial	O
tissue	O
bind	O
to	O
an	O
antigen	O
present	O
in	O
acute	O
Kawasaki	O
disease	O
ciliated	O
bronchial	O
epithelium	O
and	O
in	O
a	O
subset	O
of	O
macrophages	O
in	O
acute	O
inflamed	O
Kawasaki	O
disease	O
tissues	O
.	O

Light	O
and	O
electron	O
microscopic	O
studies	O
of	O
the	O
antigen	O
in	O
acute	O
Kawasaki	O
disease	O
ciliated	O
bronchial	O
epithelium	O
indicate	O
that	O
the	O
Kawasaki	B-PRGE
disease	I-PRGE
-	I-PRGE
associated	I-PRGE
antigen	I-PRGE
localizes	O
to	O
cytoplasmic	O
inclusion	O
bodies	O
that	O
are	O
consistent	O
with	O
aggregates	O
of	O
viral	B-PRGE
protein	I-PRGE
and	O
associated	O
nucleic	O
acid	O
.	O

All	O
serum	O
specimens	O
tested	O
negative	O
for	O
SARS	B-PRGE
antibody	I-PRGE
.	O

RESULTS	O
:	O
All	O
serum	O
specimens	O
tested	O
negative	O
for	O
SARS	B-PRGE
antibody	I-PRGE
.	O

This	O
result	O
suggests	O
that	O
not	O
only	O
E	O
.	O
R	O
.-	O
association	O
but	O
also	O
specific	O
protein	O
sequence	O
is	O
important	O
for	O
the	O
HCV	O
core	O
protein	O
signal	O
peptide	O
cleavage	O
by	O
SPP	B-PRGE
.	O

TITLE	O
:	O
Human	B-PRGE
coronavirus	I-PRGE
229E	I-PRGE
papain	I-PRGE
-	I-PRGE
like	I-PRGE
proteases	I-PRGE
have	O
overlapping	O
specificities	O
but	O
distinct	O
functions	O
in	O
viral	O
replication	O
.	O

Further	O
experiments	O
showed	O
that	O
both	O
PL1pro	O
and	O
PL2pro	O
were	O
able	O
to	O
cleave	O
the	O
nsp1	B-PRGE
-	I-PRGE
nsp2	I-PRGE
cleavage	O
site	O
,	O
with	O
PL2pro	O
cleaving	O
the	O
site	O
less	O
efficiently	O
.	O

TITLE	O
:	O
Exosomal	O
vaccines	O
containing	O
the	O
S	B-PRGE
protein	I-PRGE
of	O
the	O
SARS	O
coronavirus	O
induce	O
high	O
levels	O
of	O
neutralizing	O
antibodies	O
.	O

ABSTRACT	O
:	O
In	O
order	O
to	O
find	O
effective	O
peptide	O
inhibitors	O
against	O
SARS	B-PRGE
CoV	I-PRGE
M	I-PRGE
(	O
pro	B-PRGE
),	O
an	O
analysis	O
was	O
performed	O
for	O
11	O
oligo	O
-	O
peptides	O
that	O
can	O
be	O
cleaved	O
by	O
the	O
SARS	O
coronavirus	B-PRGE
main	I-PRGE
protease	I-PRGE
(	O
CoV	O
M	O
(	O
pro	O
),	O
or	O
3CL	O
(	O
pro	O
)).	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
shown	O
that	O
the	O
nucleocapsid	O
protein	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
activated	O
cyclooxygenase	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
COX	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
expression	O
.	O

PKC	B-PRGE
epsilon	I-PRGE
-	I-PRGE
specific	I-PRGE
siRNA	I-PRGE
also	O
attenuated	O
the	O
phosphorylation	O
of	O
JNK	B-PRGE
.	O

ABSTRACT	O
:	O
To	O
assess	O
the	O
therapeutic	O
effect	O
of	O
Caspase	B-PRGE
-	I-PRGE
1	I-PRGE
inhibitors	O
(	O
ICE	B-PRGE
-	I-PRGE
I	I-PRGE
)	O
on	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
in	O
experimental	O
severe	O
acute	O
pancreatitis	O
(	O
SAP	O
).	O

Intrapulmonary	O
expression	O
of	O
Caspase	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
18	I-PRGE
mRNA	I-PRGE
were	O
detected	O
by	O
semi	O
-	O
quantitative	O
RT	O
-	O
PCR	O
.	O

Intrapulmonary	O
expression	O
of	O
Caspase	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
18	I-PRGE
mRNA	I-PRGE
were	O
observed	O
in	O
the	O
HC	O
group	O
,	O
while	O
they	O
were	O
increased	O
significantly	O
in	O
the	O
SAP	B-PRGE
-	I-PRGE
S	I-PRGE
group	O
(	O
P	O
<	O
0	O
.	O
01	O
,	O
vs	O
HC	O
).	O

Preliminary	O
data	O
suggest	O
that	O
such	O
differential	O
signalling	O
involves	O
p38	B-PRGE
MAP	B-PRGE
kinase	I-PRGE
rather	O
than	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
.	O
SARS	O
coronavirus	O
infection	O
of	O
primary	O
human	O
macrophages	O
is	O
associated	O
with	O
a	O
strong	O
induction	O
of	O
chemokines	O
without	O
an	O
associated	O
type	O
1	O
interferon	O
response	O
.	O

TITLE	O
:	O
[	O
Expression	O
of	O
predicted	O
B	O
cell	O
epitope	O
peptide	O
in	O
S2	O
subunit	O
of	O
SARS	B-PRGE
coronavirus	I-PRGE
spike	I-PRGE
protein	I-PRGE
in	O
E	O
.	O
coli	O
and	O
identification	O
of	O
its	O
mimic	O
antigenicity	O
].	O

The	O
predicted	O
B	O
cell	O
epitope	O
peptide	O
of	O
SARS	O
coronavirus	O
S2	O
spike	O
protein	O
can	O
induce	O
the	O
antigenicity	O
of	O
S2	B-PRGE
protein	I-PRGE
,	O
which	O
provides	O
some	O
fundamental	O
data	O
for	O
developing	O
engineering	O
vaccine	O
against	O
SARS	O
coronavirus	O
infection	O
.	O

CONCLUSIONS	O
:	O
The	O
predicted	O
B	O
cell	O
epitope	O
peptide	O
of	O
SARS	O
coronavirus	O
S2	O
spike	O
protein	O
can	O
induce	O
the	O
antigenicity	O
of	O
S2	B-PRGE
protein	I-PRGE
,	O
which	O
provides	O
some	O
fundamental	O
data	O
for	O
developing	O
engineering	O
vaccine	O
against	O
SARS	O
coronavirus	O
infection	O
.	O

TITLE	O
:	O
Effective	O
inhibition	O
of	O
porcine	O
transmissible	O
gastroenteritis	O
virus	O
replication	O
in	O
ST	O
cells	O
by	O
shRNAs	O
targeting	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
gene	I-PRGE
.	O

The	O
nucleotide	O
and	O
amino	O
acid	O
sequence	O
of	O
the	O
S1	B-PRGE
gene	I-PRGE
had	O
a	O
similar	O
degree	O
of	O
identity	O
(	O
88	O
.	O
98	O
-	O
99	O
.	O
28	O
%)	O
among	O
the	O
four	O
Chinese	O
IBV	O
isolates	O
.	O

ABSTRACT	O
:	O
To	O
elucidate	O
the	O
potential	O
role	O
of	O
circulating	O
levels	O
of	O
transforming	B-PRGE
growth	I-PRGE
factor	I-PRGE
-	I-PRGE
beta1	I-PRGE
(	O
TGF	B-PRGE
-	I-PRGE
beta1	I-PRGE
),	O
soluble	O
intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
sICAM	O
-	O
1	O
),	O
soluble	O
L	O
-	O
and	O
sE	O
-	O
Selectins	O
(	O
sL	B-PRGE
-	I-PRGE
and	I-PRGE
sE	I-PRGE
-	I-PRGE
Selectins	I-PRGE
)	O
in	O
children	O
with	O
sepsis	O
,	O
traumatic	O
brain	O
injury	O
(	O
TBI	O
)	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

What	O
is	O
known	O
is	O
that	O
the	O
surface	B-PRGE
spike	I-PRGE
protein	I-PRGE
,	O
indeed	O
the	O
amino	O
-	O
terminal	O
S1	O
half	O
,	O
is	O
sufficient	O
to	O
induce	O
good	O
protective	O
immunity	O
.	O

Although	O
the	O
plasma	B-PRGE
albumin	I-PRGE
remained	O
significantly	O
elevated	O
at	O
4	O
h	O
in	O
both	O
series	O
,	O
no	O
sustained	O
improvement	O
in	O
oxygenation	O
was	O
seen	O
.	O

Western	O
blot	O
analysis	O
of	O
samples	O
from	O
Nicotiana	O
clevelandii	O
or	O
cowpea	O
tissue	O
infected	O
with	O
constructs	O
revealed	O
the	O
presence	O
of	O
SIP	B-PRGE
molecules	I-PRGE
which	O
retained	O
their	O
ability	O
to	O
dimerize	O
.	O

Oral	O
administration	O
of	O
crude	O
extracts	O
from	O
SIP	B-PRGE
-	O
expressing	O
plant	O
tissue	O
to	O
2	O
-	O
day	O
-	O
old	O
piglets	O
demonstrated	O
that	O
the	O
extracts	O
which	O
showed	O
the	O
highest	O
levels	O
of	O
in	O
vitro	O
neutralization	O
could	O
also	O
provide	O
in	O
vivo	O
protection	O
against	O
challenge	O
with	O
TGEV	O
.	O

TITLE	O
:	O
[	O
A	O
follow	O
up	O
study	O
of	O
total	O
IgM	B-PRGE
,	O
IgG	B-PRGE
,	O
nucleoprotein	O
and	O
spike	O
protein	O
antibodies	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
in	O
patients	O
with	O
SARS	O
].	O

Then	O
,	O
the	O
positive	O
rate	O
of	O
IgM	B-PRGE
went	O
down	O
gradually	O
to	O
8	O
.	O
2	O
%	O
(	O
6	O
/	O
73	O
)	O
until	O
550	O
days	O
after	O
the	O
onset	O
.	O

In	O
this	O
study	O
,	O
the	O
S	B-PRGE
glycoprotein	I-PRGE
genes	O
were	O
recovered	O
from	O
naturally	O
infected	O
civets	O
in	O
central	O
China	O
(	O
Hubei	O
province	O
),	O
extending	O
the	O
geographic	O
distribution	O
of	O
civet	O
-	O
CoV	O
beyond	O
the	O
southeastern	O
province	O
of	O
Guangdong	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
inducible	O
nitric	B-PRGE
oxide	I-PRGE
synthase	I-PRGE
attenuates	O
acute	O
endotoxin	O
-	O
induced	O
lung	O
injury	O
in	O
rats	O
.	O

It	O
is	O
clear	O
that	O
other	O
regions	O
within	O
the	O
tail	O
must	O
also	O
be	O
involved	O
in	O
helping	O
mediate	O
interactions	O
between	O
the	O
M	B-PRGE
protein	I-PRGE
and	O
the	O
nucleocapsid	O
.	O

ABSTRACT	O
:	O
The	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
(	O
S	O
)	O
is	O
the	O
main	O
target	O
of	O
the	O
protective	O
immune	O
response	O
in	O
humans	O
and	O
animal	O
models	O
of	O
SARS	O
.	O

We	O
report	O
a	O
patient	O
with	O
life	O
-	O
threatening	O
melioidosis	O
who	O
developed	O
rapid	O
progression	O
of	O
bacteremic	O
pneumonia	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
septic	O
shock	O
and	O
multiple	O
organ	O
dysfunction	O
and	O
was	O
successfully	O
treated	O
with	O
recombinant	B-PRGE
human	I-PRGE
activated	I-PRGE
protein	I-PRGE
C	I-PRGE
(	O
rhAPC	O
)	O
and	O
meropenem	O
.	O

Among	O
these	O
analogues	O
,	O
two	O
compounds	O
,	O
namely	O
,	O
1	O
and	O
11	O
,	O
exhibited	O
promising	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
activity	O
that	O
was	O
comparable	O
to	O
those	O
of	O
mizoribine	O
and	O
ribavirin	O
,	O
which	O
are	O
known	O
anti	O
-	O
SARS	O
-	O
CoV	O
agents	O
.	O

TITLE	O
:	O
Serum	B-PRGE
alpha1	I-PRGE
-	I-PRGE
acid	I-PRGE
glycoprotein	I-PRGE
(	O
AGP	B-PRGE
)	O
concentration	O
in	O
non	O
-	O
symptomatic	O
cats	O
with	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
infection	O
.	O

ABSTRACT	O
:	O
Analysis	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SCoV	O
)	O
by	O
either	O
sucrose	O
gradient	O
equilibrium	O
centrifugation	O
or	O
a	O
virus	O
capture	O
assay	O
using	O
an	O
anti	B-PRGE
-	I-PRGE
SCoV	I-PRGE
S	I-PRGE
protein	I-PRGE
antibody	I-PRGE
demonstrated	O
that	O
the	O
SCoV	B-PRGE
6	I-PRGE
protein	I-PRGE
,	O
which	O
is	O
one	O
of	O
the	O
accessory	O
proteins	O
of	O
SCoV	O
,	O
was	O
incorporated	O
into	O
virus	O
particles	O
.	O

The	O
epidemic	O
was	O
halted	O
in	O
2003	O
by	O
a	O
highly	O
effective	O
global	O
public	O
health	O
response	O
,	O
and	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
is	O
currently	O
not	O
circulating	O
in	O
humans	O
.	O

A	O
consensus	O
secondary	O
structural	O
model	O
of	O
the	O
5	O
'	O
140	O
nucleotides	O
of	O
the	O
5	O
'	O
UTRs	O
of	O
nine	O
coronaviruses	O
(	O
CoVs	O
)	O
derived	O
from	O
all	O
three	O
major	O
CoV	O
groups	O
is	O
presented	O
and	O
characterized	O
by	O
three	O
major	O
stem	O
-	O
loops	O
,	O
SL1	B-PRGE
,	O
SL2	B-PRGE
,	O
and	O
SL4	O
.	O

SL2	B-PRGE
is	O
required	O
for	O
MHV	O
replication	O
;	O
MHV	O
genomes	O
containing	O
point	O
substitutions	O
predicted	O
to	O
perturb	O
the	O
SL2	B-PRGE
structure	O
(	O
U48C	O
,	O
U48A	O
)	O
were	O
not	O
viable	O
,	O
while	O
those	O
that	O
maintain	O
the	O
structure	O
(	O
U48G	O
and	O
U49A	O
)	O
were	O
viable	O
.	O

Examples	O
of	O
CBAs	O
include	O
the	O
procaryotic	O
cyanovirin	O
-	O
N	O
(	O
CV	O
-	O
N	O
),	O
plant	O
lectins	O
such	O
as	O
HHA	O
,	O
GNA	O
,	O
NPA	O
,	O
CA	O
and	O
UDA	O
,	O
the	O
monoclonal	O
antibody	O
2G12	O
directed	O
against	O
a	O
glycan	O
-	O
containing	O
epitope	O
on	O
HIV	B-PRGE
envelope	I-PRGE
gp120	I-PRGE
,	O
and	O
the	O
mannose	O
-	O
specific	O
non	O
-	O
peptidic	O
antibiotic	O
Pradimicin	O
A	O
,	O
which	O
inhibits	O
the	O
entry	O
of	O
HIV	O
-	O
1	O
into	O
its	O
target	O
cells	O
.	O

Quantitative	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
and	O
Western	O
blot	O
analysis	O
demonstrated	O
that	O
cyclin	B-PRGE
D1	I-PRGE
was	O
reduced	O
post	O
-	O
transcriptionally	O
within	O
infected	O
cells	O
independently	O
of	O
the	O
cell	O
-	O
cycle	O
stage	O
at	O
the	O
time	O
of	O
infection	O
.	O

In	O
this	O
study	O
,	O
phage	O
-	O
expressing	O
chicken	B-PRGE
monoclonal	I-PRGE
scFv	I-PRGE
antibody	I-PRGE
was	O
chosen	O
and	O
characterized	O
with	O
phage	O
display	O
antibody	O
technology	O
.	O

Using	O
these	O
bacteria	O
-	O
derived	O
proteins	O
to	O
immunize	O
chickens	O
,	O
it	O
was	O
found	O
that	O
polyclonal	B-PRGE
IgY	I-PRGE
antibodies	I-PRGE
in	O
the	O
egg	O
yolk	O
and	O
sera	O
were	O
highly	O
reactive	O
to	O
the	O
immunogens	O
,	O
as	O
shown	O
by	O
Western	O
blot	O
and	O
immunocytochemical	O
staining	O
analysis	O
.	O

Since	O
that	O
time	O
,	O
we	O
have	O
learnt	O
that	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
is	O
not	O
the	O
only	O
protein	O
that	O
inhibits	O
apoptosis	O
and	O
that	O
p53	B-PRGE
itself	O
is	O
frequently	O
malfunctioning	O
in	O
tumors	O
.	O

Specifically	O
,	O
the	O
unmethylated	O
CpG	O
ODN	O
(	O
and	O
/	O
or	O
the	O
phosphorothioate	O
group	O
)	O
activates	O
the	O
immune	O
system	O
,	O
but	O
this	O
potentially	O
important	O
anti	O
-	O
cancer	O
effect	O
is	O
lost	O
when	O
the	O
immune	O
cells	O
undergo	O
premature	O
apoptosis	O
apparently	O
because	O
their	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
levels	O
have	O
been	O
lowered	O
by	O
the	O
antisense	O
effect	O
of	O
G3139	O
.	O

A	O
consensus	O
sequence	O
of	O
the	O
jejunum	O
-	O
derived	O
genomic	O
RNA	O
(	O
FCoV	O
C1Je	O
)	O
was	O
determined	O
from	O
overlapping	O
cDNA	O
fragments	O
produced	O
by	O
reverse	B-PRGE
transcriptase	I-PRGE
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
amplification	O
.	O

Yet	O
Drak2	B-PRGE
-	O
/	O
-	O
mice	O
are	O
resistant	O
to	O
MOG	B-PRGE
-	O
induced	O
experimental	O
autoimmune	O
encephalomyelitis	O
(	O
EAE	O
),	O
suggesting	O
that	O
DRAK2	B-PRGE
may	O
influence	O
T	O
cell	O
trafficking	O
into	O
the	O
CNS	O
.	O

Based	O
on	O
the	O
X	O
-	O
ray	O
structures	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
receptor	I-PRGE
-	I-PRGE
binding	I-PRGE
domain	I-PRGE
(	O
RBD	O
)	O
in	O
complex	O
with	O
its	O
functional	O
receptor	O
(	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
,	O
ACE2	B-PRGE
),	O
we	O
perform	O
computational	O
simulations	O
of	O
interactions	O
between	O
three	O
representative	O
RBD	O
mutants	O
and	O
four	O
host	O
species	O
-	O
specific	O
receptors	O
.	O

Taken	O
together	O
,	O
these	O
results	O
indicated	O
that	O
nucleocapsid	B-PRGE
protein	I-PRGE
may	O
be	O
a	O
useful	O
antigen	O
for	O
the	O
sera	O
-	O
diagnosis	O
of	O
PEDV	O
and	O
it	O
was	O
also	O
suggested	O
that	O
the	O
ELISA	O
is	O
a	O
highly	O
sensitive	O
and	O
specific	O
test	O
for	O
detecting	O
antibodies	O
to	O
PEDV	O
.	O

Our	O
previous	O
studies	O
using	O
nuclear	O
magnetic	O
resonance	O
revealed	O
the	O
domain	O
organization	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
.	O

TITLE	O
:	O
Murine	O
hepatitis	B-PRGE
virus	I-PRGE
replicase	I-PRGE
protein	I-PRGE
nsp10	I-PRGE
is	O
a	O
critical	O
regulator	O
of	O
viral	O
RNA	O
synthesis	O
.	O

The	O
identification	O
of	O
the	O
replicase	B-PRGE
products	I-PRGE
and	O
characterization	O
of	O
HCoV	B-PRGE
-	I-PRGE
NL63	I-PRGE
PLP	I-PRGE
DUB	I-PRGE
activity	O
will	O
facilitate	O
comparative	O
studies	O
of	O
CoV	O
proteases	O
and	O
aid	O
in	O
the	O
development	O
of	O
novel	O
antiviral	O
reagents	O
directed	O
against	O
human	O
pathogens	O
such	O
as	O
HCoV	O
-	O
NL63	O
and	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O

This	O
enzyme	O
is	O
an	O
attractive	O
target	O
since	O
it	O
is	O
essential	O
for	O
viral	O
replication	O
,	O
and	O
since	O
there	O
are	O
now	O
a	O
number	O
of	O
high	O
resolution	O
X	O
-	O
ray	O
structures	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CLpro	I-PRGE
available	O
making	O
structure	O
-	O
based	O
drug	O
-	O
design	O
possible	O
.	O

RESULTS	O
:	O
Positive	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
specific	I-PRGE
IgG	I-PRGE
antibody	I-PRGE
was	O
found	O
25	O
.	O
61	O
%	O
(	O
n	O
=	O
328	O
),	O
13	O
.	O
03	O
%	O
(	O
n	O
=	O
238	O
),	O
12	O
.	O
59	O
%	O
(	O
n	O
=	O
135	O
),	O
5	O
.	O
04	O
%	O
(	O
n	O
=	O
139	O
)	O
and	O
9	O
.	O
43	O
%	O
(	O
n	O
=	O
53	O
)	O
among	O
volunteers	O
,	O
which	O
were	O
sampled	O
in	O
May	O
2003	O
,	O
Dec	O
.	O
2003	O
,	O
Jan	O
.	O
2004	O
,	O
July	O
2004	O
and	O
June	O
2005	O
respectively	O
.	O

The	O
human	O
diphtheria	O
toxin	O
(	O
DT	O
)	O
receptor	O
(	O
DTR	B-PRGE
),	O
heparin	O
-	O
binding	O
epidermal	B-PRGE
growth	I-PRGE
factor	I-PRGE
-	I-PRGE
like	I-PRGE
growth	I-PRGE
factor	I-PRGE
(	O
HB	B-PRGE
-	I-PRGE
EGF	I-PRGE
),	O
was	O
expressed	O
under	O
the	O
control	O
of	O
the	O
lysozyme	B-PRGE
M	I-PRGE
(	O
LysM	B-PRGE
)	O
gene	O
promoter	O
in	O
the	O
mice	O
.	O

Compared	O
with	O
the	O
mice	O
in	O
which	O
both	O
AE2	O
cells	O
and	O
macrophages	O
were	O
deleted	O
by	O
DT	O
administration	O
,	O
the	O
DT	O
-	O
treated	O
LysM	B-PRGE
-	I-PRGE
DTR	I-PRGE
mice	O
with	O
DT	O
-	O
resistant	O
macrophages	O
showed	O
less	O
severe	O
lung	O
injury	O
with	O
a	O
reduced	O
amount	O
of	O
hepatocyte	B-PRGE
growth	I-PRGE
factor	I-PRGE
in	O
bronchoalveolar	O
lavage	O
fluid	O
.	O

In	O
this	O
study	O
,	O
proteome	O
analysis	O
of	O
the	O
human	O
promonocyte	O
HL	O
-	O
CZ	O
cells	O
expressing	O
SARS	B-PRGE
CoV	I-PRGE
3CLpro	I-PRGE
was	O
performed	O
using	O
2	O
-	O
DE	O
and	O
nanoscale	O
capillary	O
LC	O
/	O
ESI	O
quadrupole	O
-	O
TOF	O
MS	O
.	O

Functional	O
classification	O
of	O
identified	O
up	O
-	O
regulated	O
proteins	O
indicated	O
that	O
protein	O
metabolism	O
and	O
modification	O
,	O
particularly	O
in	O
the	O
ubiquitin	B-PRGE
proteasome	O
pathway	O
,	O
was	O
the	O
main	O
biological	O
process	O
occurring	O
in	O
SARS	B-PRGE
CoV	I-PRGE
3CLpro	I-PRGE
-	O
expressing	O
cells	O
.	O

Interestingly	O
,	O
heat	B-PRGE
shock	I-PRGE
cognate	I-PRGE
71	I-PRGE
-	I-PRGE
kDa	I-PRGE
protein	I-PRGE
(	O
HSP70	B-PRGE
),	O
which	O
antagonizes	O
apoptosis	O
-	O
inducing	O
factor	O
was	O
shown	O
to	O
down	O
-	O
regulate	O
and	O
had	O
a	O
5	O
.	O
29	O
-	O
fold	O
decrease	O
.	O

Here	O
we	O
expressed	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
-	I-PRGE
protein	I-PRGE
to	O
investigate	O
its	O
interactions	O
with	O
innate	O
immune	O
mechanisms	O
in	O
the	O
lung	O
.	O

The	O
purified	O
S	B-PRGE
-	I-PRGE
protein	I-PRGE
bound	O
to	O
Vero	O
but	O
not	O
293T	O
cells	O
and	O
was	O
itself	O
recognized	O
by	O
lung	B-PRGE
surfactant	I-PRGE
protein	I-PRGE
D	I-PRGE
(	O
SP	B-PRGE
-	I-PRGE
D	I-PRGE
),	O
a	O
collectin	O
found	O
in	O
the	O
lung	O
alveoli	O
.	O

The	O
serum	B-PRGE
collectin	I-PRGE
,	O
mannan	B-PRGE
-	I-PRGE
binding	I-PRGE
lectin	I-PRGE
(	O
MBL	B-PRGE
),	O
exhibited	O
no	O
detectable	O
binding	O
to	O
the	O
purified	B-PRGE
S	I-PRGE
-	I-PRGE
protein	I-PRGE
.	O

S	B-PRGE
-	I-PRGE
protein	I-PRGE
binds	O
and	O
activates	O
macrophages	O
but	O
not	O
dendritic	O
cells	O
(	O
DCs	O
).	O

It	O
suggests	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
interacts	O
with	O
innate	O
immune	O
mechanisms	O
in	O
the	O
lung	O
through	O
its	O
S	O
-	O
protein	O
and	O
regulates	O
pulmonary	O
inflammation	O
.	O

TITLE	O
:	O
G1	O
phase	O
cell	O
cycle	O
arrest	O
induced	O
by	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3a	I-PRGE
protein	I-PRGE
via	O
the	O
cyclin	B-PRGE
D3	I-PRGE
/	O
pRb	B-PRGE
pathway	O
.	O

Increases	O
in	O
p53	B-PRGE
phosphorylation	O
on	O
Ser	O
-	O
15	O
were	O
observed	O
in	O
both	O
SARS	O
-	O
CoV	O
M	O
and	O
3a	O
transfected	O
cells	O
,	O
suggesting	O
that	O
it	O
might	O
not	O
correlate	O
with	O
the	O
3a	O
-	O
induced	O
G0	O
/	O
G1	O
phase	O
arrest	O
.	O

Treatment	O
includes	O
starting	O
neuraminidase	B-PRGE
inhibitor	O
oseltamivir	O
as	O
early	O
as	O
possible	O
in	O
addition	O
to	O
the	O
standard	O
supportive	O
management	O
.	O

TITLE	O
:	O
Neutrophil	O
-	O
derived	O
S100A12	B-PRGE
in	O
acute	O
lung	O
injury	O
and	O
respiratory	O
distress	O
syndrome	O
.	O

We	O
analyzed	O
the	O
expression	O
of	O
neutrophil	O
-	O
derived	O
S100A12	B-PRGE
and	O
the	O
proinflammatory	O
receptor	O
for	O
advanced	O
glycation	O
end	O
products	O
(	O
RAGE	O
)	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

The	O
expression	O
of	O
S100A12	B-PRGE
and	O
RAGE	O
in	O
lung	O
biopsies	O
from	O
patients	O
was	O
analyzed	O
by	O
immunohistochemistry	O
.	O

Effects	O
of	O
S100A12	B-PRGE
on	O
endothelial	O
cells	O
were	O
analyzed	O
in	O
vitro	O
.	O

Diabetic	O
liver	O
lesions	O
include	O
glycogenic	O
hepatopathy	O
(	O
in	O
which	O
poor	O
diabetic	O
control	O
leads	O
to	O
swollen	O
,	O
glycogen	O
-	O
filled	O
hepatocytes	O
without	O
fat	O
,	O
steatohepatitis	O
or	O
fibrosis	O
)	O
and	O
diabetic	O
hepatosclerosis	O
in	O
which	O
there	O
is	O
diffuse	O
perisinusoidal	O
fibrosis	O
(	O
type	B-PRGE
IV	I-PRGE
collagen	I-PRGE
)	O
without	O
zonal	O
predilection	O
.	O

We	O
have	O
recently	O
obtained	O
evidence	O
that	O
one	O
or	O
more	O
of	O
the	O
15	O
proteins	O
encoded	O
by	O
gene	B-PRGE
1	I-PRGE
are	O
also	O
determinants	O
of	O
pathogenicity	O
.	O

TITLE	O
:	O
Cell	O
cycle	O
dependent	O
nucleolar	O
localization	O
of	O
the	O
coronavirus	B-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
.	O

Cell	O
synchronisation	O
studies	O
coupled	O
to	O
live	O
cell	O
confocal	O
microscopy	O
indicated	O
that	O
nucleolar	O
localisation	O
of	O
N	B-PRGE
protein	I-PRGE
was	O
greater	O
in	O
the	O
G2	O
/	O
M	O
phase	O
of	O
the	O
cell	O
cycle	O
than	O
at	O
other	O
stages	O
.	O

The	O
strongest	O
anti	O
-	O
coronavirus	O
activity	O
was	O
found	O
predominantly	O
among	O
the	O
mannose	B-PRGE
-	I-PRGE
binding	I-PRGE
lectins	I-PRGE
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
the	O
overexpression	O
of	O
Bcl	B-PRGE
-	I-PRGE
XL	I-PRGE
,	O
a	O
prosurvival	O
member	O
of	O
the	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
family	I-PRGE
,	O
blocks	O
7a	O
-	O
induced	O
apoptosis	O
,	O
suggesting	O
that	O
the	O
mechanism	O
for	O
apoptosis	O
induction	O
by	O
7a	O
is	O
at	O
the	O
level	O
of	O
or	O
upstream	O
from	O
the	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
family	I-PRGE
.	O

A	O
good	O
correlation	O
between	O
the	O
abilities	O
of	O
7a	O
deletion	O
mutants	O
to	O
induce	O
apoptosis	O
and	O
to	O
interact	O
with	O
Bcl	B-PRGE
-	I-PRGE
XL	I-PRGE
was	O
observed	O
,	O
suggesting	O
that	O
7a	O
triggers	O
apoptosis	O
by	O
interfering	O
directly	O
with	O
the	O
prosurvival	O
function	O
of	O
Bcl	B-PRGE
-	I-PRGE
XL	I-PRGE
.	O

Interestingly	O
,	O
amino	O
acids	O
224	O
and	O
225	O
within	O
the	O
C	O
-	O
terminal	O
transmembrane	O
domain	O
of	O
Bcl	B-PRGE
-	I-PRGE
XL	I-PRGE
are	O
essential	O
for	O
the	O
interaction	O
with	O
the	O
7a	B-PRGE
protein	I-PRGE
,	O
although	O
the	O
BH3	B-PRGE
domain	I-PRGE
of	O
Bcl	B-PRGE
-	I-PRGE
XL	I-PRGE
also	O
contributes	O
to	O
this	O
interaction	O
.	O

To	O
characterize	O
the	O
S1	B-PRGE
protein	I-PRGE
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
from	O
China	O
,	O
five	O
representative	O
nephropathogenic	O
IB	O
viruses	O
isolated	O
from	O
chickens	O
in	O
different	O
provinces	O
were	O
genetically	O
and	O
phylogenetically	O
analyzed	O
.	O

TITLE	O
:	O
[	O
Immunogenicity	O
of	O
S1	B-PRGE
gene	I-PRGE
DNA	O
vaccine	O
of	O
mouse	O
hepatitis	O
virus	O
delivered	O
by	O
attenuated	O
Salmonella	O
typhimurium	O
].	O

The	O
expressed	O
S1	B-PRGE
protein	I-PRGE
was	O
successfully	O
detected	O
with	O
indirect	O
immunofluorescent	O
assay	O
.	O

The	O
N	O
-	O
terminal	O
part	O
of	O
the	O
9b	O
protein	O
was	O
used	O
to	O
raise	O
polyclonal	O
antibodies	O
in	O
rabbits	O
,	O
and	O
these	O
antibodies	O
could	O
detect	O
9b	B-PRGE
protein	I-PRGE
in	O
infected	O
cells	O
.	O

Overall	O
,	O
114	O
TCC	O
were	O
virus	O
-	O
specific	O
,	O
31	O
were	O
specific	O
for	O
myelin	B-PRGE
Ag	I-PRGE
and	O
10	O
other	O
were	O
HCoV	O
/	O
myelin	O
cross	O
-	O
reactive	O
.	O

Sequence	O
analysis	O
of	O
the	O
SARS	O
-	O
CoV	O
-	O
like	O
virus	O
in	O
masked	O
palm	O
civets	O
indicated	O
that	O
they	O
were	O
highly	O
homologous	O
to	O
human	B-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
with	O
nt	O
identity	O
over	O
99	O
.	O
6	O
%,	O
indicating	O
the	O
virus	O
has	O
not	O
been	O
circulating	O
in	O
the	O
population	O
of	O
masked	O
palm	O
civets	O
for	O
a	O
very	O
long	O
time	O
.	O

A	O
total	O
of	O
145	O
point	O
mutations	O
and	O
one	O
nucleotide	O
deletion	O
were	O
found	O
relative	O
to	O
the	O
BCoV	B-PRGE
ENT	I-PRGE
.	O

Most	O
of	O
the	O
ORFs	O
were	O
highly	O
conserved	O
;	O
however	O
,	O
the	O
predicted	O
spike	O
protein	O
(	O
S	O
)	O
has	O
9	O
and	O
12	O
amino	O
acid	O
differences	O
from	O
BCoV	B-PRGE
LUN	I-PRGE
and	O
ENT	B-PRGE
,	O
respectively	O
,	O
and	O
shows	O
a	O
higher	O
relative	O
number	O
of	O
changes	O
than	O
the	O
other	O
proteins	O
.	O

The	O
Bayesian	O
approach	O
demonstrated	O
that	O
when	O
the	O
pretest	O
probability	O
of	O
FIP	B-PRGE
is	O
high	O
,	O
based	O
on	O
history	O
and	O
clinical	O
signs	O
(	O
groups	O
1	O
or	O
2a	O
),	O
moderate	O
serum	O
AGP	O
levels	O
(	O
1	O
.	O
5	O
-	O
2	O
mg	O
/	O
ml	O
)	O
can	O
discriminate	O
cats	O
with	O
FIP	O
from	O
others	O
,	O
while	O
only	O
high	O
serum	O
AGP	O
levels	O
(>	O
3	O
mg	O
/	O
ml	O
)	O
can	O
support	O
a	O
diagnosis	O
of	O
FIP	O
in	O
cats	O
with	O
a	O
low	O
pretest	O
probability	O
of	O
disease	O
(	O
groups	O
2b	O
to	O
2e	O
).	O

TITLE	O
:	O
Inhibition	O
of	O
the	O
alpha	B-PRGE
/	I-PRGE
beta	I-PRGE
interferon	I-PRGE
response	O
by	O
mouse	O
hepatitis	O
virus	O
at	O
multiple	O
levels	O
.	O

These	O
findings	O
show	O
that	O
MHV	O
employs	O
unique	O
strategies	O
to	O
circumvent	O
the	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
/	I-PRGE
beta	I-PRGE
response	O
at	O
multiple	O
steps	O
.	O

ACE2	B-PRGE
is	O
now	O
implicated	O
in	O
cardiovascular	O
and	O
renal	O
(	O
patho	O
)	O
physiology	O
,	O
diabetes	O
,	O
pregnancy	O
,	O
lung	O
disease	O
and	O
,	O
remarkably	O
,	O
ACE2	B-PRGE
serves	O
as	O
a	O
receptor	O
for	O
SARS	O
and	O
NL63	O
coronaviruses	O
.	O

TITLE	O
:	O
A	O
fluorogenic	O
peptide	O
containing	O
the	O
processing	O
site	O
of	O
human	B-PRGE
SARS	I-PRGE
corona	I-PRGE
virus	I-PRGE
S	I-PRGE
-	I-PRGE
protein	I-PRGE
:	O
kinetic	O
evaluation	O
and	O
NMR	O
structure	O
elucidation	O
.	O

Following	O
cleavage	O
by	O
furin	B-PRGE
,	O
the	O
sheet	O
content	O
increased	O
,	O
possibly	O
at	O
the	O
expense	O
of	O
turn	O
and	O
random	O
structures	O
.	O

The	O
prognosis	O
of	O
anti	B-PRGE
-	I-PRGE
GBM	I-PRGE
glomerulonephritis	I-PRGE
depends	O
on	O
serum	O
creatinine	O
and	O
the	O
need	O
of	O
dialysis	O
at	O
initial	O
presentation	O
.	O

ABSTRACT	O
:	O
The	O
truncated	O
fragment	O
M	O
'	O
gene	O
,	O
encoding	O
the	O
exterior	O
of	O
the	O
viral	B-PRGE
envelope	I-PRGE
protein	I-PRGE
of	O
PEDV	O
,	O
was	O
subcloned	O
into	O
prokaryotic	O
expression	O
vector	O
pGEX	O
-	O
6p	O
-	O
1	O
.	O

We	O
conclude	O
that	O
SLVI	O
within	O
the	O
BCoV	B-PRGE
nsp1	I-PRGE
coding	I-PRGE
region	I-PRGE
is	O
a	O
higher	O
-	O
order	O
cis	O
-	O
replication	O
element	O
for	O
DI	B-PRGE
RNA	I-PRGE
and	O
postulate	O
that	O
it	O
functions	O
similarly	O
in	O
the	O
viral	O
genome	O
.	O

At	O
the	O
time	O
of	O
MHV	O
-	O
induced	O
host	O
translational	O
shutoff	O
,	O
downregulation	O
of	O
numerous	O
mRNAs	O
,	O
many	O
of	O
which	O
encode	O
protein	B-PRGE
translation	I-PRGE
-	I-PRGE
related	I-PRGE
factors	I-PRGE
,	O
was	O
observed	O
.	O

Results	O
showed	O
that	O
the	O
viral	B-PRGE
nucleocapsid	I-PRGE
(	I-PRGE
N	I-PRGE
)	I-PRGE
protein	I-PRGE
activated	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
expression	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

This	O
cell	O
cycle	O
arrest	O
was	O
catalyzed	O
by	O
the	O
modulation	O
of	O
various	O
cell	O
cycle	O
regulatory	O
genes	O
and	O
the	O
accumulation	O
of	O
hypophosphorylated	O
RB	O
,	O
but	O
was	O
independent	O
of	O
p53	B-PRGE
.	O

This	O
study	O
suggests	O
that	O
the	O
probability	O
of	O
transmission	O
of	O
SARS	B-PRGE
is	O
dependent	O
upon	O
characteristics	O
of	O
the	O
index	O
patients	O
and	O
does	O
not	O
simply	O
reflect	O
temporal	O
variability	O
in	O
the	O
viral	O
load	O
of	O
SARS	O
cases	O
.	O

Based	O
on	O
the	O
sequence	O
analysis	O
and	O
comparison	O
of	O
the	O
S1	B-PRGE
gene	I-PRGE
,	O
both	O
the	O
pathogenic	O
and	O
attenuated	O
CK	O
/	O
CH	O
/	O
LDL	O
/	O
97I	O
viruses	O
were	O
populations	O
that	O
each	O
included	O
at	O
least	O
two	O
subpopulations	O
.	O

A	O
fully	O
matured	O
S	B-PRGE
glycoprotein	I-PRGE
will	O
be	O
modified	O
with	O
complex	O
oligosaccharides	O
which	O
makes	O
it	O
resistant	O
to	O
cleavage	O
by	O
EndoH	O
but	O
not	O
by	O
N	O
-	O
Gly	O
F	O
.	O
By	O
exploiting	O
this	O
characteristic	O
,	O
it	O
is	O
then	O
possible	O
to	O
determine	O
which	O
forms	O
of	O
the	O
immunoprecipitated	O
S	B-PRGE
protein	I-PRGE
are	O
properly	O
processed	O
by	O
the	O
host	O
cell	O
.	O

Accordingly	O
,	O
many	O
pharmaceutical	O
inhibitors	O
have	O
been	O
developed	O
to	O
treat	O
several	O
pathologies	O
,	O
like	O
hypertension	O
and	O
heart	O
failure	O
,	O
and	O
angiotensin	B-PRGE
converting	I-PRGE
enzyme	I-PRGE
(	O
ACE	B-PRGE
)	O
became	O
one	O
of	O
the	O
major	O
target	O
in	O
the	O
treatment	O
of	O
these	O
cardiovascular	O
diseases	O
.	O

For	O
instance	O
,	O
ACE	B-PRGE
has	O
been	O
shown	O
to	O
work	O
not	O
only	O
by	O
generating	O
angiotensin	O
-	O
II	O
but	O
also	O
by	O
interacting	O
with	O
receptors	O
outside	O
the	O
renin	B-PRGE
-	O
angiotensin	O
system	O
.	O

The	O
ResPlex	O
II	O
assay	O
also	O
differentiated	O
RSV	B-PRGE
-	I-PRGE
A	I-PRGE
and	O
RSV	B-PRGE
-	I-PRGE
B	I-PRGE
and	O
gave	O
positive	O
results	O
for	O
RhV	O
and	O
EnV	O
in	O
31	O
(	O
8	O
.	O
6	O
%)	O
and	O
19	O
(	O
5	O
.	O
3	O
%)	O
specimens	O
,	O
respectively	O
.	O

Analysis	O
of	O
the	O
immunogenicity	O
of	O
the	O
UV	O
-	O
F	O
-	O
V	O
+	O
alum	O
vaccine	O
in	O
mice	O
revealed	O
that	O
it	O
generated	O
comparable	O
neutralizing	O
serum	B-PRGE
anti	I-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
IgG	I-PRGE
antibody	I-PRGE
levels	O
as	O
the	O
UV	O
-	O
V	O
+	O
alum	O
vaccine	O
.	O

Here	O
we	O
demonstrate	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
mainly	O
utilizes	O
the	O
clathrin	B-PRGE
-	O
mediated	O
endocytosis	O
pathway	O
for	O
its	O
entry	O
to	O
target	O
cells	O
by	O
using	O
infectious	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
as	O
well	O
as	O
a	O
SARS	O
-	O
CoV	O
pseudovirus	O
packaged	O
in	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
envelope	I-PRGE
.	O

We	O
hypothesized	O
that	O
platelet	B-PRGE
-	I-PRGE
activating	I-PRGE
factor	I-PRGE
(	O
PAF	B-PRGE
)	O
and	O
associated	O
downstream	O
signaling	O
pathways	O
play	O
a	O
role	O
in	O
the	O
PLY	O
-	O
induced	O
development	O
of	O
acute	O
lung	O
injury	O
.	O

TITLE	O
:	O
Trafficking	O
motifs	O
in	O
the	O
SARS	B-PRGE
-	I-PRGE
coronavirus	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
.	O

N	B-PRGE
protein	I-PRGE
predominately	O
localises	O
in	O
the	O
cytoplasm	O
(	O
the	O
site	O
of	O
virus	O
replication	O
and	O
assembly	O
)	O
but	O
also	O
in	O
the	O
nucleus	O
/	O
nucleolus	O
.	O

The	O
other	O
ORFs	O
encode	O
for	O
four	O
structural	O
proteins	O
(	O
spike	O
,	O
membrane	O
,	O
nucleocapsid	B-PRGE
and	I-PRGE
envelope	I-PRGE
)	O
as	O
well	O
as	O
eight	O
SARS	O
-	O
CoV	O
-	O
specific	O
accessory	O
proteins	O
(	O
3a	O
,	O
3b	O
,	O
6	O
,	O
7a	O
,	O
7b	O
,	O
8a	O
,	O
8b	O
and	O
9b	O
).	O

In	O
this	O
report	O
we	O
have	O
cloned	O
the	O
predicted	O
nsp8	B-PRGE
gene	I-PRGE
and	O
the	O
ORF6	B-PRGE
gene	I-PRGE
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
studied	O
their	O
abilities	O
to	O
interact	O
with	O
each	O
other	O
.	O

A	O
mammary	O
-	O
specific	O
expression	O
vector	O
pEBS	O
containing	O
the	O
full	O
-	O
length	O
cDNA	O
of	O
S	B-PRGE
gene	I-PRGE
was	O
constructed	O
and	O
expressed	O
in	O
the	O
mouse	O
mammary	O
cells	O
(	O
EMT6	O
).	O

Endocrine	O
pancreas	O
islets	O
were	O
unremarkable	O
and	O
contained	O
insulin	B-PRGE
-	O
positive	O
beta	O
cells	O
and	O
glucagon	B-PRGE
-	O
positive	O
alpha	O
cells	O
.	O

The	O
RdRp	O
domains	O
of	O
the	O
members	O
of	O
the	O
arterivirus	O
family	O
,	O
which	O
are	O
part	O
of	O
replicase	B-PRGE
subunit	I-PRGE
nsp9	I-PRGE
,	O
were	O
compared	O
to	O
coronavirus	O
RdRps	O
that	O
belong	O
to	O
the	O
same	O
order	O
of	O
Nidovirales	O
,	O
as	O
well	O
as	O
to	O
other	O
RdRps	O
with	O
known	O
initiation	O
mechanisms	O
and	O
three	O
-	O
dimensional	O
structures	O
.	O

TITLE	O
:	O
Interferon	B-PRGE
-	O
mediated	O
immunopathological	O
events	O
are	O
associated	O
with	O
atypical	O
innate	O
and	O
adaptive	O
immune	O
responses	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

One	O
area	O
of	O
strong	O
controversy	O
is	O
the	O
role	O
of	O
interferon	B-PRGE
(	O
IFN	B-PRGE
)	O
responses	O
in	O
the	O
natural	O
history	O
of	O
SARS	O
.	O

TITLE	O
:	O
The	O
association	O
of	O
RANTES	B-PRGE
polymorphism	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
in	O
Hong	O
Kong	O
and	O
Beijing	O
Chinese	O
.	O

RANTES	O
-	O
28	O
G	O
allele	O
was	O
associated	O
with	O
SARS	B-PRGE
susceptibility	I-PRGE
in	O
Hong	O
Kong	O
Chinese	O
(	O
P	O
<	O
0	O
.	O
0001	O
,	O
OR	O
=	O
2	O
.	O
80	O
,	O
95	O
%	O
CI	O
:	O
2	O
.	O
11	O
-	O
3	O
.	O
71	O
).	O

In	O
addition	O
,	O
emerging	O
evidence	O
suggests	O
that	O
the	O
use	O
of	O
anticoagulants	O
,	O
such	O
as	O
tissue	B-PRGE
factor	I-PRGE
pathway	I-PRGE
inhibitor	I-PRGE
,	O
antithrombin	B-PRGE
,	O
thrombomodulin	B-PRGE
,	O
heparin	O
,	O
activated	B-PRGE
protein	I-PRGE
C	I-PRGE
,	O
and	O
fibrinolytics	O
(	O
plasminogen	O
activators	O
and	O
particularly	O
tissue	B-PRGE
plasminogen	I-PRGE
activator	I-PRGE
),	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
ALI	O
and	O
ARDS	O
.	O

The	O
role	O
and	O
regulation	O
of	O
the	O
neprilysin	B-PRGE
(	O
NEP	O
)	O
family	O
of	O
metalloproteinases	O
is	O
highlighted	O
in	O
particular	O
in	O
the	O
context	O
of	O
proteolytic	O
events	O
underlying	O
the	O
pathology	O
of	O
Alzheimer	O
'	O
s	O
disease	O
.	O

The	O
antigen	O
target	O
in	O
Goodpasture	O
'	O
s	O
syndrome	O
is	O
type	O
IV	O
collagen	B-PRGE
,	O
the	O
major	O
component	O
of	O
basement	O
membranes	O
.	O

Soluble	B-PRGE
N18	I-PRGE
antibody	I-PRGE
was	O
expressed	O
in	O
Escherichia	O
coli	O
HB2151	O
,	O
purified	O
by	O
Ni	O
-	O
NTA	O
affinity	O
chromatography	O
and	O
verified	O
by	O
SDS	O
-	O
PAGE	O
and	O
Western	O
blot	O
.	O

Lastly	O
,	O
we	O
found	O
that	O
expression	O
of	O
the	O
SDF	B-PRGE
-	I-PRGE
1	I-PRGE
receptor	I-PRGE
CXCR4	I-PRGE
rises	O
in	O
a	O
similar	O
temporal	O
pattern	O
on	O
neutrophils	O
in	O
both	O
the	O
blood	O
and	O
airspace	O
of	O
LPS	O
-	O
injured	O
mice	O
and	O
that	O
Ab	O
-	O
mediated	O
SDF	O
-	O
1	O
blockade	O
significantly	O
attenuates	O
late	O
but	O
not	O
early	O
pulmonary	O
neutrophilia	O
in	O
this	O
model	O
.	O

Early	O
testing	O
for	O
anti	B-PRGE
-	I-PRGE
synthetase	I-PRGE
antibodies	I-PRGE
,	O
particularly	O
anti	O
-	O
Jo	O
-	O
1	O
,	O
and	O
creatine	B-PRGE
kinase	I-PRGE
determination	O
are	O
useful	O
procedures	O
in	O
patients	O
presenting	O
with	O
ILD	O
.	O

Plasmid	O
copy	O
numbers	O
are	O
also	O
increased	O
by	O
limiting	O
selective	O
MOB1	B-PRGE
and	O
CDC28	B-PRGE
gene	I-PRGE
expression	O
prior	O
to	O
induction	O
.	O

GST	B-PRGE
-	O
or	O
6His	O
-	O
tagged	O
proteins	O
are	O
produced	O
for	O
affinity	O
purification	O
and	O
are	O
expressed	O
from	O
a	O
conditional	O
GAL1	B-PRGE
-	I-PRGE
10	I-PRGE
promoter	I-PRGE
to	O
avoid	O
potentially	O
toxic	O
effects	O
of	O
recombinant	O
proteins	O
on	O
growth	O
.	O

No	O
significant	O
association	O
to	O
susceptibility	O
to	O
SARS	O
infection	O
caused	O
by	O
the	O
novel	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
was	O
found	O
for	O
the	O
FCER2	B-PRGE
and	O
the	O
ICAM3	B-PRGE
single	O
nucleotide	O
polymorphisms	O
.	O

Raised	O
serum	B-PRGE
albumin	I-PRGE
and	O
creatinine	O
phosphokinase	O
(	O
CPK	B-PRGE
)	O
levels	O
were	O
predictive	O
of	O
hospital	O
mortality	O
during	O
this	O
period	O
.	O

TITLE	O
:	O
Leptin	B-PRGE
treatment	O
ameliorates	O
acute	O
lung	O
injury	O
in	O
rats	O
with	O
cerulein	O
-	O
induced	O
acute	O
pancreatitis	O
.	O

Blood	O
samples	O
were	O
obtained	O
for	O
the	O
determination	O
of	O
amylase	B-PRGE
,	O
lipase	B-PRGE
,	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
(	O
TNF	O
)-	O
alpha	O
,	O
interleukin	B-PRGE
(	O
IL	O
)-	O
1beta	O
,	O
macrophage	O
inflammatory	O
peptide	O
(	O
MIP	O
)-	O
2	O
and	O
soluble	B-PRGE
intercellular	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
(	O
sICAM	O
)-	O
1	O
levels	O
,	O
while	O
pancreatic	O
and	O
lung	O
tissues	O
were	O
removed	O
for	O
myeloperoxidase	B-PRGE
(	O
MPO	B-PRGE
)	O
activity	O
,	O
nitric	O
oxide	O
(	O
NOx	O
)	O
level	O
,	O
CD40	B-PRGE
expression	O
and	O
histological	O
evaluation	O
.	O

These	O
findings	O
demonstrated	O
that	O
the	O
three	O
M	O
-	O
specific	O
siRNAs	O
were	O
able	O
to	O
specifically	O
and	O
effectively	O
inhibit	O
M	B-PRGE
glycoprotein	I-PRGE
expression	O
in	O
cultured	O
cells	O
by	O
blocking	O
the	O
accumulation	O
of	O
mRNA	O
,	O
which	O
provides	O
an	O
approach	O
for	O
studies	O
on	O
the	O
functions	O
of	O
M	B-PRGE
protein	I-PRGE
and	O
for	O
the	O
development	O
of	O
novel	O
prophylactic	O
or	O
therapeutic	O
agents	O
for	O
SCoV	O
infection	O
.	O

We	O
also	O
show	O
that	O
N	O
-	O
terminal	O
deletions	O
of	O
karyopherin	B-PRGE
alpha	I-PRGE
2	I-PRGE
that	O
no	O
longer	O
bind	O
to	O
karyopherin	B-PRGE
beta	I-PRGE
1	I-PRGE
still	O
retain	O
ORF6	O
binding	O
activity	O
but	O
no	O
longer	O
block	O
STAT1	B-PRGE
nuclear	O
import	O
.	O

ORF8a	O
was	O
found	O
to	O
be	O
localized	O
in	O
mitochondria	O
,	O
and	O
overexpression	O
resulted	O
in	O
increases	O
in	O
mitochondrial	O
transmembrane	O
potential	O
,	O
reactive	O
oxygen	O
species	O
production	O
,	O
caspase	B-PRGE
3	I-PRGE
activity	O
,	O
and	O
cellular	O
apoptosis	O
.	O

Using	O
the	O
GLLAMM	O
function	O
in	O
Stata	B-PRGE
9	I-PRGE
.	O
0	O
,	O
multilevel	O
regression	O
techniques	O
were	O
employed	O
to	O
investigate	O
associations	O
between	O
management	O
practices	O
and	O
the	O
risk	O
of	O
C	O
.	O
parvum	O
shedding	O
or	O
diarrhea	O
.	O

Hsp90	B-PRGE
inhibitors	O
may	O
offer	O
a	O
new	O
pharmacological	O
tool	O
in	O
the	O
management	O
of	O
severe	O
sepsis	O
and	O
severe	O
sepsis	O
-	O
induced	O
ALI	O
.	O

ABSTRACT	O
:	O
Apart	O
from	O
bat	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
we	O
have	O
identified	O
a	O
novel	O
group	O
1	O
coronavirus	O
,	O
bat	B-PRGE
-	I-PRGE
CoV	I-PRGE
HKU2	I-PRGE
,	O
in	O
Rhinolophus	O
sinicus	O
(	O
Chinese	O
horseshoe	O
bats	O
).	O

Instillation	O
of	O
MHV	O
-	O
CXCL10	O
into	O
the	O
CNS	O
of	O
CXCL10	B-PRGE
-	O
deficient	O
(	O
CXCL10	B-PRGE
(-/-))	O
mice	O
resulted	O
in	O
viral	O
infection	O
and	O
replication	O
in	O
both	O
brain	O
and	O
liver	O
.	O

challenge	O
with	O
the	O
PAMP	O
lipopolysaccharide	O
,	O
lipoteichoic	O
acid	O
(	O
LTA	O
),	O
and	O
Zymosan	O
-	O
A	O
(	O
containing	O
1	O
,	O
3	O
beta	O
-	O
glucan	O
)	O
on	O
primary	O
and	O
secondary	O
(	O
total	O
)	O
antibody	O
(	O
Ab	O
)	O
responses	O
and	O
(	O
isotype	O
)	O
IgM	B-PRGE
,	O
IgG	B-PRGE
,	O
and	O
IgA	B-PRGE
responses	O
to	O
systemically	O
administered	O
human	B-PRGE
serum	I-PRGE
albumin	I-PRGE
(	O
HuSA	O
),	O
and	O
Ab	O
titers	O
to	O
infectious	O
bursal	O
disease	O
(	O
Gumboro	O
virus	O
)	O
and	O
infectious	O
bronchitis	O
vaccines	O
in	O
layer	O
hens	O
at	O
9	O
and	O
22	O
wk	O
of	O
age	O
.	O

Several	O
ACE2	O
variants	O
that	O
reduced	O
SARS	B-PRGE
-	O
CoV	B-PRGE
S	I-PRGE
-	I-PRGE
protein	I-PRGE
association	O
similarly	O
reduced	O
that	O
of	O
HCoV	O
-	O
NL63	O
,	O
whereas	O
alteration	O
of	O
a	O
number	O
of	O
solvent	O
-	O
exposed	O
ACE2	O
residues	O
did	O
not	O
interfere	O
with	O
binding	O
by	O
either	O
S	B-PRGE
protein	I-PRGE
.	O

These	O
studies	O
indicate	O
that	O
HCoV	O
-	O
NL63	O
,	O
like	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
associates	O
region	O
of	O
human	O
ACE2	O
that	O
includes	O
a	O
key	O
loop	O
formed	O
by	O
beta	O
-	O
strands	O
4	O
and	O
5	O
.	O

An	O
(	O
R	B-PRGE
-	I-PRGE
Ahx	I-PRGE
-	I-PRGE
R	I-PRGE
)(	O
4	O
)	O
AhxB	O
-	O
PMO	O
conjugate	O
effectively	O
inhibited	O
viral	O
replication	O
,	O
in	O
comparison	O
with	O
other	O
peptides	O
conjugated	O
to	O
the	O
same	O
PMO	O
.	O

We	O
attribute	O
the	O
success	O
of	O
this	O
CPP	O
to	O
its	O
stability	O
in	O
serum	O
and	O
its	O
capacity	O
to	O
transport	O
PMO	O
to	O
RNA	O
targets	O
in	O
a	O
manner	O
superior	O
to	O
that	O
of	O
poly	B-PRGE
-	I-PRGE
arginine	I-PRGE
CPPs	I-PRGE
.	O

ABSTRACT	O
:	O
The	O
feasibility	O
of	O
developing	O
a	O
prophylactic	O
vaccine	O
against	O
SARS	O
was	O
assessed	O
by	O
comparing	O
the	O
immune	O
responses	O
elicited	O
by	O
immunizing	O
mice	O
with	O
a	O
recombinant	B-PRGE
SARS	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
(	O
S	B-PRGE
-	I-PRGE
protein	I-PRGE
)	O
formulated	O
with	O
different	O
adjuvants	O
,	O
given	O
by	O
different	O
routes	O
.	O

High	O
titer	O
antibody	O
was	O
detected	O
in	O
the	O
serum	O
of	O
immunized	O
Balb	O
/	O
c	O
mice	O
,	O
and	O
mice	O
immunized	O
with	O
S1	B-PRGE
protein	I-PRGE
produced	O
high	B-PRGE
titer	I-PRGE
IgG1	I-PRGE
,	O
IgG2a	B-PRGE
,	O
IgG2b	B-PRGE
and	O
IgG3	B-PRGE
,	O
while	O
those	O
immunized	O
with	O
S2	B-PRGE
protein	I-PRGE
produced	O
high	B-PRGE
titer	I-PRGE
IgG1	I-PRGE
,	O
IgG2a	B-PRGE
,	O
but	O
lower	O
titer	O
IgG2b	B-PRGE
and	O
IgG3	B-PRGE
.	O

Expression	O
of	O
a	O
construct	O
containing	O
ORF8a	B-PRGE
and	I-PRGE
ORF8b	I-PRGE
generated	O
only	O
a	O
single	O
protein	O
,	O
8a	O
;	O
no	O
8b	O
protein	O
expression	O
was	O
obtained	O
.	O

In	O
the	O
absence	O
of	O
the	O
8a	O
region	O
,	O
protein	O
8b	O
undergoes	O
rapid	O
degradation	O
by	O
proteasomes	O
,	O
and	O
addition	O
of	O
proteasome	O
inhibitors	O
inhibits	O
the	O
degradation	O
of	O
protein	B-PRGE
8b	I-PRGE
as	O
well	O
as	O
the	O
protein	O
8b	O
-	O
induced	O
rapid	O
degradation	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
E	O
protein	O
.	O

TITLE	O
:	O
Amino	O
acid	O
substitutions	O
in	O
the	O
s2	O
region	O
enhance	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
infectivity	O
in	O
rat	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
-	O
expressing	O
cells	O
.	O

Analyses	O
of	O
the	O
infectivity	O
of	O
the	O
pseudotype	B-PRGE
-	I-PRGE
bearing	I-PRGE
S	I-PRGE
protein	I-PRGE
indicated	O
that	O
the	O
two	O
substitutions	O
in	O
the	O
S2	O
region	O
,	O
especially	O
the	O
S950F	O
substitution	O
,	O
were	O
responsible	O
for	O
efficient	O
infection	O
.	O

Both	O
Western	O
blotting	O
and	O
ELISA	O
demonstrated	O
that	O
fACE2	B-PRGE
could	O
react	O
with	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S1	I-PRGE
protein	I-PRGE
as	O
efficiently	O
as	O
ACE2	B-PRGE
of	O
Vero	O
E6	O
cells	O
did	O
.	O

At	O
T0	O
,	O
a	O
severe	O
and	O
highly	O
significant	O
reduction	O
in	O
SP	B-PRGE
-	I-PRGE
A	I-PRGE
,	O
SP	B-PRGE
-	I-PRGE
B	I-PRGE
and	O
SP	B-PRGE
-	I-PRGE
C	I-PRGE
,	O
the	O
LA	O
fraction	O
,	O
PC	O
and	O
phosphatidylglycerol	O
(	O
PG	O
)	O
percentages	O
,	O
and	O
dipalmitoylation	O
of	O
PC	O
(	O
DPPC	O
)	O
was	O
encountered	O
.	O

Moreover	O
,	O
productive	O
HCoV	O
-	O
229E	O
infection	O
of	O
primary	O
monocytes	O
and	O
of	O
the	O
THP	O
-	O
1	O
monocytic	O
cell	O
line	O
led	O
to	O
their	O
activation	O
,	O
as	O
indicated	O
by	O
the	O
production	O
of	O
pro	O
-	O
inflammatory	O
mediators	O
,	O
including	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
CCL5	B-PRGE
,	O
CXCL10	B-PRGE
and	O
CXCL11	B-PRGE
and	O
MMP	B-PRGE
-	I-PRGE
9	I-PRGE
.	O

BCoV	O
strains	O
with	O
99	O
-	O
100	O
%	O
nucleotide	O
identity	O
in	O
the	O
S	B-PRGE
gene	I-PRGE
were	O
isolated	O
from	O
nasal	O
,	O
ocular	O
and	O
rectal	O
swabs	O
,	O
thus	O
proving	O
the	O
absence	O
of	O
separate	O
clusters	O
of	O
virus	O
on	O
the	O
basis	O
of	O
tissue	O
tropism	O
.	O

Here	O
we	O
show	O
that	O
SARS	O
-	O
CoV	O
and	O
MHV	O
induce	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
and	O
Cxcl2	B-PRGE
mRNA	I-PRGE
transcription	O
during	O
infection	O
in	O
vitro	O
.	O

AGP	B-PRGE
plays	O
an	O
important	O
role	O
in	O
the	O
diagnosis	O
of	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
)	O
and	O
may	O
also	O
be	O
useful	O
also	O
in	O
studies	O
of	O
FIP	O
pathogenesis	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
PLpro	I-PRGE
)	O
carries	O
out	O
N	O
-	O
terminal	O
processing	O
of	O
the	O
viral	B-PRGE
replicase	I-PRGE
polyprotein	I-PRGE
,	O
and	O
also	O
exhibits	O
Lys48	O
-	O
linked	O
polyubiquitin	B-PRGE
chain	I-PRGE
debranching	O
and	O
ISG15	B-PRGE
precursor	I-PRGE
processing	O
activities	O
in	O
vitro	O
.	O

Data	O
obtained	O
with	O
truncated	O
ISG15	B-PRGE
and	O
hybrid	O
Ub	O
/	O
ISG15	B-PRGE
substrates	O
indicate	O
that	O
both	O
the	O
N	O
-	O
and	O
C	O
-	O
terminal	O
Ub	O
-	O
like	O
domains	O
of	O
ISG15	B-PRGE
contribute	O
to	O
this	O
preference	O
.	O

We	O
generated	O
CD4	B-PRGE
(+)	O
T	O
-	O
cell	O
lines	O
to	O
3	O
peptides	O
from	O
the	O
spike	O
(	O
S	O
)	O
protein	O
and	O
defined	O
their	O
HLA	B-PRGE
restriction	O
.	O

RNA	O
and	O
protein	O
composition	O
analysis	O
by	O
RNase	B-PRGE
-	O
gold	O
and	O
immunoelectron	O
microscopy	O
showed	O
that	O
rTGEV	O
-	O
DeltaE	O
virions	O
contained	O
RNA	O
and	O
also	O
all	O
the	O
structural	O
TGEV	O
proteins	O
,	O
except	O
the	O
deleted	O
E	B-PRGE
protein	I-PRGE
.	O

We	O
showed	O
that	O
parasite	O
sonicates	O
but	O
not	O
intact	O
infected	O
erythrocytes	O
disrupted	O
endothelial	O
barrier	O
function	O
in	O
a	O
Src	B-PRGE
-	I-PRGE
family	I-PRGE
kinase	I-PRGE
-	O
dependent	O
manner	O
.	O

The	O
recombinant	B-PRGE
MHV	I-PRGE
nsp1	I-PRGE
mutant	I-PRGE
grew	O
normally	O
in	O
tissue	O
culture	O
,	O
but	O
was	O
severely	O
attenuated	O
in	O
vivo	O
.	O

As	O
opposed	O
to	O
many	O
in	O
vitro	O
experiments	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
induced	O
a	O
wide	O
range	O
of	O
type	O
I	O
interferons	O
(	O
IFNs	O
)	O
and	O
nuclear	O
translocation	O
of	O
phosphorylated	B-PRGE
signal	I-PRGE
transducer	I-PRGE
and	I-PRGE
activator	I-PRGE
of	I-PRGE
transcription	I-PRGE
1	I-PRGE
in	O
the	O
lungs	O
of	O
macaques	O
.	O

Different	O
strains	O
of	O
two	O
coronaviruses	O
,	O
mouse	O
hepatitis	O
virus	O
and	O
feline	O
infectious	O
peritonitis	O
virus	O
,	O
were	O
exposed	O
to	O
CBA	O
:	O
the	O
plant	O
lectins	O
Galanthus	O
nivalis	O
agglutinin	O
,	O
Hippeastrum	O
hybrid	O
agglutinin	O
and	O
Urtica	O
dioica	O
agglutinin	O
(	O
UDA	O
)	O
and	O
the	O
non	O
-	O
peptidic	O
mannose	O
-	O
binding	O
antibiotic	O
pradimicin	O
A	O
.	O
Our	O
results	O
indicate	O
that	O
CBA	O
target	O
the	O
two	O
glycosylated	B-PRGE
envelope	I-PRGE
glycoproteins	I-PRGE
,	O
the	O
spike	O
(	O
S	O
)	O
and	O
membrane	O
(	O
M	O
)	O
protein	O
,	O
of	O
mouse	O
hepatitis	O
virus	O
and	O
feline	O
infectious	O
peritonitis	O
virus	O
.	O

The	O
ECoV	B-PRGE
nsp3	I-PRGE
protein	I-PRGE
had	O
considerable	O
amino	O
acid	O
deletions	O
and	O
insertions	O
compared	O
to	O
the	O
nsp3	B-PRGE
proteins	I-PRGE
of	O
bovine	B-PRGE
coronavirus	I-PRGE
,	I-PRGE
human	I-PRGE
coronavirus	I-PRGE
OC43	I-PRGE
,	O
and	O
porcine	O
hemagglutinating	O
encephalomyelitis	O
virus	O
,	O
three	O
group	O
2	O
coronaviruses	O
phylogenetically	O
most	O
closely	O
related	O
to	O
ECoV	O
.	O
The	O
structure	O
of	O
subgenomic	O
mRNAs	O
was	O
analyzed	O
by	O
Northern	O
blot	O
analysis	O
and	O
sequencing	O
of	O
the	O
leader	O
-	O
body	O
junction	O
in	O
each	O
sg	O
mRNA	O
.	O

Subsequently	O
,	O
a	O
pool	O
of	O
17	O
-	O
19	O
mers	O
overlapped	O
SARS	B-PRGE
CoV	I-PRGE
S	I-PRGE
peptides	I-PRGE
,	O
which	O
served	O
as	O
immunogens	O
,	O
were	O
scanned	O
to	O
identify	O
the	O
specific	O
epitopes	O
for	O
T	O
cells	O
.	O

The	O
LPV	O
/	O
RTV	B-PRGE
treatment	O
also	O
inhibited	O
the	O
formation	O
of	O
SN38	O
glucuronide	O
(	O
SN38G	O
),	O
as	O
shown	O
by	O
the	O
36	O
%	O
decrease	O
in	O
the	O
SN38G	O
/	O
SN38	O
AUCs	O
ratio	O
(	O
5	O
.	O
9	O
+/-	O
1	O
.	O
6	O
vs	O
9	O
.	O
2	O
+/-	O
2	O
.	O
6	O
,	O
P	O
=	O
0	O
.	O
002	O
)	O
consistent	O
with	O
UGT1A1	B-PRGE
inhibition	O
by	O
LPV	O
/	O
RTV	O
.	O

The	O
results	O
of	O
our	O
study	O
clearly	O
demonstrate	O
that	O
both	O
proteins	O
serve	O
as	O
receptors	O
independently	O
of	O
ACE2	B-PRGE
and	O
that	O
there	O
is	O
a	O
minimal	O
level	O
of	O
synergy	O
between	O
DC	O
/	O
L	O
-	O
SIGN	O
and	O
ACE2	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
analyses	O
have	O
identified	O
seven	O
glycosylation	O
sites	O
on	O
the	O
S	B-PRGE
protein	I-PRGE
critical	O
for	O
DC	O
/	O
L	O
-	O
SIGN	O
-	O
mediated	O
virus	O
entry	O
.	O

Irrespective	O
of	O
SCD	B-PRGE
severity	O
,	O
all	O
patients	O
appeared	O
to	O
be	O
at	O
risk	O
of	O
the	O
syndrome	O
,	O
but	O
the	O
risk	O
is	O
increased	O
by	O
VOCs	O
.	O

Thirty	O
-	O
six	O
colostrum	O
-	O
deprived	O
,	O
one	O
-	O
day	O
old	O
,	O
Large	O
White	O
-	O
Duroc	O
crossbred	O
pigs	O
were	O
randomly	O
divided	O
into	O
four	O
equal	O
groups	O
:	O
PEDV	O
,	O
PEDV	O
/	O
PGAR	B-PRGE
,	O
PGAR	B-PRGE
,	O
and	O
control	O
groups	O
.	O

Sequence	O
analysis	O
of	O
the	O
PEDV	B-PRGE
N	I-PRGE
gene	I-PRGE
revealed	O
that	O
Korean	O
field	O
PEDV	O
isolates	O
had	O
93	O
.	O
6	O
%	O
and	O
89	O
.	O
6	O
%	O
identity	O
with	O
the	O
vaccine	O
virus	O
at	O
nucleotide	O
and	O
amino	O
acid	O
sequence	O
levels	O
,	O
respectively	O
,	O
suggesting	O
progressive	O
point	O
mutations	O
of	O
the	O
PEDV	O
genome	O
in	O
the	O
field	O
.	O

nsp3a	O
exhibits	O
a	O
ubiquitin	B-PRGE
-	O
like	O
globular	O
fold	O
of	O
residues	O
1	O
to	O
112	O
and	O
a	O
flexibly	O
extended	O
glutamic	O
acid	O
-	O
rich	O
domain	O
of	O
residues	O
113	O
to	O
183	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
responsible	O
for	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
-	O
CoV	O
)	O
contains	O
a	O
small	B-PRGE
envelope	I-PRGE
protein	I-PRGE
,	O
E	O
,	O
with	O
putative	O
involvement	O
in	O
host	O
cell	O
apoptosis	O
and	O
virus	O
morphogenesis	O
.	O

It	O
has	O
been	O
suggested	O
that	O
E	B-PRGE
protein	I-PRGE
can	O
form	O
a	O
membrane	O
destabilizing	O
transmembrane	O
(	O
TM	O
)	O
hairpin	O
,	O
or	O
homooligomerize	O
to	O
form	O
a	O
regular	O
TM	O
alpha	O
-	O
helical	O
bundle	O
.	O

IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
production	O
in	O
PDC	O
and	O
PBMC	O
exposed	O
to	O
different	O
stimuli	O
was	O
significantly	O
lower	O
in	O
patients	O
than	O
in	O
controls	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

PDC	O
of	O
patients	O
showed	O
up	O
-	O
regulated	O
IFN	B-PRGE
regulatory	I-PRGE
factor	I-PRGE
-	I-PRGE
7	I-PRGE
mRNA	I-PRGE
levels	O
and	O
evidence	O
of	O
in	O
vivo	O
activation	O
(	O
CD80	B-PRGE
)	O
and	O
maturation	O
(	O
CD83	B-PRGE
)	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

These	O
data	O
support	O
a	O
risk	O
factor	O
model	O
in	O
which	O
numerical	O
and	O
functional	O
deficits	O
in	O
PDC	B-PRGE
-	O
mediated	O
innate	O
immune	O
responses	O
contribute	O
to	O
an	O
impaired	O
control	O
of	O
latent	O
herpes	O
virus	O
infections	O
and	O
subsequent	O
development	O
of	O
ARN	O
.	O

Dual	O
immunolabeling	O
of	O
type	O
I	O
cells	O
for	O
viral	B-PRGE
antigen	I-PRGE
and	I-PRGE
CXC	I-PRGE
chemokines	I-PRGE
showed	O
that	O
chemokines	O
were	O
expressed	O
primarily	O
by	O
uninfected	O
cells	O
.	O

The	O
primary	O
target	O
cells	O
are	O
pneumocytes	O
and	O
enterocytes	O
,	O
both	O
cell	O
types	O
abundantly	O
expressing	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
which	O
is	O
the	O
main	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
.	O

Here	O
,	O
we	O
review	O
studies	O
by	O
different	O
groups	O
demonstrating	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
succeeded	O
in	O
spillover	O
from	O
a	O
wildlife	O
reservoir	O
(	O
probably	O
bats	O
)	O
to	O
human	O
population	O
via	O
an	O
intermediate	O
host	O
(	O
s	O
)	O
and	O
that	O
rapid	O
virus	O
evolution	O
played	O
a	O
key	O
role	O
in	O
the	O
adaptation	O
of	O
SARS	O
-	O
CoVs	O
in	O
at	O
least	O
two	O
nonreservoir	O
species	O
within	O
a	O
short	O
period	O
.	O

These	O
inhibitors	O
were	O
designed	O
and	O
synthesized	O
based	O
upon	O
our	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
inhibitor	B-PRGE
1	I-PRGE
bound	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CLpro	I-PRGE
.	O

Little	O
is	O
known	O
about	O
the	O
biogenesis	O
of	O
these	O
complexes	O
,	O
the	O
membrane	O
anchoring	O
of	O
which	O
is	O
probably	O
mediated	O
by	O
nsp3	B-PRGE
,	O
nsp4	B-PRGE
,	O
and	O
nsp6	O
,	O
as	O
they	O
contain	O
several	O
putative	O
transmembrane	O
domains	O
.	O

These	O
observations	O
imply	O
nsp4	B-PRGE
to	O
assemble	O
in	O
the	O
membrane	O
as	O
a	O
tetraspanning	O
transmembrane	O
protein	O
with	O
a	O
Nendo	O
/	O
Cendo	O
topology	O
.	O

nsp4	B-PRGE
localized	O
to	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
when	O
expressed	O
alone	O
but	O
was	O
recruited	O
to	O
the	O
replication	O
complexes	O
in	O
infected	O
cells	O
.	O

To	O
determine	O
the	O
requirement	O
of	O
nsp4	B-PRGE
for	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
infection	O
in	O
culture	O
,	O
engineered	O
deletions	O
and	O
mutations	O
in	O
TMs	O
and	O
intervening	O
soluble	O
regions	O
were	O
analyzed	O
for	O
effects	O
on	O
virus	O
recovery	O
,	O
growth	O
,	O
RNA	O
synthesis	O
,	O
protein	O
expression	O
,	O
and	O
intracellular	O
membrane	O
modifications	O
.	O

Together	O
,	O
the	O
experiments	O
identify	O
important	O
residues	O
and	O
regions	O
for	O
studies	O
of	O
nsp4	B-PRGE
topology	O
,	O
function	O
,	O
and	O
interactions	O
.	O

The	O
COQ2	B-PRGE
gene	I-PRGE
encodes	O
the	O
para	B-PRGE
-	I-PRGE
hydroxybenzoate	I-PRGE
-	I-PRGE
polyprenyl	I-PRGE
-	I-PRGE
transferase	I-PRGE
enzyme	I-PRGE
of	O
the	O
CoQ	O
(	O
10	O
)	O
synthesis	O
pathway	O
.	O

The	O
expression	O
of	O
genes	O
associated	O
with	O
interferons	O
(	O
IFNs	O
),	O
cytokines	O
and	O
Toll	B-PRGE
-	I-PRGE
like	I-PRGE
receptors	I-PRGE
,	O
which	O
were	O
not	O
present	O
on	O
the	O
microarray	O
,	O
was	O
analysed	O
further	O
by	O
qRT	O
-	O
PCR	O
.	O

In	O
vitro	O
studies	O
confirmed	O
that	O
IFN	B-PRGE
inhibited	O
viral	O
replication	O
.	O

Further	O
,	O
this	O
protein	O
has	O
also	O
been	O
proposed	O
to	O
be	O
an	O
efficient	O
diagnostic	O
tool	O
and	O
a	O
candidate	O
vaccine	O
against	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
Hence	O
,	O
towards	O
the	O
end	O
of	O
this	O
article	O
,	O
we	O
will	O
discuss	O
some	O
recent	O
progress	O
regarding	O
the	O
possible	O
clinically	O
relevant	O
use	O
of	O
the	O
N	B-PRGE
-	I-PRGE
protein	I-PRGE
.	O

While	O
SARS	O
CoV	O
infections	O
induced	O
an	O
anamnestic	O
IgG	B-PRGE
antibody	I-PRGE
response	O
to	O
the	O
229E	O
and	O
OC43	O
viruses	O
,	O
these	O
cross	O
-	O
reactive	O
antibodies	O
remained	O
of	O
high	O
avidity	O
from	O
early	O
(	O
the	O
first	O
month	O
)	O
postinfection	O
.	O

More	O
potent	O
drugs	O
,	O
such	O
as	O
azathioprine	O
,	O
ciclosporin	O
,	O
interferon	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
infliximab	O
,	O
are	O
effective	O
in	O
the	O
suppression	O
of	O
more	O
severe	O
systemic	O
features	O
as	O
well	O
as	O
mucocutaneous	O
manifestations	O
of	O
BD	O
.	O

The	O
expression	O
of	O
full	O
length	O
recombinant	B-PRGE
SARS	I-PRGE
spike	I-PRGE
protein	I-PRGE
(	O
rSS	B-PRGE
)	O
in	O
HeLa	O
cells	O
possessing	O
specific	O
reaction	O
ability	O
to	O
chicken	B-PRGE
anti	I-PRGE
-	I-PRGE
sera	I-PRGE
was	O
confirmed	O
by	O
SDS	O
-	O
PAGE	O
and	O
Western	O
-	O
blot	O
(	O
190	O
kD	O
).	O

The	O
responsible	O
antibody	O
is	O
of	O
the	O
IgM	B-PRGE
immunoglobulin	I-PRGE
class	O
,	O
is	O
maximally	O
reactive	O
in	O
the	O
cold	O
but	O
with	O
reactivity	O
up	O
to	O
at	O
least	O
30	O
degrees	O
C	O
.	O
Therapy	O
is	O
often	O
ineffective	O
,	O
but	O
newer	O
agents	O
such	O
as	O
rituximab	O
have	O
been	O
beneficial	O
in	O
some	O
patients	O
.	O

The	O
number	O
of	O
coronavirus	O
species	O
with	O
complete	O
genomes	O
available	O
has	O
increased	O
from	O
9	O
in	O
2003	O
to	O
25	O
in	O
2007	O
,	O
of	O
which	O
six	O
,	O
including	O
coronavirus	O
HKU1	O
,	O
bat	B-PRGE
SARS	I-PRGE
coronavirus	I-PRGE
,	I-PRGE
group	I-PRGE
1	I-PRGE
bat	I-PRGE
coronavirus	I-PRGE
HKU2	I-PRGE
,	O
groups	O
2c	O
and	O
2d	O
coronaviruses	O
,	O
were	O
sequenced	O
by	O
our	O
laboratory	O
.	O

We	O
also	O
demonstrated	O
that	O
the	O
cross	O
-	O
reactivity	O
is	O
not	O
universal	O
for	O
all	O
group	O
1	O
CoVs	O
,	O
because	O
HCoV	O
-	O
NL63	O
did	O
not	O
cross	O
-	O
react	O
with	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
One	O
-	O
way	O
cross	O
-	O
reactivity	O
of	O
HCoV	O
-	O
NL63	O
with	O
group	O
1	O
CoVs	O
was	O
localized	O
to	O
aa	O
1	O
to	O
39	O
and	O
at	O
least	O
one	O
other	O
antigenic	O
site	O
in	O
the	O
N	O
-	O
protein	O
C	O
terminus	O
,	O
differing	O
from	O
the	O
cross	O
-	O
reactive	O
region	O
identified	O
in	O
SARS	O
-	O
CoV	O
N	O
protein	O
.	O

ABSTRACT	O
:	O
Mutation	O
within	O
virus	O
-	O
derived	O
CD8	B-PRGE
T	I-PRGE
-	I-PRGE
cell	I-PRGE
epitopes	I-PRGE
can	O
effectively	O
abrogate	O
cytotoxic	O
T	O
-	O
lymphocyte	O
(	O
CTL	O
)	O
recognition	O
and	O
impede	O
virus	O
clearance	O
in	O
infected	O
hosts	O
.	O

Sequence	O
and	O
phylogenetic	O
analyses	O
of	O
the	O
3	O
'	O
end	O
(	O
9	O
.	O
6	O
kb	O
)	O
of	O
the	O
BuCoV	B-PRGE
RNA	I-PRGE
revealed	O
a	O
genomic	O
organization	O
typical	O
of	O
group	O
2	O
coronaviruses	O
.	O

Studies	O
employing	O
recombinant	O
viruses	O
with	O
a	O
modified	O
spike	O
(	O
S	O
)	O
glycoprotein	O
of	O
MHV	O
-	O
JHM	O
have	O
identified	O
the	O
S	B-PRGE
gene	I-PRGE
as	O
a	O
major	O
determinant	O
of	O
neurovirulence	O
.	O

However	O
,	O
the	O
association	O
of	O
S	B-PRGE
gene	I-PRGE
variation	O
and	O
neurovirulence	O
with	O
host	O
ability	O
to	O
generate	O
anti	O
-	O
viral	O
CD8	O
T	O
cell	O
responses	O
is	O
not	O
completely	O
clear	O
.	O

The	O
purified	O
recombinant	B-PRGE
nsp14	I-PRGE
protein	I-PRGE
digested	O
a	O
5	O
'-	O
labeled	O
RNA	O
molecule	O
,	O
but	O
failed	O
to	O
digest	O
the	O
RNA	O
substrate	O
that	O
is	O
modified	O
with	O
fluorescein	O
group	O
at	O
the	O
3	O
'-	O
hydroxyl	O
group	O
,	O
suggesting	O
a	O
3	O
'-	O
to	O
-	O
5	O
'	O
exoribonuclease	O
activity	O
.	O

Furthermore	O
,	O
increased	O
pathogenesis	O
was	O
associated	O
with	O
significantly	O
enhanced	O
accumulation	O
of	O
neutrophils	O
,	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
,	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
chemokine	O
(	O
C	O
-	O
C	O
motif	O
)	O
ligand	O
2	O
,	O
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
within	O
the	O
CNS	O
.	O

This	O
occurred	O
in	O
open	O
reading	O
frame	O
8	O
(	O
ORF8	O
),	O
one	O
of	O
the	O
accessory	O
genes	O
unique	O
to	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
The	O
function	O
of	O
ORF8	O
and	O
the	O
significance	O
of	O
the	O
deletion	O
are	O
unknown	O
.	O

These	O
findings	O
suggest	O
that	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
may	O
play	O
a	O
role	O
in	O
IBV	O
-	O
induced	O
nephritis	O
and	O
may	O
open	O
an	O
avenue	O
to	O
develop	O
alternative	O
strategies	O
,	O
such	O
as	O
the	O
use	O
of	O
antiinflammatory	O
cytokines	O
,	O
to	O
overcome	O
the	O
nephropathogenic	O
effects	O
of	O
IBV	O
.	O

The	O
excellent	O
preventive	O
and	O
therapeutic	O
roles	O
of	O
equine	B-PRGE
anti	I-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
F	I-PRGE
(	O
ab	O
')(	O
2	O
)	O
in	O
several	O
animal	O
models	O
,	O
including	O
the	O
novel	O
Chinese	O
hamster	O
model	O
described	O
in	O
this	O
study	O
,	O
have	O
provided	O
exciting	O
data	O
concerning	O
its	O
potential	O
clinical	O
study	O
.	O

ABSTRACT	O
:	O
The	O
3C	B-PRGE
-	I-PRGE
like	I-PRGE
main	I-PRGE
proteinase	I-PRGE
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
(	I-PRGE
pro	I-PRGE
),	I-PRGE
is	O
widely	O
considered	O
to	O
be	O
a	O
major	O
drug	O
target	O
for	O
the	O
development	O
of	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
treatment	O
.	O

In	O
PRCV	O
/	O
DEX	O
pigs	O
,	O
significantly	O
milder	O
pneumonia	O
,	O
fewer	O
PRCV	O
-	O
positive	O
cells	O
,	O
and	O
lower	O
viral	O
RNA	O
titers	O
were	O
present	O
in	O
lungs	O
early	O
at	O
PID	O
2	O
;	O
however	O
,	O
at	O
PID	O
4	O
,	O
10	O
,	O
and	O
21	O
,	O
severe	O
bronchointerstitial	O
pneumonia	O
,	O
significantly	O
higher	O
numbers	O
of	O
PRCV	O
-	O
positive	O
cells	O
,	O
and	O
higher	O
viral	O
RNA	O
titers	O
were	O
observed	O
compared	O
to	O
results	O
for	O
PRCV	O
/	O
PBS	B-PRGE
pigs	O
.	O

Even	O
after	O
adjusting	O
for	O
these	O
baseline	O
differences	O
,	O
trauma	O
patients	O
had	O
significantly	O
lower	O
plasma	O
levels	O
of	O
intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
,	O
von	B-PRGE
Willebrand	I-PRGE
factor	I-PRGE
antigen	I-PRGE
,	O
surfactant	B-PRGE
protein	I-PRGE
-	I-PRGE
D	I-PRGE
,	O
and	O
soluble	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
receptor	I-PRGE
-	I-PRGE
1	I-PRGE
,	O
which	O
are	O
biomarkers	O
of	O
lung	O
epithelial	O
and	O
endothelial	O
injury	O
previously	O
found	O
to	O
be	O
prognostic	O
in	O
acute	O
lung	O
injury	O
.	O

These	O
results	O
are	O
discussed	O
with	O
respect	O
to	O
the	O
possible	O
roles	O
of	O
the	O
3a	B-PRGE
protein	I-PRGE
in	O
the	O
viral	O
life	O
cycle	O
.	O

We	O
used	O
cryo	O
-	O
electron	O
microscopy	O
and	O
image	O
processing	O
to	O
investigate	O
conformational	O
changes	O
that	O
occur	O
in	O
the	O
entire	O
spike	O
of	O
intact	O
virions	O
when	O
they	O
bind	O
to	O
the	O
viral	O
receptor	O
,	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
).	O

Our	O
results	O
suggest	O
that	O
a	O
specific	O
,	O
receptor	O
CEACAM1	O
-	O
independent	O
mechanism	O
restricting	O
coronaviral	O
RNA	O
synthesis	O
and	O
CPE	B-PRGE
is	O
present	O
in	O
NIH	O
3T3	O
and	O
,	O
possibly	O
,	O
other	O
cells	O
with	O
preserved	O
contact	O
inhibition	O
.	O

The	O
values	O
of	O
plasma	O
fibrinogen	B-PRGE
of	O
the	O
148	O
SARS	O
patients	O
were	O
analyzed	O
and	O
compared	O
among	O
the	O
different	O
groups	O
.	O

theses	O
results	O
suggested	O
that	O
elevation	O
of	O
peripheral	O
blood	O
fibrinogen	B-PRGE
in	O
SARS	O
patients	O
may	O
play	O
an	O
important	O
role	O
in	O
development	O
and	O
progress	O
of	O
the	O
disease	O
and	O
its	O
treatment	O
.	O

Finally	O
,	O
the	O
ubiquitinated	O
Na	B-PRGE
,	I-PRGE
K	I-PRGE
-	I-PRGE
ATPase	I-PRGE
undergoes	O
degradation	O
via	O
a	O
lysosome	O
/	O
proteasome	O
dependent	O
mechanism	O
.	O

ABSTRACT	O
:	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
3CL	O
(	O
pro	O
))	O
is	O
an	O
attractive	O
target	O
for	O
anti	O
-	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
drug	O
discovery	O
,	O
and	O
its	O
dimerization	O
has	O
been	O
extensively	O
proved	O
to	O
be	O
indispensable	O
for	O
enzymatic	O
activity	O
.	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
mutation	O
of	O
the	O
dimer	O
-	O
interface	O
residue	O
Gly	O
-	O
11	O
to	O
alanine	O
entirely	O
abolished	O
the	O
activity	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
(	O
pro	B-PRGE
).	O

As	O
the	O
first	O
reported	O
monomer	O
structure	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
(	O
pro	B-PRGE
),	O
the	O
crystal	O
structure	O
of	O
G11A	B-PRGE
mutant	I-PRGE
might	O
provide	O
insight	O
into	O
the	O
dimerization	O
mechanism	O
of	O
the	O
protease	O
and	O
supply	O
direct	O
structural	O
evidence	O
for	O
the	O
incompetence	O
of	O
the	O
dissociated	O
monomer	O
.	O

Z	B-PRGE
gene	I-PRGE
was	O
successfully	O
designed	O
and	O
expressed	O
in	O
E	O
.	O
coli	O
BL21	O
(	O
DE3	O
).	O

The	O
S1	B-PRGE
glycoprotein	I-PRGE
genes	O
of	O
these	O
IBV	O
isolates	O
were	O
amplified	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RTPCR	O
)	O
and	O
analyzed	O
by	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
analysis	O
.	O

TITLE	O
:	O
Association	O
between	O
urokinase	B-PRGE
haplotypes	O
and	O
outcome	O
from	O
infection	O
-	O
associated	O
acute	O
lung	O
injury	O
.	O

The	O
lack	O
of	O
immunological	O
reagents	O
for	O
ferrets	O
prompted	O
us	O
to	O
clone	O
CXCL9	B-PRGE
,	O
CXCL10	B-PRGE
,	O
CXCL11	B-PRGE
and	O
CXCR3	B-PRGE
and	O
,	O
in	O
the	O
case	O
of	O
CXCL10	B-PRGE
,	O
to	O
express	O
the	O
gene	O
as	O
a	O
recombinant	O
protein	O
.	O

This	O
study	O
therefore	O
represents	O
an	O
important	O
step	O
towards	O
development	O
of	O
the	O
ferret	O
as	O
a	O
model	O
for	O
the	O
role	O
of	O
CXCL9	B-PRGE
,	O
CXCL10	B-PRGE
and	O
CXCL11	B-PRGE
:	O
CXCR3	B-PRGE
axis	O
in	O
severe	O
viral	O
infections	O
.	O

In	O
particular	O
,	O
our	O
data	O
suggest	O
LFA	B-PRGE
-	I-PRGE
1	I-PRGE
to	O
be	O
an	O
attachment	O
factor	O
or	O
the	O
receptor	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
on	O
human	O
leukocytes	O
.	O

Type	B-PRGE
B	I-PRGE
insulin	I-PRGE
resistance	O
syndrome	O
.	O

On	O
d	O
10	O
,	O
20	O
,	O
30	O
,	O
40	O
,	O
and	O
50	O
after	O
the	O
first	O
vaccination	O
,	O
the	O
proliferation	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
in	O
response	O
to	O
concanavalin	O
A	O
stimulation	O
as	O
well	O
as	O
the	O
proportions	O
of	O
CD3	B-PRGE
(+),	I-PRGE
CD4	B-PRGE
(+),	O
and	O
CD8	B-PRGE
(+)	O
peripheral	O
blood	O
mononuclear	O
cells	O
were	O
determined	O
by	O
the	O
3	O
-(	O
4	O
,	O
5	O
-	O
dimethylthiazol	O
-	O
2	O
-	O
yl	O
)-	O
2	O
,	O
5	O
-	O
diphenyltetrazolium	O
bromide	O
method	O
and	O
flow	O
cytometry	O
,	O
respectively	O
.	O

Members	O
of	O
one	O
class	O
of	O
suppressor	O
were	O
mapped	O
to	O
the	O
portions	O
of	O
gene	O
1	O
that	O
encode	O
nsp8	O
and	O
nsp9	O
,	O
thereby	O
providing	O
the	O
first	O
evidence	O
for	O
specific	O
interactions	O
between	O
coronavirus	B-PRGE
replicase	I-PRGE
gene	I-PRGE
products	I-PRGE
and	O
a	O
cis	O
-	O
acting	O
genomic	O
RNA	O
element	O
.	O

ABSTRACT	O
:	O
Here	O
we	O
report	O
the	O
development	O
of	O
a	O
more	O
-	O
sensitive	O
immunoassay	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
based	O
on	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
using	O
chemiluminescence	O
(	O
CLEIA	O
)	O
to	O
detect	O
the	O
viral	B-PRGE
nucleocapsid	I-PRGE
(	I-PRGE
N	I-PRGE
)	I-PRGE
antigen	I-PRGE
in	O
nasopharyngeal	O
aspirate	O
(	O
NPA	O
)	O
from	O
patients	O
infected	O
with	O
SARS	O
coronavirus	O
(	O
CoV	O
).	O

The	O
capture	O
and	O
detecting	O
MAbs	O
of	O
the	O
CLEIA	O
reacted	O
to	O
the	O
carboxyl	O
-	O
terminal	O
and	O
amino	O
-	O
terminal	O
peptides	O
of	O
the	O
N	B-PRGE
protein	I-PRGE
,	O
respectively	O
.	O

Lung	O
tissue	O
and	O
/	O
or	O
fluid	O
and	O
/	O
or	O
the	O
peribronchial	O
lymph	O
node	O
of	O
the	O
intratracheally	O
inoculated	O
animals	O
had	O
high	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
IL	O
-	O
8	O
and	O
IL	O
-	O
12	O
levels	O
.	O

The	O
gene	O
order	O
was	O
either	O
5	O
'-	O
Pol	B-PRGE
-	I-PRGE
S	I-PRGE
-	I-PRGE
X1	I-PRGE
-	I-PRGE
E	I-PRGE
-	I-PRGE
M	I-PRGE
-	I-PRGE
N	I-PRGE
-	I-PRGE
UTR	I-PRGE
-	I-PRGE
3	I-PRGE
'	I-PRGE
or	O
5	B-PRGE
'-	I-PRGE
Pol	I-PRGE
-	I-PRGE
S	I-PRGE
-	I-PRGE
X1	I-PRGE
-	I-PRGE
E	I-PRGE
-	I-PRGE
M	I-PRGE
-	I-PRGE
5b	I-PRGE
-	I-PRGE
N	I-PRGE
-	I-PRGE
UTR	I-PRGE
-	I-PRGE
3	I-PRGE
'.	O

The	O
patients	O
and	O
196	O
donors	O
of	O
suspect	O
blood	O
products	O
were	O
screened	O
for	O
antibodies	O
to	O
HLA	B-PRGE
Class	I-PRGE
I	I-PRGE
,	O
HLA	B-PRGE
Class	O
II	O
,	O
granulocytes	O
,	O
and	O
platelets	O
.	O

Although	O
the	O
anti	B-PRGE
-	I-PRGE
HLA	I-PRGE
antibodies	I-PRGE
were	O
detected	O
more	O
frequently	O
in	O
females	O
than	O
males	O
,	O
no	O
significant	O
association	O
of	O
ANHTRs	O
including	O
TRALI	O
with	O
gender	O
,	O
not	O
only	O
for	O
patients	O
,	O
but	O
also	O
for	O
donors	O
,	O
could	O
be	O
shown	O
in	O
this	O
study	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
heterologous	O
expression	O
of	O
ORF10	B-PRGE
and	O
X5	O
genes	O
in	O
E	O
.	O
coli	O
and	O
S	O
.	O
lividans	O
TK24	O
.	O

ABSTRACT	O
:	O
Angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
-	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
)	O
is	O
a	O
regulatory	O
protein	O
of	O
the	O
renin	B-PRGE
-	O
angiotensin	O
system	O
(	O
RAS	B-PRGE
)	O
and	O
a	O
receptor	O
for	O
the	O
causative	O
agent	O
of	O
severe	O
-	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
the	O
SARS	O
-	O
coronavirus	O
.	O

Gas	B-PRGE
exchange	O
was	O
severely	O
impaired	O
and	O
a	O
chest	O
x	O
-	O
ray	O
indicated	O
chemical	O
pneumonitis	O
.	O

The	O
virus	O
replication	O
kinetics	O
,	O
histopathological	O
changes	O
and	O
mRNA	O
expression	O
levels	O
of	O
proinflammatory	O
cytokines	O
in	O
the	O
brain	O
did	O
not	O
differ	O
between	O
TNFalpha	B-PRGE
-	O
deficient	O
and	O
control	O
C57BL	O
/	O
6	O
mice	O
.	O

Fourth	O
,	O
a	O
minimal	O
insert	O
region	O
(	O
amino	O
acids	O
310	O
to	O
518	O
)	O
was	O
found	O
to	O
be	O
sufficient	O
to	O
convert	O
the	O
SL	O
-	O
CoV	O
S	O
from	O
non	O
-	O
ACE2	B-PRGE
binding	O
to	O
human	B-PRGE
ACE2	I-PRGE
binding	O
,	O
indicating	O
that	O
the	O
SL	O
-	O
CoV	O
S	O
is	O
largely	O
compatible	O
with	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
both	O
in	O
structure	O
and	O
in	O
function	O
.	O

TITLE	O
:	O
Isolation	O
of	O
inhibitory	O
RNA	O
aptamers	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
NTPase	B-PRGE
/	O
Helicase	B-PRGE
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
the	O
S	B-PRGE
protein	I-PRGE
of	O
IBV	O
is	O
retained	O
at	O
a	O
late	O
Golgi	O
compartment	O
.	O

To	O
explore	O
the	O
underlying	O
mechanisms	O
associated	O
with	O
protection	O
from	O
disease	O
in	O
MHV	O
-	O
CXCL10	O
-	O
infected	O
mice	O
,	O
the	O
functional	O
contributions	O
of	O
the	O
NK	B-PRGE
cell	I-PRGE
-	I-PRGE
activating	I-PRGE
receptor	I-PRGE
NKG2D	B-PRGE
in	O
host	O
defense	O
were	O
examined	O
.	O

TITLE	O
:	O
CD4	B-PRGE
T	O
cells	O
contribute	O
to	O
virus	O
control	O
and	O
pathology	O
following	O
central	O
nervous	O
system	O
infection	O
with	O
neurotropic	O
mouse	O
hepatitis	O
virus	O
.	O

To	O
examine	O
a	O
direct	O
role	O
of	O
CD4	B-PRGE
(+)	O
T	O
cells	O
in	O
viral	O
clearance	O
and	O
pathology	O
,	O
pathogenesis	O
was	O
compared	O
in	O
mice	O
deficient	O
in	O
both	O
perforin	B-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
that	O
were	O
selectively	O
reconstituted	O
for	O
these	O
functions	O
via	O
transfer	O
of	O
virus	O
-	O
specific	O
memory	O
CD4	B-PRGE
(+)	O
T	O
cells	O
.	O

CD4	B-PRGE
(+)	O
T	O
cells	O
from	O
immunized	O
wild	O
-	O
type	O
,	O
perforin	O
-	O
deficient	O
,	O
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	O
deficient	O
donors	O
all	O
initially	O
reduced	O
virus	O
replication	O
.	O

CD4	B-PRGE
(+)	O
T	O
-	O
cell	O
-	O
mediated	O
antiviral	O
activity	O
correlated	O
with	O
diminished	O
clinical	O
symptoms	O
,	O
pathology	O
,	O
and	O
demyelination	O
.	O

In	O
an	O
inhibition	O
assay	O
of	O
carbon	O
particle	O
phagocytosis	O
as	O
a	O
representation	O
of	O
natural	O
phagocytosis	O
,	O
neutrophils	O
binding	O
with	O
TAG3	O
or	O
TAG4	O
were	O
inhibited	O
from	O
carbon	O
particle	O
-	O
phagocytosis	O
by	O
42	O
.	O
5	O
%	O
and	O
53	O
.	O
2	O
%	O
(%	O
inhibition	O
),	O
respectively	O
,	O
but	O
in	O
an	O
inhibition	O
assay	O
using	O
TAG3	O
MoAb	O
,	O
HNA	B-PRGE
-	I-PRGE
2a	I-PRGE
strongly	O
positive	O
neutrophils	O
were	O
more	O
weakly	O
inhibited	O
than	O
HNA	B-PRGE
-	I-PRGE
2a	I-PRGE
weak	O
-	O
positive	O
neutrophils	O
,	O
39	O
.	O
2	O
%	O
and	O
54	O
.	O
0	O
%	O
(%	O
inhibition	O
),	O
respectively	O
.	O

It	O
was	O
thought	O
that	O
neutrophil	O
immune	O
-	O
phagocytosis	O
would	O
be	O
inhibited	O
by	O
antibodies	O
binding	O
with	O
FcgammaRIII	B-PRGE
,	O
and	O
that	O
HNA	B-PRGE
-	I-PRGE
2a	I-PRGE
was	O
not	O
related	O
to	O
immune	O
phagocytosis	O
.	O

Moreover	O
,	O
we	O
examined	O
the	O
subcellular	O
localization	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
in	O
these	O
cell	O
lines	O
.	O

In	O
transfected	O
Vero	O
E6	O
and	O
A549	O
cells	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
was	O
localized	O
both	O
in	O
the	O
cytoplasm	O
and	O
nucleus	O
,	O
whereas	O
in	O
Caco	O
-	O
2	O
and	O
N2a	O
cells	O
,	O
nearly	O
no	O
nuclear	O
localization	O
was	O
observed	O
.	O

In	O
the	O
absence	O
of	O
tissue	O
hypoperfusion	O
,	O
coronary	O
artery	O
disease	O
,	O
or	O
acute	O
hemorrhage	O
,	O
target	O
a	O
hemoglobin	B-PRGE
of	O
7	O
-	O
9	O
g	O
/	O
dL	O
(	O
1B	O
);	O
a	O
low	O
tidal	O
volume	O
(	O
1B	O
)	O
and	O
limitation	O
of	O
inspiratory	O
plateau	O
pressure	O
strategy	O
(	O
1C	O
)	O
for	O
acute	O
lung	O
injury	O
(	O
ALI	O
)/	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
);	O
application	O
of	O
at	O
least	O
a	O
minimal	O
amount	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
in	O
acute	O
lung	O
injury	O
(	O
1C	O
);	O
head	O
of	O
bed	O
elevation	O
in	O
mechanically	O
ventilated	O
patients	O
unless	O
contraindicated	O
(	O
1B	O
);	O
avoiding	O
routine	O
use	O
of	O
pulmonary	O
artery	O
catheters	O
in	O
ALI	O
/	O
ARDS	O
(	O
1A	O
);	O
to	O
decrease	O
days	O
of	O
mechanical	O
ventilation	O
and	O
ICU	O
length	O
of	O
stay	O
,	O
a	O
conservative	O
fluid	O
strategy	O
for	O
patients	O
with	O
established	O
ALI	O
/	O
ARDS	O
who	O
are	O
not	O
in	O
shock	O
(	O
1C	O
);	O
protocols	O
for	O
weaning	O
and	O
sedation	O
/	O
analgesia	O
(	O
1B	O
);	O
using	O
either	O
intermittent	O
bolus	O
sedation	O
or	O
continuous	O
infusion	O
sedation	O
with	O
daily	O
interruptions	O
or	O
lightening	O
(	O
1B	O
);	O
avoidance	O
of	O
neuromuscular	O
blockers	O
,	O
if	O
at	O
all	O
possible	O
(	O
1B	O
);	O
institution	O
of	O
glycemic	O
control	O
(	O
1B	O
),	O
targeting	O
a	O
blood	O
glucose	O
<	O
150	O
mg	O
/	O
dL	O
after	O
initial	O
stabilization	O
(	O
2C	O
);	O
equivalency	O
of	O
continuous	O
veno	O
-	O
veno	O
hemofiltration	O
or	O
intermittent	O
hemodialysis	O
(	O
2B	O
);	O
prophylaxis	O
for	O
deep	O
vein	O
thrombosis	O
(	O
1A	O
);	O
use	O
of	O
stress	O
ulcer	O
prophylaxis	O
to	O
prevent	O
upper	O
gastrointestinal	O
bleeding	O
using	O
H2	O
blockers	O
(	O
1A	O
)	O
or	O
proton	O
pump	O
inhibitors	O
(	O
1B	O
);	O
and	O
consideration	O
of	O
limitation	O
of	O
support	O
where	O
appropriate	O
(	O
1D	O
).	O

No	O
increase	O
in	O
mortality	O
was	O
observed	O
during	O
the	O
acute	O
phase	O
of	O
disease	O
following	O
MHV	O
infection	O
of	O
mice	O
lacking	O
CCR1	B-PRGE
(	O
CCR1	B-PRGE
-/-)	O
as	O
compared	O
to	O
wild	O
-	O
type	O
(	O
CCR1	O
+/+)	O
mice	O
.	O

Together	O
,	O
these	O
findings	O
reveal	O
that	O
T	O
-	O
cell	O
and	O
macrophage	O
trafficking	O
are	O
not	O
dependent	O
on	O
CCR1	B-PRGE
and	O
highlight	O
an	O
important	O
role	O
for	O
CCR1	B-PRGE
signaling	O
in	O
promoting	O
survival	O
during	O
chronic	O
MHV	O
infection	O
.	O

Compared	O
to	O
the	O
original	O
KT2	O
-	O
L	O
strain	O
,	O
the	O
KT2	B-PRGE
-	I-PRGE
H	I-PRGE
strain	O
differed	O
by	O
2	O
.	O
2	O
and	O
3	O
.	O
9	O
%	O
in	O
nucleotide	O
and	O
amino	O
acid	O
sequences	O
,	O
respectively	O
.	O

Specifically	O
,	O
the	O
KT2	B-PRGE
-	I-PRGE
H	I-PRGE
had	O
six	O
nucleotide	O
and	O
two	O
amino	O
acid	O
deletions	O
compared	O
to	O
the	O
original	O
KT2	O
-	O
L	O
strain	O
.	O

One	O
group	O
(	O
KT2	B-PRGE
-	I-PRGE
L	I-PRGE
,	O
KT2	B-PRGE
-	I-PRGE
H	I-PRGE
,	O
133	O
)	O
was	O
related	O
to	O
TGEV	O
strains	O
isolated	O
in	O
Japan	O
.	O

The	O
present	O
study	O
would	O
help	O
us	O
better	O
understand	O
the	O
dimerization	O
-	O
activity	O
relationship	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
pro	O
and	O
afford	O
potential	O
information	O
for	O
designing	O
anti	O
-	O
viral	O
compounds	O
targeting	O
the	O
dimer	O
interface	O
of	O
the	O
protease	O
.	O

Both	O
native	B-PRGE
E	I-PRGE
and	I-PRGE
E	I-PRGE
.	I-PRGE
T	I-PRGE
proteins	I-PRGE
localized	O
at	O
identical	O
perinuclear	O
locations	O
,	O
and	O
both	O
copurified	O
with	O
M	O
proteins	O
,	O
but	O
E	O
.	O
T	O
was	O
entirely	O
incompetent	O
for	O
VLP	B-PRGE
production	O
.	O

Antibodies	O
raised	O
against	O
the	O
S3	O
fragment	O
were	O
able	O
to	O
block	O
the	O
binding	O
of	O
a	O
panel	O
of	O
S	O
-	O
specific	O
monoclonal	B-PRGE
antibodies	I-PRGE
(	O
mAb	O
)	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
in	O
ELISA	O
,	O
further	O
demonstrating	O
the	O
immunodominance	O
of	O
this	O
region	O
.	O

Based	O
on	O
these	O
findings	O
,	O
one	O
-	O
step	O
competition	O
ELISAs	O
were	O
established	O
which	O
were	O
able	O
to	O
detect	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
antibodies	I-PRGE
from	O
human	O
and	O
at	O
least	O
seven	O
different	O
animal	O
species	O
.	O

Interestingly	O
,	O
we	O
have	O
discovered	O
that	O
the	O
INF	B-PRGE
-	I-PRGE
C	I-PRGE
esterase	I-PRGE
function	O
releases	O
acetate	O
independently	O
of	O
the	O
chemical	O
nature	O
of	O
the	O
aglycon	O
moiety	O
,	O
whereas	O
subtle	O
differences	O
in	O
substrate	O
recognition	O
were	O
found	O
for	O
BCoV	B-PRGE
esterase	I-PRGE
.	O

This	O
study	O
provides	O
valuable	O
insights	O
towards	O
the	O
design	O
of	O
drugs	O
to	O
combat	O
INF	B-PRGE
-	I-PRGE
C	I-PRGE
virus	O
and	O
coronavirus	O
infections	O
causing	O
outbreaks	O
of	O
upper	O
respiratory	O
infections	O
and	O
severe	O
diarrhea	O
in	O
calves	O
,	O
respectively	O
.	O

The	O
spike	B-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
glycoprotein	I-PRGE
has	O
been	O
identified	O
as	O
a	O
major	O
component	O
of	O
protective	O
immunity	O
,	O
and	O
23	O
different	O
amino	O
acid	O
changes	O
were	O
noted	O
during	O
the	O
expanding	O
epidemic	O
.	O

TITLE	O
:	O
Induction	O
of	O
class	B-PRGE
I	I-PRGE
antigen	I-PRGE
processing	O
components	O
in	O
oligodendroglia	O
and	O
microglia	O
during	O
viral	O
encephalomyelitis	O
.	O

In	O
one	O
design	O
,	O
a	O
biotinylated	O
target	O
is	O
used	O
and	O
the	O
detection	O
of	O
the	O
hybridization	O
reaction	O
is	O
monitored	O
using	O
alkaline	B-PRGE
phosphatase	I-PRGE
labeled	O
streptavidin	O
(	O
S	O
-	O
AP	O
).	O

Model	O
performance	O
was	O
assessed	O
as	O
goodness	O
-	O
of	O
-	O
fit	O
[	O
GOF	O
,	O
cross	O
-	O
products	O
of	O
quantiles	O
of	O
risk	O
and	O
time	O
intervals	O
(	O
P	O
>	O
or	O
=	O
0	O
.	O
1	O
),	O
Cox	O
model	O
]	O
and	O
explained	O
variation	O
('	O
R2	O
',	O
Cox	B-PRGE
and	O
ATF	B-PRGE
).	O

Likewise	O
,	O
patent	O
applications	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
protease	I-PRGE
inhibitors	O
and	O
interferon	B-PRGE
and	O
mismatched	O
dsRNA	O
also	O
need	O
to	O
be	O
watched	O
for	O
potential	O
application	O
in	O
treatment	O
and	O
prevention	O
of	O
SARS	O
-	O
CoV	O
.	O
Here	O
,	O
we	O
review	O
the	O
recent	O
advances	O
and	O
inventions	O
that	O
target	O
SARS	O
-	O
CoV	O
infection	O
in	O
humans	O
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
entry	O
into	O
host	O
cells	O
through	O
a	O
novel	O
clathrin	B-PRGE
-	O
and	O
caveolae	O
-	O
independent	O
endocytic	O
pathway	O
.	O

Nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
encapsidates	O
the	O
viral	O
RNA	O
and	O
plays	O
an	O
important	O
role	O
in	O
virus	O
particle	O
assembly	O
and	O
release	O
.	O

PIV	O
-	O
2	O
,	O
PIV	O
-	O
4	O
,	O
influenza	O
B	O
virus	O
,	O
InfA	B-PRGE
H5N1	I-PRGE
,	O
and	O
coronavirus	O
229E	O
were	O
not	O
detected	O
in	O
the	O
clinical	O
specimens	O
tested	O
.	O

Neutrophils	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
ALI	O
/	O
ARDS	O
,	O
and	O
IL	O
-	O
8	O
(	O
interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
)	O
has	O
been	O
identified	O
as	O
the	O
main	O
chemotactic	O
factor	O
for	O
neutrophils	O
in	O
lung	O
fluids	O
of	O
patients	O
with	O
ALI	O
/	O
ARDS	O
.	O

This	O
information	O
is	O
important	O
for	O
our	O
understanding	O
of	O
how	O
attenuated	O
virus	O
vaccines	O
,	O
including	O
potential	O
vaccines	O
against	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
can	O
ensure	O
long	O
-	O
term	O
survival	O
of	O
the	O
virus	O
and	O
can	O
lead	O
to	O
changes	O
in	O
pathogenesis	O
and	O
emergence	O
of	O
new	O
viral	O
pathogens	O
.	O

The	O
hypothesis	O
may	O
be	O
confirmed	O
by	O
:	O
(	O
1	O
)	O
demonstrating	O
an	O
improvement	O
in	O
physiologic	O
parameters	O
,	O
intracranial	O
pressure	O
,	O
and	O
brain	O
oxygenation	O
with	O
inhaled	O
nitric	O
oxide	O
use	O
in	O
severely	O
head	O
injured	O
patients	O
,	O
and	O
(	O
2	O
)	O
demonstrating	O
a	O
decrease	O
in	O
biochemical	O
serum	O
markers	O
in	O
such	O
patients	O
;	O
specifically	O
,	O
glial	B-PRGE
fibrillary	I-PRGE
acidic	I-PRGE
protein	I-PRGE
,	O
inflammatory	O
cytokines	O
,	O
and	O
biomarkers	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
,	O
and	O
(	O
3	O
)	O
documentation	O
of	O
outcomes	O
.	O

In	O
fact	O
,	O
in	O
transmissible	O
gastroenteritis	O
CoV	O
,	O
a	O
good	O
correlation	O
has	O
been	O
observed	O
between	O
subgenomic	B-PRGE
mRNA	I-PRGE
(	O
sg	B-PRGE
mRNA	I-PRGE
)	O
levels	O
and	O
the	O
free	O
energy	O
(	O
DeltaG	O
)	O
of	O
TRS	O
-	O
L	O
and	O
cTRS	O
-	O
B	O
duplex	O
formation	O
.	O

The	O
incidence	O
and	O
characteristics	O
of	O
OM	B-PRGE
complicating	I-PRGE
URI	I-PRGE
due	O
to	O
specific	O
viruses	O
have	O
not	O
been	O
well	O
studied	O
.	O

Biochemical	O
fractionation	O
and	O
confocal	O
imaging	O
confirmed	O
that	O
ACE2	B-PRGE
colocalized	O
with	O
raft	O
-	O
resident	O
markers	O
.	O

Furthermore	O
,	O
an	O
ectodomain	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
(	O
S1188HA	O
)	O
could	O
associate	O
with	O
lipid	O
rafts	O
after	O
binding	O
to	O
its	O
receptor	O
,	O
and	O
colocalize	O
with	O
raft	O
-	O
resident	O
marker	O
ganglioside	O
GM1	O
.	O

Plasma	O
levels	O
of	O
pseudo	B-PRGE
cholinesterase	I-PRGE
were	O
initially	O
very	O
low	O
in	O
both	O
patients	O
.	O

While	O
the	O
upper	O
region	O
of	O
SL1	B-PRGE
is	O
required	O
to	O
be	O
paired	O
,	O
we	O
observe	O
strong	O
genetic	O
selection	O
against	O
viruses	O
that	O
contain	O
a	O
deletion	O
of	O
A35	O
,	O
an	O
extrahelical	O
nucleotide	O
that	O
destabilizes	O
SL1	B-PRGE
,	O
in	O
favor	O
of	O
genomes	O
that	O
contain	O
a	O
diverse	O
panel	O
of	O
destabilizing	O
second	O
-	O
site	O
mutations	O
,	O
due	O
to	O
introduction	O
of	O
a	O
noncanonical	O
base	O
pair	O
near	O
A35	O
.	O

Viruses	O
containing	O
destabilizing	O
SL1	B-PRGE
-	I-PRGE
DeltaA35	I-PRGE
mutations	I-PRGE
also	O
contain	O
one	O
of	O
two	O
specific	O
mutations	O
in	O
the	O
3	O
'	O
UTR	O
.	O

We	O
propose	O
a	O
""""	O
dynamic	O
SL1	O
""""	O
model	O
,	O
in	O
which	O
the	O
base	O
of	O
SL1	B-PRGE
has	O
an	O
optimized	O
lability	O
required	O
to	O
mediate	O
a	O
physical	O
interaction	O
between	O
the	O
5	O
'	O
UTR	O
and	O
the	O
3	O
'	O
UTR	O
that	O
stimulates	O
subgenomic	O
RNA	O
synthesis	O
.	O

The	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
protein	I-PRGE
is	O
an	O
important	O
target	O
in	O
developing	O
safe	O
and	O
effective	O
SARS	O
vaccines	O
.	O

No	O
significant	O
immune	O
responses	O
and	O
protective	O
effects	O
were	O
detected	O
in	O
mice	O
vaccinated	O
with	O
RBD	B-PRGE
-	I-PRGE
Pep	I-PRGE
or	O
blank	O
AAV	O
alone	O
.	O

Since	O
T	B-PRGE
cell	I-PRGE
epitopes	I-PRGE
are	O
highly	O
conserved	O
and	O
boosting	O
with	O
peptides	O
may	O
induce	O
the	O
production	O
of	O
effector	O
memory	O
T	O
cells	O
,	O
which	O
may	O
be	O
effective	O
against	O
viruses	O
with	O
mutations	O
in	O
the	O
neutralizing	O
epitopes	O
,	O
our	O
results	O
suggest	O
that	O
the	O
vaccination	O
protocol	O
used	O
may	O
be	O
ideal	O
for	O
providing	O
effective	O
,	O
broad	O
and	O
long	O
-	O
term	O
protection	O
against	O
SARS	O
-	O
CoV	O
infection	O
.	O

Phylogenetic	O
analysis	O
and	O
sequence	O
alignments	O
demonstrated	O
that	O
recombination	O
events	O
had	O
occurred	O
in	O
the	O
origin	O
and	O
evolution	O
of	O
the	O
strains	O
CK	O
/	O
CH	O
/	O
LSD	B-PRGE
/	O
03I	O
and	O
CK	O
/	O
CH	O
/	O
LLN	O
/	O
98I	O
and	O
the	O
possible	O
recombinant	O
junction	O
sites	O
might	O
be	O
located	O
at	O
the	O
3c	O
and	O
M	O
genes	O
,	O
respectively	O
.	O

Structure	O
-	O
activity	O
relationships	O
and	O
modeling	O
studies	O
indicate	O
that	O
three	O
aromatic	O
rings	O
,	O
including	O
a	O
5	O
-	O
bromopyridin	O
-	O
3	O
-	O
yl	O
moiety	O
,	O
are	O
key	O
features	O
for	O
good	O
inhibition	O
of	O
SARS	B-PRGE
3CL	I-PRGE
(	I-PRGE
pro	I-PRGE
).	I-PRGE

This	O
suggests	O
that	O
recombinant	O
protein	O
/	O
peptide	O
-	O
based	O
subunit	O
vaccines	O
containing	O
the	O
spike	O
protein	O
,	O
especially	O
the	O
receptor	O
-	O
bind	O
domain	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
could	O
be	O
developed	O
as	O
safe	O
and	O
effective	O
SARS	O
vaccines	O
.	O

However	O
,	O
the	O
mechanism	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
(	O
pro	B-PRGE
)	O
dimerization	O
,	O
especially	O
the	O
roles	O
of	O
its	O
N	O
-	O
terminal	O
seven	O
residues	O
(	O
N	O
-	O
finger	O
)	O
and	O
its	O
unique	O
C	O
-	O
terminal	O
domain	O
in	O
the	O
dimerization	O
,	O
remain	O
unclear	O
.	O

Both	O
viruses	O
accumulated	O
similar	O
amounts	O
of	O
virus	O
-	O
specific	O
mRNAs	O
and	O
nsp1	B-PRGE
protein	I-PRGE
in	O
infected	O
cells	O
,	O
whereas	O
the	O
amounts	O
of	O
endogenous	O
host	O
mRNAs	O
were	O
clearly	O
higher	O
in	O
SARS	O
-	O
CoV	O
-	O
mt	O
-	O
infected	O
cells	O
than	O
in	O
SARS	O
-	O
CoV	O
-	O
WT	O
-	O
infected	O
cells	O
,	O
in	O
both	O
the	O
presence	O
and	O
absence	O
of	O
actinomycin	O
D	O
.	O
Further	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
WT	I-PRGE
replication	O
strongly	O
inhibited	O
host	O
protein	O
synthesis	O
,	O
whereas	O
host	B-PRGE
protein	I-PRGE
synthesis	O
inhibition	O
in	O
SARS	O
-	O
CoV	O
-	O
mt	O
-	O
infected	O
cells	O
was	O
not	O
as	O
efficient	O
as	O
in	O
SARS	O
-	O
CoV	O
-	O
WT	O
-	O
infected	O
cells	O
.	O

These	O
data	O
revealed	O
that	O
nsp1	B-PRGE
indeed	O
promoted	O
host	O
mRNA	O
degradation	O
and	O
contributed	O
to	O
host	O
protein	O
translation	O
inhibition	O
in	O
infected	O
cells	O
.	O

ABSTRACT	O
:	O
RNase	B-PRGE
-	O
resistant	O
,	O
noninfectious	O
virus	O
-	O
like	O
particles	O
containing	O
exogenous	O
RNA	O
sequences	O
(	O
armored	O
RNA	O
)	O
are	O
good	O
candidates	O
as	O
RNA	O
controls	O
and	O
standards	O
in	O
RNA	O
virus	O
detection	O
.	O

A	O
3V	O
armored	O
L	O
-	O
RNA	O
of	O
2	O
,	O
248	O
bases	O
containing	O
six	O
gene	O
fragments	O
-	O
hepatitis	O
C	O
virus	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	B-PRGE
-	O
CoV1	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV2	I-PRGE
,	O
and	O
SARS	O
-	O
CoV3	O
),	O
avian	O
influenza	O
virus	O
matrix	O
gene	O
(	O
M300	O
),	O
and	O
H5N1	O
avian	O
influenza	O
virus	O
(	O
HA300	O
)-	O
was	O
successfully	O
expressed	O
by	O
the	O
two	O
-	O
plasmid	O
coexpression	O
system	O
and	O
was	O
demonstrated	O
to	O
have	O
all	O
of	O
the	O
characteristics	O
of	O
armored	O
RNA	O
.	O

Elevated	O
concentrations	O
of	O
the	O
proinflammatory	O
cytokines	O
,	O
interleukin	B-PRGE
(	O
IL	O
)-	O
6	O
and	O
IL	O
-	O
8	O
,	O
in	O
both	O
plasma	O
and	O
the	O
pulmonary	O
edema	O
fluid	O
,	O
suggested	O
a	O
possible	O
role	O
of	O
systemic	O
and	O
pulmonary	O
inflammation	O
in	O
the	O
development	O
of	O
this	O
acute	O
pulmonary	O
capillary	O
leak	O
.	O

The	O
association	O
between	O
genetic	O
polymorphisms	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
gene	I-PRGE
and	O
susceptibility	O
to	O
severe	O
acute	O
respiratory	O
syndromes	O
(	O
SARS	O
)	O
was	O
conducted	O
in	O
a	O
hospital	O
-	O
based	O
case	O
-	O
control	O
study	O
including	O
75	O
SARS	O
patients	O
,	O
41	O
health	O
care	O
workers	O
and	O
92	O
healthy	O
controls	O
.	O

SNPs	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
gene	I-PRGE
of	I-PRGE
promoter	I-PRGE
region	I-PRGE
may	O
not	O
associate	O
with	O
SARS	O
-	O
CoV	O
infection	O
.	O

CONCLUSIONS	O
:	O
SNPs	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
gene	I-PRGE
of	I-PRGE
promoter	I-PRGE
region	I-PRGE
may	O
not	O
associate	O
with	O
SARS	O
-	O
CoV	O
infection	O
.	O

The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
SARS	B-PRGE
-	O
CoV	O
plays	O
an	O
important	O
role	O
in	O
the	O
virus	O
entry	O
into	O
a	O
cell	O
.	O

All	O
patients	O
presented	O
antibodies	O
to	O
lipopolysaccharides	O
and	O
alpha	B-PRGE
-	I-PRGE
hemolysin	I-PRGE
,	O
but	O
the	O
level	O
did	O
not	O
correlate	O
with	O
P	O
(	O
a	O
)	O
O	O
(	O
2	O
)/	O
F	O
(	O
i	O
)	O
O	O
(	O
2	O
).	O

Here	O
,	O
we	O
will	O
review	O
the	O
most	O
recent	O
findings	O
on	O
the	O
interaction	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
related	O
Coronaviridae	O
members	O
with	O
the	O
type	B-PRGE
I	I-PRGE
interferon	I-PRGE
and	O
cytokine	O
responses	O
and	O
discuss	O
implications	O
for	O
pathogenesis	O
and	O
therapy	O
.	O

Furthermore	O
,	O
SARS	O
-	O
CoV	O
infections	O
and	O
the	O
Spike	O
protein	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
reduce	O
ACE2	B-PRGE
expression	O
.	O

Gene	O
and	O
protein	O
expression	O
of	O
lung	O
Na	O
,	O
K	B-PRGE
-	I-PRGE
ATPase	I-PRGE
alpha1	I-PRGE
,	I-PRGE
alpha2	I-PRGE
,	I-PRGE
and	I-PRGE
beta1	I-PRGE
subunits	I-PRGE
were	O
quantified	O
via	O
real	O
-	O
time	O
PCR	O
and	O
immunobiological	O
analyses	O
,	O
respectively	O
.	O

Additionally	O
mimicyp	O
lacks	O
peptidyl	B-PRGE
-	I-PRGE
prolyl	I-PRGE
isomerase	I-PRGE
activity	O
in	O
contrast	O
to	O
human	B-PRGE
cyclophilins	I-PRGE
.	O

The	O
antibodies	O
induced	O
by	O
rMV	O
-	O
S	O
had	O
a	O
high	O
neutralising	O
effect	O
on	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
as	O
well	O
as	O
on	O
MV	O
.	O

In	O
21	O
subjects	O
with	O
tracheobronchial	O
samples	O
collected	O
within	O
6	O
.	O
5	O
hours	O
of	O
intubation	O
,	O
14	O
(	O
66	O
.	O
7	O
%)	O
developed	O
acute	O
hypoxemia	O
(	O
Pao2	B-PRGE
/	O
Fio2	O
<	O
or	O
=	O
200	O
)	O
within	O
72	O
hours	O
of	O
exposure	O
and	O
nine	O
(	O
42	O
.	O
9	O
%)	O
developed	O
ARDS	O
,	O
as	O
defined	O
by	O
the	O
American	O
-	O
European	O
consensus	O
conference	O
on	O
ARDS	O
.	O

The	O
mRNA	O
of	O
human	B-PRGE
ACE2	I-PRGE
was	O
expressed	O
efficiently	O
in	O
the	O
normal	O
lung	O
tissue	O
,	O
but	O
not	O
in	O
the	O
cartilage	O
and	O
cancellous	O
bone	O
under	O
the	O
weight	O
-	O
bearing	O
area	O
of	O
the	O
femoral	O
head	O
.	O

Phylogenetic	O
analysis	O
showed	O
co	O
-	O
circulation	O
of	O
hMPV	O
and	O
HCoV	O
NL63	O
A	O
and	O
B	O
lineages	O
,	O
although	O
only	O
HBoV	B-PRGE
genotype	I-PRGE
st2	I-PRGE
was	O
found	O
.	O

In	O
this	O
regard	O
,	O
a	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
variant	O
with	O
increased	O
replication	O
capacity	O
in	O
PTEC	O
was	O
selected	O
after	O
four	O
serial	O
subculture	O
passages	O
.	O

It	O
depressed	O
the	O
Na	B-PRGE
+-	I-PRGE
K	I-PRGE
+-	I-PRGE
ATPase	I-PRGE
activity	O
but	O
up	O
-	O
regulated	O
inducible	O
nitric	B-PRGE
oxide	I-PRGE
synthase	I-PRGE
.	O

Serological	O
cross	O
-	O
reactivity	O
between	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
human	B-PRGE
CoV	I-PRGE
-	I-PRGE
OC43	I-PRGE
(	O
HCoV	O
-	O
OC43	O
)	O
was	O
investigated	O
by	O
peptide	O
spot	O
assay	O
.	O

This	O
observation	O
suggests	O
that	O
the	O
localization	O
of	O
viral	B-PRGE
antigen	I-PRGE
to	O
white	O
matter	O
during	O
the	O
acute	O
stage	O
of	O
infection	O
is	O
essential	O
for	O
the	O
induction	O
of	O
chronic	O
demyelination	O
.	O

M	O
,	O
N	O
and	O
S2	O
protein	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
were	O
detected	O
by	O
western	O
blotting	O
and	O
immunohistochemistry	O
analysis	O
.	O

Further	O
assays	O
demonstrated	O
that	O
expression	O
of	O
hfgl2	B-PRGE
gene	I-PRGE
was	O
related	O
with	O
N	B-PRGE
protein	I-PRGE
,	O
but	O
not	O
with	O
M	O
or	O
S2	O
protein	O
in	O
THP	O
-	O
1	O
cells	O
and	O
Vero	O
cells	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
and	O
EMSA	O
assay	O
further	O
demonstrated	O
that	O
transcription	B-PRGE
factor	I-PRGE
C	I-PRGE
/	I-PRGE
EBP	I-PRGE
alpha	I-PRGE
band	O
with	O
its	O
cognate	O
cis	O
-	O
element	O
in	O
hfgl2	O
promoter	O
.	O

Similar	O
to	O
other	O
N	O
-	O
glycosylated	O
proteins	O
,	O
glycosylation	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
protein	I-PRGE
was	O
occurred	O
co	O
-	O
translationally	O
in	O
the	O
presence	O
of	O
microsomes	O
.	O

These	O
micropanned	O
epitope	O
regions	O
(	O
MER	O
)	O
were	O
focused	O
on	O
696	O
-	O
779	O
amino	O
acids	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
.	O

ABSTRACT	O
:	O
Severe	O
disease	O
induced	O
by	O
porcine	B-PRGE
circovirus	I-PRGE
type	I-PRGE
2	I-PRGE
(	O
PCV2	O
)	O
was	O
observed	O
in	O
three	O
pigs	O
originating	O
from	O
a	O
large	O
herd	O
affected	O
by	O
respiratory	O
and	O
digestive	O
signs	O
as	O
well	O
as	O
wasting	O
.	O

ABSTRACT	O
:	O
The	O
related	O
3C	O
and	O
3C	O
-	O
like	O
proteinase	O
(	O
3C	O
(	O
pro	O
)	O
and	O
3CL	O
(	O
pro	B-PRGE
))	O
of	O
picornaviruses	O
and	O
coronaviruses	O
,	O
respectively	O
,	O
are	O
good	O
drug	O
targets	O
.	O

The	O
unusually	O
complex	O
coronavirus	O
replicase	B-PRGE
/	I-PRGE
transcriptase	I-PRGE
is	O
comprised	O
of	O
15	O
or	O
16	O
virus	O
-	O
specific	O
subunits	O
that	O
are	O
autoproteolytically	O
derived	O
from	O
two	O
large	O
polyproteins	O
.	O

Furthermore	O
,	O
residues	O
Y29	O
and	O
F173	O
of	O
FCoV	O
nsp16	O
,	O
which	O
may	O
be	O
the	O
functional	O
counterparts	O
of	O
aromatic	O
residues	O
involved	O
in	O
substrate	O
recognition	O
by	O
the	O
vaccinia	B-PRGE
virus	I-PRGE
MTase	I-PRGE
VP39	I-PRGE
,	O
were	O
found	O
to	O
be	O
essential	O
for	O
both	O
substrate	O
binding	O
and	O
2	B-PRGE
'	I-PRGE
O	I-PRGE
-	I-PRGE
MTase	I-PRGE
activity	O
.	O

An	O
adoptive	O
transfer	O
model	O
was	O
used	O
to	O
elucidate	O
the	O
kinetics	O
of	O
CD8	B-PRGE
(+)	O
T	O
-	O
cell	O
priming	O
during	O
CNS	O
infection	O
with	O
RJHM	O
as	O
well	O
as	O
with	O
two	O
MHV	O
strains	O
that	O
induce	O
a	O
robust	O
CD8	B-PRGE
(+)	O
T	O
-	O
cell	O
response	O
(	O
RA59	O
and	O
SJHM	O
/	O
RA59	O
,	O
a	O
recombinant	O
A59	O
virus	O
expressing	O
the	O
JHM	O
spike	O
).	O

Notably	O
,	O
the	O
weak	O
CD8	B-PRGE
(+)	O
T	O
-	O
cell	O
response	O
elicited	O
by	O
RJHM	O
was	O
unique	O
to	O
CNS	O
infection	O
,	O
since	O
peripheral	O
inoculation	O
induced	O
a	O
robust	O
CD8	B-PRGE
(+)	O
T	O
-	O
cell	O
response	O
in	O
the	O
spleen	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
reported	O
the	O
detection	O
of	O
bat	O
coronaviruses	O
(	O
bat	B-PRGE
CoVs	I-PRGE
1A	I-PRGE
,	O
1B	O
,	O
HKU7	O
,	O
HKU8	O
and	O
bat	O
-	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
)	O
in	O
Miniopterus	O
spp	O
.	O

ABSTRACT	O
:	O
Multiple	O
lung	O
pathogens	O
such	O
as	O
chemical	O
agents	O
,	O
H5N1	B-PRGE
avian	I-PRGE
flu	I-PRGE
,	O
or	O
SARS	O
cause	O
high	O
lethality	O
due	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

The	O
oxidized	O
phospholipid	O
(	O
OxPL	O
)	O
OxPAPC	O
was	O
identified	O
to	O
induce	O
lung	O
injury	O
and	O
cytokine	O
production	O
by	O
lung	O
macrophages	O
via	O
TLR4	B-PRGE
-	I-PRGE
TRIF	I-PRGE
.	O

The	O
results	O
suggest	O
that	O
the	O
Trp	O
-	O
rich	O
region	O
of	O
S	B-PRGE
protein	I-PRGE
is	O
essential	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
infectivity	O
.	O

TITLE	O
:	O
Characterization	O
of	O
ubiquitin	B-PRGE
and	O
ubiquitin	B-PRGE
-	I-PRGE
like	I-PRGE
-	I-PRGE
protein	I-PRGE
isopeptidase	I-PRGE
activities	O
.	O

Herein	O
is	O
described	O
a	O
readily	O
quantifiable	O
novel	O
isopeptidase	O
assay	O
platform	O
consisting	O
of	O
Ub	O
or	O
UBL	O
fused	O
to	O
the	O
reporter	B-PRGE
enzyme	I-PRGE
phospholipase	I-PRGE
A	I-PRGE
(	I-PRGE
2	I-PRGE
)	I-PRGE
(	O
PLA	O
(	O
2	O
)).	O

Immunohistochemically	O
,	O
all	O
cases	O
were	O
positive	O
for	O
coronavirus	B-PRGE
antigen	I-PRGE
using	I-PRGE
monoclonal	I-PRGE
antibody	I-PRGE
FIPV3	I-PRGE
-	I-PRGE
70	I-PRGE
.	O

The	O
identification	O
of	O
antigenic	B-PRGE
N	I-PRGE
protein	I-PRGE
fragments	I-PRGE
has	O
implications	O
to	O
provide	O
basic	O
information	O
for	O
the	O
design	O
of	O
DNA	O
vaccine	O
against	O
SARS	O
-	O
CoV	O
.	O
The	O
present	O
results	O
not	O
only	O
suggest	O
that	O
DNA	O
immunization	O
with	O
pVax	O
-	O
N3	O
could	O
be	O
used	O
as	O
potential	O
DNA	O
vaccination	O
approaches	O
to	O
induce	O
antibody	O
in	O
BALB	O
/	O
c	O
mice	O
,	O
but	O
also	O
illustrates	O
that	O
gene	O
immunization	O
with	O
these	O
SARS	O
DNA	O
vaccines	O
can	O
generate	O
different	O
immune	O
responses	O
.	O

TITLE	O
:	O
The	O
nucleocapsid	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
inhibits	O
cell	O
cytokinesis	O
and	O
proliferation	O
by	O
interacting	O
with	O
translation	B-PRGE
elongation	I-PRGE
factor	I-PRGE
1alpha	I-PRGE
.	O

Using	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
with	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
as	O
a	O
bait	O
,	O
the	O
C	O
terminus	O
(	O
amino	O
acids	O
251	O
to	O
422	O
)	O
of	O
the	O
N	B-PRGE
protein	I-PRGE
was	O
found	O
to	O
interact	O
with	O
human	O
elongation	B-PRGE
factor	I-PRGE
1	O
-	O
alpha	O
(	O
EF1alpha	B-PRGE
),	O
an	O
essential	O
component	O
of	O
the	O
translational	O
machinery	O
with	O
an	O
important	O
role	O
in	O
cytokinesis	O
,	O
promoting	O
the	O
bundling	O
of	O
filamentous	O
actin	B-PRGE
(	O
F	B-PRGE
-	I-PRGE
actin	I-PRGE
).	O

SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
protein	I-PRGE
6	I-PRGE
increases	O
MHV	O
neurovirulence	O
and	O
accelerates	O
MHV	O
infection	O
kinetics	O
in	O
tissue	O
culture	O
.	O

These	O
structures	O
,	O
combined	O
with	O
a	O
previously	O
determined	O
structure	O
of	O
human	B-PRGE
ACE2	I-PRGE
complexed	O
with	O
the	O
RBD	O
from	O
a	O
human	O
SARS	O
-	O
CoV	O
strain	O
,	O
have	O
revealed	O
a	O
structural	O
basis	O
for	O
understanding	O
the	O
major	O
species	O
barriers	O
between	O
humans	O
and	O
civets	O
for	O
SARS	O
-	O
CoV	O
infections	O
.	O

They	O
show	O
that	O
the	O
major	O
species	O
barriers	O
are	O
determined	O
by	O
interactions	O
between	O
four	O
ACE2	O
residues	O
(	O
residues	O
31	O
,	O
35	O
,	O
38	O
,	O
and	O
353	O
)	O
and	O
two	O
RBD	O
residues	O
(	O
residues	O
479	O
and	O
487	O
),	O
that	O
early	O
civet	O
SARS	O
-	O
CoV	O
isolates	O
were	O
prevented	O
from	O
infecting	O
human	O
cells	O
due	O
to	O
imbalanced	O
salt	O
bridges	O
at	O
the	O
hydrophobic	O
virus	O
/	O
receptor	O
interface	O
,	O
and	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
has	O
evolved	O
to	O
gain	O
sustained	O
infectivity	O
for	O
human	O
cells	O
by	O
eliminating	O
unfavorable	O
free	O
charges	O
at	O
the	O
interface	O
through	O
stepwise	O
mutations	O
at	O
positions	O
479	O
and	O
487	O
.	O

Angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
cleaves	O
angiotensin	B-PRGE
I	I-PRGE
to	O
generate	O
angiotensin	B-PRGE
II	I-PRGE
,	O
which	O
is	O
a	O
key	O
effector	O
peptide	O
of	O
the	O
system	O
and	O
exerts	O
multiple	O
biological	O
functions	O
,	O
whereas	O
ACE2	B-PRGE
reduces	O
angiotensin	B-PRGE
II	I-PRGE
levels	O
.	O

Angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
)	O
is	O
the	O
cellular	O
receptor	O
for	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

These	O
findings	O
support	O
the	O
involvement	O
of	O
ACE2	B-PRGE
in	O
SARS	O
-	O
CoV	O
infections	O
and	O
provide	O
a	O
basis	O
for	O
further	O
studies	O
on	O
potential	O
use	O
of	O
siRNA	O
targeting	O
ACE2	B-PRGE
as	O
a	O
preventive	O
or	O
therapeutic	O
strategy	O
for	O
SARS	O
.	O

Furthermore	O
,	O
the	O
pelleted	O
RTC	O
required	O
the	O
addition	O
of	O
a	O
cytoplasmic	B-PRGE
host	I-PRGE
factor	I-PRGE
for	O
reconstitution	O
of	O
its	O
in	O
vitro	O
activity	O
.	O

Our	O
data	O
establish	O
a	O
vital	O
functional	O
dependence	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
synthesis	O
on	O
virus	O
-	O
induced	O
membrane	O
structures	O
.	O

Therefore	O
early	O
prevention	O
and	O
correct	O
management	O
on	O
the	O
risk	O
factors	O
play	O
critical	O
roles	O
in	O
reducing	O
the	O
mortality	O
of	O
SAP	B-PRGE
.	O

Multiple	O
-	O
factor	O
Logistic	O
regression	O
analysis	O
indicated	O
that	O
the	O
MODS	O
(	O
OR	O
=	O
67	O
.	O
358	O
,	O
P	O
<	O
0	O
.	O
01	O
),	O
APACHE	O
II	O
score	O
(	O
OR	O
=	O
9	O
.	O
716	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
ACS	O
(	O
OR	O
=	O
5	O
.	O
775	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
were	O
the	O
independent	O
risk	O
factors	O
affecting	O
the	O
prognosis	O
of	O
SAP	B-PRGE
during	O
its	O
early	O
stage	O
,	O
whereas	O
pancreatic	O
infection	O
(	O
OR	O
=	O
9	O
.	O
652	O
,	O
P	O
<	O
0	O
.	O
01	O
),	O
MODS	O
(	O
OR	O
=	O
5	O
.	O
212	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
celiac	O
hemorrhage	O
(	O
OR	O
=	O
4	O
.	O
707	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
were	O
the	O
independent	O
risk	O
factors	O
during	O
the	O
advanced	O
stage	O
of	O
SAP	B-PRGE
.	O

The	O
culprit	O
,	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
was	O
detected	O
in	O
patient	O
specimens	O
by	O
traditional	O
cell	O
culture	O
using	O
an	O
unusual	O
cell	O
line	O
for	O
respiratory	O
viruses	O
,	O
Vero	O
E6	O
,	O
and	O
by	O
reverse	B-PRGE
transcriptase	I-PRGE
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
targeting	O
the	O
polymerase	B-PRGE
1	I-PRGE
B	I-PRGE
region	O
of	O
the	O
genome	O
.	O

A	O
type	O
of	O
medium	O
or	O
low	O
titer	O
anti	B-PRGE
-	I-PRGE
lung	I-PRGE
tissue	I-PRGE
antibodies	I-PRGE
were	O
found	O
in	O
the	O
sera	O
of	O
SARS	O
patients	O
at	O
the	O
early	O
stage	O
of	O
the	O
disease	O
.	O

ABSTRACT	O
:	O
Rapid	O
and	O
sensitive	O
detection	O
of	O
SARS	B-PRGE
associated	O
coronavirus	O
is	O
critical	O
for	O
early	O
diagnosis	O
and	O
control	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

The	O
genotypes	O
of	O
4SNPs	O
on	O
IL	B-PRGE
-	I-PRGE
12	I-PRGE
RB1	I-PRGE
gene	I-PRGE
,	O
+	O
705A	O
/	O
G	O
,+	O
1158T	O
/	O
C	O
,	O
+	B-PRGE
1196G	I-PRGE
/	I-PRGE
C	I-PRGE
and	I-PRGE
+	I-PRGE
1664	I-PRGE
C	I-PRGE
/	O
T	O
,	O
were	O
determined	O
by	O
PCR	O
-	O
RFLP	O
.	O

Viral	B-PRGE
antigen	I-PRGE
was	O
detected	O
only	O
in	O
calves	O
inoculated	O
at	O
75	O
days	O
of	O
gestation	O
,	O
i	O
.	O
e	O
.,	O
persistently	O
infected	O
.	O

TITLE	O
:	O
Modulation	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
by	O
the	O
spike	O
protein	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
ACE2	B-PRGE
induces	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
production	O
and	O
facilitates	O
viral	O
entry	O
.	O

These	O
data	O
suggest	O
that	O
cellular	O
signals	O
triggered	O
by	O
the	O
interaction	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
with	O
ACE2	B-PRGE
are	O
positively	O
involved	O
in	O
viral	O
entry	O
but	O
lead	O
to	O
tissue	O
damage	O
.	O

We	O
designed	O
a	O
recombinant	O
HCoV	O
-	O
229E	O
and	O
a	O
recombinant	B-PRGE
HCoV	I-PRGE
-	I-PRGE
NL63	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
enzyme	I-PRGE
-	O
linked	O
immunosorbent	O
assay	O
and	O
performed	O
a	O
seroepidemiology	O
survey	O
on	O
longitudinal	O
and	O
cross	O
-	O
sectional	O
serum	O
samples	O
.	O

TITLE	O
:	O
[	O
Role	O
of	O
AQP	B-PRGE
-	I-PRGE
4	I-PRGE
in	O
pulmonary	O
water	O
metabolism	O
in	O
rats	O
in	O
early	O
stage	O
of	O
oleic	O
acid	O
-	O
induced	O
acute	O
lung	O
injury	O
].	O

ABSTRACT	O
:	O
To	O
develop	O
an	O
simple	O
and	O
sensitive	O
method	O
for	O
detecting	O
anti	B-PRGE
-	I-PRGE
coronavirus	I-PRGE
IgG	I-PRGE
antibodies	I-PRGE
in	O
bat	O
sera	O
based	O
on	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
).	O

A	O
commercial	O
ELISA	O
kit	O
for	O
detecting	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
antibody	I-PRGE
was	O
modified	O
for	O
detecting	O
coronavirus	O
antibodies	O
in	O
bat	O
serum	O
samples	O
.	O

The	O
TCoV	B-PRGE
polyprotein	I-PRGE
gene	I-PRGE
encoded	O
two	O
open	O
reading	O
frames	O
(	O
ORFs	O
),	O
which	O
are	O
translated	O
into	O
two	O
products	O
,	O
pp1a	B-PRGE
and	O
pp1ab	O
,	O
the	O
latter	O
being	O
produced	O
via	O
-	O
1	O
frameshift	O
translation	O
.	O

The	O
lung	O
superoxide	B-PRGE
dismutase	I-PRGE
(	O
SOD	B-PRGE
),	O
catalase	B-PRGE
and	O
glutathione	B-PRGE
peroxidase	I-PRGE
activities	O
were	O
decreased	O
in	O
the	O
sepsis	O
group	O
as	O
compared	O
to	O
the	O
group	O
control	O
,	O
sham	O
,	O
leflunomide	O
and	O
sepsis	O
+	O
leflunomide	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
and	O
SOD	B-PRGE
activity	O
were	O
significantly	O
higher	O
in	O
group	O
sepsis	O
+	O
leflunomide	O
than	O
sham	O
,	O
control	O
,	O
leflunomide	O
and	O
sepsis	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
results	O
showed	O
that	O
there	O
were	O
high	O
phylogenetic	O
diversity	O
among	O
the	O
IBVs	O
prevailed	O
in	O
the	O
field	O
in	O
Guangxi	O
resulting	O
from	O
the	O
commonly	O
occurred	O
mutation	O
or	O
insertion	O
within	O
the	O
S1	B-PRGE
gene	I-PRGE
HVR	I-PRGE
I	I-PRGE
of	O
the	O
viruses	O
,	O
and	O
majority	O
of	O
the	O
isolates	O
had	O
lower	O
homology	O
with	O
the	O
commonly	O
used	O
Mass	O
type	O
vaccine	O
strains	O
.	O

Here	O
,	O
the	O
crystal	O
structure	O
of	O
HLA	B-PRGE
-	I-PRGE
B	I-PRGE
*	I-PRGE
1501	I-PRGE
in	O
complex	O
with	O
a	O
SARS	O
coronavirus	O
-	O
derived	O
nonapeptide	O
(	O
VQQESSFVM	O
)	O
has	O
been	O
determined	O
at	O
high	O
resolution	O
(	O
1	O
.	O
87	O
A	O
).	O

The	O
peptide	O
is	O
deeply	O
anchored	O
in	O
the	O
B	O
and	O
F	O
pockets	O
,	O
but	O
with	O
the	O
Glu4	O
residue	O
pointing	O
away	O
from	O
the	O
floor	O
in	O
the	O
peptide	O
-	O
binding	O
groove	O
,	O
making	O
it	O
available	O
for	O
interactions	O
with	O
a	O
potential	O
T	B-PRGE
-	I-PRGE
cell	I-PRGE
receptor	I-PRGE
.	O

(	O
2	O
)	O
Caspase	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
p73	B-PRGE
mRNA	I-PRGE
expressions	O
in	O
lung	O
tissue	O
in	O
HFOV	O
group	O
and	O
HFOV	O
+	O
PS	O
group	O
were	O
significantly	O
lower	O
than	O
those	O
of	O
CMV	O
group	O
and	O
CMV	O
+	O
PS	O
group	O
(	O
all	O
P	O
<	O
0	O
.	O
01	O
).	O

Compared	O
with	O
CMV	O
or	O
CMV	O
+	O
PS	O
,	O
HFOV	O
or	O
HFOV	O
+	O
PS	O
can	O
decrease	O
the	O
concentration	O
of	O
caspase	B-PRGE
-	I-PRGE
3	I-PRGE
and	O
p73	B-PRGE
,	O
reduce	O
the	O
mRNA	O
expression	O
of	O
caspase	B-PRGE
-	I-PRGE
3	I-PRGE
and	O
p73	B-PRGE
in	O
the	O
lung	O
homogenates	O
,	O
as	O
a	O
result	O
lung	O
tissue	O
apoptosis	O
in	O
inhalation	O
injury	O
may	O
be	O
suppressed	O
.	O

Caspase	B-PRGE
-	I-PRGE
3	I-PRGE
and	O
p73	B-PRGE
mRNA	I-PRGE
expression	O
in	O
lung	O
tissue	O
in	O
groups	O
with	O
exogenous	O
PS	O
group	O
were	O
significantly	O
lower	O
than	O
those	O
of	O
the	O
corresponding	O
group	O
without	O
exogenous	O
PS	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

CONCLUSIONS	O
:	O
Compared	O
with	O
CMV	O
or	O
CMV	O
+	O
PS	O
,	O
HFOV	O
or	O
HFOV	O
+	O
PS	O
can	O
decrease	O
the	O
concentration	O
of	O
caspase	B-PRGE
-	I-PRGE
3	I-PRGE
and	O
p73	B-PRGE
,	O
reduce	O
the	O
mRNA	O
expression	O
of	O
caspase	B-PRGE
-	I-PRGE
3	I-PRGE
and	O
p73	B-PRGE
in	O
the	O
lung	O
homogenates	O
,	O
as	O
a	O
result	O
lung	O
tissue	O
apoptosis	O
in	O
inhalation	O
injury	O
may	O
be	O
suppressed	O
.	O

TITLE	O
:	O
Mouse	O
hepatitis	O
virus	O
type	O
2	O
enters	O
cells	O
through	O
a	O
clathrin	B-PRGE
-	O
mediated	O
endocytic	O
pathway	O
independent	O
of	O
Eps15	B-PRGE
.	O

In	O
addition	O
,	O
overexpression	O
of	O
a	O
dominant	O
-	O
negative	O
mutant	O
of	O
caveolin	B-PRGE
1	I-PRGE
did	O
not	O
have	O
any	O
effect	O
on	O
MHV	O
-	O
2	O
infection	O
,	O
while	O
it	O
significantly	O
blocked	O
the	O
caveolin	B-PRGE
-	I-PRGE
dependent	I-PRGE
uptake	I-PRGE
of	I-PRGE
cholera	I-PRGE
toxin	I-PRGE
subunit	I-PRGE
B	I-PRGE
.	O
These	O
results	O
demonstrate	O
that	O
MHV	O
-	O
2	O
utilizes	O
the	O
clathrin	B-PRGE
-	O
but	O
not	O
caveolin	B-PRGE
-	O
mediated	O
endocytic	O
pathway	O
for	O
entry	O
.	O

Interestingly	O
,	O
when	O
the	O
cells	O
transiently	O
overexpressed	O
a	O
dominant	O
-	O
negative	O
form	O
(	O
DIII	O
)	O
of	O
Eps15	B-PRGE
,	O
which	O
is	O
thought	O
to	O
be	O
an	O
essential	O
component	O
of	O
the	O
clathrin	B-PRGE
pathway	O
,	O
viral	O
gene	O
expression	O
and	O
infectivity	O
were	O
unaffected	O
,	O
although	O
DIII	O
expression	O
blocked	O
transferrin	B-PRGE
uptake	O
and	O
vesicular	O
stomatitis	O
virus	O
infection	O
,	O
which	O
are	O
dependent	O
on	O
clathrin	B-PRGE
-	O
mediated	O
endocytosis	O
.	O

TITLE	O
:	O
Structure	O
of	O
coronavirus	O
hemagglutinin	O
-	O
esterase	B-PRGE
offers	O
insight	O
into	O
corona	O
and	O
influenza	O
virus	O
evolution	O
.	O

ABSTRACT	O
:	O
The	O
hemagglutinin	O
-	O
esterases	O
(	O
HEs	B-PRGE
)	O
are	O
a	O
family	O
of	O
viral	B-PRGE
envelope	I-PRGE
glycoproteins	I-PRGE
that	O
mediate	O
reversible	O
attachment	O
to	O
O	O
-	O
acetylated	O
sialic	O
acids	O
by	O
acting	O
both	O
as	O
lectins	O
and	O
as	O
receptor	O
-	O
destroying	O
enzymes	O
(	O
RDEs	O
).	O

Whereas	O
the	O
structural	O
design	O
of	O
the	O
RDE	O
-	O
acetylesterase	O
domain	O
remained	O
unaltered	O
,	O
the	O
HE	B-PRGE
receptor	I-PRGE
-	I-PRGE
binding	I-PRGE
domain	I-PRGE
underwent	O
remodeling	O
to	O
such	O
extent	O
that	O
the	O
ligand	O
is	O
now	O
bound	O
in	O
opposite	O
orientation	O
.	O

We	O
attribute	O
the	O
plasticity	O
of	O
the	O
CoV	B-PRGE
HE	I-PRGE
receptor	I-PRGE
-	I-PRGE
binding	I-PRGE
site	I-PRGE
to	O
evolutionary	O
flexibility	O
conferred	O
by	O
functional	O
redundancy	O
between	O
HE	O
and	O
its	O
companion	O
spike	O
protein	O
S	O
.	O
Our	O
findings	O
offer	O
unique	O
insights	O
into	O
the	O
structural	O
and	O
functional	O
consequences	O
of	O
independent	O
protein	O
evolution	O
after	O
interviral	O
gene	O
exchange	O
and	O
open	O
potential	O
avenues	O
to	O
broad	O
-	O
spectrum	O
antiviral	O
drug	O
design	O
.	O

MHV	O
RNA	O
replication	O
was	O
not	O
sensitive	O
to	O
BFA	O
in	O
MDCK	O
cells	O
,	O
which	O
are	O
known	O
to	O
express	O
the	O
BFA	B-PRGE
-	I-PRGE
resistant	I-PRGE
guanine	I-PRGE
nucleotide	I-PRGE
exchange	I-PRGE
factor	I-PRGE
GBF1	I-PRGE
.	O

The	O
CoV	O
main	O
protease	O
(	O
M	O
(	O
pro	O
)),	O
which	O
is	O
a	O
key	O
enzyme	O
in	O
viral	O
replication	O
via	O
the	O
proteolytic	O
processing	O
of	O
the	O
replicase	B-PRGE
polyproteins	I-PRGE
,	O
has	O
been	O
recognized	O
as	O
an	O
attractive	O
target	O
for	O
rational	O
drug	O
design	O
.	O

RESULTS	O
:	O
Significantly	O
altered	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
and	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
were	O
detected	O
within	O
the	O
first	O
7	O
days	O
after	O
admission	O
in	O
serum	O
from	O
burn	O
pediatric	O
patients	O
with	O
concomitant	O
inhalation	O
injury	O
who	O
did	O
not	O
survive	O
when	O
compared	O
with	O
similar	O
patients	O
who	O
did	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
data	O
show	O
recognition	O
of	O
prokaryotically	O
expressed	O
HIV	O
-	O
1	O
Gag	B-PRGE
/	O
p24	B-PRGE
fusion	O
protein	O
by	O
Western	O
blot	O
and	O
efficient	O
affinity	O
purification	O
using	O
monoclonal	O
antibodies	O
against	O
the	O
tags	O
.	O

Plasma	B-PRGE
protein	I-PRGE
C	I-PRGE
levels	O
are	O
decreased	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
and	O
are	O
associated	O
with	O
higher	O
mortality	O
and	O
fewer	O
ventilator	O
-	O
free	O
days	O
.	O

We	O
found	O
different	O
degrees	O
of	O
genetic	O
heterogeneity	O
among	O
the	O
four	O
vaccines	O
before	O
passage	O
in	O
chickens	O
,	O
ranging	O
from	O
no	O
apparent	O
heterogeneity	O
to	O
heterogeneity	O
in	O
20	O
positions	O
in	O
the	O
S	B-PRGE
gene	I-PRGE
.	O

Antibody	O
-	O
mediated	O
blocking	O
of	O
either	O
IL	B-PRGE
-	I-PRGE
23	I-PRGE
(	O
anti	O
-	O
IL	O
-	O
23p19	O
)	O
or	O
IL	O
-	O
12	O
and	O
IL	B-PRGE
-	I-PRGE
23	I-PRGE
(	O
anti	O
-	O
IL	O
-	O
12	O
/	O
23p40	O
)	O
signaling	O
did	O
not	O
mute	O
T	O
-	O
cell	O
trafficking	O
into	O
the	O
CNS	O
or	O
antiviral	O
effector	O
responses	O
and	O
mice	O
were	O
able	O
to	O
control	O
viral	O
replication	O
within	O
the	O
brain	O
.	O

Therapeutic	O
administration	O
of	O
either	O
anti	B-PRGE
-	I-PRGE
IL	I-PRGE
-	I-PRGE
23p19	I-PRGE
or	O
anti	O
-	O
IL	O
-	O
12	O
/	O
23p40	O
to	O
mice	O
with	O
viral	O
-	O
induced	O
demyelination	O
did	O
not	O
attenuate	O
T	O
-	O
cell	O
or	O
macrophage	O
infiltration	O
into	O
the	O
CNS	O
nor	O
improve	O
clinical	O
disease	O
or	O
diminish	O
white	O
matter	O
damage	O
.	O

In	O
contrast	O
,	O
treatment	O
of	O
mice	O
with	O
anti	O
-	O
IL	O
-	O
12	O
/	O
23p40	O
or	O
anti	B-PRGE
-	I-PRGE
IL	I-PRGE
-	I-PRGE
23p19	I-PRGE
resulted	O
in	O
inhibition	O
of	O
the	O
autoimmune	O
model	O
of	O
demyelination	O
,	O
experimental	O
autoimmune	O
encephalomyelitis	O
(	O
EAE	O
).	O

These	O
data	O
indicate	O
that	O
(	O
1	O
)	O
IL	O
-	O
12	O
and	O
IL	B-PRGE
-	I-PRGE
23	I-PRGE
signaling	O
are	O
dispensable	O
in	O
generating	O
a	O
protective	O
T	O
-	O
cell	O
response	O
following	O
CNS	O
infection	O
with	O
MHV	O
,	O
and	O
(	O
2	O
)	O
IL	O
-	O
12	O
and	O
IL	B-PRGE
-	I-PRGE
23	I-PRGE
do	O
not	O
contribute	O
to	O
demyelination	O
in	O
a	O
model	O
independent	O
of	O
autoimmune	O
T	O
-	O
cell	O
-	O
mediated	O
pathology	O
.	O

TITLE	O
:	O
Distinct	O
signature	O
type	B-PRGE
I	I-PRGE
interferon	I-PRGE
responses	O
are	O
determined	O
by	O
the	O
infecting	O
virus	O
and	O
the	O
target	O
cell	O
.	O

To	O
propagate	O
a	O
chimeric	O
recombinant	O
SARS	O
-	O
CoV	O
bearing	O
an	O
SZ16	B-PRGE
spike	I-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
glycoprotein	I-PRGE
(	O
icSZ16	O
-	O
S	O
),	O
we	O
constructed	O
cell	O
lines	O
expressing	O
the	O
civet	O
ortholog	O
(	O
DBT	O
-	O
cACE2	O
)	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
(	O
hACE2	O
).	O

Our	O
large	O
study	O
suggests	O
that	O
MBL	B-PRGE
plays	O
a	O
redundant	O
role	O
in	O
human	O
defenses	O
against	O
primary	O
infection	O
,	O
at	O
least	O
in	O
adults	O
with	O
CAP	O
,	O
and	O
provides	O
,	O
for	O
the	O
first	O
time	O
,	O
evidence	O
that	O
MBL	B-PRGE
insufficiency	O
predisposes	O
to	O
higher	O
severity	O
and	O
fatal	O
outcome	O
in	O
patients	O
with	O
CAP	O
,	O
irrespective	O
of	O
the	O
causal	O
microorganisms	O
.	O

All	O
infected	O
cats	O
and	O
ferrets	O
had	O
diffuse	O
alveolar	O
damage	O
associated	O
with	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
antigen	I-PRGE
expression	O
.	O

Ultimately	O
,	O
definitive	O
diagnosis	O
of	O
GBS	O
may	O
not	O
be	O
possible	O
;	O
however	O
,	O
an	O
empiric	O
course	O
of	O
intravenous	O
immunoglobulins	O
or	O
plasma	B-PRGE
-	I-PRGE
exchange	I-PRGE
may	O
be	O
warranted	O
,	O
if	O
GBS	O
is	O
a	O
reasonable	O
possibility	O
.	O

ABSTRACT	O
:	O
DC	O
-	O
SIGN	O
,	O
a	O
C	B-PRGE
-	I-PRGE
type	I-PRGE
lectin	I-PRGE
receptor	I-PRGE
expressed	O
in	O
dendritic	O
cells	O
(	O
DCs	O
),	O
has	O
been	O
identified	O
as	O
a	O
receptor	O
for	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
,	O
hepatitis	O
C	O
virus	O
,	O
Ebola	O
virus	O
,	O
cytomegalovirus	O
,	O
dengue	O
virus	O
,	O
and	O
the	O
SARS	O
coronavirus	O
.	O

Plasma	B-PRGE
IL	I-PRGE
-	I-PRGE
6	I-PRGE
levels	O
are	O
influenced	O
mainly	O
by	O
genetic	O
determinants	O
,	O
and	O
a	O
-	O
174G	O
/	O
C	O
polymorphism	O
of	O
the	O
gene	O
has	O
been	O
recently	O
associated	O
with	O
susceptibility	O
to	O
ALI	O
.	O

Genotypes	O
of	O
the	O
-	O
174G	O
/	O
C	O
polymorphism	O
along	O
with	O
other	O
14	O
tagging	O
variants	O
of	O
the	O
IL6	B-PRGE
gene	I-PRGE
were	O
evaluated	O
.	O

Twenty	O
polymorphisms	O
unlinked	O
to	O
IL6	B-PRGE
gene	I-PRGE
were	O
additionally	O
compared	O
between	O
cases	O
and	O
controls	O
to	O
rule	O
out	O
population	O
stratification	O
.	O

We	O
immunized	O
mice	O
with	O
UV	O
-	O
inactivated	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
to	O
generate	O
three	O
anti	B-PRGE
-	I-PRGE
S	I-PRGE
monoclonal	I-PRGE
antibodies	I-PRGE
,	O
and	O
established	O
several	O
neutralization	O
escape	O
mutants	O
with	O
S	B-PRGE
protein	I-PRGE
.	O

In	O
the	O
case	O
of	O
FIPV	O
-	O
1146	O
and	O
FIPV	O
-	O
DF2	O
,	O
infection	O
of	O
primary	O
feline	O
monocytes	O
was	O
also	O
dependent	O
on	O
host	B-PRGE
cell	I-PRGE
cathepsin	I-PRGE
B	I-PRGE
activity	O
,	O
indicating	O
that	O
host	O
cell	O
cathepsins	O
may	O
play	O
a	O
role	O
in	O
the	O
distinct	O
tropisms	O
displayed	O
by	O
different	O
feline	O
coronavirus	O
biotypes	O
.	O

Treatment	O
with	O
antiviral	O
drugs	O
demonstrated	O
that	O
the	O
replication	O
could	O
be	O
significantly	O
inhibited	O
by	O
0	O
.	O
4	O
mg	O
/	O
ml	O
of	O
cysteine	B-PRGE
proteinase	I-PRGE
inhibitor	O
E	O
-	O
64D	O
,	O
but	O
not	O
by	O
ribavirin	O
.	O

Nucleocapsid	B-PRGE
protein	I-PRGE
(	O
NP	O
)	O
is	O
the	O
most	O
predominant	O
virus	O
derived	O
structural	O
protein	O
which	O
is	O
shed	O
in	O
high	O
amounts	O
in	O
serum	O
and	O
nasopharyngeal	O
aspirate	O
during	O
the	O
first	O
week	O
of	O
infection	O
.	O

Immune	O
responses	O
were	O
compared	O
in	O
immature	O
DCs	O
inoculated	O
with	O
BVLPs	O
or	O
with	O
VLPs	O
formed	O
by	O
S	O
,	O
E	O
and	O
M	O
proteins	O
of	O
human	B-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
BVLPs	O
showed	O
a	O
stronger	O
ability	O
to	O
stimulate	O
DCs	O
in	O
terms	O
of	O
cytokine	O
induction	O
as	O
evidenced	O
by	O
2	O
to	O
6	O
fold	O
higher	O
production	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
.	O

Our	O
data	O
have	O
demonstrated	O
for	O
the	O
first	O
time	O
that	O
SL	O
-	O
CoV	O
VLPs	O
formed	O
by	O
membrane	O
proteins	O
of	O
different	O
origins	O
,	O
one	O
from	O
SL	O
-	O
CoV	O
isolated	O
from	O
bats	O
(	O
BS	O
)	O
and	O
the	O
other	O
two	O
from	O
human	B-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
(	O
E	O
and	O
M	O
),	O
activated	O
immature	O
DCs	O
and	O
enhanced	O
the	O
expression	O
of	O
co	O
-	O
stimulatory	O
molecules	O
and	O
the	O
secretion	O
of	O
cytokines	O
.	O

The	O
nucleocapsid	B-PRGE
protein	I-PRGE
lacking	O
the	O
RS	O
motif	O
formed	O
high	O
-	O
order	O
RNP	O
complexes	O
,	O
which	O
may	O
also	O
account	O
for	O
its	O
enhanced	O
stress	O
granule	O
localization	O
.	O

Scanning	O
alanine	O
mutagenesis	O
identified	O
two	O
regions	O
in	O
the	O
carboxy	O
-	O
terminal	O
portion	O
of	O
the	O
TMD	O
that	O
eliminated	O
the	O
Golgi	O
complex	O
localization	O
of	O
the	O
chimeric	B-PRGE
CD4	I-PRGE
proteins	I-PRGE
or	O
ORF7b	B-PRGE
protein	I-PRGE
.	O

Virus	O
infection	O
and	O
some	O
individual	O
viral	O
proteins	O
,	O
including	O
the	O
3a	B-PRGE
protein	I-PRGE
,	O
induce	O
apoptosis	O
.	O

In	O
the	O
intrinsic	O
pathway	O
,	O
there	O
was	O
activation	O
of	O
caspase	B-PRGE
-	I-PRGE
9	I-PRGE
and	O
cytochrome	B-PRGE
c	I-PRGE
release	I-PRGE
from	O
the	O
mitochondria	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
contain	O
a	O
small	B-PRGE
envelope	I-PRGE
membrane	I-PRGE
protein	I-PRGE
with	O
cation	O
-	O
selective	O
ion	O
channel	O
activity	O
mediated	O
by	O
its	O
transmembrane	O
domain	O
(	O
ETM	O
).	O

ABSTRACT	O
:	O
Receptor	O
for	O
advanced	O
glycation	O
end	O
products	O
(	O
RAGE	O
)	O
is	O
a	O
membrane	O
bound	O
receptor	O
and	O
member	O
of	O
the	O
immunoglobulin	B-PRGE
super	I-PRGE
family	I-PRGE
and	O
is	O
normally	O
present	O
in	O
a	O
highly	O
abundant	O
basal	O
level	O
expression	O
in	O
lung	O
.	O

TITLE	O
:	O
Synthesis	O
and	O
in	O
vitro	O
anti	O
-	O
HIV	O
evaluation	O
of	O
a	O
new	O
series	O
of	O
6	O
-	O
arylmethyl	O
-	O
substituted	O
S	O
-	O
DABOs	O
as	O
potential	O
non	O
-	O
nucleoside	O
HIV	O
-	O
1	O
reverse	B-PRGE
transcriptase	I-PRGE
inhibitors	O
.	O

Challenge	O
of	O
saline	O
(	O
SAL	O
)-	O
pretreated	O
animals	O
with	O
LPS	O
resulted	O
in	O
lung	O
injury	O
as	O
evidenced	O
by	O
increases	O
in	O
wet	O
lung	O
weight	O
(	O
edema	O
),	O
increases	O
in	O
lipid	O
peroxidation	O
(	O
marker	O
of	O
oxidative	O
stress	O
),	O
decreases	O
of	O
lung	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
(	O
ACE	B-PRGE
)	O
(	O
injury	O
marker	O
for	O
pulmonary	O
endothelial	O
cells	O
)	O
and	O
increases	O
in	O
the	O
pro	O
-	O
inflammatory	O
eicosanoids	O
,	O
thromboxane	O
B	O
(	O
2	O
)	O
and	O
leukotriene	O
B	O
(	O
4	O
).	O

Their	O
natural	O
inhibitor	O
cystatin	B-PRGE
C	I-PRGE
is	O
a	O
secreted	O
protein	O
,	O
suggesting	O
that	O
it	O
functions	O
to	O
control	O
extracellular	B-PRGE
protease	I-PRGE
activity	O
.	O

The	O
uptake	O
of	O
labelled	O
cystatin	B-PRGE
C	I-PRGE
was	O
inhibited	O
by	O
unlabelled	O
inhibitor	O
,	O
suggesting	O
a	O
specific	O
pathway	O
for	O
the	O
internalization	O
.	O

AGP	O
was	O
purified	O
from	O
serum	O
and	O
Western	O
blotting	O
followed	O
by	O
lectin	B-PRGE
-	O
staining	O
of	O
alpha	O
(	O
2	O
,	O
3	O
)-	O
linked	O
and	O
alpha	O
(	O
2	O
,	O
6	O
)-	O
linked	O
sialic	O
acid	O
.	O

TITLE	O
:	O
Molecular	O
dynamic	O
simulations	O
analysis	O
of	O
ritonavir	O
and	O
lopinavir	O
as	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
inhibitors	O
.	O

However	O
,	O
it	O
was	O
found	O
that	O
a	O
mixture	O
of	O
two	O
HIV	B-PRGE
-	I-PRGE
1	I-PRGE
proteinase	I-PRGE
inhibitors	O
,	O
lopinavir	O
and	O
ritonavir	O
,	O
exhibited	O
some	O
signs	O
of	O
effectiveness	O
against	O
the	O
SARS	O
virus	O
.	O

TITLE	O
:	O
A	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
protein	I-PRGE
,	I-PRGE
ORF	I-PRGE
-	I-PRGE
6	I-PRGE
,	O
induces	O
caspase	B-PRGE
-	I-PRGE
3	I-PRGE
mediated	O
,	O
ER	O
stress	O
and	O
JNK	B-PRGE
-	O
dependent	O
apoptosis	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
overexpression	O
of	O
ORF	B-PRGE
-	I-PRGE
6	I-PRGE
also	O
induces	O
apoptosis	O
and	O
that	O
Caspase	B-PRGE
-	I-PRGE
3	I-PRGE
inhibitor	I-PRGE
and	O
JNK	B-PRGE
inhibitor	O
block	O
ORF	O
-	O
6	O
induced	O
apoptosis	O
.	O

Genetic	O
-	O
association	O
studies	O
for	O
single	O
nucleotide	O
polymorphisms	O
of	O
the	O
inflammatory	O
response	O
genes	O
,	O
namely	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
INF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
INF	B-PRGE
-	I-PRGE
beta	I-PRGE
,	O
INF	B-PRGE
-	I-PRGE
gamma	I-PRGE
,	O
IL1	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
IL1	B-PRGE
-	I-PRGE
beta	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
iNOS	B-PRGE
,	O
failed	O
to	O
show	O
a	O
significant	O
association	O
with	O
SARS	O
clinical	O
outcomes	O
or	O
susceptibility	O
.	O

Intranasal	O
vaccination	O
using	O
inactivated	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
vaccine	O
with	O
adjuvant	O
can	O
induce	O
strong	O
systemic	O
(	O
serum	O
immunoglobulin	B-PRGE
[	O
Ig	O
]	O
G	O
)	O
and	O
respiratory	O
tract	O
local	O
(	O
tracheal	O
-	O
lung	O
wash	O
fluid	O
IgA	B-PRGE
)	O
antibody	O
responses	O
with	O
neutralising	O
activity	O
.	O

TITLE	O
:	O
RNA	O
viruses	O
and	O
the	O
mitogenic	O
Raf	B-PRGE
/	O
MEK	B-PRGE
/	O
ERK	B-PRGE
signal	O
transduction	O
cascade	O
.	O

In	O
contrast	O
,	O
the	O
consequences	O
of	O
RNA	O
virus	O
-	O
induced	O
Raf	B-PRGE
/	O
MEK	B-PRGE
/	O
ERK	B-PRGE
signaling	O
were	O
less	O
clear	O
for	O
a	O
long	O
time	O
,	O
but	O
since	O
the	O
turn	O
of	O
the	O
century	O
the	O
number	O
of	O
publications	O
on	O
this	O
topic	O
has	O
rapidly	O
increased	O
.	O

After	O
predicting	O
the	O
immunogenicity	O
of	O
the	O
epitopes	O
of	O
the	O
S2	B-PRGE
domain	I-PRGE
,	O
we	O
chemically	O
synthesized	O
two	O
peptides	O
and	O
also	O
expressed	O
one	O
of	O
them	O
using	O
a	O
recombinant	O
DNA	O
method	O
.	O

When	O
coexpressed	O
,	O
the	O
native	B-PRGE
envelope	I-PRGE
trimeric	I-PRGE
S	I-PRGE
glycoprotein	I-PRGE
is	O
incorporated	O
onto	O
VLPs	O
.	O

TITLE	O
:	O
Clathrin	B-PRGE
-	O
and	O
caveolae	O
-	O
independent	O
entry	O
of	O
feline	O
infectious	O
peritonitis	O
virus	O
in	O
monocytes	O
depends	O
on	O
dynamin	B-PRGE
.	O

The	O
caveolae	O
-	O
mediated	O
pathway	O
could	O
be	O
excluded	O
based	O
on	O
the	O
inability	O
of	O
genistein	O
and	O
DN	B-PRGE
caveolin	I-PRGE
-	I-PRGE
1	I-PRGE
to	O
inhibit	O
virus	O
uptake	O
and	O
lack	O
of	O
co	O
-	O
localization	O
between	O
FIPV	O
and	O
caveolin	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Thererfore	O
,	O
the	O
tender	O
leaf	O
of	O
Toona	O
sinensis	O
Roem	O
may	O
be	O
an	O
important	O
resource	O
agninst	O
SARS	O
-	O
CoV	O
.	O
RESULTS	O
:	O
Only	O
TSL	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
the	O
extract	O
from	O
tender	O
leaf	O
of	O
Toona	O
sinensis	O
Roem	O
was	O
found	O
to	O
have	O
an	O
evident	O
effect	O
against	O
SARS	O
-	O
CoV	O
with	O
selectivity	O
index	O
12	O
approximately	O
17	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
whether	O
expression	O
of	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
7b	O
protein	O
,	O
as	O
indicated	O
by	O
the	O
presence	O
of	O
specific	O
serum	O
antibodies	O
,	O
consistently	O
correlated	O
with	O
occurrence	O
of	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	B-PRGE
)	O
in	O
cats	O
.	O

TITLE	O
:	O
Purification	O
,	O
crystallization	O
and	O
preliminary	O
crystallographic	O
analysis	O
of	O
avian	O
infectious	O
bronchitis	O
virus	O
nsp3	B-PRGE
ADRP	B-PRGE
domain	O
.	O

Three	O
viral	O
proteins	O
from	O
diverse	O
viruses	O
were	O
selected	O
which	O
localised	O
to	O
the	O
nucleolus	O
;	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
,	O
the	O
herpesvirus	B-PRGE
saimiri	I-PRGE
ORF57	I-PRGE
protein	I-PRGE
and	O
the	O
HIV	B-PRGE
-	I-PRGE
1	I-PRGE
Rev	I-PRGE
protein	I-PRGE
.	O

To	O
explore	O
this	O
possibility	O
,	O
we	O
introduced	O
a	O
furin	B-PRGE
-	O
like	O
cleavage	O
sequence	O
in	O
the	O
S	B-PRGE
protein	I-PRGE
at	O
amino	O
acids	O
798	O
to	O
801	O
and	O
found	O
that	O
the	O
mutated	B-PRGE
S	I-PRGE
protein	I-PRGE
was	O
cleaved	O
and	O
induced	O
cell	O
fusion	O
without	O
trypsin	B-PRGE
treatment	O
when	O
expressed	O
on	O
the	O
cell	O
surface	O
.	O

To	O
study	O
the	O
role	O
of	O
acute	O
SOD3	O
reduction	O
in	O
lung	O
injury	O
,	O
the	O
SOD3	B-PRGE
gene	I-PRGE
was	O
deleted	O
in	O
adult	O
mice	O
by	O
using	O
the	O
Cre	O
-	O
Lox	B-PRGE
technology	O
.	O

Treatment	O
with	O
the	O
SOD	O
mimetic	O
MnTBAP	O
and	O
intranasal	O
administration	O
of	O
SOD	B-PRGE
-	O
containing	O
polyketal	O
microparticles	O
reduced	O
mortality	O
,	O
prevented	O
the	O
histological	O
alterations	O
,	O
and	O
reduced	O
lung	O
superoxide	O
levels	O
.	O

The	O
sequences	O
of	O
the	O
M	B-PRGE
gene	I-PRGE
and	O
M	B-PRGE
protein	I-PRGE
share	O
83	O
.	O
9	O
-	O
97	O
.	O
9	O
%	O
and	O
83	O
.	O
6	O
-	O
96	O
.	O
5	O
%	O
homologous	O
identities	O
,	O
respectively	O
,	O
compared	O
with	O
29	O
IBV	O
reference	O
strains	O
derived	O
from	O
different	O
regions	O
or	O
countries	O
,	O
which	O
revealed	O
that	O
there	O
are	O
still	O
significant	O
variations	O
between	O
strains	O
.	O

The	O
immunoglobulin	B-PRGE
concentration	O
in	O
the	O
serum	O
of	O
90	O
.	O
5	O
per	O
cent	O
of	O
the	O
diarrhoeic	O
calves	O
was	O
below	O
8	O
g	O
/	O
l	O
.	O

ABSTRACT	O
:	O
Cholesterol	O
present	O
in	O
the	O
plasma	O
membrane	O
of	O
target	O
cells	O
has	O
been	O
shown	O
to	O
be	O
important	O
for	O
the	O
infection	O
by	O
SARS	O
-	O
CoV	O
.	O
We	O
show	O
that	O
cholesterol	O
depletion	O
by	O
treatment	O
with	O
methyl	O
-	O
beta	O
-	O
cyclodextrin	O
(	O
m	O
beta	O
CD	O
)	O
affects	O
infection	O
by	O
SARS	O
-	O
CoV	O
to	O
the	O
same	O
extent	O
as	O
infection	O
by	O
vesicular	O
stomatitis	O
virus	O
-	O
based	O
pseudotypes	O
containing	O
the	O
surface	O
glycoprotein	B-PRGE
S	I-PRGE
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
(	O
VSV	O
-	O
Delta	O
G	O
-	O
S	O
).	O

We	O
found	O
that	O
ACE2	B-PRGE
of	O
both	O
Vero	O
E6	O
and	O
Caco	O
-	O
2	O
cells	O
co	O
-	O
purifies	O
with	O
marker	O
proteins	O
of	O
detergent	O
-	O
resistant	O
membranes	O
supporting	O
the	O
notion	O
that	O
cholesterol	O
-	O
rich	O
microdomains	O
provide	O
a	O
platform	O
facilitating	O
the	O
efficient	O
interaction	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
with	O
the	O
cellular	O
receptor	O
ACE2	B-PRGE
.	O

In	O
addition	O
,	O
we	O
engineered	O
the	O
heterologous	O
green	B-PRGE
fluorescent	I-PRGE
protein	I-PRGE
gene	I-PRGE
in	O
place	O
of	O
open	O
reading	O
frame	O
3	O
(	O
ORF3	O
)	O
of	O
the	O
NL63	O
clone	O
,	O
simultaneously	O
creating	O
a	O
unique	O
marker	O
for	O
NL63	O
infection	O
and	O
demonstrating	O
that	O
the	O
ORF3	O
protein	O
product	O
is	O
nonessential	O
for	O
the	O
replication	O
of	O
NL63	O
in	O
cell	O
culture	O
.	O

The	O
numbers	O
of	O
NK	O
cells	O
in	O
their	O
livers	O
,	O
spleens	O
,	O
blood	O
and	O
bone	O
marrow	O
and	O
the	O
expression	O
of	O
CD69	B-PRGE
on	O
liver	O
NK	O
cells	O
at	O
0	O
,	O
24	O
,	O
48	O
and	O
70	O
h	O
after	O
MHV	O
-	O
3	O
infection	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
.	O

In	O
addition	O
,	O
an	O
increase	O
in	O
IFN	B-PRGE
gamma	I-PRGE
production	O
by	O
hepatic	O
NK	O
cells	O
was	O
observed	O
at	O
48	O
h	O
.	O
After	O
MHV	O
-	O
3	O
infection	O
,	O
NK	O
cells	O
were	O
recruited	O
to	O
the	O
liver	O
quickly	O
,	O
probably	O
from	O
the	O
spleen	O
and	O
bone	O
marrow	O
.	O

CD8	B-PRGE
(+)	O
T	O
cell	O
responses	O
were	O
more	O
frequent	O
and	O
of	O
a	O
greater	O
magnitude	O
than	O
CD4	B-PRGE
(+)	O
T	O
cell	O
responses	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

Hospital	O
size	O
was	O
controlled	O
for	O
in	O
analyses	O
involving	O
AROs	B-PRGE
and	O
surveillance	O
and	O
control	O
intensity	O
levels	O
.	O

Previously	O
we	O
showed	O
that	O
,	O
consistent	O
with	O
predictions	O
,	O
nsp4	B-PRGE
occurs	O
in	O
membranes	O
with	O
both	O
of	O
its	O
termini	O
exposed	O
in	O
the	O
cytoplasm	O
(	O
M	O
.	O
Oostra	O
et	O
al	O
.,	O
J	O
.	O
Virol	O
.	O

Recipients	O
of	O
all	O
CD4	B-PRGE
(+)	O
T	O
-	O
cell	O
populations	O
exhibited	O
demyelination	O
.	O

In	O
addition	O
,	O
the	O
overexpression	O
of	O
human	B-PRGE
apoD	I-PRGE
in	O
the	O
neurons	O
of	O
Thy	B-PRGE
-	I-PRGE
1	I-PRGE
/	O
ApoD	B-PRGE
transgenic	O
mice	O
results	O
in	O
a	O
threefold	O
increase	O
of	O
the	O
number	O
of	O
mice	O
surviving	O
to	O
HCoV	O
-	O
OC43	O
infection	O
.	O

These	O
data	O
reveal	O
a	O
role	O
for	O
apoD	B-PRGE
in	O
the	O
regulation	O
of	O
inflammation	O
and	O
suggest	O
that	O
it	O
protects	O
from	O
HCoV	O
-	O
OC43	O
-	O
induced	O
encephalitis	O
,	O
most	O
likely	O
through	O
the	O
phospholipase	B-PRGE
A2	I-PRGE
signaling	O
pathways	O
.	O

The	O
cell	O
-	O
based	O
expressed	O
full	B-PRGE
-	I-PRGE
length	I-PRGE
S	I-PRGE
-	I-PRGE
FLAG	I-PRGE
could	O
be	O
recognized	O
by	O
the	O
convalescent	O
serum	O
obtained	O
from	O
a	O
patient	O
with	O
HCoV	O
-	O
HKU1	O
pneumonia	O
.	O

The	O
resulting	O
compound	O
,	O
GRL0617	O
,	O
inhibited	O
SARS	B-PRGE
-	O
CoV	O
viral	O
replication	O
in	O
Vero	O
E6	O
cells	O
with	O
an	O
EC	O
(	O
50	O
)	O
of	O
15	O
microM	O
and	O
had	O
no	O
associated	O
cytotoxicity	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
report	O
the	O
impact	O
on	O
gene	O
expression	O
induced	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
stimulation	O
of	O
THP	O
-	O
1	O
cells	O
treated	O
with	O
an	O
antisense	O
oligonucleotide	O
(	O
ASODN	O
)	O
against	O
the	O
IRAK	B-PRGE
-	I-PRGE
1	I-PRGE
gene	I-PRGE
using	O
cDNA	O
microarrays	O
and	O
quantitative	O
RT	O
-	O
PCR	O
.	O

Refolding	O
of	O
SARS	B-PRGE
N	I-PRGE
-	I-PRGE
protein	I-PRGE
during	O
production	O
and	O
purification	O
showed	O
the	O
presence	O
of	O
two	O
additional	O
protein	O
bands	O
by	O
SDS	O
-	O
PAGE	O
.	O

Mass	O
spectroscopy	O
(	O
MALDI	O
,	O
SELDI	O
,	O
and	O
LC	O
/	O
MS	O
)	O
confirmed	O
that	O
the	O
bands	O
are	O
proteolytic	O
products	O
of	O
N	B-PRGE
-	I-PRGE
protein	I-PRGE
and	O
the	O
cleavage	O
sites	O
are	O
four	O
SR	O
motifs	O
in	O
the	O
serine	O
-	O
arginine	O
-	O
rich	O
region	O
-	O
sites	O
not	O
suggestive	O
of	O
any	O
known	O
protease	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
viral	B-PRGE
antigen	I-PRGE
-	I-PRGE
antibody	I-PRGE
complexes	I-PRGE
were	O
not	O
internalized	O
through	O
any	O
of	O
the	O
previously	O
described	O
pathways	O
.	O

ABSTRACT	O
:	O
Although	O
in	O
different	O
groups	O
,	O
the	O
coronaviruses	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
NL63	O
use	O
the	O
same	O
receptor	O
,	O
angiotensin	B-PRGE
converting	I-PRGE
enzyme	I-PRGE
(	O
ACE	B-PRGE
)-	O
2	O
,	O
for	O
entry	O
into	O
the	O
host	O
cell	O
.	O

Several	O
PP11	B-PRGE
-	I-PRGE
like	I-PRGE
proteins	I-PRGE
were	O
annotated	O
in	O
distantly	O
related	O
organisms	O
,	O
such	O
as	O
worms	O
and	O
mammals	O
,	O
suggesting	O
their	O
involvement	O
in	O
evolutionarily	O
conserved	O
processes	O
.	O

This	O
newly	O
discovered	O
enzymatic	O
activity	O
places	O
PP11	B-PRGE
-	I-PRGE
like	I-PRGE
proteins	I-PRGE
in	O
a	O
completely	O
new	O
perspective	O
.	O

We	O
demonstrate	O
that	O
a	O
single	O
amino	O
acid	O
substitution	O
at	O
a	O
secondary	O
anchor	O
residue	O
(	O
Q	O
to	O
Y	O
at	O
position	O
3	O
)	O
increased	O
the	O
stability	O
of	O
the	O
engineered	O
determinant	O
in	O
complex	O
with	O
H	B-PRGE
-	I-PRGE
2K	I-PRGE
(	I-PRGE
b	I-PRGE
).	I-PRGE

Pull	O
-	O
down	O
assay	O
revealed	O
that	O
ACE2	B-PRGE
was	O
specifically	O
captured	O
from	O
cell	O
lysate	O
,	O
indicating	O
that	O
the	O
RBD	O
was	O
biologically	O
active	O
.	O

These	O
findings	O
suggest	O
that	O
229E	O
takes	O
an	O
endosomal	O
pathway	O
for	O
cell	O
entry	O
and	O
that	O
proteases	O
like	O
CPL	B-PRGE
are	O
involved	O
in	O
this	O
mode	O
of	O
entry	O
.	O

Expressed	O
nucleocapsid	B-PRGE
gene	I-PRGE
produced	O
two	O
distinct	O
proteins	O
(	O
52	O
and	O
43	O
kDa	O
);	O
their	O
specificity	O
was	O
confirmed	O
by	O
Western	O
blotting	O
using	O
two	O
different	O
monoclonal	O
antibodies	O
.	O

Sections	O
of	O
trachea	O
,	O
lung	O
and	O
airsacs	O
were	O
stained	O
for	O
CD4	B-PRGE
,	O
CD8	B-PRGE
,	O
gammadelta	O
-	O
TCR	B-PRGE
,	O
alphabeta1	O
-	O
TCR	B-PRGE
,	O
and	O
for	O
macrophages	O
(	O
KUL	O
-	O
01	O
)	O
and	O
both	O
pathogens	O
.	O

ABSTRACT	O
:	O
The	O
heptad	O
repeats	O
(	O
HR1	O
and	O
HR2	O
)	O
of	O
the	O
spike	O
protein	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
are	O
highly	O
conserved	O
regions	O
forming	O
a	O
critical	O
6	O
-	O
helix	O
bundle	O
during	O
the	O
fusion	O
step	O
of	O
virus	O
entry	O
and	O
are	O
attractive	O
targets	O
of	O
entry	O
inhibitors	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
identified	O
the	O
major	B-PRGE
histocompatibility	I-PRGE
complex	I-PRGE
class	I-PRGE
I	I-PRGE
C	I-PRGE
molecule	I-PRGE
(	O
HLA	B-PRGE
-	I-PRGE
C	I-PRGE
)	O
as	O
an	O
attachment	O
factor	O
in	O
facilitating	O
HCoV	O
-	O
HKU1	O
spike	O
(	O
S	O
)-	O
mediated	O
infection	O
.	O

Transduced	O
cells	O
that	O
bind	O
soluble	O
HCoV	B-PRGE
-	I-PRGE
HKU1	I-PRGE
S	I-PRGE
(	I-PRGE
1	I-PRGE
-	I-PRGE
600	I-PRGE
)	I-PRGE
glycoprotein	I-PRGE
with	O
C	O
-	O
terminal	O
FLAG	O
were	O
sorted	O
.	O

When	O
HLA	B-PRGE
-	I-PRGE
C	I-PRGE
was	O
constitutively	O
expressed	O
in	O
another	O
nonpermissive	O
cell	O
line	O
,	O
NIH	O
-	O
3T3	O
,	O
quantitative	O
PCR	O
showed	O
that	O
the	O
binding	O
of	O
HCoV	O
-	O
HKU1	O
S	O
pseudotyped	O
virus	O
to	O
cell	O
surfaces	O
was	O
increased	O
by	O
200	O
-	O
fold	O
,	O
but	O
the	O
cells	O
remained	O
nonsusceptible	O
to	O
HCoV	O
-	O
HKU1	O
S	O
pseudotyped	O
virus	O
infection	O
.	O

Our	O
results	O
showed	O
that	O
high	O
levels	O
of	O
specific	O
humoral	O
responses	O
were	O
induced	O
by	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3a	I-PRGE
and	O
SL	O
-	O
CoV	O
3a	O
DNA	O
vaccines	O
.	O

We	O
also	O
identified	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
)	O
and	O
IL	O
-	O
8	O
as	O
key	O
SARS	O
-	O
CoV	O
-	O
induced	O
epithelial	O
cytokines	O
capable	O
of	O
inhibiting	O
the	O
T	O
-	O
cell	O
-	O
priming	O
ability	O
of	O
DC	O
.	O

Introduction	O
of	O
the	O
mutation	O
into	O
the	O
IBV	O
infectious	O
clone	O
system	O
showed	O
recovery	O
of	O
a	O
mutant	O
virus	O
with	O
severe	O
growth	O
defects	O
,	O
supporting	O
that	O
dimerization	O
is	O
critical	O
for	O
the	O
function	O
of	O
this	O
replicase	B-PRGE
protein	I-PRGE
.	O

Here	O
,	O
we	O
have	O
isolated	O
DNA	O
aptamers	O
against	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
helicase	I-PRGE
from	O
a	O
combinatorial	O
DNA	O
library	O
.	O

This	O
study	O
used	O
a	O
broad	O
capture	O
,	O
rapid	O
and	O
sensitive	O
method	O
(	O
multiplex	O
PCR	O
assay	O
)	O
to	O
detect	O
20	O
different	O
respiratory	O
pathogens	O
including	O
influenza	O
A	O
subtypes	O
H1	O
,	O
H3	O
,	O
and	O
H5	O
;	O
influenza	O
B	O
;	O
parainfluenza	O
types	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
4	O
;	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
groups	O
A	O
and	O
B	O
;	O
adenoviruses	O
;	O
human	O
rhinoviruses	O
;	O
enteroviruses	O
;	O
human	O
metapneumoviruses	O
;	O
human	O
coronaviruses	O
OC43	O
,	O
229E	O
,	O
and	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
;	O
Chlamydophila	O
pneumoniae	O
;	O
Legionella	O
pneumophila	O
;	O
and	O
Mycoplasma	O
pneumoniae	O
;	O
from	O
respiratory	O
specimens	O
of	O
475	O
children	O
hospitalized	O
over	O
a	O
12	O
-	O
month	O
period	O
for	O
acute	O
respiratory	O
tract	O
infections	O
.	O

Compared	O
to	O
healthy	O
group	O
and	O
SARS	O
non	O
-	O
AVNFH	O
group	O
,	O
transthyretin	B-PRGE
,	O
C4B3	O
,	O
fibrinogen	B-PRGE
gamma	I-PRGE
,	O
apolipoprotein	B-PRGE
L	I-PRGE
,	O
apolipoprotein	B-PRGE
A	I-PRGE
-	I-PRGE
IV	I-PRGE
precursor	I-PRGE
,	O
albumin	B-PRGE
and	O
prealbumin	B-PRGE
showed	O
lower	O
expression	O
,	O
inversely	O
serpin	B-PRGE
peptidase	I-PRGE
inhibitor	O
,	O
alpha	B-PRGE
-	I-PRGE
1	I-PRGE
-	I-PRGE
antitrypsin	I-PRGE
precursor	I-PRGE
and	O
serum	O
amyloid	O
P	O
components	O
showed	O
higher	O
expression	O
in	O
serum	O
in	O
the	O
SARS	B-PRGE
AVNFH	I-PRGE
necrosis	I-PRGE
group	I-PRGE
.	O

Here	O
,	O
we	O
report	O
the	O
design	O
,	O
synthesis	O
,	O
and	O
recovery	O
of	O
the	O
largest	O
synthetic	O
replicating	O
life	O
form	O
,	O
a	O
29	O
.	O
7	O
-	O
kb	O
bat	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
like	O
coronavirus	O
(	O
Bat	O
-	O
SCoV	O
),	O
a	O
likely	O
progenitor	O
to	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
epidemic	O
.	O

ABSTRACT	O
:	O
A	O
new	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)-	O
based	O
immunoglobulin	B-PRGE
G	I-PRGE
(	O
IgG	B-PRGE
)-	O
plus	O
-	O
IgM	B-PRGE
antibody	O
detection	O
test	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
has	O
been	O
developed	O
by	O
using	O
a	O
cocktail	O
of	O
four	O
recombinant	O
polypeptides	O
as	O
the	O
antigen	O
.	O

One	O
recombinant	O
polypeptide	O
,	O
S251	O
-	O
683	O
,	O
was	O
designed	O
as	O
part	O
of	O
the	O
spike	O
glycoprotein	O
,	O
and	O
the	O
other	O
three	O
polypeptides	O
comprised	O
almost	O
the	O
whole	B-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
,	O
avoiding	O
the	O
last	O
25	O
C	O
-	O
terminal	O
amino	O
acids	O
.	O

The	O
present	O
study	O
shows	O
that	O
:	O
(	O
1	O
)	O
the	O
ratio	O
of	O
peripheral	O
blood	O
sIg	O
(+)	O
CD21	O
(-)	O
B	O
-	O
cells	O
was	O
higher	O
in	O
cats	O
with	O
FIP	O
than	O
in	O
SPF	O
cats	O
,	O
(	O
2	O
)	O
the	O
albumin	B-PRGE
-	I-PRGE
to	I-PRGE
-	I-PRGE
globulin	I-PRGE
ratio	O
has	O
negative	O
correlation	O
with	O
the	O
ratio	O
of	O
peripheral	O
blood	O
sIg	O
(+)	O
CD21	O
(-)	O
B	O
-	O
cell	O
,	O
(	O
3	O
)	O
cells	O
strongly	O
expressing	O
mRNA	O
of	O
the	O
plasma	O
cell	O
master	O
gene	O
,	O
B	O
-	O
lymphocyte	O
-	O
induced	O
maturation	O
protein	O
1	O
(	O
Blimp	O
-	O
1	O
),	O
were	O
increased	O
in	O
peripheral	O
blood	O
in	O
cats	O
with	O
FIP	O
,	O
(	O
4	O
)	O
mRNA	O
expression	O
of	O
B	O
-	O
cell	O
differentiation	O
/	O
survival	O
factors	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
CD40	B-PRGE
ligand	I-PRGE
,	O
and	O
B	O
-	O
cell	O
-	O
activating	O
factor	O
belonging	O
to	O
the	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
family	I-PRGE
(	O
BAFF	B-PRGE
),	O
was	O
enhanced	O
in	O
macrophages	O
in	O
cats	O
with	O
FIP	O
,	O
and	O
(	O
5	O
)	O
mRNAs	O
of	O
these	O
B	O
-	O
cell	O
differentiation	O
/	O
survival	O
factors	O
were	O
overexpressed	O
in	O
antibody	O
-	O
dependent	O
enhancement	O
(	O
ADE	O
)-	O
induced	O
macrophages	O
.	O

ABSTRACT	O
:	O
This	O
review	O
provides	O
an	O
overview	O
of	O
the	O
development	O
of	O
viral	B-PRGE
protease	I-PRGE
inhibitors	O
as	O
antiviral	O
drugs	O
.	O

Thus	O
,	O
we	O
discuss	O
the	O
biochemistry	O
of	O
HIV	B-PRGE
-	I-PRGE
1	I-PRGE
protease	I-PRGE
,	O
inhibitor	O
development	O
,	O
clinical	O
use	O
of	O
inhibitors	O
,	O
and	O
evolution	O
of	O
resistance	O
.	O

ABSTRACT	O
:	O
The	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
structure	O
of	O
a	O
central	O
segment	O
of	O
the	O
previously	O
annotated	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
unique	O
domain	O
(	O
SUD	O
-	O
M	O
,	O
for	O
""""	O
middle	O
of	O
the	O
SARS	O
-	O
unique	O
domain	O
""")"	O
in	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nonstructural	B-PRGE
protein	I-PRGE
3	I-PRGE
(	O
nsp3	B-PRGE
)	O
has	O
been	O
determined	O
.	O

In	O
addition	O
,	O
the	O
compounds	O
blocked	O
the	O
ability	O
of	O
NS1	B-PRGE
protein	I-PRGE
to	O
inhibit	O
double	O
-	O
stranded	O
RNA	O
-	O
dependent	O
activation	O
of	O
a	O
transfected	O
beta	B-PRGE
interferon	I-PRGE
promoter	I-PRGE
construct	I-PRGE
.	O

The	O
presence	O
of	O
a	O
hemagglutinin	B-PRGE
-	I-PRGE
esterase	I-PRGE
(	O
HE	O
)	O
surface	O
glycoprotein	O
in	O
addition	O
to	O
the	O
viral	B-PRGE
spike	I-PRGE
protein	I-PRGE
is	O
a	O
distinguishing	O
characteristic	O
of	O
most	O
group	O
2a	O
coronaviruses	O
.	O

To	O
study	O
the	O
functions	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
,	O
we	O
describe	O
here	O
the	O
generation	O
of	O
SARS	O
-	O
CoV	O
S	O
protein	O
-	O
bearing	O
vesicular	O
stomatitis	O
virus	O
(	O
VSV	O
)	O
pseudotype	O
using	O
a	O
VSVdeltaG	O
*/	O
GFP	O
system	O
in	O
which	O
the	O
G	B-PRGE
gene	I-PRGE
is	O
replaced	O
by	O
the	O
green	B-PRGE
fluorescent	I-PRGE
protein	I-PRGE
(	O
GFP	O
)	O
gene	O
(	O
VSV	O
-	O
SARS	B-PRGE
-	O
CoV	O
-	O
St19	B-PRGE
/	O
GFP	O
).	O

The	O
VSVdeltaaG	O
*/	O
SEAP	O
system	O
,	O
which	O
secretes	O
alkaline	B-PRGE
phosphatase	I-PRGE
instead	O
of	O
GFP	O
,	O
was	O
also	O
generated	O
as	O
a	O
VSV	O
pseudotype	O
having	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
(	O
VSV	O
-	O
SARS	B-PRGE
-	O
CoV	O
-	O
St19	B-PRGE
/	O
SEAP	O
).	O

In	O
this	O
system	O
the	O
viral	O
RNA	O
is	O
expressed	O
in	O
the	O
cell	O
nucleus	O
under	O
the	O
control	O
of	O
the	O
cytomegalovirus	O
promoter	O
and	O
further	O
amplified	O
in	O
the	O
cytoplasm	O
by	O
the	O
viral	B-PRGE
replicase	I-PRGE
.	O

Infectious	O
recombinant	O
IBVs	O
are	O
generated	O
in	O
situ	O
following	O
the	O
transfection	O
of	O
vaccinia	O
virus	O
DNA	O
containing	O
the	O
modified	O
IBV	O
cDNA	O
into	O
cells	O
infected	O
with	O
a	O
recombinant	O
fowlpox	O
virus	O
expressing	O
T7	O
DNA	O
-	O
dependent	O
RNA	B-PRGE
polymerase	I-PRGE
.	O

FIPV	O
-	O
induced	O
p38	B-PRGE
MAPK	O
activation	O
was	O
observed	O
in	O
primary	O
feline	O
blood	O
-	O
derived	O
mononuclear	O
cells	O
individually	O
purified	O
from	O
multiple	O
SPF	O
cats	O
,	O
as	O
was	O
the	O
inhibition	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
production	O
by	O
pyridinyl	O
imidazole	O
inhibitors	O
.	O

ABSTRACT	O
:	O
The	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
of	O
acylthiocarbamates	O
(	O
ATCs	O
),	O
a	O
new	O
class	O
of	O
non	O
-	O
nucleoside	O
HIV	O
-	O
1	O
reverse	B-PRGE
transcriptase	I-PRGE
inhibitors	O
,	O
have	O
been	O
expanded	O
.	O

This	O
study	O
demonstrates	O
that	O
glial	O
cells	O
derived	O
from	O
neural	O
progenitor	O
cells	O
are	O
susceptible	O
to	O
JHMV	O
infection	O
and	O
that	O
treatment	O
of	O
infected	O
cells	O
with	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
inhibits	O
viral	O
replication	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Application	O
of	O
this	O
model	O
to	O
platelet	B-PRGE
collagen	I-PRGE
receptor	I-PRGE
signaling	O
has	O
already	O
led	O
to	O
the	O
development	O
of	O
a	O
novel	O
concept	O
of	O
platelet	O
inhibition	O
and	O
the	O
invention	O
of	O
new	O
platelet	O
inhibitors	O
,	O
thus	O
proving	O
the	O
suggested	O
hypothesis	O
and	O
highlighting	O
the	O
importance	O
and	O
broad	O
perspectives	O
of	O
the	O
SCHOOL	O
model	O
in	O
the	O
development	O
of	O
new	O
targeting	O
strategies	O
.	O

Before	O
infection	O
with	O
MHV	O
-	O
3	O
,	O
susceptible	O
BALB	O
/	O
cJ	O
mice	O
had	O
increased	O
numbers	O
of	O
Tregs	O
and	O
expression	O
of	O
fgl2	O
messenger	B-PRGE
RNA	I-PRGE
(	O
mRNA	O
)	O
and	O
FGL2	O
protein	O
compared	O
with	O
resistant	O
A	O
/	O
J	O
mice	O
.	O

Treatment	O
with	O
anti	B-PRGE
-	I-PRGE
FGL2	I-PRGE
antibody	I-PRGE
completely	O
inhibited	O
Treg	O
activity	O
and	O
protected	O
susceptible	O
BALB	O
/	O
cJ	O
mice	O
against	O
MHV	O
-	O
3	O
-	O
liver	O
injury	O
and	O
mortality	O
.	O

Based	O
on	O
sequences	O
of	O
part	O
of	O
the	O
S1	B-PRGE
gene	I-PRGE
IBV	I-PRGE
-	I-PRGE
ON2	I-PRGE
,	O
IBV	O
-	O
ON3	O
,	O
and	O
IBV	O
-	O
ON5	O
formed	O
a	O
cluster	O
and	O
they	O
were	O
closely	O
related	O
to	O
strain	O
CU	O
-	O
82792	O
.	O

Here	O
,	O
we	O
reconcile	O
these	O
apparently	O
conflicting	O
results	O
by	O
showing	O
that	O
p6	O
enhances	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
replication	O
to	O
nearly	O
the	O
same	O
extent	O
as	O
when	O
expressed	O
in	O
the	O
context	O
of	O
MHV	O
if	O
cells	O
are	O
infected	O
at	O
a	O
low	O
MOI	O
and	O
accelerates	O
disease	O
in	O
mice	O
transgenic	O
for	O
the	O
human	B-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
.	O

TITLE	O
:	O
IL	B-PRGE
-	I-PRGE
15	I-PRGE
independent	O
maintenance	O
of	O
virus	O
-	O
specific	O
CD8	B-PRGE
(+)	O
T	O
cells	O
in	O
the	O
CNS	O
during	O
chronic	O
infection	O
.	O

IL	B-PRGE
-	I-PRGE
15	I-PRGE
deficiency	O
also	O
had	O
no	O
affect	O
on	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
receptor	I-PRGE
(	O
CD127	B-PRGE
)	O
expression	O
,	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
upregulation	O
,	O
granzyme	B-PRGE
B	I-PRGE
expression	O
,	O
or	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
secretion	O
in	O
CNS	O
persisting	O
CD8	O
(+)	O
T	O
cells	O
.	O

GSK	B-PRGE
-	I-PRGE
3	I-PRGE
-	O
specific	O
inhibitor	O
treatment	O
dephosphorylated	O
the	O
N	B-PRGE
protein	I-PRGE
,	O
and	O
this	O
could	O
be	O
recovered	O
by	O
the	O
constitutively	O
active	O
GSK	B-PRGE
-	I-PRGE
3	I-PRGE
kinase	I-PRGE
.	O

The	O
effect	O
of	O
GSK	B-PRGE
-	I-PRGE
3	I-PRGE
inhibitor	O
was	O
reproduced	O
in	O
another	O
coronavirus	O
,	O
the	O
neurotropic	O
JHM	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
.	O

However	O
,	O
virus	O
replication	O
was	O
not	O
impaired	O
by	O
these	O
events	O
,	O
suggesting	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
possesses	O
a	O
mechanism	O
to	O
overcome	O
the	O
inhibitory	O
effects	O
of	O
phosphorylated	O
eIF2alpha	B-PRGE
on	O
viral	O
mRNA	O
translation	O
.	O

TITLE	O
:	O
The	O
pathogen	B-PRGE
receptor	I-PRGE
liver	O
and	O
lymph	O
node	O
sinusoidal	O
endotelial	B-PRGE
cell	I-PRGE
C	I-PRGE
-	I-PRGE
type	I-PRGE
lectin	I-PRGE
is	O
expressed	O
in	O
human	O
Kupffer	O
cells	O
and	O
regulated	O
by	O
PU	B-PRGE
.	I-PRGE
1	I-PRGE
.	O

LSECtin	B-PRGE
acts	O
as	O
a	O
pathogen	O
attachment	O
factor	O
for	O
Ebolavirus	O
and	O
the	O
SARS	O
coronavirus	O
,	O
and	O
its	O
expression	O
can	O
be	O
induced	O
by	O
interleukin	B-PRGE
-	I-PRGE
4	I-PRGE
on	O
monocytes	O
and	O
macrophages	O
.	O

Consistent	O
with	O
the	O
whole	O
cell	O
data	O
,	O
expression	O
of	O
S	O
and	O
E	O
proteins	O
decreased	O
ENaC	O
single	O
-	O
channel	O
activity	O
in	O
oocytes	O
,	O
and	O
these	O
effects	O
were	O
partially	O
abrogated	O
by	O
PKCalpha	B-PRGE
/	I-PRGE
beta1	I-PRGE
inhibitors	O
.	O

The	O
higher	O
genetic	O
diversity	O
of	O
type	B-PRGE
I	I-PRGE
FCoVs	I-PRGE
might	O
be	O
due	O
to	O
the	O
larger	O
infected	O
cat	O
population	O
and	O
to	O
the	O
long	O
period	O
of	O
viral	O
persistence	O
in	O
asymptomatic	O
cats	O
in	O
comparison	O
to	O
type	O
II	O
viruses	O
.	O

These	O
IBV	O
isolates	O
were	O
classified	O
into	O
three	O
genetic	O
groups	O
,	O
including	O
two	O
that	O
have	O
already	O
been	O
reported	O
(	O
JP	O
-	O
I	O
and	O
JP	B-PRGE
-	I-PRGE
III	I-PRGE
).	O

A	O
more	O
precise	O
identification	O
of	O
the	O
differences	O
in	O
the	O
regulation	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
beta	I-PRGE
could	O
provide	O
novel	O
targets	O
for	O
the	O
design	O
of	O
therapeutic	O
strategies	O
for	O
severe	O
human	O
H5N1	O
influenza	O
and	O
also	O
for	O
treating	O
other	O
causes	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Generation	O
of	O
bone	O
marrow	O
-	O
chimeric	O
mice	O
expressing	O
the	O
type	B-PRGE
I	I-PRGE
IFN	I-PRGE
receptor	I-PRGE
(	O
IFNAR	B-PRGE
)	O
on	O
either	O
hemopoietic	O
or	O
non	O
-	O
bone	O
marrow	O
-	O
derived	O
cells	O
revealed	O
that	O
the	O
early	O
control	O
of	O
MHV	O
depended	O
mainly	O
on	O
IFNAR	B-PRGE
expression	O
on	O
hemopoietic	O
cells	O
.	O

Focal	O
pairs	O
revealed	O
the	O
existence	O
of	O
an	O
extra	O
internal	O
layer	O
,	O
most	O
likely	O
formed	O
by	O
the	O
C	O
-	O
terminal	O
domains	O
of	O
the	O
major	B-PRGE
envelope	I-PRGE
protein	I-PRGE
M	I-PRGE
.	O
In	O
the	O
interior	O
of	O
the	O
particles	O
,	O
coiled	O
structures	O
and	O
tubular	O
shapes	O
are	O
observed	O
,	O
consistent	O
with	O
a	O
helical	O
nucleocapsid	O
model	O
.	O

TITLE	O
:	O
Production	O
of	O
protective	O
gamma	O
interferon	B-PRGE
by	O
natural	O
killer	O
cells	O
during	O
early	O
mouse	O
hepatitis	O
virus	O
infection	O
.	O

Reducing	O
tidal	O
volume	O
to	O
3	O
ml	O
.	O
kg	O
(-	O
1	O
)	O
together	O
with	O
interventional	O
lung	O
assist	O
resulted	O
in	O
a	O
decrease	O
in	O
severe	O
hypercapnia	O
without	O
alveolar	O
collapse	O
or	O
hypoxaemia	O
but	O
with	O
a	O
decrease	O
in	O
serum	O
levels	O
of	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
.	O

SARS	O
-	O
CoV	O
nonstructural	B-PRGE
protein	I-PRGE
9	I-PRGE
(	O
nsp9	O
)	O
was	O
identified	O
as	O
an	O
essential	O
protein	O
with	O
RNA	O
/	O
DNA	O
-	O
binding	O
activity	O
,	O
and	O
yet	O
its	O
biological	O
function	O
within	O
the	O
replication	O
complex	O
remains	O
unknown	O
.	O

In	O
summary	O
,	O
we	O
have	O
demonstrated	O
that	O
calmodulin	B-PRGE
is	O
able	O
to	O
bind	O
ACE2	B-PRGE
and	O
suggest	O
that	O
the	O
ACE2	B-PRGE
ectodomain	I-PRGE
shedding	I-PRGE
and	I-PRGE
/	I-PRGE
or	I-PRGE
sheddase	I-PRGE
(	I-PRGE
s	I-PRGE
)	I-PRGE
activation	O
regulated	O
by	O
calmodulin	B-PRGE
is	O
independent	O
from	O
the	O
phorbol	O
ester	O
-	O
induced	O
shedding	O
.	O

Neutrophil	O
infiltration	O
measured	O
by	O
myeloperoxidase	B-PRGE
(	O
MPO	B-PRGE
)	O
activity	O
in	O
the	O
lung	O
was	O
significantly	O
increased	O
at	O
2	O
days	O
after	O
blast	O
and	O
returned	O
to	O
controls	O
at	O
8	O
days	O
.	O

Patients	O
with	O
cardiac	O
insufficiency	O
or	O
severe	O
peripheral	O
vascular	O
disease	O
were	O
not	O
considered	O
suitable	O
for	O
iLA	B-PRGE
.	O

Also	O
,	O
titration	O
of	O
S	B-PRGE
protein	I-PRGE
-	O
specific	O
production	O
and	O
secretion	O
of	O
IL	O
-	O
8	O
by	O
ELISA	O
showed	O
that	O
the	O
dose	O
of	O
5	O
.	O
6nM	O
of	O
S	O
produced	O
a	O
significant	O
increase	O
in	O
IL	O
-	O
8	O
(	O
p	O
=	O
0	O
.	O
003	O
)	O
compared	O
to	O
mock	O
-	O
treated	O
controls	O
.	O

In	O
comparison	O
with	O
nontreatment	O
in	O
the	O
control	O
group	O
,	O
the	O
infusion	O
of	O
APC	O
significantly	O
reduced	O
the	O
increase	O
of	O
thrombomodulin	B-PRGE
level	I-PRGE
(	O
TM	O
;	O
control	O
group	O
was	O
(	O
0	O
.	O
68	O
+/-	O
0	O
.	O
06	O
)	O
ng	O
/	O
ml	O
,	O
vs	O
APC	O
group	O
of	O
(	O
0	O
.	O
62	O
+/-	O

Moreover	O
,	O
APC	B-PRGE
limited	O
the	O
histopathological	O
score	O
of	O
lung	O
injury	O
(	O
2	O
.	O
6	O
+/-	O
0	O
.	O
8	O
in	O
control	O
,	O
vs	O
1	O
.	O
4	O
+/-	O

The	O
general	O
condition	O
,	O
serum	O
total	O
bilirubin	O
,	O
albumin	B-PRGE
,	O
creatinine	O
,	O
and	O
prothrombin	B-PRGE
activity	O
,	O
Child	O
-	O
Turcotte	O
-	O
Pugh	O
(	O
CTP	O
)	O
score	O
,	O
and	O
model	O
for	O
end	O
-	O
stage	O
liver	O
disease	O
(	O
MELD	O
)	O
score	O
48	O
h	O
before	O
operation	O
were	O
recorded	O
.	O

The	O
three	O
major	O
diagnostic	O
methods	O
available	O
for	O
SARS	O
includes	O
viral	O
RNA	O
detection	O
by	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
virus	O
induced	O
antibodies	O
by	O
immunofluorescence	O
assay	O
(	O
IFA	O
)	O
or	O
by	O
enzyme	O
linked	O
immunosorbant	O
assay	O
(	O
ELISA	O
)	O
of	O
nucleocapsid	B-PRGE
protein	I-PRGE
(	O
NP	O
).	O

ABSTRACT	O
:	O
SARS	B-PRGE
coronavirus	I-PRGE
main	I-PRGE
proteinase	I-PRGE
(	I-PRGE
SARS	I-PRGE
CoVMpro	I-PRGE
)	I-PRGE
is	O
an	O
important	O
enzyme	O
for	O
the	O
replication	O
of	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
virus	O
.	O

Interestingly	O
,	O
coronavirus	O
nsp14	O
was	O
previously	O
characterized	O
as	O
a	O
3	O
'-	O
to	O
-	O
5	O
'	O
exoribonuclease	O
,	O
and	O
by	O
mutational	O
analysis	O
,	O
we	O
mapped	O
the	O
N7	B-PRGE
-	I-PRGE
MTase	I-PRGE
domain	I-PRGE
to	O
the	O
carboxy	O
-	O
terminal	O
part	O
of	O
nsp14	O
that	O
shows	O
features	O
conserved	O
with	O
cellular	B-PRGE
N7	I-PRGE
-	I-PRGE
MTase	I-PRGE
in	O
structure	O
-	O
based	O
sequence	O
alignment	O
.	O

TITLE	O
:	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
proteins	I-PRGE
expressed	O
by	O
the	O
vaccinia	O
virus	O
Tiantan	O
strain	O
:	O
secreted	O
sq	O
protein	O
induces	O
robust	O
neutralization	O
antibody	O
in	O
mice	O
.	O

A	O
virulent	O
strain	O
of	O
IBV	O
,	O
isolated	O
from	O
Arkansas	O
(	O
Ark	B-PRGE
),	O
was	O
propagated	O
in	O
embryonated	O
eggs	O
(	O
Ark	O
DPI	O
11	O
).	O

Most	O
of	O
those	O
substitutions	O
are	O
located	O
in	O
the	O
replicase	B-PRGE
1a	I-PRGE
and	O
spike	O
genes	O
.	O

When	O
expression	O
of	O
DdX5	B-PRGE
was	O
knocked	O
down	O
by	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
),	O
SARS	O
coronavirus	O
replication	O
was	O
significantly	O
inhibited	O
in	O
fetal	O
rhesus	O
kidney	O
(	O
FRhK	O
-	O
4	O
)	O
cells	O
.	O

TITLE	O
:	O
Aryl	O
diketoacids	O
(	O
ADK	O
)	O
selectively	O
inhibit	O
duplex	O
DNA	O
-	O
unwinding	O
activity	O
of	O
SARS	B-PRGE
coronavirus	I-PRGE
NTPase	I-PRGE
/	O
helicase	B-PRGE
.	O

RESULTS	O
:	O
Histopathological	O
analysis	O
of	O
adult	O
male	O
BALB	O
/	O
C	O
mice	O
after	O
N	O
-	O
protein	O
infection	O
showed	O
progressive	O
inflammatory	O
reactions	O
,	O
especially	O
pulmonary	O
edema	O
,	O
in	O
accordance	O
with	O
a	O
moderately	O
(	O
approximately	O
13	O
%)	O
elevated	O
level	O
of	O
W	O
/	O
D	O
ratio	O
at	O
24	O
h	O
.	O
Although	O
adult	O
groups	O
underwent	O
a	O
progressive	O
lung	O
inflammation	O
in	O
the	O
acute	O
phase	O
accompanied	O
by	O
raised	O
levels	O
of	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
in	O
serum	O
,	O
no	O
significant	O
changes	O
in	O
lung	B-PRGE
TNF	I-PRGE
-	I-PRGE
alpha	I-PRGE
level	O
were	O
reported	O
simultaneously	O
.	O

TITLE	O
:	O
[	O
Expression	O
,	O
purification	O
and	O
antibody	O
preparation	O
of	O
recombinat	B-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
X5	I-PRGE
protein	I-PRGE
].	O

ABSTRACT	O
:	O
X5	B-PRGE
protein	I-PRGE
is	O
one	O
of	O
the	O
putative	O
unknown	O
proteins	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
The	O
recombinant	O
protein	O
has	O
been	O
successfully	O
expressed	O
in	O
E	O
.	O
coli	O
in	O
the	O
form	O
of	O
insoluble	O
inclusion	O
body	O
.	O

Phylogenetic	O
analysis	O
of	O
S1	B-PRGE
gene	I-PRGE
and	O
sequences	O
analysis	O
of	O
M	B-PRGE
gene	I-PRGE
indicated	O
that	O
MH5365	O
/	O
95	O
and	O
V9	O
/	O
04	O
belong	O
to	O
non	O
-	O
Massachusetts	O
strain	O
.	O

The	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
+	I-PRGE
874A	I-PRGE
allele	I-PRGE
and	O
RANTES	B-PRGE
-	I-PRGE
28	I-PRGE
G	I-PRGE
allele	O
are	O
risk	O
factors	O
for	O
SARS	B-PRGE
susceptibility	I-PRGE
.	O

No	O
positive	O
selection	O
was	O
found	O
in	O
any	O
proteins	O
of	O
bat	B-PRGE
SARS	I-PRGE
-	I-PRGE
like	I-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
Furthermore	O
,	O
specific	O
amino	O
acid	O
sites	O
that	O
may	O
be	O
the	O
targets	O
of	O
positive	O
selection	O
in	O
each	O
group	O
are	O
identified	O
.	O

No	O
positive	O
selection	O
was	O
found	O
in	O
any	O
proteins	O
of	O
bat	B-PRGE
SARS	I-PRGE
-	I-PRGE
like	I-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
Furthermore	O
,	O
specific	O
amino	O
acid	O
sites	O
that	O
may	O
be	O
the	O
targets	O
of	O
positive	O
selection	O
in	O
each	O
group	O
are	O
identified	O
.	O

The	O
cell	O
tropism	O
of	O
the	O
respective	O
pseudotypes	O
corresponded	O
to	O
the	O
tropism	O
of	O
the	O
viruses	O
from	O
which	O
the	O
S	B-PRGE
protein	I-PRGE
was	O
derived	O
.	O

TITLE	O
:	O
Suppression	O
of	O
host	O
gene	O
expression	O
by	O
nsp1	B-PRGE
proteins	I-PRGE
of	O
group	O
2	O
bat	O
coronaviruses	O
.	O

Several	O
new	O
members	O
were	O
discovered	O
following	O
the	O
emergence	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
in	O
human	O
populations	O
,	O
including	O
two	O
human	O
coronaviruses	O
and	O
several	O
animal	O
coronaviruses	O
.	O

This	O
study	O
reveals	O
an	O
essential	O
function	O
of	O
actin	B-PRGE
in	O
the	O
replication	O
cycle	O
of	O
coronavirus	O
.	O

Moreover	O
,	O
a	O
high	O
level	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
production	O
,	O
but	O
not	O
other	O
18	O
cytokines	O
tested	O
,	O
on	O
days	O
2	O
and	O
3	O
after	O
SARS	O
-	O
CoV	O
infection	O
was	O
closely	O
linked	O
to	O
the	O
virus	O
replication	O
and	O
disease	O
severity	O
,	O
suggesting	O
the	O
importance	O
of	O
these	O
cytokines	O
in	O
the	O
lung	O
pathogenicity	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

Symptoms	O
did	O
not	O
improve	O
with	O
steroid	O
or	O
immunoglobulin	B-PRGE
treatment	O
,	O
but	O
improvement	O
in	O
symptoms	O
was	O
observed	O
after	O
plasmapheresis	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
reported	O
that	O
transgenic	O
(	O
Tg	O
)	O
mice	O
expressing	O
human	B-PRGE
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
hACE2	O
),	O
the	O
receptor	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
were	O
highly	O
susceptible	O
to	O
SARS	O
-	O
CoV	O
infection	O
,	O
which	O
resulted	O
in	O
the	O
development	O
of	O
disease	O
of	O
various	O
severity	O
and	O
even	O
death	O
in	O
some	O
lineages	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
reported	O
that	O
rOv	B-PRGE
-	I-PRGE
ASP	I-PRGE
-	I-PRGE
1	I-PRGE
,	O
a	O
recombinant	B-PRGE
Onchocerca	I-PRGE
volvulus	I-PRGE
activation	I-PRGE
associated	I-PRGE
protein	I-PRGE
-	I-PRGE
1	I-PRGE
,	O
was	O
a	O
potent	O
adjuvant	O
for	O
recombinant	O
protein	O
or	O
synthetic	O
peptide	O
-	O
based	O
Ags	O
.	O

In	O
this	O
study	O
,	O
we	O
further	O
evaluated	O
the	O
adjuvanticity	O
of	O
rOv	B-PRGE
-	I-PRGE
ASP	I-PRGE
-	I-PRGE
1	I-PRGE
and	O
explored	O
its	O
mechanism	O
of	O
action	O
.	O

Currently	O
,	O
the	O
lengthy	O
process	O
of	O
sequence	O
analysis	O
of	O
the	O
IBV	B-PRGE
S1	I-PRGE
gene	I-PRGE
is	O
considered	O
the	O
gold	O
standard	O
for	O
IBV	O
strain	O
identification	O
,	O
with	O
a	O
high	O
nucleotide	O
identity	O
(	O
e	O
.	O
g	O
.	O
>	O
or	O
=	O
95	O
%)	O
indicating	O
related	O
strains	O
.	O

The	O
newly	O
developed	O
RT	O
-	O
PCR	O
/	O
HRM	O
curve	O
analysis	O
model	O
could	O
detect	O
and	O
rapidly	O
identify	O
novel	O
and	O
vaccine	O
-	O
related	O
IBV	O
strains	O
,	O
as	O
confirmed	O
by	O
S1	B-PRGE
gene	I-PRGE
and	O
3	B-PRGE
'	I-PRGE
UTR	I-PRGE
nucleotide	I-PRGE
sequences	I-PRGE
.	O

The	O
development	O
of	O
specific	O
mucosal	O
immune	O
system	O
against	O
duck	O
enteritis	O
virus	O
(	O
DEV	O
)	O
infection	O
for	O
ducks	O
has	O
been	O
hindered	O
by	O
a	O
lack	O
of	O
knowledge	O
concerning	O
the	O
purification	O
of	O
immunoglobulin	B-PRGE
A	I-PRGE
(	O
IgA	B-PRGE
)	O
of	O
duck	O
.	O

Although	O
the	O
recombinant	O
protein	O
obtained	O
has	O
not	O
shown	O
the	O
expected	O
fusion	O
effect	O
with	O
Hela	O
cell	O
membrane	O
,	O
this	O
work	O
may	O
enrich	O
the	O
understanding	O
of	O
the	O
process	O
of	O
membrane	O
fusion	O
mediated	O
by	O
S2	B-PRGE
protein	I-PRGE
and	O
lay	O
the	O
foundation	O
for	O
future	O
study	O
of	O
targeting	O
cell	O
transport	O
system	O
based	O
on	O
cell	O
-	O
specific	O
binding	O
peptide	O
.	O

ABSTRACT	O
:	O
SARS	O
coronavirus	O
main	O
protease	O
(	O
M	O
(	O
pro	O
))	O
plays	O
an	O
essential	O
role	O
in	O
the	O
extensive	O
proteolytic	O
processing	O
of	O
the	O
viral	O
polyproteins	O
(	O
pp1a	B-PRGE
and	O
pp1ab	O
),	O
and	O
it	O
is	O
an	O
important	O
target	O
for	O
anti	O
-	O
SARS	O
drug	O
development	O
.	O

Overall	O
,	O
in	O
terms	O
of	O
how	O
cleavage	O
might	O
activate	O
membrane	O
fusion	O
,	O
proteolytic	O
processing	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
remains	O
unclear	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
a	O
novel	O
priming	O
mechanism	O
for	O
a	O
viral	O
fusion	O
protein	O
,	O
with	O
a	O
critical	O
proteolytic	O
cleavage	O
event	O
on	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
at	O
position	O
797	O
(	O
S2	O
'),	O
acting	O
in	O
concert	O
with	O
the	O
S1	O
-	O
S2	O
cleavage	O
site	O
to	O
mediate	O
membrane	O
fusion	O
and	O
virus	O
infectivity	O
.	O

The	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
E	I-PRGE
protein	I-PRGE
is	O
predicted	O
to	O
be	O
a	O
double	O
-	O
spanning	O
membrane	O
protein	O
lacking	O
a	O
conventional	O
signal	O
peptide	O
.	O

Further	O
analysis	O
based	O
on	O
their	O
nucleotide	O
and	O
amino	O
acid	O
sequences	O
in	O
hypervariable	O
region	O
(	O
HVR	O
)	O
1	O
and	O
the	O
intervening	O
sequence	O
including	O
HVRs	B-PRGE
1	I-PRGE
and	I-PRGE
2	I-PRGE
(	O
HVR1	B-PRGE
/	I-PRGE
2	I-PRGE
)	O
of	O
the	O
S1	B-PRGE
gene	I-PRGE
was	O
done	O
to	O
determine	O
the	O
genetic	O
relationships	O
among	O
them	O
and	O
reference	O
strains	O
.	O

TCoV	B-PRGE
serum	I-PRGE
antibody	I-PRGE
responses	O
were	O
assessed	O
with	O
two	O
recently	O
developed	O
TCoV	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
that	O
used	O
TCoV	O
nucleocapsid	O
and	O
S1	O
polypeptides	O
as	O
coating	O
antigens	O
.	O

Within	O
S	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
mediates	O
the	O
interaction	O
with	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
),	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
host	I-PRGE
cell	I-PRGE
receptor	I-PRGE
.	O

This	O
study	O
was	O
to	O
determine	O
whether	O
the	O
damage	O
was	O
correlated	O
with	O
expression	O
of	O
the	O
SARS	B-PRGE
coronavirus	I-PRGE
receptor	I-PRGE
,	O
angiotensin	B-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
),	O
in	O
different	O
organs	O
,	O
especially	O
in	O
the	O
endocrine	O
tissues	O
of	O
the	O
pancreas	O
,	O
and	O
to	O
elucidate	O
the	O
pathogenesis	O
of	O
glucose	O
intolerance	O
in	O
SARS	O
patients	O
.	O

TITLE	O
:	O
[	O
Role	O
of	O
CD4	B-PRGE
-	O
CD8	B-PRGE
-	O
T	O
cells	O
in	O
the	O
murine	O
hepatitis	O
virus	O
type	O
3	O
induced	O
chronic	O
viral	O
hepatitis	O
].	O

Viral	O
control	O
,	O
tropism	O
,	O
and	O
demyelination	O
were	O
all	O
similar	O
in	O
p35	B-PRGE
(-/-),	O
p19	B-PRGE
(-/-),	O
and	O
wild	O
-	O
type	O
mice	O
.	O

For	O
a	O
period	O
of	O
3	O
years	O
,	O
120	O
samples	O
were	O
collected	O
and	O
57	O
were	O
found	O
positive	O
for	O
FCoV	B-PRGE
RNA	I-PRGE
.	O

These	O
viral	O
sequences	O
,	O
comprising	O
a	O
region	O
within	O
gene	B-PRGE
S	I-PRGE
were	O
further	O
subjected	O
to	O
a	O
heteroduplex	O
mobility	O
assay	O
(	O
HMA	O
)	O
detecting	O
the	O
presence	O
of	O
viral	O
quasispecies	O
in	O
17	O
%	O
of	O
the	O
samples	O
.	O

Furthermore	O
,	O
it	O
was	O
investigated	O
whether	O
macrophages	O
,	O
one	O
of	O
the	O
target	O
cells	O
of	O
FIPV	O
infection	O
,	O
produce	O
neutrophil	B-PRGE
survival	I-PRGE
factors	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
,	O
and	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
).	O

TITLE	O
:	O
Genetic	O
diversity	O
of	O
avian	O
infectious	O
bronchitis	O
viruses	O
in	O
Japan	O
based	O
on	O
analysis	O
of	O
s2	B-PRGE
glycoprotein	I-PRGE
gene	I-PRGE
.	O

However	O
,	O
the	O
classification	O
based	O
on	O
the	O
S2	B-PRGE
gene	I-PRGE
of	O
IBV	O
isolated	O
in	O
Japan	O
was	O
different	O
for	O
some	O
of	O
the	O
strains	O
from	O
those	O
obtained	O
with	O
our	O
previous	O
analysis	O
of	O
the	O
S1	B-PRGE
gene	I-PRGE
.	O

Laboratory	O
investigation	O
on	O
admission	O
demonstrated	O
a	O
normal	O
white	O
cell	O
count	O
with	O
neutrophilia	O
(	O
4000	O
/	O
microl	O
,	O
90	O
.	O
5	O
%	O
neutrophils	O
),	O
an	O
erythrocyte	O
sedimentation	O
rate	O
of	O
10	O
mm	O
/	O
h	O
and	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
value	O
of	O
9	O
.	O
0mg	O
/	O
dl	O
.	O

In	O
order	O
to	O
assess	O
the	O
role	O
of	O
activated	O
neutrophils	O
,	O
pro	O
-	O
and	O
anti	O
-	O
inflammatory	O
cytokines	O
and	O
adhesion	O
molecules	O
at	O
the	O
onset	O
and	O
development	O
of	O
respiratory	O
complications	O
and	O
respiratory	O
failure	O
,	O
we	O
measured	O
the	O
serum	O
levels	O
of	O
pro	O
-	O
inflammatory	O
(	O
IL	O
-	O
1	O
beta	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	O
-	O
8	O
,	O
IL	B-PRGE
-	I-PRGE
18	I-PRGE
,	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
and	O
anti	O
-	O
inflammatory	O
(	O
IL	O
-	O
1	O
ra	O
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
)	O
cytokines	O
in	O
51	O
AP	O
patients	O
who	O
had	O
been	O
diagnosed	O
with	O
pancreatitis	O
-	O
associated	O
lung	O
injury	O
with	O
and	O
without	O
the	O
development	O
of	O
organ	O
dysfunction	O
.	O

TITLE	O
:	O
Bovine	B-PRGE
coronavirus	I-PRGE
nonstructural	I-PRGE
protein	I-PRGE
1	I-PRGE
(	O
p28	B-PRGE
)	O
is	O
an	O
RNA	O
binding	O
protein	O
that	O
binds	O
terminal	O
genomic	O
cis	O
-	O
replication	O
elements	O
.	O

ABSTRACT	O
:	O
Carcinoembryonic	O
antigen	O
-	O
related	O
cell	O
adhesion	O
molecule	O
1	O
(	O
CEACAM1	B-PRGE
)	O
regulates	O
intestinal	O
immunological	O
homeostasis	O
.	O

New	O
ligands	O
that	O
target	O
the	O
N	B-PRGE
protein	I-PRGE
may	O
thus	O
provide	O
tools	O
to	O
track	O
the	O
protein	O
inside	O
cells	O
,	O
detect	O
interaction	O
hot	O
spots	O
on	O
the	O
protein	O
surface	O
,	O
and	O
discover	O
sites	O
that	O
could	O
be	O
used	O
to	O
develop	O
new	O
anti	O
-	O
SARS	O
therapies	O
.	O

In	O
this	O
study	O
,	O
we	O
focus	O
on	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
papain	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
PLP	B-PRGE
),	O
which	O
engages	O
and	O
antagonizes	O
the	O
IFN	B-PRGE
induction	O
and	O
NF	B-PRGE
-	I-PRGE
kappaB	I-PRGE
signaling	O
pathways	O
.	O

To	O
determine	O
the	O
biological	O
relevance	O
of	O
this	O
motif	O
,	O
we	O
constructed	O
a	O
SARS	O
-	O
CoV	O
reverse	O
genetic	O
construct	O
by	O
using	O
a	O
bacterial	O
artificial	O
chromosome	O
(	O
BAC	O
)-	O
based	O
vector	O
controlled	O
by	O
a	O
T7	O
promoter	O
;	O
and	O
subsequently	O
deleted	O
the	O
SR	O
-	O
rich	O
motif	O
from	O
the	O
N	B-PRGE
gene	I-PRGE
.	O

The	O
GFP	B-PRGE
tag	I-PRGE
enables	O
a	O
relatively	O
quick	O
confirmation	O
of	O
antigen	O
expression	O
in	O
plant	O
cells	O
by	O
fluorescent	O
microscopy	O
.	O

It	O
has	O
evolved	O
various	O
strategies	O
to	O
counteract	O
the	O
production	O
and	O
action	O
of	O
type	B-PRGE
I	I-PRGE
interferons	I-PRGE
,	O
which	O
mobilize	O
the	O
front	O
-	O
line	O
defense	O
against	O
viral	O
infection	O
.	O

In	O
this	O
study	O
we	O
demonstrate	O
that	O
SARS	B-PRGE
coronavirus	I-PRGE
M	I-PRGE
protein	I-PRGE
inhibits	O
gene	O
transcription	O
of	O
type	B-PRGE
I	I-PRGE
interferons	I-PRGE
.	O

M	B-PRGE
protein	I-PRGE
physically	O
associates	O
with	O
RIG	B-PRGE
-	I-PRGE
I	I-PRGE
,	O
TBK1	B-PRGE
,	O
IKKepsilon	B-PRGE
,	O
and	O
TRAF3	B-PRGE
and	O
likely	O
sequesters	O
some	O
of	O
them	O
in	O
membrane	O
-	O
associated	O
cytoplasmic	O
compartments	O
.	O

Analysis	O
of	O
virus	O
-	O
susceptible	O
target	O
cells	O
in	O
vivo	O
revealed	O
that	O
B7	B-PRGE
-	I-PRGE
H1	I-PRGE
expression	O
was	O
regulated	O
in	O
a	O
cell	O
type	O
-	O
dependent	O
manner	O
.	O

Oligodendroglia	O
and	O
microglia	O
up	O
-	O
regulated	O
B7	B-PRGE
-	I-PRGE
H1	I-PRGE
following	O
infection	O
;	O
however	O
,	O
although	O
B7	B-PRGE
-	I-PRGE
H1	I-PRGE
expression	O
on	O
oligodendroglia	O
was	O
prominent	O
and	O
sustained	O
,	O
it	O
was	O
significantly	O
reduced	O
and	O
transient	O
on	O
microglia	O
.	O

Infection	O
of	O
mice	O
deficient	O
in	O
the	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
or	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
/	I-PRGE
beta	I-PRGE
receptor	I-PRGE
demonstrated	O
that	O
B7	B-PRGE
-	I-PRGE
H1	I-PRGE
expression	O
on	O
oligodendroglia	O
is	O
predominantly	O
regulated	O
by	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
.	O

TITLE	O
:	O
From	O
lab	O
to	O
bedside	O
:	O
emerging	O
clinical	O
applications	O
of	O
thymosin	B-PRGE
alpha	I-PRGE
1	I-PRGE
.	O

ABSTRACT	O
:	O
Thymosin	B-PRGE
alpha	I-PRGE
(	O
1	O
)	O
(	O
Talpha	O
(	O
1	O
)),	O
a	O
synthetic	O
version	O
of	O
a	O
thymic	O
-	O
derived	O
biological	O
response	O
modifier	O
was	O
the	O
first	O
of	O
the	O
thymosins	O
in	O
clinical	O
use	O
.	O

IgG	B-PRGE
antibody	I-PRGE
in	O
convalescent	O
serum	O
of	O
patients	O
with	O
SARS	O
revealed	O
an	O
increasing	O
trend	O
,	O
peaking	O
at	O
the	O
22nd	O
week	O
after	O
onset	O
of	O
illness	O
followed	O
by	O
a	O
slow	O
decline	O
.	O

IgM	B-PRGE
appeared	O
earlier	O
than	O
IgG	B-PRGE
and	O
can	O
be	O
better	O
used	O
for	O
early	O
detection	O
.	O

In	O
this	O
report	O
,	O
we	O
have	O
characterized	O
the	O
molecular	O
components	O
that	O
regulate	O
intracellular	O
localization	O
of	O
the	O
ORF	B-PRGE
3b	I-PRGE
protein	I-PRGE
.	O

This	O
study	O
describes	O
a	O
novel	O
role	O
for	O
MAVS	B-PRGE
in	O
controlling	O
viral	O
infections	O
through	O
the	O
induction	O
of	O
apoptosis	O
,	O
and	O
identifies	O
viral	O
proteins	O
which	O
inhibit	O
this	O
host	O
response	O
.	O

ABSTRACT	O
:	O
The	O
3C	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	B-PRGE
))	O
is	O
vital	O
for	O
SARS	O
-	O
CoV	O
replication	O
and	O
is	O
a	O
promising	O
drug	O
target	O
.	O

ABSTRACT	O
:	O
Angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
)	O
is	O
a	O
terminal	B-PRGE
carboxypeptidase	I-PRGE
and	O
the	O
receptor	O
for	O
the	O
SARS	O
and	O
NL63	O
coronaviruses	O
(	O
CoV	O
).	O

We	O
determined	O
that	O
the	O
ACE2	B-PRGE
cleavage	O
site	O
resides	O
between	O
amino	O
acid	O
716	O
and	O
the	O
putative	O
transmembrane	O
domain	O
starting	O
at	O
amino	O
acid	O
741	O
.	O

Interestingly	O
,	O
a	O
point	O
mutation	O
in	O
the	O
ACE2	B-PRGE
ectodomain	I-PRGE
,	O
L584A	O
,	O
markedly	O
attenuated	O
shedding	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
carry	O
out	O
molecular	O
epidemiological	O
investigation	O
on	O
enterotoxigenic	B-PRGE
Escherichia	I-PRGE
coli	I-PRGE
(	O
ETEC	O
)	O
K99	O
and	O
Salmonella	B-PRGE
spp	I-PRGE
.	O

ETEC	O
K99	O
was	O
recovered	O
from	O
20	O
(	O
10	O
.	O
36	O
%)	O
out	O
of	O
193	O
isolates	O
,	O
whereas	O
Salmonella	B-PRGE
spp	I-PRGE
.	O
was	O
recovered	O
from	O
nine	O
calves	O
(	O
4	O
.	O
09	O
%).	O

To	O
explore	O
other	O
domain	O
interactions	O
of	O
the	O
MHV	B-PRGE
N	I-PRGE
protein	I-PRGE
,	O
we	O
expressed	O
a	O
series	O
of	O
segments	O
of	O
the	O
MHV	B-PRGE
N	I-PRGE
protein	I-PRGE
as	O
fusions	O
with	O
green	B-PRGE
fluorescent	I-PRGE
protein	I-PRGE
(	O
GFP	O
)	O
during	O
the	O
course	O
of	O
viral	O
infection	O
.	O

Cytokines	O
associated	O
with	O
ARDS	O
were	O
significantly	O
upregulated	O
in	O
animals	O
experiencing	O
lung	O
pathology	O
and	O
lethal	O
disease	O
,	O
while	O
the	O
same	O
animals	O
experienced	O
downregulation	O
of	O
the	O
ACE2	B-PRGE
receptor	I-PRGE
.	O

CC	O
/	O
Fr	O
.	O
2	O
inhibited	O
the	O
internalization	O
of	O
TfR	B-PRGE
but	O
the	O
procyanidins	O
did	O
not	O
.	O

TITLE	O
:	O
Expression	O
and	O
functional	O
analysis	O
of	O
porcine	B-PRGE
aminopeptidase	I-PRGE
N	I-PRGE
produced	O
in	O
prokaryotic	O
expression	O
system	O
.	O

ABSTRACT	O
:	O
Porcine	B-PRGE
aminopeptidase	I-PRGE
N	I-PRGE
(	O
pAPN	O
)	O
is	O
a	O
cellular	O
membrane	O
protein	O
and	O
a	O
functional	O
receptor	O
for	O
porcine	O
coronaviruses	O
.	O

Because	O
of	O
the	O
high	O
mortality	O
which	O
is	O
up	O
to	O
100	O
%	O
in	O
suckling	O
piglets	O
,	O
PED	B-PRGE
is	O
an	O
important	O
porcine	O
disease	O
in	O
Korea	O
.	O

The	O
cytopathic	O
effect	O
(	O
CPE	O
)	O
reduction	O
,	O
plaque	O
reduction	O
and	O
inhibition	O
assays	O
on	O
viral	O
replication	O
,	O
and	O
virucidal	O
activity	O
were	O
further	O
conducted	O
to	O
investigate	O
the	O
anti	B-PRGE
-	I-PRGE
PrV	I-PRGE
activity	O
.	O

ABSTRACT	O
:	O
Pulmonary	O
SP	B-PRGE
-	I-PRGE
D	I-PRGE
is	O
a	O
defence	O
lectin	B-PRGE
promoting	O
clearance	O
of	O
viral	O
infections	O
.	O

The	O
significant	O
correlation	O
between	O
plasma	O
SP	B-PRGE
-	I-PRGE
D	I-PRGE
and	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
specific	I-PRGE
antibodies	I-PRGE
support	O
the	O
role	O
for	O
SP	B-PRGE
-	I-PRGE
D	I-PRGE
in	O
interlinking	O
innate	O
and	O
adaptive	O
immune	O
pathways	O
.	O

To	O
investigate	O
this	O
potential	O
,	O
we	O
redirected	O
the	O
coronavirus	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
which	O
is	O
normally	O
unable	O
to	O
infect	O
human	O
cells	O
,	O
to	O
human	O
tumor	O
cells	O
by	O
using	O
a	O
soluble	B-PRGE
receptor	I-PRGE
(	O
soR	B-PRGE
)-	O
based	O
expression	O
construct	O
fused	O
to	O
an	O
epidermal	B-PRGE
growth	I-PRGE
factor	I-PRGE
(	O
EGF	O
)	O
receptor	O
targeting	O
moiety	O
.	O

Infection	O
of	O
malignant	B-PRGE
human	I-PRGE
glioblastoma	I-PRGE
U87DeltaEGFR	I-PRGE
cells	O
gave	O
rise	O
to	O
release	O
of	O
progeny	O
virus	O
and	O
efficient	O
cell	O
killing	O
in	O
vitro	O
.	O

TITLE	O
:	O
Association	O
of	O
human	B-PRGE
leukocyte	I-PRGE
antigen	I-PRGE
class	I-PRGE
II	I-PRGE
alleles	I-PRGE
with	O
severe	O
acute	O
respiratory	O
syndrome	O
in	O
the	O
Vietnamese	O
population	O
.	O

HLA	B-PRGE
-	I-PRGE
DRB1	I-PRGE
*	I-PRGE
1202	I-PRGE
,	O
the	O
predominant	O
allele	O
in	O
the	O
Vietnamese	O
population	O
showed	O
the	O
strongest	O
association	O
with	O
SARS	O
in	O
a	O
dominant	O
model	O
(	O
corrected	O
p	O
=	O
0	O
.	O
0065	O
and	O
0	O
.	O
0052	O
,	O
depending	O
on	O
the	O
controls	O
to	O
be	O
compared	O
).	O

The	O
presence	O
of	O
SARS	O
-	O
CoV	O
in	O
the	O
heart	O
was	O
also	O
associated	O
with	O
marked	O
reductions	O
in	O
ACE2	B-PRGE
protein	I-PRGE
expression	O
.	O

Many	O
of	O
these	O
beneficial	O
effects	O
are	O
mediated	O
through	O
its	O
co	O
-	O
receptor	O
endothelial	O
protein	B-PRGE
C	I-PRGE
receptor	I-PRGE
,	O
and	O
the	O
protease	B-PRGE
-	I-PRGE
activated	I-PRGE
receptor	I-PRGE
1	I-PRGE
,	O
although	O
exact	O
mechanisms	O
remain	O
unclear	O
and	O
are	O
likely	O
pleiotropic	O
in	O
nature	O
.	O

Amphotericin	O
B	O
and	O
voriconazole	O
were	O
instituted	O
,	O
but	O
without	O
evident	O
success	O
,	O
The	O
girl	O
was	O
severely	O
distressed	O
,	O
required	O
mechanical	O
ventilation	O
with	O
an	O
F1O2	O
of	O
0	O
.	O
6	O
,	O
while	O
her	O
CRP	B-PRGE
increased	O
to	O
28	O
.	O
4	O
mg	O
dL	O
(-	O
1	O
).	O

Th2	O
cell	O
polarization	O
,	O
Smad4	B-PRGE
and	O
Smad7	B-PRGE
should	O
be	O
the	O
crucial	O
molecular	O
mechanism	O
of	O
ALI	O
-	O
induced	O
rapid	O
fibrosis	O
.	O

ABSTRACT	O
:	O
Systemic	O
administration	O
of	O
corticosteroid	O
,	O
plasmapheresis	O
and	O
high	B-PRGE
-	I-PRGE
dose	I-PRGE
immunoglobulin	I-PRGE
therapy	O
(	O
IVIG	O
)	O
are	O
the	O
main	O
treatment	O
of	O
Stevens	O
-	O
Johnson	O
syndrome	O
(	O
SJS	O
)	O
and	O
toxic	O
epidermal	O
necrolysis	O
(	O
TEN	O
).	O

Four	O
deceased	O
cases	O
of	O
TEN	B-PRGE
were	O
treated	O
with	O
corticosteroids	O
with	O
or	O
without	O
IVIG	O
,	O
and	O
2	O
of	O
them	O
merged	O
sepsis	O
.	O

(	O
III	B-PRGE
-	I-PRGE
C	I-PRGE
)	O
7	O
.	O

Respondents	O
'	O
perceptions	O
of	O
SARS	O
-	O
related	O
risks	O
were	O
significantly	O
positively	O
associated	O
with	O
PTS	B-PRGE
symptom	I-PRGE
levels	O
and	O
partially	O
mediated	O
the	O
effects	O
of	O
exposure	O
.	O

There	O
was	O
also	O
strong	O
induction	O
of	O
TNF	B-PRGE
-	O
related	O
apoptosis	O
-	O
inducing	O
ligand	O
(	O
TRAIL	O
),	O
but	O
not	O
Fas	B-PRGE
ligand	I-PRGE
gene	O
expression	O
in	O
SARS	O
-	O
CoV	O
infected	O
DCs	O
.	O

CONCLUSIONS	O
:	O
The	O
upregulation	O
of	O
chemokines	O
and	O
CCRs	O
may	O
facilitate	O
DC	O
migration	O
from	O
the	O
infection	O
site	O
to	O
the	O
lymph	O
nodes	O
,	O
whereas	O
the	O
increase	O
of	O
TRAIL	B-PRGE
may	O
induce	O
lymphocyte	O
apoptosis	O
.	O

Based	O
on	O
expert	O
opinion	O
,	O
the	O
following	O
are	O
recommended	O
:	O
1	O
)	O
avoid	O
tidal	O
volumes	O
>	O
or	O
=	O
10	O
mL	O
/	O
kg	O
body	O
weight	O
;	O
2	O
)	O
keep	O
plateau	O
pressure	O
<	O
or	O
=	O
30	O
cm	O
H2O	O
,	O
arterial	O
pH	O
at	O
7	O
.	O
30	O
to	O
7	O
.	O
45	O
,	O
and	O
Pao2	O
60	O
to	O
80	O
torr	O
(	O
8	O
to	O
10	O
.	O
7	O
kPa	O
)	O
(	O
Spo2	B-PRGE
>	O
or	O
=	O
90	O
%);	O
3	O
)	O
provide	O
sedation	O
,	O
analgesia	O
,	O
and	O
stress	O
ulcer	O
prophylaxis	O
;	O
and	O
4	O
)	O
use	O
a	O
10	O
g	O
/	O
dL	O
hemoglobin	B-PRGE
threshold	O
for	O
packed	O
red	O
blood	O
cell	O
transfusion	O
in	O
unstable	O
patients	O
(	O
shock	O
or	O
profound	O
hypoxia	O
).	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
whether	O
co	O
-	O
administration	O
of	O
a	O
plasmid	O
containing	O
a	O
chicken	B-PRGE
granulocyte	I-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
(	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
)	O
gene	O
and	O
a	O
plasmid	O
containing	O
the	O
S1	B-PRGE
gene	I-PRGE
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
could	O
enhance	O
the	O
immune	O
response	O
and	O
protection	O
efficacy	O
in	O
chickens	O
against	O
challenge	O
by	O
virulent	O
IBV	O
.	O

Under	O
the	O
condition	O
of	O
the	O
establishment	O
of	O
dendrtic	O
cells	O
(	O
DC	O
)	O
culture	O
method	O
,	O
we	O
used	O
recombinant	O
adenovirus	O
to	O
infect	O
mature	O
DC	O
to	O
make	O
clear	O
the	O
development	O
changes	O
in	O
mRNA	O
levels	O
and	O
secreted	O
protein	O
levels	O
of	O
proinflammatory	O
cytokines	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	O
-	O
8	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
by	O
using	O
RT	O
-	O
PCR	O
and	O
ELISA	O
.	O

We	O
found	O
that	O
mRNA	O
levels	O
and	O
secreted	O
protein	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
in	O
DC	O
had	O
increased	O
gradually	O
after	O
rAd	O
-	O
N	O
infection	O
during	O
first	O
24	O
h	O
compared	O
with	O
the	O
control	O
DC	O
infected	O
by	O
rAd	O
-	O
LacZ	B-PRGE
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
).	O

METHODS	O
:	O
Under	O
the	O
condition	O
of	O
the	O
establishment	O
of	O
dendrtic	O
cells	O
(	O
DC	O
)	O
culture	O
method	O
,	O
we	O
used	O
recombinant	O
adenovirus	O
to	O
infect	O
mature	O
DC	O
to	O
make	O
clear	O
the	O
development	O
changes	O
in	O
mRNA	O
levels	O
and	O
secreted	O
protein	O
levels	O
of	O
proinflammatory	O
cytokines	O
of	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	O
-	O
8	O
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
by	O
using	O
RT	O
-	O
PCR	O
and	O
ELISA	O
.	O

CONCLUSIONS	O
:	O
It	O
is	O
suggested	O
that	O
N	B-PRGE
protein	I-PRGE
may	O
be	O
related	O
to	O
the	O
excessive	O
secretion	O
of	O
proinflammatory	O
cytokines	O
during	O
SARS	O
-	O
CoV	O
infection	O
at	O
the	O
acute	O
phase	O
.	O

The	O
diversity	O
of	O
coronaviruses	O
is	O
a	O
result	O
of	O
the	O
infidelity	O
of	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
,	O
high	O
frequency	O
of	O
homologous	O
RNA	O
recombination	O
,	O
and	O
the	O
large	O
genomes	O
of	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
the	O
coronavirus	O
(	O
CoV	O
)	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
is	O
cleaved	O
into	O
S1	O
and	O
S2	O
subunits	O
at	O
the	O
furin	B-PRGE
consensus	O
motif	O
RRFRR	O
(	O
537	O
)/	O
S	O
in	O
virus	O
-	O
infected	O
cells	O
.	O

Furthermore	O
,	O
sequence	O
analysis	O
of	O
CoV	O
S	O
proteins	O
by	O
multiple	O
alignments	O
showed	O
conservation	O
of	O
an	O
XXXR	O
/	O
S	O
motif	O
,	O
cleavable	O
by	O
either	O
furin	B-PRGE
or	O
other	O
trypsin	B-PRGE
-	I-PRGE
like	I-PRGE
proteases	I-PRGE
,	O
at	O
a	O
position	O
equivalent	O
to	O
the	O
second	O
IBV	B-PRGE
furin	I-PRGE
site	I-PRGE
.	O

In	O
order	O
to	O
further	O
define	O
the	O
role	O
of	O
the	O
host	O
genetic	O
background	O
in	O
influencing	O
susceptibility	O
to	O
MHV	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
induced	O
disease	O
,	O
we	O
examined	O
14	O
different	O
inbred	O
mouse	O
strains	O
.	O

The	O
5	O
-	O
plexed	O
immunoassays	O
using	O
sets	O
of	O
9	O
-	O
plexed	O
coupled	O
fluorescent	O
beads	O
were	O
employed	O
to	O
simultaneously	O
detect	O
five	O
representative	O
biothreat	O
agents	O
,	O
including	O
B	O
.	O
anthracis	O
spore	O
,	O
Y	O
.	O
pestis	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
staphylococcal	B-PRGE
enterotoxin	I-PRGE
B	I-PRGE
(	O
SEB	B-PRGE
)	O
and	O
ricin	O
from	O
a	O
single	O
powder	O
sample	O
and	O
the	O
feasibility	O
for	O
field	O
samples	O
was	O
demonstrated	O
by	O
both	O
blinded	O
and	O
standard	O
laboratory	O
trials	O
.	O

(	O
0	O
.	O
5	O
%),	O
and	O
Mycoplasma	B-PRGE
spp	I-PRGE
.	O

Here	O
we	O
report	O
that	O
acquisition	O
of	O
the	O
cell	O
-	O
cell	O
fusion	O
activity	O
by	O
amino	O
acid	O
mutations	O
in	O
the	O
S	B-PRGE
protein	I-PRGE
determines	O
the	O
infectivity	O
of	O
IBV	O
in	O
cultured	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
immunogenicity	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
nucleocapsid	I-PRGE
DNA	I-PRGE
vaccine	O
and	O
the	O
immunoregulatory	O
activity	O
of	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
were	O
investigated	O
.	O

The	O
nucleocapsid	O
DNA	O
vaccine	O
had	O
good	O
immunogenicity	O
and	O
can	O
induce	O
specific	O
humoral	O
and	O
cellular	O
immunity	O
in	O
BALB	O
/	O
c	O
mice	O
,	O
while	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
plays	O
an	O
immunoadjuvant	O
role	O
and	O
enhances	O
specific	O
immune	O
responses	O
.	O

Nine	O
of	O
them	O
,	O
including	O
members	O
of	O
the	O
heterogeneous	B-PRGE
ribonucleoprotein	I-PRGE
family	I-PRGE
of	I-PRGE
proteins	I-PRGE
(	O
hnRNPs	O
),	O
the	O
poly	B-PRGE
(	I-PRGE
A	I-PRGE
)-	I-PRGE
binding	I-PRGE
protein	I-PRGE
(	O
PABP	B-PRGE
),	O
the	O
p100	B-PRGE
transcriptional	O
co	B-PRGE
-	I-PRGE
activator	I-PRGE
protein	I-PRGE
and	O
two	O
aminoacyl	O
-	O
tRNA	O
synthetases	O
,	O
showed	O
a	O
preferential	O
binding	O
to	O
the	O
3	O
'	O
end	O
of	O
the	O
genome	O
,	O
whereas	O
only	O
the	O
polypyrimidine	O
tract	O
-	O
binding	O
protein	O
(	O
PTB	B-PRGE
)	O
was	O
preferentially	O
pulled	O
down	O
with	O
the	O
5	O
'	O
end	O
of	O
the	O
genome	O
.	O

Gene	O
silencing	O
of	O
PABP	B-PRGE
,	O
hnRNP	B-PRGE
Q	I-PRGE
,	O
and	O
glutamyl	B-PRGE
-	I-PRGE
prolyl	I-PRGE
-	I-PRGE
tRNA	I-PRGE
synthetase	I-PRGE
(	O
EPRS	B-PRGE
)	O
caused	O
a	O
significant	O
2	O
to	O
3	O
-	O
fold	O
reduction	O
of	O
viral	O
RNA	O
synthesis	O
.	O

These	O
data	O
suggest	O
that	O
PABP	B-PRGE
,	O
hnRNP	B-PRGE
Q	I-PRGE
,	O
and	O
EPRS	O
play	O
a	O
positive	O
role	O
in	O
virus	O
infection	O
that	O
could	O
be	O
mediated	O
through	O
their	O
interaction	O
with	O
the	O
viral	O
3	O
'	O
end	O
,	O
and	O
that	O
GAPDH	B-PRGE
has	O
a	O
negative	O
effect	O
on	O
viral	O
infection	O
.	O

CONCLUSIONS	O
:	O
Mutations	O
,	O
insertions	O
,	O
deletions	O
and	O
recombination	O
of	O
the	O
S1	B-PRGE
protein	I-PRGE
gene	I-PRGE
contribute	O
to	O
the	O
genetic	O
diversity	O
of	O
IBV	O
in	O
China	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
cytokine	O
expression	O
(	O
interleukin	B-PRGE
[	I-PRGE
IL	I-PRGE
]-	I-PRGE
1beta	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	O
-	O
8	O
,	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
[	I-PRGE
TNF	I-PRGE
]-	I-PRGE
alpha	I-PRGE
),	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
,	O
and	O
endotoxins	O
on	O
the	O
first	O
day	O
of	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
admission	O
are	O
associated	O
with	O
hospital	O
mortality	O
in	O
severe	O
community	O
-	O
acquired	O
pneumonia	O
(	O
CAP	O
).	O

Furthermore	O
,	O
in	O
the	O
ARDS	O
population	O
,	O
we	O
found	O
that	O
the	O
endotoxin	O
levels	O
in	O
the	O
BAL	O
fluid	O
were	O
higher	O
in	O
the	O
survival	O
than	O
in	O
the	O
nonsurvival	O
group	O
and	O
BAL	O
fluid	O
concentrations	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	O
-	O
8	O
,	O
and	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
and	O
sera	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
were	O
lower	O
in	O
the	O
survival	O
than	O
in	O
the	O
nonsurvival	O
group	O
,	O
and	O
they	O
were	O
associated	O
with	O
a	O
high	O
negative	O
predictive	O
value	O
.	O

ABSTRACT	O
:	O
The	O
envelope	B-PRGE
(	I-PRGE
E	I-PRGE
)	I-PRGE
protein	I-PRGE
from	O
coronaviruses	O
is	O
a	O
small	O
polypeptide	O
that	O
contains	O
at	O
least	O
one	O
alpha	O
-	O
helical	O
transmembrane	O
domain	O
.	O

Three	O
trans	O
-	O
membrane	O
non	O
-	O
structural	O
proteins	O
,	O
nsp3	B-PRGE
,	O
nsp4	B-PRGE
and	O
nsp6	O
,	O
are	O
understood	O
to	O
be	O
membrane	O
anchors	O
of	O
the	O
coronavirus	O
replication	O
complex	O
.	O

Nsp4	B-PRGE
is	O
localized	O
to	O
the	O
ER	O
membrane	O
when	O
expressed	O
alone	O
but	O
is	O
recruited	O
into	O
the	O
replication	O
complex	O
in	O
infected	O
cells	O
.	O

This	O
structure	O
may	O
serve	O
as	O
a	O
basis	O
for	O
further	O
functional	O
studies	O
of	O
nsp4	B-PRGE
.	O

Studies	O
using	O
wild	O
bat	O
sera	O
revealed	O
that	O
it	O
is	O
highly	O
likely	O
that	O
the	O
immunodominant	O
epitopes	O
overlap	O
with	O
the	O
major	O
neutralizing	O
sites	O
of	O
the	O
SL	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
.	O

Group	O
selection	O
per	O
se	O
is	O
not	O
a	O
currently	O
accepted	O
idea	O
and	O
its	O
apparent	O
occurrence	O
is	O
explained	O
by	O
statistical	O
gene	O
frequency	O
models	O
of	O
kin	B-PRGE
selection	O
.	O

The	O
large	O
coronavirus	O
genome	O
(	O
26	O
-	O
31	O
kb	O
)	O
encodes	O
15	O
-	O
16	O
nonstructural	O
proteins	O
(	O
nsps	O
)	O
that	O
are	O
derived	O
from	O
two	O
replicase	B-PRGE
polyproteins	I-PRGE
by	O
autoproteolytic	O
processing	O
.	O

The	O
nsps	O
assemble	O
into	O
the	O
viral	O
replication	O
-	O
transcription	O
complex	O
and	O
nsp3	B-PRGE
,	O
nsp4	B-PRGE
and	O
nsp6	O
are	O
believed	O
to	O
anchor	O
this	O
enzyme	O
complex	O
to	O
modified	O
intracellular	O
membranes	O
.	O

The	O
largest	O
part	O
of	O
the	O
coronavirus	B-PRGE
nsp4	I-PRGE
subunit	I-PRGE
is	O
hydrophobic	O
and	O
is	O
predicted	O
to	O
be	O
embedded	O
in	O
the	O
membranes	O
.	O

There	O
are	O
six	O
amino	O
acid	O
changes	O
in	O
rdACE2	O
compared	O
with	O
huACE2	O
,	O
and	O
four	O
changes	O
compared	O
with	O
pcACE2	O
,	O
within	O
the	O
18	O
residues	O
of	O
ACE2	B-PRGE
known	O
to	O
make	O
direct	O
contact	O
with	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
.	O

ABSTRACT	O
:	O
Chronic	O
expression	O
of	O
CXC	B-PRGE
chemokine	I-PRGE
ligand	I-PRGE
10	I-PRGE
(	O
CXCL10	B-PRGE
)	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
following	O
infection	O
with	O
the	O
neurotropic	O
JHM	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
JHMV	O
)	O
is	O
associated	O
with	O
an	O
immune	O
-	O
mediated	O
demyelinating	O
disease	O
.	O

These	O
findings	O
emphasize	O
the	O
importance	O
of	O
virus	O
-	O
specific	O
CD4	B-PRGE
+	I-PRGE
T	O
cells	O
in	O
amplifying	O
demyelination	O
in	O
JHMV	O
-	O
infected	O
mice	O
.	O

Significant	O
expression	O
levels	O
were	O
identified	O
for	O
ANPEP	O
(	O
a	O
receptor	O
for	O
CoV	O
),	O
as	O
well	O
as	O
inhibition	O
of	O
the	O
STAT1	B-PRGE
pathway	O
,	O
IFNs	O
production	O
and	O
CXCL10	B-PRGE
(	O
a	O
T	O
-	O
cell	O
recruiter	O
).	O

TITLE	O
:	O
NMR	O
assignment	O
of	O
the	O
nonstructural	O
protein	O
nsp3	B-PRGE
(	O
1066	O
-	O
1181	O
)	O
from	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
ABSTRACT	O
:	O
Sequence	O
-	O
specific	O
NMR	O
assignments	O
of	O
the	O
globular	O
core	O
comprising	O
the	O
residues	O
1066	O
-	O
1181	O
within	O
the	O
non	O
-	O
structural	O
protein	O
nsp3e	O
from	O
the	O
SARS	O
coronavirus	O
have	O
been	O
obtained	O
using	O
triple	O
-	O
resonance	O
NMR	O
experiments	O
with	O
the	O
uniformly	O
[(	O
13	O
)	O
C	O
,	O
(	O
15	O
)	O
N	O
]-	O
labeled	O
protein	O
.	O

ABSTRACT	O
:	O
Red	B-PRGE
cell	I-PRGE
exchange	I-PRGE
(	O
RCE	O
)	O
is	O
part	O
of	O
the	O
management	O
of	O
acute	O
chest	O
syndrome	O
(	O
ACS	O
)	O
in	O
patients	O
with	O
sickle	O
cell	O
disease	O
.	O

TITLE	O
:	O
[	O
A	O
case	O
of	O
interstitial	O
pneumonia	O
complicating	O
RS3PE	O
syndrome	O
in	O
which	O
soluble	O
interleukin	B-PRGE
-	I-PRGE
2	I-PRGE
receptor	I-PRGE
(	O
sIL	B-PRGE
-	I-PRGE
2R	I-PRGE
)	O
proved	O
useful	O
for	O
assessing	O
symptoms	O
].	O

TITLE	O
:	O
Structure	O
-	O
based	O
design	O
,	O
synthesis	O
,	O
and	O
biological	O
evaluation	O
of	O
a	O
series	O
of	O
novel	O
and	O
reversible	O
inhibitors	O
for	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
.	O

Upon	O
the	O
basis	O
of	O
the	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
inhibitor	O
24	O
-	O
bound	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
PLpro	I-PRGE
,	O
a	O
drug	O
design	O
template	O
was	O
created	O
.	O

As	O
the	O
BALB	O
/	O
c	O
and	O
the	O
IFNAR	B-PRGE
-/-	O
129SvEv	O
mice	O
demonstrated	O
very	O
similar	O
viral	O
loads	O
in	O
their	O
brains	O
,	O
we	O
also	O
compared	O
their	O
gene	O
expression	O
profiles	O
upon	O
infection	O
with	O
MHV	O
in	O
order	O
to	O
identify	O
type	B-PRGE
I	I-PRGE
IFN	I-PRGE
-	O
dependent	O
transcriptional	O
responses	O
.	O

Overall	O
,	O
this	O
study	O
broadens	O
our	O
present	O
knowledge	O
of	O
the	O
type	O
I	O
and	O
II	O
IFN	B-PRGE
-	O
mediated	O
effector	O
responses	O
during	O
CoV	O
infection	O
in	O
vivo	O
.	O

TITLE	O
:	O
Expression	O
,	O
crystallization	O
and	O
preliminary	O
X	O
-	O
ray	O
diffraction	O
analysis	O
of	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
nsp2	B-PRGE
from	O
avian	O
infectious	O
bronchitis	O
virus	O
.	O

The	O
nsp2	B-PRGE
protein	I-PRGE
from	O
IBV	O
has	O
a	O
unique	O
and	O
novel	O
sequence	O
and	O
has	O
no	O
experimentally	O
confirmed	O
function	O
in	O
replication	O
,	O
whereas	O
it	O
has	O
been	O
proposed	O
to	O
be	O
crucial	O
for	O
early	O
viral	O
infection	O
and	O
may	O
inhibit	O
the	O
early	O
host	O
immune	O
response	O
.	O

Following	O
PRCV	O
infection	O
,	O
more	O
severe	O
PRRSV	O
-	O
related	O
pulmonary	O
alveolar	O
macrophage	O
(	O
PAM	O
)	O
apoptosis	O
occurred	O
,	O
as	O
determined	O
by	O
an	O
in	O
situ	O
terminal	B-PRGE
deoxynucleotidyl	I-PRGE
transferase	I-PRGE
-	O
mediated	O
dUTP	O
nick	O
end	O
labelling	O
assay	O
,	O
suggesting	O
increased	O
PRRSV	O
replication	O
in	O
PAMs	O
.	O

ABSTRACT	O
:	O
The	O
Sec7	B-PRGE
domain	I-PRGE
ADP	I-PRGE
-	I-PRGE
ribosylation	I-PRGE
factor	I-PRGE
(	O
Arf	B-PRGE
)	O
guanine	O
nucleotide	O
exchange	O
factors	O
(	O
GEFs	B-PRGE
)	O
are	O
found	O
in	O
all	O
eukaryotes	O
,	O
and	O
are	O
involved	O
in	O
membrane	O
remodeling	O
processes	O
throughout	O
the	O
cell	O
.	O

Preference	O
will	O
be	O
given	O
to	O
rRBD	B-PRGE
expressed	O
in	O
mammalian	O
cells	O
for	O
future	O
evaluation	O
of	O
the	O
vaccine	O
efficacy	O
in	O
a	O
non	O
-	O
human	O
primate	O
model	O
of	O
SARS	O
because	O
of	O
its	O
ability	O
to	O
refold	O
into	O
a	O
native	O
conformation	O
more	O
readily	O
and	O
to	O
induce	O
higher	O
level	O
of	O
neutralizing	O
antibody	O
responses	O
than	O
those	O
expressed	O
in	O
E	O
.	O
coli	O
and	O
insect	O
cells	O
.	O

Using	O
a	O
SELEX	O
(	O
systematic	O
evolution	O
of	O
ligand	O
by	O
exponential	O
enrichment	O
)	O
procedure	O
and	O
recombinant	O
N	O
protein	O
,	O
we	O
selected	O
a	O
high	O
-	O
affinity	O
RNA	O
aptamer	O
capable	O
of	O
binding	O
to	O
N	B-PRGE
protein	I-PRGE
with	O
a	O
dissociation	O
constant	O
of	O
1	O
.	O
65	O
nM	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
and	O
RNA	O
competition	O
experiments	O
showed	O
that	O
the	O
selected	O
aptamer	O
recognized	O
selectively	O
the	O
C	O
-	O
terminal	O
region	O
of	O
N	B-PRGE
protein	I-PRGE
with	O
high	O
specificity	O
.	O

Using	O
a	O
chemiluminescence	O
immunosorbent	O
assay	O
and	O
a	O
nanoarray	O
aptamer	O
chip	O
with	O
the	O
selected	O
aptamer	O
as	O
an	O
antigen	O
-	O
capturing	O
agent	O
,	O
we	O
could	O
sensitively	O
detect	O
N	B-PRGE
protein	I-PRGE
at	O
a	O
concentration	O
as	O
low	O
as	O
2	O
pg	O
/	O
ml	O
.	O

The	O
primary	O
function	O
of	O
the	O
HCoV	O
-	O
OC43	O
nucleocapsid	B-PRGE
protein	I-PRGE
(	O
N	B-PRGE
protein	I-PRGE
)	O
is	O
to	O
recognize	O
viral	O
genomic	O
RNA	O
,	O
which	O
leads	O
to	O
ribonucleocapsid	O
formation	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
the	O
HCoV	B-PRGE
-	I-PRGE
OC43	I-PRGE
N	I-PRGE
protein	I-PRGE
contains	O
three	O
RNA	O
-	O
binding	O
regions	O
in	O
its	O
N	O
-	O
terminal	O
region	O
(	O
residues	O
1	O
-	O
173	O
)	O
and	O
central	O
-	O
linker	O
region	O
(	O
residues	O
174	O
-	O
232	O
and	O
233	O
-	O
300	O
).	O

SPR	O
experiments	O
demonstrated	O
that	O
the	O
C	O
-	O
terminal	O
region	O
(	O
residues	O
301	O
-	O
448	O
)	O
of	O
HCoV	B-PRGE
-	I-PRGE
OC43	I-PRGE
N	I-PRGE
protein	I-PRGE
lacks	O
RNA	O
-	O
binding	O
activity	O
,	O
while	O
crosslinking	O
and	O
gel	O
filtration	O
analyses	O
revealed	O
that	O
the	O
C	O
-	O
terminal	O
region	O
is	O
mainly	O
involved	O
in	O
the	O
oligomerization	O
of	O
the	O
HCoV	B-PRGE
-	I-PRGE
OC43	I-PRGE
N	I-PRGE
protein	I-PRGE
.	O

When	O
over	O
-	O
expressed	O
in	O
HEK	O
293	O
cells	O
,	O
the	O
full	O
-	O
length	O
protein	O
but	O
not	O
the	O
variant	O
with	O
the	O
deletion	O
caused	O
interferon	B-PRGE
beta	I-PRGE
induction	O
and	O
cleavage	O
of	O
procaspase	O
3	O
.	O

The	O
exposure	O
of	O
receptor	O
-	O
bound	O
S	B-PRGE
protein	I-PRGE
to	O
trypsin	B-PRGE
or	O
cathepsin	B-PRGE
L	I-PRGE
(	O
CPL	B-PRGE
)	O
induces	O
the	O
formation	O
of	O
six	O
-	O
helix	O
bundles	O
(	O
6HB	O
),	O
the	O
final	O
conformation	O
.	O

TITLE	O
:	O
Rhesus	O
theta	B-PRGE
-	I-PRGE
defensin	I-PRGE
prevents	O
death	O
in	O
a	O
mouse	O
model	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
pulmonary	O
disease	O
.	O

ABSTRACT	O
:	O
We	O
evaluated	O
the	O
efficacy	O
of	O
rhesus	O
theta	B-PRGE
-	I-PRGE
defensin	I-PRGE
1	I-PRGE
(	O
RTD	B-PRGE
-	I-PRGE
1	I-PRGE
),	O
a	O
novel	O
cyclic	O
antimicrobial	O
peptide	O
,	O
as	O
a	O
prophylactic	O
antiviral	O
in	O
a	O
mouse	O
model	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
)	O
lung	O
disease	O
.	O

BALB	O
/	O
c	O
mice	O
exposed	O
to	O
a	O
mouse	O
-	O
adapted	O
strain	O
of	O
SARS	O
-	O
CoV	O
demonstrated	O
100	O
%	O
survival	O
and	O
modest	O
reductions	O
in	O
lung	O
pathology	O
without	O
reductions	O
in	O
virus	O
titer	O
when	O
treated	O
with	O
two	O
intranasal	O
doses	O
of	O
RTD	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
while	O
mortality	O
in	O
untreated	O
mice	O
was	O
approximately	O
75	O
%.	O

According	O
to	O
the	O
changes	O
of	O
CD4	B-PRGE
(+)	O
T	O
cell	O
,	O
immunosuppressive	O
agents	O
(	O
CsA	O
/	O
FK506	O
+	O
MMF	O
+	O
Pred	O
)	O
were	O
adjusted	O
,	O
and	O
the	O
effects	O
of	O
CMV	O
pneumonia	O
occurring	O
were	O
investigated	O
.	O

TITLE	O
:	O
[	O
Study	O
on	O
interaction	O
between	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
and	O
MAP19	O
].	O

The	O
interaction	O
between	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
and	O
MAP19	B-PRGE
would	O
be	O
further	O
tested	O
in	O
cells	O
in	O
this	O
article	O
.	O

SARS	O
-	O
CoV	O
N	O
greatly	O
increased	O
the	O
amount	O
of	O
MAP19	B-PRGE
.	O

ABSTRACT	O
:	O
Asymmetric	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
microarrays	O
were	O
combined	O
to	O
distinguish	O
4	O
viruses	O
,	O
including	O
Avian	O
influenza	O
virus	O
(	O
AIV	O
),	O
Newcastle	O
disease	O
virus	O
(	O
NDV	O
),	O
Infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
and	O
Infectious	O
bursal	O
disease	O
virus	O
(	O
IBDV	O
),	O
and	O
hemagglutinin	O
(	O
HA	O
)	O
subtypes	O
H5	O
,	O
H7	O
,	O
and	O
H9	O
,	O
and	O
neuraminidase	B-PRGE
(	O
NA	O
)	O
subtypes	O
N1	O
and	O
N2	O
of	O
AIV	O
.	O

TITLE	O
:	O
Macrophage	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
tumour	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
are	O
induced	O
by	O
coronavirus	O
fixation	O
to	O
Toll	B-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
2	I-PRGE
/	I-PRGE
heparan	I-PRGE
sulphate	I-PRGE
receptors	I-PRGE
but	O
not	O
carcinoembryonic	B-PRGE
cell	I-PRGE
adhesion	I-PRGE
antigen	I-PRGE
1a	I-PRGE
.	O

ABSTRACT	O
:	O
A	O
rapid	O
antiviral	O
immune	O
response	O
may	O
be	O
related	O
to	O
viral	O
interaction	O
with	O
the	O
host	O
cell	O
leading	O
to	O
activation	O
of	O
macrophages	O
via	O
pattern	O
recognition	O
receptors	O
(	O
PPRs	B-PRGE
)	O
or	O
specific	O
viral	O
receptors	O
.	O

We	O
report	O
that	O
the	O
induction	O
of	O
the	O
pro	O
-	O
inflammatory	O
cytokines	O
interleukin	B-PRGE
(	O
IL	O
)-	O
6	O
and	O
tumour	O
necrosis	O
factor	O
(	O
TNF	O
)-	O
alpha	O
in	O
peritoneal	O
macrophages	O
does	O
not	O
depend	O
on	O
CEACAM1a	O
,	O
as	O
demonstrated	O
in	O
cells	O
isolated	O
from	O
Ceacam1a	O
(-/-)	O
mice	O
.	O

The	O
induction	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
production	O
was	O
related	O
rather	O
to	O
the	O
fixation	O
of	O
the	O
spike	O
(	O
S	O
)	O
protein	O
of	O
MHV3	O
on	O
Toll	B-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
2	I-PRGE
(	O
TLR2	B-PRGE
)	O
in	O
regions	O
enriched	O
in	O
heparan	O
sulphate	O
and	O
did	O
not	O
rely	O
on	O
viral	O
replication	O
,	O
as	O
demonstrated	O
with	O
denatured	O
S	B-PRGE
protein	I-PRGE
and	O
UV	O
-	O
inactivated	O
virus	O
.	O

Researchers	O
expect	O
that	O
global	O
infections	O
,	O
like	O
SARS	B-PRGE
,	O
will	O
persist	O
and	O
escalate	O
in	O
the	O
future	O
.	O

Further	O
,	O
CTLs	O
induced	O
by	O
the	O
seven	O
liposomal	O
peptides	O
lysed	O
an	O
HLA	B-PRGE
-	I-PRGE
A	I-PRGE
*	I-PRGE
0201	I-PRGE
positive	O
cell	O
line	O
expressing	O
naturally	O
processed	O
,	O
pp1a	B-PRGE
-	I-PRGE
derived	I-PRGE
peptides	I-PRGE
.	O

ABSTRACT	O
:	O
Previous	O
studies	O
have	O
shown	O
that	O
proinflammatory	O
cytokines	O
,	O
such	O
as	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
and	O
interleukin	B-PRGE
6	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
),	O
are	O
differentially	O
induced	O
in	O
primary	O
mouse	O
astrocytes	O
by	O
mouse	O
hepatitis	O
virus	O
strain	O
A59	O
(	O
MHV	O
-	O
A59	O
)	O
and	O
MHV	O
-	O
2	O
.	O

The	O
results	O
showed	O
that	O
the	O
level	O
of	O
phosphorylated	O
PKR	B-PRGE
was	O
greatly	O
reduced	O
in	O
IBV	O
-	O
infected	O
cells	O
.	O

Furthermore	O
,	O
GADD34	B-PRGE
,	O
a	O
component	O
of	O
the	O
protein	O
phosphatase	B-PRGE
1	I-PRGE
(	O
PP1	B-PRGE
)	O
complex	O
,	O
which	O
dephosphorylates	O
eIF	B-PRGE
-	I-PRGE
2alpha	I-PRGE
,	O
was	O
significantly	O
induced	O
in	O
IBV	O
-	O
infected	O
cells	O
.	O

A	O
comparative	O
limit	O
of	O
detection	O
was	O
determined	O
for	O
M41	B-PRGE
,	O
an	O
embryo	O
-	O
adapted	O
strain	O
,	O
and	O
IS	O
/	O
885	O
/	O
00	O
,	O
a	O
poorly	O
embryo	O
-	O
adapted	O
variant	O
.	O

ABSTRACT	O
:	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
/	I-PRGE
beta	I-PRGE
plays	O
a	O
critical	O
role	O
in	O
limiting	O
viral	O
spread	O
,	O
restricting	O
viral	O
tropism	O
and	O
protecting	O
mice	O
from	O
neurotropic	O
coronavirus	O
infection	O
.	O

Infection	O
of	O
RNase	B-PRGE
L	I-PRGE
deficient	O
(	O
RL	O
(-/-))	O
mice	O
with	O
a	O
sub	O
-	O
lethal	O
,	O
demyelinating	O
mouse	O
hepatitis	O
virus	O
variant	O
revealed	O
that	O
the	O
majority	O
of	O
mice	O
succumbed	O
to	O
infection	O
by	O
day	O
12	O
p	O
.	O
i	O
.	O

These	O
data	O
demonstrate	O
a	O
novel	O
protective	O
role	O
for	O
RNase	B-PRGE
L	I-PRGE
in	O
viral	O
induced	O
CNS	O
encephalomyelitis	O
,	O
which	O
is	O
not	O
reflected	O
in	O
overall	O
viral	O
control	O
or	O
propagation	O
of	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
/	I-PRGE
beta	I-PRGE
mediated	O
signals	O
.	O

Firstly	O
,	O
NO	O
or	O
its	O
derivatives	O
cause	O
a	O
reduction	O
in	O
the	O
palmitoylation	O
of	O
nascently	O
expressed	O
spike	O
(	O
S	O
)	O
protein	O
which	O
affects	O
the	O
fusion	O
between	O
the	O
S	B-PRGE
protein	I-PRGE
and	O
its	O
cognate	O
receptor	O
,	O
angiotensin	B-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
.	O

TITLE	O
:	O
The	O
replicase	B-PRGE
gene	I-PRGE
of	O
avian	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
is	O
a	O
determinant	O
of	O
pathogenicity	O
.	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
demonstrated	O
that	O
the	O
replacement	O
of	O
the	O
S	B-PRGE
gene	I-PRGE
from	O
an	O
avirulent	O
strain	O
(	O
Beaudette	O
)	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
with	O
an	O
S	B-PRGE
gene	I-PRGE
from	O
a	O
virulent	O
strain	O
(	O
M41	O
)	O
resulted	O
in	O
a	O
recombinant	O
virus	O
(	O
BeauR	O
-	O
M41	O
(	O
S	O
))	O
with	O
the	O
in	O
vitro	O
cell	O
tropism	O
of	O
the	O
virulent	O
virus	O
but	O
that	O
was	O
still	O
avirulent	O
.	O

After	O
adjusting	O
for	O
a	O
reduced	O
opportunity	O
of	O
patients	O
dying	O
early	O
to	O
receive	O
neuraminidase	B-PRGE
inhibitors	O
,	O
neuraminidase	B-PRGE
inhibitor	O
treatment	O
(	O
vs	O
no	O
treatment	O
)	O
was	O
associated	O
with	O
improved	O
survival	O
(	O
odds	O
ratio	O
,	O
8	O
.	O
5	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
2	O
-	O
62	O
.	O
8	O
).	O

This	O
binding	O
site	O
is	O
similar	O
to	O
the	O
ssRNA	B-PRGE
-	I-PRGE
binding	I-PRGE
site	I-PRGE
of	O
the	O
sterile	O
alpha	O
motif	O
domain	O
of	O
the	O
Saccharomyces	B-PRGE
cerevisiae	I-PRGE
Vts1p	I-PRGE
protein	I-PRGE
,	O
although	O
the	O
two	O
proteins	O
do	O
not	O
share	O
a	O
common	O
globular	O
fold	O
.	O

MAS	B-PRGE
is	O
a	O
severe	O
disease	O
of	O
the	O
(	O
mainly	O
)	O
term	O
neonate	O
,	O
characterized	O
by	O
respiratory	O
distress	O
,	O
pulmonary	O
inflammation	O
,	O
persistent	O
pulmonary	O
hypertension	O
and	O
chronic	O
hypoxia	O
.	O

TITLE	O
:	O
A	O
two	O
-	O
pronged	O
strategy	O
to	O
suppress	B-PRGE
host	I-PRGE
protein	I-PRGE
synthesis	O
by	O
SARS	B-PRGE
coronavirus	I-PRGE
Nsp1	I-PRGE
protein	I-PRGE
.	O

Nsp1	B-PRGE
bound	O
to	O
the	O
40S	B-PRGE
ribosomal	I-PRGE
subunit	I-PRGE
and	O
inactivated	O
the	O
translational	O
activity	O
of	O
the	O
40S	O
subunits	O
.	O

Nsp1	B-PRGE
also	O
induced	O
RNA	O
cleavage	O
in	O
templates	O
carrying	O
the	O
internal	O
ribosome	O
entry	O
site	O
(	O
IRES	O
)	O
from	O
encephalomyocarditis	O
virus	O
,	O
but	O
not	O
in	O
those	O
carrying	O
IRES	O
elements	O
from	O
hepatitis	O
C	O
or	O
cricket	O
paralysis	O
viruses	O
,	O
demonstrating	O
that	O
the	O
nsp1	B-PRGE
-	O
induced	O
RNA	O
modification	O
was	O
template	O
-	O
dependent	O
.	O

ABSTRACT	O
:	O
We	O
have	O
reported	O
that	O
human	B-PRGE
respiratory	I-PRGE
coronavirus	I-PRGE
OC43	I-PRGE
(	O
HCoV	O
-	O
OC43	O
)	O
is	O
neurotropic	O
and	O
neuroinvasive	O
in	O
humans	O
and	O
mice	O
,	O
and	O
that	O
neurons	O
are	O
the	O
primary	O
target	O
of	O
infection	O
in	O
mice	O
,	O
leading	O
to	O
neurodegenerative	O
disabilities	O
.	O

Murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
nsp4	B-PRGE
is	I-PRGE
glycosylated	I-PRGE
at	I-PRGE
residues	I-PRGE
Asn176	I-PRGE
(	O
N176	O
)	O
and	O
N237	O
during	O
plasmid	O
expression	O
of	O
nsp4	B-PRGE
in	O
cells	O
.	O

To	O
test	O
if	O
MHV	B-PRGE
nsp4	I-PRGE
residues	O
N176	O
and	O
N237	O
are	O
glycosylated	O
during	O
virus	O
replication	O
and	O
to	O
determine	O
the	O
effects	O
of	O
N176	O
and	O
N237	O
on	O
nsp4	B-PRGE
function	O
and	O
MHV	O
replication	O
,	O
alanine	O
substitutions	O
of	O
nsp4	B-PRGE
N176	I-PRGE
,	O
N237	O
,	O
or	O
both	O
were	O
engineered	O
into	O
the	O
MHV	O
-	O
A59	O
genome	O
.	O

Electron	O
microscopic	O
analysis	O
of	O
ultrastructure	O
from	O
infected	O
cells	O
demonstrated	O
that	O
the	O
nsp4	B-PRGE
mutants	I-PRGE
had	O
aberrant	O
morphology	O
of	O
virus	O
-	O
induced	O
double	O
-	O
membrane	O
vesicles	O
(	O
DMVs	O
)	O
compared	O
to	O
those	O
infected	O
with	O
wt	O
virus	O
.	O

The	O
degree	O
of	O
altered	O
DMV	O
morphology	O
directly	O
correlated	O
with	O
the	O
extent	O
of	O
impairment	O
in	O
viral	O
RNA	O
synthesis	O
and	O
virus	O
growth	O
of	O
the	O
nsp4	B-PRGE
mutant	I-PRGE
viruses	O
.	O

The	O
results	O
indicate	O
that	O
nsp4	B-PRGE
plays	O
a	O
critical	O
role	O
in	O
the	O
organization	O
and	O
stability	O
of	O
DMVs	O
.	O

Recently	O
,	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
,	O
which	O
inactivates	O
angiotensin	B-PRGE
II	I-PRGE
,	O
has	O
been	O
shown	O
to	O
ameliorate	O
acute	O
lung	O
injury	O
in	O
mice	O
.	O

Multiple	O
inert	O
gas	O
elimination	O
technique	O
revealed	O
a	O
more	O
homogeneous	O
pulmonary	O
blood	O
flow	O
after	O
treatment	O
with	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
.	O

One	O
of	O
the	O
169	O
peptides	O
screened	O
,	O
peptide	O
9626	O
(	O
S	O
residues	O
217	O
-	O
234	O
),	O
inhibited	O
SARS	B-PRGE
-	O
CoV	O
S	O
-	O
mediated	O
entry	O
of	O
the	O
pseudotyped	O
virions	O
in	O
293T	O
cells	O
expressing	O
a	O
functional	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
(	O
human	B-PRGE
angiotensin	I-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
)	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
IC	O
(	O
50	O
)	O
approximately	O
11	O
microM	O
).	O

It	O
was	O
shown	O
that	O
recombinant	B-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
(	O
SARS	B-PRGE
-	I-PRGE
S	I-PRGE
)	O
downregulates	O
ACE2	O
expression	O
and	O
thereby	O
promotes	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
An	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
(	O
RdRp	O
)	O
is	O
the	O
central	O
catalytic	O
subunit	O
of	O
the	O
RNA	O
-	O
synthesizing	O
machinery	O
of	O
all	O
positive	O
-	O
strand	O
RNA	O
viruses	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
established	O
a	O
safe	O
dose	O
range	O
and	O
demonstrated	O
the	O
feasibility	O
of	O
prolonged	O
,	O
repeated	O
dosing	O
of	O
pf	O
-	O
tPA	B-PRGE
.	O

TITLE	O
:	O
Unraveling	O
the	O
complexities	O
of	O
the	O
interferon	B-PRGE
response	O
during	O
SARS	O
-	O
CoV	O
infection	O
.	O

TITLE	O
:	O
Feline	O
infectious	O
peritonitis	O
:	O
insights	O
into	O
feline	O
coronavirus	O
pathobiogenesis	O
and	O
epidemiology	O
based	O
on	O
genetic	O
analysis	O
of	O
the	O
viral	B-PRGE
3c	I-PRGE
gene	I-PRGE
.	O

ABSTRACT	O
:	O
In	O
marked	O
contrast	O
to	O
their	O
historical	O
classification	O
as	O
relatively	O
harmless	O
,	O
common	O
cold	O
-	O
causing	O
,	O
respiratory	O
pathogens	O
,	O
human	O
coronaviruses	O
(	O
HCoVs	O
)	O
are	O
associated	O
with	O
more	O
severe	O
clinical	O
complications	O
,	O
as	O
emphasized	O
by	O
the	O
discovery	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
CoV	O
(	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
)	O
in	O
2003	O
.	O

Inoculation	O
of	O
the	O
neurotropic	O
JHM	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
JHMV	O
)	O
into	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
of	O
mice	O
resulted	O
in	O
the	O
rapid	O
mobilization	O
of	O
PMNs	O
expressing	O
the	O
chemokine	B-PRGE
receptor	I-PRGE
CXCR2	I-PRGE
into	O
the	O
blood	O
.	O

Correspondingly	O
,	O
CXCR2	B-PRGE
neutralization	O
resulted	O
in	O
diminished	O
infiltration	O
of	O
virus	O
-	O
specific	O
T	O
cells	O
,	O
an	O
inability	O
to	O
control	O
viral	O
replication	O
within	O
the	O
brain	O
,	O
and	O
100	O
%	O
mortality	O
.	O

NL63	O
-	O
CoV	O
and	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
have	O
no	O
structural	O
homology	O
in	O
RBD	O
cores	O
or	O
RBMs	O
;	O
yet	O
the	O
2	O
viruses	O
recognize	O
common	O
ACE2	O
regions	O
,	O
largely	O
because	O
of	O
a	O
""""	O
virus	O
-	O
binding	O
hotspot	O
""""	O
on	O
ACE2	B-PRGE
.	O

A	O
strong	O
antiviral	O
response	O
to	O
the	O
viral	O
surface	B-PRGE
glycoprotein	I-PRGE
(	O
SU	O
)	O
was	O
noted	O
in	O
both	O
natural	O
and	O
experimental	O
infections	O
.	O

Our	O
data	O
demonstrate	O
that	O
recombinant	O
FCoVs	O
expressing	O
a	O
type	O
II	O
FCoV	B-PRGE
S	I-PRGE
protein	I-PRGE
acquire	O
the	O
ability	O
to	O
efficiently	O
use	O
fAPN	O
for	O
host	O
cell	O
entry	O
and	O
corroborate	O
the	O
notion	O
that	O
type	O
I	O
FCoVs	O
use	O
another	O
main	O
host	O
cell	O
receptor	O
.	O

We	O
also	O
observed	O
that	O
recombinant	O
FCoVs	O
display	O
a	O
large	O
-	O
plaque	O
phenotype	O
and	O
,	O
unexpectedly	O
,	O
accelerated	O
growth	O
kinetics	O
indistinguishable	O
from	O
that	O
of	O
type	B-PRGE
II	I-PRGE
FCoV	I-PRGE
strain	O
79	O
-	O
1146	O
.	O

At	O
this	O
time	O
,	O
a	O
second	O
wave	O
of	O
enhanced	O
production	O
of	O
cytokines	O
(	O
TNF	O
-	O
alpha	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
gamma	B-PRGE
interferon	I-PRGE
[	O
IFN	O
-	O
gamma	O
],	O
IL	O
-	O
2	O
,	O
and	O
IL	O
-	O
5	O
),	O
chemokines	O
(	O
CXCL9	B-PRGE
,	O
CXCL10	B-PRGE
,	O
CCL2	B-PRGE
,	O
CCL3	B-PRGE
,	O
and	O
CCL5	B-PRGE
),	O
and	O
receptors	O
(	O
CXCR3	B-PRGE
,	O
CCR2	B-PRGE
,	O
and	O
CCR5	B-PRGE
),	O
was	O
detected	O
in	O
the	O
lungs	O
,	O
associated	O
with	O
an	O
influx	O
of	O
T	O
lymphocytes	O
.	O

Our	O
findings	O
provide	O
new	O
insights	O
into	O
the	O
pathogenesis	O
of	O
SARS	O
,	O
demonstrating	O
the	O
important	O
role	O
of	O
CD4	B-PRGE
(+)	O
but	O
not	O
CD8	B-PRGE
(+)	O
T	O
cells	O
in	O
primary	O
SARS	O
-	O
CoV	O
infection	O
in	O
this	O
model	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
molecular	O
mechanisms	O
that	O
govern	O
coronavirus	O
cross	O
-	O
species	O
transmission	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
using	O
the	O
emergence	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
as	O
a	O
model	O
.	O

READILY	O
CLEAVED	O
IN	O
VITRO	O
BY	O
THREE	O
DIFFERENT	O
AIRWAY	O
PROTEASES	O
:	O
trypsin	B-PRGE
,	O
plasmin	B-PRGE
and	O
TMPRSS11a	B-PRGE
.	O

Airway	O
proteases	O
regulate	O
the	O
infectivity	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
in	O
a	O
fashion	O
dependent	O
on	O
previous	O
receptor	O
binding	O
.	O

Recombinant	B-PRGE
urate	I-PRGE
oxidase	I-PRGE
(	O
rasburicase	O
)	O
is	O
a	O
newer	O
agent	O
that	O
directly	O
cleaves	O
uric	O
acid	O
.	O

In	O
addition	O
to	O
being	O
a	O
potent	O
source	O
of	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
,	O
other	O
properties	O
of	O
these	O
porcine	O
CD4	B-PRGE
(	O
hi	O
)	O
CD172	O
(	O
lo	O
)	O
cells	O
including	O
their	O
morphological	O
transition	O
from	O
a	O
plasma	O
cell	O
-	O
like	O
shape	O
during	O
quiescence	O
to	O
one	O
resembling	O
a	O
dendritic	O
cell	O
(	O
DC	O
)	O
after	O
activation	O
by	O
TGEV	O
and	O
their	O
relatively	O
strong	O
constitutive	O
expression	O
of	O
interferon	B-PRGE
regulatory	I-PRGE
factor	I-PRGE
-	I-PRGE
7	I-PRGE
(	O
IRF	B-PRGE
-	I-PRGE
7	I-PRGE
)	O
conformed	O
to	O
the	O
expectations	O
of	O
genuine	O
pDCs	O
.	O

In	O
this	O
line	O
,	O
mechanical	O
ventilation	O
may	O
affect	O
the	O
macromolecules	O
that	O
constitute	O
the	O
extracellular	O
matrix	O
(	O
collagen	B-PRGE
,	O
elastin	B-PRGE
,	O
fibronectin	B-PRGE
,	O
laminin	B-PRGE
,	O
proteoglycan	O
and	O
glycosaminoglycans	O
),	O
suffer	O
changes	O
and	O
impact	O
the	O
biomechanical	O
behavior	O
of	O
lung	O
parenchyma	O
.	O

ABSTRACT	O
:	O
Purified	O
nucleocapsid	B-PRGE
protein	I-PRGE
(	O
N	B-PRGE
protein	I-PRGE
)	O
from	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
enhanced	O
hammerhead	O
ribozyme	O
self	O
-	O
cleavage	O
and	O
favored	O
nucleic	O
acid	O
annealing	O
,	O
properties	O
that	O
define	O
RNA	O
chaperones	O
,	O
as	O
previously	O
reported	O
.	O

Interestingly	O
,	O
N	B-PRGE
protein	I-PRGE
and	O
its	O
deletion	O
mutants	O
with	O
RNA	O
chaperone	O
activity	O
enhanced	O
template	O
switching	O
in	O
a	O
retrovirus	O
-	O
derived	O
heterologous	O
system	O
,	O
reinforcing	O
the	O
concept	O
that	O
TGEV	B-PRGE
N	I-PRGE
protein	I-PRGE
is	O
an	O
RNA	O
chaperone	O
that	O
could	O
be	O
involved	O
in	O
template	O
switching	O
.	O

The	O
rates	O
of	O
DIC	B-PRGE
,	O
ARF	B-PRGE
and	O
MODS	O
in	O
heparin	O
group	O
decreased	O
significantly	O
after	O
therapy	O
:	O
rate	O
of	O
DIC	O
,	O
15	O
.	O
4	O
%	O
vs	O
38	O
.	O
7	O
%	O
(	O
P	O
=	O
0	O
.	O
03	O
);	O
rate	O
of	O
ARF	B-PRGE
,	O
25	O
.	O
0	O
%	O
vs	O
51	O
.	O
9	O
%	O
(	O
P	O
=	O
0	O
.	O
04	O
);	O
rate	O
of	O
MODS	O
,	O
26	O
.	O
3	O
%	O
vs	O
50	O
.	O
0	O
%	O
(	O
P	O
=	O
0	O
.	O
04	O
).	O

The	O
immunized	O
mice	O
released	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
and	O
lysed	O
target	O
cells	O
upon	O
stimulation	O
with	O
Sp8	B-PRGE
peptide	I-PRGE
-	O
pulsed	O
autologous	O
dendritic	O
cells	O
in	O
comparison	O
to	O
other	O
candidates	O
.	O

Expression	O
of	O
the	O
cGM	B-PRGE
-	I-PRGE
CSF	I-PRGE
protein	I-PRGE
in	O
the	O
recombinant	O
Lactobacillus	O
was	O
confirmed	O
by	O
SDS	O
-	O
PAGE	O
and	O
Western	O
blotting	O
methods	O
.	O

The	O
role	O
of	O
Mycoplasma	B-PRGE
spp	I-PRGE
.,	O
particularly	O
Mycoplasma	O
bovis	O
in	O
BRD	O
,	O
has	O
been	O
more	O
extensively	O
studied	O
.	O

To	O
study	O
the	O
dynamics	O
of	O
these	O
coronavirus	O
replicative	O
structures	O
,	O
we	O
generated	O
recombinant	O
murine	O
hepatitis	O
coronaviruses	O
that	O
express	O
tagged	O
versions	O
of	O
the	O
nonstructural	O
protein	O
nsp2	B-PRGE
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
encodes	O
3	B-PRGE
major	I-PRGE
envelope	I-PRGE
proteins	I-PRGE
:	O
spike	O
(	O
S	O
),	O
membrane	O
(	O
M	O
),	O
and	O
envelope	B-PRGE
(	O
E	O
).	O

Previous	O
work	O
identified	O
a	O
dibasic	O
endoplasmic	O
reticulum	O
retrieval	O
signal	O
in	O
the	O
cytoplasmic	O
tail	O
of	O
SARS	O
-	O
CoV	O
S	O
that	O
promotes	O
efficient	O
interaction	O
with	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
.	O
The	O
dibasic	O
signal	O
was	O
shown	O
to	O
be	O
important	O
for	O
concentrating	O
S	O
near	O
the	O
virus	O
assembly	O
site	O
rather	O
than	O
for	O
direct	O
interaction	O
with	O
M	O
.	O
Here	O
,	O
we	O
investigated	O
the	O
sequence	O
requirements	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
protein	I-PRGE
that	O
are	O
necessary	O
for	O
interaction	O
with	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
.	O
The	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
tail	O
was	O
shown	O
to	O
be	O
necessary	O
for	O
S	O
localization	O
in	O
the	O
Golgi	O
region	O
when	O
the	O
proteins	O
were	O
exogenously	O
coexpressed	O
in	O
cells	O
.	O

Importantly	O
,	O
we	O
found	O
that	O
an	O
essential	O
tyrosine	O
residue	O
in	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
cytoplasmic	O
tail	O
,	O
Y	O
(	O
195	O
),	O
was	O
important	O
for	O
S	O
-	O
M	O
interaction	O
.	O

The	O
multifunctional	B-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
is	O
complexed	O
with	O
the	O
genomic	O
RNA	O
,	O
interacts	O
with	O
the	O
viral	O
membrane	O
protein	O
during	O
virion	O
assembly	O
,	O
and	O
plays	O
an	O
import	O
role	O
in	O
enhancing	O
the	O
efficiency	O
of	O
transcription	O
.	O

Phylogenetic	O
analysis	O
of	O
the	O
Orf1	B-PRGE
region	I-PRGE
suggested	O
that	O
the	O
human	O
SCoVs	O
are	O
phylogenetically	O
closer	O
to	O
SLCoVs	O
in	O
R	O
.	O
sinicus	O
than	O
to	O
SLCoVs	O
in	O
other	O
Rhinolophus	O
species	O
.	O

Since	O
ER	O
stress	O
can	O
cause	O
differential	O
modulation	O
of	O
the	O
unfolded	O
protein	O
response	O
(	O
UPR	O
),	O
which	O
includes	O
the	O
inositol	B-PRGE
-	I-PRGE
requiring	I-PRGE
enzyme	I-PRGE
1	I-PRGE
(	O
IRE	B-PRGE
-	I-PRGE
1	I-PRGE
),	O
activating	B-PRGE
transcription	I-PRGE
factor	I-PRGE
6	I-PRGE
(	O
ATF6	B-PRGE
)	O
and	O
PKR	B-PRGE
-	I-PRGE
like	I-PRGE
ER	I-PRGE
kinase	I-PRGE
(	O
PERK	B-PRGE
)	O
pathways	O
,	O
these	O
were	O
individually	O
tested	O
in	O
3a	O
-	O
expressing	O
cells	O
.	O

These	O
results	O
provide	O
further	O
mechanistic	O
details	O
of	O
the	O
pro	O
-	O
apoptotic	O
effects	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3a	I-PRGE
protein	I-PRGE
,	O
and	O
suggest	O
a	O
potential	O
role	O
for	O
it	O
in	O
attenuating	O
interferon	B-PRGE
responses	O
and	O
innate	O
immunity	O
.	O

RESULTS	O
:	O
There	O
were	O
34	O
patients	O
subjected	O
to	O
DPA	B-PRGE
and	O
78	O
to	O
diversion	O
.	O

The	O
infection	O
of	O
cells	O
with	O
srr7	O
(	O
soluble	O
-	O
receptor	O
-	O
resistant	O
mutant	O
7	O
)	O
is	O
dependent	O
on	O
a	O
known	O
MHV	B-PRGE
receptor	I-PRGE
(	O
MHVR	B-PRGE
),	O
carcinoembryonic	B-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
1a	I-PRGE
,	O
whereas	O
cl	O
-	O
2	O
shows	O
MHVR	O
-	O
independent	O
infection	O
.	O

Patients	O
who	O
developed	O
acute	O
lung	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ALI	O
/	O
ARDS	O
)	O
typically	O
presented	O
with	O
normal	O
leukocyte	O
count	O
,	O
lymphopenia	O
,	O
raised	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
,	O
creatinkinase	O
,	O
transaminases	O
but	O
normal	O
urea	O
and	O
creatinine	O
.	O

TITLE	O
:	O
Contribution	O
of	O
the	O
porcine	B-PRGE
aminopeptidase	I-PRGE
N	I-PRGE
(	I-PRGE
CD13	I-PRGE
)	I-PRGE
receptor	I-PRGE
density	O
to	O
porcine	O
epidemic	O
diarrhea	O
virus	O
infection	O
.	O

The	O
introduction	O
of	O
a	O
pAPN	B-PRGE
gene	I-PRGE
into	O
nonpermissive	O
ST	O
cells	O
was	O
further	O
found	O
to	O
be	O
fully	O
sufficient	O
to	O
support	O
productive	O
infection	O
,	O
revealing	O
that	O
constitutive	O
overexpression	O
of	O
pAPN	O
can	O
directly	O
rescue	O
PEDV	O
multiplication	O
.	O

ABSTRACT	O
:	O
Human	B-PRGE
pathogenic	I-PRGE
coronavirus	I-PRGE
NL63	I-PRGE
(	O
hCoV	O
-	O
NL63	O
)	O
is	O
a	O
group	O
1	O
(	O
alpha	O
)	O
coronavirus	O
commonly	O
associated	O
with	O
respiratory	O
tract	O
infections	O
.	O

By	O
fluorescence	O
microscopy	O
of	O
differently	O
tagged	O
envelope	B-PRGE
(	O
E	O
),	O
membrane	O
(	O
M	O
)	O
and	O
nucleocapsid	O
(	O
N	O
)	O
proteins	O
it	O
was	O
shown	O
that	O
ORF	B-PRGE
3	I-PRGE
protein	I-PRGE
colocalizes	O
extensively	O
with	O
E	O
and	O
M	O
within	O
the	O
ERGIC	O
.	O

RESULTS	O
:	O
In	O
-	O
silico	O
analysis	O
of	O
the	O
225	O
amino	O
acid	O
sequence	O
of	O
hCoV	B-PRGE
-	I-PRGE
NL63	I-PRGE
ORF	I-PRGE
3	I-PRGE
predicted	O
a	O
triple	O
membrane	O
-	O
spanning	O
protein	O
.	O

Thus	O
,	O
a	O
comprehensive	O
evaluation	O
of	O
the	O
complex	O
epithelial	O
signaling	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
is	O
crucial	O
for	O
paving	O
the	O
way	O
to	O
better	O
understand	O
SARS	O
pathogenesis	O
.	O

Specifically	O
,	O
we	O
found	O
a	O
temporal	O
and	O
spatial	O
activation	O
of	O
nuclear	B-PRGE
factor	I-PRGE
(	O
NF	O
)	O
kappaB	O
,	O
activator	B-PRGE
protein	I-PRGE
(	O
AP	O
)-	O
1	O
,	O
and	O
interferon	B-PRGE
regulatory	I-PRGE
factor	I-PRGE
(	O
IRF	B-PRGE
)-	O
3	O
/	O
7	O
in	O
infected	O
2B4	O
cells	O
at	O
12	O
-,	O
24	O
-,	O
and	O
48	O
-	O
hrs	O
post	O
infection	O
(	O
p	O
.	O
i	O
.),	O
resulting	O
in	O
the	O
activation	O
of	O
many	O
antiviral	O
genes	O
,	O
including	O
interferon	B-PRGE
(	O
IFN	B-PRGE
)-	O
beta	O
,	O
-	O
lambdas	O
,	O
inflammatory	O
mediators	O
,	O
and	O
many	O
IFN	B-PRGE
-	O
stimulated	O
genes	O
(	O
ISGs	O
).	O

In	O
order	O
to	O
elucidate	O
the	O
possible	O
mechanism	O
responsible	O
for	O
the	O
antiviral	O
activity	O
,	O
the	O
induction	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
release	O
as	O
well	O
as	O
the	O
attachment	O
ability	O
of	O
LAB	B-PRGE
on	O
the	O
cell	O
lines	O
was	O
investigated	O
.	O

Web	O
of	O
Science	O
and	O
PubMed	O
databases	O
were	O
searched	O
for	O
references	O
to	O
papers	O
on	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
avian	O
influenza	O
/	O
flu	B-PRGE
,	O
H5N1	O
,	O
swine	O
influenza	O
/	O
flu	B-PRGE
,	O
H1N1	O
,	O
and	O
pandemics	O
.	O

hACE2	O
Tg	O
mice	O
,	O
which	O
express	O
the	O
human	B-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
,	O
are	O
extremely	O
susceptible	O
to	O
infection	O
.	O

Interestingly	O
,	O
the	O
tree	O
topology	O
based	O
on	O
the	O
nucleotide	O
sequences	O
representing	O
the	O
S1	B-PRGE
domain	I-PRGE
or	O
the	O
S1	B-PRGE
N	I-PRGE
-	I-PRGE
terminal	I-PRGE
region	I-PRGE
most	O
nearly	O
resembled	O
the	O
full	O
S	O
gene	O
-	O
based	O
phylogenetic	O
tree	O
.	O

TITLE	O
:	O
Angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
)	O
in	O
disease	O
pathogenesis	O
.	O

Accumulating	O
evidence	O
in	O
recent	O
years	O
has	O
demonstrated	O
a	O
physiological	O
and	O
pathological	O
role	O
of	O
ACE2	B-PRGE
in	O
the	O
cardiovascular	O
,	O
renal	O
and	O
respiratory	O
systems	O
.	O

This	O
review	O
summarizes	O
and	O
discusses	O
the	O
recently	O
unveiled	O
roles	O
for	O
ACE2	B-PRGE
in	O
disease	O
pathogenesis	O
.	O

In	O
all	O
these	O
examples	O
the	O
conformational	O
epitopes	O
as	O
determined	O
by	O
the	O
X	O
-	O
ray	O
crystal	O
structures	O
of	O
the	O
antibody	B-PRGE
-	I-PRGE
antigen	I-PRGE
complexes	I-PRGE
,	O
were	O
found	O
within	O
the	O
highest	O
scoring	O
patches	O
of	O
EpiSearch	O
,	O
covering	O
in	O
most	O
cases	O
more	O
than	O
50	O
%	O
residues	O
of	O
experimental	O
observed	O
conformational	O
epitopes	O
.	O

TITLE	O
:	O
Exacerbated	O
innate	O
host	O
response	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
in	O
aged	O
non	O
-	O
human	O
primates	O
.	O

Therapeutic	O
treatment	O
of	O
SARS	O
-	O
CoV	O
-	O
infected	O
aged	O
macaques	O
with	O
type	B-PRGE
I	I-PRGE
IFN	I-PRGE
reduces	O
pathology	O
and	O
diminishes	O
pro	O
-	O
inflammatory	O
gene	O
expression	O
,	O
including	O
interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
(	O
IL	O
-	O
8	O
)	O
levels	O
,	O
without	O
affecting	O
virus	O
replication	O
in	O
the	O
lungs	O
.	O

Overexpression	O
of	O
hexokinase	B-PRGE
II	I-PRGE
prevented	O
both	O
rotenone	O
and	O
MPTP	O
-	O
induced	O
dopaminergic	O
neuronal	O
cell	O
death	O
,	O
as	O
well	O
as	O
reducing	O
the	O
associated	O
motor	O
defects	O
.	O

Here	O
we	O
demonstrate	O
the	O
self	O
-	O
assembly	O
and	O
release	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
)	O
M	B-PRGE
protein	I-PRGE
in	O
medium	O
in	O
the	O
form	O
of	O
membrane	O
-	O
enveloped	O
vesicles	O
with	O
densities	O
lower	O
than	O
those	O
of	O
VLPs	O
formed	O
by	O
M	O
plus	O
N	O
.	O
Although	O
efficient	O
N	O
-	O
N	O
interactions	O
require	O
the	O
presence	O
of	O
RNA	O
,	O
we	O
found	O
that	O
M	O
-	O
M	O
interactions	O
were	O
RNA	O
-	O
independent	O
.	O

TITLE	O
:	O
Induced	O
,	O
selective	O
proteolysis	O
of	O
MLK3	B-PRGE
negatively	O
regulates	O
MLK3	B-PRGE
/	O
JNK	B-PRGE
signalling	O
.	O

Plasma	O
levels	O
of	O
CC16	B-PRGE
and	O
KL	O
-	O
6	O
were	O
higher	O
in	O
ALI	O
/	O
ARDS	O
patients	O
at	O
baseline	O
as	O
compared	O
to	O
patients	O
without	O
lung	O
injury	O
.	O

Plasma	O
levels	O
of	O
SP	B-PRGE
-	I-PRGE
D	I-PRGE
and	O
KL	O
-	O
6	O
rise	O
with	O
potentially	O
injurious	O
ventilator	O
settings	O
,	O
and	O
thus	O
may	O
serve	O
as	O
biological	O
markers	O
of	O
VALI	O
in	O
patients	O
with	O
ALI	O
/	O
ARDS	O
.	O

Viral	O
proteases	O
represent	O
attractive	O
targets	O
for	O
the	O
design	O
of	O
anti	O
-	O
infective	O
lead	O
compounds	O
,	O
as	O
in	O
case	O
that	O
a	O
viral	O
mRNA	O
encoding	O
several	O
types	O
of	O
proteins	O
is	O
recognized	O
as	O
a	O
monocistronic	O
template	O
by	O
the	O
host	O
-	O
cell	O
translation	O
machinery	O
,	O
the	O
presence	O
of	O
protease	O
activities	O
is	O
required	O
for	O
processing	O
the	O
viral	B-PRGE
polyprotein	I-PRGE
precursor	I-PRGE
into	O
structural	O
or	O
non	O
-	O
structural	O
components	O
essential	O
for	O
the	O
formation	O
of	O
new	O
virion	O
particles	O
.	O

To	O
date	O
,	O
21	O
randomised	O
-	O
controlled	O
trials	O
have	O
enrolled	O
3	O
336	O
preterm	O
infants	O
<	O
34	O
weeks	O
of	O
gestation	O
for	O
iNO	B-PRGE
treatment	O
.	O

We	O
found	O
that	O
NL63	B-PRGE
PLP2	I-PRGE
deconjugated	O
ubiquitin	B-PRGE
(	O
Ub	O
)	O
and	O
the	O
Ub	O
-	O
line	O
molecule	O
ISG15	O
from	O
cellular	O
substrates	O
and	O
processed	O
both	O
lysine	O
-	O
48	O
-	O
and	O
lysine	O
-	O
63	O
-	O
linked	O
polyubiquitin	B-PRGE
chains	I-PRGE
.	O

This	O
PLP2	B-PRGE
DUB	I-PRGE
activity	O
was	O
dependent	O
on	O
an	O
intact	O
catalytic	O
cysteine	O
residue	O
.	O

We	O
propose	O
that	O
administering	O
inhalable	O
insulin	B-PRGE
to	O
hyperglycemic	O
ALI	O
/	O
ARDS	O
patients	O
could	O
directly	O
reduce	O
alveolar	O
inflammation	O
while	O
reducing	O
circulating	O
glucose	O
levels	O
.	O

ABSTRACT	O
:	O
Thyroid	B-PRGE
transcription	I-PRGE
factor	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
TTF	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
deficiency	O
syndrome	O
is	O
characterized	O
by	O
neurologic	O
,	O
thyroidal	O
,	O
and	O
pulmonary	O
dysfunction	O
.	O

The	O
process	O
of	O
demyelination	O
is	O
largely	O
immune	O
-	O
mediated	O
,	O
as	O
immunodeficient	O
mice	O
(	O
RAG1	O
(-/-)	O
mice	O
)	O
do	O
not	O
develop	O
demyelination	O
upon	O
infection	O
;	O
however	O
,	O
demyelination	O
develops	O
if	O
these	O
mice	O
are	O
reconstituted	O
with	O
either	O
JHMV	B-PRGE
-	I-PRGE
immune	I-PRGE
CD4	I-PRGE
or	O
CD8	B-PRGE
T	I-PRGE
cells	O
.	O

Given	O
that	O
regulatory	O
T	O
cells	O
(	O
Tregs	O
)	O
have	O
potent	O
anti	O
-	O
inflammatory	O
effects	O
,	O
we	O
adoptively	O
transferred	O
Tregs	O
into	O
infected	O
C57BL	O
/	O
6	O
and	O
RAG1	B-PRGE
(-/-)	O
mice	O
.	O

ABSTRACT	O
:	O
To	O
observe	O
the	O
effect	O
of	O
Qingyi	O
Decoction	O
(	O
QYD	O
)	O
in	O
treating	O
severe	O
acute	O
pancreatitis	O
(	O
SAP	O
)	O
and	O
its	O
impacts	O
on	O
blood	O
levels	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
),	O
interleukin	B-PRGE
6	I-PRGE
and	O
8	O
(	O
IL	O
-	O
6	O
and	O
IL	O
-	O
8	O
).	O

Immunoglobulins	O
A	O
,	O
G	B-PRGE
and	I-PRGE
M	I-PRGE
(	O
IgA	B-PRGE
,	O
G	O
and	O
M	O
)	O
types	O
of	O
anticardiolipin	O
antibodies	O
were	O
examined	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

There	O
were	O
only	O
4	O
of	O
52	O
subjects	O
in	O
the	O
control	O
group	O
(	O
7	O
.	O
7	O
%)	O
who	O
showed	O
positive	O
anticardiolipin	O
antibody	O
with	O
titers	O
of	O
IgA	B-PRGE
at	O
10	O
.	O
702	O
+/-	O

3	O
.	O
126	O
APL	B-PRGE
,	O
IgG	O
at	O
5	O
.	O
184	O
+/-	O

Plasmids	O
pEGFP	O
-	O
mfgl2	O
and	O
pEGFP	O
-	O
mTNFR1	O
expressing	O
mfgl2	O
-	O
EGFP	O
(	O
enhanced	O
green	B-PRGE
fluorescent	I-PRGE
protein	I-PRGE
)	O
and	O
mTNFR1	O
-	O
EGFP	O
fusion	O
proteins	O
were	O
also	O
constructed	O
to	O
screen	O
the	O
inhibitory	O
effect	O
of	O
p	O
-	O
mfgl2shRNA	O
and	O
p	O
-	O
mTNFR1shRNA	O
on	O
mfgl2	O
and	O
mTNFR1	O
expression	O
.	O

Thus	O
MHV	O
induction	O
of	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
/	I-PRGE
beta	I-PRGE
and	O
the	O
ability	O
to	O
induce	O
an	O
antiviral	O
state	O
in	O
response	O
to	O
interferon	B-PRGE
is	O
extremely	O
cell	O
type	O
dependent	O
.	O

An	O
equal	O
level	O
of	O
anti	O
-	O
MNV	O
-	O
S7	O
antibody	O
response	O
was	O
observed	O
in	O
BALB	O
/	O
cAJcl	O
,	O
C57BL	O
/	O
6JJcl	O
,	O
DBA	B-PRGE
/	I-PRGE
2JJcl	I-PRGE
,	O
and	O
Jcl	O
:	O
ICR	O
mice	O
;	O
whereas	O
,	O
C3H	O
/	O
HeJJcl	O
mice	O
demonstrated	O
slightly	O
lower	O
antibody	O
production	O
4	O
weeks	O
after	O
infection	O
.	O

TITLE	O
:	O
Induction	O
of	O
interferon	B-PRGE
-	I-PRGE
gamma	I-PRGE
-	O
inducible	O
protein	O
10	O
by	O
SARS	O
-	O
CoV	O
infection	O
,	O
interferon	B-PRGE
alfacon	I-PRGE
1	I-PRGE
and	O
interferon	B-PRGE
inducer	O
in	O
human	O
bronchial	O
epithelial	O
Calu	O
-	O
3	O
cells	O
and	O
BALB	O
/	O
c	O
mice	O
.	O

RESULTS	O
:	O
A	O
potent	O
,	O
prolonged	O
inhibition	O
of	O
SARS	O
-	O
CoV	O
replication	O
in	O
Calu	O
-	O
3	O
cells	O
with	O
IFN	B-PRGE
-	I-PRGE
alfacon	I-PRGE
1	I-PRGE
was	O
observed	O
.	O

The	O
results	O
demonstrated	O
that	O
priming	O
with	O
a	O
DNA	B-PRGE
vaccine	I-PRGE
encoding	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
(	O
pVAX1	O
-	O
N	O
)	O
and	O
boosting	O
with	O
the	O
inactivated	O
IBV	O
vaccine	O
led	O
to	O
the	O
dramatic	O
augmentation	O
of	O
humoral	O
and	O
cellular	O
responses	O
,	O
and	O
provided	O
up	O
to	O
86	O
.	O
7	O
%	O
rate	O
of	O
immune	O
protection	O
,	O
providing	O
an	O
effective	O
approach	O
to	O
protect	O
chickens	O
from	O
IBV	O
.	O

ABSTRACT	O
:	O
Poliovirus	B-PRGE
2B	I-PRGE
protein	I-PRGE
is	O
a	O
well	O
-	O
known	O
viroporin	O
implicated	O
in	O
plasma	O
membrane	O
permeabilization	O
to	O
ions	O
and	O
low	O
-	O
molecular	O
-	O
weight	O
compounds	O
during	O
infection	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
support	O
a	O
mechanism	O
involving	O
gap	B-PRGE
junctional	O
intercellular	O
communication	O
in	O
the	O
bystander	O
permeabilization	O
effect	O
observed	O
in	O
healthy	O
cells	O
co	O
-	O
cultured	O
with	O
poliovirus	O
2B	O
-	O
expressing	O
cells	O
.	O

ABSTRACT	O
:	O
Angiotensin	O
-	O
I	O
converting	O
enzyme	O
2	O
(	O
ACE2	B-PRGE
)	O
is	O
the	O
receptor	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

The	O
ability	O
of	O
MHV	O
to	O
delay	O
SeV	O
-	O
mediated	O
ISG	O
production	O
may	O
partially	O
involve	O
limiting	O
the	O
ability	O
of	O
IFN	B-PRGE
regulatory	I-PRGE
factor	I-PRGE
3	I-PRGE
(	O
IRF	B-PRGE
-	I-PRGE
3	I-PRGE
)	O
to	O
function	O
as	O
a	O
transcription	O
factor	O
.	O

The	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
-	O
336A	O
>	O
G	O
in	O
the	O
CD209	B-PRGE
promoter	I-PRGE
has	O
been	O
demonstrated	O
to	O
regulate	O
promoter	O
activity	O
and	O
to	O
be	O
associated	O
with	O
several	O
important	O
infectious	O
diseases	O
,	O
such	O
as	O
human	O
immunodeficiency	O
virus	O
-	O
1	O
(	O
HIV	O
-	O
1	O
),	O
Mycobacterium	O
tuberculosis	O
,	O
and	O
Dengue	O
fever	O
.	O

Type	O
I	O
interferon	B-PRGE
is	O
essential	O
to	O
prevent	O
very	O
early	O
mortality	O
after	O
infection	O
.	O

Seven	O
days	O
after	O
completion	O
of	O
immunoglobulin	B-PRGE
treatment	O
,	O
plasma	O
exchange	O
was	O
started	O
with	O
an	O
exchange	O
of	O
about	O
three	O
litres	O
of	O
plasma	O
every	O
day	O
for	O
three	O
days	O
and	O
every	O
second	O
day	O
on	O
two	O
further	O
occasions	O
.	O

The	O
current	O
review	O
would	O
be	O
of	O
interest	O
to	O
scientists	O
engaged	O
in	O
the	O
development	O
of	O
drug	O
design	O
strategies	O
to	O
target	O
the	O
cysteine	B-PRGE
proteases	I-PRGE
present	O
in	O
mammals	O
and	O
other	O
lower	O
order	O
organisms	O
.	O

By	O
means	O
of	O
an	O
evidence	O
-	O
based	O
medicine	O
tool	O
(	O
CAT	B-PRGE
)	O
we	O
approach	O
the	O
benefit	O
of	O
long	O
-	O
bone	O
fracture	O
stabilization	O
in	O
polytraumatized	O
patients	O
trying	O
to	O
answer	O
a	O
specific	O
clinical	O
question	O
from	O
a	O
concrete	O
situation	O
:	O
What	O
is	O
the	O
evidence	O
of	O
the	O
safety	O
and	O
benefit	O
of	O
early	O
stabilization	O
of	O
long	O
-	O
bone	O
fractures	O
in	O
polytraumatized	O
patients	O
?	O

TITLE	O
:	O
SARS	O
-	O
CoV	O
pathogenesis	O
is	O
regulated	O
by	O
a	O
STAT1	B-PRGE
dependent	O
but	O
a	O
type	O
I	O
,	O
II	O
and	O
III	O
interferon	B-PRGE
receptor	I-PRGE
independent	O
mechanism	O
.	O

The	O
replication	O
of	O
SARS	O
-	O
CoV	O
is	O
highly	O
dependent	O
on	O
host	B-PRGE
cell	I-PRGE
factors	I-PRGE
.	O

sIgA	B-PRGE
was	O
detected	O
in	O
saliva	O
in	O
groups	O
immunized	O
intranasally	O
but	O
not	O
in	O
groups	O
immunized	O
intraperitoneally	O
.	O

CpG	O
had	O
an	O
adjuvant	O
effect	O
on	O
IgA	B-PRGE
production	O
in	O
genital	O
tract	O
washes	O
when	O
administered	O
intranasally	O
but	O
only	O
affected	O
IgA	B-PRGE
production	O
in	O
faeces	O
samples	O
when	O
administered	O
intraperitoneally	O
.	O

In	O
summary	O
,	O
our	O
study	O
indicates	O
that	O
mucosal	O
immunization	O
with	O
rBV	B-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
VLPs	I-PRGE
represent	O
an	O
effective	O
means	O
for	O
eliciting	O
protective	O
systemic	O
and	O
mucosal	O
immune	O
responses	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
providing	O
important	O
information	O
for	O
vaccine	O
design	O
.	O

Multiplex	O
primer	O
sets	O
were	O
designed	O
to	O
amplify	O
the	O
region	O
covering	O
hypervariable	O
regions	O
1	O
and	O
2	O
of	O
the	O
S1	B-PRGE
glycoprotein	I-PRGE
gene	O
.	O

Using	O
this	O
virus	O
,	O
complexes	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
E	I-PRGE
and	O
other	O
proteins	O
were	O
purified	O
using	O
a	O
tandem	O
affinity	O
purification	O
system	O
.	O

When	O
expressed	O
on	O
cultured	O
BHK	O
cells	O
,	O
the	O
mCEACAM1b	B-PRGE
and	I-PRGE
mCEACAM1ba	I-PRGE
proteins	I-PRGE
had	O
similar	O
levels	O
of	O
MHV	B-PRGE
-	I-PRGE
A59	I-PRGE
receptor	I-PRGE
activity	O
.	O

We	O
propose	O
ATF3	B-PRGE
acts	O
to	O
counterbalance	O
CS	O
and	O
high	O
volume	O
-	O
induced	O
inflammation	O
,	O
dampening	O
its	O
ability	O
to	O
cause	O
injury	O
and	O
consequently	O
protecting	O
animals	O
from	O
injurious	O
CS	O
.	O

ABSTRACT	O
:	O
The	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
induced	O
the	O
expression	O
of	O
type	B-PRGE
I	I-PRGE
interferon	I-PRGE
(	O
alpha	B-PRGE
/	I-PRGE
beta	I-PRGE
interferon	I-PRGE
[	O
IFN	O
-	O
alpha	O
/	O
beta	O
])	O
in	O
mouse	O
oligodendrocytic	O
N20	O
.	O
1	O
cells	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
(	O
CoV	O
)	O
3C	O
-	O
like	O
proteinase	O
(	O
3CLpro	O
),	O
located	O
in	O
nonstructural	B-PRGE
protein	I-PRGE
5	I-PRGE
(	O
nsp5	B-PRGE
),	O
processes	O
the	O
replicase	B-PRGE
polyproteins	I-PRGE
1a	I-PRGE
and	I-PRGE
1ab	I-PRGE
(	O
pp1a	B-PRGE
and	O
pp1ab	O
)	O
at	O
11	O
specific	O
sites	O
to	O
produce	O
12	O
mature	O
nonstructural	O
proteins	O
(	O
nsp5	B-PRGE
to	O
nsp16	O
).	O

Our	O
results	O
demonstrated	O
that	O
a	O
P1	O
-	O
Asn	O
substitution	O
at	O
the	O
nsp4	B-PRGE
-	I-PRGE
5	I-PRGE
/	O
Q2779	O
,	O
nsp5	B-PRGE
-	I-PRGE
6	I-PRGE
/	O
Q3086	O
,	O
nsp7	O
-	O
8	O
/	O
Q3462	O
,	O
nsp8	O
-	O
9	O
/	O
Q3672	O
,	O
and	O
nsp9	O
-	O
10	O
/	O
Q3783	O
sites	O
,	O
a	O
P1	O
-	O
Glu	O
substitution	O
at	O
the	O
nsp8	O
-	O
9	O
/	O
Q3672	O
site	O
,	O
and	O
a	O
P1	O
-	O
His	O
substitution	O
at	O
the	O
nsp15	O
-	O
16	O
/	O
Q6327	O
site	O
were	O
tolerated	O
and	O
allowed	O
recovery	O
of	O
infectious	O
mutant	O
viruses	O
,	O
albeit	O
with	O
variable	O
degrees	O
of	O
growth	O
defects	O
.	O

TITLE	O
:	O
Infidelity	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
Nsp14	I-PRGE
-	I-PRGE
exonuclease	I-PRGE
mutant	I-PRGE
virus	O
replication	O
is	O
revealed	O
by	O
complete	O
genome	O
sequencing	O
.	O

ABSTRACT	O
:	O
Tumour	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
)	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
many	O
inflammatory	O
conditions	O
.	O

Currently	O
anti	B-PRGE
-	I-PRGE
TNF	I-PRGE
-	I-PRGE
alpha	I-PRGE
drugs	O
(	O
e	O
.	O
g	O
.	O
etanercept	O
)	O
are	O
used	O
in	O
humans	O
for	O
treatment	O
of	O
autoimmune	O
diseases	O
.	O

In	O
the	O
cathepsin	B-PRGE
L	I-PRGE
inhibition	O
assay	O
,	O
the	O
oxocarbazate	O
caused	O
a	O
time	O
-	O
dependent	O
17	O
-	O
fold	O
drop	O
in	O
IC	O
(	O
50	O
)	O
from	O
6	O
.	O
9	O
nM	O
(	O
no	O
preincubation	O
)	O
to	O
0	O
.	O
4	O
nM	O
(	O
4	O
-	O
h	O
preincubation	O
).	O

This	O
review	O
summarizes	O
human	O
and	O
animal	O
studies	O
on	O
biomarkers	O
in	O
primary	O
graft	O
dysfunction	O
,	O
including	O
cytokines	O
and	O
markers	O
of	O
acute	O
inflammation	O
,	O
VEGF	B-PRGE
,	O
endothelial	O
markers	O
and	O
adhesion	O
molecules	O
,	O
markers	O
of	O
coagulation	O
and	O
fibrinolysis	O
and	O
markers	O
of	O
lung	O
epithelial	O
injury	O
.	O

Angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
)	O
is	O
the	O
major	O
receptor	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
It	O
is	O
not	O
clear	O
whether	O
ACE2	B-PRGE
conveys	O
signals	O
from	O
the	O
cell	O
surface	O
to	O
the	O
nucleus	O
and	O
regulates	O
expression	O
of	O
cellular	O
genes	O
upon	O
SARS	O
-	O
CoV	O
infection	O
.	O

The	O
upregulation	O
of	O
CCL2	B-PRGE
by	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
was	O
mainly	O
mediated	O
by	O
extracellular	B-PRGE
signal	I-PRGE
-	I-PRGE
regulated	I-PRGE
kinase	I-PRGE
1	I-PRGE
and	I-PRGE
2	I-PRGE
(	O
ERK1	B-PRGE
/	I-PRGE
2	I-PRGE
)	O
and	O
AP	B-PRGE
-	I-PRGE
1	I-PRGE
but	O
not	O
the	O
IkappaBalpha	B-PRGE
-	I-PRGE
NF	I-PRGE
-	I-PRGE
kappaB	I-PRGE
signaling	O
pathway	O
.	O

Furthermore	O
,	O
ACE2	B-PRGE
receptor	I-PRGE
was	O
activated	O
by	O
casein	B-PRGE
kinase	I-PRGE
II	I-PRGE
-	O
mediated	O
phosphorylation	O
in	O
cells	O
pretreated	O
with	O
the	O
virus	O
-	O
like	O
particles	O
containing	O
spike	O
protein	O
.	O

Stress	O
-	O
induced	O
phosphorylation	O
of	O
eukaryotic	B-PRGE
translation	I-PRGE
initiation	I-PRGE
factor	I-PRGE
2alpha	I-PRGE
(	O
eIF2alpha	B-PRGE
)	O
generally	O
results	O
in	O
impaired	O
initiation	O
of	O
protein	O
synthesis	O
,	O
but	O
the	O
sensitivity	O
of	O
MHV	O
infection	O
to	O
proteasome	O
inhibitors	O
was	O
unchanged	O
in	O
cells	O
lacking	O
a	O
phosphorylatable	O
eIF2alpha	B-PRGE
.	O

TITLE	O
:	O
Feline	B-PRGE
lectin	I-PRGE
activity	O
is	O
critical	O
for	O
the	O
cellular	O
entry	O
of	O
feline	O
infectious	O
peritonitis	O
virus	O
.	O

Here	O
,	O
we	O
report	O
identification	O
and	O
analysis	O
of	O
the	O
feline	O
homologue	O
to	O
the	O
human	B-PRGE
lectin	I-PRGE
DC	I-PRGE
-	I-PRGE
SIGN	I-PRGE
and	O
show	O
that	O
it	O
is	O
a	O
coreceptor	O
for	O
virulent	O
strains	O
of	O
serotype	O
1	O
and	O
serotype	O
2	O
feline	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
Enhancing	O
innate	O
and	O
acquired	O
immunity	O
by	O
cytokines	O
such	O
as	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
appears	O
to	O
be	O
useful	O
as	O
a	O
first	O
line	O
of	O
defense	O
against	O
viral	O
infection	O
.	O

However	O
,	O
as	O
the	O
internally	O
encoded	O
3CL	B-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
gets	O
matured	O
from	O
the	O
replicase	B-PRGE
polyprotein	O
by	O
autolytic	O
cleavage	O
at	O
both	O
the	O
N	O
-	O
terminal	O
and	O
the	O
C	O
-	O
terminal	O
flanking	O
sites	O
,	O
it	O
is	O
unclear	O
whether	O
the	O
polyprotein	O
also	O
needs	O
to	O
dimerize	O
first	O
for	O
its	O
autocleavage	O
reaction	O
.	O

We	O
constructed	O
a	O
large	O
protein	O
containing	O
the	O
cyan	O
fluorescent	O
protein	O
(	O
C	O
),	O
the	O
N	O
-	O
terminal	O
flanking	O
substrate	O
peptide	O
of	O
SARS	O
3CL	O
(	O
pro	O
)	O
(	O
XX	O
),	O
SARS	B-PRGE
3CL	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
(	I-PRGE
3CLP	I-PRGE
),	I-PRGE
and	O
the	O
yellow	O
fluorescent	O
protein	O
(	O
Y	O
)	O
to	O
study	O
the	O
autoprocessing	O
of	O
3CL	O
(	O
pro	O
)	O
using	O
fluorescence	O
resonance	O
energy	O
transfer	O
.	O

Malaria	O
-	O
associated	O
ALI	O
correlated	O
with	O
high	O
levels	O
of	O
circulating	O
VEGF	B-PRGE
,	O
produced	O
de	O
novo	O
in	O
the	O
spleen	O
,	O
and	O
its	O
blockage	O
led	O
to	O
protection	O
of	O
mice	O
from	O
this	O
syndrome	O
.	O

Phosphorylation	O
levels	O
induced	O
by	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
in	O
STAT1	B-PRGE
and	O
STAT3	B-PRGE
and	O
by	O
combination	O
of	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
and	O
calcium	O
ionophore	O
A23187	O
in	O
extracellular	B-PRGE
signal	I-PRGE
-	I-PRGE
regulated	I-PRGE
kinases	I-PRGE
1	I-PRGE
/	I-PRGE
2	I-PRGE
,	O
members	O
of	O
a	O
mitogen	B-PRGE
-	I-PRGE
activated	I-PRGE
protein	I-PRGE
kinase	I-PRGE
family	I-PRGE
,	O
were	O
depressed	O
in	O
patients	O
'	O
monocytes	O
,	O
whereas	O
phosphorylation	O
levels	O
induced	O
by	O
granulocyte	B-PRGE
-	I-PRGE
macrophage	I-PRGE
colony	I-PRGE
-	I-PRGE
stimulating	I-PRGE
factor	I-PRGE
in	O
STAT5	B-PRGE
was	O
normal	O
.	O

p38	B-PRGE
activation	O
is	O
normal	O
and	O
STAT3	B-PRGE
activation	O
is	O
depressed	O
,	O
which	O
may	O
contribute	O
to	O
maintenance	O
of	O
systemic	O
inflammation	O
.	O

Extracellular	B-PRGE
signal	I-PRGE
-	I-PRGE
regulated	I-PRGE
kinases	I-PRGE
1	I-PRGE
/	I-PRGE
2	I-PRGE
activation	O
is	O
impaired	O
,	O
which	O
may	O
depress	O
monocytes	O
'	O
transmigration	O
and	O
may	O
consequently	O
increase	O
risk	O
of	O
infection	O
.	O

TITLE	O
:	O
Accessory	O
protein	O
5a	O
is	O
a	O
major	O
antagonist	O
of	O
the	O
antiviral	O
action	O
of	O
interferon	B-PRGE
against	O
murine	O
coronavirus	O
.	O

However	O
,	O
in	O
vitro	O
,	O
most	O
strains	O
of	O
MHV	O
are	O
largely	O
resistant	O
to	O
the	O
action	O
of	O
this	O
cytokine	O
,	O
suggesting	O
that	O
MHV	O
encodes	O
one	O
or	O
more	O
functions	O
that	O
antagonize	O
or	O
evade	O
the	O
IFN	B-PRGE
system	O
.	O

Subsequently	O
,	O
we	O
carried	O
out	O
lead	O
optimization	O
and	O
structure	O
-	O
activity	O
studies	O
to	O
provide	O
a	O
series	O
of	O
improved	O
inhibitors	O
that	O
show	O
potent	O
PLpro	O
inhibition	O
and	O
antiviral	O
activity	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
infected	O
Vero	O
E6	O
cells	O
.	O

TITLE	O
:	O
Attachment	O
of	O
mouse	O
hepatitis	O
virus	O
to	O
O	O
-	O
acetylated	O
sialic	O
acid	O
is	O
mediated	O
by	O
hemagglutinin	B-PRGE
-	I-PRGE
esterase	I-PRGE
and	O
not	O
by	O
the	O
spike	O
protein	O
.	O

We	O
show	O
that	O
MHV	O
co	O
-	O
opts	O
the	O
host	O
cell	O
machinery	O
for	O
COPII	O
-	O
independent	O
vesicular	O
ER	O
export	O
of	O
a	O
short	O
-	O
living	O
regulator	O
of	O
ER	O
-	O
associated	O
degradation	O
(	O
ERAD	B-PRGE
),	O
EDEM1	O
,	O
to	O
derive	O
cellular	O
membranes	O
for	O
replication	O
.	O

Vaccinated	O
birds	O
that	O
were	O
challenged	O
with	O
10	O
(	O
4	O
.	O
5	O
)	O
median	O
embryo	O
infectious	O
doses	O
of	O
pathogenic	O
GA08	O
virus	O
/	O
bird	O
at	O
28	O
days	O
of	O
age	O
were	O
protected	O
from	O
the	O
disease	O
,	O
and	O
challenge	O
virus	O
was	O
only	O
detected	O
in	O
the	O
trachea	O
of	O
one	O
of	O
21	O
birds	O
by	O
real	O
-	O
time	O
reverse	B-PRGE
transcriptase	I-PRGE
-	O
polymerase	O
chain	O
reaction	O
at	O
5	O
days	O
post	O
challenge	O
.	O

We	O
previously	O
reported	O
that	O
the	O
adaptive	O
immune	O
response	O
plays	O
an	O
important	O
protective	O
role	O
in	O
MHV	O
-	O
1	O
-	O
infected	O
resistant	O
B6	O
mice	O
and	O
that	O
both	O
CD4	B-PRGE
and	O
CD8	B-PRGE
T	O
cells	O
play	O
a	O
significant	O
role	O
in	O
the	O
development	O
of	O
morbidity	O
and	O
lung	O
pathology	O
following	O
intranasal	O
MHV	O
-	O
1	O
infection	O
of	O
susceptible	O
C3H	O
/	O
HeJ	O
and	O
A	O
/	O
J	O
mice	O
.	O

Thus	O
,	O
identification	O
of	O
novel	O
CD4	B-PRGE
and	O
CD8	B-PRGE
T	O
cell	O
epitopes	O
for	O
MHV	O
-	O
1	O
permitted	O
high	O
-	O
resolution	O
analyses	O
of	O
pulmonary	O
T	O
cell	O
responses	O
in	O
a	O
mouse	O
model	O
of	O
SARS	O
.	O

ABSTRACT	O
:	O
CD200	B-PRGE
,	O
a	O
type	B-PRGE
I	I-PRGE
membrane	I-PRGE
glycoprotein	I-PRGE
,	O
plays	O
an	O
important	O
role	O
in	O
prevention	O
of	O
inflammatory	O
disorders	O
,	O
graft	O
rejection	O
,	O
autoimmune	O
diseases	O
and	O
spontaneous	O
fetal	O
loss	O
.	O

These	O
data	O
suggest	O
that	O
M	O
.	O
daubentoni	O
and	O
R	O
.	O
sinicus	O
are	O
likely	O
to	O
be	O
susceptible	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
may	O
be	O
candidates	O
as	O
the	O
natural	O
host	O
of	O
the	O
SARS	O
-	O
CoV	O
progenitor	O
viruses	O
.	O

TITLE	O
:	O
The	O
cellular	O
RNA	O
helicase	B-PRGE
DDX1	I-PRGE
interacts	O
with	O
coronavirus	O
nonstructural	O
protein	O
14	O
and	O
enhances	O
viral	O
replication	O
.	O

MBL	B-PRGE
was	O
found	O
to	O
selectively	O
bind	O
to	O
retroviral	O
particles	O
pseudotyped	O
with	O
SARS	O
-	O
S	O
.	O
Unlike	O
several	O
other	O
viral	O
envelopes	O
to	O
which	O
MBL	B-PRGE
can	O
bind	O
,	O
both	O
recombinant	O
and	O
plasma	O
-	O
derived	O
human	O
MBL	O
directly	O
inhibited	O
SARS	O
-	O
S	O
-	O
mediated	O
viral	O
infection	O
.	O

Surprisingly	O
,	O
however	O
,	O
palmitoylation	O
of	O
S	O
was	O
not	O
required	O
for	O
interaction	O
with	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
protein	I-PRGE
.	O

RESULTS	O
:	O
In	O
105	O
patients	O
with	O
SIRS	O
score	O
3	O
and	O
higher	O
,	O
initial	O
measured	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
levels	O
were	O
significantly	O
higher	O
than	O
in	O
the	O
group	O
of	O
remaining	O
129	O
patients	O
(	O
72	O
+/-	O

Inclusion	O
of	O
CXCL1	B-PRGE
within	O
JHMV	O
infected	O
cultures	O
restricted	O
caspase	B-PRGE
3	I-PRGE
cleavage	O
and	O
increased	O
Bcl	B-PRGE
-	I-PRGE
2	I-PRGE
expression	O
that	O
was	O
associated	O
with	O
a	O
significant	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
decrease	O
in	O
apoptosis	O
.	O

These	O
findings	O
highlight	O
a	O
previously	O
unappreciated	O
role	O
for	O
CXCR2	B-PRGE
signaling	O
in	O
protecting	O
oligodendrocyte	O
lineage	O
cells	O
from	O
apoptosis	O
during	O
inflammatory	O
demyelination	O
initiated	O
by	O
viral	O
infection	O
of	O
the	O
CNS	O
.	O

Mice	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
the	O
following	O
groups	O
:	O
(	O
1	O
)	O
sham	O
-	O
operated	O
;	O
(	O
2	O
)	O
sham	O
+	O
HB	O
-	O
EGF	B-PRGE
(	O
1200	O
microg	O
/	O
kg	O
in	O
0	O
.	O
6	O
mL	O
administered	O
by	O
intra	O
-	O
luminal	O
injection	O
at	O
the	O
jejuno	O
-	O
ileal	O
junction	O
immediately	O
after	O
identification	O
of	O
the	O
superior	O
mesenteric	O
artery	O
);	O
(	O
3	O
)	O
superior	O
mesenteric	O
artery	O
occlusion	O
for	O
45	O
min	O
followed	O
by	O
reperfusion	O
for	O
6	O
h	O
(	O
I	O
/	O
R	O
);	O
or	O
(	O
4	O
)	O
I	O
/	O
R	O
+	O
HB	O
-	O
EGF	B-PRGE
(	O
1200	O
microg	O
/	O
kg	O
in	O
0	O
.	O
6	O
mL	O
)	O
administered	O
15	O
min	O
after	O
vascular	O
occlusion	O
.	O

By	O
targeting	O
angiotensin	B-PRGE
II	I-PRGE
ACE2	I-PRGE
exhibits	O
a	O
protective	O
role	O
in	O
the	O
cardiovascular	O
system	O
and	O
many	O
other	O
organs	O
.	O

A	O
TGEV	O
derived	O
vector	O
(	O
rTGEV	O
)	O
was	O
generated	O
,	O
expressing	O
PRRSV	O
wild	O
type	O
or	O
modified	O
GP5	B-PRGE
and	O
M	O
proteins	O
,	O
described	O
as	O
the	O
main	O
inducers	O
of	O
neutralizing	O
antibodies	O
and	O
cellular	O
immune	O
response	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
The	O
N	O
-	O
terminal	O
domain	O
of	O
nucleocapsid	B-PRGE
protein	I-PRGE
from	I-PRGE
human	I-PRGE
coronavirus	I-PRGE
OC43	I-PRGE
(	O
HCoV	O
-	O
OC43	O
N	O
-	O
NTD	O
)	O
mostly	O
contains	O
positively	O
charged	O
residues	O
and	O
has	O
been	O
identified	O
as	O
being	O
responsible	O
for	O
RNA	O
binding	O
during	O
ribonucleocapsid	O
formation	O
in	O
the	O
coronavirus	O
.	O

TITLE	O
:	O
Nsp1	B-PRGE
proteins	O
of	O
group	O
I	O
and	O
SARS	O
coronaviruses	O
share	O
structural	O
and	O
functional	O
similarities	O
.	O

Since	O
multiple	O
infectious	O
agents	O
can	O
be	O
involved	O
in	O
calf	O
diarrhea	O
,	O
and	O
the	O
detection	O
of	O
each	O
of	O
the	O
causative	O
agents	O
by	O
traditional	O
methods	O
is	O
laborious	O
and	O
expensive	O
,	O
a	O
panel	O
of	O
2	O
multiplex	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
assays	O
was	O
developed	O
for	O
rapid	O
and	O
simultaneous	O
detection	O
of	O
the	O
5	O
major	O
bovine	O
enteric	O
pathogens	O
(	O
i	O
.	O
e	O
.,	O
Bovine	O
coronavirus	O
[	O
BCoV	O
;	O
formally	O
known	O
as	O
Betacoronavirus	O
1	O
],	O
group	O
A	O
Bovine	O
rotavirus	O
[	O
BRV	O
],	O
Salmonella	B-PRGE
spp	I-PRGE
.,	I-PRGE
Escherichia	I-PRGE
coli	I-PRGE
K99	I-PRGE
(+),	I-PRGE
and	O
Cryptosporidium	O
parvum	O
).	O

Electron	O
microscopic	O
analysis	O
indicated	O
that	O
viral	O
inactivation	O
by	O
PPs	B-PRGE
was	O
primarily	O
a	O
consequence	O
of	O
virion	O
structural	O
damage	O
.	O

TITLE	O
:	O
Mutations	O
in	O
the	O
spike	O
glycoprotein	O
of	O
human	B-PRGE
coronavirus	I-PRGE
OC43	I-PRGE
modulate	O
disease	O
in	O
BALB	O
/	O
c	O
mice	O
from	O
encephalitis	O
to	O
flaccid	O
paralysis	O
and	O
demyelination	O
.	O

Even	O
though	O
infection	O
by	O
both	O
mutated	O
and	O
wild	O
-	O
type	O
viruses	O
led	O
to	O
neuroinflammation	O
,	O
the	O
modified	O
neuropathogenesis	O
induced	O
by	O
the	O
mutated	O
virus	O
was	O
associated	O
with	O
increased	O
viral	O
spread	O
and	O
significantly	O
more	O
CD4	B-PRGE
+	I-PRGE
and	O
CD8	B-PRGE
+	I-PRGE
T	O
-	O
lymphocyte	O
infiltration	O
into	O
the	O
central	O
nervous	O
system	O
,	O
as	O
well	O
as	O
significantly	O
increased	O
levels	O
of	O
the	O
proinflammatory	O
cytokine	O
interleukin	B-PRGE
(	O
IL	O
)-	O
6	O
and	O
the	O
chemokine	O
CCL2	O
(	O
monocyte	O
chemoattractant	O
protein	O
[	O
MCP	O
]-	O
1	O
).	O

Here	O
,	O
we	O
investigated	O
whether	O
spike	O
protein	O
of	O
SARS	B-PRGE
-	O
CoV	O
can	O
act	O
as	O
a	O
ligand	O
to	O
trigger	O
the	O
conversion	O
of	O
B	O
cells	O
to	O
macrophages	O
.	O

MHV	O
-	O
Brts31	O
has	O
near	O
-	O
normal	O
levels	O
of	O
RNA	O
synthesis	O
at	O
the	O
permissive	O
temperature	O
of	O
33	O
degrees	O
C	O
but	O
is	O
unable	O
to	O
synthesize	O
viral	O
RNA	O
when	O
the	O
infection	O
is	O
initiated	O
and	O
maintained	O
at	O
the	O
nonpermissive	O
temperature	O
of	O
39	O
.	O
5	O
degrees	O
C	O
.	O
Sequence	O
analysis	O
of	O
MHV	B-PRGE
-	I-PRGE
Brts31	I-PRGE
RNA	I-PRGE
indicated	O
that	O
a	O
single	O
G	O
-	O
to	O
-	O
A	O
transition	O
at	O
codon	O
1307	O
in	O
open	O
reading	O
frame	O
1a	O
,	O
which	O
results	O
in	O
a	O
replacement	O
of	O
methionine	O
-	O
475	O
with	O
isoleucine	O
in	O
nonstructural	B-PRGE
protein	I-PRGE
3	I-PRGE
(	O
nsp3	B-PRGE
),	O
was	O
responsible	O
for	O
the	O
ts	O
phenotype	O
.	O

It	O
participates	O
in	O
the	O
proteolytic	O
processing	O
of	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
replicase	B-PRGE
polyproteins	I-PRGE
in	O
a	O
manner	O
that	O
varies	O
among	O
different	O
coronaviruses	O
and	O
remains	O
poorly	O
understood	O
.	O

Its	O
tertiary	O
structure	O
is	O
compared	O
with	O
that	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
PL2	B-PRGE
(	O
pro	O
),	O
a	O
downstream	O
paralog	O
that	O
is	O
conserved	O
in	O
the	O
nsp3	B-PRGE
'	O
s	O
of	O
all	O
coronaviruses	O
.	O

Surface	O
expression	O
of	O
spike	O
and	O
staining	O
with	O
sera	O
of	O
SARS	O
survivors	O
suggested	O
low	O
antigenic	O
overlap	O
with	O
SARS	O
CoV	O
.	O
However	O
,	O
the	O
receptor	O
binding	O
domain	O
of	O
SARS	B-PRGE
CoV	I-PRGE
showed	O
higher	O
similarity	O
with	O
that	O
of	O
BtCoV	O
/	O
BM48	O
-	O
31	O
/	O
Bulgaria	O
/	O
2008	O
than	O
with	O
that	O
of	O
any	O
Chinese	O
bat	O
-	O
borne	O
CoV	O
.	O
Critical	O
spike	O
domains	O
472	O
and	O
487	O
were	O
identical	O
and	O
similar	O
,	O
respectively	O
.	O

TITLE	O
:	O
Electrophoretic	O
fractionation	O
of	O
creatine	B-PRGE
kinase	I-PRGE
isoenzymes	O
and	O
macroenzymes	O
in	O
clinically	O
healthy	O
dogs	O
and	O
cats	O
and	O
preliminary	O
evaluation	O
in	O
central	O
neurologic	O
disease	O
.	O

Two	O
of	O
6	O
cats	O
with	O
FIP	O
had	O
increased	O
macro	O
-	O
CK1	B-PRGE
and	O
increased	O
CK	O
-	O
BB	O
activity	O
.	O

Despite	O
a	O
deletion	O
of	O
the	O
type	B-PRGE
I	I-PRGE
interferon	I-PRGE
receptor	I-PRGE
,	O
strong	O
expression	O
of	O
interferon	B-PRGE
-	O
stimulated	O
genes	O
was	O
observed	O
in	O
the	O
lungs	O
of	O
IFNAR1	B-PRGE
-/-	O
mice	O
,	O
contributing	O
to	O
clearance	O
of	O
the	O
virus	O
.	O

We	O
propose	O
that	O
a	O
combination	O
of	O
impaired	O
viral	O
clearance	O
and	O
T	O
-	O
cell	O
/	O
macrophage	O
dysregulation	O
causes	O
the	O
formation	O
of	O
prefibrotic	O
lesions	O
in	O
the	O
lungs	O
of	O
rMA15	O
-	O
infected	O
STAT1	B-PRGE
-/-	O
mice	O
.	O

Results	O
showed	O
that	O
peptide	O
-	O
specific	O
CD8	B-PRGE
(+)	O
T	O
cells	O
secreted	O
IFN	B-PRGE
-	I-PRGE
γ	I-PRGE
,	O
TNF	B-PRGE
-	I-PRGE
α	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
expressed	O
CD107a	B-PRGE
/	O
b	O
on	O
cell	O
surface	O
.	O

The	O
phenotype	O
of	O
the	O
CD8	B-PRGE
(+)	O
T	O
cells	O
was	O
characterized	O
based	O
on	O
the	O
expression	O
of	O
IFN	B-PRGE
-	I-PRGE
γ	I-PRGE
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
that	O
immunization	O
with	O
SARS	B-PRGE
S	I-PRGE
DNA	I-PRGE
and	O
HLA	B-PRGE
-	I-PRGE
A	I-PRGE
*	I-PRGE
0201	I-PRGE
restricted	O
peptides	O
can	O
elicit	O
antigen	O
-	O
specific	O
CD8	B-PRGE
(+)	O
T	O
cell	O
immune	O
responses	O
which	O
may	O
have	O
a	O
significant	O
implication	O
in	O
the	O
long	O
-	O
term	O
protection	O
.	O

Nucleotide	O
sequencing	O
of	O
the	O
S	B-PRGE
gene	I-PRGE
of	O
25V16G	O
and	O
JHMV	O
revealed	O
a	O
deletion	O
of	O
29	O
amino	O
acids	O
encompassing	O
S	O
(	O
511	O
-	O
539	O
),	O
which	O
covers	O
a	O
major	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
epitope	O
in	O
C57BL	O
/	O
6	O
mice	O
,	O
and	O
two	O
point	O
mutations	O
resulting	O
in	O
amino	O
acid	O
changes	O
in	O
the	O
S	B-PRGE
protein	I-PRGE
of	O
25V16G	O
.	O

This	O
experimental	O
model	O
may	O
be	O
used	O
to	O
assess	O
the	O
role	O
of	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
in	O
viral	O
persistence	O
in	O
vivo	O
.	O

TITLE	O
:	O
Association	O
between	O
mannose	B-PRGE
-	I-PRGE
binding	I-PRGE
lectin	I-PRGE
gene	I-PRGE
polymorphism	O
and	O
pediatric	O
cytomegalovirus	O
infection	O
.	O

Thus	O
we	O
can	O
speculate	O
that	O
as	O
an	O
acute	O
response	O
protein	O
and	O
a	O
pattern	O
-	O
recognition	O
molecule	O
of	O
the	O
innate	O
immune	O
system	O
,	O
MBL	B-PRGE
may	O
play	O
a	O
role	O
in	O
protecting	O
against	O
HCMV	O
infection	O
in	O
children	O
,	O
and	O
MBL	B-PRGE
gene	I-PRGE
mutations	O
may	O
be	O
a	O
significant	O
risk	O
factor	O
for	O
the	O
development	O
of	O
infantile	O
HCMV	O
infection	O
.	O

The	O
M	B-PRGE
carboxy	I-PRGE
-	I-PRGE
terminal	I-PRGE
endodomain	I-PRGE
contains	O
a	O
conserved	O
domain	O
(	O
CD	O
)	O
following	O
the	O
third	O
transmembrane	O
(	O
TM	O
)	O
domain	O
.	O

Alanine	O
substitutions	O
for	O
the	O
first	O
four	O
or	O
the	O
last	O
four	O
residues	O
resulted	O
in	O
viruses	O
with	O
significantly	O
crippled	O
phenotypes	O
and	O
proteins	O
that	O
failed	O
to	O
assemble	O
VLPs	O
or	O
to	O
be	O
rescued	O
into	O
the	O
envelope	B-PRGE
.	O

N	B-PRGE
protein	I-PRGE
coexpression	O
with	O
some	O
M	O
mutants	O
increased	O
VLP	O
production	O
.	O

the	O
internal	O
control	O
,	O
ND5	B-PRGE
mRNA	I-PRGE
,	O
was	O
detected	O
successfully	O
in	O
all	O
reactions	O
.	O

The	O
current	O
study	O
examined	O
involvement	O
of	O
the	O
Rac	B-PRGE
effector	I-PRGE
p21	I-PRGE
-	I-PRGE
activated	I-PRGE
kinase	I-PRGE
(	O
PAK1	B-PRGE
)	O
in	O
ANP	B-PRGE
-	O
protective	O
effects	O
in	O
the	O
model	O
of	O
lung	O
vascular	O
permeability	O
induced	O
by	O
bacterial	O
wall	O
LPS	O
.	O

This	O
study	O
shows	O
that	O
the	O
protective	O
effects	O
of	O
ANP	O
against	O
LPS	O
-	O
induced	O
vascular	O
leak	O
are	O
mediated	O
at	O
least	O
in	O
part	O
by	O
PAK1	B-PRGE
-	O
dependent	O
signaling	O
leading	O
to	O
EC	O
barrier	O
enhancement	O
.	O

The	O
results	O
of	O
molecular	O
modeling	O
and	O
docking	O
within	O
the	O
RT	B-PRGE
non	I-PRGE
-	I-PRGE
nucleoside	I-PRGE
binding	I-PRGE
site	I-PRGE
using	O
AutoDock	O
confirmed	O
that	O
the	O
3	O
series	O
,	O
similar	O
to	O
other	O
non	B-PRGE
-	I-PRGE
nucleoside	I-PRGE
reverse	I-PRGE
transcriptase	I-PRGE
inhibitors	O
such	O
as	O
N	O
-(	O
5	O
-	O
chloro	O
-	O
2	O
-	O
pyridinyl	O
)-	O
N	O
'-[	O
2	O
-(	O
4	O
-	O
ethoxy	O
-	O
3	O
-	O
fluoro	O
-	O
2	O
-	O
pyridinyl	O
)	O
ethyl	O
]-	O
thiourea	O
(	O
PETT	O
),	O
was	O
assumed	O
in	O
a	O
butterfly	O
-	O
like	O
conformation	O
and	O
helped	O
to	O
rationalize	O
some	O
SARs	B-PRGE
and	O
the	O
biological	O
activity	O
data	O
.	O

The	O
detection	O
limit	O
of	O
the	O
RT	B-PRGE
-	I-PRGE
LAMP	I-PRGE
assay	O
was	O
approximately	O
10	O
(	O
2	O
)	O

TITLE	O
:	O
Autophagy	O
-	O
independent	O
LC3	B-PRGE
function	O
in	O
vesicular	O
traffic	O
.	O

The	O
antioxidant	O
property	O
was	O
assayed	O
for	O
specific	O
activities	O
including	O
2	O
,	O
2	O
-	O
diphenyl	O
-	O
1	O
-	O
picrylhydrazyl	O
(	O
DPPH	O
)	O
hydroxy	O
radical	O
scavenging	O
activity	O
,	O
reducing	O
power	O
capacity	O
,	O
and	O
superoxide	B-PRGE
dismutase	I-PRGE
(	O
SOD	B-PRGE
)	O
like	O
activity	O
.	O

CONCLUSIONS	O
:	O
CPAP	B-PRGE
was	O
increasingly	O
utilised	O
as	O
an	O
alternative	O
to	O
ETT	O
ventilation	O
for	O
the	O
management	O
of	O
most	O
cases	O
of	O
less	O
severe	O
acute	O
respiratory	O
distress	O
in	O
near	O
-	O
term	O
neonates	O
on	O
retrieval	O
.	O

However	O
,	O
the	O
replication	O
kinetics	O
of	O
MK	O
and	O
MK	B-PRGE
-	I-PRGE
p10	I-PRGE
did	O
not	O
differ	O
from	O
each	O
other	O
in	O
the	O
brain	O
and	O
in	O
cultured	O
cells	O
.	O

This	O
,	O
together	O
with	O
previous	O
reports	O
of	O
a	O
strong	O
humoral	O
response	O
against	O
the	O
M	B-PRGE
protein	I-PRGE
,	O
may	O
help	O
to	O
further	O
explain	O
the	O
immunogenicity	O
of	O
SARS	O
and	O
serves	O
as	O
potential	O
targets	O
for	O
SARS	O
-	O
CoV	O
vaccine	O
design	O
.	O

However	O
,	O
there	O
is	O
still	O
significant	O
mortality	O
associated	O
with	O
antineutrophil	B-PRGE
cytoplasmic	I-PRGE
antibody	I-PRGE
-	O
associated	O
vasculitis	O
.	O

Factors	O
contributing	O
to	O
the	O
continual	O
emergence	O
include	O
mutations	O
,	O
insertions	O
and	O
deletions	O
in	O
the	O
S1	B-PRGE
protein	I-PRGE
genes	I-PRGE
;	O
recombination	O
between	O
local	O
IBV	O
strains	O
circulating	O
in	O
chicken	O
flocks	O
in	O
China	O
;	O
and	O
recombination	O
between	O
local	O
strains	O
and	O
vaccine	O
strains	O
.	O

Moreover	O
,	O
the	O
fusion	O
of	O
the	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
markedly	O
increased	O
spleen	O
cell	O
proliferation	O
and	O
IFN	B-PRGE
-	I-PRGE
γ	I-PRGE
production	O
while	O
mild	O
increased	O
in	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
production	O
,	O
which	O
demonstrated	O
the	O
enhancement	O
of	O
cell	O
-	O
mediated	O
immune	O
responses	O
.	O

Compared	O
with	O
SO	O
group	O
,	O
the	O
levels	O
of	O
arterial	O
partial	O
pressure	O
of	O
oxygen	O
(	O
PaO	O
(	O
2	O
))	O
and	O
pH	O
value	O
in	O
model	O
group	O
were	O
significantly	O
decreased	O
[	O
PaO	O
(	O
2	O
)	O
(	O
mm	O
Hg	O
,	O
1	O
mm	O
Hg	O
=	O
0	O
.	O
133	O
kPa	O
):	O
79	O
.	O
24	O
±	O
5	O
.	O
84	O
vs	O
.	O
96	O
.	O
78	O
±	O
3	O
.	O
81	O
,	O
pH	O
value	O
:	O
7	O
.	O
269	O
±	O
0	O
.	O
054	O
vs	O
.	O
7	O
.	O
391	O
±	O
0	O
.	O
054	O
],	O
arterial	O
partial	O
pressure	O
of	O
carbon	O
dioxide	O
(	O
PaCO	O
(	O
2	O
)),	O
the	O
serum	O
levels	O
of	O
AMY	O
,	O
W	O
/	O
D	O
ratio	O
and	O
the	O
serum	O
levels	O
of	O
sPLA	B-PRGE
(	I-PRGE
2	I-PRGE
)	I-PRGE
were	O
significantly	O
increased	O
[	O
PaCO	O
(	O
2	O
)	O
(	O
mm	O
Hg	O
):	O
47	O
.	O
57	O
±	O
2	O
.	O
55	O
vs	O
.	O
27	O
.	O
69	O
±	O
1	O
.	O
02	O
,	O
AMY	O
(	O
U	O
/	O
L	O
):	O
7	O
144	O
.	O
19	O
±	O
727	O
.	O
91	O
vs	O
.	O
1	O
193	O
.	O
41	O
±	O
192	O
.	O
54	O
,	O
W	O
/	O
D	O
ratio	O
:	O
8	O
.	O
57	O
±	O
2	O
.	O
45	O
vs	O
.	O
3	O
.	O
70	O
±	O
0	O
.	O
90	O
,	O
sPLA	O
(	O
2	O
)	O
(	O
nmol	O
×	O
min	O
(-	O
1	O
)	O
×	O
ml	O
(-	O
1	O
)):	O
45	O
.	O
13	O
±	O
6	O
.	O
05	O
vs	O
.	O
29	O
.	O
94	O
±	O
6	O
.	O
39	O
],	O
the	O
expression	O
of	O
sPLA	B-PRGE
(	I-PRGE
2	I-PRGE
)-	I-PRGE
II	I-PRGE
mRNA	I-PRGE
(	O
1	O
.	O
28	O
±	O
0	O
.	O
21	O
vs	O
.	O
0	O
.	O
80	O
±	O
0	O
.	O
08	O
)	O
and	O
protein	O
were	O
significantly	O
increased	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

CONCLUSIONS	O
:	O
The	O
higher	O
expression	O
of	O
sPLA	B-PRGE
(	I-PRGE
2	I-PRGE
)-	I-PRGE
IIin	I-PRGE
lung	O
may	O
be	O
one	O
of	O
pathogenetic	O
factors	O
in	O
ALI	O
induced	O
by	O
SAP	B-PRGE
.	O

PALS1	B-PRGE
,	O
a	O
tight	O
junction	O
-	O
associated	O
protein	O
,	O
is	O
a	O
member	O
of	O
the	O
CRUMBS3	B-PRGE
-	O
PALS1	B-PRGE
-	O
PATJ	B-PRGE
polarity	O
complex	O
,	O
which	O
is	O
crucial	O
for	O
the	O
establishment	O
and	O
maintenance	O
of	O
epithelial	O
polarity	O
in	O
mammals	O
.	O

We	O
speculate	O
that	O
hijacking	O
of	O
PALS1	B-PRGE
by	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
E	I-PRGE
plays	O
a	O
determinant	O
role	O
in	O
the	O
disruption	O
of	O
the	O
lung	O
epithelium	O
in	O
SARS	O
patients	O
.	O

This	O
time	O
-	O
consuming	O
procedure	O
is	O
unacceptable	O
,	O
especially	O
when	O
highly	O
fatal	O
and	O
infectious	O
virus	O
arises	O
such	O
as	O
SARS	B-PRGE
and	O
H1N1	O
,	O
which	O
forces	O
the	O
scoring	O
task	O
to	O
be	O
done	O
in	O
a	O
limited	O
time	O
.	O

In	O
mice	O
infected	O
with	O
gliatropic	O
demyelinating	O
coronavirus	O
,	O
B7	B-PRGE
-	I-PRGE
H1	I-PRGE
expression	O
on	O
oligodendroglia	O
delays	O
virus	O
control	O
,	O
but	O
also	O
dampens	O
clinical	O
disease	O
.	O

Increased	O
effector	O
function	O
at	O
the	O
single	O
-	O
cell	O
level	O
was	O
also	O
evident	O
by	O
elevated	O
granzyme	B-PRGE
B	I-PRGE
expression	O
specifically	O
in	O
virus	O
-	O
specific	O
CNS	O
CD8	O
T	O
cells	O
.	O

NOS2	B-PRGE
of	O
HS	O
and	O
2LR	O
wild	O
groups	O
at	O
2	O
and	O
6	O
h	O
in	O
spleen	O
increased	O
compared	O
with	O
the	O
control	O
group	O
.	O

Reconstruction	O
of	O
one	O
variant	B-PRGE
M	I-PRGE
gene	I-PRGE
in	O
a	O
ΔE	O
background	O
showed	O
that	O
expression	O
of	O
the	O
M	B-PRGE
*	I-PRGE
protein	I-PRGE
markedly	O
enhanced	O
the	O
growth	O
of	O
the	O
ΔE	O
mutant	O
and	O
that	O
the	O
M	O
*	O
protein	O
was	O
incorporated	O
into	O
assembled	O
virions	O
.	O

TITLE	O
:	O
Biflavonoids	O
from	O
Torreya	O
nucifera	O
displaying	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
inhibition	O
.	O

Following	O
bioactivity	O
-	O
guided	O
fractionation	O
,	O
eight	O
diterpenoids	O
(	O
1	O
-	O
8	O
)	O
and	O
four	O
biflavonoids	O
(	O
9	O
-	O
12	O
)	O
were	O
isolated	O
and	O
evaluated	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
inhibition	O
using	O
fluorescence	O
resonance	O
energy	O
transfer	O
analysis	O
.	O

The	O
proportions	O
of	O
subjects	O
with	O
IgA	B-PRGE
antibodies	I-PRGE
in	O
nasal	O
wash	O
specimens	O
and	O
the	O
geometric	O
mean	O
IgA	B-PRGE
antibody	I-PRGE
titers	O
were	O
statistically	O
higher	O
for	O
HCoV	O
-	O
OC43	O
and	O
-	O
HKU1	O
than	O
for	O
HCoV	O
-	O
229E	O
and	O
-	O
NL63	O
.	O

Interestingly	O
,	O
these	O
nucleotide	O
substitutions	O
are	O
all	O
located	O
at	O
the	O
5	O
'	O
half	O
of	O
the	O
M	B-PRGE
gene	I-PRGE
.	O

The	O
effects	O
of	O
these	O
two	O
siRNAs	O
were	O
tested	O
by	O
semi	O
-	O
quantitative	O
RT	B-PRGE
-	I-PRGE
PCR	I-PRGE
and	O
EGFP	O
-	O
M	O
fusion	O
gene	O
expression	O
.	O

TITLE	O
:	O
Establishment	O
of	O
the	O
eukaryotic	O
cell	O
lines	O
for	O
inducible	O
control	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
nucleocapsid	I-PRGE
gene	I-PRGE
expression	O
.	O

A	O
set	O
of	O
double	O
-	O
stable	O
eukaryotic	O
cell	O
lines	O
(	O
BHK	O
-	O
Tet	O
-	O
SARS	O
-	O
N	O
)	O
with	O
inducible	O
control	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
neucleocapsid	I-PRGE
gene	I-PRGE
expression	O
was	O
identified	O
by	O
using	O
SDS	O
-	O
PAGE	O
and	O
Western	O
-	O
blot	O
analysis	O
.	O

ABSTRACT	O
:	O
Our	O
study	O
investigated	O
the	O
host	O
cell	O
protein	O
which	O
can	O
interact	O
with	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
protein	I-PRGE
,	O
and	O
explored	O
the	O
functional	O
connections	O
.	O

The	O
3	O
cases	O
of	O
Inf	B-PRGE
A	I-PRGE
in	O
kidney	O
transplant	O
recipients	O
recorded	O
in	O
the	O
province	O
of	O
Almeria	O
occurred	O
in	O
young	O
women	O
shortly	O
after	O
kidney	O
transplantation	O
,	O
and	O
with	O
no	O
other	O
risk	O
factors	O
apart	O
from	O
those	O
associated	O
with	O
the	O
transplantation	O
itself	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
efficiently	O
inhibit	O
interferon	B-PRGE
(	O
IFN	B-PRGE
)	O
induction	O
in	O
nonhematopoietic	O
cells	O
and	O
conventional	O
dendritic	O
cells	O
(	O
cDC	O
).	O

Exogenous	O
IFN	B-PRGE
enhanced	O
IFN	B-PRGE
-	O
dependent	O
gene	O
expression	O
in	O
BMM	O
at	O
early	O
times	O
after	O
infection	O
and	O
in	O
BMDC	O
at	O
all	O
times	O
after	O
infection	O
but	O
did	O
not	O
stimulate	O
expression	O
of	O
molecules	O
that	O
signal	O
through	O
myeloid	O
differentiation	O
factor	O
88	O
(	O
MyD88	O
),	O
such	O
as	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
(	O
TNF	B-PRGE
).	O

Further	O
,	O
our	O
results	O
also	O
show	O
that	O
BMM	O
are	O
generally	O
more	O
responsive	O
to	O
MHV	O
infection	O
,	O
since	O
MyD88	B-PRGE
-	O
dependent	O
pathways	O
are	O
also	O
activated	O
to	O
a	O
greater	O
extent	O
in	O
these	O
cells	O
than	O
in	O
BMDC	O
.	O

(	O
iii	O
)	O
Over	O
40	O
%	O
were	O
similarly	O
regulated	O
in	O
vitro	O
in	O
response	O
to	O
both	O
influenza	O
virus	O
infection	O
and	O
interferon	B-PRGE
treatment	O
.	O

ABSTRACT	O
:	O
Infection	O
of	O
mouse	O
oligodendrocytes	O
with	O
a	O
recombinant	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
expressing	O
a	O
green	B-PRGE
fluorescence	I-PRGE
protein	I-PRGE
facilitated	O
specific	O
selection	O
of	O
virus	O
-	O
infected	O
cells	O
and	O
subsequent	O
establishment	O
of	O
persistence	O
.	O

The	O
entire	O
VP1	B-PRGE
coding	I-PRGE
gene	I-PRGE
of	O
58	O
EV	O
-	O
71	O
strains	O
was	O
sequenced	O
and	O
phylogenetic	O
analyses	O
were	O
performed	O
to	O
assign	O
strains	O
to	O
genogroups	O
/	O
subgenogroups	O
and	O
to	O
compare	O
French	O
isolates	O
to	O
European	O
and	O
worldwide	O
isolates	O
.	O

The	O
Kaplan	O
-	O
Meier	O
probability	O
of	O
survival	O
at	O
1	O
-	O
year	O
follow	O
-	O
up	O
was	O
71	O
.	O
0	O
%,	O
at	O
2	O
-	O
year	O
follow	O
-	O
up	O
was	O
48	O
.	O
3	O
%,	O
and	O
3	O
-	O
year	O
follow	O
-	O
up	O
was	O
39	O
.	O
4	O
%	O
with	O
troponin	B-PRGE
T	I-PRGE
≥	O
0	O
.	O
01	O
ng	O
/	O
mL	O
and	O
at	O
1	O
-	O
year	O
follow	O
-	O
up	O
was	O
98	O
.	O
8	O
%,	O
at	O
2	O
-	O
year	O
follow	O
-	O
up	O
was	O
97	O
.	O
2	O
%,	O
and	O
at	O
3	O
-	O
year	O
follow	O
-	O
up	O
was	O
95	O
.	O
5	O
%	O
with	O
troponin	B-PRGE
T	I-PRGE
<	O
0	O
.	O
01	O
μg	O
/	O
L	O
(	O
P	O
<.	O
0001	O
).	O

RESULTS	O
:	O
Of	O
the	O
study	O
patients	O
,	O
878	O
(	O
42	O
.	O
3	O
%)	O
had	O
elevated	O
cTnT	O
and	O
1200	O
patients	O
(	O
57	O
.	O
7	O
%)	O
had	O
undetectable	O
cTnT	O
.	O
During	O
hospitalization	O
,	O
1	O
.	O
1	O
%	O
of	O
the	O
patients	O
with	O
troponin	O
T	O
<	O
0	O
.	O
01	O
ng	O
/	O
mL	O
died	O
compared	O
to	O
21	O
%	O
of	O
those	O
with	O
troponin	B-PRGE
T	I-PRGE
≥	O
0	O
.	O
01	O
ng	O
/	O
mL	O
(	O
P	O
<.	O
0001	O
).	O

Here	O
we	O
determine	O
the	O
impact	O
of	O
ectopic	O
expression	O
of	O
ISG20	B-PRGE
on	O
replication	O
of	O
several	O
positive	O
-	O
strand	O
RNA	O
viruses	O
from	O
distinct	O
viral	O
families	O
.	O

We	O
found	O
that	O
the	O
RBD	O
of	O
S	B-PRGE
protein	I-PRGE
induced	O
potent	O
antibody	O
responses	O
in	O
the	O
recovered	O
SARS	O
patients	O
and	O
RBD	O
-	O
specific	O
antibodies	O
could	O
persist	O
at	O
high	O
titers	O
over	O
three	O
year	O
follow	O
-	O
up	O
.	O

The	O
E	B-PRGE
protein	I-PRGE
is	O
made	O
in	O
excess	O
during	O
infection	O
and	O
has	O
been	O
shown	O
to	O
have	O
ion	O
channel	O
activity	O
in	O
planar	O
lipid	O
bilayers	O
.	O

Thus	O
,	O
Avian	B-PRGE
CoV	I-PRGE
can	O
be	O
efficiently	O
disseminated	O
over	O
large	O
distances	O
and	O
could	O
be	O
a	O
genetic	O
reservoir	O
for	O
future	O
emerging	O
pathogenic	O
CoVs	O
.	O

A	O
positive	O
correlation	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
8	I-PRGE
and	I-PRGE
IL	I-PRGE
-	I-PRGE
15	I-PRGE
levels	O
with	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
and	O
with	O
>	O
5	O
-	O
day	O
interval	O
between	O
symptom	O
onset	O
and	O
admission	O
,	O
and	O
a	O
negative	O
correlation	O
with	O
the	O
PaO	O
(	O
2	O
):	O
FiO	O
(	O
2	O
)	O
ratio	O
,	O
were	O
found	O
in	O
nvA	O
(	O
H1N1	O
)	O
groups	O
.	O

ABSTRACT	O
:	O
Long	O
pentraxin	O
PTX3	B-PRGE
is	O
an	O
inflammatory	O
mediator	O
and	O
a	O
component	O
of	O
the	O
humoral	O
arm	O
of	O
innate	O
immunity	O
.	O

PTX3	B-PRGE
expression	O
is	O
increased	O
in	O
animals	O
with	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
in	O
patients	O
with	O
sepsis	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
is	O
considered	O
to	O
be	O
a	O
potential	O
biomarker	O
for	O
these	O
diseases	O
.	O

However	O
,	O
the	O
role	O
of	O
PTX3	B-PRGE
in	O
the	O
pathogenesis	O
of	O
ALI	O
is	O
not	O
fully	O
understood	O
.	O

PTX3	B-PRGE
deficiency	O
also	O
enhanced	O
LPS	O
-	O
induced	O
tissue	O
factor	O
expression	O
/	O
activation	O
in	O
the	O
lung	O
and	O
increased	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
and	O
monocyte	B-PRGE
chemoattractant	I-PRGE
protein	I-PRGE
-	I-PRGE
1	I-PRGE
levels	O
in	O
the	O
plasma	O
.	O

RESULTS	O
:	O
LPS	O
instillation	O
induced	O
ALI	O
in	O
both	O
PTX3	B-PRGE
-	I-PRGE
KO	I-PRGE
and	O
WT	O
mice	O
.	O

JHM	O
.	O
SD	O
spreads	O
more	O
quickly	O
among	O
neurons	O
than	O
less	O
neurovirulent	O
MHVs	O
,	O
and	O
is	O
able	O
to	O
spread	O
in	O
the	O
absence	O
of	O
the	O
canonical	O
MHV	B-PRGE
receptor	I-PRGE
,	O
CEACAM1a	O
.	O

In	O
addition	O
,	O
JHM	O
.	O
SD	O
induces	O
only	O
a	O
minimal	O
T	O
-	O
cell	O
response	O
,	O
whereas	O
the	O
strong	O
T	O
-	O
cell	O
response	O
and	O
the	O
concomitant	O
interferon	B-PRGE
-	I-PRGE
γ	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
γ	I-PRGE
)	O
induced	O
by	O
the	O
less	O
neurovirulent	O
A59	O
is	O
protective	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
identification	O
of	O
Th1	B-PRGE
epitopes	I-PRGE
in	O
the	O
S2	O
domain	O
of	O
FIPV	O
has	O
important	O
implications	O
in	O
the	O
cat	O
.	O

Herein	O
we	O
describe	O
the	O
use	O
of	O
an	O
adenovirus	O
vectored	O
mouse	O
IFN	B-PRGE
alpha	I-PRGE
gene	I-PRGE
(	O
mDEF201	O
)	O
as	O
a	O
prophylactic	O
and	O
treatment	O
countermeasure	O
in	O
a	O
SARS	O
-	O
CoV	O
-	O
infected	O
BALB	O
/	O
c	O
mouse	O
model	O
.	O

BALB	O
/	O
c	O
and	O
STAT1	B-PRGE
-	O
deficient	O
mice	O
were	O
inoculated	O
with	O
the	O
recombinant	O
viral	O
vector	O
rTGEV	O
(	O
S	O
-	O
MHV	O
)-	O
VP7	O
,	O
which	O
replicates	O
in	O
the	O
intestine	O
and	O
spreads	O
to	O
other	O
organs	O
such	O
as	O
liver	O
,	O
spleen	O
and	O
lungs	O
.	O

Compared	O
with	O
the	O
control	O
group	O
,	O
the	O
model	O
group	O
showed	O
a	O
significantly	O
higher	O
ratio	O
of	O
IFN	B-PRGE
-	I-PRGE
γ	I-PRGE
/	I-PRGE
IL	I-PRGE
-	I-PRGE
4	I-PRGE
.	O

TITLE	O
:	O
Caveolin	B-PRGE
-	I-PRGE
1	I-PRGE
:	O
a	O
critical	O
regulator	O
of	O
lung	O
injury	O
.	O

Two	O
CCoV	O
strains	O
were	O
characterized	O
as	O
CCoV	O
-	O
II	O
and	O
one	O
as	O
CCoV	O
-	O
I	O
.	O
In	O
the	O
case	O
of	O
one	O
sample	O
,	O
PH4	O
/	O
09	O
/	O
Ire	B-PRGE
,	O
a	O
mixed	O
infection	O
with	O
CPV	O
and	O
CCoV	O
was	O
detected	O
.	O

In	O
contrast	O
,	O
the	O
activity	O
of	O
NEP	B-PRGE
in	O
the	O
BALF	O
of	O
LPS	O
-	O
treated	O
mice	O
was	O
increased	O
.	O

Diagnosis	O
of	O
IMAM	O
was	O
based	O
on	O
the	O
infiltration	O
of	O
CD68	B-PRGE
+	I-PRGE
macrophages	O
into	O
biopsied	O
specimens	O
,	O
particularly	O
the	O
fascia	O
.	O

Patients	O
with	O
clinical	O
features	O
of	O
Leptospirosis	O
and	O
who	O
tested	O
positive	O
for	O
IgM	B-PRGE
Leptospirosis	O
were	O
taken	O
as	O
IgM	B-PRGE
lepto	O
can	O
be	O
falsely	O
positive	O
.	O

Her	O
troponin	B-PRGE
I	I-PRGE
level	O
was	O
elevated	O
,	O
while	O
cardiac	O
catheterization	O
revealed	O
no	O
significant	O
coronary	O
artery	O
disease	O
.	O

Analysis	O
of	O
several	O
types	O
of	O
virus	O
-	O
like	O
particles	O
and	O
virions	O
revealed	O
that	O
S	B-PRGE
protein	I-PRGE
,	O
N	B-PRGE
protein	I-PRGE
and	O
genomic	O
RNA	O
each	O
help	O
to	O
regulate	O
virion	O
size	O
and	O
variation	O
,	O
presumably	O
through	O
interactions	O
with	O
M	O
.	O
These	O
findings	O
provide	O
insight	O
into	O
how	O
M	B-PRGE
protein	I-PRGE
functions	O
to	O
promote	O
virus	O
assembly	O
.	O

The	O
S259	O
/	O
L	O
mutation	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
helicase	I-PRGE
is	O
always	O
found	O
in	O
all	O
the	O
identified	O
bananin	O
-	O
resistant	O
variants	O
,	O
suggesting	O
a	O
primary	O
role	O
of	O
this	O
mutation	O
site	O
for	O
bananin	O
activity	O
.	O

It	O
is	O
comprised	O
of	O
ten	B-PRGE
sentinel	I-PRGE
sites	I-PRGE
which	O
send	O
weekly	O
notifications	O
of	O
acute	O
respiratory	O
illness	O
(	O
ARI	O
)	O
and	O
severe	O
acute	O
respiratory	O
illness	O
(	O
SARI	O
)	O
to	O
the	O
Office	O
of	O
the	O
National	O
Epidemiologist	O
.	O

A	O
synthetic	O
cholera	B-PRGE
toxin	I-PRGE
B	I-PRGE
subunit	I-PRGE
gene	I-PRGE
(	O
CTB	B-PRGE
)	O
was	O
fused	O
with	O
a	O
synthetic	O
neutralizing	O
epitope	O
gene	O
of	O
the	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
sCTB	O
-	O
sCOE	O
),	O
and	O
the	O
sCTB	O
-	O
sCOE	O
fusion	O
gene	O
was	O
introduced	O
into	O
a	O
plant	O
expression	O
vector	O
under	O
the	O
control	O
of	O
the	O
ubiquitin	B-PRGE
promoter	I-PRGE
.	O

Immunochemical	O
staining	O
with	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
against	O
N	B-PRGE
protein	I-PRGE
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
was	O
used	O
to	O
determine	O
the	O
stomach	O
and	O
enteric	O
tissues	O
among	O
5	O
SARS	O
patients	O
with	O
their	O
nucleocapsid	O
antibody	O
titer	O
ascended	O
obviously	O
after	O
1	O
(	O
st	O
)-	O
7	O
(	O
th	O
)	O
year	O
.	O

The	O
other	O
two	O
cases	O
showed	O
negative	O
on	O
both	O
serum	B-PRGE
N	I-PRGE
protein	I-PRGE
antibody	I-PRGE
and	O
immunohistochemical	O
expression	O
.	O

CONCLUSIONS	O
:	O
Human	B-PRGE
CoV	I-PRGE
-	I-PRGE
HKU1	I-PRGE
infection	O
exists	O
in	O
children	O
with	O
respiratory	O
tract	O
infections	O
in	O
Lanzhou	O
region	O
.	O

TITLE	O
:	O
Molecular	O
study	O
of	O
porcine	O
transmissible	O
gastroenteritis	O
virus	O
after	O
serial	O
animal	O
passages	O
revealed	O
point	O
mutations	O
in	O
S	B-PRGE
protein	I-PRGE
.	O

ABSTRACT	O
:	O
Although	O
enveloped	O
viruses	O
typically	O
trigger	O
the	O
prodigious	O
secretion	O
of	O
alpha	B-PRGE
interferon	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
α	I-PRGE
)	O
by	O
plasmacytoid	O
dendritic	O
cells	O
(	O
pDC	O
),	O
porcine	O
pDC	O
remain	O
quiescent	O
when	O
exposed	O
to	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
).	O

This	O
inactivity	O
is	O
likely	O
due	O
to	O
virus	O
-	O
mediated	O
interference	O
since	O
the	O
typical	O
IFN	B-PRGE
-	I-PRGE
α	I-PRGE
response	O
by	O
either	O
purified	O
or	O
nonsorted	O
porcine	O
pDC	O
to	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
or	O
the	O
Toll	B-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
9	I-PRGE
agonist	O
,	O
oligodeoxynucleotide	O
(	O
ODN	O
)	O
D19	O
,	O
was	O
markedly	O
reduced	O
in	O
the	O
presence	O
of	O
PRRSV	O
.	O

Similarly	O
,	O
CD4	B-PRGE
T	I-PRGE
cell	O
-	O
secreted	O
interleukin	B-PRGE
-	I-PRGE
21	I-PRGE
,	O
a	O
critical	O
regulator	O
of	O
both	O
peripheral	O
activated	O
B	O
cells	O
and	O
CD8	B-PRGE
T	I-PRGE
cells	O
,	O
was	O
sustained	O
during	O
viral	O
persistence	O
.	O

TITLE	O
:	O
Structures	O
of	O
the	O
N	O
-	O
and	O
C	O
-	O
terminal	O
domains	O
of	O
MHV	B-PRGE
-	I-PRGE
A59	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
corroborate	O
a	O
conserved	O
RNA	O
-	O
protein	O
binding	O
mechanism	O
in	O
coronavirus	O
.	O

The	O
structure	O
of	O
N	O
-	O
terminal	O
domain	O
of	O
MHV	B-PRGE
N	I-PRGE
protein	I-PRGE
also	O
implicated	O
its	O
specific	O
affinity	O
with	O
transcriptional	O
regulatory	O
sequence	O
(	O
TRS	O
)	O
RNA	O
.	O

The	O
main	O
protease	O
(	O
M	O
(	O
pro	O
))	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
is	O
an	O
attractive	O
target	O
for	O
anti	O
-	O
SARS	O
drug	O
development	O
as	O
it	O
is	O
essential	O
for	O
the	O
polyprotein	O
processing	O
.	O

HMGB1	B-PRGE
was	O
a	O
sole	O
independent	O
correlate	O
of	O
sRAGE	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
demonstrate	O
that	O
the	O
N	B-PRGE
gene	I-PRGE
does	O
not	O
carry	O
mutations	O
associated	O
with	O
the	O
pathotypical	O
switch	O
FECV	O
-->	O
FIPV	O
.	O

The	O
number	O
of	O
CD4	B-PRGE
(+)	O
and	O
CD8	B-PRGE
(+)	O
T	O
-	O
lymphocytes	O
in	O
the	O
peripheral	O
blood	O
increased	O
rapidly	O
in	O
the	O
vaccinated	O
groups	O
challenged	O
with	O
strains	O
LX4	O
,	O
LHB	B-PRGE
and	O
LHLJ04XI	O
.	O

The	O
packed	O
cell	O
volume	O
,	O
bilirubin	O
,	O
AST	B-PRGE
,	O
potassium	O
,	O
and	O
sodium	O
levels	O
were	O
established	O
to	O
predict	O
disease	O
staging	O
and	O
survival	O
time	O
.	O

We	O
demonstrate	O
that	O
human	O
and	O
mouse	B-PRGE
coronavirus	I-PRGE
mutants	I-PRGE
lacking	I-PRGE
2	I-PRGE
'-	I-PRGE
O	I-PRGE
-	I-PRGE
methyltransferase	I-PRGE
activity	O
induced	O
higher	O
expression	O
of	O
type	B-PRGE
I	I-PRGE
interferon	I-PRGE
and	O
were	O
highly	O
sensitive	O
to	O
type	B-PRGE
I	I-PRGE
interferon	I-PRGE
.	O

Notably	O
,	O
the	O
induction	O
of	O
type	B-PRGE
I	I-PRGE
interferon	I-PRGE
by	O
viruses	O
deficient	O
in	O
2	B-PRGE
'-	I-PRGE
O	I-PRGE
-	I-PRGE
methyltransferase	I-PRGE
was	O
dependent	O
on	O
the	O
cytoplasmic	O
RNA	O
sensor	O
Mda5	B-PRGE
.	O

The	O
most	O
N	O
-	O
terminal	O
portion	O
of	O
the	O
S1	O
region	O
,	O
which	O
comprises	O
antigenic	O
sites	O
C	O
and	O
B	O
,	O
is	O
needed	O
for	O
the	O
enteric	O
tropism	O
of	O
TGEV	O
,	O
whereas	O
the	O
major	O
antigenic	O
site	O
A	O
at	O
the	O
C	O
-	O
terminal	O
moiety	O
is	O
required	O
for	O
both	O
respiratory	O
and	O
enteric	O
cell	O
tropism	O
,	O
and	O
is	O
engaged	O
in	O
recognition	O
of	O
the	O
aminopeptidase	B-PRGE
N	I-PRGE
(	O
APN	O
)	O
receptor	O
.	O

Papain	O
treatment	O
identified	O
an	O
N	O
-	O
terminal	O
domain	O
(	O
D1	O
)	O
resistant	O
to	O
proteolysis	O
,	O
whereas	O
receptor	O
binding	O
defined	O
a	O
soluble	O
and	O
functional	O
APN	B-PRGE
receptor	I-PRGE
-	I-PRGE
binding	I-PRGE
domain	I-PRGE
(	O
D3	O
).	O

They	O
further	O
show	O
that	O
IFITM	O
proteins	O
differentially	O
restrict	O
the	O
entry	O
of	O
a	O
broad	O
range	O
of	O
enveloped	O
viruses	O
,	O
and	O
modulate	O
cellular	O
tropism	O
independently	O
of	O
viral	B-PRGE
receptor	I-PRGE
expression	O
.	O

However	O
,	O
the	O
isolates	O
formed	O
a	O
new	O
gene	O
cluster	O
that	O
was	O
distinguished	O
from	O
the	O
two	O
distinct	O
K	O
-	O
II	O
subgroups	O
(	O
KM91	O
-	O
like	O
and	O
QX	B-PRGE
-	I-PRGE
like	I-PRGE
).	O

In	O
addition	O
,	O
two	O
crossover	O
sites	O
were	O
observed	O
in	O
the	O
S1	B-PRGE
gene	I-PRGE
of	O
IBV	O
isolates	O
.	O

In	O
conclusion	O
,	O
simultaneous	O
blockade	O
of	O
inducible	O
and	O
neuronal	B-PRGE
NO	I-PRGE
synthase	I-PRGE
exerts	O
beneficial	O
pulmonary	O
effects	O
in	O
an	O
ovine	O
model	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
secondary	O
to	O
combined	O
burn	O
and	O
smoke	O
inhalation	O
injury	O
.	O

Importantly	O
,	O
PD098059	O
(	O
an	O
ERK1	B-PRGE
/	I-PRGE
2	I-PRGE
inhibitor	O
)	O
treatment	O
significantly	O
reduced	O
IFN	B-PRGE
-	I-PRGE
α	I-PRGE
-	O
induced	O
ERK1	B-PRGE
and	O
STAT1	B-PRGE
phosphorylation	O
,	O
inhibiting	O
IFN	B-PRGE
-	I-PRGE
α	I-PRGE
-	O
induced	O
expression	O
of	O
2	O
'-	O
5	O
'-	O
OAS	O
in	O
vector	O
control	O
cells	O
and	O
PLpro	O
-	O
expressing	O
cells	O
.	O

The	O
N	B-PRGE
protein	I-PRGE
of	O
HCoV	O
-	O
HKU1	O
was	O
expressed	O
in	O
E	O
.	O
Coli	B-PRGE
,	O
anti	O
-	O
N	O
antibody	O
assay	O
was	O
established	O
using	O
Western	O
Blotting	O
with	O
turn	O
-	O
based	O
membrane	O
.	O

Genetic	O
variations	O
in	O
the	O
gene	O
coding	O
for	O
surfactant	B-PRGE
protein	I-PRGE
B	I-PRGE
are	O
associated	O
with	O
more	O
severe	O
lung	O
injury	O
as	O
indicated	O
by	O
the	O
association	O
of	O
specific	O
single	O
nucleotide	O
polymorphism	O
genotypes	O
and	O
haplotypes	O
with	O
the	O
need	O
for	O
mechanical	O
ventilation	O
in	O
African	O
American	O
children	O
with	O
community	O
-	O
acquired	O
pneumonia	O
.	O

TITLE	O
:	O
The	O
benzodiazepine	O
Midazolam	O
mitigates	O
the	O
breathing	O
defects	O
of	O
Mecp2	B-PRGE
-	O
deficient	O
mice	O
.	O

ABSTRACT	O
:	O
Rett	O
syndrome	O
is	O
a	O
severe	O
neurodevelopmental	O
disease	O
caused	O
by	O
mutations	O
of	O
the	O
transcriptional	O
repressor	O
methyl	B-PRGE
-	I-PRGE
CpG	I-PRGE
-	I-PRGE
binding	I-PRGE
protein	I-PRGE
2	I-PRGE
(	O
MeCP2	B-PRGE
)	O
that	O
induce	O
complex	O
,	O
disabling	O
symptoms	O
,	O
including	O
breathing	O
symptoms	O
.	O

Males	O
of	O
Mecp2	B-PRGE
-	O
deficient	O
mice	O
(	O
Mecp2	O
(-/	O
y	O
))	O
normally	O
breathe	O
at	O
birth	O
but	O
develop	O
first	O
altered	O
breathing	O
regulations	O
,	O
thereafter	O
erratic	O
breathing	O
with	O
severe	O
apnoeas	O
,	O
aggravating	O
until	O
respiratory	O
distress	O
and	O
premature	O
death	O
.	O

TITLE	O
:	O
Highly	O
activated	O
cytotoxic	O
CD8	B-PRGE
T	I-PRGE
cells	O
express	O
protective	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
at	O
the	O
peak	O
of	O
coronavirus	O
-	O
induced	O
encephalitis	O
.	O

FCGR2A	B-PRGE
-	O
H131R	O
polymorphism	O
was	O
determined	O
in	O
1	O
,	O
262	O
patients	O
with	O
CAP	O
and	O
in	O
1	O
,	O
224	O
in	O
the	O
subject	O
control	O
group	O
.	O

TITLE	O
:	O
Identification	O
and	O
characterization	O
of	O
three	O
novel	O
small	O
interference	O
RNAs	O
that	O
effectively	O
down	O
-	O
regulate	O
the	O
isolated	B-PRGE
nucleocapsid	I-PRGE
gene	I-PRGE
expression	O
of	O
SARS	O
coronavirus	O
.	O

From	O
immunofluorescence	O
microscopy	O
,	O
the	O
localization	O
of	O
c	B-PRGE
-	I-PRGE
myc	I-PRGE
tagged	O
3CLpro	O
was	O
detected	O
both	O
in	O
the	O
cytoplasm	O
and	O
nucleus	O
of	O
transfected	O
A549	O
cells	O
.	O

In	O
summary	O
,	O
we	O
show	O
that	O
TMPRSS2	B-PRGE
might	O
promote	O
viral	O
spread	O
and	O
pathogenesis	O
by	O
diminishing	O
viral	O
recognition	O
by	O
neutralizing	O
antibodies	O
and	O
by	O
activating	O
SARS	O
S	O
for	O
cell	O
-	O
cell	O
and	O
virus	O
-	O
cell	O
fusion	O
.	O

Sequences	O
matching	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNAs	I-PRGE
and	O
other	O
pneumonia	O
-	O
related	O
microbes	O
were	O
found	O
.	O

Passage	O
level	O
80	O
was	O
investigated	O
for	O
safety	O
for	O
the	O
reproductive	O
tract	O
in	O
1	O
-	O
day	O
-	O
old	O
and	O
7	O
-	O
day	O
-	O
old	O
SPF	B-PRGE
chickens	I-PRGE
.	O

Then	O
,	O
the	O
difference	O
in	O
epitope	O
which	O
those	O
MAbs	O
recognise	O
was	O
demonstrated	O
by	O
competitive	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
IFN	B-PRGE
-	I-PRGE
γ	I-PRGE
neutralisation	O
tests	O
.	O

ABSTRACT	O
:	O
Green	B-PRGE
fluorescent	I-PRGE
protein	I-PRGE
(	O
GFP	O
)-	O
tagged	O
mouse	O
hepatitis	O
coronavirus	O
nonstructural	B-PRGE
protein	I-PRGE
4	I-PRGE
(	O
nsp4	B-PRGE
)	O
was	O
shown	O
to	O
localize	O
to	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
and	O
to	O
be	O
recruited	O
to	O
the	O
coronavirus	O
replicative	O
structures	O
.	O

However	O
,	O
infections	O
with	O
unrelated	O
pathogens	O
,	O
as	O
may	O
occur	O
in	O
areas	O
endemic	O
to	O
malaria	O
,	O
can	O
dramatically	O
decrease	O
pre	O
-	O
existing	O
memory	O
CD8	B-PRGE
T	I-PRGE
cells	O
.	O

It	O
remains	O
unknown	O
whether	O
unrelated	O
infections	O
will	O
compromise	O
numbers	O
of	O
Plasmodium	O
-	O
specific	O
memory	O
CD8	B-PRGE
T	I-PRGE
cells	O
and	O
thus	O
limit	O
the	O
duration	O
of	O
antimalarial	O
immunity	O
generated	O
by	O
subunit	O
vaccination	O
.	O

This	O
notion	O
was	O
further	O
supported	O
by	O
in	O
vitro	O
kinase	O
assays	O
,	O
in	O
which	O
prior	O
treatment	O
of	O
TBK1	B-PRGE
with	O
PLP2	B-PRGE
inhibited	O
its	O
kinase	O
activity	O
to	O
phosphorylate	O
IRF3	B-PRGE
.	O

TITLE	O
:	O
Longitudinal	O
profiles	O
of	O
immunoglobulin	B-PRGE
G	I-PRGE
antibodies	I-PRGE
against	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
components	O
and	O
neutralizing	O
activities	O
in	O
recovered	O
patients	O
.	O

ABSTRACT	O
:	O
Interferon	B-PRGE
gamma	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
γ	I-PRGE
)	O
plays	O
an	O
important	O
role	O
in	O
cell	O
mediated	O
responses	O
against	O
mutated	O
feline	O
coronavirus	O
strains	O
(	O
FCoV	O
)	O
involved	O
in	O
the	O
pathogenesis	O
of	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
).	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
establish	O
a	O
combined	O
in	O
silico	O
and	O
in	O
vitro	O
approach	O
to	O
assess	O
feline	O
leukocyte	O
production	O
of	O
IFN	B-PRGE
-	I-PRGE
γ	I-PRGE
in	O
response	O
to	O
selected	O
peptides	O
of	O
the	O
nucleocapside	O
protein	O
(	O
N	O
)	O
of	O
FCoVs	O
.	O

These	O
cats	O
responded	O
to	O
""""	O
avirulent	O
""""	O
or	O
""""	O
mixed	O
""""	O
peptides	O
by	O
increasing	O
the	O
concentration	O
of	O
IFN	B-PRGE
-	I-PRGE
γ	I-PRGE
and	O
the	O
expression	O
of	O
IFN	B-PRGE
-	I-PRGE
γ	I-PRGE
mRNA	I-PRGE
.	O

Consequently	O
,	O
mediating	O
the	O
dynamics	O
may	O
offer	O
a	O
potential	O
avenue	O
to	O
inhibit	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CLpro	I-PRGE
.	O

During	O
CoV	O
infection	O
,	O
PTB	O
relocalized	O
from	O
the	O
nucleus	O
to	O
novel	O
cytoplasmic	O
structures	O
different	O
from	O
replication	O
-	O
transcription	O
sites	O
in	O
which	O
stress	O
granule	O
markers	O
T	O
-	O
cell	O
intracellular	O
antigen	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
TIA	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
and	O
TIA	B-PRGE
-	I-PRGE
1	I-PRGE
-	I-PRGE
related	I-PRGE
protein	I-PRGE
(	O
TIAR	B-PRGE
)	O
colocalized	O
.	O

A	O
newer	O
generation	O
of	O
this	O
kit	O
,	O
released	O
in	O
Canada	O
in	O
early	O
2010	O
,	O
is	O
designed	O
to	O
simplify	O
the	O
procedure	O
and	O
reduce	O
the	O
turnaround	O
time	O
by	O
about	O
24	O
h	O
.	O
The	O
assay	O
methodology	O
and	O
targets	O
included	O
in	O
this	O
version	O
of	O
the	O
kit	O
are	O
different	O
;	O
consequently	O
,	O
the	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
detection	O
of	O
a	O
panel	O
of	O
respiratory	O
viral	O
targets	O
using	O
the	O
older	O
Luminex	O
xTAG	O
RVP	O
(	O
RVP	O
Classic	O
)	O
assay	O
with	O
that	O
using	O
the	O
newer	O
xTAG	B-PRGE
RVP	I-PRGE
Fast	I-PRGE
assay	O
.	O

Laboratory	O
data	O
revealed	O
severe	O
renal	O
insufficiency	O
and	O
positive	O
titers	O
for	O
the	O
myeloperoxidase	B-PRGE
anti	I-PRGE
-	I-PRGE
neutrophil	I-PRGE
cytoplasmic	I-PRGE
and	I-PRGE
anti	I-PRGE
-	I-PRGE
glomerular	I-PRGE
basement	I-PRGE
membrane	I-PRGE
antibodies	I-PRGE
.	O

Real	O
-	O
time	O
reverse	O
transcriptase	B-PRGE
polymerase	I-PRGE
chain	I-PRGE
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
was	O
used	O
for	O
detection	O
of	O
H1N1	O
virus	O
in	O
the	O
respiratory	O
specimens	O
.	O

For	O
this	O
to	O
occur	O
,	O
the	O
viral	B-PRGE
envelope	I-PRGE
proteins	I-PRGE
must	O
be	O
efficiently	O
targeted	O
to	O
the	O
Golgi	O
region	O
of	O
the	O
secretory	O
pathway	O
.	O

To	O
dissect	O
the	O
targeting	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
E	I-PRGE
protein	I-PRGE
to	O
the	O
Golgi	O
region	O
,	O
we	O
exogenously	O
expressed	O
the	O
protein	O
and	O
various	O
mutants	O
from	O
cDNA	O
and	O
determined	O
their	O
localization	O
using	O
immunofluorescence	O
microscopy	O
and	O
biochemical	O
assays	O
.	O

Infection	O
begins	O
with	O
uptake	O
of	O
particles	O
into	O
cellular	O
endosomes	O
,	O
where	O
the	O
viral	O
envelope	O
glycoprotein	B-PRGE
(	O
GP	O
)	O
catalyzes	O
fusion	O
between	O
the	O
viral	O
and	O
host	O
cell	O
membranes	O
.	O

This	O
fusion	O
event	O
is	O
thought	O
to	O
involve	O
conformational	O
rearrangements	O
of	O
the	O
transmembrane	O
subunit	O
(	O
GP2	O
)	O
of	O
the	O
envelope	B-PRGE
spike	O
that	O
ultimately	O
result	O
in	O
formation	O
of	O
a	O
six	O
-	O
helix	O
bundle	O
by	O
the	O
N	O
-	O
and	O
C	O
-	O
terminal	O
heptad	O
repeat	O
(	O
NHR	O
and	O
CHR	O
,	O
respectively	O
)	O
regions	O
of	O
GP2	B-PRGE
.	O

TITLE	O
:	O
[	O
Expression	O
of	O
green	B-PRGE
fluorescent	I-PRGE
protein	I-PRGE
using	O
an	O
infectious	O
cDNA	O
clone	O
of	O
infectious	O
bronchitis	O
virus	O
].	O

Recombinant	O
plasmids	O
were	O
digested	O
by	O
the	O
restriction	O
enzyme	O
Bsa	B-PRGE
I	I-PRGE
,	O
and	O
all	O
the	O
cDNA	O
fragments	O
were	O
recovered	O
.	O

Although	O
intraperitoneal	O
immunization	O
of	O
inactivated	O
SARS	O
-	O
CoV	O
vaccine	O
alone	O
could	O
induce	O
a	O
certain	O
level	O
of	O
neutralizing	O
activity	O
in	O
serum	O
as	O
well	O
as	O
in	O
mucosal	O
sites	O
,	O
co	O
-	O
administration	O
of	O
inactivated	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
vaccine	O
with	O
PIKA	O
as	O
adjuvant	O
could	O
induce	O
a	O
much	O
higher	O
neutralizing	O
activity	O
.	O

Fifty	O
-	O
three	O
compounds	O
from	O
35	O
main	O
groups	O
were	O
tested	O
in	O
an	O
in	O
vitro	O
assay	O
for	O
inhibition	O
of	O
3CL	B-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
expressed	O
by	O
Escherichia	O
coli	O
.	O

The	O
contents	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
α	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
α	I-PRGE
)	O
and	O
interleukin	B-PRGE
6	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
)	O
in	O
plasma	O
and	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
were	O
also	O
increased	O
distinctly	O
compared	O
with	O
the	O
control	O
group	O
[	O
TNF	B-PRGE
-	I-PRGE
α	I-PRGE
(	O
ng	O
/	O
L	O
)	O
in	O
plasma	O
:	O
328	O
.	O
89	O
±	O
6	O
.	O
26	O
vs	O
.	O
62	O
.	O
12	O
±	O
2	O
.	O
98	O
,	O
TNF	B-PRGE
-	I-PRGE
α	I-PRGE
(	O
ng	O
/	O
L	O
)	O
in	O
BALF	O
:	O
164	O
.	O
87	O
±	O
4	O
.	O
59	O
vs	O
.	O
29	O
.	O
51	O
±	O
1	O
.	O
12	O
;	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
(	O
ng	O
/	O
L	O
)	O
in	O
plasma	O
:	O
128	O
.	O
51	O
±	O
4	O
.	O
13	O
vs	O
.	O
19	O
.	O
32	O
±	O
1	O
.	O
53	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
(	O
ng	O
/	O
L	O
)	O
in	O
BALF	O
:	O
94	O
.	O
97	O
±	O
1	O
.	O
14	O
vs	O
.	O
22	O
.	O
72	O
±	O
0	O
.	O
19	O
,	O
all	O
P	O
<	O
0	O
.	O
05	O
].	O

It	O
was	O
suggested	O
that	O
vascular	O
permeability	O
factors	O
,	O
including	O
VEGF	B-PRGE
,	O
produced	O
by	O
FIPV	O
-	O
infected	O
monocytes	O
/	O
macrophages	O
might	O
increase	O
the	O
vascular	O
permeability	O
and	O
the	O
amounts	O
of	O
effusion	O
in	O
cats	O
with	O
FIP	O
.	O

To	O
date	O
,	O
two	O
different	O
CCoV	O
genotypes	O
have	O
been	O
recognized	O
,	O
CCoV	B-PRGE
type	I-PRGE
I	I-PRGE
and	O
CCoV	B-PRGE
type	I-PRGE
II	I-PRGE
.	O

Mixed	O
infection	O
of	O
both	O
subtypes	O
(	O
CCoV	B-PRGE
-	I-PRGE
IIa	I-PRGE
/	I-PRGE
IIb	I-PRGE
)	O
was	O
detected	O
in	O
the	O
faeces	O
,	O
while	O
only	O
CCoV	B-PRGE
-	I-PRGE
IIb	I-PRGE
was	O
detected	O
in	O
the	O
organs	O
.	O

Both	O
CCoV	B-PRGE
-	I-PRGE
IIb	I-PRGE
strains	O
were	O
isolated	O
on	O
cell	O
cultures	O
and	O
subjected	O
to	O
sequence	O
analysis	O
and	O
phylogeny	O
.	O

Direct	O
intracranial	O
injection	O
of	O
iBAC	O
-	O
FXN	B-PRGE
-	O
lacZ	B-PRGE
into	O
the	O
adult	O
mouse	O
cerebellum	O
resulted	O
in	O
a	O
large	O
number	O
of	O
easily	O
detectable	O
transduced	O
cells	O
,	O
with	O
LacZ	B-PRGE
expression	O
driven	O
by	O
the	O
FXN	O
genomic	O
locus	O
,	O
which	O
persisted	O
for	O
at	O
least	O
75	O
days	O
.	O

Using	O
a	O
newly	O
designed	O
real	O
-	O
time	O
reverse	B-PRGE
transcriptase	I-PRGE
-	O
polymerase	O
chain	O
reaction	O
assay	O
specific	O
for	O
the	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
and	O
turkey	O
coronaviruses	O
(	O
TCoV	O
),	O
coronaviruses	O
were	O
identified	O
in	O
37	O
%	O
of	O
the	O
intestinal	O
samples	O
collected	O
from	O
diseased	O
turkey	O
flocks	O
.	O

The	O
translation	O
of	O
most	O
of	O
the	O
sgmRNAs	O
is	O
thought	O
to	O
be	O
cap	O
dependent	O
and	O
displays	O
a	O
requirement	O
for	O
eukaryotic	B-PRGE
initiation	I-PRGE
factor	I-PRGE
4F	I-PRGE
(	O
eIF4F	B-PRGE
),	O
a	O
heterotrimeric	O
complex	O
needed	O
for	O
the	O
recruitment	O
of	O
40S	O
ribosomes	O
.	O

ABSTRACT	O
:	O
Immunoglobulin	B-PRGE
in	O
cerebral	O
spinal	O
fluid	O
and	O
antibody	O
secreting	O
cells	O
(	O
ASC	O
)	O
within	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
parenchyma	O
are	O
common	O
hallmarks	O
of	O
microbial	O
infections	O
and	O
autoimmune	O
disorders	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
RNA	O
synthesis	O
is	O
a	O
sophisticated	O
process	O
performed	O
by	O
a	O
viral	O
multienzymatic	O
replicase	B-PRGE
complex	O
,	O
together	O
with	O
cellular	O
factors	O
.	O

Several	O
subcellular	O
locations	O
and	O
topological	O
conformations	O
of	O
E	B-PRGE
protein	I-PRGE
have	O
been	O
proposed	O
.	O

TITLE	O
:	O
A	O
case	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
associated	O
with	O
novel	O
H1N1	O
treated	O
with	O
intravenous	O
immunoglobulin	B-PRGE
G	I-PRGE
.	O
ABSTRACT	O
:	O
Influenza	O
A	O
""""	O
novel	O
H1N1	O
""""	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
a	O
serious	O
illness	O
that	O
poses	O
a	O
challenge	O
to	O
clinicians	O
managing	O
such	O
cases	O
.	O

Unlike	O
CD8	B-PRGE
(+)	O
T	O
cells	O
,	O
a	O
large	O
proportion	O
of	O
CD4	B-PRGE
(+)	O
T	O
cells	O
within	O
the	O
CNS	O
retained	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
production	O
throughout	O
persistence	O
.	O

IL	B-PRGE
-	I-PRGE
10	I-PRGE
was	O
produced	O
primarily	O
by	O
the	O
CD25	B-PRGE
(+)	I-PRGE
CD4	I-PRGE
(+)	O
T	O
cell	O
subset	O
during	O
acute	O
infection	O
but	O
prevailed	O
in	O
CD25	B-PRGE
(-)	I-PRGE
CD4	I-PRGE
(+)	O
T	O
cells	O
during	O
the	O
transition	O
to	O
persistent	O
infection	O
and	O
thereafter	O
.	O

PaO2	O
/	O
Fio2	O
ratios	O
of	O
some	O
patients	O
increase	O
substantially	O
after	O
mechanical	O
ventilation	O
with	O
positive	O
end	O
-	O
expiratory	O
pressure	O
of	O
5	O
-	O
10	O
cm	O
H₂O	O
,	O
and	O
the	O
mortality	O
of	O
these	O
patients	O
may	O
be	O
lower	O
than	O
those	O
whose	O
PaO₂	B-PRGE
/	O
Fio₂ratios	O
remain	O
<	O
200	O
.	O

The	O
primary	O
purpose	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
value	O
of	O
adding	O
baseline	O
positive	O
end	O
-	O
expiratory	O
pressure	O
and	O
Fio₂	O
to	O
PaO₂	B-PRGE
/	O
Fio₂	O
for	O
predicting	O
mortality	O
of	O
acute	O
lung	O
injury	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
patients	O
enrolled	O
in	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
Network	O
clinical	O
trials	O
.	O

This	O
study	O
characterizes	O
critical	O
disease	O
models	O
in	O
the	O
evaluation	O
and	O
licensure	O
of	O
therapeutic	O
strategies	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
for	O
human	O
use	O
.	O

TITLE	O
:	O
In	O
silico	O
investigations	O
of	O
possible	O
routes	O
of	O
assembly	O
of	O
ORF	B-PRGE
3a	I-PRGE
from	O
SARS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
ORF	O
3a	O
of	O
human	O
severe	O
acute	O
respiratory	O
syndrome	O
corona	O
virus	O
(	O
SARS	O
-	O
CoV	O
)	O
has	O
been	O
identified	O
as	O
a	O
274	O
amino	O
acid	O
membrane	O
protein	O
.	O

Further	O
studies	O
will	O
be	O
required	O
to	O
define	O
whether	O
the	O
mutations	O
in	O
the	O
S	B-PRGE
gene	I-PRGE
of	O
83P	O
-	O
5	O
that	O
had	O
been	O
selected	O
and	O
accumulated	O
during	O
the	O
serial	O
passages	O
are	O
indeed	O
the	O
causalities	O
of	O
the	O
growth	O
adaptation	O
in	O
vitro	O
and	O
the	O
attenuation	O
of	O
virulence	O
in	O
vivo	O
.	O

This	O
increase	O
in	O
activity	O
correlates	O
with	O
the	O
activation	O
of	O
ERK	B-PRGE
and	O
JNK	B-PRGE
pathways	O
.	O

TITLE	O
:	O
Angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
ectodomain	I-PRGE
shedding	O
cleavage	O
-	O
site	O
identification	O
:	O
determinants	O
and	O
constraints	O
.	O

These	O
findings	O
also	O
indicate	O
that	O
Arg	O
(	O
708	O
)	O
and	O
Arg	O
(	O
710	O
)	O
play	O
a	O
role	O
in	O
site	O
recognition	O
in	O
the	O
regulation	O
of	O
ACE2	B-PRGE
ectodomain	I-PRGE
shedding	O
mediated	O
by	O
ADAM17	O
.	O

Six	O
years	O
postinfection	O
,	O
specific	O
IgG	B-PRGE
Ab	O
to	O
SARS	O
-	O
CoV	O
became	O
undetectable	O
in	O
21	O
of	O
the	O
23	O
former	O
patients	O
.	O

SARS	B-PRGE
-	O
specific	O
IgG	B-PRGE
Ab	O
may	O
eventually	O
vanish	O
and	O
peripheral	O
memory	O
B	O
cell	O
responses	O
are	O
undetectable	O
in	O
recovered	O
SARS	O
patients	O
.	O

The	O
antibody	O
5H10	O
was	O
obtained	O
by	O
vaccination	O
of	O
KM	O
mice	O
bearing	O
human	O
immunoglobulin	B-PRGE
genes	I-PRGE
with	O
Escherichia	O
coli	O
-	O
producing	O
recombinant	O
peptide	O
containing	O
the	O
dominant	O
epitope	O
of	O
the	O
viral	O
spike	O
protein	O
found	O
in	O
convalescent	O
serum	O
samples	O
from	O
patients	O
with	O
SARS	O
.	O

Polyclonal	O
antibodies	O
raised	O
against	O
expressed	O
S1	O
(	O
amino	O
acid	O
position	O
1	O
to	O
573	O
from	O
start	O
codon	O
of	O
S	B-PRGE
protein	I-PRGE
),	O
4F	O
/	O
4R	O
(	O
482	O
-	O
678	O
),	O
6F	O
/	O
6R	O
(	O
830	O
-	O
1071	O
),	O
or	O
Mod4F	O
/	O
Epi4R	O
(	O
476	O
-	O
520	O
)	O
S	O
fragment	O
recognized	O
native	O
S1	B-PRGE
protein	I-PRGE
and	O
TCoV	O
in	O
the	O
intestines	O
of	O
TCoV	O
-	O
infected	O
turkey	O
embryos	O
.	O

The	O
results	O
of	O
a	O
virus	O
neutralization	O
assay	O
indicated	O
that	O
the	O
carboxyl	O
terminal	O
region	O
of	O
the	O
S1	B-PRGE
protein	I-PRGE
(	O
Mod4F	O
/	O
Epi4R	O
)	O
or	O
the	O
combined	B-PRGE
carboxyl	I-PRGE
terminal	I-PRGE
S1	I-PRGE
and	I-PRGE
amino	I-PRGE
terminal	I-PRGE
S2	I-PRGE
protein	I-PRGE
(	O
4F	O
/	O
4R	O
)	O
possesses	O
the	O
neutralizing	O
epitopes	O
,	O
while	O
the	O
S2	O
fragment	O
(	O
6F	O
/	O
6R	O
)	O
contains	O
antigenic	O
epitopes	O
but	O
not	O
neutralizing	O
epitopes	O
.	O

In	O
this	O
study	O
,	O
the	O
role	O
of	O
fAPN	O
and	O
fDC	B-PRGE
-	I-PRGE
SIGN	I-PRGE
was	O
studied	O
at	O
different	O
stages	O
in	O
FIPV	O
infection	O
of	O
monocytes	O
.	O

Most	O
FIPV	O
I	O
particles	O
already	O
interact	O
with	O
fDC	B-PRGE
-	I-PRGE
SIGN	I-PRGE
at	O
the	O
plasma	O
membrane	O
.	O

TITLE	O
:	O
Characterisation	O
and	O
evaluation	O
of	O
antiviral	O
recombinant	O
peptides	O
based	O
on	O
the	O
heptad	O
repeat	O
regions	O
of	O
NDV	O
and	O
IBV	B-PRGE
fusion	I-PRGE
glycoproteins	I-PRGE
.	O

Multiple	O
low	O
micromolar	O
inhibitors	O
of	O
the	O
enzyme	O
were	O
identified	O
through	O
this	O
search	O
,	O
one	O
of	O
which	O
also	O
showed	O
activity	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
in	O
a	O
whole	O
cell	O
CPE	O
assay	O
.	O

Circulating	O
sES	B-PRGE
levels	O
were	O
elevated	O
in	O
pneumonia	O
patients	O
with	O
ALI	O
/	O
cALI	O
,	O
and	O
sES	O
levels	O
decreased	O
following	O
treatment	O
of	O
their	O
pneumonia	O
.	O

sES	B-PRGE
may	O
be	O
a	O
useful	O
biomarker	O
for	O
discriminating	O
complicating	O
ALI	O
/	O
cALI	O
in	O
patients	O
with	O
severe	O
pneumonia	O
.	O

Under	O
electron	O
microscopy	O
,	O
PEDV	O
-	O
infected	O
Vero	O
cells	O
,	O
as	O
well	O
as	O
PEDV	O
-	O
infected	O
Vero	O
/	O
TMPRSS2	O
cells	O
treated	O
with	O
leupeptin	O
,	O
retained	O
huge	O
clusters	O
of	O
virions	O
on	O
their	O
surfaces	O
,	O
while	O
such	O
clusters	O
were	O
rarely	O
seen	O
in	O
the	O
presence	O
of	O
trypsin	B-PRGE
and	O
the	O
absence	O
of	O
leupeptin	O
in	O
Vero	O
and	O
Vero	O
/	O
TMPRSS2	O
cells	O
,	O
respectively	O
.	O

ABSTRACT	O
:	O
Outbreaks	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
influenza	O
A	O
(	O
H5N1	O
,	O
H1N1	O
)	O
and	O
measles	O
viruses	O
in	O
recent	O
years	O
have	O
raised	O
serious	O
concerns	O
about	O
the	O
measures	O
available	O
to	O
control	O
emerging	O
and	O
re	O
-	O
emerging	O
infectious	O
viral	O
diseases	O
.	O

This	O
study	O
was	O
a	O
prospective	O
,	O
multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blinded	O
,	O
controlled	O
trial	O
designed	O
to	O
investigate	O
whether	O
EPA	B-PRGE
/	O
GLA	B-PRGE
could	O
have	O
an	O
effective	O
role	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
early	O
sepsis	O
(	O
systemic	O
inflammatory	O
response	O
syndrome	O
with	O
confirmed	O
or	O
presumed	O
infection	O
and	O
without	O
any	O
organ	O
dysfunction	O
)	O
by	O
reducing	O
the	O
progression	O
of	O
the	O
disease	O
to	O
severe	O
sepsis	O
(	O
sepsis	O
associated	O
with	O
at	O
least	O
one	O
organ	O
failure	O
)	O
or	O
septic	O
shock	O
(	O
sepsis	O
associated	O
with	O
hypotension	O
despite	O
adequate	O
fluid	O
resuscitation	O
).	O

Median	O
length	O
of	O
hospitalization	O
was	O
shorter	O
for	O
hemoglobin	B-PRGE
SC	O
episodes	O
when	O
compared	O
to	O
hemoglobin	B-PRGE
SS	O
episodes	O
(	O
3	O
.	O
0	O
vs	O
.	O
5	O
.	O
0	O
days	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

In	O
comparison	O
to	O
hemoglobin	B-PRGE
SS	O
patients	O
,	O
a	O
greater	O
proportion	O
of	O
hemoglobin	B-PRGE
SC	O
patients	O
had	O
a	O
previous	O
history	O
of	O
asthma	O
or	O
wheezing	O
(	O
50	O
.	O
7	O
vs	O
.	O
33	O
.	O
8	O
%,	O
OR	O
=	O
2	O
.	O
01	O
[	O
1	O
.	O
02	O
-	O
3	O
.	O
96	O
],	O
P	O
=	O
0	O
.	O
041	O
)	O
and	O
a	O
respiratory	O
complaint	O
of	O
wheeze	O
(	O
11	O
.	O
3	O
vs	O
.	O
2	O
.	O
8	O
%,	O
OR	O
=	O
4	O
.	O
38	O
[	O
0	O
.	O
90	O
-	O
21	O
.	O
4	O
],	O
P	O
=	O
0	O
.	O
049	O
).	O

In	O
our	O
multivariate	O
regression	O
model	O
,	O
time	O
to	O
ACS	O
diagnosis	O
and	O
total	O
number	O
of	O
days	O
of	O
oxygen	O
supplementation	O
were	O
independent	O
predictors	O
of	O
length	O
of	O
hospitalization	O
in	O
both	O
hemoglobin	B-PRGE
SC	O
and	O
SS	O
episodes	O
of	O
ACS	O
.	O

TITLE	O
:	O
Mineralocorticoid	B-PRGE
receptor	I-PRGE
antagonism	O
:	O
therapeutic	O
potential	O
in	O
acute	O
heart	O
failure	O
syndromes	O
.	O

Diuresis	O
,	O
respiratory	O
support	O
,	O
vasodilator	O
therapy	O
,	O
and	O
gradual	O
attenuation	O
of	O
the	O
activation	O
of	O
renin	B-PRGE
-	O
angiotensin	O
-	O
aldosterone	O
system	O
(	O
RAAS	O
)	O
and	O
sympathetic	O
nervous	O
system	O
(	O
SNS	O
)	O
are	O
the	O
keystones	O
of	O
AHFS	O
management	O
.	O

While	O
the	O
S1	B-PRGE
protein	I-PRGE
derived	O
from	O
the	O
nephropathogenic	O
IBV	O
strain	O
B1648	O
also	O
hardly	O
displayed	O
binding	O
to	O
respiratory	O
tract	O
cells	O
,	O
distinct	O
binding	O
to	O
kidney	O
cells	O
was	O
observed	O
,	O
but	O
only	O
after	O
the	O
removal	O
of	O
sialic	O
acid	O
from	O
S1	O
.	O

Herein	O
,	O
we	O
enzymatically	O
amplified	O
,	O
cloned	O
,	O
and	O
expressed	O
the	O
S	O
-	O
AD	O
fragment	O
from	O
TGEV	O
in	O
the	O
prokaryotic	O
expression	O
vector	O
,	O
pET	B-PRGE
-	I-PRGE
30a	I-PRGE
.	O

TITLE	O
:	O
P2Y	B-PRGE
receptors	I-PRGE
as	O
regulators	O
of	O
lung	O
endothelial	O
barrier	O
integrity	O
.	O

This	O
study	O
demonstrates	O
the	O
enhanced	O
protection	O
of	O
oral	O
co	O
-	O
administration	O
of	O
swine	O
interferon	B-PRGE
-	I-PRGE
α	I-PRGE
(	O
swIFN	O
-	O
α	O
)	O
and	O
interleukin	B-PRGE
-	I-PRGE
18	I-PRGE
(	O
swIL	O
-	O
18	O
)	O
against	O
infection	O
with	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
in	O
piglets	O
using	O
attenuated	O
Salmonella	O
enterica	O
serovar	O
Typhimurium	O
as	O
carrier	O
of	O
cytokine	O
proteins	O
.	O

These	O
PAbs	O
contained	O
the	O
IgG2a	B-PRGE
subclass	O
,	O
which	O
cross	O
-	O
reacted	O
with	O
the	O
virion	B-PRGE
-	I-PRGE
associated	I-PRGE
envelope	I-PRGE
(	I-PRGE
E	I-PRGE
)	I-PRGE
glycoprotein	I-PRGE
of	O
the	O
DENV	O
-	O
2	O
NSx	O
strain	O
,	O
suggesting	O
that	O
they	O
could	O
generate	O
its	O
AER	O
via	O
all	O
mouse	B-PRGE
Fcγ	I-PRGE
-	I-PRGE
receptor	I-PRGE
classes	O
.	O

Rous	O
sarcoma	O
virus	O
(	O
RSV	O
)	O
offers	O
a	O
unique	O
model	O
system	O
for	O
dissecting	O
these	O
early	O
steps	O
because	O
the	O
RSV	B-PRGE
Gag	I-PRGE
protein	I-PRGE
undergoes	O
transient	O
nuclear	O
trafficking	O
prior	O
to	O
plasma	O
membrane	O
transport	O
.	O

TITLE	O
:	O
IFN	B-PRGE
-	I-PRGE
γ	I-PRGE
-	O
and	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
-	I-PRGE
expressing	I-PRGE
virus	I-PRGE
epitope	I-PRGE
-	I-PRGE
specific	I-PRGE
Foxp3	I-PRGE
(+)	I-PRGE
T	I-PRGE
reg	I-PRGE
cells	O
in	O
the	O
central	O
nervous	O
system	O
during	O
encephalomyelitis	O
.	O

Using	O
MHC	B-PRGE
class	I-PRGE
II	I-PRGE
/	I-PRGE
peptide	I-PRGE
tetramers	I-PRGE
and	O
intracellular	O
cytokine	O
staining	O
,	O
we	O
identify	O
T	O
reg	O
cells	O
recognizing	O
two	O
virus	B-PRGE
-	I-PRGE
specific	I-PRGE
CD4	I-PRGE
T	I-PRGE
cell	I-PRGE
epitopes	I-PRGE
in	O
the	O
coronavirus	O
-	O
infected	O
central	O
nervous	O
system	O
as	O
well	O
as	O
naive	O
T	O
cell	O
precursor	O
pools	O
.	O

Conversely	O
,	O
in	O
vivo	O
blockade	O
of	O
IFN	B-PRGE
-	I-PRGE
γ	I-PRGE
and	O
TNF	B-PRGE
-	I-PRGE
α	I-PRGE
led	O
to	O
efficient	O
inhibition	O
of	O
FGL2	B-PRGE
expression	O
,	O
greatly	O
attenuated	O
the	O
development	O
of	O
tissue	O
lesions	O
,	O
and	O
ultimately	O
reduced	O
mortality	O
.	O

These	O
data	O
imply	O
that	O
the	O
ability	O
of	O
MHV	O
to	O
replicate	O
in	O
macrophages	O
is	O
a	O
prerequisite	O
for	O
replication	O
in	O
the	O
liver	O
and	O
induction	O
of	O
hepatitis	O
but	O
not	O
for	O
replication	O
or	O
disease	O
in	O
the	O
CNS	O
,	O
underscoring	O
the	O
importance	O
of	O
IFN	B-PRGE
signaling	O
in	O
macrophages	O
in	O
vivo	O
for	O
protection	O
of	O
the	O
host	O
from	O
hepatitis	O
.	O

EC	B-PRGE
-	I-PRGE
SOD	I-PRGE
attenuated	O
pulmonary	O
inflammation	O
,	O
decreased	O
bronchoalveolar	O
lavage	O
neutrophil	O
counts	O
,	O
and	O
reduced	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
CINC	B-PRGE
-	I-PRGE
1	I-PRGE
concentrations	O
.	O

Pulmonary	O
overexpression	O
of	O
EC	B-PRGE
-	I-PRGE
SOD	I-PRGE
protects	O
the	O
lung	O
against	O
endotoxin	O
-	O
induced	O
ALI	O
.	O

TITLE	O
:	O
Local	O
renin	B-PRGE
-	O
angiotensin	B-PRGE
II	I-PRGE
systems	O
,	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
and	O
its	O
homologue	O
ACE2	B-PRGE
:	O
their	O
potential	O
role	O
in	O
the	O
pathogenesis	O
of	O
chronic	O
obstructive	O
pulmonary	O
diseases	O
,	O
pulmonary	O
hypertension	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

The	O
enzyme	O
responsible	O
for	O
its	O
synthesis	O
,	O
Angiotensin	O
-	O
converting	O
-	O
enzyme	O
(	O
ACE	B-PRGE
),	O
is	O
present	O
in	O
high	O
concentrations	O
in	O
lung	O
tissue	O
.	O

SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
VLPs	I-PRGE
are	O
highly	O
immunogenic	O
and	O
induce	O
neutralizing	O
antibodies	O
and	O
provide	O
protection	O
against	O
lethal	O
challenge	O
.	O

Most	O
(	O
62	O
.	O
5	O
%)	O
had	O
a	O
positive	O
oxygenation	O
response	O
after	O
2	O
hrs	O
of	O
high	O
-	O
frequency	O
oscillation	O
(	O
mean	O
absolute	O
increase	O
in	O
PaO₂	B-PRGE
/	O
FiO₂	O
,	O
22	O
[	O
SD	O
,	O
54	O
];	O
95	O
%	O
confidence	O
interval	O
of	O
mean	O
14	O
-	O
31	O
).	O

Examination	O
of	O
the	O
cellular	O
PDZ	O
proteins	O
that	O
are	O
targets	O
of	O
viral	O
PBMs	O
reveals	O
that	O
the	O
viral	O
proteins	O
often	O
interact	O
with	O
the	O
same	O
or	O
similar	O
types	O
of	O
PDZ	O
proteins	O
,	O
most	O
notably	O
Dlg1	B-PRGE
and	O
other	O
members	O
of	O
the	O
membrane	B-PRGE
-	I-PRGE
associated	I-PRGE
guanylate	I-PRGE
kinase	I-PRGE
protein	I-PRGE
family	I-PRGE
,	O
as	O
well	O
as	O
Scribble	O
.	O

Ten	O
-	O
week	O
-	O
old	O
males	O
were	O
inoculated	O
with	O
Arkansas	O
(	O
Ark	B-PRGE
)	O
or	O
Massachusetts	O
(	O
Mass	O
)	O
IBV	O
virulent	O
strains	O
.	O

TITLE	O
:	O
[	O
Co	O
-	O
localization	O
analysis	O
between	O
porcine	B-PRGE
epidemic	I-PRGE
diarrhea	I-PRGE
virus	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
and	O
nucleolar	O
phosphoprotein	O
B23	O
.	O
1	O
].	O

TITLE	O
:	O
Development	O
of	O
a	O
recombinant	B-PRGE
truncated	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
based	O
immunoassay	O
for	O
detection	O
of	O
antibodies	O
against	O
human	B-PRGE
coronavirus	I-PRGE
OC43	I-PRGE
.	O

TITLE	O
:	O
Identification	O
of	O
small	O
-	O
molecule	O
inhibitors	O
of	O
the	O
XendoU	B-PRGE
endoribonucleases	I-PRGE
family	I-PRGE
.	O

This	O
was	O
an	O
observational	O
cohort	O
study	O
of	O
114	O
adults	O
with	O
SCD	O
who	O
completed	O
respiratory	O
symptom	O
questionnaires	O
and	O
had	O
serum	B-PRGE
IgE	I-PRGE
measurements	O
.	O

In	O
this	O
study	O
,	O
we	O
first	O
investigated	O
at	O
6	O
years	O
postinfection	O
whether	O
SARS	O
-	O
specific	O
memory	O
T	O
cells	O
persist	O
in	O
SARS	O
-	O
recovered	O
individuals	O
,	O
demonstrating	O
that	O
these	O
subjects	O
still	O
possess	O
polyfunctional	O
SARS	O
-	O
specific	O
memory	O
CD4	B-PRGE
+	I-PRGE
and	O
CD8	B-PRGE
+	I-PRGE
T	O
cells	O
.	O

They	O
were	O
able	O
to	O
degranulate	O
and	O
produce	O
gamma	B-PRGE
interferon	I-PRGE
,	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
,	O
and	O
macrophage	O
inflammatory	O
proteins	O
1α	O
and	O
1β	O
after	O
antigenic	O
stimulation	O
.	O

ABSTRACT	O
:	O
Fat	B-PRGE
embolization	I-PRGE
(	O
FE	O
),	O
the	O
introduction	O
of	O
bone	O
marrow	O
elements	O
into	O
circulation	O
,	O
is	O
a	O
known	O
complication	O
of	O
bone	O
fractures	O
.	O

Expression	O
of	O
l	B-PRGE
-	I-PRGE
selectin	I-PRGE
,	O
CXCR2	B-PRGE
and	O
C5aR	B-PRGE
was	O
partially	O
restored	O
at	O
24	O
h	O
after	O
injury	O
.	O

MK	B-PRGE
-	I-PRGE
p10	I-PRGE
S	I-PRGE
protein	I-PRGE
had	O
four	O
mutations	O
relative	O
to	O
the	O
original	O
virus	O
S	O
,	O
and	O
one	O
of	O
these	O
(	O
H	O
→	O
R	O
at	O
position	O
1381	O
,	O
H1381R	O
)	O
in	O
the	O
cytoplasmic	O
tail	O
(	O
CT	O
)	O
was	O
suggested	O
to	O
be	O
responsible	O
for	O
the	O
increased	O
fusion	O
activity	O
.	O

TITLE	O
:	O
Phylogenetic	O
analysis	O
of	O
the	O
S1	B-PRGE
glycoprotein	I-PRGE
gene	O
of	O
infectious	O
bronchitis	O
viruses	O
isolated	O
in	O
China	O
during	O
2009	O
-	O
2010	O
.	O

TITLE	O
:	O
Molecular	O
characterization	O
of	O
infectious	O
bronchitis	O
virus	O
isolates	O
from	O
Russia	O
and	O
neighbouring	O
countries	O
:	O
identification	O
of	O
intertypic	O
recombination	O
in	O
the	O
S1	B-PRGE
gene	I-PRGE
.	O

These	O
results	O
may	O
help	O
in	O
designing	O
gene	B-PRGE
delivery	I-PRGE
systems	I-PRGE
capable	O
of	O
binding	O
the	O
minimum	O
possible	O
quantity	O
of	O
proteins	O
that	O
influence	O
transfection	O
negatively	O
,	O
binding	O
selectively	O
proteins	O
capable	O
of	O
helping	O
in	O
steering	O
in	O
vivo	O
the	O
vector	O
toward	O
the	O
target	O
,	O
and	O
obtaining	O
more	O
efficient	O
and	O
effective	O
gene	O
therapy	O
.	O

Indeed	O
,	O
following	O
mitogenic	O
stimulation	O
,	O
T	O
cells	O
lacking	O
casp8	B-PRGE
or	O
its	O
adaptor	O
protein	O
FADD	B-PRGE
(	O
Fas	B-PRGE
-	I-PRGE
associated	I-PRGE
death	I-PRGE
domain	I-PRGE
protein	I-PRGE
)	O
develop	O
a	O
hyperautophagic	O
morphology	O
,	O
and	O
die	O
a	O
programmed	O
necrosis	O
-	O
like	O
death	O
process	O
termed	O
necroptosis	O
.	O

Recent	O
studies	O
have	O
demonstrated	O
that	O
receptor	B-PRGE
-	I-PRGE
interacting	I-PRGE
protein	I-PRGE
kinases	I-PRGE
(	O
RIPKs	O
)	O
RIPK1	B-PRGE
and	O
RIPK3	B-PRGE
together	O
facilitate	O
TNF	B-PRGE
-	O
induced	O
necroptosis	O
,	O
but	O
the	O
precise	O
role	O
of	O
RIPKs	O
in	O
the	O
demise	O
of	O
T	O
cells	O
lacking	O
FADD	B-PRGE
or	O
casp8	B-PRGE
activity	O
is	O
unknown	O
.	O

ABSTRACT	O
:	O
It	O
has	O
been	O
reported	O
that	O
lactoferrin	B-PRGE
(	O
LF	O
)	O
participates	O
in	O
the	O
host	O
immune	O
response	O
against	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
invasion	O
by	O
enhancing	O
NK	O
cell	O
activity	O
and	O
stimulating	O
neutrophil	O
aggregation	O
and	O
adhesion	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
,	O
in	O
addition	O
to	O
ACE2	B-PRGE
,	O
HSPGs	O
are	O
essential	O
cell	O
-	O
surface	O
molecules	O
involved	O
in	O
SARS	O
-	O
CoV	O
cell	O
entry	O
.	O

TITLE	O
:	O
Treatment	O
of	O
severe	O
neurological	O
deficits	O
with	O
IgG	B-PRGE
depletion	O
through	O
immunoadsorption	O
in	O
patients	O
with	O
Escherichia	O
coli	O
O104	O
:	O
H4	O
-	O
associated	O
haemolytic	O
uraemic	O
syndrome	O
:	O
a	O
prospective	O
trial	O
.	O

A	O
mutation	O
in	O
tRNA	O
(	O
Lys	O
)	O
that	O
causes	O
myoclonic	O
epilepsy	O
with	O
ragged	O
-	O
red	O
fibers	O
(	O
MERRF	O
)	O
is	O
also	O
reported	O
to	O
prevent	O
modification	O
of	O
the	O
wobble	O
U	O
.	O
Here	O
we	O
show	O
that	O
mitochondrial	O
translation	O
is	O
unaffected	O
in	O
fibroblasts	O
from	O
an	O
MTU1	O
patient	O
,	O
in	O
which	O
MTU1	B-PRGE
is	O
undetectable	O
by	O
immunoblotting	O
,	O
despite	O
the	O
severe	O
reduction	O
in	O
the	O
2	O
-	O
thiolation	O
of	O
mitochondrial	O
tRNA	O
(	O
Lys	O
),	O
tRNA	O
(	O
Glu	O
)	O
and	O
tRNA	O
(	O
Gln	O
).	O

Because	O
secreted	O
phospholipases	O
A2	O
(	O
sPLA2	B-PRGE
)	O
are	O
involved	O
in	O
inflammatory	O
processes	O
,	O
the	O
gene	O
expressions	O
of	O
sPLA2s	B-PRGE
were	O
investigated	O
in	O
both	O
healthy	O
chickens	O
and	O
chickens	O
with	O
infectious	O
bronchitis	O
and	O
lung	O
inflammation	O
.	O

Cytochrome	B-PRGE
P450	I-PRGE
Family	I-PRGE
3A	I-PRGE
(	O
CYP4F3A	O
)	O
is	O
an	O
ω	B-PRGE
-	I-PRGE
oxidase	I-PRGE
that	O
inactivates	O
Leukotriene	O
B4	O
(	O
LTB4	O
)	O
in	O
human	O
neutrophils	O
and	O
the	O
liver	O
.	O

To	O
further	O
validate	O
the	O
association	O
,	O
the	O
ten	O
tag	B-PRGE
SNPs	I-PRGE
were	O
genotyped	O
in	O
the	O
Beijing	O
cohort	O
.	O

After	O
adjusting	O
for	O
age	O
and	O
sex	O
,	O
only	O
rs2248690	O
(	O
AOR	O
,	O
1	O
.	O
63	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
30	O
-	O
2	O
.	O
04	O
)	O
was	O
found	O
to	O
be	O
associated	O
with	O
SARS	B-PRGE
susceptibility	I-PRGE
.	O

TITLE	O
:	O
The	O
sialic	O
acid	O
binding	O
activity	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
facilitates	O
infection	O
by	O
porcine	O
transmissible	O
gastroenteritis	O
coronavirus	O
.	O

Prior	O
to	O
infection	O
,	O
cultured	O
cells	O
were	O
either	O
treated	O
with	O
neuraminidase	B-PRGE
to	O
deplete	O
sialic	O
acids	O
from	O
the	O
cell	O
surface	O
,	O
or	O
mock	O
-	O
treated	O
.	O

The	O
structure	O
of	O
HR2	B-PRGE
,	O
as	O
determined	O
by	O
NMR	O
spectroscopy	O
in	O
the	O
presence	O
of	O
the	O
co	O
-	O
solvent	O
trifluoroethanol	O
(	O
TFE	O
),	O
is	O
a	O
trimer	O
of	O
parallel	O
helices	O
,	O
whereas	O
the	O
structure	O
of	O
HR2	B-PRGE
,	O
as	O
determined	O
by	O
X	O
-	O
ray	O
crystallography	O
,	O
is	O
a	O
tetramer	O
of	O
anti	O
-	O
parallel	O
helices	O
.	O

Costimulation	O
of	O
primary	O
human	O
fibroblasts	O
with	O
IL	B-PRGE
-	I-PRGE
17	I-PRGE
greatly	O
enhanced	O
respiratory	O
syncytial	O
virus	O
-	O
induced	O
or	O
synthetic	O
dsRNA	O
-	O
based	O
viral	O
mimic	O
polyinosinic	O
:	O
polycytidylic	O
acid	O
-	O
induced	O
expression	O
of	O
proinflammatory	O
genes	O
without	O
affecting	O
expression	O
of	O
IFN	B-PRGE
-	I-PRGE
β	I-PRGE
-	O
stimulated	O
or	O
IFN	B-PRGE
-	I-PRGE
stimulated	I-PRGE
genes	I-PRGE
.	O

Here	O
,	O
we	O
show	O
that	O
APE1	B-PRGE
cleaves	O
RNA	O
in	O
the	O
absence	O
of	O
divalent	O
metal	O
ions	O
and	O
,	O
at	O
2	O
mM	O
,	O
Zn	O
(	O
2	O
+),	O
Ni	O
(	O
2	O
+),	O
Cu	O
(	O
2	O
+),	O
or	O
Co	O
(	O
2	O
+)	O
inhibited	O
the	O
endoribonuclease	O
activity	O
of	O
APE1	B-PRGE
.	O

APE1	B-PRGE
is	O
able	O
to	O
cleave	O
CD44	B-PRGE
mRNA	I-PRGE
,	O
microRNAs	O
(	O
miR	O
-	O
21	O
,	O
miR	B-PRGE
-	I-PRGE
10b	I-PRGE
),	O
and	O
three	O
RNA	O
components	O
of	O
SARS	O
-	O
corona	O
virus	O
(	O
orf1b	O
,	O
orf3	B-PRGE
,	O
spike	O
)	O
suggesting	O
that	O
,	O
when	O
challenged	O
,	O
it	O
can	O
cleave	O
any	O
RNAs	O
in	O
vitro	O
.	O

ABSTRACT	O
:	O
Previous	O
studies	O
have	O
demonstrated	O
that	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
requires	O
proteolytic	O
cleavage	O
by	O
elastase	B-PRGE
,	O
cathepsin	B-PRGE
or	O
TMPRSS2	O
for	O
S	O
-	O
mediated	O
cell	O
-	O
cell	O
or	O
virus	O
-	O
cell	O
membrane	O
fusion	O
.	O

In	O
support	O
of	O
this	O
model	O
,	O
we	O
reported	O
that	O
the	O
S	B-PRGE
protein	I-PRGE
of	O
mouse	B-PRGE
hepatitis	I-PRGE
virus	I-PRGE
type	I-PRGE
2	I-PRGE
(	O
MHV	O
-	O
2	O
),	O
which	O
is	O
highly	O
similar	O
to	O
the	O
S	B-PRGE
protein	I-PRGE
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
requires	O
two	O
-	O
step	O
conformational	O
changes	O
mediated	O
by	O
sequential	O
receptor	O
binding	O
and	O
proteolysis	O
to	O
be	O
activated	O
for	O
membrane	O
fusion	O
.	O

ABSTRACT	O
:	O
After	O
human	O
coronaviruses	O
OC43	O
,	O
229E	O
and	O
NL63	O
,	O
human	B-PRGE
coronavirus	I-PRGE
HKU1	I-PRGE
(	O
HCoV	O
-	O
HKU1	O
)	O
is	O
the	O
fourth	O
human	O
coronavirus	O
discovered	O
.	O

All	O
HCoV	O
-	O
HKU1	O
genomes	O
contain	O
unique	O
tandem	O
copies	O
of	O
a	O
30	O
-	O
base	O
acidic	O
tandem	O
repeat	O
of	O
unknown	O
function	O
at	O
the	O
N	O
-	O
terminus	O
of	O
nsp3	B-PRGE
inside	O
the	O
acidic	O
domain	O
upstream	O
of	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
1	I-PRGE
.	O

Although	O
3c	B-PRGE
gene	I-PRGE
mutants	I-PRGE
in	O
this	O
study	O
were	O
not	O
horizontally	O
transmitted	O
,	O
the	O
parental	O
fecal	O
virus	O
was	O
readily	O
transmitted	O
by	O
contact	O
from	O
a	O
cat	O
that	O
died	O
of	O
FIP	O
to	O
its	O
housemate	O
.	O

Superimposition	O
of	O
the	O
PLP2	B-PRGE
model	O
on	O
the	O
PLpro	O
X	O
-	O
ray	O
structure	O
identifies	O
binding	O
site	O
residues	O
in	O
PLP2	B-PRGE
that	O
contribute	O
to	O
the	O
distinct	O
substrate	O
cleavage	O
site	O
specificities	O
between	O
the	O
two	O
proteases	O
.	O

Frequency	O
of	O
ACE	B-PRGE
I	I-PRGE
/	I-PRGE
D	I-PRGE
genotype	I-PRGE
was	O
similar	O
in	O
ARDS	O
and	O
control	O
groups	O
(	O
p	O
=	O
0	O
.	O
18	O
).	O

ABSTRACT	O
:	O
The	O
entire	O
pig	B-PRGE
aminopeptidase	I-PRGE
N	I-PRGE
(	O
pAPN	O
)	O
gene	O
was	O
amplified	O
by	O
RT	O
-	O
PCR	O
using	O
total	O
RNA	O
extracted	O
from	O
intestinal	O
brush	O
border	O
membrane	O
of	O
a	O
newborn	O
piglet	O
.	O

Total	O
lung	O
compliance	O
was	O
21	O
mL	O
cm	O
H2O	O
-	O
1	O
,	O
and	O
SAP	B-PRGE
/	O
DAP	B-PRGE
was	O
63	O
/	O
39	O
mm	O
Hg	O
).	O

TITLE	O
:	O
Structure	O
-	O
based	O
design	O
,	O
synthesis	O
,	O
and	O
evaluation	O
of	O
peptide	O
-	O
mimetic	O
SARS	B-PRGE
3CL	I-PRGE
protease	I-PRGE
inhibitors	O
.	O

ABSTRACT	O
:	O
The	O
design	O
and	O
evaluation	O
of	O
low	O
molecular	O
weight	O
peptide	O
-	O
based	O
severe	B-PRGE
acute	I-PRGE
respiratory	I-PRGE
syndrome	I-PRGE
(	O
SARS	B-PRGE
)	O
chymotrypsin	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	B-PRGE
3CL	I-PRGE
)	I-PRGE
protease	I-PRGE
inhibitors	I-PRGE
are	O
described	O
.	O

Immunohistochemistry	O
was	O
strongly	O
positive	O
for	O
IBV	B-PRGE
antigen	I-PRGE
in	O
the	O
cytoplasm	O
of	O
tubular	O
epithelial	O
cells	O
in	O
the	O
kidneys	O
and	O
also	O
in	O
the	O
epithelium	O
of	O
the	O
respiratory	O
tract	O
,	O
salivary	O
glands	O
,	O
proventriculus	O
,	O
intestine	O
,	O
and	O
bursa	O
of	O
Fabricius	O
.	O

TITLE	O
:	O
Phylogenetic	O
analysis	O
of	O
S1	B-PRGE
gene	I-PRGE
of	O
infectious	O
bronchitis	O
virus	O
isolates	O
from	O
China	O
.	O

Structural	O
analysis	O
revealed	O
that	O
nsp16	O
possesses	O
the	O
canonical	O
scaffold	B-PRGE
of	I-PRGE
MTase	I-PRGE
and	O
associates	O
with	O
nsp10	O
at	O
1	O
∶	O
1	O
ratio	O
.	O

TITLE	O
:	O
A	O
putative	O
diacidic	O
motif	O
in	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
ORF6	I-PRGE
protein	I-PRGE
influences	O
its	O
subcellular	O
localization	O
and	O
suppression	O
of	O
expression	O
of	O
co	O
-	O
transfected	O
expression	O
constructs	O
.	O

ORF6	O
showed	O
partial	O
colocalization	O
with	O
cellular	O
proteins	O
CD63	B-PRGE
and	O
Lamp1	B-PRGE
,	O
suggesting	O
that	O
the	O
vesicular	O
structures	O
may	O
be	O
a	O
subpopulation	O
of	O
endosomal	O
/	O
lysosomal	O
vesicles	O
.	O

The	O
alanine	O
substitution	O
of	O
the	O
diacidic	O
cluster	O
motif	O
also	O
altered	O
the	O
subcellular	O
localization	O
of	O
the	O
ORF6	B-PRGE
protein	I-PRGE
,	O
indicating	O
a	O
potential	O
relationship	O
between	O
the	O
subcellular	O
localization	O
of	O
the	O
ORF6	B-PRGE
protein	I-PRGE
and	O
its	O
ability	O
to	O
suppress	O
the	O
expression	O
of	O
co	O
-	O
transfected	O
expression	O
constructs	O
.	O

In	O
addition	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
E	I-PRGE
protein	I-PRGE
down	O
-	O
regulated	O
the	O
signaling	O
pathway	O
inositol	B-PRGE
-	I-PRGE
requiring	I-PRGE
enzyme	I-PRGE
1	I-PRGE
(	O
IRE	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
of	O
the	O
unfolded	O
protein	O
response	O
,	O
but	O
not	O
the	O
PKR	B-PRGE
-	I-PRGE
like	I-PRGE
ER	I-PRGE
kinase	I-PRGE
(	O
PERK	B-PRGE
)	O
or	O
activating	B-PRGE
transcription	I-PRGE
factor	I-PRGE
6	I-PRGE
(	O
ATF	B-PRGE
-	I-PRGE
6	I-PRGE
)	O
pathways	O
,	O
and	O
reduced	O
cell	O
apoptosis	O
.	O

Treatment	O
with	O
aerosolized	O
rhEC	O
-	O
SOD	B-PRGE
increased	O
the	O
survival	O
rate	O
at	O
day	O
3	O
under	O
hyperoxia	O
to	O
95	O
.	O
8	O
%,	O
which	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
control	O
group	O
(	O
57	O
.	O
1	O
%),	O
albumin	B-PRGE
treated	O
group	O
(	O
33	O
.	O
3	O
%),	O
and	O
CuZn	O
-	O
SOD	O
treated	O
group	O
(	O
75	O
%).	O

We	O
further	O
show	O
that	O
purified	O
human	O
effector	O
memory	O
CD8	O
(+)	O
T	O
lymphocytes	O
transmigrate	O
more	O
readily	O
across	O
blood	O
-	O
brain	O
barrier	O
-	O
endothelial	O
cells	O
than	O
non	O
-	O
effector	O
memory	O
CD8	O
(+)	O
T	O
lymphocytes	O
,	O
and	O
that	O
blood	O
-	O
brain	O
barrier	O
endothelium	O
promotes	O
the	O
selective	O
recruitment	O
of	O
effector	O
memory	O
CD8	B-PRGE
(+)	O
T	O
lymphocytes	O
.	O

Finally	O
,	O
we	O
show	O
that	O
in	O
vitro	O
migration	O
of	O
CD8	B-PRGE
(+)	O
T	O
lymphocytes	O
across	O
blood	O
-	O
brain	O
barrier	O
-	O
endothelial	O
cells	O
is	O
dependent	O
on	O
α4	B-PRGE
integrin	I-PRGE
,	O
but	O
independent	O
of	O
intercellular	B-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
/	I-PRGE
leucocyte	I-PRGE
function	I-PRGE
-	I-PRGE
associated	I-PRGE
antigen	I-PRGE
-	I-PRGE
1	I-PRGE
,	O
activated	B-PRGE
leucocyte	I-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
/	O
CD6	B-PRGE
and	O
the	O
chemokine	B-PRGE
monocyte	I-PRGE
chemotactic	I-PRGE
protein	I-PRGE
-	I-PRGE
1	I-PRGE
/	O
CCL2	B-PRGE
.	O

Our	O
study	O
thus	O
demonstrates	O
an	O
active	O
role	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
in	O
the	O
recruitment	O
of	O
effector	O
memory	O
CD8	B-PRGE
(+)	O
T	O
lymphocytes	O
to	O
the	O
CNS	O
compartment	O
and	O
defines	O
α4	B-PRGE
integrin	I-PRGE
as	O
a	O
major	O
contributor	O
of	O
CD8	B-PRGE
(+)	O
T	O
lymphocyte	O
entry	O
into	O
the	O
brain	O
.	O

Their	O
3C	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
3CL	O
(	O
pro	O
)),	O
which	O
catalyzes	O
the	O
proteolytic	O
processing	O
of	O
the	O
polyproteins	O
for	O
viral	O
replication	O
,	O
is	O
a	O
potential	O
target	O
for	O
anti	O
-	O
coronaviral	O
infection	O
.	O

By	O
combining	O
the	O
most	O
favorable	O
residues	O
at	O
P3	O
to	O
P5	O
positions	O
,	O
we	O
identified	O
super	O
-	O
active	O
substrate	O
sequences	O
'	O
VARLQ	O
↓	O
SGF	O
'	O
that	O
can	O
be	O
cleaved	O
efficiently	O
by	O
all	O
3CL	B-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
with	O
relative	O
activity	O
of	O
1	O
.	O
7	O
to	O
3	O
.	O
2	O
,	O
and	O
'	O
VPRLQ	O
↓	O
SGF	O
'	O
that	O
can	O
be	O
cleaved	O
specifically	O
by	O
IBV	B-PRGE
3CL	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
with	O
relative	O
activity	O
of	O
4	O
.	O
3	O
.	O

The	O
proliferation	O
of	O
the	O
peripheral	O
blood	O
mononuclear	O
cell	O
and	O
the	O
levels	O
of	O
serum	B-PRGE
IgG	I-PRGE
in	O
the	O
LPS	B-PRGE
-	I-PRGE
challenged	I-PRGE
chickens	I-PRGE
were	O
higher	O
than	O
those	O
in	O
the	O
control	O
group	O
chickens	O
at	O
21	O
and	O
42	O
d	O
of	O
age	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
Integrative	O
deep	O
sequencing	O
of	O
the	O
mouse	B-PRGE
lung	I-PRGE
transcriptome	I-PRGE
reveals	O
differential	O
expression	O
of	O
diverse	O
classes	O
of	O
small	O
RNAs	O
in	O
response	O
to	O
respiratory	O
virus	O
infection	O
.	O

Herein	O
we	O
investigated	O
the	O
role	O
of	O
Sirtuin	B-PRGE
and	O
Forkhead	B-PRGE
box	I-PRGE
O	I-PRGE
(	O
FOXO	B-PRGE
)	O
families	O
in	O
this	O
experimental	O
model	O
using	O
Nortern	O
Blot	O
and	O
Western	O
Blot	O
analysis	O
.	O

TITLE	O
:	O
Combined	O
recombinant	B-PRGE
human	I-PRGE
activated	I-PRGE
protein	I-PRGE
C	I-PRGE
and	O
ceftazidime	O
prevent	O
the	O
onset	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
severe	O
sepsis	O
.	O

Compared	O
with	O
injured	O
controls	O
,	O
the	O
treatment	O
group	O
had	O
a	O
significantly	O
higher	O
PaO₂	B-PRGE
/	O
FIO₂	O
ratio	O
,	O
and	O
the	O
onset	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
was	O
prevented	O
.	O

TITLE	O
:	O
Construction	O
and	O
characterization	O
of	O
single	O
-	O
chain	O
variable	O
fragment	O
antibody	O
library	O
derived	O
from	O
germline	B-PRGE
rearranged	I-PRGE
immunoglobulin	I-PRGE
variable	I-PRGE
genes	I-PRGE
.	O

The	O
phylogenetic	O
analysis	O
of	O
the	O
hemagglutinin	B-PRGE
gene	I-PRGE
of	O
the	O
local	O
wild	O
-	O
type	O
CDV	O
strains	O
revealed	O
that	O
the	O
seven	O
local	O
isolates	O
all	O
belonged	O
to	O
the	O
Asia	O
-	O
1	O
lineage	O
,	O
and	O
were	O
clustered	O
closely	O
with	O
one	O
another	O
at	O
the	O
same	O
location	O
.	O

TITLE	O
:	O
Potential	O
clinical	O
application	O
of	O
KGF	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
FGF	B-PRGE
-	I-PRGE
10	I-PRGE
)	O
for	O
acute	O
lung	O
injury	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

KGF	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
a	O
potent	O
alveolar	O
epithelial	O
cell	O
mitogen	O
,	O
plays	O
an	O
important	O
role	O
in	O
organ	O
morphogenesis	O
and	O
epithelial	O
differentiation	O
,	O
and	O
modulates	O
a	O
variety	O
of	O
mechanisms	O
recognized	O
to	O
be	O
important	O
in	O
alveolar	O
repair	O
and	O
resolution	O
in	O
ALI	O
/	O
ARDS	O
.	O

Cytotoxicity	O
results	O
showed	O
that	O
compound	O
1	O
has	O
low	O
toxicity	O
in	O
HepG	O
2	O
cells	O
with	O
CC	O
(	O
50	O
)	O
value	O
of	O
515	O
.	O
20μM	O
.	O
The	O
results	O
indicate	O
that	O
compound	O
1	O
can	O
efficiently	O
inhibit	O
HBV	O
replication	O
in	O
HepG	B-PRGE
2	I-PRGE
.	I-PRGE
2	I-PRGE
.	O
15	O
cells	O
line	O
in	O
vitro	O
.	O

The	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
papain	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
PLP	B-PRGE
)	O
is	O
an	O
attractive	O
target	O
for	O
pharmaceutical	O
development	O
because	O
it	O
is	O
essential	O
for	O
virus	O
replication	O
and	O
is	O
conserved	O
among	O
human	O
coronaviruses	O
.	O

Detection	O
of	O
urinary	O
Blastomyces	B-PRGE
antigen	I-PRGE
is	O
a	O
recent	O
addition	O
to	O
diagnostic	O
options	O
.	O

By	O
using	O
primarily	O
cell	O
-	O
free	O
,	O
in	O
vitro	O
translation	O
systems	O
,	O
the	O
present	O
study	O
revealed	O
that	O
the	O
nsp1	B-PRGE
induced	O
endonucleolytic	O
RNA	O
cleavage	O
mainly	O
near	O
the	O
5	O
'	O
untranslated	O
region	O
of	O
capped	O
mRNA	O
templates	O
.	O

ABSTRACT	O
:	O
CD4	B-PRGE
T	O
cell	O
activation	O
during	O
peripheral	O
infections	O
not	O
only	O
is	O
essential	O
in	O
inducing	O
protective	O
CD8	B-PRGE
T	I-PRGE
cell	O
memory	O
but	O
also	O
promotes	O
CD8	B-PRGE
T	I-PRGE
cell	O
function	O
and	O
survival	O
.	O

Delayed	O
CD4	B-PRGE
T	I-PRGE
cell	O
depletion	O
abrogated	O
CD4	B-PRGE
T	I-PRGE
cell	O
recruitment	O
to	O
the	O
CNS	O
but	O
only	O
slightly	O
diminished	O
CD8	B-PRGE
T	I-PRGE
cell	O
recruitment	O
.	O

TITLE	O
:	O
Development	O
of	O
common	O
variable	O
immunodeficiency	O
in	O
IgA	B-PRGE
-	O
and	O
IgG2	B-PRGE
-	O
deficient	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
.	O

In	O
addition	O
to	O
interferon	B-PRGE
(	O
IFN	O
)-	O
α	O
,	O
plenty	O
of	O
keratinocyte	O
-	O
derived	O
chemokines	O
(	O
KC	O
),	O
macrophage	B-PRGE
inflammatory	I-PRGE
protein	I-PRGE
2	I-PRGE
(	O
MIP	B-PRGE
-	I-PRGE
2	I-PRGE
),	O
regulated	O
on	O
activation	O
normal	O
T	O
-	O
cell	O
expressed	O
and	O
secreted	O
(	O
RANTES	O
),	O
and	O
monocyte	B-PRGE
chemotactic	I-PRGE
protein	I-PRGE
1	I-PRGE
(	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
were	O
significantly	O
released	O
into	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
of	O
the	O
model	O
.	O

The	O
present	O
study	O
suggests	O
that	O
MPO	B-PRGE
-	O
mediated	O
OCl	O
(-)	O
generation	O
affects	O
claudin	O
molecules	O
and	O
leads	O
to	O
protein	O
leakage	O
and	O
viral	O
spread	O
as	O
a	O
damage	O
factor	O
in	O
influenza	O
-	O
induced	O
ARDS	O
.	O

Detection	O
of	O
feline	B-PRGE
coronavirus	I-PRGE
antigen	I-PRGE
in	O
macrophages	O
was	O
negative	O
.	O

Vaccination	O
with	O
H120	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
rS1	O
,	O
induced	O
HI	O
and	O
virus	O
-	O
specific	O
IgG	B-PRGE
antibody	I-PRGE
production	O
.	O

When	O
adding	O
microbes	O
to	O
these	O
cultures	O
,	O
bacteria	O
and	O
virus	O
differed	O
in	O
two	O
major	O
respects	O
;	O
Firstly	O
,	O
all	O
enveloped	O
viruses	O
,	O
but	O
none	O
of	O
the	O
bacteria	O
,	O
blocked	O
Th2	B-PRGE
(	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
)	O
production	O
by	O
cord	O
CD4	B-PRGE
(+)	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
endodomain	O
of	O
several	O
coronavirus	O
(	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
proteins	O
contains	O
palmitylated	O
cysteine	O
residues	O
and	O
enables	O
co	O
-	O
localization	O
and	O
interaction	O
with	O
the	O
CoV	B-PRGE
membrane	I-PRGE
(	I-PRGE
M	I-PRGE
)	I-PRGE
protein	I-PRGE
.	O

This	O
indicated	O
that	O
these	O
palmitylated	O
cysteines	O
are	O
essential	O
for	O
S	O
incorporation	O
,	O
but	O
are	O
not	O
involved	O
in	O
S	O
co	O
-	O
localization	O
mediated	O
by	O
the	O
M	B-PRGE
protein	I-PRGE
.	O

We	O
show	O
here	O
that	O
three	O
residues	O
on	O
the	O
β3	O
(	O
Arg	O
-	O
125	O
and	O
Tyr	O
-	O
127	O
)	O
and	O
β5	O
(	O
Tyr	O
-	O
190	O
)	O
strands	O
play	O
key	O
roles	O
in	O
TRS	B-PRGE
RNA	I-PRGE
binding	O
and	O
helix	O
destabilization	O
with	O
Ala	O
substitutions	O
of	O
these	O
residues	O
lethal	O
to	O
the	O
virus	O
.	O

NMR	O
studies	O
of	O
the	O
MHV	B-PRGE
NTD	I-PRGE
·	I-PRGE
TRS	I-PRGE
complex	I-PRGE
revealed	O
that	O
this	O
region	O
defines	O
a	O
major	O
RNA	O
binding	O
interface	O
in	O
MHV	O
with	O
site	O
-	O
directed	O
spin	O
labeling	O
studies	O
consistent	O
with	O
a	O
model	O
in	O
which	O
the	O
adenosine	O
-	O
rich	O
3	O
'-	O
region	O
of	O
TRS	O
is	O
anchored	O
by	O
Arg	O
-	O
125	O
,	O
Tyr	O
-	O
127	O
,	O
and	O
Tyr	O
-	O
190	O
in	O
a	O
way	O
that	O
is	O
critical	O
for	O
efficient	O
subgenomic	O
RNA	O
synthesis	O
in	O
MHV	O
.	O

TITLE	O
:	O
Angiotensin	B-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
abrogates	O
bleomycin	O
-	O
induced	O
lung	O
injury	O
.	O

Male	O
ACE2	O
(-/	O
y	O
)	O
BLM	O
injured	O
mice	O
exhibited	O
poorer	O
exercise	O
capacity	O
,	O
worse	O
lung	O
function	O
and	O
exacerbated	O
lung	O
fibrosis	O
and	O
collagen	B-PRGE
deposition	O
compared	O
with	O
WT	O
.	O

Consistent	O
with	O
this	O
observation	O
,	O
pharmacological	O
inhibitors	O
of	O
PI4KB	B-PRGE
blocked	O
entry	O
of	O
SARS	O
pseudovirions	O
.	O

IBV	O
progeny	O
production	O
and	O
release	O
were	O
increased	O
in	O
infected	O
Mcl	B-PRGE
-	I-PRGE
1	I-PRGE
knockdown	O
cells	O
compared	O
to	O
similarly	O
infected	O
control	O
cells	O
,	O
while	O
the	O
contrary	O
was	O
observed	O
in	O
infected	O
Bak	O
knockdown	O
cells	O
.	O

However	O
,	O
a	O
recent	O
study	O
found	O
that	O
one	O
-	O
third	O
of	O
FIPV	O
isolates	O
have	O
an	O
intact	O
3c	O
and	O
suggested	O
that	O
it	O
is	O
not	O
solely	O
involved	O
in	O
FIP	B-PRGE
but	O
is	O
essential	O
for	O
intestinal	O
replication	O
.	O

The	O
underlying	O
mechanisms	O
that	O
involve	O
canonical	O
inflammatory	O
pathways	O
such	O
as	O
MAP	B-PRGE
kinases	I-PRGE
,	O
CXCR2	B-PRGE
chemokines	I-PRGE
,	O
PAF	B-PRGE
,	O
leukotrienes	O
,	O
adhesions	O
molecules	O
(	O
CD18	B-PRGE
,	O
ICAM	O
-	O
1	O
)	O
and	O
elastase	O
have	O
been	O
defined	O
relatively	O
well	O
.	O

These	O
results	O
not	O
only	O
illustrate	O
the	O
detailed	O
mechanisms	O
of	O
host	O
receptor	O
adaptation	O
by	O
SARS	B-PRGE
-	O
CoV	O
but	O
also	O
provide	O
a	O
molecular	O
and	O
structural	O
basis	O
for	O
tracking	O
future	O
SARS	O
-	O
CoV	O
evolution	O
in	O
animals	O
.	O

ABSTRACT	O
:	O
The	O
hemagglutinin	B-PRGE
-	I-PRGE
esterases	I-PRGE
(	I-PRGE
HEs	I-PRGE
),	I-PRGE
envelope	I-PRGE
glycoproteins	I-PRGE
of	O
corona	O
-,	O
toro	O
-	O
and	O
orthomyxoviruses	O
,	O
mediate	O
reversible	O
virion	O
attachment	O
to	O
O	O
-	O
acetylated	O
sialic	O
acids	O
(	O
O	O
-	O
Ac	O
-	O
Sias	O
).	O

TITLE	O
:	O
The	O
coronavirus	B-PRGE
endoribonuclease	I-PRGE
Nsp15	I-PRGE
interacts	O
with	O
retinoblastoma	B-PRGE
tumor	I-PRGE
suppressor	I-PRGE
protein	I-PRGE
.	O

The	O
known	O
isoforms	O
of	O
PSG16	O
are	O
N	O
-	O
terminally	O
truncated	O
relative	O
to	O
other	O
PSG	B-PRGE
family	I-PRGE
proteins	I-PRGE
and	O
are	O
expressed	O
in	O
neurons	O
as	O
well	O
as	O
in	O
the	O
placenta	O
.	O

ABSTRACT	O
:	O
It	O
is	O
widely	O
understood	O
that	O
tumor	O
cells	O
express	O
tumor	O
-	O
associated	O
antigens	O
(	O
TAAs	O
),	O
of	O
which	O
many	O
are	O
usually	O
in	O
low	O
immunogenicity	O
;	O
for	O
example	O
,	O
carcinoembryonic	B-PRGE
antigen	I-PRGE
(	O
CEA	B-PRGE
)	O
is	O
specifically	O
expressed	O
on	O
human	O
colon	O
cancer	O
cells	O
and	O
is	O
viewed	O
as	O
a	O
low	O
-	O
immunogenic	O
TAA	O
.	O

To	O
enhance	O
the	O
immune	O
efficiency	O
of	O
CEA	O
in	O
mice	O
that	O
received	O
,	O
we	O
fused	O
a	O
partial	O
CEA	B-PRGE
gene	I-PRGE
with	O
exogenous	O
SARS	O
-	O
CoV	O
fragments	O
.	O

Antibody	O
against	O
recombinant	B-PRGE
bat	I-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
was	O
detected	O
in	O
84	O
%	O
of	O
Chinese	O
horseshoe	O
bats	O
using	O
an	O
enzyme	O
immunoassay	O
.	O

Antibody	O
-	O
mediated	O
enhancement	O
of	O
SARS	O
-	O
CoV	O
infection	O
with	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
Spike	I-PRGE
immune	O
-	O
serum	O
was	O
observed	O
in	O
vitro	O
.	O

Antibody	O
-	O
mediated	O
infection	O
of	O
SARS	O
-	O
CoV	O
triggers	O
entry	O
into	O
human	O
haematopoietic	O
cells	O
via	O
an	O
FcγR	O
-	O
dependent	O
and	O
ACE2	B-PRGE
-,	O
pH	O
-,	O
cysteine	O
-	O
protease	O
-	O
independent	O
pathways	O
.	O

Multiple	O
CXC	O
chemokines	O
that	O
signal	O
through	O
CXCR2	B-PRGE
were	O
required	O
for	O
PMN	O
chemotaxis	O
toward	O
medium	O
from	O
RCoV	O
-	O
infected	O
AT1	O
-	O
like	O
cells	O
(	O
RCoV	B-PRGE
-	I-PRGE
AT1	I-PRGE
).	O

We	O
found	O
that	O
expression	O
of	O
the	O
membrane	O
anchored	O
PLP	B-PRGE
domain	I-PRGE
from	O
human	B-PRGE
HCoV	I-PRGE
-	I-PRGE
NL63	I-PRGE
(	O
PLP2	B-PRGE
-	I-PRGE
TM	I-PRGE
)	O
or	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
(	O
PLpro	O
-	O
TM	O
)	O
inhibits	O
STING	B-PRGE
-	O
mediated	O
activation	O
of	O
IRF	B-PRGE
-	I-PRGE
3	I-PRGE
nuclear	O
translocation	O
and	O
induction	O
of	O
IRF	B-PRGE
-	I-PRGE
3	I-PRGE
dependent	O
promoters	O
.	O

Both	O
catalytically	O
active	O
and	O
inactive	O
forms	O
of	O
CoV	O
PLPs	O
co	O
-	O
immunoprecipitated	O
with	O
STING	O
,	O
and	O
viral	B-PRGE
replicase	I-PRGE
proteins	I-PRGE
co	O
-	O
localize	O
with	O
STING	O
in	O
HCoV	O
-	O
NL63	O
-	O
infected	O
cells	O
.	O

In	O
contrast	O
,	O
mice	O
with	O
pDC	O
-	O
specific	O
loss	O
of	O
MHC	B-PRGE
class	O
II	O
expression	O
supported	O
normal	O
CD4	B-PRGE
(+)	O
T	O
-	O
cell	O
response	O
to	O
LCMV	O
.	O

As	O
compared	O
to	O
that	O
of	O
pre	O
-	O
treatment	O
period	O
,	O
white	O
blood	O
cells	O
[	O
WBC	O
,	O
×	O
10	O
(	O
9	O
)/	O
L	O
:	O
12	O
.	O
18	O
±	O
4	O
.	O
76	O
vs	O
.	O
21	O
.	O
93	O
±	O
6	O
.	O
21	O
],	O
neutrophil	O
percentage	O
(	O
0	O
.	O
87	O
±	O
0	O
.	O
05	O
vs	O
.	O
0	O
.	O
92	O
±	O
0	O
.	O
03	O
),	O
hemoglobin	B-PRGE
(	O
Hb	O
,	O
g	O
/	O
L	O
:	O
128	O
.	O
12	O
±	O
25	O
.	O
65	O
vs	O
.	O
173	O
.	O
71	O
±	O
23	O
.	O
53	O
),	O
blood	O
platelet	O
count	O
[	O
PLT	O
,×	O
10	O
(	O
9	O
)/	O
L	O
:	O
165	O
.	O
12	O
±	O
31	O
.	O
70	O
vs	O
.	O
254	O
.	O
47	O
±	O
70	O
.	O
80	O
],	O
alanine	B-PRGE
transaminase	I-PRGE
(	O
ALT	B-PRGE
,	O
U	O
/	O
L	O
:	O
70	O
.	O
71	O
±	O
46	O
.	O
70	O
vs	O
.	O
212	O
.	O
71	O
±	O
141	O
.	O
34	O
),	O
aspartate	B-PRGE
aminotransferase	I-PRGE
(	O
AST	B-PRGE
,	O
U	O
/	O
L	O
:	O
52	O
.	O
47	O
±	O
34	O
.	O
68	O
vs	O
.	O
82	O
.	O
41	O
±	O
34	O
.	O
60	O
),	O
blood	O
urea	O
nitrogen	O
(	O
BUN	O
,	O
mmol	O
/	O
L	O
:	O
5	O
.	O
83	O
±	O
4	O
.	O
09	O
vs	O
.	O
7	O
.	O
89	O
±	O
5	O
.	O
96	O
),	O
serum	O
creatinine	O
(	O
SCr	O
,	O
μmol	O
/	O
L	O
:	O
48	O
.	O
13	O
±	O
14	O
.	O
97	O
vs	O
.	O
67	O
.	O
25	O
±	O
24	O
.	O
29	O
),	O
lactate	B-PRGE
dehydrogenase	I-PRGE
(	O
LDH	B-PRGE
,	O
U	O
/	O
L	O
:	O
280	O
.	O
10	O
±	O
81	O
.	O
77	O
vs	O
.	O
586	O
.	O
35	O
±	O
186	O
.	O
71	O
),	O
creatine	B-PRGE
kinase	I-PRGE
(	O
CK	O
,	O
U	O
/	O
L	O
:	O
199	O
.	O
12	O
±	O
106	O
.	O
75	O
vs	O
.	O
683	O
.	O
00	O
±	O
323	O
.	O
21	O
),	O
MB	O
isoenzyme	O
of	O
creatine	B-PRGE
kinase	I-PRGE
(	O
CK	O
-	O
MB	O
,	O
U	O
/	O
L	O
:	O
26	O
.	O
94	O
±	O
9	O
.	O
13	O
vs	O
.	O
45	O
.	O
59	O
±	O
11	O
.	O
21	O
),	O
serum	O
chlorine	O
anion	O
[	O
Cl	O
(-),	O
mmol	O
/	O
L	O
:	O
95	O
.	O
88	O
±	O
6	O
.	O
06	O
vs	O
.	O
102	O
.	O
29	O
±	O
7	O
.	O
28	O
],	O
respiratory	O
rate	O
(	O
RR	O
,	O
beats	O
/	O
min	O
:	O
20	O
.	O
88	O
±	O
4	O
.	O
30	O
vs	O
.	O
30	O
.	O
06	O
±	O
5	O
.	O
78	O
),	O
heart	O
rate	O
(	O
HR	O
,	O
beats	O
/	O
min	O
:	O
82	O
.	O
76	O
±	O
17	O
.	O
16	O
vs	O
.	O
113	O
.	O
35	O
±	O
16	O
.	O
90	O
),	O
blood	O
pH	O
value	O
(	O
7	O
.	O
34	O
±	O
0	O
.	O
44	O
vs	O
.	O
7	O
.	O
39	O
±	O
0	O
.	O
03	O
)	O
were	O
all	O
decreased	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
).	O

TITLE	O
:	O
Nonstructural	O
proteins	O
7	O
and	O
8	O
of	O
feline	O
coronavirus	O
form	O
a	O
2	O
:	O
1	O
heterotrimer	O
that	O
exhibits	O
primer	O
-	O
independent	O
RNA	B-PRGE
polymerase	I-PRGE
activity	O
.	O

We	O
present	O
here	O
the	O
2	O
.	O
6	O
-	O
Å	O
crystal	O
structure	O
of	O
the	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
Nsp7	O
:	O
Nsp8	B-PRGE
complex	I-PRGE
,	O
which	O
is	O
a	O
2	O
:	O
1	O
heterotrimer	O
containing	O
two	O
copies	O
of	O
the	O
α	O
-	O
helical	O
Nsp7	O
with	O
conformational	O
differences	O
between	O
them	O
,	O
and	O
one	O
copy	O
of	O
Nsp8	O
that	O
consists	O
of	O
an	O
α	B-PRGE
/	I-PRGE
β	I-PRGE
domain	I-PRGE
and	O
a	O
long	O
-	O
α	O
-	O
helix	O
domain	O
.	O

Reverse	O
transcription	O
(	O
RT	O
)	O
PCR	O
methods	O
were	O
applied	O
to	O
detect	O
common	O
respiratory	O
viruses	O
including	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
human	O
rhinovirus	O
(	O
HRV	O
),	O
influenza	O
virus	O
type	O
A	O
,	O
B	O
and	O
C	O
(	O
IFA	O
,	O
IFB	B-PRGE
,	O
IFC	B-PRGE
),	O
parainfluenza	O
virus	O
(	O
PIV	O
)	O
type	O
1	O
-	O
4	O
,	O
adenovirus	O
(	O
ADV	O
),	O
enterovirus	O
(	O
EV	O
),	O
human	O
coronavirus	O
(	O
HCOV	O
),	O
human	O
metapneumovirus	O
(	O
HMPV	O
)	O
and	O
human	O
bocavirus	O
(	O
HBOV	O
).	O

The	O
sensitivity	O
of	O
the	O
developed	O
heterosandwich	O
ELISA	O
can	O
detect	O
the	O
viral	B-PRGE
antigen	I-PRGE
at	O
18	O
.	O
5	O
pg	O
/	O
mL	O
of	O
recombinant	O
NP	O
.	O

Our	O
findings	O
demonstrated	O
that	O
even	O
in	O
the	O
absence	O
of	O
avian	B-PRGE
-	I-PRGE
specific	I-PRGE
receptor	I-PRGE
,	O
DC	B-PRGE
-	I-PRGE
SIGN	I-PRGE
-	I-PRGE
like	I-PRGE
lectins	I-PRGE
are	O
capable	O
of	O
mediating	O
efficient	O
IBV	O
infection	O
.	O

Both	O
D2	O
-	O
tsS133A	O
and	O
D3	O
-	O
tsF219L	O
were	O
impaired	O
for	O
viral	O
replication	O
and	O
nsp5	B-PRGE
-	O
mediated	O
polyprotein	O
processing	O
at	O
the	O
nonpermissive	O
temperature	O
.	O

Lung	O
proinflammatory	O
cytokines	O
were	O
induced	O
at	O
1	O
to	O
14	O
dpi	O
,	O
but	O
most	O
returned	O
to	O
baseline	O
by	O
28	O
dpi	O
except	O
interleukin	B-PRGE
12	I-PRGE
(	O
IL	O
-	O
12	O
)	O
and	O
gamma	B-PRGE
interferon	I-PRGE
.	O

Using	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
against	O
MADP1	B-PRGE
,	O
defective	O
viral	O
RNA	O
synthesis	O
was	O
observed	O
in	O
the	O
knockdown	O
cells	O
,	O
therefore	O
indicating	O
the	O
importance	O
of	O
the	O
protein	O
in	O
coronaviral	O
RNA	O
synthesis	O
.	O

Taken	O
together	O
,	O
our	O
results	O
indicate	O
that	O
the	O
one	O
-	O
step	O
multiplex	O
RT	O
-	O
PCR	O
developed	O
here	O
for	O
the	O
detection	O
of	O
GAR	O
,	O
GBR	O
,	O
GCR	B-PRGE
,	O
BCV	O
,	O
and	O
BToV	O
can	O
be	O
expected	O
to	O
be	O
a	O
useful	O
tool	O
for	O
the	O
rapid	O
and	O
cost	O
-	O
effective	O
diagnosis	O
and	O
surveillance	O
of	O
viral	O
diarrhea	O
in	O
adult	O
cattle	O
.	O

We	O
found	O
that	O
depletion	O
of	O
Tregs	O
had	O
no	O
impact	O
on	O
viral	O
distribution	O
and	O
clearance	O
and	O
did	O
not	O
significantly	O
alter	O
virus	O
-	O
specific	O
CD4	B-PRGE
(+)	O
and	O
CD8	B-PRGE
(+)	O
T	O
cell	O
responses	O
.	O

Four	O
biflavonoids	O
(	O
1	O
-	O
4	O
),	O
three	O
sterols	O
(	O
5	O
-	O
7	O
),	O
and	O
two	O
stilbene	O
derivatives	O
(	O
8	O
-	O
9	O
)	O
were	O
identified	O
and	O
evaluated	O
for	O
their	O
antiviral	O
potential	O
on	O
the	O
DV	B-PRGE
-	I-PRGE
NS5	I-PRGE
RdRp	I-PRGE
.	O

Comparative	O
analysis	O
of	O
replication	O
kinetics	O
showed	O
that	O
the	O
kinetics	O
of	O
recSARS	O
-	O
CoV	O
replication	O
are	O
similar	O
to	O
those	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
Frankfurt	I-PRGE
-	I-PRGE
1	I-PRGE
,	O
although	O
the	O
titers	O
of	O
virus	O
released	O
into	O
the	O
culture	O
supernatant	O
are	O
approximately	O
10	O
-	O
fold	O
less	O
.	O

TITLE	O
:	O
Local	O
pulmonary	O
administration	O
of	O
factor	B-PRGE
VIIa	I-PRGE
(	O
rFVIIa	O
)	O
in	O
diffuse	O
alveolar	O
hemorrhage	O
(	O
DAH	O
)	O
-	O
a	O
review	O
of	O
a	O
new	O
treatment	O
paradigm	O
.	O

The	O
ORF1a	B-PRGE
,	I-PRGE
spike	I-PRGE
and	I-PRGE
nucleocapsid	I-PRGE
genes	I-PRGE
were	O
under	O
strong	O
positive	O
selective	O
pressure	O
that	O
resulted	O
in	O
genetic	O
diversity	O
in	O
relation	O
to	O
classical	O
IBV	O
isolates	O
.	O

These	O
results	O
suggest	O
that	O
multiple	O
cysteine	O
as	O
well	O
as	O
charged	O
residues	O
concurrently	O
improves	O
the	O
membrane	O
-	O
associated	O
functions	O
of	O
S	B-PRGE
protein	I-PRGE
in	O
viral	O
replication	O
and	O
cytopathogenesis	O
.	O

TITLE	O
:	O
Identification	O
of	O
common	O
biological	O
pathways	O
and	O
drug	O
targets	O
across	O
multiple	O
respiratory	O
viruses	O
based	O
on	O
human	B-PRGE
host	I-PRGE
gene	I-PRGE
expression	O
analysis	O
.	O

TITLE	O
:	O
[	O
KCTD9	B-PRGE
,	O
a	O
novel	O
potassium	O
channel	O
related	O
gene	O
,	O
was	O
highly	O
expressed	O
in	O
hepatic	O
NK	O
cells	O
and	O
T	O
cells	O
of	O
fulminant	O
hepatitis	O
mice	O
induced	O
by	O
MHV	O
-	O
3	O
].	O

ABSTRACT	O
:	O
We	O
investigated	O
the	O
clinical	O
impact	O
of	O
human	B-PRGE
coronaviruses	I-PRGE
(	O
HCoV	O
)	O
OC43	O
,	O
229E	O
,	O
HKU1	O
and	O
NL63	O
in	O
pediatric	O
patients	O
with	O
cystic	O
fibrosis	O
(	O
CF	O
)	O
during	O
routine	O
and	O
exacerbation	O
visits	O
.	O

Increasing	O
mRNA	O
levels	O
of	O
serum	B-PRGE
amyloid	I-PRGE
A	I-PRGE
could	O
be	O
a	O
confident	O
marker	O
of	O
severity	O
of	O
pulmonary	O
lesions	O
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
caudatin	O
derivatives	O
were	O
synthesized	O
,	O
and	O
their	O
anti	O
-	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
activity	O
was	O
evaluated	O
in	O
HepG	B-PRGE
2	I-PRGE
.	I-PRGE
2	I-PRGE
.	O
15	O
cells	O
.	O

The	O
effectiveness	O
of	O
the	O
scFv	O
library	O
against	O
pAPN	O
was	O
verified	O
further	O
by	O
phage	O
ELISA	O
using	O
the	O
recombinant	O
protein	O
of	O
the	O
pAPN	B-PRGE
C	I-PRGE
subunit	I-PRGE
as	I-PRGE
coating	I-PRGE
antigen	I-PRGE
.	O

Univariate	O
analysis	O
revealed	O
no	O
significant	O
pre	O
-	O
ECMO	O
risk	O
factor	O
for	O
treatment	O
failure	O
but	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
concentration	O
at	O
the	O
time	O
of	O
ECMO	O
differed	O
significantly	O
among	O
patients	O
who	O
did	O
versus	O
did	O
not	O
survive	O
after	O
ECMO	O
.	O

TITLE	O
:	O
Simultaneous	O
treatment	O
of	O
human	O
bronchial	O
epithelial	O
cells	O
with	O
serine	O
and	O
cysteine	B-PRGE
protease	I-PRGE
inhibitors	O
prevents	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
entry	O
.	O

ABSTRACT	O
:	O
The	O
type	B-PRGE
II	I-PRGE
transmembrane	I-PRGE
protease	I-PRGE
TMPRSS2	I-PRGE
activates	O
the	O
spike	O
(	O
S	O
)	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
on	O
the	O
cell	O
surface	O
following	O
receptor	O
binding	O
during	O
viral	O
entry	O
into	O
cells	O
.	O

Furthermore	O
,	O
the	O
fusion	O
protein	O
,	O
but	O
not	O
rS450	O
-	O
650	O
alone	O
,	O
was	O
able	O
to	O
elicit	O
S450	O
-	O
650	O
-	O
specific	O
IgG	B-PRGE
responses	O
in	O
T	O
cell	O
deficient	O
nude	O
mice	O
.	O

A	O
higher	O
IgA	B-PRGE
titer	O
was	O
induced	O
by	O
the	O
LAB	O
with	O
ARV	O
σC	O
protein	O
attached	O
.	O

Moreover	O
,	O
the	O
serum	O
of	O
mice	O
immunized	O
with	O
LAB	O
displaying	O
divalent	O
antigens	O
had	O
much	O
stronger	O
immune	O
reactivity	O
against	O
ARV	B-PRGE
σC	I-PRGE
protein	I-PRGE
compared	O
to	O
IBV	O
-	O
S1	O
.	O

Here	O
,	O
we	O
show	O
that	O
both	O
HAT	B-PRGE
and	O
TMPRSS2	B-PRGE
are	O
coexpressed	O
with	O
2	O
,	O
6	O
-	O
linked	O
sialic	O
acids	O
,	O
the	O
major	O
receptor	O
determinant	O
of	O
human	O
influenza	O
viruses	O
,	O
throughout	O
the	O
human	O
respiratory	O
tract	O
.	O

Similarly	O
,	O
coexpression	O
of	O
ACE2	B-PRGE
,	O
the	O
SARS	B-PRGE
-	I-PRGE
coronavirus	I-PRGE
receptor	I-PRGE
,	O
and	O
TMPRSS2	O
was	O
frequently	O
found	O
in	O
the	O
upper	O
and	O
lower	O
aerodigestive	O
tract	O
,	O
with	O
the	O
exception	O
of	O
the	O
vocal	O
folds	O
,	O
epiglottis	O
and	O
trachea	O
.	O

In	O
sum	O
,	O
our	O
results	O
show	O
that	O
TMPRSS2	B-PRGE
and	O
HAT	B-PRGE
are	O
expressed	O
by	O
important	O
influenza	O
and	O
SARS	O
-	O
coronavirus	O
target	O
cells	O
and	O
could	O
thus	O
support	O
viral	O
spread	O
in	O
the	O
human	O
host	O
.	O

As	O
a	O
result	O
,	O
15	O
-	O
16kb	O
nucleotide	O
sequences	O
encoding	O
complete	O
RNA	B-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
,	O
spike	O
,	O
envelope	B-PRGE
,	O
membrane	O
,	O
and	O
nucleocapsid	O
proteins	O
plus	O
other	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
were	O
generated	O
.	O

BtKY27	O
and	O
BtKY33	O
are	O
members	O
of	O
the	O
established	O
bat	B-PRGE
CoV	I-PRGE
species	O
in	O
Alphacoronavirus	O
genus	O
and	O
BtKY06	O
is	O
a	O
member	O
of	O
the	O
established	O
bat	B-PRGE
CoV	I-PRGE
species	O
in	O
Betacoronavirus	O
genus	O
.	O

The	O
genome	O
organization	O
of	O
these	O
seven	O
CoVs	O
is	O
similar	O
to	O
other	O
known	O
CoVs	O
from	O
the	O
same	O
groups	O
except	O
for	O
differences	O
in	O
the	O
number	O
of	O
putative	O
ORFs	O
following	O
the	O
N	B-PRGE
gene	I-PRGE
.	O

Importantly	O
,	O
they	O
inhibit	O
proteins	O
which	O
are	O
not	O
targeted	O
by	O
existing	O
antiviral	O
therapies	O
,	O
for	O
example	O
,	O
Vpu	O
of	O
HIV	O
type	O
1	O
,	O
p7	O
of	O
hepatitis	O
C	O
virus	O
,	O
E	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
and	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
of	O
coxsackievirus	O
B3	O
.	O

TITLE	O
:	O
CD200	B-PRGE
receptor	I-PRGE
controls	O
sex	O
-	O
specific	O
TLR7	B-PRGE
responses	O
to	O
viral	O
infection	O
.	O

TITLE	O
:	O
Mechanism	O
of	O
nucleic	O
acid	O
unwinding	O
by	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
helicase	I-PRGE
.	O

We	O
also	O
showed	O
that	O
nsp12	O
,	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
(	O
RdRp	O
),	O
enhances	O
(	O
2	O
-	O
fold	O
)	O
the	O
catalytic	O
efficiency	O
of	O
nsp13	O
by	O
increasing	O
the	O
step	O
size	O
of	O
nucleic	O
acid	O
(	O
RNA	O
/	O
RNA	O
or	O
DNA	O
/	O
DNA	O
)	O
unwinding	O
.	O

Our	O
data	O
provide	O
experimental	O
evidence	O
that	O
nsp13	O
and	O
nsp12	O
can	O
function	O
in	O
a	O
concerted	O
manner	O
to	O
improve	O
the	O
efficiency	O
of	O
viral	O
replication	O
and	O
enhance	O
our	O
understanding	O
of	O
nsp13	O
function	O
during	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
synthesis	O
.	O

However	O
,	O
because	O
it	O
is	O
a	O
protein	O
,	O
the	O
rOv	B-PRGE
-	I-PRGE
ASP	I-PRGE
-	I-PRGE
1	I-PRGE
adjuvant	O
may	O
also	O
induce	O
anti	O
-	O
self	O
-	O
antibodies	O
.	O

Therefore	O
,	O
it	O
was	O
important	O
to	O
verify	O
that	O
the	O
host	O
responses	O
to	O
self	O
will	O
not	O
affect	O
the	O
adjuvanticity	O
of	O
rOv	B-PRGE
-	I-PRGE
ASP	I-PRGE
-	I-PRGE
1	I-PRGE
when	O
it	O
is	O
used	O
in	O
subsequent	O
vaccinations	O
with	O
the	O
same	O
or	O
different	O
vaccine	O
antigens	O
.	O

TITLE	O
:	O
Comparative	O
in	O
vivo	O
analysis	O
of	O
the	O
nsp15	B-PRGE
endoribonuclease	I-PRGE
of	O
murine	O
,	O
porcine	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronaviruses	O
.	O

At	O
steady	O
state	O
,	O
they	O
are	O
selectively	O
removed	O
from	O
the	O
ER	O
by	O
poorly	O
defined	O
events	O
collectively	O
referred	O
to	O
as	O
ERAD	B-PRGE
tuning	O
.	O

The	O
early	O
loss	O
of	O
macrophages	O
resulted	O
in	O
reduced	O
pathogenic	O
tumour	O
necrosis	O
factor	O
α	O
(	O
TNFα	O
)	O
and	O
FGL2	B-PRGE
levels	O
and	O
lower	O
viral	O
titres	O
.	O

By	O
contrast	O
,	O
IL	B-PRGE
-	I-PRGE
17	I-PRGE
depletion	O
rescued	O
recipients	O
of	O
GKO	B-PRGE
CD4	I-PRGE
+	I-PRGE
T	I-PRGE
cells	O
from	O
rapid	O
mortality	O
without	O
diminishing	O
neutrophils	O
or	O
reducing	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
,	O
associated	O
with	O
pathogenic	O
Th17	O
cells	O
in	O
CNS	O
autoimmune	O
models	O
.	O

Furthermore	O
,	O
co	O
-	O
transfer	O
of	O
WT	O
and	O
GKO	O
CD4	B-PRGE
+	I-PRGE
T	O
cells	O
prolonged	O
survival	O
in	O
an	O
IFN	B-PRGE
-	I-PRGE
γ	I-PRGE
dependent	O
manner	O
,	O
although	O
IL	B-PRGE
-	I-PRGE
17	I-PRGE
transcription	O
was	O
not	O
reduced	O
.	O

These	O
data	O
demonstrate	O
that	O
IL	B-PRGE
-	I-PRGE
17	I-PRGE
mediates	O
detrimental	O
clinical	O
consequences	O
in	O
an	O
IFN	B-PRGE
-	I-PRGE
γ	I-PRGE
-	O
deprived	O
environment	O
,	O
independent	O
of	O
extensive	O
neutrophil	O
accumulation	O
or	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
upregulation	O
.	O

The	O
interaction	O
between	O
nonstructural	O
protein	O
(	O
nsp	O
)	O
10	O
and	O
nsp16	O
has	O
been	O
demonstrated	O
and	O
the	O
crystal	O
structure	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
nsp16	I-PRGE
/	I-PRGE
10	I-PRGE
complex	I-PRGE
has	O
been	O
revealed	O
.	O

Later	O
during	O
the	O
1990s	O
,	O
recombinant	B-PRGE
-	I-PRGE
activated	I-PRGE
factor	I-PRGE
VII	I-PRGE
(	O
FVIIa	O
)	O
was	O
purported	O
to	O
provide	O
quicker	O
hemostasis	O
in	O
patients	O
treated	O
with	O
HS	O
.	O

DIC	B-PRGE
is	O
also	O
seen	O
in	O
association	O
with	O
toxic	O
exposures	O
,	O
including	O
snake	O
bites	O
.	O

We	O
show	O
that	O
ns2	O
has	O
2	O
',	O
5	O
'-	O
phosphodiesterase	O
activity	O
,	O
which	O
blocks	O
the	O
interferon	B-PRGE
inducible	I-PRGE
2	I-PRGE
',	I-PRGE
5	I-PRGE
'-	I-PRGE
oligoadenylate	I-PRGE
synthetase	I-PRGE
(	I-PRGE
OAS	I-PRGE
)-	I-PRGE
RNase	I-PRGE
L	I-PRGE
pathway	O
to	O
facilitate	O
hepatitis	O
development	O
.	O

A	O
specific	O
decrease	O
for	O
ACE2	B-PRGE
protein	I-PRGE
level	O
was	O
observed	O
when	O
HCoV	O
-	O
NL63	O
was	O
cultured	O
at	O
34	O
°	O
C	O
.	O

These	O
results	O
indicate	O
that	O
the	O
5	O
'-	O
terminal	O
region	O
of	O
the	O
S	B-PRGE
gene	I-PRGE
is	O
not	O
essential	O
for	O
the	O
development	O
of	O
FIP	O
.	O

TITLE	O
:	O
Protective	O
effects	O
of	O
long	O
pentraxin	O
PTX3	B-PRGE
on	O
lung	O
injury	O
in	O
a	O
severe	O
acute	O
respiratory	O
syndrome	O
model	O
in	O
mice	O
.	O

These	O
mice	O
were	O
also	O
treated	O
with	O
recombinant	O
PTX3	B-PRGE
.	O

MHV	O
-	O
1	O
infection	O
led	O
to	O
acute	O
lung	O
injury	O
with	O
greater	O
severity	O
in	O
PTX3	B-PRGE
-	O
deficient	O
mice	O
than	O
that	O
in	O
WT	O
mice	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
replication	O
inhibitor	O
that	O
interferes	O
with	O
the	O
nucleic	O
acid	O
unwinding	O
of	O
the	O
viral	B-PRGE
helicase	I-PRGE
.	O

The	O
highest	O
expression	O
level	O
of	O
the	O
COE	O
-	O
Co1	B-PRGE
fusion	O
protein	O
reached	O
0	O
.	O
083	O
%	O
of	O
the	O
total	O
soluble	O
protein	O
according	O
to	O
quantitative	O
densitometry	O
of	O
Western	O
blot	O
analysis	O
.	O

TITLE	O
:	O
Oligodendroglia	O
are	O
limited	O
in	O
type	B-PRGE
I	I-PRGE
interferon	I-PRGE
induction	O
and	O
responsiveness	O
in	O
vivo	O
.	O

TITLE	O
:	O
Proteomic	O
analysis	O
reveals	O
platelet	B-PRGE
factor	I-PRGE
4	I-PRGE
and	O
beta	B-PRGE
-	I-PRGE
thromboglobulin	I-PRGE
as	O
prognostic	O
markers	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

Our	O
results	O
suggest	O
that	O
PF4	B-PRGE
and	O
beta	B-PRGE
-	I-PRGE
TG	I-PRGE
may	O
also	O
play	O
similar	O
roles	O
in	O
the	O
development	O
of	O
ARDS	O
in	O
SARS	O
patients	O
.	O

These	O
results	O
indicate	O
that	O
liver	O
TCRγδ	O
(+)	O
DN	O
T	O
cells	O
play	O
a	O
critical	O
role	O
in	O
the	O
liver	O
injury	O
in	O
MHV	O
-	O
3	O
-	O
induced	O
hepatitis	O
,	O
via	O
a	O
TNF	B-PRGE
-	I-PRGE
α	I-PRGE
dependent	O
pathway	O
.	O

Inducible	O
(	O
or	O
adaptive	O
)	O
T	O
(	O
regs	O
)	O
frequently	O
express	O
high	O
levels	O
of	O
the	O
interleukin	B-PRGE
2	I-PRGE
receptor	I-PRGE
(	O
CD25	B-PRGE
).	O

TITLE	O
:	O
Protective	O
role	O
of	O
Toll	B-PRGE
-	I-PRGE
like	I-PRGE
Receptor	I-PRGE
3	I-PRGE
-	O
induced	O
type	B-PRGE
I	I-PRGE
interferon	I-PRGE
in	O
murine	O
coronavirus	O
infection	O
of	O
macrophages	O
.	O

Bacterial	O
coinfection	O
and	O
CD4	B-PRGE
count	O
were	O
not	O
predictors	O
of	O
mortality	O
.	O

These	O
include	O
translocation	O
-	O
defective	O
RTIs	O
,	O
delayed	O
chain	O
terminators	O
RTIs	O
,	O
lethal	O
mutagenesis	O
RTIs	O
,	O
dinucleotide	O
tetraphosphates	O
,	O
nucleotide	O
-	O
competing	O
RTIs	O
,	O
pyrophosphate	O
analogs	O
,	O
RT	O
-	O
associated	O
RNase	B-PRGE
H	I-PRGE
function	O
inhibitors	O
,	O
and	O
dual	O
activities	O
inhibitors	O
.	O

ABSTRACT	O
:	O
The	O
ubiquitin	B-PRGE
-	O
proteasome	O
system	O
(	O
UPS	O
)	O
is	O
involved	O
in	O
the	O
replication	O
of	O
a	O
broad	O
range	O
of	O
viruses	O
.	O

TITLE	O
:	O
Biochemical	O
characterization	O
of	O
a	O
recombinant	B-PRGE
SARS	I-PRGE
coronavirus	I-PRGE
nsp12	I-PRGE
RNA	I-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
capable	O
of	O
copying	O
viral	O
RNA	O
templates	O
.	O

In	O
a	O
fibrotic	O
cell	O
model	O
with	O
transforming	B-PRGE
growth	I-PRGE
factor	I-PRGE
beta	I-PRGE
-	I-PRGE
1	I-PRGE
induction	O
,	O
the	O
human	O
lung	O
epithelial	O
A549	O
acquired	O
a	O
mesenchymal	O
phenotype	O
and	O
an	O
increase	O
of	O
vimentin	B-PRGE
expression	O
with	O
a	O
concomitant	O
decrease	O
of	O
E	B-PRGE
-	I-PRGE
cadherin	I-PRGE
.	O

CBP	B-PRGE
treatment	O
persisted	O
for	O
at	O
least	O
8	O
hours	O
and	O
replacement	O
+	O
dialysis	O
fluid	O
dose	O
was	O
35	O
-	O
100	O
ml	O
/(	O
kg	O
·	O
h	O
).	O

Nine	O
mRNAs	O
carrying	O
a	O
set	O
of	O
common	O
5	O
'	O
and	O
3	O
'	O
untranslated	O
regions	O
(	O
UTR	O
)	O
are	O
synthesized	O
from	O
the	O
incoming	O
viral	O
genomic	O
RNA	O
in	O
cells	O
infected	O
with	O
SCoV	O
.	O
A	O
nonstructural	O
SCoV	O
nsp1	B-PRGE
protein	I-PRGE
causes	O
a	O
severe	O
translational	O
shutoff	O
by	O
binding	O
to	O
the	O
40S	O
ribosomal	O
subunits	O
.	O

An	O
indirect	O
ELISA	O
using	O
recombinant	B-PRGE
N	I-PRGE
protein	I-PRGE
as	O
antigen	O
was	O
established	O
to	O
screen	O
antibody	O
-	O
producing	O
hybridoma	O
cell	O
lines	O
.	O

Moreover	O
,	O
the	O
receptor	O
-	O
binding	O
edge	O
is	O
a	O
major	O
antigenic	O
determinant	O
in	O
the	O
TGEV	B-PRGE
envelope	I-PRGE
S	I-PRGE
that	O
is	O
targeted	O
by	O
neutralizing	O
antibodies	O
.	O

To	O
further	O
explore	O
our	O
hypothesis	O
,	O
we	O
used	O
the	O
454	O
sequence	O
analysis	O
of	O
a	O
large	O
naïve	O
library	O
of	O
human	B-PRGE
IgM	I-PRGE
antibodies	I-PRGE
which	O
had	O
been	O
used	O
for	O
selecting	O
antibodies	O
against	O
SARS	B-PRGE
CoV	I-PRGE
receptor	I-PRGE
-	I-PRGE
binding	I-PRGE
domain	I-PRGE
(	O
RBD	O
),	O
and	O
soluble	O
G	O
proteins	O
(	O
sG	O
)	O
of	O
henipaviruses	O
.	O

TITLE	O
:	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
regulates	O
immune	O
function	O
-	O
related	O
gene	O
expression	O
in	O
human	O
monocytic	O
cells	O
.	O

TITLE	O
:	O
Characterization	O
and	O
complete	O
genome	O
sequence	O
of	O
human	B-PRGE
coronavirus	I-PRGE
NL63	I-PRGE
isolated	O
in	O
China	O
.	O

ABSTRACT	O
:	O
Human	B-PRGE
coronavirus	I-PRGE
NL63	I-PRGE
(	O
HCoV	O
-	O
NL63	O
)	O
was	O
first	O
discovered	O
in	O
Amsterdam	O
in	O
2004	O
and	O
was	O
identified	O
as	O
a	O
new	O
human	O
respiratory	O
coronavirus	O
.	O

TITLE	O
:	O
Contribution	O
of	O
IL	B-PRGE
-	I-PRGE
17	I-PRGE
to	O
mouse	O
hepatitis	O
virus	O
strain	O
3	O
-	O
induced	O
acute	O
liver	O
failure	O
.	O

The	O
results	O
also	O
suggest	O
that	O
conventional	O
weaned	O
pigs	O
may	O
represent	O
undetected	O
reservoirs	O
of	O
porcine	O
EPEC	O
,	O
potentially	O
giving	O
rise	O
to	O
the	O
emergence	O
of	O
new	O
types	O
of	O
EHEC	O
due	O
to	O
natural	O
transduction	O
by	O
Stx	B-PRGE
phages	O
.	O

The	O
isolated	O
strains	O
were	O
characterized	O
by	O
reverse	B-PRGE
transcriptase	I-PRGE
polymerase	I-PRGE
chain	O
reaction	O
and	O
sequence	O
analysis	O
of	O
the	O
hypervariable	O
region	O
3	O
of	O
the	O
S1	B-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
gene	I-PRGE
.	O

Two	O
of	O
the	O
five	O
isolates	O
showed	O
89	O
and	O
84	O
%	O
amino	O
acid	O
sequence	O
identity	O
and	O
89	O
and	O
88	O
%	O
nucleotide	O
sequence	O
identity	O
to	O
the	O
Egyptian	B-PRGE
variant	I-PRGE
1	I-PRGE
and	O
the	O
IS	O
/	O
885	O
strains	O
,	O
respectively	O
.	O

The	O
ENC	B-PRGE
×	O
GC3	B-PRGE
%	O
curve	O
indicates	O
that	O
both	O
mutational	O
pressure	O
and	O
natural	O
selection	O
are	O
the	O
driving	O
forces	O
on	O
codon	O
usage	O
pattern	O
in	O
S1	O
.	O

The	O
low	O
CAI	O
values	O
agree	O
with	O
a	O
low	O
S	B-PRGE
protein	I-PRGE
expression	O
and	O
considering	O
that	O
S	B-PRGE
protein	I-PRGE
is	O
a	O
determinant	O
for	O
attachment	O
and	O
neutralization	O
,	O
this	O
could	O
be	O
a	O
further	O
mechanism	O
besides	O
mRNA	O
transcription	O
attenuation	O
for	O
a	O
low	O
expression	O
of	O
this	O
protein	O
leading	O
to	O
an	O
immune	O
camouflage	O
.	O

We	O
also	O
report	O
the	O
high	O
-	O
resolution	O
X	O
-	O
ray	O
cocrystal	O
structures	O
of	O
NV	B-PRGE
3CLpro	I-PRGE
-,	I-PRGE
poliovirus	I-PRGE
3Cpro	I-PRGE
-,	I-PRGE
and	I-PRGE
transmissible	I-PRGE
gastroenteritis	I-PRGE
virus	I-PRGE
3CLpro	I-PRGE
-	I-PRGE
GC376	I-PRGE
inhibitor	I-PRGE
complexes	I-PRGE
,	O
which	O
show	O
the	O
compound	O
covalently	O
bound	O
to	O
a	O
nucleophilic	O
Cys	O
residue	O
in	O
the	O
catalytic	O
site	O
of	O
the	O
corresponding	O
protease	O
.	O

In	O
S	O
-	O
pseudovirus	O
,	O
the	O
incorporation	O
of	O
S	B-PRGE
protein	I-PRGE
into	O
viral	O
particles	O
was	O
obviously	O
inhibited	O
.	O

Based	O
on	O
preliminary	O
analysis	O
of	O
39	O
different	O
segments	O
of	O
the	O
N	B-PRGE
protein	I-PRGE
,	O
We	O
choosed	O
six	O
purified	O
N	B-PRGE
protein	I-PRGE
for	O
further	O
antigenicity	O
characterization	O
in	O
this	O
study	O
,	O
including	O
that	O
PN360	O
(	O
1	O
-	O
360aa	O
),	O
PN301	O
(	O
1	O
-	O
301aa	O
),	O
PN199	O
(	O
30	O
-	O
228aa	O
),	O
PN185	O
(	O
30	O
-	O
214aa	O
),	O
PN155b	O
(	O
60	O
-	O
214aa	O
),	O
and	O
PN125	O
(	O
90	O
-	O
214aa	O
).	O

Truncated	B-PRGE
N	I-PRGE
protein	I-PRGE
PN185	I-PRGE
and	O
PN155b	O
expressed	O
in	O
E	O
.	O
Coli	O
are	O
better	O
antigen	O
candidates	O
used	O
for	O
detection	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
specific	I-PRGE
antibody	I-PRGE
.	O

ABSTRACT	O
:	O
Human	B-PRGE
coronavirus	I-PRGE
229E	I-PRGE
has	O
been	O
identified	O
in	O
the	O
mid	O
-	O
1960s	O
,	O
yet	O
still	O
only	O
one	O
full	O
-	O
genome	O
sequence	O
is	O
available	O
.	O

Lab	B-PRGE
-	O
adaptation	O
might	O
have	O
resulted	O
in	O
genomic	O
changes	O
,	O
due	O
to	O
insufficient	O
pressure	O
to	O
maintain	O
gene	O
integrity	O
of	O
non	O
-	O
essential	O
genes	O
.	O

CK	O
,	O
CK	O
-	O
MB	O
and	O
cTnI	B-PRGE
could	O
be	O
used	O
as	O
auxiliary	O
criteria	O
of	O
AOPP	O
classification	O
.	O

TITLE	O
:	O
Development	O
of	O
chemical	O
inhibitors	O
of	O
the	O
SARS	B-PRGE
coronavirus	I-PRGE
:	I-PRGE
viral	I-PRGE
helicase	I-PRGE
as	O
a	O
potential	O
target	O
.	O

In	O
the	O
following	O
review	O
,	O
we	O
describe	O
the	O
characterization	O
,	O
family	O
classification	O
,	O
and	O
kinetic	O
movement	O
mechanisms	O
of	O
the	O
SARS	B-PRGE
coronavirus	I-PRGE
(	O
SCV	O
)	O
helicase	O
-	O
nsP13	O
.	O

PLpro	O
significantly	O
increased	O
TGF	B-PRGE
-	I-PRGE
β1	I-PRGE
mRNA	I-PRGE
expression	O
(	O
greater	O
than	O
fourfold	O
)	O
and	O
protein	O
production	O
(	O
greater	O
than	O
threefold	O
).	O

Proteasome	O
inhibitor	O
MG	O
-	O
132	O
significantly	O
reduced	O
expression	O
of	O
TGF	O
-	O
β1	O
and	O
vimentin	B-PRGE
.	O

Results	O
point	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
PLpro	I-PRGE
triggering	I-PRGE
TGF	I-PRGE
-	I-PRGE
β1	I-PRGE
production	O
via	O
ubiquitin	B-PRGE
proteasome	O
,	O
p38	B-PRGE
MAPK	I-PRGE
,	O
and	O
ERK1	B-PRGE
/	I-PRGE
2	I-PRGE
-	O
mediated	O
signaling	O
.	O

Surprisingly	O
,	O
however	O
,	O
infected	O
dKO	O
mice	O
remained	O
healthy	O
,	O
whereas	O
infected	O
STAT1	B-PRGE
-	O
deficient	O
mice	O
developed	O
liver	O
pathology	O
and	O
eventually	O
succumbed	O
to	O
neurological	O
disease	O
.	O

Moreover	O
,	O
S366	O
-	O
374	O
was	O
predicted	O
to	O
be	O
an	O
optimal	O
epitope	O
by	O
bioinformatics	O
tools	O
:	O
ANN	O
,	O
SMM	O
,	O
ARB	O
and	O
BIMAS	O
,	O
and	O
confirmed	O
by	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
response	O
induced	O
by	O
a	O
series	O
of	O
S358	O
-	O
374	O
-	O
derived	O
peptides	O
.	O

Additionally	O
,	O
these	O
one	O
residue	O
mutated	O
peptides	O
were	O
synthesized	O
,	O
and	O
IFN	B-PRGE
-	I-PRGE
gamma	I-PRGE
production	O
induced	O
by	O
G368	O
,	O
V369	O
,	O
A371	O
,	O
T372	O
and	O
K373	O
mutated	O
S366	O
-	O
374	O
were	O
decreased	O
obviously	O
.	O

Finally	O
,	O
we	O
showed	O
that	O
PGRN	O
/	O
TNFR2	B-PRGE
interaction	O
was	O
crucial	O
for	O
the	O
protective	O
effect	O
of	O
PGRN	O
on	O
the	O
LPS	O
-	O
induced	O
ALI	O
.	O

Of	O
the	O
isolated	O
diarylheptanoids	O
,	O
hirsutenone	O
(	O
2	O
)	O
showed	O
the	O
most	O
potent	O
PL	O
(	O
pro	O
)	O
inhibitory	O
activity	O
,	O
with	O
an	O
inhibitory	O
concentration	O
(	O
IC	O
(	O
50	O
))	O
value	O
of	O
4	O
.	O
1	O
µM	O
.	O
Structure	O
-	O
activity	O
analysis	O
showed	O
that	O
catechol	O
and	O
α	O
,	O
β	O
-	O
unsaturated	O
carbonyl	O
moiety	O
in	O
the	O
molecule	O
were	O
the	O
key	O
requirement	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
cysteine	I-PRGE
protease	I-PRGE
inhibition	O
.	O

TITLE	O
:	O
Potential	O
cross	O
-	O
reactivity	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nucleocapsid	O
(	O
N	O
)-	O
based	O
IgG	B-PRGE
ELISA	O
assay	O
for	O
plasma	O
samples	O
from	O
HIV	O
-	O
1	O
positive	O
intravenous	O
drug	O
users	O
(	O
IDUs	O
).	O

ABSTRACT	O
:	O
to	O
evaluate	O
the	O
specificity	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
protein	I-PRGE
-	O
based	O
IgG	B-PRGE
ELISA	O
assay	O
for	O
detection	O
of	O
immunoglobulin	B-PRGE
G	I-PRGE
(	O
IgG	B-PRGE
)	O
in	O
plasma	O
samples	O
obtained	O
from	O
HIV	O
-	O
1	O
positive	O
and	O
HIV	O
-	O
1	O
negative	O
intravenous	O
drug	O
users	O
(	O
IDUs	O
).	O

An	O
additional	O
palmitoylation	O
site	O
was	O
observed	O
in	O
CK	O
/	O
SWE	B-PRGE
/	O
082066	O
/	O
2010	O
a	O
QX	O
-	O
like	O
strain	O
.	O

Cleavage	O
of	O
IBV	O
spike	O
protein	O
by	O
furin	B-PRGE
may	O
contribute	O
to	O
the	O
productive	O
IBV	O
infection	O
in	O
these	O
cells	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
the	O
diagnostic	O
value	O
of	O
urine	O
soluble	B-PRGE
CD163	I-PRGE
(	O
sCD163	B-PRGE
)	O
for	O
identification	O
of	O
sepsis	O
,	O
severity	O
of	O
sepsis	O
,	O
and	O
for	O
secondary	O
AKI	O
,	O
and	O
to	O
assess	O
the	O
patients	O
'	O
prognosis	O
.	O

Bone	O
marrow	O
chimera	O
experiments	O
demonstrated	O
that	O
hematopoietic	O
cells	O
are	O
responsible	O
for	O
the	O
pathogenesis	O
in	O
STAT1	B-PRGE
(-/-)	O
mice	O
,	O
and	O
because	O
of	O
an	O
induction	O
of	O
alternatively	O
activated	O
(	O
AA	O
)	O
macrophages	O
after	O
infection	O
,	O
we	O
hypothesized	O
that	O
the	O
AA	O
macrophages	O
were	O
critical	O
for	O
disease	O
severity	O
.	O

We	O
hypothesized	O
that	O
AA	O
macrophages	O
were	O
responsible	O
for	O
this	O
STAT1	B-PRGE
-	O
dependent	O
pathology	O
and	O
therefore	O
created	O
STAT1	B-PRGE
/	O
STAT6	B-PRGE
(-/-)	O
double	O
-	O
knockout	O
mice	O
.	O

To	O
map	O
the	O
epitopes	O
on	O
the	O
PEDV	B-PRGE
M	I-PRGE
protein	I-PRGE
,	O
a	O
total	O
of	O
17	O
partially	O
overlapping	O
fragments	O
covering	O
the	O
C	O
-	O
terminus	O
of	O
M	B-PRGE
protein	I-PRGE
were	O
expressed	O
as	O
fusion	O
proteins	O
with	O
a	O
6	B-PRGE
×	I-PRGE
His	I-PRGE
tag	I-PRGE
or	O
a	O
GST	B-PRGE
tag	I-PRGE
.	O

CONCLUSIONS	O
:	O
A	O
McAb	O
,	O
4D4	O
,	O
directed	O
against	O
the	O
M	B-PRGE
protein	I-PRGE
of	O
PEDV	O
,	O
was	O
obtained	O
,	O
and	O
the	O
4D4	O
-	O
defined	O
minimal	O
epitope	O
sequence	O
was	O
195WAFYVR200	O
.	O

Acute	O
SARS	O
-	O
CoV	O
infection	O
prompted	O
coordinated	O
innate	O
immune	O
responses	O
that	O
were	O
dominated	O
by	O
antiviral	O
IFN	B-PRGE
response	I-PRGE
gene	I-PRGE
(	O
IRG	O
)	O
expression	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
nonstructural	B-PRGE
protein	I-PRGE
1	I-PRGE
(	O
nsp1	B-PRGE
)	O
binds	O
to	O
the	O
40S	B-PRGE
ribosomal	I-PRGE
subunit	I-PRGE
and	O
inhibits	O
translation	O
,	O
and	O
it	O
also	O
induces	O
a	O
template	O
-	O
dependent	O
endonucleolytic	O
cleavage	O
of	O
host	O
mRNAs	O
.	O

nsp1	B-PRGE
and	O
nsp1	B-PRGE
-	I-PRGE
CD	I-PRGE
had	O
identical	O
inhibitory	O
effects	O
on	O
mRNA	O
templates	O
that	O
are	O
resistant	O
to	O
nsp1	B-PRGE
-	O
induced	O
RNA	O
cleavage	O
,	O
implying	O
the	O
validity	O
of	O
using	O
nsp1	B-PRGE
-	I-PRGE
CD	I-PRGE
to	O
dissect	O
the	O
translation	O
inhibition	O
function	O
of	O
nsp1	B-PRGE
.	O

Primers	O
targeting	O
the	O
conserved	O
regions	O
of	O
NSP4	B-PRGE
gene	I-PRGE
of	I-PRGE
avian	I-PRGE
rotavirus	I-PRGE
,	I-PRGE
polymerase	I-PRGE
gene	I-PRGE
of	O
TAstV	O
-	O
2	O
,	O
and	O
S4	B-PRGE
gene	I-PRGE
of	O
avian	O
reovirus	O
were	O
used	O
.	O

Real	O
time	O
PCR	O
,	O
DFA	O
and	O
cell	O
culture	O
method	O
were	O
used	O
for	O
detection	O
of	O
C	B-PRGE
.	I-PRGE
pneumoniae	I-PRGE
,	I-PRGE
RSV	I-PRGE
antigen	I-PRGE
and	O
influenza	O
virus	O
respectively	O
.	O

Phylogenetic	O
analysis	O
based	O
on	O
the	O
S1	B-PRGE
gene	I-PRGE
indicated	O
that	O
one	O
isolate	O
(	O
L748	O
)	O
was	O
more	O
closely	O
related	O
to	O
the	O
Mass	O
type	O
.	O

TITLE	O
:	O
Is	O
the	O
discovery	O
of	O
the	O
novel	O
human	B-PRGE
betacoronavirus	I-PRGE
2c	I-PRGE
EMC	I-PRGE
/	I-PRGE
2012	I-PRGE
(	O
HCoV	B-PRGE
-	I-PRGE
EMC	I-PRGE
)	O
the	O
beginning	O
of	O
another	O
SARS	O
-	O
like	O
pandemic	O
?	O

The	O
research	O
questions	O
addressed	O
in	O
this	O
report	O
are	O
:	O
Does	O
ILA	B-PRGE
/	O
ECMO	O
facilitate	O
gas	B-PRGE
exchange	O
in	O
the	O
lungs	O
of	O
patients	O
with	O
severe	O
respiratory	O
failure	O
?	O
Does	O
ILA	O
/	O
ECMO	O
improve	O
the	O
survival	O
rate	O
of	O
patients	O
with	O
respiratory	O
failure	O
caused	O
by	O
a	O
range	O
of	O
underlying	O
conditions	O
including	O
patients	O
awaiting	O
LTx	O
?	O
What	O
are	O
the	O
possible	O
serious	O
adverse	O
events	O
associated	O
with	O
ILA	B-PRGE
/	O
ECMO	O
therapy	O
?	O
To	O
address	O
these	O
questions	O
,	O
a	O
systematic	O
literature	O
search	O
was	O
performed	O
on	O
September	O
28	O
,	O
2009	O
using	O
OVID	O
MEDLINE	O
,	O
MEDLINE	O
In	O
-	O
Process	O
and	O
Other	O
Non	O
-	O
Indexed	O
Citations	O
,	O
EMBASE	O
,	O
the	O
Cumulative	O
Index	O
to	O
Nursing	O
&	O
Allied	O
Health	O
Literature	O
(	O
CINAHL	O
),	O
the	O
Cochrane	O
Library	O
,	O
and	O
the	O
International	O
Agency	O
for	O
Health	O
Technology	O
Assessment	O
(	O
INAHTA	O
)	O
for	O
studies	O
published	O
from	O
January	O
1	O
,	O
2005	O
to	O
September	O
28	O
,	O
2008	O
.	O

We	O
recently	O
determined	O
the	O
crystal	O
structure	O
of	O
MHV	O
NTD	O
complexed	O
with	O
its	O
protein	O
receptor	O
murine	O
carcinoembryonic	O
antigen	O
-	O
related	O
cell	O
adhesion	O
molecule	O
1	O
(	O
CEACAM1	B-PRGE
),	O
which	O
surprisingly	O
revealed	O
a	O
human	B-PRGE
galectin	I-PRGE
(	O
galactose	B-PRGE
-	I-PRGE
binding	I-PRGE
lectin	I-PRGE
)	O
fold	O
in	O
MHV	O
NTD	O
.	O

The	O
following	O
deviations	O
from	O
treatment	O
goals	O
were	O
studied	O
:	O
intracranial	O
pressure	O
(	O
ICP	O
),	O
blood	O
pressure	O
,	O
haemoglobin	O
,	O
blood	O
glucose	O
,	O
serum	O
sodium	O
,	O
serum	O
albumin	B-PRGE
,	O
body	O
temperature	O
and	O
extracranial	O
complications	O
during	O
the	O
ICU	O
stay	O
.	O

We	O
had	O
found	O
a	O
significant	O
decrease	O
in	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
in	O
patients	O
having	O
bilateral	O
total	O
knee	O
replacement	O
who	O
received	O
two	O
doses	O
of	O
100	O
mg	O
of	O
hydrocortisone	O
eight	O
hours	O
apart	O
;	O
however	O
,	O
by	O
twenty	O
-	O
four	O
hours	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
levels	O
were	O
equal	O
to	O
those	O
in	O
the	O
group	O
that	O
received	O
a	O
placebo	O
.	O

ABSTRACT	O
:	O
Coronavirus	B-PRGE
replicase	I-PRGE
nsp4	I-PRGE
is	O
critical	O
for	O
virus	O
-	O
induced	O
membrane	O
modifications	O
.	O

For	O
A17	O
,	O
truncation	O
or	O
mutation	O
of	O
the	O
N	O
terminus	O
of	O
A17	O
engendered	O
a	O
phenotype	O
consistent	O
with	O
the	O
N	O
terminus	O
of	O
A17	O
recruiting	O
the	O
D13	B-PRGE
scaffold	I-PRGE
protein	I-PRGE
to	O
nascent	O
membranes	O
.	O

CXCL10	B-PRGE
-	O
CXCR3	B-PRGE
signaling	O
appears	O
to	O
be	O
a	O
critical	O
factor	O
for	O
the	O
exacerbation	O
of	O
the	O
pathology	O
of	O
ARDS	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
effect	O
of	O
Chaiqinchengqi	O
decoction	O
(	O
CQCQD	O
)	O
on	O
serum	B-PRGE
amyloid	I-PRGE
A	I-PRGE
(	O
SAA	B-PRGE
)	O
in	O
severe	O
acute	O
pancreatitis	O
(	O
SAP	O
)	O
patients	O
.	O

The	O
difference	O
of	O
serotypes	O
and	O
tissue	O
tropisms	O
in	O
kidneys	O
between	O
ck	O
/	O
CH	O
/	O
LZJ	O
/	O
111113	O
and	O
ck	O
/	O
CH	O
/	O
LDL	O
/	O
091022	O
may	O
have	O
been	O
contributed	O
by	O
the	O
uptake	O
of	O
the	O
S1	B-PRGE
gene	I-PRGE
by	O
a	O
ck	O
/	O
CH	O
/	O
LDL	O
/	O
091022	O
-	O
like	O
virus	O
from	O
a	O
4	O
/	O
91	O
-	O
like	O
strain	O
.	O

We	O
showed	O
by	O
immuno	O
-	O
electron	O
microscopy	O
that	O
the	O
DMVs	O
induced	O
in	O
EAV	O
-	O
infected	O
cells	O
contain	O
double	O
-	O
strand	O
(	O
ds	O
)	O
RNA	O
molecules	O
,	O
presumed	O
RNA	O
replication	O
intermediates	O
,	O
and	O
are	O
decorated	O
with	O
the	O
autophagy	O
marker	O
protein	O
microtubule	O
-	O
associated	O
protein	O
1	O
light	B-PRGE
chain	I-PRGE
3	I-PRGE
(	O
LC3	B-PRGE
).	O

Replication	O
of	O
EAV	O
,	O
however	O
,	O
was	O
not	O
affected	O
in	O
autophagy	O
-	O
deficient	O
cells	O
lacking	O
autophagy	B-PRGE
-	I-PRGE
related	I-PRGE
protein	I-PRGE
7	I-PRGE
(	O
ATG7	B-PRGE
).	O

Together	O
with	O
the	O
observation	O
that	O
EAV	O
-	O
induced	O
DMVs	O
are	O
also	O
positive	O
for	O
ER	O
degradation	O
-	O
enhancing	O
α	B-PRGE
-	I-PRGE
mannosidase	I-PRGE
-	I-PRGE
like	I-PRGE
1	I-PRGE
(	O
EDEM1	B-PRGE
),	O
our	O
data	O
suggested	O
that	O
this	O
virus	O
,	O
similarly	O
to	O
the	O
distantly	O
-	O
related	O
mouse	O
hepatitis	O
coronavirus	O
,	O
hijacks	O
the	O
ER	O
-	O
derived	O
membranes	O
of	O
EDEMosomes	O
to	O
ensure	O
its	O
efficient	O
replication	O
.	O

TITLE	O
:	O
Ezrin	B-PRGE
interacts	O
with	O
the	O
SARS	B-PRGE
coronavirus	I-PRGE
Spike	I-PRGE
protein	I-PRGE
and	O
restrains	O
infection	O
at	O
the	O
entry	O
stage	O
.	O

Leukemia	O
or	O
lymphoma	O
was	O
the	O
most	O
common	O
underlying	O
diagnosis	O
in	O
95	O
(	O
49	O
%)	O
patients	O
followed	O
by	O
solid	O
tumor	O
47	O
(	O
24	O
%),	O
posthematopoietic	B-PRGE
stem	I-PRGE
cell	I-PRGE
transplant	I-PRGE
28	I-PRGE
(	O
15	O
%)	O
and	O
brain	O
tumor	O
in	O
23	O
(	O
12	O
%)	O
patients	O
.	O

We	O
randomly	O
tested	O
(	O
30	O
min	O
)	O
while	O
recording	O
EAdi	O
:	O
(	O
1	O
)	O
PSV30	O
(	O
PSV	B-PRGE
with	I-PRGE
an	O
expiratory	O
trigger	O
at	O
30	O
%	O
of	O
flow	O
peak	O
value	O
);	O
(	O
2	O
)	O
PSV1	O
(	O
PSV	O
with	O
expiratory	O
trigger	O
at	O
1	O
%);	O
(	O
3	O
)	O
NAVA	O
.	O

Indeed	O
,	O
several	O
studies	O
have	O
described	O
the	O
ability	O
of	O
HCoVs	O
(	O
i	O
.	O
e	O
.	O
HCoV	O
229E	O
,	O
HCoV	O
OC43	O
(	O
also	O
known	O
as	O
betacoronavirus	O
1	O
),	O
NL63	O
,	O
HKU1	O
or	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
)	O
to	O
survive	O
in	O
different	O
environmental	O
conditions	O
(	O
e	O
.	O
g	O
.	O
temperature	O
and	O
humidity	O
),	O
on	O
different	O
supports	O
found	O
in	O
hospital	O
settings	O
such	O
as	O
aluminum	O
,	O
sterile	O
sponges	O
or	O
latex	O
surgical	O
gloves	O
or	O
in	O
biological	O
fluids	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	O
and	O
crystallographic	O
analysis	O
of	O
nitrile	O
-	O
based	O
broad	O
-	O
spectrum	O
peptidomimetic	O
inhibitors	O
for	O
coronavirus	B-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
proteases	I-PRGE
.	O

However	O
,	O
four	O
and	O
two	O
different	O
clusters	O
were	O
formed	O
in	O
the	O
phylogenetic	O
tree	O
based	O
on	O
S1	B-PRGE
glycoprotein	I-PRGE
and	O
M	O
gene	O
sequences	O
,	O
respectively	O
.	O

Herein	O
we	O
report	O
that	O
our	O
compounds	O
behave	O
as	O
reversible	O
,	O
competitive	O
inhibitors	O
of	O
3CL	B-PRGE
protease	I-PRGE
,	O
potently	O
inhibited	O
the	O
replication	O
of	O
feline	O
coronaviruses	O
(	O
EC	O
(	O
50	O
)	O
in	O
a	O
nanomolar	O
range	O
)	O
and	O
,	O
furthermore	O
,	O
combination	O
of	O
cathepsin	B-PRGE
B	I-PRGE
and	O
3CL	B-PRGE
protease	I-PRGE
inhibitors	O
led	O
to	O
a	O
strong	O
synergistic	O
interaction	O
against	O
feline	O
coronaviruses	O
in	O
a	O
cell	O
culture	O
system	O
.	O

We	O
have	O
studied	O
the	O
transcription	O
of	O
a	O
novel	O
sgmRNA	O
associated	O
with	O
this	O
potential	O
ORF	O
and	O
found	O
it	O
to	O
be	O
transcribed	O
via	O
a	O
previously	O
unidentified	O
noncanonical	O
TRS	O
-	O
B	O
.	O
Using	O
an	O
IBV	O
reverse	O
genetics	O
system	O
,	O
we	O
demonstrated	O
that	O
the	O
template	O
-	O
switching	O
event	O
during	O
intergenic	O
region	O
(	O
IR	O
)	O
sgmRNA	O
synthesis	O
occurs	O
at	O
the	O
5	O
'	O
end	O
of	O
the	O
noncanonical	O
TRS	O
-	O
B	O
and	O
recombines	O
between	O
nucleotides	O
5	O
and	O
6	O
of	O
the	O
8	O
-	O
nucleotide	O
consensus	O
TRS	O
-	O
L	O
.	O
Introduction	O
of	O
a	O
complete	O
TRS	O
-	O
B	O
showed	O
that	O
higher	O
transcription	O
levels	O
are	O
achieved	O
by	O
increasing	O
the	O
number	O
of	O
nucleotide	O
matches	O
between	O
TRS	O
-	O
L	O
and	O
TRS	O
-	O
B	O
.	O
Translation	O
of	O
a	O
protein	O
from	O
the	O
sgmRNA	O
was	O
demonstrated	O
using	O
enhanced	O
green	B-PRGE
fluorescent	I-PRGE
protein	I-PRGE
,	O
suggesting	O
the	O
translation	O
of	O
a	O
fifth	O
,	O
novel	O
,	O
group	O
-	O
specific	O
protein	O
for	O
IBV	O
.	O

Unlike	O
the	O
majority	O
of	O
reported	O
coronavirus	O
3CLpro	O
inhibitors	O
that	O
act	O
via	O
covalent	O
modification	O
of	O
the	O
enzyme	O
,	O
16	O
-(	O
R	O
)	O
is	O
a	O
noncovalent	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CLpro	I-PRGE
inhibitor	O
with	O
moderate	O
MW	O
and	O
good	O
enzyme	O
and	O
antiviral	O
inhibitory	O
activity	O
.	O

Our	O
data	O
show	O
that	O
hCoV	B-PRGE
-	I-PRGE
EMC	I-PRGE
does	O
not	O
need	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
to	O
infect	O
human	O
cells	O
.	O

Increased	O
anti	O
-	O
viral	O
activity	O
by	O
CD8	B-PRGE
T	I-PRGE
cells	O
in	O
the	O
CNS	O
of	O
B7	B-PRGE
-	I-PRGE
H1	I-PRGE
-/-	O
mice	O
was	O
lost	O
upon	O
depletion	O
of	O
CD4	B-PRGE
T	I-PRGE
cells	O
;	O
however	O
,	O
despite	O
concomitant	O
loss	O
of	O
viral	O
control	O
,	O
the	O
clinical	O
disease	O
was	O
less	O
severe	O
.	O

RESULTS	O
:	O
Increased	O
anti	O
-	O
viral	O
activity	O
by	O
CD8	B-PRGE
T	I-PRGE
cells	O
in	O
the	O
CNS	O
of	O
B7	B-PRGE
-	I-PRGE
H1	I-PRGE
-/-	O
mice	O
was	O
lost	O
upon	O
depletion	O
of	O
CD4	B-PRGE
T	I-PRGE
cells	O
;	O
however	O
,	O
despite	O
concomitant	O
loss	O
of	O
viral	O
control	O
,	O
the	O
clinical	O
disease	O
was	O
less	O
severe	O
.	O

In	O
the	O
early	O
phase	O
of	O
infection	O
,	O
neurons	O
,	O
astrocytes	O
and	O
neural	O
progenitor	O
cells	O
were	O
infected	O
by	O
MK	O
-	O
p10	B-PRGE
,	O
whereas	O
neural	O
progenitor	O
cells	O
were	O
the	O
only	O
target	O
cells	O
infected	O
by	O
MK	O
.	O

Collectively	O
,	O
infection	O
with	O
IBV	O
-	O
M41	O
resulted	O
in	O
activation	O
of	O
NK	O
cells	O
in	O
the	O
lung	O
and	O
blood	O
and	O
rapid	O
production	O
of	O
IFN	B-PRGE
-	I-PRGE
γ	I-PRGE
and	O
not	O
IFN	B-PRGE
-	I-PRGE
α	I-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
β	I-PRGE
compared	O
to	O
uninfected	O
birds	O
.	O

ABSTRACT	O
:	O
We	O
describe	O
here	O
the	O
design	O
,	O
synthesis	O
and	O
biological	O
evaluation	O
of	O
a	O
series	O
of	O
molecules	O
toward	O
the	O
development	O
of	O
novel	O
peptidomimetic	O
inhibitors	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
(	O
pro	B-PRGE
).	O

This	O
vaccine	O
is	O
comprised	O
of	O
a	O
recombinant	B-PRGE
receptor	I-PRGE
-	I-PRGE
binding	I-PRGE
domain	I-PRGE
(	O
RBD	O
)	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
protein	I-PRGE
and	O
formulated	O
on	O
alum	O
,	O
together	O
with	O
a	O
synthetic	O
glucopyranosyl	O
lipid	O
A	O
.	O
The	O
vaccine	O
would	O
induce	O
neutralizing	O
antibodies	O
without	O
causing	O
Th2	O
-	O
type	O
immunopathology	O
.	O

In	O
marked	O
contrast	O
,	O
CCL2	B-PRGE
Tg	I-PRGE
mice	O
infected	O
with	O
rJ2	O
.	O
2	O
ineffectively	O
cleared	O
virus	O
and	O
rapidly	O
succumbed	O
to	O
the	O
infection	O
.	O

Collectively	O
,	O
these	O
results	O
show	O
that	O
persistent	O
CCL2	B-PRGE
overexpression	O
establishes	O
and	O
sustains	O
an	O
immunological	O
milieu	O
that	O
is	O
both	O
inflammatory	O
and	O
immunosuppressive	O
and	O
predisposes	O
mice	O
to	O
a	O
defective	O
immune	O
response	O
to	O
a	O
minimally	O
lethal	O
virus	O
.	O

We	O
have	O
previously	O
determined	O
the	O
minimal	O
mechanism	O
of	O
helicase	B-PRGE
function	O
by	O
nsp13	O
where	O
we	O
demonstrated	O
that	O
the	O
enzyme	O
unwinds	O
nucleic	O
acid	O
in	O
discrete	O
steps	O
of	O
9	O
.	O
3	O
base	O
—	O
pairs	O
each	O
with	O
a	O
catalytic	O
rate	O
of	O
30	O
steps	O
per	O
second	O
.	O

We	O
report	O
30	O
novel	O
irradiation	O
-	O
sensitive	O
ligands	O
,	O
specifically	O
targeting	O
South	O
East	O
Asian	O
populations	O
,	O
which	O
provide	O
93	O
,	O
63	O
,	O
and	O
79	O
%	O
coverage	O
for	O
HLA	B-PRGE
-	I-PRGE
A	I-PRGE
,	I-PRGE
-	I-PRGE
B	I-PRGE
,	O
and	O
-	O
C	O
,	O
respectively	O
.	O

Peptide	O
exchange	O
was	O
accomplished	O
for	O
all	O
variants	O
as	O
demonstrated	O
by	O
an	O
ELISA	O
-	O
based	O
MHC	B-PRGE
stability	O
assay	O
.	O

HLA	B-PRGE
tetramers	I-PRGE
with	O
redirected	O
specificity	O
could	O
detect	O
antigen	O
-	O
specific	O
CD8	B-PRGE
(+)	O
T	O
-	O
cell	O
responses	O
against	O
human	O
cytomegalovirus	O
,	O
hepatitis	O
B	O
(	O
HBV	O
),	O
dengue	O
virus	O
(	O
DENV	O
),	O
and	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
infections	O
.	O

Indeed	O
,	O
after	O
transfecting	O
BHK	O
-	O
21	O
cells	O
with	O
various	O
cDNA	O
infectious	O
clones	O
of	O
HCoV	O
-	O
OC43	O
,	O
either	O
lacking	O
the	O
HE	B-PRGE
protein	I-PRGE
or	O
bearing	O
an	O
HE	B-PRGE
protein	I-PRGE
with	O
a	O
nonfunctional	O
acetyl	B-PRGE
-	I-PRGE
esterase	I-PRGE
enzymatic	O
activity	O
,	O
we	O
were	O
reproducibly	O
unable	O
to	O
detect	O
recombinant	O
infectious	O
viruses	O
compared	O
to	O
the	O
reference	O
infectious	O
HCoV	O
-	O
OC43	O
clone	O
pBAC	O
-	O
OC43	O
(	O
FL	O
).	O

RESULTS	O
:	O
Ten	O
mechanically	O
ventilated	O
ARDS	O
patients	O
(	O
mean	O
age	O
44	O
±	O
16	O
years	O
;	O
6	O
males	O
;	O
mean	O
hemoglobin	B-PRGE
8	O
.	O
0	O
±	O
1	O
.	O
8	O
g	O
/	O
dL	O
)	O
on	O
ECMO	O
for	O
a	O
mean	O
of	O
9	O
.	O
0	O
±	O
3	O
.	O
8	O
days	O
)	O
receiving	O
femoro	O
-	O
jugular	O
vv	O
-	O
ECMO	O
were	O
evaluated	O
.	O

This	O
study	O
demonstrates	O
that	O
CNS	O
-	O
expressed	O
CXCR3	B-PRGE
ligand	O
CXCL10	B-PRGE
is	O
the	O
critical	O
chemokine	O
regulating	O
ASC	O
accumulation	O
.	O

While	O
CXCL10	B-PRGE
was	O
predominantly	O
expressed	O
by	O
astrocytes	O
,	O
CXCL9	B-PRGE
expression	O
was	O
confined	O
to	O
the	O
vasculature	O
/	O
perivascular	O
spaces	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
that	O
the	O
induction	O
of	O
the	O
heat	O
shock	O
response	O
prevents	O
IL	O
-	O
1β	O
-	O
dependent	O
inhibition	O
of	O
αENaC	B-PRGE
mRNA	I-PRGE
expression	O
and	O
subsequent	O
channel	O
function	O
.	O

ACE2	B-PRGE
is	O
a	O
multifunctional	O
enzyme	O
and	O
thus	O
potentially	O
acts	O
on	O
other	O
vasoactive	O
peptides	O
,	O
such	O
as	O
Apelin	B-PRGE
,	O
a	O
vital	O
regulator	O
of	O
blood	O
pressure	O
and	O
myocardium	O
contractility	O
.	O

ACE2	B-PRGE
has	O
been	O
implicated	O
in	O
the	O
pathology	O
of	O
Hartnup	O
'	O
s	O
disease	O
,	O
a	O
disorder	O
of	O
amino	O
acid	O
homeostasis	O
,	O
and	O
,	O
via	O
its	O
function	O
in	O
amino	O
acid	O
transport	O
,	O
it	O
has	O
been	O
recently	O
revealed	O
that	O
ACE2	B-PRGE
controls	O
intestinal	O
inflammation	O
and	O
diarrhea	O
,	O
thus	O
regulating	O
the	O
gut	O
microbiome	O
.	O

The	O
subcellular	O
localization	O
and	O
function	O
of	O
PEDV	B-PRGE
E	I-PRGE
protein	I-PRGE
were	O
investigated	O
by	O
examining	O
its	O
effects	O
on	O
cell	O
growth	O
,	O
cell	O
cycle	O
progression	O
,	O
interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
(	O
IL	O
-	O
8	O
)	O
expression	O
and	O
cell	O
survival	O
.	O

ABSTRACT	O
:	O
Interferon	B-PRGE
-	I-PRGE
α	I-PRGE
(	O
IFNα	O
)	O
has	O
enormous	O
potential	O
for	O
anti	O
-	O
proliferative	O
and	O
anti	O
-	O
viral	O
treatments	O
.	O

Consequently	O
,	O
we	O
here	O
examined	O
whether	O
IFNα	O
immobilized	O
on	O
nanoscale	O
ferromagnetic	O
R	O
-	O
Chitosan	O
carriers	O
is	O
capable	O
of	O
inducing	O
rapid	O
and	O
sustained	O
activation	O
of	O
STAT1	B-PRGE
signaling	O
.	O

Employing	O
human	O
prostate	O
cancer	O
and	O
melanoma	O
cell	O
models	O
,	O
we	O
found	O
that	O
the	O
intensity	O
and	O
duration	O
of	O
STAT1	B-PRGE
phosphorylation	O
as	O
well	O
as	O
the	O
downstream	O
activation	O
of	O
pathobiologically	O
relevant	O
genes	O
were	O
dose	O
and	O
particle	O
dependent	O
.	O

In	O
comparison	O
with	O
free	O
IFNα	O
,	O
IFNα	O
-	O
loaded	O
spheres	O
resulted	O
in	O
a	O
more	O
sustained	O
biologically	O
relevant	O
STAT1	B-PRGE
activation	O
,	O
demonstrated	O
also	O
by	O
conferring	O
innate	O
cellular	O
immunity	O
against	O
vesicular	O
stomatitis	O
virus	O
(	O
VSV	O
)	O
infection	O
.	O

For	O
one	O
,	O
our	O
study	O
demonstrates	O
the	O
advantages	O
of	O
biodegradable	O
IFNα	B-PRGE
-	I-PRGE
coated	I-PRGE
R	I-PRGE
-	I-PRGE
Chitosan	I-PRGE
NPs	I-PRGE
for	O
controlled	O
cytokine	O
release	O
,	O
and	O
thereby	O
improved	O
therapy	O
.	O

We	O
sought	O
to	O
determine	O
oxygen	O
-	O
derived	O
effects	O
on	O
the	O
anti	B-PRGE
-	I-PRGE
inflammatory	I-PRGE
A2A	I-PRGE
adenosinergic	I-PRGE
(	I-PRGE
ADORA2A	I-PRGE
)	I-PRGE
receptor	I-PRGE
in	O
macrophages	O
,	O
and	O
the	O
role	O
of	O
the	O
ADORA2A	B-PRGE
receptor	I-PRGE
in	O
lung	O
injury	O
.	O

Treatment	O
with	O
recombinant	B-PRGE
human	I-PRGE
soluble	I-PRGE
thrombomodulin	I-PRGE
(	O
rTM	O
)	O
and	O
high	O
-	O
dose	O
methylprednisolone	O
was	O
started	O
in	O
addition	O
to	O
the	O
antituberculosis	O
chemotherapy	O
.	O

Recommendations	O
specific	O
to	O
pediatric	O
severe	O
sepsis	O
include	O
:	O
therapy	O
with	O
face	O
mask	O
oxygen	O
,	O
high	O
flow	O
nasal	O
cannula	O
oxygen	O
,	O
or	O
nasopharyngeal	O
continuous	O
PEEP	O
in	O
the	O
presence	O
of	O
respiratory	O
distress	O
and	O
hypoxemia	O
(	O
2C	O
),	O
use	O
of	O
physical	O
examination	O
therapeutic	O
endpoints	O
such	O
as	O
capillary	O
refill	O
(	O
2C	O
);	O
for	O
septic	O
shock	O
associated	O
with	O
hypovolemia	O
,	O
the	O
use	O
of	O
crystalloids	O
or	O
albumin	B-PRGE
to	O
deliver	O
a	O
bolus	O
of	O
20	O
mL	O
/	O
kg	O
of	O
crystalloids	O
(	O
or	O
albumin	B-PRGE
equivalent	O
)	O
over	O
5	O
-	O
10	O
min	O
(	O
2C	O
);	O
more	O
common	O
use	O
of	O
inotropes	O
and	O
vasodilators	O
for	O
low	O
cardiac	O
output	O
septic	O
shock	O
associated	O
with	O
elevated	O
systemic	O
vascular	O
resistance	O
(	O
2C	O
);	O
and	O
use	O
of	O
hydrocortisone	O
only	O
in	O
children	O
with	O
suspected	O
or	O
proven	O
""""	O
absolute	O
"""'"	O
adrenal	O
insufficiency	O
(	O
2C	O
).	O

RESULTS	O
:	O
Key	O
recommendations	O
and	O
suggestions	O
,	O
listed	O
by	O
category	O
,	O
include	O
:	O
early	O
quantitative	O
resuscitation	O
of	O
the	O
septic	O
patient	O
during	O
the	O
first	O
6	O
h	O
after	O
recognition	O
(	O
1C	O
);	O
blood	O
cultures	O
before	O
antibiotic	O
therapy	O
(	O
1C	O
);	O
imaging	O
studies	O
performed	O
promptly	O
to	O
confirm	O
a	O
potential	O
source	O
of	O
infection	O
(	O
UG	O
);	O
administration	O
of	O
broad	O
-	O
spectrum	O
antimicrobials	O
therapy	O
within	O
1	O
h	O
of	O
the	O
recognition	O
of	O
septic	O
shock	O
(	O
1B	O
)	O
and	O
severe	O
sepsis	O
without	O
septic	O
shock	O
(	O
1C	O
)	O
as	O
the	O
goal	O
of	O
therapy	O
;	O
reassessment	O
of	O
antimicrobial	O
therapy	O
daily	O
for	O
de	O
-	O
escalation	O
,	O
when	O
appropriate	O
(	O
1B	O
);	O
infection	O
source	O
control	O
with	O
attention	O
to	O
the	O
balance	O
of	O
risks	O
and	O
benefits	O
of	O
the	O
chosen	O
method	O
within	O
12	O
h	O
of	O
diagnosis	O
(	O
1C	O
);	O
initial	O
fluid	O
resuscitation	O
with	O
crystalloid	O
(	O
1B	O
)	O
and	O
consideration	O
of	O
the	O
addition	O
of	O
albumin	B-PRGE
in	O
patients	O
who	O
continue	O
to	O
require	O
substantial	O
amounts	O
of	O
crystalloid	O
to	O
maintain	O
adequate	O
mean	O
arterial	O
pressure	O
(	O
2C	O
)	O
and	O
the	O
avoidance	O
of	O
hetastarch	O
formulations	O
(	O
1B	O
);	O
initial	O
fluid	O
challenge	O
in	O
patients	O
with	O
sepsis	O
-	O
induced	O
tissue	O
hypoperfusion	O
and	O
suspicion	O
of	O
hypovolemia	O
to	O
achieve	O
a	O
minimum	O
of	O
30	O
mL	O
/	O
kg	O
of	O
crystalloids	O
(	O
more	O
rapid	O
administration	O
and	O
greater	O
amounts	O
of	O
fluid	O
may	O
be	O
needed	O
in	O
some	O
patients	O
(	O
1C	O
);	O
fluid	O
challenge	O
technique	O
continued	O
as	O
long	O
as	O
hemodynamic	O
improvement	O
is	O
based	O
on	O
either	O
dynamic	O
or	O
static	O
variables	O
(	O
UG	O
);	O
norepinephrine	O
as	O
the	O
first	O
-	O
choice	O
vasopressor	O
to	O
maintain	O
mean	O
arterial	O
pressure	O
≥	O
65	O
mmHg	O
(	O
1B	O
);	O
epinephrine	O
when	O
an	O
additional	O
agent	O
is	O
needed	O
to	O
maintain	O
adequate	O
blood	O
pressure	O
(	O
2B	O
);	O
vasopressin	O
(	O
0	O
.	O
03	O
U	O
/	O
min	O
)	O
can	O
be	O
added	O
to	O
norepinephrine	O
to	O
either	O
raise	O
mean	O
arterial	O
pressure	O
to	O
target	O
or	O
to	O
decrease	O
norepinephrine	O
dose	O
but	O
should	O
not	O
be	O
used	O
as	O
the	O
initial	O
vasopressor	O
(	O
UG	O
);	O
dopamine	O
is	O
not	O
recommended	O
except	O
in	O
highly	O
selected	O
circumstances	O
(	O
2C	O
);	O
dobutamine	O
infusion	O
administered	O
or	O
added	O
to	O
vasopressor	O
in	O
the	O
presence	O
of	O
(	O
a	O
)	O
myocardial	O
dysfunction	O
as	O
suggested	O
by	O
elevated	O
cardiac	O
filling	O
pressures	O
and	O
low	O
cardiac	O
output	O
,	O
or	O
(	O
b	O
)	O
ongoing	O
signs	O
of	O
hypoperfusion	O
despite	O
achieving	O
adequate	O
intravascular	O
volume	O
and	O
adequate	O
mean	O
arterial	O
pressure	O
(	O
1C	O
);	O
avoiding	O
use	O
of	O
intravenous	O
hydrocortisone	O
in	O
adult	O
septic	O
shock	O
patients	O
if	O
adequate	O
fluid	O
resuscitation	O
and	O
vasopressor	O
therapy	O
are	O
able	O
to	O
restore	O
hemodynamic	O
stability	O
(	O
2C	O
);	O
hemoglobin	B-PRGE
target	O
of	O
7	O
-	O
9	O
g	O
/	O
dL	O
in	O
the	O
absence	O
of	O
tissue	O
hypoperfusion	O
,	O
ischemic	O
coronary	O
artery	O
disease	O
,	O
or	O
acute	O
hemorrhage	O
(	O
1B	O
);	O
low	O
tidal	O
volume	O
(	O
1A	O
)	O
and	O
limitation	O
of	O
inspiratory	O
plateau	O
pressure	O
(	O
1B	O
)	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
);	O
application	O
of	O
at	O
least	O
a	O
minimal	O
amount	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
in	O
ARDS	O
(	O
1B	O
);	O
higher	O
rather	O
than	O
lower	O
level	O
of	O
PEEP	O
for	O
patients	O
with	O
sepsis	O
-	O
induced	O
moderate	O
or	O
severe	O
ARDS	O
(	O
2C	O
);	O
recruitment	O
maneuvers	O
in	O
sepsis	O
patients	O
with	O
severe	O
refractory	O
hypoxemia	O
due	O
to	O
ARDS	O
(	O
2C	O
);	O
prone	O
positioning	O
in	O
sepsis	O
-	O
induced	O
ARDS	O
patients	O
with	O
a	O
PaO	O
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
of	O
≤	O
100	O
mm	O
Hg	O
in	O
facilities	O
that	O
have	O
experience	O
with	O
such	O
practices	O
(	O
2C	O
);	O
head	O
-	O
of	O
-	O
bed	O
elevation	O
in	O
mechanically	O
ventilated	O
patients	O
unless	O
contraindicated	O
(	O
1B	O
);	O
a	O
conservative	O
fluid	O
strategy	O
for	O
patients	O
with	O
established	O
ARDS	O
who	O
do	O
not	O
have	O
evidence	O
of	O
tissue	O
hypoperfusion	O
(	O
1C	O
);	O
protocols	O
for	O
weaning	O
and	O
sedation	O
(	O
1A	O
);	O
minimizing	O
use	O
of	O
either	O
intermittent	O
bolus	O
sedation	O
or	O
continuous	O
infusion	O
sedation	O
targeting	O
specific	O
titration	O
endpoints	O
(	O
1B	O
);	O
avoidance	O
of	O
neuromuscular	O
blockers	O
if	O
possible	O
in	O
the	O
septic	O
patient	O
without	O
ARDS	O
(	O
1C	O
);	O
a	O
short	O
course	O
of	O
neuromuscular	O
blocker	O
(	O
no	O
longer	O
than	O
48	O
h	O
)	O
for	O
patients	O
with	O
early	O
ARDS	O
and	O
a	O
PaO	O
(	O
2	O
)/	O
FI	O
O	O
(	O
2	O
)	O
<	O
150	O
mm	O
Hg	O
(	O
2C	O
);	O
a	O
protocolized	O
approach	O
to	O
blood	O
glucose	O
management	O
commencing	O
insulin	B-PRGE
dosing	O
when	O
two	O
consecutive	O
blood	O
glucose	O
levels	O
are	O
>	O
180	O
mg	O
/	O
dL	O
,	O
targeting	O
an	O
upper	O
blood	O
glucose	O
≤	O
180	O
mg	O
/	O
dL	O
(	O
1A	O
);	O
equivalency	O
of	O
continuous	O
veno	O
-	O
venous	O
hemofiltration	O
or	O
intermittent	O
hemodialysis	O
(	O
2B	O
);	O
prophylaxis	O
for	O
deep	O
vein	O
thrombosis	O
(	O
1B	O
);	O
use	O
of	O
stress	O
ulcer	O
prophylaxis	O
to	O
prevent	O
upper	O
gastrointestinal	O
bleeding	O
in	O
patients	O
with	O
bleeding	O
risk	O
factors	O
(	O
1B	O
);	O
oral	O
or	O
enteral	O
(	O
if	O
necessary	O
)	O
feedings	O
,	O
as	O
tolerated	O
,	O
rather	O
than	O
either	O
complete	O
fasting	O
or	O
provision	O
of	O
only	O
intravenous	O
glucose	O
within	O
the	O
first	O
48	O
h	O
after	O
a	O
diagnosis	O
of	O
severe	O
sepsis	O
/	O
septic	O
shock	O
(	O
2C	O
);	O
and	O
addressing	O
goals	O
of	O
care	O
,	O
including	O
treatment	O
plans	O
and	O
end	O
-	O
of	O
-	O
life	O
planning	O
(	O
as	O
appropriate	O
)	O
(	O
1B	O
),	O
as	O
early	O
as	O
feasible	O
,	O
but	O
within	O
72	O
h	O
of	O
intensive	O
care	O
unit	O
admission	O
(	O
2C	O
).	O

Our	O
data	O
demonstrated	O
that	O
ORF6	B-PRGE
protein	I-PRGE
expression	O
attenuates	O
the	O
activity	O
of	O
numerous	O
karyopherin	B-PRGE
-	I-PRGE
dependent	I-PRGE
host	I-PRGE
transcription	I-PRGE
factors	I-PRGE
(	O
VDR	B-PRGE
,	O
CREB1	B-PRGE
,	O
SMAD4	B-PRGE
,	O
p53	B-PRGE
,	O
EpasI	O
,	O
and	O
Oct3	B-PRGE
/	I-PRGE
4	I-PRGE
)	O
that	O
are	O
critical	O
for	O
establishing	O
antiviral	O
responses	O
and	O
regulating	O
key	O
host	O
responses	O
during	O
virus	O
infection	O
.	O

Using	O
clinical	O
criteria	O
the	O
revised	O
Berlin	O
definition	O
for	O
ARDS	O
allowed	O
the	O
identification	O
of	O
severe	O
ARDS	O
of	O
more	O
than	O
72	O
hours	O
as	O
a	O
homogeneous	O
group	O
of	O
patients	O
characterized	O
by	O
a	O
high	O
proportion	O
of	O
DAD	B-PRGE
.	O

ABSTRACT	O
:	O
The	O
protective	O
efficacy	O
of	O
DNA	O
plasmids	O
encoding	O
avian	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
S1	O
,	O
N	O
,	O
or	O
M	B-PRGE
protein	I-PRGE
was	O
investigated	O
in	O
chickens	O
.	O

PMVEC	O
isolated	O
from	O
human	O
lung	O
were	O
treated	O
in	O
vitro	O
with	O
septic	O
stimulation	O
(	O
lipopolysaccharide	O
[	O
LPS	O
],	O
a	O
mixture	O
of	O
clinically	O
-	O
relevant	O
cytokines	O
[	O
cytomix	O
],	O
or	O
plasma	O
from	O
patients	O
with	O
severe	O
sepsis	O
),	O
and	O
the	O
trans	O
-	O
PMVEC	O
leak	O
of	O
Evans	O
Blue	O
dye	O
-	O
labeled	O
albumin	B-PRGE
assessed	O
.	O

In	O
particular	O
,	O
sVEGFR2	O
and	O
Ang2	B-PRGE
were	O
independent	O
predictors	O
of	O
developing	O
ALI	O
/	O
ARDS	O
.	O

Plasma	B-PRGE
kallistatin	I-PRGE
levels	O
on	O
day	O
1	O
of	O
ICU	O
admission	O
were	O
significantly	O
decreased	O
in	O
patients	O
who	O
developed	O
septic	O
shock	O
(	O
P	O
=	O
0	O
.	O
017	O
)	O
and	O
who	O
had	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
P	O
=	O
0	O
.	O
044	O
).	O

These	O
results	O
suggest	O
that	O
kallistatin	B-PRGE
may	O
serve	O
as	O
a	O
novel	O
marker	O
for	O
severe	O
CAP	O
prognosis	O
and	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
CAP	O
through	O
antiinflammatory	O
and	O
anticoagulation	O
effects	O
.	O

PLP2	B-PRGE
binds	O
ubiquitin	B-PRGE
using	O
a	O
zinc	O
finger	O
that	O
is	O
uniquely	O
integrated	O
into	O
an	O
exceptionally	O
compact	O
OTU	O
-	O
domain	O
fold	O
that	O
represents	O
a	O
new	O
subclass	O
of	O
zinc	O
-	O
dependent	O
OTU	B-PRGE
DUBs	I-PRGE
.	O

HBP	B-PRGE
concentrations	O
were	O
correlated	O
with	O
the	O
lowest	O
ratio	O
of	O
partial	O
pressure	O
of	O
oxygen	O
in	O
arterial	O
blood	O
to	O
fraction	O
of	O
inspired	O
oxygen	O
(	O
PF	O
ratio	O
)	O
during	O
the	O
ICU	O
stay	O
(	O
rho	O
=	O
-	O
0	O
.	O
321	O
,	O
p	O
<	O
0	O
.	O
05	O
).	O

Furthermore	O
,	O
IFN	B-PRGE
-	I-PRGE
γ	I-PRGE
production	O
in	O
the	O
lungs	O
was	O
significantly	O
reduced	O
in	O
IFN	B-PRGE
-	I-PRGE
α	I-PRGE
-	O
treated	O
mice	O
,	O
compared	O
with	O
control	O
mice	O
,	O
but	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
(	O
TNF	O
)-	O
α	O
production	O
was	O
almost	O
equivalent	O
for	O
both	O
groups	O
.	O

In	O
47	O
%	O
of	O
the	O
positive	O
samples	O
more	O
than	O
one	O
CCoV	O
genotype	O
/	O
subtype	O
were	O
detected	O
,	O
with	O
triple	O
CCoV	O
-	O
I	O
/	O
CCoV	O
-	O
IIa	B-PRGE
/	O
CCoV	O
-	O
IIb	O
infections	O
being	O
identified	O
for	O
the	O
first	O
time	O
.	O

The	O
circulation	O
of	O
highly	O
variable	O
CCoV	O
-	O
I	O
and	O
CCoV	B-PRGE
-	I-PRGE
IIb	I-PRGE
emerging	O
strains	O
,	O
as	O
well	O
as	O
the	O
detection	O
of	O
the	O
divergent	O
strain	O
,	O
raise	O
concerns	O
on	O
the	O
importance	O
of	O
these	O
new	O
strains	O
as	O
primary	O
pathogens	O
of	O
diarrhoeic	O
syndromes	O
diagnosed	O
in	O
dogs	O
.	O

A	O
marked	O
increase	O
was	O
evident	O
in	O
the	O
mRNA	O
concentrations	O
of	O
interferon	B-PRGE
-	I-PRGE
β	I-PRGE
and	O
interferon	B-PRGE
-	I-PRGE
λ	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
29	I-PRGE
)	O
and	O
in	O
a	O
large	O
number	O
of	O
proinflammatory	O
cytokines	O
and	O
chemokines	O
.	O

Importantly	O
,	O
however	O
,	O
we	O
demonstrate	O
that	O
both	O
type	B-PRGE
I	I-PRGE
and	I-PRGE
type	I-PRGE
III	I-PRGE
IFN	I-PRGE
can	O
efficiently	O
reduce	O
HCoV	O
-	O
EMC	O
replication	O
in	O
HAE	O
cultures	O
,	O
providing	O
a	O
possible	O
treatment	O
option	O
in	O
cases	O
of	O
suspected	O
HCoV	O
-	O
EMC	O
infection	O
.	O

Once	O
TEER	O
plateaus	O
at	O
or	O
above	O
1	O
,	O
000	O
Ω	O
×	O
cm	O
(	O
2	O
),	O
Calu	B-PRGE
-	I-PRGE
3	I-PRGE
LCC	I-PRGE
are	O
ready	O
to	O
use	O
to	O
examine	O
cellular	O
responses	O
to	O
respiratory	O
pathogens	O
.	O

The	O
turkeys	O
in	O
G3	O
-	O
750DDP	O
produced	O
the	O
highest	O
level	O
of	O
TCoV	B-PRGE
S	I-PRGE
protein	I-PRGE
-	I-PRGE
specific	I-PRGE
antibody	I-PRGE
and	O
virus	O
neutralization	O
(	O
VN	O
)	O
titer	O
.	O

The	O
MHV	O
PS	O
is	O
an	O
RNA	O
structure	O
that	O
maps	O
to	O
the	O
region	O
of	O
the	O
replicase	B-PRGE
gene	I-PRGE
encoding	O
the	O
nonstructural	O
protein	O
15	O
subunit	O
of	O
the	O
viral	B-PRGE
replicase	I-PRGE
-	I-PRGE
transcriptase	I-PRGE
complex	O
.	O

We	O
demonstrate	O
that	O
HCoV	O
-	O
EMC	O
resembles	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
in	O
productively	O
infecting	O
primary	O
and	O
continuous	O
cells	O
of	O
the	O
human	O
airways	O
and	O
in	O
preventing	O
the	O
induction	O
of	O
interferon	B-PRGE
regulatory	I-PRGE
factor	I-PRGE
3	I-PRGE
(	O
IRF	B-PRGE
-	I-PRGE
3	I-PRGE
)-	O
mediated	O
antiviral	O
alpha	B-PRGE
/	I-PRGE
beta	I-PRGE
interferon	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
α	I-PRGE
/	I-PRGE
β	I-PRGE
)	O
responses	O
.	O

Phylogenetic	O
analysis	O
of	O
S1	B-PRGE
subunit	I-PRGE
glycoprotein	I-PRGE
genes	I-PRGE
revealed	O
that	O
field	O
isolates	O
from	O
2009	O
-	O
2011	O
mostly	O
belonged	O
to	O
the	O
LX4	O
type	O
,	O
while	O
those	O
from	O
1985	O
-	O
2008	O
belonged	O
to	O
the	O
HN08	O
type	O
,	O
and	O
a	O
few	O
others	O
belonged	O
to	O
the	O
4	O
/	O
91	O
type	O
,	O
the	O
TW	O
type	O
and	O
the	O
Mass	O
type	O
.	O

Studies	O
in	O
humans	O
and	O
animals	O
have	O
demonstrated	O
a	O
decrease	O
in	O
the	O
expression	O
of	O
proximal	O
sodium	O
(	O
NHE3	O
)	O
and	O
water	O
tubular	O
transporter	O
,	O
aquaporin	B-PRGE
1	I-PRGE
(	O
AQP1	B-PRGE
)	O
together	O
with	O
higher	O
renal	O
expression	O
of	O
the	O
Na	B-PRGE
-	I-PRGE
K	I-PRGE
-	I-PRGE
2Cl	I-PRGE
cotransporter	I-PRGE
NKCC2	I-PRGE
.	O

In	O
an	O
experimental	O
model	O
,	O
at	O
the	O
initial	O
phase	O
of	O
the	O
disease	O
,	O
the	O
expression	O
of	O
AQP2	B-PRGE
,	O
the	O
water	O
transport	O
of	O
the	O
collecting	O
duct	O
,	O
is	O
decreased	O
,	O
which	O
explains	O
the	O
higher	O
incidence	O
of	O
nonoliguric	O
AKI	O
.	O

TITLE	O
:	O
Dipeptidyl	B-PRGE
peptidase	I-PRGE
4	I-PRGE
is	O
a	O
functional	O
receptor	O
for	O
the	O
emerging	O
human	O
coronavirus	O
-	O
EMC	O
.	O

Seroconversion	O
to	O
plague	O
F1	B-PRGE
antigen	I-PRGE
confirmed	O
plague	O
in	O
three	O
survivors	O
.	O

The	O
incidences	O
of	O
pancreatic	O
sepsis	O
,	O
multiple	O
organ	O
dysfunction	O
syndrome	O
and	O
mortality	O
were	O
lower	O
in	O
the	O
somatostatin	B-PRGE
,	O
somatostatin	B-PRGE
+	I-PRGE
ulinastatin	I-PRGE
,	O
somatostatin	B-PRGE
+	I-PRGE
S	I-PRGE
miltiorrhiza	I-PRGE
and	O
somatostatin	B-PRGE
+	O
ulinastatin	B-PRGE
+	I-PRGE
S	I-PRGE
miltiorrhiza	O
subgroups	O
compared	O
with	O
the	O
basic	O
treatment	O
subgroup	O
.	O

The	O
catalytic	O
domain	O
of	O
TMPRSS2	B-PRGE
was	O
expressed	O
in	O
Escherichia	O
coli	O
and	O
used	O
for	O
an	O
inhibitor	O
screen	O
with	O
previously	O
synthesized	O
inhibitors	O
of	O
various	O
trypsin	B-PRGE
-	I-PRGE
like	I-PRGE
serine	I-PRGE
proteases	I-PRGE
.	O

Alpha	B-PRGE
-	I-PRGE
2	I-PRGE
agonists	O
are	O
to	O
be	O
supplemented	O
,	O
if	O
appropriate	O
,	O
by	O
drugs	O
devoid	O
of	O
effect	O
on	O
respiratory	O
drive	O
(	O
neuroleptics	O
,	O
etc	O
.).	O

We	O
previously	O
showed	O
that	O
recombinant	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
(	O
Urbani	O
strain	O
based	O
)	O
lacking	O
envelope	B-PRGE
(	I-PRGE
E	I-PRGE
)	I-PRGE
protein	I-PRGE
expression	O
(	O
rU	O
-	O
ΔE	O
)	O
provided	O
good	O
but	O
not	O
perfect	O
protection	O
in	O
young	O
mice	O
against	O
challenge	O
with	O
virulent	O
mouse	O
-	O
adapted	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
(	O
MA15	O
).	O

ABSTRACT	O
:	O
Immobilized	O
fibrinogen	B-PRGE
and	O
fibrin	O
facilitate	O
leukocyte	O
adhesion	O
,	O
as	O
they	O
are	O
potent	O
ligands	O
for	O
leukocyte	B-PRGE
MAC	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
CD11b	B-PRGE
/	O
CD18	B-PRGE
).	O

However	O
,	O
fibrinogen	B-PRGE
in	O
its	O
soluble	O
form	O
also	O
binds	O
to	O
MAC	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
albeit	O
with	O
low	O
affinity	O
.	O

Soluble	O
fibrinogen	B-PRGE
functioned	O
as	O
a	O
natural	O
antagonist	O
of	O
neutrophil	O
functions	O
that	O
are	O
dependent	O
on	O
MAC	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
such	O
as	O
the	O
respiratory	O
burst	O
induced	O
by	O
unopsonized	O
zymosan	O
and	O
adhesion	O
to	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
heparin	O
.	O

Importantly	O
soluble	O
fibrinogen	B-PRGE
in	O
acute	O
-	O
phase	O
concentrations	O
(	O
4	O
-	O
10	O
mg	O
mL	O
(-	O
1	O
)	O
)	O
dose	O
-	O
dependently	O
reduced	O
neutrophil	O
firm	O
adhesion	O
to	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
α	I-PRGE
-	O
activated	O
endothelium	O
to	O
40	O
%	O
under	O
flow	O
conditions	O
.	O

The	O
plasma	O
PAI	B-PRGE
activity	O
was	O
related	O
to	O
homozygote	O
4G	O
/	O
4G	O
genotype	O
.	O

ABSTRACT	O
:	O
The	O
novel	B-PRGE
re	O
-	O
assortment	O
A	O
influenza	O
H7N9	O
(	O
nrH7N9	O
)	O
emerged	O
in	O
humans	O
in	O
the	O
Shanghai	O
and	O
surrounding	O
provinces	O
of	O
China	O
in	O
late	O
February	O
and	O
early	O
March	O
.	O

Nsp1	B-PRGE
has	O
been	O
shown	O
to	O
have	O
an	O
important	O
role	O
in	O
the	O
pathogenetic	O
mechanisms	O
of	O
coronaviruses	O
in	O
vivo	O
.	O

Furthermore	O
,	O
urine	O
L	O
/	O
M	O
ratio	O
and	O
serum	B-PRGE
endotoxin	I-PRGE
were	O
significantly	O
lower	O
in	O
the	O
SH	O
group	O
and	O
further	O
decreased	O
in	O
the	O
SHG	O
group	O
.	O

Results	O
indicated	O
that	O
combination	O
of	O
normal	O
saline	O
,	O
HES	O
and	O
glutamine	O
are	O
more	O
efficient	O
in	O
resuscitation	O
of	O
SAP	B-PRGE
by	O
relieving	O
inflammation	O
and	O
sustaining	O
the	O
intestinal	O
barrier	O
.	O

However	O
,	O
essential	O
immune	O
functions	O
of	O
FRCs	O
,	O
including	O
homeostatic	B-PRGE
chemokine	I-PRGE
and	O
interleukin	B-PRGE
-	I-PRGE
7	I-PRGE
expression	O
,	O
were	O
impaired	O
.	O

TITLE	O
:	O
Mechanism	O
for	O
controlling	O
the	O
monomer	O
-	O
dimer	O
conversion	O
of	O
SARS	B-PRGE
coronavirus	I-PRGE
main	I-PRGE
protease	I-PRGE
.	O

In	O
this	O
study	O
,	O
we	O
established	O
an	O
in	O
vitro	O
model	O
to	O
compare	O
the	O
responses	O
of	O
type	O
I	O
(	O
ATI	O
)	O
and	B-PRGE
type	I-PRGE
II	I-PRGE
(	O
ATII	O
)	O
alveolar	O
epithelial	O
cells	O
to	O
infection	O
by	O
respiratory	O
viruses	O
used	O
in	O
murine	O
models	O
:	O
mouse	O
-	O
adapted	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
,	O
v2163	O
),	O
murine	B-PRGE
coronavirus	I-PRGE
MHV	I-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
influenza	O
A	O
(	O
H1N1	O
)	O
virus	O
,	O
strain	O
PR8	O
.	O

Both	O
cell	O
types	O
had	O
increased	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
1β	I-PRGE
mRNA	I-PRGE
upon	O
viral	O
infection	O
,	O
though	O
at	O
different	O
levels	O
.	O

The	O
nine	O
isolated	O
phlorotannins	O
(	O
1	O
-	O
9	O
),	O
except	O
phloroglucinol	O
(	O
1	O
),	O
possessed	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
inhibitory	O
activities	O
in	O
a	O
dose	O
-	O
dependently	O
and	O
competitive	O
manner	O
.	O

CONCLUSIONS	O
:	O
The	O
peptides	O
identified	O
in	O
this	O
study	O
are	O
useful	O
reagents	O
for	O
detection	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O

We	O
suggest	O
the	O
use	O
of	O
epitope	O
prediction	O
methods	O
in	O
combination	O
with	O
3D	O
structural	O
modelling	O
of	O
peptide	B-PRGE
-	I-PRGE
MHC	I-PRGE
-	I-PRGE
TCR	I-PRGE
complex	I-PRGE
to	O
identify	O
MHC	B-PRGE
class	O
I	O
restricted	O
T	O
-	O
cell	O
epitopes	O
for	O
use	O
in	O
epitope	O
based	O
vaccines	O
like	O
HIV	O
and	O
human	O
cancers	O
,	O
which	O
should	O
provide	O
a	O
valuable	O
step	O
forward	O
for	O
the	O
design	O
of	O
better	O
vaccines	O
and	O
may	O
provide	O
in	O
depth	O
understanding	O
about	O
activation	O
of	O
T	B-PRGE
-	I-PRGE
cell	I-PRGE
epitopes	I-PRGE
by	O
MHC	B-PRGE
binding	I-PRGE
peptides	I-PRGE
.	O

TITLE	O
:	O
Seroepidemiological	O
Study	O
on	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
IgG	I-PRGE
Antibodies	I-PRGE
of	O
Different	O
Populations	O
from	O
Several	O
Areas	O
.	O

ABSTRACT	O
:	O
In	O
order	O
to	O
investigate	O
the	O
clinical	O
and	O
epidemiological	O
rules	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
rates	O
and	O
levels	O
SARS	O
coronavirus	O
(	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
)	O
IgG	B-PRGE
antibodies	I-PRGE
of	O
the	O
patients	O
and	O
community	O
populations	O
from	O
several	O
areas	O
were	O
detected	O
.	O

We	O
observed	O
that	O
TGEV	O
infection	O
decreased	O
p300	B-PRGE
/	O
CBP	B-PRGE
,	O
downregulated	O
MDM2	O
and	O
promoted	O
p53	B-PRGE
phosphorylation	O
at	O
serines	O
15	O
,	O
20	O
and	O
46	O
,	O
resulting	O
in	O
accumulation	O
and	O
activation	O
of	O
p53	B-PRGE
in	I-PRGE
PK	I-PRGE
-	O
15	O
cells	O
.	O

ABSTRACT	O
:	O
Blinatumomab	O
is	O
a	O
CD19	B-PRGE
/	O
CD3	B-PRGE
-	I-PRGE
bispecific	I-PRGE
T	I-PRGE
-	I-PRGE
cell	I-PRGE
receptor	I-PRGE
-	I-PRGE
engaging	I-PRGE
(	I-PRGE
BiTE	I-PRGE
)	I-PRGE
antibody	I-PRGE
with	O
efficacy	O
in	O
refractory	O
B	O
-	O
precursor	O
acute	O
lymphoblastic	O
leukemia	O
.	O

Studies	O
on	O
their	O
mechanisms	O
of	O
action	O
revealed	O
that	O
the	O
compounds	O
act	O
by	O
three	O
distinct	O
mechanisms	O
:	O
(	O
i	O
)	O
SSAA09E2	O
{	O
N	O
-[[	O
4	O
-(	O
4	O
-	O
methylpiperazin	O
-	O
1	O
-	O
yl	O
)	O
phenyl	O
]	O
methyl	O
]-	O
1	O
,	O
2	O
-	O
oxazole	O
-	O
5	O
-	O
carboxamide	O
}	O
acts	O
through	O
a	O
novel	O
mechanism	O
of	O
action	O
,	O
by	O
blocking	O
early	O
interactions	O
of	O
SARS	O
-	O
S	O
with	O
the	O
receptor	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
angiotensin	B-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
);	O
(	O
ii	O
)	O
SSAA09E1	O
{[(	O
Z	O
)-	O
1	O
-	O
thiophen	O
-	O
2	O
-	O
ylethylideneamino	O
]	O
thiourea	O
}	O
acts	O
later	O
,	O
by	O
blocking	O
cathepsin	B-PRGE
L	I-PRGE
,	I-PRGE
a	I-PRGE
host	I-PRGE
protease	I-PRGE
required	O
for	O
processing	O
of	O
SARS	O
-	O
S	O
during	O
viral	O
entry	O
;	O
and	O
(	O
iii	O
)	O
SSAA09E3	O
[	O
N	O
-(	O
9	O
,	O
10	O
-	O
dioxo	O
-	O
9	O
,	O
10	O
-	O
dihydroanthracen	O
-	O
2	O
-	O
yl	O
)	O
benzamide	O
]	O
also	O
acts	O
later	O
and	O
does	O
not	O
affect	O
interactions	O
of	O
SARS	B-PRGE
-	I-PRGE
S	I-PRGE
with	O
ACE2	B-PRGE
or	O
the	O
enzymatic	O
functions	O
of	O
cathepsin	B-PRGE
L	I-PRGE
but	O
prevents	O
fusion	O
of	O
the	O
viral	O
membrane	O
with	O
the	O
host	O
cellular	O
membrane	O
.	O

In	O
GADD153	B-PRGE
-	O
knockdown	O
cells	O
,	O
IBV	O
-	O
induced	O
apoptosis	O
was	O
suppressed	O
and	O
virus	O
replication	O
inhibited	O
,	O
revealing	O
a	O
key	O
role	O
of	O
GADD153	B-PRGE
in	O
IBV	O
-	O
induced	O
cell	O
death	O
and	O
virus	O
replication	O
.	O

Analysis	O
of	O
the	O
pathways	O
downstream	O
of	O
GADD153	B-PRGE
revealed	O
much	O
more	O
activation	O
of	O
the	O
extracellular	B-PRGE
signal	O
-	O
related	O
kinase	O
(	O
ERK	B-PRGE
)	O
pathway	O
in	O
GADD153	B-PRGE
-	O
knockdown	O
cells	O
during	O
IBV	O
infection	O
,	O
indicating	O
that	O
GADD153	B-PRGE
may	O
modulate	O
apoptosis	O
through	O
suppression	O
of	O
the	O
pathway	O
.	O

TITLE	O
:	O
Functional	O
analysis	O
of	O
the	O
stem	B-PRGE
loop	I-PRGE
S3	I-PRGE
and	I-PRGE
S4	I-PRGE
structures	O
in	O
the	O
coronavirus	O
3	O
'	O
UTR	O
.	O

Overall	O
,	O
the	O
whole	O
set	O
of	O
experiments	O
supports	O
the	O
proteolipidic	O
structure	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
E	I-PRGE
channels	I-PRGE
and	O
explains	O
the	O
large	O
difference	O
in	O
channel	O
conductance	O
observed	O
between	O
neutral	O
and	O
charged	O
membranes	O
.	O

TITLE	O
:	O
Anti	O
-	O
inflammatory	O
mechanisms	O
of	O
apolipoprotein	B-PRGE
A	I-PRGE
-	I-PRGE
I	I-PRGE
mimetic	O
peptide	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
secondary	O
to	O
sepsis	O
.	O

CART	B-PRGE
has	O
been	O
reported	O
as	O
supportive	O
therapy	O
for	O
patients	O
with	O
liver	O
cirrhosis	O
and	O
cancer	O
.	O

While	O
its	O
safety	O
has	O
not	O
been	O
fully	O
established	O
in	O
patients	O
with	O
hematological	O
disease	O
after	O
HSCT	O
,	O
CART	B-PRGE
may	O
be	O
a	O
considerable	O
supportive	O
therapy	O
for	O
SOS	O
with	O
tense	O
ascites	O
.	O

TITLE	O
:	O
Suppression	O
of	O
coronavirus	O
replication	O
by	O
cyclophilin	B-PRGE
inhibitors	O
.	O

Human	B-PRGE
ApoE	I-PRGE
consists	O
of	O
three	O
isoforms	O
(	O
E2	O
,	O
E3	O
,	O
and	O
E4	O
)	O
with	O
the	O
E4	O
and	O
E2	O
alleles	O
representing	O
a	O
greater	O
and	O
a	O
lower	O
risk	O
for	O
developping	O
AD	O
,	O
respectively	O
.	O

The	O
data	O
is	O
consistent	O
with	O
the	O
helical	O
oligomer	O
packing	O
model	O
of	O
N	B-PRGE
protein	I-PRGE
observed	O
in	O
crystal	O
.	O

The	O
in	O
vitro	O
inhibitory	O
activity	O
(	O
50	O
%	O
effective	O
concentration	O
)	O
of	O
the	O
macrocyclic	O
inhibitor	O
toward	O
enterovirus	B-PRGE
3C	I-PRGE
protease	I-PRGE
(	O
CVB3	O
Nancy	O
strain	O
),	O
and	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
norovirus	B-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
proteases	I-PRGE
,	O
was	O
determined	O
to	O
be	O
1	O
.	O
8	O
,	O
15	O
.	O
5	O
and	O
5	O
.	O
1	O
μM	O
,	O
respectively	O
.	O

Haematology	O
and	O
serum	O
biochemistry	O
demonstrated	O
a	O
moderate	O
,	O
poorly	O
regenerative	O
anaemia	O
,	O
hypoalbuminaemia	O
and	O
hyperglobulinaemia	O
with	O
a	O
low	O
albumin	B-PRGE
:	I-PRGE
globulin	I-PRGE
ratio	O
.	O

Serology	O
for	O
feline	O
coronavirus	O
antibody	O
was	O
positive	O
with	O
an	O
elevated	O
alpha	B-PRGE
-	I-PRGE
1	I-PRGE
acid	I-PRGE
glycoprotein	I-PRGE
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	O
,	O
and	O
biological	O
evaluation	O
of	O
novel	O
dipeptide	B-PRGE
-	I-PRGE
type	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
protease	I-PRGE
inhibitors	O
:	O
structure	O
-	O
activity	O
relationship	O
study	O
.	O

ABSTRACT	O
:	O
This	O
work	O
describes	O
the	O
design	O
,	O
synthesis	O
,	O
and	O
evaluation	O
of	O
low	O
-	O
molecular	O
weight	O
peptidic	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
protease	I-PRGE
inhibitors	O
.	O

Amylase	B-PRGE
and	O
lipase	B-PRGE
were	O
normal	O
.	O

His	O
antibiotic	O
regimen	O
was	O
changed	O
and	O
ventilation	O
was	O
altered	O
to	O
high	O
frequency	O
oscillations	O
,	O
and	O
despite	O
being	O
ethically	O
problematic	O
,	O
we	O
added	O
APC	B-PRGE
to	O
his	O
treatment	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	O
nucleocapsid	O
protein	O
(	O
N	O
)	O
plays	O
an	O
essential	O
structural	O
role	O
in	O
virions	O
through	O
a	O
network	O
of	O
interactions	O
with	O
positive	O
-	O
strand	O
viral	O
genomic	O
RNA	O
,	O
the	O
envelope	B-PRGE
membrane	I-PRGE
protein	I-PRGE
(	O
M	O
),	O
and	O
other	O
N	O
molecules	O
.	O

We	O
previously	O
uncovered	O
an	O
unanticipated	O
interaction	O
between	O
N	O
and	O
the	O
largest	O
subunit	O
of	O
the	O
viral	B-PRGE
replicase	I-PRGE
-	I-PRGE
transcriptase	I-PRGE
complex	I-PRGE
,	O
nonstructural	B-PRGE
protein	I-PRGE
3	I-PRGE
(	O
nsp3	B-PRGE
).	O

In	O
the	O
work	O
reported	O
here	O
,	O
we	O
constructed	O
BCoV	O
chimeras	O
and	O
other	O
mutants	O
of	O
MHV	B-PRGE
nsp3	I-PRGE
and	O
obtained	O
complementary	O
genetic	O
evidence	O
for	O
its	O
association	O
with	O
N	B-PRGE
protein	I-PRGE
.	O

The	O
latter	O
function	O
of	O
N	O
was	O
shown	O
to	O
depend	O
on	O
both	O
of	O
the	O
RNA	O
-	O
binding	O
domains	O
of	O
N	O
,	O
as	O
well	O
as	O
on	O
the	O
serine	O
-	O
and	O
arginine	O
-	O
rich	O
central	O
region	O
of	O
N	O
,	O
which	O
binds	O
nsp3	B-PRGE
.	O

Based	O
on	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
(	O
RdRp	O
)-	O
based	O
grouping	O
units	O
(	O
RGUs	O
)	O
as	O
a	O
surrogate	O
for	O
CoV	O
species	O
identification	O
,	O
the	O
50	O
viruses	O
represented	O
five	O
different	O
alphacoronavirus	O
RGUs	O
and	O
two	O
betacoronavirus	O
RGUs	O
.	O

These	O
results	O
suggested	O
that	O
PHEV	O
induces	O
apoptosis	O
in	O
PK	O
-	O
15	O
cells	O
via	O
a	O
caspase	B-PRGE
-	O
dependent	O
pathway	O
.	O

The	O
use	O
of	O
panels	O
rather	O
than	O
individual	O
tests	O
in	O
combination	O
with	O
quantitative	O
toxin	B-PRGE
gene	I-PRGE
analysis	O
enables	O
detection	O
of	O
coinfections	O
significantly	O
associated	O
with	O
risk	O
of	O
disease	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
developed	O
two	O
potent	O
chemical	O
classes	O
that	O
inhibit	O
the	O
essential	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
PLpro	O
)	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Human	B-PRGE
coronavirus	I-PRGE
NL63	I-PRGE
was	O
isolated	O
and	O
identified	O
by	O
RT	O
-	O
PCR	O
and	O
sequencing	O
,	O
and	O
its	O
replication	O
in	O
a	O
fresh	O
batch	O
of	O
RPTEC	O
and	O
another	O
type	O
of	O
primary	O
human	O
kidney	O
cells	O
was	O
confirmed	O
.	O

A	O
combination	O
therapy	O
with	O
ribavirin	O
,	O
intravenous	B-PRGE
immunoglobulin	I-PRGE
(	O
IVIG	O
)	O
and	O
steroid	O
under	O
ECMO	O
support	O
was	O
started	O
with	O
considerable	O
improvement	O
.	O

In	O
the	O
last	O
20	O
years	O
,	O
many	O
natural	O
substances	O
have	O
shown	O
antiviral	O
activity	O
against	O
HIV	O
-	O
1	O
,	O
but	O
only	O
a	O
few	O
against	O
the	O
RNase	B-PRGE
H	I-PRGE
function	O
.	O

At	O
present	O
,	O
albumin	B-PRGE
treatment	O
does	O
not	O
appear	O
to	O
be	O
justified	O
for	O
limitation	O
of	O
pulmonary	O
edema	O
and	O
respiratory	O
morbidity	O
.	O

Infection	O
results	O
in	O
profound	O
apoptosis	O
within	O
24	O
h	O
irrespective	O
of	O
its	O
production	O
of	O
titers	O
that	O
are	O
lower	O
than	O
those	O
of	O
SARS	O
-	O
CoV	O
.	O
Together	O
,	O
our	O
results	O
provide	O
new	O
insights	O
into	O
the	O
dissemination	O
and	O
pathogenesis	O
of	O
MERS	O
-	O
CoV	O
and	O
may	O
indicate	O
that	O
the	O
virus	O
differs	O
markedly	O
from	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O

By	O
using	O
special	O
staining	O
techniques	O
,	O
the	O
presence	O
of	O
myoglobin	B-PRGE
and	O
lipofuscin	O
deposits	O
was	O
confirmed	O
in	O
the	O
kidney	O
samples	O
.	O

Western	O
blot	O
analysis	O
was	O
used	O
to	O
validate	O
the	O
changes	O
of	O
alpha	B-PRGE
tubulin	I-PRGE
,	O
keratin	B-PRGE
19	I-PRGE
,	O
and	O
prohibitin	B-PRGE
during	O
TGEV	O
infection	O
.	O

XILP	O
reduced	O
the	O
activity	O
of	O
HIV	O
-	O
1	O
reverse	B-PRGE
transcriptase	I-PRGE
with	O
an	O
IC50	O
of	O
11	O
.	O
1μM	O
,	O
but	O
lacked	O
inhibitory	O
activity	O
toward	O
HIV	B-PRGE
-	I-PRGE
1	I-PRGE
integrase	I-PRGE
and	O
SARS	B-PRGE
coronavirus	I-PRGE
proteinase	I-PRGE
.	O

Here	O
we	O
report	O
a	O
case	O
of	O
severe	O
,	O
life	O
-	O
threatening	O
OHSS	O
resulting	O
in	O
ARF	B-PRGE
secondary	O
to	O
obstructive	O
uropathy	O
.	O

A	O
2	O
-	O
year	O
-	O
old	O
African	O
-	O
American	O
girl	O
with	O
co	O
-	O
inherited	O
cystic	O
fibrosis	O
and	O
sickle	B-PRGE
cell	I-PRGE
-	I-PRGE
β	I-PRGE
+	I-PRGE
thalassemia	O
developed	O
severe	O
hematologic	O
complications	O
(	O
recurrent	O
vaso	O
-	O
occlusive	O
events	O
,	O
hepatic	O
sequestration	O
,	O
and	O
acute	O
chest	O
syndrome	O
)	O
during	O
periods	O
of	O
cystic	O
fibrosis	O
pulmonary	O
exacerbations	O
and	O
weight	O
loss	O
.	O

TITLE	O
:	O
Human	B-PRGE
coronavirus	I-PRGE
HKU1	I-PRGE
infection	O
of	O
primary	O
human	O
type	O
II	O
alveolar	O
epithelial	O
cells	O
:	O
cytopathic	O
effects	O
and	O
innate	O
immune	O
response	O
.	O

Binding	O
tests	O
with	O
soluble	O
spike	O
proteins	O
carrying	O
an	O
IgG	B-PRGE
Fc	I-PRGE
-	I-PRGE
tag	I-PRGE
revealed	O
pronounced	O
differences	O
between	O
these	O
two	O
viral	O
proteins	O
.	O

In	O
present	O
study	O
,	O
the	O
expression	O
of	O
principal	O
adhesion	O
molecules	O
involved	O
in	O
leukocyte	O
transmigration	O
(	O
CD15s	O
,	O
CD11a	B-PRGE
,	O
CD11b	B-PRGE
,	O
CD18	B-PRGE
,	O
CD49d	B-PRGE
,	O
and	O
CD54	B-PRGE
)	O
on	O
peripheral	O
blood	O
leukocytes	O
from	O
cats	O
with	O
naturally	O
occurring	O
FIP	O
(	O
n	O
=	O
15	O
)	O
and	O
controls	O
(	O
n	O
=	O
12	O
)	O
was	O
quantified	O
by	O
flow	O
cytometry	O
using	O
a	O
formaldehyde	O
-	O
based	O
rapid	O
leukocyte	O
preparation	O
technique	O
.	O

T	O
-	O
and	O
B	O
-	O
lymphocytes	O
from	O
FIP	O
patients	O
exhibit	O
higher	O
expression	O
of	O
both	O
subunits	O
(	O
CD11a	B-PRGE
and	O
CD18	B-PRGE
)	O
composing	O
the	O
β2	O
integrin	O
lymphocyte	B-PRGE
function	O
-	O
associated	O
antigen	O
(	O
LFA	O
)-	O
1	O
.	O

Since	O
up	O
to	O
75	O
%	O
of	O
sepsis	O
originates	O
from	O
the	O
lung	O
,	O
aPC	B-PRGE
treatment	O
may	O
not	O
have	O
added	O
enough	O
to	O
the	O
beneficial	O
effect	O
of	O
lung	O
-	O
protective	O
ventilation	O
to	O
show	O
lower	O
mortality	O
.	O

In	O
addition	O
,	O
in	O
these	O
cell	O
lines	O
,	O
SARS	B-PRGE
-	O
CoV	O
-	O
MA15	O
induced	O
the	O
expression	O
of	O
proinflammatory	O
cytokines	O
and	O
IFN	B-PRGE
-	I-PRGE
β	I-PRGE
,	O
mimicking	O
what	O
has	O
been	O
observed	O
in	O
experimental	O
animal	O
models	O
infected	O
with	O
SARS	O
-	O
CoV	O
and	O
SARS	O
patients	O
.	O

With	O
these	O
data	O
,	O
we	O
predicted	O
that	O
the	O
urokinase	B-PRGE
and	O
other	O
wound	O
repair	O
pathways	O
would	O
regulate	O
lethal	O
versus	O
sublethal	O
disease	O
following	O
SARS	O
-	O
CoV	O
infection	O
in	O
mice	O
.	O

ABSTRACT	O
:	O
Mice	O
that	O
are	O
transgenic	O
(	O
Tg	O
)	O
for	O
T	B-PRGE
cell	I-PRGE
receptor	I-PRGE
(	O
TCR	B-PRGE
)	O
expression	O
are	O
used	O
extensively	O
to	O
analyze	O
longitudinal	O
T	O
cell	O
responses	O
during	O
effector	O
and	O
memory	O
phases	O
of	O
the	O
T	O
cell	O
response	O
.	O

We	O
generated	O
mice	O
that	O
were	O
transgenic	O
for	O
a	O
TCR	B-PRGE
responding	O
to	O
a	O
CD4	B-PRGE
T	I-PRGE
cell	I-PRGE
epitope	I-PRGE
(	O
epitope	O
M133	O
)	O
that	O
is	O
immunodominant	O
in	O
mice	O
infected	O
with	O
a	O
neurotropic	O
coronavirus	O
,	O
the	O
JHM	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
.	O

This	O
TCR	B-PRGE
-	I-PRGE
β	I-PRGE
chain	I-PRGE
was	O
introduced	O
into	O
bone	O
marrow	O
cells	O
with	O
a	O
lentivirus	O
vector	O
,	O
generating	O
TCR	B-PRGE
-	I-PRGE
β	I-PRGE
retrogenic	O
mice	O
.	O

nsp3	B-PRGE
has	O
membrane	O
disordering	O
and	O
proliferation	O
ability	O
,	O
both	O
in	O
its	O
full	O
-	O
length	O
form	O
and	O
in	O
a	O
C	O
-	O
terminal	O
-	O
truncated	O
form	O
.	O

nsp3	B-PRGE
and	O
nsp4	B-PRGE
working	O
together	O
have	O
the	O
ability	O
to	O
pair	O
membranes	O
.	O

This	O
activity	O
appears	O
to	O
require	O
the	O
full	O
-	O
length	O
form	O
of	O
nsp3	B-PRGE
for	O
action	O
,	O
as	O
double	O
-	O
membrane	O
vesicles	O
were	O
not	O
seen	O
in	O
cells	O
coexpressing	O
the	O
C	B-PRGE
-	I-PRGE
terminal	I-PRGE
truncation	I-PRGE
nsp3	I-PRGE
with	O
nsp4	B-PRGE
and	O
nsp6	O
.	O

In	O
contrast	O
,	O
the	O
expression	O
of	O
cytotoxicity	O
-	O
associated	O
genes	O
,	O
i	O
.	O
e	O
.,	O
granzyme	O
A	O
(	O
GZMA	O
)	O
and	O
perforin	B-PRGE
mRNA	I-PRGE
,	O
remained	O
associated	O
with	O
the	O
HALT	O
after	O
boosting	O
.	O

The	O
spike	B-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
glycoprotein	I-PRGE
is	O
an	O
important	O
determinant	O
for	O
PEDV	O
biological	O
properties	O
.	O

TGEV	O
RNA	O
sequences	O
identified	O
as	O
necessary	O
for	O
viral	O
genome	O
packaging	O
were	O
not	O
sufficient	O
to	O
direct	O
packaging	O
of	O
a	O
heterologous	O
sequence	O
derived	O
from	O
the	O
green	B-PRGE
fluorescent	I-PRGE
protein	I-PRGE
gene	I-PRGE
.	O

This	O
mini	O
-	O
review	O
will	O
discuss	O
recent	O
findings	O
regarding	O
the	O
interaction	O
between	O
bacterial	B-PRGE
toxins	I-PRGE
and	O
arginase	O
during	O
acute	O
lung	O
injury	O
and	O
will	O
as	O
such	O
address	O
the	O
role	O
of	O
arginase	B-PRGE
in	O
bacterial	O
toxin	O
-	O
induced	O
pulmonary	O
endothelial	O
barrier	O
dysfunction	O
.	O

The	O
gene	O
product	O
,	O
pVHL	B-PRGE
,	O
regulates	O
the	O
level	O
of	O
proteins	O
that	O
play	O
a	O
central	O
role	O
in	O
protecting	O
cells	O
against	O
hypoxia	O
.	O

While	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
MERS	O
-	O
CoV	O
are	O
genetically	O
closely	O
related	O
to	O
bat	O
coronaviruses	O
,	O
intermediate	O
host	O
(	O
s	O
)	O
is	O
(	O
are	O
)	O
likely	O
to	O
be	O
involved	O
in	O
the	O
emergence	O
and	O
cross	O
-	O
species	O
transmission	O
of	O
these	O
novel	O
human	O
viruses	O
.	O

Pathophysiological	O
mechanisms	O
implicated	O
in	O
the	O
development	O
of	O
AEP	O
in	O
our	O
patient	O
seem	O
to	O
be	O
associated	O
with	O
eotaxin	B-PRGE
and	O
serotonin	O
eosinophilic	O
-	O
specific	O
chemoattracting	O
action	O
,	O
through	O
the	O
serotoninergic	O
action	O
of	O
risperidone	O
.	O

This	O
article	O
reviews	O
the	O
latest	O
knowledge	O
about	O
how	O
RBDs	O
from	O
different	O
SARS	O
-	O
CoV	O
strains	O
interact	O
with	O
ACE2	B-PRGE
from	O
several	O
animal	O
species	O
.	O

Detailed	O
research	O
on	O
these	O
RBD	O
/	O
ACE2	B-PRGE
interactions	O
has	O
established	O
important	O
principles	O
on	O
host	O
receptor	O
adaptations	O
,	O
cross	O
-	O
species	O
infections	O
,	O
and	O
future	O
evolution	O
of	O
SARS	O
-	O
CoV	O
.	O
These	O
principles	O
may	O
apply	O
to	O
other	O
emerging	O
animal	O
viruses	O
,	O
including	O
the	O
recently	O
emerged	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

The	O
combination	O
of	O
interferon	B-PRGE
-	I-PRGE
α2b	I-PRGE
and	O
ribavirin	O
was	O
effective	O
in	O
reducing	O
MERS	O
-	O
CoV	O
replication	O
in	O
vitro	O
;	O
therefore	O
,	O
we	O
initiated	O
this	O
treatment	O
8	O
h	O
after	O
inoculation	O
of	O
rhesus	O
macaques	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
γ	O
-	O
PGA	O
induces	O
type	O
I	O
IFN	B-PRGE
signaling	O
pathway	O
via	O
the	O
TLR4	B-PRGE
signaling	O
pathway	O
.	O

The	O
induction	O
required	O
both	O
myeloid	B-PRGE
differentiation	I-PRGE
factor	I-PRGE
2	I-PRGE
(	O
MD2	B-PRGE
)	O
and	O
the	O
pattern	O
-	O
recognition	O
receptor	O
CD14	B-PRGE
,	O
which	O
are	O
two	O
TLR4	B-PRGE
-	I-PRGE
associated	I-PRGE
accessory	I-PRGE
proteins	I-PRGE
.	O

The	O
γ	O
-	O
PGA	O
with	O
high	O
molecular	O
weights	O
(	O
2000	O
and	O
5000	O
kDa	O
)	O
was	O
able	O
to	O
activate	O
the	O
subsequent	O
signals	O
through	O
TLR4	B-PRGE
/	O
MD2	B-PRGE
to	O
result	O
in	O
dimerization	O
of	O
IRF	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
a	O
transcription	O
factor	O
required	O
for	O
IFN	B-PRGE
gene	I-PRGE
expression	O
,	O
leading	O
to	O
increases	O
in	O
mRNA	O
levels	O
of	O
the	O
type	B-PRGE
I	I-PRGE
IFN	I-PRGE
-	I-PRGE
response	I-PRGE
genes	I-PRGE
,	O
2	O
'-	O
5	O
'	O
OAS	O
and	O
ISG56	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
microbial	O
biopolymer	O
γ	O
-	O
PGA	O
may	O
have	O
therapeutic	O
potential	O
against	O
a	O
broad	O
range	O
of	O
viruses	O
sensitive	O
to	O
type	B-PRGE
I	I-PRGE
IFNs	I-PRGE
.	O

Importantly	O
,	O
the	O
coronavirus	O
is	O
thought	O
to	O
enter	O
cells	O
via	O
two	O
distinct	O
pathways	O
,	O
one	O
mediated	O
by	O
TMPRSS2	O
at	O
the	O
cell	O
surface	O
and	O
the	O
other	O
mediated	O
by	O
cathepsin	B-PRGE
L	I-PRGE
in	O
the	O
endosome	O
.	O

However	O
,	O
the	O
intra	O
-	O
and	O
intermolecular	O
determinants	O
of	O
nsp5	B-PRGE
activity	O
and	O
their	O
conservation	O
across	O
divergent	O
CoVs	O
are	O
unknown	O
,	O
in	O
part	O
due	O
to	O
challenges	O
in	O
cultivating	O
many	O
human	O
and	O
zoonotic	O
CoVs	O
.	O

TITLE	O
:	O
Induced	O
expression	O
and	O
functional	O
effects	O
of	O
aquaporin	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
human	O
leukocytes	O
in	O
sepsis	O
.	O

We	O
additionally	O
determined	O
aquaporin	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
upon	O
lipopolysaccharide	O
(	O
LPS	O
)	O
exposure	O
and	O
explored	O
functional	O
effects	O
of	O
aquaporin	B-PRGE
-	I-PRGE
1	I-PRGE
induction	O
in	O
polymorphonuclear	O
granulocytes	O
(	O
PMNs	O
).	O

The	O
cardiac	O
catheterization	O
1	O
month	O
after	O
OLT	O
showed	O
:	O
mPAP	O
28	O
mm	O
Hg	O
,	O
WP	O
13	O
mm	O
Hg	O
,	O
CO	O
5	O
.	O
4	O
L	O
/	O
min	B-PRGE
,	O
PVR	B-PRGE
220	I-PRGE
dyne	I-PRGE
s	I-PRGE
/	O
cm	O
(	O
5	O
)	O
and	O
TPG	O
15	O
mm	O
Hg	O
.	O

The	O
present	O
study	O
describes	O
a	O
dynamic	O
mechanism	O
in	O
which	O
LIM	B-PRGE
kinase	I-PRGE
1	I-PRGE
(	O
LIMK1	B-PRGE
),	O
a	O
cofilin	B-PRGE
kinase	I-PRGE
,	O
and	O
slingshot	B-PRGE
-	I-PRGE
1Long	I-PRGE
(	O
SSH	B-PRGE
-	I-PRGE
1L	I-PRGE
),	O
a	O
cofilin	B-PRGE
phosphatase	I-PRGE
,	O
are	O
engaged	O
by	O
procoagulant	O
and	O
proinflammatory	O
mediator	O
thrombin	B-PRGE
to	O
regulate	O
these	O
responses	O
.	O

In	O
addition	O
,	O
LIMK1	B-PRGE
or	O
SSH	B-PRGE
-	I-PRGE
1L	I-PRGE
depletion	O
inhibited	O
RelA	B-PRGE
/	O
p65	B-PRGE
phosphorylation	O
at	O
Ser	O
(	O
536	O
),	O
a	O
critical	O
event	O
conferring	O
transcriptional	O
competency	O
to	O
the	O
bound	O
NF	O
-	O
κB	O
.	O
However	O
,	O
unlike	O
SSH	B-PRGE
-	I-PRGE
1L	I-PRGE
,	O
LIMK1	B-PRGE
knockdown	O
also	O
impairs	O
the	O
release	O
of	O
RelA	B-PRGE
/	I-PRGE
p65	I-PRGE
by	O
blocking	O
IKKβ	O
-	O
dependent	O
phosphorylation	O
/	O
degradation	O
of	O
IκBα	O
.	O

However	O
,	O
no	O
anti	B-PRGE
-	I-PRGE
S	I-PRGE
IgM	I-PRGE
was	O
detected	O
in	O
healthy	O
adults	O
.	O

There	O
is	O
,	O
however	O
,	O
little	O
information	O
on	O
the	O
reliability	O
of	O
predictive	O
algorithms	O
in	O
the	O
context	O
of	O
human	O
populations	O
,	O
in	O
particular	O
,	O
for	O
those	O
expressing	O
HLA	B-PRGE
class	I-PRGE
I	I-PRGE
molecules	I-PRGE
for	O
which	O
there	O
are	O
limited	O
experimental	O
data	O
available	O
.	O

ABSTRACT	O
:	O
The	O
IL	B-PRGE
-	I-PRGE
33	I-PRGE
/	O
ST2	B-PRGE
axis	O
is	O
known	O
to	O
be	O
involved	O
in	O
liver	O
pathologies	O
.	O

Therefore	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
expression	O
of	O
IL	B-PRGE
-	I-PRGE
33	I-PRGE
in	O
murine	O
fulminant	O
hepatitis	O
induced	O
by	O
a	O
Toll	B-PRGE
like	I-PRGE
receptor	I-PRGE
(	O
TLR3	B-PRGE
)	O
viral	O
mimetic	O
,	O
poly	O
(	O
I	O
:	O
C	O
)	O
or	O
by	O
pathogenic	O
mouse	O
hepatitis	O
virus	O
(	O
L2	O
-	O
MHV3	O
).	O

These	O
results	O
suggest	O
that	O
hepatocyte	B-PRGE
-	I-PRGE
specific	I-PRGE
IL	I-PRGE
-	I-PRGE
33	I-PRGE
expression	O
in	O
poly	O
(	O
I	O
:	O
C	O
)	O
induced	O
liver	O
injury	O
was	O
partially	O
dependent	O
of	O
NK	O
cells	O
and	O
with	O
limited	O
role	O
of	O
NKT	O
cells	O
.	O

Upon	O
a	O
combination	O
of	O
intratracheal	O
,	O
ocular	O
,	O
oral	O
,	O
and	O
intranasal	O
inoculation	O
with	O
7	O
×	O
10	O
(	O
6	O
)	O
50	O
%	O
tissue	O
culture	O
infectious	O
dose	O
of	O
the	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
isolate	I-PRGE
HCoV	I-PRGE
-	I-PRGE
EMC	I-PRGE
/	I-PRGE
2012	I-PRGE
,	I-PRGE
rhesus	I-PRGE
macaques	I-PRGE
developed	O
a	O
transient	O
lower	O
respiratory	O
tract	O
infection	O
.	O

Blood	O
samples	O
obtained	O
on	O
days	O
112	O
and	O
140	O
were	O
used	O
for	O
assessment	O
of	O
BCoV	B-PRGE
-	I-PRGE
specific	I-PRGE
serum	I-PRGE
IgG1	I-PRGE
,	O
IgG2	B-PRGE
,	O
IgM	B-PRGE
,	O
and	O
IgA	B-PRGE
titers	O
via	O
an	O
ELISA	O
.	O

ABSTRACT	O
:	O
The	O
interferon	B-PRGE
-	I-PRGE
inducible	I-PRGE
transmembrane	I-PRGE
protein	I-PRGE
(	O
IFITM	O
)	O
family	O
inhibits	O
a	O
growing	O
number	O
of	O
pathogenic	O
viruses	O
,	O
among	O
them	O
influenza	O
A	O
virus	O
,	O
dengue	O
virus	O
,	O
hepatitis	O
C	O
virus	O
,	O
and	O
Ebola	O
virus	O
.	O

MAb	O
2	O
-	O
4	O
exhibited	O
high	O
neutralizing	O
activity	O
against	O
natural	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
derived	O
from	O
FIPV	O
-	O
infected	O
macrophages	O
,	O
and	O
was	O
confirmed	O
to	O
inhibit	O
the	O
following	O
feline	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
-	O
induced	O
conditions	O
in	O
vitro	O
:	O
(	O
i	O
)	O
an	O
increase	O
in	O
the	O
survival	O
rate	O
of	O
neutrophils	O
from	O
cats	O
with	O
FIP	O
,	O
(	O
ii	O
)	O
aminopeptidase	B-PRGE
N	I-PRGE
(	O
APN	B-PRGE
)	O
mRNA	O
expression	O
in	O
macrophages	O
,	O
and	O
(	O
iii	O
)	O
apoptosis	O
of	O
a	O
feline	O
T	O
-	O
lymphocyte	O
cell	O
line	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
effects	O
of	O
TGEV	O
infection	O
on	O
the	O
cell	O
cycle	O
of	O
host	O
cells	O
and	O
the	O
roles	O
of	O
p53	B-PRGE
activation	O
in	O
this	O
process	O
.	O

Combination	O
of	O
mycophenolic	O
acid	O
and	O
interferon	B-PRGE
-	I-PRGE
β1b	I-PRGE
lowered	O
the	O
EC50	O
of	O
each	O
drug	O
by	O
1	O
-	O
3	O
times	O
.	O

Surprisingly	O
,	O
a	O
polyclonal	O
antibody	O
to	O
the	O
S	B-PRGE
protein	I-PRGE
of	O
MHV	O
,	O
a	O
group	O
a	O
murine	O
betacoronavirus	O
,	O
cross	O
-	O
reacted	O
in	O
immunoblots	O
with	O
the	O
S2	O
domain	O
of	O
group	O
c	B-PRGE
MERS	I-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
.	O

When	O
293T	O
cells	O
producing	O
MERS	O
pseudotypes	O
co	O
-	O
expressed	O
serine	B-PRGE
proteases	I-PRGE
TMPRSS	I-PRGE
-	I-PRGE
2	I-PRGE
or	I-PRGE
-	I-PRGE
4	I-PRGE
,	O
large	O
syncytia	O
formed	O
at	O
neutral	O
pH	O
,	O
and	O
the	O
pseudovirions	O
produced	O
were	O
non	O
-	O
infectious	O
and	O
deficient	O
in	O
S	B-PRGE
protein	I-PRGE
.	O

TITLE	O
:	O
Acute	O
eosinophilic	O
pneumonia	O
occurring	O
in	O
a	O
dedicator	B-PRGE
of	I-PRGE
cytokinesis	I-PRGE
8	I-PRGE
(	O
DOCK8	B-PRGE
)	O
deficient	O
patient	O
.	O

Immunological	O
assessments	O
demonstrated	O
decreased	O
IgM	B-PRGE
,	O
increased	O
IgE	B-PRGE
,	O
T	O
lymphocytepenia	O
,	O
especially	O
in	O
CD4	B-PRGE
T	I-PRGE
cells	O
,	O
decreased	O
PHA	B-PRGE
blastogenesis	O
,	O
and	O
decreased	O
CD27	B-PRGE
(+)	I-PRGE
CD19	I-PRGE
(+)	O
memory	O
B	O
cells	O
.	O

As	O
far	O
as	O
we	O
know	O
,	O
this	O
is	O
the	O
first	O
Japanese	O
case	O
of	O
DOCK8	B-PRGE
deficiency	O
.	O

TITLE	O
:	O
Adaptive	O
evolution	O
of	O
bat	O
dipeptidyl	B-PRGE
peptidase	I-PRGE
4	I-PRGE
(	O
dpp4	B-PRGE
):	O
implications	O
for	O
the	O
origin	O
and	O
emergence	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
.	O

MERS	O
-	O
CoV	O
utilizes	O
the	O
dipeptidyl	B-PRGE
peptidase	I-PRGE
4	I-PRGE
(	O
DPP4	B-PRGE
)	O
host	O
cell	O
receptor	O
,	O
and	O
analysis	O
of	O
the	O
long	O
-	O
term	O
interaction	O
between	O
virus	O
and	O
receptor	O
provides	O
key	O
information	O
on	O
the	O
evolutionary	O
events	O
that	O
lead	O
to	O
the	O
viral	O
emergence	O
.	O

TITLE	O
:	O
Human	B-PRGE
coronavirus	I-PRGE
OC43	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
binds	O
microRNA	O
9	O
and	O
potentiates	O
NF	O
-	O
κB	O
activation	O
.	O

TITLE	O
:	O
Screening	O
and	O
antiviral	O
analysis	O
of	O
phages	O
that	O
display	O
peptides	O
with	O
an	O
affinity	O
to	O
subunit	B-PRGE
C	I-PRGE
of	O
porcine	B-PRGE
aminopeptidase	I-PRGE
.	O

ABSTRACT	O
:	O
The	O
purified	O
C	O
subunit	O
of	O
the	O
recombinant	B-PRGE
porcine	I-PRGE
aminopeptidase	I-PRGE
N	I-PRGE
(	O
rpAPN	O
-	O
C	O
)	O
protein	O
was	O
used	O
as	O
an	O
immobilized	O
target	O
to	O
screen	O
potential	O
ligands	O
against	O
rpAPN	O
-	O
C	O
from	O
a	O
12	O
-	O
mer	O
phage	O
display	O
random	O
peptide	O
library	O
.	O

This	O
work	O
suggests	O
that	O
5E12	O
would	O
be	O
a	O
useful	O
tool	O
as	O
a	O
specific	O
diagnostic	O
reagent	O
for	O
detecting	O
PEDV	B-PRGE
S	I-PRGE
protein	I-PRGE
.	O

TITLE	O
:	O
Proteolytic	O
activation	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
coronavirus	I-PRGE
spike	I-PRGE
protein	I-PRGE
:	O
cutting	O
enzymes	O
at	O
the	O
cutting	O
edge	O
of	O
antiviral	O
research	O
.	O

In	O
light	O
of	O
recent	O
functional	O
,	O
biochemical	O
and	O
structural	O
findings	O
,	O
we	O
review	O
the	O
inhibition	O
mechanisms	O
of	O
RLRs	O
recognition	O
of	O
dsRNA	O
displayed	O
by	O
a	O
number	O
of	O
highly	O
pathogenic	O
RNA	O
viruses	O
with	O
different	O
disease	O
phenotypes	O
such	O
as	O
haemorrhagic	O
fever	O
(	O
Ebola	O
,	O
Marburg	O
,	O
Lassa	O
fever	O
,	O
Lujo	O
,	O
Machupo	O
,	O
Junin	O
,	O
Guanarito	O
,	O
Crimean	O
-	O
Congo	O
,	O
Rift	O
Valley	O
fever	O
,	O
dengue	O
),	O
severe	O
respiratory	O
disease	O
(	O
influenza	O
,	O
SARS	O
,	O
Hendra	O
,	O
Hantaan	O
,	O
Sin	B-PRGE
Nombre	O
,	O
Andes	O
)	O
and	O
encephalitis	O
(	O
Nipah	O
,	O
West	O
Nile	O
).	O

A	O
novel	O
betacoronavirus	O
species	O
in	O
a	O
phylogenetic	O
sister	O
relationship	O
to	O
MERS	O
-	O
CoV	O
and	O
clade	B-PRGE
c	I-PRGE
bat	I-PRGE
CoVs	I-PRGE
was	O
detected	O
and	O
characterized	O
on	O
the	O
whole	O
-	O
genome	O
level	O
.	O

Whereas	O
virus	O
control	O
was	O
not	O
affected	O
by	O
perivascular	O
retention	O
of	O
CD4	B-PRGE
⁺	I-PRGE
T	I-PRGE
cells	O
,	O
disease	O
severity	O
was	O
decreased	O
and	O
associated	O
with	O
reduced	O
IFNγ	O
(	O
interferon	B-PRGE
γ	I-PRGE
)	O
production	O
.	O

RESULTS	O
:	O
Using	O
the	O
five	O
best	O
-	O
performing	O
biomarkers	O
(	O
surfactant	O
protein	B-PRGE
-	I-PRGE
D	I-PRGE
(	O
SP	B-PRGE
-	I-PRGE
D	I-PRGE
),	O
receptor	O
for	O
advanced	O
glycation	O
end	O
-	O
products	O
(	O
RAGE	O
),	O
interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
(	O
IL	O
-	O
8	O
),	O
club	B-PRGE
cell	I-PRGE
secretory	I-PRGE
protein	I-PRGE
(	O
CC	O
-	O
16	O
),	O
and	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
))	O
the	O
area	O
under	O
the	O
receiver	O
operator	O
characteristic	O
curve	O
(	O
AUC	O
)	O
was	O
0	O
.	O
75	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
7	O
to	O
0	O
.	O
84	O
)	O
for	O
the	O
diagnosis	O
of	O
ARDS	O
.	O

(	O
ii	O
)	O
When	O
the	O
uORF	O
was	O
fused	O
with	O
genomic	O
(	O
main	O
)	O
ORF1	O
by	O
converting	O
three	O
in	O
-	O
frame	O
stop	O
codons	O
to	O
nonstop	O
codons	O
,	O
a	O
uORF	B-PRGE
-	I-PRGE
ORF1	I-PRGE
fusion	I-PRGE
protein	I-PRGE
was	O
made	O
,	O
and	O
virus	O
replicated	O
at	O
WT	O
levels	O
.	O

Immunomodulation	O
with	O
drugs	O
like	O
omalizumab	O
in	O
IgE	B-PRGE
-	O
mediated	O
asthma	O
syndromes	O
is	O
one	O
important	O
approach	O
.	O

An	O
increase	O
in	O
AQP4	B-PRGE
membrane	O
expression	O
during	O
acute	O
NMO	O
attacks	O
could	O
potentially	O
enhance	O
the	O
complement	O
-	O
mediated	O
humoral	O
immune	O
reaction	O
against	O
AQP4	B-PRGE
-	O
expressing	O
astrocytes	O
characteristic	O
for	O
NMO	B-PRGE
and	O
,	O
thus	O
,	O
result	O
in	O
more	O
severe	O
astrocytic	O
damage	O
.	O

ABSTRACT	O
:	O
The	O
type	B-PRGE
I	I-PRGE
IFN	I-PRGE
-	O
mediated	O
immune	O
response	O
is	O
the	O
first	O
line	O
of	O
antiviral	O
defence	O
.	O

Nevertheless	O
,	O
addition	O
of	O
protein	O
7a	O
to	O
FIPV	O
-	O
Δ3Δ7	O
,	O
a	O
FIPV	O
mutant	O
deleted	O
in	O
both	O
ORF3	O
and	O
ORF7	O
,	O
could	O
no	O
longer	O
increase	O
the	O
replication	O
capacity	O
of	O
this	O
mutant	O
in	O
the	O
presence	O
of	O
IFN	B-PRGE
.	O

TITLE	O
:	O
Ifit2	B-PRGE
deficiency	O
results	O
in	O
uncontrolled	O
neurotropic	O
coronavirus	O
replication	O
and	O
enhanced	O
encephalitis	O
via	O
impaired	O
alpha	B-PRGE
/	I-PRGE
beta	I-PRGE
interferon	I-PRGE
induction	O
in	O
macrophages	O
.	O

This	O
study	O
demonstrates	O
a	O
protective	O
role	O
of	O
the	O
ISG	B-PRGE
Ifit2	I-PRGE
in	O
encephalitis	O
induced	O
by	O
the	O
dual	O
hepato	O
-	O
and	O
neurotropic	O
MHV	O
-	O
A59	O
.	O

TITLE	O
:	O
Role	O
of	O
CD25	B-PRGE
(+)	I-PRGE
CD4	I-PRGE
(+)	O
T	O
cells	O
in	O
acute	O
and	O
persistent	O
coronavirus	O
infection	O
of	O
the	O
central	O
nervous	O
system	O
.	O

ABSTRACT	O
:	O
The	O
influence	O
of	O
CD25	B-PRGE
(+)	I-PRGE
CD4	I-PRGE
(+)	I-PRGE
regulatory	O
T	O
cells	O
(	O
Treg	O
)	O
on	O
acute	O
and	O
chronic	O
viral	O
infection	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
was	O
examined	O
using	O
a	O
glial	O
tropic	O
murine	O
coronavirus	O
.	O

These	O
data	O
suggest	O
that	O
CNS	O
inflammation	O
,	O
progression	O
of	O
viral	O
control	O
and	O
viral	O
persistence	O
are	O
relatively	O
independent	O
of	O
CD25	B-PRGE
(+)	I-PRGE
CD4	I-PRGE
(+)	I-PRGE
Treg	O
.	O

Sequence	O
analysis	O
revealed	O
that	O
the	O
CCoV	B-PRGE
-	I-PRGE
I	I-PRGE
and	I-PRGE
IIa	I-PRGE
strains	O
shared	O
high	O
genetic	O
similarity	O
to	O
each	O
other	O
and	O
to	O
the	O
prototypes	O
.	O

The	O
Brazilian	O
strains	O
of	O
CCoV	O
-	O
IIb	O
displayed	O
an	O
aminoacid	O
insertion	O
that	O
was	O
also	O
described	O
in	O
CCoV	B-PRGE
-	I-PRGE
IIb	I-PRGE
-	I-PRGE
UCD	I-PRGE
-	I-PRGE
1	I-PRGE
and	O
TGEV	O
strains	O
.	O

We	O
have	O
found	O
that	O
intestinal	O
I	O
/	O
R	O
increased	O
the	O
lung	B-PRGE
myeloperoxidase	I-PRGE
activity	O
and	O
Evans	O
blue	O
dye	O
extravasation	O
,	O
which	O
were	O
reduced	O
by	O
treatment	O
of	O
rats	O
with	O
E2	O
.	O

However	O
,	O
E2	O
treatment	O
reduced	O
the	O
basal	O
expression	O
of	O
platelet	B-PRGE
endothelial	I-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
1	I-PRGE
.	O

ABSTRACT	O
:	O
The	O
type	B-PRGE
II	I-PRGE
transmembrane	I-PRGE
serine	I-PRGE
proteases	I-PRGE
TMPRSS2	B-PRGE
and	O
HAT	B-PRGE
can	O
cleave	O
and	O
activate	O
the	O
spike	O
protein	O
(	O
S	O
)	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
for	O
membrane	O
fusion	O
.	O

Finally	O
,	O
TMPRSS2	B-PRGE
was	O
found	O
to	O
compete	O
with	O
the	O
metalloprotease	B-PRGE
ADAM17	B-PRGE
for	O
ACE2	B-PRGE
processing	O
,	O
but	O
only	O
cleavage	O
by	O
TMPRSS2	O
resulted	O
in	O
augmented	O
SARS	O
-	O
S	O
-	O
driven	O
entry	O
.	O

The	O
nuclear	B-PRGE
enzyme	O
poly	O
(	O
adenosine	O
diphosphate	O
-	O
ribose	O
)	O
polymerase	O
(	O
PARP	B-PRGE
)	O
enhances	O
the	O
nuclear	O
factor	O
(	O
NF	O
)-	O
κB	O
-	O
dependent	O
transcription	O
of	O
inflammatory	O
cytokines	O
.	O

All	O
of	O
these	O
effects	O
were	O
associated	O
with	O
strong	O
expression	O
of	O
PARP	B-PRGE
and	O
NF	O
-	O
κB	O
.	O
Treatment	O
with	O
3	O
-	O
AB	O
prevented	O
the	O
LPS	O
-	O
induced	O
metabolic	O
acidosis	O
and	O
hypotension	O
,	O
reduced	O
the	O
plasma	O
levels	O
of	O
lactate	O
,	O
creatinine	O
and	O
potassium	O
,	O
reduced	O
the	O
cytokine	O
mRNA	O
expressions	O
,	O
reduced	O
the	O
expression	O
of	O
PARP	B-PRGE
and	O
NF	O
-	O
κB	O
,	O
improved	O
pulmonary	O
edema	O
and	O
oxygenation	O
and	O
preserved	O
renal	O
function	O
.	O

Thus	O
,	O
we	O
have	O
identified	O
a	O
class	O
of	O
pathogen	O
-	O
derived	O
ERGIC	O
-	O
53	O
ligands	O
,	O
a	O
lectin	B-PRGE
-	O
independent	O
basis	O
for	O
their	O
association	O
with	O
ERGIC	O
-	O
53	O
,	O
and	O
a	O
role	O
for	O
ERGIC	O
-	O
53	O
in	O
the	O
propagation	O
of	O
several	O
highly	O
pathogenic	O
RNA	O
virus	O
families	O
.	O

This	O
review	O
focuses	O
on	O
the	O
dichotomous	O
role	O
of	O
HA	O
to	O
both	O
promote	O
and	O
inhibit	O
ALI	O
based	O
on	O
its	O
size	O
and	O
the	O
HA	B-PRGE
binding	I-PRGE
proteins	I-PRGE
present	O
.	O

miR	B-PRGE
-	I-PRGE
146a	I-PRGE
,	O
an	O
anti	O
-	O
inflammatory	O
microRNA	O
targeting	O
TLR4	B-PRGE
signaling	O
,	O
was	O
induced	O
during	O
the	O
late	O
phase	O
of	O
lung	O
injury	O
in	O
WT	O
mice	O
,	O
whereas	O
it	O
was	O
increased	O
early	O
in	O
Akt2	B-PRGE
(-/-)	O
mice	O
.	O

In	O
vivo	O
modulation	O
of	O
macrophage	O
phenotype	O
through	O
Akt2	B-PRGE
or	O
miR	B-PRGE
-	I-PRGE
146a	I-PRGE
could	O
provide	O
a	O
potential	O
therapeutic	O
approach	O
for	O
aseptic	O
ARDS	O
;	O
however	O
,	O
it	O
may	O
be	O
deleterious	O
in	O
septic	O
ARDS	O
because	O
of	O
impaired	O
bacterial	O
clearance	O
.	O

TITLE	O
:	O
Tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
α	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
α	I-PRGE
)	O
receptor	O
-	O
I	O
is	O
required	O
for	O
TNF	B-PRGE
-	I-PRGE
α	I-PRGE
-	O
mediated	O
fulminant	O
virus	O
hepatitis	O
caused	O
by	O
murine	O
hepatitis	O
virus	O
strain	O
-	O
3	O
infection	O
.	O

ABSTRACT	O
:	O
TNF	B-PRGE
-	I-PRGE
α	I-PRGE
plays	O
an	O
essential	O
role	O
in	O
the	O
pathogenesis	O
of	O
fulminant	O
virus	O
hepatitis	O
(	O
FH	O
)	O
caused	O
by	O
infection	O
with	O
murine	O
hepatitis	O
virus	O
strain	O
-	O
3	O
(	O
MHV	O
-	O
3	O
).	O

However	O
,	O
only	O
TNFR1	B-PRGE
(-/-)	O
mice	O
were	O
resistant	O
to	O
MHV	O
-	O
3	O
mediated	O
FH	O
,	O
as	O
displayed	O
by	O
a	O
dramatic	O
decrease	O
in	O
tissue	O
necrosis	O
and	O
cell	O
apoptosis	O
in	O
the	O
infected	O
spleens	O
and	O
livers	O
from	O
TNFR1	B-PRGE
(-/-)	O
mice	O
,	O
as	O
well	O
as	O
prolonged	O
survival	O
in	O
these	O
mice	O
compared	O
to	O
wild	O
type	O
littermate	O
controls	O
.	O

Both	O
partial	O
and	O
complete	O
nucleotide	O
sequences	O
of	O
the	O
spike	B-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
glycoprotein	I-PRGE
and	O
the	O
nucleotide	O
sequences	O
of	O
ORF3	O
genes	O
were	O
determined	O
to	O
investigate	O
the	O
genetic	O
diversity	O
and	O
molecular	O
epidemiology	O
of	O
Thai	O
PEDV	O
.	O

Based	O
on	O
the	O
analysis	O
of	O
the	O
partial	B-PRGE
S	I-PRGE
glycoprotein	I-PRGE
genes	I-PRGE
,	O
the	O
Thai	O
PEDV	O
isolates	O
were	O
clustered	O
into	O
2	O
groups	O
related	O
to	O
Korean	O
and	O
Chinese	O
field	O
isolates	O
.	O

None	O
of	O
the	O
R	O
.	O
equi	O
isolates	O
showed	O
a	O
virulent	O
(	O
vapA	B-PRGE
gene	I-PRGE
)	O
or	O
intermediately	O
virulent	O
(	O
vapB	B-PRGE
gene	I-PRGE
)	O
profiles	O
.	O

No	O
Salmonella	B-PRGE
spp	I-PRGE
.	O

The	O
phylogenetic	O
trees	O
based	O
on	O
the	O
S1	O
,	O
M	O
and	O
N	O
genes	O
exhibited	O
considerably	O
different	O
topology	O
and	O
the	O
CK	O
/	O
CH	O
/	O
LSC	B-PRGE
/	O
99I	O
-	O
type	O
isolates	O
were	O
the	O
predominant	O
IBVs	O
based	O
on	O
the	O
phylogenetic	O
analysis	O
of	O
S1	B-PRGE
gene	I-PRGE
.	O

MBL	B-PRGE
deficiency	O
and	O
susceptibility	O
to	O
different	O
types	O
of	O
infections	O
have	O
been	O
subject	O
to	O
extensive	O
studies	O
over	O
the	O
last	O
decades	O
.	O

In	O
humans	O
and	O
chickens	O
,	O
several	O
studies	O
have	O
shown	O
that	O
MBL	B-PRGE
participates	O
in	O
the	O
protection	O
of	O
hosts	O
against	O
virus	O
infections	O
.	O

The	O
clinical	O
indicators	O
,	O
including	O
the	O
initial	O
Balthazar	O
'	O
s	O
computed	O
tomography	O
(	O
CT	O
)	O
score	O
,	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHE	O
II	O
)	O
scores	O
on	O
1st	O
,	O
3rd	O
,	O
5th	O
and	O
7th	O
day	O
,	O
incidences	O
and	O
durations	O
of	O
complications	O
and	O
the	O
serum	B-PRGE
C	I-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
(	O
CRP	B-PRGE
),	O
levels	O
of	O
MMP	B-PRGE
-	I-PRGE
9	I-PRGE
on	O
the	O
1st	O
,	O
3rd	O
,	O
5th	O
and	O
7th	O
day	O
,	O
were	O
recorded	O
and	O
compared	O
between	O
the	O
two	O
groups	O
.	O

TITLE	O
:	O
Synthesis	O
,	O
modification	O
and	O
docking	O
studies	O
of	O
5	O
-	O
sulfonyl	O
isatin	O
derivatives	O
as	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
inhibitors	O
.	O

Of	O
all	O
the	O
IFNs	O
tested	O
,	O
IFN	B-PRGE
-	I-PRGE
β	I-PRGE
showed	O
the	O
strongst	O
inhibition	O
of	O
MERS	O
-	O
CoV	O
in	O
vitro	O
,	O
with	O
an	O
IC₅₀	O
of	O
1	O
.	O
37	O
U	O
ml	O
(-	O
1	O
),	O
41	O
times	O
lower	O
than	O
the	O
previously	O
reported	O
IC₅₀	O
(	O
56	O
.	O
08	O
U	O
ml	O
(-	O
1	O
))	O
of	O
IFN	B-PRGE
-	I-PRGE
α2b	I-PRGE
.	O

TITLE	O
:	O
Interferon	B-PRGE
lambda	I-PRGE
genetic	I-PRGE
polymorphisms	O
and	O
viral	O
infection	O
:	O
the	O
tip	O
of	O
the	O
iceberg	O
?	O

We	O
hypothesize	O
that	O
genetic	O
variation	O
of	O
IFN	B-PRGE
-	I-PRGE
λ	I-PRGE
could	O
potentially	O
influence	O
the	O
course	O
of	O
disease	O
during	O
infection	O
with	O
many	O
viruses	O
that	O
infect	O
epithelial	O
cells	O
.	O

However	O
,	O
PrP	B-PRGE
during	O
ECMO	O
might	O
be	O
associated	O
with	O
complications	O
such	O
as	O
dislocation	O
of	O
ECMO	O
cannulae	O
.	O

The	O
identification	O
of	O
the	O
structures	O
of	O
both	O
the	O
MERS	O
-	O
CoV	O
receptor	B-PRGE
binding	I-PRGE
domain	I-PRGE
(	O
RBD	O
)	O
and	O
its	O
complex	O
with	O
dipeptidyl	B-PRGE
peptidase	I-PRGE
4	I-PRGE
(	O
DPP4	B-PRGE
),	O
raises	O
the	O
hope	O
of	O
alleviating	O
this	O
currently	O
severe	O
situation	O
.	O

We	O
tested	O
swabs	O
with	O
RT	O
-	O
PCR	O
,	O
with	O
amplification	O
targeting	O
the	O
E	B-PRGE
gene	I-PRGE
(	O
upE	O
),	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
,	O
and	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
1a	O
.	O

This	O
review	O
describes	O
our	O
current	O
knowledge	O
of	O
VEGF	B-PRGE
biology	O
and	O
summarises	O
the	O
literature	O
investigating	O
the	O
potential	O
role	O
VEGF	B-PRGE
may	O
play	O
in	O
normal	O
lung	O
maintenance	O
and	O
in	O
the	O
development	O
of	O
lung	O
injury	O
.	O

Genomic	O
studies	O
revealed	O
that	O
two	O
viral	O
proteases	O
,	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
PLpro	O
)	O
and	O
3C	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
3CLpro	O
),	O
process	O
the	O
polyproteins	O
encoded	O
by	O
the	O
MERS	O
-	O
CoV	O
genomic	O
RNA	O
.	O

TITLE	O
:	O
Lineage	O
specific	O
antigenic	O
differences	O
in	O
porcine	O
torovirus	O
hemagglutinin	O
-	O
esterase	B-PRGE
(	O
PToV	O
-	O
HE	O
)	O
protein	O
.	O

TITLE	O
:	O
FJU	O
-	O
C4	O
,	O
a	O
new	O
2	O
-	O
pyridone	O
compound	O
,	O
attenuates	O
lipopolysaccharide	O
-	O
induced	O
systemic	O
inflammation	O
via	O
p38MAPK	B-PRGE
and	O
NF	O
-	O
κB	O
in	O
mice	O
.	O

The	O
activities	O
of	O
ERK	B-PRGE
,	O
JNK	B-PRGE
,	O
and	O
p38MAPK	B-PRGE
were	O
induced	O
by	O
LPS	O
stimulation	O
on	O
murine	O
macrophage	O
cell	O
line	O
,	O
but	O
only	O
p38MAPK	B-PRGE
signaling	O
was	O
dramatically	O
suppressed	O
by	O
pretreatment	O
with	O
the	O
FJU	O
-	O
C4	O
compound	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

High	O
levels	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
IL	O
-	O
1β	O
,-	O
6	O
,-	O
8	O
,-	O
12	O
,	O
tumour	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
alpha	I-PRGE
and	O
interferon	B-PRGE
gamma	I-PRGE
were	O
found	O
in	O
all	O
injured	O
patients	O
compared	O
to	O
healthy	O
controls	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
evaluate	O
the	O
salivary	O
interleukin	B-PRGE
(	O
IL	O
)-	O
1β	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
21	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
33	I-PRGE
,	O
and	O
pentraxin	B-PRGE
-	I-PRGE
3	I-PRGE
(	O
PTX3	B-PRGE
)	O
concentrations	O
in	O
patients	O
with	O
and	O
without	O
OSAS	O
.	O

In	O
this	O
study	O
we	O
compared	O
S	O
proteins	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
HCoV	O
-	O
HKU1	O
for	O
their	O
ability	O
to	O
activate	O
the	O
UPR	O
.	O

Transmembrane	B-PRGE
serine	I-PRGE
protease	I-PRGE
TMPRSS2	I-PRGE
catalyzed	O
the	O
cleavage	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
,	O
but	O
not	O
the	O
counterpart	O
in	O
HCoV	O
-	O
HKU1	O
.	O

RESULTS	O
:	O
In	O
this	O
study	O
we	O
compared	O
S	O
proteins	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
HCoV	O
-	O
HKU1	O
for	O
their	O
ability	O
to	O
activate	O
the	O
UPR	O
.	O

A	O
central	O
region	O
(	O
amino	O
acids	O
201	O
-	O
400	O
)	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S1	I-PRGE
was	O
required	O
for	O
this	O
activity	O
.	O

Furthermore	O
,	O
treatment	O
with	O
IFN	B-PRGE
-	I-PRGE
γ	I-PRGE
inhibits	O
JHMV	O
replication	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Our	O
results	O
suggest	O
that	O
BST2	B-PRGE
exerts	O
a	O
broad	O
blocking	O
effect	O
against	O
enveloped	O
virus	O
release	O
,	O
regardless	O
of	O
whether	O
budding	O
occurs	O
at	O
the	O
plasma	O
membrane	O
or	O
intracellular	O
compartments	O
.	O

It	O
was	O
also	O
demonstrated	O
that	O
N	B-PRGE
-	I-PRGE
protein	I-PRGE
binds	O
to	O
nucleic	O
acid	O
at	O
multiple	O
sites	O
with	O
a	O
coupled	O
-	O
allostery	O
manner	O
.	O

Etiology	O
of	O
ARF	B-PRGE
was	O
pneumonia	O
(	O
n	O
=	O
10	O
),	O
thoracic	O
manifestation	O
of	O
NHL	O
(	O
n	O
=	O
2	O
),	O
sepsis	O
of	O
nonpulmonary	O
origin	O
(	O
n	O
=	O
1	O
),	O
and	O
transfusion	O
-	O
related	O
acute	O
lung	O
injury	O
(	O
n	O
=	O
1	O
).	O

Apoptosis	O
also	O
occurred	O
in	O
the	O
pyramidal	O
neurons	O
and	O
CD11b	B-PRGE
-	O
bearing	O
cells	O
.	O

Specifically	O
,	O
we	O
have	O
shown	O
that	O
Epac	B-PRGE
-	O
specific	O
inhibitor	O
treatment	O
or	O
silencing	O
Epac	B-PRGE
-	I-PRGE
1	I-PRGE
gene	I-PRGE
expression	O
rendered	O
cells	O
resistant	O
to	O
viral	O
infection	O
.	O

The	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RT	I-PRGE
-	I-PRGE
RPA	I-PRGE
showed	O
cross	O
-	O
detection	O
neither	O
of	O
any	O
of	O
the	O
RNAs	O
of	O
several	O
coronaviruses	O
and	O
respiratory	O
viruses	O
affecting	O
humans	O
nor	O
of	O
the	O
human	O
genome	O
.	O

Furthermore	O
,	O
the	O
pigs	O
infected	O
with	O
HP	O
-	O
PRRSV	O
showed	O
the	O
higher	O
levels	O
of	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
(	O
TNF	O
)-	O
α	O
,	O
interleukin	B-PRGE
(	O
IL	O
)-	O
1β	O
,	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)-	I-PRGE
8	I-PRGE
and	O
histamine	O
,	O
leukotriene	O
B4	O
(	O
LTB4	O
),	O
platelet	B-PRGE
activation	I-PRGE
factor	I-PRGE
(	O
PAF	B-PRGE
)	O
in	O
sera	O
than	O
those	O
inoculated	O
with	O
LP	O
-	O
PRRSV	O
.	O

Here	O
we	O
characterize	O
the	O
six	O
-	O
helix	O
bundle	O
fusion	O
core	O
structure	O
of	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
S2	I-PRGE
subunit	I-PRGE
by	O
X	O
-	O
ray	O
crystallography	O
and	O
biophysical	O
analysis	O
.	O

For	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
the	O
absence	O
of	O
this	O
2	O
'-	O
O	O
-	O
MTase	B-PRGE
activity	O
results	O
in	O
significant	O
attenuation	O
characterized	O
by	O
decreased	O
viral	O
replication	O
,	O
reduced	O
weight	O
loss	O
,	O
and	O
limited	O
breathing	O
dysfunction	O
in	O
mice	O
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
novel	O
high	O
-	O
throughput	O
screening	O
assay	O
based	O
on	O
peptides	O
,	O
derived	O
from	O
the	O
glycoproteins	O
of	O
the	O
aforementioned	O
viruses	O
,	O
which	O
contain	O
the	O
cathepsin	B-PRGE
L	I-PRGE
cleavage	O
site	O
.	O

As	O
expected	O
,	O
the	O
interaction	O
of	O
N	B-PRGE
protein	I-PRGE
with	O
M	B-PRGE
protein	I-PRGE
was	O
not	O
affected	O
in	O
either	O
of	O
the	O
chimeric	O
viruses	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
and	O
arteriviruses	O
,	O
members	O
of	O
the	O
order	O
Nidovirales	O
,	O
are	O
positive	O
strand	O
RNA	O
viruses	O
that	O
encode	O
large	B-PRGE
replicase	I-PRGE
polyproteins	I-PRGE
that	O
are	O
processed	O
by	O
viral	O
proteases	O
to	O
generate	O
the	O
nonstructural	O
proteins	O
which	O
mediate	O
viral	O
RNA	O
synthesis	O
.	O

Overexpression	O
studies	O
revealed	O
that	O
viral	O
protease	O
/	O
DUB	B-PRGE
activity	O
can	O
modulate	O
or	O
block	O
activation	O
of	O
the	O
innate	O
immune	O
response	O
pathway	O
.	O

Coronavirus	O
surveillance	O
studies	O
in	O
different	O
populations	O
of	O
bats	O
have	O
suggested	O
that	O
they	O
are	O
probable	O
reservoirs	O
for	O
this	O
novel	O
virus	O
,	O
and	O
phylogenetic	O
analysis	O
of	O
both	O
the	O
spike	O
(	O
S1	O
)	O
and	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
proteins	I-PRGE
of	O
MERS	O
-	O
CoV	O
have	O
revealed	O
that	O
it	O
is	O
related	O
to	O
bat	O
viruses	O
.	O

All	O
three	O
ICA	O
kits	O
were	O
capable	O
of	O
detecting	O
anti	O
-	O
FCoV	O
antibodies	O
;	O
however	O
,	O
non	O
-	O
specific	O
positive	O
reactions	O
of	O
anti	O
-	O
FCoV	O
antibody	O
-	O
negative	O
plasma	O
samples	O
with	O
the	O
test	O
line	O
were	O
observed	O
in	O
2	O
ICA	O
kits	O
(	O
CJIgG	O
/	O
TNP	B-PRGE
and	O
CJNP	O
/	O
TNP	B-PRGE
),	O
in	O
which	O
rNP	B-PRGE
was	O
used	O
as	O
the	O
test	O
line	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
specific	O
detection	O
of	O
anti	O
-	O
FCoV	O
antibodies	O
was	O
possible	O
in	O
all	O
plasma	O
,	O
serum	O
,	O
whole	O
blood	O
,	O
and	O
ascitic	O
fluid	O
samples	O
using	O
the	O
ICA	B-PRGE
kit	I-PRGE
with	O
protein	O
A	O
blotted	O
as	O
the	O
test	O
line	O
(	O
CJNP	O
/	O
TPA	O
).	O

Since	O
inhibiting	O
MLCK	B-PRGE
with	O
ML	O
-	O
7	O
was	O
so	O
efficient	O
in	O
blocking	O
the	O
internalisation	O
pathway	O
,	O
this	O
target	O
can	O
be	O
used	O
for	O
the	O
development	O
of	O
a	O
new	O
treatment	O
for	O
FIPV	O
.	O

The	O
24	O
hours	O
urine	O
protein	O
analysis	O
revealed	O
significant	O
proteinuria	O
and	O
renal	O
biopsy	O
showed	O
global	O
and	O
seg	O
-	O
mental	O
sclerosis	O
in	O
glomeruli	O
,	O
mesangial	O
arteritis	O
,	O
proliferations	O
in	O
visceral	O
epithelial	O
cells	O
(	O
IgA	B-PRGE
nephropathy	O
).	O

TITLE	O
:	O
Middle	O
east	O
respiratory	O
syndrome	O
coronavirus	O
4a	O
protein	O
is	O
a	O
double	O
-	O
stranded	O
RNA	O
-	O
binding	O
protein	O
that	O
suppresses	O
PACT	O
-	O
induced	O
activation	O
of	O
RIG	B-PRGE
-	I-PRGE
I	I-PRGE
and	O
MDA5	B-PRGE
in	O
the	O
innate	O
antiviral	O
response	O
.	O

We	O
also	O
identified	O
peptides	O
that	O
strongly	O
induce	O
Th1	B-PRGE
activity	O
from	O
those	O
derived	O
from	O
the	O
structural	O
proteins	O
(	O
S	O
,	O
M	O
,	O
and	O
N	O
proteins	O
)	O
of	O
FIPV	O
based	O
on	O
this	O
and	O
previous	O
studies	O
(	O
Satoh	O
et	O
al	O
.	O
[	O
19	O
]).	O

When	O
3	O
of	O
these	O
peptides	O
(	O
M	O
-	O
9	O
,	O
I	O
-	O
S2	O
-	O
15	O
,	O
and	O
II	O
-	O
S1	O
-	O
24	O
)	O
were	O
selected	O
and	O
administered	O
with	O
CpG	O
-	O
ODNs	O
to	O
SPF	O
cats	O
,	O
M	O
-	O
9	O
and	O
II	O
-	O
S1	O
-	O
24	O
induced	O
Th1	B-PRGE
activity	O
.	O

TITLE	O
:	O
Yeast	O
-	O
based	O
assays	O
for	O
the	O
high	O
-	O
throughput	O
screening	O
of	O
inhibitors	O
of	O
coronavirus	B-PRGE
RNA	I-PRGE
cap	I-PRGE
guanine	I-PRGE
-	I-PRGE
N7	I-PRGE
-	I-PRGE
methyltransferase	I-PRGE
.	O

TITLE	O
:	O
IgG	B-PRGE
Fc	I-PRGE
N	I-PRGE
-	O
glycosylation	O
in	O
Guillain	O
-	O
Barré	O
syndrome	O
treated	O
with	O
immunoglobulins	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrated	O
that	O
TGEV	B-PRGE
N	I-PRGE
protein	I-PRGE
might	O
play	O
an	O
important	O
role	O
in	O
TGEV	O
infection	O
-	O
induced	O
p53	B-PRGE
activation	O
and	O
cell	O
cycle	O
arrest	O
at	O
the	O
S	O
and	O
G2	O
/	O
M	O
phases	O
and	O
apoptosis	O
occurrence	O
.	O

Cell	O
entry	O
begins	O
with	O
virus	O
spike	O
(	O
S	O
)	O
protein	O
binding	O
to	O
DPP4	B-PRGE
receptors	I-PRGE
.	O

We	O
constructed	O
chimeric	O
DPP4	B-PRGE
receptors	I-PRGE
that	O
have	O
the	O
virus	O
-	O
binding	O
domains	O
of	O
indigenous	O
Middle	O
Eastern	O
animals	O
and	O
assessed	O
the	O
activities	O
of	O
these	O
receptors	O
in	O
supporting	O
S	B-PRGE
protein	I-PRGE
binding	O
and	O
virus	O
entry	O
.	O

These	O
findings	O
suggest	O
that	O
virus	O
receptors	O
and	O
S	B-PRGE
protein	I-PRGE
-	O
cleaving	O
proteases	O
combine	O
in	O
a	O
variety	O
of	O
animals	O
to	O
offer	O
efficient	O
virus	O
entry	O
and	O
that	O
several	O
Middle	O
Eastern	O
animals	O
are	O
potential	O
reservoirs	O
for	O
transmitting	O
MERS	O
-	O
CoV	O
to	O
humans	O
.	O

This	O
tripeptidic	O
acylsulfonamide	O
inhibitor	O
of	O
the	O
NS3	B-PRGE
/	I-PRGE
4A	I-PRGE
enzyme	I-PRGE
is	O
currently	O
in	O
phase	O
III	O
clinical	O
trials	O
for	O
the	O
treatment	O
of	O
hepatitis	O
C	O
virus	O
infection	O
.	O

Here	O
we	O
demonstrate	O
that	O
CsD	B-PRGE
Alisporivir	I-PRGE
,	O
NIM811	O
as	O
well	O
as	O
novel	O
non	O
-	O
immunosuppressive	O
derivatives	O
of	O
CsA	O
and	O
FK506	O
strongly	O
inhibit	O
the	O
growth	O
of	O
human	B-PRGE
coronavirus	I-PRGE
HCoV	I-PRGE
-	I-PRGE
NL63	I-PRGE
at	O
low	O
micromolar	O
,	O
non	O
-	O
cytotoxic	O
concentrations	O
in	O
cell	O
culture	O
.	O

T	O
.	O
brucei	O
rhodesiense	O
subspecies	O
was	O
finally	O
identified	O
on	O
the	O
basis	O
of	O
the	O
characteristic	O
serum	B-PRGE
resistance	I-PRGE
-	I-PRGE
associated	I-PRGE
gene	I-PRGE
using	O
a	O
polymerase	O
chain	O
reaction	O
,	O
and	O
a	O
seroconversion	O
of	O
specific	O
immunoglobulin	B-PRGE
M	I-PRGE
and	O
G	O
antibodies	O
in	O
the	O
peripheral	O
blood	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

The	O
expression	O
of	O
CD31	B-PRGE
,	O
CD61	B-PRGE
,	O
CD	O
62p	O
,	O
CD63	B-PRGE
and	O
PAC	B-PRGE
-	I-PRGE
1	I-PRGE
on	O
platelet	O
membrane	O
in	O
26	O
patients	O
was	O
all	O
lower	O
than	O
that	O
in	O
17	O
healthy	O
subjects	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

TITLE	O
:	O
The	O
potential	O
efficacy	O
of	O
noninvasive	O
ventilation	O
with	O
administration	O
of	O
a	O
neutrophil	B-PRGE
elastase	I-PRGE
inhibitor	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
prevalence	O
,	O
characteristics	O
,	O
risk	O
factors	O
and	O
impact	O
on	O
mortality	O
of	O
hospitalized	O
patients	O
with	O
CAP	O
according	O
to	O
the	O
presence	O
of	O
ARF	B-PRGE
and	O
SS	O
on	O
admission	O
.	O

The	O
identification	O
of	O
ARF	B-PRGE
and	O
SS	O
on	O
hospital	O
admission	O
can	O
help	O
physicians	O
in	O
classifying	O
CAP	O
patients	O
into	O
three	O
different	O
clinical	O
phenotypes	O
.	O

The	O
diagnostic	O
sensitivity	O
and	O
specificity	O
of	O
the	O
developed	O
RT	B-PRGE
-	I-PRGE
LAMP	I-PRGE
assay	O
versus	O
the	O
RT	O
-	O
PCR	O
assay	O
was	O
100	O
%	O
and	O
95	O
.	O
7	O
%,	O
respectively	O
.	O

The	O
type	B-PRGE
II	I-PRGE
transmembrane	I-PRGE
serine	I-PRGE
protease	I-PRGE
TMPRSS2	I-PRGE
is	O
expressed	O
in	O
the	O
respiratory	O
tract	O
and	O
is	O
capable	O
of	O
activating	O
a	O
variety	O
of	O
respiratory	O
viruses	O
,	O
including	O
low	O
-	O
pathogenic	O
(	O
LP	O
)	O
IAVs	O
possessing	O
a	O
single	O
arginine	O
residue	O
at	O
the	O
cleavage	O
site	O
.	O

The	O
cytoplasmic	O
tail	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
contains	O
a	O
tyrosine	O
-	O
dependent	O
sorting	O
signal	O
with	O
the	O
consensus	O
sequence	O
YXXΦ	O
.	O

Transduction	O
of	O
the	O
N	B-PRGE
gene	I-PRGE
in	O
the	O
insect	O
Sf9	O
cells	O
revealed	O
a	O
high	O
level	O
of	O
protein	O
expression	O
.	O

Mouse	B-PRGE
hepatitis	I-PRGE
virus	I-PRGE
type	I-PRGE
1	I-PRGE
(	O
MHV	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
is	O
a	O
group	O
2	O
coronavirus	O
capable	O
of	O
causing	O
severe	O
morbidity	O
and	O
mortality	O
in	O
highly	O
susceptible	O
C3H	O
/	O
HeJ	O
mice	O
.	O

AM	O
depletion	O
resulted	O
in	O
a	O
decreased	O
number	O
of	O
virus	O
-	O
specific	O
CD4	B-PRGE
T	O
cells	O
in	O
the	O
lung	O
airways	O
.	O

The	O
CD4	B-PRGE
(+)	O
T	O
cells	O
rebounded	O
or	O
were	O
preserved	O
in	O
the	O
lung	O
mucosa	O
during	O
chronic	O
viral	O
infection	O
,	O
which	O
correlated	O
with	O
heightened	O
induction	O
of	O
type	B-PRGE
I	I-PRGE
IFN	I-PRGE
signaling	O
molecules	O
and	O
innate	O
viral	O
restriction	O
factors	O
.	O

Comparative	O
analysis	O
of	O
host	O
response	O
induced	O
by	O
different	O
viruses	O
indicated	O
differences	O
in	O
protein	O
expression	O
changes	O
induced	O
by	O
IBV	O
,	O
NDV	O
,	O
and	O
AIV	B-PRGE
H9	I-PRGE
may	O
be	O
responsible	O
for	O
the	O
specific	O
pathogenesis	O
of	O
these	O
different	O
viruses	O
.	O

The	O
changes	O
in	O
the	O
expression	O
of	O
genes	O
related	O
to	O
eggshell	O
formation	O
(	O
collagen	B-PRGE
types	O
I	O
and	O
V	O
,	O
and	O
CaBP	B-PRGE
-	I-PRGE
D28K	I-PRGE
),	O
densities	O
of	O
cytotoxic	O
cells	O
(	O
CD8	B-PRGE
(+)	O
and	O
TCR	B-PRGE
-	O
γδ	O
(+)	O
T	O
cells	O
),	O
and	O
gene	O
expression	O
of	O
molecules	O
related	O
to	O
cytotoxic	O
immunoreaction	O
(	O
B	O
-	O
NK	O
,	O
perforin	O
,	O
granzyme	O
,	O
and	O
IL	O
-	O
2	O
)	O
and	O
proinflammatory	O
cytokines	O
(	O
IL	O
-	O
1β	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
γ	I-PRGE
)	O
were	O
examined	O
by	O
quantitative	O
reverse	B-PRGE
transcriptase	I-PRGE
polymerase	I-PRGE
chain	I-PRGE
reaction	O
or	O
immunohistochemistry	O
in	O
the	O
isthmus	O
and	O
uterus	O
.	O

Therefore	O
,	O
strain	O
ck	O
/	O
CH	O
/	O
LJL	O
/	O
111054	O
may	O
have	O
originated	O
from	O
recombination	O
events	O
between	O
Conn	O
-	O
and	O
Mass	O
-	O
like	O
strains	O
at	O
three	O
recombination	O
breakpoints	O
:	O
two	O
located	O
within	O
the	O
nsp3	B-PRGE
gene	I-PRGE
sequence	I-PRGE
and	O
one	O
in	O
the	O
nsp12	B-PRGE
gene	I-PRGE
sequence	I-PRGE
.	O

Active	O
inflammatory	O
demyelinating	O
lesions	O
induced	O
by	O
CD8	B-PRGE
(+)	O
T	O
cells	O
or	O
by	O
innate	O
immunity	O
showed	O
macrophage	O
and	O
microglial	O
activation	O
together	O
with	O
the	O
expression	O
of	O
p22phox	B-PRGE
,	O
but	O
low	O
or	O
absent	O
iNOS	O
reactivity	O
.	O

ABSTRACT	O
:	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
develops	O
an	O
antagonistic	O
mechanism	O
by	O
which	O
to	O
evade	O
the	O
antiviral	O
activities	O
of	O
interferon	B-PRGE
(	O
IFN	B-PRGE
).	O

We	O
found	O
that	O
expression	O
of	O
the	O
membrane	O
-	O
anchored	O
PLpro	B-PRGE
domain	I-PRGE
(	O
PLpro	O
-	O
TM	O
)	O
from	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
inhibits	O
STING	B-PRGE
/	O
TBK1	B-PRGE
/	O
IKKε	O
-	O
mediated	O
activation	O
of	O
type	B-PRGE
I	I-PRGE
IFNs	I-PRGE
and	O
disrupts	O
the	O
phosphorylation	O
and	O
dimerization	O
of	O
IRF3	B-PRGE
,	O
which	O
are	O
activated	O
by	O
STING	B-PRGE
and	O
TBK1	B-PRGE
.	O

Meanwhile	O
,	O
we	O
showed	O
that	O
PLpro	O
-	O
TM	O
physically	O
interacts	O
with	O
TRAF3	B-PRGE
,	O
TBK1	B-PRGE
,	O
IKKε	O
,	O
STING	O
,	O
and	O
IRF3	B-PRGE
,	O
the	O
key	O
components	O
that	O
assemble	O
the	O
STING	O
-	O
TRAF3	B-PRGE
-	O
TBK1	B-PRGE
complex	O
for	O
activation	O
of	O
IFN	B-PRGE
expression	O
.	O

Furthermore	O
,	O
SARS	O
PLpro	O
-	O
TM	O
reduces	O
the	O
levels	O
of	O
ubiquitinated	O
forms	O
of	O
RIG	B-PRGE
-	I-PRGE
I	I-PRGE
,	O
STING	B-PRGE
,	O
TRAF3	B-PRGE
,	O
TBK1	B-PRGE
,	O
and	O
IRF3	B-PRGE
in	O
the	O
STING	B-PRGE
-	O
TRAF3	B-PRGE
-	O
TBK1	B-PRGE
complex	O
.	O

TITLE	O
:	O
Coronavirus	O
replicase	B-PRGE
-	O
reporter	O
fusions	O
provide	O
quantitative	O
analysis	O
of	O
replication	O
and	O
replication	O
complex	O
formation	O
.	O

We	O
demonstrate	O
that	O
the	O
fusion	O
of	O
green	B-PRGE
fluorescent	I-PRGE
protein	I-PRGE
and	O
firefly	O
luciferase	O
with	O
either	O
nonstructural	O
protein	O
2	O
or	O
3	O
is	O
tolerated	O
and	O
that	O
these	O
reporter	O
-	O
replicase	B-PRGE
fusions	O
can	O
be	O
used	O
to	O
quantitate	O
replication	O
complex	O
formation	O
and	O
virus	O
replication	O
.	O

The	O
results	O
show	O
that	O
the	O
replicase	B-PRGE
gene	I-PRGE
has	O
flexibility	O
to	O
accommodate	O
a	O
foreign	O
gene	O
addition	O
and	O
can	O
be	O
used	O
directly	O
to	O
study	O
replicase	B-PRGE
complex	O
formation	O
and	O
evolution	O
during	O
infection	O
as	O
well	O
as	O
to	O
provide	O
highly	O
sensitive	O
and	O
specific	O
markers	O
for	O
protein	O
translation	O
and	O
genome	O
replication	O
.	O

We	O
demonstrate	O
that	O
the	O
replicase	B-PRGE
gene	I-PRGE
tolerates	O
the	O
introduction	O
of	O
green	B-PRGE
fluorescent	I-PRGE
protein	I-PRGE
or	O
firefly	O
luciferase	O
as	O
fusions	O
with	O
replicase	B-PRGE
proteins	I-PRGE
.	O

Virus	O
infection	O
and	O
transfection	O
showed	O
that	O
N	B-PRGE
protein	I-PRGE
was	O
predominately	O
localized	O
in	O
the	O
cytoplasm	O
,	O
but	O
also	O
found	O
in	O
the	O
nucleolus	O
in	O
Vero	O
E6	O
cells	O
.	O

Nasopharyngeal	O
aspirate	O
and	O
sputum	O
samples	O
should	O
be	O
collected	O
for	O
diagnosis	O
,	O
preferably	O
using	O
reverse	B-PRGE
transcriptase	I-PRGE
-	O
PCR	O
.	O

However	O
,	O
PKR	B-PRGE
deficiency	O
only	O
modestly	O
increased	O
viral	O
replication	O
and	O
did	O
not	O
affect	O
IFN	B-PRGE
-	I-PRGE
α	I-PRGE
/	I-PRGE
β	I-PRGE
or	O
IL	O
-	O
1β	O
expression	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
express	O
a	O
deubiquitinating	O
protein	O
,	O
the	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
-	I-PRGE
2	I-PRGE
(	O
PLP2	B-PRGE
),	O
that	O
removes	O
both	O
ubiquitin	B-PRGE
and	O
the	O
ubiquitin	B-PRGE
-	O
like	O
interferon	B-PRGE
(	O
IFN	O
)-	O
stimulated	O
gene	O
15	O
(	O
ISG15	B-PRGE
)	O
protein	O
from	O
target	O
proteins	O
.	O

Infecting	O
USP18	B-PRGE
(-/-)	O
mice	O
with	O
MHV	O
-	O
3	O
resulted	O
in	O
extended	O
survival	O
(	O
8	O
±	O
1	O
.	O
2	O
versus	O
4	O
days	O
)	O
and	O
in	O
improved	O
liver	O
histology	O
,	O
a	O
decreased	O
inflammatory	O
response	O
,	O
and	O
viral	O
titers	O
1	O
to	O
2	O
logs	O
lower	O
than	O
in	O
USP18	B-PRGE
(+/+)	O
mice	O
.	O

The	O
suppression	O
of	O
viral	O
replication	O
was	O
not	O
due	O
to	O
increased	O
IFN	B-PRGE
since	O
infected	O
USP18	B-PRGE
(-/-)	O
mice	O
had	O
neither	O
increased	O
hepatic	O
IFN	B-PRGE
-	I-PRGE
α	I-PRGE
,	I-PRGE
-	I-PRGE
β	I-PRGE
,	O
or	O
-	O
γ	O
mRNA	O
nor	O
circulating	O
protein	O
.	O

Decreasing	O
ISGylation	O
by	O
knockdown	O
of	O
the	O
ISG15	B-PRGE
E1	I-PRGE
enzyme	I-PRGE
,	O
Ube1L	B-PRGE
,	O
in	O
primary	O
USP18	B-PRGE
(+/+)	I-PRGE
and	O
USP18	B-PRGE
(-/-)	O
hepatocytes	O
led	O
to	O
increased	O
MHV	O
-	O
3	O
replication	O
.	O

Overall	O
,	O
these	O
results	O
demonstrate	O
the	O
antiviral	O
effect	O
of	O
ISGylation	O
in	O
an	O
in	O
vivo	O
model	O
of	O
coronavirus	O
-	O
induced	O
mouse	O
hepatitis	O
and	O
illustrate	O
that	O
PLP2	B-PRGE
manipulates	O
the	O
host	O
innate	O
immune	O
response	O
through	O
the	O
ISG15	B-PRGE
/	O
USP18	B-PRGE
pathway	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
an	O
important	O
host	O
viral	O
defense	O
-	O
the	O
ISG15	B-PRGE
pathway	O
-	O
is	O
only	O
partially	O
effective	O
in	O
controlling	O
severe	O
coronavirus	O
infection	O
.	O

Activation	O
of	O
the	O
pathway	O
is	O
very	O
good	O
at	O
suppressing	O
viral	O
production	O
,	O
but	O
over	O
time	O
the	O
virus	O
overwhelms	O
the	O
host	O
response	O
and	O
the	O
effects	O
of	O
the	O
ISG15	B-PRGE
pathway	O
.	O

Survival	O
was	O
compared	O
in	O
quartiles	O
based	O
on	O
TIMP	B-PRGE
-	I-PRGE
1	I-PRGE
levels	O
,	O
and	O
ROC	O
analysis	O
was	O
performed	O
to	O
calculate	O
areas	O
under	O
the	O
curves	O
.	O

Recombinant	B-PRGE
spike	I-PRGE
protein	I-PRGE
-	O
specific	O
immunofluorescence	O
and	O
virus	O
neutralization	O
tests	O
enabled	O
clear	O
discrimination	O
between	O
MERS	O
-	O
CoV	O
and	O
bovine	O
CoV	O
infections	O
.	O

Antibodies	O
against	O
the	O
recombinant	B-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
of	O
the	O
virus	O
,	O
which	O
we	O
named	O
dromedary	O
camel	O
coronavirus	O
(	O
DcCoV	O
)	O
UAE	O
-	O
HKU23	O
,	O
were	O
detected	O
in	O
52	O
%	O
of	O
59	O
dromedary	O
serum	O
samples	O
tested	O
.	O

We	O
report	O
the	O
synthetic	O
reconstruction	O
and	O
testing	O
of	O
BtCoV	O
HKU5	O
containing	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	B-PRGE
spike	I-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
glycoprotein	I-PRGE
ectodomain	I-PRGE
(	O
BtCoV	O
HKU5	O
-	O
SE	O
).	O

Unlike	O
some	O
subgroup	O
2b	O
SARS	O
-	O
CoV	O
vaccines	O
that	O
elicit	O
a	O
strong	O
eosinophilia	O
following	O
challenge	O
,	O
we	O
demonstrate	O
that	O
BtCoV	O
HKU5	O
and	O
MERS	O
-	O
CoV	O
N	O
-	O
expressing	O
Venezuelan	O
equine	O
encephalitis	O
virus	O
replicon	O
particle	O
(	O
VRP	B-PRGE
)	O
vaccines	O
do	O
not	O
cause	O
extensive	O
eosinophilia	O
following	O
BtCoV	O
HKU5	O
-	O
SE	O
challenge	O
.	O

Herein	O
,	O
we	O
show	O
that	O
the	O
E	B-PRGE
protein	I-PRGE
in	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
virus	O
has	O
only	O
one	O
TM	O
domain	O
in	O
micelles	O
,	O
whereas	O
the	O
predicted	O
β	O
-	O
coil	O
-	O
β	O
motif	O
forms	O
a	O
short	O
membrane	O
-	O
bound	O
α	O
-	O
helix	O
connected	O
by	O
a	O
disordered	O
loop	O
to	O
the	O
TM	O
domain	O
.	O

Furthermore	O
,	O
pigs	O
receiving	O
high	O
Zn	O
diet	O
showed	O
a	O
down	O
-	O
regulation	O
of	O
interferon	B-PRGE
(	O
IFN	O
)-	O
α	O
,	O
oligoadenylate	B-PRGE
synthetase	I-PRGE
(	O
OAS	O
),	O
Zn	B-PRGE
transporter	I-PRGE
SLC39A4	I-PRGE
(	O
ZIP4	B-PRGE
),	O
but	O
up	O
-	O
regulation	O
of	O
metallothionein	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
MT1	B-PRGE
),	O
as	O
well	O
as	O
the	O
Zn	B-PRGE
transporters	I-PRGE
SLC30A1	I-PRGE
(	O
ZnT1	B-PRGE
)	O
and	O
SLC30A5	B-PRGE
(	O
ZnT5	B-PRGE
).	O

To	O
study	O
intratonsillar	O
/	O
nasopharyngeal	O
virus	O
detections	O
and	O
in	O
vivo	O
expressions	O
of	O
T	O
-	O
cell	O
-	O
and	O
innate	O
immune	O
response	O
-	O
specific	O
cytokines	O
,	O
transcription	O
factors	O
,	O
and	O
type	B-PRGE
I	I-PRGE
/	I-PRGE
II	I-PRGE
/	I-PRGE
III	I-PRGE
interferons	I-PRGE
in	O
human	O
tonsils	O
.	O

In	O
this	O
study	O
,	O
we	O
examine	O
routes	O
of	O
vaccine	O
administration	O
using	O
multiple	O
IBV	O
types	O
including	O
Ark	B-PRGE
in	O
an	O
effort	O
to	O
understand	O
why	O
Ark	B-PRGE
vaccines	O
do	O
not	O
provide	O
good	O
protection	O
and	O
persist	O
in	O
commercial	O
broilers	O
.	O

Alternatively	O
,	O
a	O
subpopulation	O
of	O
the	O
Ark	B-PRGE
vaccine	O
isolated	O
from	O
a	O
vaccinated	O
bird	O
,	O
Ark	B-PRGE
-	O
RI	O
-	O
EP1	B-PRGE
,	O
showed	O
a	O
peak	O
titer	O
at	O
7	O
-	O
10	O
days	O
of	O
age	O
when	O
given	O
by	O
the	O
same	O
routes	O
,	O
suggesting	O
that	O
the	O
Ark	B-PRGE
-	I-PRGE
RI	I-PRGE
-	I-PRGE
EP1	I-PRGE
was	O
more	O
fit	O
with	O
regard	O
to	O
infection	O
,	O
replication	O
in	O
the	O
birds	O
,	O
or	O
both	O
.	O

Based	O
on	O
DNA	O
sequences	O
for	O
the	O
3	O
'-	O
untranslated	O
region	O
and	O
the	O
gene	O
encoding	O
the	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
,	O
this	O
avian	O
coronaviruses	O
in	O
quail	O
is	O
an	O
IB	O
virus	O
-	O
like	O
gammacoronavirus	O
.	O

Quantitative	O
reverse	B-PRGE
transcriptase	I-PRGE
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
confirmed	O
that	O
the	O
most	O
strongly	O
affected	O
of	O
these	O
,	O
the	O
nsp3	B-PRGE
mutant	I-PRGE
,	O
produced	O
more	O
viral	O
RNA	O
than	O
wild	O
-	O
type	O
virus	O
.	O

We	O
report	O
a	O
case	O
of	O
multiple	O
drug	O
poisoning	O
:	O
ACE	B-PRGE
inhibitor	O
(	O
ACE	B-PRGE
-	I-PRGE
I	I-PRGE
),	O
beta	O
-	O
blockers	O
and	O
calcium	O
channel	O
blockers	O
.	O

Significant	O
transpulmonary	O
gradients	O
of	O
neutrophil	O
CD62L	B-PRGE
cell	O
surface	O
expression	O
were	O
observed	O
in	O
ARDS	O
compared	O
with	O
perioperative	O
controls	O
and	O
patients	O
with	O
sepsis	O
.	O

Among	O
these	O
extracts	O
,	O
CBM	O
and	O
DBM	O
also	O
showed	O
significant	O
inhibition	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
protease	I-PRGE
activity	O
with	O
IC50	O
values	O
of	O
39	O
μg	O
/	O
ml	O
and	O
44	O
μg	O
/	O
ml	O
,	O
respectively	O
.	O

We	O
found	O
that	O
both	O
of	O
the	O
indirubin	O
derivatives	O
strongly	O
suppress	O
the	O
pro	O
-	O
inflammatory	O
cytokines	O
including	O
IP	B-PRGE
-	I-PRGE
10	I-PRGE
(	O
CXCL10	B-PRGE
),	O
one	O
of	O
the	O
key	O
factors	O
which	O
contribute	O
to	O
the	O
lung	O
inflammation	O
during	O
H5N1	O
virus	O
infection	O
.	O

Notably	O
,	O
it	O
showed	O
the	O
highest	O
sequence	O
identity	O
with	O
the	O
S	B-PRGE
gene	I-PRGE
of	O
SARS	O
CoVs	O
and	O
Rs3367	O
,	O
especially	O
in	O
the	O
RBD	O
region	O
.	O

Interestingly	O
,	O
we	O
also	O
found	O
that	O
a	O
low	O
day	O
1	O
albumin	B-PRGE
level	O
was	O
an	O
independent	O
biomarker	O
for	O
predicting	O
patient	O
life	O
dependence	O
6	O
months	O
after	O
a	O
pneumonia	O
event	O
.	O

First	O
,	O
MERS	O
-	O
CoV	O
productively	O
infected	O
Mo	B-PRGE
-	I-PRGE
DCs	I-PRGE
while	O
SARS	O
-	O
CoV	O
-	O
infection	O
was	O
abortive	O
.	O

Recently	O
identified	O
viruses	O
,	O
human	B-PRGE
coronavirus	I-PRGE
HKU1	I-PRGE
and	O
human	O
bocavirus	O
were	O
not	O
detected	O
except	O
for	O
human	O
metapneumovirus	O
(	O
one	O
case	O
).	O

Neutrophil	B-PRGE
elastase	I-PRGE
,	O
nuclear	B-PRGE
factor	I-PRGE
-	I-PRGE
κB	I-PRGE
(	O
NF	O
-	O
κB	O
),	O
and	O
NF	O
-	O
κB	O
repressing	O
factor	O
(	O
NRF	B-PRGE
)	O
have	O
previously	O
been	O
shown	O
to	O
participate	O
in	O
the	O
regulation	O
of	O
macrophage	B-PRGE
inflammatory	I-PRGE
protein	I-PRGE
-	I-PRGE
2	I-PRGE
(	O
MIP	B-PRGE
-	I-PRGE
2	I-PRGE
)	O
during	O
airway	O
inflammation	O
.	O

However	O
,	O
the	O
mechanisms	O
regulating	O
interactions	O
among	O
mechanical	O
ventilation	O
,	O
neutrophil	O
influx	O
,	O
and	O
NF	B-PRGE
-	I-PRGE
κB	I-PRGE
/	I-PRGE
NRF	I-PRGE
remain	O
unclear	O
.	O

Thus	O
,	O
we	O
hypothesized	O
that	O
neutrophil	B-PRGE
elastase	I-PRGE
inhibitor	O
attenuated	O
ventilation	O
-	O
induced	O
neutrophil	O
recruitment	O
and	O
MIP	B-PRGE
-	I-PRGE
2	I-PRGE
production	O
through	O
inhibition	O
of	O
the	O
NF	O
-	O
κB	O
/	O
NRF	B-PRGE
pathway	O
.	O

Our	O
data	O
suggest	O
that	O
neutrophil	B-PRGE
elastase	I-PRGE
inhibitor	O
attenuates	O
high	O
-	O
tidal	O
-	O
volume	O
mechanical	O
ventilation	O
-	O
induced	O
neutrophil	O
influx	O
,	O
oxidative	O
stress	O
,	O
and	O
production	O
of	O
MIP	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
at	O
least	O
partly	O
,	O
through	O
inhibition	O
of	O
NF	O
-	O
κB	O
/	O
NRF	B-PRGE
pathway	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
a	O
novel	O
strain	O
of	O
infectious	O
bronchitis	O
virus	O
emerged	O
as	O
a	O
result	O
of	O
spike	B-PRGE
gene	I-PRGE
recombination	O
between	O
two	O
highly	O
diverged	O
parent	O
strains	O
.	O

The	O
S1	B-PRGE
gene	I-PRGE
for	O
N1	O
/	O
08	O
had	O
highest	O
nucleotide	O
similarity	O
with	O
subgroup	O
2	O
strains	O
,	O
which	O
is	O
interesting	O
considering	O
subgroup	O
2	O
strains	O
have	O
not	O
been	O
detected	O
since	O
the	O
early	O
1990s	O
.	O

TITLE	O
:	O
Purified	B-PRGE
coronavirus	I-PRGE
spike	I-PRGE
protein	I-PRGE
nanoparticles	O
induce	O
coronavirus	O
neutralizing	O
antibodies	O
in	O
mice	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
show	O
that	O
SHXB	O
significantly	O
impaired	O
the	O
functions	O
of	O
Mo	B-PRGE
-	I-PRGE
DCs	I-PRGE
and	O
intestinal	O
DCs	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
while	O
STC3	O
had	O
the	O
opposite	O
effect	O
.	O

Not	O
surprisingly	O
,	O
viruses	O
have	O
adapted	O
to	O
encode	O
virulence	O
factors	O
to	O
cope	O
with	O
the	O
IFN	B-PRGE
response	O
.	O

We	O
also	O
present	O
evidence	O
showing	O
that	O
IFITM	B-PRGE
family	I-PRGE
members	I-PRGE
work	O
as	O
homo	O
-	O
and	O
hetero	O
-	O
oligomers	O
to	O
modulate	O
virus	O
entry	O
.	O

Challenge	O
with	O
virulent	O
Ark	B-PRGE
was	O
performed	O
at	O
21	O
days	O
of	O
age	O
.	O

While	O
the	O
wild	B-PRGE
type	I-PRGE
3a	I-PRGE
protein	I-PRGE
is	O
efficiently	O
transported	O
to	O
the	O
plasma	O
membrane	O
,	O
the	O
protein	O
with	O
mutations	O
in	O
the	O
tyrosine	O
and	O
valine	O
residues	O
within	O
the	O
YXXV	O
motif	O
(	O
ΔYXXΦ	O
)	O
accumulated	O
in	O
the	O
Golgi	O
compartment	O
.	O

This	O
is	O
a	O
retrospective	O
analysis	O
of	O
short	O
-	O
term	O
outcomes	O
in	O
18	O
IPF	O
patients	O
being	O
administered	O
NIV	O
for	O
ARF	B-PRGE
.	O

Noninvasive	O
ventilation	O
failure	O
was	O
correlated	O
to	O
the	O
plasma	B-PRGE
NT	I-PRGE
-	I-PRGE
proBNP	I-PRGE
levels	O
at	O
RICU	O
admission	O
(	O
P	O
=.	O
0326	O
)	O
with	O
an	O
odds	O
ratio	O
of	O
12	O
.	O
2	O
(	O
95	O
%	O
CI	O
,	O
1	O
.	O
2	O
to	O
infinity	O
)	O
in	O
the	O
patients	O
with	O
abnormally	O
high	O
values	O
(>	O
900	O
pg	O
/	O
mL	O
).	O

MERS	O
-	O
CoV	O
was	O
related	O
to	O
the	O
2C	O
betacoronavirus	O
clade	O
and	O
is	O
closely	O
related	O
to	O
Tylonycteris	B-PRGE
bat	I-PRGE
coronavirus	I-PRGE
HKU4	I-PRGE
and	O
Pipistrellus	B-PRGE
bat	I-PRGE
coronavirus	I-PRGE
HKU5	I-PRGE
.	O

Here	O
,	O
we	O
used	O
a	O
well	O
-	O
characterized	O
nonimmune	O
human	O
Ab	O
-	O
phage	O
library	O
and	O
a	O
panning	O
strategy	O
with	O
proteoliposomes	O
and	O
cells	O
to	O
identify	O
seven	O
human	O
nAbs	O
against	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
Spike	I-PRGE
protein	I-PRGE
.	O

Despite	O
the	O
close	O
proximity	O
of	O
the	O
three	O
epitopes	O
on	O
the	O
RBD	O
interface	O
,	O
escape	O
from	O
one	O
epitope	O
did	O
not	O
have	O
a	O
major	O
impact	O
on	O
neutralization	O
with	O
Abs	B-PRGE
directed	O
to	O
a	O
different	O
epitope	O
.	O

Entry	O
of	O
MERS	O
-	O
CoV	O
into	O
target	O
cells	O
depends	O
on	O
binding	O
of	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
viral	B-PRGE
envelope	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
to	O
the	O
cellular	O
receptor	O
dipeptidyl	B-PRGE
peptidase	I-PRGE
4	I-PRGE
(	O
DPP4	B-PRGE
).	O

Interestingly	O
,	O
mice	O
infected	O
with	O
viruses	O
displaying	O
E	B-PRGE
protein	I-PRGE
IC	O
activity	O
,	O
either	O
with	O
the	O
wild	B-PRGE
-	I-PRGE
type	I-PRGE
E	I-PRGE
protein	I-PRGE
sequence	I-PRGE
or	O
with	O
the	O
revertants	O
that	O
restored	O
ion	O
transport	O
,	O
rapidly	O
lost	O
weight	O
and	O
died	O
.	O

Reduction	O
of	O
IL	O
-	O
1β	O
was	O
accompanied	O
by	O
diminished	O
amounts	O
of	O
TNF	B-PRGE
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
in	O
the	O
absence	O
of	O
E	O
protein	O
ion	O
conductivity	O
.	O

This	O
augmented	O
MHC	B-PRGE
binding	O
is	O
likely	O
to	O
increase	O
the	O
half	O
-	O
life	O
and	O
surface	O
density	O
of	O
the	O
heteroclitic	O
complex	O
,	O
but	O
precisely	O
how	O
this	O
enhanced	O
T	O
cell	O
response	O
occurs	O
in	O
vivo	O
is	O
not	O
known	O
.	O

ABSTRACT	O
:	O
Isolation	O
of	O
porcine	O
epidemic	O
diarrhea	O
coronavirus	O
(	O
PEDV	O
)	O
from	O
clinical	O
material	O
in	O
cell	O
culture	O
requires	O
supplementation	O
of	O
trypsin	B-PRGE
.	O

Our	O
study	O
focused	O
on	O
the	O
role	O
of	O
protease	O
activity	O
on	O
infection	O
by	O
investigating	O
the	O
spike	O
protein	O
of	O
a	O
PEDV	O
isolate	O
(	O
wtPEDV	O
)	O
using	O
a	O
reverse	O
genetics	O
system	O
based	O
on	O
the	O
trypsin	B-PRGE
-	O
independent	O
cell	O
culture	O
-	O
adapted	O
strain	O
DR13	O
(	O
caPEDV	O
).	O

The	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHEII	O
)	O
score	O
,	O
sequential	O
organ	O
failure	O
assessment	O
(	O
SOFA	O
),	O
arterial	O
oxygenation	O
index	O
(	O
PaO2	O
/	O
FiO2	O
),	O
central	O
venous	O
oxygen	O
saturation	O
(	O
ScvO2	O
),	O
arterial	O
blood	O
lactate	O
(	O
Lac	B-PRGE
),	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
(	O
CRP	B-PRGE
)	O
levels	O
of	O
two	O
groups	O
were	O
compared	O
before	O
treatment	O
and	O
48	O
hours	O
after	O
treatment	O
,	O
and	O
21	O
-	O
day	O
mortality	O
rate	O
was	O
finally	O
compared	O
.	O

Its	B-PRGE
ORF3	I-PRGE
gene	I-PRGE
,	O
however	O
,	O
fell	O
into	O
three	O
groups	O
.	O

Clinical	O
data	O
,	O
systemic	O
(	O
C	B-PRGE
reactive	I-PRGE
protein	I-PRGE
(	O
CRP	B-PRGE
),	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
procalcitonin	O
,	O
amyloid	O
-	O
A	O
,	O
fibrinogen	B-PRGE
)	O
and	O
lung	O
function	O
parameters	O
were	O
also	O
collected	O
.	O

Combination	O
therapy	O
with	O
interferon	B-PRGE
-	I-PRGE
α2b	I-PRGE
and	O
ribavirin	O
has	O
been	O
used	O
successfully	O
as	O
primary	O
treatment	O
and	O
prophylaxis	O
in	O
SARS	O
.	O

In	O
total	O
,	O
27	O
compounds	O
with	O
activity	O
against	O
both	O
MERS	O
-	O
CoV	O
and	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
were	O
identified	O
.	O

Using	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
as	O
a	O
model	O
,	O
dynamic	O
transcriptional	O
network	O
changes	O
and	O
disease	O
-	O
associated	O
phenotypes	O
have	O
been	O
identified	O
in	O
different	O
genetic	O
backgrounds	O
,	O
leading	O
to	O
the	O
promise	O
of	O
population	O
-	O
wide	O
discovery	O
of	O
the	O
underpinnings	O
of	O
Coronavirus	O
pathogenesis	O
.	O

The	O
majority	O
of	O
studies	O
carried	O
out	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
humans	O
and	O
animals	O
attribute	O
a	O
dysregulated	O
/	O
exuberant	O
innate	O
response	O
as	O
a	O
leading	O
contributor	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	O
mediated	O
pathology	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
role	O
of	O
anti	B-PRGE
-	I-PRGE
virus	I-PRGE
CD4	I-PRGE
and	O
CD8	B-PRGE
T	I-PRGE
cells	O
during	O
respiratory	O
coronavirus	O
infections	O
with	O
a	O
special	O
emphasis	O
on	O
emerging	O
coronaviruses	O
.	O

However	O
,	O
whole	O
inactivated	O
SARS	O
vaccine	O
that	O
includes	O
nucleocapsid	O
protein	O
is	O
reported	O
to	O
induce	O
eosinophilic	O
infiltration	O
in	O
mouse	O
lungs	O
after	O
challenge	O
with	O
live	O
SARS	O
-	O
CoV	O
.	O
In	O
this	O
study	O
,	O
an	O
ability	O
of	O
Toll	B-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
(	O
TLR	O
)	O
agonists	O
to	O
reduce	O
the	O
side	O
effects	O
of	O
UV	O
-	O
V	O
vaccination	O
in	O
a	O
6	O
-	O
month	O
-	O
old	O
adult	O
BALB	O
/	O
c	O
mouse	O
model	O
was	O
investigated	O
,	O
using	O
the	O
mouse	O
-	O
passaged	O
Frankfurt	O
1	O
isolate	O
of	O
SARS	O
-	O
CoV	O
.	O
Immunization	O
of	O
adult	O
mice	O
with	O
UV	O
-	O
V	O
,	O
with	O
or	O
without	O
alum	O
,	O
resulted	O
in	O
partial	O
protection	O
from	O
lethal	O
doses	O
of	O
SARS	B-PRGE
-	O
CoV	O
challenge	O
,	O
but	O
extensive	O
eosinophil	O
infiltration	O
in	O
the	O
lungs	O
was	O
observed	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	O
,	O
and	O
biological	O
evaluation	O
of	O
1	O
,	O
3	O
-	O
diarylpropenones	O
as	O
dual	O
inhibitors	O
of	O
HIV	O
-	O
1	O
reverse	B-PRGE
transcriptase	I-PRGE
.	O

For	O
these	O
latter	O
residues	O
,	O
we	O
found	O
that	O
PLpro	O
antagonism	O
of	O
the	O
nuclear	B-PRGE
factor	I-PRGE
kappa	I-PRGE
-	I-PRGE
light	I-PRGE
-	I-PRGE
chain	I-PRGE
-	I-PRGE
enhancer	I-PRGE
of	O
activated	O
B	O
-	O
cells	O
(	O
NFκB	O
)	O
signaling	O
pathway	O
is	O
abrogated	O
.	O

Multiple	O
sequence	O
alignment	O
(	O
MSA	O
)	O
approach	O
was	O
employed	O
among	O
spike	O
(	O
S	O
),	O
membrane	O
(	O
M	O
),	O
enveloped	O
(	O
E	O
)	O
and	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
and	O
replicase	B-PRGE
polyprotein	O
1ab	O
to	O
identify	O
which	O
one	O
is	O
highly	O
conserve	O
in	O
all	O
coronaviruses	O
strains	O
.	O

We	O
found	O
that	O
conserved	O
region	O
is	O
present	O
only	O
in	O
the	O
RNA	O
directed	O
RNA	B-PRGE
polymerase	I-PRGE
protein	I-PRGE
.	O

RESULTS	O
:	O
Multiple	O
sequence	O
alignment	O
(	O
MSA	O
)	O
approach	O
was	O
employed	O
among	O
spike	O
(	O
S	O
),	O
membrane	O
(	O
M	O
),	O
enveloped	O
(	O
E	O
)	O
and	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
and	O
replicase	B-PRGE
polyprotein	O
1ab	O
to	O
identify	O
which	O
one	O
is	O
highly	O
conserve	O
in	O
all	O
coronaviruses	O
strains	O
.	O

Since	O
cellular	O
immunity	O
is	O
thought	O
to	O
be	O
critical	O
in	O
preventing	O
FIP	O
and	O
because	O
diseased	O
cats	O
often	O
show	O
a	O
significant	O
decrease	O
in	O
interferon	B-PRGE
-	I-PRGE
γ	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
γ	I-PRGE
)	O
production	O
,	O
we	O
investigated	O
whether	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNP	O
)	O
in	O
the	O
feline	O
IFN	B-PRGE
-	I-PRGE
γ	I-PRGE
gene	I-PRGE
(	O
fIFNG	O
)	O
are	O
associated	O
with	O
the	O
outcome	O
of	O
infection	O
.	O

ABSTRACT	O
:	O
Three	O
phage	O
-	O
displayed	O
peptides	O
designated	O
H	O
,	O
S	O
and	O
F	O
that	O
recognize	O
porcine	B-PRGE
aminopeptidase	I-PRGE
N	I-PRGE
(	O
pAPN	O
),	O
the	O
cellular	O
receptor	O
of	O
porcine	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
were	O
able	O
to	O
inhibit	O
cell	O
infection	O
by	O
TGEV	O
.	O

TITLE	O
:	O
Host	O
species	O
restriction	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
through	O
its	O
receptor	O
,	O
dipeptidyl	B-PRGE
peptidase	I-PRGE
4	I-PRGE
.	O

Recently	O
,	O
the	O
MERS	O
-	O
CoV	O
receptor	O
dipeptidyl	B-PRGE
peptidase	I-PRGE
4	I-PRGE
(	O
DPP4	B-PRGE
)	O
was	O
identified	O
and	O
the	O
specific	O
interaction	O
of	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
and	O
DPP4	B-PRGE
was	O
determined	O
by	O
crystallography	O
.	O

We	O
show	O
that	O
the	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
DPP4	B-PRGE
plays	O
a	O
pivotal	O
role	O
in	O
the	O
observed	O
species	O
tropism	O
of	O
MERS	O
-	O
CoV	O
and	O
subsequently	O
identified	O
the	O
amino	O
acids	O
in	O
DPP4	B-PRGE
responsible	O
for	O
this	O
restriction	O
.	O

Using	O
a	O
combined	O
modeling	O
and	O
experimental	O
approach	O
,	O
we	O
predict	O
that	O
,	O
based	O
on	O
the	O
ability	O
of	O
MERS	O
-	O
CoV	O
to	O
utilize	O
the	O
DPP4	B-PRGE
of	O
common	O
Middle	O
East	O
livestock	O
species	O
,	O
such	O
as	O
camels	O
,	O
goats	O
,	O
sheep	O
,	O
and	O
cows	O
,	O
these	O
form	O
a	O
potential	O
MERS	O
-	O
CoV	O
intermediate	O
host	O
reservoir	O
species	O
.	O

Pro	O
-	O
inflammatory	O
cytokines	O
,	O
interleukin	B-PRGE
(	O
IL	O
)-	O
1β	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
(	O
TNF	O
)-	O
α	O
,	O
were	O
also	O
increased	O
significantly	O
at	O
72	O
h	O
post	O
-	O
infection	O
.	O

The	O
presence	O
of	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
in	O
milk	O
of	O
camels	O
actively	O
shedding	O
the	O
virus	O
warrants	O
measures	O
to	O
prevent	O
putative	O
food	O
-	O
borne	O
transmission	O
of	O
MERS	O
-	O
CoV	O
.	O

We	O
collected	O
1	O
,	O
254	O
samples	O
from	O
patients	O
diagnosed	O
with	O
respiratory	O
infection	O
in	O
southern	O
Thailand	O
from	O
July	O
2009	O
to	O
January	O
2011	O
and	O
screened	O
for	O
HCoV	O
by	O
RT	O
-	O
PCR	O
and	O
genotyped	O
by	O
BLAST	O
analysis	O
of	O
nsp12	B-PRGE
gene	I-PRGE
.	O

Phylogenetic	O
analysis	O
and	O
deduced	O
amino	O
acid	O
sequences	O
of	O
the	O
S	B-PRGE
gene	I-PRGE
showed	O
amino	O
acid	O
variations	O
in	O
each	O
genotype	O
.	O

The	O
upregulated	O
genes	O
were	O
mainly	O
involved	O
in	O
immune	O
system	O
processes	O
,	O
antigen	O
processing	O
and	O
presentation	O
,	O
the	O
Jak	B-PRGE
-	O
STAT	B-PRGE
signalling	O
pathway	O
,	O
the	O
RIG	B-PRGE
-	I-PRGE
I	I-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
signalling	O
pathway	O
,	O
Toll	B-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
signalling	O
and	O
apoptosis	O
-	O
related	O
proteases	O
.	O

Genbank	O
sequences	O
of	O
six	O
human	O
coronaviruses	O
,	O
including	O
HCoV	O
-	O
NL63	O
,	O
HCoV	O
-	O
229E	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
HCoV	O
-	O
OC43	O
,	O
MERS	O
-	O
CoV	O
,	O
and	O
HCoV	O
-	O
HKU1	O
,	O
were	O
included	O
as	O
reference	O
sequences	O
.	O

ABSTRACT	O
:	O
Viral	O
2	O
',	O
5	O
'-	O
phosphodiesterases	O
(	O
2	O
',	O
5	O
'-	O
PDEs	O
)	O
help	O
disparate	O
RNA	O
viruses	O
evade	O
the	O
antiviral	O
activity	O
of	O
interferon	B-PRGE
(	O
IFN	B-PRGE
)	O
by	O
degrading	O
2	O
',	O
5	O
'-	O
oligoadenylate	O
(	O
2	O
-	O
5A	O
)	O
activators	O
of	O
RNase	B-PRGE
L	I-PRGE
.	O
A	B-PRGE
kinase	I-PRGE
anchoring	I-PRGE
proteins	I-PRGE
(	O
AKAPs	O
)	O
bind	O
the	O
regulatory	O
subunits	O
of	O
protein	B-PRGE
kinase	I-PRGE
A	I-PRGE
(	O
PKA	B-PRGE
)	O
to	O
localize	O
and	O
organize	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
signaling	O
during	O
diverse	O
physiological	O
processes	O
.	O

ns2	O
confers	O
virulence	O
by	O
cleaving	O
2	O
',	O
5	O
'-	O
oligoadenylate	O
(	O
2	O
-	O
5A	O
)	O
activators	O
of	O
RNase	B-PRGE
L	I-PRGE
in	O
macrophages	O
.	O

Small	O
diameter	O
autophagosomes	O
were	O
also	O
induced	O
by	O
infection	O
of	O
cells	O
with	O
IBV	O
,	O
and	O
by	O
NSP6	O
proteins	O
of	O
MHV	O
and	O
SARS	B-PRGE
and	O
NSP5	B-PRGE
,	O
NSP6	O
,	O
and	O
NSP7	O
of	O
arterivirus	O
PRRSV	O
.	O

Both	O
20MT	O
and	O
40MT	O
induced	O
an	O
increase	O
in	O
IgG	B-PRGE
and	O
IgA	B-PRGE
levels	O
against	O
TGEV	O
,	O
as	O
determined	O
using	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

Notably	O
,	O
some	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
accessory	I-PRGE
proteins	I-PRGE
have	O
been	O
shown	O
to	O
modulate	O
the	O
interferon	B-PRGE
signaling	O
pathways	O
and	O
the	O
production	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
.	O

Since	O
the	O
S1	B-PRGE
domain	I-PRGE
is	O
involved	O
in	O
a	O
specific	O
high	O
-	O
affinity	O
interaction	O
with	O
the	O
cellular	O
receptor	O
and	O
induction	O
of	O
neutralizing	O
antibody	O
in	O
the	O
natural	O
host	O
,	O
it	O
is	O
a	O
primary	O
target	O
for	O
the	O
development	O
of	O
effective	O
vaccines	O
against	O
PEDV	O
.	O

The	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
surface	O
Spike	B-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
protein	I-PRGE
is	O
a	O
major	O
antigenic	O
determinant	O
in	O
eliciting	O
neutralizing	O
antibody	O
production	O
during	O
SARS	O
-	O
CoV	O
infection	O
.	O

The	O
common	O
viruses	O
detected	O
from	O
children	O
(	O
2	O
,	O
800	O
total	O
patients	O
)	O
were	O
human	O
rhinovirus	O
(	O
hRV	O
)	O
(	O
31	O
.	O
8	O
%),	O
adenovirus	O
(	O
AdV	O
)	O
(	O
19	O
.	O
2	O
%),	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
A	O
(	O
17	O
.	O
4	O
%),	O
RSV	B-PRGE
B	I-PRGE
(	O
11	O
.	O
7	O
%),	O
and	O
human	O
metapneumovirus	O
(	O
hMPV	O
)	O
(	O
9	O
.	O
8	O
%).	O

The	O
crystal	O
structure	O
of	O
the	O
free	O
SARS	B-PRGE
coronavirus	I-PRGE
M	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
and	O
its	O
dependence	O
on	O
pH	O
is	O
discussed	O
,	O
as	O
are	O
efforts	O
to	O
design	O
inhibitors	O
on	O
the	O
basis	O
of	O
these	O
structures	O
.	O

death	O
,	O
O2	O
dependence	O
at	O
36	O
weeks	O
(	O
BPD36wks	O
),	O
IVH	B-PRGE
III	I-PRGE
/	I-PRGE
IV	I-PRGE
,	O
ROPsur	O
,	O
NECsur	O
,	O
and	O
death	O
/	O
BPD36wks	O
.	O

This	O
report	O
details	O
the	O
subsequent	O
sequence	O
and	O
phylogenetic	O
analysis	O
of	O
the	O
TCoV	B-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
and	O
the	O
comparison	O
of	O
outbreak	O
-	O
associated	O
isolates	O
to	O
sequences	O
in	O
the	O
public	O
database	O
.	O

Quantitative	O
RT	O
-	O
PCR	O
was	O
performed	O
on	O
""""	O
dunked	O
""""	O
sputum	O
and	O
NTS	O
samples	O
for	B-PRGE
influenza	I-PRGE
A	I-PRGE
(	O
Flu	B-PRGE
A	I-PRGE
),	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
coronavirus	O
OC43	O
(	O
OC43	O
),	O
and	O
human	O
metapneumovirus	O
(	O
HMPV	O
).	O

In	O
this	O
study	O
,	O
using	O
a	O
prime	O
-	O
boost	O
immunization	O
approach	O
,	O
we	O
showed	O
that	O
virus	O
-	O
specific	O
CD8	B-PRGE
T	O
cells	O
protect	O
susceptible	O
8	O
-	O
to	O
10	O
-	O
month	O
-	O
old	O
mice	O
from	O
lethal	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
challenge	O
.	O

These	O
results	O
show	O
that	O
MERS	O
-	O
S	O
is	O
a	O
substrate	O
for	O
proprotein	O
convertases	O
and	O
demonstrate	O
that	O
processing	O
by	O
these	O
enzymes	O
is	O
dispensable	O
for	O
S	B-PRGE
protein	I-PRGE
activation	O
.	O

Taken	O
together	O
,	O
the	O
results	O
suggested	O
that	O
the	O
chimeric	O
VLP	B-PRGE
vaccine	O
represents	O
a	O
potential	O
strategy	O
for	O
the	O
development	O
of	O
a	O
safe	O
and	O
effective	O
vaccine	O
to	O
control	O
PRRSV	O
and	O
H3N2	O
influenza	O
virus	O
.	O

We	O
also	O
generated	O
monoclonal	O
antibodies	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
proteins	I-PRGE
and	O
observed	O
that	O
most	O
of	O
them	O
promoted	O
SARS	O
-	O
CoV	O
infection	O
.	O

Real	O
-	O
time	O
reverse	O
transcriptase	B-PRGE
polymerase	I-PRGE
chain	O
reaction	O
assay	O
targeted	O
the	O
UpE	O
and	O
Orf1a	O
regions	O
of	O
the	O
MERS	O
-	O
CoV	O
genome	O
.	O

The	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
region	O
from	O
four	O
highly	O
divergent	O
partial	O
viral	O
genomes	O
in	O
the	O
order	O
Picornavirales	O
were	O
sequenced	O
.	O

TITLE	O
:	O
Crystallization	O
and	O
preliminary	O
crystallographic	O
study	O
of	O
human	B-PRGE
coronavirus	I-PRGE
NL63	I-PRGE
main	I-PRGE
protease	I-PRGE
in	O
complex	O
with	O
an	O
inhibitor	O
.	O

To	O
investigate	O
the	O
DKA	O
binding	O
site	O
of	O
RNase	B-PRGE
H	I-PRGE
and	O
the	O
mechanism	O
of	O
action	O
,	O
six	O
couples	O
of	O
ester	O
and	O
acid	O
DKAs	O
,	O
derived	O
from	O
6	O
-[	O
1	O
-(	O
4	O
-	O
fluorophenyl	O
)	O
methyl	O
-	O
1H	O
-	O
pyrrol	O
-	O
2	O
-	O
yl	O
)]-	O
2	O
,	O
4	O
-	O
dioxo	O
-	O
5	O
-	O
hexenoic	O
acid	O
ethyl	O
ester	O
(	O
RDS1643	O
),	O
were	O
synthesized	O
and	O
tested	O
on	O
both	O
RNase	B-PRGE
H	I-PRGE
and	O
IN	O
functions	O
.	O

Most	O
of	O
the	O
ester	O
derivatives	O
showed	O
selectivity	O
for	O
HIV	O
-	O
1	O
RNase	B-PRGE
H	I-PRGE
versus	O
IN	O
,	O
while	O
acids	O
inhibited	O
both	O
functions	O
.	O

It	O
has	O
been	O
shown	O
that	O
the	O
envelope	B-PRGE
(	I-PRGE
E	I-PRGE
)	I-PRGE
protein	I-PRGE
plays	O
a	O
variable	O
role	O
in	O
CoV	O
morphogenesis	O
,	O
depending	O
on	O
the	O
CoV	O
genus	O
,	O
being	O
absolutely	O
essential	O
in	O
some	O
cases	O
(	O
genus	O
α	O
CoVs	O
such	O
as	O
TGEV	O
,	O
and	O
genus	O
β	O
CoVs	O
such	O
as	O
MERS	O
-	O
CoV	O
),	O
but	O
not	O
in	O
others	O
(	O
genus	O
β	O
CoVs	O
such	O
as	O
MHV	O
or	O
SARS	O
-	O
CoV	O
).	O

However	O
,	O
this	O
PLpro	O
inhibitor	O
was	O
not	O
sufficient	O
to	O
protect	O
the	O
mice	O
from	O
lethal	O
infection	O
with	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
MA15	I-PRGE
,	O
suggesting	O
that	O
further	O
optimization	O
of	O
the	O
delivery	O
and	O
stability	O
of	O
PLpro	O
inhibitors	O
is	O
needed	O
.	O

We	O
recently	O
showed	O
the	O
presence	O
of	O
both	O
epitope	O
M133	O
-	O
specific	O
Tregs	O
(	O
M133	O
Treg	O
)	O
and	O
conventional	O
CD4	B-PRGE
T	I-PRGE
cells	O
(	O
M133	O
Tconv	O
)	O
in	O
the	O
brains	O
of	O
mice	O
with	O
coronavirus	O
-	O
induced	O
encephalitis	O
.	O

Reverse	O
transcription	O
-	O
loop	O
-	O
mediated	O
isothermal	O
amplification	O
(	O
RT	O
-	O
LAMP	O
)	O
is	O
a	O
genetic	O
diagnostic	O
method	O
used	O
widely	O
for	O
the	O
detection	O
of	O
viral	O
pathogens	O
,	O
which	O
requires	O
only	O
a	O
single	O
temperature	O
for	O
amplification	O
,	O
and	O
can	O
be	O
completed	O
in	O
less	O
than	O
1	O
h	O
.	O
This	O
study	O
developed	O
a	O
novel	O
RT	O
-	O
LAMP	O
assay	O
for	O
detecting	O
MERS	O
-	O
CoV	O
using	O
primer	O
sets	O
targeting	O
a	O
conserved	B-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
region	O
.	O

First	O
,	O
whereas	O
MERS	O
-	O
CoV	O
prefers	O
human	B-PRGE
DPP4	I-PRGE
over	O
bat	B-PRGE
DPP4	I-PRGE
as	O
its	O
receptor	O
,	O
HKU4	O
shows	O
the	O
opposite	O
trend	O
.	O

These	O
results	O
establish	O
DPP4	B-PRGE
as	O
a	O
functional	O
receptor	O
for	O
HKU4	O
and	O
host	B-PRGE
cellular	I-PRGE
proteases	I-PRGE
as	O
a	O
host	O
range	O
determinant	O
for	O
HKU4	O
.	O

They	O
also	O
suggest	O
that	O
DPP4	B-PRGE
-	O
recognizing	O
bat	O
coronaviruses	O
threaten	O
human	O
health	O
because	O
of	O
their	O
spikes	O
'	O
capability	O
to	O
adapt	O
to	O
human	O
cells	O
for	O
cross	O
-	O
species	O
transmissions	O
.	O

Sequence	O
analysis	O
suggests	O
that	O
the	O
orf3a	O
aligned	O
to	O
one	O
calcium	O
pump	O
present	O
in	O
Plasmodium	O
falciparum	O
and	O
the	O
enzyme	B-PRGE
glutamine	I-PRGE
synthetase	I-PRGE
found	O
in	O
Leptospira	O
interrogans	O
.	O

Silencing	O
of	O
syntenin	B-PRGE
using	I-PRGE
siRNAs	I-PRGE
led	O
to	O
a	O
decrease	O
in	O
p38	B-PRGE
MAPK	O
activation	O
in	O
SARS	O
-	O
CoV	O
infected	O
cells	O
,	O
further	O
reinforcing	O
their	O
functional	O
relationship	O
.	O

We	O
found	O
that	O
MSPL	B-PRGE
and	O
,	O
to	O
a	O
lesser	O
degree	O
,	O
DESC1	B-PRGE
are	O
expressed	O
in	O
human	O
lung	O
tissue	O
and	O
cleave	O
and	O
activate	O
the	O
spike	O
proteins	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronaviruses	O
for	O
cell	O
-	O
cell	O
and	O
virus	O
-	O
cell	O
fusion	O
.	O

The	O
7b	B-PRGE
gene	I-PRGE
was	O
affected	O
by	O
deletions	O
only	O
in	O
one	O
cat	O
.	O

This	O
technique	O
of	O
oxygenation	O
has	O
significantly	O
increased	O
worldwide	O
with	O
the	O
H1N1	B-PRGE
flu	I-PRGE
pandemic	O
.	O

Treatment	O
with	O
FTY720	O
did	O
not	O
affect	O
virus	O
-	O
specific	O
T	O
cell	O
proliferation	O
,	O
expression	O
of	O
IFN	B-PRGE
-	I-PRGE
γ	I-PRGE
,	O
TNF	B-PRGE
-	I-PRGE
α	I-PRGE
or	O
cytolytic	O
activity	O
.	O

ABSTRACT	O
:	O
The	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
PLpro	O
)	O
domain	O
from	O
the	O
deadly	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
was	O
overexpressed	O
and	O
purified	O
.	O

MERS	O
-	O
CoV	O
PLpro	O
constructs	O
with	O
and	O
without	O
the	O
putative	O
ubiquitin	B-PRGE
-	I-PRGE
like	I-PRGE
(	O
UBL	B-PRGE
)	O
domain	O
at	O
the	O
N	O
terminus	O
were	O
found	O
to	O
possess	O
protease	O
,	O
deubiquitinating	O
,	O
deISGylating	O
,	O
and	O
interferon	B-PRGE
antagonism	O
activities	O
in	O
transfected	O
HEK293T	O
cells	O
.	O

Finally	O
,	O
potent	O
inhibitors	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
PLpro	I-PRGE
were	O
found	O
to	O
have	O
no	O
effect	O
on	O
MERS	O
-	O
CoV	O
PLpro	O
.	O

Unlocking	O
the	O
secrets	O
of	O
how	O
coronavirus	O
(	O
CoV	O
)	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
proteases	I-PRGE
(	O
PLpros	O
)	O
perform	O
their	O
multifunctional	O
roles	O
during	O
viral	O
replication	O
entails	O
a	O
complete	O
mechanistic	O
understanding	O
of	O
their	O
substrate	O
recognition	O
and	O
enzymatic	O
activities	O
.	O

Here	O
,	O
we	O
report	O
that	O
in	O
cells	O
infected	O
with	O
the	O
avian	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
ER	O
stress	O
was	O
induced	O
and	O
the	O
IRE1α	B-PRGE
-	I-PRGE
XBP1	I-PRGE
pathway	O
of	O
UPR	O
was	O
activated	O
.	O

Moreover	O
,	O
IRE1α	O
antagonized	O
IBV	O
-	O
induced	O
apoptosis	O
by	O
modulating	O
the	O
phosphorylation	O
status	O
of	O
the	O
proapoptotic	O
c	B-PRGE
-	I-PRGE
Jun	I-PRGE
N	I-PRGE
-	I-PRGE
terminal	I-PRGE
kinase	I-PRGE
(	O
JNK	B-PRGE
)	O
and	O
the	O
prosurvival	B-PRGE
RAC	I-PRGE
-	I-PRGE
alpha	I-PRGE
serine	I-PRGE
/	I-PRGE
threonine	I-PRGE
-	I-PRGE
protein	I-PRGE
kinase	I-PRGE
(	O
Akt	B-PRGE
).	O

The	O
RRP	B-PRGE
decreases	O
the	O
duration	O
of	O
antibiotic	O
use	O
,	O
the	O
length	O
of	O
inpatient	O
stay	O
,	O
and	O
the	O
time	O
in	O
isolation	O
.	O

Therefore	O
,	O
major	O
objectives	O
for	O
anesthesiologists	O
and	O
surgeons	O
are	O
first	O
to	O
prevent	O
the	O
occurrence	O
of	O
postoperative	O
complications	O
and	O
second	O
if	O
ARF	B-PRGE
occurs	O
is	O
to	O
ensure	O
oxygen	O
administration	O
and	O
carbon	O
dioxide	O
CO2	O
removal	O
while	O
avoiding	O
intubation	O
.	O

The	O
results	O
showed	O
that	O
three	O
Japanese	O
type	O
II	O
FCoVs	O
,	O
M91	O
-	O
267	O
,	O
KUK	O
-	O
H	O
/	O
L	O
and	O
Tokyo	O
/	O
cat	O
/	O
130627	O
,	O
also	O
emerged	O
by	O
homologous	O
recombination	O
between	O
type	B-PRGE
I	I-PRGE
FCoV	I-PRGE
and	O
type	B-PRGE
II	I-PRGE
CCoV	I-PRGE
and	O
their	O
parent	O
viruses	O
were	O
genetically	O
different	O
from	O
one	O
another	O
.	O

ABSTRACT	O
:	O
CD4	B-PRGE
T	O
-	O
cell	O
help	O
is	O
not	O
a	O
universal	O
requirement	O
for	O
effective	O
primary	O
CD8	B-PRGE
T	O
cells	O
but	O
is	O
essential	O
to	O
generate	O
memory	O
CD8	B-PRGE
T	I-PRGE
cells	O
capable	O
of	O
recall	O
responses	O
.	O

Nevertheless	O
,	O
impaired	O
virus	O
control	O
in	O
the	O
absence	O
of	O
CD4	B-PRGE
T	I-PRGE
cells	O
was	O
associated	O
with	O
gradually	O
diminished	O
CNS	B-PRGE
CD8	I-PRGE
T	I-PRGE
-	I-PRGE
cell	I-PRGE
interferon	I-PRGE
-	I-PRGE
γ	I-PRGE
production	O
.	O

ABSTRACT	O
:	O
Human	B-PRGE
coronavirus	I-PRGE
NL63	I-PRGE
(	O
HCoV	O
-	O
NL63	O
)	O
is	O
an	O
alphacoronavirus	O
that	O
was	O
first	O
identified	O
in	O
2004	O
in	O
the	O
nasopharyngeal	O
aspirate	O
from	O
a	O
7	O
-	O
month	O
-	O
old	O
patient	O
with	O
a	O
respiratory	O
tract	O
infection	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
ACE2	B-PRGE
protein	I-PRGE
is	O
required	O
for	O
viral	O
entry	O
but	O
that	O
it	O
is	O
not	O
the	O
primary	O
binding	O
site	O
on	O
the	O
cell	O
surface	O
.	O

Sequence	O
variations	O
in	O
different	O
genes	O
,	O
especially	O
the	O
S	B-PRGE
gene	I-PRGE
and	O
nsp3	B-PRGE
,	O
in	O
the	O
genomes	O
of	O
CK	O
/	O
CH	O
/	O
LDL	O
/	O
97I	O
viruses	O
might	O
contribute	O
to	O
differences	O
in	O
viral	O
replication	O
,	O
pathogenicity	O
,	O
antigenicity	O
,	O
immunogenicity	O
,	O
and	O
tissue	O
tropism	O
.	O

Moreover	O
,	O
C5a	B-PRGE
administration	O
stimulated	O
TNF	B-PRGE
-	I-PRGE
α	I-PRGE
production	O
by	O
CD11b	B-PRGE
(+)	O
cells	O
,	O
which	O
in	O
turn	O
promoted	O
the	O
expression	O
of	O
FGL2	B-PRGE
in	O
CD31	B-PRGE
(+)	O
LSEC	O
-	O
like	O
cells	O
in	O
vitro	O
.	O

Our	O
own	O
work	O
has	O
shown	O
that	O
the	O
NS2B	B-PRGE
/	I-PRGE
3	I-PRGE
protease	I-PRGE
complex	I-PRGE
of	O
the	O
flavivirus	O
dengue	O
virus	O
binds	O
and	O
cleaves	O
STING	O
,	O
and	O
that	O
an	O
inability	O
to	O
degrade	O
murine	O
STING	O
may	O
contribute	O
to	O
host	O
restriction	O
in	O
this	O
virus	O
.	O

The	O
expression	O
patterns	O
of	O
the	O
plasma	B-PRGE
vWF	I-PRGE
and	O
serum	B-PRGE
IL	I-PRGE
-	I-PRGE
8	I-PRGE
were	O
compared	O
between	O
different	O
groups	O
.	O

The	O
concentration	O
of	O
serum	B-PRGE
IL	I-PRGE
-	I-PRGE
8	I-PRGE
showed	O
a	O
similar	O
expression	O
pattern	O
in	O
both	O
groups	O
,	O
but	O
the	O
expression	O
increased	O
more	O
significantly	O
in	O
the	O
ARDS	O
group	O
than	O
in	O
the	O
non	O
-	O
ARDS	O
group	O
.	O

In	O
addition	O
,	O
the	O
level	O
of	O
plasma	O
vWF	B-PRGE
was	O
positively	O
correlated	O
with	O
platelet	O
count	O
,	O
but	O
negatively	O
correlated	O
with	O
oxygen	O
index	O
.	O

The	O
level	O
of	O
serum	B-PRGE
IL	I-PRGE
-	I-PRGE
8	I-PRGE
was	O
positively	O
correlated	O
with	O
white	O
blood	O
cell	O
count	O
and	O
ISS	O
score	O
,	O
and	O
inversely	O
correlated	O
with	O
oxygen	O
index	O
.	O

They	O
differed	O
genetically	O
mainly	O
in	O
the	O
N	O
-	O
terminal	O
S	O
protein	O
region	O
as	O
follows	O
:	O
(	O
1	O
)	O
strains	O
(	O
n	O
=	O
7	O
)	O
similar	O
to	O
the	O
highly	O
virulent	O
US	O
PEDV	O
strains	O
;	O
(	O
2	O
)	O
one	O
similar	O
to	O
the	O
reportedly	O
US	O
S	O
INDEL	O
PEDV	O
strain	O
;	O
and	O
(	O
3	O
)	O
one	O
novel	O
strain	O
most	O
closely	O
related	O
to	O
highly	O
virulent	O
US	O
PEDV	O
strains	O
,	O
but	O
with	O
a	O
large	O
(	O
197aa	O
)	O
deletion	O
in	O
the	O
S	B-PRGE
protein	I-PRGE
.	O

The	O
participants	O
practised	O
tai	B-PRGE
chi	I-PRGE
not	O
only	O
because	O
they	O
sought	O
to	O
improve	O
their	O
health	O
but	O
also	O
because	O
it	O
provided	O
a	O
crucial	O
social	O
function	O
and	O
meaning	O
to	O
them	O
.	O

RESULTS	O
:	O
Health	O
concerns	O
and	O
social	O
experiences	O
motivated	O
the	O
participants	O
to	O
practise	O
tai	B-PRGE
chi	I-PRGE
in	O
post	O
-	O
SARS	O
Hong	O
Kong	O
.	O

Comparing	O
to	O
the	O
typical	O
reference	O
CCV	O
strains	O
(	O
type	O
II	O
),	O
the	O
nucleotide	O
sequence	O
of	O
Korean	O
strains	O
had	O
homology	O
ranged	O
from	O
86	O
.	O
3	O
%	O
to	O
98	O
.	O
3	O
%	O
(	O
89	O
.	O
1	O
%	O
to	O
99	O
.	O
2	O
%	O
for	O
the	O
amino	O
acid	O
sequence	O
)	O
and	O
87	O
.	O
7	O
%	O
to	O
97	O
.	O
8	O
%	O
(	O
92	O
.	O
4	O
%	O
to	O
100	O
%	O
for	O
the	O
amino	O
acid	O
sequence	O
)	O
when	O
compared	O
to	O
FCoV	B-PRGE
-	I-PRGE
like	I-PRGE
CCV	I-PRGE
strains	O
(	O
type	O
I	O
).	O

This	O
study	O
was	O
the	O
first	O
to	O
identify	O
genetic	O
differences	O
of	O
the	O
M	B-PRGE
gene	I-PRGE
from	O
Korean	O
CCV	O
strains	O
and	O
provided	O
a	O
platform	O
for	O
molecular	O
identification	O
of	O
different	O
Korean	O
CCV	O
strains	O
.	O

Receptor	O
of	O
advanced	O
glycation	O
end	O
product	O
(	O
RAGE	O
)	O
is	O
a	O
multiligand	O
receptor	O
of	O
several	O
endogenous	O
alarmins	O
,	O
while	O
cytokeratin	B-PRGE
18	I-PRGE
is	O
a	O
structural	O
component	O
of	O
the	O
filament	O
of	O
epithelial	O
cells	O
.	O

Plasma	O
samples	O
of	O
77	O
patients	O
with	O
severe	O
multiple	O
trauma	O
as	O
defined	O
by	O
an	O
Injury	O
Severity	O
Score	O
(	O
ISS	O
)	O
16	O
or	O
greater	O
were	O
obtained	O
from	O
a	O
local	O
repository	O
and	O
levels	O
of	O
soluble	O
RAGE	B-PRGE
,	O
endogenous	B-PRGE
secretory	I-PRGE
RAGE	I-PRGE
,	I-PRGE
cytokeratin	I-PRGE
18	I-PRGE
,	O
cleaved	O
cytokeratin	B-PRGE
18	I-PRGE
,	O
and	O
interleukin	B-PRGE
6	I-PRGE
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

Also	O
unclear	O
are	O
the	O
molecular	O
determinants	O
governing	O
the	O
antiviral	O
activities	O
of	O
TRIM56	B-PRGE
.	O

Furthermore	O
,	O
entry	O
mediated	O
by	O
the	O
influenza	O
virus	O
hemagglutinin	O
was	O
robustly	O
inhibited	O
by	O
IFITM3	B-PRGE
but	O
was	O
insensitive	O
to	O
accumulation	O
of	O
endosomal	O
cholesterol	O
,	O
indicating	O
that	O
modulation	O
of	O
cholesterol	O
synthesis	O
/	O
transport	O
did	O
not	O
account	O
for	O
the	O
antiviral	O
activity	O
of	O
IFITM3	B-PRGE
.	O

We	O
evaluated	O
whether	O
serum	O
SP	O
-	O
A	O
levels	O
in	O
the	O
presence	O
of	O
diffuse	O
alveolar	O
damage	O
(	O
DAD	O
)	O
can	O
be	O
qualitatively	O
assessed	O
for	O
diagnosis	O
of	O
SAP	B-PRGE
-	O
induced	O
ARDS	O
.	O

However	O
,	O
the	O
stretch	O
-	O
induced	O
[	O
Ca	O
(	O
2	O
+)]	O
i	O
elevation	O
was	O
not	O
inhibited	O
by	O
ATP	B-PRGE
diphosphohydrolase	I-PRGE
apyrase	I-PRGE
or	O
a	O
purinergic	B-PRGE
receptor	I-PRGE
antagonist	O
suramin	O
.	O

In	O
the	O
current	O
study	O
,	O
in	O
a	O
lipopolysaccharide	O
-	O
based	O
mouse	O
model	O
of	O
ALI	O
,	O
we	O
found	O
that	O
insulin	B-PRGE
alleviated	O
pulmonary	O
edema	O
by	O
promoting	O
ENaC	B-PRGE
-	O
mediated	O
alveolar	O
fluid	O
clearance	O
through	O
serum	B-PRGE
and	I-PRGE
glucocorticoid	B-PRGE
induced	I-PRGE
kinase	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
SGK1	B-PRGE
).	O

The	O
data	O
revealed	O
that	O
during	O
ALI	O
,	O
insulin	B-PRGE
stimulates	O
alveolar	O
fluid	O
clearance	O
by	O
upregulating	O
the	O
expression	O
of	O
α	O
-,	O
β	O
-,	O
and	O
γ	B-PRGE
-	I-PRGE
ENaC	I-PRGE
at	O
the	O
cell	O
surface	O
,	O
which	O
was	O
,	O
at	O
least	O
,	O
partially	O
through	O
activating	O
mTROC2	O
/	O
SGK1	B-PRGE
signaling	O
pathway	O
.	O

Fifty	O
four	O
randomly	O
selected	O
patients	O
with	O
confirmed	O
SAP	B-PRGE
complicated	O
by	O
ARDS	O
after	O
being	O
admitted	O
to	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
within	O
72	O
hr	O
of	O
onset	O
were	O
included	O
in	O
the	O
study	O
.	O

This	O
interaction	O
disrupted	O
the	O
association	O
between	O
PDK1	B-PRGE
and	O
PKB	B-PRGE
/	O
Akt	B-PRGE
,	O
and	O
led	O
to	O
down	O
-	O
regulation	O
of	O
PKB	B-PRGE
/	O
Akt	B-PRGE
activity	O
.	O

The	O
established	O
method	O
had	O
a	O
good	O
linear	O
correlation	O
from	O
7	O
.	O
77	O
x	O
10	O
(	O
8	O
)	O
to	O
10	O
(	O
0	O
)	O
copies	O
/	O
microL	O
.	O
SPF	B-PRGE
chickens	I-PRGE
developed	O
typical	O
clinical	O
signs	O
of	O
IBV	O
at	O
the	O
4th	O
dpi	O
,	O
and	O
the	O
IBV	O
viral	O
concentration	O
of	O
tissues	O
and	O
organs	O
gradually	O
increased	O
with	O
a	O
peak	O
of	O
up	O
to	O
7	O
.	O
13	O
x	O
10	O
(	O
4	O
)	O
copies	O
/	O
microL	O
.	O
The	O
viral	O
concentration	O
of	O
most	O
organs	O
decreased	O
by	O
the	O
10th	O
dpi	O
,	O
but	O
those	O
of	O
the	O
kidney	O
,	O
trachea	O
and	O
lung	O
remained	O
positive	O
for	O
IBV	O
at	O
28	O
dpi	O
and	O
the	O
heart	O
was	O
still	O
positive	O
for	O
IBV	O
at	O
>	O
35	O
dpi	O
.	O

LPS	O
-	O
induced	O
acute	O
lung	O
inflammation	O
was	O
significantly	O
exacerbated	O
in	O
Spred	O
-	O
2	O
(-/-)	O
mice	O
compared	O
with	O
WT	O
mice	O
,	O
as	O
indicated	O
by	O
the	O
numbers	O
of	O
infiltrating	O
leukocytes	O
,	O
levels	O
of	O
alveolar	B-PRGE
TNF	I-PRGE
-	I-PRGE
α	I-PRGE
,	O
CXCL2	B-PRGE
and	O
CCL2	B-PRGE
in	O
a	O
later	O
phase	O
,	O
and	O
lung	O
pathology	O
.	O

Spred	O
-	O
2	O
controls	O
the	O
development	O
of	O
LPS	O
-	O
induced	O
lung	O
inflammation	O
by	O
negatively	O
regulating	O
the	O
ERK	B-PRGE
-	O
MAPK	B-PRGE
pathway	O
.	O

TITLE	O
:	O
Ribavirin	O
and	O
interferon	B-PRGE
alfa	I-PRGE
-	I-PRGE
2a	I-PRGE
for	O
severe	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
:	O
a	O
retrospective	O
cohort	O
study	O
.	O

We	O
analysed	O
20	O
patients	O
who	O
received	O
ribavirin	O
and	O
interferon	B-PRGE
(	O
treatment	O
group	O
;	O
initiated	O
a	O
median	O
of	O
3	O
days	O
[	O
range	O
0	O
-	O
8	O
]	O
after	O
diagnosis	O
)	O
and	O
24	O
who	O
did	O
not	O
(	O
comparator	O
group	O
).	O

PEDV	B-PRGE
-	I-PRGE
specific	I-PRGE
antigen	I-PRGE
was	O
detected	O
in	O
villous	O
enterocytes	O
of	O
challenged	O
pigs	O
by	O
immunohistochemistry	O
(	O
IHC	O
)	O
on	O
dpi	B-PRGE
1	I-PRGE
,	O
2	O
,	O
3	O
,	O
4	O
,	O
7	O
,	O
and	O
14	O
.	O

DDX1	B-PRGE
knockdown	O
or	O
loss	O
of	O
helicase	B-PRGE
activity	O
markedly	O
reduces	O
the	O
levels	O
of	O
longer	O
sgmRNAs	O
.	O

Finally	O
,	O
SHXB	O
inhibited	O
the	O
activation	O
of	O
nuclear	B-PRGE
factor	I-PRGE
kappa	I-PRGE
B	I-PRGE
(	O
NF	O
-	O
κB	O
)	O
in	O
these	O
cells	O
.	O

Interactions	O
of	O
the	O
viral	B-PRGE
replicase	I-PRGE
complex	I-PRGE
with	O
cis	O
-	O
acting	O
RNA	O
elements	O
located	O
in	O
the	O
5	O
'	O
and	O
3	O
'-	O
terminal	O
genome	O
regions	O
ensure	O
the	O
specific	O
replication	O
of	O
viral	O
RNA	O
.	O

Lab	B-PRGE
tests	O
made	O
upon	O
his	O
admission	O
showed	O
hyperbilirubinemia	O
at	O
a	O
level	O
of	O
50	O
mg	O
/	O
dL	O
,	O
severe	O
metabolic	O
acidosis	O
,	O
thrombocytopenia	O
,	O
creatinine	O
levels	O
of	O
5	O
.	O
6	O
mg	O
/	O
dL	O
and	O
leukocytosis	O
with	O
deviation	O
through	O
metamyelocytes	O
.	O

Virulence	O
factors	O
of	O
Escherichia	O
coli	O
were	O
identified	O
in	O
103	O
strains	O
:	O
eae	O
(	O
7	O
),	O
K99	B-PRGE
/	I-PRGE
STa	I-PRGE
(	I-PRGE
7	I-PRGE
),	I-PRGE
Stx1	I-PRGE
(	I-PRGE
7	I-PRGE
),	I-PRGE
Stx1	B-PRGE
/	I-PRGE
eae	I-PRGE
(	I-PRGE
36	I-PRGE
),	I-PRGE
Stx1	B-PRGE
/	O
Stx2	B-PRGE
/	O
eae	O
(	O
2	O
),	O
Stx2	B-PRGE
(	O
43	O
),	O
and	O
Stx2	B-PRGE
/	I-PRGE
eae	I-PRGE
(	I-PRGE
1	I-PRGE
).	I-PRGE

Furthermore	O
,	O
PLP2	B-PRGE
-	I-PRGE
TM	I-PRGE
interacts	O
with	O
the	O
key	O
autophagy	O
regulators	O
,	O
LC3	B-PRGE
and	O
Beclin1	B-PRGE
,	O
and	O
promotes	O
Beclin1	B-PRGE
interaction	O
with	O
STING	O
,	O
the	O
key	O
regulator	O
for	O
antiviral	B-PRGE
IFN	I-PRGE
signaling	O
.	O

CONCLUSIONS	O
:	O
Serious	O
community	O
-	O
based	O
infectious	O
diseases	O
are	O
a	O
personal	O
concern	O
for	O
GPs	O
and	O
FPs	B-PRGE
,	O
and	O
have	O
considerable	O
effects	O
on	O
their	O
clinical	O
practice	O
.	O

In	O
addition	O
to	O
this	O
replicative	O
function	O
,	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
PL	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
was	O
recently	O
shown	O
to	O
be	O
a	O
deubiquitinating	O
enzyme	O
(	O
DUB	O
)	O
and	O
to	O
possess	O
deISGylating	O
activity	O
,	O
as	O
previously	O
reported	O
for	O
other	O
coronaviral	O
PL	O
(	O
pro	O
)	O
domains	O
,	O
including	O
that	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Whereas	O
the	O
wild	O
-	O
type	O
PL	O
(	O
pro	O
)	O
domain	O
was	O
found	O
to	O
suppress	O
IFN	B-PRGE
-	I-PRGE
β	I-PRGE
promoter	I-PRGE
activation	I-PRGE
,	I-PRGE
PL	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
variants	I-PRGE
specifically	O
lacking	O
DUB	B-PRGE
activity	O
were	O
no	O
longer	O
able	O
to	O
do	O
so	O
.	O

To	O
determine	O
the	O
mechanisms	O
of	O
lung	O
endothelial	O
cell	O
(	O
EC	O
)	O
High	B-PRGE
Mobility	I-PRGE
Group	I-PRGE
Box	I-PRGE
1	I-PRGE
(	O
HMGB1	B-PRGE
)	O
release	O
following	O
exposure	O
to	O
RBCs	O
and	O
to	O
determine	O
whether	O
RBC	O
transfusion	O
increases	O
susceptibility	O
to	O
lung	O
inflammation	O
in	O
vivo	O
through	O
release	O
of	O
the	O
danger	O
signal	O
HMGB1	B-PRGE
.	O

RBC	O
transfusion	O
sensitized	O
mice	O
to	O
LPS	O
-	O
induced	O
lung	O
inflammation	O
through	O
release	O
of	O
the	O
danger	O
signal	O
HMGB1	B-PRGE
.	O

Although	O
many	O
biochemical	O
and	O
structural	O
studies	O
have	O
focused	O
on	O
DNA	O
sequences	O
containing	O
successive	O
,	O
adjacent	O
guanines	O
that	O
spontaneously	O
fold	O
into	O
G4s	B-PRGE
,	O
evidence	O
for	O
their	O
in	O
vivo	O
relevance	O
has	O
recently	O
begun	O
to	O
accumulate	O
.	O

Only	O
4	O
significantly	O
dysregulated	O
genes	O
are	O
common	O
between	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
MERS	O
-	O
CoV	O
,	O
including	O
NFKBIA	B-PRGE
that	O
is	O
a	O
key	O
regulator	O
of	O
immune	O
responsiveness	O
implicated	O
in	O
susceptibility	O
to	O
infectious	O
and	O
inflammatory	O
diseases	O
.	O

Higher	O
SAPS	B-PRGE
II	I-PRGE
scores	O
were	O
associated	O
with	O
HFNC	O
failure	O
in	O
multivariate	O
analysis	O
.	O

Higher	O
SAPS	B-PRGE
II	I-PRGE
scores	O
were	O
associated	O
with	O
HFNC	O
failure	O
in	O
multivariate	O
analysis	O
.	O

ABSTRACT	O
:	O
Based	O
on	O
a	O
bioinformatics	O
analysis	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavvirus	O
(	O
MERS	O
-	O
CoV	O
)	O
S	B-PRGE
protein	I-PRGE
,	O
we	O
synthesized	O
a	O
panel	O
of	O
peptides	O
coupled	O
to	O
keyhole	O
limpet	O
haemocyanin	O
and	O
used	O
them	O
to	O
raise	O
antibodies	O
in	O
rabbits	O
.	O

In	O
addition	O
,	O
the	O
recombinant	B-PRGE
receptor	I-PRGE
-	I-PRGE
binding	I-PRGE
domain	I-PRGE
(	O
RBD	O
)	O
was	O
used	O
to	O
raise	O
polyclonal	O
antibodies	O
in	O
mice	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
report	O
that	O
ACE2	B-PRGE
could	O
mediate	O
the	O
severe	O
acute	O
lung	O
injury	O
induced	O
by	O
influenza	O
A	O
(	O
H7N9	O
)	O
virus	O
infection	O
in	O
an	O
experimental	O
mouse	O
model	O
.	O

TITLE	O
:	O
[	O
The	O
levels	O
of	O
angiopoietin	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
its	O
value	O
on	O
prognosis	O
].	O

Receiver	O
operating	O
characteristic	O
curve	O
(	O
ROC	O
)	O
was	O
plotted	O
to	O
evaluate	O
the	O
value	O
of	O
Ang	B-PRGE
-	I-PRGE
2	I-PRGE
in	O
predicting	O
ARDS	O
.	O

1	O
.	O
22	O
(	O
0	O
.	O
61	O
,	O
1	O
.	O
52	O
),	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
(	O
ng	O
/	O
L	O
):	O
56	O
.	O
50	O
(	O
27	O
.	O
15	O
,	O
139	O
.	O
90	O
)	O
vs	O
.	O

The	O
area	O
under	O
the	O
ROC	O
curve	O
of	O
Ang	B-PRGE
-	I-PRGE
2	I-PRGE
was	O
0	O
.	O
964	O
,	O
the	O
optimal	O
critical	O
value	O
of	O
Ang	B-PRGE
-	I-PRGE
2	I-PRGE
was	O
1	O
.	O
79	O
μg	O
/	O
L	O
,	O
the	O
specificity	O
was	O
90	O
.	O
0	O
%,	O
and	O
sensitivity	O
was	O
92	O
.	O
5	O
%.	O

Plasma	O
levels	O
of	O
Ang	B-PRGE
-	I-PRGE
2	I-PRGE
was	O
better	O
in	O
predicting	O
ARDS	O
than	O
APACHEII	O
score	O
,	O
SOFA	O
score	O
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
.	O

Absence	O
of	O
activating	B-PRGE
transcription	I-PRGE
factor	I-PRGE
3	I-PRGE
(	O
ATF3	B-PRGE
)	O
confers	O
susceptibility	O
to	O
ALI	O
/	O
VILI	O
.	O

To	O
identify	O
cell	O
-	O
specific	O
ATF3	B-PRGE
-	O
dependent	O
mechanisms	O
of	O
susceptibility	O
to	O
ALI	O
/	O
VILI	O
,	O
we	O
generated	O
ATF3	B-PRGE
chimera	O
by	O
adoptive	O
bone	O
marrow	O
(	O
BM	O
)	O
transfer	O
and	O
randomized	O
to	O
inhaled	O
saline	O
or	O
lipopolysacharide	O
(	O
LPS	O
)	O
in	O
the	O
presence	O
of	O
mechanical	O
ventilation	O
(	O
MV	O
).	O

In	O
our	O
model	O
,	O
in	O
the	O
absence	O
of	O
ATF3	B-PRGE
in	O
parenchymal	O
cells	O
increased	O
Nrf2	B-PRGE
degradation	O
is	O
the	O
result	O
of	O
increased	O
Keap	O
-	O
1	O
expression	O
and	O
loss	O
of	O
DJ	O
-	O
1	O
(	O
Parkinson	O
disease	O
[	O
autosomal	O
recessive	O
,	O
early	O
onset	O
]	O
7	O
),	O
previously	O
not	O
known	O
to	O
play	O
a	O
role	O
in	O
lung	O
injury	O
.	O

We	O
also	O
examined	O
the	O
protein	O
products	O
of	O
these	O
genomic	O
sequences	O
for	O
their	O
structural	O
flexibility	O
and	O
found	O
that	O
it	O
is	O
not	O
necessary	O
for	O
a	O
newly	O
acquired	O
,	O
overlapping	O
protein	B-PRGE
product	I-PRGE
to	O
be	O
intrinsically	O
disordered	O
,	O
in	O
contrast	O
to	O
earlier	O
suggestions	O
.	O

Virus	O
-	O
positive	O
exacerbations	O
were	O
associated	O
with	O
a	O
greater	O
increase	O
in	O
markers	O
of	O
systemic	O
and	O
airway	O
inflammation	O
(	O
serum	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
α	I-PRGE
;	O
sputum	O
IL	O
-	O
1β	O
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
α	I-PRGE
)	O
compared	O
with	O
virus	O
-	O
negative	O
exacerbations	O
,	O
but	O
the	O
differences	O
in	O
spirometric	O
indexes	O
,	O
quality	O
of	O
life	O
,	O
and	O
bacterial	O
density	O
were	O
unremarkable	O
.	O

In	O
receiver	O
operating	O
characteristics	O
analysis	O
,	O
serum	O
interferon	B-PRGE
-	I-PRGE
γ	I-PRGE
-	O
induced	O
protein	O
10	O
yielded	O
an	O
area	O
under	O
curve	O
of	O
0	O
.	O
67	O
(	O
95	O
%	O
CI	O
,	O
0	O
.	O
53	O
-	O
0	O
.	O
77	O
;	O
P	O
=	O
.	O
018	O
).	O

For	O
prokaryotic	O
expression	O
of	O
partial	O
fragments	O
of	O
spike	O
protein	O
the	O
size	O
and	O
location	O
of	O
S1	O
,	O
S2	O
,	O
and	O
S3	O
,	O
and	O
full	B-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
,	O
polymerase	O
chain	O
reaction	O
was	O
performed	O
using	O
specific	O
primers	O
.	O

We	O
confirmed	O
that	O
the	O
carboxy	O
-	O
terminal	O
region	O
that	O
includes	O
the	O
endodomain	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
induced	O
stronger	O
neutralizing	O
activity	O
than	O
the	O
region	O
that	O
includes	O
the	O
ectodomain	O
.	O

There	O
were	O
no	O
linear	O
correlation	O
between	O
ELLB	O
/	O
ERS	B-PRGE
and	O
ELPeso	O
/	O
ERS	B-PRGE
during	O
the	O
increase	O
and	O
the	O
decrease	O
of	O
PEEP	O
(	O
R²	O
=	O
0	O
.	O
00	O
;	O
R²	O
=	O
0	O
.	O
00	O
,	O
respectively	O
).	O

There	O
were	O
no	O
linear	O
correlation	O
between	O
ELLB	O
/	O
ERS	B-PRGE
and	O
ELPeso	O
/	O
ERS	B-PRGE
during	O
the	O
increase	O
and	O
the	O
decrease	O
of	O
PEEP	O
(	O
R²	O
=	O
0	O
.	O
00	O
;	O
R²	O
=	O
0	O
.	O
00	O
,	O
respectively	O
).	O

The	O
receptor	B-PRGE
-	I-PRGE
binding	I-PRGE
S1	I-PRGE
subunit	I-PRGE
of	I-PRGE
coronavirus	I-PRGE
spike	I-PRGE
proteins	I-PRGE
contains	O
two	O
distinctive	O
domains	O
,	O
the	O
N	O
-	O
terminal	O
domain	O
(	O
S1	O
-	O
NTD	O
)	O
and	O
the	O
C	O
-	O
terminal	O
domain	O
(	O
S1	B-PRGE
-	I-PRGE
CTD	I-PRGE
),	O
both	O
of	O
which	O
can	O
function	O
as	O
receptor	O
-	O
binding	O
domains	O
(	O
RBDs	O
).	O

Here	O
we	O
discuss	O
the	O
most	O
recent	O
studies	O
on	O
the	O
structure	O
of	O
the	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
and	O
its	O
role	O
in	O
virus	O
binding	O
and	O
entry	O
,	O
and	O
the	O
development	O
of	O
MERS	O
-	O
CoV	O
entry	O
/	O
fusion	O
inhibitors	O
targeting	O
the	O
S1	B-PRGE
subunit	I-PRGE
,	O
particularly	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
),	O
and	O
the	O
S2	O
subunit	O
,	O
especially	O
the	O
HR1	O
region	O
,	O
of	O
the	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
.	O

HbS	B-PRGE
fraction	O
failed	O
from	O
69	O
%	O
to	O
30	O
%.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
infects	O
host	O
cells	O
through	O
binding	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
on	O
its	O
spike	O
glycoprotein	O
to	O
human	B-PRGE
receptor	I-PRGE
dipeptidyl	I-PRGE
peptidase	I-PRGE
4	I-PRGE
(	O
hDPP4	O
).	O

The	O
structures	O
generated	O
were	O
in	O
agreement	O
with	O
previous	O
characterizations	O
of	O
SL1	B-PRGE
through	O
SL4	O
and	O
two	O
recently	O
predicted	O
secondary	O
structure	O
elements	O
,	O
S5	O
and	O
SL5A	O
.	O

Secondary	O
structure	O
predictions	O
for	O
5	O
'	O
regions	O
of	O
MHV	O
-	O
A59	O
,	O
BCoV	O
and	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
were	O
similar	O
despite	O
high	O
sequence	O
divergence	O
.	O

The	O
pattern	O
of	O
SHAPE	O
reactivity	O
of	O
in	O
virio	O
genomic	O
RNA	O
,	O
ex	O
virio	O
genomic	O
RNA	O
,	O
and	O
in	O
vitro	O
synthesized	O
RNA	O
was	O
similar	O
,	O
suggesting	O
that	O
binding	O
of	O
N	B-PRGE
protein	I-PRGE
or	O
other	O
proteins	O
to	O
virion	O
RNA	O
fails	O
to	O
protect	O
the	O
RNA	O
from	O
reaction	O
with	O
lipid	O
permeable	O
SHAPE	O
reagent	O
.	O

Reverse	O
genetic	O
experiments	O
suggested	O
that	O
SL5C	O
and	O
SL6	O
within	O
the	O
nsp1	B-PRGE
coding	I-PRGE
sequence	I-PRGE
are	O
not	O
required	O
for	O
viral	O
replication	O
.	O

These	O
were	O
human	O
adenovirus	O
(	O
3	O
out	O
of	O
7	O
,	O
42	O
.	O
8	O
%),	O
human	B-PRGE
coronavirus	I-PRGE
OC43	I-PRGE
/	O
HKU1	O
(	O
3	O
out	O
of	O
7	O
,	O
42	O
.	O
8	O
%),	O
Haemophilus	O
influenzae	O
(	O
1	O
out	O
of	O
7	O
,	O
14	O
.	O
2	O
%),	O
and	O
Moraxella	O
catarrhalis	O
(	O
1	O
out	O
of	O
7	O
,	O
14	O
.	O
2	O
%).	O

The	O
results	O
also	O
suggest	O
that	O
nsp4	B-PRGE
glycosylation	O
serves	O
roles	O
in	O
replication	O
in	O
addition	O
to	O
the	O
organization	O
and	O
stability	O
of	O
MHV	O
-	O
induced	O
double	O
-	O
membrane	O
vesicles	O
.	O

Three	O
viral	O
nonstructural	O
proteins	O
(	O
nsps	O
),	O
nsp3	B-PRGE
,	O
nsp4	B-PRGE
,	O
and	O
nsp6	O
,	O
are	O
known	O
to	O
be	O
required	O
for	O
DMV	O
formation	O
.	O

ABSTRACT	O
:	O
Influenza	O
A	O
viruses	O
,	O
human	B-PRGE
coronaviruses	I-PRGE
(	O
hCoV	O
)	O
and	O
human	O
bocavirus	O
(	O
hBoV	O
)	O
are	O
emerging	O
respiratory	O
viruses	O
.	O

After	O
a	O
1	O
-	O
week	O
dosage	O
of	O
chemotherapeutic	O
drugs	O
(	O
pegaspargase	O
and	O
mitoxantrone	O
),	O
he	O
suffered	O
SAP	B-PRGE
combined	O
with	O
ARDS	O
.	O

This	O
finding	O
prompted	O
us	O
to	O
identify	O
other	O
potential	O
mechanisms	O
of	O
inhibition	O
of	O
PLpro	O
on	O
IFN	B-PRGE
induction	O
.	O

We	O
found	O
that	O
PLpro	O
is	O
able	O
to	O
block	O
the	O
type	B-PRGE
I	I-PRGE
IFN	I-PRGE
induction	O
of	O
a	O
constitutively	O
active	O
IRF3	B-PRGE
,	O
but	O
does	O
not	O
inhibit	O
IRF3	B-PRGE
dimerization	O
,	O
nuclear	O
localization	O
or	O
DNA	O
binding	O
.	O

ABSTRACT	O
:	O
Human	B-PRGE
coronavirus	I-PRGE
HKU1	I-PRGE
(	O
HCoV	O
-	O
HKU1	O
),	O
which	O
mainly	O
causes	O
acute	O
self	O
-	O
limited	O
respiratory	O
-	O
tract	O
infections	O
,	O
belongs	O
to	O
group	O
A	O
of	O
the	O
Betacoronavirus	O
genus	O
.	O

ABSTRACT	O
:	O
Helicases	B-PRGE
are	O
versatile	O
NTP	O
-	O
dependent	O
motor	O
proteins	O
of	O
monophyletic	O
origin	O
that	O
are	O
found	O
in	O
all	O
kingdoms	O
of	O
life	O
.	O

Median	B-PRGE
hemoglobin	I-PRGE
was	O
8	O
.	O
29	O
g	O
/	O
dL	O
.	O
A	O
median	O
of	O
1	O
.	O
0	O
units	O
(	O
range	O
,	O
250	O
to	O
300	O
mL	O
)	O
was	O
transfused	O
during	O
ECMO	O
support	O
over	O
a	O
median	O
duration	O
of	O
9	O
.	O
0	O
days	O
,	O
equivalent	O
to	O
0	O
.	O
11	O
U	O
/	O
d	O
(	O
range	O
,	O
27	O
.	O
5	O
to	O
33	O
.	O
3	O
mL	O
/	O
d	O
).	O

TITLE	O
:	O
p53	B-PRGE
degradation	O
by	O
a	O
coronavirus	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
suppresses	O
type	B-PRGE
I	I-PRGE
interferon	I-PRGE
signaling	O
.	O

By	O
promoting	O
p53	B-PRGE
degradation	O
,	O
PLP2	B-PRGE
inhibits	O
the	O
p53	B-PRGE
-	O
mediated	O
antiviral	O
response	O
and	O
apoptosis	O
to	O
ensure	O
viral	O
growth	O
in	O
infected	O
cells	O
.	O

While	O
all	O
vaccines	O
protected	O
against	O
lethal	O
infection	O
,	O
addition	O
of	O
adjuvant	O
significantly	O
increased	O
serum	B-PRGE
neutralizing	I-PRGE
-	I-PRGE
antibody	I-PRGE
titers	O
and	O
reduced	O
lung	O
virus	O
titers	O
on	O
day	O
3	O
postchallenge	O
.	O

Protection	O
against	O
eosinophilic	O
immunopathology	O
by	O
vaccines	O
containing	O
delta	O
inulin	O
adjuvants	O
correlated	O
better	O
with	O
enhanced	O
T	B-PRGE
-	I-PRGE
cell	I-PRGE
gamma	I-PRGE
interferon	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
γ	I-PRGE
)	O
recall	O
responses	O
rather	O
than	O
reduced	O
interleukin	B-PRGE
-	I-PRGE
4	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
)	O
responses	O
,	O
suggesting	O
that	O
immunopathology	O
predominantly	O
reflects	O
an	O
inadequate	O
vaccine	O
-	O
induced	O
Th1	O
response	O
.	O

To	O
identify	O
cellular	O
proteins	O
that	O
interacted	O
with	O
N	B-PRGE
protein	I-PRGE
of	O
TGEV	O
,	O
methods	O
of	O
GST	B-PRGE
pull	O
-	O
down	O
and	O
Co	O
-	O
IP	O
were	O
utilized	O
to	O
precipitate	O
cellular	O
proteins	O
of	O
swine	O
testicular	O
(	O
ST	O
).	O

Vimentin	B-PRGE
cytoskeleton	O
was	O
required	O
for	O
virus	O
replication	O
.	O

The	O
present	O
study	O
thus	O
provides	O
protein	O
-	O
related	O
information	O
about	O
interaction	O
of	O
TGEV	B-PRGE
N	I-PRGE
protein	I-PRGE
with	O
host	O
cell	O
that	O
should	O
be	O
useful	O
for	O
understanding	O
host	O
cell	O
response	O
to	O
coronavirus	O
pathogenesis	O
infection	O
and	O
the	O
underlying	O
mechanism	O
of	O
coronavirus	O
replication	O
.	O

TITLE	O
:	O
Cardiac	O
troponin	B-PRGE
I	I-PRGE
as	O
a	O
prognostic	O
factor	O
in	O
critically	O
ill	O
pneumonia	O
patients	O
in	O
the	O
absence	O
of	O
acute	O
coronary	O
syndrome	O
.	O

ABSTRACT	O
:	O
Type	O
I	O
interferon	B-PRGE
induced	O
MxA	B-PRGE
response	O
can	O
differentiate	O
viral	O
from	O
bacterial	O
infections	O
,	O
but	O
MxA	O
responses	O
in	O
rhinovirus	O
or	O
asymptomatic	O
virus	O
infections	O
are	O
not	O
known	O
.	O

Blood	O
MxA	B-PRGE
protein	I-PRGE
levels	O
are	O
increased	O
in	O
young	O
children	O
with	O
symptomatic	O
respiratory	O
virus	O
infections	O
,	O
including	O
rhinovirus	O
infections	O
.	O

In	O
vitro	O
experiments	O
revealed	O
that	O
alveolar	O
macrophages	O
and	O
neutrophils	O
promoted	O
Stat3	B-PRGE
activation	O
in	O
alveolar	O
epithelial	O
cells	O
.	O

We	O
hypothesized	O
that	O
INO	B-PRGE
may	O
act	O
not	O
only	O
by	O
vasodilation	O
in	O
ventilated	O
lung	O
regions	O
,	O
but	O
also	O
by	O
causing	O
vasoconstriction	O
via	O
endothelin	O
(	O
ET	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
in	O
atelectatic	O
,	O
nonventilated	O
lung	O
regions	O
.	O

Endotoxin	O
infusion	O
increased	O
serum	O
ET	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
INO	O
almost	O
doubled	O
the	O
ratio	O
between	O
mRNA	O
expression	O
of	O
endothelin	B-PRGE
receptor	I-PRGE
A	I-PRGE
(	O
mediating	O
vasoconstriction	O
)	O
and	O
B	O
(	O
mediating	O
vasodilation	O
and	O
clearance	O
of	O
ET	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
(	O
ET	B-PRGE
-	I-PRGE
A	I-PRGE
/	O
ET	B-PRGE
-	I-PRGE
B	I-PRGE
)	O
in	O
atelectatic	O
lung	O
regions	O
.	O

TITLE	O
:	O
Development	O
of	O
transgenic	O
mouse	O
model	O
expressing	O
porcine	B-PRGE
aminopeptidase	I-PRGE
N	I-PRGE
and	O
its	O
susceptibility	O
to	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

TITLE	O
:	O
Ebola	O
virus	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
display	O
late	O
cell	O
entry	O
kinetics	O
:	O
evidence	O
that	O
transport	O
to	O
NPC1	B-PRGE
+	I-PRGE
endolysosomes	I-PRGE
is	O
a	O
rate	O
-	O
defining	O
step	O
.	O

TITLE	O
:	O
The	O
SARS	B-PRGE
-	I-PRGE
coronavirus	I-PRGE
papain	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
:	O
structure	O
,	O
function	O
and	O
inhibition	O
by	O
designed	O
antiviral	O
compounds	O
.	O

This	O
review	O
provides	O
an	O
up	O
-	O
to	O
-	O
date	O
discussion	O
on	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
papain	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
including	O
a	O
brief	O
overview	O
of	O
the	O
SARS	O
-	O
CoV	O
genome	O
and	O
replication	O
followed	O
by	O
a	O
more	O
in	O
-	O
depth	O
discussion	O
on	O
the	O
structure	O
and	O
catalytic	O
mechanism	O
of	O
SARS	O
-	O
CoV	O
PLpro	O
,	O
the	O
multiple	O
cellular	O
functions	O
of	O
SARS	O
-	O
CoV	O
PLpro	O
,	O
the	O
inhibition	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
PLpro	I-PRGE
by	O
small	O
molecule	O
inhibitors	O
,	O
and	O
the	O
prospect	O
of	O
inhibiting	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
from	O
other	O
coronaviruses	O
.	O

M	B-PRGE
protein	I-PRGE
and	O
nsp13	O
,	O
the	O
helicase	B-PRGE
,	O
of	O
JHM	O
.	O
WU	O
are	O
required	O
for	O
efficient	O
replication	O
in	O
vitro	O
and	O
in	O
the	O
liver	O
in	O
vivo	O
.	O

Our	O
data	O
indicate	O
that	O
both	O
structural	O
and	O
nonstructural	O
proteins	O
contribute	O
to	O
MHV	O
liver	O
pathogenesis	O
and	O
support	O
previous	O
reports	O
that	O
nsp1	B-PRGE
is	O
a	O
Betacoronavirus	O
virulence	O
factor	O
.	O

Furthermore	O
,	O
the	O
hepatotropism	O
of	O
MHV	O
-	O
JHM	O
depends	O
not	O
on	O
the	O
spike	O
protein	O
and	O
viral	O
entry	O
but	O
rather	O
on	O
a	O
combination	O
of	O
the	O
structural	O
protein	O
M	O
and	O
nonstructural	O
replicase	B-PRGE
-	I-PRGE
associated	I-PRGE
proteins	I-PRGE
nsp1	B-PRGE
and	O
nsp13	O
,	O
which	O
are	O
conserved	O
among	O
betacoronaviruses	O
.	O

TITLE	O
:	O
IFITM	B-PRGE
-	I-PRGE
Family	I-PRGE
Proteins	I-PRGE
:	O

These	O
mechanisms	O
are	O
usually	O
mediated	O
by	O
antiviral	O
proteins	O
whose	O
expression	O
and	O
activities	O
can	O
be	O
constitutive	O
but	O
are	O
frequently	O
amplified	O
by	O
interferon	B-PRGE
induction	O
.	O

At	O
least	O
three	O
human	B-PRGE
IFITM	I-PRGE
proteins	I-PRGE
-	I-PRGE
IFITM1	I-PRGE
,	O
IFITM2	B-PRGE
,	O
and	O
IFITM3	B-PRGE
-	O
have	O
antiviral	O
activities	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
ability	O
of	O
Aah	B-PRGE
venom	O
to	O
increase	O
vascular	O
permeability	O
and	O
to	O
induce	O
edema	O
was	O
also	O
assessed	O
by	O
measuring	O
the	O
amount	O
of	O
Evans	O
blue	O
dye	O
(	O
EBD	O
)	O
extravasation	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluid	O
and	O
in	O
the	O
lungs	O
of	O
mice	O
.	O

The	O
massive	O
IFN	B-PRGE
secretion	O
upon	O
contact	O
suggests	O
a	O
critical	O
role	O
of	O
this	O
mechanism	O
for	O
the	O
high	O
degree	O
of	O
immune	O
activation	O
observed	O
during	O
MERS	O
-	O
CoV	O
infection	O
.	O

TITLE	O
:	O
Fused	O
-	O
ring	O
structure	O
of	O
decahydroisoquinolin	O
as	O
a	O
novel	O
scaffold	O
for	O
SARS	B-PRGE
3CL	I-PRGE
protease	I-PRGE
inhibitors	O
.	O

An	O
observational	O
retrospective	O
study	O
was	O
carried	O
out	O
at	O
a	O
single	O
center	O
of	O
all	O
five	O
DS	O
neonates	O
with	O
TL	O
,	O
GATA1	B-PRGE
mutations	O
,	O
and	O
hyperleukocytosis	O
,	O
born	O
at	O
a	O
median	O
gestational	O
age	O
of	O
34	O
weeks	O
(	O
range	O
,	O
30	O
-	O
38	O
weeks	O
)	O
with	O
birthweight	O
2556	O
g	O
(	O
range	O
,	O
1756	O
-	O
3268	O
g	O
)	O
during	O
a	O
24	O
month	O
study	O
period	O
between	O
September	O
2011	O
and	O
August	O
2013	O
.	O

The	O
addition	O
of	O
MF59	O
significantly	O
augmented	O
the	O
immunogenicity	O
of	O
S377	O
-	O
588	O
-	O
Fc	O
to	O
induce	O
strong	O
IgG	B-PRGE
and	O
neutralizing	O
antibody	O
responses	O
as	O
well	O
as	O
protection	O
against	O
MERS	O
-	O
CoV	O
infection	O
in	O
mice	O
,	O
suggesting	O
that	O
MF59	O
is	O
an	O
optimal	O
adjuvant	O
for	O
MERS	O
-	O
CoV	O
RBD	O
-	O
based	O
subunit	O
vaccines	O
.	O

For	O
analysing	O
coronavirus	O
diversity	O
in	O
a	O
bat	O
species	O
-	O
rich	O
country	O
,	O
a	O
total	O
of	O
421	O
anal	O
swabs	O
/	O
faecal	O
samples	O
from	O
Costa	O
Rican	O
bats	O
were	O
screened	O
for	O
CoV	B-PRGE
RNA	I-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
(	O
RdRp	O
)	O
gene	O
sequences	O
by	O
a	O
pancoronavirus	O
PCR	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
utilizes	O
dipeptidyl	B-PRGE
peptidase	I-PRGE
4	I-PRGE
(	O
DPP4	B-PRGE
)	O
as	O
an	O
entry	O
receptor	O
.	O

We	O
show	O
that	O
glycosylation	O
is	O
a	O
major	O
factor	O
impacting	O
DPP4	B-PRGE
receptor	I-PRGE
function	O
.	O

TITLE	O
:	O
Characterisation	O
of	O
different	O
forms	O
of	O
the	O
accessory	O
gp3	B-PRGE
canine	I-PRGE
coronavirus	I-PRGE
type	I-PRGE
I	I-PRGE
protein	I-PRGE
identified	O
in	O
cats	O
.	O

In	O
cell	O
culture	O
,	O
activation	O
of	O
Ebola	O
virus	O
,	O
as	O
well	O
as	O
SARS	O
-	O
and	O
MERS	O
-	O
coronavirus	O
can	O
be	O
accomplished	O
by	O
the	O
endosomal	O
cysteine	O
proteases	O
,	O
cathepsin	B-PRGE
L	O
(	O
CTSL	B-PRGE
)	O
and	O
cathepsin	B-PRGE
B	I-PRGE
(	O
CTSB	B-PRGE
).	O

Our	O
results	O
support	O
previous	O
studies	O
that	O
implicate	O
S	B-PRGE
protein	I-PRGE
mutations	O
in	O
the	O
pathogenesis	O
of	O
FIP	O
.	O

Here	O
,	O
we	O
show	O
that	O
MPER	B-PRGE
can	O
undergo	O
self	O
-	O
oligomerization	O
and	O
heteromerization	O
with	O
IFP	O
,	O
events	O
that	O
are	O
Trp	O
-	O
dependent	O
.	O

ABSTRACT	O
:	O
Gut	B-PRGE
health	O
is	O
very	O
important	O
to	O
get	O
maximum	O
returns	O
in	O
terms	O
of	O
weight	O
gain	O
and	O
egg	O
production	O
.	O

The	O
IBV	O
Mass	O
-	O
like	O
genotype	O
was	O
the	O
most	O
prevalent	O
and	O
was	O
detected	O
in	O
79	O
%	O
of	O
the	O
full	B-PRGE
spike	I-PRGE
protein	I-PRGE
S1	I-PRGE
gene	I-PRGE
sequences	I-PRGE
.	O

FCoV	O
seropositivity	O
was	O
also	O
associated	O
with	O
a	O
high	O
white	O
blood	O
cell	O
count	O
,	O
high	O
plasma	B-PRGE
globulin	I-PRGE
,	O
low	O
plasma	O
albumin	B-PRGE
and	O
low	O
blood	O
urea	O
nitrogen	O
.	O

Properties	O
of	O
aptamers	O
allow	O
detecting	O
virus	O
infected	O
cells	O
or	O
viruses	O
themselves	O
and	O
make	O
them	O
competitive	O
to	O
monoclonal	B-PRGE
antibodies	I-PRGE
.	O

TITLE	O
:	O
Arbekacin	O
treatment	O
of	O
a	O
patient	O
infected	O
with	O
a	O
Pseudomonas	O
putida	O
producing	O
a	O
metallo	B-PRGE
-	I-PRGE
beta	I-PRGE
-	I-PRGE
lactamase	I-PRGE
.	O

We	O
encountered	O
a	O
case	O
of	O
pneumonia	O
caused	O
by	O
a	O
Pseudomonas	O
strain	O
producing	O
a	O
metallo	B-PRGE
-	I-PRGE
beta	I-PRGE
-	I-PRGE
lactamase	I-PRGE
;	O
the	O
patient	O
was	O
successfully	O
treated	O
with	O
arbekacin	O
.	O

Strains	O
of	O
P	O
.	O
putida	O
producing	O
metallo	B-PRGE
-	I-PRGE
beta	I-PRGE
-	I-PRGE
lactamases	I-PRGE
have	O
become	O
more	O
widespread	O
in	O
recent	O
years	O
.	O

Spatially	O
invariant	O
residues	O
in	O
the	O
N6	O
and	O
influenza	O
B	B-PRGE
neuraminidase	I-PRGE
active	O
sites	O
were	O
found	O
in	O
previously	O
unidentified	O
spatially	O
equivalent	O
sites	O
in	O
the	O
N10	O
and	O
N11	O
proteins	O
.	O

ABSTRACT	O
:	O
Protein	B-PRGE
histochemistry	I-PRGE
is	O
a	O
tissue	O
-	O
based	O
technique	O
that	O
enables	O
the	O
analysis	O
of	O
viral	O
attachment	O
patterns	O
as	O
well	O
as	O
the	O
identification	O
of	O
specific	O
viral	O
and	O
host	O
determinants	O
involved	O
in	O
the	O
first	O
step	O
in	O
the	O
infection	O
of	O
a	O
host	O
cell	O
by	O
a	O
virus	O
.	O

HIV	O
infected	O
patients	O
with	O
ARDS	O
and	O
MDR	B-PRGE
bacterial	O
VAP	O
whose	O
HIV	O
replication	O
is	O
controlled	O
by	O
ART	O
could	O
be	O
successfully	O
managed	O
with	O
ECMO	O
.	O

Goat	B-PRGE
anti	I-PRGE
-	I-PRGE
turkey	I-PRGE
IgG	I-PRGE
(	O
H	O
+	O
L	O
)	O
conjugated	O
with	O
horseradish	B-PRGE
peroxidase	I-PRGE
was	O
used	O
as	O
detector	O
antibody	O
.	O

The	O
optimum	O
conditions	O
for	O
differentiation	O
between	O
anti	O
-	O
TCoV	O
hyperimmune	O
serum	O
and	O
normal	O
turkey	O
serum	O
were	O
recombinant	B-PRGE
TCoV	I-PRGE
N	I-PRGE
protein	I-PRGE
concentration	O
at	O
20	O
μg	O
/	O
ml	O
,	O
serum	O
dilution	O
at	O
1	O
:	O
800	O
,	O
and	O
conjugate	O
dilution	O
at	O
1	O
:	O
10	O
,	O
000	O
.	O

TITLE	O
:	O
Inhibitor	O
recognition	O
specificity	O
of	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
papain	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
may	O
differ	O
from	O
that	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
ABSTRACT	O
:	O
The	O
Middle	O
East	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
PLpro	O
)	O
blocking	O
loop	O
2	O
(	O
BL2	O
)	O
structure	O
differs	O
significantly	O
from	O
that	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
PLpro	I-PRGE
,	O
where	O
it	O
has	O
been	O
proven	O
to	O
play	O
a	O
crucial	O
role	O
in	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
PLpro	I-PRGE
inhibitor	O
binding	O
.	O

The	O
effects	O
of	O
the	O
recombinant	B-PRGE
human	I-PRGE
interferon	I-PRGE
alpha	I-PRGE
2b	I-PRGE
on	O
influenza	O
B	O
virus	O
,	O
parainfluenza	O
virus	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
and	O
coronavirus	O
were	O
detected	O
using	O
cytopathic	O
effect	O
(	O
CPE	O
)	O
method	O
.	O

In	O
this	O
study	O
,	O
the	O
therapeutic	O
index	O
of	O
recombinant	B-PRGE
human	I-PRGE
interferon	I-PRGE
alpha	I-PRGE
2b	I-PRGE
anti	O
-	O
HPIV	O
was	O
1476	O
.	O
63	O
,	O
the	O
therapeutic	O
index	O
of	O
recombinant	B-PRGE
human	I-PRGE
interferon	I-PRGE
alpha	I-PRGE
2b	I-PRGE
anti	I-PRGE
-	I-PRGE
RSV	I-PRGE
was	O
141	O
.	O
37	O
,	O
the	O
therapeutic	O
index	O
of	O
recombinant	B-PRGE
human	I-PRGE
interferon	I-PRGE
alpha	I-PRGE
2b	I-PRGE
anti	O
-	O
coronavirus	O
was	O
more	O
than	O
2820	O
.	O
76	O
,	O
and	O
the	O
antiviral	O
effect	O
of	O
recombinant	B-PRGE
human	I-PRGE
interferon	I-PRGE
alpha	I-PRGE
2b	I-PRGE
was	O
better	O
than	O
ribavirin	O
(	O
RBV	O
).	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
GAIT	B-PRGE
-	I-PRGE
like	I-PRGE
motif	I-PRGE
described	O
in	O
a	O
positive	O
RNA	O
virus	O
.	O

To	O
test	O
the	O
functional	O
role	O
of	O
the	O
GAIT	B-PRGE
-	I-PRGE
like	I-PRGE
RNA	I-PRGE
motif	I-PRGE
during	O
TGEV	O
infection	O
,	O
a	O
recombinant	O
coronavirus	O
harboring	O
mutations	O
in	O
this	O
motif	O
was	O
engineered	O
and	O
characterized	O
.	O

Mutations	O
of	O
the	O
GAIT	B-PRGE
-	I-PRGE
like	I-PRGE
RNA	I-PRGE
motif	I-PRGE
did	O
not	O
affect	O
virus	O
growth	O
in	O
cell	O
cultures	O
.	O

Moreover	O
,	O
the	O
disruption	O
of	O
the	O
viral	O
GAIT	O
-	O
like	O
RNA	O
motif	O
led	O
to	O
an	O
exacerbated	O
innate	O
immune	O
response	O
triggered	O
by	O
MDA5	B-PRGE
,	O
indicating	O
that	O
the	O
GAIT	B-PRGE
-	I-PRGE
like	I-PRGE
RNA	I-PRGE
motif	I-PRGE
counteracts	O
the	O
host	O
innate	O
immune	O
response	O
.	O

Sporadic	O
human	O
cases	O
of	O
avian	B-PRGE
A	I-PRGE
(	I-PRGE
H5N6	I-PRGE
),	I-PRGE
A	I-PRGE
(	I-PRGE
H10N8	I-PRGE
)	I-PRGE
and	I-PRGE
A	I-PRGE
(	O
H6N1	O
)	O
have	O
also	O
emerged	O
.	O

There	O
has	O
been	O
significant	O
concern	O
that	O
a	O
relatively	O
recently	O
described	O
pneumonia	O
category	O
,	O
HCAP	B-PRGE
,	O
requires	O
empirical	O
treatment	O
for	O
potentially	O
multidrug	O
-	O
resistant	O
organisms	O
(	O
MDRO	O
).	O

PEDV	O
recognizes	O
protein	B-PRGE
receptor	I-PRGE
aminopeptidase	I-PRGE
N	I-PRGE
from	O
pig	O
and	O
human	O
and	O
sugar	O
coreceptor	O
N	O
-	O
acetylneuraminic	O
acid	O
.	O

Severely	O
ill	O
patients	O
with	O
H7N9	O
had	O
significantly	O
longer	O
interval	O
from	O
onset	O
of	O
illness	O
to	O
neuraminidase	B-PRGE
inhibitor	O
treatment	O
and	O
to	O
death	O
.	O

RESULTS	O
:	O
At	O
ARDS	O
onset	O
,	O
173	O
patients	O
had	O
a	O
PaO₂	B-PRGE
/	O
FiO₂	O
≤	O
100	O
but	O
only	O
38	O
.	O
7	O
%	O
met	O
criteria	O
for	O
severe	O
ARDS	O
at	O
24	O
h	O
under	O
SVS	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
elucidate	O
the	O
possible	O
presence	O
of	O
oxidative	O
stress	O
in	O
cats	O
naturally	O
affected	O
by	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
)	O
by	O
investigating	O
two	O
antioxidant	O
biomarkers	O
in	O
serum	O
:	O
paraoxonase	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
PON1	B-PRGE
)	O
and	O
total	O
antioxidant	O
capacity	O
(	O
TAC	O
).	O

Only	O
2	O
close	O
contacts	O
out	O
of	O
the	O
54	O
screened	O
(	O
3	O
.	O
7	O
%)	O
were	O
positive	O
for	O
MERS	O
CoV	O
.	O
Treatment	O
with	O
ribavirin	O
and	O
IFN	B-PRGE
-	I-PRGE
a2b	I-PRGE
may	O
be	O
effective	O
in	O
patients	O
infected	O
with	O
MERS	O
CoV	O
.	O
There	O
appears	O
to	O
be	O
a	O
low	O
infectivity	O
rate	O
among	O
close	O
contacts	O
of	O
MERS	O
CoV	O
patients	O
.	O

The	O
S2	O
subunit	O
was	O
considerably	O
more	O
variable	O
containing	O
87	O
%	O
of	O
the	O
polymorphisms	O
detected	O
across	O
the	O
entire	O
S	B-PRGE
protein	I-PRGE
.	O

Given	O
the	O
lack	O
of	O
diversity	O
observed	O
at	O
the	O
sub	O
-	O
consensus	O
level	O
,	O
the	O
tenet	O
that	O
the	O
HVRs	O
in	O
the	O
S1	B-PRGE
subunit	I-PRGE
are	O
very	O
tolerant	O
of	O
amino	O
acid	O
changes	O
produced	O
by	O
genetic	O
drift	O
is	O
questioned	O
.	O

As	O
the	O
spike	O
protein	O
,	O
especially	O
in	O
the	O
hypervariable	O
regions	O
of	O
the	O
S1	B-PRGE
domain	I-PRGE
,	O
of	O
IBVs	O
contains	O
viral	O
neutralizing	O
epitopes	O
,	O
the	O
results	O
of	O
this	O
study	O
showed	O
that	O
recombination	O
of	O
the	O
S1	B-PRGE
domain	I-PRGE
resulted	O
in	O
the	O
emergence	O
of	O
a	O
new	O
serotype	O
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
phenylpropanoid	O
derivatives	O
were	O
synthesized	O
,	O
and	O
their	O
anti	O
-	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
activity	O
was	O
evaluated	O
in	O
HepG	B-PRGE
2	I-PRGE
.	I-PRGE
2	I-PRGE
.	O
15	O
cells	O
.	O

Pulmonary	O
endothelial	O
dysfunction	O
was	O
ascertained	O
by	O
bronchoalveolar	O
lavage	O
protein	O
content	O
and	O
lung	O
tissue	O
expression	O
of	O
endothelial	B-PRGE
junctional	I-PRGE
protein	I-PRGE
Vascular	B-PRGE
Endothelial	I-PRGE
cadherin	I-PRGE
by	O
immunoblotting	O
.	O

To	O
assess	O
the	O
inflammatory	O
response	O
in	O
the	O
lung	O
,	O
we	O
determined	O
bronchoalveolar	O
lavage	O
fluid	O
total	O
cell	O
content	O
and	O
neutrophil	O
fraction	O
by	O
microscopy	O
and	O
staining	O
in	O
addition	O
to	O
Matrix	B-PRGE
-	I-PRGE
Metalloprotease	I-PRGE
-	I-PRGE
9	I-PRGE
by	O
ELISA	O
.	O

Between	O
Dec	B-PRGE
1	I-PRGE
,	O
2012	O
,	O
and	O
Dec	B-PRGE
1	I-PRGE
,	O
2013	O
,	O
we	O
obtained	O
individual	O
serum	O
samples	O
from	O
10	O
,	O
009	O
individuals	O
.	O

The	O
presence	O
of	O
rBeau	O
-	O
H120	O
(	O
S1	O
)	O
was	O
verified	O
by	O
the	O
detection	O
of	O
the	O
replaced	O
ectodomain	O
region	O
of	O
the	O
H120	B-PRGE
Spike	I-PRGE
gene	I-PRGE
using	O
RT	O
-	O
PCR	O
.	O

IgM	B-PRGE
antibody	O
was	O
positive	O
in	O
all	O
the	O
17	O
cases	O
,	O
which	O
included	O
9	O
male	O
cases	O
,	O
8	O
female	O
cases	O
,	O
and	O
their	O
age	O
was	O
from	O
2	O
months	O
to	O
10	O
years	O
.	O

The	O
plasma	O
levels	O
of	O
sRAGE	O
and	O
AQP5	B-PRGE
of	O
the	O
control	O
group	O
were	O
significantly	O
lower	O
than	O
that	O
of	O
experimental	O
group	O
at	O
three	O
time	O
points	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
GATA	B-PRGE
-	I-PRGE
2	I-PRGE
transcription	I-PRGE
factor	I-PRGE
deficiency	O
has	O
recently	O
been	O
described	O
in	O
patients	O
with	O
a	O
propensity	O
towards	O
myeloid	O
malignancy	O
associated	O
with	O
other	O
highly	O
variable	O
phenotypic	O
features	O
:	O
chronic	O
leukocytopenias	O
(	O
dendritic	O
cell	O
-,	O
monocyto	O
-,	O
granulocyto	O
-,	O
lymphocytopenia	O
),	O
increased	O
susceptibility	O
to	O
infections	O
,	O
lymphatic	O
vasculature	O
abnormalities	O
,	O
and	O
sensorineural	O
deafness	O
.	O

When	O
the	O
Berlin	O
or	O
LIS	O
category	O
increased	O
,	O
albumin	B-PRGE
levels	O
decreased	O
≥	O
1	O
g	O
/	O
L	O
(	O
AUROC	O
0	O
.	O
72	O
-	O
0	O
.	O
77	O
,	O
P	O
=	O
0	O
.	O
001	O
)	O
and	O
CRP	B-PRGE
increased	O
≥	O
104	O
mg	O
/	O
L	O
(	O
only	O
significant	O
for	O
Berlin	O
,	O
AUROC	O
0	O
.	O
69	O
,	O
P	O
=	O
0	O
.	O
04	O
).	O

Albumin	B-PRGE
levels	O
below	O
20	O
g	O
/	O
L	O
as	O
well	O
as	O
a	O
decline	O
over	O
a	O
week	O
are	O
associated	O
with	O
ARDS	O
of	O
increasing	O
severity	O
,	O
irrespective	O
of	O
its	O
definition	O
.	O

LDH	B-PRGE
levels	O
predicted	O
28	O
-	O
day	O
mortality	O
.	O

The	O
bioscreeening	O
assay	O
showed	O
that	O
most	O
compounds	O
inhibited	O
LPS	O
-	O
induced	O
production	O
of	O
TNF	B-PRGE
-	I-PRGE
α	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
.	O

The	O
active	O
compounds	O
,	O
a17	O
,	O
a18	B-PRGE
,	O
c9	O
and	O
c26	O
,	O
exhibited	O
their	O
anti	O
-	O
inflammatory	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
exhibited	O
greater	O
stability	O
than	O
curcumin	O
in	O
vitro	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
synthesized	O
30	O
overlapping	O
peptides	O
based	O
on	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
S1	B-PRGE
domain	I-PRGE
of	O
the	O
type	O
I	O
FIPV	O
strain	O
KU	O
-	O
2	O
S	O
protein	O
,	O
and	O
investigated	O
their	O
inhibitory	O
effects	O
on	O
FIPV	O
infection	O
.	O

TITLE	O
:	O
IFN	B-PRGE
-	I-PRGE
α2a	I-PRGE
or	O
IFN	B-PRGE
-	I-PRGE
β1a	I-PRGE
in	O
combination	O
with	O
ribavirin	O
to	O
treat	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
pneumonia	O
:	O
a	O
retrospective	O
study	O
.	O

With	O
the	O
combined	O
use	O
of	O
intravenous	O
immunoglobulin	B-PRGE
,	O
rituximab	O
and	O
plasma	O
exchange	O
,	O
we	O
achieved	O
rapid	O
clearance	O
of	O
the	O
factor	O
V	O
inhibitor	O
within	O
1	O
week	O
so	O
as	O
to	O
allow	O
safe	O
decannulation	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

Through	O
yeast	O
two	O
-	O
hybrid	O
screening	O
,	O
we	O
identified	O
eight	B-PRGE
potential	I-PRGE
cellular	I-PRGE
P6	I-PRGE
-	I-PRGE
interacting	I-PRGE
proteins	I-PRGE
from	O
a	O
human	O
spleen	O
cDNA	O
library	O
.	O

This	O
demonstrated	O
a	O
delayed	O
production	O
of	O
IgG	B-PRGE
and	O
IgA	B-PRGE
plasma	O
antibodies	O
in	O
the	O
1	O
,	O
7	O
and	O
14	O
-	O
day	O
-	O
old	O
vaccination	O
groups	O
and	O
also	O
lower	O
IgA	B-PRGE
antibody	I-PRGE
levels	O
were	O
observed	O
in	O
plasma	O
of	O
the	O
1	O
-	O
day	O
-	O
old	O
group	O
.	O

The	O
delayed	O
and	O
/	O
or	O
lower	O
antibody	O
response	O
combined	O
with	O
lower	O
IgG	B-PRGE
avidity	O
indices	O
coincided	O
with	O
increased	O
tracheal	O
inflammation	O
and	O
depletion	O
of	O
tracheal	O
epithelia	O
cells	O
and	O
goblet	O
cells	O
upon	O
IBV	O
field	O
strain	O
challenge	O
.	O

Reverse	B-PRGE
transcriptase	I-PRGE
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
on	O
formalin	O
fixed	O
paraffin	O
embedded	O
tissue	O
from	O
the	O
lung	O
,	O
spleen	O
,	O
and	O
kidney	O
was	O
negative	O
for	O
FRSCV	O
and	O
positive	O
for	O
ferret	O
enteric	O
coronavirus	O
(	O
FRECV	O
).	O

Results	O
from	O
the	O
first	O
swab	O
sample	O
were	O
inconclusive	O
while	O
the	O
second	O
swab	O
was	O
strongly	O
positive	O
for	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
by	O
rRT	O
-	O
PCR	O
and	O
confirmed	O
positive	O
by	O
RT	O
-	O
PCR	O
and	O
partial	O
gene	O
sequencing	O
.	O

Platelet	O
counts	O
in	O
ECMO	O
-	O
treated	O
patients	O
,	O
but	O
not	O
in	O
those	O
treated	O
with	O
iLA	B-PRGE
,	O
dropped	O
significantly	O
during	O
extracorporeal	O
support	O
.	O

TITLE	O
:	O
A	O
small	O
region	O
of	O
porcine	B-PRGE
hemagglutinating	I-PRGE
encephalomyelitis	I-PRGE
virus	I-PRGE
spike	I-PRGE
protein	I-PRGE
interacts	O
with	O
the	O
neural	B-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
.	O

The	O
interaction	O
between	O
S	O
(	O
1	O
-	O
291	O
),	O
S	O
(	O
277	O
-	O
794	O
),	O
S	O
(	O
548	O
-	O
868	O
)	O
and	O
NCAM	B-PRGE
were	O
detected	O
by	O
a	O
GST	B-PRGE
pull	O
-	O
down	O
experiment	O
and	O
yeast	O
two	O
-	O
hybrid	O
assay	O
.	O

Pretreatment	O
of	O
RD	O
cells	O
with	O
neuraminidase	B-PRGE
(	O
NA	O
)	O
and	O
trypsin	B-PRGE
greatly	O
reduced	O
the	O
binding	O
,	O
suggesting	O
that	O
the	O
binding	O
was	O
mediated	O
by	O
sialic	O
acids	O
on	O
glycoproteins	O
.	O

Human	B-PRGE
coronaviruses	I-PRGE
(	O
hCoV	O
)	O
are	O
important	O
human	O
respiratory	O
pathogens	O
.	O

Identification	O
of	O
EBOV	O
VP35	O
inhibitors	O
requires	O
a	O
cellular	O
system	O
able	O
to	O
assess	O
the	O
VP35	O
-	O
based	O
inhibitory	O
functions	O
of	O
viral	O
double	O
-	O
stranded	O
RNA	O
(	O
dsRNA	O
)	O
IFN	B-PRGE
-	I-PRGE
β	I-PRGE
induction	O
.	O

Further	O
studies	O
reproduced	O
the	O
binding	O
pose	O
of	O
16R	O
within	O
the	O
active	O
site	O
of	O
the	O
generated	O
model	O
,	O
where	O
its	O
free	O
energy	O
of	O
binding	O
was	O
shown	O
to	O
equal	O
that	O
of	O
the	O
3CL	O
(	O
pro	O
)	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
a	O
receptor	O
it	O
is	O
experimentally	O
proven	O
to	O
inhibit	O
.	O

TITLE	O
:	O
Prediction	O
of	O
respiratory	O
disease	O
and	O
diarrhea	O
in	O
veal	O
calves	O
based	O
on	O
immunoglobulin	B-PRGE
levels	O
and	O
the	O
serostatus	O
for	O
respiratory	O
pathogens	O
measured	O
at	O
arrival	O
.	O

Therefore	O
,	O
the	O
first	O
objective	O
of	O
this	O
prospective	O
longitudinal	O
cohort	O
study	O
was	O
to	O
determine	O
associations	O
between	O
serum	O
protein	O
fractions	O
as	O
determined	O
by	O
routine	O
electrophoresis	O
(	O
total	O
protein	O
,	O
albumin	B-PRGE
,	O
alpha	B-PRGE
-	I-PRGE
1	I-PRGE
and	I-PRGE
-	I-PRGE
2	I-PRGE
globulins	I-PRGE
,	O
beta	B-PRGE
-	I-PRGE
globulins	I-PRGE
and	O
Ig	O
'	O
s	O
)	O
at	O
arrival	O
and	O
BRD	O
and	O
NCD	O
in	O
the	O
first	O
3	O
weeks	O
of	O
the	O
production	O
cycle	O
.	O

While	O
uninoculated	O
or	O
inoculated	O
27	O
-	O
31	O
-	O
day	O
-	O
old	O
pigs	O
showed	O
large	O
numbers	O
of	O
Ki67	O
-	O
or	O
LGR5	O
-	O
positive	O
cells	O
in	O
the	O
intestinal	O
crypts	O
,	O
there	O
was	O
a	O
lack	O
of	O
LGR5	B-PRGE
-	O
positive	O
cells	O
and	O
low	O
proliferation	O
of	O
crypts	O
in	O
jejunum	O
of	O
uninoculated	O
10	O
-	O
14	O
-	O
day	O
-	O
old	O
piglets	O
,	O
possibly	O
causing	O
a	O
slower	O
turnover	O
of	O
enterocytes	O
;	O
however	O
,	O
the	O
number	O
of	O
LGR5	B-PRGE
-	O
positive	O
cells	O
and	O
proliferation	O
of	O
intestinal	O
crypts	O
increased	O
remarkably	O
at	O
3	O
-	O
5	O
days	O
after	O
inoculation	O
.	O

He	O
was	O
treated	O
with	O
non	O
-	O
invasive	O
positive	O
pressure	O
ventilation	O
and	O
a	O
neutrophil	B-PRGE
elastase	I-PRGE
inhibitor	O
,	O
which	O
dramatically	O
alleviated	O
his	O
symptoms	O
and	O
improved	O
his	O
oxygenation	O
.	O

ABSTRACT	O
:	O
Diffuse	O
alveolar	O
damage	O
(	O
DAD	O
)	O
is	O
the	O
pathological	O
hallmark	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
however	O
,	O
the	O
presence	O
of	O
DAD	B-PRGE
in	O
the	O
clinical	O
criteria	O
of	O
ARDS	O
patients	O
by	O
Berlin	O
definition	O
is	O
little	O
known	O
.	O

Seven	O
IBV	O
variants	O
,	O
isolated	O
from	O
2008	O
to	O
2009	O
,	O
were	O
clustered	O
in	O
the	O
Thailand	O
THA001	O
group	O
I	O
while	O
15	O
IBV	O
variants	O
,	O
isolated	O
from	O
2009	O
to	O
2013	O
,	O
were	O
classified	O
into	O
the	O
QX	B-PRGE
-	I-PRGE
like	I-PRGE
group	I-PRGE
II	I-PRGE
.	O

Extracellular	O
histone	O
appearance	O
required	O
both	O
C5a	B-PRGE
receptors	I-PRGE
(	O
C5aR	B-PRGE
,	O
C5L2	B-PRGE
)	O
as	O
well	O
as	O
neutrophils	O
(	O
PMNs	O
)	O
and	O
lung	O
macrophages	O
,	O
as	O
genetic	O
loss	O
of	O
either	O
C5a	B-PRGE
receptor	I-PRGE
or	O
depletion	O
of	O
PMNs	O
or	O
macrophages	O
reduced	O
histone	B-PRGE
levels	O
found	O
in	O
BALF	O
during	O
ALI	O
.	O

Here	O
,	O
we	O
describe	O
the	O
establishment	O
of	O
tissue	O
-	O
like	O
assemblies	O
for	O
human	O
lung	O
and	O
neuronal	O
tissue	O
that	O
we	O
infected	O
with	O
a	O
variety	O
of	O
viruses	O
including	O
the	O
respiratory	O
pathogens	O
human	O
parainfluenza	O
virus	O
type	O
3	O
(	O
PIV3	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
and	O
SARS	O
corona	O
virus	O
(	O
SARS	O
-	O
CoV	O
)	O
as	O
well	O
as	O
the	O
human	B-PRGE
neurotropic	I-PRGE
herpesvirus	I-PRGE
,	I-PRGE
varicella	I-PRGE
-	I-PRGE
zoster	I-PRGE
virus	I-PRGE
(	I-PRGE
VZV	I-PRGE
).	I-PRGE

TITLE	O
:	O
Experimental	O
design	O
of	O
complement	O
component	O
5a	O
-	O
induced	O
acute	O
lung	O
injury	O
(	O
C5a	O
-	O
ALI	O
):	O
a	O
role	O
of	O
CC	B-PRGE
-	I-PRGE
chemokine	I-PRGE
receptor	I-PRGE
type	I-PRGE
5	I-PRGE
during	O
immune	O
activation	O
by	O
anaphylatoxin	O
.	O

Equimolar	O
concentrations	O
of	O
C3a	O
or	O
desarginated	O
C5a	B-PRGE
(	O
C5a	B-PRGE
(	O
desArg	O
))	O
did	O
not	O
induce	O
alveolar	O
inflammation	O
.	O

Moreover	O
,	O
treatment	O
with	O
a	O
CCR5	B-PRGE
antagonist	O
,	O
maraviroc	O
,	O
was	O
protective	O
against	O
C5a	B-PRGE
-	I-PRGE
ALI	I-PRGE
.	O

TITLE	O
:	O
Toll	O
-	O
Like	O
Receptor	O
3	O
Signaling	O
via	O
TRIF	B-PRGE
Contributes	O
to	O
a	O
Protective	O
Innate	O
Immune	O
Response	O
to	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Coronavirus	O
Infection	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
TLR3	B-PRGE
(-/-),	O
TLR4	B-PRGE
(-/-),	O
and	O
TRAM	O
(-/-)	O
mice	O
are	O
more	O
susceptible	O
to	O
SARS	O
-	O
CoV	O
than	O
wild	O
-	O
type	O
mice	O
but	O
experience	O
only	O
transient	O
weight	O
loss	O
with	O
no	O
mortality	O
in	O
response	O
to	O
infection	O
.	O

Hepatocyte	B-PRGE
growth	I-PRGE
factor	I-PRGE
(	O
HGF	B-PRGE
)/	O
c	B-PRGE
-	I-PRGE
Met	I-PRGE
and	O
transforming	B-PRGE
growth	I-PRGE
factor	I-PRGE
-	I-PRGE
α	I-PRGE
(	O
TGF	O
-	O
α	O
)/	O
epidermal	B-PRGE
growth	I-PRGE
factor	I-PRGE
receptor	I-PRGE
(	O
EGFR	B-PRGE
)	O
are	O
well	O
known	O
to	O
regulate	O
repair	O
of	O
damaged	O
alveolar	O
epithelium	O
by	O
stimulating	O
cell	O
migration	O
and	O
proliferation	O
.	O

PubMed	O
,	O
EMBASE	O
,	O
CINAHL	O
,	O
SCOPUS	O
,	O
and	O
the	O
Cochrane	O
Library	O
were	O
searched	O
from	O
inception	O
until	O
January	O
2013	O
using	O
the	O
following	O
keywords	O
in	O
various	O
combinations	O
:	O
ARDS	O
,	O
treatment	O
,	O
nitric	O
oxide	O
,	O
heliox	O
,	O
steroids	O
,	O
surfactant	O
,	O
etanercept	O
,	O
prostaglandin	O
therapy	O
,	O
inhaled	O
beta	B-PRGE
adrenergic	I-PRGE
receptor	I-PRGE
agonists	O
,	O
N	O
-	O
acetylcysteine	O
,	O
ipratroprium	O
bromide	O
,	O
dornase	O
,	O
plasminogen	B-PRGE
activators	I-PRGE
,	O
fibrinolytics	O
or	O
other	O
anticoagulants	O
,	O
and	O
children	O
.	O

The	O
attachment	O
pattern	O
of	O
the	O
hemagglutinin	B-PRGE
protein	I-PRGE
was	O
in	O
line	O
with	O
the	O
reported	O
tropism	O
of	O
influenza	O
virus	O
H5N1	O
,	O
confirming	O
the	O
validity	O
of	O
TMAs	O
in	O
profiling	O
the	O
initial	O
virus	O
-	O
host	O
interaction	O
.	O

Protein	B-PRGE
kinases	I-PRGE
are	O
key	O
regulators	O
in	O
signal	O
transduction	O
,	O
controlling	O
a	O
wide	O
variety	O
of	O
cellular	O
processes	O
,	O
and	O
many	O
of	O
them	O
are	O
targets	O
of	O
approved	O
drugs	O
and	O
other	O
compounds	O
.	O

Previous	O
studies	O
showed	O
that	O
the	O
2	O
'-	O
O	O
-	O
MTase	O
activity	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nonstructural	B-PRGE
protein	I-PRGE
16	I-PRGE
(	O
nsp16	O
)	O
needs	O
to	O
be	O
activated	O
by	O
nsp10	O
,	O
whereas	O
nsp16	O
of	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
alone	O
possesses	O
2	O
'-	O
O	B-PRGE
-	I-PRGE
MTase	I-PRGE
activity	O
(	O
E	O
.	O
Decroly	O
et	O
al	O
.,	O
J	O
Virol	O
82	O
:	O
8071	O
-	O
8084	O
,	O
2008	O
,	O
http	O
://	O
dx	O
.	O
doi	O
.	O
org	O
/	O
10	O
.	O
1128	O
/	O
JVI	O
.	O
00407	O
-	O
08	O
;	O
M	O
.	O
Bouvet	O
et	O
al	O
.,	O
PLoS	O
Pathog	O
6	O
:	O
e1000863	O
,	O
2010	O
,	O
http	O
://	O
dx	O
.	O
doi	O
.	O
org	O
/	O
10	O
.	O
1371	O
/	O
journal	O
.	O
ppat	O
.	O
1000863	O
;	O
E	O
.	O
Decroly	O
et	O
al	O
.,	O
PLoS	O
Pathog	O
7	O
:	O
e1002059	O
,	O
2011	O
,	O
http	O
://	O
dx	O
.	O
doi	O
.	O
org	O
/	O
10	O
.	O
1371	O
/	O
journal	O
.	O
ppat	O
.	O
1002059	O
;	O
Y	O
.	O
Chen	O
et	O
al	O
.,	O
PLoS	O
Pathog	O
7	O
:	O
e1002294	O
,	O
2011	O
,	O
http	O
://	O
dx	O
.	O
doi	O
.	O
org	O
/	O
10	O
.	O
1371	O
/	O
journal	O
.	O
ppat	O
.	O
1002294	O
)	O
.	O

Based	O
on	O
our	O
current	O
and	O
previous	O
studies	O
,	O
we	O
designed	O
a	O
peptide	O
(	O
TP29	O
)	O
from	O
the	O
sequence	O
of	O
the	O
interaction	O
interface	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
nsp10	O
and	O
demonstrated	O
that	O
the	O
peptide	O
inhibits	O
the	O
2	B-PRGE
'-	I-PRGE
O	I-PRGE
-	I-PRGE
MTase	I-PRGE
activity	O
of	O
different	O
coronaviruses	O
in	O
biochemical	O
assays	O
and	O
the	O
viral	O
replication	O
in	O
MHV	O
infection	O
and	O
SARS	O
-	O
CoV	O
replicon	O
models	O
.	O

By	O
combining	O
this	O
high	O
temperature	O
isothermal	O
amplification	O
method	O
with	O
a	O
thermostable	O
invertase	B-PRGE
,	O
we	O
can	O
directly	O
transduce	O
Middle	O
-	O
East	O
respiratory	O
syndrome	O
coronavirus	O
and	O
Zaire	O
Ebolavirus	O
templates	O
into	O
glucose	O
signals	O
,	O
with	O
a	O
sensitivity	O
as	O
low	O
as	O
20	O
-	O
100	O
copies	O
/	O
μl	O
,	O
equating	O
to	O
atto	O
-	O
molar	O
(	O
or	O
low	O
zepto	O
-	O
mole	O
).	O

The	O
present	O
review	O
will	O
be	O
focused	O
on	O
recent	O
structural	O
and	O
protein	O
-	O
protein	O
interaction	O
information	O
involving	O
two	O
viroporins	O
found	O
in	O
enveloped	O
viruses	O
that	O
target	O
the	O
respiratory	O
tract	O
;	O
(	O
i	O
)	O
the	O
envelope	B-PRGE
protein	I-PRGE
in	O
coronaviruses	O
and	O
(	O
ii	O
)	O
the	O
small	O
hydrophobic	O
protein	O
in	O
paramyxoviruses	O
.	O

Peptidomimetic	O
inhibitors	O
of	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
were	O
synthesized	O
and	O
utilized	O
in	O
analytical	O
ultracentrifugation	O
experiments	O
and	O
demonstrate	O
that	O
MERS	O
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
undergoes	O
significant	O
ligand	O
-	O
induced	O
dimerization	O
.	O

Interactions	O
between	O
Mo	B-PRGE
-	I-PRGE
DCs	I-PRGE
and	O
CV777	O
significantly	O
influence	O
the	O
stimulation	O
of	O
the	O
T	O
cell	O
response	O
in	O
vitro	O
.	O

ABSTRACT	O
:	O
Anthrax	O
is	O
associated	O
with	O
severe	O
vascular	O
leak	O
,	O
which	O
is	O
caused	O
by	O
the	O
bacterial	O
lethal	B-PRGE
toxin	I-PRGE
(	O
LeTx	O
).	O

TITLE	O
:	O
Endothelin	B-PRGE
-	I-PRGE
1	I-PRGE
induces	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
-	O
mediated	O
inflammation	O
via	O
receptor	B-PRGE
tyrosine	I-PRGE
kinases	I-PRGE
and	O
Elk	B-PRGE
/	O
p300	B-PRGE
in	O
human	O
tracheal	O
smooth	O
muscle	O
cells	O
.	O

Here	O
we	O
reported	O
that	O
ET	B-PRGE
-	I-PRGE
1	I-PRGE
stimulated	O
expression	O
of	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
gene	I-PRGE
on	O
HTSMCs	O
,	O
which	O
was	O
blocked	O
by	O
pretreatment	O
with	O
the	O
inhibitors	O
of	O
ET	O
receptors	O
,	O
Src	B-PRGE
,	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
),	O
epidermal	B-PRGE
growth	I-PRGE
factor	I-PRGE
receptor	I-PRGE
(	O
EGFR	B-PRGE
),	O
platelet	B-PRGE
-	I-PRGE
derived	I-PRGE
growth	I-PRGE
factor	I-PRGE
receptor	I-PRGE
(	O
PDGFR	B-PRGE
),	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI3K	B-PRGE
),	O
AKT	B-PRGE
,	O
MEK1	B-PRGE
/	I-PRGE
2	I-PRGE
,	O
and	O
p300	B-PRGE
,	O
suggesting	O
the	O
participation	O
of	O
these	O
signaling	O
components	O
in	O
ET	O
-	O
1	O
-	O
regulated	O
HTSMC	O
responses	O
.	O

Furthermore	O
,	O
transfection	O
with	O
small	O
-	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
of	O
Src	B-PRGE
,	O
AKT	B-PRGE
,	O
p42	B-PRGE
mitogen	B-PRGE
-	I-PRGE
activated	I-PRGE
protein	I-PRGE
kinase	I-PRGE
(	O
MAPK	B-PRGE
),	O
or	O
p300	B-PRGE
downregulated	O
the	O
respective	O
proteins	O
and	O
significantly	O
attenuated	O
ET	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
induced	O
VCAM	B-PRGE
-	I-PRGE
1	I-PRGE
expression	O
.	O

Preincubation	O
of	O
HTBE	O
cells	O
with	O
a	O
truncated	O
HKU1	B-PRGE
S	I-PRGE
protein	I-PRGE
that	O
includes	O
the	O
C	O
domain	O
blocked	O
infection	O
with	O
HKU1	O
virus	O
,	O
but	O
preincubation	O
of	O
cells	O
with	O
truncated	B-PRGE
S	I-PRGE
protein	I-PRGE
containing	O
only	O
the	O
NTD	O
did	O
not	O
block	O
infection	O
.	O

These	O
data	O
suggest	O
that	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
HKU1	B-PRGE
spike	I-PRGE
protein	I-PRGE
is	O
located	O
in	O
the	O
C	O
domain	O
,	O
where	O
the	O
spike	O
proteins	O
of	O
α	O
-	O
CoVs	O
and	O
β	O
-	O
CoVs	O
in	O
groups	O
B	O
and	O
C	O
bind	O
to	O
their	O
specific	O
receptor	O
proteins	O
.	O

The	O
replication	O
of	O
MHV	O
increased	O
when	O
the	O
N	O
proteins	O
were	O
expressed	O
in	O
trans	O
,	O
while	O
knockdown	O
of	O
Dicer1	B-PRGE
or	O
Ago2	B-PRGE
transcripts	I-PRGE
facilitated	O
the	O
MHV	O
replication	O
in	O
mammalian	O
cells	O
.	O

Using	O
the	O
MHV	O
-	O
A59	O
as	O
the	O
coronavirus	O
replication	O
model	O
,	O
we	O
showed	O
that	O
ectopic	O
expression	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
protein	I-PRGE
could	O
promote	O
MHV	O
replication	O
in	O
RNAi	O
-	O
active	O
cells	O
but	O
not	O
in	O
RNAi	O
-	O
depleted	O
cells	O
.	O

We	O
treated	O
human	O
lung	O
fibroblasts	O
(	O
HLF	O
)	O
with	O
PDGF	B-PRGE
,	O
or	O
TGFβ1	O
,	O
or	O
combined	O
,	O
and	O
examined	O
the	O
activation	O
of	O
p38	B-PRGE
MAPK	O
,	O
p42	B-PRGE
/	O
p44	B-PRGE
MAPK	O
and	O
SMAD3	B-PRGE
.	O

RESULTS	O
:	O
PDGF	B-PRGE
activated	O
p38	B-PRGE
MAPK	O
and	O
p42	B-PRGE
/	O
p44	B-PRGE
MAPK	O
,	O
but	O
not	O
SMAD3	B-PRGE
in	O
HLF	O
cells	O
.	O

A	O
codon	O
-	O
optimized	O
PEDV	B-PRGE
S1	I-PRGE
gene	I-PRGE
consisting	O
of	O
amino	O
acid	O
residues	O
25	O
-	O
749	O
was	O
synthesized	O
and	O
used	O
to	O
establish	O
a	O
stable	O
porcine	O
cell	O
line	O
constitutively	O
expressing	O
a	O
recombinant	B-PRGE
PEDV	I-PRGE
S1	I-PRGE
protein	I-PRGE
containing	O
the	O
chicken	B-PRGE
immunoglobulin	I-PRGE
Fc	I-PRGE
fragment	I-PRGE
at	O
its	O
C	O
-	O
terminus	O
.	O

The	O
purified	O
recombinant	B-PRGE
S1	I-PRGE
protein	I-PRGE
was	O
found	O
to	O
mediate	O
potent	O
immune	O
responses	O
in	O
immunized	O
hens	O
.	O

Specific	O
chicken	O
IgY	O
against	O
the	O
S1	B-PRGE
protein	I-PRGE
was	O
orally	O
administered	O
to	O
neonatal	O
piglets	O
,	O
and	O
their	O
responses	O
subsequent	O
to	O
a	O
virulent	O
PEDV	O
challenge	O
were	O
monitored	O
.	O

We	O
conducted	O
a	O
phase	O
IIa	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
parallel	O
-	O
group	O
study	O
to	O
evaluate	O
the	O
safety	O
and	O
tolerability	O
of	O
dilmapimod	O
,	O
a	O
novel	O
p38	B-PRGE
mitogen	B-PRGE
-	I-PRGE
activated	I-PRGE
protein	I-PRGE
kinase	I-PRGE
inhibitor	O
,	O
in	O
patients	O
at	O
risk	O
for	O
developing	O
acute	O
respiratory	O
distress	O
syndrome	O
admitted	O
with	O
an	O
Injury	O
Severity	O
Score	O
more	O
than	O
16	O
,	O
excluding	O
head	O
trauma	O
.	O

Likewise	O
,	O
measures	O
of	O
soluble	O
inflammatory	O
markers	O
including	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
C	O
-	O
reactive	O
peptide	O
,	O
interleukin	B-PRGE
-	I-PRGE
8	I-PRGE
,	O
and	O
soluble	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
receptor	I-PRGE
1	I-PRGE
were	O
most	O
different	O
between	O
this	O
dosing	O
arm	O
and	O
placebo	O
.	O

Notably	O
,	O
two	O
members	O
of	O
the	O
heat	B-PRGE
shock	I-PRGE
protein	I-PRGE
70	I-PRGE
family	I-PRGE
were	O
found	O
to	O
be	O
up	O
-	O
regulated	O
in	O
PK	O
-	O
PDCoV	O
-	O
N	O
cells	O
.	O

In	O
a	O
small	O
-	O
molecule	O
screen	O
to	O
identify	O
host	O
mediators	O
of	O
reovirus	O
infection	O
,	O
we	O
found	O
that	O
treatment	O
of	O
cells	O
with	O
5	O
-	O
nonyloxytryptamine	O
(	O
5	O
-	O
NT	O
),	O
a	O
prototype	O
serotonin	B-PRGE
receptor	I-PRGE
agonist	O
,	O
diminished	O
reovirus	O
cytotoxicity	O
.	O

An	O
indirect	O
ELISA	O
assay	O
suggested	O
that	O
when	O
mice	O
were	O
vaccinated	O
with	O
rSPV	O
-	O
SA	O
,	O
the	O
level	O
of	O
IgG	B-PRGE
against	O
TGEV	O
was	O
enhanced	O
dramatically	O
.	O

Each	O
chicken	O
in	O
the	O
control	O
and	O
infected	O
group	O
was	O
intranasally	O
inoculated	O
with	O
0	O
.	O
2	O
mL	O
sterile	O
physiological	O
saline	O
and	O
virus	O
,	O
respectively	O
,	O
after	O
which	O
serum	O
antioxidant	O
parameters	O
and	O
renal	O
XOD	B-PRGE
mRNA	I-PRGE
expression	O
in	O
growing	O
layers	O
were	O
evaluated	O
at	O
8	O
,	O
15	O
and	O
22	O
days	O
post	O
-	O
inoculation	O
(	O
dpi	O
).	O

The	O
results	O
showed	O
that	O
serum	B-PRGE
glutathione	I-PRGE
peroxidase	I-PRGE
and	O
superoxide	B-PRGE
dismutase	I-PRGE
activities	O
in	O
the	O
infected	O
group	O
were	O
significantly	O
lower	O
than	O
in	O
the	O
control	O
group	O
at	O
8	O
and	O
15	O
dpi	O
(	O
p	O
<	O
0	O
.	O
01	O
),	O
while	O
serum	O
malondialdehyde	O
concentrations	O
were	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
01	O
).	O

Here	O
we	O
demonstrate	O
the	O
use	O
of	O
the	O
VelocImmune	O
technology	O
(	O
a	O
mouse	O
that	O
expresses	O
human	B-PRGE
antibody	I-PRGE
-	I-PRGE
variable	I-PRGE
heavy	I-PRGE
chains	I-PRGE
and	O
κ	O
light	O
chains	O
)	O
alongside	O
the	O
VelociGene	O
technology	O
(	O
which	O
allows	O
for	O
rapid	O
engineering	O
of	O
the	O
mouse	O
genome	O
)	O
to	O
quickly	O
develop	O
and	O
evaluate	O
antibodies	O
against	O
an	O
emerging	O
viral	O
disease	O
.	O

This	O
strain	O
with	O
insertions	O
and	O
deletions	O
in	O
the	O
S	B-PRGE
-	I-PRGE
gene	I-PRGE
(	O
so	O
called	O
INDEL	O
strains	O
)	O
was	O
reported	O
to	O
show	O
lower	O
virulence	O
.	O

However	O
,	O
the	O
precise	O
functions	O
of	O
the	O
CoV	B-PRGE
E	I-PRGE
protein	I-PRGE
during	O
infection	O
are	O
still	O
enigmatic	O
.	O

We	O
previously	O
reported	O
that	O
the	O
hydrophobic	O
domain	O
of	O
the	O
IBV	B-PRGE
E	I-PRGE
protein	I-PRGE
,	O
a	O
putative	O
viroporin	O
,	O
causes	O
disruption	O
of	O
the	O
mammalian	O
secretory	O
pathway	O
when	O
exogenously	O
expressed	O
in	O
cells	O
.	O

Myd88	B-PRGE
deficiency	O
also	O
specifically	O
blunted	O
myeloid	O
and	O
CD4	B-PRGE
T	I-PRGE
cell	O
recruitment	O
into	O
the	O
CNS	O
without	O
affecting	O
CD8	B-PRGE
T	I-PRGE
cells	O
.	O

Uncontrolled	O
viral	O
replication	O
in	O
the	O
absence	O
of	O
Myd88	B-PRGE
leads	O
to	O
severe	O
demyelination	O
and	O
pathology	O
despite	O
overall	O
reduced	O
inflammatory	O
responses	O
.	O

The	O
incidence	O
of	O
ARDS	O
was	O
different	O
in	O
different	O
levels	O
of	O
Lac	B-PRGE
,	O
which	O
was	O
5	O
.	O
00	O
%	O
(	O
3	O
/	O
16	O
)	O
at	O
low	O
level	O
of	O
Lac	B-PRGE
(<	O
2	O
.	O
0	O
mmol	O
/	O
L	O
),	O
9	O
.	O
46	O
%	O
(	O
14	O
/	O
148	O
)	O
at	O
middle	O
level	O
of	O
Lac	B-PRGE
(	O
2	O
.	O
0	O
-	O
3	O
.	O
9	O
mmol	O
/	O
L	O
)	O
and	O
17	O
.	O
31	O
%	O
(	O
18	O
/	O
104	O
)	O
at	O
high	O
level	O
of	O
Lac	B-PRGE
(≥	O
4	O
.	O
0	O
mmol	O
/	O
L	O
).	O

LIPS	O
and	O
Lac	B-PRGE
are	O
independent	O
risk	O
factors	O
of	O
ARDS	O
in	O
patients	O
with	O
sepsis	O
in	O
emergency	O
department	O
,	O
which	O
may	O
be	O
a	O
reference	O
for	O
the	O
early	O
clinical	O
diagnosis	O
of	O
ARDS	O
.	O

A	O
pseudotype	O
bearing	O
an	O
S	O
protein	O
with	O
the	O
C	O
-	O
terminal	O
16	O
amino	O
acids	O
deleted	O
(	O
MERSpv	O
-	O
St16	O
)	O
reached	O
a	O
maximum	O
titer	O
that	O
was	O
approximately	O
tenfold	O
higher	O
than	O
that	O
of	O
a	O
pseudotype	O
bearing	O
a	O
non	O
-	O
truncated	O
full	O
-	O
length	O
S	B-PRGE
protein	I-PRGE
.	O

We	O
also	O
examined	O
associations	O
between	O
new	O
-	O
onset	O
AF	O
and	O
markers	O
of	O
inflammation	O
(	O
interleukin	B-PRGE
6	I-PRGE
and	O
interleukin	B-PRGE
8	I-PRGE
),	O
myocardial	O
injury	O
(	O
troponin	B-PRGE
I	I-PRGE
),	O
autonomic	O
activation	O
(	O
epinephrine	O
),	O
and	O
atrial	O
stretch	O
(	O
central	O
venous	O
pressure	O
)	O
as	O
well	O
as	O
other	O
clinical	O
characteristics	O
.	O

Expression	O
of	O
avian	B-PRGE
β	I-PRGE
-	I-PRGE
defensins	I-PRGE
(	O
AvBDs	O
)	O
and	O
Toll	B-PRGE
-	I-PRGE
like	I-PRGE
receptors	I-PRGE
(	O
TLRs	O
)	O
in	O
16	O
tissues	O
of	O
chicken	O
were	O
compared	O
at	O
7	O
days	O
PI	O
.	O

The	O
cleavage	O
site	O
of	O
the	O
HA	B-PRGE
gene	I-PRGE
contained	O
multiple	O
basic	O
amino	O
acids	O
,	O
indicating	O
that	O
the	O
novel	O
H5N6	O
virus	O
was	O
highly	O
pathogenic	O
in	O
chicken	O
.	O

ABSTRACT	O
:	O
The	O
oligoadenylate	B-PRGE
synthetase	I-PRGE
1	I-PRGE
(	O
OAS1	B-PRGE
)	O
enzyme	O
acts	O
as	O
an	O
innate	O
sensor	O
of	O
viral	O
infection	O
and	O
plays	O
a	O
major	O
role	O
in	O
the	O
defense	O
against	O
a	O
wide	O
diversity	O
of	O
viruses	O
.	O

It	O
interacted	O
with	O
the	O
HR1	O
peptide	O
to	O
form	O
stable	O
α	O
-	O
helical	O
complex	O
and	O
blocked	O
six	O
-	O
helix	O
bundle	O
formation	O
between	O
the	O
HR1	O
and	O
HR2	O
domains	O
in	O
the	O
viral	B-PRGE
S	I-PRGE
protein	I-PRGE
.	O

HAdV	O
-	O
B14p1	O
infected	O
cells	O
expressed	O
desmoglein	B-PRGE
2	I-PRGE
(	O
DSG2	B-PRGE
),	O
which	O
has	O
been	O
described	O
as	O
potential	O
receptor	O
for	O
HAdV	O
-	O
B14p1	O
.	O

Moreover	O
,	O
HAdV	O
-	O
B14p1	O
induced	O
proinflammatory	O
chemokines	O
IP	O
-	O
10	O
and	O
I	B-PRGE
-	I-PRGE
Tac	I-PRGE
as	O
potential	O
virulence	O
factors	O
.	O

TITLE	O
:	O
[	O
Clinical	O
efficacy	O
and	O
safety	O
of	O
ulinastatin	B-PRGE
plus	O
octreotide	O
for	O
patients	O
with	O
severe	O
acute	O
pancreatitis	O
].	O

Nearly	O
85	O
.	O
0	O
%	O
of	O
cats	O
had	O
an	O
albumin	B-PRGE
-	I-PRGE
to	I-PRGE
-	I-PRGE
globulin	I-PRGE
(	O
A	O
:	O
G	O
)	O
ratio	O
<	O
0	O
.	O
8	O
,	O
while	O
67	O
.	O
8	O
%	O
had	O
an	O
A	O
:	O
G	O
ratio	O
<	O
0	O
.	O
6	O
.	O

Commonly	O
used	O
laboratory	O
animal	O
species	O
such	O
as	O
Syrian	O
hamsters	O
,	O
mice	O
and	O
ferrets	O
are	O
not	O
susceptible	O
to	O
MERS	O
-	O
CoV	O
,	O
due	O
to	O
differences	O
in	O
the	O
MERS	O
-	O
CoV	O
receptor	O
dipeptidyl	B-PRGE
peptidase	I-PRGE
4	I-PRGE
(	O
DPP4	B-PRGE
).	O

The	O
lopinavir	O
/	O
ritonavir	O
-	O
treated	O
and	O
interferon	B-PRGE
-	I-PRGE
β1b	I-PRGE
-	O
treated	O
animals	O
had	O
better	O
outcome	O
than	O
the	O
untreated	O
animals	O
,	O
with	O
improved	O
clinical	O
(	O
mean	O
clinical	O
scores	O
↓	O
50	O
.	O
9	O
%-	O
95	O
.	O
0	O
%	O
and	O
↓	O
weight	O
loss	O
than	O
the	O
untreated	O
animals	O
),	O
radiological	O
(	O
minimal	O
pulmonary	O
infiltrates	O
),	O
and	O
pathological	O
(	O
mild	O
bronchointerstitial	O
pneumonia	O
)	O
findings	O
,	O
and	O
lower	O
mean	O
viral	O
loads	O
in	O
necropsied	O
lung	O
(↓	O
0	O
.	O
59	O
-	O
1	O
.	O
06	O
log10	O
copies	O
/	O
glyceraldehyde	B-PRGE
3	I-PRGE
-	I-PRGE
phosphate	I-PRGE
dehydrogenase	I-PRGE
[	O
GAPDH	B-PRGE
];	O
P	O
<	O
.	O
050	O
)	O
and	O
extrapulmonary	O
(↓	O
0	O
.	O
11	O
-	O
1	O
.	O
29	O
log10	O
copies	O
/	O
GAPDH	B-PRGE
;	O
P	O
<	O
.	O
050	O
in	O
kidney	O
)	O
tissues	O
.	O

Activation	O
of	O
alveolar	O
macrophages	O
in	O
the	O
donor	O
lung	O
causes	O
the	O
release	O
of	O
pro	O
-	O
inflammatory	O
chemokines	O
and	O
cytokines	O
,	O
such	O
as	O
TNF	B-PRGE
-	I-PRGE
α	I-PRGE
.	O

Our	O
findings	O
highlight	O
the	O
importance	O
of	O
IFN	B-PRGE
-	I-PRGE
β	I-PRGE
production	O
by	O
infected	O
BMECs	O
in	O
preserving	O
BBB	O
function	O
and	O
preventing	O
access	O
of	O
blood	O
-	O
borne	O
infectious	O
viruses	O
to	O
the	O
brain	O
.	O

We	O
provide	O
evidence	O
that	O
production	O
of	O
IFN	B-PRGE
-	I-PRGE
β	I-PRGE
by	O
BMECs	O
during	O
CoV	O
infection	O
may	O
prevent	O
BBB	O
breakdown	O
and	O
brain	O
viral	O
invasion	O
.	O

ABSTRACT	O
:	O
Alogliptin	O
,	O
a	O
dipeptidyl	O
peptidase	B-PRGE
-	I-PRGE
4	I-PRGE
(	O
DPP	B-PRGE
-	I-PRGE
4	I-PRGE
)	O
inhibitor	O
that	O
is	O
a	O
class	O
of	O
relatively	O
new	O
oral	O
hypoglycaemic	O
drugs	O
used	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
(	O
T2DM	O
),	O
can	O
be	O
used	O
as	O
monotherapy	O
or	O
in	O
combination	O
with	O
other	O
anti	O
-	O
diabetic	O
agents	O
,	O
including	O
metformin	O
,	O
pioglitazone	O
,	O
sulfonylureas	O
and	O
insulin	B-PRGE
with	O
a	O
considerable	O
therapeutic	O
effect	O
.	O

Serological	O
analysis	O
and	O
isolation	O
of	O
murine	B-PRGE
monoclonal	I-PRGE
antibodies	I-PRGE
revealed	O
that	O
immunization	O
elicits	O
NAbs	O
to	O
RBD	O
and	O
,	O
non	O
-	O
RBD	O
portions	O
of	O
S1	O
and	O
S2	B-PRGE
subunit	I-PRGE
.	O

Therefore	O
,	O
ORF1ab	B-PRGE
replicase	I-PRGE
polyprotein	I-PRGE
may	O
be	O
used	O
as	O
a	O
suitable	O
target	O
for	O
disease	O
control	O
.	O

Thus	O
,	O
this	O
method	O
may	O
provide	O
an	O
insight	O
for	O
the	O
chemical	O
synthesis	O
of	O
antiviral	B-PRGE
RNA	I-PRGE
molecule	I-PRGE
for	O
the	O
treatment	O
of	O
MERS	O
-	O
CoV	O
,	O
at	O
genomic	O
level	O
.	O

TITLE	O
:	O
NMR	O
and	O
MD	O
Studies	O
Reveal	O
That	O
the	O
Isolated	B-PRGE
Dengue	I-PRGE
NS3	I-PRGE
Protease	I-PRGE
Is	O
an	O
Intrinsically	O
Disordered	O
Chymotrypsin	O
Fold	O
Which	O
Absolutely	O
Requests	O
NS2B	O
for	O
Correct	O
Folding	O
and	O
Functional	O
Dynamics	O
.	O

ABSTRACT	O
:	O
Total	O
ginsenosides	O
synergize	O
with	O
ulinastatin	B-PRGE
(	O
UTI	B-PRGE
)	O
against	O
septic	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

According	O
to	O
phylogenetic	O
analysis	O
of	O
the	O
full	O
-	O
length	O
genome	O
,	O
replicase	B-PRGE
transcriptase	I-PRGE
complex	O
,	O
spike	O
protein	O
,	O
partial	O
S1	B-PRGE
gene	I-PRGE
and	O
M	B-PRGE
protein	I-PRGE
,	O
B1648	O
strain	O
clustered	O
with	O
the	O
non	O
-	O
Massachusetts	O
type	O
strains	O
NGA	O
/	O
A116E7	O
/	O
2006	O
,	O
UKr	O
27	O
-	O
11	O
,	O
QX	B-PRGE
-	I-PRGE
like	I-PRGE
ITA	I-PRGE
/	O
90254	O
/	O
2005	O
,	O
QX	O
-	O
like	O
CK	O
/	O
SWE	B-PRGE
/	O
0658946	O
/	O
10	O
,	O
TN20	O
/	O
00	O
,	O
RF	O
-	O
27	O
/	O
99	O
,	O
RF	O
/	O
06	O
/	O
2007	O
and	O
SLO	O
/	O
266	O
/	O
05	O
.	O

TITLE	O
:	O
A	O
Novel	O
Noonan	O
Syndrome	B-PRGE
RAF1	I-PRGE
Mutation	O
:	O
Lethal	O
Course	O
in	O
a	O
Preterm	O
Infant	O
.	O

ABSTRACT	O
:	O
Despite	O
the	O
identification	O
of	O
horseshoe	O
bats	O
as	O
the	O
reservoir	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
related	O
coronaviruses	O
(	O
SARSr	O
-	O
CoVs	O
),	O
the	O
origin	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
ORF8	I-PRGE
,	O
which	O
contains	O
the	O
29	O
-	O
nucleotide	O
signature	O
deletion	O
among	O
human	O
strains	O
,	O
remains	O
obscure	O
.	O

Most	O
human	O
SARS	O
-	O
CoV	O
epidemic	O
strains	O
contain	O
a	O
signature	O
29	O
-	O
nucleotide	O
deletion	O
in	O
ORF8	O
,	O
compared	O
to	O
civet	O
SARSr	O
-	O
CoVs	O
,	O
suggesting	O
that	O
ORF8	B-PRGE
may	O
be	O
important	O
for	O
interspecies	O
transmission	O
.	O

The	O
multi	B-PRGE
-	I-PRGE
fragment	I-PRGE
antigen	I-PRGE
(	O
BE	O
)	O
may	O
represent	O
a	O
promising	O
alternative	O
to	O
the	O
whole	O
virus	O
without	O
safety	O
problems	O
,	O
and	O
this	O
newly	O
established	O
ELISA	O
provides	O
an	O
effective	O
method	O
for	O
anti	O
-	O
IBV	O
antibody	O
detection	O
.	O

TITLE	O
:	O
Structural	O
basis	O
for	O
the	O
neutralization	O
of	O
MERS	O
-	O
CoV	O
by	O
a	O
human	B-PRGE
monoclonal	I-PRGE
antibody	I-PRGE
MERS	I-PRGE
-	I-PRGE
27	I-PRGE
.	O

In	O
this	O
study	O
,	O
porcine	O
small	O
intestinal	O
epithelial	O
cells	O
(	O
IECs	O
),	O
the	O
target	O
cells	O
of	O
PEDV	O
,	O
were	O
used	O
as	O
the	O
infection	O
model	O
in	O
vitro	O
to	O
identify	O
the	O
possible	O
molecular	O
mechanisms	O
of	O
PEDV	O
-	O
inhibition	O
IFN	B-PRGE
-	I-PRGE
β	I-PRGE
production	O
.	O

PEDV	O
not	O
only	O
failed	O
to	O
induce	O
IFN	B-PRGE
-	I-PRGE
β	I-PRGE
expression	O
,	O
but	O
also	O
inhibited	O
dsRNA	O
-	O
mediated	O
IFN	B-PRGE
-	I-PRGE
β	I-PRGE
production	O
in	O
IECs	O
.	O

CEK	O
adaptation	O
shifted	O
the	O
virus	O
population	O
towards	O
homogeneity	O
in	O
S	O
.	O
The	O
changes	O
achieved	O
in	O
the	O
S1	B-PRGE
gene	I-PRGE
in	O
CEKp7	O
were	O
maintained	O
after	O
a	O
back	O
-	O
passage	O
in	O
ECE	O
.	O

Inoculation	O
of	O
early	O
CEK	B-PRGE
passages	O
into	O
chickens	O
induced	O
higher	O
antibody	O
levels	O
and	O
CEKp4	O
induced	O
increased	O
respiratory	O
signs	O
compared	O
to	O
CEKp7	O
.	O

From	O
an	O
applied	O
perspective	O
,	O
the	O
fact	O
that	O
CEK	B-PRGE
adaptation	O
of	O
embryo	O
-	O
attenuated	O
Ark	O
vaccines	O
reduces	O
population	O
heterogeneity	O
,	O
and	O
that	O
changes	O
do	O
not	O
revert	O
after	O
one	O
replication	O
cycle	O
in	O
ECE	O
or	O
in	O
chickens	O
,	O
provides	O
an	O
opportunity	O
to	O
improve	O
commercial	O
ArkDPI	O
-	O
derived	O
vaccines	O
.	O

In	O
contrast	O
to	O
peptide	O
M	O
,	O
a	O
consensus	O
motif	O
'	O
PxxY	O
'	O
was	O
identified	O
on	O
both	O
peptides	O
L	O
and	O
W	O
,	O
and	O
on	O
the	O
S1	B-PRGE
protein	I-PRGE
,	O
but	O
not	O
on	O
peptide	O
H	O
.	O
Peptide	O
M	O
and	O
the	O
MAb	O
-	O
5E12	O
-	O
recognizing	O
peptides	O
L	O
and	O
W	O
significantly	O
inhibited	O
the	O
adsorption	O
of	O
PEDV	O
on	O
the	O
cell	O
surface	O
as	O
monitored	O
through	O
plaque	O
-	O
reduction	O
assays	O
.	O

Chest	O
trauma	O
led	O
to	O
elevated	O
expression	O
levels	O
of	O
inflammatory	O
and	O
coagulatory	O
proteins	O
(	O
such	O
as	O
TNFα	B-PRGE
receptor	I-PRGE
,	O
IL	O
-	O
1α	O
,	O
IL	O
-	O
1β	O
,	O
C3	O
,	O
NF	B-PRGE
-	I-PRGE
κB	I-PRGE
and	I-PRGE
plasminogen	I-PRGE
activator	I-PRGE
).	O

TITLE	O
:	O
Discovery	O
of	O
an	O
essential	O
nucleotidylating	O
activity	O
associated	O
with	O
a	O
newly	O
delineated	O
conserved	O
domain	O
in	O
the	O
RNA	B-PRGE
polymerase	I-PRGE
-	I-PRGE
containing	I-PRGE
protein	I-PRGE
of	O
all	O
nidoviruses	O
.	O

Cellular	B-PRGE
factors	I-PRGE
required	O
for	O
their	O
replication	O
are	O
poorly	O
understood	O
.	O

Furthermore	O
,	O
like	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
nsp1	I-PRGE
,	O
the	O
mRNA	O
degradation	O
activity	O
of	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
nsp1	I-PRGE
,	O
most	O
probably	O
triggered	O
by	O
its	O
ability	O
to	O
induce	O
an	O
endonucleolytic	O
RNA	O
cleavage	O
,	O
was	O
separable	O
from	O
its	O
translation	O
inhibitory	O
function	O
.	O

Detection	O
of	O
viral	O
RNA	O
was	O
performed	O
by	O
using	O
a	O
commercial	O
real	O
-	O
time	O
PCR	O
kit	O
(	O
hCoV	O
-	O
EMC	O
Real	O
-	O
Time	O
RT	O
-	O
PCR	O
,	O
Fast	O
Track	O
Diagnostics	O
,	O
Luxembourg	O
)	O
targeting	O
the	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
E	I-PRGE
protein	I-PRGE
(	O
upE	O
),	O
ORF1a	B-PRGE
and	I-PRGE
ORF1b	I-PRGE
gene	I-PRGE
regions	O
.	O

The	O
dual	O
luciferase	O
reporter	O
assay	O
showed	O
that	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
NPIPB3	O
attenuated	O
the	O
antagonistic	O
activity	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
ORF6	I-PRGE
on	O
IFN	B-PRGE
-	O
β	O
-	O
induced	O
ISRE	O
(	O
IFN	B-PRGE
stimulated	O
response	O
element	O
)-	O
responsive	O
firefly	O
luciferase	O
activity	O
.	O

In	O
addition	O
,	O
confocal	O
imaging	O
and	O
Western	O
blotting	O
assays	O
revealed	O
that	O
the	O
increases	O
in	O
STAT	B-PRGE
-	I-PRGE
1	I-PRGE
nuclear	O
translocation	O
and	O
phosphorylation	O
occurred	O
in	O
the	O
transfected	O
cells	O
expressing	O
both	O
genes	O
of	O
ORF6	B-PRGE
and	O
NPIPB3	O
,	O
but	O
not	O
in	O
the	O
ORF6	O
-	O
expressing	O
cells	O
in	O
response	O
to	O
IFN	B-PRGE
-	I-PRGE
β	I-PRGE
.	O

This	O
is	O
the	O
case	O
,	O
for	O
instance	O
,	O
of	O
rabies	O
virus	O
and	O
other	O
Lyssavirus	O
(	O
Family	O
Rhabdoviridae	O
),	O
Nipah	O
and	O
Hendra	O
viruses	O
(	O
Paramyxoviridae	O
),	O
Ebola	O
and	O
Marburg	O
viruses	O
(	O
Filoviridae	O
),	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
MERS	O
-	O
CoV	O
(	O
Coronaviridae	O
).	O

Interestingly	O
,	O
E	B-PRGE
protein	I-PRGE
IC	O
activity	O
boosted	O
the	O
activation	O
of	O
the	O
NLRP3	B-PRGE
inflammasome	I-PRGE
,	O
leading	O
to	O
IL	O
-	O
1β	O
overproduction	O
.	O

Furthermore	O
,	O
treatment	O
of	O
murine	O
macrophages	O
with	O
these	O
nanoparticles	O
blocked	O
the	O
production	O
of	O
lipopolysaccharide	O
-	O
induced	O
inflammatory	O
cytokines	O
in	O
a	O
Siglec	B-PRGE
-	I-PRGE
E	I-PRGE
-	O
dependent	O
manner	O
.	O

TITLE	O
:	O
The	O
ns12	B-PRGE
.	I-PRGE
9	I-PRGE
Accessory	I-PRGE
Protein	I-PRGE
of	O
Human	B-PRGE
Coronavirus	I-PRGE
OC43	I-PRGE
Is	O
a	O
Viroporin	O
Involved	O
in	O
Virion	O
Morphogenesis	O
and	O
Pathogenesis	O
.	O

Here	O
,	O
we	O
engineered	O
a	O
recombinant	O
mutant	O
virus	O
lacking	O
the	O
ns12	B-PRGE
.	I-PRGE
9	I-PRGE
protein	I-PRGE
(	O
HCoV	O
-	O
OC43	O
-	O
Δns12	O
.	O
9	O
)	O
to	O
characterize	O
the	O
contributions	O
of	O
ns12	O
.	O
9	O
in	O
HCoV	O
-	O
OC43	O
replication	O
.	O

Here	O
,	O
we	O
developed	O
an	O
IC	O
assay	O
that	O
detected	O
PEDV	O
antigens	O
with	O
96	O
.	O
0	O
%	O
(	O
218	O
/	O
227	O
)	O
sensitivity	O
and	O
98	O
.	O
5	O
%	O
(	O
262	O
/	O
266	O
)	O
specificity	O
when	O
compared	O
with	O
real	O
-	O
time	O
reverse	B-PRGE
transcriptase	I-PRGE
(	O
RT	O
)-	O
PCR	O
using	O
FAM	O
-	O
labeled	O
probes	O
based	O
on	O
sequences	O
from	O
nucleocapsid	O
genes	O
.	O

Whereas	O
,	O
the	O
viral	O
infection	O
in	O
IL	B-PRGE
-	I-PRGE
1β	I-PRGE
receptor	I-PRGE
-	I-PRGE
I	I-PRGE
deficient	O
(	O
IL	O
-	O
1R1	O
-/-)	O
or	O
IL	O
-	O
1R	O
antagonist	O
(	O
IL	B-PRGE
-	I-PRGE
1Ra	I-PRGE
)	O
treated	O
mice	O
,	O
show	O
reductions	O
in	O
virus	O
replication	O
,	O
disease	O
progress	O
and	O
mortality	O
.	O

Furthermore	O
,	O
the	O
proportion	O
of	O
nodes	O
with	O
high	O
posterior	O
support	O
(	O
posterior	O
probability	O
>	O
0	O
.	O
8	O
)	O
was	O
similar	O
between	O
nsp3	B-PRGE
and	O
S	O
genes	O
.	O

Moreover	O
,	O
we	O
demonstrate	O
that	O
TMPRSS2	B-PRGE
isoform	I-PRGE
1	I-PRGE
colocalizes	O
with	O
HA	O
and	O
cleaves	O
and	O
activates	O
HA	O
.	O

We	O
further	O
investigated	O
their	O
mechanisms	O
of	O
neutralization	O
by	O
crystallizing	O
the	O
complex	O
between	O
the	O
Fab	B-PRGE
fragments	I-PRGE
and	O
the	O
RBD	O
,	O
and	O
solved	O
the	O
structure	O
of	O
the	O
4C2	O
Fab	B-PRGE
/	O
MERS	O
-	O
RBD	O
complex	O
.	O

Here	O
,	O
we	O
show	O
that	O
age	O
-	O
dependent	O
increases	O
of	O
one	O
such	O
factor	O
in	O
the	O
lungs	O
,	O
a	O
phospholipase	B-PRGE
A2	I-PRGE
(	O
PLA2	O
)	O
group	O
IID	O
(	O
PLA2G2D	B-PRGE
)	O
with	O
antiinflammatory	O
properties	O
,	O
contributed	O
to	O
worse	O
outcomes	O
in	O
mice	O
infected	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

ABSTRACT	O
:	O
The	O
innate	O
immune	O
response	O
is	O
the	O
first	O
line	O
of	O
defense	O
against	O
viruses	O
,	O
and	O
type	O
I	O
interferon	B-PRGE
(	O
IFN	B-PRGE
)	O
is	O
a	O
critical	O
component	O
of	O
this	O
response	O
.	O

We	O
show	O
that	O
IBV	O
is	O
fairly	O
resistant	O
to	O
the	O
antiviral	O
state	O
induced	O
by	O
IFN	B-PRGE
and	O
identify	O
that	O
viral	B-PRGE
accessory	I-PRGE
protein	I-PRGE
3a	I-PRGE
is	O
involved	O
in	O
resistance	O
to	O
IFN	B-PRGE
,	O
as	O
its	O
absence	O
renders	O
IBV	O
less	O
resistant	O
to	O
IFN	B-PRGE
treatment	O
.	O

A	O
MERS	O
-	O
CoV	O
NP	O
capture	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
using	O
two	O
MERS	O
-	O
CoV	O
-	O
NP	O
-	O
specific	O
monoclonal	B-PRGE
antibodies	I-PRGE
(	O
MAbs	O
)	O
generated	O
was	O
developed	O
.	O

In	O
this	O
study	O
,	O
we	O
sought	O
to	O
determine	O
the	O
role	O
of	O
MDA5	B-PRGE
during	O
infection	O
with	O
mouse	O
hepatitis	O
virus	O
,	O
a	O
murine	O
coronavirus	O
used	O
to	O
model	O
viral	O
hepatitis	O
as	O
well	O
as	O
other	O
human	O
diseases	O
.	O

Although	O
they	O
are	O
both	O
autoimmune	O
conditions	O
that	O
benefit	O
from	O
the	O
administration	O
of	O
plasma	O
exchange	O
or	O
IV	B-PRGE
immunoglobulin	I-PRGE
(	O
IVIg	O
),	O
they	O
are	O
otherwise	O
very	O
different	O
disorders	O
with	O
unique	O
features	O
and	O
distinct	O
complications	O
.	O

By	O
referring	O
to	O
the	O
previous	O
studies	O
,	O
we	O
suggest	O
that	O
proteins	O
including	O
FAN	B-PRGE
,	O
CPSF2	B-PRGE
,	O
AGO1	B-PRGE
,	O
AGO2	B-PRGE
,	O
PAX5	B-PRGE
,	O
STAT1	B-PRGE
and	O
PDGFB	B-PRGE
can	O
be	O
used	O
as	O
therapeutic	O
targets	O
of	O
IAV	O
infection	O
.	O

Our	O
results	O
revealed	O
that	O
the	O
PEDV	B-PRGE
M	I-PRGE
protein	I-PRGE
is	O
localized	O
throughout	O
the	O
cytoplasm	O
.	O

Moreover	O
,	O
HLA	B-PRGE
-	I-PRGE
A	I-PRGE
*	I-PRGE
02	I-PRGE
:	O
06	O
with	O
TLR3	O
polymorphisms	O
and	O
HLA	B-PRGE
-	I-PRGE
A	I-PRGE
*	I-PRGE
02	I-PRGE
:	O
06	O
with	O
EP3	O
polymorphisms	O
exerted	O
additive	O
effects	O
in	O
SJS	O
/	O
TEN	O
with	O
SOCs	O
.	O

Although	O
the	O
functions	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
have	O
been	O
well	O
studied	O
,	O
the	O
factors	O
shaping	O
synonymous	O
codon	O
usage	O
bias	O
and	O
nucleotide	O
composition	O
in	O
the	O
S	B-PRGE
gene	I-PRGE
have	O
not	O
been	O
reported	O
yet	O
.	O

TITLE	O
:	O
Feline	O
coronavirus	O
quantitative	O
reverse	B-PRGE
transcriptase	I-PRGE
polymerase	I-PRGE
chain	O
reaction	O
on	O
effusion	O
samples	O
in	O
cats	O
with	O
and	O
without	O
feline	O
infectious	O
peritonitis	O
.	O

Feline	O
coronavirus	O
RNA	O
was	O
detected	O
using	O
a	O
reverse	B-PRGE
transcriptase	I-PRGE
quantitative	O
polymerase	O
chain	O
reaction	O
assay	O
(	O
qRT	O
-	O
PCR	O
),	O
and	O
positive	O
samples	O
underwent	O
pyrosequencing	O
of	O
position	O
1058	O
with	O
or	O
without	O
Sanger	O
sequencing	O
of	O
position	O
1060	O
in	O
the	O
FCoV	B-PRGE
spike	I-PRGE
protein	I-PRGE
.	O

Conclusions	O
and	O
relevance	O
A	O
positive	O
FCoV	O
qRT	O
-	O
PCR	O
result	O
on	O
effusions	O
appears	O
specific	O
for	O
FIP	B-PRGE
and	O
may	O
be	O
a	O
useful	O
diagnostic	O
marker	O
for	O
FIP	O
in	O
cats	O
with	O
effusions	O
.	O

Eleven	O
out	O
of	O
38	O
PEDV	O
strains	O
were	O
isolated	O
successfully	O
on	O
Vero	O
cells	O
with	O
trypsin	B-PRGE
treatment	O
and	O
subjected	O
to	O
genome	O
sequence	O
analysis	O
.	O

Combining	O
the	O
determination	O
of	O
IL28B	B-PRGE
SNPs	I-PRGE
,	O
rs8099917	O
genotyping	O
improved	O
the	O
response	O
prediction	O
in	O
rs12979860CT	O
carriers	O
only	O
in	O
mono	O
-	O
infected	O
patients	O
.	O

IMPORTANCE	O
We	O
previously	O
reported	O
that	O
Ad	O
-	O
infected	O
human	O
cells	O
exhibit	O
E1B	B-PRGE
19K	O
-	O
dependent	O
repression	O
of	O
virally	O
induced	O
,	O
NF	O
-	O
κB	O
-	O
dependent	O
macrophage	O
cytokine	O
responses	O
(	O
J	O
.	O
R	O
.	O
Radke	O
,	O
F	O
.	O
Grigera	O
,	O
D	O
.	O
S	O
.	O
Ucker	O
,	O
and	O
J	O
.	O
L	O
.	O
Cook	O
,	O
J	O
Virol	O
88	O
:	O
2658	O
-	O
2669	O
,	O
2014	O
,	O
http	O
://	O
dx	O
.	O
doi	O
.	O
org	O
/	O
10	O
.	O
1128	O
/	O
JVI	O
.	O
02372	O
-	O
13	O
).	O

This	O
is	O
the	O
first	O
evidence	O
of	O
a	O
clinical	O
relevance	O
of	O
differential	O
expression	O
of	O
the	O
small	B-PRGE
Ad	I-PRGE
E1B	I-PRGE
gene	I-PRGE
product	I-PRGE
.	O

Sequence	O
analysis	O
showed	O
that	O
these	O
isolates	O
were	O
divided	O
into	O
five	O
sub	O
-	O
clusters	O
:	O
A2	O
-	O
like	O
,	O
CKCHLDL08I	O
-	O
like	O
,	O
SAIBK	O
-	O
like	O
,	O
KM91	B-PRGE
-	I-PRGE
like	I-PRGE
and	I-PRGE
TW97	I-PRGE
/	I-PRGE
4	I-PRGE
-	I-PRGE
like	I-PRGE
.	O

When	O
the	O
full	B-PRGE
-	I-PRGE
length	I-PRGE
E	I-PRGE
protein	I-PRGE
was	O
deleted	O
or	O
its	O
PDZ	O
-	O
binding	O
motif	O
(	O
PBM	O
)	O
was	O
mutated	O
,	O
the	O
revertant	O
viruses	O
either	O
incorporated	O
a	O
novel	O
chimeric	O
protein	O
with	O
a	O
PBM	O
or	O
restored	O
the	O
sequence	O
of	O
the	O
PBM	O
on	O
the	O
E	B-PRGE
protein	I-PRGE
,	O
respectively	O
.	O

These	O
data	O
indicated	O
that	O
the	O
virus	O
requires	O
a	O
PBM	O
on	O
a	O
transmembrane	O
protein	O
to	O
compensate	O
for	O
removal	O
of	O
this	O
motif	O
from	O
the	O
E	B-PRGE
protein	I-PRGE
.	O

However	O
,	O
few	O
studies	O
have	O
been	O
conducted	O
on	O
type	B-PRGE
I	I-PRGE
FCoV	I-PRGE
.	O
Here	O
,	O
we	O
compare	O
the	O
effects	O
of	O
cholesterol	O
on	O
types	O
I	O
and	O
II	O
FCoV	O
infections	O
.	O

When	O
cells	O
were	O
treated	O
methyl	O
-	O
β	O
-	O
cyclodextrin	O
(	O
MβCD	O
)	O
and	O
inoculated	O
with	O
type	B-PRGE
I	I-PRGE
FCoV	I-PRGE
,	O
the	O
infection	O
rate	O
decreased	O
significantly	O
,	O
and	O
the	O
addition	O
of	O
exogenous	O
cholesterol	O
to	O
MβCD	O
-	O
treated	O
cells	O
resulted	O
in	O
the	O
recovery	O
of	O
the	O
infectivity	O
of	O
type	B-PRGE
I	I-PRGE
FCoV	I-PRGE
.	O
Furthermore	O
,	O
exogenous	O
cholesterol	O
increased	O
the	O
infectivity	O
of	O
type	B-PRGE
I	I-PRGE
FCoV	I-PRGE
.	O
In	O
contrast	O
,	O
the	O
addition	O
of	O
MβCD	O
and	O
exogenous	O
cholesterol	O
had	O
little	O
effect	O
on	O
the	O
efficiency	O
of	O
type	O
II	O
FCoV	O
infection	O
.	O

At	O
the	O
same	O
time	O
,	O
potentially	O
detrimental	O
hypercapnia	O
that	O
may	O
increase	O
ICP	B-PRGE
is	O
avoided	O
.	O

We	O
also	O
detected	O
an	O
association	O
of	O
TLR2	B-PRGE
gene	I-PRGE
with	O
tuberculosis	O
(	O
rs5743708	O
;	O
3	O
.	O
19	O
[	O
2	O
.	O
03	O
-	O
5	O
.	O
02	O
]).	O

Compared	O
to	O
control	O
group	O
,	O
an	O
intense	O
NIRF	O
signal	O
was	O
observed	O
in	O
ALI	O
induced	O
rats	O
in	O
the	O
window	O
6	O
-	O
24	O
h	O
post	O
-	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
instillation	O
.	O

In	O
vitro	O
studies	O
demonstrated	O
integrin	B-PRGE
receptor	I-PRGE
specificity	O
of	O
targeted	O
liposomes	O
.	O

CAT	B-PRGE
score	O
was	O
positively	O
correlated	O
with	O
LOS	O
.	O

ABSTRACT	O
:	O
Taxine	O
-	O
derived	O
alkaloids	O
,	O
taxane	O
-	O
derived	O
substances	O
,	O
and	O
glycosides	O
seem	O
to	O
be	O
responsible	O
for	O
the	O
toxicity	O
of	O
Taxus	B-PRGE
spp	I-PRGE
.	O

The	O
expression	O
level	O
of	O
the	O
PEDV	B-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
also	O
increased	O
.	O

TITLE	O
:	O
Structure	O
-	O
based	O
virtual	O
screening	O
and	O
experimental	O
validation	O
of	O
the	O
discovery	O
of	O
inhibitors	O
targeted	O
towards	O
the	O
human	B-PRGE
coronavirus	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
.	O

TITLE	O
:	O
Antiviral	O
Cystine	O
Knot	B-PRGE
α	I-PRGE
-	I-PRGE
Amylase	I-PRGE
Inhibitors	O
from	O
Alstonia	O
scholaris	O
.	O

Exposure	O
to	O
copper	O
destroyed	O
the	O
viral	O
genomes	O
and	O
irreversibly	O
affected	O
virus	O
morphology	O
,	O
including	O
disintegration	O
of	O
envelope	B-PRGE
and	O
dispersal	O
of	O
surface	O
spikes	O
.	O

A	O
microglial	O
response	O
was	O
present	O
only	O
in	O
severe	O
lesions	O
,	O
and	O
RCA	B-PRGE
-	I-PRGE
I	I-PRGE
expression	O
was	O
detected	O
primarily	O
in	O
gitter	O
cells	O
and	O
resting	O
microglia	O
.	O

However	O
,	O
influenza	O
virus	O
and	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
may	O
be	O
shed	O
into	O
the	O
environment	O
and	O
be	O
transferred	O
from	O
environmental	O
surfaces	O
to	O
hands	O
of	O
patients	O
and	O
healthcare	O
providers	O
.	O

The	O
observed	O
clinical	O
improvement	O
may	O
partially	O
be	O
due	O
to	O
the	O
anti	O
-	O
inflammatory	O
effects	O
of	O
PBMC	O
/	O
EPO	B-PRGE
to	O
promote	O
tissue	O
regeneration	O
.	O

Analysis	O
of	O
the	O
S1	B-PRGE
gene	I-PRGE
showed	O
that	O
isolate	O
ck	O
/	O
CH	O
/	O
LGX	O
/	O
130530	O
was	O
a	O
tl	O
/	O
CH	O
/	O
LDT3	O
/	O
03	O
-	O
like	O
virus	O
,	O
with	O
a	O
nucleotide	O
sequence	O
similarity	O
of	O
99	O
%.	O

Spleen	O
lymphocytes	O
were	O
collected	O
from	O
specific	O
-	O
pathogen	O
free	O
(	O
SPF	O
)	O
chicken	O
that	O
had	O
been	O
immunized	O
with	O
the	O
S1	B-PRGE
protein	I-PRGE
expression	O
plasmid	O
,	O
pV	O
-	O
S1	O
,	O
and	O
were	O
stimulated	O
by	O
the	O
synthesized	O
peptides	O
.	O

We	O
found	O
that	O
influenza	O
pneumonia	O
was	O
dramatically	O
attenuated	O
in	O
Card9	B-PRGE
-	O
deficient	O
mice	O
,	O
which	O
showed	O
improved	O
mortality	O
with	O
reduced	O
inflammatory	O
cytokines	O
and	O
chemokines	O
in	O
the	O
infected	O
lungs	O
.	O

TITLE	O
:	O
Recombinant	B-PRGE
Receptor	I-PRGE
Binding	I-PRGE
Domain	I-PRGE
Protein	I-PRGE
Induces	O
Partial	O
Protective	O
Immunity	O
in	O
Rhesus	O
Macaques	O
Against	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Challenge	O
.	O

In	O
addition	O
,	O
Ark	B-PRGE
-	I-PRGE
vaccinated	I-PRGE
chickens	I-PRGE
were	O
challenged	O
with	O
IBV	O
GA13	O
.	O

TITLE	O
:	O
Middle	O
East	B-PRGE
respiratory	I-PRGE
syndrome	I-PRGE
coronavirus	I-PRGE
ORF4b	I-PRGE
protein	I-PRGE
inhibits	O
type	B-PRGE
I	I-PRGE
interferon	I-PRGE
production	O
through	O
both	O
cytoplasmic	O
and	O
nuclear	O
targets	O
.	O

MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
IgG	I-PRGE
sero	O
-	O
positivity	O
gradually	O
increased	O
in	O
dromedary	O
calves	O
with	O
increasing	O
age	O
,	O
with	O
positivity	O
rates	O
of	O
75	O
%	O
at	O
zero	O
to	O
three	O
months	O
,	O
79	O
%	O
at	O
four	O
months	O
,	O
89	O
%	O
at	O
five	O
to	O
six	O
months	O
,	O
and	O
90	O
%	O
at	O
seven	O
to	O
twelve	O
months	O
.	O

Gas	B-PRGE
exchange	O
,	O
hemodynamics	O
,	O
hemolysis	O
,	O
and	O
coagulation	O
activation	O
were	O
examined	O
over	O
a	O
period	O
of	O
8	O
h	O
.	O
No	O
device	O
failed	O
during	O
the	O
observation	O
period	O
.	O

During	O
the	O
first	O
5	O
days	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
therapy	O
,	O
prothrombin	B-PRGE
fragment	I-PRGE
1	I-PRGE
.	I-PRGE
2	I-PRGE
(	O
F1	B-PRGE
.	I-PRGE
2	I-PRGE
)	I-PRGE
(	I-PRGE
1	I-PRGE
.	I-PRGE
36	I-PRGE
-	I-PRGE
2	I-PRGE
.	I-PRGE
4	I-PRGE
µM	I-PRGE
),	O
thrombin	B-PRGE
-	O
antithrombin	B-PRGE
complex	O
(	O
14	O
.	O
5	O
-	O
50	O
µg	O
/	O
L	O
),	O
and	O
D	O
-	O
dimers	O
(	O
6	O
.	O
00	O
-	O
27	O
.	O
0	O
mg	O
/	O
L	O
)	O
increased	O
,	O
whereas	O
fibrinogen	B-PRGE
values	O
dropped	O
from	O
5	O
.	O
8	O
to	O
4	O
.	O
1	O
g	O
/	O
L	O
.	O
The	O
three	O
different	O
extracorporeal	O
membrane	O
oxygenation	O
systems	O
did	O
not	O
show	O
any	O
differences	O
with	O
regard	O
to	O
hemostasis	O
,	O
anticoagulation	O
,	O
hemolysis	O
,	O
and	O
inflammatory	O
parameters	O
within	O
the	O
first	O
5	O
days	O
of	O
extracorporeal	O
membrane	O
oxygenation	O
therapy	O
.	O

ABSTRACT	O
:	O
Nowadays	O
,	O
a	O
large	O
number	O
of	O
people	O
in	O
the	O
world	O
are	O
suffering	O
from	O
chronic	O
Hepatitis	O
C	O
.	O
HCV	B-PRGE
NS5B	I-PRGE
polymerase	I-PRGE
conserved	O
across	O
the	O
identified	O
7	O
HCV	O
genotypes	O
is	O
considered	O
to	O
be	O
the	O
most	O
promising	O
target	O
in	O
combating	O
HCV	O
.	O

We	O
also	O
solved	O
the	O
structure	O
of	O
FIPV	B-PRGE
M	I-PRGE
(	I-PRGE
pro	I-PRGE
)	I-PRGE
complexed	O
with	O
two	O
inhibitors	O
,	O
delineating	O
the	O
structural	O
view	O
of	O
a	O
dual	O
inhibition	O
mechanism	O
.	O

Structural	O
analysis	O
suggests	O
that	O
several	O
key	O
residues	O
outside	O
the	O
catalytic	O
sites	O
of	O
PEDV	B-PRGE
nsp5	I-PRGE
probably	O
impact	O
NEMO	O
cleavage	O
by	O
modulating	O
potential	O
interactions	O
of	O
nsp5	B-PRGE
with	O
their	O
substrates	O
.	O

vWF	B-PRGE
was	O
associated	O
with	O
mortality	O
(	O
P	O
=	O
0	O
.	O
027	O
),	O
but	O
VEGF	B-PRGE
was	O
not	O
.	O

The	O
association	O
between	O
day	O
1	O
Ang	O
-	O
2	O
and	O
mortality	O
was	O
independent	O
of	O
levels	O
of	O
both	O
vWF	B-PRGE
and	O
VEGF	B-PRGE
(	O
OR	O
3	O
.	O
6	O
,	O
95	O
%	O
CI	O
1	O
.	O
1	O
-	O
12	O
.	O
1	O
,	O
P	O
=	O
0	O
.	O
039	O
,	O
for	O
each	O
log10	O
increase	O
in	O
Ang	B-PRGE
-	I-PRGE
2	I-PRGE
).	O

No	O
simple	O
,	O
single	O
-	O
reaction	O
diagnostic	O
test	O
currently	O
exists	O
for	O
the	O
simultaneous	O
detection	O
of	O
major	O
pathogens	O
commonly	O
associated	O
with	O
PRDC	B-PRGE
.	O

In	O
this	O
study	O
,	O
a	O
novel	O
prototype	O
automated	O
microarray	O
that	O
integrates	O
and	O
automates	O
all	O
steps	O
of	O
post	O
-	O
PCR	O
microarray	O
processing	O
for	O
the	O
simultaneous	O
detection	O
and	O
typing	O
of	O
eight	O
bacteria	O
and	O
viruses	O
commonly	O
associated	O
with	O
PRDC	B-PRGE
is	O
described	O
along	O
with	O
associated	O
multiplex	O
reverse	B-PRGE
transcriptase	I-PRGE
PCR	O
.	O

Therefore	O
,	O
our	O
goal	O
in	O
this	O
study	O
was	O
to	O
quantify	O
PEDV	B-PRGE
specific	I-PRGE
IgA	I-PRGE
and	O
IgG	B-PRGE
B	I-PRGE
cell	O
responses	O
in	O
sows	O
at	O
approximately	O
1	O
and	O
6	O
months	O
post	O
-	O
infection	O
in	O
commercial	O
swine	O
herds	O
,	O
including	O
parity	O
one	O
and	O
higher	O
sows	O
.	O

However	O
,	O
protein	O
interacting	O
with	O
NIMA	O
(	O
Pin1	B-PRGE
),	O
a	O
member	O
of	O
the	O
parvulin	B-PRGE
subfamily	I-PRGE
of	O
PPIases	O
that	O
differs	O
from	O
Cyps	O
and	O
FKBPs	O
,	O
is	O
essential	O
for	O
various	O
signaling	O
pathways	O
.	O

Dipentamethylene	O
thiuram	O
monosulfide	O
,	O
a	O
specific	O
inhibitor	O
of	O
Pin1	B-PRGE
,	O
inhibited	O
FCoV	O
replication	O
.	O

The	O
present	O
study	O
investigated	O
whether	O
the	O
vitamin	B-PRGE
D	I-PRGE
/	I-PRGE
vitamin	I-PRGE
D	I-PRGE
receptor	I-PRGE
(	O
VDR	B-PRGE
)	O
pathway	O
may	O
ameliorate	O
lipopolysaccharide	O
(	O
LPS	O
)‑	O
induced	O
ALI	O
through	O
maintaining	O
the	O
integrity	O
of	O
the	O
alveolar	O
epithelial	O
barrier	O
.	O

VDR	B-PRGE
knockout	O
mice	O
exhibited	O
severe	O
lung	O
injuries	O
(	O
P	O
<	O
0	O
.	O
001	O
),	O
increased	O
alveolar	O
permeability	O
[	O
demonstrated	O
by	O
a	O
higher	O
wet	O
‑	O
dry	O
ratio	O
of	O
lung	O
weight	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
greater	O
expression	O
levels	O
of	O
BALF	B-PRGE
protein	I-PRGE
(	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
fluorescein	O
isothiocyanate	O
‑	O
conjugated	O
4	O
kDa	O
dextran	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
leakage	O
into	O
the	O
alveolar	O
space	O
],	O
elevated	O
proinflammatory	O
cytokine	O
and	O
chemokine	O
mRNA	O
levels	O
,	O
as	O
demonstrated	O
by	O
reverse	O
transcription	O
‑	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
and	O
decreased	O
protein	O
and	O
mRNA	O
expression	O
levels	O
of	O
occludin	B-PRGE
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
zonula	O
occludens	O
‑	O
1	O
(	O
ZO	O
‑	O
1	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
compared	O
with	O
WT	O
mice	O
.	O

These	O
recent	O
outbreaks	O
and	O
global	O
re	O
-	O
emergence	O
of	O
PED	B-PRGE
require	O
urgent	O
attention	O
and	O
deeper	O
understanding	O
of	O
PEDV	O
biology	O
and	O
pathogenic	O
mechanisms	O
.	O

TITLE	O
:	O
Recent	O
insights	O
into	O
the	O
development	O
of	O
therapeutics	O
against	O
coronavirus	O
diseases	O
by	O
targeting	O
N	B-PRGE
protein	I-PRGE
.	O

We	O
will	O
also	O
present	O
our	O
latest	O
results	O
on	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
protein	I-PRGE
and	O
its	O
potential	O
as	O
an	O
antiviral	O
drug	O
target	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
increased	O
susceptibility	O
of	O
the	O
G6PD	O
-	O
knockdown	O
cells	O
to	O
viral	O
infection	O
was	O
due	O
to	O
impaired	O
NF	O
-	O
κB	O
signaling	O
and	O
antiviral	O
response	O
mediated	O
by	O
HSCARG	B-PRGE
.	O

Sensitive	O
,	O
validated	O
reverse	B-PRGE
transcriptase	I-PRGE
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
rtPCR	O
)-	O
based	O
diagnostics	O
have	O
been	O
available	O
almost	O
from	O
the	O
start	O
of	O
the	O
emergence	O
of	O
MERS	O
.	O

Our	O
study	O
evaluated	O
RT	O
-	O
PCR	O
PEDV	O
assays	O
that	O
detect	O
the	O
N	O
gene	B-PRGE
(	O
gN	O
)	O
and	O
S	B-PRGE
gene	I-PRGE
(	O
gS	O
)	O
for	O
their	O
ability	O
to	O
detect	O
PEDV	O
infection	O
and	O
the	O
transmission	O
potential	O
of	O
pigs	O
experimentally	O
exposed	O
to	O
PEDV	O
.	O

The	O
specificity	O
of	O
the	O
sequencing	O
step	O
could	O
not	O
be	O
determined	O
as	O
none	O
of	O
the	O
cats	O
of	O
the	O
control	O
group	O
tested	O
positive	O
for	O
FCoV	B-PRGE
RNA	I-PRGE
.	O

Finally	O
,	O
we	O
confirmed	O
the	O
clinical	O
relevance	O
and	O
found	O
that	O
IL	B-PRGE
-	I-PRGE
17	I-PRGE
expression	O
was	O
elevated	O
and	O
associated	O
with	O
the	O
disease	O
severity	O
in	O
patients	O
with	O
ARDS	O
.	O

Secondary	O
annexin	O
V	O
/	O
propidium	O
iodide	O
(	O
PI	O
)	O
staining	O
revealed	O
increased	O
numbers	O
of	O
annexin	B-PRGE
V	I-PRGE
-	I-PRGE
or	I-PRGE
PI	I-PRGE
-	O
positive	O
LLC	O
-	O
PK	O
and	O
ST	O
cells	O
at	O
21h	O
after	O
inoculation	O
,	O
compared	O
to	O
the	O
negative	O
controls	O
.	O

To	O
determine	O
if	O
AHR	B-PRGE
was	O
associated	O
with	O
asthma	O
-	O
like	O
symptoms	O
,	O
we	O
compared	O
the	O
results	O
of	O
the	O
MCT	O
to	O
a	O
validated	O
asthma	O
questionnaire	O
.	O

Inflammatory	O
markers	O
did	O
not	O
correlate	O
with	O
AHR	B-PRGE
.	O

Our	O
results	O
provide	O
further	O
evidence	O
of	O
the	O
bat	O
origin	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
highlight	O
the	O
likelihood	O
of	O
future	O
bat	O
coronavirus	O
emergence	O
in	O
humans	O
.	O

Using	O
specific	O
inhibitors	O
or	O
small	O
-	O
interfering	O
RNA	O
,	O
we	O
confirmed	O
that	O
indirubin	O
derivatives	O
can	O
suppress	O
H9N2	O
-	O
induced	O
cytokines	O
production	O
through	O
MAPKs	O
and	O
STAT3	B-PRGE
signaling	O
pathways	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
contributions	O
of	O
Oas	B-PRGE
gene	I-PRGE
expression	O
,	O
basal	O
IFN	B-PRGE
signaling	O
,	O
and	O
virus	O
-	O
induced	O
IFN	B-PRGE
to	O
RNase	B-PRGE
L	I-PRGE
activation	O
.	O

Infection	O
with	O
ns2	O
(	O
H126R	O
)	O
activated	O
RNase	B-PRGE
L	I-PRGE
in	O
Ifih1	B-PRGE
(-/-)	O
BMM	O
to	O
a	O
similar	O
extent	O
as	O
in	O
wild	O
-	O
type	O
(	O
WT	O
)	O
BMM	O
,	O
despite	O
the	O
lack	O
of	O
IFN	B-PRGE
induction	O
in	O
the	O
absence	O
of	O
MDA5	B-PRGE
expression	O
.	O

The	O
oligoadenylate	B-PRGE
synthetase	I-PRGE
(	O
OAS	O
)-	O
RNase	B-PRGE
L	O
pathway	O
is	O
a	O
potent	O
antiviral	O
activity	O
.	O

CONCLUSIONS	O
:	O
A	O
high	O
incidence	O
of	O
AKI	B-PRGE
was	O
noted	O
in	O
the	O
PICU	O
that	O
was	O
associated	O
with	O
high	O
mortality	O
.	O

RESULTS	O
:	O
All	O
bacterial	O
,	O
viral	O
,	O
protozoan	O
,	O
and	O
parasitic	O
agents	O
here	O
investigated	O
,	O
with	O
the	O
exception	O
of	O
Salmonella	B-PRGE
spp	I-PRGE
.	O

In	O
contrast	O
,	O
the	O
measurements	O
of	O
integrin	B-PRGE
expression	O
(	O
CD11b	B-PRGE
,	O
CD11a	B-PRGE
,	O
CD18	B-PRGE
,	O
CD49d	B-PRGE
)	O
and	O
leukocyte	O
-	O
endothelium	O
adhesion	O
showed	O
a	O
weak	O
and	O
slow	O
response	O
after	O
incubation	O
with	O
the	O
sera	O
of	O
patients	O
with	O
ARDS	O
(	O
several	O
hours	O
),	O
suggesting	O
a	O
lesser	O
role	O
of	O
leukocyte	O
adhesiveness	O
compared	O
with	O
leukocyte	O
stiffness	O
in	O
early	O
ARDS	O
.	O

In	O
contrast	O
,	O
the	O
measurements	O
of	O
integrin	B-PRGE
expression	O
(	O
CD11b	B-PRGE
,	O
CD11a	B-PRGE
,	O
CD18	B-PRGE
,	O
CD49d	B-PRGE
)	O
and	O
leukocyte	O
-	O
endothelium	O
adhesion	O
showed	O
a	O
weak	O
and	O
slow	O
response	O
after	O
incubation	O
with	O
the	O
sera	O
of	O
patients	O
with	O
ARDS	O
(	O
several	O
hours	O
),	O
suggesting	O
a	O
lesser	O
role	O
of	O
leukocyte	O
adhesiveness	O
compared	O
with	O
leukocyte	O
stiffness	O
in	O
early	O
ARDS	O
.	O

Here	O
,	O
we	O
present	O
the	O
crystal	O
structure	O
of	O
the	O
MHV	B-PRGE
ns2	I-PRGE
PDE	I-PRGE
domain	I-PRGE
and	O
demonstrate	O
a	O
PDE	O
fold	O
similar	O
to	O
that	O
of	O
the	O
cellular	O
protein	O
,	O
a	O
kinase	O
anchoring	O
protein	O
7	O
central	O
domain	O
(	O
AKAP7	B-PRGE
(	O
CD	O
))	O
and	O
rotavirus	B-PRGE
VP3	I-PRGE
carboxy	I-PRGE
-	I-PRGE
terminal	I-PRGE
domain	I-PRGE
.	O

We	O
found	O
that	O
the	O
IFN	B-PRGE
-	I-PRGE
β	I-PRGE
production	O
was	O
significantly	O
suppressed	O
during	O
PEDV	O
infection	O
in	O
cells	O
.	O

Treatment	O
of	O
patients	O
with	O
recombinant	O
interferon	B-PRGE
regimen	O
promises	O
beneficial	O
outcomes	O
,	O
suggesting	O
that	O
compromised	O
interferon	B-PRGE
expression	O
might	O
contribute	O
at	O
least	O
partially	O
to	O
the	O
severity	O
of	O
disease	O
.	O

A	O
single	O
therapeutic	O
dose	O
of	O
VIS410	O
given	O
24	O
h	O
after	O
virus	O
inoculation	O
resulted	O
in	O
dose	O
-	O
dependent	O
protection	O
of	O
up	O
to	O
100	O
%	O
of	O
mice	O
inoculated	O
with	O
neuraminidase	B-PRGE
inhibitor	O
-	O
susceptible	O
or	O
-	O
resistant	O
A	O
(	O
H7N9	O
)	O
viruses	O
.	O

TITLE	O
:	O
Ribonuclease	B-PRGE
H	I-PRGE
/	I-PRGE
DNA	I-PRGE
Polymerase	I-PRGE
HIV	I-PRGE
-	I-PRGE
1	I-PRGE
Reverse	I-PRGE
Transcriptase	I-PRGE
Dual	O
Inhibitor	O
:	O
Mechanistic	O
Studies	O
on	O
the	O
Allosteric	O
Mode	O
of	O
Action	O
of	O
Isatin	O
-	O
Based	O
Compound	O
RMNC6	O
.	O

Enzymatic	O
studies	O
showed	O
that	O
RMNC6	O
interferes	O
with	O
efavirenz	O
(	O
an	O
approved	O
NNRTI	O
)	O
in	O
its	O
binding	O
to	O
the	O
RT	B-PRGE
polymerase	I-PRGE
domain	I-PRGE
,	O
although	O
NNRTI	O
resistance	O
-	O
associated	O
mutations	O
such	O
as	O
K103N	O
,	O
Y181C	O
and	O
Y188L	O
had	O
a	O
minor	O
impact	O
on	O
RT	O
susceptibility	O
to	O
RMNC6	O
.	O

A	O
direct	O
interaction	O
between	O
vimentin	B-PRGE
and	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
during	O
viral	O
entry	O
was	O
observed	O
.	O

Binary	O
logistic	O
regression	O
analysis	O
showed	O
that	O
,	O
S	B-PRGE
-	I-PRGE
ChE	I-PRGE
levels	O
,	O
APACHE	O
II	O
score	O
and	O
MODS	O
score	O
were	O
found	O
to	O
be	O
the	O
independent	O
risk	O
factors	O
for	O
prognosis	O
in	O
the	O
patients	O
with	O
severe	O
pneumonia	O
,	O
respectively	O
[	O
S	O
-	O
ChE	O
:	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
0	O
.	O
084	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
95	O
%	O
CI	O
)	O
=	O
0	O
.	O
017	O
-	O
0	O
.	O
424	O
,	O
P	O
=	O
0	O
.	O
003	O
;	O
APACHE	O
II	O
score	O
:	O
OR	O
=	O
1	O
.	O
675	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
098	O
-	O
2	O
.	O
556	O
,	O
P	O
=	O
0	O
.	O
017	O
;	O
MODS	O
score	O
:	O
OR	O
=	O
2	O
.	O
189	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
262	O
-	O
3	O
.	O
800	O
,	O
P	O
=	O
0	O
.	O
005	O
].	O

The	O
area	O
under	O
ROC	O
(	O
AUC	O
)	O
for	O
S	B-PRGE
-	I-PRGE
ChE	I-PRGE
levels	O
,	O
APACHE	O
II	O
score	O
and	O
MODS	O
score	O
were	O
0	O
.	O
874	O
±	O
0	O
.	O
036	O
,	O
0	O
.	O
889	O
±	O
0	O
.	O
033	O
and	O
0	O
.	O
884	O
±	O
0	O
.	O
035	O
,	O
respectively	O
(	O
all	O
P	O
>	O
0	O
.	O
05	O
as	O
compared	O
between	O
any	O
two	O
means	O
).	O

The	O
CRP	B-PRGE
levels	O
of	O
patients	O
with	O
H7N9	O
and	O
patients	O
with	O
H1N1	O
were	O
also	O
compared	O
.	O

Several	O
cytokines	O
,	O
including	O
MIP	B-PRGE
-	I-PRGE
1β	I-PRGE
,	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
IP	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
were	O
observed	O
to	O
have	O
significantly	O
positive	O
relationships	O
with	O
CRP	B-PRGE
levels	O
,	O
whereas	O
IL	B-PRGE
-	I-PRGE
17A	I-PRGE
was	O
negatively	O
associated	O
with	O
CRP	B-PRGE
levels	O
.	O

Several	O
cytokines	O
,	O
including	O
MIP	B-PRGE
-	I-PRGE
1β	I-PRGE
,	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
IP	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
were	O
observed	O
to	O
have	O
significantly	O
positive	O
relationships	O
with	O
CRP	B-PRGE
levels	O
,	O
whereas	O
IL	B-PRGE
-	I-PRGE
17A	I-PRGE
was	O
negatively	O
associated	O
with	O
CRP	B-PRGE
levels	O
.	O

There	O
were	O
not	O
corrletions	O
between	O
IAP	B-PRGE
and	O
end	B-PRGE
-	I-PRGE
expiratory	I-PRGE
Ptp	I-PRGE
(	O
Ptp	B-PRGE
-	I-PRGE
e	I-PRGE
)	O
and	O
end	B-PRGE
-	I-PRGE
inspiratory	I-PRGE
Ptp	I-PRGE
(	O
Ptp	B-PRGE
-	I-PRGE
i	I-PRGE
)	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

Ptp	B-PRGE
-	I-PRGE
i	I-PRGE
correlated	O
with	O
Pplat	O
(	O
r2	O
=	O
0	O
.	O
523	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
end	O
-	O
inspiratory	O
esophageal	O
pressure	O
(	O
Pes	O
-	O
i	O
)	O
(	O
r2	O
=	O
0	O
.	O
231	O
,	O
P	O
<	O
0	O
.	O
05	O
),	O
but	O
did	O
not	O
correlate	O
with	O
Tidal	O
volume	O
(	O
VT	O
)	O
(	O
r2	O
=	O
0	O
.	O
052	O
4	O
,	O
P	O
>	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
Feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
replication	O
in	O
macrophages	O
/	O
monocytes	O
induced	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
(	O
TNF	O
)-	O
alpha	O
production	O
,	O
and	O
that	O
the	O
TNF	B-PRGE
-	I-PRGE
alpha	I-PRGE
produced	O
was	O
involved	O
in	O
aggravating	O
the	O
pathology	O
of	O
FIP	O
.	O

These	O
results	O
strongly	O
suggested	O
that	O
the	O
anti	B-PRGE
-	I-PRGE
fTNF	I-PRGE
-	I-PRGE
alpha	I-PRGE
antibody	I-PRGE
is	O
effective	O
for	O
the	O
treatment	O
of	O
FIP	O
.	O

Troponin	B-PRGE
I	I-PRGE
was	O
measured	O
every	O
12	O
hours	O
in	O
the	O
first	O
72	O
hours	O
from	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
admission	O
.	O

In	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	O
,	O
serial	O
troponin	B-PRGE
I	I-PRGE
assessment	O
together	O
with	O
echocardiography	O
evaluation	O
helped	O
to	O
identify	O
a	O
subgroup	O
at	O
higher	O
risk	O
for	O
in	O
-	O
ICU	O
death	O
.	O

Lactate	B-PRGE
dehydrogenase	I-PRGE
levels	O
had	O
positive	O
correlations	O
with	O
AST	O
(	O
r	O
=	O
0	O
.	O
95	O
)	O
and	O
ALT	B-PRGE
(	O
r	O
=	O
0	O
.	O
87	O
)	O
(	O
all	O
p	O
<	O
0	O
.	O
01	O
).	O

In	O
the	O
current	O
study	O
,	O
we	O
produced	O
and	O
characterized	O
7b	O
-	O
specific	O
monoclonal	B-PRGE
antibodies	I-PRGE
(	O
mAbs	O
).	O

Pathogenesis	O
following	O
infection	O
with	O
these	O
viruses	O
is	O
characterized	O
by	O
a	O
marked	O
delay	O
in	O
the	O
induction	O
of	O
Type	B-PRGE
I	I-PRGE
interferon	I-PRGE
(	O
IFN	B-PRGE
I	I-PRGE
)	O
and	O
,	O
subsequently	O
,	O
by	O
a	O
poor	O
adaptive	O
immune	O
response	O
.	O

Overall	O
,	O
our	O
study	O
indicates	O
for	O
the	O
first	O
time	O
that	O
a	O
pathogen	O
-	O
derived	O
protein	O
is	O
able	O
to	O
function	O
as	O
a	O
cytosolic	O
PAMP	O
to	O
stimulate	O
type	B-PRGE
I	I-PRGE
interferon	I-PRGE
production	O
by	O
activating	O
a	O
noncanonical	O
TLR	O
signaling	O
cascade	O
in	O
a	O
TRAF3	B-PRGE
-	O
independent	O
manner	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
membrane	O
(	O
M	O
)	O
protein	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
can	O
directly	O
promote	O
the	O
activation	O
of	O
both	O
beta	B-PRGE
interferon	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
β	I-PRGE
)	O
and	O
NF	O
-	O
κB	O
through	O
a	O
TLR	O
-	O
related	O
signaling	O
pathway	O
independent	O
of	O
TRAF3	B-PRGE
.	O

The	O
driving	O
force	O
for	O
M	O
-	O
mediated	O
IFN	B-PRGE
-	I-PRGE
β	I-PRGE
production	O
is	O
most	O
likely	O
generated	O
from	O
inside	O
the	O
cells	O
.	O

With	O
emerging	O
resistance	O
to	O
the	O
drugs	O
currently	O
licensed	O
for	O
treatment	O
and	O
prophylaxis	O
of	O
influenza	O
viruses	O
,	O
primarily	O
the	O
neuraminidase	B-PRGE
inhibitor	O
oseltamivir	O
phosphate	O
(	O
Tamiflu	O
)	O
and	O
the	O
M2	O
inhibitors	O
amantadine	O
and	O
rimantadine	O
,	O
and	O
the	O
lack	O
of	O
effective	O
interventions	O
against	O
other	O
respiratory	O
viruses	O
,	O
the	O
3	O
-	O
day	O
programme	O
focused	O
on	O
the	O
discovery	O
and	O
development	O
of	O
inhibitors	O
of	O
several	O
virus	O
targets	O
and	O
key	O
host	O
cell	O
factors	O
involved	O
in	O
virus	O
replication	O
or	O
mediating	O
the	O
inflammatory	O
response	O
.	O

TITLE	O
:	O
Recombinant	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
H120	O
vaccine	O
strain	O
expressing	O
the	O
hemagglutinin	B-PRGE
-	I-PRGE
neuraminidase	I-PRGE
(	O
HN	O
)	O
protein	O
of	O
Newcastle	O
disease	O
virus	O
(	O
NDV	O
)	O
protects	O
chickens	O
against	O
IBV	O
and	O
NDV	O
challenge	O
.	O

Meanwhile	O
,	O
fluorescent	O
quantitative	O
PCR	O
results	O
show	O
that	O
the	O
secretion	O
of	O
IFN	B-PRGE
-	I-PRGE
γ	I-PRGE
in	O
avian	O
splenic	O
lymphocytes	O
increases	O
after	O
Sp6	B-PRGE
stimulation	O
.	O

Forced	O
Tie2	B-PRGE
suppression	O
sufficed	O
to	O
attenuate	O
barrier	O
function	O
and	O
sensitize	O
endothelium	O
to	O
permeability	O
mediators	O
.	O

Rapid	O
reduction	O
of	O
pulmonary	O
Tie2	O
in	O
otherwise	O
healthy	O
animals	O
attenuated	O
downstream	O
kinase	O
signaling	O
to	O
the	O
barrier	O
effector	O
vascular	O
endothelial	O
(	O
VE	O
)-	O
cadherin	B-PRGE
and	O
induced	O
vascular	O
leakage	O
.	O

Common	O
genetic	O
variants	O
that	O
influence	O
TIE2	B-PRGE
expression	O
were	O
then	O
sought	O
in	O
the	O
HapMap3	O
cohort	O
.	O

Together	O
,	O
the	O
results	O
implicate	O
common	O
genetic	O
variation	O
at	O
the	O
TIE2	B-PRGE
locus	I-PRGE
as	O
a	O
determinant	O
of	O
vascular	O
leak	O
-	O
related	O
clinical	O
outcomes	O
from	O
common	O
infections	O
,	O
suggesting	O
new	O
tools	O
to	O
identify	O
individuals	O
at	O
unusual	O
risk	O
for	O
deleterious	O
complications	O
of	O
infection	O
.	O

Rather	O
,	O
deletion	O
of	O
a	O
63	O
-	O
residue	O
-	O
long	O
C	O
-	O
terminal	O
-	O
tail	O
portion	O
of	O
TRIM56	B-PRGE
abrogated	O
the	O
antiviral	O
function	O
.	O

Mechanistically	O
,	O
TRIM56	B-PRGE
was	O
found	O
to	O
specifically	O
impede	O
intracellular	O
influenza	O
virus	O
RNA	O
synthesis	O
.	O

For	O
the	O
M	B-PRGE
protein	I-PRGE
,	O
this	O
is	O
the	O
first	O
description	O
of	O
production	O
in	O
plants	O
,	O
while	O
for	O
plant	O
-	O
derived	O
N	B-PRGE
protein	I-PRGE
we	O
demonstrate	O
that	O
it	O
is	O
recognized	O
by	O
sera	O
of	O
patients	O
from	O
the	O
SARS	O
outbreak	O
in	O
Hong	O
Kong	O
in	O
2003	O
.	O

Herein	O
,	O
we	O
investigated	O
the	O
interactions	O
between	O
the	O
S	B-PRGE
protein	I-PRGE
and	O
its	O
receptor	O
porcine	B-PRGE
aminopeptidase	I-PRGE
N	I-PRGE
(	O
pAPN	O
)	O
or	O
co	O
-	O
receptor	O
sugars	O
.	O

Three	O
loops	O
at	O
the	O
tips	O
of	O
the	O
β	O
-	O
barrel	O
domains	O
did	O
not	O
play	O
crucial	O
roles	O
in	O
the	O
PEDV	O
S	O
-	O
pAPN	O
association	O
,	O
indicating	O
that	O
PEDV	O
conforms	O
to	O
a	O
different	O
receptor	O
recognition	O
model	O
compared	O
with	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
),	O
porcine	O
respiratory	O
CoV	O
(	O
PRCV	O
),	O
and	O
human	B-PRGE
coronavirus	I-PRGE
NL63	I-PRGE
(	O
HCoV	O
-	O
NL63	O
).	O

Strategies	O
targeting	O
the	O
receptor	B-PRGE
binding	I-PRGE
domain	I-PRGE
(	O
RBD	O
)	O
may	O
be	O
helpful	O
for	O
developing	O
vaccines	O
or	O
antiviral	O
drugs	O
for	O
PEDV	O
.	O

For	O
the	O
first	O
EQA	O
phase	O
,	O
in	O
vitro	O
transcribed	O
upstream	B-PRGE
region	I-PRGE
of	I-PRGE
the	I-PRGE
envelope	I-PRGE
gene	I-PRGE
(	O
upE	O
)	O
and	O
the	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
1a	O
RNAs	O
were	O
used	O
at	O
a	O
concentration	O
of	O
1	O
,	O
000	O
copies	O
/	O
μL	O
.	O
The	O
test	O
panel	O
for	O
the	O
second	O
EQA	O
phase	O
consisted	O
of	O
RNA	O
extracts	O
from	O
three	O
samples	O
,	O
which	O
were	O
obtained	O
from	O
two	O
MERS	O
-	O
CoV	O
positive	O
patients	O
and	O
one	O
MERS	O
-	O
CoV	O
negative	O
patient	O
.	O

RESULTS	O
:	O
The	O
first	O
EQA	O
phase	O
results	O
for	O
46	O
participants	O
showed	O
a	O
linear	O
relationship	O
between	O
the	O
threshold	O
cycle	O
(	O
C	O
(	O
T	O
))	O
values	O
of	O
RNA	O
materials	O
and	O
the	O
logarithmic	O
concentrations	O
for	O
both	O
upE	O
and	O
ORF1a	B-PRGE
gene	I-PRGE
targets	I-PRGE
(	O
R²	O
=	O
0	O
.	O
73	O
and	O
0	O
.	O
75	O
,	O
respectively	O
).	O

The	O
amino	O
acid	O
sequences	O
of	O
MHV	O
N	O
and	O
nsp3	B-PRGE
proteins	I-PRGE
have	O
similarity	O
between	O
human	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

CONCLUSIONS	O
:	O
Ribavirin	O
in	O
combination	O
with	O
interferon	B-PRGE
-	I-PRGE
α	I-PRGE
might	O
have	O
therapeutic	O
effects	O
on	O
MERS	O
patients	O
through	O
several	O
signaling	O
pathways	O
.	O

Here	O
we	O
apply	O
ribosome	O
profiling	O
to	O
cells	O
infected	O
with	O
Murine	O
coronavirus	O
,	O
mouse	O
hepatitis	O
virus	O
,	O
strain	O
A59	O
(	O
MHV	O
-	O
A59	O
),	O
a	O
model	O
coronavirus	O
in	O
the	O
same	O
genus	O
as	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
MERS	O
-	O
CoV	O
.	O
The	O
data	O
obtained	O
allowed	O
us	O
to	O
study	O
the	O
kinetics	O
of	O
virus	O
transcription	O
and	O
translation	O
with	O
exquisite	O
precision	O
.	O

Ribosome	O
pause	O
sites	O
were	O
identified	O
in	O
the	O
virus	B-PRGE
replicase	I-PRGE
polyprotein	I-PRGE
pp1a	I-PRGE
ORF	I-PRGE
and	O
investigated	O
experimentally	O
.	O

Endothelial	O
activation	O
biomarkers	O
(	O
soluble	O
vascular	B-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
[	O
sVCAM	O
-	O
1	O
],	O
soluble	O
endothelial	B-PRGE
selectin	I-PRGE
[	O
sESEL	O
],	O
angiopoietin	B-PRGE
-	I-PRGE
1	I-PRGE
[	O
Ang	B-PRGE
-	I-PRGE
1	I-PRGE
]	O
and	O
angiopoietin	B-PRGE
-	I-PRGE
2	I-PRGE
[	O
Ang	B-PRGE
-	I-PRGE
2	I-PRGE
])	O
were	O
measured	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
.	O

We	O
did	O
not	O
detect	O
significant	O
differences	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
levels	O
of	O
sESEL	O
,	O
Ang	B-PRGE
-	I-PRGE
1	I-PRGE
or	O
Ang	B-PRGE
-	I-PRGE
2	I-PRGE
between	O
patients	O
with	O
ARDS	O
and	O
healthy	O
volunteers	O
.	O

Moreover	O
,	O
melanoma	O
differentiation	O
-	O
associated	O
protein	O
5	O
(	O
MDA5	O
),	O
laboratory	B-PRGE
of	I-PRGE
genetics	I-PRGE
and	I-PRGE
physiology	I-PRGE
2	I-PRGE
(	O
LGP2	B-PRGE
),	O
stimulator	O
of	O
IFN	B-PRGE
genes	O
(	O
STING	B-PRGE
),	O
and	O
mitochondrial	O
antiviral	O
signaling	O
protein	O
(	O
MAVS	O
),	O
as	O
well	O
as	O
TANK	B-PRGE
binding	I-PRGE
kinase	I-PRGE
1	I-PRGE
(	O
TBK1	B-PRGE
),	O
inhibitor	B-PRGE
of	I-PRGE
kappaB	B-PRGE
kinase	I-PRGE
(	I-PRGE
IKK	I-PRGE
)	I-PRGE
ε	I-PRGE
,	O
IKKα	O
,	O
IKKβ	O
,	O
IFN	B-PRGE
regulatory	I-PRGE
factor	I-PRGE
(	I-PRGE
IRF	I-PRGE
)	I-PRGE
7	I-PRGE
,	O
nuclear	B-PRGE
factor	I-PRGE
of	I-PRGE
kappaB	I-PRGE
(	O
NF	O
-	O
ĸB	O
),	O
IFN	B-PRGE
-	I-PRGE
α	I-PRGE
,	O
IFN	B-PRGE
-	I-PRGE
β	I-PRGE
,	O
various	O
interleukins	B-PRGE
(	I-PRGE
ILs	I-PRGE
),	I-PRGE
and	I-PRGE
macrophage	I-PRGE
inflammatory	I-PRGE
protein	I-PRGE
-	I-PRGE
1β	I-PRGE
(	O
MIP	B-PRGE
-	I-PRGE
1β	I-PRGE
)	O
were	O
significantly	O
upregulated	O
in	O
the	O
trachea	O
and	O
downregulated	O
in	O
the	O
kidney	O
.	O

These	O
results	O
suggested	O
that	O
the	O
TLR	O
and	O
MDA5	B-PRGE
signaling	O
pathways	O
and	O
innate	O
immune	O
cytokine	O
were	O
induced	O
after	O
IBV	O
infection	O
.	O

However	O
,	O
no	O
statistical	O
difference	O
was	O
found	O
in	O
MERS	O
-	O
HCP	B-PRGE
and	O
SARS	B-PRGE
-	O
HCP	B-PRGE
.	O

The	O
TGEV	B-PRGE
spike	I-PRGE
protein	I-PRGE
is	O
capable	O
of	O
binding	O
with	O
EGFR	B-PRGE
,	O
activating	O
the	O
downstream	O
phosphoinositide	B-PRGE
-	I-PRGE
3	I-PRGE
kinase	I-PRGE
(	O
PI3K	B-PRGE
),	O
then	O
causing	O
the	O
phosphorylation	O
of	O
cofilin	B-PRGE
and	O
F	B-PRGE
-	I-PRGE
actin	I-PRGE
polymerization	O
via	O
Rac1	B-PRGE
/	O
Cdc42	B-PRGE
GTPases	I-PRGE
.	O

Additionally	O
,	O
lipid	O
rafts	O
act	O
as	O
signal	O
platforms	O
for	O
the	O
EGFR	B-PRGE
-	O
associated	O
signaling	O
cascade	O
and	O
correlate	O
with	O
the	O
adhesion	O
of	O
TGEV	O
.	O

TITLE	O
:	O
Structure	O
of	O
Main	B-PRGE
Protease	I-PRGE
from	O
Human	B-PRGE
Coronavirus	I-PRGE
NL63	I-PRGE
:	O
Insights	O
for	O
Wide	O
Spectrum	O
Anti	O
-	O
Coronavirus	O
Drug	O
Design	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
difference	O
ot	O
biological	O
characteristics	O
in	O
the	O
MERS	O
-	O
CoV	O
infected	O
mice	O
model	O
in	O
prior	O
to	O
transduction	O
with	O
different	O
dosage	O
of	O
human	O
DPP4	B-PRGE
.	O

This	O
sharing	O
suggests	O
that	O
in	O
case	O
of	O
pathogenicity	O
MERS	O
-	O
CoV	O
is	O
more	O
closely	O
related	O
to	O
HKU5	B-PRGE
bat	I-PRGE
-	I-PRGE
CoV	I-PRGE
than	O
HKU4	B-PRGE
bat	I-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
The	O
conserved	O
epitopes	O
indicates	O
their	O
evolutionary	O
relationship	O
and	O
ancestry	O
of	O
pathogenicity	O
.	O

We	O
found	O
that	O
MERS	O
-	O
CoV	O
shared	O
30	O
%	O
of	O
its	O
S	O
protein	O
antigenic	O
sites	O
with	O
HKU4	O
and	O
70	O
%	O
with	O
HKU5	B-PRGE
bat	I-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
Whereas	O
100	O
%	O
of	O
its	O
E	O
,	O
M	O
and	O
N	O
protein	O
'	O
s	O
antigenic	O
sites	O
are	O
found	O
to	O
be	O
conserved	O
with	O
those	O
in	O
HKU4	O
and	O
HKU5	O
.	O

However	O
,	O
on	O
March	O
2015	O
,	O
PDCoV	O
-	O
positive	O
samples	O
(	O
SL2	B-PRGE
,	O
SL5	O
)	O
were	O
detected	O
from	O
SL	O
swine	O
farm	O
in	O
Gyeongbuk	O
province	O
.	O

Sub	B-PRGE
-	I-PRGE
cluster	I-PRGE
C2	I-PRGE
includes	O
BCoVs	O
from	O
Europe	O
.	O

This	O
review	O
summarizes	O
our	O
current	O
knowledge	O
on	O
AIV	O
epidemiology	O
,	O
disease	O
symptoms	O
,	O
inflammatory	O
processes	O
underlying	O
the	O
AIV	O
infection	O
in	O
humans	O
,	O
and	O
recent	O
studies	O
on	O
universal	O
pre	O
-	O
existing	O
CD8	B-PRGE
(+)	O
T	O
cell	O
immunity	O
to	O
AIVs	O
.	O

The	O
neutrophils	O
that	O
infiltrate	O
the	O
lungs	O
and	O
migrate	O
into	O
the	O
airways	O
express	O
pro	O
-	O
inflammatory	O
cytokines	O
such	O
as	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
α	I-PRGE
),	O
interleukin	B-PRGE
-	I-PRGE
1	I-PRGE
beta	I-PRGE
(	O
IL	O
-	O
1β	O
),	O
and	O
contribute	O
to	O
both	O
the	O
endothelial	O
and	O
epithelial	O
integrity	O
disruption	O
of	O
the	O
barriers	O
.	O

These	O
results	O
demonstrated	O
that	O
SL7207	O
(	O
pVAXD	B-PRGE
-	I-PRGE
PS1	I-PRGE
-	I-PRGE
TS	I-PRGE
)	O
possess	O
the	O
immunological	O
functions	O
of	O
the	O
two	O
S	O
proteins	O
of	O
TGEV	O
and	O
PEDV	O
,	O
indicating	O
that	O
SL7207	O
(	O
pVAXD	B-PRGE
-	I-PRGE
PS1	I-PRGE
-	I-PRGE
TS	I-PRGE
)	O
is	O
a	O
candidate	O
oral	O
vaccine	O
for	O
TGE	O
and	O
PED	O
.	O

TITLE	O
:	O
Neonatal	O
Fc	B-PRGE
Receptor	I-PRGE
-	I-PRGE
Mediated	I-PRGE
IgG	I-PRGE
Transport	O
Across	O
Porcine	O
Intestinal	O
Epithelial	O
Cells	O
:	O
Potentially	O
Provide	O
the	O
Mucosal	O
Protection	O
.	O

Furthermore	O
,	O
pFcRn	O
-	O
transcytosed	O
viral	O
-	O
specific	O
IgG	B-PRGE
reduced	O
the	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
yield	O
from	O
the	O
luminal	O
direction	O
by	O
a	O
50	O
%	O
tissue	O
culture	O
infective	O
dose	O
(	O
TCID50	O
)	O
assay	O
.	O

Low	O
plasma	O
levels	O
of	O
adiponectin	B-PRGE
,	O
a	O
circulating	B-PRGE
hormone	I-PRGE
-	I-PRGE
like	I-PRGE
molecule	I-PRGE
,	O
have	O
been	O
implicated	O
as	O
a	O
possible	O
mechanism	O
for	O
this	O
association	O
.	O

Collectively	O
,	O
our	O
results	O
suggested	O
that	O
recombinant	O
B	O
.	O
subtilis	O
CotGSG	O
expressing	O
the	O
TGEV	B-PRGE
S	I-PRGE
protein	I-PRGE
could	O
effectively	O
induce	O
immune	O
responses	O
via	O
DCs	O
,	O
and	O
provided	O
a	O
perspective	O
on	O
potential	O
novel	O
strategy	O
and	O
approach	O
that	O
may	O
be	O
applicable	O
to	O
the	O
development	O
of	O
the	O
next	O
generation	O
of	O
TGEV	O
vaccines	O
.	O

CONCLUSIONS	O
:	O
Based	O
on	O
medical	O
examinations	O
by	O
veterinarians	O
,	O
the	O
AaMP	B-PRGE
are	O
in	O
a	O
good	O
health	O
status	O
and	O
seem	O
to	O
harbor	O
only	O
few	O
microorganisms	O
.	O

Immunohistochemical	O
analysis	O
identified	O
dipeptidyl	B-PRGE
peptidase	I-PRGE
4	I-PRGE
(	O
DPP4	B-PRGE
),	O
a	O
known	O
receptor	O
for	O
MERS	O
-	O
CoV	O
on	O
type	O
I	O
pneumocytes	O
from	O
infected	O
rats	O
.	O

Whereas	O
adult	O
rats	O
developed	O
antibodies	O
against	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
after	O
intranasal	O
inoculation	O
,	O
there	O
was	O
no	O
evidence	O
of	O
viral	O
replication	O
in	O
the	O
lungs	O
of	O
adult	O
,	O
young	O
,	O
or	O
neonatal	O
rats	O
after	O
intranasal	O
inoculation	O
with	O
MERS	O
-	O
CoV	O
.	O
In	O
addition	O
,	O
human	O
DPP4	B-PRGE
-	O
expressing	O
rat	O
kidney	O
fibroblasts	O
,	O
but	O
not	O
rat	O
DPP4	B-PRGE
-	O
expressing	O
cells	O
,	O
were	O
susceptible	O
to	O
MERS	O
-	O
CoV	O
.	O
Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
the	O
rat	O
is	O
not	O
a	O
useful	O
animal	O
model	O
for	O
studying	O
MERS	O
-	O
CoV	O
infection	O
.	O

It	O
is	O
a	O
bifunctional	O
enzyme	O
bearing	O
3	O
'-	O
to	O
-	O
5	O
'	O
exoribonuclease	O
(	O
ExoN	O
)	O
and	O
guanine	B-PRGE
-	I-PRGE
N7	I-PRGE
-	I-PRGE
methyltransferase	I-PRGE
(	O
N7	B-PRGE
-	I-PRGE
MTase	I-PRGE
)	O
activities	O
.	O

A	O
specific	O
mutation	O
within	O
zinc	B-PRGE
finger	I-PRGE
1	I-PRGE
(	O
ZF	O
-	O
C	O
)	O
led	O
to	O
production	O
of	O
a	O
viable	O
virus	O
with	O
growth	O
and	O
viral	O
RNA	O
synthesis	O
kinetics	O
similar	O
to	O
that	O
of	O
the	O
parental	O
virus	O
.	O

The	O
innate	O
immune	O
response	O
is	O
the	O
first	O
line	O
of	O
antiviral	O
defense	O
that	O
culminates	O
in	O
the	O
synthesis	O
of	O
interferon	B-PRGE
and	O
proinflammatory	O
cytokines	O
to	O
control	O
viral	O
replication	O
.	O

The	O
introduction	O
of	O
a	O
mutation	O
in	O
zinc	B-PRGE
finger	I-PRGE
1	I-PRGE
of	O
the	O
ExoN	B-PRGE
domain	I-PRGE
of	O
nsp14	O
led	O
to	O
production	O
of	O
a	O
virus	O
that	O
induced	O
a	O
weak	O
antiviral	O
response	O
,	O
most	O
likely	O
due	O
to	O
the	O
accumulation	O
of	O
lower	O
levels	O
of	O
dsRNA	O
in	O
the	O
late	O
phases	O
of	O
infection	O
.	O

In	O
this	O
L	O
.	O
casei	O
vaccine	O
,	O
repetitive	O
peptides	O
expressed	O
by	O
L	O
.	O
casei	O
(	O
specifically	O
the	O
MDP	B-PRGE
and	O
tuftsin	B-PRGE
fusion	I-PRGE
protein	I-PRGE
(	O
MT	O
))	O
were	O
repeated	O
20	O
times	O
and	O
the	O
D	O
antigenic	O
site	O
of	O
the	O
TGEV	O
spike	O
(	O
S	O
)	O
protein	O
was	O
repeated	O
6	O
times	O
.	O

TITLE	O
:	O
Middle	O
East	B-PRGE
Respiratory	I-PRGE
Syndrome	I-PRGE
Coronavirus	I-PRGE
NS4b	I-PRGE
Protein	I-PRGE
Inhibits	O
Host	B-PRGE
RNase	I-PRGE
L	I-PRGE
Activation	O
.	O

Through	O
amino	O
acid	O
sequence	O
analysis	O
of	O
S	O
proteins	O
of	O
representative	O
CoVs	O
,	O
we	O
identified	O
a	O
common	O
region	O
as	O
a	O
possible	O
FP	O
(	O
pFP	O
)	O
that	O
shares	O
the	O
characteristics	O
of	O
FPs	O
of	O
class	B-PRGE
I	I-PRGE
viral	I-PRGE
fusion	I-PRGE
proteins	I-PRGE
,	O
including	O
high	O
Ala	O
/	O
Gly	O
content	O
,	O
intermediate	O
hydrophobicity	O
,	O
and	O
few	O
charged	O
residues	O
.	O

The	O
synthetic	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
pFP	I-PRGE
core	I-PRGE
peptide	I-PRGE
(	O
955IAGVGWTAGL964	O
)	O
induced	O
extensive	O
fusion	O
of	O
liposome	O
membranes	O
,	O
while	O
mutant	O
peptide	O
failed	O
to	O
induce	O
any	O
lipid	O
mixing	O
.	O

The	O
peptide	O
-	O
like	O
E64d	O
inhibitor	O
was	O
found	O
to	O
bind	O
beneath	O
a	O
β	O
-	O
hairpin	O
at	O
the	O
interface	O
of	O
the	O
SAM	B-PRGE
MTase	I-PRGE
and	O
protease	O
domains	O
.	O

N475	O
forms	O
a	O
hydrogen	O
bond	O
with	O
R662	O
in	O
the	O
SAM	B-PRGE
MTase	I-PRGE
domain	I-PRGE
,	O
and	O
the	O
R662A	O
and	O
R662K	O
mutations	O
both	O
led	O
to	O
16	O
-	O
fold	O
decreases	O
in	O
kcat	O
/	O
Km	O
.	O

An	O
Asn	O
homologous	O
to	O
N475	O
is	O
similarly	O
found	O
in	O
coronaviral	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
proteases	I-PRGE
(	O
PLpro	O
)	O
of	O
the	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)	O
virus	O
and	O
Middle	O
East	O
Respiratory	O
Syndrome	O
(	O
MERS	O
)	O
virus	O
.	O

Virological	O
analysis	O
determined	O
that	O
the	O
virus	O
belonged	O
to	O
H5	B-PRGE
clade	I-PRGE
2	I-PRGE
.	I-PRGE
3	I-PRGE
.	I-PRGE
4	I-PRGE
.	I-PRGE
4	I-PRGE
and	O
it	O
has	O
obtained	O
partial	O
ability	O
for	O
mammalian	O
adaptation	O
and	O
amantadine	O
resistance	O
.	O

Subsequently	O
,	O
blood	O
tests	O
showed	O
elevation	O
of	O
ferritin	B-PRGE
and	O
soluble	B-PRGE
interleukin	I-PRGE
2	I-PRGE
receptor	I-PRGE
(	O
sIL2R	O
);	O
microscopic	O
examination	O
of	O
the	O
peripheral	O
blood	O
revealed	O
hemophagocytosis	O
.	O

Thus	O
,	O
we	O
expressed	O
and	O
produced	O
recombinant	B-PRGE
S1	I-PRGE
protein	I-PRGE
to	O
protect	O
newborn	O
piglets	O
by	O
immunization	O
of	O
sows	O
.	O

Similarly	O
,	O
we	O
detected	O
a	O
novel	O
betacoronavirus	O
genotype	O
from	O
Pteropus	O
alecto	O
which	O
is	O
most	O
closely	O
related	O
to	O
Bat	B-PRGE
coronavirus	I-PRGE
HKU9	I-PRGE
identified	O
in	O
other	O
pteropodid	O
bats	O
in	O
China	O
,	O
Kenya	O
and	O
the	O
Philippines	O
.	O

Rhesus	O
macaques	O
inoculated	O
with	O
MERS	O
-	O
CoV	O
VLPs	O
and	O
Alum	O
adjuvant	O
induced	O
virus	O
-	O
neutralizing	O
antibodies	O
titers	O
up	O
to	O
1	O
:	O
40	O
and	O
induced	O
specific	O
IgG	B-PRGE
antibodies	I-PRGE
against	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
),	O
with	O
endpoint	O
titers	O
reaching	O
1	O
:	O
1	O
,	O
280	O
.	O

Serum	O
,	O
colostrum	O
,	O
and	O
milk	O
were	O
tested	O
for	O
PEDV	B-PRGE
IgG	I-PRGE
,	O
IgA	B-PRGE
,	O
and	O
virus	O
-	O
neutralizing	O
antibody	O
.	O

We	O
could	O
not	O
verify	O
the	O
virus	O
itself	O
by	O
in	O
situ	O
hybridization	O
and	O
confocal	O
microscopy	O
(	O
MERS	O
-	O
CoV	O
co	O
-	O
stained	O
with	O
dipeptidyl	B-PRGE
peptidase	I-PRGE
4	I-PRGE
).	O

In	O
this	O
study	O
,	O
coronavirus	O
sequences	O
were	O
detected	O
using	O
a	O
nested	O
RT	O
-	O
PCR	O
targeting	O
440	O
bp	O
of	O
the	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
(	O
RdRp	O
)	O
in	O
six	O
of	O
79	O
fecal	O
samples	O
collected	O
from	O
an	O
urban	O
colony	O
of	O
E	O
.	O
helvum	O
in	O
Ibadan	O
,	O
Nigeria	O
.	O

Methods	O
Antibody	O
-	O
mediated	O
TRALI	O
was	O
experimentally	O
induced	O
in	O
mice	O
by	O
lipopolysaccharide	O
priming	O
followed	O
by	O
the	O
administration	O
of	O
an	O
anti	B-PRGE
-	I-PRGE
MHC	I-PRGE
I	I-PRGE
mAb	I-PRGE
.	O

Results	O
TRALI	O
was	O
tested	O
in	O
the	O
context	O
of	O
severe	O
thrombocytopenia	O
provoked	O
by	O
the	O
administration	O
of	O
diphtheria	O
toxin	O
(	O
DT	O
)	O
in	O
transgenic	O
iDTR	O
mice	O
selectively	O
expressing	O
DT	B-PRGE
receptor	I-PRGE
in	O
megakaryocytes	O
.	O

Detailed	O
methods	O
are	O
presented	O
for	O
expression	O
,	O
purification	O
,	O
and	O
release	O
testing	O
of	O
SARS	B-PRGE
recombinant	I-PRGE
spike	I-PRGE
protein	I-PRGE
antigen	I-PRGE
,	O
followed	O
by	O
adjuvant	O
formulation	O
and	O
animal	O
testing	O
.	O

Western	O
blot	O
analysis	O
revealed	O
the	O
rNP	B-PRGE
from	I-PRGE
CRCoV	I-PRGE
could	O
cross	O
-	O
react	O
with	O
mice	O
antisera	O
against	O
human	O
coronavirus	O
(	O
HCoV	O
-	O
229E	O
,	O
NL63	O
,	O
OC43	O
,	O
HKU1	O
),	O
while	O
rNP	O
of	O
CCoV	O
had	O
cross	O
-	O
reactivity	O
with	O
only	O
anti	O
-	O
sera	O
against	O
viruses	O
belonging	O
to	O
the	O
same	O
group	O
(	O
HCoV	O
-	O
229E	O
and	O
NL63	O
).	O

This	O
suppressive	O
effect	O
was	O
found	O
to	O
be	O
specific	O
for	O
the	O
activation	O
of	O
IFN	B-PRGE
regulatory	I-PRGE
factor	I-PRGE
3	I-PRGE
(	O
IRF3	B-PRGE
)	O
but	O
not	O
nuclear	O
factor	O
-	O
κB	O
.	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
protein	I-PRGE
interacted	O
with	O
TRAF3	B-PRGE
and	O
disrupted	O
TRAF3	B-PRGE
-	O
TBK1	B-PRGE
association	O
leading	O
to	O
reduced	O
IRF3	B-PRGE
activation	O
.	O

It	O
was	O
hypothesized	O
that	O
Mmp3	B-PRGE
deficient	O
(	O
Mmp3	B-PRGE
(-/-))	O
mice	O
would	O
be	O
protected	O
against	O
lung	O
dysfunction	O
associated	O
with	O
ARDS	O
and	O
maintain	O
a	O
functional	O
pulmonary	O
surfactant	O
system	O
.	O

Significant	O
increase	O
in	O
functional	O
large	O
aggregate	O
surfactant	O
forms	O
were	O
observed	O
in	O
Mmp3	B-PRGE
(-/-)	O
mice	O
compared	O
with	O
WT	O
mice	O
.	O

These	O
findings	O
further	O
support	O
a	O
role	O
of	O
Mmp3	B-PRGE
as	O
an	O
attractive	O
therapeutic	O
target	O
for	O
drug	O
development	O
in	O
the	O
setting	O
of	O
ARDS	O
.	O

Overall	O
,	O
the	O
NxTAG	O
-	O
RPP	O
demonstrated	O
≥	O
93	O
%	O
sensitivity	O
and	O
specificity	O
for	O
all	O
respiratory	O
targets	O
except	O
human	B-PRGE
coronavirus	I-PRGE
OC43	I-PRGE
(	O
HCoV	O
-	O
OC43	O
)	O
and	O
HCoV	O
-	O
HKU1	O
.	O

Coronavirus	B-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
3CL	O
(	O
pro	O
)),	O
which	O
is	O
involved	O
in	O
the	O
processing	O
of	O
viral	O
polyproteins	O
for	O
viral	O
replication	O
,	O
is	O
an	O
appealing	O
antiviral	O
drug	O
target	O
.	O

The	O
soluble	O
rGST	O
-	O
COE	O
and	O
rGST	O
-	O
S1D	O
were	O
purified	O
using	O
glutathione	B-PRGE
Sepharose	I-PRGE
4B	I-PRGE
with	O
a	O
yield	O
of	O
7	O
.	O
5	O
mg	O
/	O
l	O
and	O
5	O
mg	O
/	O
l	O
,	O
respectively	O
.	O

Finally	O
,	O
immunization	O
of	O
mice	O
with	O
10	O
μg	O
of	O
purified	O
proteins	O
elicited	O
highly	O
potent	O
serum	B-PRGE
IgG	I-PRGE
and	O
serum	B-PRGE
neutralizing	I-PRGE
antibody	I-PRGE
titers	O
.	O

Here	O
,	O
the	O
roles	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
ERRS	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
CoV	O
(	O
SARS	O
-	O
CoV	O
)	O
intracellular	O
trafficking	O
and	O
S	O
incorporation	O
into	O
virus	O
-	O
like	O
particles	O
(	O
VLPs	O
)	O
are	O
described	O
.	O

Moreover	O
,	O
the	O
intracellular	O
accumulation	O
of	O
mutant	B-PRGE
S	I-PRGE
protein	I-PRGE
,	O
particularly	O
at	O
the	O
post	O
-	O
medial	O
Golgi	O
compartment	O
,	O
was	O
significantly	O
reduced	O
compared	O
with	O
wtS	B-PRGE
.	O
A	O
VLP	O
assay	O
suggested	O
that	O
wtS	O
that	O
reached	O
the	O
post	O
-	O
medial	O
compartment	O
could	O
be	O
returned	O
to	O
the	O
ERGIC	O
for	O
subsequent	O
incorporation	O
into	O
VLPs	O
,	O
while	O
mutant	B-PRGE
S	I-PRGE
protein	I-PRGE
could	O
not	O
.	O

Epitope	O
mapping	O
and	O
subsequent	O
bioinformatic	O
analysis	O
revealed	O
that	O
these	O
mAbs	O
recognized	O
epitopes	O
located	O
within	O
relatively	O
highly	O
conserved	O
regions	O
of	O
the	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
amino	I-PRGE
-	I-PRGE
acid	I-PRGE
sequence	I-PRGE
.	O

TITLE	O
:	O
Monoclonal	O
Antibody	O
to	O
Bone	B-PRGE
Marrow	I-PRGE
Stromal	I-PRGE
Cell	I-PRGE
Antigen	I-PRGE
2	I-PRGE
Protein	I-PRGE
of	O
Swine	O
.	O

ABSTRACT	O
:	O
The	O
bone	B-PRGE
marrow	I-PRGE
stromal	I-PRGE
cell	I-PRGE
antigen	I-PRGE
2	I-PRGE
(	O
BST	O
-	O
2	O
)	O
protein	O
was	O
identified	O
as	O
a	O
novel	O
virus	O
restriction	O
factor	O
that	O
potently	O
restricts	O
the	O
replication	O
and	O
egress	O
of	O
enveloped	O
viruses	O
.	O

After	O
subcloning	O
,	O
one	O
strain	O
of	O
hybridoma	O
cells	O
named	O
1B2	O
secreting	O
porcine	O
BST	O
-	O
2	O
protein	O
monoclonal	B-PRGE
antibody	I-PRGE
(	O
MAb	O
)	O
was	O
obtained	O
.	O

Although	O
extensive	O
studies	O
have	O
been	O
carried	O
out	O
to	O
investigate	O
the	O
regulation	O
of	O
interferon	B-PRGE
(	O
IFN	B-PRGE
)	O
responses	O
by	O
alphacoronaviruses	O
,	O
betacoronaviruses	O
,	O
and	O
gammacoronaviruses	O
,	O
little	O
is	O
known	O
about	O
this	O
process	O
during	O
deltacoronavirus	O
infection	O
.	O

A	O
coupled	O
in	O
silico	O
/	O
in	O
vitro	O
investigation	O
was	O
employed	O
to	O
formulate	O
a	O
molecular	O
rationale	O
explaining	O
the	O
notable	O
affinity	O
of	O
all	O
molecules	O
to	O
BVDV	O
RNA	B-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
(	O
RdRp	O
)	O
NS5B	O
.	O

The	O
cases	O
were	O
mainly	O
confirmed	O
by	O
IgM	B-PRGE
detection	O
with	O
a	O
capture	O
enzyme	O
immunoassay	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
)	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
PLPro	O
)	O
reportedly	O
inhibits	O
the	O
production	O
of	O
type	O
I	O
interferons	O
(	O
IFNs	O
)	O
and	O
pro	O
-	O
inflammatory	O
cytokines	O
in	O
Toll	B-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
3	I-PRGE
(	O
TLR3	B-PRGE
)	O
and	O
retinoic	O
acid	O
-	O
inducible	O
gene	B-PRGE
1	I-PRGE
(	O
RIG	B-PRGE
-	I-PRGE
I	I-PRGE
)	O
pathways	O
.	O

However	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
PLPro	I-PRGE
significantly	O
inhibited	O
IMQ	O
-	O
induced	O
cytokine	O
production	O
through	O
suppressing	O
the	O
activation	O
of	O
transcription	O
factors	O
IRF	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
NF	O
-	O
κB	O
and	O
AP	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Ronivirus	B-PRGE
2	I-PRGE
'-	I-PRGE
O	I-PRGE
-	I-PRGE
MTase	I-PRGE
does	O
not	O
need	O
a	O
protein	O
cofactor	O
for	O
MTase	B-PRGE
activity	O
,	O
whereas	O
coronavirus	O
nsp16	O
needs	O
the	O
stimulating	O
factor	O
nsp10	O
for	O
its	O
full	O
activity	O
.	O

TITLE	O
:	O
X	O
-	O
Ray	O
Structure	O
and	O
Inhibition	O
of	O
3C	B-PRGE
-	I-PRGE
like	I-PRGE
Protease	I-PRGE
from	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
.	O

The	O
3C	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
3CL	O
(	O
pro	O
))	O
is	O
essential	O
for	O
the	O
coronaviral	O
life	O
cycle	O
and	O
is	O
an	O
appealing	O
target	O
for	O
the	O
development	O
of	O
therapeutics	O
.	O

Structural	O
comparison	O
reveals	O
that	O
the	O
majority	O
of	O
residues	O
involved	O
in	O
(	O
R	O
)-	O
16	O
binding	O
to	O
SARS	B-PRGE
-	I-PRGE
3CL	I-PRGE
(	O
pro	B-PRGE
)	O
are	O
conserved	O
in	O
PEDV	O
-	O
3CL	O
(	O
pro	O
);	O
however	O
,	O
the	O
sequence	O
variation	O
and	O
positional	O
difference	O
in	O
the	O
loop	O
forming	O
the	O
S2	O
pocket	O
may	O
account	O
for	O
large	O
observed	O
difference	O
in	O
IC50	O
values	O
.	O

TITLE	O
:	O
Andrographolide	O
sulfonate	O
ameliorates	O
lipopolysaccharide	O
-	O
induced	O
acute	O
lung	O
injury	O
in	O
mice	O
by	O
down	O
-	O
regulating	O
MAPK	B-PRGE
and	O
NF	O
-	O
κB	O
pathways	O
.	O

Moreover	O
,	O
andrographolide	O
sulfonate	O
markedly	O
suppressed	O
the	O
activation	O
of	O
mitogen	B-PRGE
-	I-PRGE
activated	I-PRGE
protein	I-PRGE
kinase	I-PRGE
(	O
MAPK	B-PRGE
)	O
as	O
well	O
as	O
p65	B-PRGE
subunit	I-PRGE
of	O
nuclear	B-PRGE
factor	I-PRGE
-	I-PRGE
κB	I-PRGE
(	O
NF	O
-	O
κB	O
).	O

In	O
summary	O
,	O
these	O
results	O
suggest	O
that	O
andrographolide	O
sulfonate	O
ameliorated	O
LPS	O
-	O
induced	O
ALI	O
in	O
mice	O
by	O
inhibiting	O
NF	O
-	O
κB	O
and	O
MAPK	B-PRGE
-	O
mediated	O
inflammatory	O
responses	O
.	O

To	O
study	O
the	O
genetic	O
characteristics	O
of	O
PEDV	O
strains	O
in	O
Chinese	O
mainland	O
,	O
a	O
total	O
of	O
603	O
clinical	O
samples	O
from	O
nine	O
provinces	O
/	O
districts	O
of	O
Chinese	O
mainland	O
from	O
January	O
2014	O
to	O
December	O
2015	O
were	O
collected	O
for	O
RT	O
-	O
PCR	O
detection	O
and	O
1	O
-	O
1323bp	O
of	O
S	B-PRGE
gene	I-PRGE
of	O
91	O
isolates	O
and	O
ORF3	O
gene	O
of	O
46	O
isolates	O
were	O
sequenced	O
.	O

The	O
N	O
-	O
terminal	O
of	O
S	B-PRGE
gene	I-PRGE
(	O
1	O
-	O
750bp	O
),	O
to	O
some	O
extent	O
,	O
could	O
represent	O
S1	O
or	O
full	B-PRGE
length	I-PRGE
S	I-PRGE
gene	I-PRGE
for	O
phylogenetic	O
,	O
similarity	O
,	O
antigen	O
index	O
,	O
hydrophilicity	O
plot	O
,	O
and	O
differentiation	O
analyses	O
.	O

TITLE	O
:	O
Characterization	O
of	O
the	O
Antigen	O
Processing	O
Machinery	O
and	O
Endogenous	O
Peptide	O
Presentation	O
of	O
a	O
Bat	B-PRGE
MHC	I-PRGE
Class	O
I	O
Molecule	O
.	O

ABSTRACT	O
:	O
Hemagglutinin	O
-	O
esterases	O
(	O
HEs	B-PRGE
)	O
are	O
bimodular	O
envelope	O
proteins	O
of	O
orthomyxoviruses	O
,	O
toroviruses	O
,	O
and	O
coronaviruses	O
with	O
a	O
carbohydrate	O
-	O
binding	O
""""	O
lectin	B-PRGE
""""	O
domain	O
appended	O
to	O
a	O
receptor	O
-	O
destroying	O
sialate	O
-	O
O	O
-	O
acetylesterase	O
"("""	O
esterase	B-PRGE
""")."	I-PRGE

Management	O
of	O
hyperglycaemia	O
with	O
insulin	B-PRGE
protocol	O
in	O
cases	O
with	O
value	O
>	O
200mg	O
/	O
dl	O
,	O
is	O
critical	O
in	O
improving	O
the	O
outcome	O
of	O
patients	O
with	O
TBI	O
.	O

Viral	O
infection	O
was	O
detected	O
by	O
multiplex	O
reverse	B-PRGE
transcriptase	I-PRGE
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
with	O
primers	O
specific	O
to	O
the	O
subtypes	O
HCoV	O
-	O
229E	O
/	O
NL63	O
and	O
OC43	O
/	O
HKU1	O
.	O

TITLE	O
:	O
Recognition	O
of	O
Lys48	B-PRGE
-	I-PRGE
Linked	I-PRGE
Di	I-PRGE
-	I-PRGE
ubiquitin	I-PRGE
and	O
Deubiquitinating	O
Activities	O
of	O
the	O
SARS	B-PRGE
Coronavirus	I-PRGE
Papain	I-PRGE
-	I-PRGE
like	I-PRGE
Protease	I-PRGE
.	O

In	O
contrast	O
,	O
ISG15	B-PRGE
specificity	O
is	O
dominated	O
by	O
contacts	O
in	O
the	O
S1	O
site	O
.	O

Type	O
I	O
interferons	O
(	O
IFN	B-PRGE
-	I-PRGE
α	I-PRGE
/	I-PRGE
β	I-PRGE
)	O
are	O
major	O
antiviral	O
cytokines	O
forming	O
host	O
innate	O
immunity	O
,	O
and	O
in	O
turn	O
,	O
these	O
enteric	O
coronaviruses	O
have	O
evolved	O
to	O
modulate	O
the	O
host	O
innate	O
immune	O
signaling	O
during	O
infection	O
.	O

Notably	O
,	O
UV	O
-	O
irradiated	O
inactivated	O
PEDV	O
,	O
which	O
can	O
enter	O
cells	O
but	O
cannot	O
replicate	O
inside	O
them	O
,	O
failed	O
to	O
induce	O
phosphorylation	O
of	O
p38	B-PRGE
MAPK	I-PRGE
and	O
JNK1	B-PRGE
/	I-PRGE
2	I-PRGE
suggesting	O
that	O
viral	O
biosynthesis	O
is	O
essential	O
for	O
activation	O
of	O
these	O
kinases	O
.	O

The	O
EqCoV	B-PRGE
S	I-PRGE
protein	I-PRGE
-	O
based	O
ELISA	O
was	O
able	O
to	O
reliably	O
detect	O
antibodies	O
to	O
EqCoV	O
in	O
naturally	O
infected	O
horses	O
.	O

Comparison	O
of	O
the	O
computationally	O
designed	O
ELISA	O
to	O
a	O
conventionally	O
developed	O
ELISA	O
,	O
using	O
bacterially	O
expressed	O
N	B-PRGE
protein	I-PRGE
,	O
and	O
to	O
the	O
immunofluorescence	O
assay	O
showed	O
a	O
high	O
degree	O
of	O
agreement	O
among	O
the	O
three	O
tests	O
(	O
mean	O
kappa	O
statistic	O
,	O
0	O
.	O
842	O
).	O

TITLE	O
:	O
Pig	B-PRGE
epidemic	O
diarrhoea	B-PRGE
virus	I-PRGE
S	I-PRGE
gene	I-PRGE
variant	O
with	O
a	O
large	O
deletion	O
non	O
-	O
lethal	O
to	O
colostrum	O
-	O
deprived	O
newborn	O
piglets	O
.	O

In	O
this	O
study	O
,	O
our	O
results	O
show	O
that	O
the	O
expression	O
of	O
Mo	O
-	O
DCs	O
surface	O
markers	O
such	O
as	O
SWC3a	B-PRGE
(+)	I-PRGE
CD1a	I-PRGE
(+),	I-PRGE
SWC3a	B-PRGE
(+)	I-PRGE
CD80	I-PRGE
/	I-PRGE
86	I-PRGE
(+)	I-PRGE
and	O
SWC3a	B-PRGE
(+)	I-PRGE
SLA	I-PRGE
-	I-PRGE
II	I-PRGE
-	I-PRGE
DR	I-PRGE
(+)	O
is	O
increased	O
after	O
incubation	O
with	O
UV	O
-	O
PEDV	O
for	O
24h	O
.	O

TITLE	O
:	O
Identification	O
,	O
synthesis	O
and	O
evaluation	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
inhibitors	O
.	O

TITLE	O
:	O
Feline	B-PRGE
Coronavirus	I-PRGE
3c	I-PRGE
Protein	I-PRGE
:	O
A	O
Candidate	O
for	O
a	O
Virulence	O
Marker	O
?	O

TITLE	O
:	O
Structural	O
and	O
mutational	O
analysis	O
of	O
the	O
interaction	O
between	O
the	O
Middle	O
-	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
and	O
human	B-PRGE
ubiquitin	I-PRGE
.	O

Through	O
sitedirected	O
mutagenesis	O
,	O
we	O
demonstrate	O
that	O
conserved	O
Asp165	O
and	O
non	O
-	O
conserved	O
Asp164	O
are	O
important	O
for	O
the	O
catalytic	O
activities	O
of	O
MERS	O
-	O
CoV	O
PL	O
(	O
pro	B-PRGE
).	O

Recently	O
,	O
it	O
has	O
been	O
reported	O
that	O
the	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
)	O
of	O
S1	B-PRGE
domain	I-PRGE
of	O
PEDV	B-PRGE
spike	I-PRGE
protein	I-PRGE
is	O
responsible	O
for	O
binding	O
to	O
the	O
5	O
-	O
N	O
-	O
acetylneuraminic	O
acid	O
(	O
Neu5Ac	O
),	O
a	O
possible	O
sugar	O
co	O
-	O
receptor	O
.	O

Lung	O
mononuclear	O
infiltrates	O
occurred	O
in	O
all	O
groups	O
after	O
virus	O
challenge	O
but	O
with	O
increased	O
infiltrates	O
that	O
contained	O
eosinophils	O
and	O
increases	O
in	O
the	O
eosinophil	O
promoting	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
cytokines	I-PRGE
only	O
in	O
the	O
vaccine	O
groups	O
.	O

Therefore	O
,	O
the	O
overall	O
objective	O
of	O
this	O
project	O
was	O
to	O
develop	O
and	O
validate	O
selected	O
diagnostic	O
reagents	O
and	O
assays	O
for	O
PDCoV	B-PRGE
antigen	I-PRGE
and	O
antibody	O
detection	O
.	O

The	O
oral	O
fluid	O
IgA	B-PRGE
response	O
increased	O
through	O
96	O
DPE	O
and	O
began	O
to	O
decline	O
at	O
the	O
last	O
sampling	O
on	O
111	O
DPE	O
.	O

The	O
method	O
employed	O
six	O
specially	O
designed	O
primers	O
that	O
recognized	O
eight	O
distinct	O
regions	O
of	O
the	O
HCoV	B-PRGE
-	I-PRGE
NL63	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
gene	I-PRGE
for	O
amplification	O
of	O
target	O
sequences	O
under	O
isothermal	O
conditions	O
at	O
63	O
degrees	O
C	O
for	O
1	O
h	O
Amplification	O
of	O
RT	O
-	O
LAMP	O
was	O
monitored	O
by	O
addition	O
of	O
calcein	O
before	O
amplification	O
.	O

General	O
depression	O
and	O
cough	O
were	O
the	O
signs	O
that	O
correlated	O
best	O
with	O
shedding	O
of	O
BCoV	B-PRGE
RNA	I-PRGE
,	O
while	O
peak	O
respiratory	O
rate	O
and	O
peak	O
rectal	O
temperature	O
appeared	O
more	O
than	O
a	O
week	O
later	O
than	O
the	O
peak	O
shedding	O
.	O

Here	O
,	O
we	O
report	O
that	O
ACE2	B-PRGE
prevents	O
LPS	O
-	O
induced	O
ARDS	O
by	O
inhibiting	O
MAPKs	O
and	O
NF	O
-	O
κB	O
signaling	O
pathway	O
.	O

LPS	O
-	O
induced	O
lung	O
injury	O
and	O
inflammatory	O
response	O
were	O
significantly	O
prevented	O
by	O
ACE2	B-PRGE
overexpression	O
and	O
deteriorated	O
by	O
Ace2	B-PRGE
shRNA	I-PRGE
.	O

To	O
further	O
understand	O
the	O
increased	O
prevalence	O
of	O
these	O
genotypes	O
,	O
we	O
assessed	O
and	O
compared	O
the	O
variability	O
of	O
the	O
S1	B-PRGE
gene	I-PRGE
hypervariable	I-PRGE
region	I-PRGE
of	I-PRGE
CA1737	I-PRGE
and	I-PRGE
Cal	I-PRGE
99	I-PRGE
with	O
the	O
variability	O
of	O
IBV	O
strains	O
belonging	O
to	O
the	O
Massachusetts	O
41	O
(	O
M41	O
)	O
and	O
Arkansas	O
(	O
Ark	O
)	O
types	O
during	O
serial	O
passages	O
in	O
embryonated	O
chicken	O
eggs	O
.	O

Sequencing	O
of	O
the	O
S1	B-PRGE
gene	I-PRGE
showed	O
nucleic	O
acid	O
sequence	O
identities	O
of	O
93	O
.	O
8	O
%	O
to	O
the	O
corresponding	O
region	O
of	O
IBV	O
California	O
99	O
and	O
of	O
85	O
.	O
7	O
%	O
to	O
IBV	O
Arkansas	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
antioxidant	O
,	O
antimicrobial	O
,	O
anti	O
-	O
HIV	O
,	O
and	O
cholinesterase	B-PRGE
inhibitory	O
activities	O
of	O
aqueous	O
and	O
alcoholic	O
extracts	O
from	O
leaves	O
,	O
stems	O
,	O
and	O
flowers	O
of	O
Euphorbia	O
characias	O
.	O

Linezolid	O
clearance	O
was	O
increased	O
in	O
ARDS	O
patients	O
(	O
by	O
82	O
%)	O
and	O
in	O
patients	O
with	O
elevated	O
fibrinogen	B-PRGE
or	O
decreased	O
lactate	O
concentrations	O
.	O

Nine	O
specimens	O
were	O
positive	O
and	O
eight	O
was	O
suitable	O
for	O
RdRp	B-PRGE
gene	I-PRGE
sequencing	O
.	O

Using	O
the	O
SCHOOL	O
approach	O
and	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
fusion	I-PRGE
peptide	I-PRGE
sequence	I-PRGE
,	O
we	O
rationally	O
designed	O
a	O
novel	O
immunomodulatory	O
peptide	O
that	O
targets	O
TCR	B-PRGE
.	O

Partial	O
nucleotide	O
sequences	O
of	O
the	O
S1	B-PRGE
spike	I-PRGE
gene	I-PRGE
was	O
determined	O
from	O
the	O
PEDV	O
-	O
positive	O
samples	O
and	O
compared	O
with	O
S1	O
sequences	O
from	O
other	O
countries	O
.	O

Viral	O
isolation	O
was	O
performed	O
in	O
Vero	O
cells	O
with	O
trypsin	B-PRGE
.	O

Next	O
,	O
the	O
nucleotide	O
sequence	O
of	O
the	O
3	O
'-	O
terminal	O
region	O
of	O
Saitama	O
-	O
1	O
(	O
8271	O
bases	O
)	O
strain	O
was	O
determined	O
and	O
compared	O
with	O
those	O
of	O
the	O
other	O
FRCoVs	O
,	O
indicating	O
that	O
the	O
Saitama	O
-	O
1	O
strain	O
differed	O
from	O
the	O
previously	O
reported	O
MSU	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
MSU	B-PRGE
-	I-PRGE
2	I-PRGE
strains	O
in	O
the	O
regions	O
encoding	O
spike	O
(	O
S	O
)	O
protein	O
,	O
nucleocapsid	O
,	O
and	O
open	O
reading	O
frame	O
7b	O
.	O

We	O
evaluated	O
the	O
following	O
three	O
sputum	O
-	O
homogenization	O
methods	O
:	B-PRGE
proteinase	I-PRGE
K	I-PRGE
and	O
DNase	B-PRGE
I	I-PRGE
(	O
PK	B-PRGE
-	I-PRGE
DNase	I-PRGE
)	O
treatment	O
,	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
treatment	O
,	O
and	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
and	O
sodium	O
citrate	O
(	O
NALC	O
)	O
treatment	O
.	O

Among	O
these	O
four	O
rHCoVs	O
-	O
OC43	O
,	O
rOC43	O
-	O
ns2DelRluc	O
(	O
generated	O
by	O
replacing	O
ns2	O
with	O
the	O
Rluc	B-PRGE
gene	I-PRGE
)	O
showed	O
robust	O
luciferase	O
activity	O
with	O
only	O
a	O
slight	O
impact	O
on	O
its	O
growth	O
characteristics	O
.	O

Since	O
PEDV	O
infection	O
-	O
induced	O
STAT1	B-PRGE
degradation	O
was	O
evident	O
in	O
cells	O
pretreated	O
with	O
the	O
general	B-PRGE
tyrosine	I-PRGE
kinase	I-PRGE
inhibitor	O
,	O
we	O
conclude	O
that	O
STAT1	B-PRGE
degradation	O
is	O
independent	O
of	O
the	O
IFN	B-PRGE
signaling	O
pathway	O
.	O

Pharmacological	O
inhibition	O
of	O
STAT1	B-PRGE
degradation	O
rescued	O
the	O
ability	O
of	O
the	O
host	O
to	O
suppress	O
virus	O
replication	O
.	O

The	O
molecular	O
mechanism	O
is	O
the	O
degradation	O
of	O
STAT1	B-PRGE
by	O
PEDV	O
infection	O
in	O
a	O
proteasome	O
-	O
dependent	O
manner	O
.	O

TITLE	O
:	O
Severe	O
stomatitis	O
and	O
ileocecal	O
perforation	O
developed	O
after	O
all	O
-	O
trans	O
retinoic	O
acid	O
monotherapy	O
in	O
an	O
HLA	B-PRGE
-	O
B51	O
-	O
positive	O
patient	O
with	O
acute	O
promyelocytic	O
leukemia	O
.	O

Furthermore	O
,	O
DNA	O
typing	O
of	O
the	O
HLA	B-PRGE
-	I-PRGE
B	I-PRGE
locus	I-PRGE
revealed	O
that	O
the	O
patient	O
had	O
HLA	B-PRGE
-	I-PRGE
B51	I-PRGE
associated	O
with	O
Behçet	O
'	O
s	O
disease	O
.	O

Four	O
groups	O
have	O
been	O
differentiated	O
:	O
(	O
1	O
)	O
absence	O
or	O
(	O
2	O
)	O
presence	O
of	O
systemic	O
inflammatory	O
response	O
syndrome	O
,	O
(	O
3	O
)	O
SS	O
or	O
(	O
4	O
)	O
SSh	O
;	O
and	O
2	O
groups	O
,	O
among	O
the	O
patients	O
admitted	O
for	O
acute	O
respiratory	O
failure	O
:	O
absence	O
or	O
presence	O
of	O
sCAP	B-PRGE
.	O

ABSTRACT	O
:	O
The	O
presence	O
of	O
immunoglobulin	B-PRGE
oligoclonal	O
bands	O
in	O
the	O
cerebrospinal	O
fluid	O
of	O
Multiple	O
Sclerosis	O
(	O
MS	O
)	O
patients	O
supports	O
the	O
hypothesis	O
of	O
an	O
infectious	O
etiology	O
,	O
although	O
the	O
antigenic	O
targets	O
remain	O
elusive	O
.	O

The	O
study	O
reveals	O
that	O
during	O
the	O
acute	O
stage	O
of	O
infection	O
,	O
both	O
strains	O
induce	O
inflammatory	O
innate	O
immune	O
response	O
genes	O
,	O
whereas	O
upregulation	O
of	O
several	O
immunoglobulin	B-PRGE
genes	I-PRGE
during	O
chronic	O
stage	O
infection	O
is	O
unique	O
to	O
infection	O
with	O
the	O
demyelinating	O
strain	O
.	O

Strategies	O
to	O
further	O
enhance	O
the	O
efficacy	O
of	O
MSCs	O
,	O
such	O
as	O
by	O
overexpressing	O
anti	B-PRGE
-	I-PRGE
inflammatory	I-PRGE
or	I-PRGE
pro	I-PRGE
-	I-PRGE
repair	I-PRGE
molecules	I-PRGE
,	O
are	O
also	O
being	O
investigated	O
.	O

Combining	O
these	O
technologies	O
in	O
primers	O
with	O
components	O
of	O
a	O
self	O
-	O
avoiding	O
molecular	O
recognition	O
system	O
(	O
SAMRS	O
),	O
we	O
detect	O
50	O
copies	O
of	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
in	O
a	O
multiplexed	O
respiratory	O
virus	O
panel	O
by	O
generating	O
fluorescence	O
signal	O
visible	O
to	O
human	O
eye	O
and	O
/	O
or	O
camera	O
.	O

The	O
TRP	B-PRGE
vanilloid	I-PRGE
4	I-PRGE
(	O
TRPV4	B-PRGE
)	O
ion	O
channel	O
is	O
opened	O
in	O
response	O
to	O
heat	O
,	O
mechanical	O
stimuli	O
,	O
hypo	O
-	O
osmolarity	O
and	O
arachidonic	O
acid	O
metabolites	O
.	O

Regulated	O
TRPV4	B-PRGE
function	O
is	O
also	O
essential	O
for	O
healthy	O
cardiovascular	O
system	O
function	O
as	O
a	O
potent	O
agonist	O
compromises	O
endothelial	O
cell	O
function	O
,	O
leading	O
to	O
vascular	O
collapse	O
.	O

In	O
the	O
vasculature	O
,	O
TRPV4	B-PRGE
is	O
a	O
regulator	O
of	O
vessel	O
tone	O
and	O
is	O
implicated	O
in	O
hypertension	O
and	O
diabetes	O
due	O
to	O
endothelial	O
dysfunction	O
.	O

TRPV4	B-PRGE
is	O
a	O
key	O
regulator	O
of	O
epithelial	O
and	O
endothelial	O
barrier	O
function	O
and	O
signalling	O
to	O
and	O
opening	O
of	O
TRPV4	B-PRGE
can	O
disrupt	O
these	O
critical	O
protective	O
barriers	O
.	O

Angiopoietin	B-PRGE
-	I-PRGE
2	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
receptor	I-PRGE
antagonist	O
concentrations	O
did	O
not	O
differ	O
between	O
groups	O
.	O

It	O
also	O
covers	O
a	O
new	O
definition	O
of	O
asthma	O
,	O
the	O
importance	O
of	O
confirming	O
various	O
airflow	O
limitations	O
with	O
spirometry	O
,	O
the	O
epidemiology	O
and	O
the	O
diagnostic	O
flow	O
of	O
asthma	O
in	O
Korea	O
,	O
the	O
importance	O
and	O
evidence	O
for	O
inhaled	O
corticosteroids	O
(	O
ICS	B-PRGE
)	O
and	O
ICS	B-PRGE
/	O
formoterol	O
as	O
a	O
single	O
maintenance	O
and	O
acute	O
therapy	O
in	O
the	O
stepwise	O
management	O
of	O
asthma	O
,	O
assessment	O
of	O
severity	O
of	O
asthma	O
and	O
management	O
of	O
exacerbation	O
,	O
and	O
an	O
action	O
plan	O
to	O
cope	O
with	O
exacerbation	O
.	O

Activation	O
of	O
caspase	B-PRGE
-	I-PRGE
3	I-PRGE
in	O
lung	O
tissue	O
after	O
DH	O
was	O
C5	O
-	O
dependent	O
whereas	O
local	O
inflammation	O
in	O
lung	O
tissue	O
was	O
C5	O
-	O
independent	O
.	O

TITLE	O
:	O
Relationship	O
between	O
elevated	O
soluble	O
CD74	B-PRGE
and	O
severity	O
of	O
experimental	O
and	O
clinical	O
ALI	O
/	O
ARDS	O
.	O

Porcine	B-PRGE
aminopeptidase	I-PRGE
N	I-PRGE
(	O
pAPN	O
)	O
has	O
been	O
reported	O
to	O
be	O
the	O
receptor	O
for	O
PEDV	O
,	O
although	O
robust	O
evidence	O
is	O
lacking	O
.	O

We	O
specifically	O
identified	O
the	O
imatinib	O
target	O
,	O
Abelson	B-PRGE
tyrosine	O
-	O
protein	O
kinase	O
2	O
(	O
Abl2	B-PRGE
),	O
as	O
required	O
for	O
efficient	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
replication	O
in	O
vitro	O
These	O
data	O
demonstrate	O
that	O
specific	O
approved	O
drugs	O
can	O
be	O
characterized	O
in	O
vitro	O
for	O
their	O
anticoronavirus	O
activity	O
and	O
used	O
to	O
identify	O
host	O
proteins	O
required	O
for	O
coronavirus	O
replication	O
.	O

In	O
this	O
study	O
,	O
the	O
molecular	O
cloning	O
,	O
expression	O
,	O
and	O
antiporcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
activity	O
of	O
porcine	B-PRGE
IFN	I-PRGE
-	I-PRGE
λ3	I-PRGE
(	O
poIFN	O
-	O
λ3	O
)	O
were	O
reported	O
.	O

The	O
full	O
-	O
length	O
poIFN	B-PRGE
-	I-PRGE
λ3	I-PRGE
cDNA	I-PRGE
sequence	I-PRGE
encoded	O
196	O
amino	O
acids	O
with	O
a	O
23	O
amino	O
acid	O
signal	O
peptide	O
.	O

In	O
addition	O
,	O
poIFN	O
-	O
λ3	O
was	O
able	O
to	O
induce	O
the	O
expression	O
of	O
IFN	B-PRGE
-	I-PRGE
stimulated	I-PRGE
genes	I-PRGE
,	O
including	O
ISG15	B-PRGE
,	O
OAS1	B-PRGE
,	O
and	O
Mx1	B-PRGE
in	O
Vero	O
E6	O
cells	O
.	O

HPIV	O
pneumonia	O
in	O
recipients	O
of	O
hematopoietic	B-PRGE
stem	I-PRGE
cell	I-PRGE
transplant	I-PRGE
(	O
HSCT	O
)	O
is	O
associated	O
with	O
50	O
%	O
acute	O
mortality	O
and	O
75	O
%	O
mortality	O
at	O
6	O
months	O
.	O

However	O
,	O
post	O
-	O
admission	O
decreases	O
in	O
the	O
serum	O
levels	O
of	O
interleukin	B-PRGE
(	O
IL	O
)-	O
17	O
,	O
IL	B-PRGE
-	I-PRGE
7	I-PRGE
,	I-PRGE
and	I-PRGE
monocyte	I-PRGE
chemoattractant	I-PRGE
protein	I-PRGE
-	I-PRGE
1	I-PRGE
were	O
significantly	O
greater	O
in	O
the	O
SLEDf	O
group	O
.	O

However	O
,	O
upon	O
viral	O
infection	O
or	O
Toll	B-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
2	I-PRGE
(	O
TLR2	B-PRGE
)	O
activation	O
,	O
LSECs	O
can	O
achieve	O
proinflammatory	O
functions	O
,	O
but	O
their	O
role	O
in	O
hepatic	O
inflammation	O
during	O
acute	O
viral	O
hepatitis	O
is	O
unknown	O
.	O

Disrupting	O
the	O
interaction	O
between	O
CEACAM5	B-PRGE
and	O
MERS	O
-	O
CoV	O
spike	O
with	O
anti	B-PRGE
-	I-PRGE
CEACAM5	I-PRGE
antibody	I-PRGE
,	O
recombinant	B-PRGE
CEACAM5	I-PRGE
protein	I-PRGE
,	O
or	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
knockdown	O
of	O
CEACAM5	O
significantly	O
inhibited	O
the	O
entry	O
of	O
MERS	O
-	O
CoV	O
.	O
Recombinant	O
expression	O
of	O
CEACAM5	O
did	O
not	O
render	O
nonpermissive	O
baby	O
hamster	O
kidney	O
(	O
BHK21	O
)	O
cells	O
susceptible	O
to	O
MERS	O
-	O
CoV	O
infection	O
.	O

Real	O
-	O
time	O
RT	O
-	O
PCR	O
was	O
used	O
to	O
detect	O
H5N6	B-PRGE
virus	I-PRGE
RNA	I-PRGE
in	O
clinical	O
and	O
environment	O
samples	O
.	O

The	O
protection	O
rates	O
of	O
groups	O
immunized	O
with	O
rS1	O
-	O
HA2	O
(	O
87	O
%)	O
were	O
significantly	O
higher	O
than	O
the	O
groups	O
inoculated	O
with	O
rS1	B-PRGE
(	O
47	O
%)	O
and	O
inactivated	O
M41	O
vaccine	O
(	O
53	O
%).	O

The	O
level	O
of	O
HMGB1	B-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	O
-	O
1β	O
,	O
and	O
TNF	B-PRGE
-	I-PRGE
α	I-PRGE
in	O
bronchoalveolar	O
lavage	O
fluid	O
was	O
significantly	O
increased	O
by	O
LPS	O
administration	O
after	O
pneumonectomy	O
and	O
significantly	O
decreased	O
by	O
rTM	O
administration	O
with	O
LPS	O
and	O
pneumonectomy	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

SM	B-PRGE
synthase	I-PRGE
(	O
SMS	B-PRGE
)	O
is	O
a	O
key	O
enzyme	O
in	O
the	O
synthesis	O
of	O
SM	O
,	O
however	O
,	O
the	O
effect	O
of	O
SMS	O
on	O
the	O
inflammatory	O
pathway	O
involving	O
nuclear	B-PRGE
factor	I-PRGE
(	O
NF	O
)‑	O
κB	O
induced	O
by	O
LPS	O
remains	O
to	O
be	O
elucidated	O
.	O

These	O
findings	O
suggested	O
that	O
the	O
degree	O
of	O
lung	O
injury	O
was	O
reduced	O
during	O
the	O
acute	O
inflammatory	O
reaction	O
when	O
NF	O
‑	O
κB	O
was	O
inhibited	O
,	O
and	O
that	O
the	O
expression	O
of	O
SMS2	B-PRGE
may	O
affect	O
the	O
induction	O
of	O
the	O
NF	O
‑	O
κB	O
pathway	O
by	O
LPS	O
through	O
CD14	B-PRGE
.	O

A	O
total	O
of	O
23	O
Saudi	O
patients	O
with	O
severe	O
MERS	O
-	O
CoV	O
infection	O
were	O
typed	O
for	O
HLA	B-PRGE
class	O
II	O
,	O
results	O
were	O
compared	O
with	O
those	O
of	O
161	O
healthy	O
controls	O
.	O

Two	O
HLA	B-PRGE
class	I-PRGE
II	I-PRGE
alleles	I-PRGE
were	O
associated	O
with	O
the	O
disease	O
;	O
HLA	B-PRGE
-	I-PRGE
DRB1	I-PRGE
*	I-PRGE
11	I-PRGE
:	O
01	O
and	O
DQB1	O
*	O
02	O
:	O
02	O
,	O
but	O
not	O
with	O
the	O
disease	O
outcome	O
.	O

General	O
strategies	O
to	O
design	O
specific	O
and	O
selective	O
drugs	O
targeting	O
helicase	B-PRGE
for	O
the	O
treatment	O
of	O
viral	O
infections	O
could	O
act	O
via	O
one	O
or	O
more	O
of	O
the	O
following	O
mechanisms	O
:	O
inhibition	O
of	O
the	O
NTPase	B-PRGE
activity	O
,	O
by	O
interferences	O
with	O
ATP	O
binding	O
and	O
therefore	O
by	O
limiting	O
the	O
energy	O
required	O
for	O
the	O
unwinding	O
and	O
translocation	O
,	O
or	O
by	O
allosteric	O
mechanism	O
and	O
therefore	O
by	O
stabilizing	O
the	O
conformation	O
of	O
the	O
enzyme	O
in	O
low	O
helicase	B-PRGE
activity	O
state	O
;	O
inhibition	O
of	O
nucleic	O
acids	O
binding	O
to	O
the	O
helicase	B-PRGE
;	O
inhibition	O
of	O
coupling	O
of	O
ATP	O
hydrolysis	O
to	O
unwinding	O
;	O
inhibition	O
of	O
unwinding	O
by	O
sterically	O
blocking	O
helicase	B-PRGE
translocation	O
.	O

An	O
ELISA	O
using	O
sporozoite	O
antigen	O
was	O
developed	O
for	O
the	O
specific	O
detection	O
of	O
anti	B-PRGE
-	I-PRGE
Cryptosporidium	I-PRGE
-	I-PRGE
IgG	I-PRGE
in	O
blood	O
-	O
and	O
colostral	O
serum	O
.	O

TITLE	O
:	O
p53	B-PRGE
down	O
-	O
regulates	O
SARS	O
coronavirus	O
replication	O
and	O
is	O
targeted	O
by	O
the	O
SARS	O
-	O
unique	O
domain	O
and	O
PLpro	O
via	O
E3	B-PRGE
ubiquitin	I-PRGE
ligase	I-PRGE
RCHY1	O
.	O

We	O
identify	O
cellular	O
E3	O
ubiquitin	B-PRGE
ligase	I-PRGE
ring	I-PRGE
-	I-PRGE
finger	I-PRGE
and	I-PRGE
CHY	I-PRGE
zinc	I-PRGE
-	I-PRGE
finger	I-PRGE
domain	I-PRGE
-	I-PRGE
containing	I-PRGE
1	I-PRGE
(	O
RCHY1	B-PRGE
)	O
as	O
an	O
interacting	O
partner	O
of	O
the	O
viral	O
SARS	O
-	O
unique	O
domain	O
(	O
SUD	O
)	O
and	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
PL	O
(	O
pro	O
)),	O
and	O
,	O
as	O
a	O
consequence	O
,	O
the	O
involvement	O
of	O
cellular	B-PRGE
p53	I-PRGE
as	O
antagonist	O
of	O
coronaviral	O
replication	O
.	O

We	O
addressed	O
this	O
problem	O
by	O
using	O
the	O
-	O
1	O
PRF	O
stimulation	O
pseudoknot	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
(	O
SARS	B-PRGE
-	I-PRGE
PK	I-PRGE
)	O
to	O
build	O
a	O
ligand	O
-	O
dependent	O
-	O
1	O
PRF	O
stimulator	O
.	O

CCE	O
is	O
ideally	O
suited	O
to	O
guide	O
the	O
diagnostic	O
work	O
-	O
up	O
in	O
patients	O
presenting	O
with	O
ARF	B-PRGE
since	O
it	O
allows	O
the	O
assessment	O
of	O
left	O
ventricular	O
filling	O
pressure	O
and	O
pulmonary	O
artery	O
pressure	O
,	O
and	O
the	O
identification	O
of	O
a	O
potential	O
underlying	O
cardiopathy	O
.	O

The	O
SARS	O
tragedy	O
revealed	O
faults	O
in	O
China	O
'	O
s	O
infectious	O
disease	O
prevention	O
system	O
,	O
propelling	O
the	O
Chinese	O
government	O
to	O
enact	O
reforms	O
that	O
enabled	O
better	O
combating	O
of	O
the	O
subsequent	O
H1N1	O
and	O
H7N9	B-PRGE
avian	I-PRGE
flu	I-PRGE
epidemics	I-PRGE
.	O

Dromedary	O
viruses	O
were	O
as	O
sensitive	O
to	O
the	O
human	B-PRGE
type	I-PRGE
I	I-PRGE
interferon	I-PRGE
response	O
as	O
HCoV	O
-	O
229E	O
.	O

TITLE	O
:	O
Xanthine	B-PRGE
Oxidase	I-PRGE
-	O
Derived	O
ROS	O
Display	O
a	O
Biphasic	O
Effect	O
on	O
Endothelial	O
Cells	O
Adhesion	O
and	O
FAK	B-PRGE
Phosphorylation	O
.	O

TITLE	O
:	O
Plasma	B-PRGE
syndecan	I-PRGE
-	I-PRGE
1	I-PRGE
levels	O
identify	O
a	O
cohort	O
of	O
patients	O
with	O
severe	O
sepsis	O
at	O
high	O
risk	O
for	O
intubation	O
after	O
large	O
-	O
volume	O
intravenous	O
fluid	O
resuscitation	O
.	O

The	O
assay	O
was	O
optimized	O
for	O
a	O
384	O
-	O
well	O
format	O
,	O
and	O
nafamostat	O
,	O
a	O
serine	B-PRGE
protease	I-PRGE
inhibitor	I-PRGE
,	O
was	O
identified	O
as	O
a	O
potent	O
inhibitor	O
of	O
S	O
-	O
mediated	O
membrane	O
fusion	O
in	O
a	O
screening	O
of	O
about	O
1	O
,	O
000	O
drugs	O
approved	O
for	O
use	O
by	O
the	O
U	O
.	O
S	O
.	O
Food	O
and	O
Drug	O
Administration	O
.	O

This	O
review	O
focuses	O
on	O
the	O
different	O
approaches	O
available	O
to	O
monitor	O
RNA	O
packaging	O
:	O
Northern	O
blot	O
analysis	O
,	O
ribonuclease	O
protection	O
assay	O
and	O
quantitative	O
reverse	B-PRGE
transcriptase	I-PRGE
-	O
coupled	O
polymerase	O
chain	O
reaction	O
as	O
well	O
as	O
the	O
most	O
recent	O
RNA	O
imaging	O
and	O
sequencing	O
technologies	O
.	O

TITLE	O
:	O
Antagonism	O
of	O
RNase	B-PRGE
L	I-PRGE
Is	O
Required	O
for	O
Murine	O
Coronavirus	O
Replication	O
in	O
Kupffer	O
Cells	O
and	O
Liver	O
Sinusoidal	O
Endothelial	O
Cells	O
but	O
Not	O
in	O
Hepatocytes	O
.	O

ABSTRACT	O
:	O
The	O
parapoxvirus	O
Orf	B-PRGE
virus	I-PRGE
(	O
ORFV	O
),	O
has	O
long	O
been	O
recognized	O
for	O
its	O
immunomodulatory	O
properties	O
in	O
permissive	O
and	O
non	O
-	O
permissive	O
animal	O
species	O
.	O

TITLE	O
:	O
MERS	O
coronavirus	O
induces	O
apoptosis	O
in	O
kidney	O
and	O
lung	O
by	O
upregulating	O
Smad7	B-PRGE
and	O
FGF2	B-PRGE
.	O

Smad7	B-PRGE
and	O
FGF2	B-PRGE
expression	O
were	O
elevated	O
in	O
the	O
lungs	O
and	O
kidneys	O
of	O
the	O
infected	O
animals	O
.	O

Cryo	O
-	O
preserved	O
serum	O
obtained	O
at	O
this	O
time	O
showed	O
high	O
titers	O
of	O
IgM	B-PRGE
class	O
antibodies	O
against	O
ganglioside	O
(	O
GD3	O
+++,	O
GT1a	O
++++,	O
GT1b	B-PRGE
++,	I-PRGE
GQ1b	I-PRGE
+++,	I-PRGE
and	I-PRGE
GD1b	I-PRGE
+++),	I-PRGE
which	O
had	O
been	O
negative	O
on	O
admission	O
.	O

(	O
6	O
)	O
The	O
median	O
of	O
survival	O
table	O
of	O
children	O
with	O
normal	O
pancreas	O
was	O
75	O
days	O
,	O
the	O
median	O
of	O
survival	O
table	O
of	O
children	O
with	O
elevated	O
amylase	B-PRGE
or	O
lipase	B-PRGE
was	O
24	O
days	O
.(	O
7	O
)	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
estimate	O
in	O
population	O
of	O
free	O
-	O
living	O
wild	O
boar	O
in	O
the	O
Czech	O
Republic	O
the	O
prevalence	O
of	O
enteric	O
viral	O
pathogens	O
,	O
namely	O
rotavirus	O
groups	O
A	O
and	O
C	O
(	O
RVA	O
and	O
RVC	O
),	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
),	O
and	O
members	O
of	O
family	O
Coronaviridae	O
(	O
transmissible	O
gastroenteritis	O
virus	O
-	O
TGEV	O
,	O
porcine	O
epidemic	O
diarrhea	O
virus	O
-	O
PEDV	O
,	O
porcine	O
respiratory	O
coronavirus	O
-	O
PRCV	O
,	O
and	O
porcine	O
hemagglutination	O
encephalomyelitis	O
virus	O
-	O
PHEV	O
)	O
and	O
Picornaviridae	O
,(	O
teschovirus	O
A	O
-	O
PTV	O
,	O
sapelovirus	B-PRGE
A	I-PRGE
-	I-PRGE
PSV	I-PRGE
,	O
and	O
enterovirus	O
G	O
-	O
EV	O
-	O
G	O
).	O

In	O
this	O
study	O
,	O
the	O
whole	O
S1	B-PRGE
gene	I-PRGE
of	O
five	O
Egyptian	O
IBVs	O
was	O
genetically	O
analyzed	O
.	O

Human	B-PRGE
coronavirus	I-PRGE
NL63	I-PRGE
(	O
HCoV	O
-	O
NL63	O
)	O
is	O
an	O
α	O
-	O
coronavirus	O
that	O
can	O
cause	O
severe	O
lower	O
-	O
respiratory	O
-	O
tract	O
infections	O
requiring	O
hospitalization	O
.	O

The	O
effects	O
of	O
inappropriate	O
normalization	O
on	O
the	O
transcription	O
pattern	O
of	O
a	O
cellular	O
signalling	O
gene	O
,	O
AKT1	B-PRGE
,	O
and	O
the	O
interferon	B-PRGE
-	O
inducible	O
,	O
MX1	O
,	O
were	O
studied	O
.	O

This	O
is	O
most	O
notable	O
when	O
measuring	O
the	O
transcription	O
of	O
AKT1	B-PRGE
,	O
where	O
changes	O
are	O
minimal	O
during	O
infection	O
.	O

Plasma	B-PRGE
proinflammatory	I-PRGE
markers	I-PRGE
IL	I-PRGE
-	I-PRGE
6	I-PRGE
and	O
IL	O
-	O
8	O
and	O
anti	B-PRGE
-	I-PRGE
inflammatory	I-PRGE
marker	I-PRGE
IL	I-PRGE
-	I-PRGE
10	I-PRGE
were	O
associated	O
with	O
the	O
development	O
of	O
ARDS	O
(	O
adjusted	O
hazard	O
ratio	O
(	O
HR	O
)	O
=	O
1	O
.	O
55	O
,	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1	O
.	O
14	O
,	O
2	O
.	O
11	O
,	O
P	O
=	O
0	O
.	O
005	O
for	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
;	O
adjusted	O
HR	O
=	O
1	O
.	O
32	O
,	O
CI	O
=	O
1	O
.	O
10	O
,	O
1	O
.	O
59	O
,	O
P	O
=	O
0	O
.	O
003	O
for	O
IL	O
-	O
8	O
).	O

We	O
have	O
cloned	O
,	O
expressed	O
,	O
and	O
purified	O
a	O
Strep	O
-	O
fused	O
recombinant	O
MERS	O
-	O
CoV	O
nonstructural	O
protein	O
13	O
(	O
M	O
-	O
nsp13	O
)	O
helicase	B-PRGE
.	O

Characterization	O
of	O
its	O
biochemical	O
properties	O
showed	O
that	O
it	O
unwound	O
DNA	O
and	O
RNA	O
similarly	O
to	O
severe	O
acute	O
respiratory	O
syndrome	O
CoV	O
nsp13	O
(	O
S	O
-	O
nsp13	O
)	O
helicase	B-PRGE
.	O

Thirteen	O
subjects	O
with	O
cardiovascular	O
dysfunction	O
were	O
treated	O
with	O
the	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
receptor	I-PRGE
antibody	I-PRGE
tocilizumab	O
.	O

ABSTRACT	O
:	O
A	O
recently	O
developed	O
prediction	O
score	O
based	O
on	O
age	O
,	O
arterial	O
oxygen	O
partial	O
pressure	O
to	O
fractional	O
inspired	O
oxygen	O
ratio	O
(	O
PaO2	O
/	O
FiO2	O
)	O
and	O
plateau	O
pressure	O
(	O
abbreviated	O
as	O
'	B-PRGE
APPS	I-PRGE
')	O
was	O
shown	O
to	O
accurately	O
predict	O
mortality	O
in	O
patients	O
diagnosed	O
with	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Investigation	O
of	O
the	O
temporal	O
dynamics	O
of	O
B	O
cell	O
activation	O
in	O
draining	O
cervical	O
lymph	O
nodes	O
(	O
CLN	O
)	O
and	O
the	O
CNS	O
revealed	O
that	O
peak	O
CNS	O
infiltration	O
of	O
early	O
activated	O
,	O
unswitched	O
IgD	B-PRGE

To	O
characterize	O
potential	O
for	O
interspecies	O
transmission	O
associated	O
with	O
feeding	O
behavior	O
,	O
we	O
also	O
analyzed	O
cytochrome	B-PRGE
B	I-PRGE
sequences	I-PRGE
from	O
fecal	O
samples	O
to	O
identify	O
prey	O
species	O
and	O
found	O
that	O
domestic	O
cattle	O
(	O
Bos	O
taurus	O
)	O
made	O
up	O
the	O
majority	O
of	O
blood	O
meals	O
.	O

The	O
results	O
presented	O
here	O
suggest	O
the	O
role	O
of	O
Kepi	O
in	O
the	O
host	O
response	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
as	O
well	O
as	O
inflammatory	O
activity	O
driving	O
pathogenesis	O
through	O
TNFα	O
signaling	O
in	O
SARS	O
-	O
CoV	O
infections	O
.	O

Recent	O
technological	O
developments	O
in	O
single	O
particle	O
cryo	O
-	O
electron	O
microscopy	O
allowed	O
us	O
to	O
determine	O
the	O
first	O
structure	O
of	O
a	O
coronavirus	B-PRGE
S	I-PRGE
glycoprotein	I-PRGE
trimer	O
which	O
provided	O
a	O
framework	O
to	O
understand	O
the	O
mechanisms	O
of	O
viral	O
entry	O
and	O
suggested	O
potential	O
inhibition	O
strategies	O
for	O
this	O
family	O
of	O
viruses	O
.	O

One	O
hundred	O
and	O
ninety	O
-	O
five	O
Italian	O
and	O
98	O
Spanish	O
non	O
-	O
recombinant	O
sequences	O
of	O
the	O
hyper	O
-	O
variable	O
region	O
of	O
the	O
S1	B-PRGE
gene	I-PRGE
obtained	O
between	O
2012	O
and	O
2016	O
were	O
analyzed	O
using	O
a	O
serial	O
coalescent	O
-	O
based	O
approach	O
to	O
reconstruct	O
viral	O
population	O
history	O
over	O
time	O
.	O

By	O
using	O
surface	O
plasmon	O
resonance	O
,	O
we	O
demonstrated	O
that	O
HKU9	O
-	O
RBD	O
binds	O
to	O
neither	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
ACE2	B-PRGE
nor	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
CD26	I-PRGE
.	O

Younger	O
age	O
,	O
history	O
of	O
prematurity	O
,	O
chronic	O
comorbidity	O
and	O
thrombocytosis	O
are	O
predictors	O
of	O
severe	O
RSV	B-PRGE
ALRI	I-PRGE
among	O
Malaysian	O
children	O
.	O

IFITM3	B-PRGE
knockdown	O
by	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
could	O
partially	O
rescue	O
H1N1	O
virus	O
infection	O
in	O
HULEC	O
,	O
suggesting	O
IFITM3	B-PRGE
proteins	I-PRGE
were	O
involved	O
in	O
blocking	O
human	O
influenza	O
virus	O
infection	O
in	O
endothelial	O
cells	O
.	O

Antigen	B-PRGE
-	I-PRGE
specific	I-PRGE
IL	I-PRGE
-	I-PRGE
10	I-PRGE
-	I-PRGE
secreting	I-PRGE
CD4	I-PRGE

Most	O
of	O
these	O
mutations	O
result	O
in	O
amino	O
acid	O
substitutions	O
in	O
the	O
S	B-PRGE
protein	I-PRGE
and	O
these	O
may	O
have	O
a	O
critical	O
role	O
in	O
the	O
switch	O
from	O
FECV	O
to	O
FIPV	O
.	O

The	O
two	O
coronaviruses	O
are	O
thought	O
to	O
encode	O
an	O
unusually	O
large	O
number	O
of	O
factors	O
that	O
allow	O
them	O
to	O
thrive	O
and	O
replicate	O
in	O
the	O
presence	O
of	O
efficient	O
host	O
defense	O
mechanisms	O
,	O
especially	O
the	O
antiviral	O
interferon	B-PRGE
system	O
.	O

Using	O
this	O
new	O
structural	O
insight	O
,	O
we	O
review	O
the	O
changes	O
in	O
the	O
S	B-PRGE
protein	I-PRGE
that	O
relate	O
to	O
changes	O
in	O
virus	O
tropism	O
.	O

A	O
thorough	O
understanding	O
of	O
the	O
key	O
role	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
in	O
CoV	O
entry	O
is	O
critical	O
to	O
further	O
our	O
understanding	O
of	O
virus	O
cross	O
-	O
species	O
transmission	O
and	O
pathogenesis	O
and	O
for	O
development	O
of	O
intervention	O
strategies	O
.	O

The	O
primary	O
functions	O
that	O
direct	O
coronavirus	O
RNA	O
synthesis	O
and	O
processing	O
reside	O
in	O
nonstructural	O
protein	O
(	O
nsp	O
)	O
7	O
to	O
nsp16	O
,	O
which	O
are	O
cleavage	O
products	O
of	O
two	O
large	B-PRGE
replicase	I-PRGE
polyproteins	I-PRGE
translated	O
from	O
the	O
coronavirus	O
genome	O
.	O

Coronavirus	O
replicase	B-PRGE
functions	O
include	O
more	O
or	O
less	O
universal	O
activities	O
of	O
plus	O
-	O
stranded	O
RNA	O
viruses	O
,	O
like	O
an	O
RNA	B-PRGE
polymerase	I-PRGE
(	O
nsp12	O
)	O
and	O
helicase	B-PRGE
(	O
nsp13	O
),	O
but	O
also	O
a	O
number	O
of	O
rare	O
or	O
even	O
unique	O
domains	O
involved	O
in	O
mRNA	O
capping	O
(	O
nsp14	O
,	O
nsp16	O
)	O
and	O
fidelity	O
control	O
(	O
nsp14	O
).	O

We	O
speculate	O
that	O
low	O
immunity	O
due	O
to	O
decreased	O
immunoglobulin	B-PRGE
in	O
patients	O
with	O
OHSS	O
makes	O
them	O
prone	O
to	O
SBP	B-PRGE
.	O

TITLE	O
:	O
Clinical	O
Isolates	O
of	O
Human	B-PRGE
Coronavirus	I-PRGE
229E	I-PRGE
Bypass	O
the	O
Endosome	O
for	O
Cell	O
Entry	O
.	O

After	O
20	O
passages	O
in	O
HeLa	O
cells	O
,	O
the	O
ability	O
of	O
the	O
isolate	O
to	O
use	O
cathepsin	B-PRGE
increased	O
so	O
that	O
it	O
was	O
equal	O
to	O
that	O
of	O
the	O
laboratory	O
strain	O
;	O
this	O
increase	O
was	O
caused	O
by	O
an	O
amino	O
acid	O
substitution	O
(	O
I577S	O
)	O
in	O
the	O
S	B-PRGE
protein	I-PRGE
.	O

ABSTRACT	O
:	O
Human	O
coronaviruses	O
(	O
HCoVs	O
),	O
including	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
MERS	O
-	O
CoV	O
,	O
are	O
zoonotic	O
pathogens	O
that	O
originated	O
in	O
wild	O
animals	O
.	O

Active	O
compounds	O
were	O
then	O
assayed	O
for	O
their	O
effects	O
on	O
HIV	O
-	O
1	O
mutated	O
RTs	O
,	O
integrase	B-PRGE
(	O
IN	O
)	O
and	O
viral	O
replication	O
.	O

LPS	O
-	O
induced	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
NF	O
-	O
κB	O
and	O
p38	B-PRGE
MAPK	O
were	O
blocked	O
by	O
Nur77	B-PRGE
overexpression	O
and	O
augmented	O
by	O
Nur77	B-PRGE
knockdown	O
in	O
A549	O
cells	O
.	O

In	O
vivo	O
,	O
LPS	B-PRGE
induced	O
Nur77	B-PRGE
expression	O
in	O
lung	O
in	O
ARDS	O
rats	O
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
3	O
-	O
3	O
-{	O
2	O
-[	O
2	O
-	O
3	O
-	O
methyl	O
-	O
4	O
-	O
phenyl	O
-	O
2	O
,	O
3	O
-	O
dihydro	O
-	O
1	O
,	O
3	O
-	O
thiazol	O
-	O
2	O
-	O
ylidene	O
]	O
hydrazin	O
-	O
1	O
-	O
ylidene	O
-	O
2	O
,	O
3	O
-	O
dihydro	O
-	O
1H	O
-	O
indol	O
-	O
2	O
-	O
one	O
derivatives	O
has	O
been	O
designed	O
and	O
synthesized	O
to	O
study	O
their	O
activity	O
on	O
both	O
HIV	O
-	O
1	O
(	O
Human	B-PRGE
Immunodeficiency	I-PRGE
Virus	I-PRGE
type	I-PRGE
1	I-PRGE
)	O
RT	O
(	O
Reverse	B-PRGE
Transcriptase	I-PRGE
)	O
associated	O
functions	O
.	O

The	O
aim	O
of	O
this	O
research	O
was	O
to	O
screen	O
and	O
characterize	O
the	O
compounds	O
that	O
could	O
inhibit	O
the	O
activity	O
of	O
PEDV	B-PRGE
N	I-PRGE
protein	I-PRGE
.	O

TITLE	O
:	O
Pivotal	O
Role	O
of	O
Receptor	O
-	O
Interacting	O
Protein	B-PRGE
Kinase	I-PRGE
1	I-PRGE
and	O
Mixed	O
Lineage	O
Kinase	O
Domain	O
-	O
Like	O
in	O
Neuronal	O
Cell	O
Death	O
Induced	O
by	O
the	O
Human	B-PRGE
Neuroinvasive	I-PRGE
Coronavirus	I-PRGE
OC43	I-PRGE
.	O

Here	O
,	O
we	O
constructed	O
four	O
recombinant	O
RBD	O
(	O
rRBD	O
)	O
proteins	O
with	O
single	O
or	O
multiple	O
mutations	O
detected	O
in	O
representative	O
human	O
MERS	O
-	O
CoV	O
strains	O
from	O
the	O
2012	O
,	O
2013	O
,	O
2014	O
,	O
and	O
2015	O
outbreaks	O
,	O
respectively	O
,	O
and	O
one	O
rRBD	B-PRGE
protein	I-PRGE
with	O
multiple	O
changes	O
derived	O
from	O
camel	O
MERS	O
-	O
CoV	O
strains	O
.	O

These	O
RBD	O
mutants	O
with	O
diminished	O
DPP4	B-PRGE
binding	O
also	O
led	O
to	O
virus	O
attenuation	O
,	O
suggesting	O
that	O
immunoevasion	O
after	O
RBD	O
immunization	O
is	O
accompanied	O
by	O
loss	O
of	O
viral	O
fitness	O
.	O

Moreover	O
,	O
FRC	B-PRGE
-	O
specific	O
ablation	O
of	O
the	O
innate	O
immunological	O
sensing	O
adaptor	O
MyD88	B-PRGE
unleashed	I-PRGE
IL	I-PRGE
-	I-PRGE
15	I-PRGE
production	O
by	O
FRCs	O
during	O
infection	O
with	O
an	O
enteropathogenic	O
virus	O
,	O
which	O
led	O
to	O
hyperactivation	O
of	O
group	O
1	O
ILCs	O
and	O
substantially	O
altered	O
the	O
differentiation	O
of	O
helper	O
T	O
cells	O
.	O

Next	O
,	O
we	O
challenged	O
both	O
vaccinated	O
mice	O
and	O
control	O
mice	O
with	O
MERS	O
-	O
CoV	O
after	O
adenovirus	O
transduction	O
of	O
the	O
human	B-PRGE
dipeptidyl	I-PRGE
peptidase	I-PRGE
4	I-PRGE
(	O
hDPP4	O
)	O
receptor	O
and	O
then	O
analyzed	O
the	O
ability	O
of	O
mice	O
to	O
control	O
MERS	O
-	O
CoV	O
infection	O
.	O

Given	O
the	O
numerous	O
pathophysiologic	O
roles	O
of	O
neutrophils	O
in	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
we	O
postulated	O
that	O
neutrophil	O
GILZ	B-PRGE
expression	O
might	O
be	O
induced	O
during	O
ARDS	O
,	O
to	O
modulate	O
the	O
inflammatory	O
process	O
and	O
participate	O
in	O
lung	O
repair	O
.	O

To	O
assess	O
the	O
importance	O
of	O
sPD	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
ARDS	O
,	O
ex	O
vivo	O
experiments	O
were	O
undertaken	O
.	O

sPD	B-PRGE
-	I-PRGE
1	I-PRGE
could	O
be	O
used	O
to	O
not	O
only	O
diagnose	O
ARDS	O
,	O
but	O
may	O
be	O
a	O
potential	O
therapy	O
.	O

BAL	O
fluid	O
from	O
mice	O
with	O
ARDS	O
dampens	O
the	O
TNF	B-PRGE
-	I-PRGE
α	I-PRGE
production	O
compared	O
to	O
cells	O
cultured	O
with	O
BAL	O
lacking	O
sPD	B-PRGE
-	I-PRGE
1	I-PRGE
(	O
2	O
.	O
7	O
pg	O
/	O
mL	O
(	O
SD	O
3	O
.	O
8	O
)	O
vs	O
.	O
52	O
.	O
38	O
pg	O
/	O
mL	O
(	O
SD	O
25	O
.	O
1	O
),	O
p	O
=	O
0	O
.	O
002	O
).	O

ABSTRACT	O
:	O
Dermatomyositis	O
associated	O
with	O
anti	B-PRGE
-	I-PRGE
MDA	I-PRGE
-	I-PRGE
5	I-PRGE
autoantibodies	I-PRGE
is	O
a	O
recently	O
-	O
described	O
clinical	O
entity	O
.	O

GP	B-PRGE
IIb	I-PRGE
/	O
IIIa	O
inhibitors	O
improve	O
outcome	O
in	O
patients	O
undergoing	O
percutaneous	O
coronary	O
intervention	O
for	O
acute	O
coronary	O
syndrome	O
.	O

Moreover	O
,	O
inhibition	O
studies	O
showed	O
that	O
EGFR	B-PRGE
modulated	O
glucose	O
uptake	O
in	O
control	O
and	O
TGEV	O
infected	O
cells	O
.	O

However	O
,	O
the	O
current	O
methods	O
are	O
limited	O
to	O
antigen	O
detection	O
by	O
conjugating	O
IgG	B-PRGE
antibodies	I-PRGE
on	O
S	O
.	O
aureus	O
nanoparticles	O
.	O

In	O
this	O
study	O
,	O
a	O
simple	O
way	O
to	O
conjugate	O
antigens	O
to	O
the	O
S	O
.	O
aureus	O
nanobioparticles	O
was	O
developed	O
by	O
utilizing	O
a	O
cell	O
wall	O
binding	O
domain	O
(	O
CBD	O
)	O
from	O
a	O
bacteriophage	O
lysin	B-PRGE
PlyV12	I-PRGE
.	O

ABSTRACT	O
:	O
Systemic	O
complications	O
related	O
to	O
acute	O
pancreatitis	O
include	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
multiple	O
organ	O
dysfunction	O
syndrome	O
,	O
disseminated	O
intravascular	O
coagulation	O
,	O
hypocalcemia	O
,	O
hyperglycemia	O
,	O
and	O
insulin	B-PRGE
dependent	O
diabetes	O
or	O
diabetic	O
ketoacidosis	O
.	O

Using	O
real	O
time	O
reverse	O
transcriptase	B-PRGE
polymerase	I-PRGE
chain	O
reaction	O
of	O
pediatric	O
patients	O
revealed	O
that	O
9	O
out	O
of	O
552	O
(	O
1	O
.	O
6	O
%)	O
was	O
positive	O
in	O
the	O
Kingdom	O
of	O
Saudi	O
Arabia	O
.	O

She	O
was	O
clinically	O
diagnosed	O
with	O
typical	O
CHARGE	O
syndrome	O
with	O
severe	O
combined	O
immunodeficiency	O
(	O
T	O
-,	O
B	O
+,	O
NK	O
-);	O
however	O
,	O
CHD7	B-PRGE
mutation	I-PRGE
was	O
not	O
detected	O
.	O

ABSTRACT	O
:	O
Human	B-PRGE
coronaviruses	I-PRGE
HCoV	I-PRGE
-	I-PRGE
OC43	I-PRGE
,	O
HCoV	O
-	O
229E	O
,	O
HCoV	O
-	O
NL63	O
and	O
HCoV	O
-	O
HKU1	O
are	O
common	O
respiratory	O
viruses	O
associated	O
with	O
acute	O
respiratory	O
infection	O
.	O

To	O
investigate	O
the	O
role	O
of	O
IL	B-PRGE
-	I-PRGE
17	I-PRGE
in	O
obese	O
asthma	O
in	O
both	O
acute	O
and	O
stable	O
settings	O
.	O

Both	O
stable	O
(	O
n	O
=	O
177	O
)	O
and	O
acute	O
(	O
n	O
=	O
78	O
)	O
asthmatics	O
were	O
recruited	O
and	O
categorized	O
into	O
lean	O
(	O
n	O
=	O
77	O
and	O
39	O
respectively	O
),	O
overweight	O
(	O
n	O
=	O
41	O
and	O
17	O
respectively	O
)	O
and	O
obese	O
(	O
n	O
=	O
59	O
and	O
22	O
respectively	O
)	O
groups	O
and	O
compared	O
for	O
clinical	O
characteristics	O
,	O
including	O
sputum	O
and	O
plasma	B-PRGE
IL	I-PRGE
-	I-PRGE
17	I-PRGE
protein	I-PRGE
concentrations	O
,	O
sputum	O
cellularity	O
,	O
spirometry	O
and	O
comorbidities	O
.	O

Laboratory	O
exams	O
on	O
the	O
second	O
day	O
of	O
hospitalization	O
showed	O
elevated	O
creatine	B-PRGE
kinase	I-PRGE
(	O
CK	O
)	O
and	O
troponin	B-PRGE
-	I-PRGE
I	I-PRGE
levels	O
while	O
his	O
electrocardiography	O
(	O
ECG	O
)	O
showed	O
J	O
-	O
point	O
elevation	O
in	O
V1	O
,	O
V2	O
,	O
and	O
V3	O
precordial	O
leads	O
.	O

Furthermore	O
,	O
the	O
proteins	O
expressed	O
by	O
CypA	B-PRGE
and	O
CypB	B-PRGE
harbouring	O
mutations	O
in	O
their	O
respective	O
predicted	O
peptidyl	B-PRGE
-	I-PRGE
prolyl	I-PRGE
cis	I-PRGE
-	I-PRGE
transisomerase	I-PRGE
active	O
sites	O
,	O
which	O
also	O
alter	O
the	O
affinities	O
between	O
Cyps	O
and	O
CsA	O
,	O
inhibited	O
FCoV	O
replication	O
.	O

TITLE	O
:	O
Protective	O
T	O
Cell	O
Responses	O
Featured	O
by	O
Concordant	O
Recognition	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
-	O
Derived	O
CD8	B-PRGE
+	I-PRGE
T	I-PRGE
Cell	I-PRGE
Epitopes	I-PRGE
and	I-PRGE
Host	I-PRGE
MHC	I-PRGE
.	O

ABSTRACT	O
:	O
The	O
coordinated	O
recognition	O
of	O
virus	O
-	O
derived	O
T	B-PRGE
cell	I-PRGE
epitopes	I-PRGE
and	O
MHC	B-PRGE
molecules	I-PRGE
by	O
T	O
cells	O
plays	O
a	O
pivotal	O
role	O
in	O
cellular	O
immunity	O
-	O
mediated	O
virus	O
clearance	O
.	O

Here	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
type	O
I	O
interferon	B-PRGE
(	O
IFN	B-PRGE
)	O
treatment	O
on	O
the	O
formation	O
of	O
arterivirus	O
-	O
induced	O
membrane	O
structures	O
.	O

ABSTRACT	O
:	O
Pompe	O
disease	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
caused	O
by	O
deficiency	O
of	O
the	O
lysosomal	B-PRGE
α	I-PRGE
-	I-PRGE
1	I-PRGE
,	I-PRGE
4	I-PRGE
-	I-PRGE
glucosidase	I-PRGE
leading	O
to	O
accumulation	O
of	O
glycogen	O
in	O
target	O
tissues	O
with	O
progressive	O
organ	O
failure	O
.	O

Using	O
Pteropus	B-PRGE
alecto	I-PRGE
(	I-PRGE
P	I-PRGE
.	I-PRGE
alecto	I-PRGE
)	I-PRGE
GM	I-PRGE
-	I-PRGE
CSF	I-PRGE
plus	O
IL4	B-PRGE
,	O
FLT3L	B-PRGE
and	O
CSF	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
we	O
successfully	O
generated	O
bat	O
bone	O
marrow	O
-	O
derived	O
DC	O
and	O
macrophages	O
.	O

In	O
this	O
study	O
,	O
a	O
functionalized	O
nanoparticles	O
-	O
based	O
PCR	O
method	O
(	O
UNDP	O
-	O
PCR	O
)	O
specific	O
for	O
PEDV	O
was	O
developed	O
through	O
systematic	O
optimization	O
of	O
functionalized	O
magnetic	O
beads	O
and	O
gold	O
nanoparticles	O
which	O
were	O
further	O
used	O
to	O
specifically	O
enrich	O
viral	O
RNA	O
from	O
the	O
lysate	O
of	O
PEDV	O
stool	O
samples	O
,	O
forming	O
a	O
MMPs	B-PRGE
-	I-PRGE
RNA	I-PRGE
-	I-PRGE
AuNPs	I-PRGE
complex	O
.	O

Feces	O
were	O
tested	O
by	O
PEDV	O
real	O
-	O
time	O
,	O
reverse	B-PRGE
transcriptase	I-PRGE
PCR	O
(	O
rRT	O
-	O
PCR	O
).	O

In	O
this	O
study	O
,	O
a	O
Chinese	O
PDCoV	O
strain	O
,	O
designated	O
CHN	B-PRGE
-	I-PRGE
HN	I-PRGE
-	I-PRGE
2014	I-PRGE
,	O
was	O
isolated	O
from	O
piglets	O
with	O
severe	O
diarrhea	O
on	O
a	O
pig	O
farm	O
in	O
Henan	O
Province	O
,	O
China	O
,	O
and	O
examined	O
with	O
a	O
specific	O
immunofluorescence	O
assay	O
and	O
electron	O
microscopy	O
.	O

Genomic	O
analysis	O
showed	O
that	O
CHN	B-PRGE
-	I-PRGE
HN	I-PRGE
-	I-PRGE
2014	I-PRGE
shares	O
91	O
.	O
6	O
%-	O
99	O
.	O
4	O
%	O
nucleotide	O
identity	O
with	O
other	O
known	O
PDCoV	O
strains	O
.	O

An	O
IFA	O
method	O
for	O
the	O
detection	O
of	O
TGEV	B-PRGE
M	I-PRGE
protein	I-PRGE
was	O
optimized	O
using	O
mAb	O
1C3	O
.	O

Previously	O
we	O
have	O
demonstrated	O
that	O
PDCoV	O
infection	O
suppresses	O
the	O
production	O
of	O
interferon	B-PRGE
-	I-PRGE
beta	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
β	I-PRGE
),	O
while	O
the	O
detailed	O
mechanisms	O
are	O
poorly	O
understood	O
.	O

Furthermore	O
,	O
this	O
cleavage	O
impaired	O
the	O
ability	O
of	O
NEMO	B-PRGE
to	O
activate	O
the	O
IFN	B-PRGE
response	O
and	O
downstream	O
signaling	O
.	O

1	O
h	O
after	O
the	O
first	O
administration	O
of	O
G	B-PRGE
-	I-PRGE
CSF	I-PRGE
,	O
the	O
donor	O
suddenly	O
presented	O
with	O
dry	O
cough	O
and	O
dyspnea	O
.	O

S1P	B-PRGE
at	O
physiological	O
concentrations	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
endothelial	O
barrier	O
function	O
.	O

RESULTS	O
:	O
It	O
was	O
found	O
that	O
the	O
down	O
-	O
regulation	O
of	O
TNF	B-PRGE
-	O

Detailed	O
analysis	O
suggested	O
that	O
this	O
additional	O
protein	O
band	O
represented	O
a	O
novel	O
accessory	O
protein	O
,	O
termed	O
NS7a	O
,	O
a	O
100	O
amino	O
acid	O
polypeptide	O
identical	O
to	O
the	O
3	O
'	O
end	O
of	O
NS7	B-PRGE
.	O

ABSTRACT	O
:	O
Griffithsin	O
(	O
GRFT	O
)	O
is	O
a	O
red	O
alga	B-PRGE
-	I-PRGE
derived	I-PRGE
lectin	I-PRGE
with	O
demonstrated	O
broad	O
spectrum	O
antiviral	O
activity	O
against	O
enveloped	O
viruses	O
,	O
including	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
Coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
Japanese	O
encephalitis	O
virus	O
(	O
JEV	O
),	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
),	O
and	O
herpes	O
simplex	O
virus	O
-	O
2	O
(	O
HSV	O
-	O
2	O
).	O

ABSTRACT	O
:	O
Severe	O
acute	B-PRGE
respiratory	I-PRGE
distress	I-PRGE
syndrome	I-PRGE
(	O
ARDS	O
,	O
PaO₂	B-PRGE
/	O
FiO₂	O
<	O
100	O
on	O
PEEP	O
≥	O
5	O
cm	O
H₂O	O
)	O
is	O
treated	O
using	O
controlled	O
mechanical	O
ventilation	O
(	O
CMV	O
),	O
recently	O
combined	O
with	O
muscle	O
relaxation	O
for	O
48	O
h	O
and	O
prone	O
positioning	O
.	O

This	O
conformational	O
change	O
is	O
also	O
required	O
for	O
the	O
binding	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
neutralizing	I-PRGE
antibodies	I-PRGE
targeting	O
the	O
CTD1	O
.	O

The	O
capsid	B-PRGE
structural	I-PRGE
protein	I-PRGE
of	O
CAstV	O
/	O
INDIA	O
/	O
ANAND	O
/	O
2016	O
showed	O
84	O
.	O
67	O
%	O
similarity	O
with	O
chicken	O
astrovirus	O
isolate	O
CAstV	O
/	O
GA2011	O
,	O
81	O
.	O
06	O
%	O
with	O
CAstV	O
/	O
4175	O
and	O
41	O
.	O
18	O
%	O
with	O
CAstV	O
/	O
Poland	O
/	O
G059	O
/	O
2014	O
isolates	O
.	O

TITLE	O
:	O
Structural	O
and	O
Molecular	O
Evidence	O
Suggesting	O
Coronavirus	O
-	O
driven	O
Evolution	O
of	O
Mouse	B-PRGE
Receptor	I-PRGE
.	O

TITLE	O
:	O
Novel	O
chimeric	O
virus	O
-	O
like	O
particles	O
vaccine	O
displaying	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
-	I-PRGE
binding	I-PRGE
domain	I-PRGE
induce	O
specific	O
humoral	O
and	O
cellular	O
immune	O
response	O
in	O
mice	O
.	O

We	O
report	O
here	O
the	O
efficacy	O
of	O
a	O
vaccine	O
consisting	O
of	O
chimeric	O
virus	O
-	O
like	O
particles	O
(	O
VLP	O
)	O
expressing	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
MERS	O
-	O
CoV	O
.	O
In	O
this	O
study	O
,	O
a	O
fusion	O
of	O
the	O
canine	O
parvovirus	O
(	O
CPV	O
)	O
VP2	B-PRGE
structural	O
protein	O
gene	O
with	O
the	O
RBD	O
of	O
MERS	O
-	O
CoV	O
can	O
self	O
-	O
assemble	O
into	O
chimeric	O
,	O
spherical	O
VLP	O
(	O
sVLP	O
).	O

Molecular	O
imaging	O
revealed	O
intense	O
lung	O
inflammation	O
coincident	O
with	O
massive	O
increases	O
in	O
proinflammatory	O
proteins	O
and	O
IFN	B-PRGE
-	I-PRGE
α	I-PRGE
in	O
distal	O
airways	O
.	O

TITLE	O
:	O
Roles	O
of	O
regulatory	O
T	O
cells	O
and	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
in	O
virus	O
-	O
induced	O
demyelination	O
.	O

Regulatory	O
T	O
cells	O
,	O
especially	O
those	O
that	O
are	O
specific	O
for	O
antigens	O
recognized	O
by	O
pathogenic	O
T	O
cells	O
,	O
and	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
are	O
two	O
anti	O
-	O
inflammatory	O
/	O
pro	O
-	O
resolution	O
factors	O
that	O
demonstrate	O
efficacy	O
in	O
experimental	O
models	O
of	O
virus	O
-	O
induced	O
demyelination	O
and	O
may	O
be	O
useful	O
in	O
patients	O
infected	O
with	O
viruses	O
that	O
cause	O
demyelination	O
.	O

However	O
,	O
our	O
recent	O
cellular	O
studies	O
reveal	O
that	O
removing	O
the	O
Ubl2	B-PRGE
domain	I-PRGE
from	O
MERS	O
PLpro	O
has	O
no	O
effect	O
on	O
its	O
ability	O
to	O
process	O
the	O
viral	O
polyprotein	O
or	O
act	O
as	O
an	O
interferon	B-PRGE
antagonist	O
,	O
which	O
involves	O
deubiquitinating	O
and	O
deISGylating	O
cellular	O
proteins	O
.	O

In	O
patients	O
with	O
CoV	O
-	O
CNS	O
infection	O
,	O
the	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
IL	O
-	O
8	O
,	O
MCP	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
GM	B-PRGE
-	I-PRGE
CSF	I-PRGE
were	O
significantly	O
higher	O
in	O
their	O
cerebrospinal	O
fluid	O
samples	O
than	O
in	O
matched	O
serum	O
samples	O
.	O

TITLE	O
:	O
Clinical	O
validation	O
of	O
3	O
commercial	O
real	O
-	O
time	O
reverse	O
transcriptase	B-PRGE
polymerase	I-PRGE
chain	O
reaction	O
assays	O
for	O
the	O
detection	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
from	O
upper	O
respiratory	O
tract	O
specimens	O
.	O

ABSTRACT	O
:	O
Since	O
discovery	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
a	O
novel	O
betacoronavirus	O
first	O
isolated	O
and	O
characterized	O
in	O
2012	O
,	O
MERS	O
-	O
CoV	O
real	O
-	O
time	O
reverse	O
transcriptase	B-PRGE
polymerase	I-PRGE
chain	I-PRGE
reaction	O
(	O
rRT	O
-	O
PCR	O
)	O
assays	O
represent	O
one	O
of	O
the	O
most	O
rapidly	O
expanding	O
commercial	O
tests	O
.	O

Our	O
results	O
indicated	O
that	O
NIBV	O
infection	O
caused	O
liver	O
and	O
kidney	O
damage	O
in	O
the	O
embryonic	B-PRGE
chickens	I-PRGE
,	O
and	O
the	O
results	O
also	O
demonstrated	O
that	O
the	O
liver	O
and	O
kidney	O
damage	O
was	O
strongly	O
related	O
to	O
the	O
tissue	O
viral	O
load	O
following	O
NIBV	O
infection	O
in	O
embryonic	O
chickens	O
.	O

Six	O
RT	O
-	O
LAMP	O
primers	O
were	O
designed	O
from	O
the	O
same	O
conserved	O
region	O
of	O
RT	B-PRGE
-	I-PRGE
nPCR	I-PRGE
,	O
and	O
the	O
assay	O
was	O
run	O
at	O
63	O
°	O
C	O
for	O
one	O
hour	O
.	O

Therefore	O
,	O
RT	B-PRGE
-	I-PRGE
LAMP	I-PRGE
seems	O
optimal	O
to	O
confirm	O
the	O
presence	O
of	O
the	O
virus	O
,	O
but	O
not	O
applicable	O
to	O
exclude	O
it	O
.	O

TITLE	O
:	O
IFN	B-PRGE
-	I-PRGE
lambda	I-PRGE
preferably	O
inhibits	O
PEDV	O
infection	O
of	O
porcine	O
intestinal	O
epithelial	O
cells	O
compared	O
with	O
IFN	B-PRGE
-	I-PRGE
alpha	I-PRGE
.	O

In	O
addition	O
,	O
rpIFN	O
-	O
L1	O
exhibited	O
greater	O
antiviral	O
activity	O
against	O
PEDV	O
infection	O
of	O
IPEC	O
-	O
J2	O
cells	O
than	O
that	O
of	O
porcine	B-PRGE
IFN	I-PRGE
-	I-PRGE
alpha	I-PRGE
.	O

FmoPV	O
RNA	O
-	O
positive	O
cats	O
had	O
lower	O
median	O
red	O
blood	O
cell	O
count	O
,	O
haemoglobin	O
,	O
albumin	B-PRGE
,	O
albumin	B-PRGE
/	O
globulin	O
and	O
urobilinogen	O
and	O
higher	B-PRGE
alanine	I-PRGE
transaminase	I-PRGE
,	O
alkaline	B-PRGE
phosphatase	I-PRGE
and	O
bilirubin	O
compared	O
with	O
non	O
-	O
infected	O
cats	O
.	O

We	O
developed	O
an	O
efficient	O
and	O
rapid	O
method	O
with	O
high	O
specificity	O
for	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
based	O
on	O
one	O
-	O
pot	O
reverse	O
transcription	O
loop	O
-	O
mediated	O
isothermal	O
amplification	O
(	O
one	O
-	O
pot	O
RT	B-PRGE
-	I-PRGE
LAMP	I-PRGE
).	O

MERS	O
-	O
CoV	O
vaccine	O
forms	O
and	O
delivery	O
systems	O
,	O
together	O
with	O
comparable	O
development	O
strategies	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
are	O
additionally	O
addressed	O
.	O

However	O
,	O
TMPRSS2	O
overexpression	O
decreased	O
MHV	B-PRGE
structural	I-PRGE
protein	I-PRGE
expression	O
,	O
release	O
of	O
infectious	O
particles	O
,	O
and	O
syncytium	O
formation	O
,	O
and	O
endogenous	B-PRGE
serine	I-PRGE
protease	I-PRGE
activity	O
did	O
not	O
contribute	O
greatly	O
to	O
infection	O
.	O

We	O
therefore	O
investigated	O
the	O
importance	O
of	O
other	O
classes	O
of	O
cellular	O
proteases	O
and	O
found	O
that	O
inhibition	O
of	O
matrix	B-PRGE
metalloproteinase	I-PRGE
(	O
MMP	O
)-	O
and	O
a	B-PRGE
disintegrin	I-PRGE
and	I-PRGE
metalloprotease	B-PRGE
(	I-PRGE
ADAM	I-PRGE
)-	I-PRGE
family	I-PRGE
zinc	I-PRGE
metalloproteases	I-PRGE
markedly	O
decreased	O
both	O
entry	O
and	O
cell	O
-	O
cell	O
fusion	O
.	O

These	O
findings	O
provide	O
an	O
insightful	O
interpretation	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	O
mediated	O
host	O
innate	O
immune	O
suppression	O
caused	O
by	O
the	O
N	B-PRGE
protein	I-PRGE
.	O

The	O
localization	O
of	O
the	O
EndoU	B-PRGE
activity	O
at	O
the	O
site	O
of	O
viral	O
RNA	O
synthesis	O
-	O
within	O
the	O
replicase	B-PRGE
complex	O
-	O
suggests	O
that	O
coronaviruses	O
have	O
evolved	O
a	O
viral	O
RNA	O
decay	O
pathway	O
to	O
evade	O
early	O
innate	O
and	O
intrinsic	O
antiviral	O
host	O
cell	O
responses	O
.	O

The	O
RdRp	O
domain	O
of	O
nidoviruses	O
resides	O
in	O
a	O
cleavage	O
product	O
of	O
the	O
replicase	B-PRGE
polyprotein	O
named	O
non	O
-	O
structural	O
protein	O
(	O
nsp	O
)	O
12	O
in	O
coronaviruses	O
and	O
nsp9	O
in	O
arteriviruses	O
.	O

Since	O
glycyrrhizin	O
is	O
a	O
competitive	O
inhibitor	O
of	O
high	O
mobility	O
group	O
box	O
-	O
1	O
(	O
HMGB1	B-PRGE
),	O
we	O
confirmed	O
that	O
TLR4	B-PRGE
and	O
RAGE	B-PRGE
(£	O
associated	O
with	O
PEDV	O
pathogenesis	O
during	O
the	O
infection	O
in	O
Vero	O
cells	O
.	O

We	O
'	O
ve	O
demonstrated	O
that	O
the	O
group	O
vaccinated	O
with	O
Ma5	O
and	O
4	O
/	O
91	O
strain	O
simultaneously	O
developed	O
the	O
most	O
desirable	O
immunity	O
which	O
reflects	O
the	O
level	O
of	O
CD8	B-PRGE

Univariate	O
correlation	O
analysis	O
demonstrated	O
that	O
APACHE	O
II	O
score	O
(	O
r	O
=-	O
0	O
.	O
463	O
,	O
p	O
=	O
0	O
.	O
03	O
),	O
acute	O
kidney	O
injury	O
(	O
r	O
=-	O
0	O
.	O
574	O
,	O
p	O
=	O
0	O
.	O
005	O
),	O
membrane	O
oxygenator	O
replacement	O
(	O
r	O
=-	O
0	O
.	O
516	O
,	O
p	O
=	O
0	O
.	O
014	O
)	O
and	O
total	O
length	O
of	O
hospital	O
stay	O
(	O
r	O
=	O
0	O
.	O
526	O
,	O
p	O
=	O
0	O
.	O
012	O
)	O
were	O
significantly	O
correlated	O
with	O
survival	O
to	O
hospital	O
discharge	O
,	O
and	O
that	O
the	O
evolution	O
of	O
the	O
levels	O
of	O
urea	O
nitrogen	O
,	O
platelet	O
,	O
and	O
fibrinogen	B-PRGE
may	O
help	O
to	O
determine	O
patient	O
prognosis	O
.	O

ABSTRACT	O
:	O
As	O
one	O
of	O
the	O
top	B-PRGE
pork	I-PRGE
producers	I-PRGE
in	O
China	O

Dromedary	O
CoV	O
UAE	O
-	O
HKU23	O
is	O
closely	O
related	O
to	O
human	B-PRGE
CoV	I-PRGE
OC43	I-PRGE
,	O
whereas	O
the	O
alphaCoV	O
has	O
not	O
been	O
detected	O
in	O
human	O
beings	O
to	O
date	O
.	O

This	O
differential	O
pattern	O
of	O
early	O
immune	O
responses	O
developed	O
after	O
challenge	O
with	O
IBV	O
B	O
isolate	O
,	O
related	O
to	O
the	O
downregulation	O
of	O
TLR7	B-PRGE
,	O
leading	O
to	O
insufficient	O
pro	O
-	O
inflammatory	O
response	O
and	O
lower	O
CMI	O
responses	O
,	O
seem	O
to	O
have	O
an	O
association	O
with	O
a	O
most	O
severe	O
renal	O
lesion	O
and	O
an	O
enhanced	O
capability	O
of	O
replication	O
of	O
this	O
isolate	O
in	O
chicken	O
.	O

One	O
of	O
these	O
,	O
Cbl	B-PRGE
deficiency	I-PRGE
type	I-PRGE
C	I-PRGE
(	O
CblC	B-PRGE
),	O
is	O
a	O
well	O
-	O
known	O
cause	O
of	O
thrombotic	O
microangiopathy	O
(	O
TMA	O
),	O
especially	O
in	O
infants	O
.	O

Four	O
porcine	O
sapelovirus	O
(	O
PSV	O
)	O
strains	O
(	O
designated	O
as	O
PSV	B-PRGE
-	I-PRGE
HuNs	I-PRGE
)	O
were	O
isolated	O
from	O
four	O
of	O
the	O
samples	O
.	O

Primers	O
and	O
probes	O
that	O
target	O
the	O
conserved	O
spike	O
S2	O
region	O
of	O
human	B-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
MERS	O
-	O
CoV	O
,	O
and	O
their	O
related	O
bat	O
CoVs	O
were	O
designed	O
.	O

Thai	O
PEDV	B-PRGE
spike	I-PRGE
gene	I-PRGE
have	O
higher	O
evolutionary	O
rate	O
compare	O
to	O
that	O
of	O
the	O
US	O
sequences	O
.	O

The	O
first	O
prone	O
session	O
significantly	O
increased	O
PaO	B-PRGE
Prone	O
position	O
of	O
ARDS	O
patients	O
after	O
abdominal	O
surgery	O
was	O
not	O
associated	O
with	O
an	O
increased	O
rate	O
of	O
surgical	O
complication	O
.	O

An	O
interesting	O
feature	O
is	O
the	O
dynamic	O
change	O
in	O
Ubl	B-PRGE
,	O
which	O
shows	O
a	O
rigid	O
conformation	O
in	O
the	O
free	O
form	O
of	O
Plpro	O
but	O
is	O
fully	O
flexible	O
upon	O
the	O
binding	O
of	O
ubiquitin	B-PRGE
.	O

IFIT1	B-PRGE
forms	O
a	O
water	O
-	O
filled	O
,	O
positively	O
charged	O
RNA	O
-	O
binding	O
tunnel	O
with	O
a	O
separate	O
hydrophobic	O
extension	O
that	O
unexpectedly	O
engages	O
the	O
cap	O
in	O
multiple	O
conformations	O
(	O

Tetradecyl	O
ferulate	O
(	O
8	O
)	O
showed	O
an	O
interesting	O
RNase	B-PRGE
H	I-PRGE
IC	I-PRGE

Although	O
PEDV	O
was	O
long	O
believed	O
to	O
replicate	O
in	O
the	O
intestinal	O
epithelium	O
by	O
using	O
aminopeptidase	B-PRGE
N	I-PRGE
as	O
a	O
receptor	O
,	O
the	O
mechanisms	O
of	O
PEDV	O
infection	O
are	O
not	O
fully	O
characterized	O
.	O

TITLE	O
:	O
Betacoronavirus	O
Adaptation	O
to	O
Humans	O
Involved	O
Progressive	O
Loss	O
of	O
Hemagglutinin	B-PRGE
-	I-PRGE
Esterase	I-PRGE
Lectin	I-PRGE
Activity	O
.	O

Based	O
on	O
the	O
severity	O
of	O
clinical	O
signs	O
,	O
histopathological	O
lesions	O
and	O
the	O
distribution	O
of	O
PEDV	O
antigens	O
in	O
the	O
gut	O
,	O
the	O
virulence	O
of	O
P100	B-PRGE
and	O
above	O
,	O
but	O
not	O
P95C13	O
(	O
CCL81	O
),	O
was	O
markedly	O
reduced	O
in	O
4	O
-	O
day	O
-	O
old	O
,	O
caesarian	O
-	O
derived	O
,	O
colostrum	O
-	O
deprived	O
piglets	O
.	O

In	O
addition	O
,	O
PHEV	O
induced	O
an	O
incomplete	O
autophagic	O
effect	O
because	O
the	O
degradation	O
level	O
of	O
p62	B-PRGE
did	O
not	O
change	O
in	O
PHEV	O
-	O
infected	O
cells	O
.	O

We	O
also	O
investigated	O
the	O
change	O
in	O
viral	O
replication	O
by	O
pharmacological	O
experiments	O
with	O
the	O
autophagy	O
inducer	O
rapamycin	O
or	O
the	O
autophagy	B-PRGE
inhibitor	I-PRGE
3	I-PRGE
-	I-PRGE
MA	I-PRGE
,	O
and	O
the	O
lysosomal	O
inhibitor	O
chloroquine	O
(	O
CQ	O
).	O

Instead	O
,	O
the	O
compound	O
could	O
depress	O
the	O
activity	O
of	O
IMPDH	B-PRGE
type	I-PRGE
II	I-PRGE
.	O

TITLE	O
:	O
miR	B-PRGE
-	I-PRGE
21a	I-PRGE
-	I-PRGE
5p	I-PRGE
Contributes	O
to	O
Porcine	O
Hemagglutinating	O
Encephalomyelitis	O
Virus	O
Proliferation	O
via	O
Targeting	O
CASK	O
-	O
Interactive	O
Protein1	O
ABSTRACT	O
:	O
Porcine	O
hemagglutinating	O
encephalomyelitis	O
virus	O
(	O
PHEV	O
)	O
is	O
a	O
highly	O
neurovirulent	O
coronavirus	O
that	O
can	O
cause	O
nervous	O
symptoms	O
in	O
piglets	O
with	O
muscle	O
tremors	O
,	O
hind	O
limb	O
paralysis	O
,	O
and	O
nystagmus	O
.	O

We	O
analysed	O
the	O
TGEV	B-PRGE
ORF3	I-PRGE
gene	I-PRGE
using	O
nested	O
polymerase	O
chain	O
reaction	O
and	O
identified	O
an	O
ORF3a	O
deletion	O
in	O
three	O
field	O
strains	O
of	O
TGEV	O
collected	O
from	O
piglets	O
in	O
China	O
in	O
2015	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
IBV	O
exhibits	O
strong	O
global	O
DUB	O
activity	O
with	O
significant	O
reductions	O
of	O
the	O
levels	O
of	O
ubiquitin	B-PRGE
(	O
Ub	O
)-,	O
K48	O
-,	O
and	O
K63	O
-	O
conjugated	O
proteins	O
.	O

In	O
the	O
brain	O
parenchyma	O
,	O
astrocytes	O
were	O
found	O
to	O
produce	O
the	O
main	O
components	O
of	O
mature	O
ERfibs	O
,	O
such	O
as	O
collagen	B-PRGE
,	O
laminin	B-PRGE
and	O
ERag	O
,	O
which	O
have	O
been	O
identified	O
in	O
the	O
lymphoid	O
organs	O
.	O

The	O
pattern	O
of	O
ECM	O
production	O
in	O
vitro	O
indicated	O
the	O
process	O
of	O
forming	O
mature	O
ERfibs	O
in	O
the	O
brain	O
,	O
that	O
is	O
,	O
fibers	O
made	O
of	O
collagen	B-PRGE
fibers	O
and	O
ERag	O
are	O
wrapped	O
by	O
laminin	B-PRGE
prepared	O
as	O
a	O
sheet	O
structure	O
.	O

Inhibition	O
of	O
STAT3	B-PRGE
phosphorylation	O
by	O
S3I	O
-	O
201	O
abrogated	O
the	O
antiviral	O
ability	O
of	O
mpIL	O
-	O
22	O
and	O
the	O
mpIL	O
-	O
22	O
-	O
induced	O
expression	O
of	O
BD	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
18	I-PRGE
,	O
and	O
IFN	B-PRGE
-	I-PRGE
λ	I-PRGE
.	O

Nine	O
hundred	O
and	O
seventy	O
seven	O
(	O
977	O
)	O
fecal	O
samples	O
were	O
screened	O
for	O
RNA	O
viruses	O
including	O
:	O
influenza	O
A	O
virus	O
(	O
IAV	O
),	O
avian	B-PRGE
paramyxovirus	I-PRGE
1	I-PRGE
,	O
avian	O
coronavirus	O
(	O
CoV	O
),	O
and	O
avian	O
astrovirus	O
(	O
AstroV	O
).	O

The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
,	O
the	O
major	O
structural	O
component	O
of	O
the	O
capsid	O
,	O
facilitates	O
RNA	O
packing	O
,	O
links	O
the	O
capsid	O
to	O
the	O
envelope	B-PRGE
,	O
and	O
is	O
also	O
involved	O
in	O
multiple	O
other	O
processes	O
,	O
including	O
viral	O
replication	O
and	O
evasion	O
of	O
the	O
immune	O
system	O
.	O

Although	O
the	O
role	O
of	O
N	B-PRGE
protein	I-PRGE
in	O
viral	O
replication	O
is	O
relatively	O
well	O
described	O
,	O
no	O
structural	O
data	O
are	O
currently	O
available	O
regarding	O
the	O
N	O
proteins	O
of	O
alphacoronaviruses	O
.	O

In	O
this	O
study	O
,	O
we	O
solved	O
the	O
crystal	O
structures	O
of	O
the	O
N	O
-	O
and	O
C	O
-	O
terminal	O
domains	O
(	O
NTD	O
,	O
residues	O
10	O
to	O
140	O
,	O
and	O
CTD	O
,	O
residues	O
221	O
to	O
340	O
,	O
respectively	O
)	O
of	O
the	O
N	B-PRGE
protein	I-PRGE
of	O
HCoV	O
-	O
NL63	O
,	O
both	O
at	O
a	O
1	O
.	O
5	O
-	O
Å	O
resolution	O
.	O

This	O
result	O
suggests	O
that	O
CES1	B-PRGE
is	O
inhibited	O
by	O
dexamethasone	O
in	O
humans	O
.	O

We	O
found	O
that	O
plasmids	O
expressing	O
full	B-PRGE
-	I-PRGE
length	I-PRGE
(	I-PRGE
pS	I-PRGE
)	I-PRGE
or	I-PRGE
S1	I-PRGE
-	I-PRGE
subunit	I-PRGE
(	O
pS1	B-PRGE
)	O
could	O
induce	O
significant	O
levels	O
of	O
S1	O
-	O
specific	O
antibodies	O
(	O
Abs	O
)	O
but	O
with	O
distinct	O
IgG	B-PRGE
isotype	I-PRGE
patterns	O
.	O

A	O
sensitive	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assay	O
targeting	O
the	O
IBV	B-PRGE
nucleocapsid	I-PRGE
gene	I-PRGE
(	O
N	O
)	O
was	O
developed	O
to	O
screen	O
clinical	O
samples	O
for	O
presence	O
of	O
IBV	O
.	O

In	O
addition	O
,	O
vaccination	O
with	O
the	O
rLaSota	O
-	O
S1	O
strain	O
induced	O
IBV	O
-	O
specific	O
IgG	B-PRGE
antibodies	I-PRGE
and	O
cellular	O
immunity	O
;	O
however	O
,	O
a	O
single	O
vaccination	O
provided	O
partial	O
protection	O
with	O
reduced	O
virus	O
shedding	O
.	O

Compared	O
to	O
treatment	O
with	O
the	O
prototypical	O
inflammatory	O
cytokine	B-PRGE
interleukin	I-PRGE
(	I-PRGE
IL	I-PRGE
)-	I-PRGE
1	I-PRGE
,	O
HCoV	O
-	O
229E	O
replication	O
was	O
found	O
to	O
attenuate	O
the	O
inducible	O
activity	O
of	O
the	O
transcription	B-PRGE
factor	I-PRGE
(	O
TF	O
)	O
NF	O
-	O
κB	O
and	O
to	O
restrict	O
the	O
nuclear	O
concentration	O
of	O
NF	O
-	O
κB	O
subunits	O
by	O
(	O
i	O
)	O
an	O
unusual	O
mechanism	O
involving	O
partial	O
degradation	O
of	O
IKKβ	O
,	O
NEMO	B-PRGE
and	O
IκBα	O
and	O
(	O
ii	O
)	O
upregulation	O
of	O
TNFAIP3	B-PRGE
(	O
A20	B-PRGE
),	O
although	O
constitutive	O
IKK	O
activity	O
and	O
basal	O
TNFAIP3	B-PRGE
expression	O
levels	O
were	O
shown	O
to	O
be	O
required	O
for	O
efficient	O
virus	O
replication	O
.	O

Second	O
,	O
we	O
characterized	O
actively	O
transcribed	O
genomic	O
regions	O
and	O
enhancers	O
in	O
HCoV	O
-	O
229E	O
-	O
infected	O
cells	O
and	O
systematically	O
correlated	O
the	O
genome	O
-	O
wide	O
gene	O
expression	O
changes	O
with	O
the	O
recruitment	O
of	O
Ser5	B-PRGE
-	O
phosphorylated	O
RNA	B-PRGE
polymerase	I-PRGE
II	I-PRGE
and	O
prototypical	O
histone	B-PRGE
modifications	O
(	O
H3K9ac	O
,	O
H3K36ac	O
,	O
H4K5ac	O
,	O
H3K27ac	O
,	O
H3K4me1	O
).	O

Also	O
,	O
HCoV	O
-	O
229E	O
and	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
activated	O
a	O
common	O
set	O
of	O
440	O
p65	B-PRGE
-	O
bound	O
enhancers	O
that	O
differed	O
from	O
another	O
992	O
HCoV	O
-	O
229E	O
-	O
specific	O
enhancer	O
regions	O
by	O
distinct	O
TF	B-PRGE
-	I-PRGE
binding	I-PRGE
motif	I-PRGE
combinations	O
.	O

TITLE	O
:	O
Ribonuclease	O
L	O
mediates	O
the	O
cell	O
-	O
lethal	O
phenotype	O
of	O
double	O
-	O
stranded	O
RNA	O
editing	O
enzyme	O
ADAR1	B-PRGE
deficiency	O
in	O
a	O
human	O
cell	O
line	O
.	O

We	O
show	O
that	O
overexpression	O
of	O
porcine	B-PRGE
APN	I-PRGE
renders	O
MDCK	O
cells	O
susceptible	O
to	O
TGEV	O
,	O
but	O
not	O
to	O
PEDV	O
.	O

The	O
aggravation	O
of	O
loss	O
of	O
function	O
of	O
SCN5A	B-PRGE
caused	O
by	O
VCL	B-PRGE
-	I-PRGE
D841H	I-PRGE
under	O
acidosis	O
supports	O
that	O
nocturnal	O
sleep	O
respiratory	O
disorders	O
with	O
acidosis	O
may	O
play	O
a	O
key	O
role	O
in	O
the	O
pathogenesis	O
of	O
SUNDS	O
.	O

Since	O
publication	O
of	O
the	O
ACR	O
criteria	O
for	O
vasculitis	O
,	O
the	O
sensitivity	O
for	O
each	O
type	O
of	O
vasculitis	O
,	O
except	O
GCA	B-PRGE
,	O
has	O
diminished	O
,	O
although	O
the	O
specificities	O
have	O
remained	O
high	O
,	O
highlighting	O
the	O
need	O
for	O
updated	O
classification	O
criteria	O
.	O

Among	O
the	O
latter	O
,	O
strain	O
LZHP2	O
provided	O
strong	O
evidence	O
of	O
cross	O
-	O
species	O
transmission	O
of	O
RVAs	O
from	O
bats	O
to	O
humans	O
,	O
whereas	O
strains	O
YSSK5	O
and	O
BSTM70	O
were	O
likely	O
reassortants	O
between	O
typical	O
MSLH14	B-PRGE
-	I-PRGE
like	I-PRGE
RVAs	I-PRGE
and	O
human	O
RVAs	O
.	O

TITLE	O
:	O
Cell	O
Attachment	O
Domains	O
of	O
the	O
Porcine	B-PRGE
Epidemic	I-PRGE
Diarrhea	I-PRGE
Virus	I-PRGE
Spike	I-PRGE
Protein	I-PRGE
Are	I-PRGE
Key	I-PRGE
Targets	I-PRGE
of	I-PRGE
Neutralizing	I-PRGE
Antibodies	I-PRGE
.	O

Our	O
observations	O
picture	O
the	O
antibody	O
epitope	O
landscape	O
of	O
the	O
PEDV	B-PRGE
S1	I-PRGE
subunit	I-PRGE
and	O
reveal	O
that	O
its	O
cell	O
attachment	O
domains	O
are	O
key	O
targets	O
of	O
neutralizing	O
antibodies	O
.	O

Importantly	O
,	O
with	O
the	O
exception	O
of	O
the	O
S	B-PRGE
gene	I-PRGE
,	O
the	O
genome	O
sequences	O
of	O
the	O
SARSr	O
-	O
Rh	O
-	O
BatCoVs	O
sampled	O
in	O
Guizhou	O
province	O
were	O
closely	O
related	O
to	O
SARS	B-PRGE
-	O
related	O
human	O
coronavirus	O
.	O

Although	O
the	O
expression	O
of	O
MX1	B-PRGE
and	O
viperin	B-PRGE
genes	I-PRGE
was	O
variable	O
between	O
cats	O
,	O
the	O
expression	O
of	O
these	O
two	O
genes	O
was	O
relatively	O
higher	O
in	O
cats	O
having	O
peritoneal	O
effusion	O
compared	O
to	O
cats	O
without	O
clinically	O
obvious	O
effusion	O
.	O

We	O
summarize	O
work	O
from	O
our	O
group	O
and	O
others	O
indicating	O
that	O
inhibiting	O
EGFR	B-PRGE
signaling	O
may	O
prevent	O
an	O
excessive	O
fibrotic	O
response	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
other	O
respiratory	O
viral	O
infections	O
and	O
propose	O
directions	O
for	O
future	O
research	O
.	O

ABSTRACT	O
:	O
The	O
envelope	B-PRGE
spike	I-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
proteins	I-PRGE
of	O
MERS	O
-	O
CoV	O
and	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
determine	O
the	O
virus	O
host	O
tropism	O
and	O
entry	O
into	O
host	O
cells	O
,	O
and	O
constitute	O
a	O
promising	O
target	O
for	O
the	O
development	O
of	O
prophylactics	O
and	O
therapeutics	O
.	O

Here	O
,	O
we	O
present	O
high	O
-	O
resolution	O
structures	O
of	O
the	O
trimeric	O
MERS	O
-	O
CoV	O
and	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
proteins	I-PRGE
in	O
its	O
pre	O
-	O
fusion	O
conformation	O
by	O
single	O
particle	O
cryo	O
-	O
electron	O
microscopy	O
.	O

ABSTRACT	O
:	O
Cell	O
surface	O
aminopeptidase	B-PRGE
N	I-PRGE
(	O
APN	B-PRGE
)	O
is	O
a	O
membrane	O
-	O
bound	O
ectoenzyme	O
that	O
hydrolyzes	O
proteins	O
and	O
peptides	O
and	O
regulates	O
numerous	O
cell	O
functions	O
.	O

APN	B-PRGE
is	O
also	O
a	O
major	O
cell	O
entry	O
receptor	O
for	O
coronavirus	O
,	O
which	O
binds	O
to	O
a	O
region	O
distant	O
from	O
the	O
active	O
site	O
.	O

Our	O
data	O
demonstrate	O
a	O
key	O
role	O
of	O
EGFR	B-PRGE
in	O
the	O
host	O
response	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
how	O
it	O
may	O
be	O
implicated	O
in	O
lung	O
disease	O
induced	O
by	O
other	O
highly	O
pathogenic	O
respiratory	O
viruses	O
.	O

Moreover	O
,	O
CCL2	B-PRGE
was	O
overexpressed	O
in	O
the	O
lung	O
tissue	O
of	O
infected	O
mice	O
.	O

More	O
importantly	O
,	O
CCL2	B-PRGE
deficiency	O
ameliorated	O
H7N9	O
-	O
induced	O
ALI	O
in	O
mice	O
as	O
determined	O
by	O
weight	O
loss	O
,	O
survival	O
rate	O
,	O
the	O
wet	O
:	O
dry	O
ratio	O
of	O
the	O
lung	O
,	O
and	O
pathology	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
demonstrate	O
that	O
CCL2	B-PRGE
is	O
essential	O
for	O
H7N9	O
virus	O
infection	O
and	O
thus	O
that	O
it	O
is	O
a	O
potential	O
therapeutic	O
target	O
for	O
influenza	O
.	O

Previously	O
,	O
we	O
demonstrated	O
that	O
both	O
MERS	O
-	O
CoV	O
and	O
BatCoV	B-PRGE
HKU4	I-PRGE
use	I-PRGE
CD26	I-PRGE
as	O
a	O
receptor	O
,	O
but	O
how	O
the	O
BatCoVs	O
evolved	O
to	O
bind	O
CD26	B-PRGE
is	O
an	O
intriguing	O
question	O
.	O

Here	O
,	O
we	O
solved	O
the	O
crystal	O
structure	O
of	O
the	O
S1	B-PRGE
subunit	I-PRGE
C	I-PRGE
-	I-PRGE
terminal	I-PRGE
domain	I-PRGE
of	O
HKU5	O
(	O
HKU5	B-PRGE
-	I-PRGE
CTD	I-PRGE
),	O
another	O
BatCoV	O
that	O
is	O
phylogenetically	O
related	O
to	O
MERS	O
-	O
CoV	O
but	O
cannot	O
bind	O
to	O
CD26	B-PRGE
.	O

Combined	O
with	O
sequence	O
variation	O
in	O
the	O
HKU5	B-PRGE
-	I-PRGE
CTD	I-PRGE
receptor	I-PRGE
binding	O
interface	O
,	O
we	O
propose	O
the	O
necessity	O
for	O
surveilling	O
the	O
mutation	O
in	O
BatCoV	B-PRGE
HKU5	I-PRGE
spike	I-PRGE
protein	I-PRGE
in	O
case	O
of	O
bat	O
-	O
to	O
-	O
human	O
interspecies	O
transmission	O
.	O

The	O
first	O
X	O
-	O
ray	O
structure	O
of	O
the	O
full	B-PRGE
-	I-PRGE
length	I-PRGE
mISG15	I-PRGE
protein	I-PRGE
is	O
also	O
reported	O
and	O
highlights	O
a	O
unique	O
,	O
twisted	O
hinge	O
region	O
of	O
ISG15	B-PRGE
that	O
is	O
not	O
conserved	O
in	O
hISG15	O
,	O
suggesting	O
a	O
potential	O
role	O
in	O
differential	O
recognition	O
.	O

ABSTRACT	O
:	O
GATA2	B-PRGE
mutations	O
have	O
been	O
identified	O
in	O
various	O
diseases	O
,	O
such	O
as	O
MonoMAC	O
syndrome	O
,	O
Emberger	O
syndrome	O
,	O
familial	O
myelodysplastic	O
syndrome	O
,	O
acute	O
myeloid	O
leukaemia	O
and	O
dendritic	O
cell	O
,	O
monocyte	O
,	O
B	O
-	O
cell	O
and	O
natural	O
killer	O
-	O
cell	O
deficiency	O
.	O

We	O
report	O
three	O
patients	O
presenting	O
with	O
common	O
dermatological	O
and	O
haematological	O
features	O
leading	O
to	O
the	O
diagnosis	O
of	O
GATA2	B-PRGE
deficiency	O
,	O
but	O
also	O
with	O
skin	O
manifestations	O
that	O
have	O
not	O
been	O
previously	O
described	O
:	O
gingival	O
hypertrophy	O
,	O
macroglossitis	O
and	O
glossitis	O
and	O
granulomatous	O
lupoid	O
facial	O
lesions	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
has	O
been	O
shown	O
to	O
infect	O
both	O
humans	O
and	O
dromedary	O
camels	O
using	O
dipeptidyl	O
peptidase	B-PRGE
-	I-PRGE
4	I-PRGE
(	O
DPP4	B-PRGE
)	O
as	O
its	O
receptor	O
.	O

The	O
distribution	O
of	O
DPP4	B-PRGE
in	O
the	O
respiratory	O
tract	O
tissues	O
of	O
humans	O
and	O
camels	O
reflects	O
MERS	O
-	O
CoV	O
tropism	O
.	O

In	O
order	O
to	O
gain	O
insight	O
on	O
the	O
tropism	O
of	O
these	O
viruses	O
in	O
bats	O
,	O
we	O
studied	O
the	O
DPP4	B-PRGE
distribution	O
in	O
the	O
respiratory	O
and	O
extra	O
-	O
respiratory	O
tissues	O
of	O
two	O
frugivorous	O
bat	O
species	O
(	O
Epomophorus	O
gambianus	O
and	O
Rousettus	O
aegyptiacus	O
)	O
and	O
two	O
insectivorous	O
bat	O
species	O
(	O
Pipistrellus	O
pipistrellus	O
and	O
Eptesicus	O
serotinus	O
).	O

TITLE	O
:	O
Optimization	O
of	O
the	O
Production	O
Process	O
and	O
Characterization	O
of	O
the	O
Yeast	O
-	O
Expressed	O
SARS	O
-	O
CoV	O
Recombinant	B-PRGE
Receptor	I-PRGE
-	I-PRGE
Binding	I-PRGE
Domain	I-PRGE
(	O
RBD219	O
-	O
N1	O
),	O
a	O
SARS	O
Vaccine	O
Candidate	O
.	O

Previously	O
,	O
we	O
reported	O
the	O
5	O
L	O
scale	O
expression	O
and	O
purification	O
of	O
a	O
promising	O
recombinant	O
SARS	O
vaccine	O
candidate	O
,	O
RBD219	O
-	O
N1	O
,	O
the	O
218	O
-	O
amino	O
acid	O
residue	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
SARS	B-PRGE
coronavirus	O
expressed	O
in	O
yeast	O
-	O
Pichia	O
pastoris	O
X	O
-	O
33	O
.	O

In	O
vitro	O
,	O
both	O
pharmacological	O
inhibitors	O
(	O
AG1478	O
and	O
451	O
)	O
and	O
si	O
-	O
RNA	O
silencing	O
of	O
EGFR	B-PRGE
significantly	O
inhibited	O
LPS	O
-	O
induced	O
EGFR	B-PRGE
signaling	O
activation	O
and	O
inflammatory	O
response	O
in	O
human	O
lung	O
epithelial	O
cells	O
or	O
macrophages	O
.	O

This	O
study	O
demonstrates	O
that	O
TLR4	B-PRGE
/	O
c	B-PRGE
-	I-PRGE
Src	I-PRGE
-	I-PRGE
dependent	I-PRGE
EGFR	I-PRGE
signaling	O
plays	O
an	O
important	O
role	O
in	O
LPS	O
-	O
induced	O
ALI	O
,	O
and	O
that	O
EGFR	B-PRGE
may	O
be	O
a	O
potential	O
target	O
in	O
treating	O
ALI	O
.	O

One	O
member	O
of	O
this	O
family	O
that	O
has	O
been	O
well	O
studied	O
is	O
aminopeptidase	B-PRGE
N	I-PRGE
(	O
APN	B-PRGE
),	O
a	O
multifunctional	O
protease	O
known	O
to	O
cleave	O
biologically	O
active	O
peptides	O
and	O
aide	O
in	O
coronavirus	O
entry	O
.	O

Phylogenetic	O
network	O
analysis	O
of	O
Ark	B-PRGE
isolates	O
showed	O
two	O
predominant	O
groups	O
linked	O
by	O
2	O
mutations	O
,	O
consistent	O
with	O
subpopulations	O
found	O
in	O
commercial	O
vaccines	O
for	O
this	O
IBV	O
type	O
.	O

ABSTRACT	O
:	O
In	O
acute	O
lung	O
injury	O
/	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ALI	O
/	O
ARDS	O
),	O
pathogenesis	O
is	O
associated	O
with	O
the	O
regulation	O
of	O
macrophage	O
-	O
generated	O
oxidative	O
stress	O
,	O
and	O
nicotinamide	O
adenine	O
dinucleotide	O
phosphate	O
(	O
NADPH	O
)	O
oxidase	B-PRGE
(	O
NOX	O
)-	O
derived	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
are	O
key	O
to	O
regulating	O
oxidative	O
stress	O
.	O

Respiratory	O
index	O
,	O
white	O
blood	O
cell	O
,	O
hemoglobin	B-PRGE
(	O
HBG	B-PRGE
),	O
platelet	O
(	O
PLT	O
),	O
and	O
other	O
clinical	O
factors	O
were	O
not	O
significantly	O
different	O
between	O
the	O
2	O
groups	O
.	O

Furthermore	O
,	O
the	O
apoptotic	O
cells	O
,	O
indicated	O
as	O
showing	O
caspase	B-PRGE
3	I-PRGE
(	O
Cas3	B-PRGE
)	O
activation	O
,	O
consist	O
of	O
a	O
high	O
number	O
of	O
uninfected	O
cells	O
.	O

In	O
our	O
study	O
,	O
we	O
found	O
that	O
IL	B-PRGE
-	I-PRGE
33	I-PRGE
is	O
significantly	O
elevated	O
in	O
mice	O
infected	O
with	O
murine	O
hepatitis	O
virus	O
strain	O
3	O
(	O
MHV	O
-	O
3	O
).	O

This	O
is	O
accompanied	O
by	O
an	O
increase	O
in	O
pro	O
-	O
coagulant	O
fibrinogen	B-PRGE
-	I-PRGE
like	I-PRGE
protein	I-PRGE
2	I-PRGE
(	O
FGL2	B-PRGE
)	O
in	O
the	O
liver	O
.	O

Our	O
studies	O
showed	O
that	O
IL	B-PRGE
-	I-PRGE
33	I-PRGE
administration	O
in	O
a	O
MHV	O
-	O
3	O
infection	O
promoted	O
survival	O
during	O
FH	O
,	O
with	O
a	O
significant	O
reduction	O
in	O
FGL2	B-PRGE
expression	O
and	O
liver	O
inflammation	O
.	O

In	O
conclusion	O
,	O
our	O
research	O
suggests	O
that	O
IL	B-PRGE
-	I-PRGE
33	I-PRGE
protects	O
against	O
viral	O
fulminant	O
hepatitis	O
in	O
mice	O
by	O
antagonizing	O
expression	O
of	O
the	O
pro	B-PRGE
-	I-PRGE
coagulant	I-PRGE
protein	I-PRGE
FGL2	I-PRGE
.	O

GLS	O
-	O
5300	O
,	O
a	O
prophylactic	O
DNA	O
-	O
plasmid	O
vaccine	O
encoding	O
S	B-PRGE
protein	I-PRGE
,	O
is	O
the	O
first	O
MERS	O
-	O
CoV	O
vaccine	O
to	O
be	O
tested	O
in	O
humans	O
,	O
while	O
monoclonal	O
antibody	O
,	O
m336	O
has	O
given	O
promising	O
results	O
in	O
animal	O
models	O
and	O
has	O
potential	O
for	O
use	O
in	O
outbreak	O
situations	O
.	O

Infectious	O
recombinant	O
IBVs	O
are	O
generated	O
in	O
situ	O
following	O
the	O
transfection	O
of	O
vaccinia	O
virus	O
DNA	O
,	O
containing	O
the	O
modified	O
IBV	O
cDNA	O
,	O
into	O
cells	O
infected	O
with	O
a	O
recombinant	O
fowlpox	O
virus	O
expressing	O
T7	O
DNA	O
-	O
dependant	O
RNA	B-PRGE
polymerase	I-PRGE
.	O

The	O
aim	O
of	O
our	O
review	O
is	O
to	O
evaluate	O
whether	O
GPC3	B-PRGE
has	O
utility	O
as	O
a	O
disease	O
-	O
specific	O
biomarker	O
,	O
to	O
discuss	O
the	O
potential	O
involvement	O
of	O
GPC3	B-PRGE
in	O
cell	O
biology	O
,	O
and	O
to	O
consider	O
the	O
changes	O
of	O
GPC3	B-PRGE
gene	I-PRGE
and	O
protein	O
expression	O
and	O
regulation	O
in	O
hepatocellular	O
carcinoma	O
,	O
lung	O
cancer	O
,	O
severe	O
pneumonia	O
,	O
and	O
ARDS	O
.	O

PPP	B-PRGE
were	O
localized	O
on	O
the	O
corona	O
of	O
the	O
glans	O
penis	O
(	O
100	O
%),	O
coronal	O
sulcus	O
(	O
18	O
.	O
9	O
%),	O
frenulum	O
(	O
15	O
.	O
1	O
%),	O
ventral	O
shaft	O
(	O
5	O
.	O
3	O
%),	O
and	O
dorsal	O
shaft	O
of	O
the	O
penis	O
(	O
2	O
.	O
4	O
%).	O

Taken	O
together	O
,	O
we	O
demonstrated	O
that	O
the	O
abnormal	O
neuronal	O
morphogenesis	O
underlying	O
PHEV	O
infection	O
was	O
mainly	O
caused	O
by	O
functional	O
mRNA	O
repression	O
of	O
the	O
miR	B-PRGE
-	I-PRGE
142	I-PRGE
-	I-PRGE
5p	I-PRGE
target	O
Ulk1	B-PRGE
.	O

Epithelial	O
cell	O
cultures	O
were	O
induced	O
to	O
express	O
LIF	B-PRGE
by	O
bacteria	O
and	O
by	O
sterile	O
bronchoalveolar	O
lavage	O
fluid	O
from	O
pneumonic	O
mice	O
.	O

Our	O
results	O
showed	O
that	O
TMPRSS2	O
and	O
MSPL	O
played	O
significant	O
roles	O
in	O
the	O
stages	O
of	O
cell	O
-	O
cell	O
fusion	O
and	O
virus	O
-	O
cell	O
fusion	O
,	O
whereas	O
HAT	B-PRGE
and	O
DESC1	B-PRGE
exhibited	O
weaker	O
effects	O
.	O

Moreover	O
,	O
the	O
use	O
of	O
Vero	O
cells	O
expressing	O
TMPRSS2	B-PRGE
and	O
MSPL	B-PRGE
facilitated	O
PEDV	O
replication	O
in	O
the	O
absence	O
of	O
exogenous	O
trypsin	B-PRGE
.	O

In	O
sum	O
,	O
we	O
identified	O
two	O
host	O
proteases	O
,	O
TMPRSS2	B-PRGE
and	O
MSPL	B-PRGE
,	O
which	O
may	O
provide	O
insights	O
and	O
a	O
novel	O
method	O
for	O
enhancing	O
viral	O
titers	O
,	O
expanding	O
virus	O
production	O
,	O
and	O
improving	O
the	O
adaptability	O
of	O
PEDV	O
isolates	O
in	O
vitro	O
.	O

KGF	B-PRGE
did	O
not	O
improve	O
physiological	O
or	O
clinical	O
outcomes	O
in	O
ARDS	O
and	O
might	O
be	O
harmful	O
to	O
patient	O
health	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
and	O
isolation	O
of	O
vaccine	O
strains	O
of	O
avian	B-PRGE
paramyxovirus	O
serotype	O
1	O
(	O
APMV1	O
)	O
and	O
avian	O
coronaviruses	O
(	O
ACoV	O
)	O
from	O
different	O
wild	O
bird	O
species	O
across	O
eight	O
Egyptian	O
governorates	O
between	O
January	O
2014	O
and	O
December	O
2015	O
.	O

Although	O
PEDVPT	O
-	O
P96	O
elicited	O
slightly	O
lower	O
neutralizing	O
antibodies	O
and	O
PEDV	O
-	O
specific	O
immunoglobulin	B-PRGE
G	I-PRGE
(	O
IgG	B-PRGE
)	O
and	O
immunoglobulin	B-PRGE
A	I-PRGE
(	O
IgA	B-PRGE
)	O
titers	O
,	O
a	O
reduction	O
in	O
pathogenicity	O
and	O
viral	O
shedding	O
of	O
the	O
subsequent	O
challenge	O
with	O
PEDVPT	O
-	O
P5	O
were	O
noted	O
in	O
both	O
PEDVPT	O
-	O
P5	O
-	O
and	O
PEDVPT	O
-	O
P96	O
-	O
inoculated	O
pigs	O
.	O

Moreover	O
,	O
data	O
regarding	O
viral	O
attenuation	O
and	O
potency	O
of	O
induced	O
antibodies	O
against	O
PEDVPT	O
-	O
P5	O
identified	O
PEDVPT	B-PRGE
-	I-PRGE
P96	I-PRGE
as	O
a	O
potential	O
live	O
-	O
attenuated	O
vaccine	O
candidate	O
.	O

In	O
addition	O
to	O
mAbs	O
with	O
neutralizing	O
epitopes	O
located	O
on	O
the	O
receptor	O
-	O
binding	O
domain	O
,	O
one	O
mAb	O
,	O
5F9	O
,	O
which	O
binds	O
to	O
the	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
)	O
of	O
the	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S1	I-PRGE
subunit	I-PRGE
,	O
showed	O
efficient	O
neutralizing	O
activity	O
against	O
the	O
wild	O
-	O
type	O
MERS	O
-	O
CoV	O
strain	O
EMC	O
/	O
2012	O
,	O
with	O
a	O
half	O
maximal	O
inhibitory	O
concentration	O
of	O
0	O
.	O
2	O
μg	O
/	O
mL	O
.	O
We	O
concluded	O
that	O
a	O
novel	O
neutralizing	O
epitope	O
for	O
MERS	O
-	O
CoV	O
also	O
resides	O
on	O
the	O
NTD	O
of	O
the	O
S	B-PRGE
protein	I-PRGE
,	O
indicating	O
that	O
the	O
NTD	O
might	O
be	O
important	O
during	O
the	O
viral	O
infection	O
process	O
.	O

Their	O
plasma	O
concentrations	O
of	O
kallistatin	B-PRGE
,	O
kallikrein	B-PRGE
,	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
(	O
TNF	O
)-	O
α	O
,	O
interleukin	B-PRGE
(	O
IL	O
)-	O
1β	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
and	O
IL	O
-	O
8	O
were	O
measured	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

CC16	B-PRGE
levels	O
were	O
associated	O
with	O
ICU	O
stay	O
but	O
not	O
hospital	O
stay	O
.	O

Surprisingly	O
,	O
FA	O
-	O
613	O
lost	O
its	O
antiviral	O
potency	O
in	O
the	O
interferon	B-PRGE
-	O
deficient	O
Vero	O
cell	O
line	O
,	O
while	O
maintaining	O
its	O
inhibitory	O
activity	O
in	O
an	O
interferon	B-PRGE
-	O
competent	O
cell	O
line	O
which	O
showed	O
elevated	O
expression	O
of	O
host	O
antiviral	O
genes	O
when	O
infected	O
in	O
the	O
presence	O
of	O
FA	O
-	O
613	O
.	O

A	O
unique	O
GYQEL	O
motif	O
is	O
identified	O
at	O
the	O
cytoplasmic	O
terminal	O
of	O
OC43	B-PRGE
spike	I-PRGE
protein	I-PRGE
which	O
helps	O
in	O
localization	O
in	O
the	O
lysosome	O
,	O
and	O
a	O
novel	O
KLHYT	O
motif	O
is	O
identified	O
in	O
the	O
cytoplasmic	O
tail	O
of	O
SARS	O
spike	O
protein	O
which	O
helps	O
in	O
ER	O
or	O
ERGIC	O
localization	O
.	O

MVA	O
MERS	O
with	O
mH5	O
or	O
F11	B-PRGE
promoter	I-PRGE
induced	O
similar	O
antibody	O
levels	O
;	O
however	O
,	O
F11	B-PRGE
promoter	I-PRGE
enhanced	O
the	O
cellular	O
immunogenicity	O
of	O
MVA	O
MERS	O
to	O
significantly	O
higher	O
magnitudes	O
.	O

High	O
structural	O
similarity	O
to	O
the	O
human	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
nsp3	B-PRGE
is	O
present	O
.	O

TITLE	O
:	O
Human	B-PRGE
Coronavirus	I-PRGE
-	I-PRGE
HKU1	I-PRGE
Infection	O
Among	O
Adults	O
in	O
Cleveland	O
,	O
Ohio	O
.	O

ABSTRACT	O
:	O
Chicken	B-PRGE
surfactant	I-PRGE
protein	I-PRGE
A	I-PRGE
(	O
cSP	B-PRGE
-	I-PRGE
A	I-PRGE
)	O
is	O
a	O
collectin	O
believed	O
to	O
play	O
an	O
important	O
role	O
in	O
antiviral	O
immunity	O
.	O

The	O
cSP	B-PRGE
-	I-PRGE
A	I-PRGE
mRNA	I-PRGE
and	O
its	O
protein	O
were	O
detected	O
separately	O
using	O
real	O
-	O
time	O
quantitative	O
reverse	O
transcriptional	O
polymerase	O
chain	O
reaction	O
(	O
qRT	O
-	O
PCR	O
),	O
a	O
sandwich	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
S	O
-	O
ELISA	O
),	O
and	O
an	O
immunohistochemistry	O
assay	O
(	O
IHC	O
).	O

Collectively	O
,	O
these	O
results	O
show	O
that	O
different	O
residues	O
in	O
SARS	B-PRGE
S	I-PRGE
control	O
cleavage	O
and	O
activation	O
by	O
TMPRSS2	O
,	O
suggesting	O
that	O
these	O
processes	O
are	O
more	O
complex	O
than	O
initially	O
appreciated	O
.	O

In	O
fact	O
,	O
by	O
virtue	O
of	O
its	O
numerous	O
active	O
metabolites	O
,	O
H	O
.	O
indicus	O
was	O
able	O
to	O
inhibit	O
not	O
only	O
the	O
RT	O
-	O
associated	O
RNase	B-PRGE
H	I-PRGE
function	O
,	O
but	O
also	O
the	O
HIV	B-PRGE
-	I-PRGE
1	I-PRGE
RT	I-PRGE
-	I-PRGE
associated	I-PRGE
RNA	I-PRGE
-	I-PRGE
dependent	I-PRGE
DNA	I-PRGE
polymerase	I-PRGE
activity	O
and	O
the	O
cellular	B-PRGE
α	I-PRGE
-	I-PRGE
glucosidase	I-PRGE
.	O

NF	O
-	O
κB	O
activation	O
induced	O
by	O
TGEV	O
infection	O
was	O
found	O
to	O
be	O
associated	O
with	O
two	O
convergent	O
pathways	O
,	O
IKK	B-PRGE
-	I-PRGE
2_IκBα	I-PRGE
/	O
p65	B-PRGE
and	O
JAK2	B-PRGE
mediated	O
p65	B-PRGE
phosphorylation	O
,	O
in	O
swine	O
testicular	O
cells	O
.	O

The	O
xTAG	B-PRGE
RVP	I-PRGE
Fast	I-PRGE
v2	I-PRGE
assay	O
showed	O
comparable	O
capabilities	O
compared	O
with	O
the	O
other	O
assays	O
;	O
it	O
will	O
be	O
useful	O
for	O
identifying	O
respiratory	O
viral	O
infections	O
in	O
patients	O
with	O
respiratory	O
symptoms	O
.	O

RESULTS	O
:	O
Of	O
the	O
254	O
respiratory	O
specimens	O
,	O
there	O
was	O
total	O
agreement	O
in	O
the	O
results	O
between	O
the	O
xTAG	B-PRGE
RVP	I-PRGE
Fast	I-PRGE
v2	I-PRGE
assay	O
and	O
the	O
other	O
real	O
-	O
time	O
PCR	O
assay	O
in	O
94	O
.	O
1	O
-	O
100	O
%	O
of	O
the	O
specimens	O
.	O

CHS	B-PRGE
is	O
a	O
life	O
-	O
threatening	O
disorder	O
characterized	O
by	O
hypoventilation	O
during	O
sleep	O
.	O

The	O
characteristics	O
and	O
outcomes	O
of	O
patients	O
receiving	O
PEG	O
concomitantly	O
with	O
a	O
tracheostomy	O
(	O
CTPEG	O
)	O
and	O
those	O
receiving	O
delayed	B-PRGE
PEG	B-PRGE
(	I-PRGE
DPEG	I-PRGE
)	I-PRGE
after	O
a	O
tracheostomy	O
were	O
compared	O
.	O

In	O
this	O
study	O
,	O
we	O
focus	O
on	O
the	O
nsp14	B-PRGE
protein	I-PRGE
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
virus	O
replication	O
as	O
it	O
methylates	O
the	O
RNA	O
cap	O
structure	O
at	O
the	O
N7	O
position	O
of	O
the	O
guanine	O
.	O

Here	O
,	O
we	O
describe	O
a	O
transforming	B-PRGE
growth	I-PRGE
factor	I-PRGE
(	O
TGF	O
)-	O
β	O
-	O
triggered	O
mechanism	O
,	O
in	O
which	O
megalin	B-PRGE
,	O
the	O
primary	O
mediator	O
of	O
alveolar	O
protein	O
transport	O
,	O
is	O
negatively	O
regulated	O
by	O
glycogen	B-PRGE
synthase	I-PRGE
kinase	I-PRGE
(	O
GSK	B-PRGE
)	O
3β	O
,	O
with	O
protein	B-PRGE
phosphatase	I-PRGE
1	I-PRGE
and	O
nuclear	O
inhibitor	O
of	O
protein	B-PRGE
phosphatase	I-PRGE
1	I-PRGE
being	O
involved	O
in	O
the	O
signaling	O
cascade	O
.	O

Here	O
we	O
show	O
that	O
avian	O
influenza	O
virus	O
H5N1	O
induced	O
the	O
upregulation	O
of	O
miR	B-PRGE
-	I-PRGE
200c	I-PRGE
-	I-PRGE
3p	I-PRGE
,	O
which	O
was	O
then	O
demonstrated	O
to	O
target	O
the	O
3	O
'-	O
untranslated	O
region	O
of	O
ACE2	B-PRGE
.	O

Interestingly	O
,	O
the	O
AIV	B-PRGE
-	I-PRGE
H9N2	I-PRGE
showed	O
constantly	O
high	O
shedding	O
titers	O
till	O
7DPI	O
with	O
variant	O
or	O
vaccine	O
IBV	O
co	O
-	O
infection	O
.	O

ABSTRACT	O
:	O
To	O
provide	O
optimal	O
cut	O
-	O
off	O
values	O
of	O
anti	O
-	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
serologic	O
tests	O
,	O
we	O
evaluated	O
performance	O
of	O
ELISA	B-PRGE
IgG	I-PRGE
,	O
ELISA	B-PRGE
IgA	I-PRGE
,	O
IFA	B-PRGE
IgM	I-PRGE
,	O
and	O
IFA	B-PRGE
IgG	I-PRGE
using	O
138	O
serum	O
samples	O
of	O
49	O
MERS	O
-	O
CoV	O
-	O
infected	O
patients	O
and	O
219	O
serum	O
samples	O
of	O
219	O
rRT	O
-	O
PCR	O
-	O
negative	O
MERS	O
-	O
CoV	O
-	O
exposed	O
healthcare	O
personnel	O
and	O
patients	O
.	O

These	O
new	O
breakpoints	O
are	O
markedly	O
lower	O
than	O
previously	O
suggested	O
values	O
(	O
ELISA	O
IgG	B-PRGE
OD	I-PRGE
ratio	O
1	O
.	O
1	O
,	O
sensitivity	O
34	O
.	O
8	O
%	O
and	O
specificity	O
100	O
%	O
in	O
the	O
present	O
data	O
set	O
),	O
and	O
the	O
performance	O
data	O
help	O
serologic	O
tests	O
to	O
be	O
practically	O
used	O
in	O
the	O
field	O
of	O
MERS	O
management	O
.	O

The	O
serum	O
levels	O
of	O
interferon	B-PRGE
(	O
IFN	O
)-	O
γ	O
and	O
the	O
IFN	B-PRGE
-	I-PRGE
γ	I-PRGE
/	O
interleukin	B-PRGE
(	O
IL	O
)-	O
10	O
ratio	O
were	O
higher	O
in	O
non	O
-	O
survivors	O
.	O

Additionally	O
,	O
interleukin	B-PRGE
(	O
IL	O
)‑	O
6	O
was	O
identified	O
as	O
a	O
hub	B-PRGE
protein	I-PRGE
with	O
a	O
high	O
degree	O
.	O

PEDV	O
blocked	O
the	O
p65	B-PRGE
activation	O
in	O
infected	O
cells	O
and	O
suppressed	O
the	O
PRD	B-PRGE
II	I-PRGE
-	O
mediated	O
NF	O
-	O
κB	O
activity	O
.	O

Our	O
study	O
showed	O
that	O
PEDV	O
inhibited	O
NF	O
-	O
κB	O
activity	O
and	O
nsp1	B-PRGE
was	O
a	O
potent	O
NF	O
-	O
κB	O
antagonist	O
for	O
suppression	O
of	O
both	O
IFN	B-PRGE
and	O
early	O
production	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
.	O

Agarose	O
gel	O
electrophoresis	O
of	O
three	O
diarrheic	O
fecal	O
samples	O
yielded	O
from	O
the	O
25	O
samples	O
desired	O
amplicons	O
that	O
were	O
488	O
base	O
pairs	O
and	O
sequencing	O
substantiated	O
that	O
have	O
BCoV	O
.	O
The	O
sequence	O
alignment	O
indicated	O
that	O
nucleotide	O
and	O
amino	O
acid	O
sequences	O
,	O
the	O
three	O
TWD	O
isolated	O
in	O
Thailand	O
,	O
were	O
more	O
quite	O
homologous	O
to	O
each	O
other	O
(	O
amino	O
acid	O
at	O
position	O
39	O
of	O
TWD1	B-PRGE
,	O
TWD3	O
was	O
proline	O
,	O
but	O
TWD2	O
was	O
serine	O
)	O
and	O
closely	O
related	O
to	O
OK	O
-	O
0514	O
-	O
3strain	O
(	O
virulent	O
respiratory	O
strain	O
;	O
RBCoV	O
).	O
The	O
amino	O
acid	O
sequencing	O
identities	O
among	O
TWD1	B-PRGE
,	O
TWD2	O
,	O
TWD3	O
,	O
and	O
OK	O
-	O
0514	O
-	O
3	O
strain	O
were	O
96	O
.	O
0	O
to	O
96	O
.	O
6	O
%,	O
those	O
at	O
which	O
T3I	O
,	O
H65N	O
,	O
D87G	O
,	O
H127Y	O
,	O
andQ136R	O
were	O
changed	O
.	O

Old	O
age	O
,	O
low	O
albumin	B-PRGE
,	O
altered	O
mentality	O
and	O
high	O
pneumonia	O
severity	O
index	O
score	O
at	O
admission	O
were	O
risk	O
factors	O
for	O
mortality	O
.	O

In	O
addition	O
,	O
severe	O
signs	O
of	O
inflammation	O
at	O
initial	O
presentation	O
(	O
at	O
hospital	O
days	O
1	O
-	O
4	O
),	O
such	O
as	O
high	O
inducible	O
protein	O
-	O
10	O
(	O
p	O
=	O
0	O
.	O
0013	O
),	O
monocyte	B-PRGE
chemoattractant	I-PRGE
protein	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
p	O
=	O
0	O
.	O
0007	O
)	O
and	O
interleukin	B-PRGE
6	I-PRGE
(	O
p	O
=	O
0	O
.	O
0007	O
)	O
concentrations	O
,	O
and	O
poor	O
viral	O
control	O
(	O
high	O
viral	O
load	O
at	O
hospital	O
days	O
5	O
-	O
10	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
without	O
adequate	O
antibody	O
titres	O
(	O
low	O
antibody	O
titre	O
at	O
hospital	O
days	O
11	O
-	O
16	O
,	O
p	O
=	O
0	O
.	O
07	O
)	O
during	O
the	O
course	O
of	O
disease	O
,	O
were	O
associated	O
with	O
mortality	O
.	O

To	O
determine	O
the	O
genetic	O
relationships	O
of	O
the	O
18	O
sequences	O
obtained	O
in	O
this	O
study	O
and	O
previously	O
known	O
coronaviruses	O
,	O
the	O
nucleotide	O
sequences	O
of	O
a	O
392	O
-	O
nt	O
region	O
of	O
the	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
(	O
RdRp	O
)	O
gene	O
were	O
analyzed	O
phylogenetically	O
.	O

Moreover	O
,	O
mRNA	O
levels	O
of	O
inflammatory	O
cytokines	O
(	O
TNF	O
-	O
α	O
,	O
IL	O
-	O
1β	O
,	O
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
)	O
significantly	O
increased	O
with	O
ADE	O
of	O
FIPV	O
79	O
-	O
1146	O
infection	O
in	O
primary	O
feline	O
monocytes	O
,	O
but	O
FECV	O
79	O
-	O
1683	O
did	O
not	O
demonstrate	O
an	O
increase	O
in	O
these	O
levels	O
.	O

Moreover	O
,	O
an	O
in	O
vitro	O
analysis	O
demonstrated	O
that	O
interleukin	B-PRGE
-	I-PRGE
13	I-PRGE
and	O
-	O
31	O
and	O
hemozoin	O
induced	O
pneumocytic	O
cell	O
injury	O
and	O
apoptosis	O
,	O
as	O
assessed	O
by	O
EB	O
/	O
AO	O
staining	O
,	O
electron	O
microscopy	O
and	O
the	O
up	O
-	O
regulation	O
of	O
CARD	B-PRGE
-	I-PRGE
9	I-PRGE
mRNA	I-PRGE
(	O
caspase	B-PRGE
recruitment	O
domain	O
-	O
9	O
messenger	O
-	O
ribonucleic	O
acid	O
).	O

TITLE	O
:	O
Cardiac	O
Troponin	B-PRGE
Values	O
in	O
Patients	O
With	O
Acute	O
Coronary	O
Syndrome	O
and	O
Sleep	O
Apnea	O
:	O
A	O
Pilot	O
Study	O
.	O

The	O
multivariable	O
linear	O
regression	O
analysis	O
of	O
the	O
relationship	O
between	O
peak	O
cTnI	O
value	O
and	O
patient	O
group	O
,	O
age	O
,	O
sex	O
,	O
and	O
type	O
of	O
ACS	O
showed	O
that	O
the	O
presence	O
or	O
absence	O
of	O
OSA	O
significantly	O
contributed	O
to	O
the	O
peak	O
cTnI	B-PRGE
level	O
,	O
which	O
was	O
54	O
%	O
lower	O
in	O
patients	O
with	O
OSA	O
than	O
in	O
those	O
without	O
OSA	O
.	O

Although	O
coexistence	O
of	O
nsp3	B-PRGE
and	O
nsp4	B-PRGE
is	O
known	O
to	O
cause	O
membrane	O
rearrangement	O
,	O
the	O
mechanisms	O
underlying	O
the	O
interaction	O
of	O
these	O
two	O
proteins	O
remain	O
unclear	O
.	O

TITLE	O
:	O
Permissivity	O
of	O
Dipeptidyl	B-PRGE
Peptidase	I-PRGE
4	O
Orthologs	O
to	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Is	O
Governed	O
by	O
Glycosylation	O
and	O
Other	O
Complex	O
Determinants	O
.	O

We	O
found	O
that	O
,	O
while	O
glycosylation	O
plays	O
an	O
important	O
role	O
in	O
these	O
orthologs	O
,	O
additional	O
sequence	O
and	O
structural	O
determinants	O
impact	O
their	O
ability	O
to	O
act	O
as	O
functional	O
receptors	O
for	O
MERS	O
-	O
CoV	O
.	O
These	O
results	O
provide	O
insight	O
into	O
DPP4	B-PRGE
species	O
-	O
specific	O
differences	O
impacting	O
MERS	O
-	O
CoV	O
host	O
range	O
and	O
better	O
inform	O
our	O
understanding	O
of	O
virus	O
-	O
receptor	O
interactions	O
associated	O
with	O
disease	O
emergence	O
and	O
host	O
susceptibility	O
.	O

To	O
determine	O
the	O
molecular	O
diversity	O
of	O
PEDV	O
in	O
the	O
Hubei	O
Province	O
of	O
China	O
,	O
we	O
collected	O
172	O
PED	O
samples	O
from	O
34	O
farms	O
across	O
the	O
province	O
in	O
2016	O
and	O
performed	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
by	O
targeting	O
the	O
nucleocapsid	B-PRGE
(	I-PRGE
N	I-PRGE
)	I-PRGE
gene	I-PRGE
.	O

With	O
the	O
aim	O
of	O
enhancing	O
understanding	O
of	O
the	O
binding	O
properties	O
of	O
scytovirin	O
,	O
we	O
performed	O
molecular	O
dynamics	O
(	O
MD	O
)	O
simulations	O
of	O
scytovirin	O
complexed	O
with	O
Man4	B-PRGE
.	O

Decomposition	O
of	O
the	O
binding	O
free	O
energy	O
showed	O
that	O
the	O
residues	O
that	O
interact	O
with	O
Man4	B-PRGE
were	O
different	O
in	O
the	O
three	O
systems	O
,	O
suggesting	O
that	O
the	O
binding	O
mechanism	O
of	O
Man4	B-PRGE
varies	O
between	O
full	O
-	O
length	O
protein	O
,	O
SD1	O
and	O
SD2	O
.	O

TITLE	O
:	O
Identification	O
and	O
characterization	O
of	O
a	O
Golgi	O
retention	O
signal	O
in	O
feline	B-PRGE
coronavirus	I-PRGE
accessory	I-PRGE
protein	I-PRGE
7b	I-PRGE
.	O

Based	O
on	O
this	O
information	O
,	O
rFIPVs	O
expressing	O
FLAG	B-PRGE
-	I-PRGE
tagged	I-PRGE
7b	I-PRGE
proteins	I-PRGE
were	O
generated	O
and	O
the	O
effects	O
of	O
substitutions	O
in	O
the	O
C	O
-	O
terminal	O
202KTEL206	O
sequence	O
were	O
investigated	O
.	O

TITLE	O
:	O
The	O
tetraspanin	B-PRGE
CD9	I-PRGE
facilitates	O
MERS	O
-	O
coronavirus	O
entry	O
by	O
scaffolding	O
host	B-PRGE
cell	I-PRGE
receptors	I-PRGE
and	O
proteases	O
.	O

To	O
evaluate	O
the	O
importance	O
of	O
these	O
complexes	O
in	O
an	O
in	O
vivo	O
CoV	O
infection	O
model	O
,	O
we	O
used	O
recombinant	O
Adenovirus	O
5	O
(	O
rAd5	O
)	O
vectors	O
to	O
express	O
human	B-PRGE
DPP4	I-PRGE
in	O
mouse	O
lungs	O
,	O
thereby	O
sensitizing	O
the	O
animals	O
to	O
MERS	O
-	O
CoV	O
infection	O
.	O

TITLE	O
:	O
Sensitivity	O
and	O
specificity	O
of	O
a	O
real	O
-	O
time	O
reverse	O
transcriptase	B-PRGE
polymerase	I-PRGE
chain	I-PRGE
reaction	O
detecting	O
feline	O
coronavirus	O
mutations	O
in	O
effusion	O
and	O
serum	O
/	O
plasma	O
of	O
cats	O
to	O
diagnose	O
feline	O
infectious	O
peritonitis	O
.	O

ABSTRACT	O
:	O
Feline	O
coronavirus	O
(	O
FCoV	O
)	O
exists	O
as	O
two	O
pathotypes	O
,	O
and	O
FCoV	B-PRGE
spike	I-PRGE
gene	I-PRGE
mutations	O
are	O
considered	O
responsible	O
for	O
the	O
pathotypic	O
switch	O
in	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
)	O
pathogenesis	O
.	O

In	O
the	O
small	O
airways	O
,	O
there	O
was	O
a	O
lower	O
cell	O
density	O
of	O
tryptase	O
+	O
mast	O
cells	O
and	O
dendritic	O
+	O
cells	O
and	O
an	O
increase	O
of	O
IL	B-PRGE
-	I-PRGE
17	I-PRGE
in	O
both	O
DAD	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

In	O
the	O
small	O
airways	O
,	O
there	O
was	O
a	O
lower	O
cell	O
density	O
of	O
tryptase	O
+	O
mast	O
cells	O
and	O
dendritic	O
+	O
cells	O
and	O
an	O
increase	O
of	O
IL	B-PRGE
-	I-PRGE
17	I-PRGE
in	O
both	O
DAD	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

Individual	O
samples	O
in	O
the	O
positive	O
pools	O
were	O
confirmed	O
by	O
qRT	O
-	O
PCR	B-PRGE
,	O
RT	O
-	O
PCR	O
,	O
PCR	O
and	O
Sanger	O
sequencing	O
from	O
the	O
CPE	O
culture	O
and	O
original	O
clinical	O
specimens	O
.	O

Surprisingly	O
,	O
the	O
antiviral	O
activity	O
of	O
U18666A	O
was	O
suppressed	O
by	O
the	O
histone	B-PRGE
deacetylase	I-PRGE
inhibitor	I-PRGE
(	O
HDACi	O
),	O
Vorinostat	O
.	O

HDACi	O
has	O
been	O
reported	O
to	O
revert	O
U18666A	O
-	O
induced	O
dysfunction	O
of	O
Niemann	B-PRGE
-	I-PRGE
Pick	I-PRGE
C1	I-PRGE
(	O
NPC1	B-PRGE
).	O

In	O
conclusion	O
,	O
these	O
findings	O
demonstrate	O
that	O
NPC1	B-PRGE
plays	O
an	O
important	O
role	O
in	O
type	O
I	O
FCoV	O
infection	O
.	O

Laboratory	O
results	O
show	O
increased	O
serum	B-PRGE
creatinine	I-PRGE
kinase	I-PRGE
and	O
AST	B-PRGE
.	O

Unlike	O
lipid	O
-	O
free	O
peptides	O
,	O
the	O
lipopeptides	O
suppressed	O
CoV	B-PRGE
S	I-PRGE
protein	I-PRGE
-	O
directed	O
virus	O
entry	O
taking	O
place	O
within	O
endosomes	O
.	O

Swabs	O
from	O
trachea	O
and	O
nasal	O
tract	O
along	O
with	O
tissue	O
samples	O
of	O
spleen	O
and	O
lung	O
from	O
dead	O
animals	O
were	O
found	O
positive	O
for	O
PPR	O
virus	O
based	O
on	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
using	O
H	B-PRGE
gene	I-PRGE
and	O
partial	O
N	O
gene	O
-	O
specific	O
primers	O
.	O

TITLE	O
:	O
Rapid	O
and	O
sensitive	O
detection	O
of	O
canine	O
distemper	O
virus	O
by	O
real	O
-	O
time	O
reverse	O
transcription	B-PRGE
recombinase	I-PRGE
polymerase	I-PRGE
amplification	O
.	O

The	O
RT	B-PRGE
-	I-PRGE
RPA	I-PRGE
assay	O
was	O
performed	O
successfully	O
at	O
40	O
°	O
C	O
,	O
and	O
the	O
results	O
were	O
obtained	O
within	O
3	O
min	O
-	O
12	O
min	O
.	O

TITLE	O
:	O
Pharmacological	O
modulation	O
of	O
C	B-PRGE
-	I-PRGE
X	I-PRGE
-	I-PRGE
C	I-PRGE
motif	I-PRGE
chemokine	I-PRGE
receptor	I-PRGE
4	I-PRGE
influences	O
development	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
after	O
lung	O
ischaemia	O
-	O
reperfusion	O
injury	O
.	O

RESULTS	O
At	O
the	O
calf	O
level	O
,	O
serum	B-PRGE
anti	I-PRGE
-	I-PRGE
BCV	I-PRGE
antibody	I-PRGE
abundance	O
was	O
not	O
associated	O
with	O
BCV	O
shedding	O
,	O
but	O
BCV	O
shedding	O
was	O
positively	O
associated	O
with	O
BRD	O
incidence	O
before	O
and	O
after	O
weaning	O
.	O

Therefore	O
,	O
IL	B-PRGE
-	I-PRGE
17A	I-PRGE
may	O
play	O
important	O
roles	O
in	O
asthmatic	O
exacerbation	O
,	O
and	O
its	O
high	O
level	O
,	O
in	O
combination	O
with	O
upregulated	O
Th2	O
and	O
other	O
cytokines	O
,	O
may	O
indicate	O
the	O
refractory	O
endotype	O
of	O
asthma	O
.	O

We	O
evaluated	O
the	O
performance	O
of	O
the	O
PowerChek	O
MERS	O
(	O
upE	O
&	O
ORF1a	O
)	O
real	O
-	O
time	O
PCR	O
Kit	O
(	O
PowerChek	O
MERS	O
assay	O
;	O
Kogene	O
Biotech	O
,	O
Korea	O
)	O
a	O
one	O
-	O
step	O
rRT	O
-	O
PCR	O
assay	O
for	O
the	O
qualitative	O
detection	O
of	O
MERS	O
-	O
CoV	O
.	O
We	O
evaluated	O
PowerChek	O
MERS	O
assay	O
performance	O
in	O
comparison	O
with	O
nested	O
RT	O
-	O
PCR	O
and	O
sequencing	O
of	O
the	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
(	O
RdRp	O
)	O
and	O
N	O
genes	O
.	O

The	O
PowerChek	O
MERS	O
assay	O
is	O
a	O
straightforward	O
and	O
accurate	O
assay	O
for	O
detecting	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
.	O

TITLE	O
:	O
Phylogenetic	O
analysis	O
of	O
VP1	B-PRGE
and	O
RdRP	O
genes	O
of	O
Brazilian	O
aichivirus	O
B	O
strains	O
involved	O
in	O
a	O
diarrhea	O
outbreak	O
in	O
dairy	O
calves	O
.	O

TITLE	O
:	O
The	O
FER	B-PRGE
rs4957796	I-PRGE
TT	I-PRGE
genotype	I-PRGE
is	O
associated	O
with	O
unfavorable	O
90	O
-	O
day	O
survival	O
in	O
Caucasian	O
patients	O
with	O
severe	O
ARDS	O
due	O
to	O
pneumonia	O
.	O

TITLE	O
:	O
[	O
Effect	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
nsp1	B-PRGE
on	O
type	O
Ⅰ	O
interferon	O
response	O
].	O

Our	O
results	O
implied	O
that	O
nsp1	B-PRGE
was	O
a	O
highly	O
conserved	O
protein	O
of	O
PEDV	O
and	O
exhibited	O
antagonistic	O
function	O
on	O
interferon	B-PRGE
promoter	I-PRGE
activity	O
.	O

Of	O
the	O
2	O
,	O
386	O
,	O
657	O
admissions	O
with	O
AMI	O
,	O
SCA	B-PRGE
was	O
reported	O
in	O
501	O
(	O
0	O
.	O
02	O
%)	O
patients	O
,	O
and	O
495	O
were	O
successfully	O
matched	O
to	O
controls	O
.	O

Area	O
covered	O
:	O
This	O
review	O
summarizes	O
the	O
current	O
understanding	O
of	O
the	O
structural	O
and	O
functional	O
properties	O
of	O
type	B-PRGE
II	I-PRGE
transmembrane	I-PRGE
serine	I-PRGE
proteases	I-PRGE
(	O
TTSPs	O
)	O
as	O
a	O
proteolytic	O
activator	O
of	O
influenza	O
virus	O
infection	O
and	O
discusses	O
their	O
potential	O
as	O
antiviral	O
targets	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
detection	O
of	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
IgG	I-PRGE
in	O
suspected	O
and	O
proven	O
cases	O
of	O
MERS	O
-	O
CoV	O
infection	O
.	O

A	O
virus	B-PRGE
-	I-PRGE
type	I-PRGE
-	I-PRGE
dependent	I-PRGE
IL	I-PRGE
influence	O
was	O
also	O
apparent	O
.	O

A	O
slight	O
increase	O
in	O
interferon	B-PRGE
-	I-PRGE
α	I-PRGE
protein	I-PRGE
production	O
in	O
the	O
supernatants	O
of	O
PEDV	O
-	O
infected	O
cells	O
was	O
observed	O
compared	O
to	O
mock	O
infected	O
cells	O
.	O

Animals	O
were	O
classified	O
into	O
two	O
groups	O
depending	O
on	O
their	O
initial	O
BCoV	O
IgG1	B-PRGE
Ab	O
titers	O
.	O

In	O
the	O
absence	O
of	O
IL	B-PRGE
-	I-PRGE
18	I-PRGE
,	O
mice	O
had	O
elevated	O
viral	O
replication	O
and	O
poor	O
survival	O
,	O
and	O
this	O
protective	O
effect	O
of	O
IL	B-PRGE
-	I-PRGE
18	I-PRGE
was	O
found	O
to	O
be	O
due	O
to	O
promotion	O
of	O
interferon	B-PRGE
gamma	I-PRGE
production	O
in	O
αβ	O
T	O
cells	O
.	O

The	O
results	O
reveal	O
that	O
the	O
three	O
IBV	O
isolates	O
mainly	O
exhibited	O
mutations	O
in	O
the	O
hypervariable	O
regions	O
(	O
HVRs	O
)	O
of	O
the	O
S1	B-PRGE
gene	I-PRGE
and	O
protein	O
,	O
but	O
were	O
phylogenetically	O
and	O
serologically	O
closely	O
related	O
,	O
belonging	O
to	O
lineage	O
11	O
of	O
the	O
GI	O
genotype	O
,	O
the	O
former	O
BR	O
genotype	O
I	O
.	O
All	O
three	O
isolates	O
caused	O
persistent	O
infection	O
in	O
broiler	O
breeders	O
reared	O
in	O
the	O
field	O
,	O
despite	O
high	O
systemic	O
anti	O
-	O
IBV	O
antibody	O
titres	O
,	O
and	O
exhibited	O
tropism	O
and	O
pathogenicity	O
for	O
the	O
trachea	O
and	O
kidney	O
after	O
experimental	O
infection	O
in	O
SPF	B-PRGE
chickens	I-PRGE
and	O
contact	O
birds	O
.	O

Although	O
the	O
S1	B-PRGE
subunit	I-PRGE
is	O
the	O
major	O
inducer	O
of	O
neutralizing	O
antibodies	O
,	O
vaccination	O
with	O
S1	B-PRGE
protein	I-PRGE
has	O
been	O
shown	O
to	O
confer	O
inadequate	O
protection	O
against	O
challenge	O
.	O

The	O
immune	O
evasion	O
mechanism	O
including	O
type	B-PRGE
1	I-PRGE
interferon	I-PRGE
and	O
protein	B-PRGE
kinase	O
R	O
-	O
mediated	O
antiviral	O
stress	O
responses	O
has	O
been	O
recently	O
attributed	O
to	O
the	O
involvement	O
of	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
protein	I-PRGE
4a	I-PRGE
(	O
p4a	O
)	O
that	O
masks	O
the	O
viral	O
dsRNA	O
.	O

Our	O
previous	O
study	O
found	O
that	O
interleukin	B-PRGE
(	O
IL	O
)-	O
17A	O
production	O
by	O
humans	O
or	O
mice	O
infected	O
with	O
influenza	O
A	O
(	O
H1N1	O
)	O
pdm09	O
substantially	O
contributes	O
to	O
ALI	O
and	O
subsequent	O
morbidity	O
and	O
mortality	O
.	O

However	O
,	O
the	O
cell	O
types	O
responsible	O
for	O
IL	B-PRGE
-	I-PRGE
17A	I-PRGE
production	O
during	O
the	O
early	O
stage	O
of	O
severe	O
influenza	O
A	O
(	O
H1N1	O
)	O
pdm09	O
infection	O
remained	O
unknown	O
.	O

The	O
most	O
frequent	O
autoantibody	O
detected	O
was	O
anti	B-PRGE
-	I-PRGE
SSA	I-PRGE
/	O
Ro52	B-PRGE
.	O

The	O
veno	O
-	O
venous	O
ECMO	O
-	O
treatment	O
causes	O
a	O
significant	O
reduction	O
of	O
some	O
of	O
the	O
major	O
non	O
-	O
enzymatic	O
antioxidants	O
and	O
a	O
possible	O
increase	O
in	O
insulin	B-PRGE
resistance	O
in	O
patients	O
with	O
ARDS	O
by	O
influence	O
A	O
H1N1	O
.	O

TITLE	O
:	O
First	O
characterization	O
of	O
a	O
Middle	O
-	O
East	O
GI	O
-	O
23	O
lineage	O
(	O
Var2	B-PRGE
-	I-PRGE
like	I-PRGE
)	O
of	O
infectious	O
bronchitis	O
virus	O
in	O
Europe	O
.	O

The	O
full	O
-	O
length	O
genome	O
of	O
gammaCoV	O
/	O
Ck	O
/	O
Poland	O
/	O
G052	O
/	O
2016	O
strain	O
consists	O
of	O
27596	O
nucleotides	O
and	O
has	O
typical	O
organization	O
for	O
IBV	O
(	O
UTR5	O
'-	O
POl	B-PRGE
-	I-PRGE
S	I-PRGE
-	I-PRGE
3a	I-PRGE
-	I-PRGE
3b	I-PRGE
-	I-PRGE
E	I-PRGE
-	I-PRGE
M	I-PRGE
-	I-PRGE
4b	I-PRGE
-	I-PRGE
4c	I-PRGE
-	I-PRGE
5a	I-PRGE
-	I-PRGE
5b	I-PRGE
-	I-PRGE
N	I-PRGE
-	I-PRGE
UTR3	I-PRGE
').	I-PRGE

A	O
novel	O
sgmRNA	O
(	O
M	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
was	O
identified	O
as	O
a	O
short	O
version	O
of	O
membrane	O
(	O
M	O
)	O
gene	O
.	O

IBV	O
replication	O
was	O
increased	O
by	O
blocking	O
caspase	B-PRGE
activation	O
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
single	O
-	O
tube	O
one	O
-	O
step	O
reverse	O
transcription	O
loop	O
-	O
mediated	O
isothermal	O
amplification	O
(	O
RT	O
-	O
LAMP	O
)	O
assay	O
specific	O
for	O
nucleocapsid	B-PRGE
gene	I-PRGE
to	O
diagnose	O
and	O
monitor	O
PDCoV	O
infections	O
.	O

The	O
detection	O
limit	O
of	O
RT	O
-	O
LAMP	O
assay	O
was	O
1	O
×	O
10	O
The	O
RT	B-PRGE
-	I-PRGE
LAMP	I-PRGE
assay	O
established	O
in	O
this	O
study	O
is	O
a	O
potentially	O
valuable	O
tool	O
,	O
especially	O
in	O
low	O
-	O
resource	O
laboratories	O
and	O
filed	O
settings	O
,	O
for	O
a	O
rapid	O
diagnosis	O
,	O
surveillance	O
,	O
and	O
molecular	O
epidemiology	O
investigation	O
of	O
PDCoV	O
infections	O
.	O

Those	O
findings	O
were	O
consistent	O
with	O
a	O
rare	O
form	O
of	O
IgA	B-PRGE
vasculitis	O
(	O
formerly	O
Henoch	O
-	O
Schönlein	O
syndrome	O
),	O
the	O
originality	O
of	O
the	O
case	O
lying	O
in	O
the	O
occurrence	O
of	O
a	O
kidney	O
-	O
lung	O
syndrome	O
in	O
an	O
elderly	O
patient	O
.	O

Furthermore	O
,	O
a	O
GTPase	B-PRGE
activation	O
assay	O
suggested	O
that	O
endogenous	O
Rab5	B-PRGE
is	O
activated	O
by	O
PHEV	O
and	O
is	O
crucial	O
for	O
viral	O
progression	O
.	O

Our	O
goal	O
was	O
to	O
determine	O
resistance	O
and	O
susceptibility	O
of	O
MHC	B-PRGE
B	I-PRGE
haplotype	O
in	O
congenic	O
and	O
inbred	O
chicken	O
lines	O
in	O
order	O
to	O
establish	O
a	O
resistant	O
-	O
susceptible	O
model	O
.	O

The	O
relative	O
expression	O
of	O
lnc	B-PRGE
-	I-PRGE
IL7R	I-PRGE
was	O
obtained	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
.	O

Plasma	B-PRGE
lnc	I-PRGE
-	I-PRGE
IL7R	I-PRGE
was	O
significantly	O
down	O
-	O
regulated	O
in	O
ARDS	O
compared	O
with	O
the	O
levels	O
in	O
healthy	O
control	O
individuals	O
,	O
especially	O
in	O
severe	O
ARDS	O
(	O
P	O
<	O
.	O
01	O
).	O

The	O
lnc	B-PRGE
-	I-PRGE
IL7R	I-PRGE
levels	O
were	O
correlated	O
with	O
the	O
severity	O
of	O
ARDS	O
(	O
ρ	O
=	O
-	O
0	O
.	O
31	O
,	O
P	O
=	O
.	O
0215	O
),	O
oxygenation	O
index	O
(	O
ρ	O
=	O
0	O
.	O
61	O
,	O
P	O
<	O
.	O
001	O
),	O
APACHE	O
II	O
score	O
(	O
ρ	O
=	O
-	O
0	O
.	O
04	O
,	O
P	O
=	O
.	O
0230	O
),	O
CRP	B-PRGE
(	O
ρ	O
=	O
-	O
0	O
.	O
26	O
,	O
P	O
=	O
.	O
0148	O
)	O
and	O
WBC	O
(	O
ρ	O
=	O
-	O
0	O
.	O
29	O
,	O
P	O
=	O
.	O
0064	O
).	O

survivors	O
showed	O
higher	O
lnc	B-PRGE
-	I-PRGE
IL7R	I-PRGE
level	O
and	O
lower	O
APACHE	O
II	O
score	O
,	O
SOFA	O
score	O
and	O
length	O
of	O
mechanical	O
ventilation	O
than	O
in	O
the	O
non	O
-	O
survivors	O
(	O
P	O
=	O
.	O
0109	O
,	O
P	O
<	O
.	O
001	O
,	O
P	O
<	O
.	O
001	O
and	O
P	O
=	O
.	O
017	O
,	O
respectively	O
).	O

TITLE	O
:	O
Clinical	O
significance	O
of	O
mechanical	O
ventilation	O
on	O
ischemic	O
-	O
reperfusion	O
injury	O
caused	O
by	O
lung	O
chest	O
trauma	O
and	O
VEGF	B-PRGE
expression	O
levels	O
in	O
peripheral	O
blood	O
.	O

ABSTRACT	O
:	O
We	O
investigated	O
the	O
clinical	O
significance	O
of	O
mechanical	O
ventilation	O
on	O
ischemic	O
-	O
reperfusion	O
injury	O
caused	O
by	O
lung	O
chest	O
trauma	O
as	O
well	O
as	O
vascular	B-PRGE
endothelial	I-PRGE
growth	I-PRGE
factor	I-PRGE
(	O
VEGF	B-PRGE
)	O
expression	O
levels	O
in	O
peripheral	O
blood	O
.	O

stigmatosoma	O
,	O
collected	O
from	O
30	O
sites	O
in	O
southern	O
California	O
from	O
2009	O
-	O
2012	O
,	O
were	O
processed	O
for	O
vertebrate	O
host	O
identification	O
by	O
nucleotide	O
sequencing	O
following	O
polymerase	O
chain	O
reaction	O
to	O
amplify	O
portions	O
of	O
the	O
cytochrome	B-PRGE
oxidase	I-PRGE
I	I-PRGE
and	I-PRGE
cytochrome	I-PRGE
b	I-PRGE
genes	I-PRGE
of	O
vertebrate	O
animals	O
.	O

This	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
S	B-PRGE
gene	I-PRGE
mutation	O
analysis	O
can	O
reliably	O
diagnose	O
FIP	O
.	O

A	O
successful	O
viral	O
infection	O
requires	O
fusion	O
between	O
virus	O
and	O
host	O
cells	O
carried	O
out	O
by	O
the	O
surface	B-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
or	O
S	B-PRGE
protein	I-PRGE
of	O
CoV	O
.	O
Current	O
models	O
propose	O
that	O
the	O
S2	O
subunit	O
of	O
S	B-PRGE
protein	I-PRGE
assembled	O
into	O
a	O
hexameric	O
helical	O
bundle	O
exposing	O
hydrophobic	O
fusogenic	O
peptides	O
or	O
fusion	O
peptides	O
(	O
FPs	O
)	O
for	O
membrane	O
insertion	O
.	O

The	O
data	O
indicated	O
that	O
seventy	O
-	O
five	O
dromedary	O
camels	O
were	O
positive	O
for	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
;	O
the	O
virus	O
was	O
not	O
detected	O
in	O
sheep	O
,	O
goats	O
,	O
and	O
cattle	O
.	O

In	O
light	O
of	O
the	O
pathogenic	O
mechanism	O
of	O
feline	O
coronavirus	O
that	O
relies	O
on	O
endosomal	O
acidification	O
for	O
cytoplasmic	O
entry	O
,	O
a	O
novel	O
vacuolar	B-PRGE
ATPase	I-PRGE
blocker	O
,	O
diphyllin	O
,	O
and	O
its	O
nanoformulation	O
are	O
herein	O
investigated	O
for	O
their	O
antiviral	O
activity	O
against	O
the	O
type	O
II	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
).	O

TITLE	O
:	O
Pathogenic	O
CD8	B-PRGE
ABSTRACT	O
:	O
Malaria	O
is	O
a	O
severe	O
disease	O
and	O
kills	O
over	O
400	O
,	O
000	O
people	O
each	O
year	O
.	O

We	O
demonstrated	O
increased	O
pulmonary	O
VEGF	B-PRGE
-	I-PRGE
A	I-PRGE
and	O
PlGF	B-PRGE
levels	O
in	O
lungs	O
of	O
mice	O
with	O
experimental	O
MA	O
-	O
ARDS	O
.	O

These	O
post	O
-	O
translational	O
modifications	O
may	O
assist	O
in	O
protein	O
folding	O
and	O
play	O
important	O
roles	O
in	O
the	O
functionality	O
of	O
S	B-PRGE
protein	I-PRGE
.	O

Among	O
these	O
sites	O
,	O
8	O
sites	O
were	O
confirmed	O
in	O
the	O
S	B-PRGE
protein	I-PRGE
extracted	O
from	O
partially	O
purified	O
virus	O
particles	O
by	O
proteomics	O
approaches	O
.	O

DAD	B-PRGE
was	O
found	O
in	O
two	O
-	O
thirds	O
of	O
patients	O
with	O
a	O
ratio	O
of	O
partial	O
pressure	O
of	O
arterial	O
oxygen	O
to	O
fraction	O
of	O
inspired	O
oxygen	O
≤	O
100	O
mmHg	O
and	O
opacities	O
involving	O
the	O
four	O
quadrants	O
.	O

TITLE	O
:	O
CD59	B-PRGE
association	O
with	O
infectious	O
bronchitis	O
virus	O
particles	O
protects	O
against	O
antibody	B-PRGE
-	I-PRGE
dependent	I-PRGE
complement	I-PRGE
-	I-PRGE
mediated	O
lysis	O
.	O

To	O
date	O
,	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
CD59	B-PRGE
in	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
infection	O
.	O

Risk	O
stratification	O
was	O
by	O
cutoffs	O
for	O
SpO	B-PRGE
The	O
analysis	O
included	O
456	O
patients	O
.	O

In	O
the	O
combined	O
data	O
set	O
of	O
IBV	O
challenged	O
shell	O
gland	O
samples	O
,	O
the	O
comprehensive	O
ranking	O
showed	O
TATA	B-PRGE
-	I-PRGE
box	I-PRGE
binding	I-PRGE
protein	I-PRGE
(	O
TBP	B-PRGE
)	O
and	O
tyrosine	B-PRGE
3	I-PRGE
-	I-PRGE
monooxygenase	I-PRGE
/	O
tryptophan	B-PRGE
5	I-PRGE
-	I-PRGE
monooxygenase	I-PRGE
activation	I-PRGE
protein	I-PRGE
zeta	I-PRGE
(	O
YWHAZ	B-PRGE
)	O
as	O
the	O
two	O
most	O
stable	O
,	O
and	O
succinate	B-PRGE
dehydrogenase	I-PRGE
complex	I-PRGE
flavoprotein	I-PRGE
subunit	I-PRGE
A	I-PRGE
(	O
SDHA	B-PRGE
)	O
and	O
albumin	B-PRGE
(	O
ALB	B-PRGE
)	O
as	O
the	O
two	O
least	O
stable	O
reference	O
genes	O
.	O

We	O
report	O
here	O
the	O
3	O
.	O
5	O
-	O
Å	O
-	O
resolution	O
cryo	O
-	O
electron	O
microscopy	O
structure	O
of	O
the	O
S	B-PRGE
glycoprotein	I-PRGE
trimer	O
from	O
the	O
pathogenic	O
porcine	O
deltacoronavirus	O
(	O
PDCoV	O
),	O
which	O
belongs	O
to	O
the	O
recently	O
identified	O

Complete	O
genomic	O
sequencing	O
and	O
analyses	O
of	O
SeACoV	O
indicated	O
that	O
the	O
extreme	O
amino	O
-	O
terminal	O
domain	O
of	O
the	O
SeACoV	B-PRGE
spike	I-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
glycoprotein	I-PRGE
structurally	O
similar	O
to	O
the	O
domain	O
0	O
of	O
the	O
alphacoronavirus	O
NL63	O
,	O
whereas	O
the	O
rest	O
part	O
of	O
S	O
structurally	O
resembles	O
domains	O
B	O
to	O
D	O
of	O
the	O
betacoronavirus	O
.	O

The	O
SeACoV	B-PRGE
-	I-PRGE
S	I-PRGE
domain	I-PRGE
0	I-PRGE
associated	O
with	O
enteric	O
tropism	O
had	O
an	O
extremely	O
high	O
variability	O
,	O
harboring	O
75	O
-	O
amino	O
-	O
acid	O
(	O
aa	O
)	O
substitutions	O
and	O
a	O
2	O
-	O
aa	O
insertion	O
,	O
compared	O
to	O
that	O
of	O
HKU2	O
,	O
which	O
is	O
likely	O
responsible	O
for	O
the	O
extended	O
host	O
range	O
or	O
cross	O
-	O
species	O
transmission	O
.	O

Total	B-PRGE
acidic	I-PRGE
mucins	I-PRGE
,	I-PRGE
particularly	I-PRGE
sialomucin	I-PRGE
,	O
were	O
reduced	O
in	O
PEDV	O
pigs	O
at	O
dpi	O
2	O
and	O
then	O
increased	O
compared	O
with	O
controls	O
at	O
dpi	O
7	O
and	O
14	O
.	O

We	O
subsequently	O
identified	O
novel	O
amino	O
acid	O
changes	O
within	O
the	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
and	O
nsp14	O
of	O
MHV	O
-	O
ExoN	O
(-)	O
P250	O
that	O
partially	O
accounted	O
for	O
the	O
reduced	O
susceptibility	O
to	O
nucleoside	O
analogues	O
.	O

These	O
results	O
also	O
support	O
the	O
hypothesis	O
that	O
high	O
-	O
fidelity	O
replication	O
is	O
linked	O
to	O
CoV	O
fitness	O
and	O
indicate	O
that	O
multiple	O
replicase	B-PRGE
proteins	I-PRGE
could	O
compensate	O
for	O
ExoN	O
functions	O
during	O
replication	O
.	O

We	O
constructed	O
a	O
recombinant	O
adenovirus	O
that	O
simultaneously	O
expresses	O
the	O
S1	B-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
of	O
IBV	O
and	O
the	O
TM	B-PRGE
-	I-PRGE
1	I-PRGE
protein	I-PRGE
of	O
MG	O
(	O
pBH	B-PRGE
-	I-PRGE
S1	I-PRGE
-	I-PRGE
TM	I-PRGE
-	I-PRGE
1	I-PRGE
-	I-PRGE
EGFP	I-PRGE
).	O

Interestingly	O
,	O
by	O
days	O
7	O
and	O
14	O
after	O
the	O
booster	O
immunization	O
,	O
pBH	B-PRGE
-	I-PRGE
S1	I-PRGE
-	I-PRGE
TM	I-PRGE
-	I-PRGE
1	I-PRGE
-	O
EGFP	O
-	O
induced	O
antibody	O
titre	O
was	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
compared	O
to	O
attenuated	O
commercial	O
IBV	O
vaccine	O
;	O
however	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
pBH	B-PRGE
-	I-PRGE
S1	I-PRGE
-	I-PRGE
TM	I-PRGE
-	I-PRGE
1	I-PRGE
-	O
EGFP	O
and	O
attenuated	O
commercial	O
MG	O
vaccine	O
groups	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
Hepatitis	B-PRGE
B	I-PRGE
core	I-PRGE
antigen	I-PRGE
based	O
novel	O
vaccine	O
against	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

This	O
report	O
details	O
an	O
E	O
.	O
coli	O
based	O
expression	O
and	O
purification	O
process	O
of	O
multiple	O
vaccine	O
candidates	O
for	O
PEDV	O
using	O
Hepatitis	B-PRGE
B	I-PRGE
Core	I-PRGE
Antigen	I-PRGE
(	O
HBcAg	O
)	O
as	O
a	O
backbone	O
protein	O
.	O

Here	O
,	O
we	O
showed	O
that	O
chicken	O
cells	O
transfected	O
with	O
domestic	O
goose	O
RIG	B-PRGE
-	I-PRGE
I	I-PRGE
(	O
dgRIG	O
-	O
I	O
)	O
exhibited	O
increased	O
IFN	B-PRGE
-	I-PRGE
β	I-PRGE
activity	O
after	O
IBV	O
infection	O
.	O

The	O
relationship	O
between	O
this	O
decline	O
in	O
platelet	O
aggregation	O
and	O
ARDS	O
differed	O
by	O
cigarette	O
smoke	O
exposure	O
status	O
,	O
suggesting	O
that	O
impaired	O
platelet	O
activation	O
differentially	O
affects	O
the	O
risk	O
of	O
ARDS	O
in	O
those	O
with	O
cigarette	O
smoke	O
exposure	O
(	O
arachidonic	O
acid	O
,	O
p	O
for	O
interaction	O
:	O
0	O
.	O
005	O
,	O
collagen	B-PRGE
p	I-PRGE
for	O
interaction	O
:	O
0	O
.	O
02	O
,	O
adenosine	O
diphosphate	O
,	O
p	O
for	O
interaction	O
:	O
0	O
.	O
05	O
).	O

Comparison	O
of	O
the	O
genomic	O
sequences	O
showed	O
that	O
the	O
genome	O
of	O
isolate	O
I1101	O
/	O
16	O
was	O
similar	O
to	O
that	O
of	O
strain	O
ck	O
/	O
CH	O
/	O
LJL	O
/	O
140901	O
from	O
the	O
5	O
'	O
end	O
of	O
the	O
genome	O
to	O
the	O
5	O
'	O
end	O
of	O
the	O
S2	B-PRGE
gene	I-PRGE
and	O
from	O
the	O
5	O
'	O
end	O
of	O
the	O
3a	O
gene	O
to	O
the	O
end	O
of	O
the	O
genome	O
,	O
whereas	O
the	O
remaining	O
parts	O
of	O
the	O
genome	O
sequences	O
were	O
more	O
closely	O
related	O
to	O
those	O
of	O
strain	O
4	O
/	O
91	O
than	O
those	O
of	O
ck	O
/	O
CH	O
/	O
LJL	O
/	O
140901	O
,	O
thereby	O
suggesting	O
that	O
recombination	O
might	O
have	O
occurred	O
during	O
the	O
origin	O
of	O
the	O
virus	O
.	O

TITLE	O
:	O
Ly6G	O
+	O
neutrophil	O
-	O
derived	O
miR	O
-	O
223	O
inhibits	O
the	O
NLRP3	B-PRGE
inflammasome	I-PRGE
in	O
mitochondrial	O
DAMP	O
-	O
induced	O
acute	O
lung	O
injury	O
.	O

Antigen	B-PRGE
-	I-PRGE
specific	I-PRGE
mAbs	I-PRGE
have	O
been	O
isolated	O
using	O
several	O
different	O
approaches	O
,	O
including	O
hybridoma	O
,	O
transgenic	O
mice	O
,	O
phage	O
display	O
,	O
yeast	O
display	O
,	O
and	O
single	O
B	O
-	O
cell	O
isolation	O
.	O

The	O
three	O
-	O
day	O
programme	O
encompassed	O
presentations	O
on	O
some	O
of	O
the	O
clinical	O
features	O
,	O
management	O
,	O
immune	O
responses	O
and	O
virology	O
of	O
respiratory	O
infections	O
,	O
including	O
influenza	B-PRGE
A	I-PRGE
(	I-PRGE
H1N1	I-PRGE
)	I-PRGE
pdm09	I-PRGE
and	I-PRGE
A	I-PRGE
(	O
H7N9	O
)	O
viruses	O
,	O
MERS	O
-	O
CoV	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
adenovirus	O
Type	O
80	O
,	O
enterovirus	O
D68	O
,	O
metapneumovirus	O
and	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
).	O

The	O
interleukin	B-PRGE
(	O
IL	O
)-	O
36	O
cytokines	O
(	O
IL	O
-	O
36α	O
,	O
IL	O
-	O
36β	O
and	O
IL	O
-	O
36γ	O
)	O
are	O
newly	O
described	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
like	I-PRGE
family	I-PRGE
cytokines	I-PRGE
that	O
promote	O
inflammatory	O
response	O
via	O
binding	O
to	O
the	O
IL	B-PRGE
-	I-PRGE
36	I-PRGE
receptor	I-PRGE
(	O
IL	O
-	O
36R	O
).	O

We	O
therefore	O
evaluated	O
clinical	O
and	O
microbiological	O
factors	O
associated	O
with	O
the	O
presence	O
of	O
GI	O
symptoms	O
in	O
patients	O
consulting	O
a	O
general	O
practitioner	O
(	O
GP	O
)	O
for	O
ARI	B-PRGE
.	O

TITLE	O
:	O
Complete	O
Genome	O
Sequence	O
of	O
Human	B-PRGE
Coronavirus	I-PRGE
Strain	I-PRGE
229E	I-PRGE
Isolated	O
from	O
Plasma	O
Collected	O
from	O
a	O
Haitian	O
Child	O
in	O
2016	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
role	O
of	O
cytosolic	B-PRGE
phospholipase	I-PRGE
A	I-PRGE

In	O
conclusion	O
,	O
these	O
results	O
suggest	O
that	O
APS	B-PRGE
exhibit	O
antiviral	O
activities	O
against	O
IBV	O
and	O
it	O
may	O
represent	O
a	O
potential	O
therapeutic	O
agent	O
for	O
inhibiting	O
the	O
replication	O
of	O
IBV	O
.	O

CIRD	O
affected	O
66	O
%	O
(	O
381	O
/	O
572	O
)	O
of	O
the	O
dogs	O
studied	O
,	O
including	O
both	O
pet	B-PRGE
and	O
kennelled	O
dogs	O
.	O

The	O
clustering	O
of	O
gene	O
expression	O
profile	O
among	O
the	O
three	O
virus	O
inoculated	O
groups	O
indicated	O
that	O
the	O
majority	O
of	O
up	O
-	O
regulated	O
DE	O
genes	O
on	O
apoptosis	O
in	O
very	O
virulent	O
SCDY2	O
group	O
were	O
up	O
-	O
regulated	O
more	O
or	O
less	O
in	O
virulent	O
SCK2	B-PRGE
group	O
and	O
those	O
down	O
-	O
regulated	O
on	O
innate	O
immune	O
response	O
in	O
SCDY2	O
group	O
were	O
also	O
down	O
-	O
regulated	O
differently	O
in	O
SCK2	B-PRGE
group	O
.	O

We	O
suggest	O
to	O
consider	O
inflammation	O
in	O
ARDS	O
as	O
a	O
system	O
controlled	O
by	O
scale	O
-	O
free	O
networks	O
of	O
genome	O
-	O
wide	O
molecular	O
interaction	O
with	O
hubs	O
(	O
e	O
.	O
g	O
.	O
NFκB	O
,	O
C	O
/	O
EBPβ	O
,	O
ATF3	B-PRGE
),	O
exhibiting	O
nonlinear	O
emergence	O
and	O
the	O
ability	O
to	O
adapt	O
,	O
meaning	O
for	O
instance	O
that	O
mild	O
and	O
life	O
-	O
threatening	O
inflammation	O
in	O
ARDS	O
are	O
distinct	O
processes	O
.	O

In	O
addition	O
,	O
the	O
use	O
of	O
the	O
Co1	O
ligand	O
elicited	O
a	O
splenocyte	O
proliferative	O
response	O
more	O
effectively	O
in	O
comparison	O
with	O
the	O
COE	B-PRGE
antigen	I-PRGE
alone	O
and	O
supported	O
a	O
skewed	O
T	O
helper	O
2	O
type	O
of	O
immune	O
response	O
against	O
PEDV	O
.	O

pPG	B-PRGE
-	O
COE	O
-	O
Co1	B-PRGE
/	O
L393	O
can	O
effectively	O
induce	O
mucosal	O
,	O
humoural	O
and	O
Th2	O
-	O
type	O
cellular	O
immune	O
responses	O
against	O
PEDV	O
infection	O
via	O
oral	O
administration	O
.	O

Mice	O
(	O
C57BL	O
/	O
6	O
)	O
had	O
50	O
×	O
10	O
BAL	B-PRGE
IL	I-PRGE
-	I-PRGE
6	I-PRGE
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
as	O
well	O
as	O
plasma	B-PRGE
IL	I-PRGE
-	I-PRGE
6	I-PRGE
were	O
significantly	O
lower	O
in	O
the	O
animals	O
administered	O
VPA	O
within	O
3	O
h	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
but	O
not	O
when	O
administered	O
later	O
(	O
4	O
,	O
6	O
,	O
9	O
h	O
).	O

ABSTRACT	O
:	O
The	O
Livestock	B-PRGE
Emergency	I-PRGE
Response	I-PRGE
Plan	I-PRGE
(	O
LERP	O
)	O
was	O
published	O
in	O
2014	O
as	O
a	O
toolkit	O
to	O
assist	O
state	O
agricultural	O
emergency	O
planners	O
in	O
writing	O
or	O
modifying	O
state	O
foreign	O
animal	O
disease	O
/	O
high	O
-	O
consequence	O
disease	O
(	O
FAD	O
/	O
HCD	O
)	O
plans	O
.	O

Results	O
showed	O
that	O
transaminase	O
levels	O
markedly	O
decreased	O
in	O
MHV	O
-	O
A59	O
-	O
infected	O
mice	O
treated	O
with	O
MAb	B-PRGE
anti	I-PRGE
-	I-PRGE
IL	I-PRGE
-	I-PRGE
17A	I-PRGE
whereas	O
plasmatic	O
Ig	O
concentration	O
sharply	O
increased	O
.	O

IL	B-PRGE
-	I-PRGE
17A	I-PRGE
neutralization	O
did	O
not	O
affect	O
MHV	O
-	O
A59	O
-	O
induction	O
of	O
HMGB1	B-PRGE
liberation	O
and	O
slightly	O
augmented	O
plasmatic	O
uric	O
acid	O
concentration	O
.	O

PEDV	O
nsp1	B-PRGE
blocked	O
the	O
nuclear	O
translocation	O
of	O
IRF1	B-PRGE
and	O
reduced	O
the	O
number	O
of	O
peroxisomes	O
to	O
suppress	O
IRF1	B-PRGE
-	O
mediated	O
type	B-PRGE
III	I-PRGE
IFNs	I-PRGE
.	O

The	O
full	O
-	O
length	O
genomes	O
of	O
11	O
newly	O
discovered	O
SARSr	O
-	O
CoV	O
strains	O
,	O
together	O
with	O
our	O
previous	O
findings	O
,	O
reveals	O
that	O
the	O
SARSr	O
-	O
CoVs	O
circulating	O
in	O
this	O
single	O
location	O
are	O
highly	O
diverse	O
in	O
the	O
S	B-PRGE
gene	I-PRGE
,	O
ORF3	O
and	O
ORF8	O
.	O

Importantly	O
,	O
strains	O
with	O
high	O
genetic	O
similarity	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
in	O
the	O
hypervariable	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
)	O
and	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
S1	B-PRGE
gene	I-PRGE
,	O
the	O
ORF3	O
and	O
ORF8	O
region	O
,	O
respectively	O
,	O
were	O
all	O
discovered	O
in	O
this	O
cave	O
.	O

We	O
hypothesize	O
that	O
the	O
direct	O
progenitor	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
may	O
have	O
originated	O
after	O
sequential	O
recombination	O
events	O
between	O
the	O
precursors	O
of	O
these	O
SARSr	O
-	O
CoVs	O
.	O

In	O
multivariable	O
models	O
,	O
a	O
combination	O
of	O
Stimulation	O
-	O
2	O
(	O
ST2	O
;	O
odds	O
ratio	O
[	O
OR	O
],	O
2	O
.	O
8	O
;	O
P	O
<	O
.	O
001	O
)	O
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
(	O
OR	O
,	O
1	O
.	O
4	O
;	O
P	O
=	O
.	O
025	O
)	O
was	O
the	O
best	O
panel	O
for	O
distinguishing	O
IPS	O
at	O
diagnosis	O
from	O
unaffected	O
controls	O
,	O
whereas	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
receptor	I-PRGE
1	I-PRGE
(	O
TNFR1	B-PRGE
;	O
OR	O
,	O
2	O
.	O
9	O
;	O
P	O
=	O
.	O
002	O
)	O
was	O
the	O
best	O
marker	O
when	O
comparing	O
patients	O
with	O
IPS	O
and	O
viral	O
pneumonia	O
.	O

The	O
areas	O
under	O
the	O
curve	O
of	O
the	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curves	O
for	O
discriminating	O
between	O
IPS	O
and	O
unaffected	O
controls	O
at	O
day	O
7	O
post	O
-	O
HCT	O
were	O
.	O
8	O
for	O
ST2	O
,	O
.	O
75	O
for	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
and	O
.	O
68	O
for	O
TNFR1	B-PRGE
.	O

ABSTRACT	O
:	O
We	O
utilized	O
one	O
-	O
step	O
multiplex	O
reverse	O
transcription	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
Luminex	O
xMAP	O
technology	O
to	O
develop	O
a	O
respiratory	O
multiplex	O
liquid	O
-	O
chip	O
assay	O
(	O
rMLA	O
)	O
for	O
simultaneous	O
detection	O
of	O
6	O
common	O
respiratory	O
viruses	O
,	O
including	O
influenza	B-PRGE
virus	I-PRGE
type	I-PRGE
A	I-PRGE
(	O
FluA	O
)	O
and	O
type	B-PRGE
B	I-PRGE
(	O
FluB	O
),	O
para	O
-	O
influenza	O
virus	O
type	O
3	O
(	O
PIV	O
-	O
3	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
human	O
metapneumovirus	O
(	O
MPV	O
)	O
and	O
a	O
threatening	O
virus	O
to	O
China	O
,	O
Middle	O
East	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
).	O

We	O
observed	O
a	O
significant	O
increase	O
in	O
serum	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
CINC	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
uric	O
acid	O
and	O
circulating	O
,	O
but	O
not	O
bone	O
marrow	O
,	O
leukocyte	O
numbers	O
.	O

Treatment	O
with	O
17β	O
-	O
estradiol	O
before	O
the	O
induction	O
of	O
intestinal	O
IR	O
prevented	O
the	O
systemic	O
release	O
of	O
IL	B-PRGE
-	I-PRGE
10	I-PRGE
,	O
CINC	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
and	O
uric	O
acid	O
,	O
but	O
it	O
did	O
not	O
affect	O
the	O
leukocytosis	O
.	O

Previously	O
,	O
activation	O
of	O
the	O
JNK	B-PRGE
pathway	O
has	O
been	O
detected	O
in	O
cells	O
infected	O
with	O
several	O
coronaviruses	O
.	O

The	O
S	B-PRGE
protein	I-PRGE
efficiently	O
incorporated	O
into	O
the	O
viral	O
envelope	O
and	O
mediated	O
cell	O
entry	O
through	O
binding	O
its	O
receptor	O
,	O
human	B-PRGE
DPP4	I-PRGE
.	O

CypA	B-PRGE
depletion	O
reduced	O
EAV	O
yields	O
by	O
~	O
3	O
-	O
log	O
,	O
whereas	O
MERS	O
-	O
CoV	O
progeny	O
titers	O
were	O
modestly	O
reduced	O
(	O
3	O
-	O
fold	O
)	O
and	O
HCoV	O
-	O
229E	O
replication	O
was	O
unchanged	O
.	O

Similarity	O
plots	O
of	O
CoV	O
clade	O
c	O
genomes	O
were	O
generated	O
by	O
using	O
SSE	B-PRGE
v1	I-PRGE
.	O
2	O
.	O

In	O
a	O
continuing	O
effort	O
to	O
decipher	O
the	O
molecular	O
mechanism	O
underlying	O
IFITM	O
differential	O
modulation	O
of	O
HCoV	O
entry	O
,	O
we	O
investigated	O
the	O
roles	O
of	O
structural	O
motifs	O
important	O
for	O
IFITM	B-PRGE
protein	I-PRGE
posttranslational	O
modifications	O
,	O
intracellular	O
trafficking	O
,	O
and	O
oligomerization	O
in	O
modulating	O
the	O
entry	O
of	O
five	O
HCoVs	O
.	O

TITLE	O
:	O
Alveolar	O
injury	O
and	O
regeneration	O
following	O
deletion	O
of	O
ABCA3	B-PRGE
.	O

ABCA3	B-PRGE
-	O
related	O
lung	O
dysfunction	O
was	O
associated	O
with	O
surfactant	O
deficiency	O
,	O
inflammation	O
,	O
and	O
alveolar	O
-	O
capillary	O
leak	O
.	O

Extensive	O
but	O
incomplete	O
deletion	O
of	O
ABCA3	B-PRGE
caused	O
alveolar	O
injury	O
and	O
inflammation	O
,	O
and	O
it	O
initiated	O
proliferation	O
of	O
progenitor	O
cells	O
,	O
restoring	O
ABCA3	B-PRGE
expression	O
,	O
lung	O
structure	O
,	O
and	O
function	O
.	O

A	O
divergent	O
alpha	O
-	O
CoV	O
clade	O
from	O
Myotis	B-PRGE
nattereri	I-PRGE
SpA	I-PRGE
is	O
also	O
described	O
.	O

The	O
crystal	O
structure	O
at	O
3	O
.	O
38	O
Å	O
resolution	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
nsp14	I-PRGE
in	O
complex	O
with	O
its	O
cofactor	O
nsp10	O
adds	O
to	O
the	O
uniqueness	O
of	O
CoVs	O
among	O
RNA	O
viruses	O
:	O

A	O
translational	O
success	O
story	O
about	O
the	O
escalation	O
of	O
zirconium	O
-	O
89	O
radiolabeled	O
HDL	B-PRGE
(	O

To	O
address	O
this	O
knowledge	O
gap	O
,	O
we	O
utilized	O
a	O
prime	O
-	O
boost	O
immunization	O
approach	O
to	O
induce	O
robust	O
memory	O
CD8	B-PRGE
T	I-PRGE
cell	O
responses	O
in	O
the	O
absence	O
of	O
RSV	B-PRGE
-	I-PRGE
specific	I-PRGE
CD4	I-PRGE
T	I-PRGE
cells	O
and	O
antibodies	O
.	O

Unexpectedly	O
,	O
RSV	O
infection	O
of	O
mice	O
with	O
pre	O
-	O
existing	O
CD8	B-PRGE
T	I-PRGE
cell	O
memory	O
led	O
to	O
exacerbated	O
weight	O
loss	O
,	O
pulmonary	O
disease	O
,	O
and	O
lethal	O
immunopathology	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
an	O
inefficient	O
inducer	O
of	O
interferon	B-PRGE
(	O
IFN	B-PRGE
)	O
response	O
.	O

This	O
counteracting	O
effect	O
was	O
partially	O
mediated	O
by	O
protein	O
8b	O
/	O
8ab	O
-	O
induced	O
degradation	O
of	O
IRF3	B-PRGE
in	O
a	O
ubiquitin	B-PRGE
-	O
proteasome	O
-	O
dependent	O
manner	O
.	O

We	O
previously	O
determined	O
the	O
immunogenicity	O
of	O
a	O
novel	O
dendritic	O
cell	O
(	O
DC	O
)-	O
targeted	O
PEDV	B-PRGE
S1	I-PRGE
protein	I-PRGE
-	O
based	O
subunit	O
vaccine	O
in	O
weaned	O
piglets	O
in	O
which	O
the	O
PEDV	B-PRGE
antigen	I-PRGE
was	O
targeted	O
to	O
DCs	O
through	O
a	O
porcine	B-PRGE
Langerin	I-PRGE
-	I-PRGE
specific	I-PRGE
antibody	I-PRGE
.	O

A	O
breakthrough	O
in	O
our	O
understanding	O
of	O
the	O
role	O
of	O
EndoU	B-PRGE
was	O
revealed	O
in	O
recent	O
studies	O
,	O
which	O
showed	O
that	O
EndoU	B-PRGE
mediates	O
the	O
evasion	O
of	O
viral	O
double	O
-	O
stranded	O
RNA	O
recognition	O
by	O
host	O
sensors	O
in	O
macrophages	O
.	O

This	O
new	O
discovery	O
of	O
nsp15	O
/	O
EndoU	B-PRGE
function	O
leads	O
to	O
new	O
opportunities	O
for	O
investigating	O
how	O
a	O
viral	O
EndoU	O
contributes	O
to	O
pathogenesis	O
and	O
exploiting	O
this	O
enzyme	O
for	O
therapeutics	O
and	O
vaccine	O
design	O
against	O
pathogenic	O
coronaviruses	O
.	O

We	O
retrospectively	O
analyzed	O
the	O
clinico	O
pathological	O
presentation	O
of	O
20	O
cases	O
of	O
tenofovir	O
-	O
induced	O
tubulopathy	O
,	O
and	O
investigated	O
the	O
renal	O
expression	O
of	O
the	O
megalin	B-PRGE
and	O
cubilin	B-PRGE
proteins	I-PRGE
,	O
as	O
well	O
as	O
the	O
mitochondrial	O
respiratory	O
chain	O
activity	O
.	O

Western	O
blot	O
was	O
used	O
to	O
detect	O
the	O
protein	O
expression	O
of	O
collagen	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

RESULTS	O
:	O
In	O
both	O
PCV	O
and	O
PSV	O
,	O
peak	O
transpulmonary	O
pressure	O
was	O
lower	O
,	O
whereas	O
E	B-PRGE
-	I-PRGE
cadherin	I-PRGE
tissue	O
expression	O
,	O
which	O
is	O
related	O
to	O
epithelial	O
integrity	O
,	O
was	O
higher	O
at	O
PEEP	O
=	O
5	O
cmH2O	O
than	O
at	O
PEEP	O
=	O
2	O
cmH2O	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
UTI	O
alleviates	O
ALI	O
by	O
attenuating	O
TLR4	B-PRGE
expression	O
and	O
to	O
explore	O
the	O
underlying	O
molecular	O
mechanisms	O
involved	O
.	O

We	O
found	O
that	O
patients	O
with	O
severe	O
influenza	O
showed	O
elevated	O
plasma	O
NET	B-PRGE
level	O
on	O
the	O
day	O
of	O
admission	O
.	O

The	O
FCoV	B-PRGE
spike	I-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
protein	I-PRGE
is	O
considered	O
the	O
viral	O
regulator	O
for	O
binding	O
and	O
entry	O
to	O
the	O
cell	O
.	O

Specificity	O
of	O
the	O
Cepheid	B-PRGE
®	I-PRGE
Xpert	I-PRGE
Flu	I-PRGE
was	O
95	O
.	O
8	O
%	O
for	O
H1N1	O
and	O
94	O
.	O
4	O
%	O
for	O
total	O
influenza	O
A	O
.	O
Cepheid	O
®	O
Xpert	O
Flu	O
sensitivity	O
for	O
influenza	O
A	O
was	O
100	O
%	O
for	O
younger	O
patients	O
(	O
0	O
-	O
19	O
-	O
year	O
age	O
group	O
)	O
but	O
significantly	O
lower	O
both	O
for	O
older	O
patients	O
(	O
68	O
.	O
2	O
%	O
for	O
60	O
-	O
79	O
-	O
year	O
and	O
50	O
%	O
for	O
≥	O
80	O
-	O
year	O
age	O
groups	O
)	O
and	O
overall	O
for	O
males	O
compared	O
to	O
females	O
(	O
72	O
.	O
6	O
%	O
and	O
94	O
.	O
0	O
%,	O
respectively	O
).	O

We	O
recruited	O
healthy	O
participants	O
aged	O
18	O
-	O
60	O
years	O
who	O
had	O
normal	O
laboratory	O
parameters	O
at	O
enrolment	O
,	O
a	O
body	O
-	O
mass	O
index	O
of	O
19	O
-	O
32	O
kg	O
/	O
m	O
Between	O
June	O
2	O
,	O
2016	O
,	O
and	O
Jan	B-PRGE
4	I-PRGE
,	O
2017	O
,	O
we	O
screened	O
43	O
participants	O
,	O
of	O
whom	O
38	O
were	O
eligible	O
and	O
randomly	O
assigned	O
to	O
receive	O
SAB	O
-	O
301	O
(	O
n	O
=	O
28	O
)	O
or	O
placebo	O
(	O
n	O
=	O
10	O
).	O

Human	B-PRGE
immunoglobulin	I-PRGE
derived	O
from	O
transchromosomic	O
cattle	O
could	O
offer	O
a	O
new	O
platform	O
technology	O
to	O
produce	O
fully	B-PRGE
human	I-PRGE
polyclonal	I-PRGE
IgG	I-PRGE
antibodies	I-PRGE
for	O
other	O
medical	O
conditions	O
.	O

PEDV	O
RNA	O
positive	O
rate	O
was	O
55	O
.	O
3	O
%	O
(	O
42	O
/	O
76	O
)	O
by	O
RT	B-PRGE
-	I-PRGE
RPA	I-PRGE
and	O
59	O
.	O
2	O
%	O
(	O
45	O
/	O
76	O
)	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

A	O
significant	O
RP	O
×	O
VE	O
interaction	O
effect	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
on	O
plasma	B-PRGE
globulin	I-PRGE
level	O
was	O
observed	O
.	O

Viruses	O
in	O
Group	O
1	O
have	O
the	O
insertion	O
of	O
three	O
amino	O
acids	O
at	O
positions	O
23	O
,	O
121	O
,	O
and	O
122	O
of	O
the	O
S1	B-PRGE
protein	I-PRGE
and	O
recombinant	O
events	O
detected	O
at	O
nucleotide	O
position	O
4354	O
-	O
5864	O
,	O
with	O
major	O
parental	O
sequence	O
derived	O
from	O
QX	O
-	O
like	O
(	O
CK	O
-	O
CH	O
-	O
IBYZ	O
-	O
2011	O
)	O
and	O
a	O
minor	O
parental	O
sequence	O
derived	O
from	O
Massachusetts	O
vaccine	O
strain	O
(	O
H120	O
).	O

This	O
study	O
focuses	O
on	O
a	O
new	O
mechanism	O
of	O
SPC	O
as	O
an	O
anti	O
-	O
inflammatory	O
molecule	O
using	O
SPC	B-PRGE
-	I-PRGE
TK	I-PRGE
/	O
SPC	B-PRGE
-	O
KO	O
(	O
surfactant	B-PRGE
protein	I-PRGE
C	I-PRGE
-	I-PRGE
thymidine	I-PRGE
kinase	I-PRGE
/	O
surfactant	B-PRGE
protein	I-PRGE
C	I-PRGE
knockout	O
)	O
mice	O
,	O
which	O
represent	O
a	O
novel	O
sterile	O
injury	O
model	O
that	O
mimics	O
clinical	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Hyperactivation	O
of	O
pSTAT3	O
and	O
inflammation	O
were	O
rescued	O
by	O
AZD1480	O
,	O
a	O
JAK1	B-PRGE
/	I-PRGE
2	I-PRGE
inhibitor	O
.	O

Galectin	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
a	O
β	B-PRGE
-	I-PRGE
galactoside	I-PRGE
-	I-PRGE
binding	I-PRGE
protein	I-PRGE
widely	O
distributed	O
in	O
immune	O
and	O
epithelial	O
cells	O
,	O
regulates	O
various	O
immune	O
functions	O
and	O
modulates	O
microbial	O
infections	O
.	O

Interestingly	O
,	O
we	O
also	O
found	O
that	O
both	O
in	O
isolation	O
and	O
during	O
infection	O
,	O
4b	O
interacted	O
with	O
α	B-PRGE
-	I-PRGE
karyopherin	I-PRGE
proteins	I-PRGE
in	O
an	O
NLS	O
-	O
dependent	O
manner	O
.	O

Superinfection	O
with	O
influenza	O
virus	O
and	O
GAS	B-PRGE
induced	O
invasive	O
GAS	O
infections	O
was	O
demonstrated	O
by	O
our	O
team	O
in	O
a	O
mouse	O
model	O
,	O
after	O
which	O
clinical	O
cases	O
of	O
invasive	O
GAS	O
infections	O
secondary	O
to	O
influenza	O
virus	O
infection	O
were	O
reported	O
by	O
other	O
investigators	O
in	O
Japan	O
,	O
USA	O
,	O
Canada	O
,	O
UK	O
China	O
,	O
and	O
other	O
countries	O
.	O

At	O
dpi	B-PRGE
5	I-PRGE
,	O
all	O
PEDV	O
pigs	O
were	O
PCR	O
positive	O
for	O
PEDV	O
in	O
feces	O
.	O

RESULTS	O
:	O
Although	O
all	O
nasopharyngeal	O
samples	O
were	O
negative	O
,	O
MERS	O
CoV	O
infection	O
was	O
confirmed	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
of	O
the	O
E	B-PRGE
gene	I-PRGE
(	O
UpE	O
)	O
and	O
open	O
reading	O
frame	O
(	O
ORF1b	O
)	O
on	O
sputum	O
samples	O
.	O

We	O
next	O
observed	O
that	O
the	O
EGFR	B-PRGE
downstream	O
cascade	O
STAT3	B-PRGE
was	O
also	O
activated	O
upon	O
PEDV	O
infection	O
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
that	O
PEDV	O
-	O
induced	O
EGFR	B-PRGE
activation	O
serves	O
as	O
a	O
negative	O
regulator	O
of	O
the	O
type	B-PRGE
I	I-PRGE
interferon	I-PRGE
response	O
and	O
provides	O
a	O
novel	O
therapeutic	O
target	O
for	O
virus	O
infection	O
.	O

Furthermore	O
,	O
we	O
made	O
a	O
more	O
detailed	O
classification	O
for	O
G2	O
group	O
based	O
on	O
phylogenetic	O
tree	O
,	O
in	O
which	O
G2a	B-PRGE
was	O
divided	O
into	O
two	O
subgroups	O
,	O
and	O
G2b	O
was	O
separated	O
into	O
four	O
subgroups	O
.	O

ABSTRACT	O
:	O
Human	B-PRGE
embryo	I-PRGE
lung	I-PRGE
cellular	I-PRGE
protein	I-PRGE
interacting	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
nonstructural	O
protein	O
-	O
10	O
(	O
HEPIS	O
)	O
is	O
a	O
novel	O
transcriptional	O
repressor	O
,	O
the	O
expression	O
profile	O
and	O
promoter	O
activity	O
of	O
which	O
have	O
not	O
been	O
well	O
studied	O
.	O

PCR	O
to	O
detect	O
PEDV	B-PRGE
RNA	I-PRGE
in	O
fecal	O
samples	O
seems	O
to	O
be	O
a	O
reliable	O
diagnostic	O
tool	O
during	O
and	O
after	O
the	O
acute	O
outbreak	O
.	O

The	O
effects	O
of	O
intra	O
-	O
oviductal	O
inoculation	O
with	O
attenuated	O
IBV	O
(	O
aIBV	O
)	O
on	O
the	O
expression	O
of	O
viral	B-PRGE
RNA	I-PRGE
recognition	I-PRGE
receptors	I-PRGE
and	O
innate	O
antiviral	O
factors	O
were	O
examined	O
by	O
real	O
-	O
time	O
PCR	O
and	O
immunohistochemistry	O
,	O
and	O
on	O
PGE2	O
levels	O
by	O
ELISA	O
.	O

mTOR	B-PRGE
signaling	O
pathway	O
activator	O
-	O
MHY1485	O
,	O
and	O
inhibitor	O
-	O
PP242	O
were	O
used	O
to	O
study	O
the	O
antiviral	O
function	O
.	O

Results	O
revealed	O
that	O
the	O
IRF3	B-PRGE
was	O
significantly	O
up	O
-	O
regulated	O
post	O
-	O
PEDV	O
infection	O
.	O

Although	O
most	O
of	O
the	O
IFN	B-PRGE
-	O
regulatory	O
and	O
-	O
related	O
genes	O
evaluated	O
in	O
this	O
study	O
were	O
either	O
down	O
-	O
regulated	O
or	O
remained	O
unchanged	O
,	O
IL11	B-PRGE
behaved	O
significantly	O
up	O
-	O
regulated	O
,	O
with	O
the	O
peak	O
at	O
16	O
hpi	O
.	O

IHC	O
appears	O
to	O
be	O
a	O
more	O
sensitive	O
and	O
reliable	O
test	O
for	O
confirmation	O
of	O
FIP	B-PRGE
than	O
is	O
FAT	B-PRGE
.	O

IL	O
-	O
12	O
expression	O
levels	O
showed	O
no	O
difference	O
between	O
patients	O
with	O
MERS	O
-	O
CoV	O
infection	O
and	O
the	O
healthy	O
controls	O
despite	O
the	O
significantly	O
increased	O
levels	O
of	O
IFN	B-PRGE
-	I-PRGE
α2	I-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
γ	I-PRGE
(	O
P	O
<	O
.	O
01	O
).	O

No	O
changes	O
were	O
observed	O
in	O
the	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
5	I-PRGE
,	O
IL	B-PRGE
-	I-PRGE
13	I-PRGE
,	O
and	O
TGF	O
-	O
α	O
(	O
P	O
>	O
.	O
05	O
).	O

The	O
intestinal	O
M	O
cells	O
-	O
and	O
DCs	O
-	O
targeting	O
oral	O
delivery	O
of	O
genetically	O
engineered	O
Lactobacillus	O
expressing	O
the	O
COE	B-PRGE
antigen	I-PRGE
of	O
PEDV	O
can	O
efficiently	O
induce	O
anti	O
-	O
PEDV	O
mucosal	O
,	O
humoral	O
,	O
and	O
cellular	O
immune	O
responses	O
via	O
oral	O
administration	O
,	O
suggesting	O
a	O
promising	O
vaccine	O
strategy	O
against	O
PEDV	O
infection	O
.	O

These	O
data	O
suggest	O
a	O
central	O
role	O
of	O
angiopoietin	B-PRGE
-	I-PRGE
1	I-PRGE
/-	I-PRGE
2	I-PRGE
in	O
pneumonia	O
-	O
evoked	O
inflammation	O
and	O
permeability	O
.	O

Increased	O
angiopoietin	B-PRGE
-	I-PRGE
2	I-PRGE
serum	O
levels	O
predicted	O
mortality	O
and	O
length	O
of	O
hospital	O
stay	O
,	O
and	O
angiopoietin	B-PRGE
-	I-PRGE
1	I-PRGE
may	O
provide	O
a	O
therapeutic	O
target	O
for	O
severe	O
pneumonia	O
.	O

Penicillin	O
-	O
resistant	O
pneumococci	O
and	O
β	B-PRGE
-	I-PRGE
lactamase	I-PRGE
-	O
producing	O
H	O
.	O
influenzae	O
are	O
uncommon	O
.	O

Nested	O
RT	B-PRGE
-	I-PRGE
PCR	I-PRGE
of	I-PRGE
RNA	I-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
(	O
RdRp	O
)	O
gene	O
from	O
rectal	O
swabs	O
was	O
used	O
for	O
CoV	O
detection	O
.	O

The	O
Berlin	O
definition	O
proposed	O
3	O
categories	O
of	O
ARDS	O
based	O
on	O
the	O
severity	O
of	O
hypoxemia	O
:	O
mild	O
(	O
200	O
mm	O
Hg	O
<	O
Pao2	O
/	O
Fio2	O
≤	O
300	O
mm	O
Hg	O
),	O
moderate	O
(	O
100	O
mm	O
Hg	O
<	O
Pao2	O
/	O
Fio2	O
≤	O
200	O
mm	O
Hg	O
),	O
and	O
severe	O
(	O
Pao2	B-PRGE
/	O
Fio2	O
≤	O
100	O
mm	O
Hg	O
),	O
along	O
with	O
explicit	O
criteria	O
related	O
to	O
timing	O
of	O
the	O
syndrome	O
'	O
s	O
onset	O
,	O
origin	O
of	O
edema	O
,	O
and	O
the	O
chest	O
radiograph	O
findings	O
.	O

Pharmacologic	O
therapies	O
such	O
as	O
β2	O
agonists	O
,	O
statins	O
,	O
and	O
keratinocyte	B-PRGE
growth	I-PRGE
factor	I-PRGE
,	O
which	O
targeted	O
pathophysiologic	O
alterations	O
in	O
ARDS	O
,	O
were	O
not	O
beneficial	O
and	O
demonstrated	O
possible	O
harm	O
.	O

We	O
observe	O
a	O
significant	O
up	O
-	O
regulation	O
of	O
genes	O
in	O
the	O
RIG	B-PRGE
-	I-PRGE
I	I-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
signaling	O
pathway	O
.	O

The	O
negative	O
regulators	O
of	O
interferon	B-PRGE
signaling	O
,	O
the	O
suppressors	O
of	O
cytokine	O
signaling	O
,	O
SOCS	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
SOCS	B-PRGE
-	I-PRGE
3	I-PRGE
,	O
were	O
found	O
to	O
be	O
markedly	O
up	O
-	O
regulated	O
in	O
the	O
initial	O
round	O
of	O
H5N1	O
virus	O
replication	O
.	O

ABSTRACT	O
:	O
The	O
emergence	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
MERS	O
-	O
CoV	O
,	O
triggered	O
the	O
discovery	O
of	O
a	O
high	O
diversity	O
of	O
coronaviruses	O
in	O
bats	O
.	O

To	O
prepare	O
for	O
large	O
scale	O
-	O
manufacture	O
of	O
the	O
vaccine	B-PRGE
antigen	I-PRGE
,	O
we	O
have	O
further	O
developed	O
a	O
high	O
-	O
yield	O
monoclonal	O
suspension	O
CHO	O
cell	O
line	O
.	O

There	O
was	O
significantly	O
more	O
Ty	O
-	O
BatCoV	O
-	O
HKU4	O
RNA	O
-	O
positive	O
alimentary	O
samples	O
than	O
Pi	O
-	O
BatCoV	O
-	O
HKU5	O
RNA	O
-	O
positive	O
alimentary	O
samples	O
that	O
were	O
tested	O
positive	O
by	O
the	O
rapid	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
nucleocapsid	I-PRGE
protein	I-PRGE
detection	O
assay	O
(	O
P	O
<	O
0	O
.	O
001	O
by	O
Chi	O
-	O
square	O
test	O
).	O

The	O
mechanism	O
by	O
which	O
conformational	O
changes	O
of	O
this	O
S	B-PRGE
glycoprotein	I-PRGE
can	O
be	O
triggered	O
by	O
pH	O
8	O
.	O
0	O
has	O
not	O
yet	O
been	O
determined	O
.	O

Here	O
,	O
we	O
show	O
that	O
MHV	B-PRGE
-	I-PRGE
A59	I-PRGE
S	I-PRGE
protein	I-PRGE
is	O
triggered	O
by	O
pH	O
8	O
.	O
0	O
at	O
37	O
°	O
C	O
to	O
induce	O
receptor	O
-	O
independent	O
syncytium	O
(	O
RIS	O
)	O
formation	O
on	O
293T	O
cells	O
,	O
and	O
that	O
the	O
conformational	O
changes	O
in	O
S	O
proteins	O
triggered	O
by	O
pH	O
8	O
.	O
0	O
are	O
very	O
similar	O
to	O
those	O
triggered	O
by	O
receptor	O
binding	O
.	O

Cells	O
stained	O
positive	O
for	O
IL	B-PRGE
-	I-PRGE
17A	I-PRGE
in	O
idiopathic	O
uveitis	O
but	O
not	O
in	O
FIP	O
samples	O
.	O

Compared	O
with	O
the	O
simple	O
ventilation	O
group	O
,	O
white	O
blood	O
cell	O
count	O
(	O
WBC	O
),	O
procalcitonin	O
(	O
PCT	B-PRGE
),	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
(	O
CRP	B-PRGE
)	O
at	O
24	O
hours	O
of	O
treatment	O
in	O
the	O
combined	O
treatment	O
group	O
were	O
significantly	O
decreased	O
[	O
WBC	O
(×	O
10	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
serum	O
PCT	B-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
TNF	B-PRGE
-	I-PRGE
α	I-PRGE
or	O
CD4	B-PRGE
CRRT	O
in	O
the	O
early	O
stage	O
of	O
bundle	O
therapy	O
for	O
severe	O
pneumonia	O
is	O
not	O
only	O
suggested	O
to	O
remove	O
inflammatory	O
mediators	O
and	O
improve	O
immune	O
function	O
,	O
but	O
an	O
opportunity	O
and	O
effective	O
way	O
to	O
reduce	O
complications	O
and	O
delay	O
rapid	O
progression	O
of	O
severe	O
pneumonia	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
serum	O
PCT	B-PRGE
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
TNF	B-PRGE
-	I-PRGE
α	I-PRGE
or	O
CD4	B-PRGE

TITLE	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
nsp7	B-PRGE
protein	I-PRGE
localized	O
in	O
the	O
cytoplasm	O
down	O
-	O
regulates	O
interleukin	B-PRGE
8	I-PRGE
expression	O
in	O
porcine	O
intestinal	O
epithelial	O
cell	O
.	O

However	O
,	O
the	O
subcellular	O
localization	O
and	O
other	O
functions	O
of	O
the	O
TGEV	B-PRGE
nsp7	I-PRGE
protein	I-PRGE
are	O
still	O
unclear	O
.	O

Our	O
results	O
showed	O
that	O
the	O
nsp7	B-PRGE
protein	I-PRGE
is	O
localized	O
in	O
the	O
cytoplasm	O
and	O
has	O
no	O
effect	O
on	O
intestinal	O
epithelial	O
cells	O
(	O
IECs	O
)	O
growth	O
,	O
cell	O
cycle	O
,	O
and	O
cyclin	B-PRGE
A	I-PRGE
expression	O
.	O

Our	O
primary	O
outcome	O
variables	O
were	O
the	O
change	O
in	O
concentration	O
of	O
biomarkers	O
of	O
epithelial	O
injury	O
(	O
serum	O
surfactant	B-PRGE
protein	I-PRGE
-	I-PRGE
D	I-PRGE
(	O
SP	B-PRGE
-	I-PRGE
D	I-PRGE
)),	O
endothelial	O
injury	O
(	O
von	B-PRGE
Willebrand	I-PRGE
factor	I-PRGE
(	O
VWF	B-PRGE
)),	O
and	O
systemic	O
inflammation	O
(	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)-	I-PRGE
8	I-PRGE
).	O

RESULTS	O
:	O
A	O
total	O
of	O
446	O
(	O
49	O
%)	O
patients	O
had	O
complete	O
SP	B-PRGE
-	I-PRGE
D	I-PRGE
,	O
VWF	B-PRGE
,	O
and	O
IL	O
-	O
8	O
measurements	O
on	O
study	O
enrollment	O
and	O
day	O
3	O
.	O

TITLE	O
:	O
Cellular	B-PRGE
hnRNP	I-PRGE
A1	I-PRGE
Interacts	O
with	O
Nucleocapsid	B-PRGE
Protein	I-PRGE
of	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
and	O
Impairs	O
Viral	O
Replication	O
.	O

In	O
this	O
report	O
,	O
PEDV	B-PRGE
N	I-PRGE
protein	I-PRGE
was	O
discovered	O
to	O
colocalize	O
with	O
cellular	O
hnRNP	O
A1	O
in	O
perinuclear	O
region	O
of	O
PEDV	O
infected	O
cells	O
.	O

Two	O
reaction	O
mixtures	O
(	O
Isothermal	O
Mastermix	O
,	O
OptiGene	O
Ltd	O
.	O
and	O
PCRun	O
™	O
Molecular	O
Detection	O
Mix	O
,	O
Biogal	O
)	O
were	O
tested	O
using	O
the	O
same	O
primers	O
,	O
which	O
were	O
designed	O
to	O
bind	O
to	O
a	O
conserved	O
region	O
of	O
the	O
FCoV	B-PRGE
membrane	I-PRGE
protein	I-PRGE
gene	I-PRGE
.	O

MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3CL	I-PRGE
protease	I-PRGE
is	O
essential	O
for	O
viral	O
replication	O
;	O
consequently	O
,	O
it	O
is	O
an	O
attractive	O
target	O
that	O
provides	O
a	O
potentially	O
effective	O
means	O
of	O
developing	O
small	O
molecule	O
therapeutics	O
for	O
combatting	O
MERS	O
-	O
CoV	O
.	O
We	O
describe	O
herein	O
the	O
structure	O
-	O
guided	O
design	O
and	O
evaluation	O
of	O
a	O
novel	O
class	O
of	O
inhibitors	O
of	O
MERS	O
-	O
CoV	O
3CL	O
protease	O
that	O
embody	O
a	O
piperidine	O
moiety	O
as	O
a	O
design	O
element	O
that	O
is	O
well	O
-	O
suited	O
to	O
exploiting	O
favorable	O
subsite	O
binding	O
interactions	O
to	O
attain	O
optimal	O
pharmacological	O
activity	O
and	O
PK	O
properties	O
.	O

ABSTRACT	O
:	O
Contrasting	O
evidence	O
exists	O
on	O
the	O
comparative	O
efficacy	O
and	O
safety	O
of	O
bivalirudin	O
and	O
unfractionated	O
heparin	O
(	O
UFH	O
)	O
in	O
relation	O
to	O
the	O
planned	O
use	O
of	O
glycoprotein	B-PRGE
IIb	O
/	O
IIIa	O
inhibitors	O
(	O
GPIs	O
).	O

In	O
this	O
study	O
,	O
DIC	O
,	O
and	O
AKI	B-PRGE
stage	I-PRGE
3	I-PRGE
were	O
independent	O
risk	O
factors	O
of	O
in	O
-	O
hospital	O
mortality	O
.	O

ABSTRACT	O
:	O
A	O
rapid	O
and	O
specific	O
real	O
-	O
time	O
reverse	O
-	O
transcription	O
recombinase	B-PRGE
polymerase	I-PRGE
amplification	O
assay	O
(	O
RT	B-PRGE
-	I-PRGE
RPA	I-PRGE
)	O
was	O
developed	O
to	O
detect	O
the	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
in	O
this	O
study	O
.	O

TITLE	O
:	O
Coronavirus	O
S	O
protein	O
-	O
induced	O
fusion	O
is	O
blocked	O
prior	O
to	O
hemifusion	O
by	O
Abl	B-PRGE
kinase	I-PRGE
inhibitors	O
.	O

The	O
same	O
active	O
compounds	O
affected	O
also	O
HIV	O
-	O
1	O
IN	O
strand	O
transfer	O
function	O
,	O
suggesting	O
the	O
involvement	O
of	O
the	O
RNase	B-PRGE
H	I-PRGE
active	O
site	O
.	O

The	O
duration	O
of	O
delirium	O
in	O
these	O
patients	O
was	O
associated	O
with	O
impairments	O
in	O
various	O
outcome	O
parameters	O
,	O
illustrating	O
the	O
burden	O
of	O
sCAP	B-PRGE
.	O

In	O
this	O
study	O
,	O
we	O
prepared	O
and	O
vaccinated	O
mice	O
with	O
either	O
a	O
Spike	B-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
protein	I-PRGE
or	O
inactivated	O
whole	O
MERS	O
-	O
CoV	O
(	O
IV	O
)	O
with	O
a	O
combined	O
adjuvant	O
(	O
alum	O
+	O
CpG	O
)	O
as	O
a	O
vaccine	O
formulation	O
.	O

Complete	O
genomic	O
sequence	O
analysis	O
and	O
pairwise	O
comparison	O
of	O
nucleotide	O
sequences	O
encoding	O
the	O
S1	O
subunit	O
of	O
the	O
spike	O
protein	O
and	O
other	O
structural	O
and	O
accessory	O
proteins	O
revealed	O
that	O
Chinese	O
Ark	B-PRGE
field	O
isolates	O
were	O
genetically	O
closely	O
related	O
to	O
the	O
Jilin	O
vaccine	O
and	O
American	O
ArkDPI11	O
strains	O
,	O
although	O
extensive	O
nucleotide	O
changes	O
were	O
found	O
across	O
the	O
genomes	O
of	O
Chinese	O
Ark	O
field	O
isolates	O
.	O

Two	O
different	O
models	O
were	O
developed	O
(	O
with	O
and	O
without	O
acute	O
-	O
illness	O
severity	O
scores	O
)	O
and	O
factors	O
independently	O
associated	O
with	O
5	O
-	O
year	O
mortality	O
were	O
[	O
adjusted	O
odds	O
ratio	O
(	O
95	O
%	O
confidence	O
interval	O
)]:	O
age	O
=	O
1	O
.	O
03	O
per	O
year	O
(	O
1	O
.	O
02	O
-	O
1	O
.	O
04	O
),	O
cancer	O
=	O
4	O
.	O
36	O
(	O
1	O
.	O
65	O
-	O
11	O
.	O
53	O
),	O
no	O
comorbidities	O
=	O
0	O
.	O
4	O
(	O
0	O
.	O
26	O
-	O
0	O
.	O
62	O
),	O
Karnovsky	O
Index	O
<	O
70	O
=	O
2	O
.	O
25	O
(	O
1	O
.	O
48	O
-	O
3	O
.	O
40	O
),	O
SAPS	O
(	O
Simplified	O
Acute	O
Physiology	O
Score	O
)	O
II	O
=	O
1	O
.	O
05	O
per	O
point	O
(	O
1	O
.	O
03	O
-	O
1	O
.	O
07	O
),	O
positive	O
blood	O
cultures	O
=	O
1	O
.	O
57	O
(	O
1	O
.	O
01	O
-	O
2	O
.	O
44	O
)	O
and	O
infection	O
by	O
an	O
ESKAPE	O
pathogen	O
(	O
Enterococcus	O
faecium	O
,	O
Staphylococcus	O
aureus	O
,	O
Klebsiella	O
pneumoniae	O
,	O
Acinetobacter	O
baumannii	O
,	O
Pseudomonas	O
aeroginosa	O
and	O
Enterobacter	O
species	O
)	O
=	O
1	O
.	O
61	O
(	O
1	O
.	O
00	O
-	O
2	O
.	O
60	O
);	O
and	O
in	O
the	O
second	O
model	O
[	O
without	O
SAPS	B-PRGE
II	I-PRGE
and	O
SOFA	O
(	O
Sequential	O
Organ	O
Failure	O
Assessment	O
)	O
scores	O
]:	O
age	O
=	O
1	O
.	O
04	O
per	O
year	O
(	O
1	O
.	O
03	O
-	O
1	O
.	O
05	O
),	O
cancer	O
=	O
5	O
.	O
93	O
(	O
2	O
.	O
26	O
-	O
15	O
.	O
51	O
),	O
chronic	O
haematologic	O
disease	O
=	O
2	O
.	O
37	O
(	O
1	O
.	O
14	O
-	O
4	O
.	O
93	O
),	O
no	O
comorbidities	O
=	O
0	O
.	O
45	O
(	O
0	O
.	O
29	O
-	O
0	O
.	O
69	O
),	O
Karnovsky	O
Index	O
<	O
70	O
=	O
2	O
.	O
32	O
(	O
1	O
.	O
54	O
-	O
3	O
.	O
50	O
),	O
septic	O
shock	O
[	O
reference	O
is	O
infection	O
without	O
SIRS	O
(	O
Systemic	O
Inflammatory	O
Response	O
Syndrome	O
)]	O
=	O
3	O
.	O
77	O
(	O
1	O
.	O
80	O
-	O
7	O
.	O
89	O
)	O
and	O
infection	O
by	O
an	O
ESKAPE	O
pathogen	O
=	O
1	O
.	O
61	O
(	O
1	O
.	O
00	O
-	O
2	O
.	O
60	O
).	O

RESULTS	O
:	O
Two	O
different	O
models	O
were	O
developed	O
(	O
with	O
and	O
without	O
acute	O
-	O
illness	O
severity	O
scores	O
)	O
and	O
factors	O
independently	O
associated	O
with	O
5	O
-	O
year	O
mortality	O
were	O
[	O
adjusted	O
odds	O
ratio	O
(	O
95	O
%	O
confidence	O
interval	O
)]:	O
age	O
=	O
1	O
.	O
03	O
per	O
year	O
(	O
1	O
.	O
02	O
-	O
1	O
.	O
04	O
),	O
cancer	O
=	O
4	O
.	O
36	O
(	O
1	O
.	O
65	O
-	O
11	O
.	O
53	O
),	O
no	O
comorbidities	O
=	O
0	O
.	O
4	O
(	O
0	O
.	O
26	O
-	O
0	O
.	O
62	O
),	O
Karnovsky	O
Index	O
<	O
70	O
=	O
2	O
.	O
25	O
(	O
1	O
.	O
48	O
-	O
3	O
.	O
40	O
),	O
SAPS	O
(	O
Simplified	O
Acute	O
Physiology	O
Score	O
)	O
II	O
=	O
1	O
.	O
05	O
per	O
point	O
(	O
1	O
.	O
03	O
-	O
1	O
.	O
07	O
),	O
positive	O
blood	O
cultures	O
=	O
1	O
.	O
57	O
(	O
1	O
.	O
01	O
-	O
2	O
.	O
44	O
)	O
and	O
infection	O
by	O
an	O
ESKAPE	O
pathogen	O
(	O
Enterococcus	O
faecium	O
,	O
Staphylococcus	O
aureus	O
,	O
Klebsiella	O
pneumoniae	O
,	O
Acinetobacter	O
baumannii	O
,	O
Pseudomonas	O
aeroginosa	O
and	O
Enterobacter	O
species	O
)	O
=	O
1	O
.	O
61	O
(	O
1	O
.	O
00	O
-	O
2	O
.	O
60	O
);	O
and	O
in	O
the	O
second	O
model	O
[	O
without	O
SAPS	B-PRGE
II	I-PRGE
and	O
SOFA	O
(	O
Sequential	O
Organ	O
Failure	O
Assessment	O
)	O
scores	O
]:	O
age	O
=	O
1	O
.	O
04	O
per	O
year	O
(	O
1	O
.	O
03	O
-	O
1	O
.	O
05	O
),	O
cancer	O
=	O
5	O
.	O
93	O
(	O
2	O
.	O
26	O
-	O
15	O
.	O
51	O
),	O
chronic	O
haematologic	O
disease	O
=	O
2	O
.	O
37	O
(	O
1	O
.	O
14	O
-	O
4	O
.	O
93	O
),	O
no	O
comorbidities	O
=	O
0	O
.	O
45	O
(	O
0	O
.	O
29	O
-	O
0	O
.	O
69	O
),	O
Karnovsky	O
Index	O
<	O
70	O
=	O
2	O
.	O
32	O
(	O
1	O
.	O
54	O
-	O
3	O
.	O
50	O
),	O
septic	O
shock	O
[	O
reference	O
is	O
infection	O
without	O
SIRS	O
(	O
Systemic	O
Inflammatory	O
Response	O
Syndrome	O
)]	O
=	O
3	O
.	O
77	O
(	O
1	O
.	O
80	O
-	O
7	O
.	O
89	O
)	O
and	O
infection	O
by	O
an	O
ESKAPE	O
pathogen	O
=	O
1	O
.	O
61	O
(	O
1	O
.	O
00	O
-	O
2	O
.	O
60	O
).	O

R	O
-	O
848	O
enhanced	O
the	O
antigen	O
specific	O
humoral	O
and	O
cellular	O
immune	O
responses	O
when	O
co	O
-	O
administered	O
with	O
the	O
vaccines	O
as	O
evidenced	O
by	O
an	O
increase	O
in	O
the	O
antibody	O
titre	O
in	O
ELISA	O
and	O
stimulation	O
index	O
in	O
lymphocyte	O
transformation	O
test	O
(	O
LTT	O
)	O
till	O
35	O
dpi	O
and	O
increased	O
proportion	O
of	O
CD4	B-PRGE

ABSTRACT	O
:	O
A	O
series	O
of	O
tripeptidic	O
acylsulfonamide	O
inhibitors	O
of	O
HCV	B-PRGE
NS3	I-PRGE
protease	I-PRGE
were	O
prepared	O
that	O
explored	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
at	O
the	O
P4	O
position	O
,	O
and	O
their	O
in	O
vitro	O
and	O
in	O
vivo	O
properties	O
were	O
evaluated	O
.	O

Using	O
chimeric	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
expressing	O
TMEV	O
L	O
*,	O
we	O
showed	O
that	O
L	O
*	O
efficiently	O
inhibits	O
RNase	B-PRGE
L	I-PRGE
in	O
vivo	O
.	O

ABSTRACT	O
:	O
APOBEC3	B-PRGE
family	I-PRGE
members	I-PRGE
are	O
cytidine	O
deaminases	O
with	O
roles	O
in	O
intrinsic	O
responses	O
to	O
infection	O
by	O
retroviruses	O
and	O
retrotransposons	O
,	O
and	O
in	O
the	O
control	O
of	O
other	O
DNA	O
viruses	O
,	O
such	O
as	O
herpesviruses	O
,	O
parvoviruses	O
and	O
hepatitis	O
B	O
virus	O
.	O

Discussion	O
This	O
risk	O
-	O
prediction	O
model	O
in	O
dialysis	O
patients	O
appears	O
to	O
depend	O
markedly	O
on	O
chest	O
pain	O
,	O
leukopenia	O
,	O
and	O
elevated	O
AST	B-PRGE
.	O

Overall	O
,	O
282	O
of	O
3505	O
(	O
8	O
%)	O
infants	O
experienced	O
an	O
HCoV	B-PRGE
ARI	I-PRGE
within	O
the	O
first	O
6	O
months	O
of	O
life	O
.	O

Although	O
several	O
MERS	O
-	O
related	O
CoVs	O
that	O
belong	O
to	O
the	O
same	O
species	O
as	O
MERS	O
-	O
CoV	O
have	O
been	O
identified	O
from	O
bats	O
,	O
they	O
do	O
not	O
use	O
the	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
,	O
dipeptidyl	B-PRGE
peptidase	I-PRGE
4	I-PRGE
(	O
DPP4	B-PRGE
).	O

TITLE	O
:	O
Transmembrane	O
Domains	O
of	O
Highly	O
Pathogenic	O
Viral	O
Fusion	O
Proteins	O
Exhibit	O
Trimeric	O
Association	O
ABSTRACT	O
:	O
Enveloped	O
viruses	O
require	O
viral	O
fusion	O
proteins	O
to	O
promote	O
fusion	O
of	O
the	O
viral	B-PRGE
envelope	I-PRGE
with	O
a	O
target	O
cell	O
membrane	O
.	O

PE	O
patients	O
with	O
an	O
apnea	O
-	O
hypopnoea	O
index	O
(	O
AHI	O
)	O
≥	O
15	O
/	O
h	O
were	O
significantly	O
older	O
(	O
p	O
<	O
0	O
.	O
001	O
),	O
had	O
significantly	O
impaired	O
renal	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
left	O
ventricular	O
functions	O
(	O
p	O
=	O
0	O
.	O
003	O
),	O
showed	O
significantly	O
elevated	O
troponin	B-PRGE
I	I-PRGE
(	O
p	O
=	O
0	O
.	O
005	O
)	O
and	O
D	O
-	O
dimer	O
levels	O
(	O
p	O
=	O
0	O
.	O
024	O
),	O
were	O
hospitalised	O
significantly	O
longer	O
(	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
had	O
significantly	O
elevated	O
PE	O
severity	O
scores	O
(	O
p	O
=	O
0	O
.	O
015	O
).	O

Specifically	O
,	O
among	O
different	O
genera	O
,	O
the	O
two	O
domains	O
of	O
S1	O
,	O
the	O
N	O
-	O
terminal	O
domain	O
(	O
S1	O
-	O
NTD	O
)	O
and	O
C	O
-	O
terminal	O
domain	O
(	O
S1	B-PRGE
-	I-PRGE
CTD	I-PRGE
),	O
diverge	O
from	O
simpler	O
tertiary	O
structures	O
and	O
quaternary	O
packing	O
to	O
more	O
complex	O
ones	O
,	O
leading	O
to	O
different	O
functions	O
of	O
the	O
spikes	O
in	O
receptor	O
usage	O
and	O
membrane	O
fusion	O
.	O

This	O
study	O
aims	O
to	O
characterise	O
BCoV	O
genetically	O
on	O
the	O
basis	O
of	O
the	O
N	B-PRGE
gene	I-PRGE
.	O

Our	O
study	O
showed	O
that	O
complement	O
was	O
excessively	O
activated	O
in	O
MERS	O
-	O
CoV	O
-	O
infected	O
hDPP4	O
-	O
Tg	O
mice	O
through	O
observations	O
of	O
increased	O
concentrations	O
of	O
the	O
C5a	B-PRGE
and	O
C5b	O
-	O
9	O
complement	O
activation	O
products	O
in	O
sera	O
and	O
lung	O
tissues	O
,	O
respectively	O
.	O

TITLE	O
:	O
Lectin	B-PRGE
Affinity	O
Plasmapheresis	O
for	O
Middle	O
East	O
Respiratory	O
Syndrome	O
-	O
Coronavirus	O
and	O
Marburg	O
Virus	O
Glycoprotein	O
Elimination	O
.	O

TITLE	O
:	O
miR	B-PRGE
-	I-PRGE
146a	I-PRGE
-	I-PRGE
5p	I-PRGE
promotes	O
replication	O
of	O
infectious	O
bronchitis	O
virus	O
by	O
targeting	O
IRAK2	B-PRGE
and	O
TNFRSF18	B-PRGE
.	O

This	O
is	O
the	O
first	O
study	O
demonstrating	O
that	O
IBV	O
induced	O
miR	B-PRGE
-	I-PRGE
146a	I-PRGE
-	I-PRGE
5p	I-PRGE
is	O
related	O
to	O
virus	O
pathogenesis	O
by	O
down	O
regulating	O
IRAK2	B-PRGE
and	O
TNFRSF18	B-PRGE
,	O
which	O
may	O
serve	O
as	O
a	O
therapeutic	O
strategy	O
for	O
the	O
prevention	O
of	O
IBV	O
infections	O
.	O

The	O
impairments	O
in	O
the	O
corona	O
radiata	O
had	O
significant	O
correlations	O
with	O
the	O
current	O
CD4	B-PRGE
WM	O
impairments	O
are	O
present	O
in	O
neurologically	O
asymptomatic	O
HIV	O
+	O
adults	O
,	O
periventricular	O
WM	O
(	O
corpus	O
callosum	O
and	O
corona	O
radiata	O
)	O
are	O
preferential	O
occult	O
injuries	O
,	O
which	O
is	O
associated	O
with	O
axonal	O
chronic	O
damage	O
rather	O
than	O
demyelination	O
.	O

Results	O
indicated	O
that	O
upregulation	O
of	O
proinflammatory	O
cytokines	O
(	O
such	O
as	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
IL	O
-	O
1β	O
)	O
and	O
lipopolysaccharide	O
-	O
induced	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
alpha	I-PRGE
factor	I-PRGE
(	O
LITAF	B-PRGE
)	O
expression	O
is	O
induced	O
by	O
IBV	O
M41	O
in	O
the	O
trachea	O
and	O
by	O
IBV	O
885	O
and	O
QX	O
in	O
the	O
kidney	O
,	O
which	O
mainly	O
coincides	O
with	O
tracheal	O
and	O
renal	O
histopathological	O
lesions	O
respectively	O
caused	O
by	O
these	O
strains	O
.	O

Our	O
data	O
indicate	O
that	O
both	O
primer	O
sets	O
were	O
capable	O
of	O
detecting	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
to	O
the	O
same	O
level	O
as	O
existing	O
genetic	O
diagnostic	O
methods	O
,	O
and	O
that	O
both	O
were	O
highly	O
specific	O
with	O
no	O
cross	O
-	O
reactivity	O
observed	O
with	O
other	O
respiratory	O
viruses	O
.	O

TITLE	O
:	O
Porcine	B-PRGE
Deltacoronavirus	I-PRGE
Accessory	I-PRGE
Protein	I-PRGE
NS6	I-PRGE
Antagonizes	O
Interferon	B-PRGE
Beta	I-PRGE
Production	O
by	O
Interfering	O
with	O
the	O
Binding	O
of	O
RIG	B-PRGE
-	I-PRGE
I	I-PRGE
/	O
MDA5	B-PRGE
to	O
Double	O
-	O
Stranded	O
RNA	O
.	O

In	O
an	O
independent	O
cohort	O
of	O
subjects	O
with	O
ARDS	O
,	O
PD	B-PRGE
-	I-PRGE
L1	I-PRGE
gene	I-PRGE
expression	O
and	O
PD	B-PRGE
-	I-PRGE
L1	I-PRGE
/	O
PD	O
-	O
1	O
pathway	O
-	O
associated	O
gene	O
sets	O
were	O
significantly	O
decreased	O
in	O
AMs	O
from	O
patients	O
who	O
experienced	O
prolonged	O
mechanical	O
ventilation	O
or	O
death	O
.	O

The	O
2017	O
G1b	O
and	O
G2b	O
isolates	O
shared	O
98	O
.	O
7	O
%-	O
99	O
.	O
4	O
%	O
and	O
98	O
.	O
1	O
%-	O
99	O
.	O
2	O
%	O
amino	O
acid	O
sequence	O
identity	O
at	O
the	O
S	B-PRGE
gene	I-PRGE
level	O
and	O
99	O
.	O
3	O
%	O
and	O
99	O
.	O
0	O
%-	O
99	O
.	O
6	O
%	O
nucleotide	O
sequence	O
homology	O
at	O
the	O
genome	O
level	O
compared	O
to	O
the	O
corresponding	O
Korean	O
prototype	O
G1b	O
and	O
G2b	O
strains	O
,	O
respectively	O
.	O

Moreover	O
,	O
we	O
have	O
had	O
a	O
long	O
-	O
standing	O
interest	O
in	O
the	O
role	O
of	O
CD26	B-PRGE
in	O
cancer	O
biology	O
and	O
its	O
suitability	O
as	O
a	O
novel	O
therapeutic	O
target	O
in	O
selected	O
neoplasms	O
.	O

The	O
spearman	O
'	O
s	O
test	O
showed	O
the	O
positive	O
correlation	O
between	O
knowledge	O
and	O
attitude	O
of	O
DHPs	O
about	O
MERS	O
(	O
DHPs	B-PRGE
participated	O
in	O
this	O
study	O
showed	O
good	O
knowledge	O
and	O
positive	O
attitude	O
toward	O
MERS	O
.	O

TITLE	O
:	O
Pirfenidone	O
ameliorates	O
lipopolysaccharide	O
-	O
induced	O
pulmonary	O
inflammation	O
and	O
fibrosis	O
by	O
blocking	O
NLRP3	B-PRGE
inflammasome	I-PRGE
activation	O
.	O

We	O
analysed	O
the	O
proteolytic	O
processing	O
of	O
the	O
HCoV	B-PRGE
-	I-PRGE
229E	I-PRGE
spike	I-PRGE
protein	I-PRGE
by	O
trypsin	B-PRGE
-	O
like	O
serine	B-PRGE
proteases	I-PRGE
leading	O
to	O
activation	O
of	O
the	O
fusion	O
process	O
.	O

Our	O
results	O
showed	O
that	O
the	O
full	B-PRGE
-	I-PRGE
length	I-PRGE
E	I-PRGE
and	I-PRGE
3a	I-PRGE
proteins	I-PRGE
were	O
required	O
for	O
maximal	O
SARS	O
-	O
CoV	O
replication	O
and	O
virulence	O
,	O
whereas	O
viroporin	O
8a	O
had	O
only	O
a	O
minor	O
impact	O
on	O
these	O
activities	O
.	O

Two	O
of	O
the	O
variants	O
are	O
similar	O
to	O
those	O
identified	O
in	O
Japan	O
:	O
one	O
contains	O
a	O
194	O
-	O
aa	O
deletion	O
,	O
the	O
same	O
as	O
PEDV	B-PRGE
variant	I-PRGE
TTR	I-PRGE
-	I-PRGE
2	I-PRGE
/	O
JPN	O
/	O
2014	O
,	O
while	O
the	O
other	O
contains	O
a	O
204	O
-	O
aa	O
deletion	O
,	O
the	O
same	O
as	O
PEDV	O
variant	O
JKa	O
-	O
292	O
/	O
CS1de204	O
.	O

A	O
focused	O
set	O
of	O
thienyl	O
chalcone	O
derivaties	O
II	O
-	O
VI	O
was	O
screened	O
for	O
selected	O
viruses	O
Hepatitis	O
B	O
virus	O
(	O
HBV	O
),	O
Herpes	O
simplex	O
virus	O
1	O
(	O
HSV	O
-	O
1	O
),	O
Human	B-PRGE
cytomegalovirus	I-PRGE
(	O
HCMV	O
),	O
Dengue	O
virus	O
2	O
(	O
DENV2	O
),	O
Influenza	O
A	O
(	O
H1N1	O
)	O
virus	O
,	O
MERS	O
coronavirus	O
,	O
Poliovirus	O
1	O
(	O
PV	O
1	O
),	O
Rift	O
Valley	O
fever	O
(	O
RVF	O
),	O
Tacaribe	O
virus	O
(	O
TCRV	O
),	O
Venezuelan	O
equine	O
encephalitis	O
virus	O
(	O
VEE	O
)	O
and	O
Zika	O
virus	O
(	O
ZIKV	O
)	O
using	O
the	O
National	O
Institute	O
of	O
Allergy	O
and	O
Infectious	O
Diseases	O
(	O
NIAID	O
)'	O
s	O
Division	O
of	O
Microbiology	O
and	O
Infectious	O
Diseases	O
(	O
DMID	O
)	O
antiviral	O
screening	O
program	O
.	O

TITLE	O
:	O
Characterization	O
of	O
the	O
interaction	O
between	O
recombinant	B-PRGE
porcine	I-PRGE
aminopeptidase	I-PRGE
N	I-PRGE
and	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

Phylogenetic	O
analysis	O
based	O
on	O
26	O
CaAstV	B-PRGE
partial	I-PRGE
ORF1a	I-PRGE
and	I-PRGE
ORF1b	I-PRGE
sequences	I-PRGE
revealed	O
that	O
most	O
CaAstV	O
strains	O
showed	O
unique	O
evolutionary	O
features	O
.	O

The	O
features	O
of	O
this	O
genome	O
include	O
putative	O
recombination	O
events	O
in	O
the	O
ORF1a	B-PRGE
,	I-PRGE
ORF1b	I-PRGE
and	I-PRGE
ORF2	I-PRGE
genes	I-PRGE
,	O
while	O
the	O
ORF2	O
gene	O
had	O
a	O
continuous	O
insertion	O
of	O
7	O
aa	O
in	O
region	O
II	O
compared	O
with	O
the	O
other	O
complete	O
ORF2	O
sequences	O
available	O
in	O
GenBank	O
.	O

Life	O
span	O
until	O
the	O
first	O
exchange	O
and	O
exchange	O
criteria	O
were	O
analyzed	O
for	O
all	O
systems	O
(	O
PLS	O
,	O
Cardiohelp	O
HLS	O
-	O
set	O
,	O
both	O
Maquet	O
Cardiopulmonary	O
,	O
Rastatt	O
,	O
Germany	O
;	O
Deltastream	O
/	O
Hilite7000LT	O
,	O
iLA	B-PRGE
-	O
activve	O
,	O
Xenios	O
/	O
NovaLung	O
,	O
Heilbronn	O
,	O
Germany	O
;	O
ECC	O
.	O
O5	O
,	O
LivaNova	O
,	O
Mirandola	O
,	O
Italy	O
).	O

Further	O
investigation	O
determined	O
that	O
the	O
ectopic	O
expression	O
of	O
Rab5	B-PRGE
mutants	I-PRGE
induces	O
aberrant	O
endosomal	O
accumulation	O
of	O
activated	O
pTrkA	O
,	O
proving	O
that	O
targeting	O
of	O
Ulk1	B-PRGE
-	O
TrkA	B-PRGE
-	O
NGF	B-PRGE
signaling	O
to	O
the	O
retrograde	O
transport	O
route	O
in	O
the	O
neurodegenerative	O
process	O
that	O
underlies	O
PHEV	O
infection	O
is	O
dependent	O
on	O
Rab5	B-PRGE
GTPase	I-PRGE
activity	O
.	O

Therefore	O
,	O
we	O
described	O
a	O
long	O
-	O
distance	O
signaling	O
mechanism	O
of	O
PHEV	O
-	O
driven	O
deficits	O
in	O
neurons	O
and	O
suggested	O
that	O
such	O
Ulk1	B-PRGE
repression	O
may	O
result	O
in	O
limited	O
NGF	B-PRGE
/	O
TrkA	B-PRGE
retrograde	O
signaling	O
within	O
activated	O
Rab5	B-PRGE
endosomes	I-PRGE
,	O
explaining	O
the	O
progressive	O
failure	O
of	O
neurite	O
outgrowth	O
and	O
survival	O
.	O

Aminopeptidase	B-PRGE
N	I-PRGE
(	O
APN	B-PRGE
)	O
is	O
a	O
known	O
receptor	O
of	O
TGEV	O
.	O

This	O
study	O
discovered	O
that	O
the	O
extracellular	B-PRGE
receptor	I-PRGE
binding	I-PRGE
domain	I-PRGE
1	I-PRGE
pertaining	O
to	O
epidermal	B-PRGE
growth	I-PRGE
receptor	I-PRGE
(	O
EGFR	B-PRGE
)	O
interact	O
with	O
TGEV	B-PRGE
spike	I-PRGE
protein	I-PRGE
.	O

TGEV	O
promotes	O
APN	B-PRGE
and	O
EGFR	B-PRGE
clustering	O
early	O
in	O
infection	O
.	O

Patients	O
with	O
AKI	O
had	O
significantly	O
lower	O
PaO	O
AKI	B-PRGE
is	O
common	O
in	O
children	O
with	O
ARF	B-PRGE
.	O

Positive	O
end	O
expiratory	O
pressure	O
and	O
serum	O
creatinine	O
are	O
independently	O
associated	O
with	O
AKI	B-PRGE
.	O

ABSTRACT	O
:	O
The	O
replicase	B-PRGE
gene	I-PRGE
of	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
encodes	O
15	O
non	O
-	O
structural	O
proteins	O
(	O
nsps	O
).	O

Nsp	B-PRGE
3	I-PRGE
is	O
a	O
multi	O
-	O
functional	O
protein	O
containing	O
a	O
conserved	O
ADP	B-PRGE
-	I-PRGE
ribose	I-PRGE
-	I-PRGE
1	I-PRGE
″-	I-PRGE
phosphatase	I-PRGE
(	O
ADRP	B-PRGE
)	O
domain	O
.	O

One	O
vaccine	O
candidate	O
is	O
based	O
on	O
live	O
-	O
attenuated	O
measles	O
virus	O
(	O
MV	O
)	O
vaccine	O
encoding	O
the	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
(	O
MERS	O
-	O
S	O
).	O

In	O
addition	O
,	O
nasal	O
swabs	O
of	O
661	O
camels	O
,	O
alpacas	O
and	O
lamas	O
,	O
obtained	O
from	O
January	O
2015	O
to	O
December	O
2017	O
,	O
were	O
tested	O
for	O
the	O
presence	O
of	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RNA	I-PRGE
.	O

ABSTRACT	O
:	O
Pig	B-PRGE
diarrhea	O
causes	O
high	O
mortality	O
and	O
large	O
economic	O
losses	O
in	O
the	O
swine	O
industry	O
.	O

While	O
FHS	B-PRGE
-	I-PRGE
1	I-PRGE
cells	O
are	O
not	O
suitable	O
for	O
in	O
vitro	O
study	O
of	O
FIP	O
using	O
strain	O
79	O
-	O
1146	O
,	O
they	O
may	O
be	O
applicable	O
for	O
studies	O
aimed	O
at	O
developing	O
new	O
diagnostic	O
and	O
therapeutic	O
strategies	O
for	O
feline	O
HS	O
.	O

This	O
report	O
details	O
several	O
design	O
changes	O
made	O
to	O
a	O
Hepatitis	B-PRGE
B	I-PRGE
virus	I-PRGE
core	I-PRGE
antigen	I-PRGE
(	O
HBcAg	O
)-	O
based	O
recombinant	O
vaccine	O
strategy	O
,	O
and	O
their	O
effect	O
in	O
vivo	O
.	O

To	O
assess	O
whether	O
a	O
GBF1	O
/	O
class	O
II	O
Arf	B-PRGE
pathway	O
is	O
conserved	O
among	O
positive	O
-	O
sense	O
single	O
-	O
stranded	O
RNA	O
viruses	O
,	O
we	O
investigated	O
yellow	O
fever	O
virus	O
(	O
YFV	O
),	O
Sindbis	O
virus	O
(	O
SINV	O
),	O
coxsackievirus	O
B4	O
(	O
CVB4	O
)	O
and	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
).	O

For	O
sensitivity	O
and	O
specificity	O
analysis	O
of	O
ELISA	B-PRGE
IgG	I-PRGE
in	O
predicting	O
neutralization	O
activity	O
,	O
a	O
data	O
set	O
of	O
138	O
previously	O
evaluated	O
MERS	O
-	O
CoV	O
-	O
infected	O
patients	O
was	O
used	O
.	O

We	O
also	O
demonstrated	O
that	O
the	O
impact	O
of	O
TCs	B-PRGE
on	O
VILI	O
repair	O
might	O
partially	O
due	O
to	O
vascular	B-PRGE
endothelial	I-PRGE
growth	I-PRGE
factor	I-PRGE
(	O
VEGF	B-PRGE
)	O
secreted	O
by	O
TCs	B-PRGE
upon	O
VILI	O
stimulation	O
,	O
and	O
that	O
VEGF	B-PRGE
could	O
induce	O
the	O
proliferation	O
of	O
hemangioendothelioma	O
endothelial	O
cells	O
(	O
EOMA	O
).	O

The	O
percentages	O
of	O
H7N9	O
-	O
specific	O
IFN	B-PRGE
-	I-PRGE
γ	I-PRGE
-	O
secreting	O
T	O
cells	O
tended	O
to	O
increase	O
over	O
time	O
in	O
patients	O
≥	O
60	O
years	O
or	O
in	O
critically	O
ill	O
patients	O
requiring	O
ventilation	O
.	O

Here	O
,	O
we	O
investigate	O
whether	O
the	O
virus	O
uses	O
the	O
canonical	O
autophagic	O
signaling	O
complex	O
,	O
consisting	O
of	O
the	O
ULK1	B-PRGE
/	I-PRGE
2	I-PRGE
kinases	I-PRGE
,	O
ATG13	B-PRGE
,	O
RB1CC1	B-PRGE
,	O
and	O
ATG101	B-PRGE
,	O
to	O
activate	O
autophagy	O
.	O

Surprisingly	O
,	O
autophagic	O
signaling	O
appears	O
to	O
increase	O
as	O
ULK1	B-PRGE
levels	O
decrease	O
.	O

TITLE	O
:	O
Alk5	B-PRGE
/	O
Runx1	B-PRGE
signaling	O
mediated	O
by	O
extracellular	O
vesicles	O
promotes	O
vascular	O
repair	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

The	O
ELISA	O
results	O
showed	O
that	O
higher	O
level	O
of	O
secreted	O
IL	B-PRGE
-	I-PRGE
1beta	I-PRGE
varies	O
,	O
depending	O
on	O
the	O
viral	O
interference	O
conditions	O
between	O
both	O
viruses	O
,	O
during	O
mixed	O
infections	O
.	O

The	O
CD4	B-PRGE
T	I-PRGE
cell	O
-	O
induced	O
autoimmune	O
murine	O
model	O
of	O
MS	O
,	O
experimental	O
autoimmune	O
encephalitis	O
(	O
EAE	O
),	O
in	O
which	O
BMDM	O
are	O
essential	O
for	O
demyelination	O
,	O
has	O
revealed	O
pathogenic	O
and	O
repair	O
-	O
promoting	O
phenotypes	O
associated	O
with	O
BMDM	O
and	O
microglia	O
,	O
respectively	O
.	O

Of	O
the	O
studied	O
cytokines	O
,	O
only	O
newly	O
discovered	O
anti	B-PRGE
-	I-PRGE
inflammatory	I-PRGE
cytokine	I-PRGE
IL	I-PRGE
-	I-PRGE
37	I-PRGE
,	O
was	O
independently	O
associated	O
with	O
tonsillar	O
hypertrophy	O
showing	O
slightly	O
stronger	O
anti	O
-	O
inflammatory	O
response	O
in	O
these	O
patients	O
.	O

To	O
assess	O
the	O
association	O
of	O
IL1RA	B-PRGE
gene	I-PRGE
polymorphism	O
on	O
serum	O
levels	O
of	O
IL1RA	B-PRGE
and	O
with	O
AO	O
in	O
children	O
under	O
5	O
years	O
of	O
age	O
hospitalized	O
with	O
WHO	O
-	O
defined	O
severe	O
CAP	O
.	O

Serum	B-PRGE
IL1RA	I-PRGE
(	O
ng	O
/	O
mL	O
)	O
was	O
statistically	O
significantly	O
elevated	O
in	O
CAP	O
with	O
AO	O
(	O
2	O
.	O
55	O
±	O
1	O
.	O
44	O
)	O
versus	O
uncomplicated	O
(	O
0	O
.	O
87	O
±	O
0	O
.	O
52	O
)	O
(	O
P	O
<	O
0	O
.	O
0001	O
).	O

Double	O
immunolabeling	O
demonstrated	O
cytokeratin	B-PRGE
(	O
CK	O
)	O
18	O
expressing	O
epithelial	O
cells	O
to	O
be	O
the	O
prevailing	O
target	O
cell	O
of	O
MERS	O
-	O
CoV	O
,	O
while	O
CK5	B-PRGE
/	I-PRGE
6	I-PRGE
and	O
CK14	B-PRGE
expressing	O
cells	O
did	O
not	O
co	O
-	O
localize	O
with	O
virus	O
.	O

IAP	B-PRGE
was	O
measured	O
in	O
301	O
patients	O
(	O
80	O
·	O
5	O
per	O
cent	O
),	O
of	O
whom	O
274	O
(	O
91	O
·	O
0	O
per	O
cent	O
)	O
had	O
IAH	O
and	O
103	O
(	O
34	O
·	O
2	O
per	O
cent	O
)	O
acute	O
compartment	O
syndrome	O
.	O

TITLE	O
:	O
Lead	O
Molecule	O
Prediction	O
and	O
Characterization	O
for	O
Designing	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
Protease	I-PRGE
Inhibitors	O
:	O
An	O
In	O
silico	O
Approach	O
.	O

In	O
our	O
study	O
we	O
predicted	O
compounds	O
which	O
are	O
capable	O
of	O
inhibiting	O
3C	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
,	O
and	O
thus	O
inhibit	O
the	O
lifecycle	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
using	O
in	O
silico	O
methods	O
.	O

All	O
the	O
compounds	O
are	O
not	O
a	O
substrate	O
of	O
P	B-PRGE
-	I-PRGE
glycoprotein	I-PRGE
.	O

Although	O
all	O
anti	B-PRGE
-	I-PRGE
MDA5	I-PRGE
-	O
positive	O
patients	O
with	O
CADM	O
had	O
ILD	O
,	O
the	O
MAA	O
-	O
positive	O
patients	O
showed	O
a	O
lower	O
risk	O
of	O
developing	O
RP	O
-	O
ILD	O
(	O
p	O
=	O
0	O
.	O
03	O
),	O
a	O
more	O
favorable	O
response	O
to	O
combination	O
therapy	O
of	O
corticosteroids	O
and	O
immunosuppressive	O
agents	O
,	O
and	O
a	O
lower	O
mortality	O
rate	O
than	O
patients	O
with	O
no	O
MAAs	O
(	O
p	O
=	O
0	O
.	O
03	O
).	O

They	O
are	O
differentiated	O
by	O
insertions	O
/	O
deletions	O
in	O
the	O
S1	O
nucleotide	O
sequence	O
of	O
the	O
S	B-PRGE
gene	I-PRGE
,	O
and	O
differences	O
in	O
virulence	O
were	O
observed	O
from	O
the	O
clinical	O
cases	O
.	O

TITLE	O
:	O
Canine	O
respiratory	O
coronavirus	O
employs	O
caveolin	B-PRGE
-	I-PRGE
1	I-PRGE
-	O
mediated	O
pathway	O
for	O
internalization	O
to	O
HRT	O
-	O
18G	O
cells	O
.	O

The	O
virus	O
is	O
a	O
betacoronavirus	O
and	O
a	O
close	O
relative	O
of	O
human	B-PRGE
coronavirus	I-PRGE
OC43	I-PRGE
and	O
bovine	O
coronavirus	O
.	O

The	O
N	B-PRGE
protein	I-PRGE
of	O
the	O
epidemic	O
strain	O
could	O
antagonize	O
type	B-PRGE
III	I-PRGE
IFN	I-PRGE
,	O
but	O
not	O
type	O
I	O
or	O
type	O
II	O
IFN	B-PRGE
expression	O
induced	O
by	O
polyinosinic	O
-	O
polycytidylic	O
acid	O
(	O
poly	O
(	O
I	O
:	O
C	O
))	O
in	O
IPEC	O
-	O
J2	O
cells	O
.	O

Together	O
,	O
the	O
results	O
indicate	O
that	O
targeting	O
the	O
CoV	B-PRGE
2	I-PRGE
'	I-PRGE
O	I-PRGE
MTase	I-PRGE
in	O
parallel	O
with	O
other	O
conserved	O
attenuating	O
mutations	O
may	O
provide	O
a	O
platform	O
strategy	O
for	O
rapidly	O
generating	O
live	O
attenuated	O
coronavirus	O
vaccines	O
.	O

Moreover	O
,	O
we	O
demonstrate	O
that	O
TMPRSS11A	B-PRGE
is	O
expressed	O
in	O
murine	O
tracheal	O
epithelium	O
,	O
which	O
is	O
a	O
target	O
of	O
FLUAV	O
infection	O
,	O
and	O
in	O
human	O
trachea	O
,	O
suggesting	O
that	O
the	O
protease	O
could	O
support	O
FLUAV	O
spread	O
in	O
patients	O
.	O

Our	O
results	O
suggest	O
that	O
TMPRSS11A	B-PRGE
could	O
promote	O
FLUAV	O
spread	O
in	O
target	O
cells	O
and	O
that	O
HA	O
-	O
activating	O
TTSPs	O
exhibit	O
differential	O
sensitivity	O
to	O
blockade	O
by	O
cellular	B-PRGE
serine	I-PRGE
protease	I-PRGE
inhibitors	O
.	O

PDCoV	B-PRGE
antigen	I-PRGE
was	O
detected	O
in	O
the	O
cells	O
showing	O
CPE	O
.	O

By	O
double	O
IF	O
and	O
TUNEL	O
staining	O
,	O
most	O
PDCoV	B-PRGE
antigen	I-PRGE
-	O
positive	O
IPEC	O
-	O
J2	O
cells	O
failed	O
to	O
show	O
TUNEL	O
-	O
positive	O
signals	O
,	O
indicating	O
that	O
PDCoV	O
-	O
infected	O
IPEC	O
-	O
J2	O
cells	O
may	O
not	O
undergo	O
apoptosis	O
,	O
but	O
rather	O
necrosis	O
,	O
similar	O
to	O
necrotic	O
cell	O
death	O
of	O
infected	O
enterocytes	O
in	O
vivo	O
.	O

Phylogenetic	O
analysis	O
based	O
on	O
the	O
S	B-PRGE
gene	I-PRGE
and	I-PRGE
ORF3	I-PRGE
gene	I-PRGE
of	O
these	O
17	O
novel	O
PEDV	O
strains	O
and	O
PEDV	O
reference	O
strains	O
indicated	O
that	O
all	O
the	O
PEDV	O
strains	O
fell	O
into	O
two	O
groups	O
designated	O
G1	O
and	O
G2	O
.	O

TITLE	O
:	O
N	O
-	O
terminal	O
Domain	O
of	O
the	O
Spike	B-PRGE
Protein	I-PRGE
of	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
as	O
a	O
New	O
Candidate	O
Molecule	O
for	O
a	O
Mucosal	O
Vaccine	O
.	O

Heatmap	O
cluster	O
analysis	O
showed	O
that	O
the	O
vast	O
majority	O
of	O
the	O
viral	O
groups	O
were	O
differentially	O
expressed	O
in	O
miRNA	O
compared	O
with	O
the	O
control	O
group	O
,	O
Go	O
analysis	O
showed	O
that	O
miRNAs	O
are	O
widely	O
involved	O
in	O
combination	O
,	O
binding	O
protein	O
,	O
protein	B-PRGE
kinase	I-PRGE
activity	O
,	O
transfer	O
enzyme	O
activity	O
,	O
phosphorus	O
containing	O
radicals	O
transfer	O
,	O
phosphotransferase	O
enzyme	O
activity	O
and	O
other	O
biological	O
effects	O
.	O

TITLE	O
:	O
Heme	B-PRGE
Oxygenase	I-PRGE
-	I-PRGE
1	I-PRGE
Reduces	O
Sepsis	O
-	O
Induced	O
Endoplasmic	O
Reticulum	O
Stress	O
and	O
Acute	O
Lung	O
Injury	O
.	O

Also	O
the	O
involvement	O
of	O
the	O
FK	B-PRGE
-	I-PRGE
506	I-PRGE
-	I-PRGE
binding	I-PRGE
proteins	I-PRGE
and	O
parvulins	O
is	O
discussed	O
.	O

Nucleic	O
acid	O
testing	O
(	O
NAT	O
)	O
is	O
the	O
preferred	O
method	O
for	O
the	O
detection	O
of	O
MERS	O
-	O
CoV	O
.	O
A	O
single	O
round	O
of	O
a	O
Proficiency	O
Testing	O
Program	O
(	O
PTP	O
)	O
was	O
used	O
to	O
assess	O
the	O
capability	O
of	O
laboratories	O
globally	O
to	O
accurately	O
detect	O
the	O
presence	O
of	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
using	I-PRGE
NAT	I-PRGE
.	O

We	O
found	O
that	O
the	O
furin	B-PRGE
inhibitor	O
dec	B-PRGE
-	I-PRGE
RVKR	I-PRGE
-	I-PRGE
CMK	I-PRGE
blocked	O
entry	O
of	O
MERS	O
-	O
CoV	O
harboring	O
an	O
S	B-PRGE
protein	I-PRGE
lacking	O
furin	B-PRGE
cleavage	O
sites	O
;	O
it	O
even	O
blocked	O
entry	O
into	O
furin	B-PRGE
-	O
deficient	O
LoVo	O
cells	O
.	O

In	O
an	O
unadjusted	O
logistic	O
regression	O
model	O
,	O
for	O
each	O
SD	O
increase	O
in	O
plasma	B-PRGE
TIMP	I-PRGE
-	I-PRGE
3	I-PRGE
,	O
the	O
odds	O
of	O
ARDS	O
increased	O
significantly	O
,	O
OR	O
1	O
.	O
5	O
(	O
95	O
%	O
CI	O
1	O
.	O
1	O
to	O
2	O
.	O
1	O
).	O

In	O
an	O
unadjusted	O
logistic	O
regression	O
model	O
,	O
for	O
each	O
SD	O
increase	O
in	O
plasma	B-PRGE
TIMP	I-PRGE
-	I-PRGE
3	I-PRGE
,	O
the	O
odds	O
of	O
death	O
increased	O
significantly	O
,	O
OR	O
1	O
.	O
7	O
(	O
95	O
%	O
CI	O
1	O
.	O
2	O
to	O
2	O
.	O
3	O
).	O

TITLE	O
:	O
Hepatitis	O
C	O
virus	O
enters	O
liver	O
cells	O
using	O
the	O
CD81	B-PRGE
receptor	I-PRGE
complex	O
proteins	O
calpain	O
-	O
5	O
and	O
CBLB	O
.	O

Here	O
we	O
mapped	O
33	O
host	O
protein	O
interactions	O
of	O
CD81	B-PRGE
in	O
primary	O
human	O
liver	O
and	O
hepatoma	O
cells	O
using	O
high	O
-	O
resolution	O
quantitative	O
proteomics	O
.	O

The	O
expression	O
of	O
antiviral	O
genes	O
involved	O
in	O
the	O
type	B-PRGE
I	I-PRGE
IFN	I-PRGE
and	O
NF	O
-	O
κB	O
signaling	O
pathways	O
was	O
also	O
downregulated	O
in	O
the	O
presence	O
of	O
HCoV	O
-	O
OC43	O
structural	O
or	O
accessory	O
proteins	O
.	O

ABSTRACT	O
:	O
Since	O
being	O
first	O
described	O
more	O
than	O
60	O
years	O
ago	O
,	O
Na	B-PRGE
,	I-PRGE
K	I-PRGE
-	I-PRGE
ATPase	I-PRGE
has	O
been	O
extensively	O
studied	O
,	O
while	O
novel	O
concepts	O
about	O
its	O
structure	O
,	O
physiology	O
,	O
and	O
biological	O
roles	O
continue	O
to	O
be	O
elucidated	O
.	O

At	O
the	O
acute	O
phase	O
of	O
infection	O
,	O
elevated	O
levels	O
of	O
plasma	B-PRGE
proinflammatory	I-PRGE
cytokines	I-PRGE
/	I-PRGE
chemokines	I-PRGE
were	O
detected	O
in	O
proportion	O
to	O
the	O
severity	O
of	O
the	O
disease	O
.	O

Distinctively	O
high	O
frequencies	O
of	O
MERS	B-PRGE
coronavirus	I-PRGE
-	I-PRGE
reactive	I-PRGE
CD8	I-PRGE
+	I-PRGE
T	O
cells	O
were	O
also	O
observed	O
in	O
patients	O
with	O
severe	O
/	O
moderate	O
illness	O
,	O
whereas	O
antibody	O
and	O
CD4	B-PRGE
+	I-PRGE
T	O
-	O
cell	O
responses	O
were	O
minimally	O
detected	O
at	O
this	O
stage	O
.	O

While	O
CD8	B-PRGE
+	I-PRGE
T	I-PRGE
cells	O
responded	O
preferentially	O
to	O
the	O
viral	B-PRGE
S	I-PRGE
protein	I-PRGE
compared	O
with	O
E	O
/	O
M	O
/	O
N	O
proteins	O
,	O
especially	O
at	O
the	O
acute	O
stage	O
,	O
slightly	O
more	O
CD4	O
+	O
T	O
cells	O
recognized	O
E	O
/	O
M	O
/	O
N	O
proteins	O
compared	O
with	O
S	B-PRGE
protein	I-PRGE
at	O
the	O
convalescent	O
phase	O
.	O

RESULTS	O
:	O
At	O
the	O
acute	O
phase	O
of	O
infection	O
,	O
elevated	O
levels	O
of	O
plasma	B-PRGE
proinflammatory	I-PRGE
cytokines	I-PRGE
/	I-PRGE
chemokines	I-PRGE
were	O
detected	O
in	O
proportion	O
to	O
the	O
severity	O
of	O
the	O
disease	O
.	O

Two	O
doses	O
of	O
the	O
nasal	O
spray	O
H7N9	O
vaccine	O
induced	O
higher	O
titers	O
of	O
HI	O
(	O
6	O
.	O
7	O
±	O
0	O
.	O
67	O
vs	O
.	O
5	O
.	O
3	O
±	O
1	O
.	O
16	O
,	O
P	O
=	O
0	O
.	O
004	O
)	O
and	O
anti	B-PRGE
-	I-PRGE
HA	I-PRGE
IgG	I-PRGE
in	O
sera	O
(	O
19	O
.	O
26	O
±	O
0	O
.	O
67	O
vs	O
.	O
13	O
.	O
97	O
±	O
0	O
.	O
82	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
of	O
anti	B-PRGE
-	I-PRGE
HA	I-PRGE
sIgA	I-PRGE
(	O
7	O
.	O
13	O
±	O
2	O
.	O
54	O
vs	O
.	O
0	O
,	O
P	O
=	O
0	O
.	O
0000	O
)	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
than	O
one	O
dose	O
of	O
intramuscular	O
H7N9	O
vaccine	O
3	O
weeks	O
after	O
the	O
last	O
immunization	O
.	O

However	O
,	O
when	O
we	O
immunized	O
the	O
mice	O
with	O
two	O
doses	O
of	O
both	O
vaccines	O
separately	O
,	O
the	O
nasal	O
spray	O
H7N9	O
vaccine	O
induced	O
higher	O
titers	O
of	O
anti	B-PRGE
-	I-PRGE
HA	I-PRGE
IgG	I-PRGE
(	O
19	O
.	O
26	O
±	O
0	O
.	O
67	O
vs	O
.	O
17	O
.	O
56	O
±	O
0	O
.	O
57	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
anti	B-PRGE
-	I-PRGE
HA	I-PRGE
sIgA	I-PRGE
(	O
7	O
.	O
13	O
±	O
2	O
.	O
54	O
vs	O
.	O
4	O
.	O
02	O
±	O
0	O
.	O
33	O
,	O
P	O
=	O
0	O
.	O
0026	O
)	O
than	O
did	O
the	O
intramuscular	O
H7N9	O
vaccine	O
,	O
and	O
there	O
was	O
no	O
difference	O
in	O
HI	O
titer	O
between	O
the	O
two	O
groups	O
(	O
P	O
=	O
0	O
.	O
3745	O
).	O

The	O
replicase	B-PRGE
polyproteins	O
pp1a	B-PRGE
and	O
pp1ab	O
,	O
which	O
had	O
4382	O
and	O
7094	O
amino	O
acid	O
residues	O
,	O
respectively	O
,	O
were	O
predicted	O
to	O
be	O
cleaved	O
into	O
16	O
subunits	O
by	O
two	O
viral	O
proteinases	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
ability	O
of	O
human	B-PRGE
β	I-PRGE
-	I-PRGE
defensin	I-PRGE
(	I-PRGE
HBD	I-PRGE
)	I-PRGE
2	I-PRGE
to	O
promote	O
antiviral	O
immunity	O
in	O
vitro	O
and	O
in	O
vivo	O
using	O
a	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
spike	O
protein	O
(	O
S	O
RBD	O
)	O
as	O
a	O
model	O
antigen	O
(	O
Ag	O
).	O

Immunization	O
of	O
4	O
-	O
week	O
-	O
old	O
SPF	B-PRGE
chickens	I-PRGE
with	O
the	O
rNDV	O
expressing	O
S	B-PRGE
protein	I-PRGE
elicited	O
IBV	O
-	O
specific	O
neutralizing	O
antibodies	O
and	O
provided	O
complete	O
protection	O
against	O
virulent	O
IBV	O
and	O
virulent	O
NDV	O
challenges	O
.	O

These	O
results	O
suggest	O
that	O
the	O
rNDV	O
expressing	O
the	O
S	B-PRGE
protein	I-PRGE
of	O
IBV	O
is	O
a	O
safe	O
and	O
effective	O
bivalent	O
vaccine	O
candidate	O
for	O
both	O
IBV	O
and	O
NDV	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	O
,	O
docking	O
studies	O
and	O
biological	O
screening	O
of	O
2	O
-	O
thiazolyl	O
substituted	O
-	O
2	O
,	O
3	O
-	O
dihydro	O
-	O
1H	O
-	O
naphtho	O
[	O
1	O
,	O
2	O
-	O
e	O
][	O
1	O
,	O
3	O
]	O
oxazines	O
as	O
potent	O
HIV	O
-	O
1	O
reverse	B-PRGE
transcriptase	I-PRGE
inhibitors	O
.	O

Furthermore	O
,	O
camel	O
/	O
human	O
chimeric	O
HCAbs	O
-	O
composed	O
of	O
the	O
camel	O
VHH	O
linked	O
to	O
a	O
human	B-PRGE
Fc	I-PRGE
domain	I-PRGE
lacking	O
the	O
CH1	B-PRGE
exon	O
-	O
had	O
an	O
extended	O
half	O
-	O
life	O
in	O
the	O
serum	O
and	O
protected	O
mice	O
against	O
a	O
lethal	O
MERS	O
-	O
CoV	O
challenge	O
.	O

Structural	O
comparisons	O
suggested	O
that	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
glycoprotein	I-PRGE
retains	O
a	O
prefusion	O
architecture	O
after	O
trypsin	B-PRGE
cleavage	O
into	O
the	O
S1	O
and	O
S2	O
subunits	O
and	O
acidic	O
pH	O
treatment	O
.	O

Molecular	O
clock	O
analysis	O
showed	O
that	O
divergence	O
of	O
the	O
GII	B-PRGE
-	I-PRGE
c	I-PRGE
subgroup	I-PRGE
spike	I-PRGE
gene	I-PRGE
occurred	O
in	O
April	O
2010	O
,	O
suggesting	O
that	O
the	O
subgroup	O
originated	O
from	O
recombination	O
events	O
before	O
the	O
PEDV	O
re	O
-	O
emergence	O
outbreaks	O
.	O

TITLE	O
:	O
Adaptive	O
Evolution	O
of	O
MERS	O
-	O
CoV	O
to	O
Species	O
Variation	O
in	O
DPP4	B-PRGE
.	O

These	O
findings	O
demonstrate	O
that	O
MERS	O
-	O
CoV	O
spike	O
can	O
utilize	O
multiple	O
paths	O
to	O
rapidly	O
adapt	O
to	O
novel	O
species	O
variation	O
in	O
DPP4	B-PRGE
.	O

TITLE	O
:	O
γδ	O
T	O
Cells	O
Contribute	O
to	O
the	O
Outcome	O
of	O
Murine	O
Fulminant	O
Viral	O
Hepatitis	O
via	O
Effector	O
Cytokines	B-PRGE
TNF	I-PRGE
-	I-PRGE
α	I-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
γ	I-PRGE
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
role	O
of	O
gamma	B-PRGE
delta	I-PRGE
T	I-PRGE
cell	I-PRGE
receptors	I-PRGE
(	O
γδ	O
)	O
T	O
cells	O
in	O
the	O
pathogenesis	O
of	O
fulminant	O
viral	O
hepatitis	O
(	O
FVH	O
)	O
induced	O
by	O
murine	O
hepatitis	O
virus	O
strain	O
3	O
(	O
MHV	O
-	O
3	O
).	O

Balb	O
/	O
cJ	O
mice	O
died	O
in	O
3	O
to	O
6	O
days	O
post	O
MHV	O
-	O
3	O
infection	O
,	O
with	O
severe	O
hepatic	O
necrosis	O
and	O
significant	O
augmentation	O
of	O
serum	O
ALT	B-PRGE
and	O
AST	B-PRGE
levels	O
.	O

To	O
explore	O
the	O
effect	O
of	O
PERK	B-PRGE
inhibition	O
on	O
VILI	O
,	O
we	O
ventilated	O
live	O
rats	O
and	O
compared	O
lung	O
injury	O
parameters	O
to	O
non	O
-	O
ventilated	O
controls	O
.	O

PERK	B-PRGE
inhibition	O
resulted	O
in	O
dose	O
-	O
dependent	O
improvement	O
of	O
alveolar	O
inflammation	O
and	O
permeability	O
.	O

In	O
addition	O
,	O
nonstructural	B-PRGE
protein	I-PRGE
4a	I-PRGE
(	O
NSP4a	O
),	O
NSP4b	O
,	O
and	O
NSP15	O
inhibit	O
double	B-PRGE
-	I-PRGE
stranded	I-PRGE
RNA	I-PRGE
sensors	I-PRGE
.	O

In	O
experiment	O
1	O
,	O
Groups	O
1	O
and	O
2	O
were	O
inoculated	O
with	O
H9N2	B-PRGE
AIV	I-PRGE
through	O
nasal	O
route	O
in	O
1	O
day	O
old	O
,	O
Groups	O
1	O
and	O
3	O
were	O
vaccinated	O
with	O
live	O
infectious	O
bronchitis	O
coronavirus	O
(	O
IBV	O
)	O
vaccine	O
in	O
5	O
days	O
old	O
,	O
and	O
Group	O
4	O
was	O
left	O
as	O
a	O
negative	O
control	O
.	O

The	O
humoral	O
immune	O
response	O
against	O
H9N2	B-PRGE
AIV	I-PRGE
,	O
NDV	O
,	O
and	O
IBV	O
revealed	O
a	O
significant	O
increase	O
in	O
H9N2	O
AIV	O
titer	O
in	O
Groups	O
1	O
and	O
5	O
,	O
NDV	O
titer	O
showed	O
a	O
significant	O
increase	O
in	O
Group	O
7	O
,	O
and	O
IBV	O
titer	O
increased	O
in	O
Groups	O
1	O
,	O
3	O
,	O
and	O
5	O
.	O

We	O
screened	O
and	O
obtained	O
two	O
new	O
complete	O
genomes	O
,	O
five	O
N	O
and	O
five	O
S	O
genes	O
of	O
SADS	O
-	O
CoV	O
.	O
Phylogenetic	O
analysis	O
based	O
on	O
these	O
sequences	O
revealed	O
that	O
all	O
SADS	O
-	O
CoV	O
sequences	O
in	O
this	O
study	O
clustered	O
with	O
previously	O
reported	O
SADS	O
-	O
CoV	O
strains	O
to	O
form	O
a	O
well	O
defined	O
branch	O
that	O
grouped	O
with	O
the	O
bat	B-PRGE
coronavirus	I-PRGE
HKU2	I-PRGE
strains	O
.	O

ABSTRACT	O
:	O
In	O
host	O
innate	O
immunity	O
,	O
type	B-PRGE
I	I-PRGE
interferons	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
I	I-PRGE
)	O
are	O
major	O
antiviral	O
molecules	O
,	O
and	O
coronaviruses	O
have	O
evolved	O
diverse	O
strategies	O
to	O
counter	O
the	O
IFN	B-PRGE
-	I-PRGE
I	I-PRGE
response	O
during	O
infection	O
.	O

Dipeptidyl	O
peptidase	O
-	O
4	O
(	O
DPP4	B-PRGE
)	O
inhibitors	O
,	O
widely	O
used	O
for	O
the	O
treatment	O
of	O
diabetes	O
mellitus	O
,	O
have	O
been	O
reported	O
to	O
have	O
possible	O
anti	O
-	O
inflammatory	O
effects	O
.	O

The	O
first	O
discovered	O
19	O
-	O
nt	O
cpsRNA	O
UUAACAAGCUUGUUAAAGA	O
,	O
named	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
cpsR	I-PRGE
-	I-PRGE
19	I-PRGE
,	O
was	O
detected	O
from	O
a	O
22	O
-	O
bp	O
DNA	O
complemented	O
palindrome	O
TCTTTAACAAGCTTGTTAAAGA	O
in	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
genome	O
.	O

These	O
results	O
indicate	O
that	O
the	O
ArkGA	B-PRGE
P60	I-PRGE
vaccine	O
is	O
safe	O
for	O
spray	O
vaccination	O
of	O
broiler	O
chicks	O
and	O
induces	O
suitable	O
protection	O
against	O
challenge	O
with	O
pathogenic	O
Ark	O
-	O
type	O
virus	O
.	O

ABSTRACT	O
:	O
Base	B-PRGE
on	O
the	O
sequence	O
of	O

RESULTS	O
:	O
From	O
2005	O
to	O
2017	O
,	O
47	O
patients	O
(	O
23	O
males	O
;	O
median	O
age	O
60	O
[	O
1st	O
-	O
3rd	O
quartiles	O
52	O
-	O
69	O
]	O
years	O
,	O
no	O
comorbidity	O
85	O
%)	O
were	O
admitted	O
to	O
the	O
ICU	O
for	O
ARF	B-PRGE
revealing	O
AS	O
(	O
n	O
=	O
28	O
,	O
60	O
%)	O
or	O
aMDA	O
-	O
5	O
(	O
n	O
=	O
19	O
,	O
40	O
%)	O
syndromes	O
.	O

Therefore	O
,	O
chitosan	O
efficiently	O
clarified	O
OF	O
specimens	O
without	O
affecting	O
the	O
results	O
of	O
the	O
PEDV	B-PRGE
IgG	I-PRGE
and	O
IgA	B-PRGE
antibody	I-PRGE
ELISAs	O
.	O

To	O
further	O
understand	O
the	O
evolutionary	O
relationship	O
between	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
its	O
reservoirs	O
,	O
334	O
bats	O
were	O
collected	O
from	O
Zhoushan	O
city	O
,	O
Zhejiang	O
province	O
,	O
China	O
,	O
between	O
2015	O
and	O
2017	O
.	O

Over	O
the	O
past	O
decade	O
,	O
we	O
aimed	O
to	O
decipher	O
how	O
the	O
extra	O
domains	O
/	O
co	O
-	O
factors	O
mediate	O
the	O
catalytic	O
machineries	O
of	O
SARS	O
3C	O
-	O
like	O
,	O
Dengue	O
and	O
Zika	O
NS2B	B-PRGE
-	I-PRGE
NS3	I-PRGE
proteases	I-PRGE
by	O
characterizing	O
their	O
folding	O
,	O
structures	O
,	O
dynamics	O
and	O
inhibition	O
with	O
NMR	O
,	O
X	O
-	O
ray	O
crystallography	O
and	O
MD	O
simulations	O
,	O
and	O
the	O
results	O
revealed	O
:	O
1	O
)	O
the	O
chymotrypsin	B-PRGE
fold	O
of	O
the	O
SARS	B-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
can	O
independently	O
fold	O
,	O
while	O
,	O
by	O
contrast	O
,	O
those	O
of	O
Dengue	O
and	O
Zika	O
proteases	O
lack	O
the	O
intrinsic	O
capacity	O
to	O
fold	O
without	O
co	O
-	O
factors	O
.	O

2	O
)	O
Mutations	O
on	O
the	O
extra	O
domain	O
of	O
SARS	B-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
can	O
transform	O
the	O
active	O
catalytic	O
machinery	O
into	O
the	O
inactive	O
collapsed	O
state	O
by	O
structurally	O
-	O
driven	O
allostery	O
.	O

Moreover	O
,	O
our	O
findings	O
verified	O
the	O
significantly	O
enhanced	O
PEDV	B-PRGE
-	I-PRGE
specific	I-PRGE
IgA	I-PRGE
antibody	I-PRGE
titers	O
in	O
small	O
intestinal	O
and	O
lung	O
in	O
the	O
mice	O
immunized	O
with	O
PEDV	O
vaccine	O
and	O
CVC1303	O
.	O

In	O
these	O
cells	O
,	O
transfer	O
of	O
miR	B-PRGE
-	I-PRGE
17	I-PRGE
-	I-PRGE
5p	I-PRGE
strongly	O
downregulated	O
expression	O
of	O
the	O
antiviral	B-PRGE
factor	I-PRGE
Mx1	I-PRGE
and	O
significantly	O
enhanced	O
IAV	O
replication	O
.	O

The	O
three	O
IBV	O
isolates	O
were	O
avirulent	O
when	O
they	O
infected	O
SPF	B-PRGE
chickens	I-PRGE
.	O

TITLE	O
:	O
The	O
papain	B-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
determines	O
a	O
virulence	O
trait	O
that	O
varies	O
among	O
members	O
of	O
the	O
SARS	O
-	O
coronavirus	O
species	O
.	O

The	O
presence	O
of	O
the	O
TGEV	B-PRGE
antigen	I-PRGE
was	O
confirmed	O
by	O
monoclonal	O
specific	O
immunohistochemistry	O
,	O
and	O
final	O
confirmation	O
of	O
a	O
metabolically	O
-	O
active	O
virus	O
was	O
performed	O
by	O
in	O
situ	O
hybridization	O
to	O
detect	O
a	O
TGE	B-PRGE
mRNA	I-PRGE
encoding	O
spike	O
protein	O
.	O

ABSTRACT	O
:	O
Cell	O
entry	O
by	O
coronaviruses	O
involves	O
two	O
principal	O
steps	O
,	O
receptor	O
binding	O
and	O
membrane	O
fusion	O
;	O
the	O
latter	O
requires	O
activation	O
by	O
host	B-PRGE
proteases	I-PRGE
,	I-PRGE
particularly	I-PRGE
lysosomal	I-PRGE
proteases	I-PRGE
.	O

Here	O
,	O
we	O
examined	O
the	O
roles	O
of	O
lysosomal	B-PRGE
proteases	I-PRGE
in	O
activating	O
coronavirus	O
surface	O
spike	O
proteins	O
for	O
membrane	O
fusion	O
,	O
using	O
the	O
spike	O
proteins	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
as	O
the	O
model	O
system	O
.	O

In	O
addition	O
,	O
when	O
fcwf	O
-	O
4	O
cells	O
were	O
adsorbed	O
by	O
FIPV	O
and	O
then	O
stimulated	O
with	O
Poly	O
(	O
I	O
:	O
C	O
),	O
type	O
II	O
FCoV	O
infection	O
inhibited	O
Poly	O
(	O
I	O
:	O
C	O
)-	O
induced	O
IFNβ	B-PRGE
gene	I-PRGE
expression	O
.	O

Also	O
,	O
the	O
proliferation	O
of	O
type	O
I	O
FIPV	O
was	O
enhanced	O
by	O
a	O
IFN	B-PRGE
inhibitor	O
.	O

These	O
results	O
suggested	O
that	O
Pandemic	O
G2a	B-PRGE
and	O
G2b	O
are	O
predominant	O
PEDV	O
genotype	O
circulating	O
in	O
central	O
China	O
.	O

We	O
detected	O
antibodies	O
to	O
CDV	O
,	O
CHV	O
-	O
1	O
,	O
CPV	O
-	O
2	O
,	O
CPIV	O
-	O
2	O
,	O
CCV	O
,	O
WNV	B-PRGE
,	O
and	O
ADV	O
in	O
seven	O
(	O
29	O
%),	O
three	O
(	O
12	O
%),	O
two	O
(	O
8	O
%),	O
two	O
(	O
8	O
%),	O
one	O
(	O
4	O
%),	O
one	O
(	O
4	O
%),	O
and	O
one	O
(	O
4	O
%)	O
bear	O
,	O
respectively	O
.	O

Non	O
-	O
survivors	O
showed	O
lower	O
values	O
of	O
pH	O
(	O
7	O
.	O
32	O
±	O
0	O
.	O
09	O
,	O
P	O
=	O
0	O
.	O
03	O
)	O
and	O
higher	O
troponin	B-PRGE
I	I-PRGE
levels	O
(	O
0	O
.	O
32	O
(	O
0	O
.	O
08	O
-	O
0	O
.	O
46	O
),	O
P	O
=	O
0	O
.	O
04	O
),	O
NT	B-PRGE
-	I-PRGE
pro	I-PRGE
BNP	I-PRGE
(	O
3091	O
(	O
2662	O
-	O
7128	O
),	O
P	O
=	O
0	O
.	O
009	O
),	O
and	O
SAPS	B-PRGE
II	I-PRGE
(	O
60	O
.	O
3	O
±	O
9	O
.	O
6	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

RESULTS	O
:	O
One	O
hundred	O
and	O
eighty	O
-	O
one	O
patients	O
were	O
diagnosed	O
with	O
AKI	B-PRGE
caused	O
by	O
venomous	O
creatures	O
.	O

The	O
data	O
showed	O
that	O
ssc_circ_009380	O
and	O
miR	B-PRGE
-	I-PRGE
22	I-PRGE
might	O
have	O
interaction	O
relationship	O
.	O

Moreover	O
,	O
silencing	O
of	O
ssc_circ_009380	O
inhibited	O
accumulation	O
of	O
p65	B-PRGE
in	O
nucleus	O
and	O
phosphorylation	O
of	O
IκB	O
-	O
α	O
.	O

Moreover	O
,	O
silencing	O
of	O
ssc_circ_009380	O
inhibited	O
accumulation	O
of	O
p65	B-PRGE
in	O
nucleus	O
and	O
phosphorylation	O
of	O
IκB	O
-	O
α	O
.	O

ANPEP	B-PRGE
null	O
pigs	O
did	O
not	O
support	O
infection	O
with	O
TGEV	O
,	O
but	O
retained	O
susceptibility	O
to	O
infection	O
with	O
PEDV	O
.	O

This	O
study	O
takes	O
advantage	O
of	O
the	O
progeny	O
of	O
mice	O
expressing	O
tamoxifen	O
-	O
inducible	O
Cre	B-PRGE
recombinase	I-PRGE
(	O
Cre	O
-	O
ERT2	B-PRGE
)	O
under	O
the	O

Reduced	O
ENaC	B-PRGE
and	O
CFTR	B-PRGE
led	O
to	O
changes	O
in	O
airway	O
surface	O
liquid	O
morphology	O
of	O
human	O
tracheobronchial	O
cultures	O
and	O
airways	O
of	O
IAV	O
-	O
infected	O
mice	O
.	O

We	O
investigated	O
the	O
role	O
of	O
PHD2	B-PRGE
in	O
ECs	O
during	O
endotoxin	O
-	O
induced	O
lung	O
inflammatory	O
responses	O
with	O
EC	O
-	O
specific	O
PHD2	B-PRGE
inducible	O
knockout	O
mice	O
.	O

The	O
inhibition	O
of	O
endothelial	O
PHD2	B-PRGE
activity	O
may	O
be	O
a	O
new	O
therapeutic	O
strategy	O
for	O
acute	O
inflammatory	O
diseases	O
.	O

Our	O
study	O
investigated	O
the	O
possibility	O
that	O
TfR1	B-PRGE
can	O
serve	O
as	O
a	O
receptor	O
for	O
TGEV	O
infection	O
and	O
enables	O
the	O
invasion	O
and	O
replication	O
of	O
TGEV	O
.	O

TGEV	O
infection	O
and	O
replication	O
were	O
inhibited	O
by	O
occluding	O
TfR1	O
with	O
antibodies	O
or	O
by	O
decreasing	O
TfR1	B-PRGE
expression	O
.	O

Finally	O
,	O
we	O
used	O
this	O
method	O
to	O
refine	O
carbohydrates	O
of	O
the	O
human	B-PRGE
coronavirus	I-PRGE
NL63	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
and	O
of	O
an	O
HIV	B-PRGE
envelope	I-PRGE
glycoprotein	I-PRGE
,	O
demonstrating	O
its	O
usefulness	O
for	O
cryoEM	O
refinement	O
.	O

Furthermore	O
,	O
the	O
506	O
-	O
2G10G5	O
monoclonal	O
antibody	O
significantly	O
reduced	O
plaque	O
formation	O
in	O
MERS	O
-	O
CoV	O
infected	O
Vero	O
cells	O
compared	O
to	O
normal	O
mouse	O
IgG	B-PRGE
and	O
492	O
-	O
1G10E4E2	O
.	O

Neither	O
binding	O
to	O
ACE2	B-PRGE
nor	O
cleavage	O
by	O
trypsin	B-PRGE
at	O
the	O
S1	O
/	O
S2	O
cleavage	O
site	O
impart	O
large	O
conformational	O
changes	O
within	O
stabilized	O
SARS	O
-	O
CoV	O
S	O
or	O
expose	O
the	O
secondary	O
cleavage	O
site	O
,	O
S2	O
'.	O

In	O
this	O
study	O
,	O
we	O
performed	O
qRT	O
-	O
PCR	O
and	O
viral	O
metagenomic	O
analysis	O
of	O
the	O
extraction	O
efficiency	O
of	O
four	O
commonly	O
used	O
Qiagen	O
extraction	O
kits	O
:	O
QIAamp	O
Viral	B-PRGE
RNA	I-PRGE
Mini	I-PRGE
Kit	I-PRGE
(	O
VRMK	O
),	O
QIAamp	O
MinElute	B-PRGE
Virus	I-PRGE
Spin	I-PRGE
Kit	I-PRGE
(	O
MVSK	O
),	O
RNeasy	O
Mini	O
Kit	O
(	O
RMK	O
),	O
and	O
RNeasy	B-PRGE
Plus	I-PRGE
Micro	I-PRGE
Kit	I-PRGE
(	O
RPMK	O
),	O
using	O
a	O
mixed	O
respiratory	O
clinical	O
sample	O
without	O
any	O
pre	O
-	O
treatment	O
.	O

This	O
sample	O
contained	O
an	O
adenovirus	O
(	O
ADV	O
),	O
influenza	O
virus	O
A	O
(	O
Flu	B-PRGE
A	I-PRGE
),	O
human	O
parainfluenza	O
virus	O
3	O
(	O
PIV3	O
),	O
human	B-PRGE
coronavirus	I-PRGE
OC43	I-PRGE
(	O
OC43	O
),	O
and	O
human	O
metapneumovirus	O
(	O
HMPV	O
).	O

TITLE	O
:	O
YiQiFuMai	O
lyophilized	O
injection	O
attenuates	O
particulate	O
matter	O
-	O
induced	O
acute	O
lung	O
injury	O
in	O
mice	O
via	O
TLR4	B-PRGE
-	O
mTOR	B-PRGE
-	O
autophagy	O
pathway	O
.	O

Furthermore	O
,	O
we	O
also	O
found	O
that	O
YQFM	O
significantly	O
inhibited	O
the	O
PM	O
-	O
induced	O
myeloperoxidase	B-PRGE
(	O
MPO	B-PRGE
)	O
activity	O
in	O
lung	O
tissues	O
,	O
decreased	O
the	O
PM	O
-	O
induced	O
inflammatory	O
cytokines	O
including	O
interleukin	B-PRGE
-	I-PRGE
1β	I-PRGE
(	O
IL	O
-	O
1β	O
)	O
and	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
α	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
α	I-PRGE
),	O
reduced	O
nitric	O
oxide	O
(	O
NO	O
)	O
and	O
total	O
protein	O
in	O
bronchoalveolar	O
lavage	O
fluids	O
(	O
BALF	O
),	O
and	O
effectively	O
attenuated	O
PM	O
-	O
induced	O
increases	O
lymphocytes	O
in	O
BALF	O
.	O

In	O
conclusion	O
,	O
these	O
findings	O
indicate	O
that	O
YQFM	O
had	O
a	O
critical	O
anti	O
-	O
inflammatory	O
effect	O
due	O
to	O
its	O
ability	O
to	O
regulate	O
both	O
TLR4	B-PRGE
-	O
MyD88	B-PRGE
and	O
mTOR	B-PRGE
-	O
autophagy	O
pathways	O
,	O
and	O
might	O
be	O
a	O
possible	O
therapeutic	O
agent	O
for	O
PM	O
-	O
induced	O
ALI	O
.	O

We	O
subsequently	O
identified	O
NF	O
-	O
κB	O
-	O
inhibitor	O
α	O
and	O
suppressor	O
of	O
cytokine	O
signaling	O
1	O
,	O
negative	O
regulators	O
of	O
the	O
NF	O
-	O
κB	O
pathway	O
,	O
as	O
miR	B-PRGE
-	I-PRGE
221	I-PRGE
-	I-PRGE
5p	I-PRGE
targets	I-PRGE
.	O

Our	O
focus	O
is	O
on	O
platelet	B-PRGE
-	I-PRGE
endothelial	I-PRGE
cell	I-PRGE
adhesion	I-PRGE
molecule	I-PRGE
-	I-PRGE
1	I-PRGE
,	O
which	O
contributes	O
to	O
the	O
maintenance	O
and	O
restoration	O
of	O
vascular	O
integrity	O
following	O
barrier	O
disruption	O
.	O

Doctors	O
and	O
nurses	O
embraced	O
CPAP	B-PRGE
use	I-PRGE
but	O
identified	O
barriers	O
to	O
implementation	O
which	O
will	O
need	O
to	O
be	O
addressed	O
in	O
order	O
not	O
to	O
impact	O
on	O
safety	O
and	O
quality	O
of	O
care	O
.	O

Ensuring	O
a	O
supportive	O
and	O
enabling	O
environment	O
is	O
in	O
place	O
will	O
be	O
crucial	O
if	O
CPAP	B-PRGE
is	O
to	O
be	O
scaled	O
-	O
up	O
more	O
widely	O
.	O

Immunization	O
with	O
the	O
TGEV	B-PRGE
antigen	I-PRGE
conjugated	O
to	O
GNPs	O
as	O
a	O
carrier	O
activates	O
the	O
respiratory	O
activity	O
of	O
lymphoid	O
cells	O
and	O
peritoneal	O
macrophages	O
,	O
which	O
is	O
directly	O
related	O
to	O
their	O
transforming	O
activity	O
and	O
to	O
the	O
activation	O
of	O
antibody	O
generation	O
.	O

In	O
infected	O
cells	O
,	O
PEDV	O
-	O
induced	O
apoptosis	O
is	O
accompanied	O
by	O
nuclear	O
concentration	O
and	O
fragmentation	O
as	O
a	O
result	O
of	O
caspase	B-PRGE
-	I-PRGE
3	I-PRGE
and	O
caspase	B-PRGE
-	I-PRGE
8	I-PRGE
activation	O
and	O
AIFM1	B-PRGE
and	O
PARP	B-PRGE
cleavage	O
.	O

The	O
levels	O
of	O
IL	B-PRGE
-	I-PRGE
33	I-PRGE
and	O
MMP2	B-PRGE
/	I-PRGE
9	I-PRGE
in	O
BALF	O
increased	O
in	O
all	O
the	O
ALI	O
rats	O
with	O
severe	O
lung	O
injury	O
.	O

LPS	O
-	O
induced	O
IL	B-PRGE
-	I-PRGE
33	I-PRGE
autocrine	O
upregulated	O
the	O
expression	O
of	O
MMP2	B-PRGE
and	O
MMP9	B-PRGE
through	O
activating	O
STAT3	B-PRGE
.	O

Moreover	O
,	O
a	O
potential	O
cathepsin	B-PRGE
L	I-PRGE
cleavage	O
site	O
in	O
MERS	O
-	O
S	O
has	O
been	O
reported	O
.	O

Moreover	O
,	O
a	O
phylogenetic	O
analysis	O
of	O
the	O
18	B-PRGE
complete	I-PRGE
VP1	I-PRGE
sequences	I-PRGE
from	O
this	O
study	O
revealed	O
that	O
14	O
strains	O
belonged	O
to	O
lineage	O
1	O
and	O
4	O
strains	O
belonged	O
to	O
lineage	O
3	O
.	O

The	O
analysis	O
of	O
a	O
fragment	O
of	O
the	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
(	O
RdRp	O
)	O
showed	O
the	O
correlation	O
of	O
the	O
Italian	O
strains	O
with	O
CoVs	O
that	O
was	O
only	O
detected	O
in	O
the	O
bat	O
Pipistrellus	O
genera	O
(	O
Pipistrellus	O
kuhlii	O
and	O
Pipistrellus	O
Pipistrellus	O
)	O
in	O
European	O
countries	O
.	O

UMIN	B-PRGE
-	I-PRGE
CTR	I-PRGE
,	O
UMIN000019742	O
.	O

TITLE	O
:	O
Insights	O
into	O
Ebola	O
Virus	O
VP35	O
and	O
VP24	B-PRGE
Interferon	I-PRGE
Inhibitory	O
Functions	O
and	O
their	O
Initial	O
Exploitation	O
as	O
Drug	O
Targets	O
.	O

Hence	O
,	O
to	O
sustain	O
their	O
infection	O
,	O
viruses	O
evolved	O
efficient	O
counteracting	O
strategies	O
to	O
evade	O
IFN	B-PRGE
control	O
.	O

Several	O
of	O
the	O
investigated	O
compounds	O
inhibited	O
various	O
PKs	B-PRGE
with	O
IC	O

However	O
,	O
whether	O
there	O
be	O
an	O
interaction	O
between	O
p53	B-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
β	I-PRGE
signaling	O
in	O
the	O
process	O
of	O
TGEV	O
infection	O
is	O
unknown	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrated	O
that	O
p53	B-PRGE
may	O
mediate	O
IFN	B-PRGE
-	I-PRGE
β	I-PRGE
signaling	O
to	O
inhibit	O
viral	O
replication	O
early	O
after	O
TGEV	O
infection	O
.	O

TITLE	O
:	O
Effects	O
of	O
beta	B-PRGE
-	I-PRGE
1	I-PRGE
,	I-PRGE
3	I-PRGE
-	I-PRGE
glucan	I-PRGE
(	O
AletaTM	O
)	O
on	O
vaccination	O
response	O
in	O
broiler	O
chickens	O
.	O

ABSTRACT	O
:	O
This	O
study	O
investigated	O
the	O
co	O
-	O
localization	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
and	O
its	O
receptor	O
dipeptidyl	O
peptidase	B-PRGE
-	I-PRGE
4	I-PRGE
(	O
DPP4	B-PRGE
)	O
by	O
immunohistochemistry	O
(	O
IHC	O
)	O
across	O
respiratory	O
and	O
lymphoid	O
organs	O
of	O
experimentally	O
MERS	O
-	O
CoV	O
infected	O
pigs	O
and	O
llamas	O
.	O

Tripartite	O
motif	O
8	O
(	O
TRIM8	B-PRGE
)	O
contains	O
an	O
N	O
-	O
terminal	O
RING	O
finger	O
,	O
which	O
is	O
followed	O
by	O
two	O
B	O
-	O
boxes	O
and	O
a	O
coiled	O
-	O
coil	O
domain	O
,	O
belonging	O
to	O
the	O
TRIM	B-PRGE
/	O
RBCC	B-PRGE
family	O
and	O
playing	O
significant	O
role	O
in	O
meditating	O
inflammation	O
,	O
oxidative	O
stress	O
and	O
apoptosis	O
.	O

In	O
addition	O
,	O
LPS	O
-	O
induced	O
oxidative	O
stress	O
was	O
accelerated	O
by	O
TRIM8	B-PRGE
over	O
-	O
expression	O
,	O
while	O
being	O
alleviated	O
by	O
TRIM8	B-PRGE
knockdown	O
by	O
regulating	O
Nrf2	B-PRGE
signaling	O
.	O

ABSTRACT	O
:	O
Previous	O
findings	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)-	O
related	O
viruses	O
in	O
bats	O
,	O
and	O
the	O
ability	O
of	O
Tylonycteris	O
-	O
BatCoV	O
HKU4	O
spike	O
protein	O
to	O
utilize	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
receptor	I-PRGE
,	O
human	B-PRGE
dipeptidyl	I-PRGE
peptidase	I-PRGE
4	O
hDPP4	O
,	O
suggest	O
a	O
bat	O
ancestral	O
origin	O
of	O
MERS	O
-	O
CoV	O
.	O
We	O
developed	O
12	O
primary	O
bat	O
cell	O
lines	O
from	O
seven	O
bat	O
species	O
,	O
including	O
Tylonycteris	O
pachypus	O
,	O
Pipistrellus	O
abramus	O
and	O
Rhinolophus	O
sinicus	O
(	O
hosts	O
of	O
Tylonycteris	O
-	O
BatCoV	O
HKU4	O
,	O
Pipistrellus	O
-	O
BatCoV	O
HKU5	O
,	O
and	O
SARS	O
-	O
related	O
-	O
CoV	O
respectively	O
),	O
and	O
tested	O
their	O
susceptibilities	O
to	O
MERS	O
-	O
CoVs	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
and	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
).	O

Screened	O
CTL	O
and	O
HTL	O
epitopes	O
were	O
found	O
to	O
have	O
high	O
propensity	O
for	O
stable	O
molecular	O
interaction	O
with	O
HLA	B-PRGE
alleles	I-PRGE
molecules	I-PRGE
.	O

TITLE	O
:	O
The	O
Human	B-PRGE
Sodium	I-PRGE
Iodide	I-PRGE
Symporter	I-PRGE
as	O
a	O
Reporter	O
Gene	O
for	O
Studying	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Pathogenesis	O
.	O

Viral	O
entry	O
is	O
affected	O
by	O
the	O
disruption	O
of	O
actin	B-PRGE
kinetics	O
or	O
alteration	O
of	O
cofilin	B-PRGE
activity	O
.	O

In	O
contrast	O
,	O
relatively	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
T	O
cell	O
responses	O
and	O
the	O
antigenic	O
targets	O
of	O
MERS	O
-	O
CoV	O
that	O
are	O
recognized	O
by	O
CD8	B-PRGE
+	I-PRGE
T	O
cells	O
.	O

TITLE	O
:	O
Evaluation	O
of	O
a	O
non	O
-	O
prime	O
site	O
substituent	O
and	O
warheads	O
combined	O
with	O
a	O
decahydroisoquinolin	O
scaffold	O
as	O
a	O
SARS	B-PRGE
3CL	I-PRGE
protease	I-PRGE
inhibitor	O
.	O

TITLE	O
:	O
Hemolytic	O
uremic	O
syndrome	O
associated	O
with	O
Bordetella	O
pertussis	O
infection	O
in	O
a	O
2	O
-	O
month	O
-	O
old	O
infant	O
carrying	O
a	O
pathogenic	O
variant	O
in	O
complement	B-PRGE
factor	I-PRGE
H	I-PRGE
.	O
ABSTRACT	O
:	O
Hemolytic	O
uremic	O
syndrome	O
(	O
HUS	O
)	O
has	O
been	O
associated	O
with	O
a	O
number	O
of	O
infectious	O
agents	O
.	O

A	O
nasopharyngeal	O
swab	O
was	O
taken	O
for	O
multiplex	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
detection	O
of	O
influenza	O
virus	O
,	O
rhinovirus	O
,	O
parainfluenza	O
virus	O
(	O
HPIV	O
),	O
human	B-PRGE
coronavirus	O
(	O
HcoV	O
),	O
adenoviurs	O
,	O
human	O
bocavirus	O
(	O
HboV	O
),	O
human	O
metapneumovirus	O
(	O
hMPV	O
),	O
and	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
).	O

Although	O
microorganisms	O
responsible	O
of	O
VAP	O
on	O
ECMO	O
are	O
similar	O
to	O
those	O
found	O
in	O
non	O
-	O
ECMO	O
patients	O
,	O
classical	O
suspicion	O
criteria	O
of	O
VAP	B-PRGE
are	O
no	O
longer	O
relevant	O
on	O
ECMO	O
.	O

To	O
identify	O
the	O
cellular	O
proteins	O
that	O
interact	O
with	O
the	O
TGEV	B-PRGE
M	I-PRGE
protein	I-PRGE
,	O
yeast	O
two	O
-	O
hybrid	O
screening	O
was	O
employed	O
,	O
and	O
seven	O
cellular	O
proteins	O
were	O
identified	O
M	O
-	O
binding	O
partners	O
.	O

Additionally	O
,	O
confocal	O
microscopy	O
revealed	O
that	O
EIF4A2	B-PRGE
and	O
M	O
were	O
colocalized	O
in	O
the	O
cytoplasm	O
.	O

ABSTRACT	O
:	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
plays	O
a	O
critical	O
role	O
in	O
the	O
development	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

MK2	B-PRGE
regulates	O
the	O
expression	O
of	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
in	O
human	O
pulmonary	O
microvascular	O
endothelial	O
cells	O
.	O

To	O
explore	O
whether	O
the	O
inhibition	O
of	O
MK2	B-PRGE
activation	O
has	O
the	O
same	O
effect	O
in	O
experimental	O
animals	O
,	O
MMI	O
-	O
0100	O
,	O
a	O
peptide	O
-	O
mediated	O
inhibitor	O
of	O
MK2	B-PRGE
,	O
was	O
used	O
to	O
verify	O
whether	O
MMI	O
-	O
0100	O
can	O
ameliorate	O
lung	O
inflammation	O
in	O
a	O
mouse	O
model	O
of	O
ARDS	O
by	O
reducing	O
endothelial	O
expression	O
of	O
ICAM	B-PRGE
-	I-PRGE
1	I-PRGE
.	O

Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
can	O
provide	O
effective	O
respiratory	O
support	O
and	O
win	B-PRGE
time	O
for	O
the	O
treatment	O
of	O
severe	O
H7N9	O
.	O

Specific	O
primers	O
were	O
designed	O
based	O
on	O
the	O
conserved	O
region	O
within	O
the	O
M	B-PRGE
gene	I-PRGE
of	O
the	O
viral	O
genome	O
.	O

Functional	O
inactivation	O
of	O
Rab5	B-PRGE
and	O
Rab7	B-PRGE
significantly	O
inhibited	O
IBV	O
infection	O
.	O

We	O
were	O
aware	O
that	O
methylene	O
blue	O
is	O
a	O
contraindication	O
in	O
patients	O
with	O
G6PD	B-PRGE
deficiency	O
but	O
considering	O
patient	O
being	O
Caucasian	O
and	O
low	O
risk	O
for	O
it	O
and	O
his	O
deteriorating	O
respiratory	O
condition	O
,	O
it	O
was	O
decided	O
to	O
offer	O
the	O
treatment	O
and	O
patient	O
received	O
1	O
dose	O
of	O
methylene	O
blue	O
which	O
failed	O
to	O
improve	O
his	O
methemoglobinemia	O
.	O

In	O
this	O
review	O
,	O
we	O
propose	O
that	O
the	O
tumour	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
α	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
ADAM	I-PRGE
-	I-PRGE
17	I-PRGE
could	O
be	O
the	O
master	O
molecule	O
involved	O
in	O
regulating	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
class	O
switching	O
and	O
through	O
this	O
in	O
controlling	O
pro	O
-	O
and	O
anti	O
-	O
inflammatory	O
responses	O
to	O
viral	O
antigenic	O
stimuli	O
.	O

While	O
type	B-PRGE
I	I-PRGE
interferons	I-PRGE
are	O
essential	O
to	O
limit	O
virus	O
spread	O
associated	O
with	O
early	O
mortality	O
,	O
perforin	B-PRGE
,	O
and	O
interferon	B-PRGE
-	I-PRGE
γ	I-PRGE
promote	O
further	O
virus	O
clearance	O
in	O
astrocytes	O
/	O
microglia	O
and	O
oligodendrocytes	O
,	O
respectively	O
.	O

We	O
previously	O
identified	O
a	O
fusion	O
inhibitory	O
peptide	O
(	O
HR2P	O
-	O
M2	O
)	O
targeting	O
the	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S2	I-PRGE
protein	I-PRGE
HR1	I-PRGE
domain	I-PRGE
and	O
a	O
highly	O
potent	O
neutralizing	O
monoclonal	O
antibody	O
(	O
m336	O
)	O
specific	O
to	O
the	O
S1	B-PRGE
spike	I-PRGE
protein	I-PRGE
receptor	I-PRGE
-	I-PRGE
binding	I-PRGE
domain	I-PRGE
(	O
RBD	O
).	O

However	O
,	O
we	O
herein	O
report	O
that	O
the	O
combination	O
of	O
m336	O
and	O
HR2P	O
-	O
M2	O
exhibited	O
potent	O
synergism	O
in	O
inhibiting	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
protein	I-PRGE
-	O
mediated	O
cell	O
⁻	O
cell	O
fusion	O
and	O
infection	O
by	O
MERS	O
-	O
CoV	O
pseudoviruses	O
with	O
or	O
without	O
mutations	O
in	O
the	O
RBD	O
,	O
resulting	O
in	O
the	O
enhancement	O
of	O
antiviral	O
activity	O
in	O
contrast	O
to	O
either	O
one	O
administered	O
alone	O
.	O

Here	O
,	O
the	O
role	O
of	O
Poldip2	B-PRGE
in	O
regulating	O
vascular	O
permeability	O
and	O
inflammation	O
in	O
a	O
mouse	O
model	O
of	O
ARDS	O
was	O
assessed	O
.	O

TITLE	O
:	O
Depletion	O
of	O
RIPK1	B-PRGE
in	O
hepatocytes	O
exacerbates	O
liver	O
damage	O
in	O
fulminant	O
viral	O
hepatitis	O
.	O

ABSTRACT	O
:	O
The	O
protein	B-PRGE
kinase	I-PRGE
RIPK1	I-PRGE
plays	O
a	O
crucial	O
role	O
at	O
the	O
crossroad	O
of	O
stress	O
-	O
induced	O
signaling	O
pathways	O
that	O
affects	O
cell	O
'	O
s	O
decision	O
to	O
live	O
or	O
die	O
.	O

Compared	O
with	O
the	O
P120	O
group	O
,	O
pigs	O
in	O
the	O
P100C4	O
group	O
had	O
a	O
more	O
rapid	O
decline	O
in	O
fecal	O
PEDV	O
RNA	O
shedding	O
titers	O
,	O
higher	O
titers	O
of	O
serum	B-PRGE
PEDV	I-PRGE
-	I-PRGE
specific	I-PRGE
IgG	I-PRGE
,	O
IgA	B-PRGE
,	O
and	O
VN	B-PRGE
Abs	I-PRGE
,	O
and	O
higher	O
numbers	O
of	O
intestinal	O
IgA	B-PRGE
Ab	I-PRGE
-	O
secreting	O
cells	O
.	O

Here	O
,	O
the	O
structure	O
of	O
ISG15	B-PRGE
from	O
the	O
bat	O
species	O
Myotis	O
davidii	O
solved	O
to	O
1	O
.	O
37	O
Å	O
resolution	O
is	O
reported	O
.	O

In	O
this	O
review	O
,	O
we	O
describe	O
the	O
relevant	O
features	O
of	O
the	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
-	I-PRGE
protein	I-PRGE
RBD	I-PRGE
,	O
summarize	O
recent	O
advances	O
in	O
the	O
development	O
of	O
MERS	O
-	O
CoV	O
RBD	O
-	O
based	O
vaccines	O
and	O
therapeutic	O
antibodies	O
,	O
and	O
illustrate	O
potential	O
challenges	O
and	O
strategies	O
to	O
further	O
improve	O
their	O
efficacy	O
.	O

ABSTRACT	O
:	O
Angiopoietin	B-PRGE
-	I-PRGE
2	I-PRGE
(	O
AGPT2	B-PRGE
)	O
has	O
been	O
proposed	O
as	O
a	O
key	O
mediator	O
of	O
organ	O
dysfunction	O
,	O
mainly	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

The	O
continuous	O
net	O
reclassification	O
improvement	O
(	O
NRI	O
)	O
in	O
the	O
ARDS	O
group	O
resulting	O
from	O
AGPT2	B-PRGE
inclusion	O
was	O
64	O
.	O
1	O
%	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
the	O
integrated	O
discrimination	O
improvement	O
(	O
IDI	O
)	O
index	O
was	O
0	O
.	O
057	O
(	O
P	O
=	O
0	O
.	O
003	O
).	O

ABSTRACT	O
:	O
Vascular	B-PRGE
endothelial	I-PRGE
cadherin	I-PRGE
(	O
VE	B-PRGE
-	I-PRGE
cadherin	I-PRGE
)	O
is	O
a	O
membrane	O
protein	O
that	O
is	O
the	O
major	O
component	O
of	O
adherens	O
junctions	O
between	O
endothelial	O
cells	O
.	O

Primary	O
analysis	O
focused	O
on	O
the	O
association	O
between	O
sVE	B-PRGE
-	I-PRGE
cadherin	I-PRGE
levels	O
and	O
the	O
development	O
of	O
AKI	B-PRGE
,	O
AKI	B-PRGE
-	O
RRT	O
,	O
other	O
organ	O
dysfunction	O
as	O
defined	O
by	O
Brussels	O
organ	O
failure	O
scores	O
,	O
pulmonary	O
versus	O
non	O
-	O
pulmonary	O
sepsis	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
and	O
in	O
-	O
hospital	O
mortality	O
.	O

Plasma	B-PRGE
sVE	I-PRGE
-	I-PRGE
cadherin	I-PRGE
levels	O
at	O
enrollment	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
AKI	O
-	O
RRT	O
compared	O
with	O
patients	O
without	O
AKI	O
-	O
RRT	O
(	O
p	O
=	O
0	O
.	O
003	O
).	O

Further	O
studies	O
of	O
sVE	B-PRGE
-	I-PRGE
cadherin	I-PRGE
as	O
a	O
biomarker	O
of	O
disease	O
severity	O
in	O
clinical	O
sepsis	O
are	O
needed	O
to	O
better	O
elucidate	O
the	O
role	O
of	O
VE	B-PRGE
-	I-PRGE
cadherin	I-PRGE
shedding	O
in	O
sepsis	O
-	O
induced	O
severe	O
organ	O
dysfunction	O
.	O

Both	O
rS1	B-PRGE
-	O
and	O
rS	O
-	O
ELISAs	O
maintained	O
high	O
sensitivity	O
and	O
specificity	O
(≥	O
90	O
%)	O
across	O
a	O
wider	O
range	O
of	O
OD	O
values	O
compared	O
to	O
rN	O
-	O
ELISA	O
.	O

Expression	O
of	O
genes	O
encoding	O
transcription	B-PRGE
factors	I-PRGE
STAT1	I-PRGE
and	I-PRGE
2	I-PRGE
,	O
regulating	O
signalling	O
pathways	O
,	O
particularly	O
of	O
the	O
interferons	O
,	O
was	O
also	O
higher	O
.	O

Accordingly	O
,	O
the	O
full	O
genome	O
sequence	O
was	O
retrieved	O
from	O
the	O
UK	O
rat	O
coronavirus	O
,	O
along	O
with	O
partial	O
genome	O
sequences	O
from	O
the	O
UK	O
field	O
vole	O
and	O
Poland	O
-	O
resident	O
bank	O
vole	O
CoVs	O
,	O
and	O
a	O
short	O
conserved	O
ORF1b	O
fragment	O
from	O
the	O
French	O
rabbit	O
CoV	O
.	O
Genome	O
and	O
phylogenetic	O
analysis	O
showed	O
that	O
despite	O
their	O
diverse	O
geographic	O
origins	O
,	O
all	O
rodent	O
alpha	O
-	O
CoVs	O
formed	O
a	O
single	O
monophyletic	O
group	O
and	O
shared	O
similar	O
features	O
,	O
such	O
as	O
the	O
same	O
gene	O
constellations	O
,	O
a	O
recombinant	B-PRGE
beta	I-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
gene	I-PRGE
,	O
and	O
similar	O
core	O
transcriptional	O
regulatory	O
sequences	O
(	O
TRS	O
).	O

TITLE	O
:	O
Characterization	O
of	O
intestinal	B-PRGE
Escherichia	I-PRGE
coli	I-PRGE
isolated	O
from	O
calves	O
with	O
diarrhea	O
due	O
to	O
rotavirus	O
and	O
coronavirus	O
.	O

<	O
strong	O
>	O
CONCLUSIONS	O
</	O
strong	O
>	O
Decreased	O
HIPK1	B-PRGE
in	O
ALI	O
showed	O
protective	O
effects	O
in	O
attenuating	O
inflammation	O
and	O
oxidative	O
stress	O
and	O
enhancing	O
autophagy	O
,	O
indicating	O
HIPK1	B-PRGE
as	O
a	O
possible	O
target	O
in	O
ALI	O
management	O
.	O

A	O
wild	O
type	O
and	O
two	O
modified	O
versions	O
of	O
the	O
IBV	B-PRGE
S	I-PRGE
protein	I-PRGE
were	O
expressed	O
individually	O
by	O
rNDV	O
.	O

TITLE	O
:	O
MicroRNA	O
‑	O
223	O
attenuates	O
LPS	O
‑	O
induced	O
inflammation	O
in	O
an	O
acute	O
lung	O
injury	O
model	O
via	O
the	O
NLRP3	B-PRGE
inflammasome	I-PRGE
and	O
TLR4	B-PRGE
/	O
NF	O
‑	O
κB	O
signaling	O
pathway	O
via	O
RHOB	O
.	O

TITLE	O
:	O
Immunoprofiling	O
of	O
peripheral	O
blood	O
from	O
infectious	O
bronchitis	O
virus	O
vaccinated	O
MHC	B-PRGE
-	I-PRGE
B	I-PRGE
chicken	I-PRGE
lines	I-PRGE
-	I-PRGE
Monocyte	I-PRGE
MHC	I-PRGE
-	I-PRGE
II	I-PRGE
expression	O
as	O
a	O
potential	O
correlate	O
of	O
protection	O
.	O

Non	O
-	O
vaccinated	O
and	O
vaccinated	O
MHC	B-PRGE
haplotypes	O
presented	O
differential	O
leucocyte	O
composition	O
and	O
IBV	O
viral	O
load	O
.	O

In	O
addition	O
,	O
a	O
strong	O
effect	O
of	O
MHC	B-PRGE
-	I-PRGE
B	I-PRGE
and	O
vaccination	O
on	O
monocyte	O
MHC	B-PRGE
-	I-PRGE
II	I-PRGE
expression	O
showed	O
that	O
animals	O
with	O
highest	O
monocyte	O
MHC	B-PRGE
-	I-PRGE
II	I-PRGE
expression	O
had	O
weakest	O
vaccine	O
-	O
induced	O
protection	O
.	O

ABSTRACT	O
:	O
A	O
maximum	O
clade	O
credibility	O
tree	O
constructed	O
using	O
the	O
full	O
-	O
length	O
spike	O
(	O
S	O
)	O
and	O
hemagglutinin	B-PRGE
-	I-PRGE
esterase	I-PRGE
genes	I-PRGE
revealed	O
that	O
Vietnamese	O
Bovine	O
coronavirus	O
(	O
BCoV	O
)	O
strains	O
belong	O
to	O
a	O
single	O
cluster	O
(	O
C1	O
);	O
therefore	O
,	O
they	O
might	O
share	O
a	O
common	O
origin	O
with	O
Cuban	O
and	O
Chinese	O
BCoV	O
strains	O
.	O

The	O
lowest	O
detection	O
limit	O
of	O
the	O
PDCoV	B-PRGE
RT	I-PRGE
-	I-PRGE
RPA	I-PRGE
assay	O
was	O
100	O
copies	O
of	O
RNA	O
molecules	O
per	O
reaction	O
;	O
moreover	O
,	O
the	O
RT	B-PRGE
-	I-PRGE
RPA	I-PRGE
assay	O
had	O
no	O
cross	O
-	O
reaction	O
with	O
other	O
common	O
swine	O
viruses	O
.	O

TITLE	O
:	O
Dampened	O
NLRP3	B-PRGE
-	O
mediated	O
inflammation	O
in	O
bats	O
and	O
implications	O
for	O
a	O
special	O
viral	O
reservoir	O
host	O
.	O

Here	O
,	O
we	O
report	O
significantly	O
dampened	O
activation	O
of	O
the	O
NLRP3	B-PRGE
inflammasome	I-PRGE
in	O
bat	O
primary	O
immune	O
cells	O
compared	O
to	O
human	O
or	O
mouse	O
counterparts	O
.	O

Lower	O
induction	O
of	O
apoptosis	O
-	O
associated	O
speck	O
-	O
like	O
protein	O
containing	O
a	O
CARD	O
(	O
ASC	O
)	O
speck	O
formation	O
and	O
secretion	O
of	O
interleukin	B-PRGE
-	I-PRGE
1β	I-PRGE
in	O
response	O
to	O
both	O
'	O
sterile	O
'	O
stimuli	O
and	O
infection	O
with	O
multiple	O
zoonotic	O
viruses	O
including	O
influenza	O
A	O
virus	O
(-	O
single	O
-	O
stranded	O
(	O
ss	O
)	O
RNA	O
),	O
Melaka	O
virus	O
(	O
PRV3M	O
,	O
double	O
-	O
stranded	O
RNA	O
)	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(+	O
ssRNA	O
)	O
was	O
observed	O
.	O

Among	O
many	O
systems	O
producing	O
ROS	O
,	O
nicotinamide	O
-	O
adenine	O
dinucleotide	O
phosphate	O
(	O
NADPH	O
)	O
oxidase	B-PRGE
-	O
mediated	O
ROS	O
is	O
the	O
main	O
source	O
,	O
and	O
its	O
functional	O
subunit	O
is	O
the	O
transmembrane	O
subunit	O
NOX	O
family	O
.	O

ABSTRACT	O
:	O
Bats	O
are	O
known	O
to	O
harbor	O
and	O
transmit	O
many	O
emerging	O
and	O
re	O
-	O
emerging	O
viruses	O
,	O
many	O
of	O
which	O
are	O
extremely	O
pathogenic	O
in	O
humans	O
but	O
do	O
not	O
cause	O
overt	O
pathology	O
in	O
their	O
bat	O
reservoir	O
hosts	O
:	O
henipaviruses	O
(	O
Nipah	O
and	O
Hendra	O
),	O
filoviruses	O
(	O
Ebola	O
and	O
Marburg	O
),	O
and	O
coronaviruses	O
(	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
MERS	O
-	O
CoV	O
).	O

In	O
conclusion	O
,	O
the	O
combination	O
of	O
live	O
attenuated	O
vaccine	O
containing	O
the	O
Massachusetts	O
strain	O
with	O
a	O
booster	O
dose	O
of	O
an	O
inactivated	O
vaccine	O
,	O
containing	O
a	O
BR	O
-	O
I	O
IBV	O
strain	O
,	O
confers	O
effective	O
protection	O
against	O
infection	O
with	O
nephropathogenic	O
homologous	O
IBV	O
strain	O
because	O
of	O
the	O
induction	O
of	O
consistent	O
memory	O
immune	O
responses	O
mediated	O
by	O
IgG	B-PRGE
antibodies	I-PRGE
and	O
TCD8	O
cells	O
in	O
the	O
mucosal	O
and	O
systemic	O
compartments	O
of	O
chickens	O
submitted	O
to	O
this	O
vaccination	O
regime	O
.	O

In	O
the	O
moderate	O
and	O
severe	O
groups	O
,	O
PAP	B-PRGE
was	O
significantly	O
higher	O
in	O
neonates	O
with	O
pulmonary	O
ALI	O
/	O
ADDS	O
(	O
ALI	O
/	O
ARDSp	O
)	O
than	O
in	O
neonates	O
with	O
extrapulmonary	O
ALI	O
/	O
ARDS	O
(	O
ALI	O
/	O
ARDSexp	O
)	O
(	O
62	O
.	O
5	O
±	O
5	O
.	O
4	O
vs	O
68	O
.	O
0	O
±	O
6	O
.	O
5	O
,	O
54	O
.	O
7	O
±	O
5	O
.	O
9	O
vs	O
64	O
.	O
2	O
±	O
4	O
.	O
9	O
;	O
t	O
=	O
3	O
.	O
264	O
,	O
3	O
.	O
123	O
;	O
P	O
=	O
.	O
004	O
,.	O
039	O
).	O

PAP	B-PRGE
was	O
positively	O
correlated	O
with	O
the	O
OSI	O
index	O
(	O
r	O
=	O
0	O
.	O
823	O
).	O

Another	O
benefit	O
comes	O
from	O
its	O
versatility	O
as	O
it	O
can	O
be	O
applied	O
to	O
envelope	O
proteins	O
belonging	O
to	O
all	O
three	O
classes	O
of	O
viral	B-PRGE
fusion	I-PRGE
proteins	I-PRGE
,	O
such	O
as	O
the	O
class	O
I	O
influenza	O
hemagglutinin	O
(	O
HA	O
)	O
and	O
Ebola	O
virus	O
glycoprotein	B-PRGE
(	O
GP	O
),	O
the	O
class	B-PRGE
II	I-PRGE
Semliki	I-PRGE
forest	I-PRGE
virus	I-PRGE
E1	I-PRGE
protein	I-PRGE
,	O
or	O
the	O
class	O
III	O
vesicular	O
stomatitis	B-PRGE
virus	I-PRGE
G	I-PRGE
glycoprotein	I-PRGE
.	O

Interestingly	O
,	O
we	O
also	O
demonstrated	O
that	O
while	O
the	O
V672F	O
mutation	O
is	O
critical	O
for	O
the	O
syncytium	O
formation	O
in	O
VeroE6	B-PRGE
-	I-PRGE
APN	I-PRGE
cells	O
,	O
it	O
exerts	O
a	O
minimal	O
effect	O
in	O
Huh	O
-	O
7	O
cells	O
,	O
thereby	O
suggesting	O
the	O
difference	O
in	O
receptor	O
preference	O
of	O
PEDV	O
among	O
host	O
cells	O
.	O

Phylogenetic	O
analysis	O
of	O
the	O
S	B-PRGE
gene	I-PRGE
showed	O
that	O
the	O
CH	O
/	O
JLDH	O
/	O
2016	O
strain	O
was	O
clustered	O
into	O
G2b	O
subgroup	O
.	O

Our	O
results	O
demonstrated	O
that	O
simultaneous	O
expression	O
of	O
these	O
specific	O
shRNA	O
molecules	O
inhibited	O
expression	O
of	O
PEDV	B-PRGE
M	I-PRGE
gene	I-PRGE
,	O
SADS	B-PRGE
-	I-PRGE
CoV	I-PRGE
M	I-PRGE
gene	I-PRGE
,	O
and	O
PDCoV	B-PRGE
N	I-PRGE
gene	I-PRGE
RNA	I-PRGE
by	O
99	O
.	O
7	O
%,	O
99	O
.	O
4	O
%,	O
and	O
98	O
.	O
8	O
%,	O
respectively	O
,	O
in	O
infected	O
cell	O
cultures	O
.	O

TITLE	O
:	O
A	O
Highly	O
Immunogenic	O
,	O
Protective	O
,	O
and	O
Safe	O
Adenovirus	O
-	O
Based	O
Vaccine	O
Expressing	O
Middle	O
East	B-PRGE
Respiratory	I-PRGE
Syndrome	I-PRGE
Coronavirus	I-PRGE
S1	I-PRGE
-	I-PRGE
CD40L	I-PRGE
Fusion	I-PRGE
Protein	I-PRGE
in	O
a	O
Transgenic	O
Human	B-PRGE
Dipeptidyl	I-PRGE
Peptidase	I-PRGE
4	I-PRGE
Mouse	O
Model	O
.	O

Coimmunoprecipitation	O
studies	O
are	O
consistent	O
with	O
an	O
interaction	O
between	O
the	O
macrodomain	O
and	O
PLP2	B-PRGE
.	O

Efforts	O
to	O
develop	O
antibody	O
-	O
based	O
therapies	O
have	O
focused	O
on	O
neutralizing	O
antibodies	O
that	O
target	O
the	O
receptor	O
binding	O
domain	O
of	O
the	O
viral	B-PRGE
spike	I-PRGE
protein	I-PRGE
thereby	O
blocking	O
receptor	O
binding	O
.	O

TITLE	O
:	O
SARS	B-PRGE
coronavirus	I-PRGE
protein	I-PRGE
nsp1	I-PRGE
disrupts	O
localization	O
of	O
Nup93	B-PRGE
from	O
the	O
nuclear	O
pore	O
complex	O
.	O

Our	O
results	O
suggest	O
that	O
nsp1	B-PRGE
,	O
alone	O
,	O
can	O
regulate	O
multiple	O
steps	O
of	O
gene	O
expression	O
including	O
nuclear	O
-	O
cytoplasmic	O
transport	O
.	O

Specimens	O
were	O
examined	O
at	O
our	O
collaborating	O
institutions	O
with	O
a	O
panel	O
of	O
molecular	O
assays	O
for	O
viral	O
pathogens	O
including	O
influenza	O
A	O
(	O
IAV	O
),	O
IBV	O
,	O
ICV	O
,	O
and	O
IDV	O
,	O
human	O
adenovirus	O
(	O
AdV	O
),	O
human	O
enterovirus	O
(	O
EV	O
),	O
human	O
coronavirus	O
(	O
CoV	O
),	O
respiratory	O
syncytial	O
virus	O
subtype	O
A	O
(	O
RSV	O
-	O
A	O
)	O
or	O
RSV	B-PRGE
-	I-PRGE
B	I-PRGE
,	O
and	O
parainfluenza	O
virus	O
(	O
PIV	O
)	O
types	O
1	O
-	O
4	O
.	O
Of	O
599	O
samples	O
examined	O
,	O
288	O
(	O
48	O
%)	O
had	O
molecular	O
evidence	O
of	O
1	O
or	O
more	O
respiratory	O
viruses	O
.	O

Furthermore	O
,	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
)	O
and	O
IL	O
-	O
8	O
concentrations	O
were	O
lower	O
,	O
which	O
was	O
second	O
to	O
mice	O
treated	O
with	O
the	O
rectal	O
administration	O
of	O
20	O
µg	O
CpG	O
ODN	O
.	O

More	O
studies	O
are	O
needed	O
to	O
further	O
determine	O
the	O
protective	O
mechanism	O
of	O
CpG	B-PRGE
ODN	I-PRGE
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
novel	O
linear	O
B	O
-	O
cell	O
epitope	O
within	O
the	O
collagenase	B-PRGE
equivalent	O
domain	O
of	O
porcine	B-PRGE
epidemic	I-PRGE
diarrhea	I-PRGE
virus	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
.	O

Updates	O
were	O
presented	O
on	O
several	O
influenza	O
antivirals	O
including	O
baloxavir	O
,	O
CC	O
-	O
42344	O
,	O
VIS410	O
,	O
immunoglobulin	B-PRGE
,	O
immune	O
plasma	O
,	O
MHAA4549A	O
,	O
pimodivir	O
(	O
JNJ	O
-	O
63623872	O
),	O
umifenovir	O
,	O
and	O
HA	O
minibinders	O
;	O
RSV	O
antivirals	O
including	O
presatovir	O
(	O
GS	O
-	O
5806	O
),	O
ziresovir	O
(	O
AK0529	O
),	O
lumicitabine	O
(	O
ALS	O
-	O
008176	O
),	O
JNJ	O
-	O
53718678	O
,	O
JNJ	O
-	O
64417184	O
,	O
and	O
EDP	O
-	O
938	O
;	O
broad	O
spectrum	O
antivirals	O
such	O
as	O
favipiravir	O
,	O
VH244	O
,	O
remdesivir	O
,	O
and	O
EIDD	O
-	O
1931	O
/	O
EIDD	O
-	O
2801	O
;	O
and	O
host	O
directed	O
strategies	O
including	O
nitazoxanide	O
,	O
eritoran	O
,	O
and	O
diltiazem	O
.	O

For	O
comparative	O
analyses	O
,	O
two	O
eS770	O
proteins	O
lacking	O
the	O
IgG4	B-PRGE
Fc	I-PRGE
domain	I-PRGE
were	O
generated	O
using	O
the	O
IdeS	B-PRGE
protease	I-PRGE
(	O
eS770	O
-	O
ΔFc	O
)	O
or	O
His	O
tag	O
attachment	O
(	O
eS770	O
-	O
His	O
)	O
and	O
the	O
immunogenicity	O
of	O
the	O
above	O
constructs	O
were	O
examined	O
following	O
intramuscular	O
immunization	O
in	O
mice	O
.	O

The	O
RT	B-PRGE
-	I-PRGE
PSR	I-PRGE
was	O
optimized	O
,	O
and	O
PEDV	O
could	O
be	O
detected	O
after	O
a	O
50	O
min	O
incubation	O
at	O
62	O
°	O
C	O
,	O
in	O
addition	O
to	O
the	O
15	O
min	O
required	O
for	O
reverse	O
transcription	O
.	O

Although	O
previous	O
studies	O
have	O
suggested	O
that	O
the	O
HR1	O
of	O
HCoV	O
spike	O
(	O
S	O
)	O
protein	O
is	O
an	O
important	O
target	O
site	O
for	O
inhibition	O
against	O
specific	O
HCoVs	O
,	O
whether	O
this	O
conserved	O
region	O
could	O
serve	O
as	O
a	O
target	O
for	O
the	O
development	O
of	O
broad	B-PRGE
-	I-PRGE
spectrum	I-PRGE
pan	I-PRGE
-	I-PRGE
CoV	I-PRGE
inhibitor	O
remains	O
controversial	O
.	O

VPS36	B-PRGE
was	O
found	O
to	O
interact	O
with	O
ORF3	O
regardless	O
of	O
its	O
GLUE	O
domain	O
.	O

As	O
a	O
result	O
of	O
VPS36	B-PRGE
-	I-PRGE
ORF3	I-PRGE
interaction	O
,	O
PEDV	O
replication	O
was	O
substantially	O
suppressed	O
in	O
cells	O
overexpressing	O
VPS36	B-PRGE
.	O

TITLE	O
:	O
P53	B-PRGE
supports	O
endothelial	O
barrier	O
function	O
via	O
APE1	B-PRGE
/	O
Ref1	B-PRGE
suppression	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
immunogenicities	O
of	O
five	O
different	O
forms	O
of	O
the	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
S	I-PRGE
glycoprotein	I-PRGE
were	O
compared	O
:	O
the	O
full	B-PRGE
-	I-PRGE
length	I-PRGE
S	I-PRGE
glycoprotein	I-PRGE
,	O
the	O
full	B-PRGE
-	I-PRGE
length	I-PRGE
S	I-PRGE
glycoprotein	I-PRGE
with	O
the	O
transmembrane	O
domain	O
of	O
the	O
G	B-PRGE
glycoprotein	I-PRGE
of	O
VSV	O
(	O
S	O
-	O
G	O
),	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
S	B-PRGE
glycoprotein	I-PRGE
,	O
the	O
membrane	O
-	O
fused	O
RBD	O
(	O
the	O
RBD	O
fused	O
with	O
the	O
transmembrane	O
domain	O
of	O
the	O
VSV	B-PRGE
G	I-PRGE
glycoprotein	I-PRGE
(	O
RBD	O
-	O
G	O
)),	O
and	O
the	O
RBD	O
fused	O
with	O
Fc	B-PRGE
of	I-PRGE
human	I-PRGE
IgG1	I-PRGE
(	O
RBD	O
-	O
Fc	O
).	O

Furthermore	O
,	O
we	O
found	O
that	O
VIP	B-PRGE
inhibited	O
the	O
expression	O
of	O
IL	O
-	O
17R	O
in	O
the	O
lungs	O
of	O
mice	O
with	O
ARDS	O
and	O
NIH3T3	O
cells	O
stimulated	O
with	O
LPS	O
,	O
which	O
was	O
partly	O
inhibited	O
by	O
antagonists	O
of	O
protein	B-PRGE
kinase	I-PRGE
A	I-PRGE
and	O
protein	B-PRGE
kinase	I-PRGE
C	I-PRGE
.	O
Taken	O
together	O
,	O
our	O
results	O
demonstrated	O
that	O
VIP	B-PRGE
inhibited	O
the	O
activation	O
of	O
fibroblast	O
via	O
downregulation	O
of	O
IL	O
-	O
17RC	O
,	O
which	O
may	O
contribute	O
to	O
the	O
protective	O
effects	O
of	O
VIP	O
against	O
ARDS	O
in	O
mice	O
.	O

TITLE	O
:	O
UBXN1	B-PRGE
interacts	O
with	O
the	O
S1	B-PRGE
protein	I-PRGE
of	O
transmissible	O
gastroenteritis	O
coronavirus	O
and	O
plays	O
a	O
role	O
in	O
viral	O
replication	O
.	O

In	O
this	O
study	O
,	O
the	O
pro	O
-	O
apoptotic	O
effect	O
of	O
PEDV	O
was	O
examined	O
in	O
Vero	O
cells	O
and	O
we	O
observed	O
that	O
PEDV	O
infection	O
increased	O
MDM2	B-PRGE
and	O
CBP	B-PRGE
,	O
promoted	O
p53	B-PRGE
phosphorylation	O
at	O
serine	O
20	O
and	O
,	O
promoted	O
p53	B-PRGE
nuclear	O
translocation	O
,	O
leading	O
to	O
p53	B-PRGE
activation	O
in	O
Vero	O
cells	O
.	O

Activated	O
p38	B-PRGE
MAPK	O
and	O
SAPK	B-PRGE
/	O
JNK	B-PRGE
exerted	O
no	O
influence	O
on	O
PEDV	O
-	O
induced	O
apoptosis	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
the	O
SARS	O
-	O
CoV	O
open	O
reading	O
frame	O
3a	O
(	O
ORF3a	O
)	O
accessory	O
protein	O
activates	O
the	O
NLRP3	B-PRGE
inflammasome	I-PRGE
by	O
promoting	O
TNF	B-PRGE
receptor	O
-	O
associated	O
factor	O
3	O
(	O
TRAF3	B-PRGE
)-	O
mediated	O
ubiquitination	O
of	O
apoptosis	O
-	O
associated	O
speck	O
-	O
like	O
protein	O
containing	O
a	B-PRGE
caspase	I-PRGE
recruitment	I-PRGE
domain	I-PRGE
(	O
ASC	B-PRGE
).	O

ORF3a	O
-	O
induced	O
elevation	O
of	O
IL	O
-	O
1β	O
secretion	O
was	O
independent	O
of	O
its	O
ion	O
channel	O
activity	O
or	O
absent	O
in	O
melanoma	O
2	O
but	O
required	O
NLRP3	B-PRGE
,	O
ASC	B-PRGE
,	O
and	O
TRAF3	B-PRGE
.	O

The	O
relationship	O
among	O
the	O
number	O
and	O
type	O
of	O
comorbidities	O
,	O
Charlson	O
comorbidity	O
index	O
(	O
CCI	O
),	O
clinical	O
characteristics	O
and	O
the	O
levels	O
of	O
plasma	O
inflammatory	O
markers	O
[	O
interleukin	B-PRGE
(	I-PRGE
IL	I-PRGE
)-	I-PRGE
6	I-PRGE
,	O
high	O
sensitivity	O
C	B-PRGE
-	I-PRGE
reaction	I-PRGE
protein	I-PRGE
(	O
hs	B-PRGE
-	I-PRGE
CRP	I-PRGE
),	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
-	I-PRGE
α	I-PRGE
(	O
TNF	B-PRGE
-	I-PRGE
α	I-PRGE
),	O
IL	O
-	O
8	O
]	O
were	O
studied	O
.	O

The	O
level	O
of	O
plasma	B-PRGE
IL	I-PRGE
-	I-PRGE
6	I-PRGE
was	O
greater	O
in	O
higher	O
CCI	O
score	O
(≥	O
4	O
)	O
group	O
compared	O
with	O
lower	O
CCI	O
score	O
(<	O
4	O
)	O
group	O
(	O
CONCLUSIONS	O
:	O
Patients	O
with	O
a	O
higher	O
CCI	O
score	O
had	O
more	O
severe	O
symptoms	O
,	O
functional	O
impairment	O
and	O
higher	O
level	O
of	O
inflammatory	O
factors	O
and	O
high	O
frequency	O
of	O
hospital	O
admission	O
due	O
to	O
acute	O
exacerbation	O
.	O

To	O
understand	O
whether	O
10d	O
interfered	O
with	O
virus	O
attachment	O
to	O
target	O
cells	O
or	O
virus	O
-	O
cell	O
fusion	O
events	O
,	O
inhibitory	O
activity	O
tests	O
against	O
the	O
RSV	B-PRGE
mutant	I-PRGE
strain	O
B1	O
cp	O
-	O
52	O
-	O
expressing	O
only	O
the	O
F	B-PRGE
envelope	I-PRGE
glycoprotein	I-PRGE
-	O
and	O
a	O
plasmid	O
-	O
based	O
reporter	O
assay	O
that	O
quantifies	O
the	O
bioactivity	O
of	O
viral	O
entry	O
were	O
also	O
performed	O
.	O

The	O
saturation	O
of	O
blood	O
plasma	O
transferrin	B-PRGE
by	O
iron	O
was	O
significantly	O
reduced	O
-	O
for	O
15	O
.	O
27	O
%	O
in	O
patients	O
with	O
severe	O
course	O
of	O
influenza	O
stomatitis	O
.	O

In	O
the	O
emergency	O
room	O
(	O
ER	O
),	O
the	O
patient	O
was	O
found	O
to	O
have	O
an	O
elevated	O
serum	B-PRGE
troponin	I-PRGE
of	O
15	O
.	O
61	O
ng	O
/	O
L	O
(	O
normal	O
<	O
0	O
.	O
05	O
ng	O
/	O
L	O
).	O

We	O
highlight	O
this	O
case	O
to	O
discuss	O
the	O
importance	O
of	O
maintaining	O
a	O
broad	O
differential	O
and	O
pursuing	O
complete	O
work	O
-	O
up	O
when	O
treating	O
younger	O
patients	O
with	O
chest	O
pain	O
and	O
elevated	O
serum	O
troponin	B-PRGE
who	O
lack	O
typical	O
risk	O
factors	O
for	O
CAD	O
.	O

TITLE	O
:	O
S	B-PRGE
gene	I-PRGE
and	O
5a	O
accessory	O
gene	O
are	O
responsible	O
for	O
the	O
attenuation	O
of	O
virulent	O
infectious	O
bronchitis	O
coronavirus	O
.	O

T	O
cells	O
recognize	O
antigens	O
specifically	O
through	O
a	O
membrane	O
protein	B-PRGE
T	I-PRGE
cell	I-PRGE
receptor	I-PRGE
(	O
TCR	B-PRGE
).	O

TITLE	O
:	O
The	O
coronavirus	O
macrodomain	O
is	O
required	O
to	O
prevent	O
PARP	B-PRGE
-	O
mediated	O
inhibition	O
of	O
virus	O
replication	O
and	O
enhancement	O
of	O
IFN	B-PRGE
expression	O
.	O

ABSTRACT	O
:	O
ADP	O
-	O
ribosylation	O
is	O
a	O
ubiquitous	O
post	O
-	O
translational	O
addition	O
of	O
either	O
monomers	O
or	O
polymers	O
of	O
ADP	O
-	O
ribose	O
to	O
target	O
proteins	O
by	O
ADP	B-PRGE
-	I-PRGE
ribosyltransferases	I-PRGE
,	O
usually	O
by	O
interferon	B-PRGE
-	O
inducible	O
diphtheria	B-PRGE
toxin	I-PRGE
-	I-PRGE
like	I-PRGE
enzymes	I-PRGE
known	O
as	O
PARPs	O
.	O

PARP14	B-PRGE
was	O
also	O
important	O
for	O
the	O
induction	O
of	O
interferon	B-PRGE
in	O
mouse	O
and	O
human	O
cells	O
,	O
indicating	O
a	O
critical	O
role	O
for	O
this	O
PARP	B-PRGE
in	O
the	O
regulation	O
of	O
innate	O
immunity	O
.	O

Analyses	O
of	O
nucleotide	O
and	O
deduced	O
amino	O
acid	O
sequences	O
showed	O
that	O
NB1	B-PRGE
differed	O
from	O
18	O
other	O
Korean	O
PEDV	O
mostly	O
in	O
4	O
protein	O
coding	O
genes	O
:	O
ORF1a	O
,	O
ORF1b	O
,	O
S	O
,	O
and	O
N	O
.	O
Two	O
amino	O
acid	O
substitutions	O
(	O
V635E	O
and	O
Y681Q	O
)	O
in	O
the	O
COE	B-PRGE
and	I-PRGE
S1D	I-PRGE
neutralizing	I-PRGE
epitopes	I-PRGE
of	O
NB1	O
resulted	O
in	O
antigenic	O
index	O
alteration	O
of	O
the	O
adjacent	O
sites	O
,	O
one	O
of	O
which	O
contributed	O
to	O
a	O
mutation	O
that	O
escaped	O
neutralizing	O
antibodies	O
.	O

Patient	O
studies	O
have	O
suggested	O
a	O
link	O
between	O
von	B-PRGE
Willebrand	I-PRGE
factor	I-PRGE
(	O
VWF	B-PRGE
)	O
and	O
malaria	O
severity	O
.	O

Plasmodium	O
berghei	O
NK65	O
-	O
E	O
(	O
PbNK65	O
)	O
parasites	O
were	O
injected	O
in	O
Vwf	B-PRGE
In	O
accordance	O
with	O
patients	O
with	O
severe	O
malaria	O
,	O
plasma	O
VWF	O
levels	O
were	O
increased	O
and	O
ADAMTS13	O
activity	O
levels	O
were	O
reduced	O
in	O
experimental	O
MA	O
-	O
ARDS	O
.	O

Thrombocytopenia	O
was	O
VWF	O
-	O
independent	O
because	O
it	O
was	O
observed	O
in	O
both	O
Vwf	O
This	O
study	O
suggests	O
that	O
parasite	O
load	O
together	O
with	O
malarial	O
anemia	O
,	O
rather	O
than	O
alveolar	O
leakage	O
,	O
might	O
contribute	O
to	O
shortened	O
survival	O
in	O
PbNK65	O
-	O
infected	O
Vwf	B-PRGE
RESULTS	O
:	O
In	O
accordance	O
with	O
patients	O
with	O
severe	O
malaria	O
,	O
plasma	O
VWF	O
levels	O
were	O
increased	O
and	O
ADAMTS13	O
activity	O
levels	O
were	O
reduced	O
in	O
experimental	O
MA	O
-	O
ARDS	O
.	O

Compared	O
with	O
the	O
survival	O
group	O
,	O
the	O
death	O
group	O
was	O
older	O
(	O
years	O
old	O
:	O
58	O
.	O
50	O
±	O
14	O
.	O
86	O
vs	O
.	O
46	O
.	O
67	O
±	O
13	O
.	O
40	O
),	O
APACHE	O
II	O
score	O
was	O
higher	O
(	O
21	O
.	O
50	O
±	O
3	O
.	O
93	O
vs	O
.	O
13	O
.	O
58	O
±	O
4	O
.	O
12	O
),	O
neutral	O
red	O
phagocytosis	O
ability	O
and	O
alkaline	B-PRGE
phosphatase	I-PRGE
activity	O
of	O
alveolar	O
macrophages	O
were	O
significantly	O
decreased	O
(	O
A	O
value	O
:	O
0	O
.	O
265	O
±	O
0	O
.	O
050	O
vs	O
.	O
0	O
.	O
338	O
±	O
0	O
.	O
016	O
;	O
μmol	O
/	O
L	O
:	O
12	O
.	O
06	O
±	O
1	O
.	O
24	O
vs	O
.	O
17	O
.	O
96	O
±	O
3	O
.	O
90	O
),	O
and	O
the	O
length	O
of	O
ICU	O
stay	O
was	O
significantly	O
longer	O
(	O
days	O
:	O
22	O
.	O
00	O
±	O
14	O
.	O
59	O
vs	O
.	O
11	O
.	O
50	O
±	O
3	O
.	O
17	O
),	O
hospitalization	O
cost	O
was	O
significantly	O
increased	O
(	O
10	O
thousand	O
Yuan	O
:	O
24	O
.	O
17	O
±	O
11	O
.	O
02	O
vs	O
.	O
13	O
.	O
44	O
±	O
3	O
.	O
53	O
),	O
the	O
total	O
hospitalization	O
time	O
was	O
shorter	O
(	O
days	O
:	O
25	O
.	O
25	O
±	O
15	O
.	O
01	O
vs	O
.	O
35	O
.	O
67	O
±	O
8	O
.	O
58	O
),	O
and	O
the	O
difference	O
was	O
statistically	O
significant	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

Previous	O
studies	O
have	O
suggested	O
that	O
PDCoV	O
infection	O
antagonizes	O
RIG	B-PRGE
-	I-PRGE
I	I-PRGE
-	I-PRGE
like	I-PRGE
receptor	I-PRGE
(	O
RLR	B-PRGE
)-	O
mediated	O
IFN	B-PRGE
-	I-PRGE
β	I-PRGE
production	O
to	O
evade	O
host	O
innate	O
immune	O
defense	O
,	O
and	O
PDCoV	B-PRGE
-	I-PRGE
encoded	I-PRGE
nonstructural	I-PRGE
protein	I-PRGE
nsp5	I-PRGE
and	O
accessory	B-PRGE
protein	I-PRGE
NS6	I-PRGE
are	O
associated	O
with	O
this	O
process	O
.	O

The	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
envelope	I-PRGE
spike	I-PRGE
protein	I-PRGE
serves	O
as	O
a	O
crucial	O
target	O
for	O
neutralizing	O
antibodies	O
and	O
vaccine	O
development	O
,	O
as	O
it	O
plays	O
a	O
critical	O
role	O
in	O
mediating	O
viral	O
entry	O
through	O
interactions	O
with	O
the	O
cellular	O
receptor	O
,	O
dipeptidyl	B-PRGE
peptidase	I-PRGE
4	I-PRGE
(	O
DPP4	B-PRGE
).	O

The	O
most	O
frequently	O
observed	O
co	O
-	O
infections	O
with	O
double	O
causative	O
agents	O
were	O
HRV	O
and	O
INF	B-PRGE
-	I-PRGE
B	I-PRGE
,	O
HRV	O
and	O
PIV	O
,	O
HRV	O
and	O
HBoV	O
,	O
HRV	O
and	O
AdV	O
combinations	O
.	O

A	O
translocation	O
model	O
is	O
proposed	O
for	O
the	O
Upf1	B-PRGE
-	I-PRGE
like	I-PRGE
helicase	I-PRGE
members	I-PRGE
according	O
to	O
three	O
different	O
structural	O
conditions	O
in	O
solution	O
characterized	O
through	O
H	O
/	O
D	O
exchange	O
assay	O
,	O
including	O
substrate	O
state	O
(	O
SARS	O
-	O
Nsp13	O
-	O
dsDNA	O
bound	O
with	O
AMPPNP	O
),	O
transition	O
state	O
(	O
bound	O
with	O
ADP	O
-	O
AlF4	O
-)	O
and	O
product	O
state	O
(	O
bound	O
with	O
ADP	O
).	O

Furthermore	O
,	O
we	O
have	O
shown	O
that	O
the	O
RNA	B-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
(	O
RdRp	O
),	O
SARS	B-PRGE
-	O
Nsp12	O
,	O
can	O
enhance	O
the	O
helicase	B-PRGE
activity	O
of	O
SARS	B-PRGE
-	I-PRGE
Nsp13	I-PRGE
through	O
interacting	O
with	O
it	O
directly	O
.	O

This	O
structure	O
illuminates	O
the	O
assembly	O
of	O
the	O
coronavirus	O
core	O
RNA	O
-	O
synthesis	O
machinery	O
,	O
provides	O
key	O
insights	O
into	O
nsp12	B-PRGE
polymerase	I-PRGE
catalysis	O
and	O
fidelity	O
and	O
acts	O
as	O
a	O
template	O
for	O
the	O
design	O
of	O
novel	O
antiviral	O
therapeutics	O
.	O

However	O
,	O
PDCoV	B-PRGE
N	I-PRGE
protein	I-PRGE
restrained	O
the	O
pRiplet	B-PRGE
binding	I-PRGE
pRIG	I-PRGE
-	I-PRGE
I	I-PRGE
to	O
inhibit	O
pRIG	O
-	O
I	O
K63	O
-	O
linked	O
polyubiquitination	O
.	O

We	O
recently	O
demonstrated	O
that	O
integrin	B-PRGE
α5β1	I-PRGE
plays	O
a	O
critical	O
role	O
in	O
PHEV	O
invasion	O
in	O
vitro	O
.	O

TITLE	O
:	O
DL	O
-	O
3	O
-	O
n	O
-	O
butylphthalide	O
attenuates	O
lipopolysaccharide	O
-	O
induced	O
acute	O
lung	O
injury	O
via	O
SIRT1	O
-	O
dependent	O
and	O
-	O
independent	O
regulation	O
of	O
Nrf2	B-PRGE
.	O

The	O
results	O
demonstrated	O
that	O
NBP	B-PRGE
could	O
activate	O
Nrf2	B-PRGE
antioxidant	O
signaling	O
in	O
a	O
SIRT1	B-PRGE
-	O
dependent	O
and	O
SIRT1	B-PRGE
-	O
independent	O
manner	O
,	O
resulting	O
in	O
the	O
amelioration	O
of	O
oxidative	O
stress	O
,	O
inflammation	O
and	O
pulmonary	O
edema	O
.	O

ABSTRACT	O
:	O
BST2	B-PRGE
/	O
tetherin	B-PRGE
,	O
an	O
interferon	B-PRGE
-	O
inducible	O
antiviral	O
factor	O
,	O
can	O
block	O
the	O
cellular	O
release	O
of	O
various	O
enveloped	O
viruses	O
.	O

Here	O
we	O
report	O
our	O
new	O
finding	O
that	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
glycoprotein	O
,	O
similar	O
to	O
Vpu	O
,	O
is	O
capable	O
of	O
antagonizing	O
the	O
BST2	O
tethering	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
HCoV	O
-	O
229E	O
,	O
and	O
HIV	O
-	O
1	O
virus	O
-	O
like	O
particles	O
via	O
BST2	B-PRGE
downregulation	O
.	O

Our	O
study	O
suggested	O
that	O
PIV3	O
is	O
a	O
new	O
risk	O
factor	O
for	O
VRI	B-PRGE
in	I-PRGE
PSPs	I-PRGE
.	O

ABSTRACT	O
:	O
ADP	O
-	O
ribosylation	O
is	O
a	O
reversible	O
chemical	O
modification	O
catalysed	O
by	O
ADP	B-PRGE
-	I-PRGE
ribosyltransferases	I-PRGE
such	O
as	O
PARPs	O
that	O
utilize	O
nicotinamide	O
adenine	O
dinucleotide	O
(	O
NAD	O
+)	O
as	O
a	O
cofactor	O
to	O
transfer	O
monomer	O
or	O
polymers	O
of	O
ADP	O
-	O
ribose	O
nucleotide	O
onto	O
macromolecular	O
targets	O
such	O
as	O
proteins	O
and	O
DNA	O
.	O

In	O
macrophages	O
,	O
ORF8b	O
robustly	O
activates	O
the	O
NLRP3	B-PRGE
inflammasome	I-PRGE
by	O
providing	O
a	O
potent	O
signal	O
2	O
required	O
for	O
activation	O
.	O

TITLE	O
:	O
Broad	O
spectrum	O
antiviral	O
remdesivir	O
inhibits	O
human	O
endemic	O
and	O
zoonotic	O
deltacoronaviruses	O
with	O
a	O
highly	O
divergent	O
RNA	B-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
.	O

However	O
AAV	B-PRGE
-	I-PRGE
Pck2	I-PRGE
overexpression	O
reduced	O
TA	O
muscle	O
weights	O
(	O
p	O
=	O
0	O
.	O
0434	O
),	O
particularly	O
in	O
the	O
Control	O
(	O
vehicle	O
treated	O
)	O
mice	O
(	O
p	O
=	O
0	O
.	O
059	O
for	O
AAV	O
x	O
Clenbuterol	O
interaction	O
)	O
and	O
increased	O
the	O
expression	O
of	O
Seryl	B-PRGE
-	I-PRGE
tRNA	I-PRGE
Synthetase	I-PRGE
(	O
Sars	O
)	O
mRNA	O
(	O
p	O
=	O
0	O
.	O
0477	O
).	O

The	O
aim	O
of	O
this	O
immunocytochemical	O
study	O
was	O
to	O
compare	O
mannose	B-PRGE
-	I-PRGE
binding	I-PRGE
lectin	I-PRGE
(	O
MBL	B-PRGE
)	O
production	O
induced	O
by	O
avian	O
coronavirus	O
in	O
the	O
spleen	O
and	O
caecal	O
tonsil	O
(	O
CT	O
).	O

The	O
combination	O
of	O
lopinavir	O
/	O
ritonavir	O
and	O
interferon	B-PRGE
-	I-PRGE
beta	I-PRGE
-	I-PRGE
1b	I-PRGE
showed	O
excellent	O
results	O
in	O
common	O
marmosets	O
and	O
currently	O
is	O
in	O
a	O
randomized	O
control	O
trial	O
.	O

The	O
study	O
is	O
based	O
on	O
a	O
combination	O
of	O
lopinavir	O
/	O
ritonavir	O
and	O
interferon	B-PRGE
-	I-PRGE
beta	I-PRGE
-	I-PRGE
1b	I-PRGE
.	O

Specific	O
mutations	O
were	O
found	O
in	O
S1	B-PRGE
gene	I-PRGE
as	O
well	O
as	O
in	O
3	O
'	O
UTR	O
region	O
.	O

We	O
compared	O
the	O
expression	O
of	O
six	O
tight	O
junction	O
proteins	O
(	O
ZO	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
ZO	B-PRGE
-	I-PRGE
2	I-PRGE
,	O
Occludin	B-PRGE
,	O
Claudin	B-PRGE
-	I-PRGE
1	I-PRGE
,	O
Claudin	B-PRGE
-	I-PRGE
4	I-PRGE
,	O
and	O
Claudin	O
-	O
5	O
)	O
between	O
seven	O
-	O
day	O
-	O
old	O
piglets	O
infected	O
with	O
PEDV	O
and	O
normal	O
piglets	O
,	O
as	O
well	O
as	O
in	O
PEDV	O
-	O
infected	O
porcine	O
intestinal	O
epithelial	O
cells	O
(	O
IPEC	O
-	O
J2	O
).	O

The	O
expression	O
of	O
Claudin	B-PRGE
-	I-PRGE
5	I-PRGE
in	O
the	O
jejunum	O
was	O
significantly	O
lower	O
in	O
PEDV	O
-	O
infected	O
piglets	O
than	O
in	O
the	O
normal	O
animals	O
(	O
p	O
⟨	O
0	O
.	O
01	O
).	O

It	O
has	O
been	O
detected	O
that	O
the	O
levels	O
of	O
PEDV	O
-	O
specific	O
antibodies	O
(	O
IgG	B-PRGE
and	O
IgA	B-PRGE
)	O
in	O
their	O
sera	O
and	O
milks	O
were	O
higher	O
than	O
other	O
negative	O
groups	O
(	O
P	O
<	O
0	O
·	O
001	O
or	O
P	O
<	O
0	O
·	O
05	O
).	O

Conditions	O
at	O
the	O
time	O
of	O
death	O
were	O
sepsis	O
(	O
25	O
),	O
pneumonia	O
(	O
16	O
),	O
AKI	O
(	O
15	O
),	O
bleeding	O
disorders	O
(	O
11	O
),	O
neurological	O
complications	O
(	O
10	O
),	O
ARDS	O
(	O
10	O
),	O
CKD	O
(	O
4	O
),	O
AKI	B-PRGE
in	O
addition	O
to	O
CKD	O
(	O
3	O
).	O

The	O
role	O
of	O
various	O
biomarkers	O
,	O
such	O
as	O
Clara	B-PRGE
cell	I-PRGE
protein	I-PRGE
16	I-PRGE
,	O
von	B-PRGE
Willebrand	I-PRGE
factor	I-PRGE
,	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
,	O
and	O
angiopoietin	O
,	O
has	O
been	O
studied	O
in	O
trauma	O
-	O
related	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Our	O
study	O
demonstrates	O
that	O
serum	B-PRGE
ACE	I-PRGE
levels	O
are	O
increased	O
in	O
thoracic	O
trauma	O
patients	O
with	O
higher	O
levels	O
,	O
indicating	O
the	O
severe	O
nature	O
of	O
trauma	O
in	O
concordance	O
with	O
increased	O
TTSS	O
scores	O
.	O

Although	O
plasma	B-PRGE
NT	I-PRGE
-	I-PRGE
proBNP	I-PRGE
levels	O
were	O
lower	O
after	O
7	O
months	O
compared	O
to	O
the	O
baseline	O
,	O
the	O
levels	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
SGMT	O
and	O
standard	O
therapy	O
groups	O
at	O
baseline	O
(	O
579	O
±	O
1117	O
vs	O
.	O
611	O
±	O
899	O
pg	O
/	O
dL	O
,	O
p	O
=	O
.	O
851	O
)	O
or	O
at	O
7	O
months	O
(	O
90	O
±	O
167	O
vs	O
.	O
93	O
±	O
174	O
pg	O
/	O
dL	O
,	O
p	O
=	O
.	O
996	O
).	O

Similar	O
findings	O
were	O
observed	O
for	O
the	O
plasma	B-PRGE
ST2	I-PRGE
and	O
hs	B-PRGE
-	I-PRGE
CRP	I-PRGE
levels	O
.	O

High	B-PRGE
-	I-PRGE
throughput	I-PRGE
16S	I-PRGE
rRNA	I-PRGE
gene	I-PRGE
sequencing	O
was	O
performed	O
to	O
explore	O
differences	O
.	O

Regarding	O
the	O
effect	O
of	O
biosecurity	O
measures	O
during	O
PED	O
outbreak	O
on	O
TAC	B-PRGE
and	O
DP	B-PRGE
/	I-PRGE
S	I-PRGE
,	I-PRGE
longer	I-PRGE
TAC	I-PRGE
was	O
observed	O
in	O
Actinobacillus	O
pleuropneumoniae	O
-	O
positive	O
farms	O
and	O
farms	O
outsourcing	O
pig	O
transport	O
to	O
the	O
slaughterhouse	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

Here	O
,	O
we	O
examined	O
the	O
intermediate	O
conformation	O
of	O
the	O
murine	B-PRGE
coronavirus	I-PRGE
fusion	I-PRGE
protein	I-PRGE
,	O
called	O
the	O
spike	O
protein	O
,	O
which	O
must	O
be	O
cleaved	O
by	O
a	O
cellular	O
protease	O
following	O
receptor	O
binding	O
.	O

Using	O
viruslike	O
particles	O
lacking	O
the	O
spike	O
(	O
S	O
)	O
protein	O
,	O
we	O
demonstrate	O
that	O
binding	O
to	O
the	O
cell	O
is	O
not	O
S	B-PRGE
protein	I-PRGE
dependent	O
.	O

In	O
addition	O
,	O
cubic	O
spline	O
regression	O
demonstrated	O
that	O
mortality	O
sharply	O
increased	O
at	O
a	O
fibrinogen	B-PRGE
level	O
of	O
approximately	O
<	O
200	O
mg	O
/	O
dL	O
and	O
at	O
an	O
antithrombin	B-PRGE
activity	O
of	O
approximately	O
<	O
50	O
%.	O

RESULTS	O
:	O
The	O
decreased	O
levels	O
of	O
the	O
fibrinogen	B-PRGE
and	O
antithrombin	B-PRGE
activity	O
were	O
significantly	O
associated	O
with	O
an	O
increase	O
in	O
mortality	O
(	O
P	O
=	O
0	O
.	O
011	O
and	O
0	O
.	O
002	O
,	O
respectively	O
).	O

The	O
surface	O
spike	O
(	O
S	O
)	O
glycoprotein	O
of	O
MERS	O
-	O
CoV	O
,	O
which	O
binds	O
to	O
the	O
cellular	O
receptor	O
dipeptidyl	B-PRGE
peptidase	I-PRGE
4	I-PRGE
(	O
DPP4	B-PRGE
),	O
is	O
considered	O
as	O
a	O
major	O
target	O
for	O
MERS	O
-	O
CoV	O
vaccine	O
development	O
.	O

Postoperative	O
hemoglobin	B-PRGE
level	O
(	O
odds	O
ratio	O
[	O
OR	O
]:	O
0	O
.	O
78	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]:	O
0	O
.	O
62	O
-	O
0	O
.	O
99	O
)	O
and	O
perioperative	O
blood	O
transfusion	O
volume	O
(	O
OR	O
:	O
1	O
.	O
07	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
03	O
-	O
1	O
.	O
12	O
)	O
were	O
associated	O
with	O
ARDS	O
risk	O
.	O

ABSTRACT	O
:	O
To	O
identify	O
the	O
clinical	O
correlations	O
between	O
mechanical	O
power	O
and	O
transforming	B-PRGE
growth	I-PRGE
factor	I-PRGE
-	I-PRGE
β1	I-PRGE
(	O
TGF	O
-	O
β1	O
)	O
and	O
connective	B-PRGE
tissue	I-PRGE
growth	I-PRGE
factor	I-PRGE
(	O
CTGF	B-PRGE
)	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
patients	O
,	O
their	O
clinical	O
significance	O
in	O
pulmonary	O
structural	O
remodeling	O
in	O
ARDS	O
patients	O
was	O
investigated	O
.	O

The	O
current	O
study	O
employs	O
a	O
variety	O
of	O
unfolded	O
protein	O
response	O
(	O
UPR	O
)	O
activators	O
and	O
inhibitors	O
to	O
investigate	O
the	O
regulation	O
of	O
P53	B-PRGE
by	O
UPR	O
in	O
lung	O
cells	O
.	O

On	O
the	O
contrary	O
,	O
the	O
UPR	O
inhibitors	O
N	O
-	O
acetyl	O
cysteine	O
,	O
kifunensine	O
,	O
and	O
ATP	O
-	O
competitive	O
IRE1α	B-PRGE
kinase	I-PRGE
-	I-PRGE
inhibiting	I-PRGE
RNase	I-PRGE
attenuator	I-PRGE
;	O
produced	O
the	O
opposite	O
effects	O
.	O

The	O
fluctuations	O
in	O
leukocyte	O
populations	O
measured	O
by	O
Vetscan	B-PRGE
HM5	I-PRGE
were	O
corroborated	O
by	O
standard	O
flow	O
cytometry	O
,	O
thus	O
confirming	O
the	O
utility	O
of	O
this	O
approach	O
.	O

Nonstructural	B-PRGE
protein	I-PRGE
15	I-PRGE
(	O
nsp15	O
)	O
encodes	O
an	O
endoribonuclease	O
that	O
is	O
highly	O
conserved	O
among	O
vertebrate	O
nidoviruses	O
(	O
coronaviruses	O
and	O
arteriviruses	O
)	O
and	O
plays	O
a	O
critical	O
role	O
in	O
viral	O
replication	O
and	O
transcription	O
.	O

TITLE	O
:	O
IFN	B-PRGE
-	I-PRGE
I	I-PRGE
response	O
timing	O
relative	O
to	O
virus	O
replication	O
determines	O
MERS	O
coronavirus	O
infection	O
outcomes	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
spike	O
(	O
S	O
)	O
proteins	O
of	O
the	O
prototypic	O
Arabian	O
MERS	O
-	O
CoV	O
strain	O
,	O
human	O
betacoronavirus	O
2c	O
EMC	O
/	O
2012	O
,	O
and	O
the	O
above	O
stated	O
African	O
MERS	O
-	O
CoV	O
variants	O
do	O
not	O
appreciably	O
differ	O
in	O
expression	O
,	O
DPP4	B-PRGE
binding	O
and	O
ability	O
to	O
drive	O
entry	O
into	O
target	O
cells	O
.	O

The	O
level	O
of	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
was	O
decreased	O
,	O
and	O
the	O
percent	O
of	O
natural	O
killer	O
cells	O
(%)	O
was	O
improved	O
in	O
the	O
continuous	O
renal	O
replacement	O
therapy	O
group	O
compared	O
with	O
the	O
noncontinuous	O
renal	O
replacement	O
therapy	O
group	O
.	O

Application	O
of	O
the	O
RNA	O
adjuvant	O
in	O
mouse	O
enhanced	O
the	O
efficacy	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
spike	O
protein	O
,	O
a	O
protein	O
-	O
subunit	O
vaccine	O
and	O
human	O
papillomavirus	O
L1	O
protein	O
,	O
a	O
virus	O
-	O
like	O
particle	O
vaccine	O
,	O
by	O
activating	O
innate	O
immune	O
response	O
through	O
TLR7	B-PRGE
and	O
enhancing	O
pAPC	O
chemotaxis	O
,	O
leading	O
to	O
a	O
balanced	O
Th1	O
/	O
Th2	O
responses	O
.	O

Single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
the	O
genes	O
encoding	O
interferon	B-PRGE
gamma	I-PRGE
(	O
DNA	O
was	O
extracted	O
from	O
tissue	O
(	O
n	O
=	O
32	O
)	O
or	O
blood	O
(	O
n	O
=	O
3	O
)	O
and	O
PCR	O
performed	O
for	O
regions	O
of	O
No	O
significant	O
association	O
was	O
found	O
between	O
the	O
genotype	O
and	O
FIP	O
status	O
for	O
any	O
SNP	O
analysed	O
.	O

Tissue	O
culture	O
-	O
adapted	O
type	B-PRGE
I	I-PRGE
FCoV	I-PRGE
shows	O
reduced	O
FIP	O
induction	O
in	O
experimental	O
infections	O
,	O
which	O
complicates	O
the	O
understanding	O
of	O
FIP	O
pathogenesis	O
caused	O
by	O
type	O
I	O
FCoV	O
.	O
We	O
previously	O
found	O
that	O
the	O
type	B-PRGE
I	I-PRGE
FCoV	I-PRGE
strain	O
C3663	O
efficiently	O
induces	O
FIP	O
in	O
specific	O
-	O
pathogen	O
-	O
free	O
cats	O
through	O
the	O
naturally	O
infectious	O
route	O
.	O

Overall	O
,	O
we	O
succeeded	O
in	O
obtaining	O
infectious	O
cDNA	O
clones	O
derived	O
from	O
type	B-PRGE
I	I-PRGE
FCoV	I-PRGE
that	O
retained	O
its	O
virulence	O
.	O

For	O
pathogenicity	O
evaluation	O
of	O
PEDV	O
HLJBY	O
strain	O
,	O
colostrum	O
deprivation	O
piglets	O
were	O
challenged	O
with	O
PEDV	O
HLJBY	O
,	O
and	O
PEDV	O
reference	O
strain	O
CV777	O
as	O
a	O
control	O
,	O
the	O
results	O
showed	O
that	O
animals	O
challenged	O
with	O
either	O
of	O
these	O
PEDV	O
strains	O
developed	O
diarrhoea	O
,	O
and	O
histopathological	O
examination	O
of	O
small	O
intestines	O
of	O
challenged	O
animals	O
showed	O
acute	O
viral	O
enteritis	O
with	O
villous	O
atrophy	O
in	O
either	O
PEDV	B-PRGE
HLJBY	I-PRGE
-	I-PRGE
P10	I-PRGE
or	O
PEDV	O
CV777	O
-	O
P8	O
inoculated	O
piglets	O
.	O

The	O
amino	O
acid	O
residues	O
at	O
positions	O
590	O
-	O
1	O
,	O
215	O
in	O
Nsp3	B-PRGE
compose	O
the	O
critical	O
domain	O
that	O
mediates	O
NF	O
-	O
κB	O
inhibition	O
.	O

Furthermore	O
,	O
the	O
amino	O
acid	O
residues	O
at	O
positions	O
590	O
-	O
1	O
,	O
215	O
in	O
Nsp3	B-PRGE
were	O
demonstrated	O
to	O
inhibit	O
the	O
degradation	O
of	O
IκBα	O
by	O
inhibiting	O
the	O
IκBα	O
ubiquitination	O
.	O

Plasma	O
and	O
bronchoalveolar	O
lavage	O
soluble	O
receptor	O
for	O
advanced	O
glycation	O
end	O
-	O
products	O
,	O
plasma	O
interleukin	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
and	O
monocyte	O
chemotactic	O
protein	O
-	O
1	O
were	O
sampled	O
preextracorporeal	O
membrane	O
oxygenation	O
and	O
after	O
12	O
hours	O
at	O
each	O
step	O
.	O

Immunoglobulin	B-PRGE
levels	O
were	O
examined	O
and	O
immunophenotyping	O
was	O
performed	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
show	O
that	O
the	O
incorporation	O
of	O
the	O
Rho	B-PRGE
-	I-PRGE
associated	I-PRGE
protein	I-PRGE
kinase	I-PRGE
(	O
ROCK	O
)	O
inhibitor	O
(	O
Y	O
-	O
27632	O
)	O
during	O
cell	O
propagation	O
extends	O
the	O
life	O
span	O
of	O
primary	O
human	O
cells	O
in	O
vitro	O
and	O
thereby	O
facilitates	O
the	O
incorporation	O
of	O
lentivirus	O
-	O
based	O
expression	O
systems	O
.	O

The	O
positive	O
result	O
of	O
IgM	B-PRGE
and	O
IgG	B-PRGE
was	O
considered	O
the	O
application	O
of	O
ganglioside	O
and	O
blood	O
-	O
brain	O
barrier	O
might	O
be	O
damaged	O
after	O
meningioma	O
surgery	O
which	O
eased	O
the	O
drug	O
to	O
enter	O
the	O
cerebrospinal	O
fluid	O
circulation	O
and	O
induced	O
lesions	O
,	O
therefore	O
the	O
etiology	O
on	O
this	O
GBS	O
case	O
was	O
of	O
high	O
confidence	O
of	O
administrating	O
ganglioside	O
drugs	O
.	O

Coumarin	O
-	O
based	O
molecules	O
already	O
proved	O
to	O
act	O
as	O
HIV	O
-	O
1	O
Protease	B-PRGE
(	O
PR	O
)	O
or	O
Integrase	B-PRGE
(	O
IN	O
)	O
inhibitors	O
and	O
also	O
to	O
target	O
HIV	O
-	O
1	O
reverse	B-PRGE
transcriptase	I-PRGE
(	O
RT	O
),	O
blocking	O
the	O
DNA	O
-	O
dependent	O
DNA	B-PRGE
-	I-PRGE
polymerase	I-PRGE
activity	O
or	O
the	O
RNA	O
-	O
dependent	O
DNA	B-PRGE
-	I-PRGE
polymerase	I-PRGE
activity	O
working	O
as	O
common	O
NNRTIs	O
.	O

Of	O
note	O
,	O
MDA5	B-PRGE
protein	I-PRGE
levels	O
were	O
significantly	O
down	O
-	O
regulated	O
by	O
ORF8b	O
and	O
co	O
-	O
expression	O
of	O
ORF4a	B-PRGE
and	I-PRGE
ORF4b	I-PRGE
.	O

ECCO	O
Based	O
on	O
a	O
registry	O
,	O
we	O
report	O
a	O
low	O
rate	O
of	O
ECCO	O
ClinicalTrials	O
.	O
gov	O
:	O
Identifier	O
:	O
NCT02965079	O
retrospectively	O
registered	O
https	O
://	O
clinicaltrials	O
.	O
gov	B-PRGE
/	O
ct2	B-PRGE
/	O
show	O
/	O
NCT02965079	O
.	O

Incidence	O
of	O
ARF	B-PRGE
was	O
less	O
after	O
off	O
-	O
pump	O
coronary	O
artery	O
bypass	O
surgery	O
compared	O
with	O
on	O
-	O
pump	O
interventions	O
(	O
1	O
.	O
6	O
vs	O
.	O
3	O
.	O
5	O
%,	O
p	O
=	O
0	O
.	O
0469	O
).	O

This	O
study	O
was	O
aimed	O
at	O
evaluating	O
whether	O
microRNAs	O
(	O
miRNAs	O
)	O
in	O
circulating	O
exosomes	O
have	O
the	O
predictive	O
values	O
for	O
patients	O
at	O
risk	O
of	O
developing	O
ARDS	O
due	O
to	O
SCAP	B-PRGE
.	O

The	O
altered	O
levels	O
of	O
circulating	O
exosomal	O
microRNAs	O
may	O
be	O
useful	O
biologic	O
confirmation	O
of	O
ARDS	O
in	O
patients	O
with	O
SCAP	B-PRGE
.	O

Overexpression	O
of	O
exogenous	B-PRGE
G3BP1	I-PRGE
,	O
on	O
the	O
other	O
hand	O
,	O
lowered	O
virus	O
replication	O
by	O
100	O
-	O
fold	O
compared	O
to	O
vector	O
control	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
G3BP1	B-PRGE
plays	O
an	O
antiviral	O
role	O
and	O
impairs	O
PEDV	O
replication	O
.	O

ABSTRACT	O
:	O
Sickle	O
cell	O
disease	O
(	O
SCD	O
)	O
is	O
a	O
hereditary	O
hemoglobinopathy	O
resulting	O
in	O
sickling	O
hemoglobin	B-PRGE
.	O

Using	O
phage	O
display	O
technology	O
and	O
periplasmic	O
extraction	O
ELISA	O
(	O
PE	O
-	O
ELISA	O
),	O
anti	B-PRGE
-	I-PRGE
PEDV	I-PRGE
N	I-PRGE
protein	I-PRGE
nanobodies	I-PRGE
from	O
three	O
strains	O
of	O
PEDV	O
were	O
successfully	O
isolated	O
after	O
three	O
consecutive	O
rounds	O
of	O
bio	O
-	O
panning	O
from	O
a	O
high	O
quality	O
phage	O
display	O
VHH	O
library	O
.	O

RESULTS	O
:	O
Using	O
phage	O
display	O
technology	O
and	O
periplasmic	O
extraction	O
ELISA	O
(	O
PE	O
-	O
ELISA	O
),	O
anti	B-PRGE
-	I-PRGE
PEDV	I-PRGE
N	I-PRGE
protein	I-PRGE
nanobodies	I-PRGE
from	O
three	O
strains	O
of	O
PEDV	O
were	O
successfully	O
isolated	O
after	O
three	O
consecutive	O
rounds	O
of	O
bio	O
-	O
panning	O
from	O
a	O
high	O
quality	O
phage	O
display	O
VHH	O
library	O
.	O

Here	O
,	O
we	O
report	O
the	O
cryo	O
-	O
electron	O
microscopy	O
structure	O
of	O
the	O
PEDV	B-PRGE
S	I-PRGE
protein	I-PRGE
in	O
the	O
prefusion	O
conformation	O
at	O
a	O
resolution	O
of	O
3	O
.	O
1	O
Å	O
.	O
Our	O
studies	O
revealed	O
that	O
the	O
sialic	O
acid	O
-	O
binding	O
domain	O
at	O
the	O
N	O
terminus	O
of	O
the	O
S1	O
subunit	O
has	O
an	O
orientation	O
that	O
is	O
substantially	O
different	O
from	O
that	O
observed	O
in	O
the	O
previously	O
determined	O
spike	O
structure	O
from	O
human	B-PRGE
alphacoronavirus	I-PRGE
NL63	I-PRGE
.	O

As	O
a	O
first	O
step	O
toward	O
understanding	O
the	O
biology	O
of	O
the	O
PDCoV	O
accessory	O
proteins	O
,	O
we	O
established	O
a	O
stable	O
porcine	O
cell	O
line	O
constitutively	O
expressing	O
the	O
PDCoV	B-PRGE
NS7	I-PRGE
protein	I-PRGE
in	O
order	O
to	O
investigate	O
the	O
functional	O
characteristics	O
of	O
NS7	B-PRGE
for	O
viral	O
replication	O
.	O

ABSTRACT	O
:	O
The	O
efficacy	O
of	O
ustekinumab	O
,	O
an	O
antagonist	O
of	O
the	O
p40	B-PRGE
subunit	I-PRGE
of	O
interleukin	B-PRGE
-	I-PRGE
12	I-PRGE
and	O
interleukin	B-PRGE
-	I-PRGE
23	I-PRGE
,	O
as	O
induction	O
and	O
maintenance	O
therapy	O
in	O
patients	O
with	O
ulcerative	O
colitis	O
is	O
unknown	O
.	O

Potently	O
neutralizing	O
antibodies	O
targeting	O
the	O
receptor	B-PRGE
-	I-PRGE
binding	I-PRGE
domain	I-PRGE
(	O
RBD	O
)	O
on	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
protein	I-PRGE
have	O
been	O
characterized	O
,	O
but	O
much	O
less	O
is	O
known	O
about	O
antibodies	O
targeting	O
non	O
-	O
RBD	O
epitopes	O
.	O

The	O
CLR	B-PRGE
and	O
RLR	B-PRGE
pathways	O
are	O
activated	O
and	O
contribute	O
to	O
the	O
proinflammatory	O
response	O
in	O
MERS	O
-	O
CoV	O
-	O
infected	O
macrophages	O
.	O

ABSTRACT	O
:	O
Growth	O
Hormone	O
-	O
Releasing	O
Hormone	O
(	O
GHRH	B-PRGE
)	O
regulates	O
the	O
release	O
of	O
growth	O
hormone	O
from	O
the	O
anterior	O
pituitary	O
gland	O
.	O

GHRH	B-PRGE
antagonists	O
suppressed	O
the	O
activation	O
of	O
MLC2	B-PRGE
,	O
ERK1	B-PRGE
/	I-PRGE
2	I-PRGE
,	O
JAK2	B-PRGE
/	O
STAT3	B-PRGE
pathway	O
and	O
increased	O
the	O
intracellular	O
P53	B-PRGE
and	O
pAMPK	O
levels	O
.	O

In	O
contrast	O
,	O
both	O
GHRH	B-PRGE
and	O
GHRH	B-PRGE
agonist	O
MR409	O
exerted	O
the	O
opposite	O
effects	O
.	O

TITLE	O
:	O
Integrin	B-PRGE
αvβ3	I-PRGE
enhances	O
replication	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
on	O
Vero	O
E6	O
and	O
porcine	O
intestinal	O
epithelial	O
cells	O
.	O

The	O
integrin	B-PRGE
αv	I-PRGE
and	I-PRGE
β3	I-PRGE
subunits	I-PRGE
were	O
both	O
involved	O
in	O
the	O
enhancement	O
of	O
PEDV	O
infection	O
,	O
the	O
Arg	B-PRGE
-	I-PRGE
Gly	I-PRGE
-	I-PRGE
Asp	I-PRGE
peptides	I-PRGE
targeting	O
integrin	B-PRGE
αvβ3	I-PRGE
significantly	O
inhibited	O
replication	O
of	O
PEDV	O
in	O
Vero	O
E6	O
cells	O
,	O
and	O
co	O
-	O
expression	O
of	O
integrin	B-PRGE
αvβ3	I-PRGE
with	O
pAPN	O
significantly	O
enhanced	O
replication	O
of	O
PEDV	O
in	O
Vero	O
E6	O
and	O
BHK	O
-	O
21	O
cells	O
.	O

TITLE	O
:	O
Circular	O
RNA	O
CircEZH2	O
Suppresses	O
Transmissible	O
Gastroenteritis	O
Coronavirus	O
-	O
induced	O
Opening	O
of	O
Mitochondrial	O
Permeability	O
Transition	O
Pore	O
via	O
Targeting	O
MiR	B-PRGE
-	I-PRGE
22	I-PRGE
in	O
IPEC	O
-	O
J2	O
.	O

TITLE	O
:	O
An	O
in	O
vivo	O
cell	O
-	O
based	O
assay	O
for	O
investigating	O
the	O
specific	O
interaction	O
between	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
N	I-PRGE
-	I-PRGE
protein	I-PRGE
and	O
its	O
viral	O
RNA	O
packaging	O
sequence	O
.	O

Our	O
results	O
demonstrate	O
that	O
the	O
N	B-PRGE
-	I-PRGE
protein	I-PRGE
specifically	O
recognizes	O
the	O
SARS	O
-	O
CoV	O
packaging	O
signal	O
with	O
greater	O
affinity	O
compared	O
to	O
signals	O
from	O
other	O
coronaviruses	O
or	O
non	O
-	O
coronavirus	O
species	O
.	O

The	O
purified	O
SΔTM	O
from	O
silkworm	O
larvae	O
and	O
S	B-PRGE
protein	I-PRGE
-	O
displaying	O
nanovesicles	O
from	O
Bm5	O
cells	O
may	O
lead	O
to	O
the	O
development	O
of	O
nanoparticle	O
-	O
based	O
vaccines	O
against	O
MERS	O
-	O
CoV	O
and	O
the	O
diagnostic	O
detection	O
of	O
MERS	O
-	O
CoV	O
.	O

The	O
BCoV	B-PRGE
antigen	I-PRGE
distribution	O
was	O
prominent	O
within	O
the	O
necrotic	O
crypts	O
in	O
the	O
jejunum	O
and	O
cryptic	O
micro	O
-	O
abscesses	O
in	O
the	O
colon	O
and	O
ileum	O
.	O

Like	O
the	O
natural	O
penicillins	O
,	O
aminopenicillins	O
have	O
a	O
thiazolidine	O
ring	O
structure	O
connected	O
to	O
a	O
beta	O
-	O
lactam	O
ring	O
which	O
makes	O
these	O
agents	O
susceptible	O
to	O
inactivation	O
by	O
beta	B-PRGE
-	I-PRGE
lactamase	I-PRGE
,	O
the	O
usual	O
cause	O
of	O
bacterial	O
resistance	O
to	O
the	O
penicillins	O
.	O

In	O
addition	O
,	O
amoxicillin	O
is	O
commonly	O
used	O
in	O
combination	O
with	O
the	O
beta	B-PRGE
-	I-PRGE
lactamase	I-PRGE
inhibitor	O
clavulanic	O
acid	O
.	O

ABSTRACT	O
:	O
The	O
coronavirus	B-PRGE
S	I-PRGE
-	I-PRGE
protein	I-PRGE
mediates	O
receptor	O
binding	O
and	O
fusion	O
of	O
the	O
viral	O
and	O
host	O
cell	O
membranes	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
evidence	O
suggesting	O
that	O
recombinant	O
IBV	O
with	O
a	O
mutant	O
S2	O
'	O
site	O
(	O
furin	B-PRGE
-	I-PRGE
S2	I-PRGE
'	I-PRGE
site	I-PRGE
)	O
leads	O
to	O
higher	O
mortality	O
.	O

Furthermore	O
,	O
whole	O
-	O
genome	O
sequencing	O
identified	O
13	O
amino	O
acid	O
changes	O
in	O
P120	O
,	O
which	O
might	O
be	O
responsible	O
for	O
the	O
attenuated	O
virulence	O
of	O
P120	B-PRGE
.	O

In	O
addition	O
,	O
PSN	O
decreased	O
the	O
content	O
of	O
TNF	B-PRGE
-	I-PRGE
α	I-PRGE
,	O
IL	O
-	O
1β	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
the	O
expression	O
of	O
iNOS	O
,	O
as	O
well	O
as	O
the	O
production	O
of	O
NO	O
in	O
HKMRSA	O
-	O
induced	O
bone	O
marrow	O
derived	O
macrophages	O
(	O
BMDMs	O
).	O

Furthermore	O
,	O
treatment	O
with	O
PSN	O
suppressed	O
the	O
activation	O
of	O
MAPKs	O
(	O
e	O
.	O
g	O
.	O
p38	B-PRGE
MAPK	O
,	O
JNK	B-PRGE
and	O
ERK	B-PRGE
)	O
and	O
NF	O
-	O
κB	O
.	O
Collectively	O
,	O
our	O
results	O
suggest	O
that	O
PSN	O
ameliorates	O
gram	O
-	O
positive	O
bacteria	O
-	O
induced	O
ALI	O
in	O
mice	O
by	O
inhibition	O
of	O
the	O
MAPK	B-PRGE
and	O
NF	O
-	O
κB	O
signaling	O
pathways	O
,	O
and	O
our	O
studies	O
suggest	O
that	O
PSN	B-PRGE
might	O
be	O
a	O
novel	O
candidate	O
for	O
treating	O
ALI	O
/	O
ARDS	O
.	O

As	O
a	O
key	O
cytoplasmic	O
sensor	O
,	O
melanoma	O
differentiation	O
-	O
associated	O
gene	B-PRGE
5	I-PRGE
(	O
MDA5	B-PRGE
)	O
can	O
recognize	O
viral	O
RNA	O
and	O
enhance	O
the	O
antiviral	O
immune	O
response	O
.	O

Moreover	O
,	O
other	O
factors	O
including	O
hydrophobicity	O
and	O
aromaticity	O
have	O
been	O
also	O
found	O
to	O
influence	O
the	O
codon	O
usage	O
variation	O
among	O
the	O
PEDV	B-PRGE
orf3	I-PRGE
genes	I-PRGE
.	O

This	O
study	O
not	O
only	O
represents	O
the	O
most	O
systematic	O
analysis	O
of	O
codon	O
usage	O
patterns	O
in	O
PEDV	B-PRGE
orf3	I-PRGE
genes	I-PRGE
,	O
but	O
also	O
provides	O
a	O
basic	O
shaping	O
mechanism	O
of	O
the	O
codon	O
usage	O
bias	O
.	O

During	O
the	O
2014	O
-	O
2015	O
Ebola	O
outbreak	O
,	O
the	O
LRN	B-PRGE
-	I-PRGE
B	I-PRGE
uncovered	O
important	O
gaps	O
in	O
biosafety	O
and	O
biosecurity	O
practices	O
.	O

CONCLUSIONS	O
:	O
The	O
present	O
study	O
identified	O
several	O
MERS	B-PRGE
-	I-PRGE
COV	I-PRGE
S	I-PRGE
protein	I-PRGE
epitopes	I-PRGE
that	O
are	O
conserved	O
among	O
various	O
isolates	O
from	O
different	O
countries	O
.	O

However	O
,	O
CD4	B-PRGE

Both	O
DUB	B-PRGE
and	O
deISG	O
activities	O
are	O
implicated	O
in	O
suppressing	O
innate	O
immune	O
responses	O
;	O
however	O
,	O
the	O
precise	O
role	O
of	O
each	O
activity	O
in	O
this	O
process	O
is	O
still	O
unclear	O
due	O
in	O
part	O
to	O
the	O
difficulties	O
in	O
separating	O
each	O
activity	O
.	O

The	O
pathogenicity	O
of	O
rIBYZ	O
and	O
recombinant	O
viruses	O
was	O
examined	O
in	O
1	O
-	O
day	O
-	O
old	O
SPF	B-PRGE
chickens	I-PRGE
.	O

In	O
addition	O
,	O
artificial	O
changes	O
in	O
mortalin	O
expression	O
affected	O
the	O
cell	O
entry	O
of	O
transferrin	B-PRGE
,	O
further	O
confirming	O
the	O
above	O
results	O
.	O

The	O
large	O
economic	O
impact	O
of	O
PED	B-PRGE
on	O
the	O
swine	O
industry	O
worldwide	O
has	O
made	O
the	O
development	O
of	O
an	O
effective	O
PED	O
vaccine	O
a	O
necessity	O
.	O

Here	O
,	O
at	O
the	O
molecular	O
level	O
,	O
we	O
found	O
that	O
all	O
purified	O
bat	B-PRGE
CD26s	I-PRGE
(	O
bCD26s	O
)	O
from	O
a	O
diverse	O
range	O
of	O
species	O
interact	O
with	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
MERS	O
-	O
CoV	O
,	O
with	O
equilibrium	O
dissociation	O
constant	O
values	O
ranging	O
from	O
several	O
to	O
hundreds	O
at	O
the	O
micromolar	O
level	O
.	O

TITLE	O
:	O
Nucleocapsid	B-PRGE
Protein	I-PRGE
Recruitment	O
to	O
Replication	O
-	O
Transcription	O
Complexes	O
Plays	O
a	O
Crucial	O
Role	O
in	O
Coronaviral	O
Life	O
Cycle	O
.	O

In	O
infected	O
cells	O
,	O
N	O
proteins	O
are	O
present	O
at	O
the	O
replication	O
-	O
transcription	O
complexes	O
(	O
RTCs	O
),	O
the	O
sites	O
of	O
CoV	B-PRGE
RNA	I-PRGE
synthesis	O
.	O

It	O
has	O
been	O
shown	O
that	O
N	O
proteins	O
are	O
important	O
for	O
viral	O
replication	O
and	O
that	O
the	O
one	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
a	O
commonly	O
used	O
model	O
CoV	O
,	O
interacts	O
with	O
nonstructural	B-PRGE
protein	I-PRGE
3	I-PRGE
(	O
nsp3	B-PRGE
),	O
a	O
component	O
of	O
the	O
RTCs	O
.	O

A	O
selective	O
N	O
protein	O
variant	O
carrying	O
point	O
mutations	O
in	O
these	O
two	O
regions	O
fails	O
to	O
bind	O
nsp3	B-PRGE

When	O
compared	O
with	O
HBoV	O
detection	O
alone	O
,	O
the	O
co	O
-	O
detection	O
of	O
RSV	B-PRGE
and	O
HBoV	O
was	O
associated	O
with	O
male	O
sex	O
(	O
P	O
=	O
0	O
.	O
013	O
),	O
younger	O
age	O
(	O
P	O
=	O
0	O
.	O
01	O
),	O
and	O
lower	O
blood	O
neutrophil	O
count	O
(	O
P	O
=	O
0	O
.	O
032	O
).	O

Subsequent	O
review	O
of	O
the	O
patient	O
'	O
s	O
medical	O
history	O
and	O
correlation	O
with	O
autopsy	O
findings	O
confirmed	O
the	O
presence	O
of	O
multiple	O
organ	O
involvement	O
,	O
consistent	O
with	O
APS	B-PRGE
type	I-PRGE
1	I-PRGE
.	O

TITLE	O
:	O
Structures	O
of	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
in	O
complex	O
with	O
sialoside	O
attachment	O
receptors	O
.	O

TITLE	O
:	O
Development	O
and	O
Validation	O
of	O
a	O
S1	B-PRGE
Protein	I-PRGE
-	O
Based	O
ELISA	O
for	O
the	O
Specific	O
Detection	O
of	O
Antibodies	O
against	O
Equine	O
Coronavirus	O
.	O

Previously	O
,	O
we	O
demonstrated	O
that	O
MERS	O
-	O
CoV	O
-	O
encoded	O
ORF8b	O
strongly	O
inhibits	O
MDA5	B-PRGE
-	O
and	O
RIG	B-PRGE
-	I-PRGE
I	I-PRGE
-	O
mediated	O
induction	O
of	O
the	O
interferon	B-PRGE
beta	I-PRGE
(	O
IFN	B-PRGE
-	I-PRGE
β	I-PRGE
)	O
promoter	O
activities	O
.	O

Antigen	O
-	O
specific	O
humoral	O
and	O
cellular	O
immune	O
responses	O
were	O
evaluated	O
in	O
serum	O
and	O
in	O
cell	O
culture	O
following	O
S1	B-PRGE
protein	I-PRGE
expression	O
was	O
only	O
detected	O
by	O
IHC	O
in	O
the	O
kidneys	O
of	O
the	O
Ad	O
-	O
MERS	O
-	O
S1	O
group	O
at	O
week	O
6	O
from	O
first	O
immunization	O
,	O
and	O
in	O
both	O
lungs	O
and	O
kidneys	O
of	O
Ad	O
-	O
MERS	O
-	O
S1	O
group	O
by	O
conventional	O
PCR	O
at	O
weeks	O
3	O
and	O
5	O
post	O
-	O
prime	O
.	O

TITLE	O
:	O
In	O
silico	O
and	O
in	O
vitro	O
analysis	O
of	O
small	O
molecules	O
and	O
natural	O
compounds	O
targeting	O
the	O
3CL	B-PRGE
protease	I-PRGE
of	O
feline	O
infectious	O
peritonitis	O
virus	O
.	O

ABSTRACT	O
:	O
Interleukin	B-PRGE
-	I-PRGE
11	I-PRGE
(	O
IL	B-PRGE
-	I-PRGE
11	I-PRGE
),	O
a	O
well	O
-	O
known	O
anti	O
-	O
inflammatory	O
factor	O
,	O
provides	O
protection	O
from	O
intestinal	O
epithelium	O
damage	O
caused	O
by	O
physical	O
or	O
chemical	O
factors	O
.	O

The	O
potential	O
of	O
IL	B-PRGE
-	I-PRGE
11	I-PRGE
to	O
be	O
used	O
as	O
a	O
novel	O
therapeutic	O
against	O
devastating	O
viral	O
diarrhea	O
in	O
piglets	O
deserves	O
more	O
attention	O
and	O
study	O
.	O

Prof	O
.	O
Chyi	O
-	O
Her	O
Lin	B-PRGE
assembled	O
a	O
team	O
for	O
planning	O
medical	O
curricular	O
reform	O
.	O

MALAT1	B-PRGE
interacted	O
with	O
miR	O
-	O
425	O
and	O
protected	O
phosphatase	B-PRGE
and	I-PRGE
tensin	I-PRGE
homolog	I-PRGE
(	O
PTEN	B-PRGE
)	O
expression	O
in	O
A549	O
and	O
HFL	O
-	O
1	O
cells	O
.	O

Exosomes	O
from	O
ARDS	O
patients	O
delivered	O
less	O
miR	O
-	O
425	O
into	O
A549	O
and	O
HFL	O
-	O
1	O
cells	O
and	O
induced	O
cell	O
apoptosis	O
via	O
upregulating	O
PTEN	B-PRGE
.	O

The	O
most	O
frequent	O
mutations	O
were	O
present	O
in	O
the	O
collagenase	B-PRGE
equivalent	I-PRGE
(	O
COE	O
)	O
and	O
epitope	O
regions	O
of	O
the	O
spike	O
gene	O
of	O
the	O
PEDVs	O
currently	O
circulating	O
in	O
the	O
field	O
.	O

Here	O
,	O
we	O
present	O
a	O
method	O
based	O
on	O
western	O
blot	O
analysis	O
to	O
investigate	O
spike	O
protein	O
proteolytic	O
cleavage	O
by	O
transient	O
transfection	O
of	O
HEK	O
-	O
293	O
T	O
cells	O
allowing	O
expression	O
of	O
the	O
spike	O
protein	O
of	O
the	O
highly	O
pathogenic	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
in	O
the	O
presence	O
or	O
absence	O
of	O
a	O
cellular	B-PRGE
trypsin	I-PRGE
-	I-PRGE
like	I-PRGE
transmembrane	I-PRGE
serine	I-PRGE
protease	I-PRGE
,	I-PRGE
matriptase	I-PRGE
.	O

TITLE	O
:	O
Deducing	O
the	O
Crystal	O
Structure	O
of	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
Helicase	I-PRGE
.	O

To	O
study	O
the	O
pathogenesis	O
of	O
MERS	O
-	O
CoV	O
infection	O
and	O
development	O
of	O
medical	O
countermeasures	O
(	O
MCMs	O
)	O
for	O
MERS	O
,	O
a	O
number	O
of	O
genetically	O
modified	O
mouse	O
models	O
have	O
been	O
developed	O
,	O
including	O
various	O
versions	O
of	O
transgenic	O
mice	O
expressing	O
the	O
human	B-PRGE
DPP4	I-PRGE
viral	I-PRGE
receptor	I-PRGE
.	O

ABSTRACT	O
:	O
Indirect	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
enables	O
detection	O
and	O
quantification	O
of	O
antigen	B-PRGE
-	I-PRGE
specific	I-PRGE
antibodies	I-PRGE
in	O
biological	O
samples	O
such	O
as	O
human	O
or	O
animal	O
sera	O
.	O

SADS	O
-	O
CoV	O
also	O
blocked	O
poly	O
(	O
I	O
:	O
C	O
)-	O
induced	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
IRF	B-PRGE
-	I-PRGE
3	I-PRGE
and	O
NF	O
-	O
κB	O
.	O
Furthermore	O
,	O
SADS	O
-	O
CoV	O
did	O
not	O
interfere	O
with	O
the	O
activity	O
of	O
IFN	B-PRGE
-	I-PRGE
β	I-PRGE
promoter	I-PRGE
stimulated	O
by	O
IRF3	B-PRGE
,	O
TBK1	B-PRGE
and	O
IKKε	O
,	O
but	O
counteracted	O
its	O
activation	O
induced	O
by	O
IPS	B-PRGE
-	I-PRGE
1	I-PRGE
and	O
RIG	B-PRGE
-	I-PRGE
I	I-PRGE
.	O
Collectively	O
,	O
this	O
study	O
is	O
the	O
first	O
investigation	O
that	O
shows	O
interactions	O
between	O
SADS	O
-	O
CoV	O
and	O
the	O
host	O
innate	O
immunity	O
,	O
which	O
provides	O
information	O
of	O
the	O
molecular	O
mechanisms	O
underlying	O
SASD	O
-	O
CoV	O
infection	O
.	O

Here	O
,	O
the	O
role	O
of	O
TER94	B-PRGE
in	O
the	O
prototypic	O
baculovirus	O

The	O
type	B-PRGE
I	I-PRGE
interferon	I-PRGE
(	O
type	B-PRGE
I	I-PRGE
IFN	I-PRGE
)-	O
mediated	O
immune	O
responses	O
provide	O
host	O
protection	O
from	O
infectious	O
diseases	O
.	O

However	O
,	O
whether	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
)	O
antagonizes	O
the	O
type	B-PRGE
I	I-PRGE
IFN	I-PRGE
signaling	O
remains	O
unclear	O
.	O

Further	O
investigation	O
revealed	O
that	O
the	O
cleavage	O
products	O
of	O
NEMO	O
lost	O
the	O
ability	O
to	O
activate	O
the	O
IFN	B-PRGE
-	I-PRGE
β	I-PRGE
promoter	I-PRGE
.	O

Mechanistically	O
,	O
the	O
nsp5	B-PRGE
-	O
mediated	O
NEMO	O
cleavage	O
disrupted	O
the	O
recruitment	O
of	O
the	O
TRAF	B-PRGE
family	I-PRGE
member	I-PRGE
-	I-PRGE
associated	I-PRGE
NF	I-PRGE
-	I-PRGE
κB	I-PRGE
activator	I-PRGE
(	O
TANK	B-PRGE
)	O
to	O
NEMO	O
,	O
which	O
reduced	O
the	O
phosphorylation	O
of	O
interferon	B-PRGE
regulatory	I-PRGE
factor	I-PRGE
3	I-PRGE
(	O
IRF3	B-PRGE
),	O
leading	O
to	O
the	O
inhibition	O
of	O
type	B-PRGE
I	I-PRGE
IFN	I-PRGE
production	O
.	O

Although	O
both	O
enzymes	O
belong	O
to	O
the	O
same	O
exo	B-PRGE
(	I-PRGE
ribo	I-PRGE
)	I-PRGE
nuclease	I-PRGE
superfamily	I-PRGE
,	O
available	O
data	O
indicate	O
that	O
they	O
are	O
involved	O
in	O
very	O
different	O
pathways	O
.	O

Indeed	O
,	O
the	O
exoribonuclease	O
activity	O
carried	O
by	O
the	O
arenavirus	O
nucleoprotein	O
seems	O
to	O
counteract	O
the	O
innate	O
immunity	O
antiviral	O
response	O
while	O
the	O
exoribonuclease	O
activity	O
carried	O
by	O
the	O
coronavirus	O
nsp14	B-PRGE
protein	I-PRGE
is	O
likely	O
involved	O
in	O
a	O
unique	O
RNA	O
repair	O
mechanism	O
.	O

Therapeutic	O
LPV	O
/	O
RTV	B-PRGE
-	O
IFNb	B-PRGE
improves	O
pulmonary	O
function	O
but	O
does	O
not	O
reduce	O
virus	O
replication	O
or	O
severe	O
lung	O
pathology	O
.	O

Within	O
the	O
P	O
[	O
5	O
]	O
genotype	O
,	O
our	O
isolates	O
were	O
divided	O
into	O
two	O
lineages	O
:	O
P	B-PRGE
[	I-PRGE
5	I-PRGE
]-	I-PRGE
III	I-PRGE
and	O
P	B-PRGE
[	I-PRGE
5	I-PRGE
]-	I-PRGE
VIII	I-PRGE
.	O

Treatment	O
with	O
half	O
to	O
three	O
-	O
fourths	O
of	O
the	O
full	O
UVC	O
dose	O
(	O
0	O
·	O
2	O
J	O
/	O
cm	O
Our	O
study	O
demonstrates	O
that	O
both	O
THERAFLEX	O
UV	O
-	O
Platelets	O
(	O
UVC	O
)	O
and	O
THERAFLEX	B-PRGE
MB	I-PRGE
-	I-PRGE
Plasma	I-PRGE
(	O
MB	O
/	O
light	O
)	O
effectively	O
reduce	O
the	O
infectivity	O
of	O
SARS	O
-	O
CoV	O
,	O
CCHFV	O
and	O
NiV	O
in	O
platelet	O
concentrates	O
and	O
plasma	O
,	O
respectively	O
.	O

Lnc	O
-	O
MALAT1	B-PRGE
expression	O
and	O
inflammatory	O
cytokines	O
levels	O
were	O
detected	O
using	O
real	O
-	O
time	O
qPCR	O
and	O
ELISA	O
assay	O
respectively	O
.	O

Feline	O
enteric	O
coronavirus	O
(	O
FeCV	O
)	O
was	O
detected	O
in	O
46	O
%	O
of	O
fecal	O
samples	O
(	O
86	O
/	O
185	O
),	O
all	O
were	O
FeCV	B-PRGE
type	I-PRGE
1	I-PRGE
,	O
with	O
no	O
difference	O
between	O
household	O
or	O
shelter	O
cats	O
.	O

Three	O
intramuscular	O
or	O
oral	O
vaccinations	O
with	O
rAd	B-PRGE
-	I-PRGE
LTB	I-PRGE
-	I-PRGE
COE	I-PRGE
at	O
two	O
-	O
week	O
intervals	O
induced	O
robust	O
humoral	O
and	O
mucosal	O
immune	O
responses	O
.	O

The	O
antibody	O
designated	O
4E88	O
had	O
highest	O
binding	O
affinity	O
with	O
the	O
N	B-PRGE
protein	I-PRGE
and	O
was	O
chosen	O
for	O
in	O
-	O
depth	O
examination	O
.	O

In	O
present	O
study	O
,	O
we	O
investigated	O
the	O
role	O
of	O
gga	B-PRGE
-	I-PRGE
miR	I-PRGE
-	I-PRGE
30d	I-PRGE
in	O
the	O
process	O
of	O
IBV	O
infection	O
of	O
HD11	O
cell	O
line	O
in	O
vitro	O
.	O

By	O
transfecting	O
the	O
mimics	O
and	O
inhibitor	O
of	O
gga	B-PRGE
-	I-PRGE
miR	I-PRGE
-	I-PRGE
30d	I-PRGE
,	O
it	O
was	O
found	O
that	O
overexpressed	O
gga	B-PRGE
-	I-PRGE
miR	I-PRGE
-	I-PRGE
30d	I-PRGE
inhibited	O
IBV	O
replication	O
.	O

Serum	O
concentrations	O
of	O
vascular	B-PRGE
endothelial	I-PRGE
growth	I-PRGE
factor	I-PRGE
(	O
VEGF	B-PRGE
)	O
and	O
angiopoietin	B-PRGE
2	I-PRGE
(	O
Ang2	B-PRGE
)	O
were	O
determined	O
.	O

ECMO	O
support	O
in	O
ARDS	O
is	O
specifically	O
associated	O
with	O
an	O
increased	O
number	O
of	O
circulating	O
MSC	B-PRGE
,	O
most	O
likely	O
due	O
to	O
enhanced	O
mobilization	O
,	O
but	O
not	O
with	O
a	O
higher	O
numbers	O
of	O
EPC	O
or	O
serum	O
concentrations	O
of	O
VEGF	B-PRGE
and	O
Ang2	B-PRGE
.	O

During	O
ECMO	O
,	O
VEGF	B-PRGE
and	O
Ang2	B-PRGE
serum	I-PRGE
levels	O
remained	O
unchanged	O
compared	O
to	O
the	O
non	O
-	O
ECMO	O
group	O
(	O
p	O
=	O
0	O
.	O
16	O
),	O
but	O
Ang2	B-PRGE
serum	I-PRGE
levels	O
in	O
non	O
-	O
survivors	O
of	O
ARDS	O
were	O
significantly	O
increased	O
by	O
100	O
%	O
(	O
p	O
=	O
0	O
.	O
02	O
)	O
compared	O
to	O
survivors	O
.	O

The	O
nasopharyngeal	O
or	O
throat	O
swabs	O
of	O
these	O
six	O
patients	O
were	O
negative	O
for	O
known	O
respiratory	O
microbes	O
by	O
point	O
-	O
of	O
-	O
care	O
multiplex	O
RT	O
-	O
PCR	O
,	O
but	O
five	O
patients	O
(	O
four	O
adults	O
and	O
the	O
child	O
)	O
were	O
RT	O
-	O
PCR	O
positive	O
for	O
genes	O
encoding	O
the	O
internal	O
RNA	B-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
and	O
surface	B-PRGE
Spike	I-PRGE
protein	I-PRGE
of	O
this	O
novel	O
coronavirus	O
,	O
which	O
were	O
confirmed	O
by	O
Sanger	O
sequencing	O
.	O

By	O
Jan	B-PRGE
2	I-PRGE
,	O
2020	O
,	O
41	O
admitted	O
hospital	O
patients	O
had	O
been	O
identified	O
as	O
having	O
laboratory	O
-	O
confirmed	O
2019	O
-	O
nCoV	O
infection	O
.	O

TITLE	O
:	O
Return	O
of	O
the	O
Coronavirus	O
:	O
2019	O
-	O
nCoV	O
.	O
ABSTRACT	O
:	O
The	O
emergence	O
of	O
a	O
novel	O
coronavirus	O
(	O
2019	O
-	O
nCoV	O
)	O
has	O
awakened	O
the	O
echoes	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
from	O
nearly	O
two	O
decades	O
ago	O
.	O

Since	O
the	O
SARS	O
-	O
CoV	O
outbreak	O
in	O
2002	O
,	O
extensive	O
structural	O
analyses	O
have	O
revealed	O
key	O
atomic	O
-	O
level	O
interactions	O
between	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
spike	I-PRGE
protein	I-PRGE
receptor	I-PRGE
-	I-PRGE
binding	I-PRGE
domain	I-PRGE
(	O
RBD	O
)	O
and	O
its	O
host	O
receptor	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
),	O
which	O
regulate	O
both	O
the	O
cross	O
-	O
species	O
and	O
human	O
-	O
to	O
-	O
human	O
transmissions	O
of	O
SARS	O
-	O
CoV	O
.	O
Here	O
,	O
we	O
analyzed	O
the	O
potential	O
receptor	O
usage	O
by	O
2019	O
-	O
nCoV	O
,	O
based	O
on	O
the	O
rich	O
knowledge	O
about	O
SARS	O
-	O
CoV	O
and	O
the	O
newly	O
released	O
sequence	O
of	O
2019	O
-	O
nCoV	O
.	O
First	O
,	O
the	O
sequence	O
of	O
2019	O
-	O
nCoV	O
RBD	O
,	O
including	O
its	O
receptor	O
-	O
binding	O
motif	O
(	O
RBM	O
)	O
that	O
directly	O
contacts	O
ACE2	B-PRGE
,	O
is	O
similar	O
to	O
that	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
strongly	O
suggesting	O
that	O
2019	O
-	O
nCoV	O
uses	O
ACE2	O
as	O
its	O
receptor	O
.	O

For	O
example	O
,	O
some	O
bats	O
have	O
an	O
antiviral	O
immune	O
response	O
called	O
the	O
interferon	B-PRGE
pathway	O
perpetually	O
switched	O
on	O
.	O

Here	O
,	O
we	O
propose	O
for	O
the	O
first	O
time	O
that	O
inflammation	O
by	O
coronavirus	O
maybe	O
inhibited	O
by	O
anti	O
-	O
inflammatory	O
cytokines	O
belonging	O
to	O
the	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
family	I-PRGE
members	I-PRGE
.	O

In	O
our	O
baseline	O
scenario	O
,	O
we	O
estimated	O
that	O
the	O
basic	O
reproductive	O
number	O
for	O
2019	O
-	O
nCoV	O
was	O
2	O
·	O
68	O
(	O
95	O
%	O
CrI	O
2	O
·	O
47	O
-	O
2	O
·	O
86	O
)	O
and	O
that	O
75	O
815	O
individuals	O
(	O
95	O
%	O
CrI	O
37	O
304	O
-	O
130	O
330	O
)	O
have	O
been	O
infected	O
in	O
Wuhan	O
as	O
of	O
Jan	B-PRGE
25	I-PRGE
,	O
2020	O
.	O

We	O
cloned	O
camel	O
IFN	B-PRGE
-	I-PRGE
α	I-PRGE
coding	O
sequences	O
and	O
identified	O
a	O
total	O
of	O
eleven	O
subtypes	O
.	O

These	O
results	O
demonstrate	O
that	O
TGEVs	O
enter	O
ST	O
cells	O
via	O
clathrin	B-PRGE
-	O
and	O
caveolae	O
-	O
mediated	O
endocytic	O
,	O
actin	B-PRGE
-	I-PRGE
dependent	I-PRGE
,	I-PRGE
and	I-PRGE
dynamin	I-PRGE
2	I-PRGE
-	O
dependent	O
pathways	O
.	O

Herein	O
in	O
the	O
present	O
study	O
,	O
we	O
investigated	O
effects	O
of	O
Nox2	B-PRGE
,	O
the	O
catalytic	O
subunit	O
of	O
nicotinamide	O
adenine	O
dinucleotide	O
phosphate	O
(	O
NADPH	O
)	O
oxidase	O
type	O
2	O
,	O
on	O
LPS	O
-	O
induced	O
epithelium	O
injury	O
in	O
ARDS	O
mice	O
and	O
in	O
human	O
alveolar	O
epithelial	O
A549	O
cells	O
.	O

Moreover	O
,	O
VAS2870	O
proved	O
to	O
inhibit	O
Nox2	B-PRGE
expression	O
,	O
reduce	O
ROS	O
generation	O
,	O
restore	O
epithelium	O
barrier	O
integrity	O
,	O
and	O
preserve	O
cell	O
viability	O
in	O
LPS	O
-	O
induced	O
A549	O
cells	O
.	O

Drugs	O
are	O
possibly	O
effective	O
for	O
2019	O
-	O
nCoV	O
include	O
:	O
remdesivir	O
,	O
lopinavir	O
/	O
ritonavir	O
,	O
lopinavir	O
/	O
ritonavir	O
combined	O
with	O
interferon	B-PRGE
-	I-PRGE
β	I-PRGE
,	O
convalescent	O
plasma	O
,	O
and	O
monoclonal	O
antibodies	O
.	O

Exosomes	O
containing	O
self	O
-	O
antigens	O
,	O
20S	B-PRGE
proteasome	I-PRGE
,	O
and	O
viral	O
antigens	O
were	O
detected	O
at	O
significantly	O
higher	O
levels	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
serum	O
of	O
recipients	O
with	O
symptomatic	O
respiratory	O
viral	O
infections	O
(	O
n	O
=	O
35	O
)	O
as	O
compared	O
with	O
stable	O
controls	O
(	O
n	O
=	O
32	O
).	O

EIC	B-PRGE
mutations	O
were	O
also	O
implicated	O
in	O
regulating	O
IBV	O
-	O
induced	O
apoptosis	O
,	O
induction	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
and	O
viral	O
pathogenicity	O

Oseltamivir	O
is	O
the	O
most	O
widely	O
used	O
neuraminidase	B-PRGE
inhibitor	O
for	O
treatment	O
of	O
influenza	O
;	O
data	O
suggest	O
that	O
early	O
use	O
is	O
associated	O
with	O
reduced	O
mortality	O
in	O
critically	O
ill	O
patients	O
with	O
influenza	O
.	O

TITLE	O
:	O
Recombinant	O
infectious	O
bronchitis	O
coronavirus	O
H120	O
with	O
the	O
spike	B-PRGE
protein	I-PRGE
S1	I-PRGE
gene	I-PRGE
of	O
the	O
nephropathogenic	O
IBYZ	O
strain	O
remains	O
attenuated	O
but	O
induces	O
protective	O
immunity	O
.	O

TITLE	O
:	O
The	O
spike	O
glycoprotein	O
of	O
the	O
new	O
coronavirus	O
2019	O
-	O
nCoV	O
contains	O
a	O
furin	B-PRGE
-	O
like	O
cleavage	O
site	O
absent	O
in	O
CoV	O
of	O
the	O
same	O
clade	O
.	O

The	O
binding	O
of	O
COVID	O
-	O
19	O
and	O
ACE2	B-PRGE
resulted	O
in	O
the	O
exhaustion	O
of	O
ACE2	B-PRGE
,	O
and	O
then	O
ACE2	B-PRGE
/	I-PRGE
Ang	I-PRGE
(	I-PRGE
1	I-PRGE
-	I-PRGE
7	I-PRGE
)/	I-PRGE
Mas	I-PRGE
receptor	I-PRGE
pathway	O
was	O
inhibited	O
.	O

CDV	B-PRGE
RNA	I-PRGE
was	O
mainly	O
detected	O
in	O
the	O
Canidae	O
family	O
,	O
with	O
viral	O
nucleic	O
acid	O
recorded	O
between	O
2005	O
and	O
2008	O
with	O
a	O
peak	O
prevalence	O
of	O
67	O
%	O
among	O
the	O
wolf	O
population	O
,	O
followed	O
by	O
a	O
sharp	O
decline	O
,	O
suggesting	O
an	O
epizootic	O
behaviour	O
of	O
the	O
virus	O
.	O

TITLE	O
:	O
Potent	O
binding	O
of	O
2019	O
novel	O
coronavirus	O
spike	O
protein	O
by	O
a	O
SARS	B-PRGE
coronavirus	I-PRGE
-	I-PRGE
specific	I-PRGE
human	I-PRGE
monoclonal	I-PRGE
antibody	I-PRGE
.	O

Considering	O
the	O
relatively	O
high	O
identity	O
of	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
in	O
2019	O
-	O
nCoV	O
and	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
it	O
is	O
urgent	O
to	O
assess	O
the	O
cross	O
-	O
reactivity	O
of	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
CoV	I-PRGE
antibodies	I-PRGE
with	O
2019	O
-	O
nCoV	O
spike	O
protein	O
,	O
which	O
could	O
have	O
important	O
implications	O
for	O
rapid	O
development	O
of	O
vaccines	O
and	O
therapeutic	O
antibodies	O
against	O
2019	O
-	O
nCoV	O
.	O
Here	O
,	O
we	O
report	O
for	O
the	O
first	O
time	O
that	O
a	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
specific	I-PRGE
human	I-PRGE
monoclonal	I-PRGE
antibody	I-PRGE
,	O
CR3022	O
,	O
could	O
bind	O
potently	O
with	O
2019	O
-	O
nCoV	O
RBD	O
(	O
KD	O
of	O
6	O
.	O
3	O
nM	O
).	O

The	O
epitope	O
of	O
CR3022	O
does	O
not	O
overlap	O
with	O
the	O
ACE2	B-PRGE
binding	I-PRGE
site	I-PRGE
within	O
2019	O
-	O
nCoV	O
RBD	O
.	O

TITLE	O
:	O
Effect	O
of	O
Intravenous	O
Interferon	B-PRGE
β	I-PRGE
-	I-PRGE
1a	I-PRGE
on	O
Death	O
and	O
Days	O
Free	O
From	O
Mechanical	O
Ventilation	O
Among	O
Patients	O
With	O
Moderate	O
to	O
Severe	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
:	O
A	O
Randomized	O
Clinical	O
Trial	O
.	O

At	O
28	O
days	O
,	O
the	O
median	O
composite	O
score	O
of	O
death	O
and	O
number	O
of	O
ventilator	O
-	O
free	O
days	O
at	O
day	O
28	O
was	O
10	O
days	O
(	O
interquartile	O
range	O
,	O
-	O
1	O
to	O
20	O
)	O
in	O
the	O
IFN	B-PRGE
-	I-PRGE
β	I-PRGE
-	I-PRGE
1a	I-PRGE
group	O
and	O
8	O
.	O
5	O
days	O
(	O
interquartile	O
range	O
,	O
0	O
to	O
20	O
)	O
in	O
the	O
placebo	O
group	O
(	O
P	O
=	O
.	O
82	O
).	O

The	O
ECEs	O
of	O
9	O
-	O
11	O
days	O
old	O
were	O
treated	O
with	O
different	O
doses	O
(	O
high	O
,	O
intermediate	O
and	O
low	O
)	O
of	O
TLR	O
-	O
2	O
(	O
Pam3CSK4	O
),	O
TLR	O
-	O
4	O
(	O
LPS	B-PRGE
)	O
and	O
TLR	O
-	O
21	O
(	O
CpG	O
ODN	O
)	O
ligands	O
.	O

iNOS	B-PRGE
and	O
OAS	O
genes	O
in	O
CAM	O
.	O

HSP90	B-PRGE
/	O
p23	B-PRGE
is	O
a	O
novel	O
RIP3	B-PRGE
-	O
and	O
MLKL	B-PRGE
-	I-PRGE
interacting	I-PRGE
complex	I-PRGE
in	O
RIP	B-PRGE
-	O
MLKL	B-PRGE
-	O
mediated	O
necroptosis	O
,	O
inflammation	O
and	O
endothelial	O
dysfunction	O
.	O

The	O
overall	O
mortality	O
was	O
11	O
.	O
5	O
%,	O
the	O
non	O
-	O
survivors	O
revealed	O
significantly	O
higher	O
D	O
-	O
dimer	O
and	O
fibrin	O
degradation	O
product	O
(	O
FDP	B-PRGE
)	O
levels	O
,	O
longer	O
prothrombin	B-PRGE
time	O
and	O
activated	O
partial	O
thromboplastin	B-PRGE
time	O
compared	O
to	O
survivors	O
on	O
admission	O
(	O
P	O
<	O
.	O
05	O
);	O
71	O
.	O
4	O
%	O
of	O
non	O
-	O
survivors	O
and	O
0	O
.	O
6	O
%	O
survivors	O
met	O
the	O
criteria	O
of	O
disseminated	O
intravascular	O
coagulation	O
during	O
their	O
hospital	O
stay	O
.	O

ABSTRACT	O
:	O
This	O
is	O
the	O
third	O
epidemiological	O
report	O
for	O
coronavirus	O
disease	O
2019	O
(	O
COVID	O
-	O
19	O
),	O
previously	O
known	O
as	O
novel	O
coronavirus	O
(	O
2019	O
-	O
nCoV	O
),	O
from	O
the	O
virus	O
now	O
known	O
as	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
,	O
reported	O
in	O
Australia	O
as	O
at	O
19	O
:	O
00	O
Australian	O
Eastern	O
Daylight	O
Time	O
[	O
AEDT	O
]	O
15	O
February	O
2020	O
.	O

The	O
CoV	B-PRGE
spike	I-PRGE
(	I-PRGE
S	I-PRGE
)	I-PRGE
glycoprotein	I-PRGE
is	O
a	O
key	O
target	O
for	O
vaccines	O
,	O
therapeutic	O
antibodies	O
,	O
and	O
diagnostics	O
.	O

We	O
also	O
provide	O
biophysical	O
and	O
structural	O
evidence	O
that	O
the	O
2019	B-PRGE
-	I-PRGE
nCoV	I-PRGE
S	I-PRGE
protein	I-PRGE
binds	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
)	O
with	O
higher	O
affinity	O
than	O
does	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	O
S	O
.	O
Additionally	O
,	O
we	O
tested	O
several	O
published	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
RBD	I-PRGE
-	I-PRGE
specific	I-PRGE
monoclonal	I-PRGE
antibodies	I-PRGE
and	O
found	O
that	O
they	O
do	O
not	O
have	O
appreciable	O
binding	O
to	O
2019	O
-	O
nCoV	O
S	O
,	O
suggesting	O
that	O
antibody	O
cross	O
-	O
reactivity	O
may	O
be	O
limited	O
between	O
the	O
two	O
RBDs	O
.	O

Significantly	O
higher	O
levels	O
of	O
D	O
-	O
dimer	O
,	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
,	O
and	O
procalcitonin	O
were	O
associated	O
with	O
severe	O
patients	O
compared	O
to	O
nonsevere	O
patients	O
(	O
all	O
P	O
<	O
.	O
001	O
).	O

Phylogenetic	O
analyses	O
of	O
whole	O
genome	O
sequences	O
showed	O
that	O
it	O
clustered	O
with	O
other	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
reported	O
from	O
Wuhan	O
.	O

TITLE	O
:	O
Structure	O
analysis	O
of	O
the	O
receptor	O
binding	O
of	O
2019	O
-	O
nCoV	O
.	O
ABSTRACT	O
:	O
2019	O
-	O
nCoV	O
is	O
a	O
newly	O
identified	O
coronavirus	O
with	O
high	O
similarity	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
We	O
performed	O
a	O
structural	O
analysis	O
of	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
spike	O
glycoprotein	O
responsible	O
for	O
entry	O
of	O
coronaviruses	O
into	O
host	O
cells	O
.	O

Finally	O
,	O
antibodies	O
and	O
small	O
molecular	O
inhibitors	O
that	O
can	O
block	O
the	O
interaction	O
of	O
ACE2	B-PRGE
with	O
RBD	O
should	O
be	O
developed	O
to	O
combat	O
the	O
virus	O
.	O

Therefore	O
,	O
a	O
successful	O
PEDV	O
vaccine	O
must	O
induce	O
protective	O
maternal	O
IgA	B-PRGE
antibodies	I-PRGE
that	O
passively	O
transfer	O
into	O
colostrum	O
and	O
milk	O
.	O

PDCoV	O
has	O
been	O
successfully	O
isolated	O
using	O
various	O
medium	O
additives	O
including	O
trypsin	B-PRGE
,	O
and	O
although	O
we	O
know	O
it	O
is	O
important	O
for	O
viral	O
replication	O
,	O
the	O
mechanism	O
has	O
not	O
been	O
fully	O
elucidated	O
.	O

We	O
also	O
demonstrated	O
that	O
trypsin	B-PRGE
promotes	O
PDCoV	O
replication	O
by	O
enhancing	O
cell	O
-	O
to	O
-	O
cell	O
membrane	O
fusion	O
.	O

Overall	O
,	O
these	O
results	O
clarify	O
that	O
trypsin	B-PRGE
promotes	O
PDCoV	O
replication	O
by	O
mediating	O
cell	O
-	O
to	O
-	O
cell	O
fusion	O
transmission	O
but	O
is	O
not	O
crucial	O
for	O
viral	O
entry	O
.	O

One	O
possible	O
answer	O
is	O
antibody	O
dependent	O
enhancement	O
(	O
ADE	O
)	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
due	O
to	O
prior	O
exposure	O
to	O
other	O
coronaviruses	O
.	O

The	O
coronavirus	B-PRGE
3C	I-PRGE
-	I-PRGE
like	I-PRGE
protease	I-PRGE
(	O
3CL	O

We	O
speculate	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
may	O
be	O
detected	O
in	O
the	O
tears	O
and	O
conjunctival	O
secretions	O
in	O
NCP	O
patients	O
with	O
conjunctivitis	O
.	O

Currently	O
,	O
a	O
novel	O
coronavirus	O
(	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
),	O
which	O
has	O
become	O
the	O
cause	O
of	O
the	O
outbreak	O
of	O
Coronavirus	O
Disease	O
2019	O
(	O
COVID	O
-	O
19	O
),	O
was	O
discovered	O
.	O

The	O
temperature	O
profile	O
of	O
NPA	O
exhibits	O
30	O
cycles	O
between	O
98	O
and	O
60	O
°	O
C	O
for	O
a	O
total	O
of	O
3	O
min	O
and	O
30	O
s	O
during	O
the	O
cyclic	O
excitation	O
of	O
white	O
LED	B-PRGE
light	I-PRGE
.	O

TITLE	O
:	O
The	O
neuroinvasive	O
potential	O
of	O
SARS	B-PRGE
-	O
CoV2	O
may	O
play	O
a	O
role	O
in	O
the	O
respiratory	O
failure	O
of	O
COVID	O
-	O
19	O
patients	O
.	O

We	O
have	O
developed	O
a	O
rapid	O
and	O
simple	O
point	O
-	O
of	O
-	O
care	O
lateral	O
flow	O
immunoassay	O
which	O
can	O
detect	O
IgM	B-PRGE
and	O
IgG	B-PRGE
antibodies	I-PRGE
simultaneously	O
against	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
virus	O
in	O
human	O
blood	O
within	O
15	O
minutes	O
which	O
can	O
detect	O
patients	O
at	O
different	O
infection	O
stages	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
is	O
to	O
communicate	O
the	O
most	O
recent	O
information	O
regarding	O
the	O
highly	O
interrelated	O
P53	B-PRGE
/	O
RhoA	B-PRGE
network	O
.	O

By	O
considering	O
the	O
hydrophobic	O
complementarity	O
during	O
the	O
virtual	O
screening	O
step	O
,	O
we	O
identified	O
5	O
-	O
benzyloxygramine	O
as	O
a	O
new	O
N	B-PRGE
protein	I-PRGE
PPI	O
orthosteric	O
stabilizer	O
that	O
exhibits	O
both	O
antiviral	O
and	O
N	O
-	O
NTD	O
protein	O
-	O
stabilizing	O
activities	O
.	O

ABSTRACT	O
:	O
Targeting	O
inflammasome	O
activation	O
to	O
modulate	O
interleukin	B-PRGE
(	O
IL	O
)-	O
1β	O
is	O
a	O
promising	O
treatment	O
strategy	O
against	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
ventilator	O
-	O
induced	O
lung	O
injury	O
(	O
VILI	O
).	O

Using	O
a	O
multiple	O
linear	O
regression	O
model	O
(	O
F	O
=	O
2	O
.	O
669	O
,	O
P	O
=	O
0	O
.	O
044	O
,	O
and	O
adjusted	O
R	O
=	O
0	O
.	O
122	O
),	O
the	O
analysis	O
showed	O
that	O
the	O
CD4	B-PRGE
+	I-PRGE
T	O
lymphocyte	O
count	O
may	O
help	O
predict	O
the	O
duration	O
of	O
viral	O
RNA	O
detection	O
in	O
patients	O
'	O
stools	O
(	O
t	O
=	O
-	O
2	O
.	O
699	O
,	O
P	O
=	O
0	O
.	O
010	O
).	O

Multivariate	O
logistic	O
analysis	O
indicated	O
that	O
age	O
(	O
odds	O
ratio	O
[	O
OR	O
],	O
8	O
.	O
546	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]:	O
1	O
.	O
628	O
-	O
44	O
.	O
864	O
;	O
P	O
=	O
0	O
.	O
011	O
),	O
history	O
of	O
smoking	O
(	O
OR	O
,	O
14	O
.	O
285	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
577	O
-	O
25	O
.	O
000	O
;	O
P	O
=	O
0	O
.	O
018	O
),	O
maximum	O
body	O
temperature	O
at	O
admission	O
(	O
OR	O
,	O
8	O
.	O
999	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
036	O
-	O
78	O
.	O
147	O
,	O
P	O
=	O
0	O
.	O
046	O
),	O
respiratory	O
failure	O
(	O
OR	O
,	O
8	O
.	O
772	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
942	O
-	O
40	O
.	O
000	O
;	O
P	O
=	O
0	O
.	O
016	O
),	O
albumin	B-PRGE
(	O
OR	O
,	O
7	O
.	O
353	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
098	O
-	O
50	O
.	O
000	O
;	O
P	O
=	O
0	O
.	O
003	O
),	O
and	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
(	O
OR	O
,	O
10	O
.	O
530	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
224	O
-	O
34	O
.	O
701	O
,	O
P	O
=	O
0	O
.	O
028	O
)	O
were	O
risk	O
factors	O
for	O
disease	O
progression	O
.	O

ABSTRACT	O
:	O
A	O
newly	O
emerged	O
Human	B-PRGE
Coronavirus	I-PRGE
(	O
HCoV	O
)	O
is	O
reported	O
two	O
months	O
ago	O
in	O
Wuhan	O
,	O
China	O
(	O
COVID	O
-	O
19	O
).	O

SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
is	O
a	O
novel	O
corona	O
virus	O
,	O
the	O
onset	O
of	O
COVID	O
-	O
19	O
is	O
slow	O
,	O
and	O
the	O
pathogenesis	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
remains	O
unclear	O
and	O
may	O
lead	O
to	O
multiple	O
organ	O
damage	O
.	O

Routes	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
transmission	O
are	O
diversified	O
and	O
the	O
main	O
routes	O
of	O
transmission	O
for	O
COVID	O
-	O
19	O
are	O
droplet	O
transmission	O
and	O
close	O
contact	O
transmission	O
.	O

Potential	O
therapeutic	O
tools	O
to	O
reduce	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
-	O
induced	O
inflammatory	O
responses	O
include	O
various	O
methods	O
to	O
block	O
FcR	O
activation	O
.	O

Vehicle	O
,	O
nafithromycin	O
(	O
100	O
mg	O
/	O
kg	O
),	O
azithromycin	O
(	O
600	O
mg	O
/	O
kg	O
)	O
and	O
dexamethasone	O
(	O
20	O
mg	O
/	O
kg	O
)	O
were	O
administered	O
orally	O
,	O
1	O
h	O
prior	O
to	O
LPS	O
challenge	O
and	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluid	O
was	O
collected	O
thereafter	O
at	O
18	O
,	O
24	O
and	O
48	O
h	O
to	O
determine	O
the	O
total	O
cell	O
count	O
,	O
total	O
protein	O
,	O
myeloperoxidase	B-PRGE
(	O
MPO	B-PRGE
),	O
tumor	B-PRGE
necrosis	I-PRGE
factor	I-PRGE
(	O
TNF	O
)-	O
α	O
and	O
interleukin	B-PRGE
(	O
IL	O
)-	O
6	O
.	O

TITLE	O
:	O
Angiotensin	B-PRGE
receptor	I-PRGE
blockers	O
as	O
tentative	O
SARS	O
-	O
CoV	O
-	O
2	O
therapeutics	O
.	O

ABSTRACT	O
:	O
Angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
)	O
is	O
the	O
cellular	O
receptor	O
for	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
the	O
new	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
-	O
2	O
)	O
that	O
is	O
causing	O
the	O
serious	O
epidemic	O
COVID	O
-	O
19	O
.	O

ABSTRACT	O
:	O
In	O
late	O
December	O
2019	O
,	O
a	O
cluster	O
of	O
cases	O
with	O
2019	O
Novel	O
Coronavirus	O
pneumonia	O
(	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
)	O
in	O
Wuhan	O
,	O
China	O
,	O
aroused	O
worldwide	O
concern	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
239	O
patients	O
were	O
included	O
with	O
139	O
(	O
58	O
.	O
2	O
%)	O
and	O
100	O
(	O
41	O
.	O
8	O
%)	O
in	O
the	O
iEPO	O
and	O
iNO	B-PRGE
groups	O
,	O
respectively	O
.	O

The	O
mean	O
change	O
in	O
Pao	O
CONCLUSIONS	O
:	O
Fixed	O
-	O
dose	O
iEPO	O
was	O
comparable	O
to	O
iNO	B-PRGE
in	O
patients	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	O
for	O
oxygenation	O
and	O
ventilation	O
parameters	O
as	O
well	O
as	O
clinical	O
outcomes	O
.	O

Subsequent	O
investigations	O
revealed	O
a	O
novel	O
coronavirus	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
,	O
as	O
the	O
causative	O
agent	O
now	O
at	O
the	O
heart	O
of	O
a	O
major	O
outbreak	O
.	O

COVID	O
-	O
19	O
causes	O
COVID	O
-	O
19	O
disease	O
that	O
has	O
similar	O
symptoms	O
as	O
SARS	O
-	O
CoV	O
.	O
Studies	O
suggest	O
that	O
the	O
human	O
receptor	O
for	O
COVID	O
-	O
19	O
may	O
be	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	I-PRGE
ACE2	I-PRGE
)	I-PRGE
receptor	I-PRGE
similar	O
to	O
that	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
.	O
The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
COVID	O
-	O
19	O
has	O
nearly	O
90	O
%	O
amino	O
acid	O
sequence	O
identity	O
with	O
SARS	O
-	O
CoV	O
.	O
The	O
N	O
protein	O
antibodies	O
of	O
SARS	B-PRGE
-	O
CoV	O
may	O
cross	O
react	O
with	O
COVID	O
-	O
19	O
but	O
may	O
not	O
provide	O
cross	O
-	O
immunity	O
.	O

In	O
a	O
similar	O
fashion	O
to	O
SARS	O
-	O
CoV	O
,	O
the	O
N	B-PRGE
protein	I-PRGE
of	O
COVID	O
-	O
19	O
may	O
play	O
an	O
important	O
role	O
in	O
suppressing	O
the	O
RNA	O
interference	O
(	O
RNAi	O
)	O
to	O
overcome	O
the	O
host	O
defense	O
.	O

We	O
also	O
recorded	O
the	O
information	O
from	O
research	O
documents	O
published	O
in	O
global	O
scientific	O
journals	O
indexed	O
in	O
ISI	O
Web	O
of	O
Science	O
and	O
research	O
centers	O
on	O
the	O
prevalence	O
,	O
biological	O
and	O
clinical	O
characteristics	O
of	O
2019	O
-	O
nCoV	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
and	O
MERS	O
-	O
CoV	O
.	O
Worldwide	O
,	O
SARS	O
-	O
CoV	O
involved	O
32	O
countries	O
,	O
with	O
8422	O
confirmed	O
cases	O
and	O
916	O
(	O
10	O
.	O
87	O
%)	O
casualties	O
from	O
November	O
2002	O
to	O
August	O
2003	O
.	O

The	O
fatality	O
rate	O
of	O
coronavirus	O
MERS	O
-	O
CoV	O
was	O
(	O
34	O
.	O
77	O
%)	O
higher	O
than	O
SARS	O
-	O
CoV	O
(	O
10	O
.	O
87	O
%)	O
and	O
2019	O
-	O
nCoV	O
(	O
2	O
.	O
08	O
%);	O
however	O
,	O
the	O
2019	O
-	O
nCoV	O
transmitted	O
rapidly	O
in	O
comparison	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
and	O
MERS	O
-	O
CoV	O
.	O

However	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
possesses	O
powerful	O
pathogenicity	O
as	O
well	O
as	O
transmissibility	O
and	O
still	O
holds	O
many	O
mysteries	O
that	O
are	O
yet	O
to	O
be	O
solved	O
,	O
such	O
as	O
whether	O
the	O
virus	O
can	O
be	O
transmitted	O
by	O
asymptomatic	O
patients	O
or	O
by	O
mothers	O
to	O
their	O
infants	O
.	O

In	O
contrast	O
,	O
the	O
seropositivity	O
rate	O
of	O
MERS	B-PRGE
-	I-PRGE
CoV	I-PRGE
IgG	I-PRGE
in	O
humans	O
did	O
not	O
differ	O
significantly	O
by	O
any	O
of	O
the	O
studied	O
factors	O
.	O

ABSTRACT	O
:	O
While	O
erythromycin	O
has	O
caused	O
numerous	O
cases	O
of	O
acute	O
liver	O
failure	O
(	O
ALF	O
),	O
clarithromycin	O
,	O
a	O
similar	O
macrolide	O
antibiotic	O
,	O
has	O
caused	O
only	O
six	O
reported	O
cases	O
of	O
ALF	B-PRGE
.	O

Review	O
of	O
6	O
previously	O
reported	O
and	O
current	O
case	O
of	O
clarithromycin	O
-	O
associated	O
ALF	B-PRGE
revealed	O
that	O
patients	O
had	O
AST	B-PRGE
and	O
ALT	B-PRGE
values	O
in	O
the	O
thousands	O
.	O

ABSTRACT	O
:	O
Following	O
reports	O
of	O
patients	O
with	O
unexplained	O
pneumonia	O
at	O
the	O
end	O
of	O
December	O
2019	O
in	O
Wuhan	O
,	O
China	O
,	O
the	O
causative	O
agent	O
was	O
identified	O
as	O
coronavirus	O
(	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
),	O
and	O
the	O
2019	O
novel	O
coronavirus	O
disease	O
was	O
named	O
COVID	O
-	O
19	O
by	O
the	O
World	O
Health	O
Organization	O
.	O

The	O
role	O
of	O
fibrinolytic	O
components	O
such	O
as	O
Urokinase	B-PRGE
Plasminogen	I-PRGE
activator	I-PRGE
(	O
uPA	B-PRGE
),	O
uPA	B-PRGE
receptor	I-PRGE
(	O
uPAR	B-PRGE
)	O
and	O
Plasminogen	B-PRGE
activator	I-PRGE
inhibitor	I-PRGE
-	I-PRGE
1	I-PRGE
(	O
PAI	B-PRGE
-	I-PRGE
1	I-PRGE
)	O
has	O
been	O
detailed	O
in	O
I	O
.	O
Curcumin	O
is	O
known	O
to	O
possess	O
anti	O
-	O
inflammatory	O
and	O
anti	O
-	O
fibrotic	O
effects	O
.	O

A	O
2019	O
-	O
nCoV	O
related	O
pangolin	B-PRGE
coronavirus	I-PRGE
GX_P2V	I-PRGE
/	O
pangolin	B-PRGE
/	O
2017	O
/	O
Guangxi	O
was	O
described	O
.	O

ABSTRACT	O
:	O
The	O
Severe	O
Acute	B-PRGE
Respiratory	I-PRGE
Syndrome	I-PRGE
Coronavirus	I-PRGE
2	I-PRGE
(	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
)	O
first	O
broke	O
out	O
in	O
Wuhan	O
(	O
China	O
)	O
and	O
subsequently	O
spread	O
worldwide	O
.	O

In	O
addition	O
,	O
a	O
combination	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
protease	O
inhibitors	O
,	O
lopinavir	O
/	O
ritonavir	O
,	O
and	O
interferon	B-PRGE
beta	I-PRGE
(	O
LPV	O
/	O
RTV	B-PRGE
-	I-PRGE
INFb	I-PRGE
)	O
were	O
shown	O
to	O
be	O
effective	O
in	O
patients	O
infected	O
with	O
SARS	O
-	O
CoV	O
.	O
LPV	O
/	O
RTV	B-PRGE
-	I-PRGE
INFb	I-PRGE
also	O
improved	O
clinical	O
parameters	O
in	O
marmosets	O
and	O
mice	O
infected	O
with	O
MERS	O
-	O
CoV	O
.	O
Remarkably	O
,	O
the	O
therapeutic	O
efficacy	O
of	O
remdesivir	O
appeared	O
to	O
be	O
superior	O
to	O
that	O
of	O
LPV	O
/	O
RTV	B-PRGE
-	O
INFb	B-PRGE
against	O
MERS	O
-	O
CoV	O
in	O
a	O
transgenic	O
humanized	O
mice	O
model	O
.	O

In	O
this	O
study	O
,	O
a	O
fundamental	O
knowledge	O
gap	O
question	O
is	O
to	O
be	O
resolved	O
by	O
evaluating	O
the	O
differences	O
in	O
biological	O
and	O
pathogenic	O
aspects	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
and	O
the	O
changes	O
in	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
in	O
comparison	O
with	O
the	O
two	O
prior	O
major	O
COV	O
epidemics	O
,	O
SARS	O
and	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
coronaviruses	O
.	O

We	O
noted	O
low	O
sensitivity	O
of	O
upper	O
respiratory	O
specimens	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
,	O
which	O
could	O
further	O
complicate	O
recognition	O
of	O
the	O
full	O
extent	O
of	O
disease	O
.	O

TITLE	O
:	O
Human	B-PRGE
coronavirus	I-PRGE
OC43	I-PRGE
and	O
other	O
respiratory	O
viruses	O
from	O
acute	O
respiratory	O
infections	O
of	O
Egyptian	O
children	O
.	O

This	O
study	O
investigated	O
prevalence	O
of	O
10	O
respiratory	O
viruses	O
;	O
Adenovirus	O
,	O
influenza	O
A	O
,	O
B	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
Parainfluenza	O
virus	O
(	O
PIV	O
)	O
type	O
1	O
-	O
4	O
,	O
enterovirus	O
,	O
and	O
human	B-PRGE
coronavirus	I-PRGE
OC43	I-PRGE
(	O
HCoV	O
-	O
OC43	O
)	O
among	O
children	O
in	O
Alexandria	O
,	O
Egypt	O
presenting	O
with	O
acute	O
lower	O
respiratory	O
tract	O
infections	O
.	O

IEDB	O
services	O
is	O
one	O
of	O
the	O
computational	O
methods	O
;	O
the	O
output	O
of	O
this	O
study	O
showed	O
that	O
S	B-PRGE
glycoprotein	I-PRGE
,	O
envelope	B-PRGE
(	I-PRGE
E	I-PRGE
)	I-PRGE
protein	I-PRGE
,	O
and	O
S	O
and	O
E	O
protein	O
modified	O
sequences	O
of	O
MERS	O
-	O
CoV	O
might	O
be	O
considered	O
as	O
a	O
protective	O
immunogenic	O
with	O
high	O
conservancy	O
because	O
they	O
can	O
elect	O
both	O
neutralizing	O
antibodies	O
and	O
T	O
-	O
cell	O
responses	O
when	O
reacting	O
with	O
B	O
-	O
cell	O
,	O
T	O
-	O
helper	O
cell	O
,	O
and	O
cytotoxic	O
T	O
lymphocyte	O
.	O

Common	O
laboratory	O
findings	O
include	O
normal	O
/	O
low	O
white	O
cell	O
counts	O
with	O
elevated	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
(	O
CRP	B-PRGE
).	O

It	O
has	O
been	O
known	O
since	O
the	O
2003	O
SARS	O
epidemic	O
that	O
the	O
receptor	O
critical	O
for	O
SARS	O
-	O
CoV	O
entry	O
into	O
host	O
cells	O
is	O
the	O
angiotensin	B-PRGE
-	I-PRGE
converting	I-PRGE
enzyme	I-PRGE
2	I-PRGE
(	O
ACE2	B-PRGE
).	O

In	O
this	O
short	O
communication	O
,	O
we	O
performed	O
phylogenetic	O
-	O
structural	O
sequence	O
analysis	O
of	O
pp1ab	B-PRGE
protein	I-PRGE
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
.	O

While	O
comparing	O
pp1ab	B-PRGE
protein	I-PRGE
with	O
other	O
betacoronaviruses	O
,	O
we	O
found	O
a	O
42	O
amino	O
acid	O
signature	O
that	O
is	O
only	O
present	O
in	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
(	O
AS	O
-	O
SCoV2	O
).	O

TITLE	O
:	O
The	O
potential	O
chemical	O
structure	O
of	O
anti	B-PRGE
-	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
RNA	I-PRGE
-	I-PRGE
dependent	I-PRGE
RNA	I-PRGE
polymerase	I-PRGE
.	O

Here	O
,	O
we	O
investigate	O
the	O
density	O
of	O
the	O
expression	O
levels	O
of	O
ACE2	B-PRGE
in	O
the	O
CNS	O
,	O
the	O
host	O
-	O
virus	O
interaction	O
and	O
relate	O
it	O
to	O
the	O
pathogenesis	O
and	O
complications	O
seen	O
in	O
the	O
recent	O
cases	O
resulting	O
from	O
the	O
COVID	O
-	O
19	O
outbreak	O
.	O

TITLE	O
:	O
Single	O
-	O
cell	O
RNA	O
-	O
seq	O
data	O
analysis	O
on	O
the	O
receptor	O
ACE2	B-PRGE
expression	O
reveals	O
the	O
potential	O
risk	O
of	O
different	O
human	O
organs	O
vulnerable	O
to	O
2019	O
-	O
nCoV	O
infection	O
.	O

Moreover	O
,	O
lung	O
cells	O
that	O
have	O
ACE2	B-PRGE
expression	O
may	O
be	O
the	O
main	O
target	O
cells	O
during	O
2019	O
-	O
nCoV	O
infection	O
.	O

Suppression	O
of	O
pro	O
-	O
inflammatory	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
family	I-PRGE
members	I-PRGE
and	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
have	O
been	O
shown	O
to	O
have	O
a	O
therapeutic	O
effect	O
in	O
many	O
inflammatory	O
diseases	O
,	O
including	O
viral	O
infections	O
.	O

IL	O
-	O
37	O
performs	O
its	O
immunosuppressive	O
activity	O
by	O
acting	O
on	O
mTOR	B-PRGE
and	O
increasing	O
the	O
adenosine	O
monophosphate	O
(	O
AMP	O
)	O
kinase	O
.	O

This	O
cytokine	O
inhibits	O
class	O
II	B-PRGE
histocompatibility	I-PRGE
complex	I-PRGE
(	O
MHC	B-PRGE
)	O
molecules	O
and	O
inflammation	O
in	O
inflammatory	O
diseases	O
by	O
suppressing	O
MyD88	B-PRGE
and	O
subsequently	O
IL	O
-	O
1β	O
,	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
,	O
TNF	B-PRGE
and	O
CCL2	B-PRGE
.	O

Another	O
inhibitory	O
cytokine	O
is	O
IL	O
-	O
38	O
,	O
the	O
newest	O
cytokine	O
of	O
the	O
IL	B-PRGE
-	I-PRGE
1	I-PRGE
family	I-PRGE
members	I-PRGE
,	O
produced	O
by	O
several	O
immune	O
cells	O
including	O
B	O
cells	O
and	O
macrophages	O
.	O

The	O
proportion	O
of	O
lymphocytes	O
in	O
the	O
elderly	O
group	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
the	O
young	O
and	O
middle	O
-	O
aged	O
group	O
(	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
the	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
was	O
significantly	O
higher	O
in	O
the	O
young	O
group	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

Clinical	O
records	O
,	O
laboratory	O
results	O
,	O
and	O
chest	O
CT	O
scans	O
were	O
retrospectively	O
reviewed	O
for	O
55	O
patients	O
with	O
laboratory	O
-	O
confirmed	O
COVID	O
-	O
19	O
pneumonia	O
(	O
i	O
.	O
e	O
.,	O
with	O
throat	O
swab	O
samples	O
that	O
were	O
positive	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
)	O
who	O
were	O
admitted	O
to	O
Zhongnan	O
Hospital	O
of	O
Wuhan	O
University	O
,	O
Wuhan	O
,	O
China	O
,	O
from	O
Jan	O
.	O
8	O
to	O
Feb	O
.	O
10	O
,	O
2020	O
.	O

After	O
14	O
days	O
,	O
15	O
(	O
94	O
%)	O
of	O
16	O
and	O
9	O
(	O
52	O
·	O
9	O
%)	O
of	O
17	O
,	O
respectively	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
could	O
not	O
be	O
detected	O
(	O
p	O
<	O
0	O
·	O
05	O
).	O

The	O
values	O
of	O
D	O
-	O
dimer	O
,	O
fibrin	O
/	O
fibrinogen	B-PRGE
degradation	O
products	O
(	O
FDP	O
),	O
and	O
fibrinogen	B-PRGE
(	O
FIB	B-PRGE
)	O
in	O
all	O
SARS	O
-	O
CoV	O
-	O
2	O
cases	O
were	O
substantially	O
higher	O
than	O
those	O
in	O
healthy	O
controls	O
.	O

Thrombin	B-PRGE
time	O
in	O
critical	O
SARS	O
-	O
CoV	O
-	O
2	O
patients	O
was	O
also	O
shorter	O
than	O
that	O
in	O
controls	O
.	O

Human	O
infection	O
with	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
leads	O
to	O
a	O
wide	O
range	O
of	O
clinical	O
manifestations	O
ranging	O
from	O
asymptomatic	O
,	O
mild	O
,	O
moderate	O
to	O
severe	O
.	O

Here	O
,	O
we	O
review	O
the	O
discovery	O
,	O
zoonotic	O
origin	O
,	O
animal	O
hosts	O
,	O
transmissibility	O
and	O
pathogenicity	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
in	O
relation	O
to	O
its	O
interplay	O
with	O
host	O
antiviral	O
defense	O
.	O

RESULTS	O
:	O
Compared	O
with	O
general	O
COVID	O
-	O
19	O
patients	O
(	O
45	O
.	O
2	O
%),	O
refractory	O
patients	O
had	O
an	O
older	O
age	O
,	O
male	O
sex	O
,	O
more	O
underlying	O
comorbidities	O
,	O
lower	O
incidence	O
of	O
fever	O
,	O
higher	O
levels	O
of	O
maximum	O
temperature	O
among	O
fever	O
cases	O
,	O
higher	O
incidence	O
of	O
breath	O
shortness	O
and	O
anorexia	O
,	O
severer	O
disease	O
assessment	O
on	O
admission	O
,	O
high	O
levels	O
of	O
neutrophil	O
,	O
aspartate	B-PRGE
aminotransferase	I-PRGE
(	O
AST	B-PRGE
),	O
lactate	B-PRGE
dehydrogenase	I-PRGE
(	O
LDH	B-PRGE
)	O
and	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
,	O
lower	O
levels	O
of	O
platelets	O
and	O
albumin	B-PRGE
,	O
and	O
higher	O
incidence	O
of	O
bilateral	O
pneumonia	O
and	O
pleural	O
effusion	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Seasonal	O
forcing	O
on	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
should	O
thus	O
be	O
taken	O
into	O
account	O
in	O
the	O
further	O
monitoring	O
of	O
the	O
global	O
transmission	O
.	O

We	O
decided	O
to	O
test	O
them	O
all	O
for	O
SARS	B-PRGE
-	O
Cov2	O
twice	O
in	O
order	O
to	O
reduce	O
anxiety	O
among	O
the	O
population	O
and	O
decision	O
-	O
makers	O
.	O

Detection	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
RNA	I-PRGE
was	O
then	O
carried	O
out	O
using	O
several	O
real	O
-	O
time	O
reverse	O
transcription	O
(	O
RT	O
)-	O
PCR	O
assays	O
.	O

At	O
this	O
point	O
in	O
the	O
global	O
pandemic	O
of	O
COVID	O
-	O
19	O
infection	O
there	O
is	O
no	O
evidence	O
that	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
undergoes	O
intrauterine	O
or	O
transplacental	O
transmission	O
from	O
infected	O
pregnant	O
women	O
to	O
their	O
fetuses	O
.	O

RESULTS	O
:	O
Of	O
all	O
91	O
patients	O
,	O
88	O
(	O
96	O
.	O
70	O
%)	O
were	O
laboratory	O
-	O
confirmed	O
COVID	O
-	O
19	O
with	O
throat	O
swab	O
samples	O
that	O
tested	O
positive	O
for	O
SARS	B-PRGE
-	I-PRGE
Cov	I-PRGE
-	I-PRGE
2	I-PRGE
while	O
3	O
(	O
3	O
.	O
30	O
%)	O
were	O
clinical	O
-	O
diagnosed	O
COVID	O
-	O
19	O
cases	O
.	O

The	O
area	O
under	O
the	O
ROC	O
curve	O
(	O
AUC	O
)	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
combined	O
with	O
D	O
-	O
Dimer	O
was	O
0	O
.	O
840	O
.	O

The	O
specificity	O
of	O
predicting	O
the	O
severity	O
of	O
COVID	O
-	O
19	O
during	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
D	O
-	O
Dimer	O
tandem	O
testing	O
was	O
up	O
to	O
93	O
.	O
3	O
%,	O
while	O
the	O
sensitivity	O
of	O
IL	B-PRGE
-	I-PRGE
6	I-PRGE
and	O
D	O
-	O
Dimer	O
by	O
parallel	O
test	O
in	O
the	O
severe	O
COVID	O
-	O
19	O
was	O
96	O
.	O
4	O
%.	O

This	O
report	O
provided	O
evidence	O
of	O
low	O
risk	O
of	O
intrauterine	O
infection	O
by	O
vertical	O
transmission	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
.	O

Aerosolized	B-PRGE
dornase	I-PRGE
alfa	I-PRGE
was	O
shown	O
to	O
reduce	O
trauma	O
-	O
induced	O
lung	O
injury	O
in	O
experimental	O
models	O
and	O
to	O
improve	O
arterial	O
oxygenation	O
in	O
ventilated	O
patients	O
.	O

Here	O
,	O
we	O
evaluated	O
the	O
host	O
transcriptional	O
response	O
to	O
infection	O
with	O
murine	O
coronaviruses	O
encoding	O
independent	O
mutations	O
in	O
one	O
of	O
two	O
different	O
viral	O
antagonists	O
:	O
the	O
deubiquitinase	O
(	O
DUB	B-PRGE
)	O
within	O
nonstructural	O
protein	O
3	O
or	O
the	O
endoribonuclease	O
(	O
EndoU	O
)	O
within	O
nonstructural	O
protein	O
15	O
.	O

This	O
study	O
highlights	O
the	O
role	O
of	O
viral	B-PRGE
interferon	I-PRGE
antagonists	O
in	O
shaping	O
the	O
kinetics	O
and	O
magnitude	O
of	O
the	O
host	O
response	O
during	O
virus	O
infection	O
and	O
demonstrates	O
that	O
inactivating	O
a	O
dominant	O
viral	O
antagonist	O
,	O
the	O
coronavirus	O
endoribonuclease	O
,	O
dramatically	O
alters	O
the	O
host	O
response	O
in	O
macrophages	O
.	O

We	O
reported	O
the	O
median	O
(	O
IQR	O
)	O
incubation	O
period	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
.	O

TITLE	O
:	O
From	O
SARS	O
to	O
COVID	O
-	O
19	O
:	O
A	O
previously	O
unknown	O
SARS	O
-	O
related	O
coronavirus	O
(	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
)	O
of	O
pandemic	O
potential	O
infecting	O
humans	O
-	O
Call	O
for	O
a	O
One	O
Health	O
approach	O
.	O

However	O
,	O
PMX	B-PRGE
-	I-PRGE
HP	I-PRGE
has	O
seldom	O
achieved	O
expectations	O
in	O
randomized	O
trials	O
targeting	O
nonspecific	O
overall	O
sepsis	O
patients	O
.	O

To	O
identify	O
best	O
targets	O
for	O
PMX	B-PRGE
-	I-PRGE
HP	I-PRGE
,	O
we	O
developed	O
a	O
non	O
-	O
linear	O
restricted	O
cubic	O
spline	O
model	O
including	O
two	O
-	O
way	O
interaction	O
term	O
(	O
treatment	O
×	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
[	O
APACHE	O
]	O
II	O
score	O
/	O
Sequential	O
Organ	O
Failure	O
Assessment	O
[	O
SOFA	O
]	O
score	O
)	O
and	O
three	O
-	O
way	O
interaction	O
term	O
(	O
treatment	O
×	O
age	O
×	O
each	O
score	O
).	O

ABSTRACT	O
:	O
Stevens	O
-	O
Johnson	O
syndrome	O
and	O
toxic	O
epidermal	O
necrolysis	O
(	O
SJS	B-PRGE
/	O
TEN	B-PRGE
)	O
are	O
extremely	O
rare	O
but	O
potentially	O
life	O
-	O
threatening	O
disorders	O
.	O

This	O
article	O
reviews	O
the	O
immunological	O
changes	O
of	O
coronaviruses	O
like	O
SARS	O
,	O
MERS	O
and	O
other	O
viral	O
pneumonia	O
similar	O
to	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
.	O

The	O
laboratory	O
results	O
showed	O
that	O
compared	O
to	O
the	O
normal	O
values	O
,	O
the	O
patients	O
'	O
lymphocytes	O
were	O
reduced	O
(	O
4	O
[	O
80	O
%]	O
patients	O
),	O
and	O
liver	O
function	O
ALT	B-PRGE
and	O
AST	B-PRGE
(	O
2	O
[	O
40	O
%]	O
patients	O
,	O
2	O
[	O
40	O
%]	O
patients	O
)	O
and	O
C	B-PRGE
-	I-PRGE
reactive	I-PRGE
protein	I-PRGE
(	O
4	O
[	O
80	O
%]	O
patients	O
)	O
were	O
increased	O
when	O
admitted	O
to	O
hospital	O
.	O

We	O
found	O
genomic	O
and	O
evolutionary	O
evidence	O
of	O
the	O
occurrence	O
of	O
a	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
-	I-PRGE
like	I-PRGE
CoV	I-PRGE
(	O
named	O
Pangolin	B-PRGE
-	I-PRGE
CoV	I-PRGE
)	O
in	O
dead	O
Malayan	O
pangolins	O
.	O

We	O
also	O
establish	O
a	O
mechanism	O
for	O
EndoU	B-PRGE
activity	O
to	O
cleave	O
and	O
limit	O
the	O
accumulation	O
of	O
this	O
PAMP	O
.	O

RESULTS	O
:	O
The	O
median	O
duration	O
of	O
IgM	B-PRGE
and	O
IgA	B-PRGE
antibody	I-PRGE
detection	O
were	O
5	O
days	O
(	O
IQR	O
3	O
-	O
6	O
),	O
while	O
IgG	B-PRGE
was	O
detected	O
on	O
14	O
days	O
(	O
IQR	O
10	O
-	O
18	O
)	O
after	O
symptom	O
onset	O
,	O
with	O
a	O
positive	O
rate	O
of	O
85	O
.	O
4	O
%,	O
92	O
.	O
7	O
%	O
and	O
77	O
.	O
9	O
%	O
respectively	O
.	O

All	O
of	O
the	O
patients	O
received	O
antiviral	O
therapy	O
(	O
135	O
[	O
100	O
%]	O
(	O
Kaletra	O
and	O
interferon	B-PRGE
were	O
both	O
used	O
),	O
antibacterial	O
therapy	O
(	O
59	O
[	O
43	O
.	O
7	O
%]),	O
and	O
corticosteroids	O
(	O
36	O
[	O
26	O
.	O
7	O
%]).	O

In	O
these	O
high	O
risk	O
populations	O
,	O
protocols	O
for	O
screening	O
for	O
SARS	B-PRGE
-	O
Cov2	O
may	O
be	O
needed	O
to	O
be	O
re	O
-	O
evaluated	O
.	O

Intriguingly	O
,	O
we	O
found	O
that	O
the	O
candidate	O
co	O
-	O
receptors	O
,	O
manifesting	O
the	O
most	O
similar	O
expression	O
patterns	O
with	O
ACE2	O
across	O
13	O
human	O
tissues	O
,	O
are	O
all	O
peptidases	O
,	O
including	O
ANPEP	B-PRGE
,	O
DPP4	B-PRGE
and	O
ENPEP	B-PRGE
.	O

Here	O
,	O
we	O
evaluated	O
and	O
ranked	O
the	O
receptor	O
-	O
utilizing	O
capability	O
of	O
ACE2s	O
from	O
various	O
species	O
by	O
phylogenetic	O
clustering	O
and	O
sequence	O
alignment	O
with	O
the	O
currently	O
known	O
ACE2s	O
utilized	O
by	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
.	O

We	O
hereby	O
reported	O
an	O
asymptomatic	O
discharged	O
patient	O
with	O
COVID	O
-	O
19	O
who	O
was	O
retested	O
positive	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
,	O
which	O
arouses	O
concern	O
regarding	O
the	O
present	O
discharge	O
standard	O
of	O
COVID	O
-	O
19	O
.	O

TITLE	O
:	O
Spike	O
protein	O
recognition	O
of	O
mammalian	O
ACE2	O
predicts	O
the	O
host	O
range	O
and	O
an	O
optimized	O
ACE2	B-PRGE
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
infection	O
.	O

ABSTRACT	O
:	O
The	O
pneumonia	O
caused	O
by	O
novel	O
coronavirus	O
(	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
)	O
in	O
Wuhan	O
,	O
China	O
in	O
December	O
2019	O
is	O
a	O
highly	O
contagious	O
disease	O
.	O

ABSTRACT	O
:	O
Signal	B-PRGE
transducer	I-PRGE
and	I-PRGE
activator	I-PRGE
of	I-PRGE
transcription	I-PRGE
3	I-PRGE
(	O
STAT3	B-PRGE
)	O
is	O
a	O
transcription	O
factor	O
which	O
can	O
be	O
activated	O
by	O
cytokines	B-PRGE
,	I-PRGE
growth	I-PRGE
factor	I-PRGE
receptors	I-PRGE
,	O
and	O
nonreceptor	O
-	O
like	O
tyrosine	B-PRGE
kinase	I-PRGE
.	O

As	O
little	O
is	O
currently	O
known	O
about	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
,	O
it	O
is	O
likely	O
that	O
lessons	O
learned	O
from	O
these	O
major	O
epidemics	O
can	O
be	O
applied	O
to	O
the	O
new	O
pandemic	O
,	O
including	O
the	O
use	O
of	O
novel	O
immunosuppressive	O
drugs	O
.	O

TITLE	O
:	O
Recommendations	O
by	O
the	O
SEPD	O
and	O
AEG	O
,	O
both	O
in	O
general	O
and	O
on	O
the	O
operation	O
of	O
gastrointestinal	O
endoscopy	O
and	O
gastroenterology	O
units	O
,	O
concerning	O
the	O
current	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
pandemic	O
(	O
March	O
,	O
18	O
).	O

The	O
presence	O
of	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
RNA	I-PRGE
in	O
the	O
feces	O
of	O
patients	O
infected	O
with	O
the	O
virus	O
,	O
and	O
occasionally	O
in	O
colonic	O
biopsy	O
samples	O
,	O
has	O
been	O
consistently	O
documented	O
.	O

Nevertheless	O
,	O
there	O
is	O
limited	O
knowledge	O
regarding	O
feline	O
IFN	B-PRGE
-	I-PRGE
ω	I-PRGE
(	O
feIFN	O
-	O
ω	O
),	O
compared	O
to	O
IFN	B-PRGE
-	I-PRGE
α	I-PRGE
and	O
IFN	B-PRGE
-	I-PRGE
β	I-PRGE
.	O

At	O
present	O
there	O
is	O
limited	O
clinical	O
information	O
of	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
and	O
there	O
is	O
no	O
specific	O
treatment	O
recommended	O
,	O
although	O
technical	O
guidances	O
and	O
suggestions	O
have	O
been	O
developed	O
and	O
will	O
continue	O
to	O
be	O
updated	O
as	O
additional	O
information	O
becomes	O
available	O
.	O

RESULTS	O
:	O
Over	O
our	O
study	O
period	O
,	O
no	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
was	O
detected	O
.	O

The	O
structural	O
divergence	O
was	O
determined	O
by	O
using	O
SuperPose	O
Version	O
1	O
.	O
0	O
based	O
on	O
cryo	O
-	O
EM	O
structure	O
of	O
the	O
SARS	B-PRGE
coronavirus	I-PRGE
spike	I-PRGE
glycoprotein	I-PRGE
.	O

When	O
tested	O
against	O
the	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
pseudovirus	I-PRGE
,	I-PRGE
SARS	I-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
convalescent	O
patient	O
sera	O
showed	O
high	O
neutralizing	O
potency	O
,	O
which	O
underscore	O
its	O
potential	O
as	O
therapeutics	O
.	O

Seven	O
clusters	O
for	O
human	O
coronaviruses	O
(	O
229E	O
,	O
NL63	O
,	O
OC43	O
,	O
HKU1	O
,	O
MERS	O
-	O
CoV	O
,	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
and	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
)	O
were	O
found	O
.	O

The	O
cluster	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
was	O
very	O
close	O
to	O
that	O
for	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
,	O
which	O
suggests	O
that	O
both	O
of	O
viruses	O
have	O
the	O
same	O
human	O
receptor	O
(	O
angiotensin	B-PRGE
converting	I-PRGE
enzyme	I-PRGE
II	I-PRGE
).	O

Compared	O
to	O
the	O
recovered	O
group	O
,	O
more	O
patients	O
in	O
the	O
death	O
group	O
exhibited	O
characteristics	O
of	O
advanced	O
age	O
,	O
pre	O
-	O
existing	O
comorbidities	O
,	O
dyspnea	O
,	O
oxygen	O
saturation	O
decrease	O
,	O
increased	O
WBC	O
count	O
,	O
decreased	O
lymphocytes	O
,	O
and	O
elevated	O
CRP	B-PRGE
levels	O
.	O

ABSTRACT	O
:	O
The	O
SARS	B-PRGE
-	I-PRGE
CoV	I-PRGE
-	I-PRGE
2	I-PRGE
(	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
2	O
)	O
epidemic	O
has	O
spread	O
to	O
virtually	O
every	O
continent	O
in	O
the	O
world	O
.	O

